[{"article": "More than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nAn editorial in the same journal by an expert who was not part of the study praised the research, saying it was well designed and carefully performed.\nDr. Bisgaard said it was not possible to tell from the study whether pregnant women could benefit from simply eating more fish.\nThe author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\nThe incidence has more than doubled in developed countries in recent decades.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was a strong point of the story, giving us both absolute and relative risk figures up front in the second paragraph:\nAmong children whose mothers took fish-oil capsules, 16.9 percent had asthma by age 3, compared with 23.7 percent whose mothers were given placebos. The difference, nearly 7 percentage points, translates to a risk reduction of about 31 percent.\nToo often, even when stories do provide absolute risk figures, they highlight relative risks high up in the story and bury the absolute risk information far down in the text where it\u2019s less likely to be read.", "answer": 1}, {"article": "EEGs measure brain electrical activity through electrodes attached to the scalp.\nAlso, the study predicted who was at high risk of autism, but it's unknown if those babies actually went on to develop autism, he noted.\n\"If it can eventually be shown that this technique can reliably identify which children will indeed develop autism, then we will have a valuable tool for early detection,\" Ewen said.\nBut accuracy for girls at that age was only 60 percent, not statistically significant.\nDr. Joshua Ewen, a neurologist and director of the clinical neurophysiology laboratory at the Kennedy Krieger Institute in Baltimore, said the study is well done and looks promising, but needs to be replicated.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides a lot of percentages but very little in terms of absolute differences or clear, hard numbers. It says that \u201cPrior research has shown that about 20 percent of siblings of children with autism will also develop autism and another 40 to 50 percent will have some characteristics of the disorder, such as repetitive behaviors or problems with social interaction, language or communication, but not the full-blown disorder.\u201d That\u2019s a great piece of context and should have guided the rest of the reporting. Instead, the story says that \u201cWhen the babies were nine months old, researchers could predict who was in the high-risk autism group \u2014 that is, they had a sibling with autism \u2014 with nearly 80 percent accuracy.\u201d It goes on to say, \u201cWhen broken out by gender, researchers found other differences. For example, at nine months they were able to predict which boys were in the high-risk group with near 100 percent accuracy. But accuracy for girls at that age was only 60 percent, not statistically significant.\u201d Are readers to take this to mean that the statistically significant predictions for boys were averaged with the statistically insignificant predictions for girls to arrive at the \u201cnearly 80 percent\u201d figure? If so, this seems problematic. Regardless, readers deserved absolute numbers.", "answer": 0}, {"article": "Sept. 6, 2011 -- \"A drink a day keeps disease away\" may be the new motto for middle-age women hoping to age gracefully.\nIn the study, researchers looked at the effects of drinking alcohol at midlife on the risk of diseases commonly associated with aging in a group of 13,894 women enrolled in the Nurses' Health Study.\nResearchers then analyzed health status information collected after the women turned 70.\nAfter taking into account other factors that might affect health and disease risk, like smoking, researchers found women who drank light or moderate amounts of alcohol were less likely to develop chronic diseases as they aged.\nFor example, compared to nondrinkers, women who drank up to one alcoholic drink per day were 20% more likely to be disease-free at age 70 than nondrinkers.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We expect that a story will attempt to\u00a0provide us with some measure of the size of an association beyond just the relative risks, which can often give an inflated sense of the effects. That\u2019s what happens in this story when it says that women who drank lightly almost every day \u201cwere nearly 50% less likely to develop disease.\u201d Sounds like a big difference, but the figure would certainly be much smaller\u00a0if expressed in absolute terms. The story\u00a0could\u00a0have made these statistics more\u00a0meaningful with comments from an independent expert.\nSee how the \u201cBehind the Headlines\u201d project in the UK analyzed the evidence and included the absolute differences. ", "answer": 0}, {"article": "About the American College of Surgeons\n\nThe American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for surgical patients.\nAlong with discovering that the use of laparoscopy for the surgical treatment of GERD has increased significantly in the last decade, the researchers also found that, on average, the minimally invasive approach reduced length of hospital stay by approximately two days, and open operations were more than $9,000 more expensive than minimally invasive procedures.\nThe study showed that the rate of laparoscopic procedures increased from 24.8 percent in 2000 to 84.3 percent in 2013.\n\"We found that laparoscopic surgery is associated with significantly lower costs.\nThe researchers also found that laparoscopic procedures were better for patients in terms of fewer complications.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release summarized how minimally invasive techniques reduced the length of hospital stay and complication rates for patients.\n\u201cResearchers also found that, on average, the minimally invasive approach reduced length of hospital stay by approximately two days, and open operations were more than $9,000 more expensive than minimally invasive procedures.\nThe researchers also found that laparoscopic procedures were better for patients in terms of fewer complications. Laparoscopic anti-reflux operations were less likely to result in postoperative blood clots, wound complications, surgical site infection, esophageal perforation (which can be life threatening), bleeding, cardiac failure, and death.\u201d\nWe rate this satisfactory, but just barely, for citing cost differences between the two types of surgery and the average reduction in the number of days a patient must remain hospitalized.\u00a0 We do wish the release had delved more into the specifics of reduced complications. How common were the surgical complications in each surgical method?", "answer": 1}, {"article": "What happens with age-related macular degeneration is that the center of the retina deteriorates, and people gradually lose sight.\nThis is why the telescope is implanted in only one eye.\nDespite its terrific potential, the new eye telescope isn't for everyone.\nThe treatment doesn't work for those who have had cataract surgery.\nAnd 75 percent of them, like Orr, had major improvement.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t spend a lot of time with the numbers, but it does a pretty good job capturing the potential benefits.", "answer": 1}, {"article": "Merck & Co. and Schering-Plough Corp. said a long-awaited trial showed their cholesterol drug Vytorin failed to slow progression of heart disease better than a cheaper drug, threatening the companies' $5 billion-a-year cholesterol-fighting franchise.\n\nSchering-Plough's shares fell 8% to $25.52 and Merck declined 1.3% to $59.78 at 4 p.m. in New York Stock Exchange composite trading.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was clear about the benefits of this treatment (i.e. that the outcomes from use of the combination medication were no better than a statin alone).", "answer": 1}, {"article": "Cocoa or cacao beans are not beans but the seeds of the fruit of the Theobroma cacao tree.\nA new study suggests that dark chocolate and cocoa powder may be the next \"super foods\" thanks to their high antioxidant content.\nTwo groups of antioxidants in particular, polyphenols and flavonols, which are found in various fruits and seeds, have been the focus of much research due to their potentially healthy effects.\nFoods and fruits high in these antioxidants have been dubbed as \"super foods\" or \"super fruits\" by the media.\nAntioxidants are a group of compounds known to fight the damaging effects of oxidative stress on cells within the body and are increasingly thought to have many heart-healthy properties.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Overall,\u00a0WebMD\u2019s characterization of chocolate as a \u201csuperfood\u201d\u00a0makes it sound like an arm of the Hershey marketing department. More specifically,\u00a0although the story provides data on some of the results, it doesn\u2019t quantify others and\u00a0doesn\u2019t point out that no\u00a0actual health outcomes were assessed.\u00a0In addition, it doesn\u2019t identify misleading comparisons that\u00a0might make chocolate look better than the other foods included in the study. Examples:", "answer": 0}, {"article": "Patients lie in a CT scanner, which takes a series of pictures from a variety of different angles, and a computer compiles the snapshots in two different ways.\nThat\u2019s a bit of a surprise, given that not all medical experts agree on whether the virtual screen is as reliable as a traditional colonoscopy, in which doctors insert a scope with a small camera into the colon.\nBut according to Dr. Marc Gollub, director of CT and gastrointestinal radiology at Memorial Sloan-Kettering Cancer Center, \u201cthe radiation is much lower than a regular CT scan and has not been proven to be of any risk.\nAnd given the relatively low cost of investing in the software and other equipment required to run a virtual scan, more hospitals may be adding the option to their patient services.\nVirtual colonoscopy is a good option for those who can\u2019t be sedated for colonoscopy, or who simply can\u2019t tolerate the scope.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No quantification of benefit.\u00a0 And no adequate comparison with other colon cancer screening techniques.", "answer": 0}, {"article": "The GI tract is also home to the intestinal microbiome, a complex population of roughly 100 trillion microorganisms (more than ten times the number of cells that make up the human body) that interacts with the mucosal lining of the GI tract.\nAnd a new study from Baltimore's Sheppard Pratt Health System, conducted by a research team led by Faith Dickerson, finds that a probiotic supplement may reduce inflammation of the gut, which is known to exacerbate bipolar disorder.\nA group of patients recently hospitalized for mania participated in a 6-month study to track the effects of probiotic treatment on both their mood and the status of their immune system.\nThe beneficial effects were most pronounced in those patients who exhibited abnormally high levels of inflammation at the beginning of the study.\nOverall, these results indicate that changes in intestinal inflammation can alter the trajectory of psychiatric mood disorders and that modulating the intestinal microbiota may be a new avenue of treatment for patients suffering from these diseases.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release notes that the 6-month study yielded the following results:\nThe group randomized to receive the probiotic, on average, \u201cdidn\u2019t return to hospital as quickly \u2026 required less in-patient treatment time \u2026 [and the] beneficial effects were most pronounced in those patients\u00a0 who exhibited abnormally high levels of inflammation\u201d when compared to the placebo group.\nHowever no data are provided to support these outcomes.\u00a0The news release should have included information about the number of patients in the trial, the schedule of probiotic dosing given to the participants, the changes in inflammation levels, the difference in number of rehospitalizations, and other details.\nThe release also includes some other unsubstantiated claims, such as:", "answer": 0}, {"article": "Scientists have found an unexpected use for virtual reality headsets: to help pinpoint people who may later develop Alzheimer\u2019s disease.\n\u201cThe aim of the study is very simple: can we detect changes in brain function before people are aware that they have them?\u201d\n\nResearchers recently pinpointed the significance of a tiny area of the brain known as the entorhinal cortex, which acts as a hub in a widespread brain network that controls navigation.\nBy identifying potential patients far earlier than is possible at present, researchers hope it should then become easier in the long term to develop treatments aimed at halting or slowing their condition.\nThis now appears to be the first part of the brain that succumbs to Alzheimer\u2019s.\nThe goal of the work is to help people as they develop the disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is tricky. The study has not yet taken place, so there are no benefits to discuss \u2014 which makes it difficult to ding the story for failing to quantify the benefits. As such, we\u2019ll rate this as not applicable. However, our reasons for rating it N/A highlight a critical problem with the story, which we address in Quality of Evidence and Availability, below.", "answer": 2}, {"article": "\u201cMy nightmare was that nothing would be different from the placebo group, and there would be nothing of interest to talk about,\u201d he says.\nI think resveratrol is an engaging target that\u2019s very interesting and could be pharmacologically manipulated to develop a treatment.\u201d\n\nMORE: Red Wine Not That Healthy After All, Study Shows\n\nThe resveratrol group showed no change in the levels of a protein that builds up in the brains of Alzheimer\u2019s patients.\nIn what the authors describe as the largest and longest study of resveratrol in people with mild to moderate Alzheimer\u2019s disease, there\u2019s encouraging news that the component, which is found in red wine, grapes and dark chocolate, may keep the disease from progressing.\nThe amounts of resveratrol in the purified doses that the participants took were extremely high and beyond those found on the market currently \u2014 around what would be contained in about 1,000 bottles of red wine.\nTurner says the findings don\u2019t suggest that red wine is a cure for Alzheimer\u2019s.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story has a fundamental flaw. The key finding of the study is that high doses of resveratrol can have an effect on the production of amyloid-beta40, a biomarker that declines as Alzheimer\u2019s disease advances. Specifically, the study looked at 119 patients with mild to moderate Alzheimer\u2019s disease. Patients who received the high doses of resveratrol did not see declines in the biomarker, whereas patients who received a placebo did see declines in amyloid-beta40. Couching that as \u201cnew evidence resveratrol may slow Alzheimer\u2019s,\u201d as we see in the headline, is misleading. More accurate is the line in the eighth paragraph: \u201cHow resveratrol may be affecting the Alzheimer\u2019s disease process isn\u2019t clear yet.\u201d And it\u2019s not until the last line of the story that readers find: \u201cWe need more studies to see if it really does have benefit and then it could be turned into more effective drugs that can better target Alzheimer\u2019s.\u201d That\u2019s a qualifier that should have found placement much higher in the story.\nAnother concern is the story\u2019s reporting on brain volume decline in the resveratrol group, which it says is \u201ca positive sign, as the disease can cause inflammation and swelling that can interfere with nerve connections.\u201d Characterizing a shrinking brain as a \u201cpositive sign\u201d seems problematic at best. The study itself says that the \u201cThe\u00a0etiology and interpretation of brain volume loss\u00a0observed here and in other studies are unclear.\u201d And in the news release issued for the study, Dr. Turner acknowledges,\u00a0\u201cWe\u2019re not sure how to interpret this finding.\u201d\nAnd finally, the story also points to \u201cslight improvements\u201d among patients receiving resveratrol \u2014 but doesn\u2019t explain exactly what that means. More on this below in \u201cQuality of Evidence.\u201d", "answer": 0}, {"article": "MayoClinic: Find out more about melanoma\n\nOne study presented at the American Society of Clinical Oncology's (ASCO) conference on Sunday focused on the experimental drug vemurafenib.\nNearly 90% benefited from this new targeted drug, Schuchter said.\nResearchers compared this new drug, which comes in pill form, to the only FDA-approved chemotherapy drug for melanoma, dacarbazine: It has been used to treat melanoma patients since 1975, but is only effective in about 10% of patients.\nAmong 502 patients enrolled in this clinical trial, half were given Yervoy plus dacarbazine and the other half were given a placebo and chemotherapy.\nHe also points out that both drugs do have side effects so patients have to be monitored.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate explanation of the benefits reported in both studies.", "answer": 1}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story informed the reader that half of the people taking the rimonabant brought their blood sugar to the range considered to be the target for good glucose control, the story did not provide information about the starting blood-sugar levels for this cohort.\u00a0 In addition, the story mentions in passing that the improvements were linked to weight loss.\u00a0 It is not clear from the story whether weight loss alone was sufficient to elicit the benefits in blood-sugar level observed.", "answer": 0}, {"article": "Bisphosphonates include such common drugs as Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate) and Reclast (zoledronic acid).\nCommenting on the study, Eric Jacobs, Strategic Director of Pharmacoepidemiology at the American Cancer Society, said that \"the lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing.\"\nA randomized trial is need to prove that bisphosphonates are protective against colorectal cancer, Rennert said.\n\"The adverse effects profile is of major importance if bisphosphonates are going to be recommended for cancer prevention in healthy people,\" the study authors cautioned.\n\"Results from the only other study of bisphosphonate use and colorectal cancer, a recent large study from the United Kingdom, do not support an important protective effect,\" Jacobs noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The lead says, \u201cPeople who take drugs called bisphosphonates to prevent bone loss may also reduce their risk of developing colorectal cancer by almost 60 percent compared to those not on the drugs, a new study suggests.\u201d What this story and the Reuters Health story failed to do was give the raw numbers that are provided in the study itself.\u00a0The story should have said that 138 women in the non-cancer group took biophosphonates and 97 in the cancer group took them, meaning that 41 women appear to have benefited from taking the drugs. If the study had found that 97 women had taken these drugs in both groups, the study would not have made headlines. Also, it might have been helpful to show that there were actually larger differences in some of the other factors that were studied. For example, 120 women in the group of cancer patients had a history of colorectal cancer in the family compared to 75 women in the control group.\nThis story did a better job of mentioning \u201cThe magnitude of the reduced risk is less important because this is an association study\u2026\u201d But then it goes on to say that the magnitude of the benefit is similar to cholesterol lowering medicines. The main difference is that this story, despite the caveats mentioned, is more enthusiastic about the findings than the Reuters story.\n", "answer": 0}, {"article": "Autism is a spectrum disorder that includes repetitive behaviors and impairments in language, communication and social skills.\nHowever, if this test could be done in really young children, it might help identify autism so that treatment can begin early, Lopez-Alberola suggested.\nFor one, this study was done in school-aged children, many of whom were actually teenagers, so it is impossible to know if these differences in neuroimaging would also be found in younger patients, Adesman pointed out.\nAlthough this study was done with school-aged children and teens, the same test can be done with children as young as 18 months, Hirsch noted.\n\"The other major limitation of this study is that the investigators did not look at whether these brain differences are specific to children with autism, or if they would also be seen, for example, in children with language delays who are not autistic,\" Adesman said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story starts off with a very vague description of the study\u2019s findings, saying, \u201cThe researchers found no differences in the activity in the hearing area of the brain between the two groups. However, in the language comprehension area, there was significantly more activity among typical children than among children with autism, Hirsch\u2019s group noted.\u201d What would be considered significant when comparing one group of 12 to another group of 15? The story does provide a bit more specific information later saying, \u201cTo further test this screening approach, another group of 27 autistic children, aged 5 to 17, underwent fMRI and the researchers were able to identify 26 of them as autistic.\u201d We felt this was inadequate and also misleading. As the story goes on to point out, the brain differences that were found may not be exclusive to autism. There\u2019s a chance, in fact, that were the study group much larger that there would have been many other subjects who had the same brain activity but were not otherwise diagnosed as autistic.", "answer": 0}, {"article": "Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys.\nOverall, the nano-therapeutic treatments showed a more pronounced effect in MYCN-amplified cells, which are traditionally more resistant to drug therapies.\nThis research is an excellent example of the collaboration between Nemours Children's Hospital and the University of Central Florida.\n\"High-risk neuroblastoma can be resistant to traditional therapy, and survival can be poor.\nThe study, conducted in partnership by researchers at Nemours Children's Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does not provide any data to support its claims. Instead, sweeping phrases are used to describe the benefits of curcumin-loaded nanoparticles: \u201cThis formulation included substantial cell death in neuroblastoma cells while producing no or only minor toxicity in healthy cells.\u201d\nMoreover, \u201cnano-therapeutic treatments showed a more pronounced effect\u201d in cell lines of a high-risk form of neuroblastoma, the news release states. No other benefit data are given.\nWe like to see news releases giving a quantitative estimate of the potential benefit using numbers, instead of using broad, ambiguous terms like \u201csubstantial,\u201d \u201cminor\u201d and \u201cmore pronounced.\u201d Therefore, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "It is known as BMS-790052.\nA unique thing about the NS5A-targeting drug, according to Meanwell, is that laboratory studies show it to be effective against all HCV genotypes.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nIn fact, no fewer than 90 studies are currently underway examining different HCV-targeting drugs.\nIn preliminary research published this week in Nature, researchers from Bristol-Myers Squibb -- the maker of the drug -- report that patients who took the drug showed dramatic reductions in viral load while exhibiting few side effects.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story got a little carried away here. It said participants treated with the experimental drug had a \"dramatic\" reduction in viral load. While this may be true, it would have been helpful to point out, as the HealthDay story did, that the study lasted only a few days.\u00a0We don\u2019t know whether this benefit can be maintained\u00a0over a longer period of time, especially considering that the\u00a0hepatitis C virus has proven to be quite capable of developing resistance to antivirals over time.\u00a0", "answer": 0}, {"article": "For more information, visit www.aacc.org.\nThis test detects the presence of a protein in the blood produced by a specific variation of the apolipoprotein gene (ApoE4), which is associated with increased risk of developing Alzheimer's disease.\n\"Cerebrospinal Fluid Angiotensin-Converting Enzyme Activity Levels of Patients With Alzheimer's and Parkinson's Disease\" (A-118)\n\u2022 Researchers have shown that a specific protein in blood plasma could serve as a biomarker for early detection of AD.\nIn addition to this study, researchers will present the latest in Alzheimer's disease at the AACC Annual Scientific Meeting & Clinical Lab Expo, including:\n\u2022 New research explores using the level of angiotensin-converting enzyme (ACE) in the brain and spinal cord as a biomarker for neurodegenerative diseases, including Parkinson's disease and AD.\n\"This type of testing is important in our quest to understand and diagnose Alzheimer's and empower patients to understand risks, consider medication, and even make early lifestyle changes.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release names several benefits of the new test \u2014 accuracy, speed, affordability, ability to run multiple tests from one blood sample \u2014 but provides little quantification, and only in terms of its 100 percent accuracy in detecting a protein in the blood associated with increased AD risk.\nThe release suggests that early testing showing a person carries a genetic risk for AD is a benefit because they can consider medications or lifestyle changes as interventions to stall the disease. However, having a certain genetic profile does not mean a person will develop AD. Nor are there any current medications that effectively prevent or stall AD, or lessen its symptoms.", "answer": 0}, {"article": "Worse, Anderson says, \"I could feel the tumors getting bigger.\nAfter one year, the once palpable tumors were no longer detectable in diagnostic scans.\nStill, the study stands as \"a major landmark in cancer immunotherapy,\" says Dr. Bernard Fox, president of the International Society for Biological Therapy of Cancer.\nResearchers linked 14 deaths to the study drugs, half caused by immune-system reactions.\nSerious side effects also became clear.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "good job providing absolute benefit data from the trial.", "answer": 1}, {"article": "Up to 30% of men suffer some degree of premature ejaculation, defined as ejaculation that occurs within one minute of vaginal penetration.\nThe rest of the men used a placebo spray.\nAll used the product for three months, for a total of 23,000 doses.\nThe numbers aren't huge.\nA total of 358 of the men gave themselves three quick sprays of PSD502 to the head of the penis five minutes before sex and then wiped it off right before penetration.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The \"ejaculatory control scale\" wasn\u2019t explained very well.\u00a0 But the numbers were there.\u00a0 ", "answer": 1}, {"article": "Larsson isn't sure why.\nIn this group, the median intake (half ate more, half less) was about 2.3 ounces a week.\n\"The protection started at more than 45 grams [about 1.5 ounces] a week,\" says researcher Susanna C. Larsson, PhD, of the Karolinska Institutet in Stockholm, Sweden.\nThose who ate the most chocolate were protected a bit more from strokes caused by hemorrhage than strokes caused by obstruction such as blood clots.\nOct. 10, 2011 -- A healthy chocolate habit -- about two chocolate bars a week -- appears to help women reduce their risk of stroke, according to new research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that researchers observed a 20% reduction in strokes among participants eating the most chocolate relative to those eating the least \u2014 a statistic that\u00a0conveys very little useful information. Compare this with the much more informative\u00a0Reuters description that provides absolute risks\u00a0from data contained in one of the study tables:\u00a0\u201cAmong those with the highest weekly chocolate intake, more than 45 grams, there were 2.5 strokes per 1,000 women per year. That figure was 7.8 per 1,000 among women who at the least, less than 8.9 grams a week.\u201d", "answer": 0}, {"article": "The newest scientific report for the U.S.D.A.\nI can\u2019t think of any other product that has this much positive epidemiologic evidence going for it.\nFinally, while the coffee may be healthy, that\u2019s not necessarily true of the added sugar and fat that many people put into coffee-based beverages.\nIt\u2019s important to remember that we usually conduct those trials to see if what we are observing in epidemiologic studies holds up.\nI\u2019m also not suggesting that people start drinking coffee by the gallon.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The range of studies cited and their conclusions is impressive, but the actual quantification of benefits is scant and sometimes misleading. Look at the quantification of benefits related to liver cancer which gives a relative risk reduction. \u201cA\u00a0meta-analysis published in 2007 found that increasing coffee consumption by two cups a day was associated with a lower relative risk of liver cancer by more than 40 percent.\u201d Really? 40% of what? My lifetime risk of liver cancer to start with, according to the American Cancer Society, is \u201c1 in 81, while an average woman\u2019s risk is about 1 in 196\u201d \u00a0(this equates to 1.23% for men and 0.51% in women). Reducing my (a man\u2019s) relative risk of liver cancer then goes from 1.2% down to 0.72%, a difference of about 0.48%. \u00a0Is that worth an extra 2 cups of coffee per day? If you don\u2019t like the stuff, again, you need to know these slight differences.", "answer": 0}, {"article": "It is a bold move, but bold moves are what our patients deserve.\"\nMore than improving the results of the initial treatment, the MASTER study will treat patients for the necessary time to confirm elimination of minimal residual disease and then discontinue therapy.\nThe hope is that the therapies will eradicate the disease in a significant proportion of patients and measure disease response more accurately than ever before.\nAs it stands, patients with billions of cancer cells in their bodies and patients with true disease eradication will both appear to be in complete remission using current methods to measure disease response to therapy.\nThe clinical trial Monoclonal Antibody Sequential Therapy for Deep Remission in Multiple Myeloma, also known as MASTER, utilizes next generation sequencing technology to detect minimal residual disease down to a level of one cancer cell in 100,000 \u2014 or 100- to 1,000-fold more sensitive than traditional methods to evaluate response.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "By definition, the benefits of an experimental treatment are unknown. The release should not dangle the potential of unproven benefits, including eradicating multiple myeloma, without acknowledging that this experimental treatment may turn out to be no better, or even less beneficial, than standard treatments. In the interview mentioned above, the lead investigator noted, \u201cThere is no proof that a new therapy is better, otherwise would be no need for the clinical trial.\u201d The release should have included that fundamental caveat.\nWe think it\u2019s important to stress that a trial to determine the best therapy would ideally compare  National Comprehensive Cancer Network (NCCN) recommended treatments such as revlimid, dexamethasone and velcade with a proposed therapy.", "answer": 0}, {"article": "But in either case, \"Something is better than nothing,\" Sayre said.\nSayre said the association took the unusual step of making the changes now - the next update wasn't due until 2010 - because three studies last year showed hands-only was as good as traditional CPR.\nBut less than a third of victims get this essential help.\nIn a major change, the American Heart Association said Monday that hands-only CPR - rapid, deep presses on the victim's chest until help arrives - works just as well as standard CPR for sudden cardiac arrest in adults.\nNow the heart association has given equal standing to hands-only CPR.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The segment fails to report the percentage of the targeted population that survives witnessed sudden cardiac arrest with either of the methods of CPR. \nIn none of the studies, using various outcome measures, does survival exceed 20 percent. Viewers should know this. ", "answer": 0}, {"article": "However, contrary to the popularly held belief that a greater number of concussions are linked to CTE , no connection was found between levels of CCL11 and reported number of concussions.\n\"This may be one of the abnormalities [of the disease], but it may take 2-3 to be useful to diagnose CTE,\" said McKee.\nFurthermore, they found that the more years someone played football, the higher amount of the protein.\n\"This is something new,\" said Dr. Ann McKee , a neuropathologist and senior author of the studyMcKee has performed many of the high profile diagnoses of CTE among former pro-football players and is director of the Boston University CTE Center.\nAlthough there are different stages of the disease that indicate how far it has progressed, this study was unable to determine any connections between levels of CCL11 and severity of CTE.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story discusses benefits here:\nThe paper evaluated the brains of 23 deceased football players with CTE, and compared them to the brains of 50 deceased people diagnosed with Alzhiemer\u2019s disease and the brains of 18 deceased non-athletes. When compared to the brains without CTE, researchers found those brains with CTE had significantly higher amounts of CCL11, even when compared to those brains with Alzheimer\u2019s, another degenerative brain disease. Furthermore, they found that the more years someone played football, the higher amount of the protein.\nHow much higher was the protein, in numerical terms? And how do they know it\u2019s significant\u2013that the higher level means anything? All lab values have normal ranges\u2013how do they know if these measurements were abnormal? Instead of providing insight on this, the story explains that it\u2019s really too early to tell if any of this means anything valuable. So why report on it now?", "answer": 0}, {"article": "Further,Dr.\nCrucially, this woman was in good health, suggesting that therapies aimed at blocking PCSK9 would not only be effective, but also safe.\nWe\u2019d exhausted the other options in trying to control his cholesterol.\u201d\n\nTwo months after he started his biweekly injections of the new drug, Mr. Brown\u2019s LDL cholesterol level was down to 111 \u2013 not quite normal, which is 100 or less \u2013 but an almost 50 percent reduction from the level it had been for years.\nEven with this trio of medicines, Mr. Brown\u2019s LDL cholesterol level hovered around 200.\nMr. Brown had been part of a clinical trial testing the safety and effectiveness of one of the new PCSK9 inhibitors and, when the drugs were approved, Dr. Khera began working to get Mr. Brown approved by his insurance to be on the new regimen.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This falls short in two different ways. First, the release only tells readers how much one patient\u2019s LDL cholesterol dropped (from 384 to 111). That\u2019s anecdotal data. And, because the release doesn\u2019t tell readers which drug the patient was taking, it is not even clear which drug was responsible for that single patient\u2019s lower cholesterol numbers. Second, the release doesn\u2019t tell readers what this reduction in LDL cholesterol means in terms of the patient\u2019s actual health. Does it reduce the patient\u2019s risk of a heart attack? If so, by how much \u2014 a lot? A little?", "answer": 0}, {"article": "The way it works: A doctor draws a vial of your blood and separates it into its key components, the red blood cells, the clear serum and the platelets. The physician then adds vitamins and amino acids to the mix, and the enriched serum is injected into your face.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "None provided. Just the lone doctor\u2019s claims that it \"stimulates DNA repair, heals scars and revitalizes wizened skin.\" ", "answer": 0}, {"article": "\"Now they tell me, 'You never say 'What?'\nOften, it meant only being able to do one thing at a time, explained the mother of three young children.\nThe implant is permanent.\nSince her teens, Lesa Merlo, of Hinsdale, had learned to compensate as her hearing declined.\nMerlo had Esteem implanted in her left ear in September.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits detailed in the story are only anecdotal \u2013 from a single patient and one implant surgeon. No quantitative data or scientific evidence are given to support the patient\u2019s claims. Is her experience typical? Out of the 40 patients who received Esteem implants in the Chicago area, did all of them have similar outcomes? And what about nationwide? How was hearing improvement for all of these patients measured?\u00a0We are not told of the clinical trial that was used to obtain FDA approval (easily available at http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/EarNoseandThroatDevicesPanel/ucm146740.htm).", "answer": 0}, {"article": "The women were followed for an average of about 3.5 years.\n\"These findings really emphasize how important it is for all women with a family history of early breast or ovarian cancer to undergo genetic testing,\" said Dr. Virginia Kaklamani, co-author of an editorial that accompanied the study.\nHowever, \"what our findings show is that women who choose to have these surgeries will reduce their risk of dying of breast or ovarian cancer by about 70 to 80 percent, which is pretty profound,\" said study senior author Dr. Timothy Rebbeck, a professor of epidemiology at the University of Pennsylvania School of Medicine.\nTUESDAY, Aug. 31, 2010 (HealthDay News) -- Women who carry genetic mutations that boost their odds of breast and ovarian cancer can live longer and reduce their cancer risk by having preventive surgery, a new study suggests.\nKaklamani added that she hoped the findings would encourage more women to ask their primary care physicians whether they are candidates for genetic counseling.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nThis story presents a generally positive portrayal of the benefits of preventive surgery. Coupled with the absence of information about harms, the overall impression might be considered out of balance. But the story does not give the impression that surgery eliminates the risk of cancer and it includes cautionary comments, for instance referring to the \u201cvery complex set of considerations\u201d facing women who are considered to have a high cancer risk based on genetic test results. The story also includes some of the absolute percentages of women who developed cancer. In sum, then the overall balance seems reasonable.\n", "answer": 1}, {"article": "In Belgium, engineer and nuclear physicist Yves Jongen is pioneering a new therapy that targets cancers with proton radiation; a therapy that offers precision and minimal side effects.\n\"If you look at leukemia, which is cancer of the blood cells, there is nowhere to shoot -- it's all through the body.\"\n\"It would be much less expensive making it more possible for a hospital to afford it -- a smaller system can already treat a relatively large number of patients per year.\"\nWhile proton therapy is a giant step forward, it's not yet the magic bullet that clinicians are looking for.\n\"That's the great thing about proton therapy.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "These statements from an entrepreneur clearly do not constitute documentation of benefit:\n\u201cwhere patients receive a powerful dose of targeted radiation that kills only those cancerous cells\u2026.\u201d \u201ca therapy that offers precision and minimal side effects.\u201d \u201cIt does a lot less collateral damage to the patient \u2013 that\u2019s the great thing about proton therapy\u201d \u201cI have a number of letters from parents of young kids saying if it had not been for this treatment we would have lost our kid,\u201d he said. \u201cThat\u2019s something I really cherish. When I feel a bit depressed, for whatever reason, I go back to those letters and they are very exciting.\u201d", "answer": 0}, {"article": "Other researchers contributing to this study include: Robert L. Coleman, M.D., Alpa M. Nick, M.D., Pedro T. Ramirez, M.D., Lois M. Ramondetta, M.D., Diana Urbauer, Jack L. Watkins, all from MD Anderson; Susan K. Lutgendorf, Ph.D. from University of Iowa; Sanjeev Kumar, M.B., B.S.\n\"The stratification of patients by beta-blocker use and selectivity in this study makes it unique among all other studies examining the impact of these drugs on cancer.\nThe research team found:\n\u2022 For patients receiving any beta-blocker, the median overall survival was 47.8 months versus 42 months for nonusers.\nFurther examination revealed that NSBB users had improved overall survival regardless of the presence of such prognostic factors or comorbidities.\nThis study builds on a large body of research by principal investigator Anil Sood, M.D., professor in Gynecologic Medical Oncology and Cancer Biology at MD Anderson.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release provides an understandable summary of the benefits seen in this retrospective review.\u00a0 \u201cThe release reports that EOC patients nonselective beta antagonists (NSBBs \u2014 a type of beta blocker) had a median overall survival of of 94.9 months. That\u2019s compared to 42 months for EOC patients who did not take beta blockers, and 38 months for those receiving beta-1-adrenergic receptor selective agents (SBBs \u2014 another type of beta blocker).\u201d\u00a0 But we think a few words about a couple of important provisos which we comment on under Quality of evidence should have been included.", "answer": 1}, {"article": "Dr. PK Shah, cardiologist at the Cedars-Sinai Heart Institute, said that he\u2019s encouraged by DEFINE but that some of the details give him pause.\n\u201cIt appears to be safe and to not raise blood pressure,\u201d Shah told CNN, \u201cbut it\u2019s not a slam-dunk.\u201d For one thing, despite improved cholesterol levels, patients did not see less inflammation in their blood vessels.\nIf the same benefit were seen in all patients at risk of heart disease \u2013 far from a sure thing \u2013 it would translate to hundreds of thousands of fewer deaths and heart attacks over a five-year period, according to Dr. Christopher Cannon, the lead study author and a cardiologist at Brigham and Women\u2019s Hospital in Boston.\nPeople who can\u2019t control cholesterol with diet, exercise and statin drugs could soon have a new option.\nBy then, results will also be in on a large study of a similar drug, dalcetrapib, made by Merck\u2019s competitor, Roche.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story does include several comments that further testing is needed before researchers will be able to say whether or not anacetrapib can save lives or reduce the risk of heart disease. However, it appears to ignore all the cautionary statements when talking about the \u201cbenefits\u201d shown in this specific trial. It reports the changes in cholesterol levels seen in this trial and then continues with a comment about the potential life-saving effect \u201cif the same benefit\u201d were seen in all patients at risk of heart disease.\nThe problem is that this new class of drugs alters cholesterol levels using a different biological mechanism than statins. While it is understandable to hope that the changes in cholesterol will predict changes in disease risk, the way they sometimes can for certain patients taking statins, that fundamental question has yet to be tested\u2026 and it certainly was not asked in this trial.\nAs mentioned above, despite the cautionary statements from independent experts, the thrust of this story assumes that changing cholesterol numbers means changing lives. Not only is that link yet to be proven for this class of drugs, but journalists have an obligation to remind people that the simple marketing messages used to promote cholesterol-lowering statins obscure a far more complex reality. ", "answer": 0}, {"article": "Fish-oil supplements don't appear to help pregnant women prevent post-partum depression or boost the baby's brain development as previously believed, according to a large trial published Tuesday in the Journal of the American Medical Association.\n\nThe 2,400-woman, randomized study complicates the advice for pregnant women. It adds to a body of mixed research on some potential benefits of the popular omega-3 fatty acid known as DHA, or docosahexaenoic acid. DHA, which can move from the mother to the baby during pregnancy, accumulates...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Overall, we would have wished for more specificity on the data that was reported.\u00a0 There were glimpses of specifity, as when the story reported:\u00a0\"The latest study does suggest that some subgroups of women might benefit from fish-oil supplements. For instance, those with a history of clinical depression\u2014and thus are at higher risk of post-partum depression\u2014who took 800 milligrams of fish oil daily lowered their risk of getting depressed after the birth by about 4% compared with those who didn\u2019t take fish oil. However, the difference wasn\u2019t statistically significant because of the small number of women in the study who had been previously depressed, said Dr. Makrides, who is also a professor of human nutrition at the University of Adelaide.\"\nBut we were disappointed that the story didn\u2019t disclose how much preterm birth risk was reduced \u2013 an issue of vital concern to many readers. A preemie and an induction (covered as a harm but also without any numbers provided) aren\u2019t necessarily equal.\u00a0\u00a0 \nOn balance, we just didn\u2019t get enough data on benefits. ", "answer": 0}, {"article": "Differences in mean changes in swallowing at radiotherapy week 4 (\u221215 in the CRT group and \u221225 in the radiotherapy alone group, P = .02), loss of appetite at radiotherapy week 4 (\u221211 in the CRT group and \u221218 in the radiotherapy alone group, P = .03), nausea at week 8 after radiotherapy (\u22127.3 in the CRT group and 0.3 in the radiotherapy alone group, P = .04), coughing at radiotherapy week 4 (7.4 in the CRT group and \u22125.6 in the radiotherapy alone group, P = .02) and at week 8 after radiotherapy (\u22123.2 in the CRT group and 1.1 in the radiotherapy alone group, P = .04), constipation at month 8 (2.6 in the CRT group and \u221219 in the radiotherapy alone group, P < .001), and cognitive functioning at month 12 (\u22127.0 in the CRT group and 4.6 in the radiotherapy alone group, P = .04) were not seen at the other time points.\nThe use of concomitant cisplatin and radiotherapy resulted in a statistically significant improvement in laryngeal preservation compared with radiotherapy alone, with a hazard ratio of 0.46.\nOne of the largest randomized clinical trials was designed to evaluate laryngeal preservation compared with radiotherapy alone, concomitant chemoradiotherapy, and induction chemotherapy followed by radiotherapy.13,14 Each treatment group included at least 180 patients, thus providing much greater statistical power than the current communication.\nThe 2.2% and 11.1% absolute improvements in the rates of laryngeal preservation, at 2 and 3 years, respectively, favored CRT compared with radiotherapy alone (Figure 2).\nA pharmacologic profile was also performed weekly on patients receiving cetuximab infusion (CRT group).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release addresses three benefits, and provides numbers for all three. That\u2019s good. However, the release doesn\u2019t tell readers that these numbers, given the size and nature of the study, are not statistically significant. There appears to be no advantage in taking a drug that is both costly and can cause significant adverse side effects.", "answer": 0}, {"article": "One week after surgery I was off the crutches, walking on my own,\" Wallace said.\nThe best candidates for the procedure are patients who still have some cartilage protecting their joint, but have somehow \"overloaded\" and injured the bone, causing swelling and pain, Hepinstall said.\nIt is much less invasive than a knee or hip replacement, and typically is performed on an outpatient basis, Vasileff said.\nThose with full-blown bone-on-bone arthritis or joint pain caused by damage to the cartilage and ligaments will get little to no relief from the procedure, Vasileff said.\nThe procedure involves a smaller incision than joint replacement surgery, so there's less risk of infection, and a quicker recovery time that means fewer of the side effects associated with being bedridden, Vasileff said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Beyond serving as a \u201cless invasive,\u201d outpatient alternative to joint replacement surgery, there was no discussion about how to quantify these benefits.", "answer": 0}, {"article": "Common symptoms are abdominal pain and diarrhea, and it can lead to bowel perforations.\nHe said a 100-point drop in the CDAI was clinically meaningful to patients.\nThe rate of infections and other serious side effects was similar in the Stelara and placebo groups, researchers said.\nThe intravenous biotech drug met the primary goal of the study as almost 40 percent of patients who received the 6 milligrams per kilogram of weight dose of Stelara achieved a clinical response \u2014 defined as a 100-point reduction in the Crohn\u2019s Disease Activity Index (CDAI) \u2014 after six weeks of treatment.\n\u201cIt\u2019s effective in the patient population that has the greatest unmet need at this point in time,\u201d Sandborn said of patients who do not respond to anti-TNF drugs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The study presented lots of numbers and defined the scales. We appreciated the Crohn\u2019s Disease Activity Index (CDAI) thresholds for clinical response and remission, the subjects\u2019 baseline CDAI scores, and the explanation of what a 100-point drop feels like to patients. Bravo for including these points and for mentioning that the study met its \u2018primary goal.\u2019 Great facts for readers to consider that are often left out of news coverage.", "answer": 1}, {"article": "...\nMaryam Farvid, a fellow at the Harvard School of Public Health who is lead author of the study, says the influence of fiber on cancer risk may be time-sensitive.\nIn a commentary accompanying the study in Pediatrics, Blackwell writes, \"There is longstanding evidence that dietary fibers may reduce circulating estrogen levels.\"\nOne limitation of this new study is that it relies on data from women who had to recall what they ate during high school.\nMost Americans don't get the 25 to 38 grams a day that's recommended, depending on age and gender.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We recognize that it would be challenging for any journalist covering this story to report on the absolute risks seen in the study. The study does not report absolute risks, although it\u2019s possible to calculate them based on the data provided. One could look at the\u00a0number of cases in each quintile of dietary fiber (found in Table 2) and divide that by the number of people in each quintile (which is found in Table 1). There are several steps involved, but for the example of early adulthood dietary fiber and breast cancer risk in this cohort, you could do the following calculation:\n\u2013 613 cases in quintile 1 / 18,364 women in quintile 1 = 3.3% later developed breast cancer (pre or post menopause).\n\u2013 567 cases in quintile 5/ 18,167 women in quintile 5 = 3.1% later developed breast cancer (pre or post menopause).\n\u2013 The difference is 0.2 percentage point, which is quite a small absolute risk reduction.\nWhen such results aren\u2019t reported in a study, we think journalists should press their sources to provide these numbers so that they can be disseminated to the public. The issue of absolute risk reduction is key to helping readers understand the impact of changing dietary behaviors. We think it\u2019s important enough to rate any story Not Satisfactory when these numbers aren\u2019t provided.", "answer": 0}, {"article": "Evolve recently completed a $40M Series C round of funding co-led by the Bill & Melinda Gates Foundation and Horizons Ventures, the venture division of the Li Ka Shing Foundation.\nIn a landmark clinical trial, Evivo produced rapid, substantial and persistent stabilization of the infant gut microbiome, to help set a foundation for life-long health.\nEvolve BioSystems' Evivo is the only baby probiotic clinically proven to restore Bifidobacterium to a baby's gut and reduce potentially harmful bacteria by 80 percent.\nEvivo's quick and non-invasive test measures the presence of markers that indicate low or high levels of good Bifidobacterium , such as acetate and lactate.\n\"The ability to quickly measure levels of Bifidobacterium in a stool sample would enable pediatricians to identify babies with low levels of these beneficial bacteria and take appropriate action.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Testing a baby\u2019s stool for Bifidobacterium is presumably beneficial, according to the release, because not having low levels may allow \u201cfor potentially harmful bacteria such as E. Coli and Clostridia to thrive, which are linked to higher risk of short- and long-term health issues such as colic, eczema, allergies, diabetes, and obesity.\u201d Likewise, the release implies taking the Evivo probiotic product can \u201creduce potentially harmful bacteria by 80 percent.\u201d\nBut these statements and figures are inadequate. There is not yet definitive, causal evidence that Bifidobacterium can prevent\u00a0\u201charmful\u201d bacteria from overtaking the gut and causing health problems. Both studies intimate as much by highlighting the findings are correlations, and that long-term longitudinal studies are required.\nIt\u2019s misleading to claim a benefit from testing when there is no causal link to harm in people.", "answer": 0}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the article does an estimable job of describing the benefit of bystander CPR \u00a0on a select few very lucky survivors, it doesn\u2019t talk about the rates of success of various types of CPR or alternatives such as the solo or combined use of AEDs now available in many public spaces. The story says that survival rates \u201cmore than double\u201d with the use of bystander CPR, but there\u2019s no context provided with that statistic. What is the rate without CPR and what does it \u201cdouble\u201d to? The benefits are described primarily in emotional terms; we wanted to see that emotion supplemented with facts.", "answer": 0}, {"article": "Elective Caesarean-section deliveries can increase problems for a newborn if done too early -- even when the baby has technically reached full term, according to a large new study.\n\nThe findings could help diminish a widely popular practice -- now about one in every 14 births -- in which mothers choose to schedule c-sections, or surgical removal of the baby. The study, published in the New England Journal of Medicine, found that about a third of elective c-sections are done too early -- before 39 weeks. Although a fetus is considered...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The reporter does a diligent job of quantifying the results, using both relative risks and percentage of bad outcomes in the studied population. \nThe story usefully distinguishes among results for c-sections done at 37, 38 and 39 weeks.\n\u00a0", "answer": 1}, {"article": "For more on medical marijuana, visit the U.S. National Institute on Drug Abuse.\nThe study found that after a year, the treatment resulted in a 50 percent reduction in seizures for 10 participants -- about 40 percent of the group.\nIf CBD proves effective in controlled trials, it could be two to five years before the drug is approved by the U.S. Food and Drug Administration, Devinsky noted.\nBut experts say these positive findings may have been influenced by a \"placebo effect.\"\nBut, researchers believe it may interact with a brain receptor that plays a role in the development of seizures, Devinsky said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is fairly specific about the fates of two groups of individuals\u2014mostly children\u2014with epileptic seizures resistant to\u00a0available medications. But since it uses only relative risk reduction figures to quantify the benefit, it doesn\u2019t go far enough to satisfy this criterion. The story says, for example, that \u201cseizure frequency declined by an average 45 percent in all participants.\u201d Did they go from two seizures to one seizure per day or from 10 to 5? Providing the absolute numbers would have clarified the size of the benefit.", "answer": 0}, {"article": "Referring to Lozano's second clinical study, Dr. Nader Pouratian, a neurosurgeon and DBS researcher at UCLA, comments, \"The recent deep brain stimulation trial for Alzheimer's disease clearly demonstrates the safety of this approach for trying to treat the progression of disease.\nGiven that so few people have had electrical stimulation applied to memory circuits, perhaps the most significant finding was that both the surgery itself and DBS of the fornix appear safe.\nThe technique is also approved for obsessive-compulsive disorder and is being looked at for a number of other brain disorders, including depression, chronic pain and, as in Lozano's work, dementia.\nYet the fact that the therapy can in some people rescue recollections \u2013 albeit random ones \u2013 and possibly induce new neuron growth in memory regions of the brain seems reason enough to pursue it further.\nUsing a 3-dimensional brain mapping technique called standardized low-resolution brain electromagnetic tomography, or sLORETA, Lozano's group uncovered an explanation for the unexpected findings.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It\u2019s unclear what if any benefit DBS might offer for Alzheimer\u2019s patients, a point that could have been made more explicitly. There were no quantified benefits included, instead the story states that results for the phase 2 study were \u201cmixed but encouraging.\u201d It does not explain that the trial was aimed at determining only the 90-day postoperative safety of the procedure, not its efficacy, and that it included only patients with mild Alzheimer\u2019s. It further states that after one year there \u201cwere no significant differences in cognition\u201d between the treatment groups, but differences \u201cmay take time to become noticeable\u201d because the disease progresses slowly.\nWhile some researchers hope DBS might be able to slow progress of the disease, the story suggests it might actually reverse memory loss. It likens DBS to \u201cretrieving memories by hot-wiring the brain\u201d and leads with an anecdote about a 63-year-old women with Alzheimer\u2019s who retrieved a latent childhood memory as a result of deep brain stimulation, though apparently under a \u201clofty voltage\u201d only safely achievable in a hospital. The story states that a finding of increased glucose utilization in patients who have received brain stimulation \u201ccould mean there\u2019s a way to overcome some of the damage from Alzheimer\u2019s.\u201d Given there was no clinical correlation, it doesn\u2019t seem relevant, and we\u2019re not sure why it was included as a sign of benefit.", "answer": 0}, {"article": "Accumulations of neurotoxic beta-amyloid protein can be detected with positron emission tomography, or PET scans, and analysis of cerebrospinal fluid, but these are invasive, inconvenient and costly, making them impractical for routine screening and follow-up evaluation.\nWith the imaging technology's ability to detect autofluorescence signal related to retinal beta-amyloid, these findings may lead to a practical approach for large-scale identification of the at-risk population and monitoring of Alzheimer's, the researchers say.\nThis clinical trial is reinforced by an in-depth exploration of the accumulation of beta-amyloid in the retina of Alzheimer's patients versus matched controls, and a comparison analysis between retina and brain pathologies.\n\"In 2010, our research group published an article providing the first evidence for the existence of Alzheimer's-specific plaques in the human retina, and we demonstrated the ability to detect individual plaques in live mouse models using a modified ophthalmic device.\"\nThe study's first author, Yosef Koronyo, a research associate at Cedars-Sinai and a scientist and inventor at NeuroVision, said the latest findings cap a decade of study that has produced several landmark discoveries.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In a news release of more than 1,000 words, we would expect some data to back things up. Instead, this release offers just two numbers by way of quantification, and both of them are couched in relative terms that, to any reader other than the authors of the study, may be meaningless. The release says:\n\u201cAmong key findings, the researchers report a 4.7-fold increase in retinal plaque burden in patients with Alzheimer\u2019s, compared to controls, and they provide observations regarding geometric distribution and layer location of amyloid pathology in the retina. \u2026 The demonstration of a fully automated calculation quantifying retinal autofluorescence that showed a 2.1-fold increase in patients with Alzheimer\u2019s, compared with controls.\u201d\nIn a study that compared the brains of 23 deceased people with Alzheimer\u2019s to 13 people without, what do these numbers mean?\nBecause the research is very preliminary, and given there is no treatment for Alzheimer\u2019s pathology and most people with dementia who are in their 80s have multiple cognitive issues, it\u2019s difficult to see how identifying amyloid \u2014 or even multiple types of pathology \u2014 is going to benefit patients.", "answer": 0}, {"article": "Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases.\n\nThe Food and Drug Administration's approval of Halaven in November for treating late-stage breast cancer was a triumph of chemistry and tenacious research. Its path, extending nearly three decades from the first studies, demonstrates not only potential...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "The hope is that our positive surgical experience will help pave the way for future research into DBS and Alzheimer's,\" says Dr. Ponce.\nThe ADvance Trial, using a device from Functional Neuromodulation, Inc., is aimed at evaluating the safety, efficacy and tolerability of DBS in this patient population.\nResults from the Phase 2 study, reported in the Journal of Neurosurgery on Dec. 18, 2015, demonstrated the safety of DBS in Alzheimer's patients.\nWhile the study was relatively small, we believe the data suggest that DBS surgery targeting the fornix can be performed safely in this patient population.\nDuring the trial, 42 patients with mild Alzheimer's disease underwent the surgical procedure and were closely monitored for adverse effects.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This release summarizes a stage 2 trial looking primarily at safety following the first 90 days of the trial. It did not report on whether or not the device implantation improved cognition or slowed or halted decline. The news release says Dr. Ponce will report on potential efficacy after the last patient finishes two years of the study. The release was appropriately mum on this point and didn\u2019t make predictions/guesses based on incomplete and preliminary data.", "answer": 2}, {"article": "What to do?\nHowever, the study also found that those risk factors -- a small body frame, a history of fractures, or taking medications that could thin bones -- had only a slight effect on a woman's decision to get her bones tested.\nOver seven years, more than 42 percent of eligible women aged 65 to 74 were not screened, Amarath's team found, nor were nearly 57 percent of those older than 75.\n\"DXA screening was underused in women at increased fracture risk, including women aged 65 years and older.\nMONDAY, May 25, 2015 (HealthDay News) -- Too few women at high risk for osteoporosis are being tested for the bone-depleting condition, while too many women at low-risk are being screened, a new study suggests.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that the US Preventive Services Task Force recommends the screening test for women without other risk factors beginning at age 65. And it provides some statistics to document the possible overuse of scanning in younger women and underuse in older women. That\u2019s all good reporting. But what\u2019s missing is why the reader should care about these numbers. The story does not say that drugs are available that can reduce the risk of fracture among those at high risk. It wouldn\u2019t have take much space or many words to deliver that important context.\nWe\u2019re also a little concerned about how some of the findings are framed by the story\u2013 for example, the fact that certain risk factors \u201chad only a slight effect on a woman\u2019s decision to get her bones tested.\u201d \u00a0That sounds a little bit like the women are being blamed for the inappropriate testing found in this study. While it is probably true that patient demand drives some inappropriate bone density testing in younger women, the majority of screening decisions are likely to be made by the physician, not the woman.", "answer": 0}, {"article": "Cytoxicity refers to being toxic to cells in the body.\nThe urumin peptide could be a novel treatment since it targets the hemagglutinin, unlike current drugs on the market which target other parts of the virus, resulting in less impact, Jacob said.\nGregory Chinchar, a professor in the University of Mississippi Medical Center's department of microbiology and immunology, said that he was surprised that the peptide targeted the hemagglutinin on the flu virus.\nFerrets are next, then possibly humans\n\nA challenge to possibly using frog mucus as a flu-fighting treatment in humans is figuring out how to get the urumin peptide to attach to flu virus cells in the human body, Jacob said.\n\"In this paper we screened 32 peptides, and the surprise was that four out of 32 had activity against the virus,\" Jacob said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was a tough call. The story reports that the peptide killed all of the H1 versions of the influenza A virus that it encountered in laboratory settings. And the text\u00a0sends up a cautionary flag early in the story that the peptide has not yet been tested in human beings. In fact, the next step appears to be testing in ferrets.\nBut, it doesn\u2019t really say\u00a0much about the mice research. How did they determine that it worked? Did it clear infections? We were somewhat unclear on that aspect of the story.\nAgain, though, because the story didn\u2019t oversell the findings, we\u2019re leaning toward Satisfactory.", "answer": 1}, {"article": "Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment.\nThe article, entitled \u201cHealthy Dietary Patterns, Mortality and End-Stage Kidney Disease in CKD: A Meta-Analysis of Cohort Studies,\u201d will appear online at http://cjasn.asnjournals.org/ on December 8, 2016, doi: 10.2215/CJN.\nThe findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).\nHighlight\n\u2022 A healthy diet high in fruits, vegetables, fish, legumes, cereals, whole grains, and fiber, and low in red meat, salt, and refined sugars was linked with a reduced risk of early death in an analysis of 7 studies.\nAll content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does provide some numbers around the benefits, but they are mostly in relative terms, not allowing reporters or other readers to assess how many people really ended up benefiting from the healthy diets. It says, for example,\u00a0\u201cIn 6 studies, healthy dietary patterns were consistently associated with a 20% to 30% lower rate of mortality, with 46 fewer deaths per 1000 people over 5 years.\u201d It\u2019s hard to understand from this sentence what this means. If it is a range from 20% to 30% lower mortality rates, does this mean that \u201c46 fewer deaths per 1,000 people\u201d is the average reduction in mortality? And this is 46 fewer deaths than what? Than 100? Than 900? Precision would have helped here.", "answer": 1}, {"article": "Furthermore, a study from the University of Rochester, published in March in Environmental Health Perspectives, found that men with shorter anogenital spans had lower sperm counts, poorer quality sperm, lower sperm concentrations and lower motility.\n\"Together the two studies make a strong case that this simple measure (the anogenital distance) reflects early genital development and predicts semen quality and fertility,\" she said.\nBut one urologist said the the finding is too preliminary to introduce into clinical practice, however.\n\"This paper also provides new data on infertile men, who have shorter (less masculine) anogenital distance.\"\nSwan said that she and her colleagues published similar findings last month.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are not addressed \u2013 and this ties in to our comments in the \u201charms\u201d criterion above.\u00a0 You don\u2019t test unless you know what good it will do.\u00a0 And the story is silent on that potential benefit. It just raises the picture of more testing without any discussion of benefit.", "answer": 0}, {"article": "McCabe, medical director for the March of Dimes.\nThe Norwegian study is the largest to date on the benefits of folic acid for autism prevention, and marks one of the first tangible things a woman can do to reduce her risk of giving birth to a child with the disorder.\nTaking folic acid before pregnancy, and through the first several weeks of pregnancy, may help reduce the risk of autism for those children, according to a new study published Tuesday in the Journal of the American Medical Association (JAMA).\n\"It is possible that folic acid ... might provide protection against other neurodevelopmental disorders like autism,\" said Zachary Warren, director of the Treatment and Research Institute for Autism Spectrum Disorders at Vanderbilt University, who was also not involved in the study.\nDespite the fact that a link between taking folic acid and reducing autism risk isn't fully proven, Halladay says there's no harm in taking the supplement, and women should be taking it anyway to prevent birth defects.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says women who took folic acid \u201cwere 39% less likely to have children with autism.\u201d This is inadequate, because it doesn\u2019t reflect just how rare a diagnosis of autism was in this study. (Only 114 children out of about 85,000 received that diagnosis.) The findings in absolute terms would have been more informative, as they show that autism was diagnosed in\u00a00.10% of children whose mothers took folic acid compared with\u00a00.21% of children whose mothers didn\u2019t.", "answer": 0}, {"article": "An infarct, a kind of stroke, happens when the passage of blood is slowed or completely blocked by clotting.\nIt is possible that the diet protects the brain vessels themselves, irrespective of other problems such as high blood pressure, Scarmeas said.\nThe next step would be to have controlled experiments concerning food and dementia in which participants are randomly assigned to follow a diet, Cole said.\nThe bottom line for dementia is that fish oil may help in the very early stages, but more research must be done to confirm this, he said.\nThe study relates diet to strokes, said Dr. Nikolaos Scarmeas, a neurologist at Columbia University Medical Center and lead author of the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story specified that those following a Mediterranean diet were \u201836% less likely to have areas of brain damage\u2019. \u00a0This is an inadequate presentation of information because the reader has no sense of how common the thing prevented might be (36% of what?) and also how well this measurement of brain damage correlates with a clinical parameter of concern to real people. There can be a difference between being able to find something and whether that something has significance in people\u2019s lives. ", "answer": 0}, {"article": "\u201cWe\u2019ll also advance key parts of our tobacco plan very soon,\u201d he said.\nThe move was part of a comprehensive plan the agency announced last summer to regulate tobacco and nicotine, FDA Commissioner Scott Gottlieb said on a call with reporters.\nThe FDA is seeking additional research and data for public review, Gottlieb said, as it tries to develop a nicotine product standard.\nThe FDA will seek public input and scientific research on the role that flavors such as menthol play in tobacco addiction, and for the regulation of premium cigars, Gottlieb said.\nThe comment period will be open through mid-June, said Mitch Zeller, director of FDA\u2019s Center for Tobacco Products.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story informed readers that the FDA\u2019s own analysis predicts \u201cwould help 5 million smokers quit within a year and prevent more than 33 million teens and young adults from becoming regular smokers\u00a0by the year 2100.\u201d We think more could have said about the data this was based, but we address that below, in evidence quality.", "answer": 1}, {"article": "D.C.I.S.\nMore important, the difference between the numbers of side effects was not statistically significant, meaning that it could have occurred by chance and that the drugs could be similar or even the same.\nBut Dr. Leslie Ford, an associate director for clinical research at the cancer institute, said that the differences could not be ignored because they came so near to being significant.\nBased on those findings, it is easy to see why raloxifene was declared the winner.\nOn average, the participants actually had more than twice that risk, around 4 percent, meaning that 40 of 1,000 would be affected.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a very good job of quantifying the benefits of raloxifene compared to tamoxifen. Not only did the story provide absolute numbers in quantifying the benefit, but it also explained why presenting only relative risk reductions can be deceiving.", "answer": 1}, {"article": "As measured by an electroencephalogram (EEG), small children's brains show a specific pattern of activity when they look at a picture of a human face.\nJust the reverse happens in children with autism.\n\"The children that received the interventions normal in their communities continued to show the reversed pattern.\"\nNormal child development depends on interactions with parents and other people.\nWithout such interactions, language and social skills do not develop.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes a bold claim in the lead: \u201cEarly, intensive autism treatment improves children\u2019s brain development, a new study shows.\u201d It does not go on to quantify the benefits found in the study. How many of the kids showed brain improvement? And how was that improvement measured? The story provided only the qualitative description\u00a0\u201cThe [brains of] children who received the ESDM looked virtually identical to typical 4-year-olds,\u201d Dawson says. \u201cThe children that received the interventions normal in their communities continued to show the reversed pattern.\u201d\nIn addition, we don\u2019t know the clinical significance of a change in EEG.", "answer": 0}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story uses numbers (447 cognitively healthy participants divided among three groups) to describe the participants but doesn\u2019t quantify the findings related to the Mediterranean diet with similar precision. Instead it provides this summary: \u201cThe results showed that, compared with the control group, memory function remained stronger in the Mediterranean diet plus nuts group, while frontal (attention and executive function) and global cognition benefited in the Mediterranean diet plus olive oil group.\u201d\nHow much stronger? How did the investigators reach that conclusion?\nNumbers are always welcome. And yet in this case, we\u2019re not sure how much it would\u2019ve added for readers to know the change in \u201ccognitive composite Z scores\u201d that were reported in the study. These certainly could\u2019ve been explained and quantified, but we think it was acceptable for the story to turn to a\u00a0Mayo Clinic neuropsychologist for interpretation instead. That expert tells us, \u201cThe changes observed in cognition were very small and didn\u2019t actually show that those diets improved cognition, they just showed less decline.\u201d We\u2019ll call that good enough for a Satisfactory rating.", "answer": 1}, {"article": "CT scans expose patients to radiation, for example, which can increase the likelihood of developing cancer.\nUsing national data, the researchers found the rate of so-called pulmonary embolisms, or PEs, nearly doubled with the introduction of a new powerful diagnostic test more than a decade ago.\n\u201cRather than an epidemic of disease, we think the increased incidence of PE reflects an epidemic of diagnostic testing that has created overdiagnosis,\u201d the researchers write in the Archives of Internal Medicine.\nThe new findings add to other evidence showing that medical testing is on the rise across the U.S., although in many cases the impact on overall health remains unclear.\nYet there was only a slight drop in deaths from the condition over the same period, suggesting many of the clots were too small to cause harm.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story succinctly summarized:", "answer": 1}, {"article": "During transcranial magnetic stimulation (TMS), a doctor places a large magnetic coil against the patient\u2019s scalp, which creates electric currents to stimulate nerve cells.\nThere were no improvements seen in test scores of those who got the other treatment.\nThe overactive brain circuits also improved among people who got the TMS treatment, the study showed.\nTen out of 20 people who faced this problem following a stroke received the magnet therapy daily for two weeks.\nThis is often not enough to make a meaningful improvement.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us that patients receiving TMS improved \u201c16.3% immediately following treatment and by 22.6% two weeks later.\u201d Fair enough. But it didn\u2019t tell us whether that type of improvement represents a meaningful change in patients\u2019 ability to function and care for themselves. Reuters, by contrast, cautioned that \u201cit\u2019s not clear what the amount of improvement they observed would mean for patients in their daily lives.\u201d\nWe were also confused by this story\u2019s use of the\u00a0word \u201cneglect\u201d without defining what the term means clinically. Better to leave it out entirely or give a complete explanation of the meaning, as Reuters did. ", "answer": 0}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are quantified in relative terms only. The reader is told that raloxifene and tamoxifen both reduce the incidence of breast cancer by 50%, however there is no context provided for these numbers. Viewers would want to know 50% of what? They would want to know the absolute risk reduction. Viewers should have been told that even though the women in the study were high risk, the incidence of breast cancer over 5 years was still very low. The story also does not mention that raloxifene does not reduce the incidence of ductal carcinoma in situ (DCIS, which tamoxifen does), so it is not clear that when the story says the benefits are equivalent between the two drugs, if it will hold true if they include all breast cancer events (including DCIS, which is being found much more commonly now).The story also omits an important fact: the decrease in incidence of uterine cancer and clots associated with raloxifene was not statistically significant.", "answer": 0}, {"article": "Outside of heart attacks, doctors are often too quick to use a common $20,000 procedure to treat patients suffering from coronary artery disease, a new study suggests.\n\nAbout 600,000 angioplasty procedures, which almost always involve placement of a tiny metal tube called a stent, are done in the U.S. each year. Roughly 70% of these procedures are performed on patients suffering symptoms of a heart attack and aren't medically controversial. But the remainder are done on stable patients who are suffering mild symptoms or no symptoms...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Let\u2019s look at appropriate use as the \u201cbenefit\u201d here \u2013 and, yes, the story quantified this \u2013 and the inappropriate use.", "answer": 1}, {"article": "\"Our finding is so exciting because there is already an approved drug against RANKL called \u201eDenosumab\u201d.\nScientists at the University of Maryland School of Medicine in Baltimore have already tried the preventive use of a RANKL blocking drug in mice.\nMoreover, the scientists \u2013 together with colleagues in Barcelona and from the CIMBA* consortium mapping more than 23,000 women \u2013 showed that genetic variants in the RANK gene are associated with a higher risk of developing breast cancer in women who carry BRCA1 and also BRCA2 mutations.\nThe second group received RANKL blockade treatment for prevention with the result that virtually no malignant changes in breast tissue could be observed even over a longer period of observation.\nIf the uncovered mechanism indeed works in the prevention of breast cancer in high risk patients, this could possibly be used to prevent breast cancer in general.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the release states that the cell cultures receiving the RANKL blockade treatment had \u201csignificant reduction of growth and spreading of breast tissue cells\u201d and \u201cvirtually no malignant changes in breast tissue\u201d compared to those in the control group that developed multiple early breast cancer lesions. But no hard numbers or percentages are provided to quantify what a \u201csignificant reduction\u201d is or what \u201cvirtually\u201d means in this case.\nWe also want to underscore that the results were only seen in cell cultures and in mice, not in humans.", "answer": 0}, {"article": "An experimental spray improved sex for some men who regularly experience premature ejaculation, according to the results of two studies set to be presented Tuesday at a urology conference.\n\nMen who applied the aerosol spray, a mixture of the anesthetics lidocaine and prilocaine, reached orgasm a mean of 3 minutes 18 seconds after beginning sex, compared with about 56 seconds for those who got a placebo spray. The 539 men completing the two studies, who were randomly assigned to the real drug or the fake version, had an average...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It presents the benefits in both relative and absolute terms in the second paragraph of the story. It would be nice to have a NNT or number needed to treat in here. It also would be nice to see the range of performance after using the drug. Did some of the men on placebo have gains in ejaculation time that were unusually high? Did some on the drug have no gain or even a loss of time? It\u2019s also not clear how the researchers knew what the \"no drug\" ejaculation time was, how they were chosen for the research or whether they fell into a particular age bracket. The story did a \"satisfactory\" job quantifying the benefits, not a perfect job. And in an imperfect world of health stories, this part of the story was actually above average.", "answer": 1}, {"article": ".\nMagnetic stimulation is aimed at patients with such \u201ctreatment-resistant depression.\u201d\n\nSupporters say rTMS is worth the cost \u2014 between $6,000 and $12,000 for the four-to-six-week treatment \u2014 because it enables people such as Curtis to resume productive lives.\nThat 19-member panel voted 10 to 5 last year that studies of the treatment showed it to be as good as or better than usual care for depression.\nSupporters such as those at TMS NeuroHealth say they are seeing better results than that among their patients, who can continue taking antidepressants along with their treatment.\n\u201cThe initial treatment with rTMS is $12,000: That\u2019s a lot of generic Prozac or Effexor,\u201d which are cost-effective antidepressants with long track records, said Joel Rubinstein, associate medical director of Harvard Pilgrim HealthCare, an insurer that does not cover rTMS.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The use of statistics in this piece was generally appropriate, and we were pleased to see reference to the Number Needed to Treat \u2014 an intuitive measure of a treatment\u2019s real world effectiveness. If there\u2019s one area in which we think the story could have done a better job, it\u2019s explaining that the benefits reported with rTMS, though larger than those associated with a placebo/sham treatment, are small in absolute terms. This could have been accomplished with less optimistic framing of certain study results. For example, the story notes that \u201cup to 17 percent of patients\u201d were symptom free after treatment in one study \u2014 \u201cabout twice as many as those treated with a sham rTMS machine.\u201d The story could have qualified this by adding that the vast majority of even rTMS-treated patients (83%) were not symptom-free. In another study, rTMS was \u201cfour times as likely to get patients symptom-free as was a sham procedure,\u201d according to the story. But again, the absolute number of patients who benefited was very small \u2014 \u00a0\u00a014.1% for active rTMS vs. 5.1% for the sham group. The authors of that study concluded that \u201c\u2026the overall number of remitters and responders was less than one would like with a treatment that requires daily intervention for 3 weeks or more, even with a benign adverse effect profile.\u201d\nNote: the AHRQ review referenced in the story concludes that the evidence in insufficient to determine the effects of ECT vs rTMS but the limited evidence suggest no difference.", "answer": 1}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes note of quantitative results related to tumor shrinkage, as well as remission data\u00a0six months\u00a0after treatment. It\u00a0also pointed out\u00a0that median survival in the study is not known.\nThere is one anecdotal quote by a patient who was facing potential stem cell transplant, but opted for\u00a0CAR-T therapy, and went into complete remission and saw his tumors \u201cshrink like ice cubes.\u201d", "answer": 1}, {"article": "Deep brain stimulation involves implanting electrodes in the brain, then connecting them to a pulse generator placed under the skin of the chest.\nWhat's needed, said Fargo, is research that compares deep brain stimulation against a placebo device.\nInstead, he said, these findings suggest that deep brain stimulation is \"a reasonable route\" to study in larger clinical trials.\nBut it's far too early to know whether it has value for people with Alzheimer's, Scharre stressed.\nRight now, Scharre noted, medications for Alzheimer's target brain chemicals involved in memory.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This study wasn\u2019t designed to prove a benefit, although the story could have explained that more clearly. We\u2019re rating this Not Satisfactory because it confuses readers with a headline stating the device \u201cmight help slow Alzheimer\u2019s,\u201d while the story itself focuses on the clinical outcomes of the three patients in the study, citing \u201csignals\u201d that the device slowed two patients\u2019 decline, for example. The fact that two of the three patients declined at slower rate compared to 96 patients in a database doesn\u2019t say anything about whether the device is really effective. Even so, there\u2019s no specific data on how those patients\u2019 outcomes differed and what was measured.", "answer": 0}, {"article": "In a similar study published in the journal Pediatrics in 2004, researchers recruited 100 children with upper respiratory tract infections who had been coughing for an average of over three days.\nUltimately, the honey produced the greatest improvements when it came to better sleep and reduced cough frequency and severity.\nAlthough children in all three groups experienced a reduction in coughing, those who received the flavored water fared the best.\nThe children were given a cough syrup with dextromethorphan, a cough syrup containing an antihistamine, or a placebo, which was essentially flavored water.\nIn this occasional series, the New York Times \u201cReally?\u201d columnist, Anahad O\u2019Connor, explores the claims and the science behind alternative remedies that you may want to consider for your family medicine cabinet.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story could have provided some of the specific differences between the treatments. Our guess is that with a study on only 100 patients, the absolute differences were probably not that large. Putting some more numbers in the story would help parents see the results in better context.", "answer": 0}, {"article": "\"And in that case, I see this as just a waste of money.\"\nThis tissue, the authors noted, is known to play a role in communication between various brain regions.\nUsing MRI imaging, the team searched for differences in brain activity patterns in the microstructure of white matter tissue in 80 autism patients between the ages of 10 and 35.\nThe current effort, focused on patients already diagnosed with autism, used MRIs to locate areas of the brain where the left and right hemispheres do not communicate properly.\nThe study was limited to high-functioning males and so did not allow researchers to generalize the findings to females, younger children, or \"lower functioning\" individuals with autism, the researchers wrote.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are not quantified. The implication here is that these physical defecits are only found in patients with autism and are never found in patients with \"normal\" brains or with any other disorders. This, of course, is difficult to conclude based on a study of 80 patients.", "answer": 0}, {"article": "\u201cIt\u2019s a promising result from an interesting data set,\u201d he said.\nThe study, known as Active, examined the effects of cognitive training programs on 2,785 healthy older adults.\nEdwards did a secondary analysis of the 10-year data, looking at the time it took individuals to develop dementia.\nPeople who completed 11 or more speed training sessions were at 48 percent less risk for developing dementia over the 10 years of the study, Edwards said.\nShe found that the group that did speed training showed 33 percent less risk of dementia relative to the control group, while the memory and the reasoning interventions offered no such benefit.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "After an initial analysis revealed lukewarm associations between brain games and various cognitive functions, a secondary analysis was undertaken whose findings are reported in this article. Study participants were divided into three groups who received training for either memory improvement, reasoning, or\u00a0speed-of-processing.\u00a0The findings of the secondary analysis reveal that\n\u201cspeed training showed 33 percent less risk of dementia relative to the control group, while the memory and the reasoning interventions offered no such benefit.\u201d\nand that\n\u201cpeople who completed 11 or more speed training sessions were at 48 percent less risk for developing dementia over the 10 years of the study\u201d\nBut these are relative risk reductions, and the readers has no way to judge the magnitude of the benefit in absolute terms. A competing STAT story, by contrast, gave us the figures we were looking for:\n14 percent of ACTIVE participants who received no training had dementia 10 years later, said psychologist Jerri Edwards of the University of South Florida, who led the study. Among those who completed up to 10 60-to-75-minute sessions of computer-based training in speed-of-processing \u2014 basically, how quickly and accurately they can pay attention to, process, and remember brief images on a computer screen \u2014 12.1 percent developed dementia. Of those who completed all 10 initial training sessions plus four booster sessions a few years later, 8.2 percent developed dementia.", "answer": 0}, {"article": "A three-year-old Silicon Valley start-up, Counsyl Inc., won the Bronze Innovation Award for its simple, low-cost genetic test that can alert prospective parents who might be carrying genes that could cause hereditary diseases in their children.\n\nCounsyl's technology promises a \"high quality-of-life impact for families at risk for conceiving children with familial diseases,\" says Larry Bock, an Innovation Awards judge and special limited partner at venture firm Lux Capital. \"This technology bundles previously...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story addresses two major advantages to Counsyl\u2019s test \u2013 the fact that it much cheaper and much easier. On the latter point, previous genetic tests typically covered a single disease and required a blood sample. Counsyl\u2019s new method covers about 100 disorders, as mentioned above, with a saliva test. But the\u00a0focus\u00a0should have been expanded beyond mere\u00a0convenience.\u00a0Does this test\u00a0improve the quality of life for \"families at risk for conceiving children with familial diseases\"? No evidence is presented suggesting that it does. Does the test \"significantly reduce, and possibly eliminate, hereditary diseases\"? No evidence is presented suggesting that it does.", "answer": 0}, {"article": "Allergy shots may be used for hay fever when antihistamines and other allergy medications do not control a person\u2019s symptoms adequately, or for people who want to reduce their reliance on medication.\nIn addition, the long-term effectiveness of the grass-pollen tablets is not yet fully clear.\nOn the other hand, Nelson said, allergy shots appear to outperform the oral versions, with a symptom reduction about twice that of sublingual immunotherapy.\nDr. Harold Nelson, an allergist at National Jewish Health in Denver, said that the body of evidence indicates that sublingual immunotherapy beats antihistamines and other medications used to control hay fever symptoms.\nEven though the effectiveness is less than that of allergy shots, the convenience of an at-home version of immunotherapy is a plus, and the sublingual therapy tends to have fewer side effects than shots, according to Nelson.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n \nThe story only presents the benefits of therapy in terms of relative risk compared with placebo, rather than absolute risk.\u00a0 The reader is not given any information about what a 20% reduction in symptoms would mean for them. The benefit may be statistically significant, but is it clinically significant? The story should have also reported that the same benefit was not seen in children.\n", "answer": 0}, {"article": "The beneficial effects of traditional acupuncture, according to the researchers, did not appear to be associated with changes in levels of hormones that trigger menopause and its associated symptoms.\nAfter 10 weeks, the women in the traditional acupuncture group had significantly less severe hot flashes and mood swings than those who'd gotten the fake treatment.\nThe research included 53 postmenopausal women, with about half receiving traditional Chinese acupuncture twice a week and the others given sham acupuncture treatments.\nThe findings were published online March 7 in Acupuncture in Medicine.\nThough the researchers acknowledged that they did not monitor how long symptom relief lasted, they suggested that traditional acupuncture may offer an alternative for women who can't or don't want to use hormone replacement therapy to ease menopause symptoms.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only stated that women who got acupuncture \u201chad significantly less severe hot flashes and mood swings.\u201d What does that mean?\u00a0 How was it measured?", "answer": 0}, {"article": "\"Those same benefits translate to people seeking to fight off the common cold, flu and other seasonal illnesses.\"\nImmediate massage benefits included reduced anxiety while the long-term impact increased serotonin values, natural killer cell numbers and lymphocytes,iii which work to strengthen the immune system and cognitive function during sickness.\nRegular massages have been shown to make the immune system stronger, according to studies.\nIndividuals should consult with a professional massage therapist to determine the best massage therapy approach for their specific needs.\nThe immune changes included increased white blood cells knowns as natural killer (NK) cells, which provide rapid responses to viral-infected cells.ii\n\nAn additional randomized study found women with stage 1 and 2 breast cancer may benefit from massage therapy for enhancing dopamine and serotonin while also increasing NK cell number and lymphocytes.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release cited three studies, but descriptions of the research were too vague to be helpful.\u00a0 Readers aren\u2019t given any benefit data or any quantitative estimate on how well massage therapy actually works. We don\u2019t know how many participants were in each trial and who actually benefited from massage therapy. The release alludes to the fact several times that the immune system became stronger, but how was this measured? There are also non-specific references to the benefits of massage therapy, such as increasing the activity of white blood cells and reducing anxiety levels, but again, we don\u2019t know who actually benefited and by how much.\nWhen we looked at the studies cited we were surprised to find that none of them related to massage therapy for reducing rates of the \u201ccommon cold, flu and other seasonal illnesses,\u201d as claimed in the release.\nThe first study was from 2010 and is described by its authors as \u201cpreliminary\u201d work that looks at a \u201csingle-session comparison of Swedish Massage Therapy with a light touch control condition\u201d measuring \u00a0\u201cOxytocin (OT), arginine-vasopressin (AVP), adrenal corticotropin hormone (ACTH), cortisol (CORT), circulating phenotypic lymphocytes markers, and mitogen-stimulated cytokine production.\u201d\u00a0 This study is far removed from patient-oriented, or even disease-oriented outcomes, and has nothing to do with their sweeping comments that massage may fend off flu and the common cold.\nThe second study (from 2001) involved 12 HIV patients. It\u2019s hard to see how the results from this study translate to healthy individuals seeking relief from seasonal colds and flu. The third study (from 2004) enrolled 34 women with breast cancer whose outcomes following massage were \u201creduced anxiety, depressed mood, and anger. The longer term massage effects included reduced depression and hostility and increased urinary dopamine, serotonin values, NK cell number, and lymphocytes.\u201d Again, this study does not provide evidence for the news release\u2019s claims.", "answer": 0}, {"article": "47(5) pp.\nResults of the study were based on a double-blinded randomized, sham-controlled trial of 387 patients, about half of whom received treatment with the Obalon balloon and the other half with a sugar-filled sham capsule designed to look like the device.\nThe Agency for Healthcare Research and Quality (AHRQ) reported significant improvements in the safety of metabolic/bariatric surgery due in large part to improved laparoscopic techniques.\nSix months after the balloons were removed, 89.5 percent of the average total weight lost during the treatment period was maintained.\nAll patients at the 15 study sites also underwent 25 minutes of lifestyle therapy administered by a blinded registered dietitian every three weeks.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We will give the release a satisfactory rating because it notes that after one year patients receiving the Obalon balloon and counseling had lost about 7 percent of their total body weight (or about a quarter of their \u201cexcess\u201d weight) compared to a bit less than 4 percent total weight loss for those given a sham balloon and counseling. However, since other intragastric balloons are already on the market, most people would want to know how the Obalon device compares. The release should have noted that because the trial did not include competing devices, there is no evidence that indicates whether the new device is any better or worse than other devices.", "answer": 1}, {"article": "Troponin I is a protein that is released into the bloodstream when the heart muscle has been damaged such as during a heart attack.\nThe troponin tests were more predictive than other biomarkers used to make the diagnosis, the study showed.\nNot all EKG readings are abnormal during a heart attack, Chaparro explained.\nA more sensitive test could save a lot of money, she noted.\nThe new study looked at a highly sensitive type of troponin I test that may be more accurate in less time.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Explaining sensitivity, specificity and negative predictive value is admittedly a task in and of itself.\u00a0 But the difficulty in explaining the concepts and applying them to the results of a study does not exempt a story from trying.\u00a0 The story only referred to the new test being \u201cmore predictive than other biomarkers\u201d or \u201cmore sensitive than the existing one.\u201d But even those relative references weren\u2019t quantified.\u00a0 No sense of the scale of improvement of was provided. That\u2019s not helpful.", "answer": 0}, {"article": ".\nThe current results demonstrate the importance of prompt imaging and treatment of patients with clot-caused stroke, even in those who wake up having experienced a stroke or who for other reasons are not identified in the first few hours after the onset of symptoms.\nThe international DAWN trial previously demonstrated that patients with a small area of irreversible brain damage and a large area of brain at jeopardy of being lost if the clot remains are more likely to recover with minimal disability if the clot is removed up to 24 hours after symptoms begin or were noticed.\nThe association has strict policies to prevent these relationships from influencing the science content.\nThe Dallas-based association officially launched in 1998 as a division of the American Heart Association.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release describes benefits in terms of relative risk, not absolute risk numbers. Each one-hour delay of treatment, they wrote, reduces the chance of recovery with minimal damage by 11%. Furthermore, patients who had their clots removed were 35.5% more likely to have minimal disability in the future. This was helpful, but it would be more informative to tell us how many patients had clots removed and what their outcomes were.\nIt also should have been emphasized that not all stroke patients are eligible for the procedure after 6 hours; according to the updated recommendations from the American Heart Association (AHA) and the American Stroke Association (ASA), only patients with a blood clot in a specific area of the brain, who have clinical symptoms that are disproportionate to the size of the stroke, are eligible for treatment after 6 hours.", "answer": 0}, {"article": "Injections of botulinum toxin, best known as a wrinkle treatment, are now being used increasingly to prevent chronic migraine sufferers. Scientific data are mixed, but two large recent studies show Botox can reduce the number of headache days in chronic sufferers.\n\nMigraine headache is a debilitating neurological condition that manifests itself as an intense throbbing pain on one or both sides of the head, according to the Migraine Research Foundation, a New York nonprofit. Some 14 million people experience migraine attacks...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was careful to explicitly describe the modest advantage of Botox over placebo injections\u2014in terms of the absolute number of headache days associated with each intervention.", "answer": 1}, {"article": "In its statement, the panel said that \"for some adults ages 76 to 85, the benefits of screening are smaller, and the potential for harm greater.\nHowever, the U.S. Preventive Services Task Force stopped short of saying any one screening method was better than another.\nPeople with disorders or medical histories that raise their odds for colon cancer may need more rigorous screening, the USPSTF said.\nAll of the recommendations are specific to symptom-free people 50 years of age or older with an average risk colorectal cancer, the panel stressed.\n\"There are multiple screening options for colorectal cancer that reduce the risk of dying from the disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of the different colon cancer screening methods. While we\u2019re sympathetic to the challenges of doing so on deadline\u2013especially when the task force went out of its way to not cover this ground\u2013this nonetheless should have been included.\u00a0The effectiveness of different screening tests differ, as well as the quality of that evidence, and readers would welcome knowing these differences in quantified terms.", "answer": 0}, {"article": "The use in spine surgery of bone-growth proteins like Medtronic Inc.\u2019s product Infuse has led to widespread nationwide increases in hospital charges ranging from 11% to 41% above conventional surgical costs, researchers found.\n\nThe researchers studied the results of a broad U.S. sample of 328,000 spine surgeries from 2002 through 2006. They report their findings this week in JAMA, the Journal of the American Medical Association.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The JAMA study is silent on whether BMP \"works\"\u2013which is to say, whether BMP improves outcomes, quality of life, morbidity or mortality.\u00a0\nNo harm in that: This piece of research is designed to look only at prevalence, complications and costs.\nBut the news story\u2019s shorthand conclusions\u2013that the surgery is common, costly and linked to certain complications\u2013begs the question of whether better outcomes outweigh those negatives. It\u2019s hard to imagine what kind of reader would not want to know the answer.\u00a0 \nCertainly at least some comparative outcome data exists. [Or if not, then that is worth mentioning.] The reporter didn\u2019t even mention the issue.\u00a0 \u00a0 ", "answer": 0}, {"article": "test found a small cancer, and he does not want to take a chance that it will grow slowly and not cause him problems.\n\u201cIt is not all pure data that is promoting aggressive screening.\u201d Dr. Andriole is directing a National Cancer Institute study of 76,000 men that failed to find a screening benefit after 10 years.\nA 75-year-old Connecticut man said he had the test because he was healthy and wanted to stay that way.\nAnd doctors, he added, have many inducements to screen.\nOften it is easier to just order the test.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did mention a \u201cNational Cancer Institute study of 76,000 men that failed to find a screening benefit after 10 years\u201d", "answer": 1}, {"article": "Currently, people who do not have HIV but are at substantial risk of getting it--because they have multiple sexual partners, for example, or an HIV-infected partner--can receive antiviral medications to prevent disease, a strategy called pre-exposure prophylaxis (PrEP).\nThis is why researchers continue to look for other ways to control the virus--and broadly neutralizing antibodies could prove to be part of an alternate treatment strategy.\nAlthough these patients were found to have some resistant virus in their blood, further research in the lab showed that those viruses were still sensitive to other broadly neutralizing antibodies, including 3BNC117, that target different parts of the pathogen.\nThe majority of the people in the trial were enrolled at The Rockefeller University Hospital, while some of the HIV-1 infected participants received the antibody at the University of Cologne, in Germany.\nThe purpose was to determine whether the antibody was safe and whether it had antiviral activity in humans.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release could do a better job of explaining that this is a very limited study looking primarily at safety. There are no meaningful clinical outcomes reported.\nWhen the release states \u201camong 13 HIV-infected people who received the highest dose of 10-1074, 11 showed a rapid decline in the amount of virus\u201d \u2014 we need to know what that means. What is rapidity and how is it important? Is it relevant to patients that the trial drug was \u201csensitive to other broadly neutralizing antibodies, including 3BNC117?\u201d What does this mean?", "answer": 0}, {"article": "March 31, 2010 -- A widely prescribed drug used to shrink enlarged prostates appears to reduce the incidence of prostate cancer in men with an increased risk for the disease.\nStudy researcher Gerald L. Andriole, MD, says a significant proportion of men screened for prostate cancer fall into this clinically ambiguous category of having elevated PSAs and negative biopsies.\nWhile the studies suggest a role for Avodart and Proscar in the prevention of prostate cancer, experts tell WebMD that important questions remain about using the drugs for this purpose.\nIn a trial involving more than 8,000 men from 42 countries, those who took the drug Avodart had a 23% lower risk of being diagnosed with prostate cancer over four years of treatment, compared to men who did not take the drug.\n\"We now have two studies showing that two different drugs in this category can reduce the overall risk of prostate cancer,\" American Cancer Society Director of Prostate and Colorectal Cancers Durado Brooks, MD, tells WebMD.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies the potential benefits of Avodart in both relative and absolute terms. (However, we wish the absolute data had been described more clearly and with more emphasis.)\u00a0 First, the story describes the benefits in relative terms by stating that Avodart reduced the chance of developing prostate cancer by 23% in men with an elevated PSA but no prostate cancer on biopsy. Then it provides the same information in absolute terms by describing the incidence of cancer as 20% in the Avodart group and 25% in the placebo group. These two sets of numbers provide different perspective on the potential benefits of the drug.", "answer": 1}, {"article": "The Department of Nutrition, Exercise and Sports conducts research, education, innovation, and dissemination of information in nutrition, human physiology and sports at the highest international level, and incorporates the humanities as well as health and social sciences.\nThe latest findings, as published in AJCN, concluded that a personalized nutritional approach based on an individual's biomarkers will lead to improved weight loss and maintenance success.\nThe research analyzed data from three diet clinical trials which collectively looked at more than 1,200 individuals - Diet, Obesity, and Genes (DiOGenes); the OPUS Supermarket intervention (SHOPUS); and the Nutrient-gene interactions in human obesity (NUGENOB).\nFor people with type 2 diabetes, the analysis found that a diet rich in healthy fats from plant sources would be effective for achieving weight loss.\nThe different studies (six in total) employed a variety of nutrition strategies, including caloric restriction and ad libitum diets, varying the contributions of carbohydrate and fat, and increasing fiber intake.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Since the main claim being made is the value of using biomarkers to personalize a weight loss plan the release should have included some basic facts about how much weight study volunteers lost by following a personalized eating plan. How did their weight loss compare to others not on the personalized plan?\nThe release included some specifics about the meal plans studied. \u201cThe findings suggest that for most people with prediabetes, a diet rich with vegetables fruits and whole grains should be recommended for weight loss and could potentially improve diabetes markers. For people with type 2 diabetes, the analysis found that a diet rich in healthy fats from plant sources would be effective for achieving weight loss. These diets could also be effective independent of caloric restriction.\u201d \u00a0We\u2019d like to see some numbers attached to these claims.", "answer": 0}, {"article": "Breakfast on the diet might consist of bacon, eggs with cheese, and a cup of heavy cream diluted with water; some children drink oil to obtain the fats that they need.\nAs the first randomized trial of the diet, the new study lends legitimacy to a treatment that has been used since the 1920s but has until recently been dismissed by many doctors as a marginal alternative therapy.\n\u201cThis is the first time that we\u2019ve really got Class 1 evidence that this diet works for treatment of epilepsy,\u201d said Dr. J. Helen Cross, professor of pediatric neurology at University College London and Great Ormond Street Hospital.\nA formerly controversial high-fat diet has proved highly effective in reducing seizures in children whose epilepsy does not respond to medication, British researchers are reporting.\nBreaking the diet with so much as a few cookies can cause seizures to flare up.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story accurately reported on the level of benefit observed in the study it reported on. \u00a0However, the story should have mentioned that the timeframe of the study reported on was 90 days. \u00a0This is of concern to readers who might be evaluating the benefits to be obtained through adherence to the diet.", "answer": 1}, {"article": "This is really a game changer.\"\nIn fact, an interim review of the Partners data on effectiveness was so compelling that the trial was stopped early and the placebo arm was discontinued.\nThe CDC says the next step is to fully review all the data and begin to develop guidelines for the use of these drugs in heterosexual men and women here in the U.S.\nAn earlier PrEP trial, the iPrEx study, looked at treatment in men who have sex with men.\nThe Partners PrEP study participants took either TDF/FTC, the drug tenofovir\u2013brand name Viread, or a placebo.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers should have been given a bit more information on actual number of infections seen in the study groups. The story states that infection risk for drug-treated individuals was 63% to 73% lower relative to individuals who received the placebo. However, the story never provides the absolute risk data that are essential to determining the true magnitude of the benefit. Elsewhere, the story states that infection rates were decreased by 78% in those \u201cwho actually got the drugs.\u201d This is a confusing statement. The story should have explained that this was an analysis of outcomes based on participants\u2019\u00a0adherence to the medication regimen; those who\u00a0took the drug more\u00a0regularly were more likely to see a benefit.", "answer": 0}, {"article": "Metabolic syndrome is characterized by obesity, hypertension and other cardiac risk factors.\nFunding for the study was provided by Wakunaga of America Co., Ltd., the producer of Kyolic Aged Garlic Extract.\nFollowing evaluation, the participants were given either a placebo or a dose of 2,400 milligrams of Aged Garlic Extract every day.\n\"This study is another demonstration of the benefits of this supplement in reducing the accumulation of soft plaque and preventing the formation of new plaque in the arteries, which can cause heart disease,\" said Matthew J. Budoff, MD, an LA BioMed lead researcher.\nThe study involved 55 patients, aged 40 to 75 years, who had been diagnosed with metabolic syndrome.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The closing paragraph of the release claims that the supplement \u201chad slowed total plaque accumulation by 80%, reduced soft plaque and demonstrated regression (less plaque on follow-up) for low-attenuation plaque.\u201d\u00a0 However, the opening paragraph of the release goes quite a bit further, stating that \u201cthe supplement Aged Garlic Extract can reverse the buildup of deadly plaque in arteries and help prevent the progression of heart disease\u201d \u2014 a far more definitive claim than the release\u2019s information can substantiate. There\u2019s nothing in this release to suggest that the supplement affects any outcome that matters to patients such as actual heart attacks and strokes.", "answer": 0}, {"article": "Doctors who have turned surgery into a popular treatment for obesity are setting their sights on a burgeoning new market: diabetes patients.\n\nA growing amount of research suggests that bariatric surgery, which shrinks the stomach and sometimes reroutes the intestines, has a lasting effect on the most common form of diabetes, and not just because patients lose weight. Studies have found that more than 75% of patients with this type of diabetes who undergo the surgery see their disease disappear. They can go on to live diabetes-free...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article opens with a claim that studies show over 75 percent of\u00a0diabetics who get bariatric surgery\u00a0\"see their disease disappear.\" While this sounds like an exaggerated claim,\u00a0it is backed up by two specific citations of remission data from credible journals later in the story.\u00a0 ", "answer": 1}, {"article": "UT Southwestern physicians provide care in about 80 specialties to more than 100,000 hospitalized patients, 600,000 emergency room cases, and oversee approximately 2.2 million outpatient visits a year.\nPrevious studies from Dr. Levine's research program have shown substantial improvements in cardiac compliance in young individuals after a year of training, but surprisingly little change if the training was started after age 65.\nHowever, the researchers also found that the heart chamber in competitive masters-level athletes remains large and elastic, and that even four to five days of committed exercise over decades is enough for noncompetitive athletes to reap most of this benefit.\nTo reap the most benefit, the exercise regimen should begin by late middle age (before age 65), when the heart apparently retains some plasticity and ability to remodel itself, according to the findings by researchers at the Institute for Exercise and Environmental Medicine (IEEM), which is a collaboration between UT Southwestern Medical Center and Texas Health Presbyterian Hospital Dallas.\nCollaborators on the study included first author Dr. Erin Howden, Research Fellow with UT Southwestern's Graduate School of Biomedical Sciences and the IEEM and now a faculty member at the Baker Heart and Diabetes Institute in Melbourne, Australia.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The headline of the news release claims \u2018Proper exercise can reverse damage from heart aging,\u2019 but the study documents two outcomes: an \u201818% improvement\u2019 in maximal oxygen uptake, and a \u201825% improvement\u2019 in the elasticity of the left ventricle (the chamber primarily responsible for pumping oxygenated blood throughout the body).\n\u201cReversal\u201d implies a return to a previous state of function, but this study merely documents improvement in two cardiovascular outcomes that are commonly seen with regular aerobic exercise. It\u2019s not clear if this change does in fact represent a \u201creversal.\u201d\nIn addition, \u201cdamage from heart aging\u201d is a confusing phrase. Poor oxygen uptake and a loss of heart elasticity are as much a consequence of sedentary lifestyle as they are a result of an aging heart. This is why a headline implying that exercise actually reverses aging in the heart is misleading.\nFinally, the first paragraph of the release claims that exercise can help prevent the risk of future heart failure, even though the study itself makes it clear this outcome is speculative. At the very least, the release should have cautioned that a much larger and longer study would be needed to document any impact on heart failure outcomes.", "answer": 0}, {"article": "The higher a person's insulin levels are, the more likely they are to have or develop insulin resistance, which can increase blood sugar levels and diabetes risk.\nThe findings are important because many of the participants in this study likely already had some level of cardiac damage, such as thickened arteries or heart walls, says Geetha Raghuveer, a pediatric cardiologist at Children's Mercy Kansas City in Missouri who was not involved in the study.\nBefore surgery, only 3 percent of the teens had no cardiac risk factors at all, but three years later, just over half of them (52 percent) had no risk factors.\nIn fact, the majority of the participants \u2014 83 percent \u2014 had only one or no risk factors three years after their surgeries.\nJust 5 percent had all four cardiac risk factors before their surgeries, but none had all of them three years later.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states: \u201cBefore surgery, only 3 percent of the teens had no cardiac risk factors at all, but three years later, just over half of them (52 percent) had no risk factors. Just 5 percent had all four cardiac risk factors before their surgeries, but none had all of them three years later. In fact, the majority of the participants \u2014 83 percent \u2014 had only one or no risk factors three years after their surgeries. The proportion of participants with two or three risk factors also dropped substantially.\u201d\nThis is a useful start,\u00a0but the story needed to remind readers: Changes in risk factors predicated on lab values are surrogate markers, so they may not actually lead to improved \u201cheart health\u201d as the story states.", "answer": 0}, {"article": "In practice, Performance with Purpose means providing a wide range of foods and beverages, from treats to healthy eats; finding innovative ways to minimize our impact on the environment and reduce our operating costs; providing a safe and inclusive workplace for our employees globally; and respecting, supporting and investing in the local communities where we operate.\nNewly published research in the Journal of the American College of Nutrition showed that a hearty bowl of instant oatmeal helped curb food intake at lunch better than a leading oat-based, cold cereal -- even when each bowl provided the same number of calories.\nAuthors stated that the processing of the cold cereal might lead to changes in the oat fiber that reduced its ability to enhance satiety.\nAfter an analysis of the types of fiber in each cereal, the researchers suspected that the higher molecular viscosity of the beta-glucan in the instant oatmeal contributed to its satiating effect over the oat-based, cold cereal.\n\"When we took it a step further and evaluated the intake four hours post-breakfast, we found that after consuming instant oatmeal, the participants chose to eat significantly less at lunch compared to those who ate the oat-based, cold cereal.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release talks about two types of benefits. \u201cSatiety,\u201d meaning how full people felt after eating oatmeal, and how much they actually ate after eating oatmeal. It says, \u201cThe satiety benefits of instant oatmeal alone were important findings,\u201d And it says that \u201cTotal calorie intake was significantly lower following consumption of instant oatmeal compared to the cold cereal.\u201d Neither of these benefits are quantified.", "answer": 0}, {"article": "Varicose veins are one of the more unsightly signs of aging. But new, less-invasive treatments are making it easier to remove them painlessly, bypassing a difficult surgical procedure that was often the only option in the past.\n\nAs many as 25% of women and 15% of men suffer from varicose veins; over the age of 50, one out of two people are affected. Heredity plays a part, but obesity, prolonged standing on the job and hormone therapy increase the risks. Sometimes, varicose veins have no signs or symptoms and require no treatment,...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We would have liked to have seen some hard numbers attached to the benefits of these therapies. One of the studies for the foam therapy approach, led by Suman Rathbun, who was quoted in the story, covered 166 patients over a three year period. The results are clearly enumerated in that study and could have been cited here.", "answer": 0}, {"article": "CHICAGO (Reuters) - Pathway Genomics, a company known for pushing the boundaries of direct-to-consumer genetic testing, on Thursday will launch a cancer screening test designed to detect bits of cancer DNA in the blood of otherwise healthy people.\nSeveral oncology experts said liquid biopsy tests like Pathway\u2019s, while exciting, still require large clinical studies proving they help people beat cancer through early detection.\nThe company is focusing on mutations that are relatively well-understood, and for which there are specific treatments, said Chief Executive Jim Plante.\nDr. Bert Vogelstein, a cancer geneticist at Johns Hopkins University in Baltimore, said Pathway\u2019s figure represents the test\u2019s technical ability to detect DNA in the blood.\nThe test represents a first in the rapidly developing field of \u201cliquid biopsies,\u201d which use gene sequencing technology to screen blood samples for trace amounts of DNA associated with different cancers.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites a company figure stating that the test \u201cis more than 99 percent accurate in detecting mutations in blood samples that contain at least nine copies of a tested mutation.\u201d\nIt then knocks down that figure with a quote from a researcher who says the statistic represents the test\u2019s \u201ctechnical ability to detect DNA in the blood.\u201d It goes on to state that a large clinical trial would be needed to determine the test\u2019s true accuracy, including false positive and false negative results. But such a study hasn\u2019t yet been done.", "answer": 1}, {"article": "This type of drug development program, which enrolled patients with different tumors but a common gene mutation, wouldn\u2019t have been possible a decade ago because we knew a lot less about such cancer mutations,\" said Dr. Gottlieb.\n\"Using our breakthrough therapy designation and accelerated approval processes, we support innovation in precision oncology drug development and the evolution of more targeted and effective treatments for cancer patients,\" the FDA stated.\nFor the second time, the U.S. Food and Drug Administration has approved a drug that, instead of targeting tumors by location\u2014breast cancer, prostate cancer, lung cancer\u2014attacks cancers according to specific genetic structures, known as biomarkers.\nIts approval reflects advances in the use of biomarkers to guide drug development and the more targeted delivery of medicine.\"\n\"This new site-agnostic oncology therapy isn\u2019t specific to a cancer arising in a particular body organ, such as breast or colon cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The headline calls this drug \u201caggressive.\u201d But the story doesn\u2019t report data on the drug\u2019s response rate, which is the percentage of patients whose tumors shrunk after treatment. Response rate was the basis of the FDA\u2019s approval.\nAccording to FDA, there was a 75% overall response rate across different types of solid tumors, with 73% of responses lasting at least six months and 39% lasting a year or more.\nReaders are not told that there is no evidence to show patients who get this drug actually live longer or have a better quality of life than those who don\u2019t get it. (More on this under the quality of evidence rating, below.)", "answer": 0}, {"article": "He says:\n\n\"When I was diagnosed with early prostate cancer, I had the option of active surveillance but I didn't want to wait until it got worse so when I was offered a place on the trial I signed up straight away.\nWith such an approach we should be able to achieve a significantly higher remission rate than in the trial and send nearly all low-risk localised prostate cancers into remission.\n\"New procedures are generally associated with a learning curve, but the lack of complications in the trial suggests that the treatment protocol is safe, efficient and relatively easy to scale up.\nThe chances of cancer progressing to a more dangerous stage were three times lower for patients on VTP, and the treatment doubled the average time to progression from 14 months to 28 months.\n\"The fact that the treatment was performed so successfully by non-specialist centres in various health systems is really remarkable,\" says Professor Emberton, who is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that the study found that 49% of patients treated with VTP went into \u201ccomplete remission\u201d compared with 13.5% in the control group. It further states:\nIn the trial only 6% of patients treated with VTP needed radical therapy compared with 30% of patients in the control arm who were under active surveillance.\nWhile it\u2019s good to see some numbers, we have concerns about the \u201cradical therapy\u201d statistic and what it means, which we\u2019ll address below in the \u201cEvidence Quality\u201d criterion.\nWe also call foul on a patient quoted in the release who says. \u201cI\u2019m now cancer-free with no side-effects and don\u2019t have to worry about needing surgery in future.\u201d Unless he has a crystal ball, there\u2019s no way to know with certainty whether he\u2019ll need surgery or not in the future.\nPerhaps the biggest issue, however, is that the outcomes reported in the news release\u2013and the study\u2013are only surrogate markers. They are proxies for the things we care about like length of life and quality of life. The key question\u2013which would take at least a decade to answer\u2013is whether men undergoing initial VTP are less likely to die from prostate cancer than those opting for active surveillance. And the release doesn\u2019t make this clear.\nWe\u2019re also uncomfortable with the release\u2019s description of patients achieving \u201ccomplete remission,\u201d \u00a0a phrase that we\u2019ve never seen used to describe prostate cancer treatments. \u00a0All we know is that these men had no evidence of prostate cancer on repeat biopsy. \u00a0However, biopsies sample only a small portion of the prostate and often miss areas of cancer. Using the phrase \u201ccomplete remission\u201d is likely to give readers a false sense of how beneficial this treatment really is.", "answer": 0}, {"article": "Professor Tim Newton from the Dental Institute at King's College London and lead author of the study said: \"People with dental phobia are most commonly given sedation to allow them to become relaxed enough for a short period of time to have their dental treatment performed.\nNearly all patients (94%) reported a knock-on effect from problems with their teeth, mouth or gums on their daily living and quality of life.\nThe average number of CBT appointments required before a patient received dental treatment without sedation was five.\nThe latest study, published in the British Dental Journal, looked at the characteristics of 130 patients (99 women and 31 men) attending a psychologist-led CBT service and the outcomes of their treatment.\nCognitive behavioural therapy could help many people with a dental phobia overcome their fear of visiting the dentist and enable them to receive dental treatment without the need to be sedated, according to a new study by King's College London.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit here is the ability of a patient to receive dental care without sedation \u2014 which carries its own costs and health risks. The release states that 79% of patients who participated in the study \u201cwent on to have dental treatment without the need for sedation.\u201d Only 6% of patients had treatment under sedation. The remaining 15% either dropped out of CBT or were removed from the study because they were identified as having other psychological problems that required treatment. Of the patients who completed the CBT (i.e., didn\u2019t drop out and weren\u2019t removed from the study), 93% went on to have dental treatment without sedation.", "answer": 1}, {"article": "\"Nothing happens,\" he told Stahl.\nIt was that relentlessness of leukemia that had given Kanzius the idea to build his radio wave machine in the first place.\nBut Kanzius wasn't happy with all the time it would take Curley to get through the usual human clinical trials and approval by the FDA.\nSo he wondered: if he injected a cancerous tumor with some kind of metal, would radio waves heat up the metal and cook the cancer cells to death, and only the cancer cells?\nWhat he did have was a deadly form of leukemia and a determination to use whatever time he had left to come up with a better way to treat the disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nDespite a litany of caveats near the end of the story, the overall portrayal of the Kanzius device as offering potentially revolutionary advantages over conventional treatments is without basis. It is appalling to see Stahl tease the audience by suggesting that John Kanzius\u2019s temporarily improved health might be a result of his self-treatment with radio waves, rather than the expected outcome of conventional chemotherapy. Stahl marveled at the fact that Kanzius\u2019s blood cell counts improved at one point; but since he had been through several rounds of treatment with conventional chemotherapy agents, the improvement should not have been any surprise.", "answer": 0}, {"article": "Ulcerative colitis, which affects about 38,000 people in the United States annually, is a chronic condition causing abdominal pain, intestinal ulcers, bloody diarrhea and weight loss.\nBoth 6 mg/kg and 130 mg doses of the intravenous treatment showed clinical remission in significantly more patients, compared with those on placebo, after eight weeks, the company said.\nThe treatment and the placebo arms reported similar proportion of side effects, with one patient on the 6 mg/kg dose dying following excessive bleeding, J&J said.\nTwo doses of Stelara, already approved for psoriasis, psoriatic arthritis and Crohn\u2019s disease, was tested in 961 patients with moderate-to-severe ulcerative colitis (UC) who had failed prior therapy.\n\u201cMore than half of UC patients have not experienced remission with currently available treatment options,\u201d the study\u2019s lead investigator Bruce Sands said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that either dosage of Stelara \u201cshowed clinical remission in significantly more patients, compared with those on placebo, after eight weeks.\u201d But what does that mean? One percent more of patients? Ninety-nine percent more of patients? The story notes that the patients in this study had not responded to available treatment options, and also states that \u201cMore than half of UC patients have not experienced remission with currently available treatment options.\u201d But the story fails to say what percentage of patients who received Stelara experienced remission. (According to a news release, the answer was 15.5 or 15.6 percent, depending on which dosage they received.)", "answer": 0}, {"article": "The I.V.\nThe author, Dr. Alan Gaby, has long promoted the use of intravenous vitamins for a wide range of clinical conditions.\nSchwartz, though, said the supplements are completely safe.\nA longitudinal study would be needed to back those claims with evidence, she added.\nOne didn\u2019t turn up any significant improvement in patients who received the infusions.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story hinges on the lack of benefits, and we think it chose credible sources for questions about that. Besides quoting nutrition researchers Goodstein and Miller, we liked how the story explained the history behind the \u201cMyers\u201d cocktail and links to a review published in an alternative medicine journal. Readers are given their own way to check the credibility of claims of \u201cevidence.\u201d", "answer": 1}, {"article": "Trisha Bradbury was one of the participants allocated to the FIT study, and she explains: \"I lost my mum at 60, and being 59 myself with a variety of health problems, my motivation was to be there for my daughter.\n\"As well as being delighted by the success of the study in the short term, there are very few studies that document weight loss past the end of treatment, so to see that people continued to lose weight despite not having any support shows the sustainability and effectiveness of this intervention.\"\nIn addition, users of FIT lost 4.3cm more around their waist circumference in six months - and continued to lose weight after the intervention had finished.\nThe study showed how after six months people who used the FIT intervention lost an average of 4.11kg, compared with an average of 0.74kg among the MI group.\nLed by Dr Linda Solbrig from the School of Psychology, the research involved 141 participants, who were allocated either to FIT or Motivational Interviewing (MI) - a technique that sees a counsellor support someone to develop, highlight and verbalise their need or motivation for change, and their reasons for wanting to change.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release describes benefits in terms of kilograms lost at six months and twelve months after the FIT/MI intervention. Benefits are also described in terms of centimeters lost from their waist circumference. This information would have been more meaningful if it had provided information about the starting weight and waist circumference for the groups, since that would have shed light on whether one group would find it more difficult to shed kilograms or centimeters.", "answer": 1}, {"article": "A downloadable photo of Dr. Mark Loeb is available here\nDr. Mark Loeb, lead author of the study, says his team's findings challenge the ACIP's recommendations towards flu shots, or inactivated vaccines.\nThe original intention of the study was to show that nasal spray vaccines would provide better protection than flu shots, but Loeb says the conclusions of the study are now especially important, given the ACIP's recommendations.\nFor the study, Loeb's team conducted a three-year trial in a Hutterite colony, where people live communally and are relatively isolated from cities and towns, to determine whether vaccinating children and adolescents with the flu nasal spray provided better direct and community protection than the standard flu shot.\nIn fact, as late as June 2014, the live vaccine was preferred.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release reports similar rates of vaccine uptake for intranasal vaccine and standard flu shots.\u00a0 But it does not quantify benefits for the main outcome of the study, that is, rates of influenza in communities vaccinated with nasal vs injected vaccine over the course of the study.\u00a0 These rates were statistically no different: 5.2% for the standard vs 5.3% for the nasal vaccine.", "answer": 0}, {"article": "All rights reserved.\nThat is less effective than a good diet, exercise and not smoking, each of which can lower cancer risk by 20% to 30%, cancer experts say.\nThere also was a trend toward fewer cancer deaths among multivitamin users, but the difference was so small it could have occurred by chance alone.\nIn the new study, multivitamins cut the chance of developing cancer by 8%.\nAfter about 11 years, there were 2,669 new cancers, and some people had cancer more than once.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was very cautious in its framing of the results, quoting a researcher who called the effect \u201cvery mild\u201d and who said he wasn\u2019t sure it\u2019s\u00a0significant enough to recommend to anyone. The story also took the time to explain exactly what the benefit looked like in absolute terms: \u201cAfter about 11 years, there were 2,669 new cancers, and some people had cancer more than once. For every 1,000 men per year in the study, there were 17 cancers among multivitamin users and more than 18 among those taking the placebo pills. That worked out to an 8% lower risk of developing cancer in the vitamin group.\u201d The competing Reuters coverage didn\u2019t provide these details.", "answer": 1}, {"article": "Older people tend to get less slow-wave sleep and are at greater risk for memory impairment.\nBut first, says Zee, larger and longer studies are needed to confirm the findings and show that there are benefits to long-term use, rather than on just one night.\nOn one of those nights, headphone-clad participants were played a series of short bursts of pink noise during deep sleep, spaced out enough to prevent the brain from getting used to and ignoring them.\nZee and her fellow researchers had 13 adults ages 60 and older spend two nights in a sleep lab.\nZee says that the effectiveness of pink noise is all in the timing.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us slow wave oscillations increase, but not by how much, or whether the increase is significant. The article is lacking important details around the intervention such as what an increase of slow wave oscillations might mean, say to a sleep wave expert or to an individual with sleep problems.\u00a0Readers also learn that in a memory test taken in the morning, participants did three times better. But there are no details on what the memory test is or even what the \u201cthree times better\u201d is compared to. (To the memory test the evening before? Or to the morning memory test after the no pink noise night?)\nThe absolute number (exact number of patients seeing a measured benefit) would be preferable to the relative number (\u201cperformed three times better\u201d), particularly in a small study like this one, with only 13 participants.\nIn addition, there\u2019s no discussion of how a memory test after sleeping can relate to long-term term memory effects. Improving memory for one day is not likely to be meaningful clinically.", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nAs noted in the comments on the quality of the evidence, this story left out essential information about the key published trial data of bronchial thermoplasty. While the story includes several patients telling how much better they feel after treatment, it fails to tell readers that most of the patients in the control group also reported feeling much better after undergoing sham treatment. As the editorial accompanying the journal article on the trial noted, it is crucial to include a comparison with a control group when assessing the overall benefit of this sort of intervention. The story fails to give readers that important context.\nThe story reports that the treated patients were less likely than control group participants to have an asthma attack, go to an ER, or lose work or school days. But not only does the story leave out the absolute improvements, it fails to inform readers that when adverse events related to the treatment itself are included, there was no net benefit seen over the first year. \nOddly, the story leaves out any mention of the primary outcome measure of the key trial: what the patients reported on a standard questionnaire about their asthma-related quality of life. The story should have pointed out that while about four out of five people treated with bronchial thermoplasty reported clinically significant improvement, almost two out of three people given the sham treatment reported similar improvement. Based on the results reported by researchers, about seven asthma patients would have to be treated in order to get one additional person who says he or she has a significantly better quality of life. The story includes only glowing reports from treated patients and thus gives readers a flawed view of the potential benefits.", "answer": 0}, {"article": "In 2014, prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men.\nWhen compared to surrounding healthy tissues, it\u2019s hoped that contrast enhanced MRIs will reveal the shape and nature of any tumors present.\nBy doing both, the ability of imaging to accurately plot a tumor\u2019s location is increased and there is a more refined sense of the tumor\u2019s extent, said Nathan White, PhD, assistant project scientist at UC San Diego, study co-author and co-inventor of the RSI-MRI technique.\nIn a related paper to be published in the journal Frontiers in Oncology, the same team of researchers reported that RSI-MRI appears to predict tumor grade.\nThe technique is also valuable in surgical planning and image staging, said David S. Karow, MD, PhD, assistant professor of radiology at UC San Diego and the study\u2019s corresponding author.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release provides no data to justify repeated claims that this technique performs better than existing technology. And we think the release misstates the findings of the study that forms the basis for these claims. For example, the releases talks about the new technology\u2019s ability to find small, localized tumors to guide biopsy. However, the actual study addresses only the ability of the new technology to detect cancers that have extended beyond the prostate. In addition, we found the closing quote from professor Robert Reiter, MD, about the value of the new technology, to be misleading. He says, \u201cIf by imaging we could predict the tumor grade, we may be able to spare some patients from prostate resection and monitor their cancer with imaging.\u201d \u00a0But some patients currently already enjoy the option of watchful waiting. If the biopsy grade, clinical exam, and PSA all indicate a low-risk tumor, then the patient can be offered active surveillance and avoid the need for resection.", "answer": 0}, {"article": "; Eur Uro 2016 \n\niii Loeb et al.\nThe researchers found that incorporating SelectMDx resulted in an average gain of 0.045 life years, or approximately 16 days, in full health gained at a cost-savings of $1,694 for each patient undergoing biopsy.\nSince the introduction of the SelectMDx test in mid-2016, over 23,000 patients have been tested and 15 commercial contracts have been signed with US based insurance companies.\nThe SelectMDx test can help predict the likelihood that clinically significant prostate cancer will be found by a biopsy.\nThe test helps to reduce the need for MRI procedures and invasive prostate biopsies by up to 50%, thereby improving quality of life and lowering healthcare costs per patient.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a good job of explaining the benefits of the SelectMDx test at both individual and societal levels.\u00a0 Those benefits are pretty modest for a patient: a gain of 16 days of health at a cost savings of nearly $1700, on average.\u00a0 But they are impressive when one ramps up to a societal level, given that more than 300,000 patients a year consider undergoing biopsies.\nBut it needs to be recognize that benefits and cost savings are estimated. The authors acknowledged that literature estimates for clinical benefits may not be applicable for the general population and the actual cost savings are uncertain because commercial payment rates are unknown.\n\u00a0", "answer": 1}, {"article": "Melanoma is the most serious, and often deadly, form of skin cancer.\nThe phase 1 and 2 study was sponsored by GlaxoSmithKline, which developed both drugs.\nBy targeting different points in the same growth-factor pathway, the kinase inhibitor drugs dabrafenib and trametinib postponed the development of drug resistance in patients with BRAF-positive metastatic melanoma, the study authors said.\nThe drug combination is now being tested in a larger phase 3 study, which is required for U.S. Food and Drug Administration approval.\n\"We investigated this (drug) combination because of research we and others have conducted into the molecular underpinnings of resistance to BRAF inhibitor therapy,\" study lead author Dr. Keith Flaherty, of the Massachusetts General Hospital Cancer Center, said in a hospital news release.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not overhype the findings and uses statistics appropriately, reporting that after one year,\u00a0\u201c41 percent of patients receiving the full-dose combination treatment had no progression of their melanoma, compared with 9 percent of those receiving dabrafenib alone.\u201d\nOf course, this does not tell us whether the drug combination actually prolonged life, and the story does not\u00a0explore or\u00a0explain this important\u00a0nuance.\u00a0This is something we\u2019ll address under the\u00a0Quality of Evidence criterion below.", "answer": 1}, {"article": "They include people like Danielle Denlein, who, to her total shock, developed a serious heart problem.On October 20, 2008, at 1:50 p.m., Ms. Denlein was driving to a drug store to buy formula for her 5-day-old baby girl.\nOne solution, being tested by St. Jude Medical, a medical device company in St. Paul, is to let patients deal with important data.\nThe devices transmit useful data along with data whose significance is not clear, like variations in heart rate.\nThose with the nontransmitting device were seen in their doctor\u2019s offices every few months, the standard of care.\n\u201cIt\u2019s just a phenomenal tool.\u201d\n\nThere is a downside, though: \u201cInformation overload is a very serious problem\u201d for the doctors, said Dr. Lynne Warner Stevenson, director of the Heart Failure Program at Brigham and Women\u2019s Hospital in Boston and a professor at Harvard Medical School, who counts herself as a proponent of smart devices.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0Information about the potential to increase longevity was presented from a study that has not yet been published. \u00a0The information was presented as a relative increase rather than an absolute increase. \u00a0The story didn\u2019t contain sufficient information to quantify the benefit to any specific group of patients.", "answer": 0}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story repeats the relative risk reduction of major cardiovascular events of 25% that the company provided. But it doesn\u2019t grapple with the vital question: 25% of what? The true size of the benefit depends on the baseline risk of these participants, which is unknown and probably won\u2019t be known until the results are presented at a conference in November. (Read our primer on absolute risk for more information on why this is important.)\nThe story does note that the company is withholding details about the study results for now, but readers should have been clearly alerted to the fact that without knowing how many events occurred or what they were, it is impossible to judge the importance of the results. The study outcome was a combination of cardiovascular disease death, heart attack, stroke, coronary revascularization procedures and hospitalization for unstable angina. The story would have been better if it had alerted readers that based on the sketchy information released by the company, it is impossible to say whether there was an important reduction in deaths, heart attacks or strokes. It could be that much or even all of the reduction was in the number of times patients were hospitalized for chest pain. (Read our primer\u00a0Why you should be careful with composite outcomes in clinical trials\u00a0for more information on why this is important.)", "answer": 0}, {"article": "In his study published in the International Journal of Radiation Oncology, Biology, Physics, he and his colleagues found, \"in circumstances where surgery may result in significant neurologic or organ dysfunction, patients can be treated definitively with radiation therapy alone.\nWhile the findings were written for health care professionals and very technical, Tracy was encouraged.\nThe San Francisco radiation oncologist not only shared Dr. Kabolizadeh's research paper, but also his contact information.\nEven with surgery, there was a high risk of recurrence.\n\"I then determined, definitive radiation therapy was the way to go, but I had to decide which type and where.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Not only does the release neglect to offer quantified benefits for context on the effectiveness of proton therapy in treating sacral chordoma in general, it doesn\u2019t even articulate how effective the treatment was in treating the sole patient discussed throughout the release.\u00a0Nor are we told how the patient\u2019s response to the treatment was measured.", "answer": 0}, {"article": "\"We need people to swim against the stream.\nThe new device was about that accurate at differentiating between severe and less severe heart failure patients.\nThe goal of the project is to develop a simple, accurate, noninvasive, and reproducible method for early identification of chronic heart failure, he tells WebMD.\nThe researchers are now testing more than 1,000 patients and trying to identify the odorous molecules unique to heart failure patients, Kechagias says.\nThe new study involved 27 people with heart failure so severe that they were comfortable only at rest, 25 people with less severe heart failure, and 28 healthy people.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "This aspect needs to be thoroughly explored,\" says Ulrik Dalgas.\nThe study shows that resistance training has a number of positive effects on the brain, which go beyond what can be achieved through effective disease specific medication.\nThe researchers behind the study are still unable to explain why training has a positive effect on the brain in people with multiple sclerosis.\nOn the other hand, the study indicates that systematic physical training can be a far more important supplement during treatment than has so far been assumed.\nDrugs can counter this development, but we saw a tendency that training further minimises brain shrinkage in patients already receiving medication.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No numbers putting the benefits in context are given. Instead, the release uses broad, sweeping language to describe the benefits of resistance training. \u201cThe study shows that resistance training has a number of positive effects on the brain,\u201d it states. Resistance training also \u201cminimizes brain shrinkage in patients already receiving medication,\u201d while some patients saw their brains \u201cgrow in response to training.\u201d\nIn the original journal article, researchers state that 19 out of 74 cortical areas showed absolute increases in thickness, with a mean thickness being 0.03 mm, when comparing absolute values before and after resistance training of all participants. Researchers then compared these cortical areas to changes in muscle strength and motor function by looking at various physical and psychological parameters. Patients in the intervention group had increased knee muscle strength and performed better on a couple of motor tests (9-hole peg test and the timed 25-foot walk test) compared to those in the control group.\nWe wish the news release would have explained how these numbers might differ from what researchers would expect to see.\nIt is unclear from the journal article whether all patients displayed thicker brain cortexes after resistance training. We feel the news release could have included this information by following up with researchers. Therefore, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "In addition, Drs.\nThe pump is reusable; the balloon, microchip, and lab test together cost around $20, all supporting the increasing acceptance of breath tests as a cost-effective, easy-to-perform, non-invasive, and rapid option for the diagnosis of lung cancer.\nBeing able to identify this lung cancer \u201csignature\u201d through a simple breath test has emerged as one of the most promising ways to diagnose the disease.\n\u201cWe hope that the breath analysis can serve as the primary screening tool for cancer recurrence and a CT scan ordered only if the breath test suggests that there has been a change,\u201d said Dr. van Berkel.\nNewswise \u2014 Chicago \u2014 A single breath may be all it takes to identify the return of lung cancer after surgery, according to a study posted online today by The Annals of Thoracic Surgery.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides a good narrative of the potential benefits of the breath test (lower cost, reduces exposure to repeat CT scans) but does not provide any quantification. The release notes that \u201cThe researchers found a significant decrease in overall carbonyl VOC levels following surgery; in fact, three of the four carbonyl VOCs normalized after surgery, matching levels of the control group.\u201d\u00a0 We aren\u2019t told what a \u201csignificant decrease\u201d means or what a \u201cnormalized\u201d level would be. The release would have been more complete if it had given us some idea of the test\u2019s ability to accurately detect or rule out lung cancer recurrence. ", "answer": 0}, {"article": "The most common side effects of atezolizumab included skin rash, colitis, and low thyroid hormone.\nThis is the first phase III trial of an immunotherapy-based combined modality treatment to show a significant improvement in progression-free survival in advanced squamous NSCLC, according to the authors.\nAlthough the difference between treatment groups is modest, a statistically significant improvement shows that, overall, people with advanced squamous lung cancer can benefit when immunotherapy is added to standard treatment, according to the authors.\nAlthough the rate of severe side effects was higher with the combined modality treatment than with chemotherapy alone (68% vs. 57%), it had a manageable safety profile, consistent with known safety risks of the individual therapies.\nTumors were tested for PD-L1 expression, but patients were included in the trial regardless of tumor PD-L1 expression level.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the release and accompanying research abstract include specific results, the release spins them by proclaiming benefits in the headline and lead paragraph, while burying the caveats that there\u2019s no evidence patients lived any longer and that those who received immunotherapy suffered more severe or life-threatening side effects. The release highlighted a higher rate of progression-free survival, but that term can be confusing, because it doesn\u2019t necessarily mean patients lived any longer, just that more time passed (in this case a median of about three weeks) before their cancers showed signs of progression. Neither the release nor the abstract discussed the quality of life of the patients in the study groups.", "answer": 0}, {"article": "The paper \"Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening\" is available at: https:/\n\nTo request a copy of the study, please contact: Daniel Luzer\n\n daniel.luzer@oup.com\nGiven the rarity of cancers among screened women, the contribution of the Pap test to screening translated to earlier detection of at most five cases per million women per year.\nThe analysis found that HPV testing identified more women subsequently diagnosed with cancer and precancer than the Pap test.\nHowever, reports of rare HPV-negative, Pap-test-positive cancers are motivating continued use of both tests (cotesting) despite increased testing costs.\nTwo-thirds (67.9%) of women found to have cancer up to 10 years of follow-up at Kaiser Permanente were detected by the first cotest performed.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is comparing two different screening methods, which both have benefits, to using either one of them alone.\nWe were especially pleased that the release included a clear description of the benefit using absolute, rather than just a relative, risk number.\n\u201cGiven the rarity of cancers among screened women, the contribution of the Pap test to screening translated to earlier detection of at most five cases per million women per year. Two-thirds (67%) of women found to have cancer up to 10 years of follow-up at Kaiser Permanente were detected by the first cotest performed.\u201d\nBesides this number, the release included specific numbers for benefits of each test.\n\u201cHPV-negative/Pap test-positive results preceded only small fractions of cases of precancer (3.6%) and cancer (5.9%); these cancers were more likely to be regional or distant stage than other cases.\u201d", "answer": 1}, {"article": "George Bray, an obesity researcher at Pennington Biomedical Research Center in Baton Rouge who has also studied this topic and who wrote the accompanying editorial in JAMA, says that other studies \"show that you can do well on any diet as long as you stick to it.\nOn a low-glycemic index diet, you would avoid highly processed carbs such as white bread, white rice, many snack foods, prepared breakfast cereals, sugary desserts and sugary beverages, she says.\nThe study, funded by the National Institutes of Health, was designed to see if changing the type of diet people consumed helped with weight maintenance because dieters often regain lost weight.\n\"Participants burned 150 calories more on the low-glycemic index diet than the low-fat diet.\nSo scientists had 21 obese participants, ages 18 to 40, lose 10% to 15% of their initial body weight (about 30 pounds).\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The opening sentence of this story as originally published is incorrect. It states that dieters \u201cwere more successful maintaining weight on a low-carb diet than they were on a low-fat diet.\u201d According to the study, there was no statistically significant difference in participant weights during the 3 diet phases. The main finding was that participants resting energy expenditure was increased during low-carb and low glycemic-index phases than during the low-fat phase, which might theoretically improve weight loss maintenance. The story did do a good job of characterizing the difference in energy expenditure between the 3 diets and what it would take to burn the same amount of energy via physical activity.\n[Note: the incorrect opening line appears to have been pulled from an updated version of the story.]", "answer": 0}, {"article": "You've seen high-definition televisions. Now some medical centers are marketing their high-definitioncolonoscopes, which they say will detect more pre-cancerous polyps. Several recent studies have found a small benefit to high-definition colonoscopy over the standard variety, but gastroenterologists say physician technique is more important in detecting polyps than equipment.\n\nColonoscopy, a screening test doctors recommend for most people starting at age 50, allows doctors to remove pre-cancerous growths before they become...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story mentions two different studies as part of a broader evaluation of the new technology. In both cases, it shows that the new technology is a minor improvement. This point could have been made more forcefully by providing some absolute numbers. It says \"A 2,430-patient study by researchers at the Mayo Clinic in Jacksonville, published earlier this year in Clinical Gastroenterology and Hepatology, found adenomas in 28.8% of patients examined with high-definition colonoscopy, compared with 24.3% in those examined with standard colonoscopy. Polyps were found in 42.2% versus 37.8%. The scope tested, from Olympus, had both high-definition and a wide-angle view.\" Assuming that the groups were split exactly in half, this means that adenomas were found in about 350 patients versus about 300 with the standard method. ", "answer": 1}, {"article": "\"We found comparable detection between self-collection and physician-collection,\" Des Marais said.\nEarlier this year, the U.S. Preventive Services Task Force gave an \"A\" rating to HPV primary screening alone for women aged 30 to 65.\nThe researchers compared the results from self- and clinician-samples - which were tested for high-risk HPV strains that are linked to cervical cancer - to the Pap results and the results of cervical biopsies collected during colposcopy, which is a secondary diagnostic test that confirms the presence of cervical pre-cancerous lesions among women with abnormal Pap smear results.\nSmith said there is more work to be done, such as identifying ways to make the self-collection process more efficient and cost-effective, and getting FDA approval for the clinical use of self-collection for cervical cancer screening.\nFor the study, researchers mailed at-home, self-collection kits to low-income women in North Carolina who were overdue for screening by national guidelines.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a tricky question, as it is not clear how one should define the relevant benefit. The paper itself defines the goal of the study as evaluating the \u201cvalidity and acceptability\u201d of at-home self-collection of samples for HPV screening. If part of assessing \u201cacceptability\u201d was determining whether mailing self-collection kits improved screening rates, should the benefit be defined as successfully submitting a sample for screening? If so, the release failed, since it doesn\u2019t even tell readers how many women received screening tests through the mail (284 women, according to the related paper). However, validity is easier to address. How well did the at-home, self-collected samples compare to other screening tests? The release does address this head on. It states that the at-home, self-collected test indicated 12.4% of women had high-risk HPV infections. In-clinic, self-collected tests indicated 15.5% had high-risk HPV infections. And clinician-collected tests indicated 11.4% of women had high-risk HPV infections. Those are hard numbers, and we\u2019ll give the release the benefit of the doubt on this one. However, those three different numbers raise some questions, which the release doesn\u2019t do a good job of addressing. More on that below.", "answer": 1}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This entire story is essentially about comparing the benefits and risks of bisphosphonate use for treating osteoporosis. The story states early on that \u201cAn analysis in the New England Journal of Medicine last month estimated that for every 1,000 women with osteoporosis treated up to five years, bisphosphonates prevented 100 fractures and caused at most 1.\u201d But the story also notes that \u201cSome critics say the new analysis overestimates the benefits and underestimate the number of sudden thigh-bone fractures.\u201d There are some issues with the story handles benefits, but we\u2019ll address that under \u201cQuality of Evidence.\u201d \u00a0We\u2019d add that as much as we would like there to be simple and incontrovertible answers to questions surrounding benefits and risks, these numbers simply do not exist.", "answer": 1}, {"article": "Excessive drinking alone is linked to 88,000 deaths each year.\nThe good news is that the research suggests the spiritual aspect doesn\u2019t fully explain why the 12 steps are effective for some people.\nThere\u2019s a good explanation for that: While the research shows that 12-step treatment can be as effective as professional treatment modalities like cognitive behavioral therapy, the research also shows that the 12 steps don\u2019t work for everyone.\nWhile alternatives like SMART or LifeRing do exist, they\u2019re not nearly as available as AA \u2014 and they certainly aren\u2019t built into professional treatment programs in the same way as the 12 steps.\nOne tricky thing with this line of research is you can\u2019t really force people to participate in certain groups \u2014 so studies that randomly assign participants to AA, SMART, LifeRing, or Women for Sobriety may not be easy to do.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports the researchers\u2019 conclusion that\u00a0\u201c[Women for Sobriety], LifeRing, and SMART are as effective as 12-step groups for those with AUDs.\u201d\nThe story also quantifies that level of effectiveness when it says that studies broadly find that \u201cabout a third of people maintain recovery from alcohol addiction due to 12-step treatment, another third get something out of the treatment but not enough for full recovery, and another third get nothing at all.\u201d\nThe story acknowledges that there were some differences in the data \u2014 for example that those who reported SMART as their primary group \u201cseemed to have worse substance use outcomes,\u201d and that \u201cthere were lower odds of total abstinence among LifeRing members.\u201d It explains that those differences might be explained by the differing goals of the programs, as LifeRing doesn\u2019t emphasize complete abstinence as intensely as the 12-step programs. While it would be interesting to know just how much worse the outcomes were with these alternate groups, we don\u2019t think the omission is enough to merit a not satisfactory grade.", "answer": 1}, {"article": "Pulses become more intense when arteries near the heart are worn down -- usually by lifestyle factors such as poor diet and drug use -- and can no longer \"cushion\" the blood flow coming from the heart.\nIf the findings are confirmed by larger studies, they could vastly improve the ability to detect dementia in middle age.\nThe test, which analyzes the pulse of blood vessels in the neck, could become part of routine testing for cognitive decline, according to the study by scientists at University College London (UCL), who presented their work Sunday at the American Heart Association's annual scientific conference.\nThere is currently no cure for dementia, though medication can be used to temporarily treat its symptoms.\nMore research is needed to determine whether neck scans should become a part of routine testing for dementia.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Here\u2019s what the story says: \u201cPeople with the most intense pulses, which pointed to a greater and more irregular blood flow, were up to 50% more likely to suffer reduced cognitive functions.\u201d\nFirst, we need to point out that it wasn\u2019t a pulse researchers were measuring, but something known as forward compression waves (FCW) in the neck arteries.\nThe story doesn\u2019t include vital data-driven information for readers, such as:\nAlso the story never makes it clear that, based on these observational study results, we don\u2019t really know if doctors can \u201cspot dementia 10 years earlier\u201d just because of FCW. Nor that we have no know way of knowing to what extent identifying this risk allows patients to take action to improve their FCW score and therefore improve cognitive outcomes.\nSome useful reading:\nObservational studies: Does the language fit the evidence? Association vs. causation\nAbsolute vs relative risk", "answer": 0}, {"article": "Prostate cancer patients had a 28 percent higher relative chance of having a fatal heart attack and a 21 percent increased chance of dying from heart disease.\nStill, these risks were low in absolute terms: researchers estimated the hormone therapies would cause an extra 10 heart problems \u2013 like chest pain or a heart attack \u2013 a year for every 1,000 prostate cancer patients.\nHelen Rippon, head of research management at Britain's Prostate Cancer Charity, said the benefits of hormone therapy ultimately outweighed the increased risk of heart problems.\n\"What we can do with these results is to raise a flag with hormone treatments,\" said Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London and the study's lead researcher.\nExperts said the findings could make doctors think twice before prescribing the standard hormone treatment to men with prostate cancer, particularly if they are at risk of heart disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nOther than one general quote at the very end of the story, there is no explanation of why some men with prostate cancer are given hormonal therapies or how the expected benefits of the therapies compared with potential side effects.", "answer": 0}, {"article": "For more information visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.\nHalf of the study participants were randomly selected to receive 2,000 IU of vitamin D daily for the duration of the year-long trial, and the other half received an identical-appearing placebo, or dummy vitamin.\nHowever, those who saw the most significant decline in markers of inflammation were those who took vitamin D and lost 5 to 10 percent of their baseline weight.\nBiomarkers of inflammation were measured at the beginning and end of the study.\nAt the end of the study, all of the participants had reduced levels of inflammation, regardless of whether they took vitamin D, \"which highlights the importance of weight loss in reducing inflammation,\" Duggan said.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a good job of comparing data and providing explanations for the measurements used. We\u2019ll award a Satisfactory for that precision, but as noted below under \u201cEvidence,\u201d there was no explicit caution regarding the fact that measurements of interleukin-6 (IL-6) are only surrogates for the effects of weight loss and vitamin D on clinical outcomes related to inflammation (e.g. cancer diagnoses). IL-6 levels dropped in both the placebo and vitamin D arms, and it\u2019s not clear whether the statistically significant additional decline in IL-6 observed in the vitamin D group is clinically important.", "answer": 1}, {"article": "\"It's premature to make any conclusions,\" he said.\nBut Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, said that this study was too small to reach any definitive conclusion about the value of vitamin D in fighting prostate cancer.\nHowever, the study was small, and results from a larger trial aren't expected for several years, he added.\nThe findings also need to be replicated in a much larger number of patients, D'Amico said.\nMONDAY, March 23, 2015 (HealthDay News) -- Vitamin D supplements may slow or prevent low-grade prostate cancer from progressing, a small new study suggests.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says, \u201cmany who received vitamin D had improvements in their prostate tumors, while the tumors in the placebo group remained the same or got worse.\u201d It adds some quantification with this quote from a researcher: \u201cIn greater than 60 percent of those taking it, vitamin D actually made the cancer better.\u201d But this is not enough information for a satisfactory rating here. How much \u201cbetter\u201d were the cancers in the vitamin D group? How was this measured? Would the size of the difference be considered meaningful for the patient, or is it merely a \u201cstatistically significant\u201d difference? Since findings like this are likely to generate significant interest, the story had an obligation to explore these questions more thoroughly.", "answer": 0}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explained that women who used an IUD were 30% less likely to develop cervical cancer but did not provide any quantification of that number. Readers need to know: 30% less than what? The incidence of the disease would have improved the story and placed the 30% reduction into perspective. There are approximately 400-500,000 case of cervical cancer diagnosed annually with a 50% death rate overall worldwide. \u00a0The incidence of the disease varies widely with an incidence of approximately 16/100,000 in developing countries compared to approximately 10/100,000 in the developed world.", "answer": 0}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u2019s focus is on harms of treatment, but readers are left wondering about its purported benefits. (e.g. cutting less tissue and muscle, shorter scar, quicker recovery, less postoperative pain). The story provides no quantitative estimate of these (or other) potential benefits, though several studies have looked at them. This is a major limitation of the news story. By focusing on personal stories about complications, the story doesn\u2019t give readers the hard data about benefits they need to make a well-informed medical decision. (See evidence above.)", "answer": 0}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No quantification of benefits is provided.", "answer": 0}, {"article": "Researchers told the American Diabetes Association\u2019s (ADA) annual meeting that 13.0 percent of patients on Victoza died from cardiovascular causes or suffered non-fatal heart attacks or strokes, against 14.9 percent of those on placebo.\nThe Victoza trial, known as Leader, had been designed to show Novo\u2019s drug did not increase heart risk, so its superiority is welcome news for the company, especially as Sanofi\u2019s (SASY.PA) rival Lyxumia failed to show heart benefits in an earlier test.\nThere was also concern that Victoza did not appear to lower heart risks in American patients monitored in the study, despite doing so in other parts of the world and producing a solid result globally.\nJefferies analyst Jeffrey Holford said market expectations had been for a mid-to-high teens percent reduction in complications.\nMads Krogsgaard Thomsen, Novo\u2019s chief science officer, said the results should encourage doctors to use Victoza earlier, since they could now see it offered \u201clife-expanding\u201d treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u2019s\u00a0key\u00a0figure, which features in the headline, is a 13% reduction in the risk of heart attack, stroke and cardiovascular death. Unfortunately this figure\u00a0only measures the relative risk reduction; i.e. the change\u00a0in\u00a0risk for patients\u00a0who got Victoza as a percentage of the actual\u00a0risk of heart attacks, strokes or cardiovascular death for patients who didn\u2019t get Victoza.\nHowever, the story does also give actual risk figures\u00a0for\u00a0the treatment and placebo\u00a0group (13.0% vs. 14.9%). This allows a keen eyed reader to calculate the absolute risk reduction: a less impressive sounding\u00a01.9%. Because of this, the story rates Satisfactory on this criterion. It\u2019s worth nothing the news release didn\u2019t include the placebo group reductions.", "answer": 1}, {"article": "NEW YORK (Reuters Life!)\nEveryone in the study, published in the Journal of the American Medical Association, was at least 60 years old, and the researchers didn\u2019t include anybody for whom the live vaccine is not recommended.\nBut researchers cautioned that because they did not follow patients over the longer term, they didn\u2019t know how effective the vaccine is years later.\n\u201cThe human cost of shingles is enormous,\u201d said Michael Oxman, who studies infectious diseases at the University of California, San Diego, and was involved in a previous study of the vaccine.\nThe study, led by Hung Fu Tseng, a research scientist at Kaiser Permanente in Southern California, compared about 75,000 vaccinated members of the Kaiser Permanente Health plan with about 225,000 similarly aged members who weren\u2019t vaccinated.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThis story reports the apparent reduction in shingles risk among vaccinated participants in three ways:\n\u00a0\n\nAlthough the half-as-likely description got top billing, readers are given the results in complementary ways that help them understand just how common shingles is among the people studied and how much difference vaccination may make. The study authors highlighted these different ways of looking at the results, thus helping journalists provide a more complete picture to the public.\nThis story is the only one of the three we reviewed that clearly noted that the study looked at a limited time span and that the researchers can\u2019t say whether the effects of the vaccine persist through later years. That\u2019s an important caveat, since a 60-year-old who had chicken pox as a child is at risk for a shingles attack for the remaining decades of life. If the vaccine cuts the risk of attacks in half, but only for the first few years after vaccination, then the lifetime reduction in risk would be much smaller.", "answer": 1}, {"article": "Gastric bypass surgery involves making the stomach smaller, and attaching the lower part of the small intestine directly to the stomach, so much of the small intestine is bypassed.\nThe new study is notable because of the decade-long follow-up, said Maciejewski, who is also a research career scientist at Durham Veterans Affairs Medical Center.\nAt the study's one-year mark, those who had the bypass had lost 31 percent of their starting weight, but the non-surgical patients had lost just 1 percent.\nThe study helps address a knowledge gap about long-term outcomes of bariatric surgery, said Dr. Jon Gould, chief of general surgery at the Medical College of Wisconsin in Milwaukee.\nAnother possible limitation was the loss of patients during the follow-up, which could have affected the results, the researchers noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a nice job of making the weight loss comparisons\u2014both over time for gastric bypass surgery and across surgical options\u2014clear.", "answer": 1}, {"article": "\"I called the doctor back in and said, 'We're doing the chemo.'\nThe drawback of that study, Dr. Glick notes, is that it was not a large prospective randomized clinical trial, the gold standard in medicine.\nThe study is ethical, said Dr. Larry Norton of Memorial Sloan-Kettering Cancer Center in New York, because the only women whose treatment will be decided at random are those in a kind of gray area, not women for whom chemotherapy would be a clear benefit or clearly unnecessary.\nThe American study may eventually add such women, said Sheila E. Taube, who directs the cancer diagnosis program at the National Cancer Institute.\nAfter all, he notes, the national guidelines were based on results from large randomized clinical trials.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Again, Dr. Berry\u2019s subgroup analysis of several large chemotherapy trials, published in The Journal of the American Medical Association, was mentioned but the story didn\u2019t give quantified details. The combined absolute benefit of chemotherapy for disease free survival at 5 years was 22.8% for estrogen-receptor-(ER) negative women compared with 7.0 % for estrogen receptor positive women treated with tamoxifen. The 5-year absolute survival benefit of chemotherapy for women with ER-negative tumors was 16.7 % vs. 4.0% for ER-positive women treated with tamoxifen. Nonetheless, the overall quality of the discussion warrants a satisfactory score. ", "answer": 1}, {"article": "Aug. 10, 2011 -- Two of three patients dying of chronic lymphocytic leukemia (CLL) appear cured and a third is in partial remission after infusions of genetically engineered T cells.\nBut the therapy worked vastly better than University of Pennsylvania researchers David L. Porter, MD, Carl H. June, MD, and colleagues had dared to hope.\nWhat's new about the current treatment is the addition of a special signaling molecule called 4-1BB.\n\"Our results were absolutely dramatic.\nThe treatment success came in a pilot study that was only meant to find out whether the treatment was safe, and to determine the right dose to use in later studies.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story described very well the specific experiences of the patients who were involved in the study. It showed how two were in full remission and one was in partial remission.\nBut someone at WebMD has to take responsibility for that headline and the repeated reference to \u201ccure\u201d\u00a0 that is bothersome.\u00a0 Even when the story finally comes around to asking \u201cIs he cured?\u201d it still fails to directly address the unknowns and uncertainties. \u201cCure\u201d is such a loaded term \u2013 it is almost unhelpful in discussing such research.\nEven if investigators choose to use that term, journalists have an obligation to tackle the age-old baggage and consumer confusion that comes with it.\u00a0 This story started to try to do this, but fell short in our eyes.", "answer": 0}, {"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article reports that the drug showed a 94 percent success rate in the current trial, but does not provide any more detail.\u00a0 ", "answer": 0}, {"article": "MRI has long been known as an effective breast cancer screening modality that offers better sensitivity than mammography and ultrasound.\nHowever, with breast cancer remaining a major cause of cancer death in women, there is good reason to pursue the search for improved screening methods, according to the study's lead author, Christiane Kuhl, M.D., chair of the Department of Radiology at RWTH Aachen University in Aachen, Germany.\nThe new study showed that, consistent with previous research, breast MRI can depict these rapidly growing cancers with high reliability.\nAccording to Dr. Kuhl, the results suggest that MRI can serve as a useful supplemental screening tool for women at average risk, especially those with dense mammographic tissue, and that MRI is superior to supplemental ultrasound for this purpose.\nOf the 60 cancers detected in the study group over the observation period (7,007 screening rounds), 59 were found only using MRI, one was found also by mammography, and none by mammography or ultrasound alone.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The\u00a0supplemental cancer detection rate seems to be the main metric of success for the MRI screening. The news release does a good job presenting absolute benefits, not just relative benefits:\n\u201cBreast MRI detected 60 additional breast cancers, including 40 invasive cancers, for an overall supplemental cancer detection rate of 15.5 per 1,000 women. Of the 60 cancers detected in the study group over the observation period (7,007 screening rounds), 59 were found only using MRI, one was found also by mammography, and none by mammography or ultrasound alone.\u201d\nBut the news release only reports sensitivity and begs the question on the matter of specificity. Sensitivity and specificity are two sides of the same coin when it comes to assessing any screening method. A bit of digging on our own reveals that the MRI screening had a low false-positive rate of 2.9%.", "answer": 1}, {"article": "Researchers from Norway and Harvard University compared the death rates from breast cancer in four groups: one group of women from 1996 through 2005 who were living in Norwegian counties with screening; another group in the same time period who were living in counties without screening; and two similar groups from 1986 through 1995.\nIt concluded the availability of mammography screening corresponded with a reduction in the rate of death from breast cancer, \"but the screening itself accounted for only about a third of the total reduction.\"\nThe publication notes that in 2002, the World Health Organization concluded that mammography screening for women between ages 50 and 69 reduced the death rate from breast cancer by 25 percent.\nThe study, published in the New England Journal of Medicine, analyzed data from more than 40,000 women with breast cancer.\n\"Among women in the nonscreening group, there was an 18 percent reduction in the rate of death from breast cancer, as compared with the preceding 10-year period, presumably as a result of increased breast-cancer awareness, improved therapy, and the use of more sensitive diagnostic tools,\" the findings state.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "One of the strengths of the competing WebMD story was its use of quotes and stats from the accompanying editorial.\u00a0 This story didn\u2019t even acknowledge that there was an editorial.\u00a0 We don\u2019t understand how that could be overlooked. ", "answer": 0}, {"article": "In a statement, Dr. Lesley Russell, Cephalon's chief medical officer, said:\n\nThe most common side effects for Nuvigil, include diarrhea, headache, insomnia and nausea, according to Cephalon.\nBut the regulators weren't buying the evidence put forward by the company to prove the medicine's benefits in treating travelers' \"excessive sleepiness\" outweighed its risks.\nThe regulators just gave a second thumbs down to drugmaker Cephalon's application to sell Nuvigil as a remedy for jet lag.\nSo who wouldn't want a pill to fight the doldrums caused by skipping too many time zones too fast?\nFinally, it should be said that the Drug Enforcement Administration has made Nuvigil a federally controlled substance because it has the potential for abuse and dependence.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 There was no quantification of benefit \u2013 so we can\u2019t give a satisfactory score.\u00a0 But we also don\u2019t feel an unsatisfactory score is warranted since the story made clear that \u201cregulators weren\u2019t buying the evidence put forward by the company to prove the medicine\u2019s benefits in treating travelers\u2019 \u201cexcessive sleepiness\u201d outweighed its risks.\u201d", "answer": 2}, {"article": "The surgery \u201chad a transforming effect on how they get along in life,\u201d Dr. Tripathi said.\nYet the cases were judged to be a success because the seizures decreased in frequency over time.\n\u201cThe study in kids shows if you reduce the time from the onset of seizures from the 15 to 20 years you see in adults down to four to five years, the outcome is much better.\nSuccess rates ranged from 87 percent to 100 percent depending on the type of surgery used to correct the child\u2019s particular brain abnormality.\nThe researchers said that was to be expected and, without surgery, patients probably would have experienced similar problems as a result of their continuing seizures.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although there is some quantification of benefits, the article doesn\u2019t specify the actual number of children who had the primary outcome \u2014 a year without seizures.\u00a0 And thus the statement in the lead that brain surgery in the study group can produce a 10-fold increase in the odds of being seizure free after one year will be difficult for readers to put into perspective. And as noted above, the article does not specify how many operations or what types of surgery were performed on what ages of children.\nEditor\u2019s note: While the story doesn\u2019t state the absolute amount of children who experienced improvement after surgery compared to the control group, the story does give readers enough information to understand the measured benefits. For this reason, we changed our initial rating from Not Satisfactory to Satisfactory.\nSeventy-seven percent of the children were free of seizures at one year after the surgery, compared with seven percent in a control group of youngsters who received medical therapy alone while waiting for surgery.", "answer": 1}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This article presented no data whatsoever.\u00a0 In terms of descriptive information about benefits, it had, on the one hand, \u00a0the expert, Irwin Rosenberg indicating that if individuals are not vitamin B12 deficient, then there is no evidence that \u00a0B12 supplements are of benefit. \u00a0 On the other, you had an individual (Jane Riester, 27) indicating that although her B12 level was in the normal range (i.e. 200 pg/ml), she personally experienced benefit from supplementation.\nBy juxtaposing anecdote and evidence, it confuses the value of evidence.", "answer": 0}, {"article": "(\u201cEnjoyed\u201d?\nThe Baylor scientists were able to correct for those variables.\nThe mice with running wheels voluntarily ran an average of more than six miles a night, decreasing to about two miles late in pregnancy.\nThe research in question involved mice, not women.\nThe offspring of those mothers turned out to be about 50 percent more physically active than those born to mothers that hadn\u2019t had the exercise wheel option.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains that levels of physical activity in mouse kids of active mouse moms were 50% greater than were activity levels of kids of mouse moms who were prevented from using a wheel.\u00a0Normally, we\u2019d expect to see these numbers quantified in absolute terms, but since we\u2019re talking about mice, we don\u2019t think it\u2019s essential to get too precise, as that might feed the perception that the results are applicable to humans.", "answer": 1}, {"article": "Nucleix Ltd. develops, manufactures and markets innovative, non-invasive, molecular cancer diagnostic tests.\nTherefore, a screening test aimed at the entire risk group to assist in the early detection of the disease is highly needed and can dramatically increase lung cancer survival.\nTo date, there is no adequate screening process for the early detection of lung cancer, bringing 5-year survival rate to approximately 15%.\nSuch promising results combined with the simplicity of the test, could allow us to detect lung cancer at the early stages and hence improve 5-year survival from about 15% to about 50-70%.\nAt the moment, low-dose computerized tomography (LDCT) screening which has been shown to reduce mortality from lung cancer in the very large NLST study is only reimbursed in the US for high-risk individuals.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release touts this as a new screening tool to detect lung cancer, and the release provides numbers on both the specificity and sensitivity of the test, indicators of how good the test is at detecting disease and at ignoring disease-free individuals.\nWhile that\u2019s a good start, there are also big problems here. The\u00a0release claims that the test will assist with the early detection of lung cancer in people who are seemingly healthy. And yet the data referenced in the release came from patients already known\u00a0to have lung cancer and either current or former smokers who didn\u2019t have lung cancer \u2014 not a general population of at-risk people whose lung cancer status is unknown. This is a crucial distinction. Testing in\u00a0a much broader group is needed to determine how effective the test would actually be when used to screen healthy people in practice.", "answer": 0}, {"article": "Angioplasty, which uses a balloon to open blocked arteries, has been a popular alternative to bypass surgery in part because it brings less trauma to the patient.\n\"The exactness of bypass surgery is so high that many people are reluctant to do it without tactile as well as visual feedback.\"\nThe maker of the robotic systems, Intuitive Surgical Inc. of Sunnyvale, Calif., is an enthusiastic backer of the University of Chicago's initiative.\nUsing robotics to bypass major blocked arteries and putting stents in other blocked arteries is gaining some currency, Rabbitt said, although few surgeons have come close to Srivastava's familiarity with the robot.\nSrivastava said it is true that the normal sense of touch is missing from robotic work, and that is a shortcoming, but it can be overcome with practice.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article does not cite specific figures of benefits. It uses several anecdotes that suggest the surgery is safe, effective and likely to speed recovery time. ", "answer": 0}, {"article": "They were then randomized to receive either Forteo or a placebo.\nAfter eight weeks of treatment with Forteo, though, the pain went away and the osteonecrosis resolved, reported the authors, from Austin Health in Melbourne, Australia.\nAfter six weeks of therapy, patients in the Forteo arm saw greater healing of their jawbone and this continued throughout one year of follow-up.\n\"There was a significant improvement in clinical measures of gum and bone,\" McCauley stated.\nBut the two papers in the Oct. 16 online issue of the New England Journal of Medicine report success with teriparatide (Forteo) in rebuilding bone.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits described in the clinical trial were not quantified or described in sufficient detail. It simply states that \u201cgreater healing\u201d was noted in patients receiving Forteo. The exact meaning of the phrase is unclear and could leave readers with an overly optimistic impression of the value of Forteo in this group of patients.\n The story provides an adequate amount of detail concerning the case report, noting the patient was pain-free after treatment. It should have noted however how long the patient was followed.", "answer": 0}, {"article": "The amygdala processes incoming emotionally salient stimuli, whereas the prefrontal cortex, as the executive center of the brain, decides whether the incoming stimuli are noteworthy.\nThe initial results demonstrate that the efficacy of this digital therapeutic is comparable to drug therapy, with a highly favorable safety profile.\n\"The aim is to target the thinking abnormality we see in patients with MDD - that of perseverating, ruminating, obsessing, dwelling on the negative - by activating these two nodes (emotion processing and cognitive control) simultaneously.\nThis treatment was developed at the Icahn School of Medicine at Mount Sinai by Brian Iacoviello, PhD, an Assistant Professor of Psychiatry who is Director of Scientific Affairs for Click Therapeutics, and Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean and Professor of Psychiatry, Neuroscience, and Pharmacological Sciences.\nPatients using this therapeutic are asked to identify an emotion displayed in a series of faces, and for each face, they are asked to identify the number of faces earlier in the series in which they encountered the same emotion.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides only percentages, with no actual numbers for the patients who did and did not receive the therapy. We don\u2019t know if it was 10 patients or 10,000 patients. We also don\u2019t know how the symptoms were measured, nor how severe the depression was in the two groups at baseline and afterward. (We looked up a presentation of the study: It had just 26 people.)\nExcerpt: \u201cIn the trial, the therapeutic reduced MDD symptoms by 42 percent in the experimental group after six weeks compared to 15.7 percent in the control group, which was given a similar task using simple shapes instead of emotions.\u201d\nAlso: If the groups received therapy for six weeks, how often did they receive it each week? What was the control group receiving? Was it once for 45 minutes or twice a week for 30 minutes? All these details would help us understand this.", "answer": 0}, {"article": "\u201cPeople who smoke a pack of cigarettes a day are chronically inflaming their lungs,\u201d he says.\nThe inexpensive CRP test could identify those with higher inflammation, who might be candidates for taking a drug like canakinumab.\nWhen it comes to heart disease, however, it\u2019s clear that inflammation-fighting medications like canakinumb may represent the next generation of treatment.\nBut whether anti-inflammatory agents, like canakinumab, or even over-the-counter drugs like aspirin, should be part of standard cancer treatment isn\u2019t clear yet.\nSo the study further solidifies the fact that heart doctors should be measure inflammation as well as cholesterol in their heart patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states:\n\u201cAfter four years, the people who received the drug had a 15% lower chance of having a heart attack or stroke compared to people who didn\u2019t get the drug.\u201d\nThis is an error. The benefit only applied to second heart attacks, not strokes.\nAlso, what does 15% translate to in absolute numbers? This wasn\u2019t explained, so we\u2019ll elaborate here:\u00a0The way researchers measured results was in \u201cevents per 100 person-years\u201d, and the \u201cevents\u201d were non-fatal heart attack, non-fatal stroke, or death from a cardiovascular-related cause. In the placebo group, there were 4.50 cardiac events per 100 person-years. In the group receiving 150 mg doses of\u00a0canakinumab, there were 3.86 events per 100 person years. Of the various doses given (50, 150 and 300 milligrams), the 150 mg dose was the only statistically significant result, and it was only because of non-fatal heart attacks.\nAs noted in an editorial that accompanied the study, this was translated as a \u201cmodest\u201d benefit. The story fails readers by not including that detail. For a comparison on how to write about the study results more responsibly, see the Reuters story.", "answer": 0}, {"article": "GAITHERSBURG, Md.\nThe therapy is exciting, AIDS specialists say, even though it is at least three years from market, because it could offer a completely new tool to combat a 25-year-old foe.\nThat's why some patients, doctors, and researchers are excited about an experimental drug based on an herb known by the Latin name Syzigium claviflorum that had been used in Taiwan to treat diarrhea and stop bleeding.\nBevirimat is being developed as physicians begin to use drugs from different classes in combination to fight the virus at different steps in its life cycle.\nNow its derivative is being tapped to fight HIV by a small Watertown-based biotechnology company.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "If the story is even going to report on a drug that is three or more years away from FDA approval and still undergoing initial safety testing in humans, it should at least temper enthusiasm. The story did point out that the drug is at least three years away from being on the market and still being tested. And the story did end with a \u201cproof of the pudding\u201d comment from NIH\u2019s Dr. Fauci. However what is missing is a comment that we do not know how much impact the drug would have on survival or quality of life, for example. And the story is laden with comments such as \u201cgenerating excitement\u2026researchers are excited\u2026the therapy is exciting\u2026so far it looks potent and it has a great safety profile\u201d \u2014 all without any hard data provided. ", "answer": 0}, {"article": "Co-authors include: Drs.\nThe results of the study show that choice of sedation medication had the biggest impact on the incidence of adverse events and need for significant interventions in response to those events.\nThis study was funded by a Canadian Institutes of Health Research (CIHR) team grant in Pediatric Emergency Medicine.\n\"We've been able to identify sedation medications and practices associated with the best clinical outcomes, which is practice-changing.\"\nThe overall incidence of adverse events in the study population was 11.7%.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release did not give absolute numbers for the benefits, just percentages. The main benefit statement is in the excerpt below. We wish the release had told us the number of patients in the groups with the highest and lowest risk for side effects.\n\u201cThe results of the study show that choice of sedation medication had the biggest impact on the incidence of adverse events and need for significant interventions in response to those events. The incidence of serious adverse events was lowest among patients sedated with ketamine-alone and highest among patients sedated with combination drugs ketamine plus propofol or fentanyl.\u201d", "answer": 0}, {"article": "LONDON -- AstraZeneca PLC said Monday its experimental heart pill Brilinta was more effective at preventing heart attacks and strokes in a large clinical trial than the blockbuster pill Plavix, boosting commercial prospects for the U.K. drug maker's still unmarketed treatment.\n\nPlavix, which is marketed by Sanofi-Aventis SA and Bristol-Myers Squibb Co., was the second-biggest-selling drug in the world last year, with global revenue of $8.6 billion, according to IMS Health. Any competitor to it could have a shot at big sales.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes the study as \"unusually large,\" invovling 18,600 patients with acute coronary syndromes. It describes the trial as a head-to-head comparison between Brilinta and Plavix and specifies the clinical end points used in the research.\u00a0 \nThe story cites the company\u2019s description of the results as \"statistically significant\" in a way that favors Brilinta over Plavix.\nGiven the fact that little additonal data has been released [see the company\u2019s press release on the early Brilinta results], the story earns a \"Satisfactory\" rating under this criterion. ", "answer": 1}, {"article": "More than 25 million people in the United States and about 2.5 million Canadians suffer from chronic rhinosinusitis, or sinus infection, and experience compromised quality of life.\nPatients who were instructed to use nasal irrigation showed improvement at 3 and 6 months, as measured by the Rhinosinusitis Disability Index.\nSince the impact was less than in previous studies that had used more intensive coaching about nasal irrigation, the authors suggest that further research is needed to understand how much coaching of patients is required.\n\"Although there was no significant difference in either physician visits or antibiotic use, as might be expected over only a 6-month follow-up period, our findings concerning consultations are important in the longer term, given antibiotic use increases the risk of antimicrobial resistance.\"\nThe study involved 871 patients from 72 primary care practices in England who were randomly assigned to 1 of 4 advice strategies: usual care, daily nasal and saline irrigation supported by a demonstration video, daily steam inhalation, or combined treatment with both interventions.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits information was pretty spare. We would have liked some numbers \u2014 rather than simply this sentence:\n\u201cPatients who were instructed to use nasal irrigation showed improvement at 3 and 6 months, as measured by the Rhinosinusitis Disability Index. Steam inhalation did not appear to alleviate symptoms of sinusitis.\u201d\nHow much improvement? Is there a percentage or absolute number that could have been included?\nAccording to the published study, \u201cBy 6 months, significantly more patients maintained a 10-point clinically important improvement in the RSDI score with nasal irrigation (44.1% v. 36.6%); fewer used over-the-counter medications (59.4% v. 68.0%) or intended to consult a doctor in future episodes.\u201d", "answer": 0}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that patients who received whole-brain radiation \u201cperformed significantly worse\u201d three months after treatment on memory and verbal communication tests, as well as scoring lower on a quality of life questionnaire. However, the story doesn\u2019t tell us what \u201csignificantly worse\u201d means, nor does it say how much lower the quality of life scores were. The story also doesn\u2019t tell us if all of the relevant patients scored lower, or if there was a significant amount of variation in terms of patient response. Because the relevant study is not available for review (it was presented at a conference), and the story doesn\u2019t link to the relevant study abstract, it\u2019s difficult or impossible for readers to look up these details.", "answer": 0}, {"article": "\u201cLow levels of vitamin B12 are surprisingly common in the elderly.\"\nDuring the study, published in Neurology, 17 people developed Alzheimer\u2019s disease.\nBlood levels of folate, another nutrient believed to lower homocysteine levels, were not linked to Alzheimer's disease risk.\nIn addition, each micromolar increase in blood homocysteine level raised the risk of Alzheimer's disease by 16%.\nResearchers found that each picomolar increase in blood vitamin B12 level was associated with a 2% reduction in the risk of Alzheimer's disease among the elderly.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "Malignant pleural mesothelioma is a rare and aggressive cancer that represents about 90 percent of all malignant mesothelioma cases.\nThe study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.\nThere are multiple studies going on right now to confirm these findings, which the authors note is a necessary step before the drug can become a standard second-line therapy.\nFourteen patients passed away during the study, while four were still undergoing treatment as of the study's writing.\nPHILADELPHIA - Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits aren\u2019t put into clear context. It is only partially useful to know that 14 of 25 patients had \u201creduced tumor size\u201d with pembrolizumab every two weeks. How much reduction was there?\nWithout a control group we have no idea how long patients would survive in the absence of the therapy, even if we are told in the release that \u201cMost patients survive less than a year\u201d with chemotherapy as the first-line treatment. We\u2019re told that patients given pembrolizumab \u201cwent about six months without their disease progressing\u201d and that 14 patients passed away during the study, and that four were still undergoing therapy.\nHow significant is it that 14 patients died during the study?\nThe study states the median survival from pembrolizumab treatment to be 5.7 to 10.7 months, very similar to the 6-7 months of standard second-line therapy noted in the news release.\nMoreover, the goal of the study is to show safety, so claiming it\u2019s \u201ceffective\u201d is premature.", "answer": 0}, {"article": "For men, the difference came out to 103 fewer cancer deaths a year per 100,000 people; for women, the number was 42.\nDr. Kausik Ray of St. George\u2019s University of London, who has studied aspirin, said the new study did not look at overall death rates or side effects such as serious stomach bleeds.\nEarlier this year, Ray\u2019s team published an analysis of previous aspirin trials showing the medication did not prevent deaths from heart disease or cancer, and was likely to cause more harm than good.\nStill, Thun said the results would favor broadening the aspirin guidelines to include cancer prevention based on an individual risk-benefit assessment.\nOne of the problems with the new study as well as with previous aspirin trials, he said, is something called detection bias.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Much better than the competing WebMD story, this story appropriately stated:\n\u201cPeople who said they took daily aspirin \u2013 whether \u2018baby\u2019 or adult strength \u2013 had a 16-percent lower risk of dying from cancer than non-users overall, Thun and his colleagues found.\nFor men, the difference came out to 103 fewer cancer deaths a year per 100,000 people; for women, the number was 42.\u201d", "answer": 1}, {"article": "\"My reaction was, 'Well, you smoked for 30 years.\nAnd, after five years, almost 9 out of 10 patients were alive and cancer free.\nOne year after surgery, more people had died from other causes than died from lung cancer.\nBut many patients can survive and even thrive after surgery, says Dr. Prasad Adusumilli, a thoracic surgeon at Memorial Sloan Kettering Cancer Center in New York.\nThis was the case for Morton Pollner, who is one of Adusumilli's patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is\u00a0only one short paragraph dedicated to quantifying the benefits of surgery, and it\u2019s inaccurate:\n\u201cOne year after surgery, more people had died from other causes than died from lung cancer. And, after five years, almost 9 out of 10 patients were alive and cancer free.\u201d\n\u201c9 out of 10\u201d would mean 90% survived and 10% died within the five years. But as the study revealed, 19.9% of all patients had died within five years:\n\u201cThe 30-day, 90-day, 1-year, and 5-year mortality rates were 0.7%(n=15), 1.2%(n=27), 4.1%(n=90), and 19.9%(n= 436).\u201d\nThis means nearly twice as many people died than what the NPR study suggests.", "answer": 0}, {"article": "In undeveloped countries, 75,000 women die from pre-eclampsia each year.\nThe cost of treating mothers with pre-eclampsia is $45 billion a year in the United States, Europe, Asia, Australia and New Zealand, the researchers said.\nSuch a \u201cmetabolic fingerprint\u201d test could save the lives of thousands of women, Philip Baker of the University of Alberta in Canada, who helped lead the study, said in a statement.\nIt detected around 90 percent of the cases, with a false positive rate of about 24 percent, meaning 24 percent of the women flagged in the test as having a risk of pre-eclampsia would never actually develop it.\nThey found a series of 45 different compounds linked with metabolism that were different in the women destined to develop the condition, and said that could form the basis of a test.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that the study\u00a0\"identified 40 organic molecules to be significantly elevated and 5 that were reduced in plasma at 14 to 16 weeks\u2019 gestation,\" quoting the study. It would have been nice to have some context for those numbers. Is elevation bad? Is reduction good? The numbers just float and don\u2019t add to our understanding. The story goes on to say, \"From this series of compounds they narrowed down a list of 14 sugars, fats and amino acids that were different in the women who developed the condition. It detected around 90 percent of the cases, with a false positive rate of about 24 percent, meaning 24 percent of the women flagged in the test as having a risk of pre-eclampsia would never actually develop it.\" Given that the sample size is so small, the story should have provided the numbers both in percentages and in absolute terms. That 90 percent figure sounds huge, but we are still only talking about 71 women. And, of those, 17 were false positives. Those numbers would have been good context for helping readers understand the findings. The study itself is actually fairly easy to understand.", "answer": 0}, {"article": "And then there's the lengthy recovery ahead, a less than ideal situation to find yourself in.\"\nThe team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells.\nThe researchers are continuing to investigate the use of this drug to treat Dupuytren's disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.\nIn conjunction with Professor Sir Ravinder Maini, Sir Marc identified TNF as a therapeutic target in patients with rheumatoid arthritis.\nThis randomised trial (phase 2a) recruited 28 patients with Dupuytren's disease who were scheduled to have surgery in Edinburgh to remove diseased tissue in their hand.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "According to the release, a single injection of Humira \u201cresults in the reduction of the cell characteristics responsible for progression of Depuytren\u2019s disease.\u201d\nThis is vague, misleading, and inaccurate because what causes progression in this disabling hand disease is unknown, and most certainly can not be definitively attributed to \u201ccell characteristics.\u201d\nThe study was designed to better understand the impact of adalimumab on local level of several disease markers namely myofibroblast phenotype and collagen production in excised nodule samples and not necessarily on disease progression. \u00a0The results were far from as conclusive as the report would suggest with only one marker demonstrating a difference over placebo at the highest dose level.", "answer": 0}, {"article": "Added Dr. John C. LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: \"It's very preliminary but it's important because the last drug out of the barrel of this type was not a success.\n\"We saw very encouraging reductions in clinical events,\" said Dr. Christopher Cannon, lead author of the study, which also appears in the Nov. 18 issue of the New England Journal of Medicine.\n\"Currently, we're not convinced that manipulation of HDL matters, though certainly it's promising,\" said Weintraub, who added that results should be available relatively soon from other trials exploring the issue.\nA big study to confirm the results would take four to five years to complete so the drug is still years away from market, said Cannon, who is a cardiologist with Brigham and Women's Hospital in Boston.\nIt also didn't result in the blood pressure increases that helped doom torcetrapib.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story emphasizes the safety questions that were at the heart of this trial. It also tells readers plainly that it is unknown whether the changes in cholesterol levels seen in this trial have beneficial health effects. It does an impressive job in describing the uncertainties associated with drug manipulation of HDL blood levels. After reporting that the HDL cholesterol numbers rose from 41 mg/dl to 101 mg/dl, the story quotes an independent source saying, \u201cCurrently, we\u2019re not convinced that manipulation of HDL matters, though certainly it\u2019s promising.\u201d Unlike some other stories about these trial results, this report repeatedly tells readers that any discussion of real health benefits will have to wait at least until after a trial designed specifically to measure such outcome is conducted.", "answer": 1}, {"article": "\"I no longer work for a living,\" notes Dr. Ross, who now resides in Westfir, Ore. \"I wake up every day eager to hear about how a plant-based diet and a healthful lifestyle is changing and saving lives in our community.\nFor clinicians concerned about spending extra time in and outside of the exam room, the study authors encourage time-strapped health care providers to refer patients to registered dietitians who can help with the transition to a plant-based vegetarian diet.\nThe meta-analysis appears as an online advance in Nutrition Reviews.\nThe authors predict the strong correlation between vegetarian diets and lower cholesterol levels may be due to the association a plant-based diet has with a lower body weight, a reduced intake of saturated fat, and an increased intake of plant foods, like vegetables, fruits, legumes, nuts, and whole grains, which are naturally rich in components such as soluble fiber, soy protein, and plant sterols.\nWASHINGTON--A new dietary review of 49 observational and controlled studies finds plant-based vegetarian diets, especially vegan diets, are associated with lower levels of total cholesterol, including lower levels of HDL and LDL cholesterol, compared to omnivorous diets.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This release clearly states the benefits of a plant-based vegetarian diet for cholesterol. In clinical trials, a plant-based diet was reported to lower total, high-density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol levels by 12.5 mg/dL, 3.4 mg/dL, and 12.2 mg/dL respectively. In observational studies, a plant-based diet was associated with reductions in total, HDL, and LDL cholesterol levels of 29.2 mg/dL, 3.6 mg/dL, and 22.9 mg/dL respectively. The release also included information on the lack of association between dietary patterns and blood triglyceride (a type of fat) levels \u2014 an important mention of results that were not statistically significant.\nHowever, the case description based on the physician\u2019s subjective personal experience was over the top and detracted from the more balanced aspects of the release.", "answer": 1}, {"article": "The National Fibromyalgia Association estimates that about 10 million Americans, mostly women, have fibromyalgia, an unexplained condition characterized by chronic pain and fatigue.\nAlso, small, preliminary studies suggested the drug can reduce pain and fatigue in people with fibromyalgia.\nXyrem also helped reduce fatigue, stiffness, and other symptoms, she tells WebMD.\nXyrem, which is approved by the FDA for the treatment of narcolepsy, corrects the same disturbed sleep patterns that studies have shown are common in fibromyalgia patients, Jones says.\nThe new study was presented at the annual meeting of the American Pain Society.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "When a person has diabetes, their body either doesn't produce enough insulin or doesn't process blood sugar properly.\nAt the root of that is the failure of beta cells, whose job it is to produce insulin.\nBut here's the thing: BYU researchers have discovered certain compounds found in cocoa can actually help your body release more insulin and respond to increased blood glucose better.\nTo discover this, collaborators at Virginia Tech first fed the cocoa compound to animals on a high-fat diet.\nWhile there has been a lot of research on similar compounds over the past decade, no one has been able to pinpoint which ones are the most beneficial or how exactly they bring about any benefit -- until now.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This news release would have been fine if it had stuck to the statement in the last paragraph that the research points the way toward refining specific compounds and then testing them as potential treatments. But that measured summary is negated by the absurd suggestion near the top of the release that people might get some benefit by eating a lot of cocoa (even though the release then questions its own suggestion). It\u2019s strange that one of the researchers gave a quote about eating chocolate when their journal article clearly states that the key insulin-secreting beta cells \u201cwon\u2019t be exposed to sufficient concentrations under physiologic conditions.\u201d\nNeither the release or the study provide any hard numbers for context, only a description of the results and\u00a0the drawings, which make the differences seem much less than \u201cdramatic.\u201d ", "answer": 0}, {"article": "Therefore, despite pancreatic cancer representing less than 3% of all cancer cases, more people currently die from it than breast cancer.\nA new blood test developed by researchers at Lund University in Sweden, Herlev Hospital, Knight Cancer Center and Immunovia AB, can detect pancreatic cancer in the very earliest stages of the disease.\nSince the immune system is the first to respond to threats like complex diseases, such as cancer, autoimmune diseases and infections, the microarray was designed to mirror this early response.\nFrom those hundreds of markers, 29 markers were selected to detect pancreatic cancer with 96% accuracy at stage I and II.\nThis provides information about the development of tumours long before being visible on CT or detected by ctDNA.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "From the lead author:\n\u201cOur test can detect pancreatic cancer with 96% accuracy at stage I and II while there is still the possibility of successful surgical intervention\u201d\nUsing \u201caccuracy\u201d without context is misleading for two reasons. First, it\u2019s not until the end of the news release that we learn that these impressive results are in people with already documented pancreatic cancer. Second, the 96% is somehow\u00a0correlated with specificity (number of true cancers picked up by the test) and sensitivity (number of true cancers missed). That means 4% of those with cancer will be missed by the test (but the paper reports 6% false-positives; again, confusing).", "answer": 0}, {"article": "Migraines are characterised by an intense, throbbing headache, sensitivity to light and noise, nausea, vomiting, low energy, and visual disturbances.\nLead investigator Prof Peter Goadsby, from King\u2019s College hospital, London, said: \u201cStrive \u2026 represents an incredibly important step forward for migraine understanding and migraine treatment.\u201d\n\nThe findings, reported in the New England Journal of Medicine, clearly showed that blocking the CGRP pathway could reduce the impact of migraine, he said.\nThe trial, called Strive, compared patients taking erenumab for six months with others given a non-active placebo dummy drug.\nHowever, those given a placebo also saw benefits, with 26.6% of participants in this group experiencing such a reduction.\nIn half the patients treated, migraine duration was reduced at least by half.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story does a decent job summing up the study design and presenting key results from the study, down to the differences between dosage and even placebo groups.\nWhile we give the story a satisfactory score on this criterion, we also suggest that the numbers could have been explained far more clearly. Our heads are still spinning a bit from this paragraph in the story:\nThe research revealed that by months four to six, at least a 50% reduction in mean migraine days per month was achieved for just over 43% of patients injected under the skin with 70-mg of erenumab each month, while half of patients injected with the higher dose of 140-mg had such results. However, those given a placebo also saw benefits, with 26.6% of participants in this group experiencing such a reduction.\nA sidebar infographic would have helped, breaking down precisely how many days, how many people, and on what dose. Yes, the results were quantified, but in a less than optimal way.", "answer": 1}, {"article": "Kale and oranges are high in vitamin C, another antioxidant.\nIn the study, Farvid and her team could not find any significant relationship between fruit juice and breast cancer risk; that may be because fruit\u2019s anti-cancer effects may have to do with the fiber found in the whole fruit, which is stripped out of juice.\nAbout half of the 90,000 women who participated in the Nurses\u2019 Health Study also answered questions about their typical diet while they were teens.\n\u201cThis study also has an important message for schools and the need to provide students with the opportunity to consume more fruits and vegetables as part of the school meal program.\u201d\n\nFarvid wasn\u2019t able to document a strong relationship between vegetables and lower breast cancer risk, but says that may be because the study wasn\u2019t powered enough to detect an effect.\nWhile challenging, changing diet can be a relatively easy way to alter a woman\u2019s breast cancer risk equation, beginning even at a young age.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells readers that women \u201cwho reported eating nearly three servings of fruit a day on average [during adolescence] had a 25% lower risk of developing breast cancer than those who ate half a serving of fruit.\u201d However, it\u2019s not clear where that number comes from. And what does that mean in terms of absolute risk? I.e., how likely is someone who ate only half a serving of fruit as a teen to get cancer? The story doesn\u2019t tell us \u2014 and that is key. If a story tells readers that eating \u201cnearly three servings of fruit\u201d as a teen means a \u201c25% lower\u201d risk, it needs to say 25% lower than what.", "answer": 0}, {"article": "\"If someone said to my husband, 'I know this has been a rough road for you, and a big impact on your sex life, but if she stays on it another five years.\nThat's significant, given that tamoxifen is used by hundreds of thousands of women worldwide, says Gray, whose study was presented Wednesday at the annual San Antonio Breast Cancer Symposium.\nStudies show that only 80% of women take tamoxifen for five years, Litton says.\nTamoxifen is the only hormonal option for women before menopause, Litton says.\nSome patients may be reluctant to prolong their use of a drug that causes so many side effects, says Boston breast cancer survivor Alicia Staley.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story was reviewed by two breast cancer survivors, both trained in how to evaluate evidence by the National Breast Cancer Coalition\u2019s Project LEAD training.\u00a0 In addition, one earned her PhD in epidemiology. Here\u2019s how they reacted:\nBenefits were confused from the beginning of the article. \u00a0Assuming all breast cancer patients have the same profile and benefit is misinformation. For example, the Young Survival Coalition sent out a statement to members that pointed out:\nOverall, the patient population in this study tended to have low nodal involvement and most participants were over the age of 45 at time of initial diagnosis.\u00a0 53% of the 10-year group were node negative and 54% of the five-year group were node negative.\u00a0 Only 16% of both groups had four or more nodes involved.\u00a0 Also, only 19% of the 10-year group and 18% of the five-year group were under age 45 at time of diagnosis.\u00a0 In both the five and 10-year group, 89% of study participants were postmenopausal at time of their entry into the ATLAS trial.\u00a0 In the five-year and 10-year groups , 47% and 48% of patients respectively had tumor sizes ranging from 1 to 20 mm (equivalent to 2 cm or under), while 39% and 38% respectively had tumor sizes between 21-50 mm (2 to 5 cm).\nWomen with breast cancer look for this kind of detail in order to make the findings meaningful in their lives.\u00a0 There are ways to summarize this data in a way even in a daily news story.\nAllowing the study author to use the word \u201ccure\u201d in an unchallenged manner is troublesome.\nA major omission from this story was survival benefits were not seen until years AFTER tamoxifen treatment had ended (rather than\u00a0during treatment).", "answer": 0}, {"article": "CT scanning uses X-rays and computers to produce a clearer image than traditional X-ray techniques, but CT also uses higher radiation doses to generate those images.\nThat\u2019s consistent with the findings of the National Lung Screening Trial in the U.S., which in November released data \u2014 published online in the New England Journal of Medicine last week \u2014 showing that 20 percent fewer middle-aged heavy smokers died of lung cancer when they were screened annually with a CT scan compared to a standard, less detailed chest X-ray.\nFive years after their diagnosis, 95 percent of people whose cancers were found through a CT scan were still alive, compared to 73 percent diagnosed with an X-ray and 40 percent of patients who had not been screened and whose symptoms led to discovery their disease.\nDr. Christine Berg, one of the leaders of the U.S. screening studies, said that generally about a quarter of chest CT scans show some kind of abnormality \u2014 but 96 percent of those abnormal scans turn out not to be lung cancer.\nMoreover, they warn that while regular screening might help doctors catch cancer earlier, it also comes with a high price tag and added risks to patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explained:\u00a0\u201cFive years after their diagnosis, 95 percent of people whose cancers were found through a CT scan were still alive, compared to 73 percent diagnosed with an X-ray and 40 percent of patients who had not been screened and whose symptoms led to discovery their disease.\u201d", "answer": 1}, {"article": "\u201cIf out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it\u2019s a lot.\u201d\n\nAccording to Alvaro Pascual-Leone, director of the hospital\u2019s Berenson-Allen Centre for Non-invasive Brain Stimulation, brain stimulation - or transcranial magnetic stimulation - involves a very low current applied to a specific part of the brain and is approved by the FDA for treatment of a variety of ailments and diagnostic applications.\nThe device, which consists of a chair containing an electronic system and software in the back and a coil placed at the head, has been tested on mild to moderate Alzheimer\u2019s patients who suffer from dementia but are not totally dependent.\nThe device, which combines electromagnetic stimulation with computer-based cognitive training, is already approved for use in Europe, Israel and several Asian countries such as Singapore.\n\u201cWe see improvement lasting for 9-12 months and the good thing is that patients can return and undergo treatment again,\u201d Baror said.\nPascual-Leone, who is principal investigator in the Harvard trial, said that of 12 patients in the study, six received the real treatment and all showed cognitive improvement.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The way benefits were framed in this story is almost a carbon copy of how company-controlled release of data is communicated to the public.\nThe story quoted the company CEO (!) saying \u201cWe see improvement lasting for 9-12 months and the good thing is that patients can return and undergo treatment again. If out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it\u2019s a lot.\u201d\nHow many see improvement lasting 9-12 months?\u00a0 All of them? (Later in the story, an investigator said only 6 patients received the real treatment (!) and all showed cognitive improvement.)\nHow is \u201cimprovement\u201d defined and measured?\nYou also have to read the piece carefully.\u00a0 The \u201ctreatment\u201d does not include just sitting in a chair.\u00a0 It also includes unspecified cognitive training.\u00a0 Since the study design is not noted we don\u2019t know if there was a control group or a group who simply received cognitive training without the use of transcranial stimulation.\n\u00a0", "answer": 0}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does report on the results of a major trial from 20 years ago that concluded patients who were randomized to surgery had about a 5 percent risk of stroke or death within three years, \u201cless than half that of people treated only with drugs.\u201d But this statistic is overwhelmed by the headline (The Scan that Saved My Life) and the punchline, \u201cmostly I feel lucky to have gotten a test that may have saved my life.\u201d\nA more recent review of the evidence by the international Cochrane Collaboration concludes that the \u201cnumber needed to treat\u2018 (for the type of blockage and symptoms the reporter had) would be six patients. Meaning, six people have to be treated to prevent one stroke or death over a five-year period. In other words, the surgery likely does not alter the outcomes of five out of six patients. Either they wouldn\u2019t have had a stroke or died even without treatment or they did have a stroke or died despite undergoing surgery.", "answer": 0}, {"article": ".\nIn a second, simultaneous trial, termed METREO, the team assessed the effect of a higher dose of mepolizumab in 675 patients with elevated eosinophil levels.\nPatients included in the trials were still having flare-ups despite a year of a standard treatment known as \"triple inhaled therapy\" that includes bronchodilators and glucocorticoids.\nThis finding indicates that patients with higher initial eosinophil counts benefited more from mepolizumab than those with lower eosinophil counts, Sciurba said.\nThe safety profile of mepolizumab did not differ from placebo in either trial.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The primary endpoint of the studies was to reduce the number of flare-ups that sent COPD patients either to the hospital or to the emergency room.\nThe release reports on the findings of two studies looking at the\u00a0usefulness of the drug in a subset of COPD patients. For the METREX trial, which enrolled 837 volunteers for one year, it says, \u201cThe patients with high eosinophil counts who received mepolizumab had a statistically significant 18 percent lower rate of moderate/severe exacerbations (1.4 per year compared to 1.7 per year) than those in the placebo group.\u201d\nIt\u2019s not clear what a difference in exacerbation rate of 0.3\u00a0per year really means. Does this mean that each person will get one less exacerbation about every 3 years? That doesn\u2019t\u00a0sound like much of a difference.\nFor the METREO trial, the release said, \u201cthe exacerbation rate was reduced by 20 percent in the high eosinophil group after 100 milligrams of mepolizumab. The METREO results narrowly missed statistical significance.\u201d", "answer": 1}, {"article": "The Walter and Eliza Hall Institute is the research powerhouse of the Victorian Comprehensive Cancer Centre, an alliance of leading Victorian hospitals and research centres committed to controlling cancer.\nProfessor Lindeman, who is also a medical oncologist at The Royal Melbourne Hospital, said the discovery of RANK as a marker of cancer precursors was an important breakthrough, because inhibitors of the RANK signalling pathway were already in clinical use.\n\"We therefore investigated what effect RANK inhibition had on the cancer precursor cells in BRCA1-mutant breast tissue.\"\nBy pinpointing the cells that give rise to breast cancers in women who have inherited a faulty version of the BRCA1 gene, Walter and Eliza Hall Institute researchers have identified that the drug denosumab may have potential to prevent breast cancer from developing.\nProfessor Visvader said the discovery had its basis in more than a decade of investigations of breast stem cell function.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits aren\u2019t quantified at all. Clinical trials have not yet been conducted, so it\u2019s impossible to determine how the drug may perform at preventing breast cancer in patients with the BRCA1 mutation. However, the release says that \u201cRANK inhibition switched off cell growth in breast tissue from women with a faulty BRCA1 gene and curtailed breast cancer development in laboratory models.\u201d (RANK proteins were found by the researchers to be markers associated with pre-cancerous cells.) However, the release doesn\u2019t tell us about the amount of denosumab needed to inhibit these RANK proteins. Nor does the release offer any numbers related to these preliminary tests in laboratory models. For example, what does \u201ccurtailed breast cancer development in laboratory models\u201d mean? Did it stop the development of cancerous growth completely? Slow it down a little? A lot? Details matter.\nThis study was performed in laboratory animals and that must be considered when attributing benefits. As we\u2019ve found with other cancer treatments, switching off a protein or blocking a pathway may be effective in killing cancer cells in laboratory or animal models, but does not always translate to clinical benefit when used in patients. The laboratory studies are an extremely important first step, but it is a huge leap to translate this to clinical benefit.", "answer": 0}, {"article": "\"First, I think it's very important that we investigate potential new therapies, and that we shouldn't be dissuaded from doing that just because something can be misused,\" he said.\nThis effect, the Bedi and his team suggested, could help people improve their social skills by shielding them from the negative emotions of others.\nIn a study involving a small group of healthy people, investigators found that the drug -- also known as MDMA -- prompted heightened feelings of friendliness, playfulness and love, and induced a lowering of the guard that might have therapeutic uses for improving social interactions.\n\"More controlled research is needed to establish whether MDMA can safely and effectively add to psychotherapy for some conditions and, if so, what the mechanisms of these effects are,\" Bedi said.\nEach session lasted at least 4.5 hours, or until all effects of the drug had worn off.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "What does it mean to suggest that the drug \u201csignificantly increase feelings of loving, friendliness and playfulness\u201d?\nHow was this measured?\nDid it occur in everyone?", "answer": 0}, {"article": "The information entered on this page will not be used to send unsolicited email, and will not be sold to a third party.\nBased on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy.\nThe study focused on the most common way that children become infected with hepatitis B, an incurable viral infection that causes liver disease and cancer, which is through infection during the perinatal period.\n\u201cWe believe that these findings will not only save many lives, but could also help to eradicate hepatitis B nationally and abroad.\u201d\n\nThe study was conducted in five locations in China, where HBV infection is endemic.\nTreatment effectively reduced the viral load of the pregnant women, says Pan.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release clearly says that 68 percent of women receiving the drug reduced their viral load while only 2 percent of the women in the control group had that success. It also says that the transmission of hepatitis B from mother to newborn dropped from 18 percent to 5 percent, an important clinical outcome.", "answer": 1}, {"article": "\"I hear a lot of moms say, 'I'm disappointed I had to have a C-section.'\nBut for many women, being told they need a C-section is unpleasant news.\nCamann says the gentle C-section is not a replacement for a vaginal birth; it's just a way to improve the surgical experience.\nShe says she'd like nothing more than to know that other women having C-sections are able to have the same amazing experience she had.\nAnd there were a bunch of little adjustments, such as moving the EKG monitors from their usual location on top of the mother's chest to her side.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The family-centered or gentle cesarean is put forth as a good alternative to traditional C-sections, since mothers play more of more of an active role during and after the birth of their children. The piece talked about how the family-centered cesarean allows mothers to see their babies being born, with newborns being placed immediately on the mother\u2019s chest after birth. The skin-to-skin contact helps to stimulate bonding and breast feeding, the report said.\nWhile the benefits are addressed in broad strokes, we can\u2019t rate the story satisfactory because there are no numbers to back them up. (There are studies that could\u2019ve been used to quantify benefits.) We\u2019d also caution that while the notion of\u00a0a more active role for the mother seems intuitively desirable, there is no balance in this story from the perspective of a woman\u00a0who might not be so gung-ho about the idea of watching a baby being extracted from her pelvis. We do know that not all patients like to watch procedures they are undergoing.", "answer": 0}, {"article": "\u2018What insanity is that?\u2019 Hundreds of NC children are being killed or injured by guns.\n\nDid you realize that in the past five years, hundreds of teens and youth have been killed or hurt by gunfire in North Carolina? Here\u2019s what some say you can do about it.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The AP story accurately reports the proportion of children who benefited from either the inhaled vaccine or shots, i.e. the \u201cabsolute efficacy\u201d of the two vaccinations. Although the inactivated vaccine appeared to be more effective, the difference was not significant. The story states in closing that the two methods were similarly effective in preventing type A flu, the historically more common strain. But the headline is confusing and misleading. \u00a0 ", "answer": 1}, {"article": "July 14, 2010 -- An experimental weight loss drug that targets the brain\u2019s hunger center was shown to be safe and effective for helping dieters shed pounds in a two-year study, researchers say.\nBy the end of year one, 55% of the patients in the placebo group and 45% of those taking the diet drug had dropped out of the study.\nHe says that all the patients in the study were monitored closely for heart valve irregularities, and no difference was seen in the two treatment groups.\nThe company hopes to win FDA approval to market the new drug later this year.\nAbout one in five lorcaserin users lost 10% or more of their body weight, compared to one out of 14 placebo users.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "See comments above about evaluating the evidence. We\u2019ll rule this satisfactory because the story did a decent job of quantifying the likely magnitude of weight loss, both in terms of expected pounds lost, % who drop out, and % losing 5% or 10% body weight.", "answer": 1}, {"article": "By the time most lung cancers are diagnosed -- which usually involves an invasive examination of the lungs -- patients already have advanced malignancies.\nMaybe one day, screening could be done using an even simpler nasal or sputum test, the researchers said.\nCurrently, there is no good way to detect lung cancer -- the number one cancer killer -- in its early stages when it's most treatable.\nThe minimally invasive procedure involves using a small brush to collect a smattering of cells from the windpipe (a bronchoscopy), explained study co-author Andrea Bild, an assistant professor of pharmacology and toxicology at the University of Utah in Salt Lake City.\nAnd when treated with the compound myo-inositol, the gene pathway activity declined along with improvement in the troublesome lesions, the researcher noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Didn\u2019t give any numbers on how well the test performed.\u00a0 And didn\u2019t explain that inositol was tested in just a few people.\u00a0 Very weak in this area. ", "answer": 0}, {"article": "But we don't know we're right yet.\"\nBut there are reasons to think aducanumab may succeed where other drugs have failed.\nResults from a small number of patients who received a high dose of the drug, called aducanumab, hint that it may also be able to slow the loss of memory and thinking.\nThese early reports suggested the drug had a remarkable ability to remove plaques in the brain.\nThose efforts have failed to produce a single approved drug so far.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story suggests that treatment with\u00a0aducanumab results in \u201cstriking,\u201d \u201cdramatic\u201d and \u201cremarkable\u201d reductions in amyloid plaques in the brain. But it doesn\u2019t quantify what that means. How many patients saw their plaque levels go down? By how much? Is the reduction bigger than what has been seen with other experimental Alzheimer\u2019s drugs? These details would\u2019ve been helpful.", "answer": 0}, {"article": "\u201cIt\u2019s a tricky thing to get your mind around,\u201d Whitlock said.\nThe report, in the Annals of Internal Medicine, sums up a research review done for the U.S. Preventive Services Task Force (USPSTF), an expert medical panel supported by the federal government.\nAnd no one knows yet whether HPV testing actually catches cervical cancer at an earlier stage, or reduces deaths from the disease, compared with Pap tests.\nYou\u2019re trying to make a tradeoff between sensitivity and specificity.\u201d\n\nSince cervical cancer screening is repeated over time, what\u2019s needed is evidence of the longer-term effects of different tests, according to Whitlock.\nBut many women still do not get regular Pap screening, Whitlock pointed out.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains the potential benefit, if more-sensitive testing for the virus turns out to prove itself effective in reducing deaths from cervical cancer.", "answer": 1}, {"article": "The rate was 26 percent lower in counties with screening.\nThe study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\nThe study\u2019s authors include Dr. Stephen Duffy, an epidemiologist at the University of London, and Dr. Laszlo Tabar, professor of radiology at the University of Uppsala School of Medicine in Sweden, who have long been advocates of mammography screening.\nResearchers reported Wednesday that mammograms can cut the breast cancer death rate by 26 percent for women in their 40s.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story highlights the 26 percent difference in breast cancer death rates, but fails to include any information about the overall risk. The researchers reported that based on their results you would have to screen 1252 women for a decade in order to prevent one breast cancer death. In other words, for the remaining 1251 women, a decade of mammograms did not alter their breast cancer mortality.", "answer": 0}, {"article": "He says he plays basketball with his granddaughter, works on his farm, and gets on the treadmill for 30 minutes three times a week.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\nIt's early -- results are in for only the first 16 patients -- but the results already are drawing praise from experts not easily impressed by first reports.\nThe breakthrough comes just as researchers were becoming discouraged by studies in which bone-marrow stem cells failed to heal damaged hearts.\n\"The reported benefits are of an unexpected magnitude,\" writes Gerd Heusch, MD, PhD, chair of the Institute of Pathophysiology at the University of Essen, Germany, in an editorial in the Nov. 14 online issue of The Lancet.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\n\nThe story could have benefited from an info-graphic to break down all the numbers of patients used at various times in the story: 20 enrolled, \u201cresults are in for only the first 16,\u201d 14 patients analyzed so far, 8 seen for one year.\u00a0 Wouldn\u2019t that have been much more clear than scattering all of these numbers throughout the story? That makes it difficult to understand the scope of the benefits.\u00a0 The story spends a lot of time talking about just one patient and, in an unusual move for a study like this, the story names the patient:\u00a0 Michael Jones. \n\n\n\nThis anecdote may not reflect the results seen to date in all the subjects treated.\u00a0 Preliminary results can be statistically important but may not be clinically important in the long run. The researchers saw an improvement in the ejection fraction in subjects treated (on average going from 30.3% to 38.5%)\u00a0 It should be noted that to be enrolled, all patients needed to have an ejection fraction of less than 40%. So, in spite of the improvement, the subjects on average still had severe heart failure at the end of this phase of the study. \n", "answer": 0}, {"article": "\u201cBut this is a small study, a proof of concept.\nGenazzani said the results showed DHEA has potential, especially for those women who may have problems in taking more conventional HRT.\nAfter 12 months, all the women on hormone replacements had improvements in menopausal symptoms, but those taking vitamin D and calcium did not show any significant improvement.\nThe results for the HRT group were similar, and both the HRT DHEA groups showed a higher level of sexual intercourse in comparison to the control group, the researchers said.\nAt the start of the trial, all groups had similar sexual activity, but after the year, those taking calcium and vitamin D scored an average of 34.9 on the questionnaire scale, while those taking DHEA had a score of 48.6, showing that those on DHEA had more sexual interest and activity.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a nice job specifically explaining the benefits or lack thereof. It says, \u201cAfter 12 months, all the women on hormone replacements had improvements in menopausal symptoms, but those taking vitamin D and calcium did not show any significant improvement. At the start of the trial, all groups had similar sexual activity, but after the year, those taking calcium and vitamin D scored an average of 34.9 on the questionnaire scale, while those taking DHEA had a score of 48.6, showing that those on DHEA had more sexual interest and activity.\u201d By presenting the actual scores, readers are able to see how close the scores were and decide for themselves whether the increased benefit was worth the risk of possible side effects.\n\u00a0", "answer": 1}, {"article": "\"We're always searching for simpler things to do,\" Brooks said.\nAnother big question, he added, is whether breath analysis could pinpoint people with colon polyps.\nIt's all based on studies showing that breath samples from cancer patients tend to have a distinguishing pattern of so-called volatile organic compounds (VOCs).\nWhat's more, he added, there are already several good ways to catch colon cancer -- or, even better, precancerous growths called polyps, which can then be removed before a tumor develops.\nBrooks said it would be nice to have a very simple, accurate screening test -- whether that means a breath test or blood or urine tests.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Both this story and the competing WebMD piece repeated the accuracy statistic provided by the study (76%), but neither story provides much detail\u00a0as to what this figure means. Good diagnostic tests not only have to be able to identify people with diseases correctly, but they also have to be able to rule out people who don\u2019t have the disease correctly. Ideally the story should report true positive rate (sensitivity) and the false positive rate (1- the specificity), though it\u2019s not clear that the percentages listed represent those rates. We would have preferred to see the absolute numbers of people in each group (the cancer patients and controls) who were accurately diagnosed, and a comparison of how that stacks up against currently available tests.\nThis story did note that the primary benefit of a breath test would be increased convenience and less of an \u201cick\u201d factor compared with existing tests. In addition, it pointed out that\u00a0a 75% accuracy rate is a failure for\u00a025% of patients \u2014 a nuance missing from WebMD\u2019s coverage. In\u00a0also explained\u00a0that\u00a0we don\u2019t whether this kind of\u00a0test can detect precancerous polyps, which\u00a0should ideally be identified and removed before they have a chance to develop into cancer.\nA mixed bag, but overall,\u00a0it meets our standard for a satisfactory.", "answer": 1}, {"article": "Overweight people on low-carbohydrate and Mediterranean diets lost more weight and got greater cardiovascular benefits than people on a conventional low-fat diet, according to a study that endorses alternative diets published in a major medical journal.\n\nThe study, which tracked 322 Israelis for two years, surprisingly found that a low-carb diet, often associated in the U.S. with high levels of meat consumption -- was better than a low-fat diet in boosting blood levels of \"good\" cholesterol, or high-density lipoproteins...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This article does a very good job of documenting the absolute and relative benefits of each of the three diets. Also see Evidence comments.", "answer": 1}, {"article": "Developed in the laboratory of UHN transplant surgeon Dr. Markus Selzner, with the help of UHN transplant surgeons Drs.\n\u201cThis technique will change the landscape of organ donation by improving organ preservation, allowing us to better assess and regenerate the donor organ on the device before we transplant it into a patient.\nSince 2012, there has been an unprecedented 63 per cent increase in lung transplants at TG as a result of this system.\nThe new warm preservation technique avoids the damage of cold storage and instead allows the donor organ to improve and repair itself, potentially leading to better outcomes for patients.\n\u201cThis new technology can help us answer the critical question, \u2018What\u2019s the best way to improve function and recover and repair the kidney before transplantation to get the best results for our patients?\u2019\u201d\n\nDr. Grant, who is also Professor of Surgery at the University of Toronto, emphasized that high-impact research projects such as this require strong collaborative teams \u2013 including researchers, surgical residents, nurses, Canadian Blood Services, perfusionists, colleagues at SickKids - working together on experimental and clinical trials.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release compares the health of a kidney preserved via ex vivo organ perfusion favorably to the health of a kidney preserved using cold storage preservation, going so far as to say that a kidney preserved using the new technology is \u201cimproved.\u201d But the release offers no numbers to support such a claim,\u00a0and then gives anecdotal comments from the single study participant to have undergone the new procedure\u2013\u201cI feel great\u201d\u2013and from the surgeon: \u201cIt\u2019s a champion!\u201d One of the goals of the ongoing study is the outcome of the transplant at just 90 days.", "answer": 0}, {"article": "U.S. doctors do at least two stenting procedures these days for every coronary bypass operation.\nBut Dr. Laura Mauri says in an accompanying editorial that the new study can't settle any debates.\nPut another way, 21 percent of stented patients had died after four years compared with 16 percent of surgery patients.\nNow the biggest collection of cases so far comes out in favor of surgery on the all-important question of mortality.\nAlthough the pro-surgery outcome is not a game-changer, Weintraub says it might cause some doctors and patients to consider surgery.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantified the benefits two different ways. It says, \u201cFour years after the procedure, patients over 65 who had coronary artery bypass surgeries (called CABG or \u201ccabbages\u201d) were almost 20 percent less likely to die.\u00a0Put another way, 21 percent of stented patients had died after four years compared with 16 percent of surgery patients.\u201d\nThis would have been a good time to use the Number Needed to Treat statistic.\u00a0 Overall, the story made a good effort to give readers numbers in a way they could easily understand.", "answer": 1}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story does a good job of summarizing the benefits that accrued in the course of several studies.", "answer": 1}, {"article": "Lucinda Bateman is a doctor at the Fatigue Consultation Clinic in Salt Lake City who specializes in chronic fatigue syndrome.\nShe's skeptical about the Lancet study, pointing out that patients improved only moderately, and not much more than those who were counseled about pacing themselves.\nWhen patients adopt a more positive attitude, Barsky points out, it often translates into greater confidence and more energy.\nIn the study, over 600 patients with chronic fatigue syndrome were assigned to different treatments.\nA study published this year in the Lancet found that a form of talk therapy, as well as exercise, offered relief for some patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the potential benefits. Instead it says that the therapy \u201coffered relief for some patients,\u201d and it later says that those who received therapy and exercise, \u201cimproved the most, reporting less fatigue, insomnia and anxiety.\u201d Everyone knows that exercise can make a person feel healthier and more alert, but this study was looking at a more difficult question than that. Hard numbers quantifying the actual benefits of this approach would have helped readers understand the value to place on this research.", "answer": 0}, {"article": "High cholesterol levels can increase the risk of heart attack.\nHowever, the safety of selenium has not been studied, and the authors said the findings weren't significant enough to recommend supplementation of the trace mineral.\nNoting that blood selenium levels were relatively low across the board at the study's launch, the authors found that selenium levels did rise as a result of supplementation, while those taking selenium also experienced a slight drop in both bad cholesterol (LDL) and overall cholesterol levels.\nThey also noted that the results can't necessarily be applied to Americans, because of differences in the food supply and diets of each country.\nThe finding comes from a six-month examination of the impact of various dosages of the supplement on the cholesterol levels of healthy people in England.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story\u00a0correctly explains that selenium supplements are not\u00a0an effective means to reduce cholesterol levels, the\u00a0coverage\u00a0is too\u00a0vague when\u00a0it says that individuals\u00a0taking selenium \u201cexperienced a slight drop in both bad cholesterol (LDL) and overall cholesterol levels\u201d and that \u201cGood cholesterol (HDL) levels rose a bit solely among those assigned to the highest selenium dosage.\u201d Instead of relying on imprecise descriptions such as \u201cslight\u201d and \u201ca bit,\u201d the story\u00a0should have provided the actual numbers, as the competing Reuters story did. The Reuters story also described\u00a0the ranges for normal and elevated\u00a0cholesterol levels, which helps puts the changes observed into context.", "answer": 0}, {"article": "\"Why does it work for some people and not others?\"\nInterestingly, sham acupuncture came in second place for effectiveness, the researchers said.\n\"There is a component of behavior of doing a sham procedure, so it psychologically may trigger a different kind of reaction from patients versus taking the placebo pill.\"\nFurthermore, the effects of acupuncture were \"significant and enduring for hot flashes while gabapentin's effect only happened when a patient was taking the medication,\" said study first author Dr. Jun Mao, an associate professor of family medicine and community health at the University of Pennsylvania in Philadelphia.\nDeng pointed out that clinicians have come to realize that the placebo effect is very important in treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits of the treatments were measured at 8, 12 and 24 weeks after receiving the treatment yet the magnitude of those effects are not quantified\u00a0nor explained in any detail. Measurements looked at\u00a0frequency and severity of hot flashes but we don\u2019t have any idea what the baseline was, or how that may have changed due to the different modalities. We\u2019re told that acupuncture had the greatest effect, but not how big that effect was or how meaningful it was for patients.", "answer": 0}, {"article": "Pacemakers zap the heart with low levels of electricity when the heartbeat becomes too fast, too slow or too irregular.\nStill, he said, the new device will probably be more expensive than other pacemakers, and may pose special risks of its own.\nWhy get a wire-free pacemaker?\nIt's only been implanted in a few dozen people who were studied for a matter of months, limiting information about its long-term use and safety.\nStill, a new company-funded study shows that \"this is now a possibility\" that could reduce infections and the severity of pacemaker surgery, said study author Dr. Vivek Reddy, director of the Cardiac Arrhythmia Service at Mount Sinai Hospital in New York City.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only mention of benefits was this:\u00a0 \u201cThe researchers reported positive results at up to three months.\u201d\nWhat does that mean?", "answer": 0}, {"article": "Lung function got 10 percentage points better, on average, in people who got the drug compared with those taking a placebo.\nBut these results, even with plenty of caveats, suggest the drug is on the right track.\nThe improvement at six months was still present almost a year after the study's start.\nThe experimental medicine, taken twice a day, goes by the code name VX-770.\n\"It is larger than any other clinical intervention we've ever had in cystic fibrosis.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Good enough.\u00a0 We appreciate at least the attempt to explain that the 10 percentage points improvement in lung function \u201cis a big deal for CF patients.\u201d", "answer": 1}, {"article": "Cocoa contains flavanols, plant-based compounds that also are credited with giving red wine its heart-healthy benefits.\nVolunteers for the study ate just over six grams of dark chocolate daily for almost five months \u2014 one square from a German chocolate bar called Ritter Sport, equal to about 1\u00bd Hershey's Kisses.\nUniversity of Cologne researcher Dr. Dirk Taubert, the study's lead author, said the blood pressure reductions with dark chocolate were small but still substantial enough to potentially reduce cardiovascular disease risks, although study volunteers weren't followed long enough to measure that effect.\nThe research involved just 44 people aged 56 through 73, but the results echo other small studies of cocoa-containing foods.\nTests suggested that steady exposure to dark chocolate prompted chemical changes that helped dilate blood vessels and regulate blood pressure, the researchers said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit reported was a \"slightly lower blood pressure in people with hypertension.\" But it didn\u2019t say how much.\u00a0 \nThe study was conducted in a group of individuals who were prehypertensive or had stage-1 hypertension; there was no benefit in terms of blood pressure reduction at 6 weeks, however after 12 weeks of dark chocolate consumption, there was a statistically significant nearly 2.5 mmHg reduction in systolic pressure and by 18 weeks, it was nearly 3.0 mmHg lower. Why not tell viewers just how much BP dropped? ", "answer": 0}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "On the one hand the article is appropriately cautious in stating:\nBut while genetic testing offers tools to better guide patients\u2019 treatment, it cannot tell doctors which medicines will work \u2014 or necessarily provide the key to enduring remission from depression.\nOn the other hand, the results of Myriad\u2019s recently published \u201clarge-scale test\u201d on outcomes are given as \u201cpatients were 30 percent more likely to respond to treatment\u201d when guided by their GeneSight test.\nBut, as\u00a0we wrote back in May in a review of a Wall Street Journal article on the test, there\u2019s problems with that percentage:\n\u201cNo absolute numbers are given \u2026 just a relative improvement in \u2018response\u2019 to medication (ie. 30% greater response to the medicine when the test was applied).\u201d\nThe Philadelphia Inquirer story quotes an independent source saying he\u2019s impressed by the response rate (50%) and remission rate (40%) at six months, but again, these are relative numbers. Myriad did not provide the absolute numbers at 6 months \u2026 only at 8 weeks \u2026. at which time the absolute difference in achieving remission between those who did and did not receive genetic testing was only 5%.", "answer": 0}, {"article": "\"It's very stressful because you're sleep-deprived, you're not eating right ... you're working back-to-back shifts and you're trying to catch up on sleep but you can't,\" Dalechek said.\nGuille said offering web-based therapy routinely to medical residents could be beneficial, if her research results are confirmed in a broader study.\nThe research involved about 200 medical interns \u2014 residents in their first post-graduate year, which is often one of the most intense periods of doctor training.\nThe online program included sessions about how to put feelings of stress or despair into perspective.\nSarah Dalechek, a first-year psychiatry resident at that university, said her program requires two month-long rotations of 16-hour overnight shifts in an emergency room.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story has some useful information on the benefits of the online therapy. We are told that, \u201cOverall, 12 percent of interns who got online therapy said they had thought about suicide during the year, versus 21 percent of the interns who received four weekly emails with information on depression and where to seek help\u201d and \u201cthat interns who got the sessions were 60 percent less likely to have those thoughts than the other group.\u201d \u00a0However there is no mention of timeframe or the durability of the benefit over time. \u00a0The suicidal ideation actually increased in both groups from baseline. (Figure 3 in the manuscript highlights the data collection) The figures provided reflect the numbers of interns who had suicidal ideation at least once during the one year data collection. It is also important to point out that 48% of the medical interns participating had a baseline history of depression. And while suicidal thoughts might have been prevented, we don\u2019t know if the intervention would have any effect on actual suicide attempts or success rates.", "answer": 1}, {"article": "Kisco, N.Y.\nMore of those undergoing lap-banding, however, needed repeat surgeries (13 percent vs. 2 percent).\nIn Campos' study, roughly equal numbers of patients in each group experienced complications after one year (12 percent in the gastric bypass group compared to 15 percent in the lap-banding group); these included infection, internal bleeding and blood clots, but no deaths.\nThe study led by Campos compared weight loss and diabetes outcomes in 100 patients who underwent gastric bypass surgery with 100 patients who underwent lap-banding.\nMONDAY, Feb. 21, 2011 (HealthDay News) -- When it comes to shedding pounds and improving or eliminating type 2 diabetes, gastric bypass surgery may be better than other surgical weight-loss procedures, two new studies find.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A little bit better job with the numbers than the LA Times. The same weight loss data are provided in absolute terms, but this story also attaches a figure to the number of patients whose diabetes resolved after bypass compared with the band procedure. The LA Times called the results here \u201cfar better\u201d for gastric bypass, but HealthDay notes that improvement or resolutions was seen in three-fourths of bypass patients and half of band patients \u2014 a more precise characterization.", "answer": 1}, {"article": "\"Blueberries are one of the more potent foods in terms of protecting the brain,\" Morris said.\nBut the MIND diet also differs from those plans in a few significant ways and proved more effective than either of them at reducing the risk of Alzheimer's.\nNow here are the five food groups it says you should avoid to reduce your risk of developing dementia...\n\nYou already know they're not so good for your waistline, and it turns out pastries and other sweets could have a negative effect on brain health as well.\nThe MIND diet recommends limiting yourself to no more than five of these treats per week.\nBut the MIND diet helped slow the rate of cognitive decline and protect against Alzheimer's regardless of other risk factors.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The evidence for the efficacy of the MIND diet over the DASH diet and Mediterranean diet exists in the paper, but is not fully conveyed in the story.\u00a0\u00a0It was challenging for the story to quantify benefits from the study because\u00a0the paper itself did not publish any absolute numbers or percentages in the key tables or in the text of the article, making it impossible to calculate absolute risk reductions without pressing the study authors for more information. We are holding the bar high here, but unapologetically so, because we believe that provision of only relative risks gives a misleading and inflated estimate of benefit. The story says that the MIND diet can provide a 53 percent reduction in the risk of Alzheimer\u2019s Disease. While this may be technically accurate, the true size of the benefit is impossible to gauge without knowing the overall rate at which participants developed Alzheimer\u2019s disease in the study. In addition, the story could have noted that the Mediterranean diet was reported at 54 percent reduction when closely followed, too. One of the most important findings was for those who don\u2019t follow diets perfectly, but perhaps moderately. The story makes a reference to this, but it does not include how well the other diets performed when only moderately followed.", "answer": 0}, {"article": "Shares of Zafgen, which traded as high as $55.36 on the Nasdaq stock exchange last year, closed Tuesday at $5.62, down nearly 3.3 percent for the day.\nZafgen has not identified the patients who died or said at which of 14 US trial sites they were taking the drug.\n\u201cThis is a patient population that\u2019s at risk for thrombotic [clotting] issues.\u201d\n\nZafgen said its six-month study involving 107 patients suffering from Prader-Willi syndrome met its two primary goals, known as end points: showing significant weight loss by many patients and a decrease of hyperphagia-related behavior, meaning excessive eating.\nThomas E. Hughes, chief executive of Zafgen, said the Boston company will use the data to prepare a \u201crisk-mitigation\u201d plan to help persuade the Food and Drug Administration to lift its so-called clinical hold on the late-stage trial, allowing it to resume.\nSome analysts have suggested the FDA might approve the drug, despite the adverse events, if Zafgen can prove its benefits outweigh its risks to some patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article only states that the data shows\u00a0beloranib met its two primary endpoints of\u00a0significantly reducing weight and decreasing excessive eating. No numbers are attached to these statements, however. In particular, how is excessive eating measured? Clearly this is harder to define than weight loss. Presumably, surrogate variables were introduced to quantify the degree of excessive eating. A significant decrease in these surrogate variables can be difficult to interpret in many situations.", "answer": 0}, {"article": "(One British unit of alcohol equals a small glass of wine.)\nBut for those women who drink before finding out they\u2019re pregnant or who have an occasional glass of wine afterward, this study can provide reassurance that very low levels of alcohol consumption during pregnancy are unlikely to cause serious problems.\nThe authors had earlier published similar results looking at the data for children in the study when they were 3, finding those whose mothers who didn\u2019t drink had slightly more behavior problems and slightly poorer performance on mental tests than kids born to light drinkers; the results also showed increasingly negative effects of alcohol going from moderate to heavy drinking.\nWhen researchers controlled for factors like maternal education and income, which tend to be higher in light drinkers, it significantly reduced the positive effects associated with alcohol.\nThis data is notoriously hard to interpret, however, in part because it is based on women\u2019s self-reports: the public health message against drinking during pregnancy has been so widely adopted that women who do drink may significantly underreport their consumption to researchers.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Unlike the other story reviewed, this story notes that the children of mothers who drank lightly\u00a0were \"slightly less likely to have behavioral problems and performed somewhat better on cognitive tests.\" This is a startling finding, to say the least, but then the story, importantly, adds that\u00a0\"this does *not* mean that light drinking in pregnancy is good for your baby. When researchers controlled for factors like maternal education and income, which tend to be higher in light drinkers, it significantly reduced the positive effects associated with alcohol. For example, before adjusting for these kinds of differences between the groups, the researchers found that light drinking was connected with 33% lower rates of overall behavior problems in boys \u2014 after the adjustment, that effect fell to 23%.\" But the story should have included the actual rates, for instance that the rates for high total difficulties was 6.6 percent for sons of light drinkers vs. 9.6 percent for sons of mothers who did not drink during pregnancy. Including those numbers would point out that the overwhelming majority of children in both groups did not have major problems.", "answer": 0}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies the benefits by explaining that about 65 percent of patients lose 5 percent or more of their weight. That\u2019s enough to earn a satisfactory rating, though we wondered 65% of what? How many patients are we referring to? And were they all following the three main treatment options discussed in the story (exercise, diet changes and counseling)? More details here would have been helpful to put the benefits in context.", "answer": 1}, {"article": "Cervical cancer is the fourth most common cancer in women, with more than 500,000 new cases occurring annually worldwide.\nAsiedu is also working to automate the screening process.\nThe device also includes a channel through which contrast agents used for the cervical cancer screening procedure can be applied.\nIf widely adopted, women might even use the device to self-screen, transforming screening and cure rates in low-income countries and regions of the United States, where cervical cancer is most prevalent.\nHealth providers -- or even women themselves -- are able to capture images of the cervix using the rounded tip of the device to manipulate its position if necessary.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The cost saving of this innovation is\u00a0the main benefit touted, but it\u2019s not quantified. The release does speak to the usability of the device when quoting one of the researchers who describes the experience of 15 university volunteers who tried the device. She says that \u201cmore than 80 percent of the women who tried the device were able to get a good image.\u201d But what exactly \u201ca good image\u201d means is not explained. (Is it good enough for an accurate diagnosis?) The release does state that trials are planned to compare the new device with the traditional colposcope, but it should have been clearer about the fact that the device\u2019s accuracy has not been objectively assessed.", "answer": 0}, {"article": "New research analyzing more than 22,000 U.S. cases of aortic aneurysm repair is likely to hasten the trend toward more procedures being done with a device called a stent-graft instead of the typical surgery that requires up to eight weeks of recovery.\n\nThe study by doctors at Harvard Medical School and the federal Centers for Medicare and Medicaid Services found the death rate in surgery, 4.8%, was four times that of the 1.2% death rate in placing stent-grafts to seal off the aneurysm. Surgery tended to provide a more permanent...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did include clear numbers for potentially lethal ruptures following surgery, reinterventions, later abdominal operations, and most importantly, it did provide the surgical mortality rates for both procedures. \u00a0It did not , however provide sufficient information about the risk of death from aortic aneurysms if left untreated in order for the reader to evaluate the relative benefit to be gained from the treatments discussed.\u00a0 We\u2019ll give a satisfactory score here, but address this in the \"Treatment Options\" section below. ", "answer": 1}, {"article": "Doctors can slow macular degeneration with vitamins, laser surgery, stem cell treatments, and even implantable miniature telescopes.\nBut Dr. Grazia Pertile, director of ophthalmology at the Sacred Heart Don Calabria in Negrar, Italy and one of the Italian researchers, said in a written statement that her team's device could be \u201ca turning point in the treatment of extremely debilitating retinal diseases.\u201d\n\nShe\u2019s not alone in that assessment.\nBut many sufferers ultimately go blind.\nRelated: This Revolutionary Gene-Editing Tool Could Change the World\n\nWhen the prosthesis was tested in rats, the animals' pupils constricted in response to exposure to light.\n\u201cThis is definitely a game changer,\u201d Dr. Kapil Bharti, an investigator at the National Eye Institute in Bethesda, Maryland who is not involved with the research, says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is tricky because both devices are still under pre-clinical development. The story\u00a0says that the Italian model allowed rats to detect light for up to six months. That\u2019s interesting, but hard for readers to assess. And it\u2019s irresponsible at this stage to extrapolate animal findings to people, especially with a headline like \u201cThis Tiny Device Is a \u2018Game Changer\u2019 for People Facing Blindness.\u201d That\u2019s far from certain.", "answer": 0}, {"article": "For more information on Down syndrome, visit the U.S. National Library of Medicine.\nDr. Brian Skotko, clinical fellow in genetics at Children's Hospital Boston and a spokesman for the National Down Syndrome Society, said this study has widespread implications for the incidence of Down syndrome.\nIt also can identify Down syndrome in the 11th week of pregnancy, early enough for a woman to end her pregnancy if she chooses, Patsalis said.\nIf larger clinical trials confirm the results, the test could become standard practice, Patsalis said.\n\"With our method we identify all normal and all Down syndrome [pregnancies],\" Patsalis said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explained that \u201cthe test quickly pinpointed the chromosomal variation, identifying 14 Down syndrome cases and 26 normal fetuses.\u201d", "answer": 1}, {"article": "Deaths from adenomatous lung cancer were cut 30 percent, those from colorectal cancer 40 percent, and those from prostate cancer 10 percent.\nTo be sure, the U.S. Preventive Services Task Force's currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work.\nThe benefits of daily low-dose aspirin can exceed the risks for many middle-aged and older people when it comes to preventing heart attacks and strokes, the task force says.\nYes, scientists have already published strong evidence suggesting aspirin can cut bowel cancer and deaths.\nA final word about dose: The new study didn't find any additional anticancer benefit for aspirin doses above 75 milligrams a day -- the British dose for a \"baby\" aspirin.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story does not put the relative differences between aspirin and placebo in these studies into the proper perspective. The story says, \u201cFor some of these cancers, the reduction in death was remarkable.\u201d What is considered remarkable? \u201cTwenty years after people had started taking aspirin regularly (and kept it up for at least five years), their deaths from esophageal cancer were reduced by 60 percent compared to study subjects who got a placebo.\u201d How many people died from esophageal cancer? We never find out. In fact, we don\u2019t know how many people died period. There is a mangled sentence in the story that indicates that the study captured \u201ccancer deaths for up to 20 years after those studies ended\u00a0[for]\u2026\u00a0nearly 13,000 people.\u201d Esophageal cancer is rare compared to other cancers studied, and its low numbers may account for the high relative difference in preventative benefits of aspirin. To make that determination, though, readers would need the absolute differences. The story should have at least mentioned the number of cancer deaths. Telling readers that 674 participants died of cancer out of more than 25,000 included in the original studies would help them understand the actual size of any reduction in risk. The same is true for the claims about risk reduction over a 20 year period, where there were a total of 1634 cancer deaths among 12,659 participants. When readers are told of a \u201c20 percent reduction\u201d they should be told it was 20 percent of the number of actual cancer deaths, not 20 percent of the much, much larger total number of participants.", "answer": 0}, {"article": "It will still grow shorter and slower than scalp hair,\u201d he said.\n\u201cHe had resorted to cropping his hair short to obscure the problem.\u201d\n\nWith the patients under local anesthesia, Dr. Umar used a device that creates microscopic wounds around hair follicles in the back of the leg; the follicles were then removed and transplanted to the hairline.\n\u201cThe hairline was fully grown and soft-looking by nine months\u201d in the 35-year-old, he wrote, \u201cat which time the patient started combing his hair backward and sporting a ponytail, exposing his hairline comfortably.\u201d\n\nSince then, Dr. Umar has done eight more of the procedures, including one in a woman.\nIn each case, Dr. Umar and his team extracted about 1,000 leg hair follicles and grafted them, one by one, to the patients\u2019 hairlines.\nAbout 75 to 80 percent of the transplanted leg hair grew successfully on the patients\u2019 heads after the operations, and both men were happy with the results, Dr. Umar said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no clear quantification of benefits. The story says, \u201cAbout 75 to 80 percent of the transplanted leg hair grew successfully on the patients\u2019 heads after the operations, and both men were happy with the results, Dr. Umar said. \u201cThe hairline was fully grown and soft-looking by nine months\u201d in the 35-year-old, he wrote, \u201cat which time the patient started combing his hair backward and sporting a ponytail, exposing his hairline comfortably.\u201d What does successfully mean? How does one judge happiness in a case like this? What is the long-term potential for this hair to stay in and to continue to grow normally? Will, as is often the case with hair transplants, the transplanted hair stay in one spot while the hair the men were born with continue to thin?\n\u00a0", "answer": 0}, {"article": "The group that received standard education lowered their scores by an average of 1 point.\nBlack said the benefits of mindfulness training were on par with what's been found in studies of sleep medications and cognitive behavioral therapy -- a form of \"talk therapy\" that is often helpful for insomnia, for example.\nIn fact, they did better than their counterparts who were given conventional lessons on good sleep habits, the study authors said.\nOn top of that, poor sleep itself can lead to psychological \"distress,\" such as depression symptoms, Black said.\nThe problem, Spira said, is that behavioral therapy for sleep problems is not always easily found -- and even when it's available, the process takes some effort.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In broad strokes, the benefits are satisfactorily described. But a look under the hood reveals a missing explanation of what the \u201cthe sleep-problem scale\u201d is and what its point values mean. The story\u00a0says, \u201cBy the end of the study, the mindfulness group was showing a significant improvement \u2014 shaving about three points, on average, from their scores on the sleep-problem scale.\u201d By comparison the \u201cgroup that received standard education lowered their scores by an average of 1 point.\u201d How many points were on the scale? If the people meditating were three points lower on a 50-point scale, that\u2019s not quite as good as three points lower on a 10-point scale. The story does provide an additional point of reference by comparing the benefits to\u00a0sleep medications and \u2018talk therapy.\u2019", "answer": 1}, {"article": "\u2022 Swelling or thickening in part of the breast.\nAnd there are some lifestyle-related risk factors that can be controlled, such as hormone therapy after menopause, obesity, alcohol intake and physical inactivity, Evers said.\nIn some cases, women never develop any of these symptoms, Evers noted.\nThere are three tests often used to look for breast cancer, Evers said.\nOlder age is a leading risk factor for breast cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Beyond vague generalizations of benefits, this article is essentially data free. Based on research, to what degree do these various screening methods save lives? The story doesn\u2019t say.", "answer": 0}, {"article": "Parkinson's disease is a degenerative condition that affects the central nervous system.\nHe also said it will be important to confirm these findings in other studies and learn the mechanism of how berries and other flavonoids appear to offer some protection against Parkinson's disease.\nAlso, recollections of dietary intake may be faulty, and it's possible that other properties of fruits and vegetables might have influenced the results, the authors said.\nBut, when the researchers looked at the dietary compounds individually, it was clear that berries could benefit both men and women, lowering the risk of Parkinson's disease by about 25 percent for those who had at least two servings of berries a week.\nThe study findings should be interpreted cautiously because the participants were mostly white professionals, and the results might not apply to other ethnic groups.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It should be possible to calculate absolute risks from the data in this cohort study. However, this story reported only relative risks, which likely overstate the magnitude of the potential benefit.The absolute risk reduction for dietary changes and Parkinson\u2019s risk is likely to be very small.", "answer": 0}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In the second paragraph the story explains that, according to the current study, 58 percent of patients receiving the Heartmate II survived for two years. The story does an excellent job comparing this outcome to that for heart transplant [70 percent alive after 10 years] and to an earlier version of the device [24 percent after two years]. ", "answer": 1}, {"article": "No question,\u201d he said.\nThe Phase II study included 173 women whose cancer had spread and who had received other treatments.\nThe best overall tumor response rate, of 20 percent, was in those given Erbitux.\nIt is the first time researchers have shown that a drug like Erbitux, which targets a protein called epidermal growth factor involved in cancer cell growth, can provide substantial benefit in difficult-to-treat \u201ctriple negative\u201d breast cancer.\nDr. Fabrice Andre from Institut Gustave Roussy in Villejuif, France, who was not involved in the research, said the results were \u201cextremely important\u201d but echoed the view that the findings now had to be confirmed in larger-scale clinical tests.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "A qualified claim means there is evidence supporting the claim, but it is not conclusive.\nThe Food and Drug Administration allowed the new item, developed by a physician, to make the claim just months after the nation\u2019s top allergy experts reversed longstanding advice on preventing peanut allergies, dropping recommendations to withhold all peanut-containing foods in early childhood in favor of early, frequent exposure, starting with peanut powder or extract for infants beginning to eat solid food.\nA new powdered peanut product is the first food item allowed to claim it may reduce peanut allergies in infants, though parents of susceptible babies are urged to consult a doctor before trying it.\nWhile many foods like whole grains, nuts and supplements carry qualified health claims stating that they may reduce the risk of diseases like cancer or heart disease, this is the first time a food product label will be allowed to make a qualified claim that it reduces the risk of an allergy, officials said.\nThe product, called Hello, Peanut, can be mixed into pur\u00e9ed baby food to expose infants to peanuts starting around five months old.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The LEAP study spurred the reversal in advice for exposing infants to peanuts, a decision that then led to the formulation and release of Hello, Peanut! as well as the qualified health claim it now carries.\nThe NYT story details the fact that LEAP study results indicated that by the time infants turned 5, only 1.9% of the 530 allergy-prone children who had been fed peanuts regularly since infancy had developed an allergy, compared with 13.7% of the children who had not consumed peanuts.", "answer": 1}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story relates the benefits of immunotherapy reported in a published, New England Journal of Medicine study in simple, absolute terms\u2014complete remission from a late-stage cancer that \u201chas stayed away for more than two years.\u201d It also uses a loaded term\u2013\"cured\"\u2014to describe this remission. However, it is not yet known if this man is \"cured.\" And if the man has been lost to follow-up, as another news report suggests, we may never know. The story\u2019s reporting of unpublished data by Dr. Rosenberg is also incomplete, stating only that \"52 of 93 patients experienced a positive result.\" What does \"positive result\" mean? ", "answer": 0}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story misleads the reader by citing 19,000 patients in the IDEA study. However the results described actually refer to 3,979 patients from whom data were analyzed. (The story does mention that these are preliminary results, but we think it could have been much clearer on this point.)\nThe endpoint in the study was whether patients treatment plans changed after their PET scans were analyzed by doctors. The story says roughly two-thirds of patients \u201csaw their medication regimens changed or were counseled differently by their doctors about what to expect.\u201d We\u2019d like to see the breakdown \u2014 how many changed medications? how many changed prognosis? Also, a change in prognosis might go in either direction \u2014 better or worse \u2014 and might be subtle or profound.\nThe story does include a patient whose faced a worse prognosis after his PET scan, but it\u2019s not clear whether he\u2019s representative. It\u2019s a compelling patient narrative, but was it a common result?", "answer": 0}, {"article": "\u201cIt\u2019s a mixed bag,\u201d Elliott says.\nBurgoon\u2019s group has persuaded some states to bar physical therapists from the practice.\nTestimonials like that are a big reason dry needling has caught on with some physical therapists, athletes and other patients, Briggs says.\nWhile some studies have shown promise, he says, \u201cthe quality of the evidence is not strong.\u201d That\u2019s why Briggs and his colleagues are starting a study looking at dry needling in \u201crunner\u2019s knee,\u201d the condition that has plagued Pierce.\nHe says many acupuncturists do exactly what the physical therapists describe, with the same kind of needles.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was a tough call, since the story includes a general discussion of the benefits. But what it doesn\u2019t do is report on any quantified benefits, such as\u00a0how much pain relief people report in the studies, or for how long. It does tell us that the evidence shows the technique \u201cmay be useful\u201d and points out other findings, such as the evidence overall shows \u201cmixed results.\u201d", "answer": 0}, {"article": "T. Kondo, R. Goto, K. Ono, S. Kitano, M. A. Suico, M. Sato, M. Igata, J. Kawashima, H. Motoshima, T. Matsumura, H. Kai, and E. Araki, \"Activation of heat shock response to treat obese subjects with type 2 diabetes: a prospective, frequency-escalating, randomized, open-label, triple-arm trial,\" Scientific Reports, vol.\nFurthermore, adding the MES+HS treatment to a DPP-4 inhibitor, which is the most often used therapeutic drug for diabetes in Japan, showed an even stronger blood glucose improvement.\nIn the researcher's next clinical trial, 60 obese patients with type 2 diabetes from both genders were given a 12-week treatment with the belt-shaped MES+HS medical device.\nThe first trial showed that activation of the HSR produced a large therapeutic effect.\nAbout half of all subjects (52.5%) achieved less than 7.0% HbA1c, which is a treatment goal for diabetes.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides quantification of the benefits of the device but would have been a lot stronger with a better description of what some of the numbers mean. It states:\n\u201cThe reduction in the visceral fat area was 5.37 sq. cm in the 2 treatment per week group, 14.24 sq. cm in the 4 per week group and 16.45 sq. cm in the 7 per week group. Declines in HbA1c were 0.10%, 0.36%, and 0.65% in the 2, 4, and 7 treatment-per-week groups respectively.\u201d\nIt also stated, \u201cAbout half of all subjects (52.5%) achieved less than 7.0% HbA1c, which is a treatment goal for diabetes\u201d in reference to the first study. (HbA1c refers to glycated haemoglobin (A1c), which identifies average plasma glucose concentration.) But the release doesn\u2019t explain the relationship between lowering of HbA1c and improvements in heat shock protein, an important underpinning of the research. The information detailed in the graphic, while related to the basic research, is confusing since it relates to the animal and not the human research described in the release.\nA statement from the lead investigator appears premature. Dr. Kondo commented: \u201cEven in patients who have difficulty exercising, such as those who are overweight, elderly, or have some form of disability, this device can be expected to provide acceptable treatment in addition to conventional diabetic medical care.\u201d", "answer": 1}, {"article": "Prostate cancer cells express up to 100 times more PCA3 RNA than do normal cells.\nThe PSA test detects prostate-specific antigen, a protein given off by all prostate cells.\nThe test, which is approved in some European countries but not in the U.S., detects genetic material -- RNA -- from prostate cancer gene 3 or PCA3.\nIt showed that the test accurately predicts whether a prostate biopsy will reveal cancer in high-risk men.\nThe PCA3 test can do things the PSA test can't, says Jack Groskopf, PhD, of Gen-Probe Inc., which manufactures the test and funded the new research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did mention that biopsies for prostate cancer can result in infection and that the test might have utility in that it might reduce the number of biopsies done.\nIn general, the story focused on\u00a0enhanced ability to diagnosis prostate cancer. But the story failed to question the value of the test in providing any long term benefit to the men involved. \u00a0Did it result in fewer prostate cancer deaths? \u00a0Did it result in fewer cases of metastatic disease? The story did not examine these important features for determining value and benefit. ", "answer": 0}, {"article": "\"And I thought, 'If we could do that in people, this is going to be amazing.'\nWhat Belvin didn't know at the time was that a revolutionary treatment for melanoma had begun testing in clinical trials.\nAn immunologist named Jim Allison, now at the University of Texas MD Anderson Cancer Center, had figured out that if the immune system was tweaked just right, it could do a better job of killing the cancer than the usual treatments.\nAllison's treatment was still experimental, but if it worked, it had the potential to save Belvin's life.\nIn those days, most firms were focused on drugs that would target tumors directly, and Allison was asking them to try something very different.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits aren\u2019t quantified. The story relates the experiences of one patient who went into full remission, and notes that \u201cEach case is different, and using a patient\u2019s own cells to destroy tumors won\u2019t work in every patient or in every type of cancer.\u201d\nBut it offers no information on how often ipilimumab results in complete remission, how often it causes tumors to shrink, how long it prolongs survival in patients, or how often it fails to work at all. For one patient, at least, it worked amazingly well \u2014 which is great. Without offering broader information about how well it works in larger populations, this could easily mislead readers into thinking it works for almost everybody. Yet, it doesn\u2019t work for everybody \u2014 and even for patients that see benefits, it doesn\u2019t always mean long-term remission (as the FDA noted in a news release about ipilimumab last year).", "answer": 0}, {"article": "\u201cFar too many cancers are picked up too late, when it is no longer possible to operate and the chances of survival are slim,\u201d he said.\nThe test was most accurate for diagnosing pancreatic, ovarian, liver and gallbladder cancers, correctly finding the diseases in at least four out of five patients.\n\u201cThe goal is to develop a blood test, such as this one, that can accurately identify cancers in their earliest stages.\u201d\n\nKlein added: \u201cIt is several steps away and more research is needed, but it could be given to healthy adults of a certain age, such as those over 40, to see if they have early signs of cancer.\u201d\nFor example, although the test detected ovarian cancer with 90% accuracy, only 10 ovarian cancers in total were detected.\nResearchers said their results showed promise in the approach of blood screenings for cancer, but noted further \u201cclinical development\u201d was needed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story errs on the side of promoting potential benefits without providing critical context.\nIt includes two reckless quotes (one by a lead author, another by an independent source) which suggest that the liquid biopsy:\nThis study did not address cure, survival, or productivity.\nFurthermore, the story lists the accuracy of \u201cdiagnosing\u201d 10 different types of cancer (with an \u2018accuracy\u2019 of 56% \u2013 90% depending on the cancer) without making it clear these are the percentage of people already known to have cancer who had a positive test confirm its presence.\nWe did appreciate this inclusion:\nThe number of patients in who cancers were detected was small. For example, although the test detected ovarian cancer with 90% accuracy, only 10 ovarian cancers in total were detected.\nTo be useful to readers, the story should have included the rate of false-positives and false-negative results. Or, what\u2019s known as test sensitivity \u2014 how often the test is correct when the disease is present; and specificity \u2013 how often the disease tests negative when the disease is not present. The percentages reported likely represent the sensitivity. So the article did provide some numbers, but it was limited and not explained in a way that would allow the reader to appreciate how good (or not good) the test really was.", "answer": 0}, {"article": "Malignant mesothelioma is an aggressive and almost uniformly fatal tumor caused primarily by exposure to asbestos.\nA 510(k) application is being prepared for submission to the FDA to register the ONCOblot test as a medical device.\nIn this study, the serum presence of a mesothelioma-specific form of the ENOX2 protein (a recently identified marker of malignancy) was found within the serum of asbestos-exposed individuals an average of 6.2 years in advance of clinical symptoms by using the ONCOblot tissue of origin cancer detection test.\nThe ONCOblot Test is CLIA registered and meets all current FDA regulations as an LDT.\nThe ONCOblot\u00ae test is based on more than 20 years of basic research.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states it\u2019s \u201can exciting sign of progress in the cancer detection field\u201d because researchers detected \u201ctwo mesothelioma-specific ENOX2 protein transcript variants\u201d in the blood serum of individuals exposed to asbestos \u201can average of 6.2 years\u201d before they were clinically diagnosed.\nUnfortunately, that\u2019s the only attempt at quantification found in the release. There\u2019s no mention of accuracy or sensitivity of the test, how many people were tested, or how long the study lasted.\nIt\u2019s not enough to claim that the test is useful. The sponsors should provide some data on how it improves patient outcomes, not just sound an alarm in order to get individuals to take a test. The unfortunate reality is that patients diagnosed with stage 1 disease have a median survival of 21 months and those diagnosed at stage 4 have a median survival of 12 months. It remains to be seen if early detection provides any advantage and a large clinical trial will be needed to see if this is true.", "answer": 0}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article did a good job describing the current evidence for deep brain stimulation on insulin sensitivity, which is still in the earliest of stages. A single patient receiving DBS for obsessive-compulsive disorder reduced his need for insulin dose by 80%. Description of more fundamental experiments were not quantitatively detailed, which seems acceptable for the health focus here.", "answer": 1}, {"article": "Coronary heart disease, which causes heart attacks and angina -- chest pain resulting from the heart not getting enough blood -- is the leading cause of death in the United States, with nearly 450,000 in 2005, according to the American Heart Association.\nThis method of intravenous injection means that the procedure theoretically could be performed in a doctor's office or clinic, increasing the accesibility to patients, Karp said.\nThe phase I results from 53 patients are not definitive proof that the treatment is effective, but do suggest so, Hare said.\nThe study is a step forward in a field in which a lot of approaches have been tried in animals and preliminary human trials, but none has been approved for widespread clinical use for heart patients.\nThe research, published in the Journal of the American College of Cardiology, were part of a phase I study that set out to show safety.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Since the study is designed to prove safety, there are no credible benefits data to report. \nThe report does allow sources to make general claims of benefit based on that preliminary data, but the reporter shows restraint by not plucking benefits data points from the study.\u00a0\nOn a close call, the story earns a satisfactory rating. ", "answer": 1}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story fails to describe the improvement in blood flow in absolute terms, instead noting only relative or percent improvement (e.g. 37% compared to baseline for consumption of artificially sweetened cocoa). The reported 37% improvement is much greater than that reported in a press release from the American College of Cardiology (2.4% over baseline); the reason for the discrepancy is unclear.", "answer": 0}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As mentioned above, one of the most significant benefits of the bilateral surgery is cost. However, there are others \u2014 such as the fact that a patient only has to be anesthetized once, and will likely spend less time (overall) in the hospital. The story says that the 2013 study where it got its cost numbers \u201cconcluded that bilateral surgery is more cost-effective with better outcomes for the average patient than staged procedures for two knees.\u201d We italicized the \u201cwith better outcomes\u201d part, because that\u2019s the sticking point. What does it mean? In order for readers to make sense of a term like \u201cbetter outcomes\u201d it needs to be both clearly defined and quantified. On a side note, it would be great if the story linked to the relevant 2013 study.", "answer": 0}, {"article": ".\n\u201cAt the 1.67 percent high-risk threshold,\u201d Georgetown\u2019s Lin says, \u201cevery woman age 62 and older would be [considered] high-risk.\u201d That might lead to a situation in which millions of women would be encouraged, unnecessarily,to consider this therapy, along with its potential harmful effects.\nThe studies that served as the basis for the FDA approval of the drugs, along with recently released guidelines from the American Society of Clinical Oncology (ASCO), set the threshold at a five-year Gail score of 1.67 percent.\nAfter looking at multiple trials of tamoxifen and raloxifene, the task force noted that these drugs reduced new cases of breast cancer significantly: from 23 cases per 1,000 women in the control groups to 16 cases per 1,000 women in the treatment groups.\nKala Visvanathan, the lead author of the ASCO recommendations and a faculty member at the Johns Hopkins School of Medicine, said the cutoffs provide only a rough estimate of risk.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u2019s initial discussion of benefits focuses mainly on very attractive relative risk figures. It notes that in one study, women who took tamoxifen \u201cwere half as likely to develop breast cancer as similar women who did not take the drug.\u201d And an expert says that high-risk women \u201ccould reduce their risks for invasive cancer by approximately 30 to 50 percent.\u201d\u00a0\u00a0It\u2019s not until further down in the study that the much less glamorous absolute risk estimate is provided. The story notes that \u201cafter looking at multiple trials of tamoxifen and raloxifene, the [U.S. Preventives Services Task Force]\u00a0noted\u00a0that these drugs reduced new cases of breast cancer significantly: from 23 cases per 1,000 women in the control groups to 16 cases per 1,000 women in the treatment groups.\u201d\nWhile the story\u2019s framing is problematic, we give the story credit for eventually getting to the key statistics that consumers need. We also applaud the inclusion of nuance from an independent expert. The story quotes Kenneth Lin, a family physician at Georgetown University who worked on developing the task force\u2019s SERM guidelines. He notes that while SERMs may have reduced new cases, they \u201chave not been shown to reduce breast cancer mortality in any study or meta-analysis.\u201d He explains that the drugs may be effective at preventing nonlethal cancers rather than the more serious ones.", "answer": 1}, {"article": "\u201cIt\u2019s not going to be a panacea,\u201d says Thomas.\nImportantly, this vaccine is designed to work against only heroin, not other opioids.\nThe compound, created by chemists at the Scripps Research Institute, works in a way that\u2019s similar to other vaccines.\nThe current study of the vaccine, published in the Journal of the American Chemical Society, follows eight years of laboratory research and studies in rodents that indicated the compound could neutralize heroin at different doses.\nIn this case, the vaccine introduces a piece of the heroin molecule to the immune system.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits were not put in quantified terms. Instead, qualitative terms are used.\u00a0Phrasing like, \u201celicited a successful immune response that neutralized heroin\u2026\u201d and, \u201c\u2026hinting that their immune systems were already primed\u2026\u201d provide insight to medical professionals, but are perhaps confusing to lay readers. With research this preliminary, far more caveats were needed to pass this criterion.", "answer": 0}, {"article": "Of these, 85 percent were mild or moderate.\nSalloway's study looked at the drug's safety in 194 Alzheimer's patients, most of whom had mild- to-moderate Alzheimer's and participated in a long-term (78 weeks or longer) study.\nThe studies were funded by Pfizer Inc. and Janssen Alzheimer Immunotherapy.\nBecause this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nBut no problems were seen with lower doses.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story merely mentions that this drug had \u2018shown promise\u2019 and that the studies reported are \u2018encouraging\u2019 because they indicate that people can tolerate the drug for 2- 4 years without safety concerns.\nPromise of what? \u00a0What does the drug do? \u00a0Although the story mentions amyloid accumulation, it failed to explain that though amyloid accumulation is seen in Alzheimer\u2019s disease, it isn\u2019t clear whether it causes symptoms or is secondary to the disease process.\nThe story would have added valuable context by at least mentioning the results of the placebo-controlled study from which the patients in this extension study were drawn.  http://newsroom.elan.com/phoenix.zhtml?c=88326&p=irol-newsArticle&ID=1166655 That study found that the drug had no effect on symptoms in the study group overall, although specific subgroups seemed to benefit in an after-the-fact analysis that was not part of the original study design.", "answer": 0}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No data were given about potential benefits.\u00a0 ", "answer": 0}, {"article": "One of the most frustrating aspects of brain injuries is that they can be difficult to diagnose; emergency rooms can sometimes miss subtle symptoms, leading to improper treatment and potentially catastrophic consequences. Now, researchers are close to identifying so-called biomarkers that may soon make it possible to pinpoint brain injuries with a simple blood test.\n\nPresence of these biomarkers\u2014proteins produced by an injured brain\u2014could end up determining the future treatment of the estimated 1.4 million athletes, car-crash...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although it\u2019s too early to quantify the technique\u2019s benefits, this story does that. We\u2019re told that the study of 66 patients found that those with the most severe brain injury had 16 times the level of UCH-L1 as those without brain injury. What is the true clinical significance of that result?\nThe benefits of using biomarkers wouldn\u2019t be just they can detect brain injury but they can do so better and more usefully than the methods we have now. Otherwise, how does it benefit us? What\u2019s the clinical meaning of the 16x difference for this one biomarker? What about the other biomarkers in the panel alluded? Could the researchers use this result to distinguish mild from severe, or mild from normal, or cases that are hard-to-catch vs those that are obvious? (Dr. Hall suggests there are questions about mild cases.)\nWe\u2019re given the analogy to troponin tests for heart attacks, which is \"more precise than having a patient describe symptoms.\" The implication, thus, is that this 16x difference is a hugely superior signal to the standard cues we use to diagnose severe brain injury. But the researchers didn\u2019t compare this new technique to current diagnostic ones.\u00a0In short, the story does a poor job of describing how such a test will lead to improved care. The analogy to troponin is a good point, because early identification of a heart attack leads to treatments that have been shown to be lifesaving. A similar evidence base would be needed for biomarker identification of brain injuries.\nThat\u2019s a big problem with reporting on laboratory research like it\u2019s clinical research: we don\u2019t have hard outcomes to look at, only surrogate ones. The true benefits would be the test\u2019s specificity, sensitivity, and speed, and its effects on actual people\u2019s lives\u00a0comparative\u00a0to the standard approach. ", "answer": 0}, {"article": "\u201cIt\u2019s very muddy now exactly how long we need to treat patients,\u201d George said.\nBased on the results, George and his team say, it would be necessary to treat 12 depressed patients with TMS in order to have one patient recover.\nGeorge said he and his colleagues would like to study whether giving people TMS intermittently instead of putting them on antidepressants would produce equally durable effects.\nGeorge said he hopes that by better understanding where TMS should be delivered and by figuring out the best dose and duration of treatment, success rates closer to those of ECT might be achieved.\n\u201cIt looks as if from this trial you at least need to try three weeks and maybe even six weeks before you would give up.\u201d\n\nPatients who got better were prescribed venlafaxine - marketed as Effexor \u2014 and a small dose of lithium, noted George, a combination that\u2019s been shown to help people stay well after their depression has remitted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article describes the percentage of patients who benefited from TMS in absolute terms and tells us that\u00a012 patients would need to be treated with TMS to achieve 1 treatment success. These descriptions give readers a realistic\u00a0idea of how likely a patient will be\u00a0to benefit from TMS.\u00a0\u00a0\nAn even clearer approach would have been to\u00a0say that\u00a013 of 92 (14%) benefited from\u00a0TMS and that 5 of 98 (5%) benefited from\u00a0sham treatment.\u00a0The other critical missed opportunity is to remind readers that these are remission rates in those who failed at least 1 prior treatment.\u00a0For\u00a0patients who have never been treated for depression, remission rates are much higher with any first-line treatment.", "answer": 1}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nAdditionally, results showed that tree nut consumption may be particularly important for lowering the risk of heart disease in individuals with type 2 diabetes.\nTrials directly provided nuts to the intervention group rather than relying solely on dietary advice to consume nuts.\n\u2022 Kris-Etherton P. Walnuts decrease risk of cardiovascular disease: a summary of efficacy and biologic mechanisms.\nWalnuts were investigated in 21 of the 61 trials, more than any other nut reviewed in this study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While in most cases the release carefully states that the study analysis included \u201ctree nuts, such as walnuts\u201d without claiming the focus of the research was walnuts alone, in one paragraph the release says that decades of research have shown that walnuts can help reduce cardiovascular disease risk by decreasing LDL (bad) cholesterol by 9 to 16% and diastolic blood pressure by 2 to 3 mmHg.\nBut according to the study:\n\u201cConclusions: Tree nut intake lowers total cholesterol, LDL cholesterol, ApoB, and triglycerides. The major determinant of cholesterol lowering appears to be nut dose rather than nut type. Our findings also highlight the need for investigation of possible stronger effects at high nut doses and among diabetic populations.\u201d\nThe release could have done a better job giving and explaining absolute risk reduction for the cholesterol findings. From the study: Of 2,582 volunteers involved in one of 61 studies, lowered total cholesterol was \u22124.7 mg/dL; 95% CI: \u22125.3, \u22124.0 mg/dL.", "answer": 1}, {"article": "The new research, reported Oct. 10 in the journal Nature Communications, was led by Charles Brenner, PhD, professor and Roy J.\nThe experiments also revealed more detail about NAD+ metabolic pathways.\nThe information from the mouse study subsequently helped Brenner's team design the formal clinical trial.\nThe study showed for the first time that oral NR is superior to nicotinamide, which is better than niacin in terms of the total amount of NAD+ produced at an equivalent dose.\nIn the first controlled clinical trial of nicotinamide riboside (NR), a newly discovered form of Vitamin B3, researchers have shown that the compound is safe for humans and increases levels of a cell metabolite that is critical for cellular energy production and protection against stress and DNA damage.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Since there are no proven benefits to humans for NR, there are no benefits to quantify, but that didn\u2019t stop the release from strongly suggesting benefits.\nA reader could assume from reading the release that claims of efficacy in humans were being made. For example:\n\u201cVitamin safely boosts levels of important cell metabolite linked to multiple health benefits\u201d\n\u201cBecause the levels of supplementation in mice that produce beneficial effects are achievable in people, it appears than health benefits of NR will be translatable to humans safely.\u201d\nThis was a short-term Phase 1 safety trial, which is meant to determine whether a drug is safe by testing it on a small number of people. Phase 2 and 3 trials test a drug\u2019s efficacy as a treatment among larger groups of people.", "answer": 0}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Includes the caveat that \u201cSolid evidence of the lasers\u2019 effectiveness, is scant. In clinical practice, results have varied, according to doctors who have used the laser.\u201d\nIt was quite specific about a small, short-term study and how often it s howed \u201cnew growth without fungus\u201d or \u201cat least three millimeters of clear new nail.\u201d\nAll very helpful details to guide readers\u2019 decisions about whether this is worth it.", "answer": 1}, {"article": ".\nIt is estimated that one third of women in the United States will get a UTI by the age of 24.2\n\n\"Findings like this,\" adds Dr. Luis, \"give practitioners a viable, inexpensive, non-antibiotic option to help patients reduce the recurrence of an uncomfortable and potentially debilitating infection.\"\na total of 28 studies showing results from nearly 5,000 patients were considered.\n\"While recommendations for dosage and duration of treatment require further study, the efficacy of the medicinal properties of cranberry products has been well-established.\"\nThe review explains that the medicinal properties of cranberries may be attributed to their unique polyphenol, proanthocyanidins - or PACs, for short.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are not quantified. According to the release, \u201cAuthors found a statistically significant risk reduction in repeat UTIs overall, but not significant for any particular subgroup.\u201d But what does \u201cstatistically significant risk reduction\u201d mean? Were patients 10 percent less likely to get a UTI? 0.1 percent? Those are both\u00a0statistically significant, but there\u2019s a world of difference. In fact, the published study reported that the risk of recurrent infection was reduced by approximately 33 percent. Including this quantitative information would greatly strengthen the release.", "answer": 0}, {"article": "While the disease is rare, with about 3,100 new diagnoses and 330 deaths in the United States each year, it often goes undiagnosed until it affects vision. Sacks \u2014 known for books including Awakenings and The Mind's Eye, in which he tells the story of his own cancer \u2014 said his symptoms hit suddenly, wiping out a triangular chunk of the vision in his right eye.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Because the story deals with one patient who is participating in an early stage clinical trial, there is little concrete benefit information to report. The story says that the doctor conducting the clinical trial found, a month after the first treatment, that this first patient\u2019s tumor \u201chad begun to atrophy,\u201d but it notes that data from animal trials of the drug suggest that it would take \u201cthree or four months to gauge the response.\u201d The bottom line here is that because the story focuses on the first human patient in the earliest of three levels of clinical trials required for FDA approval, no one really knows how much benefit this drug will produce. The story should have noted that\u2013strongly.", "answer": 0}, {"article": "-- Icing the bottom of the foot, sometimes using ice to massage the heel area\n\n-- Using cups made of gel in shoes to cushion the heel (and many orthopedic surgeons say expensive custom-made orthotics are not necessary)\n\n-- Wearing a night splint, a simple brace that holds the foot in a flexed position to keep the plantar fascia stretched during sleep\n\n-- Physical therapy, though some studies indicate that some PT practices such as ultrasound and whirlpool are not helpful\n\n-- Use of NSAID (non-steroidal anti-inflammatory) drugs such as ibuprofen and naproxen\n\n-- Corticosteroid injections into the heel, though this is controversial and should not be used repeatedly\n\n-- Backing off activities like running until the pain goes away, and then reinitiating them gradually\n\nAbout 90 percent of sufferers will get better with time.\nBut while inflammation can be involved in plantar fasciitis, it doesn't seem to be the cause, Duggal says.\nDuggal says foot specialists don't really know what causes the pain of plantar fasciitis.\nSo the hope is that platelet injections will stimulate healing without the damaging effects of shock-wave therapy.\nThat's presumably why sufferers of plantar fasciitis feel the pain in the heel.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Even when it\u2019s quoting a doctor who is clearly a proponent of shockwave therapy (as discussed above in the Evidence Quality criterion),\u00a0the story\u00a0treats benefits with appropriate caution and doesn\u2019t succumb to hype. This story also seems to have avoided the compulsory anecdote about the patient who is feeling dramatically better after a new high-tech treatment. In\u00a0fact,\u00a0the story\u00a0seems to go out of its way to provide the perspective of someone got better with low-tech\u00a0standbys\u00a0such as stretching, taping, and ice \u2014 valuable \u00a0context that is\u00a0often lacking in coverage of medical treatments.\nOn the downside, the story focuses exclusively on pain and doesn\u2019t tell us whether patients who receive shockwave treatment had improved functioning\u00a0or could participate in more activities\u00a0afterward. These are\u00a0important\u00a0measures of a treatment\u2019s overall effect on patients.\u00a0", "answer": 1}, {"article": "Age-related macular degeneration (AMD) is a condition that affects older people.\nIt provides an image that has been magnified more than two times, the FDA says in a news release.\nIt is intended for use in only one eye because the other eye is used for peripheral vision, the FDA says.\nBefore implantation, patients will be trained with an external telescopic device to see if they may benefit from the product.\nThe device is intended for patients 75 and older with severe to profound vision impairment that has been stable over time due to blind spots from end-stage AMD.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately quantified the benefits seen in the study that led to FDA approval. ", "answer": 1}, {"article": "\"It is very big.\nVeridex launched the first commercial test using circulating tumor cell technology in 2004, the company said.\nResearchers hope the test will be used by oncologists as a diagnostic tool aimed at discovering as early as possible if a cancer has spread, as well as by researchers in coming up with new drug therapies.\nToner says the test is like a liquid biopsy and targets almost all solid cancers -- cancers found in \"solid\" organs like the breast or prostate.\nDr. Mehmet Toner, director of the BioMicroElectroMechanical Systems Resource Center in Massachusetts General's Center for Engineering in Medicine, says while it will take at least five years before the test is on the market, it's another step toward personalized medicine and the implications for patients are significant.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As mentioned above, the story regurgitates unsupported promises that early detection of cancer is inherently beneficial. But it gives no data on how the test has fared in studies to date. ", "answer": 0}, {"article": "Harvard T.H.\n\"From many other studies we know that breast tissue is particularly influenced by carcinogens and anticarcinogens during childhood and adolescence,\" said Walter Willett, Fredrick John Stare Professor of Epidemiology and Nutrition at Harvard Chan School and senior author of the study.\n\"Previous studies of fiber intake and breast cancer have almost all been non-significant, and none of them examined diet during adolescence or early adulthood, a period when breast cancer risk factors appear to be particularly important,\" said Maryam Farvid, visiting scientist at Harvard Chan School and lead author of the study.\nThe researchers looked at a group of 90,534 women who participated in the Nurses' Health Study II, a large long-running investigation of factors that influence women's health.\nOther Harvard Chan School researchers involved in the study included Heather Eliassen, associate professor in the Department of Epidemiology, and Xiaomei Liao, research scientist in the Departments of Epidemiology and Biostatistics.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We recognize that it would be challenging for anyone writing a news release about this study to report on the absolute risks seen in the study. The study does not report absolute risks, although it is possible to calculate them based on the data provided in the tables. One could look at the number of cases in each quintile of dietary fiber (found in Table 2) and divide that by the number of people in each quintile (which is found in Table 1). There are several steps involved, but for the example of early adulthood dietary fiber and breast cancer risk in this cohort, you could do the following calculation:\n\u2013 613 cases in quintile 1 / 18,364 women in quintile 1 = 3.3% later developed breast cancer (pre or post menopause)\n.\u2013 567 cases in quintile 5/ 18,167 women in quintile 5 = 3.1% later developed breast cancer (pre or post menopause).\n\u2013 The difference is 0.2 percentage point, which is quite a small absolute risk reduction.\nWhen absolute risk numbers aren\u2019t reported in a study, we think press officers should ask the researchers to provide these numbers so that they can be disseminated to the public. The issue of absolute risk reduction is key to helping readers understand the impact of changing dietary behaviors. We think it\u2019s important enough to rate any news release Not Satisfactory when these numbers aren\u2019t provided.", "answer": 0}, {"article": "These new drugs \"could be for someone who needs an addition to statin, or it could be instead of statin,\" Martin said.\nThe results, published in the Annals of Internal Medicine, also show that the drugs have a significant effect on reducing heart attacks and overall mortality.\nResearchers analyzed 24 randomized control trials to assess the efficacy and safety of the new drugs, called PCSK9 antibodies, in adults with high cholesterol levels.\nIn an editorial published along with the study, experts note that although the results are promising, more long-term research is needed to make definitive conclusions about the drug.\nOthers have such high cholesterol that taking statins alone is not enough.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story implies that the risk of heart attacks to patients is reduced by half with the new drugs. However, that\u2019s a relative risk reduction that likely overstates the size of the benefit \u2014 we think absolute risk is more helpful to readers. The key point is that this short-term benefit of a 50% risk reduction is impressive in the studied populations, but the absolute risks were very small. The absolute rates of heart attack in PCSK9 groups were 0.58% compared with 1% for placebo, a difference of less than half a percentage point. Presumably longer studies or studies in higher risk populations may show more impressive absolute reductions. It would also be relevant to compare the results of this new class to statins, the current standard. Generally statins demonstrate ~30% risk reduction. So this may be a more potent class of drugs, but the improvement (if confirmed in additional studies) will be incremental.", "answer": 0}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits from supplementation with additional vitamin D were not quantified. \u00a0In fact, as the older offspring of the author were not reported to be suffering from rickets, one might question whether increased vitamin D intake has merit.", "answer": 0}, {"article": "\u201cI don\u2019t want this strategy to be used widely in any person, clearly,\u201d Molina said.\nBut such a strategy, which was tested in a population of men who had frequent unprotected sex with a number of male sex partners, could spark a controversy over the use of antibiotics and the general threat of growing antibiotic resistance.\nLike Molina and his co-authors, they said STI preventive use at this point is premature.\nA commentary published with the study argued that reducing infection rates in men who have sex with men and who are highly sexually active might lower STI infection rates more generally in a community.\nMolina noted that antibiotic resistance to doxycycline has not been seen in chlamydia or syphilis, despite the fact that the drug has been used to treat these infections for decades.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives some relative reductions, but doesn\u2019t provide enough comparative data to give readers the scope of the benefits. For example, overall, without the antibiotic, the rate of new infection, given that condoms were not used, was 42% (45 men), and with the antibiotic, 22% (28 men).\nAlso, the story implies that there might be a benefit for anyone who is sexually active. Although it notes that the study participants were \u201cmen who had frequent unprotected sex with a number of male sex partners,\u201d the story does not make clear just how unusual the men in the study were. For example, while the story reports that syphilis rates for the general US population have risen to almost 9 per 100,000 during a year, the syphilis infection rate in the control group was 11 percent (that is, 11 per 100, not 100,000) over 9 months; a rate that is more than 1,000 times the rate in the general population. The story should have made the point that the men in the study do not resemble the general population.", "answer": 0}, {"article": "\"That makes for a powerful marketing advantage,\" Sullivan said.\nThe HSRx product demonstrated superior treatment performance throughout the entire clinical study.\nAfter 24 hours treatment, the percentage of subjects with reduced acne count was 64% greater for those using HSRx 2121 than for subjects using the competing product.\nAt seven days, the percentage of subjects exhibiting reduced severity was six times greater for those using HSRx 2121, compared to those using the competing product.\nAt 24 hours, the percentage reduction in total acne count with HSRx 2121 was 20 times greater than it was for subjects using the competing product.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told that \u201cAfter 24 hours treatment, the percentage of subjects with reduced acne count was 64% greater for those using HSRx 2121 than for subjects using the competing product.\u201d Various other relative comparisons are provided that are all about as clear as mud since they don\u2019t contain any absolute numbers. Example: \u201cthe percentage of subjects with unsightly acne-associated redness was reduced nearly three times as much\u2026\u201d Three times as much as what?", "answer": 0}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No estimate for the percentage of patients who \ndid not respond to standard treatment and who would be expected to die within the time frame of the study. (However \u2013 and \nthis is no excuse for the journalist \u2013 this information was not in the original research reported on either.)", "answer": 0}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that these drugs in combined form would \u201cbattle heart disease, diabetes and other illnesses all at the same time,\u201d but there is no quantification of how much they would help a healthy older adult.", "answer": 0}, {"article": "A study believed to be the largest of its kind suggests that the physical aspects of yoga are effective at relieving low back pain, but it didn't find any evidence that yoga provided broader mental benefits.\n\nThe study, funded by the National Institutes of Health's National Center for Complementary and Alternative Medicine, was published online Monday in the Archives of Internal Medicine. It was lead by researchers at Seattle's Group Health Research Institute.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "For a short article, the Wall St. Journal story framed and quantified the benefits adequately.\n\n\n\n ", "answer": 1}, {"article": "The stool was more solid, the diarrhea goes away, and the bloating is much less.\"\nThat can translate to big changes in the lives of those with IBS, estimated to affect about 15% of adult Americans.\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\nThe study looked only at those IBS patients with the non-constipation form, he tells WebMD.\n''The major finding was that all IBS symptoms improved,\" says Mark Pimentel, MD, director of the GI Motility Program at Cedars-Sinai Medical Center, Los Angeles, who led the clinical trial of the drug at Cedars.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "When quantifying benefits, the story allows hype to take the place of hard data. The second quote in the story, from the lead researcher, who has just been paid by the drug company to conduct this study, says, \u201cWith the new antibiotic treatment, Pimentel tells WebMD, many participants \u201dsay they are 80% improved, 90% improved, that kind of results.\u201d\u201d Note that phrase: \u201cmany participants.\u201d Just how many? And what does 80% or 90% improved mean?\u00a0 What objective measure of this was made?\nThe story also glosses over the significant placebo response in comparison with the drug group response, reporting:\n\u201cJust 31.7%\u201d ??? This is biased framing.", "answer": 0}, {"article": "She\u2019s healed, basically,\u201d she said.\nIt was of tremendous magnitude in the last [blood] draw.\u201d\n\nThe next step will be to take bone and CT scans to see if the cancer is disappearing internally as well as externally, which Young will receive in a couple of weeks.\nReferred to City of Hope by her physician at Davis, she began responding to the experimental treatment right away, Yuan said, her skin tumors disappearing and the latest biopsies showing no cancer.\n\u201cEven the marks where it was climbing up my neck are all gone.\u201dFurther study needed\n\nWhat Diamond is hoping for now is funding for a full clinical trial so that he can test the combination in advanced triple-negative breast cancer patients who test positive for p53.\n\u201cSix weeks into her treatment, the skin lesions were gone, her itchiness went away.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It\u2019s irresponsible to suggest a sample of one patient represents a miracle cure as this release does, particularly without providing any hard data to back up the claims.\u00a0The release noted that the patient\u2019s skin lesions had diminished and that biopsies showed no cancer, but we do not know beyond this patient what sort of benefit the drug treatment combination should yield. The release noted that in previous trials on different types of cancer, patients had an immune response but provided no details.\nThe release also noted that the patient had not yet undergone bone and CT scans to assess whether other sites of tumor have regressed and it states the\u00a0patient was still undergoing treatment. Therefore, benefits are ambiguous at best \u2014 and should have been treated as such throughout the release.", "answer": 0}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In some cases, we might give a passing grade to a story that tells readers that one trial \u201cfound that in 17 of 30 advanced cancer patients, pembrolizumab stopped or reversed the progression of cancer, and 24 patients were still alive a year after starting the drug,\u201d but this story should have alerted readers to the fundamental difference between these sorts of trial results and what people really care about: \u201cDoes the drug extend or improve the lives of patients?\u201d\nThis point is particularly important because of mounting evidence that the slowing of cancer progression and other surrogate endpoints may not really answer the important questions about survival and quality of life. For example, one review\u00a0of the 36 cancer drugs approved by the FDA from 2008 through 2012 based on surrogate endpoints revealed that only five later showed real survival benefits. A follow-up review looked at 55 cancer drugs approved based on surrogate endpoints. Reviewers found evidence of trials eventually showing improved survival for only 10 of the 55 drugs.", "answer": 0}, {"article": "Those in the lower group ate an average of 0.5 meals per week.\nThe results were the same after researchers adjusted for other factors that could affect memory and thinking skills, such as education, physical activity, smoking and participating in mentally stimulating activities.\nThey also had slower rates of decline in a test of perceptual speed, or the ability to quickly compare letters, objects and patterns.\nThe study did not find a significant difference in the rate of decline in episodic memory (recollection of personal experiences), working memory (short-term memory used in mental function in the immediate present) and visuospatial ability (comprehension of relationships between objects).\nDuring the course of the study, each person received annual, standardized testing for cognitive ability in five areas -- episodic memory, working memory, semantic memory, visuospatial ability and perceptual speed.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are discussed using only vague language. For example: \u201cage-related memory loss and thinking problems of participants in the study who reported eating seafood less than once a week declined more rapidly compared to those who ate at least one seafood meal per week.\u201d How much more rapidly? Or: \u201cPeople who ate more seafood had reduced rates of decline in the semantic memory, which is memory of verbal information. They also had slower rates of decline in a test of perceptual speed, or the ability to quickly compare letters, objects and patterns.\u201d But how much less decline was there of semantic memory? And how much slower was the decline in regard to perceptual speed? The release doesn\u2019t tell us.\nIt would have been helpful for the news release to present the raw numbers relating to cognitive decline in each group and to provide some context to help readers understand their significance (such as \u201cperformance on the semantic memory test dropped by X amount in this group and Y in the other group,\u201d for example).", "answer": 0}, {"article": "\"There is a lot of unmet medical need out there in the treatment of migraine,\" he says.\nCompared to patients who got sham treatments, more patients treated with the experimental device, known as single-pulse transcranial magnetic stimulation (sTMS), were pain-free two hours later.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\n\"Some people don't tolerate the drug treatments very well and others just want to avoid them.\"\nMarch 3, 2010 -- A handheld device that magnetically zaps pain may be a promising new treatment for patients with a common type of migraine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article does not give the reader a sense of how significant the pain relief or avoidance was.\u00a0There was a significant improvement in rate of freedom from pain at two hours for the first treated episode (39% in the treatment arm versus 22% in the sham treatment arm), but about half the subjects in both arms thought their pain relief was fair to poor.\u00a0\u00a0 ", "answer": 0}, {"article": "Platelet-rich plasma (PRP) is blood that has been spun in a centrifuge to separate the blood cells.\n\u201cPRP is probably the best treatment for chronic refractory lateral epicondylitis if it is used after classical types of treatment like rest, braces, nonsteroidal anti inflammatory drugs, cortisone injections or physiotherapy have all failed,\u201d Thanasas said.\n\u201cThere is now a solution for patients suffering from unrelenting \u2018tennis elbow,\u2019\u201d said Christos Thanasas from Henry Dunant Hospital, Athens, who led the study.\n\u201cWhole blood treatment is a god alternative in remote areas or in health systems that do not support financially the use of PRP,\u201d he told Reuters Health in an email.\nThe findings were published in The American Journal of Sports Medicine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are essentially quantified, but we thought the story could have gone further in helping readers understand what the numbers mean.", "answer": 1}, {"article": "Newswise \u2014 Bethesda, Md.\nThe article is published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nThe researchers acknowledge that statin drugs can contribute to liver damage in some people, but for people with advanced liver disease, \u201c[s]tatins are cost-effective, generally well-tolerated by patients and the benefits of statin treatment in most patients outweigh their potential hepatotoxic risk.\u201d\n\nRead the full article, \u201cRationale for the use of statins in liver disease\u201d published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nIn some studies, the research team found that statins reduced inflammatory molecules that are typically elevated with liver disease and improved inflammation in the endothelium (cells that line the blood vessels).\nBut in a new review of more than 50 studies, researchers cite reductions in liver inflammation and improvements in other related factors as reasons why statins make good candidates for treating chronic liver disease.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Multiple benefits are mentioned, as well as what may take place biologically in the body when taking stains, but there are no numbers illustrating an advantage for such treatment. A measurement of the benefit would only come from high quality randomized trials. What may take place biologically in the body when taking statins is not an adequate substitute for trials that show an actual cause and effect.\nIf statins can reduce inflammation in chronic liver disease one has to ask: \u00a0Do the statin patients live any longer? If there is no observable benefit on quality or quantity of life, does statin therapy make any sense? ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article does not quantify benefits. It reports puported benefits (less blood loss, avoid damaging nerves during surgery) but there isn\u2019t much evidence to support these claims. ", "answer": 0}, {"article": "In Alzheimer\u2019s disease, this area of the brain is affected early on, when signs of dementia begin to appear.\nDr. Sandra Black, a brain researcher at the University of Toronto who wrote an editorial on the current study, said the findings could have implications for early stage Alzheimer\u2019s disease if tests were developed to identify this process early through imaging or genomics.\nSuzanne Haber, a neuroscientist at the University of Rochester Medical Center in New York who was not involved in the study, said she was \u201cvery excited about the finding,\u201d but she cautioned that the treatment is very invasive, very expensive and unproven in Alzheimer\u2019s patients.\nThey also saw signs the treatment might have an effect on memory.\nIn a study published in the Annals of Neurology in 2010 researchers tested deep brain stimulation in six patients over the course of a year and found the treatment to be relatively safe.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is clear that this test was just a preliminary experiment to see if brain stimulation can have any memory effects in people. It notes that while researchers say it is worth exploring as a potential treatment for Alzheimer\u2019s disease, there is no evidence yet that it provides such benefits.", "answer": 1}, {"article": "In addition, some people have implanted defibrillators or pacemakers.\n\"These findings need to be replicated in larger trials, and you have to be able to predict whether improved heart function from cimaglermin will help people live longer and feel better,\" she noted.\nCimaglermin, however, may be such a drug, she said.\nA phase 1 trial like this one is designed to see if a new drug is safe, not to test its effectiveness.\nPeople with heart failure often take a combination of drugs, Lenihan said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While this story discusses that the drug seemed to benefit patients and was effective, it doesn\u2019t say how that was measured, and by how much the measurement improved due to the drug.\n(By digging into the research paper, via figure 3, we found that the benefits were measured by tracking absolute increases in\u00a0ejection fraction, which is the amount of blood pumped out the ventricles. It increased 8% in the group receiving a medium or high dose of the medicine.)\nOne issue that might be confusing for readers: The story notes that a \u201cphase 1 trial like this one is designed to see if a new drug is safe, not to test its effectiveness.\u201d If that\u2019s the case, then why is the framing of the story about how effective it was?", "answer": 0}, {"article": "That wouldn\u2019t be surprising.\nTeen girls, who are in crucial bone-building years, often have diets that fall short of their needs, 1,300 mg a day, Wallace says.\nThere are other reasons not to take calcium supplements.\nA second, wider-ranging study found no heart risks and was the basis of new guidelines from two medical groups saying that calcium supplements should be considered heart safe.\nSome people do need supplements.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story does several things well here, but it does not give us any sense of the measured benefits of taking calcium supplements\u2013a systematic review\u00a0determined the evidence was \u201cweak and inconsistent.\u201d That lack of quantification is why this earns a \u201cnot satisfactory\u201d rating.\nThat said, let\u2019s look at the things the story does well. First, the story makes clear that many people do not need calcium supplements, discussing what constitutes the recommended level of calcium intake per day, and that fact that many people meet that mark through their daily diet. Second, the story also makes clear that some people can benefit from calcium supplements, pointing specifically to older adults who have been diagnosed with osteoporosis and teen girls, whose diets may not include the recommended 1,300 milligrams of calcium per day.", "answer": 0}, {"article": "Using electromagnetic radiation, infrared lamps warm your body directly.\nBeever\u2019s review also looked at some of the other purported health benefits of infrared saunas\u2014including pain management.\nThe heart health benefits were even greater for men who sweated it out in a sauna more frequently.\nHe says there\u2019s evidence to support the use of infrared saunas for high blood pressure, congestive heart failure and chronic pain.\nBeever makes it clear all of these reports were based on small groups and require further study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The discussion of benefits when quantified, relied on relative and vague numbers, such as \u201cpeople who spent 15 minutes a day for two weeks in an infrared sauna enjoyed a significant drop in blood pressure compared to a control group.\u201d We\u2019re not told by how many points their pressure dropped, nor if the change was clinically meaningful.\u00a0Also, the unhelpful fact that a study in Finnish men \u201cenjoyed\u00a0a 23% drop in their risk for a fatal heart disease or episode\u201d doesn\u2019t really give us a sense of the overall magnitude of the effect. (As a side note, the verb \u201cenjoy\u201d was used three times to explain findings\u00a0in clinical studies\u2013which isn\u2019t the most accurate way to explain to readers what was measured.)", "answer": 0}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story accurately reports\u00a0the study\u2019s implications in the middle of the piece when it says: \u201cThe results support current guidelines that say non-BRCA mutation carriers in families affected by the BRCA genes don\u2019t need special screening beyond mammography as recommended for the general population\u2026\u201d And the study does\u00a0go into detail and quantify how the test helps refine estimates of breast and ovarian cancer risk.\nHowever, the headline and opening sentence bothered our reviewers. The story suggests that women who are relatives of BRCA carriers, but who tested negative for the mutation themselves, no longer need to consider preventive mastectomies\u00a0to reduce their risk of developing breast cancer. In fact, preventive mastectomy would be considered an extreme intervention in women who test negative for the BRCA mutation,\u00a0so these findings may have little bearing on\u00a0such decisions. The findings also have no bearing on\u00a0the decision\u00a0of women who are\u00a0BRCA-positive to\u00a0undergo preventive mastectomy.\u00a0Accordingly, the results\u00a0are neither \u201creassuring\u201d\u00a0nor \u201cweaken the case\u201d for preventive mastectomy in women\u00a0who might be considering this intervention.", "answer": 1}, {"article": "But study author Anna Giuliano believes that, \"vaccinating males would have a direct benefit that men would receive, as well as a community benefit.\nAmong participants who completed the three-vaccine series, Gardasil afforded 90 percent protection against HPV.\nThis study involved more than 4,000 boys and men aged 16-to-26 from 18 different countries who were randomly assigned to get the vaccine or not.\nAccording to a study presented last year by researchers at the University of Maryland, just one-third of teen girls and young women who start the three-dose series actually finish, and almost three-quarters don't start it at all.\n\"This well-designed study reinforces the idea that there is value in vaccinating young men against a virus that is nearly ubiquitous among sexually active individuals.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Neither this nor the WebMD story gets high marks on describing the potential benefits seen in the study. Although a total of seven endpoints were described in the study results, the writer chose to use the most optimistic of the lot. The 90% efficacy quoted is a far cry from the actual 60% efficacy based on an intention to treat analysis. The study results are complicated and simply picking one number of the many does not provide the reader with the correct information. THe vaccine was not shown to be 90% effective overall.", "answer": 0}, {"article": "His own previous research indicates that cannabis was used as early as 1800 B.C.\nStill, Hall said the research, which carefully measured safety and efficacy for a \"substantial\" number of children, showed \"clear evidence of benefits in reducing seizure frequency and severity over the duration of the trial.\"\nBased on the overall results, Devinsky believes CBD should be evaluated for epilepsy types beyond Dravet syndrome, which is caused by a genetic mutation and affects about one in 20,000 to 40,000 children in the United States.\nThe Epilepsy Foundation's Fureman said, \"before publication of this trial, much of the clinical evidence about CBD's effects on people's seizures was uncontrolled and anecdotal.\"\nPorter believes the study may open the door to having \"more thoughtful discussions with our patients about the efficacy and the side effects\" of cannabidiol.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says in the first paragraph: \u201cAmong children taking cannabidiol, the decrease in the frequency of\u00a0convulsive seizures\u00a0\u2014 which involve a loss of consciousness, stiffened muscles and jerking movements \u2014 was 23 percentage points greater than the decrease in seizures among children taking a placebo.\u201d\nWhat exactly does this mean? That, for example, the children taking a placebo experienced seizures on 73 out of every 100 days during the trial and that those taking the drug experienced seizures on 50 out of every 100 days? We would need to know the actual number of children who did and did not experience seizures and then know more about the frequency of those seizures to understand this reduction.\nLater in the story, there is a better explanation of the comparison of frequency of seizures, and the story does something that most stories don\u2019t ever do. It explains the range of experiences during the trial, not just the average. It says, \u201cWithin the study, individual participants experienced convulsive seizures at a rate ranging from four per month, on average, to 1,717 per month. During the 14-week study, frequency of convulsive seizures decreased from an average of 12.4 to 5.9 per month in the cannabidiol group, compared with 14.9 to 14.1 in the placebo group. On average, the change in seizure frequency amounted to a 39% decrease for the cannabidiol group patients, compared with a roughly 13% decrease among the placebo group.\u201d\nThat\u2019s quite a range, and it would have been good for the story to include a sentence explaining that the sheer variety in the patient population would make it difficult to adequately assess the efficacy of the drug in a trial this small in size. We\u2019re unclear on the math here, though. It looks to us that there was a 26 percentage point difference between the reduction in the drug group and the placebo group.\nStill, this is a lot of data-driven detail we don\u2019t normally see in news stories, so we appreciated this.\n\u00a0", "answer": 1}, {"article": "A total of 117 clusters (or \"rings\") were identified, each made up of an average of 80 people.\nIn addition to showing high efficacy among those vaccinated, the trial also shows that unvaccinated people in the rings were indirectly protected from Ebola virus through the ring vaccination approach (so-called \"herd immunity\").\nThe study found that the vaccine was safe and induced an immune response that peaked at 28 days, but decreased during the six months post injection.\nAmong the 5,837 people who received the vaccine, no Ebola cases were recorded 10 days or more after vaccination [3].\nThe vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release explains that, among participants vaccinated immediately, no Ebola cases were identified 10 days or more after vaccination, compared to 23 cases among individuals assigned to the delayed vaccination group. The data also suggested that the vaccine reduced Ebola risks for unvaccinated individuals within the contact rings of those who were vaccinated, but the news release notes that the study was not designed to test this so-called \u201cherd immunity\u201d effect, so it will require further research to confirm that vaccinating some individuals reduces the likelihood of their contacts developing Ebola.\nThe release could have explained more clearly that the virus has a 10 day incubation period during\u00a0which the virus can develop in the\u00a0patient and not be affected by the vaccine as the body won\u2019t have time to develop immunity. But the fact that the two groups (vaccinated and delayed vaccination) had equal numbers during the 0 to 10 day period helps to confirm that the two groups were equal in their exposure to the virus and risk of developing Ebola.", "answer": 1}, {"article": ".\nThe article entitled \"Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder\" is coauthored by Steven Pliszka, MD, from The University of Texas Health Science Center at San Antonio and colleagues from Massachusetts General Hospital (Boston, MA), Westside Medical Family Practice (Clinton, UT), University of Tennessee Health Science Center (Memphis, TN), Meridien Research (Maitland and Bradenton, FL), Children's Development Center (Winter Park, FL), Ironshore Pharmaceuticals & Development (Grand Cayman, Cayman Islands), and Mount Sinai Medical Center (New York, NY), on behalf of the HLD200-108 Study Group.\nThe article is available free on the Journal of Child and Adolescent Psychopharmacology website.\nChildren taking the delayed-release stimulant did not have to wait for a morning dose to take effect and also benefited from improved symptoms later in the afternoon and evening, according to the study results published in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.\nThe Journal is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As far as benefits of this new\u00a0drug go, the release only states that it \u201cled to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.\u201d\u00a0 It adds that, \u201cchildren taking the delayed-release stimulant did not have to wait for a morning dose to take effect and also benefited from improved symptoms later in the afternoon and evening.\u201d\u00a0 There is no explanation of the degree of improvement among children taking the drug compared to those on a placebo, and therefore, readers are at a loss to gauge the real value of the new formulation.\nMoreover, the new formulation is compared to placebo, but it is already known that stimulants are superior to placebo for most ADHD-related outcomes. If the novel element of this new (and presumably more expensive) formulation is that it improves morning symptoms compared to standard early AM dosing, then a more appropriate control group (or perhaps a 3rd volunteer group) would have been morning dosing of standard formulation methylphenidate.", "answer": 0}, {"article": "\"This is a multi-channel implantable device,\" Peckham explains.\nIt was the lowest point of Annette's life; the woman who once trained dogs to assist the disabled would now be relying on one herself.\nThat's what happened to Annette in 2002 when a car accident left her paralyzed.\n\"I've always compared it to being like a toddler learning how to, you know, walk, write, eat.\"\nBack then, she couldn't even wipe the tears from her eyes \u2014 and there were plenty of tears shed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not attempt to quantify the benefits. By focusing on one patient\u2019s positive experience, the story implies that the treatment works perfectly for all people. In reality, the basic question \u201chow well does this treatment work?\u201d is not answered.", "answer": 0}, {"article": "\"Not every cancer cell becomes a metastatic cancer cell.\nIn the new study, if even one cell was detected in the bloodstream, a woman had a greater chance of her cancer recurring and of dying.\nThe problem is that just having circulating tumor cells may not be enough information to foretell the future, she noted.\n\"This may help with prognosis and staging of the cancer and, in the future, with targets for breast cancer treatments,\" said study lead author Dr. Anthony Lucci, a professor of surgery at the University of Texas MD Anderson Cancer Center, in Houston.\nBlood tests similar to the one investigated in this study have been found to be useful to gauge how well patients who already have metastatic cancer will do.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The writer makes it clear that while\u00a0lymph node status\u00a0\u201cis currently the best way to predict survival in women with breast cancer\u201d some women\u00a0with no cancer in their lymph nodes will eventually\u00a0experience a relapse of their cancer.\nBut then the story never discussed comparing this approach with current approaches to predict risk (including Oncotype, Adjuvant online, lymph node status etc).\nSo what is the comparative benefit?", "answer": 0}, {"article": "\"It didn't stop the drinking,\" says researcher David M. Penetar, PhD, assistant professor of psychology at McLean Hospital and Harvard Medical School.\nThe study is published in Drug and Alcohol Dependence.\n\"They still drank, but they drank less.\"\nHe studied the extract puerarin.\nIt is one of the substances known as isoflavones found in kudzu.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Nice job here. Instead of just telling us that the participants \u201cdrank less\u201d while taking the supplement, they quantified the reduction: about one beer less, on average, during the experimental drinking sessions (2.4 vs. 3.5 beers), and about half a beer less per day during the week they were taking the supplement compared with placebo (3 vs. 3.4 beers).", "answer": 1}, {"article": "CHICAGO\u2014For patients facing a choice between bypass surgery and a popular, less-invasive procedure to treat heart blockages, surgery improves chances of long-term survival, researchers said Tuesday.\n\nIn a study that analyzed data on nearly 190,000 Medicare patients treated between 2003 and 2007, 16.4% of surgery patients had died after four years, compared with 20.8% treated with angioplasty and a stent to prop open diseased vessels.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did a reasonable job in describing the benefits and placing them in context with comments about potential harms", "answer": 1}, {"article": ".\nThe findings also underscore the importance of flu vaccination for this risk group.\nThe current study, based on data from a nationwide flu surveillance network including 14 states, focused on pregnant women hospitalized with laboratory-confirmed flu over four recent flu seasons, from 2010 to 2014.\n\"All pregnant women should receive annual influenza vaccination to prevent influenza and associated complications for themselves and their infants,\" the study authors wrote.\nFor expectant mothers hospitalized with flu, early treatment with the influenza antiviral drug oseltamivir may shorten their time in the hospital, especially in severe cases, suggests a new study published in The Journal of Infectious Diseases and available online.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is a mixed bag here. The release adequately describes some aspects of the benefits. For example, pregnant women hospitalized with severe flu that were given oseltamivir within two days of exhibiting flu symptoms spent a median of 2.2 days in the hospital; as compared to 7.8 days for pregnant women hospitalized with severe flu that were given oseltamivir more than two days after exhibiting flu symptoms. In addition, the release addresses the benefit of vaccination by saying: \u201cpregnant women hospitalized with severe flu illness were half as likely to have been vaccinated as women hospitalized with milder illness (14 percent vs. 26 percent).\u201d But the release would have been stronger if it had done a couple additional things.\nFirst, the release notes that \u201cPregnant women hospitalized with less severe illness who were treated early also had a shorter hospital stay than those treated later, but the difference was not as great.\u201d If you\u2019re going to mention this benefit at all, even using modest language, it would be better to put a number to it. (Was it a difference of a day? 0.2 days?) Also, the release specifically mentions \u201cserious illness and complications, including death\u201d in its opening paragraph \u2014 but never tells readers whether the study found any potential connection between early antiviral treatment and reduced risk of complications for mother or child. Even if the study didn\u2019t find any such relationship, the release could have said that.", "answer": 1}, {"article": "But it also lowered women's risk of dying from breast cancer by 11% and men's risk of dying from prostate cancer by 23%.\n\"This study found strong evidence that aspirin use may reduce cancer death.\nCao hopes her study will continue to broaden the body of research to include cancer-related deaths overall.\nNot everyone can take aspirin, particularly if you are at high risk for ulcers and gastrointestinal bleeding.\nIt may also reduce your chances of dying from cancer, according to a study on long-term regular aspirin use and different kinds of cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states the percentages of reduction of cancer among aspirin users as opposed to those who do not take aspirin and divides the results by men and women. This is a good start, but readers deserve to see the actual numbers\u2013known as the absolute risk reduction\u2013along with the relative percentages.", "answer": 0}, {"article": "She is taking the antidepressant Effexor to help control the night sweats and hot flashes caused by tamoxifen.\nThe new study, known as Atlas, included nearly 7,000 women with ER-positive disease who had completed five years of tamoxifen.\nDr. Eric P. Winer, chief of women\u2019s cancers at the Dana-Farber Cancer Institute in Boston, said that even women who completed their five years of tamoxifen months or years ago might consider starting on the drug again.\nThere was virtually no difference in death and recurrence between the two groups during the five years of extra tamoxifen.\n\u201cThe treatment effect is real, but it\u2019s modest,\u201d said Dr. Paul E. Goss, director of breast cancer research at the Massachusetts General Hospital.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Description of benefits was adequate.\u00a0 Absolute differences between the treatment groups was provided \u2013 although AP\u2019s story broke it down a little bit farther and better for lay readers with this line:\u00a0 \u201cIn absolute terms, continuing on tamoxifen kept three additional women out of every 100 from dying of brest cancer within five to 14 years from when their disease was diagnosed.\u201d", "answer": 1}, {"article": "Dr. Henderson stated, \"Misconceptions about ketamine abound among psychiatrists, particularly related to possible chemical dependence problems.\nAnother conclusion Dr. Henderson highlights is ketamine infusions can relieve refractory depression symptoms persistently, perhaps for years.\nThrough a handful of ketamine infusions directed by Theodore Henderson, MD, PhD, refractory depression symptoms can be relieved significantly and persistently.\nDr. Henderson's findings challenge the oft-held beliefs that ketamine must be given frequently to have any benefit and that ketamine has no long-lasting benefit.\nIn contrast, this retrospective study of over three years of clinical experience, shows lasting benefits for many patients, with no apparent risk of addiction.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Claimed benefits are not quantified in the release. The only number we are provided comes from this statement: \u201cPatients in the study complete the Quick Inventory of Depressive Symptoms (QIDS-SR), among other scales, and 80% showed persistent positive response to the ketamine infusions treatments.\u201d\nHow many patients? The study says 100, but the news release says nothing. How long did the \u201cpersistent\u201d response last? We never find out. The news release does say that the study included more than \u201cthree years of clinical experience,\u201d but does not say how long the improvements were seen.\nThe release relies almost exclusively on the professional experience of the study author to make its case. Referring to Henderson, \u201chis clinical experience shows ketamine can invoke long-lasting effects often with less than six infusions.\u201d\nThe most intriguing possibility suggested is this: \u201cAnother conclusion Dr. Henderson highlights is ketamine infusions can relieve refractory depression symptoms persistently, perhaps for years.\u201d Alas, that statement, too, is not followed by supporting data, nor are they apparent in the study itself.\nWe aren\u2019t even told how depression is diagnosed. Without a randomized trial (and this study is a retrospective look at past studies, not a randomized controlled trial) no definitive conclusions can be drawn.", "answer": 0}, {"article": "In 2016, breast cancer accounted for 29 percent of all new cancers identified in the United States and was responsible for 14 percent of all cancer-related deaths.\n\"Our new approach utilizing urine and exhaled breath samples, analyzed with inexpensive, commercially available processes, is non-invasive, accessible and may be easily implemented in a variety of settings.\"\nThe researchers were able to isolate relevant data to more accurately identify breast cancer biomarkers using two different electronic nose gas sensors for breath, along with gas-chromatography mass spectrometry (GC-MS) to quantify substances found in urine.\n\"With further study, it may also be possible to analyze exhaled breath and urine samples to identify other cancer types, as well.\"\n\"Breast cancer survival is strongly tied to the sensitivity of tumor detection; accurate methods for detecting smaller, earlier tumors remains a priority,\" says Prof. Yehuda Zeiri, a member of Ben-Gurion University's Department of Biomedical Engineering.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only benefits statement is that \u201cresearchers detected breast cancer with more than 95 percent average accuracy using an inexpensive commercial electronic nose (e-nose) that identifies unique breath patterns in women with breast cancer. In addition, their revamped statistical analyses of urine samples submitted both by healthy patients and those diagnosed with breast cancer yielded 85 percent average accuracy.\u201d\nReaders need the total number of patients screened and other details on how results of the study were measured.\nIt\u2019s important to keep in mind that the study was about developing a better algorithm to funnel out the noise from these tests and focus on the signal that would indicate whether someone did or did not have cancer. Any benefit described should be related to the development of a better algorithm, versus developing a better physical test.", "answer": 0}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that \u201cAt the end of two years, patients treated with Rez\u016bm showed a 51% reduction in urinary symptoms (as measured by a seven-question survey), compared with the beginning of the study.\u201d\nHowever, without knowing what a sample baseline was, it\u2019s hard to say if this is a big improvement. (51% of what?)\nWe also wanted to know more about the patients:\u00a0Average\u00a0age, average prostate size, whether subjects had tried medications, whether investigators assessed improvement in not just self-reported\u00a0symptoms but also urinary stream.", "answer": 0}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Even with a Q&A format, articles about allergies can be more useful by making sure to include relative and absolute rates of benefit from various treatments. This article leaves the readers with the idea that all or most people get relief from one or more of the triad of treatment approaches: avoidance of allergy triggers, OTC or prescription drugs like antihistamines and nasal steroids, and immunotherapies like allergy shots. But drawbacks\u00a0and side effects should be made clear, so that the true benefit is more accurate.\nFor example, while the article does note that successful immunotherapy often takes years, it doesn\u2019t report:", "answer": 0}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news article does not quantify the potential benefits of treatment with these two Parkinson\u2019s drugs, instead describing them only in general terms. A little more information \u2013 a risk/benefit tally \u2013 might help readers weigh their advantages and disadvantages. ", "answer": 0}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says Lynparza \u201cmodestly delayed the time until cancer worsened \u2014 7 months versus 4 months for women given one of three commonly used chemotherapies. About half the study participants responded to Lynparza compared with about a quarter of those only treated with chemotherapy. It\u2019s unknown whether treatment increases survival.\u201d\nThe story could have emphasized that last point more strongly. The outcome that was studied, known as progression-free survival, is a surrogate marker. In fact, the drug claims no benefit in terms of the most vital outcome: extending survival.", "answer": 1}, {"article": "\"We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion,\" conclude study researcher Christopher P. Cannon, MD, and colleagues.\nAnd in the new study, patients had less bleeding after stent installation.\nBoth drugs increase the risk of dangerous bleeding.\nAnd since the drugs irreversibly bind to blood-clotting platelets, a patient has to stop taking these drugs for five to seven days before the body can make enough new platelets.\nBut there's a problem with Plavix, and with a newer, stronger drug in the same class called Effient.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story highlighted the potential benefits of this drug over the current medication as reducing overall death rates by 1.1%\u00a0\n\n", "answer": 1}, {"article": "The University of Texas Medical Branch \n\nOffice of Marketing and Communications \n\n301 University Boulevard, Suite 3.518 \n\nGalveston, Texas 77555-0144 \n\nUTMB Newsroom \n\n@utmbnews\n\nABOUT UTMB HEALTH: Texas' first academic health center opened its doors in 1891 and today has three campuses, four health sciences schools, three institutes for advanced study, a research enterprise that includes one of only two national laboratories dedicated to the safe study of infectious threats to human health, and a health system offering a full range of primary and specialized medical services throughout Galveston County and the Texas Gulf Coast region.\nThe goal of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD.\n\"We found that testosterone users had a greater decrease in respiratory hospitalizations compared with non-users.\n\"The findings suggest that testosterone replacement therapy may slow the progression of disease in men with COPD.\"\nThey also used the national Medicare database to study data from 253 men with COPD aged 66 and older who initiated testosterone replacement therapy between 2008 and 2013.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits were reported in quantitative terms:\u00a0 \u201cmiddle-aged testosterone replacement therapy users had a 4.2 percent greater decrease in respiratory hospitalizations compared with non-users and older testosterone replacement therapy users had a 9.1 percent greater decrease in respiratory hospitalizations compared with non-users.\u201d\u00a0 Even though this suggests that testosterone replacement therapy may slow the progression of disease in men with COPD, one is still left wondering how often that occurs. We aren\u2019t given any baseline numbers so the 4.2% and the 9.1% relative risk numbers lack context.", "answer": 0}, {"article": "Prostate cancer becomes more common as men age \u2014 autopsies of elderly men find that most had prostate cancer, whether they knew it or not.\nBut some said that if the test leads to more screening, it is not necessarily a good thing.\n\u201cWe are just feeding off of this cancer phobia.\u201d\n\nWhat is needed, and what the new test does not provide, is a way to decide which cancers are dangerous and which are not, Dr. Isaacs said.\nStill, he said the new test could help patients if it was used with caution.\nThe next step was to ask whether those variants really could predict who had prostate cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did provide some discussion on the\u00a0conundrum\u00a0presented by prostate cancer detection \u2013 namely that it is really an incomplete piece of information. The real goal is to develop a means of distinguishing between indolent and deadly prostate cancer. \u00a0The risk of the former would not warrant treatment likely to render the individual impotent and/or incontinent. \u00a0The risk of the latter might be worth the risk, or at least participation in active surveillance to allow for detection of a cancer while it is still localized. \u00a0The story did mention this conundrum though it might have spent more time on it.\nThe benefit of this treatment is an early warning of a pathology that might develop; it is less clear what a man in his 30s would do with this information.\u00a0", "answer": 1}, {"article": "Legumes, beans, whole grains and some seeds have it, as do uncooked potatoes and unripe bananas.\n\u201cThe potential for a nutritional lifestyle intervention to counter obesity driven by high-carbohydrate food, though we don\u2019t know yet how significantly, is fascinating,\u201d Arciero says\u2014especially when it\u2019s as simple and delicious as reheating your pasta.\nBut that\u2019s not the case with resistant starches, so named because they resist digestion.\nMost intriguing and surprising of all is that so many leftovers contain resistant starch.\nArciero and his team monitored the women after each meal for three hours and used a device to see how many calories they burned, and what type.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not use quantified benefits. One opportunity where that could have been added is in this section:\n\u201cArciero and his team monitored the women after each meal for three hours and used a device to see how many calories they burned, and what type. To Arciero\u2019s surprise, after women ate pancakes containing resistant starch plus protein, they experienced an increase in fat burning, compared to all of the other kinds of pancakes.\u201d\nAdding numbers for the calories burned or the \u201cincrease\u201d in fat burning would be beneficial. Minus these numbers, we can\u2019t assess\u00a0the credibility of the conclusions.", "answer": 0}, {"article": "A tiny but promising study suggests that a medicine used for immune disorders may offer long-term benefits to Alzheimer's patients\u2014a result likely to spur demand for the treatment even though it is in limited supply and isn't approved for the memory-debilitating disease.\n\nThe treatment, intravenous immunoglobulin therapy, or IVIG, is made from the blood plasma of healthy young adults. Since 2004 it had shown early promise for Alzheimer's, which afflicts some five million Americans.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t give a clear picture of how many were enrolled in the study and what happened to them.\nReuters did a better job, reporting:\nRelkin presented three-year data on 16 patients in Baxter\u2019s Phase 2 study of Gammagard, which originally enrolled 24 participants.\nOverall, all 11 study participants who got Gammagard for the full three years showed improvements in thinking abilities, behavior and daily functioning.\nOf these, the four patients who received the most effective dose (0.4g/kg) for the full 36 months fared the best, showing no decline on several standard measures of cognition, memory, daily functioning and mood.\nBut Reuters also didn\u2019t explain what happened to the other 8 participants originally enrolled.", "answer": 0}, {"article": ".\nThis suggests that the blood test could be used by clinicians for up to a week after injury to detect brain injury.\nThe results showed that the blood test was able to detect brain injuries with 94 percent accuracy, nearly as effective as state-of-the art CT scans.\nWhen cross-checked with scans, the blood test was able to detect mild to moderate traumatic brain lesions with up to 97 percent accuracy in patients 18 years and older.\nThe discovery could greatly expand the window for diagnosing concussions, especially in patients who experience a delayed onset of symptoms.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that the blood test \u201cwas able to detect mild to moderate traumatic brain lesions with up to 97 percent accuracy in patients 18 years and older.\u201d According to the published study, researchers used a statistic called Area Under Curve (AUC), a predictive model, that reflects both the sensitivity and specificity of the test. A value of\u00a00.5 implies that the test has the diagnostic accuracy of a coin flip, whereas a value of 1.0 indicates perfect discrimination between diseased and non-diseased patients. Sensitivity and specificity are important characteristics of any screening or diagnostic test and we encourage health care journalists to incorporate these concepts into their reporting. The 97 percent accuracy figure used in the story appears to refer to the state of metabolic blood levels at 36 to 60 hours after injury. It appears that the initial determination over whether the patient had mild traumatic brain injury was highly accurate.", "answer": 1}, {"article": "In Manhattan some raw-milk drinkers hire a mule to bring the white stuff to an agreed-upon location in...\nNow that's trickier.\nNo?\nGot milk?\nAnd they consider themselves lucky.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story mentioned a number of health claims so-called \u2018fans\u2019 of raw milk postulate can be derived through the use of raw milk. \u00a0(The story also included comments from the FDA in which these claims were refuted.) \u00a0It should have included some critical examination of the health claims made.", "answer": 0}, {"article": "\u201cThis is the first on walnuts and diabetes.\nEating walnuts may reduce the risk for Type 2 diabetes in women, a large new study concludes.\nThe scientists, writing in the April issue of The Journal of Nutrition, used dietary and health data on 138,000 women participating in a large continuing study of women\u2019s health.\nWalnuts may have some unique benefits.\u201d\n\nThe study was supported with grants from the National Institutes of Health and the California Walnut Commission.\nThey found 5,930 cases of Type 2 diabetes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated:\n\u201ccompared with women who ate no walnuts, those who consumed 8 ounces of walnuts or more a month reduced their risk for Type 2 diabetes by 24 percent.\u201d\n24% of what?\u00a0 Why not provide the absolute numbers of what was observed?", "answer": 0}, {"article": "Find out more about brain health at the Alzheimer's Association.\nA clinical trial comparing high and low intake of omega-3s in relation to brain imaging would help answer those questions, he said.\nTan added, however, that it remains possible that factors they did not control for, such as fruit and vegetable consumption, are really responsible for the brain benefits.\nBut questions remain over whether fatty-acid levels really influence changes in brain size, Scarmeas added.\nThis suggests they may play a role in promoting general vascular, or blood vessel, health in the brain, similar to how they are thought to help heart health, rather than acting on just one brain area, Tan said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although we think readers will come away with the correct bottom line message on this study, we\u2019re going to rate this criterion unsatisfactory, for two reasons:", "answer": 0}, {"article": "He was not involved in the study.\nThe protective effect of the daily pill was described as \u201cmodest\u201d by the trial investigators who emphasized that the primary use of vitamins was to prevent nutritional deficiencies.\nThey also saw a 12 percent reduction in the risk of death from cancer, although those findings also were not statistically significant.\nThe U.S. Physicians Health Study II included nearly 50,000 male doctors aged 50 and older and spanned more than 10 years.\n\u201cIt doesn\u2019t seem like there is any particular risk associated with taking a vitamin and there might be a small benefit,\u201d said Dr. David Weinberg, chief of the department of medicine at Fox Chase Cancer Center in Philadelphia.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits\u00a0were reasonably framed using words like \u201cmodest\u201d and \u201csmall.\u201d But the only hard numbers\u00a0provided pertain to the relative risk of cancer in the multivitamin group compared with placebo. And\u00a0it can be difficult to judge exactly what\u00a0this 8% reduction in cancer cases\u00a0looks like\u00a0without more detail.\u00a0As the competing AP coverage explains, the benefit worked out to about one fewer cancer per thousand men each year. In the AP\u2019s words: \u201cFor every 1,000 men per year in the study, there were 17 cancers among multivitamin users and more than 18 among those taking the placebo pills.\u201d That\u2019s a much more informative way to describe things\u00a0than simply calling it an\u00a08% reduction, as Reuters did. The absolute risk reduction was clearly stated in the abstract and did not even require digging into the tables of the published manuscript.\n\u00a0", "answer": 0}, {"article": "\"People were saying, 'I had absolutely zero symptoms.\nHe says the benefits of the worms definitely didn't outweigh the bad side effects.\nIt could be that the whipworm larvae weren't prepared correctly.\nBack in Berkeley, Velasquez-Manoff thought he might one of the lucky ones.\nHe talked to many people who were using an unlikely tool to treat their problems: parasitic worms that live in your gut \u2014 permanently.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There don\u2019t appear to be quantifiable benefits associated with this treatment because it hasn\u2019t been well studied in humans, and\u00a0we are told this much: \u201cThe controlled trials, thus far, in a variety of different diseases including childhood allergies and asthma have not been positive.\u201d Also, the patient interviewed experienced a negative result. With no proof of benefit and plenty of risks to ingesting parasitic\u00a0worms, we\u2019re left to wonder\u00a0why this story emerged and was run on NPR with a headline that hinted there was potential for this treatment.", "answer": 1}, {"article": "Traditional knee surgery cuts through muscles and tendons.\nO'Brien spent just a few hours in the hospital after surgery before she was well enough to go home.\nHelp for O'Brien finally arrived in a new kind of knee surgery, developed and perfected at Chicago's Rush University Medical Center by Dr. Richard Berger.\nO'Brien successfully charted the course and headed out of the hospital to a smooth recovery.\nFor Linda O'Brien, a grandmother and scratch golfer, chronic knee pain was making life unbearable.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The patient in this story was presented as being pain free nearly immediately after surgery, without mention of any analgesic medication she may have been taking. This patient was also shown driving a golf ball 2 weeks after surgery, though again, it is not known whether this is a realistic expectation for a few, some, or most patients after this type of knee replacement.", "answer": 0}, {"article": "For more on irregular heartbeats, visit the U.S. National Library of Medicine.\nThe findings are reported by study author Dr. Vivek Y. Reddy, a senior faculty member in medicine and cardiology at the Mount Sinai Medical Center in New York City, and colleagues in the May 26 online edition of Circulation: Arrhythmia and Electrophysiology.\nThe current study focused on 27 patients (66 percent men), all of whom were diagnosed with a form of atrial fibrillation.\nIn fact, with this new approach, the study team found that physicians could destroy such cells with 100 percent accuracy.\nThis, they said, is due to the procedure's use of a slender medical device called an endoscope, which when inserted into the target region provides a continuous real-time image of the culprit cells.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The claims of \"100% accuracy\" and that \"The investigators found that after just one laser treatment, misfiring ceased in 84 percent of the treated veins, and 90 percent remained inactive three months after treatment\" aren\u2019t put into any meaningful context about what difference this made in patient outcomes.\u00a0 Of course, what can you possibly say about outcomes after just three months?\u00a0 Which is exactly the point of raising this issue at all.\u00a0", "answer": 0}, {"article": "The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\n\"The study found an interesting protective association between low-dose aspirin and breast cancer,\" said lead author Christina A. Clarke, Ph.D., M.P.H., from the Cancer Prevention Institute of California.\nThis study differed from other studies that have looked at aspirin and cancer risk because it focused on the dose levels of the aspirin women had taken and tracked the frequency of the use of low-dose aspirin as opposed to regular aspirin.\nThe team of researchers chose to focus on low-dose \"baby\" aspirin, because not only is it inexpensive and readily available as potential means of prevention, but because there are already a lot of people already taking it for prevention of other diseases such as heart disease and even colon cancer.\nThis study -- which is the first to suggest that the reduction in risk occurs for low-dose aspirin -- was proposed by City of Hope's Leslie Bernstein, Ph.D., professor and director of the Division of Biomarkers of Early Detection and Prevention, and published online in the journal, Breast Cancer Research.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release shares relative risk reduction numbers only, not the actual numbers of people who reduced their risk of breast cancer by taking aspirin.\nThe release notes that the research team \u201csaw an overall 16 percent lower risk of breast cancer in women who reported using low-dose aspirin at least three times per week. Such regular use of low-dose aspirin reduced the risk by 20 percent of estrogen or progesterone receptor positive, HER2 negative breast cancer, which is the most common breast cancer subtype.\u201d That\u2019s fine. The problem is that, as noted above, this was an observational study, not a clinical study designed to determine whether a specific intervention (i.e., aspirin use) was responsible for reducing cancer risk.", "answer": 0}, {"article": "The study described in the article \"Effect of Foeniculum vulgare Mill.\nIn the end, fennel was concluded to be a safe and effective treatment to reduce menopause symptoms without serious side effects.\nImprovements were compared between the intervention and placebo groups at four, eight, and 10 weeks, with a significant statistical difference documented.\nThe study was completed in Tehran, Iran, where the average age of women at menopause is younger than in the United States: 48.2 years versus 51 years, respectively.\nIn this small trial of 79 Iranian women aged 45 to 60 years, soft capsules containing 100 mg of fennel were administered twice daily for eight weeks.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We were disappointed to read only very vague terms such as \u201csignificant statistical difference\u201d and \u201cimproved menopause symptoms\u201d used to describe improvements in hot flashes, sleeplessness, vaginal dryness, and anxiety.\nThe release could have done better on this score had it told us something about the scales used to measure improvement (What was the minimum and maximum score for hot flashes? The improvement in sleeplessness went from what to what?) and the absolute difference from the beginning of the trial to completion of the trial.", "answer": 0}, {"article": "Then they took tests involving memorizing words.\nDr. Fl\u00f6el said the memory improvement might be linked to a decrease in insulin and inflammation in the calorie-restricted participants, who lost four to seven pounds.\nParticipants were advised by dietitians but monitored their own eating over three months, Dr. Fl\u00f6el said.\nThe study, published Monday in The Proceedings of the National Academy of Sciences, appears to be the first to link calorie-restricted diets with improved memory in people.\nThe calorie-restricted group averaged 20 percent improvement in memory performance.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that the caloric restriction group saw a 20 percent average improvement in memory performance. The report also describes the size of the group tested and the duration of the study.\u00a0\nIt would have been useful to know how memory was tested in order to appreciate what a 20 percent improvement means in practical terms. 20% of what?\u00a0 20% that makes what kind of difference in daily functioning? Maddeningly, the story does not report how many calories the restriction group ate on a given day. \u00a0 \n\u00a0", "answer": 0}, {"article": "\u201cIt\u2019s like you\u2019re possessed,\u201d said Lorie Novak, who has suffered from chronic migraines since childhood.\nBut the companies\u2019 fortunes are intertwined, he said, and \u201cthe class only wins if headache care in America improves.\u201d\n\nAiming to prevent migraines before they start\n\nThere\u2019s plenty of room for improvement.\nThat medication, Topamax, has been dubbed dubbed \u201cSleepomax\u201d by doctors and patients because it\u2019s also a heavy sedative.\nTargeting CGRP is not a particularly new idea.\n(Merck\u2019s failed pill, by contrast, was meant as an on-the-spot treatment after the pain started.)\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is an attempt to quantify the benefits, but it wasn\u2019t sufficient to earn a Satisfactory rating:\n\u201cIn mid-stage clinical trials, each of the four treatments has eased symptoms for about half of study participants, cutting the number of days they\u2019re afflicted by migraines roughly in half.\u201d\nThe story\u00a0needs to report enough data so we know the number of subjects in the trial(s), the number of migraine-days they had (in this case) at baseline, and the number of migraine days they had on treatment. The question is: \u201cHalf of what?\u201d", "answer": 0}, {"article": "So, indeed, there has been a strong interest in giving the best additional therapy possible,\" Choti added.\nAfter nearly three years of treatment, the researchers found almost no difference between survival rates in the two groups.\nThe study authors noted that, currently, the prognosis for pancreatic cancer is very poor, with a five-year survival rate of less than 5 percent.\nAt the three-year mark, patients on the gemcitabine regimen achieved an average survival rate of 23.6 months.\nThose who received fluorouracil and folinic acid chemotherapy had lived an average of 23 months.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Average survival times and survival rates at\u00a0one and\u00a0two years of follow-up were provided for both treatment groups.", "answer": 1}, {"article": "The retina is the light-sensing nerve tissue at the back of the eye.\nThe stem cell injection resulted in 130 days of preserved vision in laboratory rats, which roughly equates to 16 years in humans.\n\u201cThese induced neural progenitor stem cells are a novel source of adult-derived cells which should have powerful effects on slowing down vision loss associated with macular degeneration,\u201d said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and contributing author to the study.\nThis work was supported by the Simon and Beathrice Apple Stem Cell Fund for Eye Research, the David and Janet Polak Foundation Stem Cell Core Laboratory; National Institutes of Health (R01 EY020488), Department of Defense (W81XWH-12-1-0617), Foundation Fighting Blindness and the Knights Templar Eye Foundation Inc.\n\u201cThis is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration,\u201d said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Now that we\u2019ve established that the work was done in lab rats, did the news release quantify how successful the experimental approach was? \u00a0Did it give numbers about how many animals were \u201ctreated\u201d and how many benefited?\nNo.\nThe release only stated: \u201cThe stem cell injection resulted in 130 days of preserved vision in laboratory rats, which roughly equates to 16 years in humans.\u201d \u00a0But that doesn\u2019t give any idea of the rate of effectiveness \u2013 even in rats. \u00a0And equating this \u2013 at this early stage \u2013 to what could happen in humans is, well, imaginative.", "answer": 0}, {"article": "The new research provides more evidence of the need for new regional centers of care, in order to minimize the time it takes to transport a patient to hospital capable of providing stent therapy, according to Dr. William J.\nRelated: New Recommendations Say More Americans Should Take Aspirin\n\nFor Reisch, the impact was almost immediate: he began to regain feeling while undergoing the procedure.\n\u201cThey are destined to be in a nursing home or to be dead and when we re-establish blood flow \u2014 often times right there on the table \u2014 they get better.\u201d\n\nStent retriever therapy is a new procedure experts call the most major advance in stroke treatment in two decades.\n\u201cThe earlier that patients with acute ischemic stroke get to a hospital offering the appropriate treatment, the higher the likelihood is of a good outcome,\u201d said the study\u2019s lead author, Dr. Mayank Goyal of the Hotchkiss Brain Institute at the University of Calgary.\nAt the hospital, the first-line therapy, a powerful blood-thinning medication called tissue plasminogen activator or tPA could not dissolve the blood clots in Reisch\u2019s brain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story mainly discusses the benefits as they pertain to one patient.\u00a0We had to read the story multiple times\u00a0to realize that the study in question went beyond this one patient.\nA review of the study itself shows that 196 patients were part of the study, and less than half \u2014 96 \u2014 underwent the treatment described in the story. The study says that, \u201cIn the stent retriever arm of the study, symptom onset to reperfusion time of 150 minutes led to 91% estimated probability of functional independence, which decreased by 10% over the next hour and by 20% with every subsequent hour of delay.\u201d\u00a0The story accurately reports this finding, saying, \u201crestoration of blood flow within 2.5 hours of stroke onset was associated with minimal or no disability in 91 percent of patients.\u201d\nDespite this attempt at quantification, we think the story relies excessively on an individual patient\u2019s story that is likely not representative of the broader experience. Since the optimal time window to perform this procedure is so small,\u00a0many stroke patients may not be eligible for the therapy. \u00a0In addition, the story does not explain that the study was done in 39 centers and only managed to randomize 196 patients over a 2-year period. This comes out to 5 patients per center or an average of one patient every 4 months, hardly a large\u00a0number (or even percentage) of stroke patients who would benefit from (or be eligible for) this technology.", "answer": 0}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes it clear that benefits of the lice control products have not been established.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate intake of vitamin D is necessary for prevention of rickets, a bone-deforming disease.\u00a0 The other benefits postulated in the story included prevention of a wide range of diseases for which there is not conclusive data.\u00a0 The story, however, made it seem like these were a slam dunk.\u00a0 \nIt would have been interesting to quantify \u2013 in absolute terms \u2013 the benefit of vitamin D on at least one specific disease before and after national supplementation of the milk supply (e.g. the incidence of rickets) and contrast it with the claims being made for vitamin D that aren't well supported by strong data.", "answer": 0}, {"article": "They identified a total of 24 breasts reconstructed by DTI in 19 patients, all with at least 30 days' follow-up and most with one year of follow-up\n\nPatient characteristics and outcomes were compared to those of 109 breasts with TEI reconstruction in 98 patients.\nDr. Moreira adds, \"In appropriately selected cases, DTI reconstruction is a viable alternative to staged techniques requiring multiple surgeries.\"\nThe researchers believe the DTI technique may expand the options for older women, who are less likely to undergo breast reconstruction.\n\"The DTI approach is a powerful tool for breast reconstruction in elderly patients,\" comments ASPS Member Surgeon Andrea Moreira, MD, of the Cleveland Clinic.\nThe researchers emphasize that DTI isn't an option for every patient, depending on breast shape and other factors.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Multiple follow-up benefits (measured at 30 days and 1 year) are cited, with the DTI group having fewer readmissions, fewer days with a drain in place (13 vs 23), fewer days in hospital after the procedure, and fewer follow-up office visits (6.5 office visits vs 12 visits for the non-DTI group.)\nThe news release highlights the following benefit: \u201cavoiding some of the inconvenience and risks of staged approaches to breast construction.\u201d So,\u00a0It would have been helpful to clarify for readers what the staged approach with tissue expanders involves; mainly inserting an inflatable expander in the space left by the removed breast, gradually filling the expander with saline over weeks or months, and eventually placing an implant once the area can safely and comfortably accommodate it.", "answer": 1}, {"article": "Curcumin is an ingredient found in the common spice turmeric.\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\nThis study published reports that topical curcumin gel applied soon after mild to moderate burns and scalds appears to be remarkably effective in relieving symptoms and improved healing of the affected skin.\nIn this report, use of curcumin after burns and scalds were found to reduce the severity of the injury, lessen pain and inflammation, and improve healing with less than expected scarring, or even no scarring, of the affected skin.\nBased on studies that she has done both in the laboratory and in patients over 25 years, the key to curcumin's effectiveness on burns and scalds is that it is a natural inhibitor of an enzyme called phosphorylase kinase.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t give any numbers to support the author\u2019s statements about benefits. There is only one paragraph devoted to benefits in the news release, which states the \u201cuse of curcumin after burns and scalds were found to reduce the severity of the injury, lessen pain and inflammation, and improve healing with less than expected scarring, or even no scarring, of the affected skin.\u201d Without any numbers, we don\u2019t know the extent of the reduction from this vague, comparative wording. And how were these parameters measured?\nThe original journal article also doesn\u2019t provide any benefits data. Instead, it shows before and after pictures of three patients and then describes their recovery ranging from one day to six months after treatment.\nWe still expect the news release to provide the quantitative scope of the potential benefits by asking the researcher to supply these numbers. Since no data are given, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story simply stated, \"The cream succeeded in 9 out of 10 cases with the rats.\"\u00a0 How is the \"success\" of an anti-impotence cream measured in rats?\u00a0 Inquiring minds want to know.\u00a0\nAgain, at least a line is warranted about the leap from animal research to human application. \u00a0", "answer": 0}, {"article": "Philadelphia, PA, April 18, 2017 - In the past, all forms of metastatic prostate cancer have been considered incurable.\nWhile the study is only a first step, one-fifth of the patients treated had no detectable disease, with an undetectable prostate-specific-androgen (PSA) and normal blood testosterone, after 20 months.\nOf the five patients with extra-pelvic lymph node involvement, four achieved an undetectable PSA after ADT and surgery, while the fifth needed radiation to reach this milestone.\nThe results suggest that some men who have previously been considered incurable can possibly be cured; investigators also establish a new paradigm for testing various drug combinations in conjunction with local treatment of the prostate to determine which is the best approach (ie, has the highest undetectable disease rate).\nLonger follow-up is needed to determine whether these patients were in fact cured.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit here was the elimination of detectable prostate cancer within 20 months of beginning drug treatment. The release makes clear that four of the 20 patients in the study reached this endpoint. But there are some problems. For one thing, the release notes that, of the four patients who reached the relevant endpoint, the cancer \u201cremained undetectable in two patients for 27 and 46 months, respectively.\u201d What happened after 27 and 46 months? Was the cancer detected again? Or was that simply when researchers submitted the paper? And what happened to the other two patients? According to the journal manuscript, the cancer remained undetectable for the other two patients for five and six months, respectively. But, again, it\u2019s not clear if the cancer then came back or if that was simply when the study ended. Given that the entire release hangs on whether people still have prostate cancer, this should be crystal clear to readers \u2014 and it\u2019s not. In addition, it would have been very easy to include the numbers for all four patients who reached the endpoint, so this looks like cherry-picking. Lastly, it\u2019s worth noting that the benefit was not clearly defined until the sixth paragraph. Since this was the defined endpoint for the study, the release would have been stronger if it had noted this earlier.\nIn addition, the 20 month time period strikes us as arbitrary for a study endpoint. Typically, when oncologists speak of cure it implies that there is no evidence of disease five years after treatment. An undetectable PSA is a surrogate measure and we do not know whether the multiple treatment approach can \u201ccure\u201d cancer or even extend survival. The longer-term follow-up data (which was variable in length\u00a0because patients were not enrolled at the same time),\u00a0indicated\u00a0that two of the four patients did have not have recurrence of the cancer (at least based on detectable PSA). \u00a0However, this seems to imply that two of the patients could have had recurrence after 20 months.  ", "answer": 0}, {"article": "New guidelines\u2026 (Photo illustration by Gary\u2026)\n\n\u201cMigraine is a condition that involves recurring headaches.\nThese medications \u201care effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity,\u201d Silberstein and colleagues wrote in the new guidelines, which were based on a review of 284 publications.\nNeurologists say that only about one-third of those who could benefit by migraine-preventing medication actually use it.\nMany migraines can be prevented by taking medication every day.\nThe guidelines will be published in Tuesday\u2019s edition of the journal Neurology.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Here\u2019s what the story states: \u201cNeurologists estimate that about 38% of people who suffer from migraines stand to benefit with such a regimen, and studies suggest that as many as half of migraines can be prevented with drugs.\u201d\nThanks to the competing USA Today coverage, we know that this is an overly optimistic assessment, since in that story it was noted that patients may need to try 3 or 4 different drugs, alternative therapies, and lifestyle changes to achieve a 50% reduction in headaches.\n\u00a0", "answer": 0}, {"article": "I think there is a greater capacity to be open-minded and let science dictate our conclusion, not politics,\u201d Grob said.\nIt revives a promising field of study lasting from the 1950s to the early 1970s that suggested some patients experienced powerful and sustained improvement in mood and anxiety from hallucinogens.\nGrob\u2019s study looked to see whether psilocybin could help ease some of the anxiety of dying cancer patients.\nThe treatments were given in random order and neither the doctors nor the patients were told which compound was administered.\nPatients seemed somewhat less anxious, they reported in the Archives of General Psychiatry.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "We need to be proactive in our approach.\"\nThis led researchers to further develop a risk prediction tool to better identify which patients undergoing a hip replacement may be at higher risk for dislocation, and then implement a treatment algorithm to help reduce that risk.\nBeginning in 2016, surgeons used the standardized risk prediction model and treatment algorithm developed at NYU Langone, which factored in data collected from preoperative imaging taken while the patient was sitting and standing, and other measures that might affect risk for dislocation, including presence of a previous lumbar fusion.\nUsing the risk assessment tool, the researchers identified 192 of 1,009 patients as high risk for a dislocation after surgery.\nThese findings represent a six-fold decrease in the rate of dislocation in the high-risk group.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This study was done in two parts.\nPart one: a retrospective review of 1,082 conventional (not dual cup) total hip replacements (THRs), over 2 years, in which the dislocation rate was 1.8% (19 patients). We\u2019re told about a third of the total cohort (320 of the 1,082) had \u201cspinal disease and deformity\u201d on imaging scans. In this group of 320, 10 patients (3.1%) had subsequent dislocations.\nPart two: Beginning in 2016 researchers began employing their risk assessment tool \u2014 pre-operative sitting/standing scans of the hip, and factoring in other risk factors like previous spinal fusion \u2014 and identified 192 of 1,009 patients (19%) as \u2018high risk\u2019 for dislocation. About three-fourths of these patients received dual cup transplants with only 1 having a subsequent dislocation (0.5%).\nThe news release gives us the absolute rate of dislocations in both high-risk groups (3.1% vs. 0.5%), which is vital information to understand the scope of the potential benefit. And on that basis we\u2019ll award a satisfactory grade here. However, we note limitations under the Evidence criterion below that have a bearing on these statistics.", "answer": 1}, {"article": "A decision by the FDA is due by May 17.\nReuter said the 17-point gap between the treatment and placebo groups was in line with previous Aimovig studies.\nAmgen said Aimovig trial patients also had statistically and clinically meaningful improvements in secondary trial goals including fewer monthly migraine days and better physical function.\nThe 12-week trial, presented this week at the annual meeting of the American Academy of Neurology, involved 246 patients suffering four to 14 migraine headaches a month who had tried two to four preventive treatments that either did not work for them or had intolerable side effects.\nHe said previous studies excluded patients who had tried more than two other treatments.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says the drug \u201creduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal.\u201d\nAlthough this is a faithful account of what the study authors reported in the abstract, this somewhat tortured description is not helpful for readers, since it doesn\u2019t convey just how few people benefited from the drug. Nor does it explain what a reduction of \u201cat least half\u201d means. The story should have stated how many migraines participants experienced before treatment and how many afterward.\nBottom line: If 30% of participants had a 50% reduction in migraine days, this means that 70% of participants didn\u2019t achieve such benefits. The story should\u2019ve spelled this out more clearly.", "answer": 0}, {"article": "Both Prozac and Celexa belong to a class of antidepressants known as selective serotonin reuptake inhibitors, or SSRIs.\nWhen taking Prozac, Hollander says, \u201cPatients acknowledge experiencing less discomfort.\nTaking Prozac (fluoxetine) doubled the chances that a patient would show overall improvement, measured by their clinicians.\n\u201cIt takes the edge off,\u201d Hollander explains, noting that the findings were statistically significant and clinically meaningful.\nThe research, which included 37 high-functioning autistic adults, mainly diagnosed with Asperger\u2019s syndrome, followed participants for 12 weeks.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "After explaining that the story was quite small and covered only a few months time, the story provides a quick summation of the benefits found in the study saying, \u201chalf of the participants taking Prozac had significant reductions in obsessive-compulsive symptoms, compared with 8% taking placebo.\u201d\u00a0 But given the very small sample size, natural frequencies would have been more informative and less likely to be misinterpreted. Also, a bit more detail on what a \u201csignificant reduction\u201d means in an autistic disorder would have been welcome.\n\u00a0", "answer": 1}, {"article": "Air is suctioned through the side channels to emulate breathing.\nMore often than not, these studies produce mixed data that don\u2019t tell researchers much about whether it is safe and effective for humans.\nThis proved the chips could provide real world information to scientists studying the effects of new drug compounds.\n\u201cBiology is very complex.\u201d\n\nIncorporating the chips into drug testing could save millions of dollars and years of time on research.\nThe chips will also provide researchers with information on dosing at a much earlier stage in drug studies\u2014particularly helpful because animals metabolize chemical substances at a different rate than humans.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article cites two experiments, in which the chip\u2019s lung channel behaved like human lungs. In both cases the story says the results were \u201cexactly\u201d what would happen in human lungs under the same circumstances.\nIt\u2019s probably difficult or impossible to provide any quantitative benefit regarding this technology at the current time. Nevertheless, we think the language of the story is not measured enough. Human organs work with millions of other cells and are influenced by countless other genetic and environmental factors that cannot be duplicated in these early experiments. Human systems are variable and dynamic, and doctors often don\u2019t know ahead of time how patients would respond to a disease or treatment. So to suggest that the organs-on-a-chip behave exactly like human organs is not really supported at present.\nAnother example of the story\u2019s enthusiasm: \u201cThe chips will also provide researchers with information on dosing at a much earlier stage in drug studies\u2014particularly helpful because animals metabolize chemical substances at a different rate than humans.\u201d \u00a0While these initial studies are encouraging, these chips haven\u2019t yet been compared to existing tools used in drug development. Until this is done, a more cautious tone regarding benefits \u2014 \u201cmay,\u201d \u201cmight,\u201d and \u201ccould\u201d rather than \u201cwill\u201d \u2014 is warranted.", "answer": 0}, {"article": "Instead, they recruited 20 volunteers who were overweight or obese and assigned them to a week of either egg breakfasts or ready-to-eat cereal breakfasts.\nBoth types of breakfasts had the same number of calories, but the egg breakfasts contained \u201chigher protein quality,\u201d according to an abstract for the study, posted online here.\nThat\u2019s right \u2013 the folks who sell eggs paid for a study that comes to the shocking conclusion that eggs are an ideal breakfast food.\nThe folks who carried out this egg industry-funded research were from the Pennington Biomedical Research Center in Baton Rouge, La.\nNews flash: Eggs are really good for you.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t quantify the findings. It doesn\u2019t say how much less hungry the participants felt during the egg vs. the cereal phase of the study or how much less they ate. It doesn\u2019t tell us if the differences in hormone levels reported would be considered clinically meaningful.\u00a0 Was it a difference of 50 fewer calories at lunch?\u00a0 250? How big a deal was this?", "answer": 0}, {"article": "\"Our idea was to ask, 'What are the most important proteins we could find in Alzheimer's patients?'\nMucke acknowledged that there are very few medical treatments for patients once they are diagnosed with Alzheimer's.\nMore intriguing is a test that examined stored blood samples and predicted Alzheimer's disease in 20 of 22 patients who developed the disease 2 to 5 years later.\nDr. Jerome Goldstein, director of the San Francisco Alzheimer's and Dementia Clinic, said there are very few objective tests to diagnose Alzheimer's disease, and most of them are complex and expensive.\nAlthough the studies were small in scale, researchers said the experiment proved that the concept of screening for chemical signals was promising and that the first Alzheimer's blood test might be within reach after further large scale studies.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was really not clear about the benefits to be gained by early identification of pending Alzheimer\u2019s disease.\u00a0 Although one expert was quoted as saying that he was a \"proponent of knowing what is ahead\" and the value in doing so while people can still \"speak for themselves\", it is not clear from this story what one would do with advance knowledge that one was going to develop Alzheimer\u2019s disease.Not everyone is a proponent of knowing what is ahead, especially given uncertainty about effective treatment.\u00a0 ", "answer": 0}, {"article": "Bochner and his colleagues Drs.\nIf the results are favorable, the next step would be to get funding to actually test whether taking a BTK inhibitor will improve the ability of food-allergic adults to eat foods they're allergic to.\nAnne Marie Singh and Melanie Dispenza are now testing how successful the drug is at targeting allergies to food, such as tree nuts and peanuts.\nThe cancer patients who were allergic to allergens such as cat dander and ragweed saw their allergic skin test reactivity reduced by 80 to 90 percent in one week, and this persisted with continued use of the drug for at least one to two months.\n\"It almost completely knocked out the patients' skin test and blood cell allergic reactivity,\" said senior author Dr. Bruce Bochner, the Samuel M. Feinberg Professor of Medicine at Northwestern University Feinberg School of Medicine.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides only relative reductions in skin reactivity tests. It reports neither absolute numbers nor a description of the clinical relevance; that is, whether the patients felt their allergies symptoms had improved. The release does not tell readers that one of the patients continued to take anti-allergy medication or that the other patient was not taking any anti-allergy medication; these points in the research report raise questions about whether the patients felt any improvement in their allergy symptoms.\nThere is also no mention that the researchers wrote in their journal letter that they have yet to show that the drug has benefits for people with more than one allergy. The release touts speculation about the drug\u2019s potential to prevent or treat food allergies, even though such trials are just getting started. The senior author of the letter to the editor noted, however: \u201cI don\u2019t know if this or similar drugs will ever make it possible for a peanut-allergic person to eat peanut butter and jelly sandwiches, but we\u2019re excited to use this approach to teach us how to lessen the risks of food allergy reactions.\u201d", "answer": 0}, {"article": "The American Heart Association reports that more than 80 percent of smokers say they want to quit.\nTherefore, quitting leads to a quick drop in endorphin levels, he said.\nUsing acupuncture methods to treat addictions such as smoking is not new, White said, but there is still no clear evidence that treatment with needles has any therapeutic effects either.\nBut the government organization had only dealt with drugs - not new technology - for smoking cessation, which has slowed down the process, Camera said.\nStill, Laser Therapeutics\u2019 Camera said, the treatment won\u2019t work on everybody.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The alleged benefits are quantified, and, from there, the story takes pains to explain how much evidence supports these claims.", "answer": 1}, {"article": "Learn about diagnosis and treatment of prostate cancer from the U.S. National Cancer Institute.\nThe Hopkins work was described as \"outstanding\" by Dr. William J. Catalona, director of the prostate cancer program at Northwestern Memorial Hospital's Robert H. Lurie Comprehensive Cancer Center, who pioneered the use of the standard PSA test and helped develop the new version of the test.\nThe study included 71 men originally diagnosed as having small, low-grade and low-stage prostate cancer, the kind whose ultimate aggressiveness is often in doubt.\nThe regimen found unfavorable indications for 39 of the cancers -- meaning progression of cancer grade or tumor size -- and favorable for the 32 others, Veltri said.\nAnother report at the same meeting described use of a microchip to detect tumor cells in the blood of people with prostate cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t provide quantitative data on potential benefit. The story indicated the test might help identify men who could delay or defer treatment of their prostate cancer, but it did not provide any estimate of the proportion of men that might be expected to reap this benefit. \u00a0\u00a0\nThe story also mentioned in passing an additional benefit \u00a0which was that the test might reduce the frequency of prostate biopsies from every year to every other year. \u00a0However it should be noted that current guidelines for the frequency of follow-up biopsies are variable and some recommend intervals of up to at least 18 to 24 months \u2013 which would mean this test would result in no change.\n", "answer": 0}, {"article": "American veterans coping with PTSD are traveling to lodges in the Amazon that offer ayahuasca, a hallucinogenic brew. Some say it has helped them manage emotional trauma from war, but others say it\u2019s not worth the journey. Photo: Ryan Dube/WSJ\n\nAfter surviving firefights and a roadside bomb in Afghanistan, U.S. Army veteran Asa Barrett tried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\n\nBut then, like many other foreigners, he journeyed to Peru\u2019s remote Amazonian jungle to drink ayahuasca, a centuries-old, sacred indigenous brew that some Western scientists think can help to heal psychological traumas.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Without research studies to quantify the benefits of ayahuasca, the story relies on anecdotes. \u201cProponents say that it can provide users with spiritual and personal guidance. Others report that it has allowed them to overcome traumas that conventional therapy and antidepressants haven\u2019t cured,\u201d the story says.\nThe story mentions more several\u00a0patients who\u2019ve tried it successfully, including a Chicago man who said ayahuasca \u201ceased his depression,\u201d a Texas woman who said it \u201chelped to cure her debilitating migraines, which she thinks were tied to childhood abuse,\u201d and an Oklahoma woman who said the substance help her \u201covercome the trauma\u201d of her first husband\u2019s death. There\u2019s no indication that the reporter attempted to contact clinical professionals who could comment on these claims.", "answer": 0}, {"article": "February 28, 2017 - For infants with congenital malformations of the ear, a treatment system called EarWell can gently reshape the ear--avoiding the pain and cost of later surgery, reports a study in the March issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\nAbout 70 percent of ears with constricted malformations were graded as having no deformity after treatment.\nWhile the EarWell system is not new, the report is the largest study of congenital ear malformations treated with this approach--including a standardized approach to treatment and assessment of the results.\nDr. Byrd comments, \"The EarWell system is effective in eliminating or reducing the need for surgery in all but the most severe congenital ear malformations.\"\nEarWell treatment was highly successful in correcting or reducing the severity of congenital ear malformations.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is not satisfactory for several reasons. First, as noted above, the release does not tell readers that there is a difference between an ear deformity and malformation of the ear. As a result, it would be very easy for readers to assume that the benefits for patients with ear deformities would apply to patients with ear malformation. There are some other problems as well. Here\u2019s some of the language from the release: \u201cResults were judged good to excellent in 97 percent of ears with one simple deformity and 88 percent with more complex \u2018mixed\u2019 deformities. About 70 percent of ears with constricted malformations were graded as having no deformity after treatment.\u201d Here are the problems: What does it mean that results were \u201cgood to excellent\u201d? What is the difference between \u201csimple\u201d and \u201cmixed\u201d deformities? How are those different from \u201cconstricted malformations\u201d? And how many patients were in each group? Percentages can be misleading if any of the listed subgroups were particularly large or small. Benefits should be clearly explained and quantified, and that wasn\u2019t the case here.\nWe aren\u2019t told what proportion of the less severe deformations would have spontaneously improved. The study and news release claim a high rate of success but it\u2019s not clear what this should be compared to. It\u2019s possible that some reasonable proportion of such ears do OK without intervention.", "answer": 0}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article cites data from a recent review article in a medical journal that outlines the effectiveness (or lack thereof) of the medicinal treatments. \u201cThe medications have been found to be from 68% to 87% effective after one or two applications. Most don\u2019t require combing,\u201d the story says. We do wish they story explained what \u201c67% effective\u201d means\u00a0for a typical person, however.\nThe careful reader will note that the evidence for the effectiveness of the featured combing salons is mostly anecdotal, and it would have greatly strengthened the article to have been more explicit about this, as well as including more solid proof that standard lice medications are not as effective as they used to be.", "answer": 1}, {"article": "; Menno V. Huisman, M.D., Ph.D.; Pieter W. Kamphuisen, M.D., Ph.D.; J\u00f6rg Kreuzer, M.D.\nThe new results are part of a large on-going phase III study testing idarucizumab in a range of patients who take dabigatran and have dangerous bleeding or need urgent surgery or other procedures that carry serious bleeding risks.\nAn interim analysis of the first 90 patients in a study called RE-VERSE AD (REVERSal Effects of idarucizumab in patients on Active Dabigatran) showed that idarucizumab effectively reversed dabigatran's anticoagulant effects, said Richard A. Bernstein, M.D., Ph.D., lead study author and director of the stroke program at Northwestern Memorial Hospital in Chicago, Illinois.\n\"I see the biggest impact of idarucizumab as providing reassurance to patients that if bleeding while taking dabigatran does occur, we can quickly reverse the dabigatran.\nVideo clips with researchers/authors of the studies will be added to the release link as available.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit as described in the release is stopping dabigatran\u2019s blood-thinning effects, and the release states that: \u201cIn patients who received two 2.5-gram of idarucizumab infusions in a 15-minute period, blood tests revealed that dabigatran\u2019s blood-thinning effect was 100 percent reversed in all 18 patients with brain bleed.\u201d Because the findings were presented at a conference, there is no paper for us to read (and we looked for \u2014 but could not find \u2014 the study abstract), so it\u2019s impossible for us to compare the language in the release to any material written by the researchers conducting the study.\nWe do have some concerns about the presentation of the benefits. How the reversal of dabigatron anticoagulant effect was measured is not described. The patients included in the study had all previously suffered an intracranial bleed. Their long term outcomes are unknown and we do not know if those treated with\u00a0idarucizumab have better outcomes. We discuss some of these problems in more detail below under the \u201cEvidence\u201d criterion.", "answer": 1}, {"article": "To learn more about breast cancer surgery, visit the American Cancer Society.\nLooking at the volume of tissue excised, the researchers said not much more tissue was removed when the device was used compared to tissue removed in the initial and subsequent surgeries among the control-group patients, Boolbol said.\n\"We looked at whether we could lower the [repeat surgery] rate by using this device,\" Boolbol said.\nIn June, the radiation-free device won the blessing of a U.S. Food and Drug Administration advisory panel.\nIf the results are repeated in larger studies, it could be a welcome addition to doctors' techniques, she said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The piece notes that patients were followed for two months after their lumpectomy.\u00a0 And the story did an adequate job in describing benefits, clearly presenting the proportion of patients in each group who required a second surgery.", "answer": 1}, {"article": "That could have affected survival, of course.\nThe greater risk reduction in women aged 70 to 75, Otto said, is probably a result of the long-term good effects of screening participation in the earlier target age group, 50 to 69, before the upper age limit for screening was extended in the Netherlands from 69 to 75.\nThe risk reduction in younger women, aged 50 to 69, was smaller, at 39 percent, but still considered substantial.\nTUESDAY, Dec. 6 (HealthDay News)-- Women who get routine mammograms can lower their risk of dying from breast cancer by nearly half, a new Dutch study suggests.\n\"Our study adds further to the evidence that mammography screening unambiguously reduces breast cancer mortality,\" said Dr. Suzie Otto, a senior researcher in the department of public health at Erasmus Medical Center in Rotterdam, the Netherlands.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While making an attempt to quantify benefits, the author frames the information in confusing language that appears to indicate cause and effect: \u00a0\u201cwomen who underwent screening reduced the risk of dying from breast cancer by 49 percent.\u201d\u00a0\u00a0Mammography is screening, not treatment, and does not prevent or cure breast cancer. Citing the conflicting evidence about the benefits of breast cancer screening would improve the quality of the article. \u00a0For instance, in two large, randomized\u00a0clinical trials that looked at the benefits of screening mammography for survival,\u00a0the Malmo and Canadian trials, the women who chose mammography screening had the same breast cancer mortality or death rate as the women who did not.\n\u00a0", "answer": 0}, {"article": "Insulin helps glucose (sugar) enter cells to provide fuel for those cells.\nBaker said the researchers also saw a mild improvement in verbal memory in those treated with GHRH, but the results weren't as strong as for the executive function tasks.\nIn the current study, they wanted to see if GHRH could help restore some function in people who were showing signs of a condition known as mild cognitive impairment.\nDr. Joel Zonszein, an endocrinologist from Montefiore Medical Center, in New York City, praised the study but said some questions still remain.\n\"Growth hormone-releasing hormone doesn't target one specific area in the body and brain,\" said study lead author Laura Baker, an associate professor of psychiatry and behavioral science at the University of Washington School of Medicine, in Seattle.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We were puzzled by the lack of clarity of the benefits.\u00a0 While benefits were not quantified, the impact of GHRH on IGF-1 was.\u00a0 We think that the statement in the Reuters story: \u201cIt\u2019s unclear how the test differences will translate into real life,\u201d provided a clear statement on benefit", "answer": 0}, {"article": "In 2012, the Food and Drug Administration updated labeling on statins to include warnings about confusion and memory loss, elevated blood sugar leading to Type 2 diabetes, and muscle weakness.\nAnd if even more people were given statins -- if they were given to people with a 3 percent risk of developing heart disease over 10 years -\u2013 another 160,000 heart attacks and strokes would be prevented, they estimated.\nLimiting factors should be a patient's own preference about taking a daily pill, price and the risk of diabetes, they said.\nOne of the recommendations was that statins should be prescribed to anyone with a 7.5 percent risk or higher of developing heart disease over the next 10 years.\nTreating more Americans with statins is worth the small risk of side-effects and would be cost-effective, a new report finds.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did quantify benefits using absolute numbers when describing the potential impact on heart attacks from wider statin use.\u00a0The story said that\u00a0\u201cif even more people were given statins \u2014 if they were given to people with a 3 percent risk of developing heart disease over 10 years \u2014 another 160,000 heart attacks and strokes would be prevented, they estimated.\u201d We thought the Times, though, did a better job overall providing context for those numbers.", "answer": 1}, {"article": "A Harvard researcher hopes an old arthritis drug, which he read about in a 19th century German medical journal, could be a cheap new treatment for diabetes.\n\nIn the late 1990s, Steven Shoelson's research suggested that the drug, called salsalate, might also help diabetics. The idea sent him into the basement stacks of a Harvard library to see whether anyone else had pursued the notion.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not provide information about the magnitude of benefit, either in terms of the drug\u2019s ability to improve glucose load or about longer term benefits such as its impact on the predicted chance of heart attack. \u00a0", "answer": 0}, {"article": "Luxturna is a liquid that is injected directly into the eye with a microscopic needle during a surgical procedure.\nIn the phase 3 clinical trial, 27 out of 29 participants -- 93% -- who received the gene therapy demonstrated a gain in functional vision as assessed by a mobility test performed in a maze, according to the company.\nThe drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.\nOne-time-only treatments for rare genetic disorders are still unique, he noted.\n(CNN) A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited disorder, will cost $425,000 per eye.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated that 27 of 29 phase 3 clinical trial patients experienced \u201ca\u00a0gain in functional vision as assessed by a mobility test performed in a maze.\u201d That\u2019s not enough to give readers a sense of scope of the benefits. How did that compare to the control group? And what was everyone\u2019s vision like before? Given the extreme cost of the therapy, it would be useful to provide plenty of details to explain if the cost is worth the results.\nFor example, it would have been helpful to point out that the way the researchers measured success\u2013completing a maze\u2013is not the gold standard for measuring vision improvement. Instead, measuring visual acuity, such as the ability to read different-sized letters, is more common. Why was it different for this study?", "answer": 0}, {"article": "Trigeminal neuralgia (TN) is a very painful nerve disorder that causes an electrical shock feeling in the face, usually in older people.\nIn the research, radiosurgery helped improve the quality of life for patients with trigeminal neuralgia and reduced their depression, which is often exacerbated by the side effects of other treatments.\nThe authors, from Cleveland Clinic in the US, say considering radiosurgery earlier on could make a big difference to patients' lives.\nThe team plans to analyze the impact of other treatment options and carry out a cost-based analysis to establish the best treatment options for TN.\nOn a scale of 1-10, patients often describe the pain as 15 - off the scale.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are no numbers to back up the claims in the release. The release does not share information about the actual scores from patients in this study. In addition to providing data on the EuroQOL 5-Dimension questionairre scores before and after treatment, the release should have also provided information about what constitutes a meaningful change in the EQ-5D score.", "answer": 0}, {"article": "\u201cWith medicine, you always want to optimize a patient\u2019s outcome,\u201d Shastri said.\nPlus, the American Society for Reproductive Medicine (ASRM) committee opinion on IVM states that implantation rates for IVM\u2014between 5.5 and 21.6 percent\u2014 are a more reliable indicator of IVM success and are lower than expected for women of the same age who use IVF.\nA study in the journal Facts, Views and Vision found that IVM achieved up to a 35 percent clinical pregnancy rate in young women, which is comparable to IVF.\nIVM has the potential to improve the chances for women to have babies without a long course of hormones.\nFor starters, since there is less time involved with IVM, women who are undergoing chemotherapy, radiation or plan to have surgery may be good candidates.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We award a Satisfactory rating here because the story does quote a range of claimed \u201cimplantation\u201d success rates for IVM and IVF given by the American Society of Reproductive Medicine, noting that IVM appears to have much lower success rates. The article would be much stronger if it had also cited data for live births from IVF and IVM, along with the rate of adverse outcomes.\u00a0Overall, 47% of assisted reproductive technology embryo transfers result in pregnancy; 38% result in live births.", "answer": 1}, {"article": "\u201cWe can offer people hope from the start.\u201d\nNearly half of people in the study who were given a six-month diet plan and lost an average of 30 pounds went into remission and no longer had diabetes.\n\u201cIt isn\u2019t an irreversible, inexorable condition that you can never escape from \u2014 at the moment, people are told that.\u201d\n\nPrevious studies have suggested that lifestyle changes, including diet and exercise, can be powerful ways to lose weight and combat diabetes.\nAfter a year, most of the people in the diet group lost about 22 pounds, compared to two pounds in the control group.\nIn the study, Dr. Roy Taylor, professor of medicine and metabolism at Newcastle University, and his colleagues randomly assigned nearly 300 people to either a weight management program or their usual treatments, including diabetes medications.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies how much weight people lost and how many people went into remission, both in the group on the liquid diet and the control group (in which subject received the usual care for diabetes). That\u2019s good, and worthy of a satisfactory.\nHowever, the story does not explain what remission is or how it was measured. The study used hemoglobin A1c levels, which indicate blood sugar levels over the previous three months, and is often used to diagnose type 2 diabetes. Remission was defined as having a hemoglobin A1c level below the threshold for diagnosis without taking any diabetes medications. (This good outcome might still be characterized as pre-diabetes.)\nIn addition, readers aren\u2019t told how high blood sugars readings were before the diet, so it\u2019s impossible to tell how big the change was with weight loss.", "answer": 1}, {"article": "Feb. 22, 2012 -- When women in their 40s get breast cancer , their tumors need less intense treatment and recur less often if they were first detected during routine mammogram screening.\nEven the USPSTF accepts the fact that beginning breast cancer screening at age 40 saves lives.\nThese women will suffer the harms of early screening.\nBut the picture isn't so clear for women in their 40s.\n\"If all those women were screened in their 40s, only 8,500 would die.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Surprisingly, the story didn\u2019t include a single statistic from the study it was reporting on.", "answer": 0}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The column presents a small amount of data on the relative effectiveness of the methods discussed (\u201cIn India, the first men to test it have had it for 20 years, with no pregnancies\u2026;\u201d \u201c\u2026ineffective in about 10% of men;\u201d) for RISUG and hormone treatment. The story also points out that Vitamin A derivatives have not been tested in humans.", "answer": 1}, {"article": "An additional 1,551 women were given only materials about the importance of eating five servings of fruits and vegetables a day.\nResearchers noted that none of the breast cancer survivors lost weight on either diet.\nThe government study found no benefit from a mega-veggie-and-fruit diet over the U.S. recommended serving of five fruits and vegetables a day -- more than most Americans eat.\nAll the women had been successfully treated for early-stage breast cancer.\nThe average age was 53 when the study began.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided information that the two groups did not differ in terms of rates for breast cancer recurrence, the main outcome of the study. \n\u00a0", "answer": 1}, {"article": "For that reason, UV devices are often used for sterilization \u2014 for medical equipment in hospitals, for example, or drinking water for backcountry campers.\n\u201cThink about doctor\u2019s waiting rooms, schools, airports and airplanes\u2014any place where there\u2019s a likelihood for airborne viruses.\u201d And unlike the flu vaccine, he says, far-UVC light is likely to be effective against all airborne microbes, including newly emerging virus strains.\nNow, Brenner and his colleagues have show that UVC light can effectively kill airborne influenza.\n\u201cIf you have a lamp over the surgical site that can sterilize the air, you can prevent the bacteria from floating down and contaminating the wound.\u201d\n\nBrenner can\u2019t predict how long it might take for these lamps to be commercially available, but he says he\u2019s \u201cextremely optimistic\u201d about the technology.\n\u201cThere has been no way of killing viruses in the air in public spaces, and this is an approach that may solve that problem.\u201d\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told: \u201c\u2026 aerosolized particles of the H1N1 seasonal flu virus were released into a test chamber and exposed to very low doses of far-UVC light. The light inactivated the viruses with about the same efficiency as conventional germicidal UV light, while a control group of bacteria, not exposed to light, remained active.\u201d\nWe\u2019re also told previous studies by the same authors have shown that far-UVC light \u201ccan kill MRSA bacteria, a common cause of infections after surgery.\u201d\nHowever, it would be helpful to have data to support these claims, but that\u2019s not provided.", "answer": 0}, {"article": "A new method for performing a \u201cvirtual\u201d colonoscopy that requires less unpleasant preparation was shown in a new study to accurately detect larger precancerous polyps\u2014and was a better experience for patients.\n\nThe second-leading cause of cancer deaths in the U.S., colon cancer can be prevented if precancerous polyps\u2014known as adenomas\u2014are found and removed during a colonoscopy\u2026.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story starts by making two claims. It says that the new technique \u201cwas shown in a new study to accurately detect larger precancerous polyps\u201d and it also says that the procedure \u201cwas a better experience for patients.\u00a0It backs the first claim up by saying that \u201cThe laxative-free scan accurately identified 91% of patients with polyps of 10 mm or larger \u2014 those at highest risk of becoming cancerous,\u201d but it didn\u2019t make clear \u2013 as MedPage Today did in its story \u2013 that \u201cwasn\u2019t significantly different than the rate of 95% with standard optical colonoscopy.\u201d\nThere were no data presented to back up the second claim about patient experience. This may be a quibble given that avoiding the discomfort that comes with a colonscopy has to be a better experience, but we would have liked to have seen some attempt to quantify patient satisfaction. The promoters of virtual colonscopy make the claim, after all, that the main barrier to people being screened is a fear of discomfort.\nWith any claim about any new test, we expect to see both sensitivity and specificity details.\u00a0 MedPage Today reported: \u201cFor a diagnostic threshold of 8 or 6 mm, sensitivity was clinically significantly lower and specificity statistically significantly lower than with the conventional colon screen.\u201d\u00a0 And they gave specific numbers.\u00a0 This story didn\u2019t.", "answer": 0}, {"article": "Studies have found that runners have significantly higher injury rates than walkers (one study found that young men who run or jog had a 25 percent higher risk of injuries than walkers), and that ultramarathoners are at an even greater risk.\nAll this research, while illuminating, didn\u2019t offer up any clear conclusions on whether running or walking was better for you overall.\nI wanted to see what the highest-quality evidence \u2014 trials and reviews are the gold standard \u2014 said about the relative risks and benefits of these two forms of exercise.\nIn many ways, Sarah is a perfect case study in how to think about the benefits and risks of running versus walking.\nInterestingly, it seems you can walk pretty much endlessly without any increased risk of hurting yourself.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was a tough call\u2013the story\u00a0does an impressive job of discussing various\u00a0benefits of both walking and running and of comparing the health benefits of the two types of exercise. Yet, they were very general takeaways, and we wanted to know more specifics. For example:\nEven five to 10 minutes per day of jogging at around 6 miles per hour can reduce the risk of death from cardiovascular disease and other causes.\nWe wondered by how much does it reduce the risk of death from heart disease?", "answer": 0}, {"article": "\u201cWe call this disease a \u2018thief of vision\u2019 because most people with it have no idea that they have lost sight until it is too late to bring it back,\u201d Iwach says.\nThose with the narrowest vessels at the beginning of the study were four times more likely to have developed glaucoma a decade later.\nIn the study, researchers were able to predict who was at increased risk of developing the eye disease with some accuracy by measuring blood vessel thickness in the retinas of study participants using a computer-based imaging tool.\nEarly detection is key, but without regular eye exams, most people don\u2019t know they have a problem, says ophthalmologist Andrew Iwach, MD.\nThe study appears in the latest issue of the journal Ophthalmology.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A clear example of how incomplete relative risk reduction/benefit figures can be.\u00a0 The story only says that \u201cThose with the narrowest vessels at the beginning of the study were four times more likely to have developed glaucoma a decade later.\u201d\nBut it does not explain:", "answer": 0}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Here the story excels at providing important context. Benefits, in the case of barrier condoms, are measured in \u201cfailure rates.\u201d These rates depend on behavior. The story makes this clear.\nSome of what the story gave us in benefits:\n\u201cBefore we get into the numbers, it\u2019s helpful to understand that birth control effectiveness is measured in terms of failure rates, or the percentage of people who get pregnant within the first year of using this method.\nFemale condoms have a 5% failure rate with perfect use (using it consistently and correctly every single time), making them 95% effective. In contrast, male condoms have a perfect use failure rate of 2%, making them 98% effective.\nThe failure rate for both male and female condoms goes up when you also include people who used the method inconsistently or incorrectly (referred to as \u201ctypical use\u201d). Female condoms have a typical use failure rate of 21%, while male condoms have a typical use failure rate of 18%.\nThe effectiveness of FC2 is actually taken from research on the effectiveness of its predecessor, FC1 (the original female condom approved in 1993). Since the FC2 is an improved version of FC1 (made of nitrile instead of polyurethane), no further FDA studies were required, said Fisch.\u201d\nIt also discussed two possible, but not proven, benefits that the condom may decrease the spread of sexually transmitted diseases and improve sensation. We wish the story had hedged a little more on these\u2013even a minimal degree of skin-to-skin contact can transmit some infections, such as herpes or human papilloma virus.", "answer": 1}, {"article": "But the F.D.A.\nThe tests, though, were not necessarily specific for Alzheimer\u2019s and none had been studied to see if they accurately predicted plaque on autopsy.\nOther companies, still doing their studies, did not yet have data to examine.\nThere was no plaque when their brains were biopsied.\nThe Swedish doctors were convinced they were seeing actual plaque.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story is ALL\u00a0about the potential benefits. It says, \"Brain scans that showed plaque could help with some fundamental questions \u2014 who has or is getting Alzheimer\u2019s, whether the disease ever stops or slows down on its own and even whether plaque is the main culprit causing brain cell death.\" But it makes no attempt to quantify.", "answer": 0}, {"article": "Carl Alexander, a spokesman from the charity Cancer Research UK, said: \u201cThis study is an exciting example of how research can find clues in our genes to help us uncover those more likely to develop the disease.\nBy testing a man\u2019s DNA, researchers can look for genes linked to the disease, which one in seven men in the Western world will be diagnosed with in their lifetime.\nIf it is found to be effective, it could be an important tool for physicians.\nRosalind Eeles, an author of the study at the U.K.-based Institute of Cancer Research (ICR) who specializes in finding genetic variants that increase the risk of prostate cancer, told The Guardian the team is \u201cexcited by the test\u201d because it can be used by doctors to offer patients targeted screenings.\nThe resulting test hones in on these and the existing 100 known markers to pinpoint the 1 percent of men who are at six times greater risk of developing the condition, and the 10 percent of men who have a threefold greater risk of developing the disease, a study author told The Guardian.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story says the test could \u201cpinpoint the 1 percent of men who are at six times greater risk of developing the condition, and the 10 percent of men who have a threefold greater risk of developing the disease.\u201d\nBut it didn\u2019t clarify two things that are essential to interpreting this result:", "answer": 0}, {"article": "Cystic fibrosis (CF) is a genetic disorder that causes persistent lung infections.\nWhat's most exciting, they said, is that the triple-drug approach could open up new options to nearly all cystic fibrosis patients.\nBut experts said they were optimistic the results will hold up in the larger, longer-term trials already underway.\nThe trials were short-term, finding that the drug combinations improved adult patients' lung function over four weeks.\nAfter four weeks, the trial found, the triple-drug therapy had improved lung function in patients with both types of mutations.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story said the patients\u2019 performance on a pulmonary function test called FEV1 rose by \u201cas much as 13 percentage points, on average.\u201d That\u2019s not enough information. What was the average starting number? And how did the control groups do in comparison? We\u2019re not told.\nAlso, FEV1 is a surrogate marker and we don\u2019t know how it translates into real-world benefits on infection rates, hospitalizations, quality of life and lifespan. That should have been pointed out.", "answer": 0}, {"article": "The average age for menopause is 51, with ovulation in most women ending sometime between age 40 and 60.\nWells said Tehrani\u2019s team appeared to have hit upon a \u201cfairly accurate algorithm\u201d for predicting menopause.\n\u201cWe developed a statistical model for estimating the age at menopause from a single measurement of AMH concentration,\u201d Tehrani explained in a report on the study.\nExperts commenting on the work agreed it was promising, but said its findings would need to be confirmed in larger trials.\nBut said it would be important to see if the method could also help predict the time when fertility effectively ends.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the potential benefits of the AMH test.", "answer": 0}, {"article": "The majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London\n\nThe majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London (QMUL).\nDespite the limitations, the researchers say that the study provides a reasonable reassurance that vaping does not promote respiratory infections and may in fact reduce them.\n\"The study needs to be interpreted with caution because it is based on self-reported data, and further studies using objective measures are needed.\nThis misinformation includes a misreported study on rats that claimed that vaping may increase vulnerability to infections.\nThe researchers say that it is not surprising that the survey respondents noticed improvements in their respiratory health.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release says of 941 respondents, 66 percent reported an improvement in respiratory symptoms, 29 percent reported no change and 5 percent reported worsening. However, respondents were not required to quantify the extent of changes in their symptoms, so it\u2019s hard to tell how significant these reported improvements are.\nWe disagree with a researcher\u2019s conclusion that the survey results \u201cprovide sufficient information to suggest that vaping does not increase infection rates and may in fact lead to a decrease in infections.\u201d That\u2019s something that requires a controlled trial.", "answer": 0}, {"article": "Sorry. The page you requested is not available", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article does a good job of sketching the benefits shown in this research. Focusing on the clinical endpoint of relapse, and using percentages of relapse with the drug and the placebo, makes it easy for readers to understand.", "answer": 1}, {"article": "NSAIDs - which include aspirin, naproxen (marketed as Aleve), and ibuprofen (Advil) \u2014 have side effects, she noted, such as stomach bleeding.\nThe findings are interesting, but should not lead people to conclude that popping a few painkillers will reduce their risk of skin cancer, cautioned Dr. Maryam Asgari of Kaiser Permanente Northern California and the University of California San Francisco, who co-authored the 2008 study.\n\u201cI think the jury is still out.\u201d\n\nThere\u2019s reason to hope NSAIDs might offer some protection against this type of cancer, however - earlier this year, a review found that people who use painkillers such as ibuprofen on a regular basis may be less likely to get bladder cancer.\nAs a result, \u201cI wouldn\u2019t recommend (taking NSAIDs to reduce melanoma) just based on this\u201d new study, Asgari noted.\nNow, a smaller study that asked people with melanoma and those without the disease to recall their use of NSAIDs has found that taking these drugs - particularly aspirin - at least once a week for more than 5 years may have offered some protection against the deadly disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately explained: \u201c..more than 40 percent of people who were cancer-free said they\u2019d been taking NSAIDs at least once per week for more than 5 years, versus only 28 percent of those who developed melanoma.\u201d\nMore importantly, it quoted one expert, \u201cI wouldn\u2019t recommend (taking NSAIDs to reduce melanoma) just based on this\u201d new study.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070805/13folate.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story described the benefit of folate fortification of the food supply as cutting the 3,000 cases of spina bifida in half (i.e. eliminating 1500 cases of spina bifida per year).", "answer": 1}, {"article": "[2] Quotes direct from author and cannot be found in text of Article.\n\"We have identified a cardiac troponin concentration (less than 5 nanograms per deciliter; <5 ng/L) below which patients are at very low risk of heart attack either during the admission or in the ensuing 30 days.\nThis study shows that low plasma cardiac troponin concentrations at presentation identify up to two-thirds of patients who are at very low risk of heart attack and could be safely discharged from the Emergency Department.\nUsing this threshold in routine practice could potentially double the number of patients suitable for immediate discharge directly from the emergency department, say the authors.\nUsing this test, troponin levels were measured in over 6000 patients with chest pain admitted to four hospitals in Scotland and the USA.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a mixed bag. On the one hand, the news release refers to the high negative predictive value of the test (99.6%), which suggests that the test is very good at finding those who aren\u2019t at risk of a heart attack or death over the next 30 days. But it also relies on relative risk comparisons, and does not offer data in absolute terms about risks of heart attack or cardiac death in those with various ranges of troponin levels. It refers to patients \u201cat very low risk\u201d of a heart attack in the next 30 days, but never tells readers what that means (1%? 5%? 15% chance of a heart attack?). \u00a0Despite these shortcomings, we think the reader will come away with a decent understanding of the potential benefits of the more sensitive test, and so we\u2019ll award a Satisfactory rating here.", "answer": 1}, {"article": "Guyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \"trigger sites\" and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief. He has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated:\nGuyuron conducted a clinical trial, the most rigorous design, in which 75 patients were randomly assigned to migraine surgery or a sham procedure.\nOf those who underwent the real thing, 57 percent said their migraines were eliminated, compared with 4 percent in the control group. Headache pain, frequency, and duration were reduced by at least half in 84 percent of surgery patients compared with 58 percent of controls \u2013 a difference too big to occur by chance. The most common complication was slight hollowing of the temple.", "answer": 1}, {"article": "Phentermine quickly suppresses appetite, while the controlled-release topiramate decreases appetite and increases satiety throughout the day.\nOverall, people who took the combination pill lost more weight than their counterparts who were given a placebo.\nThe people who took the lowest dose of the drug dropped about 5.1% of body weight at six months, and, on average, gained some back by one year.\nThose who took the medium dose of the pill lost 8% of their body weight at six months and 8.2% by one year.\nTopiramate also has blood pressure-lowering effects, she says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story included quantitive information about weight loss over time. It did not quantify the impact on blood pressure.", "answer": 1}, {"article": "Being around for my daughter, my son, my wife.\nAbout eight months after a single treatment, 39 percent of patients had no evidence of cancer.\nSandoval is alive today because of an experimental form of immunotherapy called CAR-T.\n\u201cThat\u2019s actually quite remarkable knowing that at best only one out of 10 of these patients could have complete disappearance of their lymphoma with standard chemotherapy,\u201d Locke said.\nDespite chemotherapy and a stem cell transplant, the cancer returned before his daughter\u2019s first birthday.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "After featuring a patient who is\u00a0\u201cis alive today because of an experimental form of immunotherapy called CAR-T,\u201d the story reports that \u201cabout eight months after a single treatment, 39 percent of patients had no evidence of cancer.\u201d\nWhile the results look remarkably better than expected for patients whose cancer has returned after several rounds of standard treatments, there has not been a head-to-head comparison (a point the story does not make clear), so claims about the benefit of this treatment compared to alternatives must be made cautiously. Notably, the story never mentions how many of the patients in this trial died despite receiving the new treatment. About 20% were not alive at the six-month mark.", "answer": 0}, {"article": "Radiotracers work by injecting a small amount of a compound tagged with a radionuclide into patients.\nTwo prostate cancer experts said the tool, if borne out in patients, could prove very useful.\nHe noted that, as of now, doctors typically rely on results of the PSA blood test and/or standard diagnostic scans to help guide treatment decisions.\nThe study also revealed the radiotracer could help identify cases where prostate cancer had spread to the bone.\nThe researchers pointed out traditional bone scans are unable to differentiate between malignant and nonmalignant lesions.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The potential benefit wasn\u2019t quantified \u2013 not even for the mice in question.\nAs with any test, questions about sensitivity and specificity should have been addressed.", "answer": 0}, {"article": "Finasteride blocks the conversion of testosterone to dihydrotestosterone, a hormone active mostly in the prostate and the scalp, and that all prostate cancers need to grow.\nThe reason was that the results were overwhelmingly compelling \u2014 men taking the drug were not getting prostate cancer.\nThe study researchers, though, wondered if that conclusion was correct.\nThe concern was that the drug might be preventing cancers that never spread.\nMaybe, they thought, by shrinking the prostate, the drug was just making it easier to find aggressive tumors.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Mixed grade on this criterion.\u00a0 The story provided both relative and absolute risk reduction figures \u2013 although it gave more space and prime real estate (the beginning and end of the story) to the more impressive-sounding relative risk figures. But, with some hesitation, we\u2019ll give the story the benefit of the doubt. ", "answer": 1}, {"article": "\u201cThat would be the quickest path to insolvency,\u201d he said.\nEteplirsen, which Sarepta says has shown no side effects so far, is vying with a similar drug being developed by GlaxoSmithKline to become the first medicine that works by directly countering the cause of the disease.\nEteplirsen could also be the first drug to reach the market for Sarepta since it was founded 32 years ago.\nIf eteplirsen gets to market, it would come nearly three decades after the 1986 discovery of the gene responsible for Duchenne.\nOne possible reason for skepticism is that two of the boys on a lower dose of the drug rapidly lost the ability to walk, even though the level of dystrophin in their muscles increased substantially.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided just enough caveats to the positive aspect of the study results.\u00a0 \u201cThe study measured how far the boys could walk in six minutes. Those who received the higher dose walked an average of 21 meters farther after 48 weeks of treatment than at the beginning of the trial, a gain of about 5 percent. The boys in the placebo group walked 68 fewer meters at the end than at the beginning, a decline of about 17 percent.\u00a0 One possible reason for skepticism is that two of the boys on a lower dose of the drug rapidly lost the ability to walk, even though the level of dystrophin in their muscles increased substantially.\u201d\nThe story added a key piece of information at the end, \u201cEteplirsen actually turns off just one part of the dystrophin gene, known as exon 51, which contains a mutation that in some patients stops production of dystrophin. By skipping over this exon, muscle cells can produce an imperfect form of dystrophin that nonetheless is at least partly functional.", "answer": 1}, {"article": "[1] Quotes direct from authors and cannot be found in text of Article.\n[1]\n\nIn this study, the researchers compared the diagnostic accuracy of the new RDT against the benchmark RT-PCR test (altona Diagnostics) being used for clinical diagnosis in the field reference laboratory run by Public Health England at Port Loko in Sierra Leone.\n[1]\n\nWriting in a linked Comment, Dr Nahid Bhadelia from Boston University School of Medicine and Boston Medical Center, Boston, USA says, \"[This study] validates the accuracy of the ReEBOV RDT in patients who are well into their illness...suggesting it could be used to triage this subset of patients if RT-PCR is not available, particularly in those with a high index of clinical suspicion for a differential diagnosis...the data presented provide crucial information about the point of-care function of this rapid diagnostic test, such as ease of use, quality of samples taken at the bedside, and the concordance with venous samples...the results raise caution regarding the performance of the widely used altona RT-PCR assay, which the authors suggest might have underperformed because of laboratory specific technical and performance factors.\"\nThe authors caution that given the limitations of the performance of the altona RT-PCR reference test in patients with low levels of the virus in their blood, more research is needed to assess how the new RDT will perform in patients very early in the course of EVD.\nThe study is the first to show that a point-of-care EVD test (ReEBOV Antigen Rapid Test; Corgenix) is faster than and as sensitive as a conventional laboratory-based molecular method used for clinical testing during the recent outbreak in Sierra Leone.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release\u00a0dedicates two paragraphs to describing the\u00a0results, including comparing them to standard tests made by two different companies. We were particularly pleased to see reporting on the sensitivity and specificity of the test, as well as descriptions of what those numbers mean. We think those figures are important to include in any discussion of screening or diagnostic testing, but they\u2019re often not provided or reported incompletely.", "answer": 1}, {"article": "Follow us: twitter.com/CocoaHealthSci\n\nIn 1911, Frank C. Mars made the first Mars candies in his Tacoma, Washington kitchen and established Mars' first roots as a confectionery company.\nThis study, conducted by researchers from Italy's University of L'Aquila and Mars, Incorporated, reinforces the results of several recent cognitive studies--throwing more light on the important role diet plays in maintaining cognitive health.\nExcitingly, there was also evidence of improvements in these cardiometabolic outcomes.\nNote to Editors: This research trial was carried out with a special cocoa flavanol test product, designed to deliver a standardized amount of flavanols within a nutritionally suitable drink.\nThis test product is currently not commercially available.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does not include a single number related to the benefits, and notes merely that there was \u201csignficant\u201d improvement with some dosages of flavanols. The release is structured in such a convincing way, as is the\u00a0accompanying video, that it almost makes you believe that you should go out and try to make one of these drinks for yourself. Where are the numbers to back these assertions up?", "answer": 0}, {"article": "\u201cTo me, the take-home message is that we don\u2019t have a perfect test, unfortunately,\u201d Dr. Paik said.\nDr. Soonmyung Paik, who presented the second study at the cancer conference, said the problem might lie not in sloppy testing but rather in the cutoff used to determine which women get Herceptin.\nDr. Paik, who is with the National Surgical Adjuvant Breast and Bowel Project, said that about 40 percent of women had intermediate levels of Her2.\nShe said the findings raised questions of whether women who were Her2-negative should be tested again.\nSome experts were skeptical, saying the number of patients in the two studies was too small to draw firm conclusions.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story mentions that Herceptin could reduce the risk of recurrence by half. The story does not mention the benefit of re-testing women previously thought to be Her2/neu negative. And if these women are now considered positive, how will they receive Herceptin if they have already had chemotherapy? The story lists some of the problems of inconsistent cutoff values for testing, but only provides limited quantitative evidence. ", "answer": 0}, {"article": "In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back.\n\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\n\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n\nWhite wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story suggests benefits throughout:\nBut the study it reported only pointed to surrogate markers \u2013 hormone levels \u2013 not to any outcomes that are immediately meaningful in women\u2019s lives.\u00a0 The limitations of this finding simply weren\u2019t discussed.\nReaders would be well advised to read last Friday\u2019s blog post about The Ten Commandments of the New Therapeutics.\u00a0 Two of them came into play in this story:", "answer": 0}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story mentioned a 47% increase in cancer detection, but 47% of what? \u00a0Also, the story mentioned the recall rate for women needing a follow up mammogram was reduced with the new device from 11% to 6.6%, but recall rate is not the true gold standard of how the device could be beneficial to women.", "answer": 0}, {"article": "A birth-control pill that eliminates women's monthly periods could hit pharmacy shelves later this year, marking the latest effort by a drug company to expand a contraceptive's features beyond preventing pregnancy.\n\nSince \"The Pill\" was introduced nearly a half-century ago, most regimens have mimicked a woman's cycle by having a pill-free week each month when women can have bleeding and other symptoms.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article notes the percentage of women who took the new pill and stopped having periods\u2013but it does not note how often this happens in women who take currently available pills. It\u2019s also not clear how long the pill was taken by women who resumed menstruating after they stopped taking it\u2013and how it compares with the experience of women who take traditional pills. ", "answer": 0}, {"article": "http://www.\nThis new method, fully funded by the Children's Health Foundation and conducted by the Western Concussion Study Group, is unique in that previous attempts have looked unsuccessfully for a single highly accurate protein biomarker that can distinguish concussed from non-concussed adolescent patients.\nIn the new study, researchers have demonstrated that a blood test can now accurately diagnose a concussion using a form of blood profiling known as metabolomics.\n\"With further research, we anticipate that our blood test will also aid clinicians in predicting concussion outcome, as well as aid rehabilitation after concussion.\"\nLONDON, ON - Scientists from Children's Health Research Institute, a program of Lawson Health Research Institute, and Western University have developed a new blood test that identifies with greater than 90 per cent certainty whether or not an adolescent athlete has suffered a concussion.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Even though we are told that \u201cwith fine tuning we can now look at sets of as few as 20-40 specific metabolites and maintain the diagnostic accuracy level of the test over 90 per cent,\u201d we\u2019re not sure what this means. It appears that the reference to more than 90 percent comes from the study abstract. While this provides some quantitative data on the overall effect, it does not provide the sensitivity (how many with a concussion had a positive test results) or specificity (how many without a concussion didn\u2019t have a positive test result).\nA key question is diagnosing a concussion at the time of the potential injury is to determine whether a player can return to the game. It appears this test is not designed for that. The question then is how could this test be used. It isn\u2019t clear.", "answer": 0}, {"article": "\"They do research online, are more informed and sometimes go to the doctor demanding, 'I think I need an MRI.'\nIt's estimated that every year 12 million Americans go to the doctor seeking help for headaches.\nBut even a little can help, and according to Bernstein it doesn't have to be jogging for miles and miles.\nShe has far fewer headaches and when she does have them, they're far less severe.\nBernstein says she sees lots of desperate patients like Bradford.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "When you first read the headline of this story \u2014 \u201cFor Headaches, A Lifestyle Change May Be Better Than A Doctor Visit\u201d \u2014 you assume that it will show you evidence of lifestyle changes improving a significant number of people\u2019s lives where medicine has failed. The story does not do that. It provides no quantification of the benefits of lifestyle changes and, in fact, does not even mention them until the final two paragraphs of the story.", "answer": 0}, {"article": "Nuts, seeds, whole grains, legumes and even dark chocolate are high in fiber\u2014as are vegetables.\nSonnenburg was not involved with this study, but research from his lab also suggests that fiber plays a big role in promoting good bacteria.\nYou can increase these bacterial populations by eating fiber, Cani\u2019s research suggests, which acts as a prebiotic in the gut and has a beneficial effect on some bacteria.\n\u201cThat means if you\u2019re not eating dietary fiber, your immune system may be existing in kind of a simmering pro-inflammatory state,\u201d he says\u2014the very state that predisposes us to different Western diseases.\nPeople who started out with lower stores of had more after they followed the fiber-rich calorie-restricted diet.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that: \u201cPeople who started out with lower stores of Akkermansia had more after they followed the fiber-rich calorie-restricted diet. You can increase these bacterial populations by eating fiber, Cani\u2019s research suggests, which acts as a prebiotic in the gut and has a beneficial effect on some bacteria.\u201d We applaud the cautious language used here (i.e., employing the phrase \u201cresearch suggests\u201d). However, that language only presents half of the research findings. As the BMJ paper itself reports, study participants who began the study with higher levels of A. muciniphila actually saw their abundance of the bacteria decline after following the six-week, high-fiber, calorie-restricted dietary intervention in the study. And that decrease in A. muciniphila abundance continued even after the participants returned to a more \u201cnormal\u201d diet for an additional six weeks. While it\u2019s not clear if that decrease in A. muciniphila has any affect on reducing health risks, it\u2019s worth mentioning. In addition, the story would have been more useful for readers if it had offered even general information on what constitutes a \u201chealthy\u201d amount of fiber. For example, Harvard\u2019s School of Public Health reports that adults and children should get \u201cat least 20 to 30 grams of fiber per day.\u201d", "answer": 0}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are no\u00a0data provided for the potential benefit of \u201cincreased strength\u201d that the article says is possible if surgery is chosen \u201cearlier\u201d in the progress of the damage to the rotator cuff. The story does not give attribution for this claim: \u201cone\u2019s strength tends not to improve without surgery.\u201d While the entire story makes a case for the benefits of the newest surgical techniques, no data is provided comparing new to old or new to non-surgical alternatives directly.", "answer": 0}, {"article": "Visit the U.S. Centers for Disease Control and Prevention for more on obesity.\nSix months after the balloons were removed, nearly 90 percent maintained the weight loss they achieved during treatment, Pryor said.\nAn advantage of the balloons is that patients have no downtime and can go back to work the same day, the researchers said.\nPeople treated with the balloons lost an average of 7 percent of their weight, compared to less than 4 percent for those who received the sham device, the researchers found.\nWhether the weight loss will last over the long term isn't known, said lead researcher Dr. Aurora Pryor, director of the Bariatric and Metabolic Weight Loss Center at Stony Brook University in New York.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantified benefits by stating:\nObese patients who swallowed balloon capsules that helped them eat less lost an average of 15 pounds, roughly two times more weight than patients who just dieted and exercised, researchers report.\nand:\nPeople treated with the balloons lost an average of 7 percent of their weight, compared to less than 4 percent for those who received the sham device, the researchers found. Six months after the balloons were removed, nearly 90 percent maintained the weight loss they achieved during treatment, Pryor said.\nIn addition to reporting the weight loss results announced by researchers and that, unlike other balloons, this device doesn\u2019t require patients to be sedated during placement, the story adds important context by including comments from independent sources who are skeptical that many patients will maintain their lower weight long after the device is removed.", "answer": 1}, {"article": "\u2018\u2018I\u2019ve had chemotherapy.\n\u2018\u2018These patients who had low risk scores by Oncotype did extraordinarily well at five years,\u2019\u2019 said Dr. Hope Rugo, a breast cancer specialist at the University of California, San Francisco, with no role in the study.\nBut independent monitors recommended the results on the low-risk group be released, because it was clear that adding chemo would not improve their fate.\nIn the study, women who skipped chemo based on the test had less than a 1 percent chance of cancer recurring far away, such as the liver or lungs, within the next five years.\nThe study involved the most common type of breast cancer \u2014 early stage, without spread to lymph nodes; hormone-positive, meaning the tumor\u2019s growth is fueled by estrogen or progesterone; and not the type that the drug Herceptin targets.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In the low risk population, women who had foregone chemotherapy had less than a 1 percent chance of cancer occurrence at another faraway spot, the story says. It also mentions that 16 percent of the 10,253 study participants were classified as low risk.\nLater down in the article, it lists more study findings: \u201cAfter five years, about 99 percent had not relapsed, and 98 percent were alive. About 94 percent were free of any invasive cancer, including new cancers at other sites or in the opposite breast.\u201d\nThe only feedback we have is that the story could have been a bit clearer in pointing out that all of these figures pertained to the low-risk group.\nBut the quantifying of benefits was good enough to merit a Satisfactory rating here.", "answer": 1}, {"article": "\"The work by [first author] Price et al.\nTesting the effect of resveratrol on SIRT1 in mice was difficult, Sinclair said.\nstrongly supports the basic rationale being pursued at Sirtris, which focuses on the development of small-molecule compounds that directly activate the enzymatic activity of SIRT1 as a new therapeutic approach to many diseases of aging,\" Vlasuk wrote in an email to the journal.\nThe study is in the May 1 issue of Cell Metabolism.\nInstead, the goal is to develop synthetic resveratrol compounds that activate SIRT1 and could be taken as medication.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "If an entire consumer-targeted story is going to be based on research into mitochondrial function in mice, it could at least discuss how much such function improved. A little?\u00a0 A lot?\u00a0 In a few mice?\u00a0 All mice?\u00a0 How many mice?\u00a0 This story whiffed on giving any sense of the scope of the finding.", "answer": 0}, {"article": "\u2022 None 6 things you can do right now to help prevent the flu \n\n\n\nThe drug uses a different approach to fight the flu than other medications.\nThe experimental drug worked three times faster than another antiviral drug, Tamiflu, the company told the Journal.\nIn a clinical trial, a single dose of the drug made by the pharmaceutical company eliminated the virus from people's bodies in a median time of 24 hours, The Wall Street Journal reported.\nThe experimental drug, however, kicks into action earlier, working to block the virus from hijacking cells in the first place, the Journal said.\nExisting drugs, including Tamiflu, work to block these viral copies from escaping the cell, the Journal reported.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article says a \u201csingle dose\u201d of the \u201cnew drug\u201d was tested in a clinical trial and eliminated the virus in 24 hours. But we learn nothing about how many and people of what ages of people were involved in the clinical trial, how viral load was measured, whether elimination of the virus was complete or partial, or whether there were drug failures.\nWe also don\u2019t learn exactly when the drug was given \u2014 i.e. at what stage or stages of flu infection or who the control group were (Tamiflu patients, or those without Tamiflu treatment- i.e. already out of the effective treatment window). We\u2019re told that the drug worked \u201cthree times faster\u201d than Tamiflu, but not how fast Tamiflu works. In short, readers learn nothing that supports the drugmaker\u2019s claim.", "answer": 0}, {"article": "Packaged in powder form and mixed with liquid, alginate expands in the stomach to form a thick gel, mimicking the effect of a large meal.\nAmong people who stuck with the trial, those on the fiber supplement lost 15 pounds, on average, compared to 11 pounds in the placebo group.\nFor Mette Kristensen, one of the study\u2019s authors, the message seems clear: \u201cIf you actually comply with the treatment, you do have the improvement in weight loss.\u201d\n\nHowever, effects on blood pressure were less promising.\nAccording to the researchers, the higher sodium content of the alginate drink \u2014 a little over one gram per dose, or about half a teaspoon of salt \u2014 could have offset any potential blood-pressure reducing effect of the supplement.\nFive people taking the fiber gel left the study due to problems with stomach bloating, nausea and diarrhea.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantified the weight loss, with caveats about \u201cno significant difference between the two treatment groups when all 96 original participants were included in the analysis.", "answer": 1}, {"article": "Jan. 25, 2010 -- A low-carbohydrate diet may have health benefits that go beyond weight loss.\nResearchers say studies have already shown that the two weight loss methods are effective at promoting weight loss, but it's the first time the health effects of each have been compared head to head.\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\n\"It's important to know you can try a diet instead of medication and get the same weight loss results with fewer costs and potentially fewer side effects,\" Yancy says.\n\"If people have high blood pressure and a weight problem, a low-carbohydrate diet might be a better option than a weight loss medication.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story earns points for noting the absolute reduction in blood pressure in each group. We wish, though, that it had provided the weight loss in similar terms of actual\u00a0pounds or kilograms lost instead of as a percentage of bodyweight.", "answer": 1}, {"article": "Some recreational swimming pools and homeowners with backyard pools have manual treadmills that are water-safe and can be plunked right in the water.\nBudd Coates, training director at Runner\u2019s World magazine, said runners don\u2019t just plunge into water\u200b therapy when they\u2019re injured; it\u2019s a great conditioning method for healthy athletes, too.\n\u201cThe study proposes a different, very innovative approach\u201d to rehabilitation after stroke, said Dr. Gisele Wolf-Klein, director of geriatric education at Northwell Health in Great Neck, New York.\nAt chest height, it\u2019s about 30 percent of body weight,\u201d Johnson said, noting, for example, that a person with an injured knee who weighs 100 pounds who is running in waist-high water would only feel like 50 pounds on the bad knee.\nThe water height can be adjusted to the patient\u2019s abilities.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story focuses on multiple benefits, none of which are quantified. For example, the story discusses the ways in which being underwater can reduce joint pain during exercise. How much does it reduce pain? What are the benefits in terms of health outcomes? Unclear. There also was no attempt to quantify speed of recovery and final recovery state compared to other treatments such as standard physical therapy.\nIt also cites a study showing cardiovascular benefits for stroke patients, but it doesn\u2019t even appear that this study directly compared outcomes of water-based PT vs. standard PT in patients following a stroke. Rather, it sounds like the study compared physiologic measures in stroke patients comparing two forms of exercise testing, which isn\u2019t proof that one method resulted in better recovery outcomes for patients.", "answer": 0}, {"article": "Presenting at the meeting, Shraddha Sapkota, a graduate student in neuroscience at University of Alberta, and her colleagues described how they carefully analyzed the saliva of a group of volunteers participating in an aging study.\nThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s, but that\u2019s the goal, says Sapkota.\nExperts now believe that the biological processes behind the neurodegenerative condition begin years, if not decades, before memory problems and confusion become noticeable.\nBy comparing their saliva components, the scientists found that each of the three groups showed slightly different patterns of compounds, which could form the basis of a relatively easy and non-invasive way to determine which people are at higher risk of developing more serious degenerative brain conditions.\nIdeally, for example, isolating those with MCI might help doctors to focus in on a group of patients who might be at higher risk of developing Alzheimer\u2019s and therefore might need more intensive and regular testing.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the story outlines the potential benefits of such a test in general terms, it does not quantify the results of the study or tell readers how accurate the test was found to be. We think any story about diagnostic testing or screening should discuss the sensitivity and specificity of the test \u2014 numbers which tell us about how well the test finds people who actually have the disease and rules out people who don\u2019t have it.", "answer": 0}, {"article": "Those on beta blockers had a substantial reduction in the formation of distant cancers, or metastases, and of local recurrence.\nAs in other retrospective studies, he said, more research is needed to verify the potential link.\nPrevious research, Lichtenfeld said, has found a reduced rate of skin cancer among men who take another type of blood pressure-lowering drug.\n\"Our study was performed retrospectively, using patient notes [from women] that had received treatment in the late 1980s and 1990s,\" Powe said.\nFRIDAY, March 26, 2010 (HealthDay News) -- Treatment with blood pressure-lowering drugs known as beta blockers appears to help reduce the spread of breast cancer in women, a team of British and German researchers report.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story indicates that those taking beta blockers reduced their risk of dying by 71% compared to those not taking beta blockers. The story also suggests that beta blockers reduce the risk of recurrence by 57%; however, it is not apparent how this percentage was calculated, as it does not appear in the abstract.\u00a0 The results are only provided in terms of relative risk, but absolute risk would give\u00a0the reader\u00a0a better sense of the magnitude of the benefit. See our primer on this topic. ", "answer": 0}, {"article": "The shortage has eased, but some supply issues remain.\nThe fluids cost about the same \u2014 a dollar or two per IV \u2014 and many suppliers make both types, so switching should not be hard or expensive, doctors said.\nFor every 100 people on balanced fluids, there was one fewer death or severe kidney problem.\nKellum had no role in the two studies, which were discussed Tuesday at a critical care conference in San Antonio and published by the New England Journal of Medicine.\nIVs are one of the most common things in health care.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article states:\nFor every 100 people on balanced fluids, there was one fewer death or severe kidney problem.\nAnd not much else is said. Unfortunately, this is an oversimplification, combining the findings of two studies (one on critically ill patients, one on non-critically ill patients) into one result. CNN\u2019s reporting was much more detailed:\nAlso, regarding this statement in the AP story: \u201cThe difference could mean 50,000 to 70,000 fewer deaths and 100,000 fewer cases of kidney failure each year in the U.S.\u201d\nThis should be edited to include the statement, \u201cif the study is replicated across the country.\u201d", "answer": 0}, {"article": "Send your questions to Julia via the submission form or @juliaoftoronto on Twitter.\nThis is why aspirin has its place as a protective agent against strokes and heart attacks for people at a higher risk.\nIbuprofen doesn't have these two problems \u2014 it's less toxic than the others in the doses that give people pain relief.\nBut a final caveat here: If your child is older than 6 months, it's not all that clear that acetaminophen outperforms ibuprofen for reducing fevers, and the same is true for adults.\n(Ibuprofen also has potential side effects; more on that below.)\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article takes a close look at the drawbacks and benefits of each drug. For example, while the experts said acetaminophen is less effective than ibuprofen in treating pain (and carries more risks than the others), it is beneficial in\u00a0treating fever, especially in children age three and up. Ibuprofen is deemed less toxic for pain relief but it carries the risk of\u00a0bleeding in the gastrointestinal tract and kidney damage. There\u2019s also a reasonable amount of quantification provided by an expert source, Dr. Andrew Moore, who says:\u00a0\u201cIf you\u2019re talking about aspirin in doses of 500 to 1,000 mg or two tablets, 30 percent of people get relief from acute pain. For acetaminophen at doses of 500 to 1,000 mg, about 40 percent have a success. For ibuprofen, in its normal formulation at something around 400 mg or two tablets, about 50 percent have success.\u201d The story would have been even stronger had it provided links or additional details regarding where this expert obtained his estimates.", "answer": 1}, {"article": "(For a chart with a little more detail, see here.)\nBut somehow we've arrived at a point when some physicians are prescribing large doses of Vitamin D supplements for their patients in the hope of preventing cancer, cardiovascular disease, diabetes, autoimmune disorders and other maladies, despite a lack of evidence that this works, according to a new commentary in the Journal of the American Medical Association.\n\"Large trials of other widely used supplements have sometimes found benefits,\" Manson wrote, \"but in other cases--such as with high doses of beta carotene, vitamin E and selenium--have disproven some health claims for these supplements and identified health risks that may not have otherwise been detected.\"\nYou should consume modest amounts in your diet, if possible (and for most people that is quite possible), or in the form of supplements if you can't get enough via food and drink.\nThe recommended dietary allowance works out to three or four servings each day of \"fortified\" foods such as milk, yogurt, soy beverages, orange juice or cereal, plus fatty fish twice a week, according to Manson's commentary.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story talks about vitamin D-rich foods and supplements (including high-dose supplements). Are there benefits? Yes, and the story addresses (some of) them. The story makes clear that vitamin D is an essential nutrient for bone health, and that if you cannot get enough vitamin D from your diet (or from exposure to sunlight), then supplements can help you reach your target vitamin D consumption goal \u2014 which is 600 international units (IUs) per day for men and women between the ages of 1 and 70. The story could also have mentioned that vitamin D is involved in a variety of other health functions, including \u201cmodulation of cell growth, neuromuscular and immune function, and reduction of inflammation,\u201d according to the CDC.\nAnother strong point of the story is explaining that many of the purported health benefits of high-dose vitamin D supplementation \u2014 for example, prevention of cardiovascular disease, diabetes, and cancer \u2014 have not been based on strong scientific evidence.", "answer": 1}, {"article": "L-Nutra, to sell products that serve this purpose, which may be seen as a conflict of interest.\nThis activation, or reduction, of pathways is why the components of the diet, such a proteins, must also be controlled.\nFasting has been performed by communities and cultures for millennia and Longo's team are curious about the advantages.\nWhen cells in the body age, their ratios change and Longo believes the body's reaction -- and repair methods -- to fasting help restore them to when you were younger.\n\"The results of the study are encouraging and warrant more research in this area,\" says Toribio-Mateas.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story is painfully lacking in quantified benefits. How many people were in the study? And what kind of people were they? (Overweight or healthy weight? Male or female?) Were they compared against a control group?\u00a0How much actual weight did participants lose? What specific aging\u00a0risk factors were researchers measuring and how much did those improve? Similar information is missing for the mice portion of the study.\nWe were also dismayed at the extent of medical jargon included in the piece, since uselessly granular details about cellular pathways, cell regeneration and \u201chormone-like growth factors\u201d don\u2019t provide important details about if this research is actually meaningful and worth reading about. What it does instead is fluff up the piece by making it sound smarter than it actually us.", "answer": 0}, {"article": "\u201cBut it does give us hope.\u201d\nOne of the study\u2019s limitations is its small size, and researchers cautioned that families should not try to replicate the treatment at home.\nChildren without autism were used as a control for the study, the news release reported.\nResearchers also asked the children\u2019s doctors to perform pre- and post-diagnostic evaluations, which suggested lasting benefits.\nOn average, the score on a scale for ranking gastrointestinal symptoms dropped 82 percent from the beginning to the end of treatment, while average developmental age increased by 1.4 years, according to the release.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Here is what the story offered for the benefits:\n\u201cOn average, the score on a scale for ranking gastrointestinal symptoms dropped 82 percent from the beginning to the end of treatment, while average developmental age increased by 1.4 years, according to the release. Researchers also asked the children\u2019s doctors to perform pre- and post-diagnostic evaluations, which suggested lasting benefits.\u201d\nThis is not enough information to assess the scope of the potential benefits. For example, related to the 82% drop, what was the average number on the scale before\u00a0the study and after? If it wasn\u2019t that high to begin with, then an 82% drop isn\u2019t very notable.", "answer": 0}, {"article": "To complicate matters, many migraine sufferers can also experience severe bouts of nausea and vomiting.\nIt's not clear how much the patches will cost, but the class of medications known as triptans can be expensive, as much as $300 a month (although sumatriptan now has a generic version), Waltman said.\nResearch involving 800 patients ultimately led to the approval of Zecuity.\nA nasal spray is available, as is an injection, but many patients aren't comfortable with these options, Khan and Waltman noted.\nAccording to Dr. Fawad Khan, a neurologist with Ochsner Neuroscience Institute in New Orleans, few drugs are approved for the treatment of acute, symptomatic migraine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides active and placebo group response rates for patients in the Zecuity studies, which we\u2019ll call good enough for a satisfactory. However, the story doesn\u2019t compare these results with injection and nasal spray treatments \u2014 the other options that are available for patients with severe nausea who can\u2019t tolerate pills. That information would have been helpful.", "answer": 1}, {"article": "Brown rice is a whole grain \u2014 white rice before it has been refined and polished and stripped of the bran covering, which is high in fiber and nutrients.\nBut, Dr. Sun said, there were many possible explanations for why brown rice eaters are at lower risk for Type 2 diabetes.\nBut the Harvard study is one of the first to distinguish between brown rice and white rice consumption in the United States, where rice is not a staple food and relatively little is eaten overall, said Dr. Qi Sun, an instructor in medicine at Brigham and Women\u2019s Hospital, which is affiliated with Harvard Medical School.\nJust replacing a third of a serving of white rice with brown each day could reduce one\u2019s risk of Type 2 diabetes by 16 percent, a statistical analysis showed.\nThe study, which was published in The Archives of Internal Medicine and used data from two Harvard nurses\u2019 health studies and a separate study of health professionals, isn\u2019t the first to point a finger at foods like white rice as a culprit in Type 2 diabetes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story presented the potential benefit only as relative not absolute risk of developing type II diabetes, which we find troubling.\u00a0 What does it mean when you say \"reduce their risk of developing Type 2 diabetes by about 10 percent\" or \"almost 20 percent more likely to develop Type 2 diabetes\"?\u00a0 10 percent of what?\u00a0 20 percent of what?\u00a0 What were the absolute numbers in this huge observational study? \nThe statement \"Just replacing a third of a serving of white rice with brown rice each day could reduce one\u2019s risk of type II diabetes by 16%\" is just not helpful for consumer comprehension. \u00a0 ", "answer": 0}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\nThis story fails this criterion because it reports that the trial showed benefits of exercising to piano music, when in fact the trial was not capable of showing that music or any other specific feature of the classes could claim credit for the lower rate of falls and improved walking technique that was observed.\n\u00a0\nThe story does include some of the specific information expected to meet this criterion, including the number of falls in each group of participants, although it gives readers only vague descriptions of \u201csignificant improvements in balance and overall function\u201d and \u201cincreased their usual walking speed and stride length and improved their overall manner of walking\u201d without providing any specific numbers.", "answer": 0}, {"article": "Or eat turkey or bananas, both of which contain tryptophan, which is believed to trigger sleepiness.\nIf sleep extension could have a salutary effect on helping people lose weight,\" he says, we'd have another tool in the fight against obesity.\nIf your teen has to get up at, say, 6:30 to be at school by 7:30, that means bedtime's at 9:15 or 9:30 p.m.)\n\nVorona says he'd like to delve deeper into the sleep-obesity question.\nInstead, choose whole-wheat crackers, which can control insulin.\nThat means turning off all electronics, including the TV, and creating as quiet a sleep space as you can.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Again, there are no interventional trials discussed, only biological studies of hormones, so benefits shouldn\u2019t be relevant. But by passing along Aziz and Vorona\u2019s recommendations, the author claims that these interventions have weight loss benefits. Those benefits are not quantified. \nOne could say that the benefits can\u2019t be quantified because there are no studies. And that\u2019s the point.", "answer": 0}, {"article": "\u2022 Kim TI, Lee YK, Park SG, et al.\nHowever, more research is needed to clarify the nature of the beneficial association between the EGCG and cognitive training intervention (ie, synergistic or additive).\"\n2012; http://www.ndss.org/Down-Syndrome/What-Is-Down-Syndrome/.\n\"This new research adds to the growing body of evidence that suggests compounds in green tea, such as EGCG, may support cognitive health.\"\nEighty-seven volunteers aged 16 to 34 with Down syndrome were enrolled in the phase 2, randomized, controlled trial.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t provide any context for understanding the clinical importance of the observed changes in memory, control, and adaptive behavior. Vague language (\u201csome measures of cognition and behavior\u201d) is used to describe the benefits experienced by subjects in the study. We are told that participants taking the supplement showed improvements in neuronal connectivity and had \u201cscored significantly better on assessments of visual recognition memory, inhibitory control and adaptive behavior,\u201d compared to those who took the rice flour pills.\nBut we aren\u2019t told the extent of the benefit, how long the benefits lasted and how many people even took the supplements out of the original 87 volunteers. And the use of the word \u201csignificantly\u201d here could be confusing for readers, since it\u2019s meant as \u201cstatistically significant\u201d instead of the colloquial use of the term, which could mean \u201cimpressively\u201d or \u201clargely.\u201d\nWe are told that participants underwent a series of \u201cassessments\u201d for cognition and behavior, but we don\u2019t know how these evaluations were conducted and what exactly these neuropsychological measures were.\nWe think quantification of potential benefits and a description of the measurement tools used are necessary in a news release, which is why we are giving it an Unsatisfactory rating here.", "answer": 0}, {"article": "\"If you are an Asian kid, you've had these placed on you since time immemorial,\" he said.\nPain patches have a number of benefits, Rosenquist and Dombrowski said, not the least of which is convenience.\nThe main downside to pain patches, however, apparently comes from their effect on the skin.\nThe patches also deliver their medicine directly to the site of a person's pain.\nAnd, because patches release their medication slowly into the body through the skin, people also should get more consistent pain relief than they do with pills.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story alludes to the benefits but never attempts to back them up with data. \u201cThe patches also deliver their medicine directly to the site of a person\u2019s pain. This may eliminate some of the side effects that come with taking pills. For instance, some analgesics are likely to cause an upset stomach unless they\u2019re taken with food. \u2026 And, because patches release their medication slowly into the body through the skin, people also should get more consistent pain relief than they do with pills.\u201d Note that in the previous sentences, there are no declarative statements about benefits. \u201cThis may eliminate,\u201d the story says. \u201cPeople also should get more,\u201d it says. Is the story hedging because of a lack of evidence or because the evidence was never reviewed?", "answer": 0}, {"article": "\"We talk with older folks and many say, 'I can't exercise, but maybe I can become more physically active.'\nThe study followed participants for about 2.7 years, and found that the physical activity program cut the amount of time that people spent with a \"major mobility disability\" \u2014 defined as being unable to walk a quarter mile \u2014 by 25 percent compared to the education program.\n\" Study participants were advised to \"start low and go slow,\" and some were even able to get rid of their canes after six months of exercise, which Gill says they found particularly rewarding.\n\"Walking was the cornerstone of the program,\" says Thomas Gill, a professor of geriatrics at the Yale School of Medicine and an author of the study, which appears in Annals of Internal Medicine.\nThe exercise program pretty closely followed the government's recommendations for all adults, including older ones: 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity exercise per week, plus two strength sessions that hit all the major muscle groups.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While quantification was minimal in this story, we\u2019ll rate it barely satisfactory since it states those participating in the physical activity part of the study \u201ccut the amount of time that people spent with a \u201cmajor mobility disability\u201d \u2014 defined as being unable to walk a quarter mile \u2014 by 25 percent compared to the education program.\u201d \u00a0But 25% of what?\nIt also stated that, \u201cPrevious findings from the same study showed that the exercise program lowered the risk of becoming disabled in the first place; this one showed that it sped recovery from an episode of disability and lowered the risk of subsequent episodes.\u201d\u00a0 However, it failed to explain how much that risk was lowered, or whether it was an absolute risk or a relative risk.\u00a0 Statements offered by others in the story said that \u201cpeople who engage in physical activity have a lower risk for heart disease, diabetes, certain cancers, depression, cognitive impairment and functional decline,\u201d but gave no measures of how much those risks were lowered.", "answer": 0}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We note a couple of flaws:\u00a0", "answer": 0}, {"article": "Coffee or tea?\nGood clinical studies are few, however, and although I and other physicians tell our patients to drink green tea, there hasn't been any definitive proof of the value of that advice.\nWe've heard a lot about the health benefits of tea, especially green tea.\nThere's a growing body of research to suggest that both are probably good for you.\nThat's why I was so interested in a report last week in the Journal of the American...\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits of drinking 5 or more cups of green tea a day was presented as a decreased chance of dying in the 11 year period of the study. However, there was no information about the amount that risk decreased. Although increased green tea consumption was seen to be associated with decreased risk of death from heart disease, the percentage of individuals dying of heart disease was less than half the number in Americans of comparable age. It is difficult to know the meaning of this difference.\nThere is no evidence presented about the how the type of green tea may influence the outcome of cardiovascular mortality, only that the larger amount of green tea consumed was associated with decreased cardiovascular mortality.", "answer": 0}, {"article": "SOURCE: bit.ly/2rcPLh0 Annals of the Rheumatic Diseases, online May 22, 2017.\nIn addition, U.S.-based studies of chondroitin have had mixed results, said Shepard, who wasn\u2019t involved in the study.\nDr. Michael Shepard of Hoag Orthopedic Institute in Orange, California, noted that the study had a relatively low number of participants and that most U.S. studies of this type would run two years rather than six months.\nReginster told Reuters Health the findings are in line with earlier studies showing pharmaceutical-grade chondroitin sulfate could significantly decrease the progression of knee osteoarthritis over a period of three years.\n\u201cChondroitin is not a miracle pill, but if it allows people to feel less pain and be more active, thereby losing weight and strengthening muscles, then I think there may benefit,\u201d Wolfe told Reuters Health by email.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers learn the qualitative benefits\u2013better than placebo and on par with the analgesic drug Celebrex\u2013but no quantitative data is cited.", "answer": 0}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes the main outcome measure \u2014 how long subjects could exercise on a treadmill before experiencing pain \u2014 and the change in exercise duration \u2014 a 28 second improvement after stent insertion versus 12 second improvement after sham surgery. Readers are told that no statistical difference exists between those averages.", "answer": 1}, {"article": "\"You're going through all this suffering and stuff and you want to know, am I going to survive?\nGraham said there are maybe a dozen published human studies so far, most involving too few patients to draw a firm conclusion.\nThe hope is that, over time, FLT PET would prove reliable for giving a faster answer on whether an experimental treatment is working.\nOne report that impressed him involved 28 patients in Korea who were treated for advanced lung cancer \u2013 just like Stevens, who had to wait six weeks to learn whether it was working.\nAs a practical matter, the goal of researchers is to convince federal regulators to cover the procedure under Medicare and Medicaid, which would open the door to routine use.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes brief references to two studies, one involving 28 people in Korea, the other 7 patients in the U.S. \nThe reporter cites positive results of the studies, implying efficacy. But no caveats other than small study size are offered to provide a more balanced view. ", "answer": 0}, {"article": "The scans, called coronary computed tomography angiography or CCTA, produce a detailed image of the heart that reveals cholesterol buildups in the coronary arteries.\n\u201cTesting might lead to more harm than good,\u201d McEvoy told Reuters Health, adding that heart scans may cost $600 or more.\nIn an editorial, Dr. Michael S. Lauer of National Heart, Lung, and Blood Institute in Bethesda, Maryland, said the new study serves as a reminder of the downsides of screening.\nYet there\u2019s no evidence that treating people based on heart scan results does any good, said Dr. John McEvoy, of Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, who led the new study.\nHis team looked at 1,000 Korean patients who chose to get a heart scan as part of a health screening program at Seoul National University Bundang Hospital.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Much more clearly than the competing WSJ story, Reuters reported:\u00a0\u201c\u201dTesting might lead to more harm than good.\u201d", "answer": 1}, {"article": "After adjusting for age, diabetes, hypertension and other factors, men who took a daily aspirin or another Nsaid reduced their risk of moderate or severe urinary symptoms by 27 percent, and their risk of an enlarged prostate by 49 percent.\nThe study, published online by The American Journal of Epidemiology, had limited data on dosage, but scientists believe that even low doses of anti-inflammatory drugs reduce the risk of urological problems.\nDr. Lieber acknowledged that the study was observational and not a placebo-controlled trial.\n\u201cSo this is a possible fringe benefit.\u201d\n\nResearchers studied 2,447 men over 12 years, examining them every other year.\n\u201cAt least half the patients I see are taking a daily aspirin for other health reasons,\u201d said Dr. Michael M. Lieber, an author of the study and a Mayo Clinic urologist.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes benefits in relative terms vs. absolute rates (which is the gold standard). It also does not tell readers that the most benefit was seen in older men. ", "answer": 0}, {"article": "\"These are very basic facts, concerning simply who lived and died,\" he noted.\nThe same is true for 88 percent of CRT-D patients, they noted.\nThe study team also found that patients whose implants were monitored remotely, on a continual basis, by a health facility network were about half as likely to die as patients who only had intermittent in-person assessments.\nRemote monitoring via telephone lines and online physician access is available for all ICD and CRT-D devices, the authors noted, and enrollment in such programs is typically free with a cardiologist's recommendation.\nThe poorer prognosis for CRT-only patients was attributed to their older average age (76 years), and the fact that they may be relatively sicker overall.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We give the story a barely passing grade here for at least providing readers with some numbers, although we feel that ultimately the numbers provide very little clarity. What was needed were some absolute numbers to show how many patients were in each group, how many died, how many lived and how many suffered side effects, etc. Instead, we are given sentences like this, \u201cAmong those outfitted with CRT devices alone, one-year survival was pegged at 82 percent, while five-year survival came in at 48 percent, the investigators found.\u201d\nIn addition, the study was observational and as such, the benefits of remote monitoring seen may not be applicable to all patients. For example a selection bias (motivated patients and physicians signed on to the manufacturers registry) could explain a good deal of the results. The cautionary comments of Dr. Prystowsky provided sufficient balance to the comments of the investigator.\n", "answer": 1}, {"article": "Food sources of vitamin E include wheat germ, nuts such as almonds and hazelnuts, vegetable oils such as sunflower and safflower oils, and some green vegetables, such as spinach and broccoli.\nAccording to Breteler\u2019s team, studies should continue to look at the relationship between antioxidant intake and dementia \u2014 including whether antioxidant consumption at different points in life might have different effects on dementia risk.\nNor is it clear why vitamin E, but not vitamin C or beta-carotene, was linked to a lower dementia risk.\nBut the finding is in line with a previous study of U.S. adults that found that a higher intake of vitamin E, but not vitamin C or beta-carotene, was related to a lower risk of developing Alzheimer\u2019s over two years.\nResearchers found that among 5,400 Dutch adults age 55 and older, the one-third who reported the highest vitamin E intake from food were 25 percent less likely to develop dementia, including Alzheimer\u2019s disease, over the next decade than the third with the lowest intakes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story comes a whisker away from earning a satisfactory on this one.\u00a0It leads by noting that participants with the highest vitamin E intakes had a 25% lower risk of dementia compared with those who had the lowest intakes, It more precisely quantifies this benefit later in the story, where it\u00a0explains\u00a0that\u00a0120 people developed dementia in the group with the highest vitamin E intake compared with 164\u00a0people in the low- intake\u00a0group.\u00a0What would have been most informative, however,\u00a0is if the story\u00a0had provided some\u00a0denominators for this comparison \u2014 that is,\u00a0120 out of how many people developed dementia in the first group compared with 164 out of how many people in the second?\u00a0This would given readers a better sense of the\u00a0absolute risk reduction associated with higher vitamin E intake. We know this sets the bar high, but for good reason, we think. ", "answer": 0}, {"article": "To place an electronic embedded link to this study in your story: This link will be live at the embargo time: http://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2016.4219\n\nIn a study published online by JAMA Surgery, Daniel E. Hall, M.D., M.Div., M.H.Sc., of the Veterans Affairs Pittsburgh Healthcare System and University of Pittsburgh, and colleagues examined the effect of a Frailty Screening Initiative (FSI) on death and complications by comparing the surgical outcomes of patients treated before and after implementation of the FSI.\nOn the basis of this review, clinicians from surgery, anesthesia, critical care, and palliative care were notified of the patient\u2019s frailty and associated surgical risks; if indicated, perioperative plans were modified based on team input.\nThis study included 9,153 patients (average age, 60 years) from a Veterans Affairs medical center who presented for major, elective, noncardiac surgery.\n\u201cThis study reveals the feasibility of facility-wide frailty screening in elective surgical populations.\nIt also suggests the potential to improve postoperative survival among the frail through systematic administrative screening, review, and optimization of perioperative plans.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a very strong point for the release. It states clearly that absolute reductions were seen before and after the intervention: \u00a0i.e.: \u00a0\u201coverall 30-day mortality decreased from 1.6 percent (84 of 5,275 patients) to 0.7 percent (26 of 3,878 patients) after FSI implementation. Improvement was greatest among frail patients (12.2 percent to 3.8 percent), although mortality rates also decreased among the robust patients (1.2 percent to 0.3 percent).\u201d", "answer": 1}, {"article": "Side effects including shaking, headaches, vomiting and swollen gums\u2014as well as unwanted hair growth.\nAn existing drug used to treat a common bone disorder could hold the key to the cure for baldness, according to a new study.\nDr. Hawkshaw said in a statement: \u201cThe fact this new agent, which had never even been considered in a hair-loss context, promotes human hair growth is exciting because of its translational potential: It could one day make a real difference to people who suffer from hair loss.\u201d\n\n\u201cClearly though, a clinical trial is required next to tell us whether this drug or similar compounds are both effective and safe in hair-loss patients.\u201d\n\nA British Association of Dermatologists spokesperson said in a statement the results were interesting.\nThe research team, led by Dr. Nathan Hawkshaw at the University of Manchester, in the U.K., investigated whether CsA could provide some clues for treating baldness.\nThe compound WAY-316606 could therefore be used to treat baldness, without patients suffering the same side effects as they would on CsA.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Since WAY-316606 hasn\u2019t apparently been tested on actual human heads, there are no benefits to quantify, but that didn\u2019t stop the story from suggesting benefits, stating the drug \u201ccould hold the key to the cure for baldness.\u201d\nThe story stated that CsA \u201cchanged how the follicles expressed a protein called SFRP1, which stunts the development and growth of hair follicles and other tissue in the body,\u201d and that WAY-316606 \u201chas a similar effect\u201d and \u201ccould therefore be used to treat baldness.\u201d\nThe story had no data on the size of the effect this drug had on hair follicles in the lab.", "answer": 0}, {"article": "The United Kingdom\u2019s National Health Service offers free HIV testing.\nAnd because the incidence of other sexually transmitted infections declined for these men, after the diagnosis, the scientists had reason to believe the self-reports of condom usage were accurate.\nAdopting some version of the British at-home test could help Americans who have already been tested keep up their screening schedule.\nThe Home Access HIV-1 Test System lets patients collect blood at home, but it must then be sent to a clinic for testing.\nOraQuick, on the other hand, is an oral-based at-home test that does let users see their results immediately, but it has an 8.3 percent chance of a false negative.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides concrete percentages\u00a0for false negative rates and does a good job explaining the different methods for calculating undiagnosed cases. But it doesn\u2019t substantiate or quantify the main benefits that home testing should presumably deliver \u2014 earlier treatment and fewer infections. In fact, the benefits of testing that are mentioned in the story are based on studies of testing that is coupled with counseling, not self-testing. The story does not include any evidence that self-testing, unconnected with counseling, leads to either earlier treatment or safer sex behavior.", "answer": 0}, {"article": "Co-authors include Loki Natarajan, Dorothy Sears and Sheri Hartman of UC San Diego; and Linda Gallo and Elva Arredondo of San Diego State University.\n\u201cNew evidence suggests that when and how often people eat can also play a role in cancer risk.\u201d\n\nWomen in the study reported eating five times per day with a mean nighttime fasting of 12 hours.\n\u201cIncreasing the duration of overnight fasting could be a novel strategy to reduce the risk of developing breast cancer,\u201d said Catherine Marinac, UC San Diego doctoral candidate and first author on the paper.\n\u201cThe dietary advice for cancer prevention usually focuses on limiting consumption of red meat, alcohol and refined grains while increasing plant-based foods,\u201d said co-author Ruth Patterson, PhD, UC San Diego Moores Cancer Center associate director for population sciences and program leader of the cancer prevention program.\nThe findings were presented at the American Association of Cancer Research\u2019s annual meeting in Philadelphia.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release discusses how increasing nighttime fasting is associated with a lower postprandial glucose level, but there is no discussion about\u00a0how this is associated with a reduced breast cancer risk. This is a significant gap that needed to be addressed.", "answer": 0}, {"article": "Omega-3 fatty acids are unsaturated fats found in most fish, but especially in fatty fish that live in cold seawater, such as salmon and herring.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nCAVEATS Most participants were white.\nTesting and measurements were done once, providing no data for comparison over time or to determine any link to dementia.\nNonetheless, conclusive evidence about a treatment's effectiveness is rarely found in a single study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us individuals with lower omega-3 levels \u201cscored lower on cognitive tests measuring such things as memory, problem solving, abstract thinking and multi-tasking.\u201d But how much lower were the scores and did they indicate a meaningful difference in how these people functioned? The story doesn\u2019t say.", "answer": 0}, {"article": "Researchers believe electrical pulses can act like a sort of pacemaker in the brain, heading off the chaotic \"electrical storms\" that cause epileptic seizures.\nAnd the trigeminal nerve stimulator is not the first time researchers have used electrical pulses to prevent seizures.\nThe approach, which is not yet approved by the FDA, could offer an alternative or enhancement to treatment with drugs, says Christopher DeGiorgio, the neurologist at UCLA who invented the new approach.\nAnd DeGiorgio says he's found an interesting benefit to trigeminal nerve stimulation.\nIn 2005, the FDA approved a device that stimulates another nerve that leads to the brain \u2014 the vagus nerve.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is one attempt to quantify the benefits in the story. It says, \u201cA study of 50 people with drug-resistant epilepsy found that the trigeminal nerve stimulator was able to greatly reduce seizures for about 40 percent of them.\u201d This does not give people enough information to make an informed choice about their treatment options. For example, what does \u201cgreatly reduce\u201d mean? Did people go from 10 seizures a week to one seizure? Did people stop taking their medications and only use the device or just reduce the amount of medicaiton, as the woman in the story did? To back up the headline that says \u201cNew Device Reduces Seizures, No Surgery Required,\u201d we expect the story to quantify the scope of benefits better than it did.", "answer": 0}, {"article": "People who have chronic inflammation because of chronic infection, autoimmune disease or conditions such as obesity have a higher cancer risk because of damage to normal cells.\nThis is a neat solution: blocking the uptake of a nutrient needed by prostate cancer cells with nutrients that are commonly in the human diet.\nThe researchers first tested 142 natural compounds on mouse and human cell lines to see which inhibited prostate cancer cell growth when administered alone or in combination with another nutrient.\nPublished online this week in Precision Oncology, the new paper uses a novel analytical approach to screen numerous plant-based chemicals instead of testing a single agent as many studies do, discovering specific combinations that shrink prostate cancer tumors.\n\"These nutrients have potential anti-cancer properties and are readily available,\" says Tiziani.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release mentions only potential benefits for human beings. There\u2019s no data on how much of these substances might need to be consumed over what period of time and in what quantity to offer cancer protection or tumor shrinkage. A researcher\u2019s comment that \u201cwe were able to inhibit tumor growth in mice without toxicity\u201d sheds no meaningful light on these questions.\nAlso, the news release seems to contradict itself by suggesting that eating a diet containing cancer-fighting substances could offer a benefit, but later quoting a researcher saying, \u201cWe only need to increase concentration beyond levels found in a healthy diet for an effect on prostate cancer cells.\u201d This comment seems to suggest people would have to take a supplement in order to get a benefit.", "answer": 0}, {"article": "Dr. David Rosenstreich, director of the division of allergy and immunology at Montefiore Medical Center in New York City, added: \"An objective and fast test for diagnosing asthma would be helpful, and this test seems to be a non-invasive way of sampling for the underlying problem.\nThe electronic nose was able to correctly differentiate healthy people from those with physician-diagnosed asthma in 87.5 percent of the cases.\nWhen combined with another test, called the fractional exhaled nitric oxide (FENO) test, the electronic nose did an even better job at detecting asthma, the study found.\nWhen the electronic nose and FENO were combined, the two tests together correctly identified almost 96 percent of the asthma cases.\nThose with asthma had a history of allergies, and none had been treated with corticosteroids for at least four weeks prior to the start of the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us the percentage of asthma patients who were correctly diagnosed by the electronic nose, fractional exhaled nitric oxide, and spirometry. It provided this data in absolute terms and didn\u2019t muddy the waters with relative comparisons of the three techniques. Although the study data by itself might suggest that the new device is superior to the other methods, the comments from the expert sources put the results in the appropriate context. They make it clear that we\u00a0can\u2019t tell yet whether this\u00a0technology represents\u00a0a better option than existing techniques.", "answer": 1}, {"article": "MRI highlights angiogenesis, the formation of new blood vessels, especially those that feed cancerous tissues.\nHowever, still more research is needed to clarify the role of MRI in this population, she said.\nWith the MRI screen, \"we found cancer in just over 3 percent of women [with a personal history], which was double [that found in those with a genetic or family history],\" she said.\nWhile the society recommends neither for nor against MRI imaging for those with a personal history of breast cancer, he said it regularly reviews study findings to determine if the guidelines need updating.\nOverall, the MRI detected 25 of 27 cancers, DeMartini said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nAs noted above, the story reports that this study indicates women who have had breast cancer could benefit from annual MRI scanning. But since the women in the study had just one scan, not a series of scans over time, it does not appear to be able to evaluate the potential benefits of annual scans.", "answer": 0}, {"article": "A patient calls you up and says \"I'm losing my memory a little, would you be tempted to put them on a statin, LaPook asked.\nAnd despite this study, there is not enough evidence to prescribe statins for the brain.\nThose who were taking a cholesterol-lowering statin such as Lipitor, had a surprising result.\nSince cholesterol is part of the tell-tale plaques on the brains of Alzheimer's patients, it made sense to think that statins might help.\nBut today's study looked at people before any hint of dementia.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The correspondent reports that study subjects taking statins \"were about half as likely\" to develop dementia or early warning signs. On-screen, a graphic shows this number more precisely, 52 percent.\u00a0 But that\u2019s a relative risk number, which can be less helpful to understanding.\u00a0 \nThe report should have stated what the absolute risk of dementia was in the statin group and the non-statin group. According to the study abstract, the risks of developing dementia or early signs within five years appeared to be about 8 percent for the non-statin group and about 3.5 percent for the statin group.", "answer": 0}, {"article": "He walks about 50,000 steps a week, golfs, works out and tap dances and consumes about 1,800 daily calories.\nThat means lifestyle changes were twice as effective as medicine in delaying or preventing diabetes.\nThe study, known as DPPOS, puts science behind Mr. Held's success.\nThat was 10 years ago, when he joined the Diabetes Prevention Program Outcomes Study with the University of Pittsburgh Graduate School of Public Health, one of 27 institutions participating in the research.\nJohn Held, with a family history of type 2 diabetes, watched as his own blood-sugar levels crept over the normal range, identifying him as a prime candidate for the disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The reporter\u00a0 quantifies the benefits of the lifestyle or drug intervention, but never does so in absolute risk reduction terms.\u00a0 So when the story states risk reductions of 34% or 18%, we want to know \"34% or 18% of what?\"\u00a0 \n\u00a0", "answer": 0}, {"article": "Functional MRI scans generate a dynamic map of the outer surface of the brain, showing changing hot spots of activity over time.\nIt's exciting to think that these individual differences may be related to personality, cognitive ability, or psychiatric or neurological disease.\nWe show here that it's not measuring what you're thinking, but how your brain is organized.\nAlthough the technique's potential to identify brain disorders and diseases was noted years ago, fcMRI-based diagnostic tests have yet to make their way into doctors' offices.\nAll of the scanned brains belonged to young, healthy scientists and doctors.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Some numbers would have been helpful here to put the findings in context. Consistency of the brain scans for the various mental tasks is not quantified in the news release. Furthermore, contrary to the implications of the headline, this study didn\u2019t actually develop any diagnostic tools for depression, migraines, or other brain ailments.\u00a0It simply laid the groundwork for research about these issues by testing whether functional networks in individuals\u2019 brains are relatively stable over time. That\u2019s a preliminary step that is needed, but it\u2019s still preliminary.", "answer": 0}, {"article": "Foods with fiber, such as fruits, vegetables and whole grains, can reduce cholesterol levels, while carbohydrates that are low in fiber tend to raise triglyceride levels and lower \"good\" HDL cholesterol levels.\nWhat effects, if any, the prunes had on cholesterol levels were not mentioned in the study abstract.\nDespite the addition of several hundred calories a day to their diet, the apple-eating women didn't gain weight over the course of the study.\nTUESDAY, April 12, 2011 (HealthDay News) -- Eating apples every day may be good for your cardiovascular health, new research suggests.\nThe addition of apples to the diet probably kept the women feeling fuller because of the fiber content in the apples, she explained.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Again, the supposed benefits were only stated in terms of test scores \u2013 and then only in relative risk reduction terms, not absolute.\u00a0 Read our primer on this topic. ", "answer": 0}, {"article": "BioZorb has received 510(k) clearance from the U.S. Food and Drug Administration.\nThe study also noted that the device provides a helpful guide for post-treatment mammograms and other long-term follow-up to check for any cancer recurrence in these patients.\nBy providing better targeting, they said, the marker could also play a role in facilitating the use of external beam partial breast irradiation.\nThe article reports that the device provides clear visualization of the surgical site where the tumor was removed, thereby improving communication between the surgeon and radiation oncologist.\nThe authors said use of the marker facilitated their shift toward these shorter courses of radiotherapy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although there were numerous potentially useful benefits stated, there was no attempt in the news release to quantify them. Rather, the claims made were quite general: \u201cless radiation,\u201d \u201cbetter overall cosmetic outcome,\u201d \u201cmarker allowed physicians to be more confident in their targeting.\u201d The release would have benefited from quantified measures of at least some of the benefits listed.", "answer": 0}, {"article": "Complications can include fluid buildup around the heart, called cardiac tamponade, which makes it difficult for the heart to pump blood.\nAtrial arrhythmias in the first three months after ablation were classified as early recurrences and not considered as failures, Arbelo said.\n\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\nHe said, \"Relief of symptoms in patients with atrial fibrillation can be challenging.\"\nAblation was successful in 74 percent of patients, Arbelo said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story does provide a numerical picture of the data analysis. It states: \u201cAblation was successful in 74 percent of patients, Arbelo said. These patients had no atrial arrhythmias\u2013irregular heart beats\u2013for three to 12 months after the procedure.\u201d This means that nearly three out of four patients benefited in some way\u00a0by having the surgery, although it was not a permanent solution.\nHowever, the story didn\u2019t mention that the success rate fell to 66% when you considered the entire 12 month period, including the first 3 months.", "answer": 1}, {"article": "\"These are children who could have died from a teaspoon of milk before,\" Wood said.\nA mere sip would leave her vomiting and gasping for breath.\nThe strategy is being tested in a handful of small studies that are part of a surge of research in a field that for years showed little progress.\n\"The side effects were so great that they were as bad if not worse than the disease itself,\" Burks said.\nBut even that can be helpful.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story included absolute risk reduction data from the milk and peanut studies. \u00a0\n\u00a0", "answer": 1}, {"article": "Dr. Scolnick has not seen the results of the Novartis trial, but was told of them and concluded that if the drugs work in fragile X, \u201cthere\u2019s nothing to say that they won\u2019t work in some cases of broader autism-spectrum disorders.\u201d\n\nThe roots for the Novartis results began in 1982 when Stephen T. Warren, then a graduate student in genetics at Michigan State University, was looking for a job and something to research.\nWhen a doctor finally thought to do a fragile X test, Ms. Clapp and her husband, Dr. Michael Tranfaglia \u2014 both Harvard graduates with post-graduate degrees \u2014 researched the disease and came to two conclusions: fragile X was potentially treatable; and only about five researchers in the world were working toward a cure.\nThe results of the trial were something of a jumble until Novartis scientists noticed that patients who had a particular, undisclosed biological trait improved far more than others.\nThe predictions were premature because, like most of genetic research, discovering how the flawed gene caused disease was far harder than anticipated and required multiple leaps in neurology and biology.\n\u201cThis may be the key to solving the mystery of autism and other developmental disorders.\u201d\n\nGeraldine Dawson, chief science officer at Autism Speaks, the world\u2019s largest autism advocacy organization, said that a growing body of research suggests that the many genetic causes of autism all seem to affect synapses, suggesting that a treatment for one form of the disease might help others.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Again, the story falls down here when it passes along\u00a0a Novartis researcher\u2019s vague account of what happened in the study instead of providing us with actual statistics. \u00a0The researcher says there was \"clear improvement\" in the treated patients, but the\u00a0story should have pressed for a more\u00a0detailed account of how many patients benefited,\u00a0by how much, and according to what outcome.\u00a0Also unsatisfactory\u00a0was the rampant speculation about who else might benefit from the drug beyond\u00a0patients with fragile X syndrome.\u00a0According to\u00a0the Novartis account of the\u00a0research, only a\u00a0subgroup of patients with\u00a0an \"undisclosed biological trait\" benefited from therapy with the experimental drug. And this was in a study that was already\u00a0extremely small (\"a few dozen patients\") to begin with.\u00a0But\u00a0The Times\u00a0quotes\u00a0three different sources\u00a0who suggest, based on no evaluation of the data,\u00a0that the drug might be\u00a0useful for\u00a0a broader spectrum of autism disorders. And the quotes include some over-the-top language about the drug perhaps being \"the key to solving the mystery of autism and other developmental disorders.\" \nBy relentlessly playing up the positives and failing to rein in these more exuberant proponents, we think the story\u00a0gives an unbalanced view\u00a0of progress in the development of this drug and what it will likely be capable of. The fact is\u00a0that very few drugs in this stage of development\u00a0will be\u00a0approved by the\u00a0FDA and become available to patients. \u00a0\u00a0", "answer": 0}, {"article": "Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide.\nCoauthors Lana Warren, EdD, OT/L and Patricia Rao, PhD, Kennedy Krieger Institute, Baltimore, MD, and David Paton, DAc, LAc, Starting Point Acupuncture and Health Services, Catonsville, MD, identified the most positive outcome of the study as the high compliance rate, with all parents of the children ages 3-10 completing the intervention.\nThe study design and results, which suggest further controlled studies of this intervention approach in ASD, are published in the Journal of Alternative and Complementary Medicine (JACM), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.\nIn the article entitled \"A Pilot Observational Study of an Acupressure/Acupuncture Intervention in Children with Autism Spectrum Disorder,\" most parents reported that the intervention had a positive impact on their relationship with their child.\nThe researchers measured the effects of the intervention on factors such as the children's behavior, ability to pay attention, sleep, and aspects of parenting stress.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "According to the news release, the researchers \u201cidentified the most positive outcome of the study as the high compliance rate, with all parents of the children ages 3-10 completing the intervention.\u201d While it is good to know that the patients were able to complete the study, most readers probably wanted to know if the patients benefited from the treatment in any way. The release notes that \u201cresearchers measured the effects of the intervention on factors such as the children\u2019s behavior, ability to pay attention, sleep, and aspects of parenting stress\u201d \u2014 but doesn\u2019t tell readers whether any of those things changed as a result of treatment.\nThe closest the release comes to quantifying a benefit is when it states that \u201cmost parents reported that the intervention had a positive impact on their relationship with their child.\u201d It\u2019s not clear what they mean by \u201cmost parents,\u201d how much their relationship improved, how it improved, or why it may have improved. In fairness, the release states that the goal of the study was \u201cto determine if young children with autism spectrum disorder and their parents would tolerate and adhere to an office- and home-based acupuncture/acupressure intervention.\u201d However, the release also says \u201cWhile a small study, the tolerance and adherence with acupressure this pilot [sic] are both hopeful signs for families of those in their care with autism spectrum disorder.\u201d Why should families be hopeful? Who knows? Given that there had been more than a dozen clinical trials involving acupuncture and children with ASD as of 2012, it\u2019s not clear what questions this new study has answered.", "answer": 0}, {"article": "\u201cI\u2019d be very rich.\u201d\nWith Dr. Korn\u2019s help, BioSpecifics licensed the drug to Auxilium in a matter of weeks, receiving $5 million initially.\nAuxilium sought approval for treating Dupuytren\u2019s first because it was easier to measure success in straightening fingers.\nIt tested that drug for numerous uses, including herniated disks.\napproval was a belated triumph for the drug\u2019s original developer, BioSpecifics Technologies of Lynbrook, N.Y., on Long Island.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The sidebar describes the\u00a0outcomes\u00a0of the main clinical trial of Xiaflex in absolute terms. It reports that 64% of treated joints straightened out, compared with 7% of control group joints. The story relied a bit heavily on a positive patient anecdote in the sidebar lead-in, but it also managed to find a second patient who offered\u00a0a unique perspective on the treatment.\u00a0This second patient\u00a0had successful Xiaflex injections on three fingers and open surgery on a fourth finger which didn\u2019t respond to the\u00a0drug.\u00a0In this patient\u2019s view, the drug was\u00a0preferable to surgery.", "answer": 1}, {"article": "Sabourin Lussier, born with spina bifida, faced the possibility of kidney failure when she was just 19 years old. Her bladder, damaged by the devastating birth disorder, leaked uncontrollably and often backed urine up into her kidneys.\n\nA conventional surgery to reconstruct her bladder with intestinal tissue threatened further health complications. So in May 2000, Ms. Lussier and her mother, Gail Johnston, agreed to an experiment under which she and eight other patients with spina bifida would receive partial, laboratory-built...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is still a very new procedure and there is not much long-term data on outcomes from humans with reconstructed bladders. There is no quantitative data from the results of this study. This study also is very small (9 recruited, 7 had the transplant), and so results would not be generalizable to a larger population. The story discusses this limitation", "answer": 1}, {"article": "\"There was no significant difference,\" Boden said.\nBut Boden said that the study did include patients with moderate to severe heart disease and that many such patients undergo the procedure in the belief it will protect them against heart attacks.\nAlthough study patients receiving angioplasty were somewhat more likely to be free of chest pain, known as angina, even that benefit was marginal, Boden said.\nThe researchers and others stressed that angioplasty clearly benefits patients who are in the throes of a heart attack or are at very high risk for one.\nAfter about five years, the number of patients who experienced a heart attack, were hospitalized or died because of their heart problems was virtually identical in the two groups, the researchers found.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not provide actual rates of events (the primary outcome) between the two groups, although it does state that the numbers were not statistically significant.\u00a0 The story does provide absolute rates for angina, a secondary outcome which was significantly different between groups.\u00a0 Yet, it would have been best to report absolute rates, even if they are non-significant, for the primary outcome. There was no discussion about what \"statistically non-significant\" might mean.\u00a0 ", "answer": 0}, {"article": "An epileptic seizure occurs when large groups of neurons in the brain begin firing uncontrollably, disrupting the balance of electrical activity and causing changes in mental function, motor function and behavior.\nIt\u2019s not known what sets off a seizure, but lately scientists like Dr. Devinsky have been gathering evidence that inflammation, the immune system\u2019s response to injuries or foreign organisms, plays a pivotal role.\n\u201cThe challenge for the next few years is to find out the limitations, the boundaries, the real mechanisms.\u201d\n\nStill, whatever the role of inflammation in epilepsy, Elisa Moller says that anti-inflammatories were a miracle intervention for her son.\nAt William\u2019s worst point, a night in July 2010, he had a seizure every time he fell asleep, suffering 23 grand mals between midnight and 6 a.m.\n\nDr. Devinsky had prescribed weekly doses of prednisone, a steroid, and in desperation Ms. Moller decided to administer a mega dose.\nAs Dr. Devinsky noted, seizures in turn may produce further inflammation, perpetuating the cycle.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Everyone loves emotional anecdotes, and what could be more compelling than the story of a young boy who collapses and hits his head every time he suffers an epileptic seizure? Now that same boy, William Moller, is on a restrictive diet and is taking high doses of steroids regularly because his mother and his doctor believe that the steroids will control the inflammation that is leading to his seizures. In this 1,100-word story, 30% of the text is devoted to Moller, and the fact that his seizures have been under control for one year is used as the framing for a story claiming that \u201cinflammation, the immune system\u2019s response to injuries or foreign organisms, plays a pivotal role.\u201d What would have been much more useful to readers is more proof, both to back up the claim that Moller has had a \u201cmiracle intervention,\u201d as the story says, and to back up the claims in the story that, anti-inflammatory therapies \u201ccould at least supplement, and perhaps replace, anticonvulsants,\u201d the drugs of choice currently for epilepsy. Yet the actual benefits from all the studies mentioned in this story are never quantified.", "answer": 0}, {"article": "Vegetables particularly high in alpha-carotene include yellow-orange vegetables, such as carrots, sweet potatoes, pumpkin, and winter squash, and dark green vegetables, such as broccoli, green beans, green peas, spinach, turnip greens, collards, and lettuce.\nResearchers wanted to see if other carotenoids may also play a role in reducing the risk of disease.\nThe study shows that eating foods rich in antioxidants, like vegetables and fruits, fights disease and may prolong life.\nResearchers found that people with the highest levels of the antioxidant alpha-carotene in their blood had a 39% lower risk of death from any cause, including heart disease and cancer, than those who had the lowest levels of the antioxidant during the 14-year study.\n\"These findings support increasing fruit and vegetable consumption as a means of preventing premature death,\" write researcher Chaoyang Li, MD, PhD, of the CDC and colleagues in the Archives of Internal Medicine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story is simply wrong to state that the \u201cstudy shows that eating foods rich in antioxidants, like vegetables and fruits, fights disease.\u201d As noted above, this story does mention that \u00a0after similar studies pointing to health benefits of certain fruits and vegetables, follow-up studies have not shown that beta-carotene supplements reduce risks of dying from heart disease or cancer; nevertheless, the overall thrust of the story is that the study provides evidence of benefits\u2026 when the researchers actually limit themselves to saying the results are consistent with potential benefits and that they encourage further studies.\nThe story reports only the relative differences in death rates associated with one-time measurements of alpha-carotene blood levels, which is what the researchers and the news release highlighted. The actual numbers of deaths were in the article in the Archives of Internal Medicine, but they are hard to interpret, since they are not adjusted for age or other factors that were included in the analysis.", "answer": 0}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not adequately explain the intended appropriate use for this new stent. \u00a0The story indicated that the new stent decreased the need for repeat treatment in the target vessel and that the new stent decreased the occurrence rate for heart attacks. \u00a0There was no comparison of this stent with no stent at all. \u00a0In addition \u2013 as the information provided either came from the oral presentation at a conference or from the company news release \u2013 and has not been peer reviewed \u2013 the story should have been explicit about the source of the limited information it did present.", "answer": 0}, {"article": "These studies have been done with people, but other promising research has only been done with lab animals so far. In one 2009 study in the Journal of Medicinal Food, tart cherries helped fat rats. Not our favorite role models perhaps, but the obese beasties' risk of Type 2 diabetes and heart disease were reduced significantly, and parallel studies are now in the works with members of our own species, says lead author E. Mitchell Seymour: \"There are some interesting and potentially exciting results on the horizon. Stay tuned.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Many different claims were made in the story from several different studies over time.\u00a0 But only vague descriptions of benefit were provided \u2013 no quantification.\nThe claim that the women \u201cwho got the real stuff\u201d had significantly less inflammation, as measured by C-reactive protein (CRP), as compared to those who drank a placebo, is not accurate.\u00a0 The researchers only saw the decrease in CRP in a subset of 12 of the women who had active inflammation and thus elevated CRP.\nWhat\u2019s not mentioned in the story is that in the study on women with OA, only 1 of the 4 serum biomarkers of inflammation (TNF-a) showed a statistically significant decrease.\nThis is another example of a news story reporting on a surrogate marker (read our primer on this topic), but not on an outcome such as \u201cWhat difference did that make in their everyday lives?\u201d\n\u00a0", "answer": 0}, {"article": "Impaired insulin sensitivity is one risk factor for type 2 diabetes, which is associated with age and obesity and happens when the body can\u2019t properly convert blood sugar into energy.\nIn the real world, when people don\u2019t get enough sleep they tend to overeat, which may limit how much results from this lab experiment might happen in reality, the authors note in a report scheduled for publication in the journal Diabetes Care.\nAfter the four nights of sleep deprivation, the volunteers\u2019 insulin sensitivity had fallen by 23 percent and their bodies had started to produce extra insulin.\nBut when researchers checked again after two nights of extended rest, the men\u2019s insulin sensitivity, and the amount of insulin their bodies produced, had returned to normal, mirroring what was seen during the portion of the experiment when the volunteers consistently got a good nights\u2019 rest.\n\u201cIt gives us some hope that if there is no way to extend sleep during the week, people should try very hard to protect their sleep when they do get an opportunity to sleep in and sleep as much as possible to pay back the sleep debt,\u201d said lead study author Josaine Broussard of the University of Colorado Boulder.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are not quantified in a meaningful way. The story says, \u201cinsulin sensitivity had fallen by 23 percent and their bodies had started to produce extra insulin. But when researchers checked again after two nights of extended rest, the men\u2019s insulin sensitivity, and the amount of insulin their bodies produced, had returned to normal.\u201d \u00a0A 23% drop sounds substantial, but was it clinically important? What were the absolute numbers? We think the story could have done more here to help readers understand what was observed and what it means.", "answer": 0}, {"article": "For example, she says, someone might say, \" 'I find that I'm staying in my room, not answering the phone, not answering texts, not answering emails.'\nThat follow-up is key, says Julie Goldstein Grumet, a psychologist at the Zero Suicide Institute at the Education Development Center, a Washington, D.C.-based nonprofit.\nIn other words, the intervention had nearly halved the risk of suicide in the six months after discharge.\nYet only 50 percent of those people have been diagnosed with a mental illness.\nThe findings offer a way for hospitals and clinics to help reduce the rising numbers of death by suicide across the country.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains that people who received the Safety Planning Intervention cut their odds of repeated suicidal behavior in the next six months by nearly half. But that what\u2019s known as the relative risk reduction, and it\u2019s not the full picture.\nMore precisely, 3.03% of the patients who received the SPI intervention engaged in suicidal behavior compared to 5.29% of those receiving usual care. This is a key example of why news stories should report the absolute risk reduction.", "answer": 0}, {"article": "\"It wasn't a huge, overwhelming difference,\" O'Neil said.\nThe Weight Watchers study is new evidence of what that help might include when it comes to a side effect of weight gain: Type 2 diabetes.\nO'Neil said because Weight Watchers has centers all over the country, including sites in small towns with limited or no medical facilities, its program could help meet this need if combined with diabetes-specific counseling.\nThat's why he said it was important for MUSC to be involved in the study, which was funded by a grant from the commercial weight loss program, Weight Watchers.\nWhile the Weight Management Center has a high success rate at helping patients lose weight to fight diabetes, many people with the condition don't live near a specialized program and need help that's readily available.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides minimal quantification of the weight loss results in the two groups of participants:\n\u201cAfter a year, people in the Weight Watchers group had an average weight loss of about 4 percent of their starting weight, compared to 2 percent for the standard care group.\u201d\nBut we wanted it to go further, especially with respect to outcomes most specific to type 2 diabetes which is the focus of the headline.\u00a0The release states, \u201cThe Weight Watchers group also had a bigger improvement in a measure of long-term control of their blood sugar, which can reduce the risk for serious problems related to Type 2 diabetes.\u201d It would have been helpful had the release told us what measure they are talking about, how much it changed, and provided readers with a target or range of preferred blood sugar levels. We would also liked to have seen weight loss described in actual pounds lost, since that is how most people track their own weight.\nIn general, the release got the headline right, but overall took far too long to make clear exactly what the end points of the study were (weight loss primarily) and how small \u2014 albeit statistically significant \u2014 they were.", "answer": 0}, {"article": "Cancer is the No.\nThe test is a long way from being used to screen for cancer, but the study shows a way to get there, the team reported in the journal Science Translational Medicine.\nThe blood test detected the majority of cancers in people with four of the biggest cancer killers: breast, colon, lung and ovarian cancer, the team at Johns Hopkins University said.\nResearchers say they have taken a big step towards developing a test that can tell people if they have cancer long before the first symptoms show up.\nWyndham said it will be important to study such tests in large groups of people who have not had cancer diagnosed, to see if it can truly be used to screen asymptomatic people for cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says, \u201cThey identified 62 percent of the patients with stage I cancer \u2013 four out of eight colon cancer patients, and 90 percent of colon cancer patients with stage II, III or IV disease. They got a positive in 45 percent of the lung cancer patients with stage I disease, 67 percent of ovarian cancer patients with stage I disease and 67 percent of breast cancer patients with stage I disease.\u201d\nThis is a good start and we\u2019ll rate it Satisfactory, but one very important thing to make clear with this type of research: It used samples where cancer was already confirmed to exist\u2013which is different from testing only on samples where it\u2019s not known if there is any cancer present. That could affect the accuracy.", "answer": 1}, {"article": "There are many factors that cause obesity but there is a growing weight of evidence that shows obesity is not just caused by a behavioural disorder, such as a lack of self-control, but that many overweight people are physically addicted to foods rich in fat and sugar.\n\"The drug improves self-control, which is a key factor in determining obesity, so our hypothesis is that this drug should help in treating the disease.\"\nThere is mounting evidence to show that there is a substantial number of obese people who are food addicts because they have an inability to control their impulsive actions and this drug has shown it can give them more control, which will help overweight people lose weight and so improve their health.\n\"It has been shown to reduce impulsiveness in a variety of disorders such as alcohol dependence, schizophrenia and ADHD.\n\"Modafinil was found to have an effect on impulsivity in healthy individuals and so would be able to have an even bigger effect on food addicts, who are lacking in certain types of dopamine,\" said Professor Vlaev.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is filled with general statements about the\u00a0benefits of Modafinil in reducing impulse eating but provides no numerical data to back up the claims. It uses\u00a0statements such as \u201cWe found Modafinil . . . did reduce people\u2019s impulsive behavior,\u201d and \u201cModafinil was found to have an effect on impulsivity in healthy individuals.\u201d\nThe study was based on just a single dose given to healthy volunteers who were followed up with psychological testing. The release does not provide any explanation of what the test measured or revealed, only that Modafinal \u201csignificantly reduced level of impulsiveness.\u201d", "answer": 0}, {"article": "They included sharing news about friends or relatives or plans for the day as a way to involve their spouse in day-to-day events; waiting patiently and keeping eye contact while spouses searched for words; and finding alternate ways to communicate \u2014 for example, singing songs together when attempts to engage the spouse in certain topics failed.\nThe couples, who were recruited from a day program for people with memory disorders and their spouses, were receiving coaching in communication, with caregivers learning to listen, to avoid arguing, to not treat their spouse like a child.\nFuture research might focus on interventions that could help diffuse these frustrations, the paper noted.\nThe caregiving spouses seemed to value their partners\u2019 efforts to communicate as much as or more than the actual content of their conversations.\nA new study identifies patterns of communication that can help couples affected by Alzheimer\u2019s maintain a sense of connection, which could improve quality of life for both partners.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The headline of this story reads, \u201cBetter communication can help couples affected by Alzheimer\u2019s,\u201d and the lead sentence says, \u201cA new study identifies patterns of communication that can help couples affected by Alzheimer\u2019s maintain a sense of connection, which could improve quality of life for both partners.\u201d But these claims don\u2019t seem to be supported in the body text of the story. There\u2019s nothing in the story that quantifies how these couples were helped, and there\u2019s no description to support the claims of increased connectedness or improved quality of life. The researchers reviewed and analyzed recorded conversations between patients and caregivers and then derived what seemed to be the most successful approaches in fostering communications. How those successful approaches were identified by the researchers, or what effects they had on the couples, are described only in the most general of terms. The story does suggest a \u201clist\u201d of actions caregivers can take in these conversations, which is helpful.", "answer": 0}, {"article": "Dr Allan Pantuck, the lead clinician of the study, added, \"With fixed dose therapy, patients are often switched to other drugs when they no longer respond to treatment.\nThe research team successfully utilised CURATE.AI to continuously identify the optimal doses of each drug to result in a durable response, allowing the patient to resume a completely normal and active lifestyle.\nOur clinical study has shown that dosing can profoundly affect the efficacy and safety of treatment.\nThis advance is expected to dramatically improve response rates for all combination therapies that are being developed for oncology as well as virtually all other diseases.\nTo overcome the challenges of conventional combination therapy, the NUS team of engineers developed the CURATE.AI platform, which uses the patient's own clinical data - such as their drug doses and corresponding changes to tumour sizes or levels of cancer biomarkers in the blood - to calibrate his or her unique response to treatment.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does not attempt to quantify benefits. In fact, it would be impossible for the release to address this issue in any meaningful way, given that the relevant study was of one patient. The release says that the patient was \u201csuccessfully treated\u201d \u2014 but what does that mean? Lower down in the release, readers are told that \u201cdisease progression was halted,\u201d meaning that the cancer was not getting worse. Further, no information is given about the tumor\u2019s biology nor can any conclusions be drawn in the absence of a comparator such as\u00a0enzalutamide alone vs the combination.\nReaders are told that \u201cpatient care guided by CURATE.AI is currently ongoing.\u201d In other words, by the time anyone is reading the release, the patient could be in remission. Or the cancer may have spread. Or the patient\u2019s condition may not have changed at all. We just don\u2019t know.", "answer": 0}, {"article": "; Francesca Cesari, MSc., Ph.D.; Anna Maria Gori, MSc.\nIn an editorial accompanying the study, Cheryl A. M. Anderson, Ph.D., M.P.H., M.S., an associate professor of preventive medicine at the University of California, San Diego, in California, wrote that there were similarities between the two diets that may explain the results.\nMost participants were able to stay on both diets.\nAnderson, who was not involved in the study, added that promoting both diets by healthcare professionals \"offer a possible solution to the ongoing challenges to prevent and manage obesity and cardiovascular diseases.\"\nAfter three months, the participants switched diets.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Both the lacto-ovo vegetarian diet (Vd) and the Mediterranean diet (Md) were effective in reducing body weight, body fat, and body mass index with no significant differences between them. The release presents these benefits in absolute numbers. However, the Md led to greater reductions in triglyceride levels, while the Vd led to greater reductions in low-density lipoproteins (so called \u201cbad\u201d cholesterol). These were well covered in the news release.\nBut the latter benefits are changes in surrogate markers measured over just 3 months in people at a low risk for cardiovascular disease. Whether these results translate into meaningful, sustained, and clinically relevant outcomes that actually affect people\u2019s risk for developing heart or vascular disease can not be answered by this small randomized, controlled study.", "answer": 1}, {"article": "Want to embed a link to this report in your story?\nStudy Conclusions: The association between bariatric surgery and a lower rate of death from any cause adds to the limited literature describing the beneficial outcomes of these surgical procedures for obese patients.\nWhy The Research Is Interesting: Much is known about the short-term outcomes of bariatric surgery for weight loss but relatively little is known about its long-term effects.\nSome previous research has been limited by a number of factors, including the lack of a comparison group of obese patients who did not undergo bariatric surgery.\nBottom Line: Obese patients who underwent weight-loss surgery had a lower rate of death from any cause compared with obese adults who received nonsurgical care to manage their obesity.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that \u201cThe rate of death from any cause over about 4.5 years was lower among obese patients who underwent bariatric surgery compared with patients who managed their obesity with nonsurgical care.\u201d\nThe release further notes that \u201cThe association between bariatric surgery and a lower rate of death from any cause adds to the limited literature describing the beneficial outcomes of these surgical procedures for obese patients.\u201d\nBut the results state only that the rates of death were \u201clower\u201d over the 4.5 year follow up period.\u00a0 There is no attempt to put the size of the difference in context.", "answer": 0}, {"article": "\u201cRemember this day.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\nRival drugmaker Bristol-Myers Squibb had tried a catch-all approach with its Opdivo drug but it failed to help previously untreated patients when given on its own in a trial that included people with low levels of a protein called PD-L1.\nLead researcher Martin Reck of Germany\u2019s Lung Clinic Grosshansdorf predicted that testing for the PD-L1 biomarker would now become standard \u201cfrom today\u201d.\nAnd when given with two older chemotherapy drugs in non-selected patients, it was almost twice as likely to shrink tumors as chemotherapy alone.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story summarizes findings\u00a0of clinical study results, all of them positive. But what is a reader to make of relative risk claims such as the treatment \u201chalved the risk of disease progression and cut overall deaths by 40%\u201d compared to standard chemotherapy treatment? What does this mean in actual terms?\nOne story disseminated by Targeted Oncology\u00a0and\u00a0also apparently stemming from the Copenhagen\u00a0oncology\u00a0conference where these results were reported, noted that the \u201cestimated 6-month overall survival (OS) rate was 80.2% with pembrolizumab (Keytruda) versus 72.4% with chemotherapy.\u201d And when it came to risk of disease progression, the\u00a0median \u201clength of progression-free survival was 10.3 months with pembrolizumab versus 6.0 months with chemotherapy.\u201d", "answer": 0}, {"article": "While Drs.\nThe present analysis was not supported by industry funding.\n\"Our trial over its entire follow-up shows us that the longer you observe these patients, the more pronounced the benefits of the initial PCI become,\" said Dr. J\u00fcni, who is also a Canada Research Chair and a Professor of Medicine at the University of Toronto.\nThe trial was initially sponsored by St. Jude Medical, a global medical device company, until the three-year follow-up.\nThe FAME 2 trial was supported by St. Jude Medical.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that PCI resulted in a \u201csignificant reduction in urgent hospital admissions and revascularizations to restore blood flow in the blood vessels of the heart and a likely reduction in heart attacks as compared to medication as the only treatment.\u201d However, it does not give any numbers that would help readers understand the size of the benefit we\u2019re talking about.", "answer": 0}, {"article": "These forward-looking statements speak only as of the date hereof.\n\"The publication of this clinical utility study clearly demonstrates that the Oncotype DX DCIS Score can play a key role in enhancing cancer care for patients with DCIS, and we believe that these results will support expanded adoption of and access to the DCIS Score.\"\nAdditionally, the test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS.\n\"These results highlight the need to optimize treatment of this non-invasive, indolent form of breast disease, and the importance of Oncotype DX in helping physicians reduce over- and under-treatment of DCIS.\"\nConducted in collaboration with Partnership for Health Analytic Research, this prospective study analyzed 115 patients from 10 cancer centers in the United States.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release highlights the fact that information from the test changed physician recommendations for treatment. Some physicians changed to recommending whole breast irradiation while others recommended against. A company official says the study is evidence that the test \u201ccan play a key role in enhancing cancer care for patients with DCIS, and we believe that these results will support expanded adoption of and access to the DCIS Score.\u201d\nBut while changing practice recommendations may be an indication that the information provided by the test could\u00a0be useful and beneficial, it\u2019s not evidence that the test actually improves results for patients. Without clinical outcomes, it\u2019s difficult to know the true extent of benefits \u2014 if any. The release should have qualified the findings with some mention of the fact that the study was not designed to\u00a0assess outcomes that are meaningful to patients. Without such a warning it\u2019s too easy for readers/patients to be misled about the real impact of the test. Any statement along those lines would have earned the release a Satisfactory rating here.", "answer": 0}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We would have liked some more information here. Although the news release says: \u201cMore than 66 percent of patients treated with the DigniCap reported losing less than half their hair,\u201d we don\u2019t have a comparison to the control group. Without treatment, how much hair do patients actually lose?\nThere are other unanswered questions: How many times throughout the month did patients have to wear the caps to prevent hair loss? How long will patients have to undergo this therapy? And how long will the benefits last? How did the rate of hair loss compare with women who didn\u2019t use the cap?\nIn addition, the patients themselves assessed how much hair they actually lost based on photographs and questionnaires, making this step prone to recall bias. Since this also was not a double-blind trial, this could have also introduced other biases into the data.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "An important benefit for people to know who may be thinking about this would be their chance of kidney survival with a live-organ donation. Those numbers are provided (84% at 5 years for live-donor kidneys). Another benefit of interest would be how many more people might be able to receive a transplant through organ swapping. Those estimates are provided, although they are based on theoretical modeling. Interestingly, large numbers of people are required to increase the number of matches made, and even then, the increases are quite small. ", "answer": 1}, {"article": "Susan Pisano, a spokeswoman for the Association of Health Insurance Plans, the largest trade group, said insurers would wait for guidance from the FDA, but adds, \"If the FDA pulls back its approval for this particular indication, it would trigger a review of plan policies.\nDoctors told Gilbert she'd be lucky to be alive in five years, but with chemotherapy and radiation, she fought off the cancer, again.\nA few years later, she felt chest pains, and doctors thought she was having a heart attack.\nBut gratitude is tinged with worry, because the Food and Drug Administration is considering the unusual step of revoking its approval of Avastin as a treatment for metastatic breast cancer.\nBut some physicians, including Perez, say the issue is getting harder to ignore.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "For more information, visit www.chronothera.com.\nThe data were presented today at the Society for Research on Nicotine & Tobacco's 22nd Annual Meeting.\n\"Gums and patches are designed to help manage cravings, but they are only 5 to 9 percent effective.\nThe clinical trial was a randomized, double blinded study of 24 adult males who smoked 11 or more cigarettes per day, indicating a high level of nicotine dependence.\nTest group subjects had nicotine administered over a 30-hour time period via Chrono's prototype device that delivered nicotine according to Chrono's \"peaks and troughs\" profile.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that \u00a0\u201ctest subjects had a statistically significant and clinically meaningful reduction in cravings for all assessment methods (p=0.035; p=0.034 and p=0.016, respectively).\u201d Although we appreciate the mention of the p-values, it would have been more helpful to understand what a reduction in nicotine cravings meant in real terms, and if it could be sustained since the trial was only over 30 hours. In addition, it should be made clear that craving reduction is not synonymous with smoking cessation. The news release also uses a quote from a member of Chrono\u2019s Board of Directors who\u00a0says that this product has \u201cthe potential to solve such a serious problem.\u201d There doesn\u2019t seem to be enough evidence to say that this device would \u201csolve\u201d smoking in the United States.", "answer": 0}, {"article": "AMHERST, Mass.\nBoutot and Bertone-Johnson add, \"Though relatively few women in our study consumed very high levels of vegetable protein and our power for analyses of more extreme intake levels was limited, women consuming 9 or more percent of their calories from vegetable protein had a hazard ratio of 0.41 (95 percent confidence interval = 0.19-0.88)\" compared to those eating less than 4 percent.\nParticipants in the study contributed more than 1 million person-years of follow-up, during which 2,041 women experienced early menopause.\nFew studies have evaluated how protein intake is associated with menopause timing, they add, and to their knowledge this is the first to look specifically at early menopause.\nEarly menopause, the cessation of ovarian function before age 45, affects about 10 percent of women and is associated with higher risk of cardiovascular disease, osteoporosis and early cognitive decline, the authors note.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does the minimum in conveying the size of the link between diet and early menopause risk, saying women who consumed about 6.5 percent of their daily calories as vegetable protein had a 16 percent lower risk compared with women whose vegetable protein intake was approximately 4 percent of calories.\nIt further states: \u201cFor a woman with a 2,000 calorie per day diet, the authors explain, this is equal to three to four servings of such foods as enriched pasta, breakfast cereal, tofu and nuts, or about 32.5 grams a day.\u201d\nThe release could have provided better perspective by giving some absolute numbers. With a 10 percent overall risk, a 16 percent reduction would amount to one or two women in every hundred.\nIt also could have helped readers interpret this quote from researchers: \u201cThough relatively few women in our study consumed very high levels of vegetable protein and our power for analyses of more extreme intake levels was limited, women consuming 9 or more percent of their calories from vegetable protein had a hazard ratio of 0.41 (95 percent confidence interval = 0.19-0.88)\u201d compared to those eating less than 4 percent.\nIn more understandable terms, women consuming 9 percent or more of the calories from vegetable protein developed early menopause at slightly less than half the rate of those getting less than 4 percent of their calories from vegetable protein.", "answer": 1}, {"article": "\"I think there\u2019s no one answer,\u2019\u2019 Goldstein said.\n\"I\u2019m hoping this will help the women who need it.\u2019\u2019\n\nOne expert, Andrew Goldstein who runs the Sexual Wellness Center in Annapolis, Md., described a \"huge\u2019\u2019 unmet need for a medical treatment.\nA once-a-day drug being developed to treat women with low libido proved to boost desire and led to better sex among female patients participating in late-stage studies, according to publications presented today during a medical meeting in Lyon, France.\nRaymond Rosen, the former chief psychologist and associate dean at Robert Wood Johnson Medical School and now chief scientist at the New England Research Institutes, said that like the introduction of Viagra, a treatment for women\u2019s dysfunction will provide an opportunity for women to discuss the problem with their doctors.\nWomen who took the medicine, known as flibanserin, reported 22 percent more \"satisfying sexual events\" than those given a placebo in two clinical tests of 1,378 patients, according to abstracts released today at the European Society for Sexual Medicine annual meeting in Lyon, France.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Most of the benefits reported in the story were described in general, lay terms:\u00a0having more sex, wanting more sex and experiencing less distress related to lack of desire.\u00a0 The only detailed\u00a0benefit reported in the story was\u00a0the result of 2 clinical trials in 1,378 women that reported a 22% increase in \"satisfying sexual experiences\" compared to women taking a placebo.\u00a0 \"Satisfying sexual events\" was not defined and the 22% is not accurate based upon the data presented in the research abstracts.\u00a0The story should have placed\u00a0any benefits in context and\u00a0noted that while results were\u00a0statistically significant the medical or individual significance appears to be quite small.\u00a0 For example, the story should have noted that\u00a0women taking flibanserin had an average increase of 1.7 \"sexually satisfying events\" over the course of 6 months compared to an average increase of 1 event in women taking placebo.\u00a0", "answer": 0}, {"article": "But plasma insulin response was sharply lower in fructose drinkers, which may affect what we eat, according to the senior author, Dr. Kathleen A.\nThe type of sugar you eat may affect your cravings for high-calorie foods, researchers report.\nBut it also sends a signal to the brain that says \u2018you\u2019ve eaten.\u2019 Fructose doesn\u2019t stimulate insulin secretion, and if there\u2019s no insulin, you don\u2019t get the information that you\u2019re full.\u201d\n\nDoes this mean that it is a good idea to avoid fruit, because it contains fructose?\nThe fructose drink also produced greater activity in the visual cortex when volunteers looked at images of food, a finding that suggests increased craving compared with glucose.\nBefore having their drinks, the participants rated their desire to eat on a one-to-10 scale from \u201cnot at all\u201d to \u201cvery much.\u201d Then they drank the liquids and had functional magnetic resonance imaging brain scans while looking at images of food and of neutral objects like buildings or baskets.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that avoiding fructose may curtail cravings for high-calorie foods. But it never quantifies this finding. For example, the story says, \u201cWhen choosing between tasty high-calorie food or a delayed monetary reward, fructose drinkers were more likely than glucose drinkers to choose the food.\u201d What amount of money are we talking about? How much more likely? How was this measured? We thought the story needed some numbers to earn a Satisfactory rating on quantification.", "answer": 0}, {"article": "Mammography with ultrasound spotted 78 percent.\nAnd it's an important story, because about half of women under the age of 50 are found to have dense breast tissue when they get their mammograms.\nIn today's study of about 2,809 women with dense tissue and other risk factors, mammography alone found only half of the cancers.\nBut this study - the most definitive so far - may encourage more doctors to consider ultrasound, which is easier and less expensive.\nA mammogram had missed her cancer, CBS News medical correspondent Dr. Jon LaPook reports.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify some of the benefits of treatment, namely, 49% of cancers were detected by mammogram alone, and 78% of cancers were detected by mammography plus ultrasound. The broadcast does not list important absolute data included in the study, namely, that the addition of ultrasound found about 4 additional cancers per 1000 women (7.6 per 1000 with mammography v. 11.8 per 1000 with ultrasound and mammography). We believe that absolute benefit data are far more helpful for viewers and should have been included. \u00a0 \n ", "answer": 0}, {"article": "Tobias Hartmann, the project's coordinator, said, \"We have known for a while that diet can reduce the risk of developing dementia.\nThe LipiDiDiet study illustrates that this nutritional intervention can help to conserve brain tissue and also memory and patients' ability to perform everyday tasks - possibly the most troubling aspects of the disease.\nAs part of the LipiDiDiet project, the first randomised clinical trial to investigate the effects of a medical food Fortasyn Connect (Souvenaid), in patients with very early AD (pre-dementia), has just been completed.\nThe primary outcome parameter was selected to assess the effect on cognitive function (a broad measure of thinking) during 24 months intake of Fortasyn Connect compared with a control product.\n[2]\n\nThe trial was the first to investigate the impact of Fortasyn Connect on patients with very early AD (pre-dementia) who were randomised to receive either Fortasyn Connect or an iso-caloric control drink once daily.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We had to read the release three times to make sure, but, rest assured, there are no useful numbers about the benefits found in this study. Let\u2019s be clear, the study did not meet its expected primary outcome related to cognitive function and only three of the host of secondary outcomes. \u00a0So, from the purely scientific approach, Fortasyn Connect did not demonstrate a predefined clinical effect. The Australian not-for-profit, NPS Medicine Wise group concluded in a 2014 report that Fortasyn failed to demonstrate a significant effect in cognitive decline based on three previously published studies.", "answer": 0}, {"article": "\"It's kind of amazing that something so simple could be an answer,\" Paul said.\nHoney may suppress cough because its sweetness causes salivation that coats the throat, authors of the study suggested.\nOne local pediatrician said she wouldn't discourage parents from trying honey with their children, but more studies are needed to draw solid conclusions.\n\"(Honey) is a cheap and effective treatment,\" said Dr. Ian Paul, lead investigator for the study.\nPaul's group tested buckwheat honey instead of the lighter, more popular varieties because it's known to have more antioxidant and antimicrobial effects, which have been shown in other studies to help wounds heal.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of honey. By how much did the children cough less and sleep better? Did this result in a shorter duration of symptoms?", "answer": 0}, {"article": "Philadelphia, PA, August 14, 2017 - Stanford University scientists have described a new type of test that can detect genetic mutations in minute amounts of DNA released from cancer cells into the blood.\nAccording to the report in The Journal of Molecular Diagnostics, this highly sensitive test has the potential to be personalized to recognize mutations unique to any individual cancer.\nIn contrast, molecular tests like the one we have developed will enable patients to be monitored at every visit, and thus have the potential for quickly tracking cancer growth and spread.\nAfter generation of customized mutation detection assays, the researchers were able to identify tumor-derived circulating DNA from three out of six patients.\nThe three patients, whose samples did not show elevated cancer DNA, were undergoing active treatment at the time of collection.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We were expecting a thorough explanation and some numbers that illustrate how this test could more regularly track the growth and spread of cancer cells. But there was no quantification in the release.", "answer": 0}, {"article": "I couldn't get anything done,\" Ham said.\nBut there's a problem: There is very little research showing marijuana works as a treatment for such addictions.\nMany medical professionals say there's not enough evidence for them to confidently prescribe it.\nGetting on that list is crucial and has resulted in a tug of war in many states, including several in which veterans have been unsuccessful in getting post-traumatic stress disorder approved for marijuana treatment.\nIt would also be wrong to portray marijuana as completely safe, they say, because it can also be addictive.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are many mentions of research studies and evidence but very little detail in terms of quantified benefits. Even the mention of the\u00a02014 JAMA study showing that \u201cstates with medical marijuana laws had nearly 25 percent fewer opioid-related overdose deaths than those without,\u201d would have been more complete if we\u2019d known what that amounted to in absolute terms. The implications are that a 25% drop in opioid overdoses would be huge, but we\u2019re not really sure.", "answer": 0}, {"article": "About the UNM Comprehensive Cancer CenterThe University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Cancer Center in a 500-mile radius.\nThese study results are essential to new approaches in cancer prevention, particularly those that are investigating combined approaches of cervical screening and vaccination in adult women.\nThe study showed that women in this age group were still protected from HPV infections.\nThis study focused on the benefit of vaccinating women 26 years and older.\nWhenThe paper, \u201cEfficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study,\u201d was published in the June 28, 2016 online edition of The Lancet (www.thelancet.com/infection).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits of HPV vaccination for women 26 years and older are qualitatively described in the news release in statements such as:\n\u201cThe study showed that women in this age group were still protected from HPV infections\u201d and \u201cThe scientists followed each woman for four to seven years. They found that the vaccine protected the women against HPV infections during the follow-up period and that the women were protected from many types of HPV across a broad age range.\u201d\nBoth statements lack quantification. In the first statement, the reader is left wondering exactly how many women were still protected. The second statement seems to suggest that the vaccination protects against any types of HPV infections while a close reading of the study suggests that only certain strains of HPV were considered, and for those strains only persistent infections were counted.\nIn general, statements such as the ones above\u00a0should be tempered with further details on the study design. In this case, there is a lack of crucial information such as how\u00a0many women were enrolled in the study and what proportion already had a history of HPV. Finally, what was the measured outcome? What does it mean exactly to be \u201cstill protected from HPV infections?\u201d Did none of the women enrolled in the study have HPV going into the study? The release isn\u2019t clear.", "answer": 0}, {"article": "\"If you have your choice, you want to get poked with a needle or you want to try this?\nA number of the people in the flu patch study applied it to themselves.\nGomaa's hope is that vaccine patches will cost less than vaccinations do now.\nAnd the patch can be administered by people who aren't trained health professionals.\nBut one version developed by Georgia Tech's Laboratory for Drug Delivery showed promising results in its first human clinical trial, according to a study published in The Lancet in June.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The quantification of benefits in this article is a mixed bag. The description of the Georgia Institute of Technology flu patch study does provide some information about benefits of this vaccine delivery methods, but there is no\u00a0description of the measured benefits of the jet injectors.\u00a0The most complete comparative data on the benefits of the vaccine delivery method are in the briefer discussion of nasal spray. There we learn that the CDC reported the effectiveness of the spray was only 3 percent, so low that \u201cno protective benefit could be measured\u201d for children ages 2 to 17.\u00a0The effectiveness of the flu shot was about 63% for the same age group. We would have liked to have seen this kind of discussion for all three alternatives in the story.", "answer": 0}, {"article": "\"It can be extremely painful to pass these jagged little crystallized minerals and it's very common for sufferers to go to an emergency department for treatment.\nEMF Australasia Chair, Associate Professor Sally McCarthy said this research had the potential to help millions of Australians suffering with this extremely painful condition.\n\"This means patients with large stones might not need more complicated treatments including surgeries, and this has potential to improve care and reduce costs.\n\"It may also have implications for patients living in rural and regional areas, where access to urologists - the specialist doctors who treat this condition - can be limited.\"\nPatients with kidney stones were treated with the drug Tamsulosin in an Emergency Medicine Foundation Australasia (EMF) funded clinical trial run across five Australian hospital emergency departments.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In the release, the clinical trial leader describes the benefits as:\n\u201cOf more than 400 patients in the trial, we found those who received tamsulosin passed their large kidney stones more often than the placebo group.\n\u201cThis means patients with large stones might not need more complicated treatments including surgeries, and this has potential to improve care and reduce costs. We\u2019re very excited because Tamsulosin treatment may also allow patients to be treated closer to home rather than needing referral to a major centre.\u201d\nThe release would have been much better had it stated what \u201cmore often\u201d actually meant. How many more patients on tamsulosin passed their stones compared to those on placebo?\nIn addition, the release could have more carefully differentiated which patient group might benefit from the drug intervention. According to the study abstract:\n\u201cWe found no benefit overall of 0.4 mg of tamsulosin daily for patients with distal ureteric calculi less than or equal to 10 mm in terms of spontaneous passage, time to stone passage, pain, or analgesia requirements. In the subgroup with large stones (5 to 10 mm), tamsulosin did increase passage and should be considered.\u201d\nThe published study reported that of the 36 patients on the drug with large kidney stones \u2014 those between 5 and 10 mm \u2014 30 (83.3%) passed their stones compared with 25 of the 41 (61%) volunteers with large stones who were given placebo. Those would have been good numerical reference points to include in the release.", "answer": 0}, {"article": "Drs.\nAsher and Burri, along with their co-investigators, now recommend that patients with one to three brain metastases should no longer receive routine whole brain radiation therapy, and should be treated with focused therapy alone to better preserve cognitive function and quality of life.\nThe study, released on July 26, 2016, shows that patients with the most common form of brain tumor can be treated in an effective and substantially less toxic way by omitting a widely used portion of radiation therapy.\nThis is a very relevant finding, as over 200,000 patients still receive whole brain radiation in the United States each year, and the majority of patients with brain metastases have a limited number (typically three or less) of brain lesions.\nAsher and Burri emphasize that the real importance of this study is its potential to make us think differently about what really matters in cancer therapy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is far more emphatic than the study. The release says focused radiation treatment alone proved to be \u201csubstantially less toxic\u201d than a combination of focused and whole brain radiation treatment for these brain tumor patients. By contrast, the study referred to \u201cless cognitive deterioration\u201d and lower rates of decline in the quality of life. However, the lack of detail about benefits in the release is largely due to the lack of detail in the study itself, which reported only on a combined measure of cognitive function and did not spell out specific benefits. The same can be said of the discussion of survival rates, because the study itself said only that there was no significant difference between the treatment groups. The release should have included a vital point: that few patients in either group lived more than a few months. Indeed, 20 percent had died before the first evaluation just three months after treatment.\nOn the other hand, the release does a great service by highlighting the finding that although patients who received whole brain radiation in addition to focused radiation had better brain scan results, they did not live any longer than those whole were given only focused radiation treatment. The finding is yet another example of the danger of putting too much stock in measures of disease progression or other tests that logically seem to be related to important health outcomes, but often fall short.", "answer": 0}, {"article": "In the Swiss research, animals took a drug that dissolved a barrier around the part of the brain where mammals store their fear memories. Afterward, they stopped being afraid of noises that were linked to electric shocks, which meant their bad memories had been erased, according to the Mail. Human brains, explains NYU neuroscience Prof. Joseph LeDoux, could actually \"overwrite\" memories with happier thoughts if the medication is developed for people, according to the Daily Mail.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the story mentions that \u201cbad memories had been erased\u201d in the mice, it does not provide any data or any indication\u00a0of how fear manifests\u00a0in a mouse. Furthermore, the story should have made it clear that is it not known if this same effect would be seen in humans. ", "answer": 0}, {"article": "After five years, 74 percent of the angioplasty group and 72 percent of the medication group were free of chest pain \u2014 \"no significant difference,\" Boden said.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\nThe stunning results found angioplasty did not save lives or prevent heart attacks in non-emergency heart patients.\nAlso, the clogs treated with angioplasty are not the really dangerous kind.\nAt the start of the study, 80 percent had chest pain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits of treatment, reduction in chest pain, rates of heart attack and death, were presented.", "answer": 1}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not include specific numbers on specificity and sensitivity (see harms, below), only stating that the Facebook model was \u201cmoderately accurate.\u201d\nAlso, we think it would have been helpful to point out that the U.S. Preventive Services Task Force recommends depression screening, giving the evidence a B rating, meaning that there is moderate certainty that screening will be beneficial.", "answer": 0}, {"article": "Army veteran Vivian Cooke has long struggled with debilitating depression.\nFinzi notes previous studies show between 50 to 60 percent of patients may benefit from the treatment.\n\u201cSo Botox basically inhibits the muscle and calms it down, so it becomes more difficult to feel those negative emotions.\u201d\n\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression.\n\u201cI had less problems with depression.\u201d\n\nEven though the study she took part in is now over, she said she will continue to get Botox injections.\nAs for Cooke, she said she noticed a change in her depression almost immediately.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article gives next to no\u00a0information about the size of the benefit. A single statement by Eric Finzi, a cosmetic dermatologist, explains that 50 to 60 percent of patients may benefit from botox as treatment for depression. (CBS reported those estimates came from past studies, but provided no details about nor links to those studies.)\u00a0How big are those benefits?\u00a0Are they sufficient to make a notable difference in daily life? Are they a slight improvement that is useful only when combined with other treatments? The article doesn\u2019t address those questions.", "answer": 0}, {"article": "GLYX-13 targets parts of the brain linked to learning and memory.\nAn advantage is that the drug doesn't have the side effects of other drugs that target these same areas, such as hallucinations and schizophrenia-like symptoms, the researchers noted.\nBecause the drug targets these areas of the brain it might also help people with other problems such as schizophrenia, bipolar disorder, anxiety and Alzheimer's disease, the researchers suggested.\nThe effect of the drug was substantially better than seen with other antidepressants, the researchers found.\nMoskal, however, said he is confident that this drug will be a breakthrough in treating depression.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story talks about how antidepressant effects of the drug were seen within 24 hours, but it fails to quantify\u00a0how many patients out of the 120 saw such effects. And how were the effects measured in these patients? The article also notes, \u201cThe effect of the drug was substantially better than seen with other antidepressants,\u201d but what exactly was better? How much were depressive symptoms reduced?\u00a0 What proportion of study participants benefited?", "answer": 0}, {"article": "For example, a normal-weight woman should gain between 25 and 35 pounds, while an overweight woman should gain between 15 and 25 pounds.\nThere was no clear benefit among the women in the diet and exercise groups when the researchers looked at other complications, such as cesarean delivery, but it did look like there may be some benefit, they write.\nWhile the new study generally did not show fewer complications in the diet and exercise group, Dr. Loralei Thornburg told Reuters Health that it\u2019s good that there was no increase in complications.\nAfter including the new studies, the new review found \u201chigh-quality evidence\u201d to show diet, exercise or both can reduce the risk of excessive weight gain during pregnancy, write the researchers in The Cochrane Library.\nWomen who took part in diet, exercise or combination programs were about 20 percent less likely than women in standard-care groups to gain too much weight while pregnant, the researchers report.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that women who took part in \u201cdiet, exercise or combination programs were about 20 percent less likely than women in standard-care groups to gain too much weight.\u201d And the story does a nice job of articulating that there is significant variation in how much weight is \u201ctoo much,\u201d depending on the mother\u2019s weight prior to pregnancy. However, the absolute reduction in risk was also reported in the study tables, and so we would\u2019ve expected the story to cite that information. The study reported that excessive weight gain would be expected in 452 of 1000 women in the standard care groups compared with 362 per 1000 in the diet and exercise groups \u2014 that\u2019s the 20% reduction mentioned in the story.\nThe story also wasn\u2019t quite as clear as it could have been when discussing other potential benefits of diet and exercise. For example, the story says \u201cThere was no clear benefit among the women in the diet and exercise groups when the researchers looked at other complications, such as cesarean delivery, but it did look like there may be some benefit, they write.\u201d That statement is a little confusing. To clarify,\u00a0the article could have said something like: Women who participated in combined diet and exercise programs were 13% less likely to have a C-section compared to women who did not, though this difference was not quite statistically significant \u2014 in other words, it may have arisen by chance.", "answer": 0}, {"article": "Microcapsules loaded with stem cell-derived insulin-producing cells retrieved after they had been transplanted into a mouse.\nThe researchers behind two studies published Monday demonstrated they had made progress on both fronts, encapsulating the cells in a protective bubble to shield them from the body\u2019s immune response, and creating beta cells from stem cells, which are potentially limitless.\nVegas said that if the primate studies are successful, the next step will be developing a therapy to be used in people.\nJust because the system produced strong results in mice does not mean people will respond the same way.\nBut experts say the findings provide hope for future treatments for people.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not break down the actual number of positive findings in either study, and we wish it had. It may be that the way in which the benefits were measured was hard to explain. But we still think the story should try to give readers some specifics. We\u00a0want to know more than just that the beta cells performed \u201cevery bit as good as the body\u2019s own cells.\u201d", "answer": 0}, {"article": "For more details and to read the full study, please visit the For The Media website.\nA total of 19 patients (53 percent) in the YAG laser group reported significantly or completely improved symptoms vs 0 individuals in the sham group.\nA limitation of the study was its small sample size and short follow-up period.\n\u201cGreater confidence in these outcomes may result from larger confirmatory studies of longer duration,\u201d the authors write.\nSix months after treatment, the YAG group reported significantly greater improvement in self-reported floater-related visual disturbance (54 percent) compared with sham controls (9 percent).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release briefly summarizes the results. It states, \u201cA total of 19 patients (53 percent) in the YAG laser group reported significantly or completely improved symptoms vs 0 individuals in the sham group.\u201d\nIt also notes that both the small sample size and short follow-up period were limitations of the study. ", "answer": 1}, {"article": "The page you are looking for has either moved or is not available (error 404).\n\nPlease return to the homepage or use the search box above to see if the page is available in a new location.\n\nIf you think this message is in error or need assistance, please email the webmaster.", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release discusses benefits in only the broadest of terms, citing \u201cpositive preliminary results,\u201d and fails to quantify those results.", "answer": 0}, {"article": "\"I don't think pregnancy should be the thing that tips the scale,\" said Caughey.\nBut Caughey, who wrote an editorial accompanying the new research, said women considering weight-loss surgery should make the decision based on the long-term health benefits of the procedure -- not on potential pregnancy-related benefits.\nCaughey agreed with the researchers that any pregnancy occurring after weight-loss surgery merits a higher level of monitoring and should be considered high-risk.\nBut Johannson said those outcomes might be due to reduced nutrient absorption resulting from the surgery, with a fetus not receiving sufficient nutrition.\nOnly 2 percent of women who had weight-loss surgery developed gestational diabetes, compared to 7 percent of the other group, the researchers said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article generally does a good job of describing the benefits. In one instance, it mentions the absolute difference in outcomes between the intervention and control group for gestational diabetes. (\u201cOnly 2 percent of women who had weight-loss surgery developed gestational diabetes, compared to 7 percent of the other group, the researchers said.\u201d). That\u2019s very useful. But we\u2019re concerned that the story never explains why readers should be worried about a \u201clarger than normal\u201d baby. It sounds, at most, mildly worrisome, and some readers might even hope for a baby that\u2019s \u201clarger than normal.\u201d But a baby that\u2019s significantly larger than normal can increase risks for a variety of delivery complications such as difficult labor and need for cesarean delivery, vaginal tearing, and bleeding after delivery. Although we wish the story had explained this, we think its overall treatment of benefits merits a satisfactory rating.", "answer": 1}, {"article": "CHICAGO (Reuters) - Children in rural Nepal whose mothers were given iron and folic acid supplements during pregnancy were smarter, more organized and had better fine motor skills than children whose mothers did not get them, U.S. researchers said on Tuesday.\n\u201cIt had an impact across a range of function, including intellectual function, executive function and fine motor function,\u201d factors that could affect a child\u2019s later academic success, Christian said.\nThey said ensuring that pregnant women get this basic prenatal care could have a big effect on the educational futures of children who live in poor communities where iron deficiency is common.\nShe said many children in poor communities would benefit from better prenatal programs that include the low-cost nutritional supplements.\nChristian\u2019s team studied 676 school-age children whose mothers had been in a clinical trial in which some got iron and folic acid supplements and other nutrients while they were pregnant.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are not quantified, which is a shame. If there were tangible differences between the groups of kids, they should be spelled out. Literally billions of dollars in global health funding could be at stake for programs like this. Policymakers need strong guidance not optimistic quotes. We need to understand the absolute benefits of this program and others like it.", "answer": 0}, {"article": "Prediabetics are at increased risk for developing diabetes, which can damage the eyes, kidneys, nerves and blood vessels and often leads to cardiovascular disease.\n\"Assessment of sleep apnea should be considered in patients at high risk for diabetes and cardiovascular disease, since our study shows that treatment of sleep apnea can reduce these risks.\"\n\"Our study showed that CPAP in patients with prediabetes can lower their risk of progressing to diabetes when CPAP is used for eight hours, a full night's sleep,\" said the study's lead author, Sushmita Pamidi, MD, a former fellow at the University of Chicago who is now on the faculty at McGill University in Montreal, Canada.\nUsing a simple device for eight hours a night to treat sleep apnea can help people with prediabetes improve their blood sugar levels and may reduce the risk of progressing to diabetes, according to a new study published online in the April 21, 2015, issue of the American Journal of Respiratory and Critical Care Medicine.\nAfter two weeks, blood sugar control, as measured by an oral glucose tolerance test, improved for those in the CPAP group compared to the oral placebo group.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is fairly vague on the benefits conferred on prediabetic patients using CPAP devices. For example, the release notes that \u201cblood sugar control, as measured by an oral glucose tolerance test, improved for those in the CPAP group compared to the oral placebo group.\u201d But this improvement is not quanitified. In addition,\u00a0the study was not designed to show how likely it is that this improvement measured during\u00a0a 2 week test period has a lasting impact on developing frank diabetes or, if so, how big that impact might be.\nAnd although the original study paper was clear to state the limits of the findings, the first author exaggerates them in the news release. Consider the following comparison:\nPaper: \u00a0\u201cIn this proof of concept study, the CPAP treatment was limited to 2-weeks, and thus the study does not provide information on the potential effects of CPAP on glucose metabolism over a longer period of time. Importantly, in our study, CPAP was applied in the laboratory under continuous supervision, but 8-hour nightly CPAP use may be difficult to achieve in real-life conditions. Thus, our findings should be interpreted with caution, particularly in regards to CPAP recommendations to patients in clinical settings.\u201d\nAuthor in release: \u201cOur study showed that CPAP in patients with prediabetes can lower their risk of progressing to diabetes when CPAP is used for 8 hours, a full night\u2019s sleep.\u201d\nBenefits are further exaggerated (by implying that a population beyond that studied [everyone with sleep apnea, not just prediabetics with OSA] could benefit)\u00a0in the following statement from the author in the release: \u201cOur results should provide a strong incentive for anyone with sleep apnea, especially prediabetic individuals, to improve adherence to their treatment for cardio-metabolic risk reduction.\u201d", "answer": 0}, {"article": "The skin synthesizes vitamin D when exposed to sunlight, making supplementation all the more important where long winters reduce the opportunity for this to happen.\nWhile there were no significant differences in body composition across the different dosage groups, the researchers found children who had vitamin D stores above the threshold recommended by the Canadian Paediatric Society (CPS) averaged around 450 grams less body fat at 3 years of age.\nFurther analysis also indicated a correlation between lean muscle mass and the average level of vitamin D in the body over the first three years of a child's life.\nThe new study confirmed the importance for the development of strong bones of a vitamin D supplement of 400 IU/day during a baby's first year.\nThe researchers found that higher doses did not provide any additional benefit -- at least not in terms of bone development.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019ll give this a borderline Satisfactory rating because the release provides a number associated with vitamin D supplements \u2014\u00a0 450 grams less body fat. However, the release presents some of the findings in a confusing way that could be misleading to readers. It confuses blood levels of vitamin D with doses of vitamin D supplements and it reports that children with higher blood levels of vitamin D averaged around 450 grams (1 pound) less body fat, but the headline says supplements reduce body fat. The researchers clearly stated, \u201cThis long-term follow-up of a vitamin D supplementation study in children demonstrates no difference in body composition across any dosage groups (400, 800, 1200 and 1600\u2009IU).\u201d The release notes that \u201cthere were no significant differences in body composition across the different dosage groups\u201d, which makes the headline claiming that vitamin D supplements reduced body fat incompatible with what the researchers actually reported.\nThe release does report that physical activity also made a difference, but did not offer any comparison to the claimed effects of vitamin D levels.", "answer": 1}, {"article": "Use our submission form, or ask @juliaoftoronto on Twitter.\nSo, yes, the flu vaccine can prevent illness, but it's hard to detect major effects on public health in the data.\nSo, as this Cochrane review notes, it's impossible to draw firm conclusions on the effectiveness of the flu vaccine for those over 65 because the data is so biased and poor.\nThat seems to be the same conclusion that other studies have drawn \u2014 the flu vaccine is modestly helpful, and doesn't hurt.\nOn the other hand, the evidence suggests that there's no harm in getting a flu shot, either.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job of explaining what the actual benefits of the influenza vaccine really are.\u00a0 Just as a recent HealthNewsReview.org\u00a0blog post did, the story goes way beyond the typical media version touting claims of X-percent effectiveness and explains what that means in terms of individual people escaping flu symptoms.\u00a0 This accuracy of interpretation does carry with it, however, one risk:\u00a0 For a public so used to hearing that vaccines are, say, 60 percent effective, actually finding out that they\u2019d only prevent one person from getting symptoms for every 33 people vaccinated may\u00a0not sound good enough for the\u00a0lay person.", "answer": 1}, {"article": "The F.D.A.\nAnd new data from another large study by Edwards found that patients at intermediate risk did better with the newest version of its valve than would be expected with surgery in the first 30 days, when most deaths occur.\nThe result was a requirement that a hospital should be doing at least 50 surgical aortic valve replacements a year to have access to the technology.\nMore recent 2015 data from Medtronic indicates that its valve is better than surgery for high-risk patients, resulting in fewer deaths, at least in the first two years.\n\u201cThere are very few treatments in all of cardiovascular medicine that could claim that \u2014 I can think of heart transplant, and that\u2019s it.\u201d\n\nThe results were even more notable, he said, because the early versions of the devices were clunky, stiff and difficult to use.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article mentions several studies and case reports of the benefits of this procedure, but does not share details necessary to evaluate it. The article says \u201cFor those who could not have surgery, a\u00a0valve replacement\u00a0with TAVR reduced the death rate by 20 percent in the first year.\u201d \u2013 20% from what? Compared to what?\nThe article also says: \u201cMore recent 2015 data from Medtronic indicates that its valve is better than surgery for high-risk patients, resulting in fewer deaths, at least in the first two years. And new data from another large study by Edwards found that patients at intermediate risk did better with the newest version of its valve than would be expected with surgery in the first 30 days, when most deaths occur.\u201d\nWe would hope to see absolute numbers here, not just percentages. How many fewer deaths compared to surgery? In what way did patients at intermediate risk do better?", "answer": 0}, {"article": "The panel suggests that heart patients be screened by first asking two standard questions: In the past two weeks, have you had little interest or pleasure in doing things?\nPsychiatrist Michelle Riba said the statement\u2019s emphasis on frequent screening is important.\n\u201cA lot of patients with depression don\u2019t follow up on it,\u201d said Dr. Mary Whooley, a professor of medicine at the University of California, San Francisco, who was not on the panel.\n\u201cWhat you want to see in a particular patient is how they do over time,\u201d said Riba, past president of the American Psychiatric Association, which has endorsed the heart association\u2019s recommendations.\nOne doctor said screening isn\u2019t enough; patients need close monitoring to make sure they get help.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not attempt to quantify the benefits of depression screening.", "answer": 0}, {"article": "Until now, there has been little research into its activity.\nThe researchers tested the therapy in a small group of patients with Addison's disease.\nThe team found that corticosterone was as effective as cortisol, but had reduced effects on fat cells compared with cortisol.\nThe researchers say that, with further research, these findings may one-day lead to improved therapies for other conditions that respond to steroid treatment, including asthma and rheumatoid arthritis.\nProfessor Brian Walker, Head of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"These findings suggest that corticosterone could provide a safer alternative to traditional cortisol replacement therapy for conditions such as Addison's disease and congenital adrenal hyperplasia.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a brief but nice job of explaining the effects of corticosterone on fat cells. We would have liked to have seen a bit of quantification of the differences between cortisol and corticosterone. The study demonstrated statistically significant differences on fat cells but the duration of the study in a small number of patients with Addison\u2019s disease was 330 minutes.", "answer": 0}, {"article": "The beleaguered parent now drags hollering kid to the doctor's office, only to find the pediatrician reluctant to prescribe antibiotics.\nFull study report at http://clearpop.com \n\n\n\nEAR INFECTION AND ANTIBIOTICS\n\nEar infections are the Number One reason kids aged 5 and under receive oral antibiotics.\nCLINICAL TESTS\n\nChildren diagnosed with Acute Otitis Media, or ear infection, consumed the xylitol and Vitamin C-based product in pediatric offices.\nClearPop for Rapid Earache Relief has been shelved by Raley's (CA, NV) select RiteAid locations, and is available at boutique drugstores and Amazon.\nAfter 20 minutes, 88.5% reported their ear pain dramatically reduced or vanished.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release\u00a0does not adequately quantify the benefits of the lollipops. It says:\n\u201cChildren diagnosed with Acute Otitis Media, or ear infection, consumed the xylitol and Vitamin C-based product in pediatric offices. After 20 minutes, 88.5% reported their ear pain dramatically reduced or vanished.\u00a0The earache episode was totally resolved for 80%.\u201d\nIt does not explain how many children were studied. Is it 88.5% of 100 kids? Is it 88.5% of 50 kids? As it turns out, the number is 88.5% of 25 kids, meaning 22 kids. The release should say, \u201cOut of the 25 children studied, 22 reported their ear pain reduced by X on a scale of Y.\u201d\nUsing\u00a088.5% is also misleading (on the part of the study report and the press release) because it doesn\u2019t include in the denominator the number of subjects who stopped the treatment.", "answer": 0}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains why a portable, inexpensive device that could determine if a lump\u00a0is probably\u00a0benign or malignant would be a useful tool for patients in rural areas and in developing countries.\nReaders should be told before the 5th paragraph that a pilot\u00a0test on the featured device included only 7 patients.\nAt this stage of development, any presumed benefits should by couched very carefully.\u00a0 Although the story does provide several provisos, we think that readers should have been told bluntly that because the device is only in very early testing its sensitivity and specificity in detecting breast cancer is purely speculative.", "answer": 0}, {"article": "Chronic rhinosinusitis (CRS) affects a sizable minority -- 14 percent to 16 percent -- of U.S. residents.\nThis second finding is probably explained by the fact that people going for second or further surgeries were probably sicker to begin with, Josephson said.\n\"These were patients who have chronic sinusitis so, by definition, they have at least three months of symptoms and they have evidence of an ongoing inflammation or infection of their nose and sinuses on either a CT scan or an examination of the nose and sinuses,\" Smith said.\nThe condition, marked by symptoms such as sinus pain and pressure, headache, stuffy nose and sneezing, can compromise quality of life more than even congestive heart failure, back pain or chronic obstructive pulmonary disease, the study authors said.\nFRIDAY, Jan. 1, 2010 (HealthDay News) -- Three-quarters of patients undergoing surgery for stubborn sinusitis saw significant improvements in their quality of life, new research shows.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "Given in the abdomen, AMG145 reduced low-density lipoprotein (LDL) cholesterol levels among a group of healthy volunteers.\nFormer AHA President Dr. Ralph Sacco said that it is too early to make any predictions about what role, if any, this therapy will have in lowering cholesterol levels, but it could one day fill an important void.\nThe new drug did hit its target, PCSK9, and decreased levels of LDL cholesterol by up to 64 percent.\nResearchers measured LDL cholesterol levels for 85 to 113 days after treatment.\nMONDAY, Nov. 14, 2011 (HealthDay News) -- Preliminary research suggests that a single injection of a man-made protein might lower levels of \"bad\" cholesterol.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The\u00a0says that AMG 145 decreased LDL cholesterol by up to 64%. Although this description isn\u2019t quite as useful as simply telling us what the cholesterol numbers were before and after treatment, the number does convey the point that this was an impressive amount of cholesterol lowering \u2014\u00a0which is accurate. The story also explains other features\u00a0of the drug that might be attractive \u2014\u00a0e.g.\u00a0the potential for less\u00a0frequent dosing and fewer muscle-related adverse effects compared with statins. As already noted, the potential limitation of impacting a surrogate marker was worth mentioning. There\u00a0was room for improvement here, but we\u2019ll call it satisfactory.", "answer": 1}, {"article": "\"But it's a slippery slope to saying 'OK, maybe two is better.'\nStudies will continue, and not everyone has given up the idea that moderate drinking \u2014 up to two drinks a day for men and one day for women \u2014 might have some cardiovascular benefits.\nOne theory, backed by the new British study: the results are skewed by the fact that some non-drinkers are former drinkers with health problems.\nThere's no evidence drinking in your 20s or 30s has any health benefits.\nBut that's not the only reason, says Lori Mosca, a professor of medicine at Columbia University Medical Center and a spokesperson for the American Heart Association.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article stated: \u201cthe science suggesting a benefit has never been conclusive,\u201d which could explain why the story hesitated to put numbers down in this case.\nBut the story pointed out that women over the age 65 could be an exception, as this age group experienced some health benefits with moderate drinking. What were these health effects? And how much more benefit did this group see?\nAlso, with a Swedish study mentioned in the story, it\u2019s said that middle-aged people who had more than two drinks a day \u201chad a markedly increased stroke risk.\u201d What does that mean? And by how much?\nSome numbers could have clarified sweeping statements such as these.", "answer": 0}, {"article": "\u201cIf you can give [someone like Robison] an idea of what emotions may be hidden behind a voice or face, then it enables his brain, without TMS, to change the way he approaches life and people.\u201d\n\nNevertheless, Pascual-Leone acknowledges that these changes can be challenging as well as beneficial, as Robison describes.\nStill, for all the positive changes described in \u201cSwitched On,\u201d Robison\u2019s fourth book, there were negatives he was forced to deal with.\n\u201cThe experience was richer and deeper, with an added layer of feeling,\u201d he writes.\nYet it is more than a linear account of a life transformed by cutting-edge medical technology.\nBut his book does illustrate that the consequences can be long-lasting, and detrimental.\u201d\n\nRobison remains optimistic that as research continues, the potential benefits will outweigh the risks.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While Robison refers to improvements in his life, there is no discussion of how long the effects last, what changes occurred and how they actually benefited Robison. And, while personal anecdotes are powerful, they don\u2019t provide evidence that can be used to assess the likelihood of benefit or harm in general. A discussion of the research in this area should have been included.", "answer": 0}, {"article": "Bracing is one of a number of noninvasive ways to treat knee OA and/or delay the need for joint replacement surgery.\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing.\nThe study was also presented at the recent annual meeting of the American Academy of Orthopaedic Surgeons in New Orleans.\nNew research presented at a media briefing Tuesday in New York City suggests that Peterson is not the only one to find relief from knee bracing.\nAll study participants led active lifestyles before they got sidelined by knee OA, and said they hoped to return to their previous level of activities.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported on what the company media briefing wanted to report:\u00a0 less pain, stiffness, disability and decreased use of pain medications in the braced group.\u00a0 But the story didn\u2019t say if there was a control group and how results compared. \u00a0\u00a0 ", "answer": 0}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story indicated that 215 individuals who were screened were identified as having heart disease and received additional testing and treatment. \u00a0Nonetheless, there was no statistical benefit between the groups of healthy individuals who did and did not undergo a CCTA test.", "answer": 1}, {"article": "Co-authors with Sharma, who presented the data at ASCO, are Petri Bono, Helsinki University Hospital, Helsinki, Finland; Joseph Kim, Yale Cancer Center; Pavlina Spiliopoulou, Beatson, West of Scotland Cancer Centre, Glasgow; Emiliano Calvo, Centro Integral Oncol\u00f3gico Clara Campal, Madrid,Spain; Rathi Pillai, Emory Winship Cancer Institute, Atlanta; Patrick Ott, Dana Farber Cancer Institute, Boston; Filippo DeBraud, Istituto Nazionale dei Tumori, Milan, Italy; Michael Morse, Duke University Medical Center, Durham, N.C.; Dung Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore; Dirk Jaeger, Heidelberg University Hospital, Heidelberg, Germany; Emily Chan, Vanderbilt University, Nashville, Tenn.; Chris Harbison, Chen-Sheng Lin, Marina Tschaika, Alex Azrilevich, of Bristol-Myers Squibb, and Jonathan Rosenberg of Memorial Sloan Kettering Cancer Center.\nThis Phase I/II clinical trial treated 78 patients: five (6.4 percent) had complete responses, 14 (18 percent) had partial responses, in which tumor burden shrinks by at least 30 percent, and 22 (28.2 percent) had stable disease.\nOverall survival will be analyzed in conjunction with the Phase II portion of this clinical trial, which provides nivolumab or a combination of nivolumab plus the immune checkpoint inhibitor ipilimumab.\nLong-term follow up shows 22 percent of those treated with the drug survive 10 years or longer.\nThe U.S. FDA approved atezolizumab, which blocks PD-L1, for these patients.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a pretty good job here, explaining that: \u201cThis Phase I/II clinical trial treated 78 patients: five (6.4 percent) had complete responses, 14 (18 percent) had partial responses, in which tumor burden shrinks by at least 30 percent, and 22 (28.2 percent) had stable disease. Thirty (38 percent) patients had disease progression.\u201d Later, the release states that \u201cAt a median follow up of 213 days, 33.3 percent remained on treatment, and 45.6 percent of patients survived for at least one year, which [one doctor] noted \u2018is better than anything we\u2019ve seen in the past.'\u201d The release also places analysis of survival in context by noting that \u201cOverall survival will be analyzed in conjunction with the Phase II portion of this clinical trial, which provides nivolumab or a combination of nivolumab plus the immune checkpoint inhibitor ipilimumab.\u201d", "answer": 1}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides data that there was little positive difference between radiologists' and CAD detection of cancer via mammogram images.\u00a0 However, the story does not mention results of any other evaluations of the technology (e.g. how it has been used in UK and other countries where results did show benefit in terms of increased detection of cancer). ", "answer": 1}, {"article": "\"Historically, patients with chronic systolic heart failure were considered too frail to exercise and, through the late 1980s, avoidance of physical activity was a standard recommendation,\" the study's authors write.\nThe study authors say there's a usually a strong relationship between depression and heart failure, so the fact that tai chi helped cheer people up was an especially good sign.\nThe researchers recruited 100 people with the chronic condition from heart clinics in Boston.\nThe Archives of Internal Medicine study is the first large clinical trial to look at whether a tai chi program can do anything for people with heart failure.\nIn a quality of life questionnaire the researchers gave out, those who practiced tai chi scored significantly higher than those who hadn't been doing the movement.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Not detailed enough. The story says that participants in the tai chi group \u201cscored significantly higher\u201d on a quality of life questionnaire\u00a0\u00a0and \u201creported an improvement in mood.\u201d\u00a0Readers\u00a0deserve to have these benefits quantified in absolute terms so they can judge for themselves how \u201csignificant\u201d the\u00a0findings are. The story also failed to mention that tai chi had no effect on participants\u2019 peak oxygen uptake or performance on a six-minute walk test, which are objective\u00a0measures\u00a0of functional capacity.\u00a0While it is useful and important to know that\u00a0heart\u00a0patients \u201cfeel\u201d better after tai chi, as the\u00a0quality of life measures suggest, it\u2019s also key to point out that\u00a0patients should not\u00a0expect to function more effectively just because they\u2019re taking a\u00a0tai chi class.", "answer": 0}, {"article": "When a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.\nThe study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.\n\"Most treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all of the types of tests.\nProfessor Christopher Brightling, who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.\n\"This new drug could be a game changer for future treatment of asthma\" - Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester\n\nThe first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "If this release would have only discussed the primary outcome goal of the study \u2014 \u201cto examine the effects on inflammation in the airway by measuring the sputum eosinophil count\u201d \u2014 then we\u2019d probably give it a satisfactory rating on this category since it provided clear numerical data showing a significant reduction in percentages among patients taking the drug versus those on placebo. But the release didn\u2019t stop there. It had the principle investigator add glowingly, \u201cA unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works.\u201d\nIf these additional measurements were so significant in the study, then why was that data excluded from the release?\u00a0 We need quantification of the actual results of the clinical tests to be able to judge benefits.", "answer": 0}, {"article": "Compared with the 35 stroke patients who got clot-dissolving medicine alone, the 35 who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days. Imaging results revealed that for those who got both treatments, 100% of the brain tissue initially affected by a clot had blood flowing to it after 24 hours. Among the subjects who only got alteplase, the median level of restored blood flow was 37%.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was a borderline call that we ultimately ruled unsatisfactory. \u00a0On the positive side, certain aspects of the two studies published in the NEJM are well described: \u201c\u2026among the 35 subjects who were assigned to get both treatments, 100% of the subjects\u2019 brain tissue initially affected by blockage had blood flowing to it after 24 hours. Among the subjects who only got alteplase, also known as tPA, the median level of restored blood flow was 37%.\u201d \u201cThe studies suggest that for every 2.5 to 4\u00a0patients, on average, treated with intra-arterial therapy, one could be expected to have an outcome better than they would have had with alteplase alone.\u201d\nHowever, percentage of brain tissue affected by blockage isn\u2019t the most important outcome for readers \u2014 they\u2019re more interested in results like neurologic function and death. And on those key statistics, the story relies mainly on relative risk figures that likely inflate the benefits of the procedure. Example: \u201cCompared with stroke patients who got clot-dissolving medicine alone, those who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days, had 81% better function 90 days after their stroke, and were nearly half as likely to die.\u201d \nIn these types of situations, absolute risk is the number that really matters to patients. So we\u2019d prefer for the story to have reported 1. the percentage of\u00a0patients who got\u00a0clot-dissolving medicine alone and regained function, and 2. the percentage of those who got both treatments and regained function. That would give readers a more accurate sense of how well the treatment works.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies benefits in relative terms only. The story should have provided context for these numbers by showing the actual rates of fracture in the treatment group compared to the placebo group. Furthermore, the story only presents one outcome, vertebral fractures. These are fractures found on x-rays that only sometimes cause symptoms. Treatment reduced the chance of vertebral fractures from 10.9% to 3.3%.\u00a0Equally important would be risk of hip fracture, which can substantially impact an individual's quality of life. In this study, the risk of hip fracture was reduced from 2.5% over 3 years\u00a0in the placebo group to 1.4% in the treatment group.", "answer": 0}, {"article": "To resolve that possibility, a new trial is under way at 20 cancer centers, including M.D.\nHe noted the impressive results could be the result of cherry-picking patients, accepting only those whose tumors had been excised by surgery and radiation.\nAlmost all the patients mounted an immune response.\nAfter surgery and follow-up radiation, he and his doctors decided to combine Temodar, the now-standard chemotherapy, and the vaccine, until then only used alone.\nThe trial's big surprise was that the chemotherapy didn't stop the vaccine from prompting a strong immune response and instead enhanced it.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The impact of the treatment on time to cancer recurrence was provided in the story. \u00a0The story included a hint that the study may also demonstrate an increase of survival time. \u00a0However since the information about survival time was not available at the time the story was published, it is not fair to make this suggestion. \u00a0Inclusion by the clinician involved in the story that\u00a0\"It appears very promising for a cancer where there\u2019s been little hope.\" may suggest more benefit than may be attained with this treatment.", "answer": 0}, {"article": "CT scans became popular because they offer a quick, relatively cheap and painless way to get 3D pictures so detailed they give an almost surgical view into the body.\nThat puts them at risk of developing radiation-induced cancer, Brenner and Hall said.\nThe radiation and risk from one CT scan is low, but it carries a dose 50 to 100 times greater than a traditional X-ray, reports LaPook.\nIt's also a good idea to keep a diary of X-ray exposure, especially for children.\nA previous study by the same scientists in 2001 led the federal Food and Drug Administration to recommend ways to limit scans and risks in children.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Since the story focused on the harms of the approach, quantifying the benefits of CT scans is not imperative in this case. ", "answer": 2}, {"article": "Cannabidiol, or CBD, is a compound in the cannabis plant that does not contain psychoactive properties that induce a high.\nSpecifically, seizure frequency dropped in the CBD-treated group by 39 percent from a median of nearly 12 convulsive seizures per month before the study to about six; three patients' seizures stopped entirely.\nThe new study confirms results from a December 2015 open-label expanded access program led by Dr. Devinsky that reported reductions in seizure frequency.\nFor the study, 120 children and adolescents with Dravet Syndrome between the ages of 2 and 18 years were randomized across 23 sites in the United States and Europe to receive either CBD 20 mg/kg or placebo added to their existing treatment over a 14-week period.\nThe study included a liquid pharmaceutical formulation of CBD, called Epidiolex, which is manufactured by GW Pharmaceuticals and has not been approved by the U.S. Food and Drug Administration.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release describes benefits in clear terms, and provides numbers to add context. It states:\n\u201cSpecifically, seizure frequency dropped in the CBD-treated group by 39 percent from a median of nearly 12 convulsive seizures per month before the study to about six; three patients\u2019 seizures stopped entirely. In the placebo group, there was a 13 percent reduction in seizures from about 15 monthly seizures to fourteen.\u201d\nIt also notes that the difference in the degree of seizure reduction between the CBD group and the placebo group was \u201cboth statistically significant and clinically consistent.\u201d", "answer": 1}, {"article": "Bernard M.Y.\nThe reduction in LDL cholesterol from the higher dose ended up decreasing the risk of a major cardiac event by 6 percent, the researchers found, although the statistic in itself was not clinically significant.\nThis trial looked at the benefits of statin therapy with 80 milligrams (mg) versus 20 mg simvastatin (Zocor) among 12,000 heart attack survivors.\nFor this reason, they noted that the incidence of severe muscle disease on 80 mg of Zocor might be an \"underestimate.\"\nThis applied even if the patients already had low levels of low-density lipoprotein (LDL, or \"bad\") cholesterol, he noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story failed to provide information about the absolute benefit that might be expected to be obtained with higher statin dose use. \u00a0For example, by presenting the 13% reduction in cardiovascular death or heart attack rate, a reader has no way of knowing what the actual rate was to start with.", "answer": 0}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article was about one patient\u2019s subjective account of pain relief. The only mention of evidence is by one of the doctors quoted, saying he did a literature search and found the evidence supporting this treatment to be \u201cgrim.\u201d A quantitative assessment of that evidence would have been useful to include.", "answer": 0}, {"article": "\"It's very exciting,\" Klein says.\nWhile Americans spend an estimated $1 billion on nonprescription weight loss products, few if any of those products have undergone the rigorous testing that is required by the FDA for prescription medications.\nAnd many consumers may be put off by the drug's significant gastrointestinal side effects, including flatulence, diarrhea and anal leakage.\nAt the current recommended prescription dose -- 120 milligrams taken up to three times per day, for example up to 360 milligrams daily -- about 70 percent of users experience gastrointestinal complications, Klein says.\nBut it's important to know that the weight loss that's typical for users of the drug -- 5 to 10 percent of total weight -- will be less than many dieters expect.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Provides at least a ball park estimate for people about the amount of weight that might be \nanticipated to be lost with the use of this medication.", "answer": 1}, {"article": "But all I need to do is add 5 and 5.\u201d\n\nEspecially in a time of concern over rising medical costs, \u201cwe should not simply use the highly sophisticated technology just because it\u2019s there,\u201d Falcone said.\nIn this case, the robot could turn what would have to be an open surgery into a simpler one.\nBecause the robot lets the surgeon get a better picture of the inside of the body, the authors had expected that surgeries using the robot would go more smoothly than those without it.\n\u201cWe were surprised that (surgery with the robot) did not have better outcomes than (the surgeon alone), as we have always believed if you can see more and see better you can do more and do better,\u201d the authors write.\nTo test this idea, they looked back at 78 minor surgeries that were done on women with endometriosis - half using the assistance of a robot, half without it.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are two possible benefits here. 1. People spend less time in surgery to achieve roughly the same outcome and potentially a better outcome, which, by all accounts, is better. 2. Hospitals and medical groups spend less money on robots and are allowed to devote those health resources elsewhere. Both are not so much quantified as addressed. In order to truly establish the second point, one would need to perform a longer term and larger study to find\u00a0out whether\u00a0humans outperform robots on a wider range of surgeries. These $1.5 million machines are not just specific to endometriosis. They are used for hundreds of procedures, and so to decide whether they are worth the money would require more research. Still, the story is measured in its claims.", "answer": 1}, {"article": "Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow.\nFurthermore, approximately half of those patients are considered suitable for intensive treatment.\nThe median overall survival for patients treated with VYXEOS in the study was 9.56 months compared to 5.95 months for patients receiving 7+3, representing a 3.61 month improvement in favor of VYXEOS.\nIn the intent-to-treat population, Grade 3 or higher, non-hematologic adverse events were similar across all organ systems, including cardiac, gastrointestinal, general systems, metabolic disorders, musculoskeletal, nervous system, respiratory, skin and renal.\nIn the intent-to-treat population, Grade 3 or higher, hematologic adverse events were similar for overall infections, febrile neutropenia, and bleeding events.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release gave extensive data on median overall survival (9.56 months compared to 5.95 months for patients receiving 7+3, the standard treatment) and the \u201cpercentage of patients alive 24 months after randomization\u201d (31.1% in the treatment\u00a0arm compared to 12.3% on the 7+3 arm).\nIt also, helpfully, added the \u201csixty-day all-cause mortality\u201d as 13.7% versus 21.2%, in favor of patients treated with\u00a0the intervention\u00a0drug. The release notes that the treatment gives a Number Needed to Treat (NNT) of about 7, which is very good. (NNT is a measurement of the impact of a therapy by estimating the number of patients that need to be treated in order to have an impact on one person.) The median survival doesn\u2019t look as good. In about half of the patients, there is a four month or less increased survival. This implies that there is a group that has much longer survival. To see that there is a clinically important survival benefit (14% absolute increase) does make a difference.", "answer": 1}, {"article": "It's very exciting.\"\nMelton and other researchers cautioned that many years of research lay ahead to prove whether the development would translate into cures.\nAlthough the experiment involved mice, Melton and other researchers were optimistic that the approach would work in people.\nThe experiments, detailed online yesterday in the journal Nature, raise the prospect that patients suffering from not only diabetes but also heart disease, strokes and many other ailments could eventually have some of their cells reprogrammed to cure their afflictions without the need for drugs, transplants or other therapies.\nThe work was hailed as a welcome development even by critics of research involving embryonic stem cells, which can be coaxed to become any tissue in the body but are highly controversial because they are obtained by destroying embryos.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Framing this approach as one that could someday cure not only diabetes, but also heart disease, stroke, and \u2018many other ailments\u2019 is troubling.\u00a0 This extrapolation to diseases other than diabetes was not supported by the data presented in the study reported on.\u00a0 There is a great gulf between proof of concept in an animal model and cinical application in a single disease.\u00a0 Suggesting the same approach could be applied to other diseases is pure speculation that is not supported by the data in the Nature study. ", "answer": 0}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides some absolute data on patients' self-reported recoveries and mood. At 26 weeks follow-up, of 366 bipolar patients, 27% of patients who took a mood stabilizer and placebo experienced 8 weeks of of positively improved mood, but did not become manic; 23.%5 of patients receiving anti-depressants and a mood stabilizer achieved the same 8-week period of improved mood. ", "answer": 1}, {"article": "Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by red, swollen and cracked skin with intense itching.\nThe successful results of the Phase 2 trial of MM36 have been published by the Journal of the American Academy of Dermatology (JAAD), the leading peer-reviewed journal in dermatology.\nMM36 was also associated with improvement in patient-reported outcomes, most notably rapid and sustained itch relief, with Visual Analog Scale scores showing improvement from moderate to mild within the first week (36.4% mean change; p=.0011).\nMM36 is expected to be the 2nd topical PDE4 inhibitor in the market after the potential approval of Anacor Pharmaceuticals' crisaborole product.\nIt has been estimated that approximately 18 million people are living with AD in the U.S. and this disease accounts for up to 20% of patient visits to dermatology offices.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the release does give the mean percentage improvement scores compared to baseline measures and patient-reported outcomes (39% improvement for those volunteers assigned the MM36 compound compared to 3% on the placebo at week 2 and throughout the remainder of the 8-week study), it could have been greatly improved by saying specifically how many of the 121 experienced what percentage of improvement. There also is no information on what it actually means to say a condition has improved from \u201cmoderate\u201d to \u201cmild,\u201d especially given that the treatment is being tested only for those with \u201cmoderate to mild\u201d eczema. According to the published study, the number needed to treat (NNT, or the number of patients that need to be treated for one to benefit compared with a control in a clinical trial) was about 6 for an improvement of at least 2 levels on a 0 \u2013 5 scoring system. According to that measure, the difference in improvement between the high dose cream and the placebo was about 18%.", "answer": 0}, {"article": "\"Doing that could be a lot easier than nudging children about going to bed,\" Raine said.\nThe researchers also want to add to this current observational study to establish, through randomized controlled trials, that eating fish can lead to better sleep, better school performance and other real-life, practical outcomes.\nAnalyzing these data points, the Penn team found that children who reported eating fish weekly scored 4.8 points higher on the IQ exams than those who said they \"seldom\" or \"never\" consumed fish.\nGiven the young age of this study group, Liu and colleagues chose not to analyze the details participants reported about the types of fish consumed, though they plan to do so for work on an older cohort in the future.\nFor the work, a cohort of 541 9- to 11-year-olds in China, 54 percent boys and 46 percent girls, completed a questionnaire about how often they consumed fish in the past month, with options ranging from \"never\" to \"at least once per week.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We are told that children who said they ate fish weekly \u201cscored 4.8 points higher on the IQ exams than those who said they \u201cseldom\u201d or \u201cnever\u201d consumed fish.\u201d\u00a0 The children who reportedly \u201csometimes\u201d ate fish consumers scored 3.3 points higher. How big is a 4-point difference on the IQ test and would it translate to better school performance or other outcomes that would be meaningful for the children? That question isn\u2019t addressed.\nThe release also claims that those who consumed fish had fewer sleep disturbances but doesn\u2019t give us any clue as to how sleep disturbances changed \u2014 from what to what?  \nIt would also be useful to know how much fish they ate and what kinds.  ", "answer": 0}, {"article": "Some critics say Medicare would not be doing a review of a drug already approved by the F.D.A.\nSo it cannot be completely ruled out that XL184 somehow stopped bone growth without killing the cancer.\nHowever, the panel gave very low scores to evidence that the drug would help prostate cancer patients other than the type who participated in the clinical trial, which were men with advanced cancer, but no or minimal symptoms.\nA late-stage trial could begin as early as next year, he said.\nHowever, Dr. Smith said he doubted that was the case because there were signs the drug also controlled tumors outside the bones.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story included the numbers of men who were seen to have improvement in their bone scans. \u00a0While reporting on the improved bone scans seen in the men treated with XL184, the story did include some balance by indicating that this scan change might not translate into a change in the cancer in the bone and that nothing was yet known about how the drug affected longer term outcomes.\nThe increase in median longevity observed with Provenge was reported from one study, without including the insight from the two other larger scale studies.\nIn a split decision, we\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 0}, {"article": "Since 1998, the Food and Drug Administration has required that breakfast cereals, breads, rice, pasta and other grain products made with enriched flour come fortified with folic acid.\nBut there's one notable exception to this success story \u2014 Hispanic women \u2014 and researchers think the reason may lie in a staple of their diet: tortillas.\n\"The FDA is concerned that the breakdown of folic acid in corn masa flour could yield a substance that raises concerns about safety.\"\n\"The story of folic acid is one of the great public health stories of \u2014 ever,\" says Dr. R.J. Berry, who works with the Division of Birth Defects and Developmental Disabilities of the Centers for Disease Control and Prevention in Atlanta.\nSo why does the FDA currently ban dosing corn masa flour with folic acid?\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives the reader an idea of how many neural defects could be prevented by adding folic acid to corn flour. \u201cAnd studies suggest that fortifying corn masa with folic acid could prevent an additional 40 to 120 cases of neural tube defects among babies born to Hispanic mothers each year.\u201d", "answer": 0}, {"article": "\u201cShe couldn\u2019t get over the background buzzing,\u201d Dr. Kaufman said.\nAnother concern is that patients who require high doses of stimulation drain the battery quickly, requiring surgery to replace the device.\nDoctors say simple adjustments to the device may solve that problem.\nBut spinal cord stimulators offer significant relief to only about half the patients who try them.\nThe syndrome may follow 5 percent of all injuries, according to the Reflex Sympathetic Dystrophy Association, an advocacy group for people with chronic pain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story accurately characterizes the results of a 2007 multinational randomized trial showing that the device helped reduce pain by about half in about half of people who received the treatment, compared to only 9% of people receiving conventional medical treatments. The study is the largest of its kind and a fair representation of the literature. A 2004 review, for example, found that spinal cord stimulators provide mild to moderate pain relief in selected individuals for anywhere from 6 months to several years. (Pain 2004;108:137-47)\u00a0 Still, the story could have probed the absolute reduction in pain.\u00a0 For instance, halving moderate pain may be less beneficial than halving severe pain.\u00a0 ", "answer": 1}, {"article": "And the warriors had a 40 percent lower risk of cardiovascular death and an 18 percent lower risk for cancer-related death.\nThis study shows that it doesn\u2019t matter how you decide to split up the recommended weekly amount of exercise.\nThis could be something as simple as a brisk walk or other low-impact options for vigorous exercise about 20 minutes a day.\nRelated: Post-workout cold immersion likely won\u2019t help you heal\n\nThere are risks that come with a weekend warrior exercise schedule, especially for people who aren\u2019t used to being active.\nHowever, there are also some limitations to this study, the researchers say.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story used only relative risk numbers to quantify the benefit. This is inadequate, as we explain in Reporting the findings: Absolute vs relative risk.\nAlso, the story confused association with causation, i.e.,\u00a0\u201cresearchers in the U.K. found that weekend exercise appears to be just as effective at preventing heart disease and cancer as exercise done more frequently.\u201d\nThe title of the paper suggests otherwise: \u201cAssociation of Weekend Warrior and other Leisure Time Activity Patterns with Risk of All Cause Cardiovascular Disease and Cancer Mortality.\u201d See more on the importance of not overstating observational findings.", "answer": 0}, {"article": "Infants exposed to partial treatment in the womb healthier than those not exposed.\nThe new study, supported by NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), provides strong evidence that even a partial course can have some benefit.\nInfants in the partial treatment group fared better than untreated infants.\nThe study followed the infants from birth to 18 to 22 months of age and measured survival and brain and nervous system outcomes.\nResearchers evaluated 6,121 extremely premature infants who had been born between 22 and 27 weeks of pregnancy at sites in NICHD\u2019s Neonatal Research Network.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the news release gives figures for the number of study participants and their gestational ages, it doesn\u2019t provide any quantitative data on the benefits of steroid therapy. Instead, it uses broad, vague language, such as \u201csignificant differences in rates of death.\u201d It also states, \u201cInfants in the complete treatment group fared best,\u201d and \u201cinfants in the partial treatment group fared better than untreated infants.\u201d\nAs we have pointed out in previous reviews, the word \u201csignificant\u201d is confusing and ambiguous, since it could mean \u201cstatistically significant\u201d or \u201cremarkable/substantial,\u201d the colloquial use of the term.\nWithout any numbers to put \u201cbest\u201d and \u201cbetter\u201d into perspective, readers are left wondering just how well each group fared. The original journal article gives the rates of various complications in percentages. Since the study\u2019s primary objective was to compare the rates of death or neurodevelopmental impairment in infants born between 22-27 weeks, it would have been sufficient to disclose only these figures for the three groups. Researchers wrote, \u201cDeath or neurodevelopmental impairment occurred in 68.1%, 54.4% and 48.1% of patients in the no, partial and complete ANS (antenatal steroids) groups, respectively.\u201d\nSince the news release does not quantify the benefits for its readers, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "Trials of that vaccine in people, which is also based on man-made copies of virus proteins, began on August 2, when the first study volunteer was given a vaccination through a needle free injector, said Dr. Anthony Fauci, head of the National Institute for Allergy and Infectious Diseases.\nThe protein/cold virus vaccine was especially effective, sparking a significant immune response after just one dose.\nThis kind of vaccine is much safer than ones that depend on live virus particles to foster immunity.\nRelated: New Study Shows Just How Tricky the Zika Virus Is\n\nThe two other experimental vaccines described in the new report also sparked an immune response in monkeys.\nRight now, just one of those three vaccines will be progressing to clinical trials.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Mixed bag. \u00a0We could have gone either way with this grade but give the story the benefit of the doubt. The story does detail the findings of one of the four vaccines being tested: That 16 monkeys appeared to become immune to Zika.\u00a0More information about the three other vaccine trials should have been given, though.", "answer": 1}, {"article": "Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug \"significantly\" reduced chronic lower-back pain.\n\nLilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "How is a 50% reduction in pain measured?\u00a0 What are the potential flaws in such measurements or self-assessments?\u00a0 31% of how many?\u00a0 These are critical lapses. These questions were better answered in a company news release than they were in the WSJ news story. ", "answer": 0}, {"article": "Mayta-Apaza AC, Pottgen E, De Bodt J, et al.\nWhile the dietary intervention was based on a limited number of human volunteers and more research is needed to support these conclusions, the results help build the foundation for future research and suggest Montmorency tart cherries can play a role in positively shaping the microbiome and maintaining gut health.\nWhile previous studies on Montmorency tart cherries have ranged from heart health and exercise recovery to sleep, this is the first study to explore the potential gut health benefits.\nHowever, the new study does suggest that Montmorency tart cherries can be added to the list of gut-friendly foods.\nAn international team of scientists found that Montmorency tart cherries helped to positively impact the gut microbiome - a collection of trillions of bacteria and other microbes that live in the intestinal tract.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The lead author of the study is quoted as saying:\nOur results suggest that the unique polyphenol mixture in tart cherries may help positively shape the gut microbiome, which could potentially have far-reaching health implications.\nWhat are the \u201cfar-reaching health implications\u201d? They\u2019re not specified. Nor are any specific benefits described. The release says the researchers analyzed study participants\u2019 stool samples but offers readers no glimpse into the findings or what was measured.", "answer": 0}, {"article": "Friedman, who is now 70 and lives in Los Angeles, lost 175 pounds.\nIt's one of several procedures designed to help people maintain the benefits of bariatric surgery.\nSo Friedman opted for a less invasive procedure to make her stomach smaller again.\nFriedman kept the weight off for almost 10 years.\nAbout one in three patients regain significant amounts of weight a few years after surgery to reduce the size of the stomach pouch.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story links to an abstract from a randomized trial of the procedure, the story is almost purely dependent on the experience of one person and the comments of an expert: \u00a0\u201cAfter the surgery, Watson says, patients report feeling fuller and less hungry and they ultimately gain greater control over what they are eating. And\u00a0research\u00a0conducted over the past decade suggests it works.\u201d\u00a0The story does not provide any additional details. How well did TORe work in the research? \u00a0Did it work for everyone? \u00a0How long did the researchers follow the subjects?\nIt would have been especially useful, in our opinion, to point out that the weight loss was modest in the intervention group (3.5% from baseline) and that most everyone in the study (including 78% of the control group that received a sham procedure) achieved weight loss or stabilization.", "answer": 0}, {"article": "For the study, the researchers followed 57,872 women in B.C.\nThe study, published today in the British Medical Journal Open, found that low-income pregnant women who receive care from a midwife compared to a physician are less likely to go into early labour, to have a baby with a low birth weight, or to have a small-for-gestational age birth, meaning a fetus or infant that is smaller or less developed than normal for the number of weeks in pregnancy.\nAfter controlling for differences such as age, previous pregnancies, where they lived and pre-existing medical conditions, the researchers found that low-income women who were receiving prenatal care from a midwife had 29 per cent lower odds of a small-for-gestational age birth compared to women who received care from a GP.\nCompared to those who received care from an OB, low-income women receiving midwifery care had a 41 per cent reduction in odds for small-for-gestational age birth, the researchers found.\nThey used maternity, medical billing and demographic data to investigate the odds of small-for-gestational age birth, pre-term birth and low birth weight for low-income women receiving care from a midwife, GP, or OB.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The study looked at three specific pregnancy outcomes:\u00a0 babies who were small for gestational age, had a low birth weight, or were delivered pre-term.The news release said low-income women who received prenatal care from a midwife had a 29% \u201clower odds\u201d of a small-for-gestational age birth compared to women who received care from a general practitioner and a 41% \u201creduction in odds\u201d compared with women who used an obstetrician.\nThis was insufficient for two reasons.\nFirst, it didn\u2019t provide absolute numbers that would give readers an idea of the size of the difference.\nAccording to the study, 7.09% of all births were small-for-gestational age births. Of those who used midwives, 4.83% had small-for-gestational age births, compared with 7.06% of women who used general practitioners and 8.59% of women who used obstetricians.\nSecond, the news release did not give any figures about the study\u2019s findings that women who used midwives were less likely to go into early labor or to have a low birth weight baby.", "answer": 0}, {"article": "Nerve cells in the brain die, and in a few short years, children lose the ability to walk or talk.\nThey usually die within five years of diagnosis.\nThe patients were children who had inherited a mutated gene causing a rare disorder, adrenoleukodystrophy, or ALD.\nFor the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible.\nOne of medicine\u2019s greatest villains: HIV.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes the outcomes for all 17 patients who were enrolled in the study, 15 of whom did not have symptoms of ALD after two years.", "answer": 1}, {"article": "In the new study of 24 patients, scores on a standard test measuring the disturbances of memory, language, attention, and other cognitive skills that are hallmark symptoms of Alzheimer's disease dropped an average of slightly more than five points in those treated with IVIG.\nThe IVIG treatment also appeared to slow the rate of brain shrinkage by about 45%, he tells WebMD.\nThe findings were presented at the American Academy of Neurology meeting.\nIt's a form of intravenous immunoglobulin, or IVIG, drugs that are usually used to treat immune system disorders.\nResearchers believe the drug can replenish a depleted pool of natural antibodies against beta-amyloid protein, which forms the sticky plaques that riddle Alzheimer's patients' brains.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "For reasons described in the Evidence criterion above, we don\u2019t think the story adequately explained what the study found. ", "answer": 0}, {"article": "Vitamin D can be obtained in the diet, particularly from fortified foods, from supplements, and from sun exposure.\n\"This study adds new information that agencies can use when reviewing evidence for vitamin D guidance and suggests that the concentrations recommended for bone health may be lower than would be optimal for colorectal cancer prevention.\"\nOptimal vitamin D concentrations for colorectal cancer prevention may be higher than the current National Academy of Medicine recommendations, which are based only on bone health.\nThese associations persisted even after adjusting for known colorectal cancer risk factors.\nThe few randomized clinical trials of vitamin D supplementation and colorectal cancer completed thus far have not shown an effect; but study size, supplementation duration, and compliance may have contributed to their null findings.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are only presented in relative terms \u2014 not absolute numbers.\u00a0For example: \u201cthose with deficient concentrations of vitamin D had a 31% higher risk of colorectal cancer during follow-up, which averaged 5.5 years (range: 1 \u2013 25 years). Similarly, concentrations above bone health sufficiency were associated with a 22% lower risk.\u201d\nWhile that\u2019s not good enough for a satisfactory rating, we acknowledge that it would probably be quite difficult to provide absolute risk reduction figures based on these data. And the release does provide the lifetime absolute risk of colon cancer in men (4.5%) and women (4.2%) \u2014 which helps contextualize the 22% relative reduction associated with higher vitamin D levels.\nTo meet our standard, however, the release should have attempted to provide some clarity on what that 22% reduction might indicate in terms that are actually meaningful for readers. In other words, if my lifetime risk of colorectal cancer is 1 out of 22 (the rate given for men in the news release), how might a 22% reduction change that risk?", "answer": 0}, {"article": "Post-traumatic stress disorder (PTSD) is a term for a broad range of psychological symptoms that can develop after someone experiences or witnesses a traumatic event.\nThis is called 'reconsolidation', and we now plan to test the effect of doxycycline on reconsolidation of fear memories.\nA week later, under no medication, participants returned to repeat the experiment.\nTo treat such diseases, we already have clinically approved drugs that block these enzymes, including the antibiotic doxycycline, so we wanted to see if they could help to prevent fear memories from forming in the brain.\nThe study, published in Molecular Psychiatry, was a pre-registered, placebo-controlled, double-blind randomised controlled trial in 76 healthy volunteers.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear from the release how statistically strong the results are. The release notes that volunteers taking the antibiotic had a 60% lower fear response in the first session compared to those who took the placebo, \u201csuggesting that the fear memory was significantly suppressed by the drug.\u201d But that number is an average response rate in the treated group and we\u2019d like to see some actual numbers \u2014 the number of responses and the range of responses \u2014 to assess how many people were helped and to what degree.\nThe article published in Molecular Psychiatry also reports only the approximate percentage of study volunteers who experienced a reduced reaction to the fear marker, so there are no absolute numbers that could be taken from the study and used in the news release. However, communications staff and journalists are the eyes and ears for readers and it behooves them to seek clarity from the authors of research.", "answer": 0}, {"article": "In the 1960s sitcom Leave It to Beaver, Beaver Cleaver was so impressed by his dad's tales of ice cream and pretty nurses that he schemed to have his tonsils out, even though he didn't need it.\nThat's a far cry from the 1950s and '60s, when tonsillectomy was used to fight frequent sore throats.\nDespite hundreds of studies, there's still surprisingly little research on whether tonsillectomy really helps reduce the risk of sore throats.\nObviously, parents could use some help in deciding whether surgery is needed.\nThey'd recommend surgery if a child has five or more throat infections a year for two years, or three or more in three years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are never quantified, which is a big problem in this case because so much time is spent on the anecdotal family in the lead. We can\u2019t understand why a headline this bold was put on a story that actually takes pains to point out the lack of evidence supporting tonsil surgeries.", "answer": 0}, {"article": "\"We're kind of on the edge of this becoming more accepted.\"\nUp to now, however, there's been little evidence showing that a calcium scan can provide a solid assessment of a person's long-term health risk, the study authors said in background information.\nPeople with many calcium deposits can improve their long-term prospects by eating right, exercising, and taking medication to treat heart risk factors such as high blood pressure, elevated blood cholesterol and type 2 diabetes, Shaw said.\nThe results of a calcium scan can be reassuring for people with few or no calcium deposits, and can provide people with high calcium levels with added impetus to take better care of themselves, Shaw said.\nThe test, called a coronary calcium scan, uses a regular CT scan to look for calcium deposits in the three major arteries that carry blood away from the heart, said lead author Leslee Shaw, a professor of cardiology at Emory University in Atlanta.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that CAC testing can provide health benefits, but that\u2019s not what the study looked at.\nThe story includes a claim by an expert that this study confirms the usefulness of CAC testing for determining the best treatment of people who do not have symptoms of heart disease, but do have high cholesterol or a family history of heart problems. However, the research article cautions that, \u201cDespite evidence of increased risk, current effectiveness evidence does not support targeted treatment of patients with high-risk CAC scores to improve outcomes.\u201d In other words, even if people in this study who had higher scores were more likely to die, this study does not provide any evidence that more or different treatment would extend their lives.\nThe story also quotes a researcher saying that telling someone they have a high CAC score \u201ccan be a very potent motivator\u201d for changing lifestyle or sticking with treatment. However, once again, the actual text of the research article undercuts this claim, noting that any effect of CAC test results on patient behaviors \u201ccannot be quantified\u201d. What\u2019s more, health behavior literature generally indicates that test results by themselves tend to have little effect on people\u2019s behavior, unless ongoing support is provided.\nLastly, the story describes a 68% increase in risk of death for those with small amounts of CAC and a risk that was \u201c6 times greater\u201d for those with another group. But these are relative comparisons that are difficult to interpret. It would have been easier and more informative to simply give the absolute rate of death in each group as the study did \u2014 these rates were 3% in the zero CAC group, 6% for those with small amounts of CAC, and 28% for those with large amounts of CAC.", "answer": 0}, {"article": "Researchers at Brigham and Women's Hospital and Harvard Medical School set out to test melatonin's effects...\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nThat's why there's so much interest in a study in the current issue of the journal Sleep.\nDo melatonin supplements really help people sleep?\nThere's no question that the hormone helps the brain tell a.m. from p.m.--regulating sleep cycles and circadian timing--when it is produced naturally by the body at night.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit of treatment, an extra half-hour of sleep compared with control subjects in a trial, was presented. Kudos for clearly laying out that the gain in sleep time was not helpful for all insomnia \u2013 only that from change in time zone or shift work.", "answer": 1}, {"article": "After adjusting for non-modifiable stroke risk factors (such as age and family history), researchers found stroke risk among women who breastfed their babies was on average:\n\u2022 19 percent lower in women who had breastfed for up to six months.\nHowever, because the Women's Health Initiative is large, researchers were able to adjust for many characteristics, and the effects of breastfeeding remained strong, Jacobson said.\n\u2022 Available multimedia including photos and an audio interview are on the right column of the release link - https:/\n\u2022 Story on previous JAHA study (June 21, 2018): Breastfeeding may reduce a mother's heart attack and stroke risk\n\u2022 For updates and new science from JAHA, follow @JAHA_AHA\n\nStatements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position.\nResearchers analyzed data on 80,191 participants in the Women's Health Initiative observational study, a large ongoing national study that has tracked the medical events and health habits of postmenopausal women who were recruited between 1993 and 1998.\nThis is among the first studies to examine breastfeeding and a possible relationship to stroke risk for mothers, as well as how such a relationship might vary by ethnicity.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a tough one to call. The release clearly lays out the research findings that breastfeeding is associated with reductions in stroke risk, even breaking it down by subgroups. That\u2019s good. However, the release only tells readers about relative reductions in risk, as opposed to absolute reductions in risk. What does that mean? Well, let\u2019s say that the women in a study have a 0.25% risk of getting Disease X. If the study reports that a specific behavior doubles the risk of Disease X, that sounds like a big deal \u2014 a 100% increase in risk! But that\u2019s a 100%\u00a0\u00a0relative increase in risk. The absolute risk would go from 0.25% to 0.5%. The difference between relative and absolute risk is something HealthNewsReview.org has written about, and it is a key distinction that we feel is important. So, when the release tells us that breastfeeding was associated with a 23% decrease in stroke risk, readers still don\u2019t know what that means in terms of absolute risk. And because the baseline absolute risk numbers aren\u2019t mentioned, savvy readers can\u2019t even do the calculation for themselves.", "answer": 0}, {"article": "Chronic idiopathic constipation is a diagnosis given to those who experience persistent constipation and for whom there is no structural or biochemical explanation.\nThe safety and effectiveness of Trulance have not been established in patients less than 18 years of age.\nTrulance should be avoided in patients six years of age to 18 years of age.\nThe safety and efficacy of Trulance were established in two 12-week, placebo-controlled trials including 1,775 adult participants.\nTrulance should not be used in patients with known or suspected mechanical gastrointestinal obstruction.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As noted in the summary above, the release did not provide readers with a realistic picture of the actual rate of improvement over placebo in the two clinical trials cited by the FDA in its approval process.", "answer": 0}, {"article": "Newswise \u2014 Columbus, OH.\nThe team\u2019s next move is to focus on the bioelectric bandage as a treatment for chronic wounds in a patient population; however, the technology could also be used to treat acute injuries.\nMade of silk and silver, the experimental dressing includes a self-contained battery that delivers a continuous, safe, low-level electrical current to the injury.\nThe patch\u2019s design significantly advances existing FDA-approved wireless electroceutical dressing (WED) that harnesses the body\u2019s innate response to injury to help wounds heal.\nEarly results, which were presented at the Wound Healing Society\u2019s Annual Meeting in April 2016 indicate that infected wounds covered by the experimental bioelectric dressing healed better and more quickly than those covered with a plain dressing that is commonly used in the care of wounds today.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No quantification of benefits is provided. A scientist is quoted as saying the research takes the technology \u201cto the next level\u201d and that they have \u201coptimized the bandage\u2019s design and the amount of electrical current delivered\u201d allowing \u201celectric fields and currents to penetrate more deeply into wounds, and really get to where these biofilms may be hiding,\u201d but offers no data to support the claims.\nIn comparing the technology to traditional dressings, the release states that \u201cinfected wounds covered by the experimental bioelectric dressing healed better and more quickly than those covered with a plain dressing that is commonly used in the care of wounds today.\u201d\u00a0 We aren\u2019t given any data on what \u201chealed better\u201d\u00a0 and \u201cmore quickly\u201d actually means.", "answer": 0}, {"article": "that its retinal cells contained virtually no residual embryonic stem cells.\nAlso, he said, there is less chance of rejection of the implanted cells because the eye is shielded somewhat from the body\u2019s immune system.\nThe hope is that the implanted cells will replace those injured by the disease.\nDr. Peter J. Francis, an associate professor at the Oregon Health and Science University, which will be a site for the trial, says the eye is a good place to test stem cell therapy because it is accessible.\nIt is likely to be several years before such a treatment can reach the market, if it works.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A pretty good job here. The story notes that the major benefit of the new drug over existing treatments would be the potential for less frequent dosing and follow-up visits. It also quantifies the benefit in terms of the numbers of letters and lines that were legible on any eye chart \u2014 a metric that should have \u201creal-world\u201d significance for most readers.", "answer": 1}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The piece states that statins reduced the rate of deaths by half compared to those not taking statins; however, it would have been more useful to the reader had the results been presented in terms of absolute risk reduction. (See our primer on absolute vs. relative risks.)\u00a0 ", "answer": 0}, {"article": "It needs to be tested in large trials,\" he said.\nIn this latest trial, researchers found that routinely removing clots was not beneficial, Jolly said.\nAnother trial in 2013, however, suggested that removing clots was not beneficial, he added.\nHowever, preliminary results from small trials of mechanical clot removal have not been promising, Jolly noted.\nJolly said the lesson from his team's trial is that clot removal should be used only as a rescue treatment when an angioplasty fails to clear an artery.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports the absolute difference in the primary composite outcome in the two groups in this study (in fact there was no difference between those groups, indicating no added benefit for clot removal), which earns the story a satisfactory rating here.\nWith that being said, the general benefits of angioplasty are not really discussed in the story. The assumption made is that after a heart attack, where clogged arteries occur, angioplasty is an accepted and effective treatment.\u00a0 A bit of background on angioplasty as a treatment and stent placement might have filled out this story and made it clearer why these two approaches were being evaluated in the first place.", "answer": 1}, {"article": "Olive oil users may, for example, have higher incomes, eat better overall or exercise more often than people who never use the oil.\nThe findings, according to Scarmeas, argue for more research into olive oil\u2019s potential benefits against not only heart disease, but stroke and other neurological diseases as well.\nAnd after they did, olive oil was still linked to a lower stroke risk.\nPeople who said they used olive oil for both cooking and as a dressing were considered \u201cintensive users.\u201d\n\nOver the next five to six years, those intensive users suffered strokes at a rate of 0.3 percent per year.\nThe study found a correlation between people\u2019s olive oil use and their stroke risk, he told Reuters Health \u2014 but that doesn\u2019t necessarily translate into cause-and-effect.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story did the best job of the three stories we reviewed in quantifying the potential benefits observed in the study.\n\u201cOver the next five to six years, those intensive users suffered strokes at a rate of 0.3 percent per year. That compared with just over 0.5 percent among non-users, and 0.4 percent among moderate users.\nWhen the researchers factored in other diet habits, exercise levels and major risk factors for stroke \u2014 like high blood pressure and diabetes \u2014 heavy olive oil use was tied to 41 percent reduction in the odds of stroke.\u201d\nThere are better ways to try to communicate numbers of less than one percent.\u00a0 But we applaud the detail provided.", "answer": 1}, {"article": "Most Australian adults have been infected with the herpes zoster virus and are at risk of shingles, even if they do not remember having chicken pox.\nThe vaccine also contains an adjuvant--a substance that helps your body fight off the virus.\nLead researcher Professor Tony Cunningham from the Westmead Institute for Medical Research said the study shows that the vaccine stimulates production of a specific immune memory cell (CD4 T cells), generating a strong and sustained protection against the virus.\nA new study has shown how the body's immune system responds to the new shingles vaccine, Shingrix, making it more than 90% effective at protecting against the virus.\nWe are seeing results comparable to those of childhood vaccinations.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The primary benefit being reported here is that \u201c90% of recipients had an increased immune response sustained across the 3-year duration of the study.\u201d\u00a0 It would have been more helpful if the release had noted the actual incidence of shingles in those vaccinated with the new vaccine versus the old (or no vaccine).\nThe news release says the study \u201cshows that the vaccine stimulates your immune system to produce more antibodies and it generates a 24-fold increase in T cells. This is 12 times higher than other less effective shingles vaccines.\u201d T cells are white blood cells that kill infected cells.\nWe did have some concerns with a statement in the release projecting how long the vaccine protects against shingles. The release quotes a researcher saying, \u201cWe anticipate that this protection will actually last much, much longer. We are now measuring the efficacy of the vaccine over the next 10 years and are very optimistic about the results.\u201d However, it doesn\u2019t say when and if that will translate into a benefit for patients.", "answer": 1}, {"article": "Feb. 6, 2012 -- You may have heard about brown fat -- a unique type of fat that acts like a furnace in the body to burn calories instead of storing them as excess weight.\nIf studies show the same thing in humans, the heart hormone may hold the key to an effective weight loss treatment, says researcher Sheila Collins, PhD, of Sanford-Burnham Medical Research Institute in Orlando, Fla.\n\u201cThese hormones are involved in fluid regulation, but we showed in this study that they also play a role in breaking down fat,\u201d she says.\nResearchers found that the hormones, known as cardiac natriuretic peptides, caused regular energy-storing white fat cells to turn into energy-burning brown fat in mice.\nAdults don\u2019t have much brown fat, but a new study suggests that hormones produced by the heart just might help them make more.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story suggests that certain heart hormones, if they behave the same way in humans as they do in mice, may hold \u201cthe key to an effective weight loss treatment.\u201d We think this is a premature and misleading statement. Even if these hormones do activate brown fat in humans (something yet to be determined), there\u2019s no guarantee this will translate into weight loss or that the weight loss that is produced will be safe or beneficial (see more under the \u201charms\u201d criterion).", "answer": 0}, {"article": "Follow her on Twitter @drfernstrom.\nWhile the study has many limitations because it doesn\u2019t take into account genetic or lifestyle factors that are proven important in both heart disease risk and longevity, it suggests that blood cholesterol levels are only one factor.\nBut that\u2019s a misleading association because a variety of illnesses can also cause drop in cholesterol, which is unrelated to diet.\nThe new report, which analyzed 40-year-old data from the Minnesota Coronary Experiment, found no association between lower cholesterol levels and longer life, suggesting that reducing the amount of saturated fat in the diet isn\u2019t enough to reduce risk of death from heart disease.\nIn fact, the study found that the lower the cholesterol, the greater the risk of death.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify. We are told the 45-year-old data showed a \u201clowering\u201d of cholesterol for study participants who swapped animal fats for vegetable fats. But we aren\u2019t given any numbers for by how much or even by what percentage.\nIn a similar shortcoming, one of the most counter-intuitive findings was dismissed.\n\u201cIn fact, the study found that the lower the cholesterol, the greater the risk of death. But that\u2019s a misleading association because a variety of illnesses can also cause drop in cholesterol, which is unrelated to diet.\u201d\nThe story should have given us some numbers for that \u201cgreater risk.\u201d Even if it is misleading, we are entitled to know the size of the risk found in the study.", "answer": 0}, {"article": "Patients with cancers of the immune system, like multiple myeloma, are especially susceptible to common infections, and a bout of the flu can lead to serious illness and even death.\nThe booster strategy lowered the flu infection rate among patients to 6% versus an expected rate of 20%, and it improved protection against all flu strains covered by the vaccine in 66% of patients, said the study's first author Andrew Branagan, M.D., a postdoctoral associate in medicine (hematology).\nThe Yale researchers developed a strategy that entailed offering patients a high-dose flu vaccine followed by a second high-dose booster shot one month later.\nThe high-dose vaccine (Fluzone High-Dose) was approved in 2009 by the FDA as a single dose for adults over 65.\nEven though patients with multiple myeloma and other plasma cell disorders may receive an annual flu vaccine, studies show that a one-time flu shot does not offer adequate immune response.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that the flu infection rate fell to 6% in the patients who received a booster vaccine 30 days after the first shot, compared to the \u201cexpected\u201d rate of 20% infection. We\u2019d much rather see actual numbers here than percentages. How many people were vaccinated with the follow-up booster shot? Was there a comparison group that received only one high-dose shot during the same flu season?\nThe release also claims that the booster strategy protected against all flu strains in 66% of patients.\u00a0 Again, 66% of how many?\nThe study was small with just 51 patients. To say the vaccine lowered the infection rate to 6% is misleading because there was no comparison group. It would have been helpful to point out that a 6% infection rate is lower than historical controls, but that the effectiveness needs to be studied in a controlled clinical trial to really see the benefit.", "answer": 0}, {"article": "And for the test to be useful, \"you've got to find cancer that's going to otherwise be lethal, and not cancer that would otherwise be destined to do nothing,\" Prasad says.\nOf course, the ultimate goal of this test is to find cancer in people who haven't already been diagnosed.\nAn effective screening test would hold lots of potential for cancer patients, Prasad says.\nBut Schiffman points out that there are many issues to work out \u2013 even assuming the test proves reliable among people who have not been previously diagnosed with cancer.\nTheir experience will help answer the next big question, which is whether CancerSEEK will pick up cancer in people who don't have symptoms.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes the two key results of the test quite clear. First, that the 1,005 people tested already had been diagnosed with one of eight common cancers, and the blood test was able to detect cancer in about 70 percent of them. Second, the test was also given to 812 people without cancer and only a false reading for cancer less than 1 percent of the time.\nIncluding the additional finding that the test was only able to detect cancer in about 40 percent of the patients with early cancer (ie. stage I) was a thoughtful way of introducing the relevant issue of falsely negative tests.", "answer": 1}, {"article": "None had been diagnosed with breast cancer.\nBut the review of female patients between the ages of 40 and 44 found that 50 percent had an above-average risk for breast cancer, and therefore would be eligible to begin screening mammography at age 40, said lead researcher Dr. Jennifer Plichta.\nBreast cancer risk assessments are typically not a part of standard care for this age group, the researchers noted.\nThe study also found a significant percentage of women would qualify for other breast screening methods, including breast MRI and genetic testing, Plichta said.\nThe finding is important because the latest guidelines on mammograms advise that most women can wait until the age of 45 or 50 to start having annual screenings.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is the claim of benefit made in the story: \u201cMany women could benefit from earlier mammograms, analysis finds.\u201d But this claim is left unsupported, only describing the number of women at higher risk identified by the study. Of the women identified, what number would actually go on to experience some meaningful beneficial outcome like detection of an invasive cancer, or more importantly, a longer life? Even if the study didn\u2019t dig into those numbers, it\u2019s crucial to explicitly state in the story that the numbers reported don\u2019t reflect the actual number of women who might experience a meaningful benefit\u2013only the number who would be screened.", "answer": 0}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us that in one study, \u201c32% of subjects on Deplin had responded, compared with 15% on the placebo.\u201d Although\u00a0 this is better than saying simply that twice as many patients responded to Deplin as to placebo\u00a0(which is how some stories would no doubt have communicated this statistic), the story never says\u00a0how the researchers defined \u201cresponse\u201d to the medication, which is an important omission. Typically, a \u201cresponse\u201d\u00a0means that patients had a >50% reduction on a depression symptom scale, but readers of this story can\u2019t be expected to know this.\nIn addition, there are other trials with different formulations of folate (some that can be purchased over the counter for pennies per pill) that are relevant to the evidence.\u00a0 Collectively, these trials raise the possibility that the forumulation (L-methylfolate, folinic acid, or folic acid) may be important.", "answer": 0}, {"article": "The first line of defense are anti-perspirants.\nIn the first trial, a significant improvement in the severity of sweating was seen in 52.8 percent of the patients treated with the drug, compared with 28.3 percent patients in the control group, on a scale designed by the company.\n(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\nAbout two-thirds of the total 697 enrolled in the two trials for the company\u2019s topical treatment, DRM04, were treated with wipes containing DRM04, while the rest were not.\nIn the second trial, a significant improvement was seen in 66.1 percent of the drug-treated patients, compared with 26.9 percent in the control group.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Not enough detail is contained in the description of the drug\u2019s benefits: \u201ca significant improvement in the severity of sweating was seen in 52.8 percent of the patients treated with the drug, compared with 28.3 percent patients in the control group, on a scale designed by the company. (and\u00a066.1 percent versus\u00a026.9 percent in the control group in the second trial).\nHow are we to know what this means\u00a0when we don\u2019t know how \u201cimprovement\u201d or \u201cseverity\u201d is measured?", "answer": 0}, {"article": ".\nDr. Sharaiha noted that these findings do not suggest that endoscopic sleeve gastroplasty will replace the two surgical treatments as weight-loss interventions.\nWhen examining cost, researchers reported endoscopic sleeve gastroplasty resulted in the lowest-cost, with an average institutional procedure cost of $12,000, compared to $22,000 for laparoscopic sleeve gastrectomy and $15,000 for laparoscopic banding.\nInstead, these results show that endoscopic sleeve gastroplasty is another possibility that patients and health-care providers should consider when discussing options.\nResearchers found that patients who received endoscopic treatment had lower complications (1 percent) than those who received surgical treatment (10 percent for laparoscopic sleeve gastrectomy and 11 percent for laparoscopic banding).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a direct comparison between the three procedures: \u201cAt one-year follow-up, patients who chose laparoscopic sleeve gastrectomy surgery achieved the greatest percent total body weight loss at 29.28 percent, compared to 17.57 percent for [ESG] patients and 14.46 percent for laparoscopic banding patients.\u201d That earns it a satisfactory rating. However, based on an abstract of the conference presentation, the researchers also collected data on weight loss 18 months after the procedure. This raises the question: why didn\u2019t they include the 18-month follow-up numbers here? In addition, the release would have been stronger if it had told readers whether there was any significant variation between the patients who had the various procedures. For example, were the patients who had the gastrectomy procedure more obese to start with? Or were there differences in age across groups?\nIn addition, following surgery the patient volunteers all went to a weight-loss \u201ccenter of excellence\u201d for a full year. \u00a0The release doesn\u2019t mention whether that made a difference in the results within each group or among the entire group. In any case, \u00a0this year-long stay at a weight loss center after a procedure is not likely to be replicated in other studies and in the real word.", "answer": 1}, {"article": "It matters.\nThe current standard treatments for metastatic melanoma -- chemotherapy and interleukin-2 (IL2) -- only have response rates in about 15 percent of these patients, said Dr. Paul Chapman, senior author of a study in which the findings are described.\nThe drug, PLX4032, just completed a phase 1 clinical trial in which 81 percent of participants with a particular gene mutation had a partial response, meaning at least some shrinkage of the tumor.\nThat finding opened the door to potential targeted, molecular therapies for melanoma, which has been sorely lacking in effective treatments.\nOne expert cautioned that it's too early to say whether the drug will actually prolong patient's lives, or if it might be helpful to patients in earlier stages of the disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The\u00a0story does a good job of\u00a0quantifying the benefits. It explained that 81% of patients had a partial response, meaning some shrinkage\u00a0of the tumor,\u00a0and gives the absolute number of people this represents. It also explains that the drug is effective in only the 50% of advanced melanoma\u00a0patients with a\u00a0specific\u00a0genetic mutation.\u00a0Although\u00a0it cautions that a \"sizable proportion\" of patients developed\u00a0resistance to the drug,\u00a0we wish it had been a bit\u00a0more precise in\u00a0its\u00a0characterization of this problem.\u00a0\u00a0\u00a0", "answer": 1}, {"article": "There were 812 deaths (32.2 percent) among heart failure patients not treated with Plavix and 709 deaths (28.1 percent) among heart failure patients treated with Plavix.\nMONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\nThe mean follow-up was 18 months for both heart failure groups and just over two years for both non-heart failure groups.\nThere were 294 deaths (9.7 percent) among non-heart-failure patients not treated with Plavix and 285 deaths (9.4 percent) among non-heart failure patients who were given the drug.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided absolute numbers for two categories of patients who had had heart attacks and did not have angioplasty. \u00a0In the first group, the chance of survival for those with heart failure at 18 months appeared to be higher for those that took Plavix than those who did not. \u00a0In the second group, at two years, there did not appear to be a difference in survival between those without heart failure whether they took the drug or not.\u00a0\nWhile presenting the reader with the quantitative results, the story neglected to indicate if the differences observed were statistically significant.\nIt would also have been helpful to note the number needed to treat:\u00a0 37 heart failure patients would need to be treated for a year in order for one life to be saved.\u00a0 For non-heart-failure patients, 667 patients would need to take the drug for a year in order for one life to be saved. ", "answer": 1}, {"article": "Behavioral counseling is widely recommended, with medication, to help smokers quit.\nBetter strategies are needed to prevent relapse, he tells WebMD.\nThe findings are at odds with clinical trials, Connolly says.\nThe results of the new study are published online in Tobacco Control.\nSmoking cessation experts and a maker of nicotine replacement therapies took issue with the findings.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story, like the others, provides no hard numbers for quantifying the benefits, but we thought it did an adequate job explaining what the study found. Unlike the NY Times and LA Times stories, this one provided accurate information about the number of subjects who started and completed the study.\nAll three of the stories have the same problem of not explaining whether ultimately two-thirds of the study participants relapsed or the same one-third relapsed at two different intervals.\nNonetheless, we\u2019ll give the story the benefit of the doubt with a satisfactory score on this.", "answer": 1}, {"article": "We've found a way to block CatK only in bone tissue that we think will prevent these other negative effects.\"\nThe study builds on previous research by Br\u00f6mme and his team that looked at the effectiveness of red sage, known as Danshen in Chinese and used to treat bone ailments, in stopping the activity of CatK in limited ways.\nThey found that it prevented bone loss and increased the bone mineral density of the mice treated with the compound by 35 per cent, when compared with the control group.\nThe researchers tested a compound derived from red sage in human and mouse bone cells and a mouse model.\nThe treatment could also potentially be used to treat a variety of other bone and cartilage diseases such as arthritis and certain bone cancers.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release says the red sage compound was tested \u201cin human and mouse bone cells and a mouse model. They found that it prevented bone loss and increased the bone mineral density of the mice treated with the compound by 35 per cent, when compared with the control group.\u201d\nThe release should have mentioned that benefits shown in mice don\u2019t necessarily translate to humans. The release doesn\u2019t provide any results relating to the chemical compound\u2019s effect on the cells that were tested.\nFurther, bone mineral density doesn\u2019t precisely measure fracture risk, which is what matters to patients. None of these important caveats are mentioned.", "answer": 0}, {"article": "Minimally invasive procedures increased to 31 percent of all radical prostatectomies in 2005 from 12.2 percent in 2003.\nBut the surgery increases the chance for longer term problems that require further therapy, the research says.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\nThe study, published on May 10 in The Journal of Clinical Oncology, examined a sample of 2,702 Medicare patients undergoing radical prostatectomy, the complete removal of the prostate, from 2003 to 2005.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article does a thorough job of describing the findings by specifying the percentage of patients who had minor and more serious complications. It also compares days spent in the hospital.\u00a0 \nHowever, the article reports a 27 percent reduction in risk of short-term complications and a 40 percent greater risk of scarring without indicating the underlying risks for either of these outcomes.\u00a0 See our primer on absolute versus relative risk statements. ", "answer": 1}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated that \u201cThey found that during the study, patients who received candesartan were 66 percent less likely to develop true hypertension than those who received the placebo.\u201d That\u2019s a relative risk reduction (or benefit, depending on how you view it); but readers would be better guided by the absolute risk reduction figures. ", "answer": 0}, {"article": "Melanoma is one of the most common forms of cancer and the most serious type of skin cancer.\nThe researchers found that in nearly all cases, the IMS analysis was a more accurate predictor, both of benign lesions and melanomas, than standard microscopic examination.\nFor the study, a former associate professor of Dermatology and Pathology at Yale University, Rossitza Lazova, M.D., collaborated with a national and international team of researchers to determine whether atypical moles could be more accurately diagnosed as either benign or cancerous (melanoma) using imaging mass spectrometry (IMS) \u2014 a technology that enables pathologists to focus in on individual proteins within sampled skin cells.\nIn this study, mass spectrometry correlated better than the gold standard of histologic examination to determine if an atypical mole was in fact benign or a melanoma.\n\u201cThis test integrates anatomic pathology and analytical chemistry in a very useful and meaningful way.\u201d\n\nThe finding suggests that IMS analysis, based on proteomic signatures, may improve both diagnosis and prediction of outcomes for patients with ambiguous moles, the researchers said.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A report on a diagnostic procedure should at the very least tell readers the proportion of patients with disease who tested positive (sensitivity) and the proportion of patients without disease who tested negative (specificity). Neither the news release nor the study on which it\u2019s based offer these numbers.\nIn fact, there are no figures in the news release summarizing the accuracy of IMS in diagnosing the 102 ambiguous tumors included in the study, or comparing it with the accuracy of using a microscope. In each case, the initial diagnosis with a microscope was compared to a diagnosis of the same tumor with IMS and the patient\u2019s clinical outcomes. According to our review of the study data, IMS correctly identified as benign 38 tumors that had been classified as ASM, or indeterminate, when previously examined under a microscope.\nThe news release offers this quote from a researcher: \u201cInstead of pathologists being dependent solely upon the physical appearance of the cells, they now have the additional advantage of molecular information regarding the protein makeup (of cells) provided by mass spec imaging. \u2026 This test integrates anatomic pathology and analytical chemistry in a very useful and meaningful way.\u201d\nIf it\u2019s useful and meaningful, there should be data showing how. In addition, even some reporters without a strong grasp of statistics may have difficulty gleaning the numbers from the published manuscript. That makes it even more important to include reliable data in a news release.", "answer": 0}, {"article": "Millions of Americans suffer from pet allergies that prevent them from enjoying the benefits of owning a dog or a cat.\nShe consulted an allergist at Weill Cornell Medicine/New York-Presbyterian Hospital, where a clinical trial involving immunotherapy toothpaste was taking place.\nJoyce, who lives in the Bronx, New York, signed on for the year-long study that required six of the 12 volunteers to brush their teeth for two minutes using two pumps of the toothpaste in either the morning or night, and the other six to use drops under their tongue.\nVolunteers using the toothpaste were also required to log their usage in a journal.\nI was really uncomfortable and miserable.\u201d\n\nJoyce tried over-the-counter medications but couldn\u2019t find relief.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no quantification of benefits in this story, period. \u00a0It states that both groups in the trial \u201creported a significant decrease in their symptoms,\u201d but offered no numbers to back that up. Nor do we know exactly what \u201csymptoms\u201d they are referring to that supposedly decreased. Where these the itchy, watery eyes and sneezing or where they more subtle symptoms? The only other \u201cresults\u201d are basically a testimonial from one participant, which has little or no value to readers.", "answer": 0}, {"article": "LONDON (Reuters) - British scientists conducting early-stage research have found that a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia(MLL) \u2014 the most common form of leukemia in babies.\nIn a study published in the journal Nature, scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151, mimics a chemical tag which is key to preventing the process of activating the leukemia genes.\nUsing I-BET151 to treat leukaemias in mice and human cancer cells in a lab, the researchers found that the chemical could halt the disease, paving the way for more research to be done in first-stage, or so-called Phase I, human trials.\n\u201cIt is important to remember we will need to be successful on a number of additional steps before we can move this from the lab to testing this compound in humans.\u201d\n\nMLL leukemia is thought to account for up to 80 percent of cases of acute leukemia in children below two years old, and up to one in 10 cases in adults.\n\u201cWe urgently need better ways to treat children with more aggressive forms of leukemia, such as MLL,\u201d said Lesley Walker, CRUK\u2019s director of information.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Inadequate explanation.\u00a0 See \u201cevidence\u201d criterion above. While the story does provide several qualifications, it fails to place this very early research into perspective. Given the tortuous road to a drug\u2019s demonstration of effectiveness and eventual approval any suggestion of patient benefit (such as \u201cearly potential\u2026could treat\u2026could halt the disease\u201d) is excessive.", "answer": 0}, {"article": "USUALLY NOT THE FIRST STEP\n\n\u201cI have a long list of chronic pain patients coming to seek acupuncture,\u201d said Jongbae Park, head of Asian Medicine & Acupuncture Research at the University of North Carolina at Chapel Hill School of Medicine.\nBut patients treated with fake or \u201csham\u201d acupuncture - using retracting needles that don\u2019t stick in the skin, for example - estimated their pain at somewhere in between the other two groups, suggesting that they also got some benefit from the procedure.\nIt\u2019s usually \u201cnot their first approach to address the condition,\u201d he said - rather people seek acupuncture when traditional care fails to stop their pain.\nThey estimated in their Archives of Internal Medicine report that about 50 percent of patients had their symptoms cut in half with acupuncture, compared to almost 43 percent of those treated with sham acupuncture and 30 percent with no acupuncture-like therapy.\nPark, who was not involved in the new study, said acupuncture focuses on healing the underlying tissue injury that is causing pain, rather than treating the pain itself as medications would.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story puts the benefits in terms readers can understand and that accurately reflects the magnitude of the benefit: \u201c\u2026about 50 percent of patients had their symptoms cut in half with acupuncture, compared to almost 43 percent of those treated with sham acupuncture and 30 percent with no acupuncture-like therapy.\u201d", "answer": 1}, {"article": "Dr Joanna Bowtell, head of Sport and Health Sciences at the University of Exeter, said: \"Our cognitive function tends to decline as we get older, but previous research has shown that cognitive function is better preserved in healthy older adults with a diet rich in plant-based foods.\nIn the study, healthy people aged 65-77 who drank concentrated blueberry juice every day showed improvements in cognitive function, blood flow to the brain and activation of the brain while carrying out cognitive tests.\nCompared to the placebo group, those who took the blueberry supplement showed significant increases in brain activity in brain areas related to the tests.\n\"In this study we have shown that with just 12 weeks of consuming 30ml of concentrated blueberry juice every day, brain blood flow, brain activation and some aspects of working memory were improved in this group of healthy older adults.\"\nThe new paper, \"Enhanced task-related brain activation and resting perfusion in healthy older adults after chronic blueberry supplementation\", is published in the journal Applied Physiology, Nutrition and Metabolism.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release gives us the broadest brush about benefits, but does not provide numbers or quantify how much improvement occurred.\nIt states that \u201cbrain blood flow, brain activation and some aspects of working memory were improved in this group of healthy older adults\u201d\u00a0 and\u00a0 \u201cCompared to the placebo group, those who took the blueberry supplement showed significant increases in brain activity in brain areas related to the tests.\u201d\nHow much improvement was there? How did brain activity change before and after taking the supplement?\nBut even with those numbers, brain activity is not a clinically meaningful measure. It\u2019s a surrogate end point, not a measurable clinical benefit. ", "answer": 0}, {"article": "Aneurysms are weakening, or bulging, of blood vessels that can rupture and become life-threatening.\n\u201cPrior to gaining approval from the Food and Drug Administration, patients with many types of aneurysms and aortic conditions had limited treatment options,\u201d said Azizzadeh, director of Vascular Surgery at the Smidt Heart Institute at Cedars-Sinai.\nCompared to other technologies, the stent graft can travel through smaller, curvy vessels and better adjust to a patient\u2019s anatomy.\nNewswise \u2014 LOS ANGELES (Dec. 5, 2018) - Vascular surgeon Ali Azizzadeh, MD, was the first to use a newly approved, minimally invasive device to perform a series of innovative surgeries on patients with aneurysms of the aorta, the main vessel that delivers blood from the heart to the rest of the body.\n\u201cNow, patients can undergo a minimally invasive procedure to fix complex problems of the aorta without having open surgery.\u201d\n\nThe Valiant Navion\u2122 thoracic stent graft system is delivered from a groin blood vessel into the aorta, is positioned above the affected aneurysm, and is deployed under x-ray guidance.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No benefits were mentioned other than this treatment might be better than open surgery. The surgeon points out that:\u00a0\u201cNow, patients can undergo a minimally invasive procedure to fix complex problems of the aorta without having open surgery.\u201d \u00a0We have consistently advised readers to be wary of claims about \u201cminimally invasive procedures.\u201d", "answer": 0}, {"article": ".\nThe study shows that for adults aged 75 years and older with high blood pressure, a systolic blood pressure goal of less than 120 mm Hg reduced rates of cardiovascular events, such as heart attack and heart failure, as well as stroke, by 33 percent.\nTo address this issue, the SPRINT study tapped more than 2,600 volunteers aged 75 and older, assigning half to a target blood pressure of less than 140 mm Hg and half to target of less than 120 mm Hg.\nThese additional results of the Systolic Blood Pressure Intervention Trial (SPRINT) appear in the current online issue of the Journal of the American Medical Association (JAMA).\nAlthough the standard blood pressure treatment goal is 140 mm Hg, various medical panels have provided inconsistent guidance about what is the optimal blood pressure goal for the senior population.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release points out that those study participants whose blood pressure goal was 120 mm of mercury had 33 percent fewer cardiovascular events, such as heart attacks or heart failure, and had a 32 percent reduction in the risk of death, compared to those participants with a higher goal.\u00a0 Based on this, it recommends that people 75 and older benefit from a lower systolic blood pressure.\nBut these numbers don\u2019t tell the whole story. It should be noted that these relative reductions correspond with absolute risk reductions of only about 0.8 to 1.3 percentage points \u2014 reflecting a number needed to treat (NNT) of roughly\u00a0100. In other words, approximately 100 people need to be treated to this target in order for 1 person to experience an improved outcome. The other 99 don\u2019t benefit but have the potential to experience adverse effects.", "answer": 0}, {"article": "Jay Konduros used to rush home several times a year after accidentally cutting or bumping himself.\nThe treatment also \u201cnearly universally eliminated\u201d the need for preventive infusions of clotting factor a few times a week, the scientists said.\nThe results, published Wednesday online in the New England Journal of Medicine, represent \u201canother example of the gene-therapy renaissance,\u201d Matthew Porteus, a pediatrician at Stanford University, wrote in an accompanying editorial.\nThe researchers presented earlier findings on the gene therapy a year ago at the American Society of Hematology's annual meeting, but the latest data covers a larger patient group and a longer time period.\nIn addition, he said, researchers need to find ways to provide the therapy to a broader group of people, including children, and to figure out how to reduce the costs involved.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story summarizes the outcome of the small, 10-person trial that dominates this narrative:\nLindsey George, the lead investigator and a hematologist at Children\u2019s Hospital of Philadelphia, said that nine of the 10 men in the trial didn\u2019t experience any bleeding episodes after the gene therapy treatment. The one patient who needed clotting factor because of bleeding used 91 percent less than before, she said.", "answer": 1}, {"article": "\u201cIf screening is going to work, you\u2019ve got to keep at it.\u201d\nThis latest study, published in the journal Lung Cancer, looked at death rates in a different, smaller population of heavy smokers, and estimated that those who received up to two CT scans would have between a 36 and 64 percent lower risk of dying, compared to those who went unscreened.\nThe results are in keeping with those of a much larger study published last month, which showed that these 3-D X-rays, or CT scans, reduced the death rate among 53,000 current and former heavy smokers by 20 percent compared with screening using regular chest X-rays.\nOverall, research is suggesting that CT scans of people at risk of lung cancer might make a dent in cancer mortality, and it\u2019s possible that more frequent screening might make an even bigger dent, Hanley noted.\nThe data are \u201cconsistent\u201d with earlier studies but there are still many issues to resolve regarding lung cancer screening, Johnson said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThis story generally meets the specific requirements of this criterion, but the overall tone and structure of the report lead readers toward an exaggerated sense of the benefits reported in this study. \nPutting aside fundamental questions about study design addressed earlier, there should have been more attention to the absolute differences in the actual versus expected outcomes for the smokers included in this study. The story highlights mortality reductions of 36 to 64 percent. While it does report deep into the story that 64 smokers died of lung cancer out of almost 8,000 in the main study group, readers would have to pull out their calculators to learn that based on these numbers\u2026 a 36 percent relative reduction in lung cancer mortality translates into an absolute reduction of less than half a percent. Specifically, 0.8 percent (64 out of 7995) of the smokers screened with CT died of lung cancer, while based on one comparison the researchers say the expected lung cancer death rate would be 1.2 percent (99.8 out of 7995). That is a difference of 0.4 percent. The story should have noted that based on these statistics, more than 200 smokers would have to be screened in order to make a difference for one of them.\nThe story also errs by highlighting that another report (based on an actual comparison of screening to not-screening) reported a 20 percent reduction in lung cancer deaths, without also noting that those researchers reported about 300 smokers would have to be screened in order to stave off one lung cancer death.\nThe story should have also clearly told readers that even if screening reduced lung cancer deaths by 20 percent in the most rigorous trial to date, that does not mean that screening would prevent 30,000 lung cancer deaths a year (20 percent of the 157,000 lung cancer deaths per year reported in the story).", "answer": 0}, {"article": "The investigators found that the less salt people ate, the more likely they were to die of heart disease \u2014 50 people in the lowest third of salt consumption (2.5 grams of sodium per day) died during the study as compared with 24 in the medium group (3.9 grams of sodium per day) and 10 in the highest salt consumption group (6.0 grams of sodium per day).\nBut, Dr. Alderman said, the new study is not the only one to find adverse effects of low-sodium diets.\nLowering salt consumption, Dr. Alderman said, has consequences beyond blood pressure.\n\u201cThey do not tell you what will happen if you change peoples\u2019 sodium intake.\u201d\n\nWhat is needed, Dr. Alderman said, is a large study in which people are randomly assigned to follow a low-sodium diet or not and followed for years to see if eating less salt improves health and reduces the death rate from cardiovascular disease.\n\u201cThe low-salt advocates suggest that all 300 million Americans be subjected to a low-salt diet.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "There were no complete responses with Yervoy alone.\nTwenty-two percent of those combination patients had a complete response, meaning no sign of tumor.\nIn a separate group of 33 patients with a mutation of the BRAF gene involved in cancer cell growth, the overall response rate was 52 percent for the combination.\n\u201cThe response rates and the depth of responses are quite impressive,\u201d Dr. Stephen Hodi, director of the Melanoma Center at Dana-Farber Cancer Institute and co-lead author of the study, said in an interview.\nThe overall response rate, defined as tumors that shrank by at least 30 percent, was 61 percent for the 72 patients who received the combination versus 11 percent among the 27 who got Yervoy alone.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Admittedly, the published study in NEJM provides a bewildering array of information about outcomes that would confuse many medical professionals. Nevertheless, simply recounting the information from a press release or from the study abstract does little to inform the average reader. The outcomes reported by the story were tumor shrinkage and disease progression. These are what are known as \u201csurrogate endpoints\u201d \u2014 i.e. proxies for more important outcomes that patients care about, such as survival. Surrogates can certainly be useful and important indicators of a treatment\u2019s effectiveness, but they may also fail to accurately reflect an outcome that\u2019s important to the patient. In our view, a story that ONLY reports surrogate endpoints MUST provide some cautionary language about the limitations of those surrogates. In this case, the study hasn\u2019t been going on long enough to determine whether the treatment confers a survival advantage, and the story appropriately called attention to that fact. Some additional caution on the limits of surrogates would also have been useful.", "answer": 0}, {"article": "Feb. 20, 2017.\nThe research, published Feb. 20 in JACC: Cardiovascular Interventions, suggests that the lower costs of the wrist approach largely are due to the fact that patients experience fewer complications and can be discharged earlier, compared with procedures that access the heart through the larger, deeper artery in the groin.\nOf the study\u2019s patient population receiving PCI, 9 percent received the procedure in which doctors used wrist access.\nAccording to Amin, improved technology has allowed wrist access to become a viable route to the coronary arteries, even for complex cases, and should be considered for more patients.\nThe researchers estimated that shifting standard practice by 30 percent to the wrist approach, along with same-day discharge, could save the United States $300 million per year.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The main benefit discussed here was the cost savings since that was the focus of the study. But what are the tangible benefits to patients who might be facing this procedure? The claims made are backed up by estimates of the cost savings based on the 9% of PCI patients that had the procedure using the wrist method. The first author of the study mentions reduced bleeding and fewer complications from angioplasty procedures that use the wrist artery and discharge patients on the same day, but it doesn\u2019t provide any numbers for a reference point.\nThe published report stated that bleeding at the arterial site, the most common problem examined, occurred in 1.4% of patients receiving the lower cost wrist procedure and in 3% of those receiving the traditional groin entrance procedure (use of the femoral artery and at least one overnight hospital stay). While the complication rates are pretty low in both procedures, it\u2019s something that could have been better explained in the release.", "answer": 0}, {"article": "A vicious cycle ensues: The heart enlarges, so the mitral valve leaks.\nBut that research included many patients with less severe valve problems, the procedure was not performed as adeptly, and the patients\u2019 medications were not as well optimized as in the new study.\nA smaller study in France with similar patients failed to find a benefit for the MitraClip.\nThe result was to convert a valve that barely functioned into one able to regulate blood flow in and out of the heart.\nUntil today, researchers were not sure that fixing the mitral valve would do much to help these patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story said: \u201cAmong those who received only medical treatment, 151 were hospitalized for heart failure in the ensuing two years. Sixty-one died. In contrast, just 92 who got the device were hospitalized for heart failure during the period, and 28 died.\u201d\nWe wish the story had clarified that the figures for deaths referred only to deaths from heart failure, not deaths from any cause.\nAlso, the story could have provided percentages to help readers draw precise comparisons. Among those who received only medical treatment, 56.7% were hospitalized for heart failure and 25.9% died from heart failure. Among those with the device, 35.7% were hospitalized for heart failure and 12% died from heart failure.\nDeath from any cause: During the study period, 29.1% in the device group died, and 46.1% in the control group died.", "answer": 1}, {"article": "What's more, \"people tended to measure the outcomes very differently,\" Matthews says.\nBut Matthews says reviewers found few high-quality studies about any treatment.\nAnd there wasn't much hard data on psychological, social or economic outcomes, according to the report.\nAnd here's a biggie: There wasn't much information about adverse effects on women and babies, something everyone would certainly want to know.\nDublin City University's Anne Matthews, the review's lead researcher, says it was disappointing not to find more studies that were consistent in testing the same approaches.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A mixed bag here, but ultimately unsatisfactory in our view. The story does note that there \"wasn\u2019t much hard data\" on psychological, social or economic outcomes \u2014 all of which are important to look at considering the lost work time, anxiety, and reduced quality of life that women may experience because of morning sickness.\u00a0But then the story goes on to state that there was\u00a0\"some evidence\" that ginger, vitamin B-6 and anti-vomiting drugs relieved nausea. Well, how much evidence was there and what exactly did it show? While the story states that the evidence for these treatments \"isn\u2019t strong enough to make a recommendation,\" we feel the story should\u00a0have tried to quantify this benefit\u00a0in a way that would be meaningful for readers, whether\u00a0as episodes of nausea/vomiting or some other \"real world\" outcome.\u00a0", "answer": 0}, {"article": "\u201cYou are looking at a therapy that can avert, we hope, complications and be as effective,\u201d he said.\nDr. Douglas P. Zipes, a professor at the Indiana University School of Medicine in Indianapolis, said the new device could someday displace existing models used in many patients Every month, about 10,000 patients in this country get a defibrillator, either for the first time or as replacements for devices whose batteries have worn out.\nBut Dr. Bardy estimated that the device could work in about 25 percent of patients who now get a defibrillator.\nDr. Bardy said the cost of the new device is about the same as a standard defibrillator.\nHundreds of patients who received the model have had to undergo new operations to replace it.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\nThis story outlines the problems with the electrical lead wires of existing devices that have harmed patients and required re-operations and recalls. It explains that by using wires placed under the skin, instead of through blood vessels into the heart, the new device might reduce the risks associated with implantable defibrillators for certain patients. The story cautions that only about a quarter of patients who currently are given implantable defibrillators might be candidates for the new type of device.", "answer": 1}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story had lots of interesting anecdotal discussion but few numbers.\u00a0\u201cThere is less muscle injury\u201d and a patient\u2019s early recovery is \u201cdefinitely better\u201d is one example. Those are huge claims for the story to trumpet without including any data to back them up. The story also talks about less need for pain medication but doesn\u2019t quantify the benefit. The anecdotes are very much stacked in favor of the same-day procedure.\nThe story also had a link to a head-to-head comparison study. That is great. Those readers who take the time to click on the link will find interesting stuff. But while it\u2019s a close call here, we are not persuaded that including a link is enough.", "answer": 0}, {"article": "\"Doing something is better than doing nothing.\"\nHe said the latest research on CPR supports the notion that in the critical minutes before an ambulance or defibrillation device arrives, it is very important to provide uninterrupted, deep chest compressions.\nTwo years ago, after considering multiple studies, the Heart Association recommended hands-only CPR only in cases where people were unwilling or unable to provide the rescue breaths as well.\nThe Heart Association also stressed that three-quarters of sudden cardiac arrest cases outside the hospital occur in the home.\nAlthough survival rates for cardiac arrest hover around 10 percent with CPR, Hazinski noted that rates have been pushed as high as 30 percent in cities, such as Seattle, that combine high bystander participation with a strong system of professional emergency medical response.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article says that CPR in any form \"may double the rate of survival from cardiac rest.\" According to a spokesperson for the American Heart Association, this means that \u201cwe can save tens of thousands of lives.\u201d\u00a0 Later in the story the spokesperson is reported as saying that when more people use CPR in cities such as Seattle, survival rates have jumped to as high as 30%. An AHA scientific statement says cities such as Seattle have reported survival of \u201cmore than 15%.\u201d It adds that hands-only CPR and other changes (e.g. dispatcher-assisted \"telephone\" CPR) could save \"thousands of additional lives\" every year.\" This mix of relative and absolute estimates suggest there is surely some real benefit to increasing the use of CPR, but the precise amount of that benefit remains a bit fuzzy.", "answer": 0}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that some DXA scanners \u201cestimate how much visceral fat you have, a measure that can help predict risk for diabetes and cardiovascular disease.\u201d It also states that scans\u00a0show \u201cthe amount of fat and lean tissue in each body part, such as the right arm or left leg\u2014information that can be helpful for athletes to see if an injured limb is regaining muscle.\u201d However, these claims are not quantified. How much different might one\u2019s risk for diabetes or cardiovasular disease be on a DXA scan vs. traditional body composition measures? How much faster might one recover from an injury using DXA monitoring? To its credit, the story does note that one study found that 18.5% of women with a normal BMI had excess fat when measured using a DXA scan \u2014 \u201cmaking them \u2018skinny fat.'\u201d But readers aren\u2019t told what \u201cskinny fat\u201d means \u2014 does it have health implications? Does it increase risk and by how much? More quantification here would have helped readers judge the value of this tool.", "answer": 0}, {"article": "JACC is ranked No.\nResearchers from Emory University Hospital in Atlanta set out to learn more about the relationship between depressive symptoms and heart disease.\nResearchers used questionnaires to evaluate patients for depression and levels of physical activity.\n\"There are many patients with heart disease who also experience depression - we need to study whether encouraging them to exercise will reduce their risk of adverse outcomes.\"\n\"Our findings highlight the link between worsening depression and cardiovascular risk and support routinely assessing depression in patients to determine heart disease risk.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the news release does provide some numbers on the association between cardiovascular risk and depression, it does not do enough to quantify the effect\u00a0of exercise in modulating the relationship between the two.\nStating that people who exercised regularly had less arterial stiffening and inflammation in general than those that didn\u2019t exercise isn\u2019t enough to show causation. Even if the goal was to show causation, numbers weren\u2019t provided.\nIt should also be pointed out that the patients enrolled weren\u2019t clinically depressed as the title may indicate. They had not previously been diagnosed with depression and were evaluated with a symptom scale for two weeks, with most of them coming up with minimal to mild symptoms.\nAs any person seeking treatment for depression learns there\u2019s a wide spectrum of diagnoses and treatments falling under the broad heading of depression: general anxiety disorder, dysthymia, major depressive disorder and postpartum depression to name a few. Some, but not all, can be mitigated with exercise alone.", "answer": 0}, {"article": "\"When parents have a child diagnosed with an autism spectrum disorder, one of the first questions they often ask is 'how did this happen?'\nBetween 10 percent and 15 percent of autism cases can be traced to a known genetic cause, the researchers noted.\nWhile both Children's Hospital Boston and Montefiore have offered CMA testing for several years, not all hospitals do, nor does all insurance pay for it, the researchers noted.\nCMA detected chromosomal abnormalities in slightly more than 7 percent of patients, making it the best available genetic test for autism spectrum disorders, the study authors said.\nResearchers offered about 933 people aged 13 months to 22 years who had been diagnosed with an autism spectrum disorder three genetic tests: G-banded karyotype testing, fragile X testing or chromosomal microarray analysis (CMA), which has been available only for the past few years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately presents the efficacy of three different genetic tests in identifying abnormalities that may be associated with autism\u2014karyotype: 2%; fragile X: 0.5%; CMA: 7%.\u00a0 It would have been helpful to let readers know that not all 933 people included in the study were tested with each of the three tests. According to the results, the CMA tests performed best in females with autistic disorder, but this was not reported. ", "answer": 1}, {"article": "Learn more about omega-3 fatty acids, including DHA, and infant health from the March of Dimes.\nBut, she added that the supplements did appear to be safe for pregnant women to take.\nAt times, however, babies in the DHA group experienced longer duration of rashes and vomiting, the study authors noted.\nRamakrishnan said it's probably too soon to recommend routine use of DHA supplements for pregnant women, because the findings weren't \"dramatic.\"\nRamakrishnan said Mexican women tend to be deficient in DHA, much like many American women are.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits associated with prenatal exposure to DHA supplement were reported only as relative benefits. \u00a0So while there was a 24% drop in the odds of having cold symptoms, 26% shorter cough duration, 15% less phlegm and etc., the reader really has no insight about whether these differences were meaningful or not.\u00a0 Is a 24% drop the same as only 1 less cold over the course of a year?\u00a0 The story needed to explain.\nIn addition \u2013 while these differences may have been statistically significant, would they really make a difference to the baby or its parents?\nBesides \u2013 the lead researcher on the project was quoted as indicating that the findings weren\u2019t \u2018dramatic\u2019. \u00a0Does this suggest that there are more impactful ways to infant health?", "answer": 0}, {"article": "But an electrolyte imbalance caused by dehydration, influenza or other health problems that deplete the system of potassium, magnesium and other minerals also can cause cardiac arrest.\nDr. Ashis Tayal, an AGH stroke neurologist, said trials are under way to use the therapy to help stroke victims.\nMr. Beck said he didn't regain full consciousness for nine days.\nClinical trials showed a 20 percent increase survival with hypothermia, Dr. Granato said.\nBut putting the therapy into practice in many hospitals has been slow.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story estimates that this treatment could save \"tens of thousands\" of lives, though\u00a0this estimate is several orders of magnitude greater than the data\u00a0in the article supports.\nIt contains a quote from a physician who stated that\u00a0they\u00a0\"believe the people who do go home have fewer neurological problems,\" but no evidence is given for this.\u00a0 ", "answer": 0}, {"article": ".\nThe researchers said the risk reduction among the control group may have been caused by the fluoride toothpaste enhancing tooth repair, as well as the mouth rinse enhancing saliva flow and having bactericidal effects.\nOverall, the researchers found that a significantly greater percentage of high-risk participants were classified at lower risk after receiving CAMBRA preventive therapies.\nOf the 192 low-risk participants (93 intervention, 99 control), most participants remained low risk, indicating that the assessment correctly identifies who is at risk for caries.\nThe authors said now that this has been shown to be effective in a non-academic clinical setting, there also is potential for insurance companies to reimburse CAMBRA and other preventive therapies for adults, thereby lowering patient costs while increasing profits for dental practices.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release described benefits this way:\nAmong 242 patients (137 intervention, 105 control) initially identified as high risk for caries, only a quarter of the patients remained at high risk in the CAMBRA group at 24 months, while just over half (54 percent) of the control group did. Of the 192 low-risk participants (93 intervention, 99 control), most participants remained low risk.\nAs noted under Evidence criteria below, the release listed as a limitation the fact that only about one-third of the patients who started the study completed the 24 month checkup.", "answer": 1}, {"article": "\u201cHe said, \u2018Doc, give me what I got last time.\n\u201cIt truly has revolutionized the field,\u201d changing scientists\u2019 views on how depression affects the brain and showing that rapid relief is possible, said Yale University psychiatrist Dr. Gerard Sanacora, who has done research for or consulted with companies seeking to develop ketamine-based drugs.\nUntil there are answers, Zarate of the mental health institute said ketamine should be a last-resort treatment for depression after other methods have failed.\nFor now, ketamine has not received approval from the U.S. Food and Drug Administration for treating depression, though doctors can use it for that purpose.\nKetamine\u2019s potential for almost immediate if temporary relief is what makes it so exciting, said Dr. Jennifer Vande Voort, a Mayo Clinic psychiatrist who has used ketamine to treat depression patients since February.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t focus on a particular study that measured a benefit. It said: \u201cStudies suggest that a single IV dose of ketamine far smaller than used for sedation or partying can help many patients gain relief within about four hours and lasting nearly a week or so.\u201d\nHowever, the story could have given readers a more detailed description of ketamine\u2019s benefits, as measured in clinical trials.\nFor example, a meta-analysis of five randomized placebo-controlled trials concluded ketamine had a \u201clarge\u201d immediate effect \u2014 measured one day after treatment \u2014 on symptoms in patients with major depressive disorder and bipolar depression. That effect fell to \u201cmedium\u201d after seven days. The studies used various standardized rating scales to track symptoms such as reduced appetite or sleep, difficulty concentrating, sadness, and suicidal thoughts.", "answer": 0}, {"article": "Dr Carol Routledge, from Alzheimer's Research UK, said: \"The diseases that cause dementia begin in the brain up to 20 years before any symptoms start to show, presenting a vital window of opportunity for us to intervene before widespread damage occurs.\nThe Alzheimer's algorithm was able to teach itself to recognize patterns in brain scans that indicated disease.\nIt proved to be 100 percent accurate at detecting Alzheimer's disease many years before the patient was later diagnosed.\n\"This study highlights the potential of machine learning to assist with the early detection of diseases like Alzheimer's, but the findings will need to be confirmed in much larger groups of people before we can properly assess the power of this approach.\"\nThe system was able to identify dementia in 40 patients an average of six years before they were formally diagnosed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story highlights a single benefit:\n\u201cThe [artificial intelligence algorithm] was able to identify dementia in 40 patients an average of six years before they were formally diagnosed \u2026 with 100% accuracy\u201d\nBut who these patients were, and how they were chosen is not mentioned. Nor is it mentioned that the specificity was 82%. In other words, nearly 1 in 5 subjects (18%) were predicted to develop dementia who were never diagnosed with it (aka a \u201cfalse positive test\u201d).", "answer": 0}, {"article": "Prostate cancer begins when cells in a man\u2019s prostate gland mutate and start to grow uncontrollably.\nThis procedure is the first in the world that is precise enough to potentially avoid negative ramifications like urinary incontinence or sexual impotency.\nThe fusion of MRI and ultrasound imaging technology that we use to accurately identify and diagnose the cancer, combined with the extreme precision of the gold nanoshells in targeting the diseased cells, allows us to be incredibly accurate at obliterating them.\n\u201cThe side effects of current prostate cancer treatments can be extremely traumatic.\nI am excited as we continue tracking the progress of this groundbreaking improvement to prostate cancer care.\u201d\n\nDoug Flewellen, the first patient in Texas to receive the new method of care, says for him, the procedure was a no-brainer.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are no data to speak of in this news release so no reliable discussion of benefits either.", "answer": 0}, {"article": "New Jersey and Ohio were the first to participate statewide in the program.\nThe boxes aren\u2019t the only option for safe sleeping, of course, but health officials say they\u2019re a useful part of a broader safe-sleep education program.\nThe boxes provide a clutter-free sleep space that has been shown to reduce accidental and unexpected deaths, she said.\nBut when they\u2019re linked to a practice that started in Finland decades ago to help babies sleep safely, they\u2019re taking on a new purpose as so-called baby boxes make their way to the U.S.\n\nParents are beginning to take baby boxes home from hospitals along with their newborns.\nThe idea for baby boxes started in Finland in the 1930s, and is tied to a sharp drop in sudden infant deaths, according to Dr. Kathryn McCans, a pediatrician who chairs New Jersey\u2019s Child Fatality and Near Fatality Review Board.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify any of the benefits. It does not tell us how much risk of sudden infant death is decreased by the child sleeping in these particular boxes. In the excerpt below, a pediatrician is quoted saying the boxes \u201cprovide a clutter-free sleep space\u201d and that has been shown to reduce accidental deaths. But just to clarify \u2013 it would seem you don\u2019t have to use one of these boxes in order to provide a \u201cclutter-free sleep space?\u201d Can\u2019t a family create a clutter free space in their own cardboard or an empty clutter-free crib?\nThe quoted pediatrician does not give us any research source for the proof of a benefit.\n\u201cThe idea for baby boxes started in Finland in the 1930s, and is tied to a sharp drop in sudden infant deaths, according to Dr. Kathryn McCans, a pediatrician who chairs New Jersey\u2019s Child Fatality and Near Fatality Review Board. The boxes provide a clutter-free sleep space that has been shown to reduce accidental and unexpected deaths, she said.\u201d\nCan\u2019t parents provide a clutter-free sleep space for their infants on their own? Yes, but it doesn\u2019t mean they will. The convenience and no cost of the box to the parents might be sufficient motivation to use it and the parents don\u2019t need to do anything to make it safe \u2014 it already is. This in essence makes the right thing to do into the easy thing to do \u2014 a key tenet of patient safety. However, the concern that there simply are no numbers showing a benefit is a real one.", "answer": 0}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In the story\u2019s descriptions of \u201cpromising\u201d drugs from Biogen, Merck and Lilly, there is essentially zero quantification data. There needed to be some, even in a wrap-up or trend article such as this.", "answer": 0}, {"article": ".\nTechnically known as single-port cryosurgery, the technique is used only for cancers no bigger than an inch and a half wide that haven't spread beyond the kidney, Lee said.\nThis technique, which Lee helped develop and has been using for about a year, represents a big advance over conventional kidney-cancer surgery, which can require a foot-long incision and, sometimes, removal of a rib so the doctor can reach the malignancy, according to experts.\nOnly one incision is required because Lee and other doctors can use a device called a trocar, which has holes for each instrument and the endoscope.\nThat was what happened to Davis, who had gone to a hospital for a kidney stone.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not adequately quantify the benefit of cryosurgery, other than in reducing recovery time.", "answer": 0}, {"article": "Claudia Kawas, a geriatric neurologist at the University of California, Irvine, said a patient strode into her office soon after the FDA approved the procedure and asked for the \"Alzheimer's test.\" In one hand, he held an article about the approval of Amyvid. In the other, he had a document from a right-to-die group. If the test was positive, he told her, he would get his affairs in order and kill himself within 60 days.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did a nice job outlining the potential benefit of the test and the number of limitations", "answer": 1}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Some trial data on benefits were cited for both Solesta and InterStim.", "answer": 1}, {"article": "\u201cHe wanted to be at home with his dog.\nHe wanted to be able to go to the beach.\u201d\n\nA nephrologist at the University of North Carolina School of Medicine, Dr. Hladik understood better than most how kidney dialysis could consume a patient\u2019s days.\nGerald J. Hladik was 74 when the day long anticipated by his doctors arrived: His kidneys, damaged years earlier by a viral infection, had lost 85 percent of their function.\nSo after considerable discussion, Mr. Hladik decided to skip the three weekly trips to a renal center, along with the resulting fatigue and dietary and travel restrictions.\nHe died at home in November, a year and a half after saying no to dialysis.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article cited appropriate studies for a range of statistics. \u00a0We learn, for example, that \u201c58% of patients died within a year of beginning dialysis\u201d and that\u00a0about 40% of patients over 75 with end-stage renal disease die within a year. We also learn about the concerns of the patients, including the fact that 61% of patients in one study said they regretted starting dialysis. It adds that \u201cwithdrawal from treatment accounted for about a quarter of deaths of dialysis patients in 2006,\u201d though that seems a little unsatisfying in terms of what additional lifespan might be attributed to dialysis. Another fact included is that 66% of patients in one study told researchers that their doctors had not mentioned the treatment\u2019s risks or burdens, and they felt they had no choice.", "answer": 1}, {"article": "With advanced heart failure, a leading cause of hospitalizations, blood-pumping ability is diminished as the heart\u2019s left ventricle becomes enlarged and weakened.\n\u201cFor patients, this is a really hopeful thing.\u201d\n\nHenry, who presented the data at the ACC meeting, stressed the need for larger trials to prove the benefit of ixmyelocel-T\n\nFor the treatment, bone marrow is taken from the patient and enhanced over two weeks to increase two types of cells associated with healing.\n\u201cThis is strong evidence in a well-designed trial that we can decrease events,\u201d said Dr. Timothy Henry, the study\u2019s lead investigator and chief of cardiology at Cedars Sinai Heart Institute in Los Angeles.\n\u201cPeople were looking for downside and they had one.\u201d\n\nThe data compared Vericel\u2019s bone marrow-derived ixmyelocel-T stem cells with placebo in 109 well-treated patients with advanced heart failure who had exhausted medical and device therapies.\nVericel last month reported that the study succeeded.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This article outlined the 37 percent reduction in adverse events due to the stem cell therapy, and explained that the outcome was mainly due to difference in deaths and hospitalizations between the therapy and placebo groups. And, we were very pleased to see the inclusion of absolute numbers related to this\u2013i.e., 7 deaths versus 2 deaths. The story also let us know that the study didn\u2019t show a benefit in secondary endpoints, like heart pumping efficiency and a walk test.\nHowever, we\u2019d have liked to have seen more discussion\u2013ideally from an independent medical experts\u2013on what investors already seem to know, but the reader is left to deduce: Were these results as meaningful as the lead investigator is making them out to be?", "answer": 1}, {"article": "By Amy Norton NEW YORK (Reuters Health) - People with multiple sclerosis have long said that smoking marijuana helps ease their painful muscle cramping.\n\u201cSpasticity is a big problem for many people with MS, and the current medications don\u2019t necessarily work for everyone,\u201d said LaRocca, who was not involved in the new study.\n\u201cWhat effects that might have had on the results is unclear.\u201d\n\nCorey-Bloom said that should not have influenced the spasticity findings, since an independent researcher (who didn\u2019t know whether patients were smoking marijuana or the placebo) rated spasticity using a standard scale.\nBoth LaRocca and Corey-Bloom said there were limitations to the current study.\nBut another limitation, she pointed out, is that the study looked at the effects, and side effects, of marijuana over only a few days.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Many times a story stops at reporting something like \u201cbrought some relief.\u201d\nThis story explained exactly how the study was conducted, what the measurement scale for improvement was, and what was observed on that scale.\nAnd then it carefully itemized limitations of the study.", "answer": 1}, {"article": "www.petermunkcardiaccentre.ca\nThe CardioMEMS\u2122 HF System is designed to monitor heart failure patients whose condition is serious but who are not so ill that the technology cannot improve their outcome.\nThe first Canadian patient implanted with the heart monitor will be among 25 patients within the Ted Rogers Centre for Heart Research at the Peter Munk Cardiac Centre to be fitted with the device over the next nine months.\nThe system features a small butterfly-like sensor that then sits inside the pulmonary artery of a heart failure patient.\nThis technology is a way to directly measure how much fluid is in a patient, allowing us to intervene before they develop symptoms of congestion, before they end up in hospital.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We only know that one heart failure patient in Canada underwent the implantation procedure. \u201cThe device\u2026was successfully implanted by interventional cardiologists,\u201d the news release states.\nNo other data were given. We don\u2019t know how other patients have fared after the fact, including the one mentioned in the news release.\nAlthough this is a first for Canada, the US has been treating heart failure patients with the CardioMEMS system since 2007. The US FDA approved CardioMEMS after reviewing results from the CHAMPION clinical trial (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients). Clinicians followed 550 heart failure patients and looked at heart failure-related hospitalizations in the treatment group versus the control group at 6 months. At this point in time, there was a 28 percent reduction in heart failure hospitalizations, with 84 hospitalizations in the treatment group, compared to 120 in the control group. Researchers also observed a 37 percent reduction in heart failure-related hospitalizations in the treatment group during the entire follow-up period of approximately 15 months.\nSince none of this data were given, we rate this one Not Satisfactory.", "answer": 0}, {"article": "\u201cEveryone has gotten on the bandwagon.\nSuch findings are why she, Mowry and Pittas strongly advise people against taking more than the currently recommended upper daily limit of 4,000 IU, even though doses as high as 10,000 IU are available online and at many stores.\nThe one thing the research leaders are certain of is that the public\u2019s faith in vitamin D as a modern panacea has far outpaced what the scientific evidence proves.\nTo Autier, a researcher at the Strathclyde Institute of Pharmacy and Biomedical Sciences in Glasgow, Scotland, the widespread faith in vitamin D\u2019s benefits is like a religion.\n\u201cBut keep in mind, there isn\u2019t yet evidence that taking those higher amounts will confer any benefits beyond the recommended daily allotment of 600 to 800 IU.\u201d\n\nSome studies, she noted, have even found evidence that very high levels of vitamin D circulating in the blood might be just as unhealthful as very low levels.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story begins from a baseline context of controversy and uncertainty, rather than one of assumed benefit \u2014 an approach that frames the issue appropriately in our view. There is detailed discussion of research showing benefits, and research NOT showing benefits. In the absence of definitive large trials, the benefits accepted by the Institute of Medicine are limited to bone health.\nThe story quotes the Institute of Medicine, which concludes that vitamin D and calcium are \u201cnecessary for bone health\u201d but that as for preventing cancer, heart disease, diabetes and autoiummune disorders, the evidence was insufficient.", "answer": 1}, {"article": "\"Sadly,\" they write, \"we are left in a conundrum.\nBut this isn't the first study to call into question the benefits of mammography and whether women are too often the victims of overdiagnosis.\nAnd yet, a new study published in JAMA Internal Medicine has found something that may seem counterintuitive: More breast cancer screening didn't actually save lives.\nYou can see this clearly in the chart below: The number of diagnosed breast cancers rose with more screening, yet the number of deaths from breast cancer 10 years later remained stubbornly stable.\nIn a related commentary in the journal, a pair of doctors from the University of Washington School of Medicine note that the estimates of overdiagnosis of breast cancer are \"frustratingly broad\" \u2014 from less than 10 percent to 50 percent or more of women who get screened.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story satisfactorily reports the main results of the study and describes the benefits of mammography as seen across a large body of research. It explains that in the study, \u201cThe number of diagnosed breast cancers rose with more screening, yet the number of deaths from breast cancer 10 years later remained stubbornly stable.\u201d It doesn\u2019t quantify the increase in breast cancer detection in the text (the study reported a 16% increase in breast cancer diagnoses for every 10 percentage point increase in screening), but it does include a figure from the study which clearly demonstrates that while more cancers were found, mortality from breast cancer remained stable.\nThe story also includes a risk communication illustration, based on a systematic review of available evidence, that presents the absolute mortality benefits (as well as harms) for women over 50 who participate in screening for at least 10 years.\nThe story mentions that screening may be more effective in women with a family history of breast cancer. It does not discuss whether the study found any significant results among demographic subgroups for whom screening mammography may be more effective, but it doesn\u2019t appear that the authors were capable of making such distinctions based on the data available (see Evidence section below).", "answer": 1}, {"article": "He drank to forget.\n\u201cThe MDMA alone or the therapy alone don\u2019t appear to be as effective,\u201d Dr. Mithoefer said.\n\u201cThe MDMA seems to act as a catalyst that allows the healing to happen.\u201d\n\nWhat do patients say about it?\nThe drug floods the brain with hormones and neurotransmitters that evoke feelings of trust and well-being, users report.\nI realized I had viewed myself as a monster, and I was able to start to have some compassion for myself.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told that after two sessions of MDMA-assisted psychotherapy \u2026\n\u2026 a majority of 26 combat veterans and first-responders with chronic PTSD (who had not been helped by traditional methods) saw dramatic decreases in symptoms. The improvements were so dramatic that 68 percent of the patients no longer met the criteria for PTSD. Patients taking the drug also experienced \u201cdrastic\u201d improvements in sleep and become more conscientious, according to the study.\nThis is enough to rate Satisfactory, but we think the story needed more details on how the study was designed to help readers understand this result (see evidence quality, below).", "answer": 1}, {"article": "\"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability,\" said the study's lead author Amy S. Clark, MD, MSCE, an assistant professor of Hematology/Oncology at Penn's Perelman School of Medicine and ACC.\nAnother phase 2 trial with 29 sarcoma patients treated with palbociclib showed a progression-free survival of 66 percent at 12 weeks.\nAt the recommended doses, evidence of the desired drug effect in tumors has been obtained using novel PET imaging at Penn.\nIn addition to inhibiting the cell cycle, palbociclib has been shown, for example to alter several recently described non-cell cycle functions of CDK4/6, a finding expected to expand its therapeutic role, O'Dwyer added.\nAssessing 130 relevant publications in the literature, as well as interpreting their own continuing studies, the all-Penn team found that in addition to its safety and effectiveness in fighting certain types of breast cancer, early trials of palbociclib have shown promise of effectiveness in cases of lymphoma, sarcoma, and teratoma, tumors that while rare, often afflict younger patients.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release claims that the drug offers lower toxicity than other drugs, ease of use, and effectiveness as either an add-on or stand alone treatment but with very little data backing up the claims. The release summarizes the outcomes of two small trials using palbociclib in somewhat muddy terms. In one involving 17 previously treated mantel-cell lymphoma patients, the drug is attributed to one \u201ccomplete\u201d response and \u201ctwo partial responses.\u201d Another trial with 29 sarcoma patients treated with palbociclib showed \u201cprogression-free survival of 66 percent at 12 weeks.\u201d\nThe release might have added more specifics about the impact and meaning of \u201ccomplete\u201d and \u201cpartial\u201d responses as well as extended \u201cprogression-free survival\u201d with hard data that would help readers compare such survival with and without the use of the drug.", "answer": 0}, {"article": "According to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nJay lays out the hows and whys of spinal stimulation, and she paints a vivid picture of a life in agony, a journey that has included skeptical doctors, plenty of painkillers and unanswered questions about the future.\nBut the pain is far more controlled, and I can function much better at my current level of discomfort.\u201d\n\nAs the human and financial costs of the opioid crisis rise, spinal stimulation may become more popular, even though it\u2019s expensive.\nA next-generation implant deep in Jay\u2019s back stimulates her spinal cord, overriding her body\u2019s pain signals to give her some relief from the back pain that has plagued her for years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "To its credit, the story offered a nuanced view of the benefits as seen through the eyes of this single patient:\n\u201cEven for me, the battle is not over,\u201d Jay writes. \u201cSince this surgery I\u2019ve actually had another disc herniate, complicating everything. My spine isn\u2019t cured, and I still hurt all the time. But the pain is far more controlled, and I can function much better at my current level of discomfort.\u201d\nStill, it didn\u2019t give readers a picture of an idea of the scope of the benefits for all patients who have had this procedure. What percentage see improvements? And how much better are they? We aren\u2019t told.\nIn essence, there is no information provided to say what the chance of the next person having this procedure is of achieving pain relief. Moreover, it isn\u2019t clear how this may compare to other treatments. It is implied that this was the last step, but that is rarely the case.", "answer": 0}, {"article": "But in leg arteries, the active flexing can cause a stent to break.\nThomas Gunderson, a senior analyst for Piper Jaffray & Co., said the Covidien study could lead to greater use of atherectomy and a bigger market.\nThe study is the largest to look at the effectiveness of atherectomy, Covidien said, and enrolled 800 patients at 47 centers in the U.S. and Europe.\nThe company says this is a major step forward in treating PAD because, unlike stents, atherectomy \"leaves no metal behind.\"\n\"I think it has the potential to increase business for Covidien,\" Garcia, chief of interventional cardiology and vascular interventions at St. Elizabeth's Medical Center in Boston, said Thursday.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No data were provided \u2013 only superlatives from the local company:\nA company news release did provide more details on potential benefits.", "answer": 0}, {"article": "Normally it's the very old or very young that die from flu, but every year there are deaths from influenza A,\" said Gilbert.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\nThe initial results are positive, says Peter Palese, professor and chair of microbiology at Mount Sinai School of Medicine, New York, but more research is needed before the new treatment is approved.\nThe results, say Gilbert, are important in developing a new form of protection that researchers hope could spell the end of flu vaccination supply problems.\n\"Whether it's this vaccine or another one someone else develops, I don't think we'll be continuing with the type of flu vaccines that we have at the moment.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "Cabozantinib, also known as XL184, is an oral drug designed to limit blood supply to tumors and to block two segments of a pathway used by cancer cells to grow and spread.\nOther Phase 2 data presented over the weekend showed that treatment with cabozantinib led to significant tumor shrinkage in 24 percent of patients with metastatic ovarian cancer.\nThe drug reduced by 87 percent the risk of disease progression or death.\nThe study results were reported on Monday at the American Society of Clinical Oncology\u2019s annual meeting.\nThe disease remained stable in 23 other patients, or 21 percent, and worsened in three.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story presents the reader with a set of apparently contradictory information on the benefits of the drug.\nHow many patients were in the study: 108 or 31? What were the results and when were they recorded? While all of the statistics are indeed correct, they are not provided in a way that a reader can get a true picture.", "answer": 0}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies overall outcomes and benefits for the 61 patients followed for three years in absolute terms. It notes that \u201cForty percent of those who had received a gastric bypass procedure and 29% who received a gastric band were considered in remission from diabetes and no longer needed to take medication after three years. In comparison, no one in the group who received intensive lifestyle intervention resolved their diabetes.\u201d\nThe story would have benefited from more information about the participants\u2019 full spectrum of risk factors and the impact of the surgery on those markers (e.g. blood pressure). It also would have been more enlightening if it had stated clearly how many of the 61 study subjects got what kind of bariatric surgery and supplemental therapy. But the story does a good job of covering the necessities here.", "answer": 1}, {"article": "People with cluster headaches can have as many as eight per day in bouts that last for weeks or months.\nNo serious harmful side effects were reported after high-flow oxygen treatment, according to the report published in the Dec. 9 issue of the Journal of the American Medical Association.\n\"This work paves the way for further studies to optimize the administration of oxygen and its more widespread use as an acute attack treatment in cluster headache, offering an evidence-based alternative to those who cannot take triptan agents,\" they concluded.\n\"To our knowledge, this is the first adequately powered trial of high-flow oxygen compared with placebo, and it confirms clinical experience and current guidelines that inhaled oxygen can be used as an acute attack therapy for episodic and chronic cluster headache,\" wrote Anna S. Cohen, of the National Hospital for Neurology and Neurosurgery in London, and colleagues.\nThis new study included 76 adult patients, aged 18 to 70, with either episodic cluster headache (57) or chronic cluster headache (19).\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story outlines the most basic outcomes\u2013that 78 percent of patients receiving oxygen reported relief at 15 minutes, and that pain relief was better than placebo at 30 and 60 minutes. Still, both the study and the article fail to address longer-term benefits or harms. ", "answer": 1}, {"article": "About the American Urological Association: The 111th Annual Meeting of the American Urological Association takes place May 6 \u2013 10 at the San Diego Convention Center in San Diego, CA.\nFollowing a 13-week efficacy phase, men continued to receive their assigned treatment for up to 52 weeks.\nThe research will be highlighted by study authors during a special press conference to be moderated by Tobias S. K\u00f6hler, MD, MPH, FACS, AUA spokesperson and associate professor of Surgery at Southern Illinois University on May 8, 2016 at 7:30 a.m. PT in the San Diego Convention Center.\n\"Making sure an oral treatment is safe and effective for men and for the children and partners at risk for inadvertent testosterone transference is the top priority, and what we've found so far has shown we're on the right track.\"\nIt is often administered as a gel, patch, injection or implant (pellet).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t quantify potential benefits of oral testosterone therapy. It barely mentions why it might surpass one currently available form, topical products, which carry FDA warnings related to inadvertent transfer to other people. \u201cMaking sure an oral treatment is safe and effective for men and for the children and partners at risk for inadvertent testosterone transference is the top priority, and what we\u2019ve found so far has shown we\u2019re on the right track,\u201d says Tobias S. K\u00f6hler, MD, an AUA spokesperson, in the release. More light is shed on the web site of the drug manufacturer. In a company-sponsored survey of 28 leading endocrinologists and urologists reported on the manufacturer\u2019s web site, 94% of responded that they believed an oral testosterone replacement therapy would improve patient compliance. The web site\u00a0 also cited problems with existing products, including skin rashes for topical products and risk of infection, scarring, injection site reactions, and lung impairment for injectables.", "answer": 0}, {"article": "Laurie Fenton, president of the Lung Cancer Alliance, an advocacy group headquartered in Washington, said: \"We think this is a breakthrough for lung cancer.\nBut while the research clearly shows that the interval between diagnosis and death was longer in screened patients, it does not definitively show they lived longer -- a subtle difference with significant public health consequences.\nOf that group, 85 percent had small tumors that had not spread.\nOthers, including researchers and policymakers in the government, say it is a question that will not be settled for five or six years, when other studies are complete.\nIn the ensuing years, about 27,000 more scans were done, with some people having them annually.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately quantifies the benefits of treatment. Because this study had no control group, there is no way to directly compare screening to no screening \u2013 and the story explains that. Furthermore, the story rightly points out that the study looked at survival at 10 years as the outcome (although the study only followed patients for an average of 3 years and 10-year survival was estimated), not mortality, leaving open the question about whether or not screening actually extends life or if\u00a0it only pushes forward the time of diagnosis (a\u00a0situation known as lead-time bias).", "answer": 1}, {"article": "The iron in the blood increases infants' iron storage, and iron is essential for healthy brain development.\nMuch of the research has focused on preterm infants, who appear to benefit most from delayed cord clamping, Rabe said.\nBut Rabe said these infants may actually benefit most from the practice.\nUntil recently, clinicians believed early clamping reduced the risk of hemorrhaging in the mother, but research hasn't borne that out.\nThis study is among the few looking at healthy, full-term infants in a country high in resources, as opposed to developing countries where iron deficiency may be more likely.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a tough call. This story did put some context around the benefits \u2014 calling them \u201cmodestly higher scores in social skills and fine motor skills.\u201d It also pointed out that only the boys showed \u201cstatistically significant improvement.\u201d But we\u2019d like to have seen some actual numbers (for example, 3.7% of delayed cord clamping children scored 2 standard deviations below average in fine motor skills compared to 11% in the early cord clamping group). The story could\u00a0easily have massaged that technical language to make this understandable to an average reader. In addition, it might have added some nice color and helped readers to get a sense of the nature of the benefits if the article described the sorts of tasks the subjects were asked to do (e.g. threading beads).", "answer": 0}, {"article": "\"Weight loss was similar but substantial in both groups we studied, but blood pressure improved more in the low-carb dieters,\" said study author Dr. William Yancy Jr., an associate professor of medicine at Duke University Medical Center and a staff physician at the Department of Veterans Affairs Medical Center in Durham, N.C.\n\n\"There are options out there.\nThe more intensive intervention was more successful with 31 percent losing more than 5 percent of their body weight, compared to just 9 percent of the Internet group.\nTheir study, published in the Jan. 25 issue of the Archives of Internal Medicine, found that both diets helped participants lose almost 10 percent of their body weight.\nThe group taking orlistat received a 120-milligram dose of the drug three times daily and got less than 30 percent of their calories from fat.\nAnd, she said, these studies show that you don't necessarily need to get to your \"ideal body weight\" to make substantial improvements to your health.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives a reasonable\u00a0overview of the effects of the two interventions on a variety of\u00a0different\u00a0markers associated with health. Although it earns points for noting the absolute reduction in blood pressures and not just providing them as a percentage, it\u00a0should have\u00a0provided the weight loss in similar terms of actual\u00a0pounds or kilograms lost instead of as a percentage of bodyweight.\u00a0\u00a0", "answer": 1}, {"article": "Symptoms of heart failure include fatigue, breathlessness and swelling in the limbs.\nBut the study was small, and the stem cells had only a minor impact on patients' heart function.\nThe tactic appeared safe, the researchers said, and there were signs of symptom improvements over the next six months to a year.\nBut it's not clear whether the stem-cell tactic was actually effective, said Gorodeski, who was not involved in the study.\nThat's because the study didn't include a comparison group that did not receive stem cells.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t quantify benefits, instead using general language: \u201cOver the next year, the patients generally showed small improvements in their symptoms \u2014 including the ability to walk without becoming breathless and fatigued.\u201d How was that measured? And by how much did those measurements change?\nThat said, we\u2019d really like to applaud the way that the story made clear the benefits couldn\u2019t be explicitly tied to the stem cell treatment. We\u2019ll talk about that a bit more under \u201cQuality of Evidence.\u201d", "answer": 0}, {"article": "In one study, researchers found that people who have long telomeres, the small strips of DNA that cover the ends of chromosomes, have a 30 percent increased risk of developing colon cancer.\nAccording to Ahlquist, Cologuard is the first noninvasive test to detect pre-cancerous polyps, he added.\nIn addition, the test is the only one that is able to identify cancer in all locations throughout the colon, something which other tests either can't or don't do well, Ahlquist said.\nSavings over time on a more accurate test done fewer times could justify the higher cost of the Cologuard test, Ahlquist said.\nThe sensitivity of the test is much better than what has been seen in other stool screening tests, the ACS' Brooks added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify the potential benefits, although the numbers are incomplete. It\u2019s not clear, for one, how this compares to other colon cancer screening tests.\nThe story didn\u2019t specify the sensitivity of the test, but stated:\u00a0\u201cThe sensitivity of the test is much better than what has been seen in other stool screening tests, the ACS\u2019 Brooks added.\nOverall, we didn\u2019t think the story gave readers a way to judge the scope of the potential benefits.", "answer": 0}, {"article": "\u201cAnd you need all hands on deck.\u201d\nWhen the injections stopped, many in the study relapsed.\nDr. Joshua Lee, of New York University\u2019s medical school, said more evidence is needed to determine whether the medication can help substantial numbers of people and whether it\u2019s worth paying for, but the early results are encouraging.\nThe results, published in March in the New England Journal of Medicine, have been promoted by the drugmaker, Ireland-based Alkermes, as it markets Vivitrol to U.S. correctional systems.\nThe drug\u2019s manufacturer hopes prisons will be the gateway to a larger market.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "One randomized clinical study of Vivitrol was published recently\u00a0in The New England Journal of Medicine, and this AP story gives it ample space. We\u2019re told specifics like \u201cAfter six months, the Vivitrol group had a lower rate of relapse, 43 percent compared with 64 percent.\u201d\nThe experiment found no overdoses and fewer relapses in the Vivitrol group compared to individuals referred to a treatment program instead. However, within months of the study\u2019s end, relapses among those in the Vivitrol group rose to the same level as that of the control group; the story makes that quite clear as well.", "answer": 1}, {"article": "Atrial fibrillation is a common heart abnormality that affects nearly 3 million American adults.\nThe longer the delay in giving blood thinners, the more the risk for dementia, the researchers said.\nIn patients with atrial fibrillation, the risk of stroke is usually measured using the so-called CHADS score, the researchers said.\nThe researchers said that the key is to start blood thinners, such as warfarin, soon after atrial fibrillation is diagnosed.\nThat's true even for people at low risk of a stroke who wouldn't normally be given blood thinners.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story renders benefits not in terms of reduction in risk but, rather, in terms of increased risk for signs of dementia. Specifically, it notes that delaying use of blood thinners in patients at low risk of stroke increases the risk of dementia by 30% and, in patients at high risk of stroke, by 136%. What it does not provide is any baseline numbers to permit a reader to judge \u201cpercentage of what?\u201d Without that, it is difficult to decide if these risk increases are substantial or trivial. See more on the importance of including absolute risk numbers.\u00a0", "answer": 0}, {"article": "Newsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nFrom a Catholic school uniform to a hijab, LIers talk about their religious clothing.\nA hijab, a turban, a beard: What aren\u2019t you seeing?\nAt 14, MS-13 was his family.\nHere\u2019s how he got out.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Examples of benefit are presented in very general terms (walked a little faster, fewer falls) without any frame of reference for the magnitude of improvement or whether the change was statically or clinically significant.", "answer": 0}, {"article": "[3] Quote direct from author and cannot be found in text of Article.\nThe study, published in The Lancet, also found that grip strength is a stronger predictor of death than systolic blood pressure, and the authors suggest that it could be used as a quick, low-cost screening tool by doctors or other healthcare professionals to identify high-risk patients among people who develop major illnesses such as heart failure and stroke.\nWeak grip strength is linked with shorter survival and a greater risk of having a heart attack or stroke, according to an international study involving almost 140000 adults from 17 culturally and economically diverse countries [1].\nBut until now, information on the prognostic value of grip strength was limited, and mainly obtained from select high-income countries.\nThese associations persisted even after taking into account differences in other factors that can affect mortality or heart disease such as age, education level, employment status, physical activity level, and tobacco and alcohol use.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does not tell readers how important a 7 to 17 percent increase in risk for the measured outcomes really is. There are no absolute figures included, only relative risks. What\u2019s more, the release makes no mention of how this sort of risk stratification would be used. Would people identified as having a 10-20 percent higher risk of certain conditions be offered different tests or treatments than those with stronger grips? Without this sort of context, readers of this release don\u2019t have any way of knowing what the benefits of grip testing might be.\nIt is also odd that the headline and lead paragraph of the release highlighted heart attack and stroke, when the risk stratifications for those events were smaller than those for other outcomes.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Some quantitative benefits of treatment provided, but it would have been better if the story provided a statement of baseline risk of transmission instead of \u201ccuts risk in half.\u201d However the point of the article is that the transmission rates with and without exposure to drug during prior pregnancy are the same (14.6 vs 17.6%). The problem here is that we don\u2019t have an explicit transmission rate for comparison. The literature says it was 25 to 40% in Africa before antiretroviral therapy. Thus rates of both 14.6% and 17.6% would represent a significant reduction in transmission.", "answer": 0}, {"article": "In the new study from Denmark, taking low-dose aspirin continuously for at least five years appeared to reduce the risk of colorectal cancer by 27%, and using nonaspirin NSAIDs for at least five years appeared to reduce it by 30%.\nDr. Friis emphasized that people should not start taking aspirin or NSAIDs on the basis of the new findings.\nOn the other hand, merely having taken aspirin did not alter the colorectal cancer risk, they reported in Annals of Internal Medicine.\nNow, using data on more than 113,000 individuals, researchers have been trying to sort out the relationship between aspirin and NSAIDs, duration of treatment, and colorectal cancer rates.\nNonaspirin NSAIDs were also protective against colorectal cancer with consistent long-term use, \u201cand there was some indication that even non-continuous use of these agents may be (marginally) effective for the prevention of colorectal cancer,\u201d Dr. Friis said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites a 27 percent decrease among low-dose aspirin users who had taken the drug for five years or more. It also notes the incidence of the disease among different populations, and even gives readers a link to a risk calculator to determine their individual risk.\nOf course, we almost always prefer stories to use absolute risk reductions over the relative risk reduction reported here (technically an odds ratio \u2014 not a \u201crisk\u201d reduction per se). But in a case-control study such as this one, the issue can be complicated. We\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "\u201cCAR-T is not the EpiPen,\u201d he said.\nAnd childhood leukemia is just the start for a field that has attracted intense interest in academia and industry.\nSuch results are why the treatment is on track to become the first gene therapy approved by the Food and Drug Administration.\nMany of them took part in the clinical trial, and all have gotten extensive training by Grupp and others.\nAnd although checkpoint inhibitors are off the shelf, with every patient getting the same drug, CAR T-cell therapy is customized to an individual.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is satisfactory, but barely. Here\u2019s how the story addresses benefits for the CAR T-cell treatment: \u201cIn the pivotal trial testing the therapy in almost a dozen countries, 83 percent of patients went into remission. A year later, two-thirds remained so.\u201d\nThat information would be much more useful if it placed those numbers in context. For example, how many patients were enrolled in the study? 83 percent could be 13 out of 16 patients, or it could be 1,328 patients out of 1,600. And how does 83 percent compare to standard treatment?\nSimilarly, is the story telling us that two-thirds of all patients were still in remission a year later? Or did it mean that two-thirds of the 83 percent were still in remission a year later? Contextual information would have provided some much-needed clarity here.", "answer": 1}, {"article": "\u201cBut it is definitely a breakthrough.\nIn addition, the symptoms caused by the 100-fold higher dose at the end of the study were milder than the symptoms on the lower dose at the beginning of the study.\u201d\n\nEXPERTS: CHILDREN AT RISK OF LEAD POISONING IN CHATTANOOGA\n\nWith FDA approval this drug would mark the first treatment available by prescription for peanut allergies.\n\u201cOn average, the participants were able to tolerate a 100-fold higher dose of peanut at the end of the study than they did at the beginning.\n\u201cReactions from the oral challenges at the end of the study were much milder than prior to treatment,\u201d Tilles said, according to EurekAlert.\nThe study\u2019s authors noted that patients would need to stay on the drug in order to receive protection against the allergy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports the benefits of treatment in two different ways: \u201ctwo thirds of people in the study were able to tolerate the equivalent of two peanuts per day after nine to 12 months of treatment,\u201d and on average, \u201cparticipants were able to tolerate a 100-fold higher dose of peanut at the end of the study than they did at the beginning.\u201d\nThat barely passes the bar.\nUnfortunately, both those descriptions are in the form of canned quotes from the study author and neither compares the result to the control group (which had a placebo treatment).\nWe also think more detail could have been added to show the extent of benefit, and what it means for kids. For example, it would have been helpful to note that almost 20% of the treatment group withdrew from the study, which suggests many patients might quit the therapy.", "answer": 1}, {"article": "Both are reasonable options.\u201d\nNow a placebo-controlled study has found that the treatments are equally useful in reducing the frequency of episodes of incontinence, but vary in side effects and long-term effectiveness.\nThe scientists, writing online on Oct. 4 in The New England Journal of Medicine, found that both treatments significantly reduced incontinence episodes.\nSignificantly, those who took Botox were more likely to have their symptoms completely disappear.\n\u201cThese are both effective treatments,\u201d said the lead author, Dr. Anthony G. Visco, an associate professor of obstetrics and gynecology at Duke.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story briefly mentions that the two treatments \u201cvary in side effects and long-term effectiveness,\u201d but these are never quantified. Instead, the article mentions the certain side effects are \u201cmuch more common,\u201d such as dry mouth for the anticholinergic drugs, but actual figures would have helped to put expressions like \u201cmuch more\u201d into perspective.\nThe article twice uses the word \u201csignificantly.\u201d For example, the story states : \u201cScientists\u2026 found that both treatments significantly reduced incontinence episodes,\u201d and also, \u201cSignificantly, those who took Botox were more likely to have their symptoms completely disappear.\u201d And here, actual figures are a must, since \u201csignificantly\u201d has a very different meaning to the general population than to researchers, who usually mean \u201cstatistical significance.\u201d For example, 27 percent of the botox group saw their urinary symptoms disappear, versus 13 percent of the anticholinergic group. The inclusion of these figures put the story\u2019s \u201csignificantly\u201d into perspective.\nJournalists can help readers understand the difference between statistical significance and clinical significance.", "answer": 0}, {"article": "As myelin damage continues over the course of the disease, neurons progressively lose their ability to reliably transmit electrical signals, resulting in progressive loss of vision, weakness, walking difficulties, and problems with coordination and balance.\nThe new results are particularly notable, Chan said, because patients in the trial had suffered from MS symptoms caused by injury to myelin for years.\nThe drug tested in the trial, clemastine fumarate, was first identified as a candidate treatment for MS in 2013 by UCSF's Jonah R. Chan, PhD, Debbie and Andy Rachleff Distinguished Professor of Neurology, vice chief of the Division of Neuroinflammation and Glial Biology, and senior author of the new study.\nThat myelin increases the speed of neural transmission is one of the most well-established concepts in neurobiology, and combined with the clear evidence from Chan's preclinical research showing that clemastine fumarate promotes myelin formation, myelin regeneration is the only plausible explanation for the VEP results, the authors said.\nThe researchers said that the Phase II results, published online on 10 October, 2017 in The Lancet, are the first in which a drug has been shown to reliably restore any brain function damaged by a neurological disease in human patients.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t cite any figures to support its benefits claims. It only states that neural signals from the eyes to the brain were \u201csignificantly accelerated over baselines measurements.\u201d\nThe study authors report that clemastine reduced the delay by 1.7 ms/eye in the treatment group compared to the placebo group.\nWe caution against using the word \u201csignificant\u201d when describing benefits data due to its ambiguity. \u201cSignificant\u201d in a scientific context usually refers to a result being \u201cstatistically significant,\u201d which means the result is probably not attributable to chance.\nIt\u2019s important to recognize the distinction between significance on a lab test (a surrogate outcome) and something patients actually care about\u2013a clinical improvement in a symptom. In this study they measured visual acuity, for example, and found no difference between the groups. Perhaps in a longer trial they would find a difference, but this should be made clear. A lot more work needs to be done to see if this drug will be truly useful.\nSince benefits data are not given quantitatively, we rate this one Not Satisfactory.", "answer": 0}, {"article": "If nothing else, \"The Business of Being Born,\" with its indelible image of a naked, exhilarated Ricki Lake cooing \"Hi there!\"\nWolf and other natural-birth advocates say we need a better idea of what normal birth looks like, as movies and TV usually depict the process as painful and bloody.\nThis, according to Lake, the executive producer of the film, and Abby Epstein, the film's director, is the right reaction: one of their messages is that C-sections should only be performed when needed to guarantee the well-being of the mother and infant, and should not be a first choice for healthy mothers.\nBut the image that viewers may find most shocking is that of a baby being cut out of a woman's abdomen via Caesarean.\nDoctors such as Stark say we need a better sense of what goes on while the baby is still in utero.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides information on the risks of C-section versus vaginal birth in absolute terms. [Because the story focuses on the harms of C-section, this criteria will be applied to the presentation of harms of the surgery, not the benefits.]", "answer": 1}, {"article": "In 2016, he was ranked the No.\nIn a commentary published in the current issue of the American Journal of Medicine, researchers from the Charles E. Schmidt College of Medicine at Florida Atlantic University reassure clinicians and their patients that varenicline, whose brand name is Chantix, is a safe and effective way to achieve smoking cessation and that failure to use this drug has caused preventable heart attacks and deaths from cardiovascular disease.\nThe authors speculate that if use of varenicline had not plummeted by 76 percent following the black box warning in 2009, perhaps 17,000 premature deaths from cardiovascular disease may have been avoided each year during the last few years.\n\"The existing totality of evidence suggests an urgent need to increase the use of varenicline in the general population as well as in those with serious mental illness who on average die about 20 years earlier than the general population, in part, because their smoking rates may be as high as 75 percent,\" said Hennekens.\nIn 2006, varenicline was approved as a safe and effective means to quit smoking and achieved permanent quit rates of approximately 25 percent.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits here would presumably be the reduction in premature deaths among people who successfully quit smoking. The release provides one number, saying: \u201cThe authors speculate that if use of varenicline had not plummeted by 76 percent following the black box warning in 2009, perhaps 17,000 premature deaths from cardiovascular disease may have been avoided each year during the last few years.\u201d However, that\u2019s a somewhat vague estimate, and it\u2019s not clear exactly where this number comes from. To be clear: the number may be completely accurate, but the release needs to explain where the number comes from. And it doesn\u2019t.\nIt also states that those using Chantix have a 25 percent success rate at stopping smoking, but they don\u2019t say how this compares to overall success rates for those attempting to quit.", "answer": 0}, {"article": "Lovaza is an omega-3 drug FDA-approved for the treatment of severe high triglycerides at the dose of 4 milligrams daily.\nThese findings may help to support future research looking at the direct effect of omega-3 supplementation on breast cancer incidence in obese women.\nManni added that, with obesity-related cancers on the rise, the findings could have implications beyond breast cancer.\nAt the conclusion of the two-year study, the researchers found that increasing levels of omega-3 in the blood were associated with reduced breast density\u2014but only in women with a body mass index above 29, bordering on obesity.\nThe study included 266 healthy postmenopausal women with high breast density detected by routine mammograms.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The headline states,\u201dOmega-3 Fatty Acids May Lower Breast Cancer Risk in Postmenopausal Obese Women,\u201d and the opening paragraph follows with basically the same statement. But nowhere in the release does it explain how much this supplement may lower a woman\u2019s risk. It says that breast cancer density is a biomarker for breast cancer risk and that obese women taking the supplement had a reduction in tissue density after two years but no details to back up the claim. In stories and releases focusing on cancer risk, the public wants, and rightly deserves, real numbers so that they can make informed decisions. This release only offers a vague prediction of risk reduction. Lastly, the release states that the omega-3s \u201cmay lower\u201d the cancer risk, but readers could just as easily conclude that it \u201cmay not\u201d without more information.", "answer": 0}, {"article": "\"It is not going to be reimbursed by insurance, at least for the first generation and certainly for the foreseeable future,\" he said.\nPatients who did not receive the device lost about half that amount of weight -- just over 3 percent of their total body weight, the FDA said.\nThat clinical trial was funded by the company that makes the ReShape system, according to a presentation from the Obesity Society annual meeting in Boston.\nBut the device can only be used for six months at a time, and it is not likely to be an alternative for people who require lap-band surgery, stomach stapling or other forms of bariatric surgery, said Dr. Mitchell Roslin, chief of obesity surgery for Lenox Hill Hospital in New York City.\nThe device doesn't change the stomach's natural anatomy, according to the FDA.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u00a0states \u201cthe ReShape system helped people more than double their weight loss compared to those trying to lose weight through diet and exercise.\u201d\u00a0We also\u00a0also note that because\u00a0previous studies on weight loss suggest that the average individual is hoping for a loss of 20% or more of presenting weight, \u201cdouble\u201d as a descriptor, when discussing very small losses, may be a bit loaded.\nIn\u00a0the final paragraph, the story includes absolute values of weight loss:\n\u201cIn the clinical trial, the 187 participants who used the device lost an average of more than 14 pounds, or about 7 percent of their total body weight. Patients who did not receive the device lost about half that amount of weight \u2014 just over 3 percent of their total body weight, the FDA said.\u201d\nKudos to the writer for including the comments from the researcher who said the results may be temporary.", "answer": 1}, {"article": "In early September, the FDA held scientific meetings to clarify how to regulate such practices.\nThe researchers say such testing is needed because there are at least 600 stem cell clinics in the U.S. offering one form of stem cell therapy or another to an estimated 100,000-plus patients, who pay thousands of dollars, out of pocket, for the treatment, which has not undergone demanding clinical study.\nHe adds that these findings are important because while use of a patient\u2019s own stem cells for regenerative therapy is extraordinarily popular, the treatments may be untested and are often poorly regulated.\nGiven that the stem cell-treated knee was no better than the control-treated knee \u2014 both were significantly better than before the study began \u2014 the researchers say the stem cells\u2019 effectiveness remains somewhat uninterpretable.\nThey are only able to conclude the procedure is safe to undergo as an option for knee pain, but they cannot yet recommend it for routine arthritis care.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release talks about \u201cdramatic improvement\u201d in the injected knees, but gives the reader no clue about what the baseline level of pain was, or how the improvement was measured. The investigators used a standard international measure of pain relief and function to score the patients before and after treatment. The release needed to describe the results more meaningfully. For example, it could have noted the range of improvement in the 25 patient volunteers.\nIt\u2019s unclear why the release positioned this as a positive study suggesting that the treated knee got better. The problem is that the study design was testing to see if there was a difference between treatment and placebo \u2014 and there wasn\u2019t. This means that the stem cell treatment was no better than the saline placebo, or a sham treatment. In claiming that the stem cell treatment was effective, the release quotes a study investigator saying that it is possible that the injection of stem cells into one knee resulted in benefit to the other.\nNo evidence is provided to support this hypothesis.\u00a0", "answer": 0}, {"article": "I hurt so bad, everything hurt,\" Marylin adds.\nLaPook notes that it will be a few more years before this procedure is widely available.\nThat's still the standard procedure for the 50,000 Americans who are operated on each year for this problem.\n\"I was so happy that I was OK, that I had escaped the open heart,\" Barletta says.\nHe says it's in the final stages of testing at about 30 hospitals around the country.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "What we learn about benefits in this story are that the use of this procedure reduces time spent in the hospital, the length of the recovery period, and eliminates having the scar associated with an open heart procedure.\u00a0 \nHowever, the story included nothing about the extent to which the medical problems associated with heart valve disease are repaired with this device, how long the repair is expected to be functional, or other benefits that might come from the use of this device.", "answer": 0}, {"article": "When patients are in an abnormal irregular heart rhythm called atrial fibrillation, blood clots can form in the LAA, which can then circulate out through the bloodstream and cause stroke.\nThe researchers found that while results from the trials varied, the device did appear to be more cost-effective in the larger, longer-term trial.\nHowever, longer-term results are needed to be completely certain of the device's value in clinical practice, he said.\nIt has been suggested that as treatment for atrial fibrillation, the Watchman device may be preferable to standard blood thinning medications, such as warfarin, which raise the risk of bleeding.\nTo assess the cost-effectiveness of the device versus medication, the researchers developed a statistical model based on data from two key research trials, known as PROTECT AF and PREVAIL.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release says that \u201cthe device did appear to be more cost-effective in the larger, longer-term trial,\u201d but it does not say what made it appear to be more cost-effective.\nIt then adds a quote from the lead author, Dr. James Freeman, in which he says longer-term results are needed to be certain of the device\u2019s value in clinical practice. But, since it never quantifies the length of the results that were obtained, we do not know how long the longer-term data need to be.\nPerhaps more importantly, it does not talk about the effectiveness of the product compared with the effectiveness of standard treatments.", "answer": 0}, {"article": "Dr. Matthew Brams, M.D., Clinical Assistant Professor at Baylor College of Medicine and principal investigator for study 305, added: \"The study of SHP465 in children and adolescents is an essential next step to progressing the clinical program.\n\"These results represent an important step toward a new treatment option for patients with ADHD.\nThe CGI-I is a standardized assessment tool that allows clinicians to rate the severity of ADHD illness, change over time and efficacy of medication.\nOnce the pharmacokinetic study and an additional safety and efficacy Phase 3 trial in adults currently under way are complete later this year, Shire plans to add these study results to its existing SHP465 data set to submit a Class 2 resubmission for FDA approval of the medicine for treatment of ADHD.\nIncluding study 305 and previous studies, Shire now has a robust database of 15 clinical studies evaluating SHP465 in more than 1,100 subjects.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does a good job of explaining the benefits of the drug to children and adolescents with ADHD in relationship to a placebo and to a standardized measurement of improvement, but does not compare this new drug with existing treatments. It\u2019s difficult to estimate how many people would want a stimulant that lasts 16 hours. Even if they do, it would be much cheaper to take a dose of an existing, shorter acting drug in the early afternoon.", "answer": 1}, {"article": "Mannitol pulls water out of the tightly packed cells lining the capillaries so that they shrink and pull away from one another, opening up gaps through which drug molecules can pass into the brain.\nThat means a lot to me.\u201d\n\nDr. Boockvar said: \u201cAvastin may not be the best drug for this delivery technique.\nBut a scan found a brain tumor nearly the size of a golf ball.\n\u201cNobody knows.\u201d\n\nIndeed, the death of the first patient was a reminder that glioblastoma can invade other parts of the brain and the spinal fluid and that the highly localized spray of Avastin might miss deadly seeds of cancer.\nThen Dr. Boockvar ticked off the risks from a second brain operation.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "With only a Phase I study underway, there is no data to report. The story makes this clear. ", "answer": 1}, {"article": "Previous studies have shown that nitrites \u2014 also found in high concentrations in celery, cabbage, and other leafy, green vegetables like spinach \u2014 widen blood vessels, but researchers say this was the first to find that nitrites also increase blood flow to the brain .\nAn hour later, an MRI scan recorded brain flow in each person\u2019s brain.\nOn the second day, after another 10-hour fast, the participants returned to the lab and ate their assigned breakfasts.\nOn the third and fourth days, researchers switched diets and repeated the process for each person.\nMRI scans showed that after eating a high-nitrate diet, the older adults had increased blood flow to the white matter of the frontal lobes, which are the areas of the brain most commonly associated with the degeneration that leads to dementia and other cognitive conditions.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As we said in the \u201cdisease-mongering\u201d criterion above, benefits were not expressed in terms of any outcomes that people would really care about in their lives, but, rather, only in terms of improved test scores which may not correlate with improved outcomes.", "answer": 0}, {"article": "According to the Centers for Disease Control and Prevention (CDC), birth defects caused by genetic disorders affect one in every 33 births in the United States.\nSpecialists now have a way to test the parents-to-be that may not only increase their chances of getting pregnant but also reduce the risk of them passing on certain genetic diseases.\nExperts say the couples are not the only people who benefit from these tests.\nA diagnosis before pregnancy may sound like a designer baby, but doctors say that\u2019s not the case.\nPre-implantation genetic screening doesn\u2019t necessarily get patients pregnant unless they have good embryos, Robbins noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t quantify benefits. The story tells readers 1 out of 33 births has a genetic disorder. We want to know: Does the screening identify all of them? How accurate are the tests? How much do they \u201climit the chances of an embryo carrying a chromosomal disorder from being implanted?\u201d Readers deserve to see numbers around these limits. It\u2019s also far from clear this applies only to IVF. The story makes it sound like this applies to any pregnancy.", "answer": 0}, {"article": "For example, many hips and knees use a combination of metal and polyethylene parts, and continuous motion can wear away small polyethylene particles.\nPatients say that regaining function after surgery requires enormous mental and physical effort.\n\"Pre-hab\"\u2014building up strength before the surgery\u2014is just as important as re-hab afterward, they say.\nSeveral studies of hips and knees implanted in patients long ago have found that 85% to 90% are still functioning well after 20 years.\nLast year, one manufacturer, Smith & Nephew , won clearance from the Food and Drug Administration to market its latest technology as a \"30-year knee\" based on tests mimicking 30 years of wear.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article did not adequately quantify the benefits of knee and hip replacement in terms of pain relief, function, or quality of life.\u00a0 It would have been useful, for instance, for readers to learn that in older patients roughly 90% of primary knee and hip replacement procedures result in significant pain relief and functional improvement\u2014with low levels of complications. Younger patients might expect similar short-term outcomes but their long-term outcomes would be less predictable. (The story cited studies showing 85-90% of implants \u201cstill functioning well after 20 years\u201d but that\u2019s not a comment on pain relief and peoples\u2019 functional improvement.)\n\n \n", "answer": 0}, {"article": "\u201cShe sent me a picture of Giovanni playing in his front yard,\u201d Kefalis said.\nTeichner asked, \u201cDo you believe that gene therapy is finally coming into its own?\u201d\n\nThe MLD trial, she thinks, demonstrates what\u2019s possible -- offering promise to the 30 million Americans who suffer from some 7,000 rare diseases.\nOne sign: Dr. Biffi is now head of the gene therapy program at Dana-Farber/Boston Children\u2019s Cancer and Blood Disorders Center.\nAnd when Kefalis learned about the Italian trial, and the fact that Amy Price had to keep going back to Milan with Giovanni and Ceci, it was clear she would use the money to help families get to Italy.\nAnd it runs in families.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not clearly state the quantified benefits seen in the experimental trial, though it does make reference to the research. All we\u2019re told is \u201cAt least 70-80% of them have an outstanding benefit coming from the treatment.\u201d But, what does \u201coutstanding\u201d mean? And how many kids are we talking about? It sounds like possibly 24, but we\u2019re not sure. And, what\u2019s happening to the other third who aren\u2019t seeing \u201coutstanding\u201d benefits?\nThe reporter\u00a0does say that \u201cit will take years to know for sure\u201d if the treatment works, but ends the story on the word \u201cmiracle\u201d and leans heavily on the anecdotal experience of a single family, which diminishes the previous cautious statements.", "answer": 0}, {"article": "\"So, yes, one of the limitations of this kind of study is always the question of its generalizability to other populations,\" he cautioned.\nRamsden acknowledged that the Sydney study had been narrowly focused on a specific group of people: middle-aged men with a history of heart disease, who were asked to consume linoleic acid in quantities far exceeding both AHA guidelines and the dietary habits of most Americans.\nBut an updated look at the study indicates that heart disease patients who follow this advice may actually increase their risk for death.\nWEDNESDAY, Feb. 6, 2013 (HealthDay News) -- Enduring dietary wisdom -- that polyunsaturated vegetable fats are better for your heart than saturated animal fats -- may be turned on its head by a fresh analysis of a nearly 50-year-old study.\nThe 458 male participants in the original study had been between the ages of 30 and 59 at enrollment, and all had a history of heart disease, with most having survived a heart attack.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not provide statistics regarding the percentage of people who died, from what causes, in each group of this study. That information would have been easy to communicate, so we\u2019ll provide it here:", "answer": 0}, {"article": "Hospice care is intensive palliative care including home nursing, but insurers and Medicare usually cover it only if the patient abandons medical treatment and two doctors certify that death is less than six months away.\nIn practice, Medicare and private insurers do pay for some palliative care, said Dr. Gail Austin Cooney, a former president of the palliative medicine academy.\nIt shows that palliative care and cancer care aren\u2019t mutually exclusive.\u201d\n\nDr. Atul Gawande, a Harvard Medical School surgeon and writer who just published a long article in The New Yorker about hospitalized patients\u2019 suffering before death, called the study \u201camazing.\u201d\n\n\u201cThe field was crying out for a randomized trial,\u201d he added.\n\u201cBut I couldn\u2019t have completed the program without the psychosocial support.\u201d\n\nPalliative care experts now want to study patients with other cancers, heart disease, stroke, dementia and emphysema.\nThis trial was paid for by the American Society of Clinical Oncology and private philanthropy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Like the competing coverage, this story\u00a0featured prominent discussion of\u00a0the survival benefit associated with palliative care.\u00a0We were pleased to see that it also\u00a0spent\u00a0some time on\u00a0the improvement in quality of life\u00a0and depression scores as well as the reduction in aggressive chemotherapy usage toward the end of life in the palliative care group. We wish the story had been more precise in its quantification of some the benefits \u2014 it notes that the palliative care group reported \"less depression\" and \"happier lives\" but offers no way to judge the magnitude of the benefit. However, we don\u2019t think these\u00a0shortcomings\u00a0were enough to throw the story out of balance.", "answer": 1}, {"article": "Although TEPI patch remains highly tacky and adheres well to skin, it is not uncomfortable to peel off, unlike many traditional plasters.\nWe\u2019re controlling the dosage and we\u2019re keeping it there for a prolonged period of time.\u201d\n\nThe patches could help treat conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally.\nUniversity of Warwick research chemist Professor David Haddleton told Reuters that the polymer matrix in the patch acts as a reservoir for the drug, capable of releasing between five and ten times the amount of drugs used in gels and patches currently on the market, for periods of six hours, 12 hours, and even 24 hours.\nHe said Medherant\u2019s technology would eliminate most side effects created by oral medication.\nThe team says that popular ibuprofen gels make it difficult to control dosage and can be easily rubbed off.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is full of superlatives but provides absolutely no information on how the TEPI patches were tested. \u00a0All of the information provided appears to be related to results in the lab and not on people. \u00a0We are told, \u201c\u2026capable of releasing between five and ten times the amount of drugs used in gels and patches currently on the market, for periods of six hours, 12 hours, and even 24 hours.\u201d How long do current gels and patches last? How much medication do they release? Is is important to be able to achieve the higher dosages discussed in this story? While it all sounds very impressive,\u00a0the reader isn\u2019t provided enough information to tell if any of these results are meaningful.", "answer": 0}, {"article": "Tremors limited to the hand and forearm, for instance, might respond better than tremors that also affect the shoulder.\nMuscle weakness was the most common side effect in this study, van der Walt said.\nLarger studies, of more-diverse groups of MS patients, are needed, he said.\nThe study\u2019s lead researcher agreed on the need for more work.\nOn average, the patients\u2019 tremor \u201cscores\u201d had gone from a 5 to a 3 six weeks after Botox treatment \u2014 which essentially means moving from \u201cmoderate\u201d to \u201cmild,\u201d LaRocca said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate.\nThe story reported:\nOn average, the patients\u2019 tremor \u201cscores\u201d had gone from a 5 to a 3 six weeks after Botox treatment \u2014 which essentially means moving from \u201cmoderate\u201d to \u201cmild,\u201d LaRocca said. Their ability to write and draw a straight line had also improved by week six, and the benefits were still there at week 12.\nIn contrast, there were no improvements after the placebo injections.\nBut the \u201con average\u201d doesn\u2019t tell much about the range of progress across the 23 people.\u00a0 That wouldn\u2019t have been difficult to explain.", "answer": 1}, {"article": "So patients are caught in the middle.\"\nIn an editorial accompanying the new paper, another addiction and pain specialist, William C. Becker, Ph.D. of Yale University and the Connecticut VA, notes that the new results are even more impressive because ImPAT was compared with another psychosocial approach.\nAnd the study's authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\nAddiction treatment programs often have patients who suffer from chronic pain, but offer few options to treat them, Ilgen says.\nIlgen and his colleagues hope their results will help bring the techniques into addiction treatment settings, where the cognitive behavioral therapy approach is often used.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release addresses benefits in two ways: perceived effects, and how long they last. Here\u2019s what it said about the beneficial effects: Patients \u201cfound that the intensity of their pain decreased, their ability to function increased, and their alcohol use went down, compared to [patients] who received a less-focused approach. However, the two groups had similar rates of drug use.\u201d Kudos to the release for highlighting the lack of effect on rates of drug use.\nHowever, it\u2019s important to tell readers how much the patients\u2019 pain decreased, alcohol use went down and ability to function increased. Are we talking about a statistically significant, but functionally irrelevant, margin? Or are we talking about a substantive difference? Readers want to know.\nThe release also notes that \u201cJust 10 weekly sessions of [ImPAT] had an effect that lasted up to a year in 55 [patients] who took part.\u201d That\u2019s good to know \u2014 but that\u2019s 55 patients out of how many? If you read the paper, you\u2019ll see that the finding was true for 55 out of 65 patients who participated in ImPAT. That\u2019s a strong result. But readers can\u2019t know that if the release doesn\u2019t tell them.", "answer": 0}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides early data from a trial of metastatic breast cancer patients. Cancers in these patients remained stable (i.e. it did not spread further in the body) nearly twice as long with the addition of lapatinib to chemotherapy (8.5 months vs. 4.5 months). There were fewer incidents of metastases to the brain in the women who took lapatinib and chemotherapy compared with chemotherapy alone (4 vs. 11 cases of cancer spreading to the brain). However, many drugs have been shown to effective in prolonging response in metastatic disease without impacting length of life so it would be good to get data on survival data to back up these claims or at least on quality of life to see whether it made a difference and how much.", "answer": 1}, {"article": "For nine months, the developing fetus is attached to its mother by the umbilical cord.\nIron is essential to the developing brain, he said, and deficiencies during early months \u2014 perhaps linked to early clamping \u2014 could affect nerve and muscle control, making it harder for the child to later control a pen or interact comfortably with peers.\nAndersson's study marks the first time researchers have followed children to see whether the clamping makes a difference later in life.\nHis previous research has shown that babies whose cords were clamped a few minutes later than usual were 90% less likely than others to have iron-deficiency anemia when they were 4 months old.\nIn the new study, Andersson found that healthy, full-term newborns whose umbilical cords were left attached for three extra minutes had better fine motor control when they reached preschool than those clamped immediately.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story asserts that healthy, full-term newborns whose cords were left unclamped for three extra minutes at birth \u201chad better fine motor control when they reached preschool\u201d than a control group whose cords were clamped immediately. But we aren\u2019t provided adequate context or any numbers for how much better some of the children performed. Was this a large, meaningful benefit? Or something barely distinguishable from statistical noise?\nThe story also notes: \u201cHis previous research has shown that babies whose cords were clamped a few minutes later than usual were 90% less likely than others to have iron-deficiency anemia when they were 4 months old.\u201d This is an incomplete representation of the benefit, since the absolute reduction in anemia was lower than this number suggests.", "answer": 0}, {"article": "When considering where to give birth, most parents-to-be and doctors in Western nations believe a hospital is the best place.\n\nNot so Jean Stevens, 32, who chose to deliver two children at home in the U.K. She says her two labors were nearly pain-free.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story addresses benefits in only general terms. For example, when summarizing the NICE guidance, the story states \u201chome births are safer than hospital births for women who are having their second or later child with a low-risk pregnancy.\u201d And when describing the findings of the U.K. study that was the basis for the guidance, the story notes that \u201camong low-risk women who chose to have a second or later child at home, there were fewer interventions and complications, such as cesarean sections, forceps delivery, infections and hemorrhage compared with hospital births, while the health of babies didn\u2019t differ.\u201d How much safer are home births under the relevant circumstances? How much lower was the risk of complications? It would be helpful to have at minimum an estimate of a summary figure, such as the frequency of complications and interventions overall for home and/or hospital births. In addition, while the story makes clear that the reduced risk is only for women with low-risk pregnancies \u2014 it doesn\u2019t tell readers what that means. Does having had a previous C-section rule out a low-risk pregnancy? Which chronic medical conditions might rule a low-risk pregnancy out? It\u2019s not clear.", "answer": 0}, {"article": "As examples, smoking rates were highest among those without a graduate education degree certificate and lowest among those with a graduate degree; higher among those living below the poverty level versus above it; and higher among some minorities such as American Indians and Alaska Natives, multiple- race individuals and blacks.\nAlso, about half of patients screened continue to smoke so screening might also be a logical point for smoking intervention, Schroeder said.\nLike the previous experiences, the Augusta area screening that started in 2014, also reiterated the ability of LDCT to find lung cancer early, said Schroeder, corresponding author of the study in Southern Medical Journal.\n\"That's why the acid test for screening is not how many cancers you find or what stage the cancer is,\" Thomson said, rather what screening does to lung cancer death rates.\nFollowing the trial, the National Comprehensive Cancer Network, a nonprofit organization of cancer centers that develop guidelines for cancer diagnosis and treatment, along with the United States Preventive Services Task Force, which makes recommendations for preventive medicine, recommended screening high-risk individuals on a slightly broader scale, which the Lahey and Augusta area screening used.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release tells us how many cancers were found with the screening program, but it includes a misleading statement about what this might mean for survival rates. It notes that if lung cancer is identified in its early stages, the \u201coverall survival rate\u201d is 90 percent, whereas five-year survival rates for patients whose cancer is identified in the advanced stages is approximately 5 percent.\nA 90% vs. a 5% survival rate sounds impressive, but this is likely a significant overstatement of the true difference. Why? As Professor Gerd Gigerenzer of the Max Planck Institute explained in a BMJ editorial, the answer has to do with something called \u201clead time bias.\u201d He said, \u201cEarlier detection implies that the time of diagnosis is earlier; this alone leads to higher survival at five years even when patients do not live any longer.\u201d\nThis Youtube video by Dr. H Gilbert Welch discusses this issue in more detail. The bottom line is that when cancers are diagnosed at an earlier stage due to screening, patient survival time will be longer than if they were diagnosed later. This may or may not mean their survival was prolonged. They may have been destined to die at the same age regardless of when the cancer was diagnosed.", "answer": 0}, {"article": "Ms.\nTo be sure, more than half of patients with metastatic melanoma would not be helped all that much by either drug.\nThe new trial of this drug, by contrast, involved patients who were getting treated for the first time.\nThe effect was so marked that the trial was stopped early for ethical reasons, so that patients in the control group could be offered the new drug.\nIn the trial, sponsored by Roche and led by Dr. Paul B. Chapman of the Memorial Sloan-Kettering Cancer Center in New York, 38 percent of participants had to stop taking the drug or lower the dose because of side effects, including rash and joint pain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Good job describing the benefits reported in the two drug studies. The two papers present a bewildering array of statistics. This story did a nice job distilling the information into a couple of very understandable sentences.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Did not present estimate of absolute risk or benefit.", "answer": 0}, {"article": "Keytruda is already approved for treating melanoma, lung cancer, head and neck cancer and Hodgkin lymphoma.\nMerck said data from an open-label Phase 3 trial of 542 advanced bladder cancer patients showed median survival of 10.3 months for Keytruda patients and 7.4 months for patients given second-line chemotherapy.\nThe Merck drug is awaiting U.S. Food and Drug Administration approval, but Tecentriq was approved by the agency last year, contingent on verification of its clinical benefit.\nThe data, to be presented next month at a meeting of the American Society of Clinical Oncology, follow last week\u2019s announcement that rival drug Tecentriq, from Roche Holding AG, did not improve survival when used as a second-line treatment for bladder cancer in a trial.\nAfter 18 months, 36 percent of Keytruda patients were alive, compared with 20.5 percent of chemotherapy patients, according to research published by ASCO.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify the benefits of the intervention, and it does so in absolute terms.\n\u201cMerck said data from an open-label Phase 3 trial of 542 advanced bladder cancer patients showed median survival of 10.3 months for Keytruda patients and 7.4 months for patients given second-line chemotherapy. The study\u2019s median follow-up was 18.5 months. After 18 months, 36 percent of Keytruda patients were alive, compared with 20.5 percent of chemotherapy patients, according to research published by ASCO. The study did not detect a difference in the length of time patients lived without their disease getting worse.\u201d\nThis is sufficient to be satisfactory, but we do think more could be said about if this minimal time difference truly make an impact on patients\u2019 lives, or not. Are the patients healthy enough to make meaningful use of the additional time they receive with treatment?", "answer": 1}, {"article": "Their median age was 63.\nBut with better therapies to control the cancer systemically and improved imaging that finds ever-smaller deposits of cancer in other parts of the body, it may be time to see whether surgery also can help increase the length of survival times, they said.\nIn retrospective research, it's impossible to filter out the countless reasons that a woman and her doctor might have made the decision to treat the cancer with or without surgery, leaving the conclusions unreliable for clinical decision-making, he said.\nTwo small prospective studies have suggested no survival difference among women with Stage 4 breast cancer who have surgery and those who don't, he said.\nStill there may be reasons to remove the cancer in the breast.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The Washington Post story quantifies the potential benefits of surgery, detailing that women who underwent breast surgery had better survival rates than those that didn\u2019t (median of 28 months versus 19 months). Despite the better outcomes, the article adds the number of surgeries dropped from 67.8 percent in 1998 to 25.1 percent in 2011, which it describes as an \u201cintriguing question\u201d about that approach.\nFurthermore, the story is quick to point out early in the story that surgery may not be the right option for all women and \u201cmay be better for some women than it was in 1995.\u201d\nWe applaud the fact that the benefits are reported in absolute terms and in a more cautionary manner, which is why we give it a Satisfactory rating here.", "answer": 1}, {"article": "\"Everyone heals differently.\nThere are different pathways to healing, and whether you feel you're better off with chiropractic, home exercises or medications, this study shows that all three are basically just as effective.\nThere also isn't a great deal of information on how effective medications or home exercise programs are for treating neck pain, the researchers noted.\nThe goal of the home-exercise program was to improve movement in the neck area.\nAll three experts said anyone experiencing neck pain needs to have it evaluated to make sure there isn't a serious or correctable cause of the pain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story includes both some of the specific results reported by researchers as well as more conversational descriptions of the overall experiences of people in this trial. Readers get the message that people with neck pain tend to feel better as time passes no matter which treatment option they used and that none of the treatments is clearly superior or can deliver sure-fire pain relief.", "answer": 1}, {"article": "The U.S. National Cancer Institute has more about colon and rectal cancer.\n\"The results of our study help to further clarify the importance of different durations of NSAID use over time for the risk for dying from colorectal cancer,\" Coghill noted in the news release.\nStudy participants were enrolled in the Women's Health Initiative, which \"represents a large and well-characterized cohort [group] of postmenopausal women, and the medication data collected in this cohort made it possible for us to investigate multiple types, durations and strengths of NSAID use,\" Coghill explained.\nIn the study, researchers examined the use of aspirin and non-aspirin NSAIDs among more than 160,000 postmenopausal women in relation to deaths from colorectal cancer.\nThe findings were slated for presentation on Sunday at the AACR International Conference on Frontiers in Cancer Prevention Research, in Boston.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only benefit mentioned in the story was the \u201croughly 30 percent lower rate of death from colorectal cancer,\u201d as stated in the press release, but 30 percent of what?", "answer": 0}, {"article": "For more fitness, food and wellness news, follow us on Facebook and Twitter, or sign up for our newsletter.\nHowever, the data do begin to shed light on why babies born through vaginal birth may have fewer health risks than babies born by C-section.\nThe finding suggests that the arduous experience of labor \u2014 that exhausting, sweaty, utterly unpredictable yet often strangely exhilarating process \u2014 may give children a healthy start, even when it\u2019s interrupted by a surgical birth.\nThe findings are a reminder that although C-sections are appropriate in some circumstances, they are a poor substitute for labor.\nThe Scottish study took advantage of the small country\u2019s rich trove of linked birth and medical databases to track the long-term health of 321,287 babies.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article doesn\u2019t go far enough in explaining the difference in risk between the planned and unplanned C-sections, and the vaginal deliveries.\nThe story presented only the relative increased risk of 35% (from a hazard ratio of 1.35) in type 1 diabetes, despite the fact that the absolute risk was 0.22 (less than 1/4 of 1 percent!). This is a VERY modest increase and was only statistically significant because of the huge sample size.\nReaders need this kind of context to be able to interpret the findings.", "answer": 0}, {"article": ".\nResults of the human study showed that imaging was effective for the evaluation of metastatic prostate cancer, and subsequent therapy resulted in a drop in prostate-specific antigen levels from 38.0 to 4.6 nanograms per milliliter.\nDiagnosis and therapy with the theranostic agent PSMA-617 could offer more effective and sensitive visualization, better staging and significantly higher therapeutic potential.\nDiagnostic imaging was followed by a therapy-grade radionuclide, lutetium-177, which delivers a more powerful dose of radiation that penetrates and destroys the cells and tissues of tumors when combined with PSMA-617.\nPositive response to therapy was verified via combined PET and computed tomography (PET/CT), a hybrid imaging system that shows both functional and structural aspects of the body.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We are told that PSA\u00a0levels dropped from 38.0 to 4.6 nanograms per milliliter and that the result was verified by PET scan and computed tomography. But we have no information about the time period over which the PSA dropped, whether there were additional treatments, and whether PSA\u00a0levels remained low (and for how long) \u2014 and whether the patient is still alive. In treating metastatic cancers,\u00a0survival benefits are often quite short, e.g., the median survival benefit for sipuleucel (Provenge vaccine) was only 4 months. So we\u2019d want some evidence that patients are living longer (and more than just one of them) before talking about \u201cnew hope\u201d for this disease. We also disagree with the comment that \u201ccurrent clinical methods are not sensitive enough for detecting disease beyond the prostate.\u201d Currently used radionuclide bone scans can readily detect metastatic disease.", "answer": 0}, {"article": "Senator Arlen Specter, a Pennsylvania Democrat and longtime advocate for cancer screening, said in an interview: \u201cAnd this Pap smear guideline is yet another cut back in screening?\nThe doctors\u2019 group also felt it was safe to test women less often because cervical cancer grows slowly, so there is time to catch precancerous growths.\nDr. Kevin M. Holcomb, an associate professor of clinical obstetrics and gynecology at NewYork-Presbyterian/Weill Cornell hospital, said that when he heard the advice to delay Pap testing until 21, \u201cMy emotional response is \u2018Wow, that seems dangerous,\u2019 and yet I know the chances of an adolescent getting cervical cancer are really low.\u201d\n\nAs with the new mammogram recommendations, women may not readily give up a yearly cancer test.\nIn addition, Dr. Saslow said, doctors in this country have been performing 15 million Pap tests a year to look for cervical cancer in women who have no cervix, because they have had hysterectomies.\nStill, the new recommendations for Pap tests are likely to feed a political debate in Washington over health care overhaul proposals.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify benefits of screening.\u00a0 ", "answer": 0}, {"article": "For more information on stents, visit the U.S. National Library of Medicine.\nIn preventing major cardiac events, the researchers found that zotarolimus-coated stents, the new entry in the field, were less effective than the sirolimus-eluting stents, but better than stents coated with paclitaxel.\n\"Similar to other comparative stent trials, the sirolimus-eluting stent seemed to come out ahead in safety and efficacy,\" said Fonarow, who is also a cardiology professor at the University of California, Los Angeles.\nAfter a year, Park's team tallied the number of adverse cardiac events the patients experienced, including death, heart attack and the need for a new angioplasty on the same artery in which the stent was placed.\nThe number of heart attacks and deaths was about the same in each group, but the rate of blood clots in the stents was significantly lower with sirolimus-eluting stents, Park's team also found.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article gives the absolute rates of major adverse cardiac events for each treatment group.\u00a0\nAlso, while this is likely not a major issue for most readers and not an official strike against the article, as an FYI we point out that there are some interwoven\u00a0concepts that can be confusing. The article\u2019s headline is that SES won this contest. If you want to get technical, there are two buts.\u00a0First, while SES did have the fewest cardiac events of the 3 stents, the difference with ZES wasn\u2019t statistically significant. In other words, the apparent superiority of SES may have been do to chance. Or not. We don\u2019t know. Researchers call this\u00a0a trend but not significant evidence. \u00a0Second, this contest, the study, wasn\u2019t designed to answer whether SES was the best. The researchers concluded,\u00a0as quoted in the story,\u00a0that this study answered two main questions:\u00a0ZES and SES were similar, and ZES fared better than PES did. Notice it didn\u2019t say SES was the best.\u00a0", "answer": 1}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story used absolute measures to report the patients\u2019 outcomes, but it focused on results that showed the greatest advantage for surgery. The researchers presented several analyses. One analysis showed a very small but significant (~8/100 points) advantage for surgery at 2 years in pain reduction, but no advantage in function or disability; these were the outcomes of the randomized patients, analyzed according to their assigned treatments (an intention-to-treat analysis), and likely underestimate the value of surgery. Another analysis looked at all patients according to the treatments they actually received, and showed a modest but significant 11- to 14-point advantage for surgery in pain relief, function and disability. The news story did not report either of these analyses. The \u201ctruth,\u201d many observers would say, likely lies somewhere between the minimal/modest benefits that the news story did not report and the larger benefits that it did.", "answer": 0}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Insufficient.\u00a0 All we\u2019re told is that \u201c29 out of 36 participants experienced a decrease in histological grade of the precancerous lesion, or a slowing in the growth of the lesion.\u201d\u00a0 We\u2019re not told what the grade was to begin with nor what it decreased to nor how many of the 29 had what degree of decrease.\u00a0 And again, there was no discussion about what\u2019s known at all about the potential benefits of treating precancerous esophageal lesions.", "answer": 0}, {"article": "\"It's automatically responsive to our body function, producing stimulation when needed,\" says Wang.\n\"One potential advantage of the new device over existing vagus nerve stimulators is that it does not require external battery charging, which is a significant advantage when you consider the inconvenience that patients experience when having to charge a battery multiple times a week for an hour or so.\"\nThat means the device only stimulates the vagus nerve when the stomach moves.\nIn laboratory testing, the devices helped rats shed almost 40 percent of their body weight.\nUnlike gastric bypass, which permanently alters the capacity of the stomach, the effects of the new devices also are reversible.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release refers to \u201cseveral advantages over an existing unit that stimulates the vagus nerve for weight loss;\u201d however, since this device has yet to be tested in human subjects, it is too early to claim that it offers benefits greater than the FDA-approved device. What\u2019s more, while the release states that rats in this trial lost almost 40% of their body weight, studies of the existing weight loss device say people lost less than 10 percent of their body weight, and that was when they were in a program that included diet and exercise counseling. These important caveats should have been included.", "answer": 0}, {"article": "Letters being mailed to study participants advise them to discuss with their doctors whether they should have additional scans or not.\nMany smokers already had sought out spiral CTs, even though the American Cancer Society hasn't recommended the test - citing a lack of clear evidence that they work - and most insurance doesn't cover the $300 to $400 cost.\nIt found 20 percent fewer deaths from lung cancer among those screened with spiral CTs than among those given chest X-rays, the NCI said Thursday, a difference significant enough that it ended the study early.\nThe massive National Lung Screening Trial enrolled 53,000 current or former smokers to try to settle the debate.\nNor is it clear if the study results are applicable to all smokers.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThis story does a better job than some others in how it portrays the potential benefits of CT screening for lung cancer. The headline and lead report that deaths were reduced somewhat. The third paragraph of the story notes that among the 53,000 participants there were 20 percent fewer deaths among those offered CT scans compared to those offered chest x-rays, but that the \u201cactual number of deaths averted was fairly modest\u201d (354 in the CT group vs. 442 in the x-ray group). This way of presenting the results helps readers put the results in perspective. The story also notes that the National Cancer Institute said \u201cit\u2019s not clear that all smokers should get the scans.\u201d However, the story could have made it more clear that the reduction in lung cancer death rates was seen after five years of folllow-up, which leaves open the question about whether that difference will persist over a longer time frame.\nIt would have been helpful for this story to tell readers that 300 smokers had to be screened in this trial in order to extend the life of one of them.", "answer": 1}, {"article": "Among them: engaging in regular physical activity, maintaining a healthy weight, and not smoking cigarettes.\nEven so, he says, \"our results provide additional support for the potential benefit of daily aspirin for [reducing] cancer mortality.\"\nMany other strategies will also reduce the risk of cancer, he says.\nThe benefit, however, may not be as great as believed, says researcher Eric Jacobs, PhD, of the American Cancer Society.\nA previous study by others found daily aspirin reduced cancer death risk by 37%.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re going to take an admittedly hard-line stance on this because we think such a story can easily do a better job.\nThe story acknowledges at one point that the study \u201cfound an association, not cause and effect.\u201d\u00a0 Yet it uses cause and effect language in various places, such as:\n\u201cBenefit\u201d and \u201crisk reduction\u201d and \u201creduced risk\u201d convey more than an association.\u00a0 Those terms convey cause and effect.\u00a0 Take aspirin, get the \u201cbenefit\u201d of \u201creduced risk.\u201d\u00a0 This study, strongly suggestive though it may be given the numbers of people involved, cannot establish cause and effect.\nSo the suggestion of benefit needs to be couched in more careful language than this story did.\nThe competing Reuters story gave absolute risk reduction and was more cautious in general in interpreting results.\n\u00a0", "answer": 0}, {"article": "\"I'm not sure I'd want to sign up for that one before I had longer-term results,\" Califf said.\nUse as a single drug treatment for elevated cholesterol levels could follow, first in selected patients, then more widely, he said.\nThe trial's researchers were careful to list indications of possible harmful side effects, such as a reduction in levels of HDL (\"good\") cholesterol, Califf said.\nBut he echoed the thought that a longer-term and larger test is needed to determine the incidence of some possible major side effects, such as impotence.\nIf eprotirome does pass all the anticipated tests successfully, its use at first probably would be in combination with a statin, Angelin said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A major weakness of the story:\u00a0 it did not quantify the effects seen in the study in any way. ", "answer": 0}, {"article": "The American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\nGreatest changes were seen in the ability of patients to perform Sports and with improvement in healthful daily activity.\n\"Our findings note that patients older than 40 may benefit from using a fresh osteochondral allograft transplantation to treat focal cartilage defects, a common cause of knee pain in adults,\" said lead author, Dennis Crawford, MD, PhD from the Oregon Health and Science University in Portland, Oregon.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\nA statistically significant improvement for both groups was noted for the final follow-up for IKDC and all five KOOS sub-scores.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are not quantified at all. The release refers only to \u201cstatistically significant improvement\u201d for IKDC and \u201call five KOOS sub-scores.\u201d The release does not tell readers what \u201cstatistically significant improvement\u201d means, nor do they explain what IKDC or KOOS stand for \u2014 much less what the various sub-scores are. We assume from the language in the release that it is intended largely for an expert audience. However, news releases are ultimately aimed at reporters \u2014 that\u2019s what makes them news releases. While some reporters may be familiar with IKDC or KOOS, many reporters (even very good ones) are not. It would be more than worthwhile to include a few additional sentences articulating what the scores are, what the relevant numerical benefits were, and why the researchers deemed the changes in these scores to be important.", "answer": 0}, {"article": "In addition to He and Dibaba, other contributors included Pengcheng Xun, a faculty member in IU's Department of Epidemiology and Biostatistics; Kuninobu Yokota of The Jikei University School of Medicine in Tokyo, Japan; and Emily White of the University of Washington in Seattle.\nThe study found that every 100-milligrams-per-day decrease in magnesium intake was associated with a 24 percent increase in the occurrence of pancreatic cancer.\nThe study also found that the effects of magnesium on pancreatic cancer did not appear to be modified by age, gender, body mass index or non-steroidal anti-inflammatory drug use, but was limited to those taking magnesium supplements either from a multivitamin or individual supplement.\nBut few studies have explored the direct association of magnesium with pancreatic cancer; of those that did, their findings were inconclusive, said Daniel Dibaba, a Ph.D. student at the School of Public Health-Bloomington, who led the IU study.\n\"The five-year survival rate is really low, so that makes prevention and identifying risk factors or predictors associated with pancreatic cancer very important.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There\u2019s very little quantification offered in the release. The release states that the 66,000 people who missed the recommended daily intake for magnesium by 100 mg were at a 24% increased risk for developing pancreatic cancer. Then it makes a strong recommendation to increase magnesium through diet and supplements.\nThe release would have been much stronger had it included measures of absolute risk. Unfortunately, the abstract and paper both make it difficult to calculate the absolute numbers. From Table 2, we can see that 44/14395 (0.30%) people in the cohort who were in the <75% of the RDA group developed pancreatic cancer, compared with 64/35348 (0.18%)people in the >100% of RDA group. \u00a0The absolute risk difference is 0.12%. \u00a0That is extremely small. \u00a0Giving only relative reductions is very, very misleading. \u00a0And, when the appropriate exclusions are done (the people who had cancers diagnosed in the first two years of the study), the results are not statistically significant anyway.", "answer": 0}, {"article": "\u201cHowever, we still don\u2019t know whether it will provide protection against Ebola infection in a real-world situation,\u201d he said.\nThe early-stage Phase I trial of GSK\u2019s vaccine was primarily designed to test safety, but Adrian Hill, who led the work at Oxford\u2019s Jenner Institute, said it was \u201cencouraging\u201d that the shot also prompted responses from the immune system.\nJeremy Farrar, director of the Wellcome Trust charity which helped fund the trial, said it provided \u201cgood initial evidence that the GSK vaccine will be safe to use in people\u201d.\nThe vaccine is being developed by the U.S. National Institutes of Health (NIH) and GSK against the Zaire strain of Ebola \u2014 the one circulating in West Africa \u2014 and the first doses for a larger trial arrived in Liberia last week.\nThe data, published in the New England Journal of Medicine, were from 60 healthy volunteers given the vaccine in Britain between Sept. 17 and Nov. 18 last year.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides a well balanced and thoughtful presentation of the benefits seen in the trial. \u00a0It notes the study was a phase 1 trial designed to identify safety. \u00a0We liked the caveats given in the story. \u00a0\u201cIt is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed.\u201d \u201c\u2026the immune responses are okay, but not great\u2026\u201d \u201cHowever, the antibody response was weaker than was found in a trial of the same Ebola vaccine in macaque monkeys\u2026\u201d The reader gets a good overall impression of the study results and the need for additional information on the efficacy of the vaccine and that repeated dosing may be needed. The last sentence summarizes the study well, \u201c\u2026we still don\u2019t know whether it will provide protection against Ebola infection in a real-world situation.\u201d", "answer": 1}, {"article": "The editorial was written by Dr. Philip Greenland of Northwestern University, who is also a senior editor of JAMA, and Dr. Michael S. Lauer of the National Heart, Lung and Blood Institute.\nThe other suggests that treating people based on the new guidelines would be cost-effective, even with the tremendously increased use of statins.\nBut they could help dispel some of the criticism of the new guidelines and strengthen the position of those who contend treatment should be extended to more people.\nThe new studies are not large clinical trials that will definitively settle the matter of whether to expand drug treatment to millions more people in hopes of preventing cardiovascular disease, the leading killer of Americans.\nTwo studies published Tuesday lend support to controversial new cholesterol guidelines that could vastly increase the number of Americans advised to take cholesterol-lowering drugs called statins.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story nicely explained that while one of the new studies showed, as expected, that following the updated statin guidelines did increase the number of people who would be treated with statins, following the guidelines would apparently not have saved a significant number of people from dying or having a heart attack\u00a0or stroke. The story said, \u201cAmong the people eligible for statins under the old guidelines, 6.9 percent had a heart attack or\u00a0stroke\u00a0or died from coronary disease over the ensuing nine years. Among those eligible for statins under the new guidelines, the figure was 6.3 percent, almost as high.\u00a0That suggests that the new guidelines do not lead to treatment of many more people who do not need statins.\u201d\nAt the same time, the story noted that the new guidelines \u201cover all did a better job in discriminating between those who should and should not get statins.\u201d It said that \u201conly 1 percent of participants deemed ineligible for statins under the new guidelines had a heart attack or stroke over nine years, compared with 2.4 percent of those ineligible under the old guidelines.\u201d\nWhile an NBC story also used absolute numbers in talking about the potential benefits in terms of heart attacks, we liked the greater level of context provided in the Times piece. Nevertheless, we think it would have been useful for the Times to include the Number Needed to Treat in its discussion of benefits \u2014 \u00a0this is an easy-to-understand metric that was reported in the study. In addition, we question the Times\u2019s contention that the new criteria \u201cdo not lead to treatment of many more people who do not need statins.\u201d According to the study, approximately 94% of both guideline groups did not have a cardiovascular event, and yet the new criteria now extend the use of statins to much larger number of people. In light of such findings, it\u2019s unclear that the new criteria don\u2019t lead to unnecessary treatment for more people as the Time states. We wish the story had explored this result more thoroughly.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe safety and efficacy of Epclusa was also evaluated in a clinical trial of 267 subjects with decompensated cirrhosis (moderate to severe cirrhosis), of whom 87 subjects received Epclusa in combination with ribavirin for 12 weeks, and 94 percent of these patients had no virus detected in the blood 12 weeks after finishing treatment.\nResults demonstrated that 95\u201399 percent of patients who received Epclusa had no virus detected in the blood 12 weeks after finishing treatment, suggesting the patients\u2019 infections had been cured.\nThe safety and efficacy of Epclusa for 12 weeks was evaluated in three Phase III clinical trials of 1,558 subjects without cirrhosis or with compensated cirrhosis (mild cirrhosis).\nEpclusa also carries a warning not to use with certain drugs that may reduce the amount of Epclusa in the blood which could lead to reduced efficacy of Epclusa.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release includes results from Phase III clinical trials in about 1,600 patients showing a benefit.\n\u201cResults demonstrated that 95\u201399 percent of patients who received Epclusa had no virus detected in the blood 12 weeks after finishing treatment, suggesting the patients\u2019 infections had been cured.\u201d\nThe release also notes that after 12 weeks, 94 percent of patients with more advanced disease who received Epclusa in combination with ribavirin showed no virus in their blood.", "answer": 1}, {"article": "Prostate cancer is the most common cancer among men.\nOverall, about 95% of the men were cancer-free after a full year following the trial.\nIn this study, after 12 months, it\u2019s a 9-in-10 chance.\u201d\n\nThe men in the study were aged 45 to 80 with medium- to high-risk cancer, and would likely have undergone surgery or radiotherapy down the line.\nNone of the patients reported urinary incontinence a year after treatment, and only 1 in 10 suffered from poor erections.\nAhmed told Bloomberg that HIFU may also be cheaper than other standard treatments, noting that the cost of the MRI and mapping was an estimated $2,400, plus about $1,600 for HIFU; in comparison, removing the prostate costs about $7,100.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told that \u201cOverall, about 95% of the men were cancer-free after a full year following the trial.\u201d But, again, that may have been an incomplete picture.\nThe Lancet article indicates that this includes 4 men who required retreatment.\u00a0 \u201cCancer-free\u201d is based on MRI results.\u00a0 Most men were also biopsied after 6 months to determine whether there was microscopic evidence of cancer and 9 of 39 did have evidence.", "answer": 0}, {"article": "\"I'm single, I'm bouncing around, and I'd like the opportunity to have a family, so I just figured, 'Why not?'\nAll told, costs can easily exceed $40,000, money Montoro doesn't have.\nNow, technology is dangling the possibility that women can stop that clock, at least for a while.\nStill, Widra would like a larger-scale, longer-term track record.\nThe bigger challenge, Sher and others say, is reaching out to younger women \u2014 getting them to take action before it's too late.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Yes. The story is generous with describing the potential benefits.", "answer": 1}, {"article": "I am cancer-free,\" he says.\nIf Lazarus hadn't had any studies, says Dr. Harvey Pass of the NYU Medical Center in New York, the tumor would have grown causing pain, cough bleeding and maybe not have been able to be surgically removed.\nThat's because standard chest X-rays too often can't spot it until it's too late, reports.\nBut doctors decided to use a more sophisticated test \u2014 a CT scan that can detect tumors as small as a kernel of rice.\nSays Henschke: \"This is a way of finding it early and taking it out early, because it is a much better chance of being cured from the disease.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not adequately quantify the benefits of screening. Furthermore, highlighting a patient who had symptoms is inappropriate in this situation. The purpose of screening is to find people before they have symptoms, not after, when treatment is less likely to be helpful. Also, the story implies that the test can save lives, a fact that is still uNPRoven.", "answer": 0}, {"article": "In patients with age-related macular degeneration - or AMD - the center of the retina responsible for vision deteriorates over time.\nThree months ago, he noticed his vision was distorted.\nShe's had two doses of Lucentis.\nHe was diagnosed with wet macular degeneration, the most acute form, affecting 1.7 million Americans.\nIt's not a cure, but it's a blessing for Rochelle Faller.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides estimates of benefit for the drug group only. The story should have given the estimates of benefit for both the drug group and the control group.", "answer": 0}, {"article": "Their average age was 69.\nThere needs to be a large head-to-head trial between Forteo and abaloparatide, she said, to really see which drug is better.\nAn editorial accompanying the study said which drug is selected may be less important than identifying and starting an approved treatment.\nAmong the nearly 2,000 women who completed the trial, increases in bone mineral density were greater with abaloparatide than placebo, the researchers found.\nAbaloparatide works differently from Forteo and improves bone density more than Forteo, Miller said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a\u00a0good\u00a0job discussing\u00a0the quantitative evidence from the study. (The few missteps, which are actually quite critical in their nature, were related to a not-entirely-adequate grasp of the study design. This we discuss in detail in a separate criterion, Quality of Evidence, below.)\nThe story discusses several measures by which the effectiveness of abaloparatide was compared to the placebo (and Forteo), including the number of spine fractures, the number of other types of fractures, and the number of cases of hypercalcemia. And it does so using actual numbers. For example:\n\u201cFewer women on the injectable drug abaloparatide had spine fractures (0.58 percent) than women receiving a placebo (4.22 percent)\u2026\u201d", "answer": 1}, {"article": "In 2015, he was ranked the No.\nThe researchers selected 69 as the lower age limit because Medicare coverage of the general population begins at age 65, and the exposure of interest was regular mammography screening in the four years immediately preceding breast cancer diagnosis.\nAlthough many guidelines rely on self-reports, Hennekens and his collaborators from Baylor College of Medicine and Meharry Medical College, used the Surveillance, Epidemiology, and End Results (SEER) program file linked to the Medicare administrative claims file, which allowed them to identify screening mammography use from 1995 to 2009 from 64,384 non-Hispanic women (4,886 black and 59,498 white).\nThese linked files also permitted them to explore breast cancer mortality differences between elderly black or white women who self-selected for regular annual or biennial mammography screening.\nThey looked at data from non-Hispanic, white or black women; Hispanics were not included because Hispanic white women have substantially lower mortality than non-Hispanic whites, and the number of Hispanic blacks is small.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release says the study revealed that \u201cblack and white women ages 75 to 84 years who had an annual mammogram had lower 10-year breast cancer mortality than corresponding women who had biennial or no/irregular mammograms.\u201d\nThe implication is, of course, that having a mammogram during those years and receiving treatment for it (surgery, chemotherapy, radiation) lowers the risk of dying from breast cancer.\nHowever, the release doesn\u2019t tell us how many women went on to receive a cancer diagnosis, how many received any treatment and if so, what kind. The study is observational and doesn\u2019t prove that annual mammograms in elderly women extends life.", "answer": 0}, {"article": "Another person said of their pet birds: \"If I didn't have my pets I think I would be on my own.\nThe pets provided more than just emotional support and companionship, participants said.\nBrooks says, \"Many felt deep emotional connections with their pet that weren't available from friends and family.\"\nThis may be especially true for people with serious mental illness, a study finds.\nHe feels this study is important because, although there's a lot of work looking at the benefits of trained therapy animals, they can be expensive and out of the reach of many patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits associated with pet ownership for patients with schizophrenia or bipolar disorder\u2013perhaps because the study being reported on doesn\u2019t quantify benefits. But, in this case, where the benefits can\u2019t be quantified, the story should tell us why that\u2019s case (i.e. the researchers didn\u2019t systematically measure the effects of pet ownership). What the story does instead is essentially present a series of anecdotes from people who are already benefiting from pet ownership, which isn\u2019t reflective of the full range of experiences.", "answer": 0}, {"article": "In the United States, the National Heart, Lung and Blood Institute, a unit of the National Institutes of Health, is supporting efforts by two separate groups, one led by Dr. O. H. Frazier of the Texas Heart Institute in Houston, the other by Dr. Leonard A. R. Golding of the Cleveland Clinic.\nThe device was developed over 15 years by a team that included Alain F. Carpentier, the French surgeon-scientist who, along with Albert Starr, received the 2007 Albert Lasker Award for Clinical Medical Research.\nAnother device is being developed by scientists at the Helmholtz-Institute for Biomedical Engineering at the University of Aachen in Germany.\nIts device, powered by a small air compressor that can be carried in a backpack, has been implanted in more than 800 patients as a bridge before transplant.\nImplanted in the patient\u2019s chest after the diseased heart is removed, it uses information gleaned from sensors to mimic the activity of the natural organ.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No data, no evidence of any kind provided. ", "answer": 0}, {"article": "According to Kramer, \"This randomized study concludes that [aspirin's] use is not only effective for reducing the incidence of preeclampsia at term, but also preterm.\nThere were no serious side effects for expectant mothers, or adverse events for the babies related to aspirin use during pregnancy, the researchers noted.\nJust 13 women in the aspirin group developed preeclampsia, while 35 women in the placebo group developed the complication, the findings showed.\nWomen who delivered at less than 34 weeks were 82 percent less likely to have preeclampsia if they were taking 150 mg of aspirin, Nicolaides said.\nACOG already recommends that women who are at high risk of preeclampsia take a low-dose baby aspirin beginning between 12 and 28 weeks of pregnancy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story offered, \u201cJust 13 women in the aspirin group developed preeclampsia, while 35 women in the placebo group developed the complication, the findings showed.\u201d We appreciated that this was given in absolute terms, instead of just percentages, so we could get clearer sense of the impact.\nHowever, the story does not make it clear that this is referring to women who delivered at or\u00a0before 37 weeks.\nThis is important because for deliveries that occurred after 37 weeks (which is when most preeclampsia develops), there\u00a0was no statistically significant benefit to taking aspirin. In this group, preeclampsia affected 53 of the women in the aspirin group and 59 in the placebo group.", "answer": 0}, {"article": "NEW YORK (Reuters) - The U.S. Food and Drug Administration approved on Tuesday the sale of Amgen Inc\u2019s osteoporosis drug Prolia to help prevent fractures in post-menopausal women just days after the medicine received European approval.\nThe approval comes with a risk evaluation and mitigation strategy (REMS) that includes a medication guide for patients and information for healthcare providers that explains the risks and benefits of the drug, the FDA said.\nAmgen said the drug will be available within the next two weeks and cost $825 per 60 milligram injection based on wholesale acquisition cost.\nAmgen last month applied for U.S. approval to market the drug for reduction of fractures and other skeletal-related problems in patients with advanced cancer.\n\u201cI believe it will have gradual uptake in the commercial setting given that this is a silent disease and existing therapies are pretty good,\u201d Schmidt said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "\u201cNow we know that electrical impulses to the olfactory bulb can provide a sense of smell \u2014 and that\u2019s encouraging.\u201d\n\nIn addition to Dr. Holbrook, authors on the International Forum of Allergy & Rhinology study include co-first author Sidharth V. Puram, MD, PhD, of Washington University School of Medicine, Reiner B.\nIn the report, the researchers describe endoscopic procedures to position electrodes in the sinus cavities of five patients with an intact ability to smell.\nReporting online today in International Forum of Allergy & Rhinology, the research team describes their results, which provide a proof of concept for efforts to develop implant technology to return the sense of smell to those who have lost it.\nThis breakthrough in human patients opens the door for a \u201ccochlear implant for the nose\u201d to be developed \u2014 though the study authors caution that the concept of an olfactory stimulator is more challenging than existing technologies.\nNewswise \u2014 Boston, Mass \u2013 Physicians at Massachusetts Eye and Ear have, for the first time, induced a sense of smell in humans by using electrodes in the nose to stimulate nerves in the olfactory bulb, a structure in the brain where smell information from the nose is processed and sent to deeper regions of brain.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release suggests that this is a \u201cbreakthrough for human patients.\u201d \u00a0None of the participants (incorrectly referred to as patients) in the study had lost their sense of smell, so none could have their sense of smell restored. The release notes that three of the five participants who underwent the experiment reported sensations of smell when their nerves were stimulated by electrodes. Importantly, the release neglects any qualification or description of the sensations. \u00a0The manuscript notes the smells as \u201conion like,\u201d \u201d fruity but bad,\u201d \u201cantiseptic like\u201d and \u201csour.\u201d \u00a0Yes, electrical stimulation did create smells but creating de novo smells is hardly a benefit.\u00a0 Indeed the sensation of smells where none are present is referred to as olfactory hallucination.", "answer": 0}, {"article": "The F.D.A.\nBy contrast, they say, carotid surgery -- called endarterectomy -- has no significant room for improvement.\nEven stenting proponents worry about overuse of the technology in challenging cases.\nhas also tentatively approved a stent system from the Cordis division of Johnson & Johnson.\nEveryone agrees that clinical evidence about the relative risks in different types of patients is only beginning to emerge.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Mentions 10% risk of stroke or death following stenting, though data source is not mentioned. Mentions side effects without \nrates. Includes report from one patient of perceived benefit. Therefore incomplete.", "answer": 0}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that a mother getting a Tdap vaccine in her third trimester cuts the risk by 78% of a baby less than 2 months old of getting pertussis \u2014 and that even when a mother-vaccinated baby did get the disease, 90% of cases were mild.\nHowever, the story cites risk numbers calculated from odds ratios \u2014 a statistical concept that most readers are not familiar with. A clearer way to present the results would have focused on absolute numbers. For example: 7% of vaccinated mothers had babies who contracted pertussis within the first 2 months of life, and 90% of those cases were mild. A comparison of unvaccinated mothers showed the infection rate to be about 43%. That said, this was a retrospective case control study, which can have many \u201cconfounders\u201d that could have affected the results (see evidence quality, below).", "answer": 0}, {"article": "Mammograms, for example, prevent 25 percent of breast cancer deaths, and the PSA test for men has not been shown to prevent prostate cancer deaths.\nStill, he said, that does not mean that patients should have more frequent colonoscopies.\nDr. Ransohoff and other screening experts say patients should continue to have the test, because it is still highly effective.\nCT colonoscopies, so-called virtual colonoscopies, are not a solution, some screening experts said.\nBut gastroenterologists say that, if nothing else, the study points up the paucity of evidence for the common suggestion that anyone who had a clean bill of health from a colonoscopy is almost totally protected for at least a decade.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately quantifies the mortality benefit from colonoscopy screening. But we wish the story had quantified the benefit in absolute rather than relative terms.", "answer": 1}, {"article": "Saturated fat has been thought to promote cardiovascular diseases by raising the \"bad\" LDL cholesterol in the blood.\nEven the participants who increased their energy intake during the study showed substantial reductions in fat stores and disease risk.\n\"Participants on the very-high-fat diet also had substantial improvements in several important cardiometabolic risk factors, such as ectopic fat storage, blood pressure, blood lipids (triglycerides), insulin and blood sugar.\"\nThe researchers found strikingly similar health effects of diets based on either lowly processed carbohydrates or fats.\n\"The very high intake of total and saturated fat did not increase the calculated risk of cardiovascular diseases,\" says professor and cardiologist Ottar Nyg\u00e5rd who contributed to the study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release did not use many numbers to quantify the benefits of consuming one diet over another. For example, it states:\n\u201cIn the randomized controlled trial, 38 men with abdominal obesity followed a dietary pattern high in either carbohydrates or fat, of which about half was saturated. Fat mass in the abdominal region, liver and heart was measured with accurate analyses, along with a number of key risk factors for cardiovascular disease.\n\u201cThe very high intake of total and saturated fat did not increase the calculated risk of cardiovascular diseases,\u201d says professor and cardiologist Ottar Nyg\u00e5rd who contributed to the study.\u201d\nThe italicized words reflect where some quantification would have helped the release. What does \u201chigh\u201d refer to? Which measuring tools were used to assess fat mass in the abdomen, liver and heart?", "answer": 0}, {"article": "\"Because cancer cells are different to healthy ones, they produce a different mixture of chemicals.\nThe researchers said they are planning a larger trial of the breath test over the next three years.\nMarkar added that the test needs to be validated in a bigger group before it could be used on patients.\nIt was 85 percent accurate in detecting these cancers in more than 300 patients, the new study found.\nBoth tend to be diagnosed at a late stage and the five-year survival rate for the two cancers is 15 percent, the researchers said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We were glad that the story did provide a number, which was that the test seemed to be \u201c85 percent accurate.\u201d But, that\u2019s not enough information, because this is trickier than it sounds. Health professionals need to know both a diagnostic tool\u2019s sensitivity \u2014 which is how good the test is at positively identifying people who actually have the problem \u2014 and the tool\u2019s specificity \u2013 how good the test is at ruling out people who don\u2019t have the problem. Presumably, the breath test has an 85 percent success rate in regard to its sensitivity (though that\u2019s not entirely clear). But we don\u2019t know the\u00a0tool\u2019s specificity \u2014 and it\u2019s difficult or impossible to tell how useful a diagnostic tool is without understanding both. (According to the news release, the test had a sensitivity of 80 percent and a specificity of 81 percent.) And, as well, this test was performed on people who had advanced cancer\u2013not early cancer\u2013which may not be as detectable, and the numbers may be different.\nYet, the story quotes a researcher (in a line from the news release) as saying that the breath test could mean earlier diagnosis and treatment of stomach and esophageal cancers, with a higher survival rate. This is speculation\u2013we don\u2019t know if this test picks up early forms of these cancers, nor if earlier detection means a higher rate of survival, or just getting bad news earlier. The accuracy of the test when used to detect early cancer in healthy-seeming people is also likely to be far lower, as our review of the news release points out in some detail.", "answer": 0}, {"article": "\u201cHeating ducts that have mold and spores in them can make respiratory symptoms worse in the winter when hot air is blowing through them.\nIf you already have a smart device system for your home, Awair is working on partnerships with several connected devices like Nest thermostat and other smart appliances so you can manage the air quality in your home or office when you're not there.\nEvery room in your house could be susceptive to some form of an air pollutant, but now there is a new device and app that says it can help you breathe easier by tracking air quality.\nDry air can also exacerbate some illnesses and can be a problem as well.\u201d\n\nDifferent sources of air pollution in your home could include paints that release lead or volatile organic compounds (VOCs), carpets that harbor dirt, dust mites, and fungus and even nitrogen dioxide from gas stoves, but these aren\u2019t the worst culprits, Lahita said.\nThe app also provides Mayo Clinic \u201cmessage cards\u201d that give relevant information and recommendations for ways to keep your indoor environment healthy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Not only are the benefits not quantified, but the potential benefits are not clearly defined at all. Instead, the story makes statements like \u201c[Awair] can help you breathe easier by tracking air quality.\u201d But what are the benefits of knowing the air quality levels via this device compared to other monitors? Or no monitors at all?", "answer": 0}, {"article": "\u201cBut I wasn\u2019t really doing well,\u201d said Ms. Schomaker, 73.\n\u201cI had many interests.\u201d She traveled and even tried dating again.\nFriends thought Anne Schomaker was coping well with her loss, she recalled.\n\u201cI had terrible pangs of sadness and despondency.\n\u201cThe pain just didn\u2019t go away,\u201d she said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains how the participants in one small study were randomly assigned to different kinds of psychotherapy. The group receiving what is called \u201ccomplicated\u201d therapy showed more than 70 percent\u00a0 \u201cmuch improved\u201d or \u201cvery much improved\u201d in the severity of their symptoms and impairment, compared with 32 percent in the standard psychotherapy group. That\u2019s a useful and user-friendly way to characterize the results. Much better than saying something like, \u201cMore than twice the number of patients receiving complicated therapy saw significant improvement,\u201d which is how many stories might have put it.", "answer": 1}, {"article": "\u201cI don\u2019t think at this point this one test is going to prevent further testing.\nIn an editorial accompanying the study, however, experts wrote that using CT scans to gauge bone density could lead to some people being incorrectly diagnosed, particularly if people at low risk are tested.\nDr. Sumit Majumdar, who wrote an editorial accompanying the new study, said a lower threshold for bone density would catch most cases of osteoporosis and limit \u201cincidentaloporosis\u201d - incorrect osteoporosis diagnoses \u201cdiscovered\u201d while doctors were looking for something else.\nThe idea, say the researchers, is doctors can use patients\u2019 CT scans that are ordered for another reason - such as looking for tumors - to also check for signs of osteoporosis.\nThe researchers, who published their findings in the Annals of Internal Medicine on Monday, compared patients\u2019 CT scans to their dual-energy X-ray absorptiometry (DXA), which is traditionally used to diagnose osteoporosis.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story never actually described the sensitivity, specificity or positive predictive value of CT scans \u2013 something described clearly in the study on which the story is based.\u00a0 Granted, this can get to be complicated stuff, but we think the story could have tried.\nThe benefit of the strategy of using CT scans obtained for another purpose to also diagnose osteoporosis could have been discussed in more detail. The article correctly notes that CT scans are regarded as an overused test.\u00a0CT overuse carries the harms of\u00a0 radiation exposure, costs and risks associated with additional testing for incidental findings that are more often than not clinically unimportant. The notion that\u00a0these downsides of an overused technology can be mitigated by the benefit of picking up a small number of cases of osteoporosis seems like a stretch.", "answer": 0}, {"article": "The outcomes are getting better and better.\"\nThat could change with the results from a clinical trial co-led by investigators from NYU Langone Medical Center, which shows giving high doses of a commonly-used chemotherapy drug increases the survival rate for these patients.\nThe clinical protocol also examined how to best use a steroid formulation called decadron to treat high-risk ALL patients.\nPrior to the release of the initial study results, which were first presented last year at the annual meeting of the American Society of Clinical Oncology (ASCO), the standard of care for high-risk ALL patients in North America was escalating methotrexate.\nThe high-dose methotrexate protocol outlined in the study - along with a parallel finding that the steroid decadron is beneficial for younger (but not older) patients - has quickly become the standard practice for the treatment of high-risk ALL patients in North America, the researchers report in the April XX issue of the Journal of Clinical Oncology.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that patients receiving high doses of the drug methotrexate \u201chad a significantly better outcome, by 5 to 6 percent\u201d than did patients receiving the current standard of care, which is gradually escalating doses of the drug. The release also explains that patients nine years old or younger who were also treated with a steroid called decadron (dexamethasone) for\u00a0half as long as normal (14 versus 28 days) benefited from the treatment while patients 10 and older did not.\nWe\u2019re not sure of the meaning behind these results as portrayed in the release. Which outcome was better by 5 or 6 percent? The study has several. Does that mean the relapse rate was reduced or is it the event free survival that was better? It would be more meaningful to readers if the release had included the actual relapse and event free survival rates for each group analyzed in terms most people can understand. For example: \u201crelapse rates were 5 percent lower in Group X compared to Group Y.\u201d", "answer": 0}, {"article": "At 40Hz the flicker of the light is barely discernible and would be \u201cnot offensive at all\u201d for a person to have in the background.\nBoosting this synchronous brain activity appeared to act as a cue for the brain\u2019s immune cells, prompting them to absorb the sticky amyloid proteins that are the most visible hallmarks of the disease in the brain\u2019s of people with Alzheimer\u2019s.\nThe study, published on Wednesday in the journal Nature, hinges on the observation that Alzheimer\u2019s patients show a loss of synchronised brain activity, known as gamma oscillations, which is linked to attention and memory.\nThe latest intervention, scientists predict, should be quicker and cheaper to confirm in humans than pharmaceuticals, which typically take more than a decade to develop and assess for safety before the clinical efficacy is even examined.\nThe authors caution that a \u201cbig if\u201d remains over whether the findings would be replicated in humans \u2013 and whether cognitive deficits as well as visible symptoms of the disease would be improved.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Given that the research under consideration here involved mice \u2014 and genetically bred mice at that \u2014 there\u2019s no way to determine whether the intervention\u00a0would have any benefit at all to people, let alone to quantify the likely benefits for human.\u00a0The story does acknowledge this. But in the process, it also overstates what is known about the causes of Alzheimer\u2019s and therefore how relevant this approach is to treating it. The story states flatly that \u201ctoxic proteins\u201d are the culprit, but this is the subject of much debate within the Alzheimer\u2019s research community and increasing evidence points against it.", "answer": 0}, {"article": "The median age was 70, with a range of 50 to 88.\nQuality of life was not adversely affected by surgery at any time in patients who, prior to surgery, had performance status of 1 or 2; a tumor volume greater than 600 ml.\nThe study is titled \u201cQuality of Life in Patients Undergoing Pleurectomy and Decortication for Malignant Pleural Mesothelioma.\u201d The surgeries were performed by Dr. Vigneswaran at University of Chicago Medicine, where he practiced before recently joining Loyola.\nPrior to surgery, 31 percent of the patients had a performance status score of 0 (fully functional); 65 percent had a performance status score of 1 (able to do light house work or office work); and 4 percent had a performance status of 2 (ambulatory and capable of self-care, but unable to work).\nBut a study led by a Loyola Medicine thoracic surgeon has found just the opposite: Patients who underwent an operation called pleurectomy and decortication (PD) generally reported their quality of life improved after surgery.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release gives the impression that all patients experienced improved quality of life after surgery: \u201cPatients who underwent an operation called pleurectomy and decortication (PD) generally reported their quality of life improved after surgery.\u201d It also states, \u201cImproved quality of life was observed in the first month after surgery and was maintained at late follow-up in all patients.\u201d In the abstract, however, researchers explicitly state that not all patients experienced a benefit. For example, pain, fatigue and insomnia were worse at 1 month in all groups, while overall global health worsened at the first post-operative month, according to researchers. In one subset of patients, quality of life remained unchanged, while functional domain, physical functioning, role functioning and social functioning deteriorated at 1 month. \nIn the abstract, researchers conclude that quality of life was not significantly better among patients with epithelioid (a type of immune cell) histology, pre-operative performance status of 0 and tumor volume <600 mL. But the news release didn\u2019t include these findings but instead cited only the positive cases, ignoring the fact that all patients experienced worsening symptoms at 1 month.\u201dQuality of life was not adversely affected by surgery at any time in patients who, prior to surgery, had performance status of 1 or 2; a tumor volume greater than 600 mL or a type of tumor cell called non-epithelioid,\u201d it states. \nDue to all these factors, we give it a \u201cNot Satisfactory\u201d rating here. ", "answer": 0}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers of this story are likely to get an exaggerated sense of the benefits of this drug. As noted above, the preliminary trials completed so far did not produce evidence of improved outcomes or survival, nor did those trials include any comparison of the new treatment with existing alternatives. The story reports that \u201ctumors disappeared, shrank or stopped growing in just over half of patients for nearly two years on average.\u201d The drug label indicates that tumors \u201cdisappeared\u201d in only three patients out of 255. The story reports on two patients who gave glowing reports of their responses, but there were no quotes from more typical patients who had limited, if any, responses or who endured serious side effects. The story then includes a reference to the short survival of typical lung cancer patients, without included the necessary caveat about the unreliability of such historical comparisons.\nThe one-sided reporting provides an unbalanced view of the drug\u2019s potential benefits. The story should have been clearer that the main reason this drug received conditional approval is that there is a reasonable likelihood of benefit; and that we won\u2019t know if that benefit is real until the ongoing trials are completed.", "answer": 0}, {"article": "Commenting, Professor Andreas Meyer-Lindenberg, Central Institute of Mental Health, Mannheim and member of the ECNP executive board, said: \"This work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia.\nThis is the first controlled trial to show an improvement in these patients by targeting a specific area of the brain and using high frequency TMS.\nThe French research team worked with 26 patients who received active TMS treatment, and 33 as a control group, who received sham (placebo) treatment.\nTo move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\nThey have been able to show in a controlled trial that targeting this area with magnetic pulses can improve the condition in some patients.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that \u201cresearchers found that 34.6% of the patients being treated by TMS showed a significant response, whereas only 9.1% of patients in the sham group responded.\u201d Of equal importance, the release clearly defined what \u201csignificant response\u201d meant: \u201ca more than 30% decrease in the Total Auditory Hallucinations Rating Scale score.\u201d In addition, the release quotes one study author\u2019s qualification of the finding: \u201ctreatment with high frequency TMS makes a difference to at least some sufferers, although there is a long way to go before we will know if TMS is the best route to treat these patients in the long-term.\u201d That\u2019s good context.", "answer": 1}, {"article": "Watching her patients undergo bone marrow transplant ?\nBecause it was the first study of this particular approach, the researchers focused on a high-risk group -- AML patients undergoing bone marrow transplant who had certain genetic or disease characteristics that decrease the chance of long-term transplant success -- \"a hard population of patients,\" Chapuis said, many of whom \"were horribly sick.\"\nOf the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.\nThis is the team's first trial of this strategy, which was initially developed in the lab of Dr. Phil Greenberg, one of the study's leaders and the head of Fred Hutch's Program in Immunology.\nThe study was supported by funding from the National Institutes of Health and spinoff Juno Therapeutics, of which Greenberg is a scientific co-founder.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release reports that all 12 participants in the trial (those who received the T-cell therapy after a transplant) remained in remission during a median follow-up period of more than two years, while more than a quarter of transplant-only patients relapsed within 10 months. Although that seems like clear quantification of benefits, there are many examples of cancer treatments that have produced higher remission rates, but ultimately failed to help patients live longer or better. To be clear, we have no problem with the release reporting on the surrogate outcome, which may be the only measure available to estimate the treatment\u2019s effects in these patients. However, we believe that the release should have cautioned that the remission rates do not necessarily predict survival or even quality of life\u2026and that these factors, the ones that really matter to patients, will be measured only in future experiments.", "answer": 0}, {"article": "; Walter Rocca, M.D.\nIn the study, women with APOE e4 \u2014 one form of the most common gene associated with late-onset Alzheimer's disease \u2014 had lower levels of amyloid deposits.\n\u201cThis study showed, for the first time, that the brain amyloid deposition \u2500 a hallmark of Alzheimer\u2019s disease \u2500 is reduced in newly postmenopausal women who received 17beta-Estradiol patch form of hormone therapy,\u201d says lead author Kejal Kantarci, M.D., a Mayo Clinic radiologist.\nIn contrast, the multicenter Kronos Early Estrogen Prevention Study tested the hypothesis that healthy and younger women would respond to menopausal hormone therapy more favorably.\nThe authors are seeking funding to perform amyloid PET imaging at eight more Kronos Early Estrogen Prevention study sites around the U.S.\n\n\u201cIf our results are confirmed in the larger group of women, this finding has the potential to change the concepts for preventive interventions that drive the Alzheimer\u2019s disease field today,\u201d Dr. Kantarci says.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the news release summarizes the pattern of results\u2014that recently postmenopausal women who received estrogen via a skin patch were found to have \u201clower\u201d amyloid depositions in their brains relative to those who took estrogen by mouth or who were in the placebo group\u2014that pattern is not explained in any numerical or statistical way.\u00a0 Is it a strong association?\u00a0 A weak one?\u00a0 We have no idea from the release.\nAccording to the published report, the benefits were statistically significant but the sample size was too small to be meaningful. Just 21 of the enrolled women received the patch, 30 received a placebo and 17 received estrogen orally.", "answer": 0}, {"article": "Dominic Gessler lifts two squirming mice from their cages.\nScientists now argue it is our best, and perhaps only, chance at curing many diseases of the brain.\n\u201cAnd other than gene therapy, there was no other way.\u201d\n\nGene therapy is well-suited for treating inherited brain diseases.\nAt the time, only one gene therapy had been commercially approved in the world: a cancer drug in China.\nIt worked\u2014with continued treatments, both children showed signs of a restored immune system and went on to lead normal lives.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports chiefly on what appear to be full recoveries in some mice engineered to have genetic deficiencies, but we\u2019re given no details on the quantified results nor any words of caution on the limitations of extrapolating these benefits to humans. For the one human research trial that\u2019s discussed (for a vision disorder unrelated to Canavan disease), we\u2019re\u00a0told 21 vision-impaired patients experienced \u201cmaximum possible benefit\u201d of vision restoration, a description that sounds like good news, but falls short of quantifying the actual benefits.", "answer": 0}, {"article": "scans on 991 people ages 50 to 90.\nThe question, though, was whether it helped the patients and their doctors to know what the M.R.I.\u2019s had found.\nIf you are a 60-year-old guy, the chance that you have a meniscal tear is 40 percent.\u201d\n\nIt is a result that paralleled what spine researchers found over the past decade in what is perhaps the best evidence on what shows up on scans of healthy people.\nThat led Dr. Felson and his colleagues to do the first and so far the only large study of knees, asking what is normal.\nHowever, Dr. Modic said, there was one effect of being told \u2014 patients felt worse about themselves when they knew they had a bulging disk.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not say how many meniscal tears were found on MRI in the current study. The story could have also\u00a0said that there have been no randomized trials of MRIs for knee pain that quantify the benefits and harms of such a management strategy.", "answer": 0}, {"article": "Pancreatic cancer is the fourth leading cause of death from cancer in the United States.\nPart of the group was given gemcitabine, the most favored treatment according to oncologists.\nOnly about 6 percent of those with the diagnosis live longer than five years.\nThe other patients were given a combination of four chemotherapy drugs, (oxaliplatin, irinotecan, fluorouracil and leucovorin) known as FOLFIRINOX.\nThe purpose of the study was to record the overall survival rates of each group.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story barely explained the benefits seen in the study, and failed to put them into the context of what pancreatic cancer patients face as well as the competing USA Today story did.", "answer": 0}, {"article": "Worldwide, more than 10 million people have impaired vision or blindness as a result of corneal damage, but only a small fraction ever receive transplants from cadaver donors.\n\u201cWe are still in the prototype stage, but this shows that regenerating a human cornea is possible.\u201d\n\nTwo years after having the corneas implanted, six of the 10 patients had improved vision .\nIn a newly released study, investigators from Canada and Sweden reported results from the first 10 people in the world treated with the biosynthetic corneas.\nNine of the 10 experienced cell and nerve regeneration, meaning that corneal cells and nerves grew into the implant.\nIt has been 10 years since Griffith and colleagues first reported the development of a material with the potential to grow healthy new tissue in people with damaged corneas.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "All the stories reported the results in absolute terms, which emphasizes for readers that the study is very small and that even though most people ultimately had better vision, we are still only talking about 10 people.", "answer": 1}, {"article": "\"They have a lot of promise and are potentially very important,\" said Katherine Hamilton, a headache specialist at Penn Medicine. The drugs, which are injected under the skin, offer hope for patients who have not responded to other treatments, but Hamilton said that what is \"potentially even more clinically relevant is they have a lower side-effect profile\" than other medications commonly used for migraine. She added, though, that it remains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was a tough call. The story reported that the drugs \u201cappeared to be equally effective. About half the patients had a 50 percent or greater reduction in the number of headaches they experienced. Almost three-quarters had at least a 30 percent reduction.\u201d\nThat\u2019s not really enough information to assess the benefits (what was the frequency of headaches per month?), but the story follows that up with:\nIt also reported that chronic migraine patients \u201chad about two fewer headache days a month than those who took placebos. The placebo group had a small reduction in headaches, too. In the treatment groups, the intensity of the headaches also went down.\u201d\nWhile this is more informative, it still doesn\u2019t give readers a sense of the scope\u2013how many migraine days were people experiencing before taking the drug, and then after? What about the placebo group?\nFor example, in a trial for Emgality, patients who averaged 19.4 migraine days per month saw their migraine days reduced by 4.8 or 4.6 days per month depending on their dosage, versus a reduction of 2.7 days for those who took a placebo.\nThis gives a more specific sense of the benefits than what the story included. It\u2019s especially interesting to see how the drug compared to the placebo.", "answer": 0}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not quantify how effective liver transplants are or how effective various treatments are at reducing non-alcoholic cirrhosis of the liver. \u00a0While the two cases reported on were said to demonstrate relief of symptoms \u2013 one child being treated with a liver transplant and the other child being treated with lifestyle change \u2013 the story did not indicate how successful either approach was in a broader population. \u00a0Although it mentioned that the boy who had the liver transplant had not been successful with his weight loss efforts to date, there was no discussion about what that might mean in terms of longer term prognosis for his new liver.", "answer": 0}, {"article": "\"Our goal is to reach 100 percent.\"\nThat's why the American Cancer Society, which estimates there will be about 108,000 new cases of colon cancer and 40,700 new cases of rectal cancer this year, added the stool DNA test to its screening guidelines this spring.\nAnd you've probably heard about how early screening means early detection and removal of polyps before they turn into cancer.\n\"Clearly by itself, it is not reaching other people,\" said Markowitz, who sits on the medical advisory board of the National Colorectal Cancer Research Alliance.\nAnd that early screening also means that colorectal cancer can be treated more effectively.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article says that experts at the American Cancer Society have added the newly recommended stool DNA screen to its screening guidelines because many people are averse to the leading alternative\u2013invasive, inconvenient, and expensive colonoscopies. But when it says the screen is \u201ca huge step forward\u201d that can \u201csignificantly increase the rate of detection,\u201d the story\u2019s quantification of benefits is more hype than help. By how much will this screen reduce the likelihood that someone will die of colorectal cancer? How many people over the age of 50 will need to be screened\u2014for how long, and how often\u2014to prevent one death by colon cancer? How does that compare to other screening methods? (For example, with the traditional fecal occult blood test, about 1000 people over the age of 50 must be screened for 10 years to prevent one death from colon cancer.) Is there evidence that \"you could reach a lot of people and prevent deaths from happening every day of the year\"? Compared to other methods, is there any added benefit for people whose genetic makeup increases their likelihood of colorectal cancer?\u00a0", "answer": 0}, {"article": "Performed through the urethra, an urologist uses the UroLift System to push aside the obstructive prostate lobes and positions small, tailored permanent UroLift implants to hold the prostate lobes in the retracted position.\nPatients recover from the procedure quickly, and return to their normal routines with minimal downtime.\nAdverse reactions associated with UroLift System treatment were comparable to other minimally invasive surgical therapies as well as standard cystoscopy.\nThe UroLift System provides an alternative to tissue removing surgery for the treatment of an enlarged prostate.\nPatients also experienced a significant improvement in quality of life.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We learn that \u201cdata from clinical trials showed that patients receiving UroLift implants reported rapid symptomatic improvement, improved urinary flow rates, and sustained sexual function. Patients also experienced a significant improvement in quality of life.\u201d\u00a0 All is good, but what was the magnitude of benefits and, more importantly, \u201ccompared to what\u201d?", "answer": 0}, {"article": "The Hass Avocado Board (HAB) is an agriculture promotion group established in 2002 to promote the consumption of Hass Avocados in the United States.\nThe research, \"Impact of avocado-enriched diets on plasma lipoproteins: A meta-analysis,\" conducted at the University of the Pacific and independently funded , looked at 10 unique avocado studies with 229 participants, assessing the impact of avocados on cholesterol levels.\nClinical studies are currently underway to investigate the relationship between avocado consumption and risk factors for heart disease, diabetes, support of weight management and healthy living.\"\nOn the heels of this advice, a new meta-analysis (considered the best evidence and an unbiased overview of the body of knowledge on a specific topic), published in the Journal of Clinical Lipidology, adds to the growing body of research that supports the use of avocados in lieu of solid fats (and foods that have higher saturated fat content) to significantly change lipid profiles.\n(See conclusion of study)\n\n\"Interestingly, our results indicate that even healthy subjects with a relatively normal baseline TC (100 to 240 mg/dL), LDL-C (75 to 150 mg/dL), and TG (50 to 175 mg/dL) had significant reductions,\" says Sachin Shah, PharmD, corresponding author and expert in cardiovascular health.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are several benefit claims but no quantification is provided. For example:\n\u201cResearchers found avocado consumption (1 to 1.5 per day) significantly reduced total cholesterol (TC), \u201cbad\u201d low density lipoprotein cholesterol (LDL-C) and triglycerides (TG) when they were substituted for sources of saturated fat.\u201d\nHow much is a significant reduction? From what level to what level?\n\u201cInterestingly, our results indicate that even healthy subjects with a relatively normal baseline TC (100 to 240 mg/dL), LDL-C (75 to 150 mg/dL), and TG (50 to 175 mg/dL) had significant reductions,\u201d says Sachin Shah, PharmD, corresponding author and expert in cardiovascular health.\u201d\nAgain: what were the actual reductions?\nStatistically significant findings are not the same as clinically important findings, and the public needs to know how much cholesterol reduction was found in the study. It would also be useful to point out that cholesterol changes do not necessarily equate to reduced risk of actual heart attacks and strokes.", "answer": 0}, {"article": "Of the men who had a raised platelet count of the same value or higher six months after being diagnosed with thrombocytosis, 18.1% developed cancer, while for women the figure was 10.1%.\nThat, say the researchers, makes testing for raised platelet count a valuable tool, and could speed up cancer diagnosis by at least three months for thousands of patients a year.\nBut it remained unclear whether the condition could signal an increased risk of all cancers, and how it ties in with factors such as age and sex.\n\u201cThis work should begin to change practice, so that GPs should be testing patients with raised platelet counts for cancer, especially those without other potential cancer symptoms,\u201d he added.\nFor about a third of cases of lung and colorectal cancer in patients with thrombocytosis, there had been no other symptoms that raised the suggestion of cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u2019s author did a good job of describing the numbers of patients whose data were\u00a0drawn from a national database, and the percentages across ages and genders who were identified with some form of cancer within a year of a high platelet count, compared to percentages of who were not diagnosed with cancer. It also noted the rate of cancer diagnosis in the general population overall as a comparative factor. There were also data given about the types of cancer most diagnosed and the potential impact for early diagnosis. The thoughtful reader will come away with the notion that even if platelet counts are utilized widely, they are not going to serve as markers for\u00a0most cancers that arise in adults.\nOne thing the story needed on this note was\u00a0better framing on how these results differed by age. Our\u00a0concern is there may be unnecessary anxiety for some people to pressure their doctor into performing a platelet count beginning at a young age that may not be necessary.", "answer": 1}, {"article": "Vertigo -- episodes of dizziness that can last for minutes or days -- may be triggered by a number of health issues, ranging from an inner ear disorder to tumors.\nFor the study, researchers recruited 338 people who had vertigo with an unknown cause.\nThirty-five study participants had this form of vertigo.\nThose with the new form of vertigo were also more likely to have severe motion sickness than those with other forms of the condition, the study showed.\nThey were compared to 35 others whose vertigo is triggered by other conditions, including the inner ear disorder Meniere's disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story fails to provide clear information on benefits.\u00a0 It does effectively quantify the number of patients in the study thought to have this new form of vertigo \u2014 35 \u2014 and also cited how many patients with it who appeared to benefit from the unnamed medication \u2014 one-third of 20.\u00a0 It\u2019s worth noting that those suspected of having this new form of vertigo comprise only 10 percent of those recruited in the study, and only two percent of the total recruited were successfully treated by the unnamed medication.", "answer": 0}, {"article": "So our recommendation is not to consume any alcohol at all,\" Pressman tells WebMD.\nIndeed, many of the women included in the \"light drinkers\" group had no more than a drink or two during their entire pregnancy.\nChildren in high-income households tend to perform better on behavioral and cognitive tests -- which could mask some possible harms from their mothers' light drinking during pregnancy.\nMothers were first asked about their alcohol use when the kids were 9 months old.\nWomen were defined as light drinkers if they had no more than one or two drinks a week.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not provide readers with specifics. It reports that the children of light drinkers did not appear to have a greater risk of behavioral problems than the children of women who reported not drinking during pregnancy. But what are the risks of problems? Readers are not told. Including a few statistics, for example that the rate of high total difficulties was about 7 percent for sons of light drinkers vs. about 10 percent for sons of non-drinkers would have revealed both the differences and provided a sense of the overall risk; that is, that in both groups the overwhelming majority of children appeared to be fine. In fairness, the main and most reliable finding of the study was failure to show an association between light drinking and adverse behavioral/cognitive effects.", "answer": 0}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides one surgeon\u2019s average fat-grafting and stem cell survival rate, about 54%.\u00a0\u00a0 The story notes current research on this new fat-grafting to determine short and long-term health and cosmetic outcomes.\u00a0 The story clearly and carefully explains the procedure and the rationale for the addition of stem cells to a transfer of a woman\u2019s fat to her breast tissue. The story notes that the makers of a machine that would mix fat and stem cells more effectively is sponsoring tests in Europe and is proposing tests in the U.S. ", "answer": 1}, {"article": "In a related editor's note, Mitchell H. Katz, M.D., a deputy editor of JAMA Internal Medicine, writes: \"Of course, no study is perfect.\nMiguel A. Mart\u00ednez-Gonz\u00e1lez, M.D., of the University of Navarra in Pamplona and CIBEROBN in Madrid, Spain, and coauthors analyzed the effects of two interventions with the Mediterranean diet (supplemented with extra virgin olive oil [EVOO] or nuts) compared with advice to women to follow a low-fat diet.\nThe study was conducted within the framework of the large PREDIMED (Prevenci\u00f3n con Dieta Mediterr\u00e1nea) trial, which was designed to test the effects of the Mediterranean diet on the primary prevention of cardiovascular disease.\nThe authors note a number of limitations in their study including that breast cancer was not the primary end point of the trial for which the women were recruited; the number of observed breast cancer cases was low; the authors do not have information on an individual basis on whether and when women in the trial underwent mammography; and the study cannot establish whether the observed beneficial effect was attributable mainly to the EVOO or to its consumption within the context of the Mediterranean diet.\n\"The results of the PREDIMED trial suggest a beneficial effect of a MeDiet [Mediterranean diet] supplemented with EVOO in the primary prevention of breast cancer.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release points out that the participants following the Mediterranean Diet supplemented by EVOO experienced a 68 percent lower relative risk of breast cancer than did the control group. While that\u2019s one way to report the findings, we always ask that stories also include a measure of the absolute risk, which provides important additional information to help readers gauge the size of the benefit. These absolute risk figures were reported in the study abstract and could have easily been included in the release as well. The researchers found breast cancer rates of 1.1 per thousand people per year in the Med Diet plus EVOO group, 1.8 per thousand people per year in the Med Diet plus nuts group, and 2.9 per thousand people per year in the control group.", "answer": 0}, {"article": "Larry Holzman \u2014 avid mountain-biker, skier and guitarist in a band \u2014 plays hard.\nBishop says the benefit of the FlexBar, which costs between $16 and $33, over traditional hand weights is that it helps people strengthen without recreating the symptoms.\nAnd the FlexBar makes it simple to do this kind of stretch.\nA study by researchers at the Nicholas Institute of Sports Medicine and Athletic Trauma, Lenox Hill Hospital in New York demonstrated this benefit.\nBut he understands the appeal: The FlexBar is easy to use and you can do it at home.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes no attempt to quantify the benefits associated with the FlexBar, and we don\u2019t think linking to the study abstract is sufficient to satisfy this criterion (especially when the full text of the published study is also available online). The average reader can\u2019t be expected to interpret differences on a \u201cvisual analog pain scale\u201d or \u201cDASH questionnaire\u201d without some explanation of what these measures mean.", "answer": 0}, {"article": "June 28, 2010 -- Cholesterol-lowering statin drugs appear to reduce the risk for prostate cancer recurrence in patients who have had a surgical procedure called radical prostatectomy.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nBut the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\nThose who took the highest doses saw their recurrence risk drop by half.\nThe research does not prove that taking cholesterol-lowering drugs directly slows the growth and progression of prostate cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As explained above, there are many numbers given about the potential benefits, but it is hard to say what they all mean. A big missing piece is some explanation of what they did to \"control for other factors.\"", "answer": 0}, {"article": "As most C. trachomatis infections are asymptomatic, chlamydia can often go untreated and lead to upper genital tract infections, pelvic inflammatory disease, and infertility.\nThis is why the promise of a vaccine would be extremely beneficial, says David Bulir, co-author of the study.\nThe results look very promising, said senior author James Mahony, a professor of Pathology and Molecular Medicine for McMaster's Michael G. DeGroote School of Medicine and a researcher at St. Joseph Healthcare Hamilton's Research Institute where the work was performed.\n\"Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.\"\nCo-author and McMaster PhD student, Steven Liang, explains, \"not only is the vaccine effective, it also has the potential to be widely protective against all C. trachomatis strains, including those that cause trachoma.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release\u00a0mentions the antigen being studied,\u00a0BD584, \u201cwas able to reduce chlamydial shedding \u2013 a symptom of C. trachomatis \u2013 by 95 per cent.\u201d Without any context for how many people (or mice in this case) were studied, we have no way of knowing what that means.", "answer": 0}, {"article": "\u201cYou don\u2019t need any fancy equipment.\nHe said the findings, published in the journal Autism Research, were very preliminary, but if confirmed in several more and larger studies, they might replace current subjective tests now used to diagnose the disorder.\nBy measuring six aspects of the brain\u2019s circuitry, the test was able to correctly pick out people who had been diagnosed with autism with 94 percent accuracy.\n\u201cHowever, it has been shown that in the early stages of development, individuals have been aided by intense one-on-one caring to help them with language, social function with their peers and also with emotional problems,\u201d he said.\nLange said the findings should help make the process of diagnosing autism more scientific because it would rely on a test rather than a subjective assessment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The second sentence of the story says, \u201cThe test, which uses conventional magnetic resonance imaging or MRI machines, detected 94 percent of individuals with a high-functioning form of autism, they reported on Thursday.\u201d The 94 percent number is completely out of context and exactly the kind of overstated statistic that gives readers false hope based on flimsy evidence. This was, after all, a study in 30 people with autism and 30 without.\u00a0 Unlike the CNN story we reviewed, this story fails in keeping inappropriate enthusiasm at bay. The potential benefits of such a scan can only be speculated at this stage, and readers should have been provided absolute numbers to make it clear how many people were correctly identified, at what ages and to what end.", "answer": 0}, {"article": "Insurance coverage varies, and doctors often only offer this testing to women at higher risk because of things like advanced maternal age.\nStudies have shown that the new fetal DNA tests do a better job, says Norton.\nThis can reveal if there's an increased risk of certain disorders, but it's not very accurate and produces a lot of false alarms.\n\"Approximately 1 in 700 pregnancies there's an extra X or extra Y,\" she says, noting that these are mild conditions that would normally go undetected, unless a woman had an invasive test like an amnio.\nShe didn't want an invasive procedure like amniocentesis or chorionic villus sampling.Those are considered the gold standard for prenatal genetic testing, but doctors must put a needle into the womb to collect cells that contain fetal DNA, which means a small risk of miscarriage.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The accuracy level\u00a0of the new screening tests was described as better than existing screening\u00a0tests (blood tests plus ultrasound), but this benefit was not quantified (i.e., the screening tests can detect X disease Y% of the time compared with traditional tests, or false alarms occur for X% of new tests vs Y% for traditional screening tests). A linked study abstract provided this detail, but the jargon-filled text would be difficult for most readers to understand. A quick rundown of those numbers would have been easy to provide in the story itself.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Science doesn\u2019t just help to invent new products, it can push existing ones.\nHe pointed out it was hard to draw any conclusions from this part of the study because it didn\u2019t include any data.\nOf more than a dozen researchers and dermatologists contacted about the quality of this study, only Schalock agreed to comment.\nSchalock told Reuters Health he has a \u201chard time seeing that statistically or scientifically they have proven it.\u201d\n\nThe fact that the company did the testing itself could also raise a red flag.\n\u201cThe efficacy of our nutritional supplement was demonstrated by rigorous studies,\u201d said Nathalie Piccardi, of Laboratoires Inneov, who worked on the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes clear the expert opinions that \"there are no data there.\" ", "answer": 1}, {"article": "It's a substantial number of women,\" Lyman said.\nThe study, involving nearly 900 women who were treated at 115 sites across the country, found that those who did have their lymph nodes removed were no more likely to survive five years after the surgery than those who did not, the researchers reported in a paper published in the Journal of the American Medical Association.\nThe researchers noted that the study was limited to women with tumors known as T1 or T2, meaning they were relatively small, had no enlarged nodes that could be felt, and the cancer had not spread elsewhere.\nThe study provides \"strong evidence\" that many women can safely forgo lymph node removal, they wrote.\nIn a telephone interview, Gary Lyman of the American Society of Clinical Oncology said the findings will probably prompt the group to revise its recommendations for breast cancer patients accordingly.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The potential benefits were included in the article.\u00a0 The \u201cfive-year\u00a0\u2018disease free\u2019 survival rate was 83.9%\u2026\u201d for women who did not\u00a0have the more aggressive surgery \u201c\u2026compared with 82.2% in those who did\u2026\u201d \u00a0Because full axillary lymph node dissection did not decrease mortality or decrease disease free survival, this may no longer be the standard recommendation.", "answer": 1}, {"article": "\u201cBut we do expect the patients to have significant improvements in mobility.\u201d\n\nNearly 30,000 Asterias\u2019s shares were traded by 12:30 p.m.\nThe early study tested the benefits of a smaller dose of 2 million stem cells that are tuned to develop into nerves.\nLichtinger said he was confident the data would be positive but was not expecting miracles.\nThe therapy, AST OPC-1, is the first product derived from human embryos to be tested on humans.\nData showed that the severity of the spinal injury was reduced in the first patient and two other patients were able to resume their rehabilitation programs soon after being injected with the stem cells.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We think this report could have done a more thorough job here, especially since its headline claims the stem cell therapy \u201cshows promise.\u201d We think that it is helpful to point out that this is a phase 1/2 trial and is the first cohort of patients to be enrolled.\u00a0 A very early stage in the arduous path to commercialization.\nThe only mention of benefits in this Reuters story is that \u201cseverity of the spinal injury was reduced in the first patient,\u201d but the story doesn\u2019t try to quantify his improvement. To what extent was the spinal injury reduced? And in what time frame? Since there is no control group in this study, it would have been helpful to know if patients normally experience improvements over time. The news release provides a bit more useful information in this regard with a quote from one of the investigators;\u00a0\u201cThis progress in the first patient is very encouraging and is observed in less than 5 percent of our AIS A patients at this stage of their recovery.\u201d\nThe story does include a restraining quote from the company CEO who says,\u00a0\u201cIt is important to know that we do not expect patients to get up and play basketball. But we do expect the patients to have significant improvements in mobility.\u201d But what does \u201csignificant improvement\u201d mean?", "answer": 0}, {"article": "The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top \"Honor Roll\" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751.\nBased on the preliminary results at Penn Medicine, the cancer detection rate of AB-MR screening is 25 cancers per 1,000 patients.\n\"Having dense breast tissue makes it more difficult to detect a cancer on a mammogram,\" said the study's lead author, Susan Weinstein, MD, an associate professor of Radiology and the director of breast MRI at Penn Medicine.\n\"Based on the literature and our results, women with dense breast tissue who desire supplemental screening, these results suggest that AB-MR may be a better option than other supplemental screening tests such as whole breast ultrasound.\nTo put this in perspective, the cancer detection rate of mammography is roughly 4 cancers in 1,000 women who have a mammogram.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release described better cancer detection rates using the abbreviated breast MRI compared with mammography and 3D mammography. Unfortunately, the release didn\u2019t compare the cancer detection rate of the abbreviated breast MRI with whole breast screening ultrasound which is the current standard supplemental screening tool to use for women who are asymptomatic.\nIt remains unclear if the abbreviated breast MRI is better than ultrasound, the current standard of care.\nWhile calling out ultrasound screening for having a high number of false positives, the release offers no details on the number of false-positives for abbreviated MRI screening.\nFurther, the release offers no information about the stage of the cancers diagnosed with abbreviated MRI. Readers deserve to know how many cancers identified in the study were ductal carcinoma in situ (DCIS). Many healthcare professionals believe DCIS should be re-named because this condition refers to abnormal cells inside a milk duct in the breast, is not invasive, and there\u2019s a debate over whether it is breast cancer.  ", "answer": 0}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nResearchers said that in some cases MRI findings of additional cancers not seen on mammography may necessitate a change in treatment.\nOf the 2,021 patients, 285, or 14 percent, had additional cancer detected on MRI that was hidden from view on mammography.\n\"Patients with clinically insignificant cancers undergoing potential overtreatment versus patients who may be undertreated is at the heart of the controversy surrounding breast MRI,\" said the study's lead author Chiara Iacconi, M.D., from the Breast Unit at USL1 Massa-Carrara in Carrara, Italy.\nHowever, MRI also detected additional disease in 19 percent of patients with fatty or scattered fibroglandular tissue.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release notes that potential benefits are uncertain and that the researchers\u2019 conclusions that additional cancers found through MRI imaging might justify altering treatment plans is based on a belief that tumors larger than 1 cm are clinically significant, not specific study evidence. But we believe that the release\u00a0should have specifically noted (as the journal article did) that other studies have not found benefits to treating tumors discovered through preoperative MRI, and then explained the different way this study looked at the issue.\u00a0We have no data to suggest that treatment of the additional cancers (which in the case of multicentric disease would require mastectomy) improves outcomes. We know that if we look harder for additional cancers, we will find them. What is unclear is which of the additional cancers need to be found.", "answer": 0}, {"article": "The etonogestrel implant is a small plastic rod resembling a matchstick that is inserted under the skin in the upper arm.\nThe risk of an unwanted pregnancy with these other methods was especially high among women under 21, whose rate of unintended pregnancy was nearly double that among older women.\nYet fewer than 10 percent of sexually active women currently rely on long-acting reversible contraception, and a major reason is doctors\u2019 reluctance to recommend them.\nIn real-world use, these methods are associated with a one-year pregnancy rate of less than one per 100 women.\nOf course, some couples fail to use any contraception, but others rely on contraceptive methods that have significant failure rates even when properly used.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives figures on the effectiveness of a variety of contraception methods.\nHere is an excerpt:\nIn a 2012 study of 7,486 women aged 14 to 45, long-acting reversible contraceptives, or LARCs, were shown to be 20 times as effective in preventing pregnancy than the pill, contraceptive patch or vaginal ring. The risk of an unwanted pregnancy with these other methods was especially high among women under 21, whose rate of unintended pregnancy was nearly double that among older women.\nAbsolute risks are also cited in the report on one-year pregnancy rate with real-world use, which is another strength of the story.", "answer": 1}, {"article": "\"We need a lot more options in terms of medicines to help curb drinking,\" he said.\nExactly how this drug curbs drinking is not fully understood, but its use may increase blood pressure, heart rate and feelings of sadness and nausea, thereby blunting the pleasurable effects of alcohol, the researchers said.\nWhether the drug might someday be approved to help problem drinkers cut back remains to be seen, said the researchers, who acknowledged that the study's small size is a limitation.\nMore research is needed, he noted, but \"this medication may be helpful for people with a drinking problem who are also smokers.\"\nThe participants found the Chantix-booze combination increased the unpleasant effects of alcohol and reduced the rewarding aspects of drinking.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The lead of the story misstates the results of the study. These researchers measured how a few participants felt after taking Chantix or a placebo and drinking alcohol or a placebo drink. They found that overall the participants did not feel as good after drinking a low dose of alcohol, if they had taken a Chantix pill earlier. However, they didn\u2019t see the same difference with higher doses of alcohol. This test did not look at whether these people voluntarily would change the amount of alcohol they drank when they took Chantix. The story headline and lead both focus on the possibility that Chantix could curb problem drinking. Although some other reports indicate people taking Chantix might drink less that is not what this test looked at.", "answer": 0}, {"article": "Uterine fibroids are benign tumors that grow in and around the uterus.\nThe drugs, experts say, would provide a new treatment option for a condition most commonly treated with a hysterectomy, or removal of the uterus.\nPatients with the condition say it\u2019s time for better treatments.\nIf a woman has no symptoms, treatment of fibroids isn\u2019t necessary, experts say.\nWomen often must take it with hormone replacement therapy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article offers general statements about the \u201cdramatic\u201d and rapid effects of UA from Allergan researchers, but does not provide any numerical context or offer summaries of research with that information.", "answer": 0}, {"article": "The Food and Drug Administration approved a new drug on Tuesday to treat serious cases of eczema.\nIt\u2019ll cost $37,000 a year but the drug\u2019s makers, Regeneron Pharmaceuticals and Sanofi, have stressed that\u2019s the wholesale price and make a point of saying there will be programs to help people pay for it.\n\u201cOf the adults with uncontrolled moderate to severe atopic dermatitis in the United States, it is estimated that 300,000 are most in need of new treatment options,\u201d Regeneron said.\nThe agency gave it both priority review and breakthrough therapy status, speeding it through the approval process.\nStudies of about 2,000 people showed Dupixent injections resulted in clear skin or nearly clear skin for about two-thirds of those who tried it, and it reduced itching sharply in 40 percent.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that studies in about 2,000 people showed injections \u201cresulted in clear skin or nearly clear skin for about two-thirds of those who tried it, and it reduced itching sharply in 40 percent.\u201d\nThis is enough for a satisfactory rating, but the story should have mentioned that close to 10 percent of patients on a placebo saw the same improvement in their rash. It also would have been stronger if it had explained how the benefits were measured (how is a \u201csharp\u201d reduction in itching measured?), how much time it took to achieve the results, and if the results were sustained.", "answer": 1}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\nRelated: Why Young Women are Having Heart Attacks\n\nThe team studied more than 450 people having heart bypass surgery, removing some of the fat clogging their arteries.\n\u201cBut until now, there's been no way to detect inflammation in the coronary arteries.\u201d\n\nRelated: Half of People Who Have Heart Attacks Don\u2019t Even Know It\n\nDoctors run many different tests to assess someone\u2019s risk of heart disease.\nResearchers say they\u2019ve developed a better way of scanning someone\u2019s heart to predict who is most at risk of a heart attack or stroke \u2014 long before conventional imaging methods can do it.\n\u201cTreatments that are known to reduce the risk of heart attacks, such as statin drugs, reduce inflammation much more than any detectable reduction in coronary artery narrowing,\u201d said Oxford\u2019s Keith Channon, who also worked on the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t provide any data to give a sense of the potential benefit of the new approach. No numbers were given to explain how well it worked.", "answer": 0}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is insufficient detail about the benefits and how long they last. We learn that at least one urologist who has become a convert to the procedure is \u201cunsure how long the improvement will last.\u201d \u00a0The link to a study abstract\u00a0adds a bit more detail, but its not discussed much in the story. We learn that the manufacturer-funded trial found \u201cpeak urinary flow have lasted so far for five years,\u201d but no details on how this compares to controls. It is useful to know that \u201cone in 10 patients\u00a0ended up needing surgery anyway.\u201d", "answer": 0}, {"article": "\"It's a very fragile organ to begin with,\" Kavaler said, \"and if you start to do all these things to it you can disfigure it...\nLong-term vacuum treatments did not appear effective, producing no significant physical changes after six months, Gontero said, but did provide a degree of psychological satisfaction.\nThese devices yielded average flaccid length increases of between 0.2 inches and 1 inch, Gontero said, and men achieving better results noted their satisfaction.\n\"No study has, however, specifically addressed the extent and type of sexual bother in this patient category.\"\nHe and his colleagues found no scientific evidence to support penile-lengthening exercises.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are discussed but not adequately quantified.", "answer": 0}, {"article": ".\nThey also calculated the elasticity ratio of the lesions and adjacent normal skin and used laboratory analysis to confirm their diagnoses.\nIn another study scheduled to be presented at the meeting, researchers found that high-frequency ultrasound with elastography can help distinguish between cancerous and benign skin lesions, which could improve the efficiency of skin cancer diagnosis.\nThey found that elastography correctly identified 98 percent of cancerous lesions and 82 percent of benign lesions, and they also determined that elastography was more accurate than ultrasound in gauging the size of the lesions.\n\"High-frequency ultrasound provides almost microscopic resolution and enables us to get size, shape and extent of the lesion prior to biopsy.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story repeats the quantification of benefits as they are presented in the press release but these differ slightly from what is published in the abstracts. The story mentions that elastography correctly identified 98% of cancerous lesions and 82% of benign lesions, however the abstract states that elastography identified 76% of benign lesions. It isn\u2019t clear where this discrepancy comes from and for that reason we must judge this unsatisfactory. The story states that these numbers are better than conventional utrasonography but provides no quantification for comparison. The story should have placed them both into context with other technologies including MRI, computer assisted detection and full field mammography as well as ultrasonography. ", "answer": 0}, {"article": "Unlike common polyps, they tend to be flat and the same color as the colon lining.\nSome of the study authors and the Mayo Clinic have a financial interest related to technology used with this research.\nThe DNA stool test methods were developed at the Mayo Clinic.\nTUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\nCompared with widely used fecal blood tests, stool DNA testing has higher detection rates for curable stage colorectal cancer and for common precancerous polyps (adenomas), according to the Mayo Clinic-led research teams.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did an adequate job of quantifying the benefits seen in two trials, but didn\u2019t comment on the small sample size in one study and didn\u2019t disclose the size of the sample studied in the other. ", "answer": 0}, {"article": "Atopic dermatitis is inherited and involves patches of highly itchy skin on any part of the body.\nTrial results were also reported on Tuesday in the New England Journal of Medicine, along with an editorial that said results of the study appeared \u201ccompelling\u201d at first glance and superior to those seen in previous studies of other asthma drugs.\nBut the editorial said effectiveness of dupilumab has been established in just a \u201climited subpopulation of patients with asthma\u201d because only 21 percent of those screened for enrollment in the study met its criteria.\n\u201cWe do not know whether dupilumab will be effective in other patient populations,\u201d the editorial said, including patients that stay on their standard therapies and who do not have high levels of eosinophils.\n\u201cWe have been treating asthma with sort of Band-Aid therapies that didn\u2019t get at the underlying causes,\u201d Wenzel said in an interview, adding that dupilumab could be an important step in going to the root of the problem.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story starts out by providing what appears to a quantification of the benefits of the drug saying that the \u201casthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent,\u201d and it goes on to quickly provide some much needed context by saying that the drug was studied in a trial involving 104 patients. It takes quite a while for the story to explain where that 87% number came from, and the explanation itself is a little unsatisfactory. It says, \u201c\u2019By end of the trial, after 12 weeks, 44 percent of those in the placebo group had exacerbations, compared with 5 percent of those on dupilumab,\u2019 Wenzel said. That represented an 87 percent reduction in exacerbations, which was highly statistically significant.\u201d We don\u2019t doubt that it was statistically significant, but we would have liked to have known how many patients really saw a benefit.\nHere\u2019s what the authors said in the paper:\n\u201cAsthma exacerbations occurred in 26 patients: 3 receiving dupilumab (6%) and 23 receiving placebo (44%) (odds ratio with dupilumab, 0.08; 95% confidence interval [CI], 0.02 to 0.28; P<0.001).\u201d", "answer": 0}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\nThe advanced form of radiation therapy (RT) was well tolerated among this relatively understudied elderly population, indicating that SBRT is a viable option for patients who may otherwise be offered no curative treatment.\n\u201cElderly patients, who are otherwise doing well, should not have treatment withheld based solely on concerns about side effects and age.\u201d\n\nThe abstract, \u201cStereotactic body radiotherapy for early stage non-small cell lung cancer in patients 80 years and older: A multi-center analysis,\u201d will be presented in detail during the poster session at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco (full details below).\n\u201cThe low rates of side effects from SBRT for this elderly population in our study indicate that these concerns should not prevent physicians from considering definitive treatment for their inoperable octogenarian and nonagenarian patients with early stage lung cancer.\u201d\n\nFindings are based on a retrospective analysis of 58 consecutive patients who received definitive lung SBRT across four academic sites within Emory between 2010 and 2015.\nAt two years following definitive SBRT for lung cancer among elderly patients, survival rates were 73 percent for cancer specific survival (CSS) and 57 percent for overall survival (OS).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides some data on benefits with this statement: \u201cAt two years following definitive SBRT for lung cancer among elderly patients, survival rates were 73 percent for cancer specific survival (CSS) and 57 percent for overall survival (OS).\u201d\nSo the release is claiming that SBRT can add years to the lives of elderly patients. But the study was merely a review of a series of cases and did not actually compare SBRT to any other treatment, so it provides no direct evidence of a survival benefit. The same section of the release refers to other studies, but provides no numerical description of the benefits from the other studies. In fact, other studies have relied on comparisons to historical controls, not randomized trials, so even though SBRT has become standard care for this sort of lung cancer patient when surgery is not an option, there is a lack of evidence about the precise benefits.", "answer": 0}, {"article": "Wasting syndrome is characterized by a loss of weight and muscle atrophy, and largely found in patients who suffer from cancer, kidney disease, chronic obstructive pulmonary disease, and heart failure.\n\u201cWe tested these compounds in sedentary mice and found a dramatic improvement in exercise endurance and a mild increase in muscle size of certain muscle groups,\u201d Sah says.\n\u201cThis same calcium signal also activates signaling pathways to increase skeletal muscle endurance and also skeletal muscle size.\u201d\n\nSah\u2019s research team hypothesized that low level calcium cycling induced by these natural compounds might promote improved exercise capacity and overall metabolic health associated with healthy muscle mass.\nThe discovery was a \u201cserendipitous finding\u201d in the lab of Rajan Sah, M.D., Ph.D., assistant professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa.\nThe intellectual property associated with this discovery was recently licensed by the UI Research Foundation to Innovus Pharma, an over-the-counter consumer goods and specialty pharmaceutical company that commercializes non-prescription medicine and consumer care products.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that, \u201ccompounds in thyme and oregano have demonstrated a greater than 37 percent increase in exercise tolerance and a 15 percent increase in muscle mass of certain body muscles.\u201d\u00a0 But there is no information as to how these measurements were acquired, or to which of the \u201ccertain body muscles\u201d they were referring.\u00a0 And again, there is no mention of what these compounds actually were. Simply throwing out some percentages without providing an adequate context isn\u2019t helpful for readers.\nIf the release had transparently claimed that the benefits listed above applied to the \u201csedentary mice\u201d finally mentioned at the end of the release, we\u2019d still rate this criteria as Not Satisfactory. The mice were not noted to have cancer, COPD, heart failure, and other conditions which brought about wasting sickness. The findings, as such, are specific to non-human species without any of the conditions that are purported to be creating the setting for wasting.", "answer": 0}, {"article": "The amygdala and hypothalamus are regions of the brain that control several memory and emotional functions.\nThe double-blind, placebo-controlled study involved 40 adults between the ages of 50 and 90 years who had mild memory complaints.\nThe people who took curcumin experienced significant improvements in their memory and attention abilities, while the subjects who received placebo did not, Small said.\nThe research, published online Jan. 19 in the American Journal of Geriatric Psychiatry, examined the effects of an easily absorbed curcumin supplement on memory performance in people without dementia, as well as curcumin\u2019s potential impact on the microscopic plaques and tangles in the brains of people with Alzheimer\u2019s disease.\nIn memory tests, the people taking curcumin improved by 28 percent over the 18 months.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release mentions these benefits in the 21 subjects who took curcumin: \u201csignificant improvements in their memory and attention abilities (ie. \u2018improved 28 percent over the 18 months\u2019) \u2026 mild improvements in mood \u2026and their PET scans showed significantly less amyloid and tau signals in the amygdala and hypothalamus\u201d when compared to the 19 subjects in the placebo group.\nWe are told that standardized tests were used but not where the improvements were seen or how widespread the improvements were seen. Nor are we given context to answer \u201c28 percent of what\u201d? We\u2019re also given no context to understand what reduced amyloid and tau signals mean (nor what \u201csignificantly less\u201d means), only that \u201cthe amygdala and hypothalamus are regions of the brain that control several memory and emotional functions.\u201d", "answer": 0}, {"article": "And if you wake up in the middle of night and don\u2019t fall back asleep easily, get out of bed.\u201d\n\n\u201cYou don\u2019t want to have any linkage between the experience of lying in bed and being awake,\u201d he said.\nWhen the researchers looked at information from a different, more in-depth sleep monitoring system, however, they failed to find significantly better outcomes with the behavioral therapy.\n\u201cMore consolidated sleep is more refreshing.\u201d\n\nBased on questionnaires and sleep diaries, the researchers found that two out of every three participants receiving the behavioral intervention responded favorably by the end of 4 weeks, while just one out of every four receiving the printed material experienced substantial improvement in their sleep.\nThese improvements were sustained for at least 6 months, and were backed up by data from a sleep monitor worn on the wrist or ankle.\nBuysse and his colleagues wondered if the pill-free treatment could be shortened and simplified, providing more rapid results at a lower cost.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story tells readers that 55 percent of people in the active intervention group no longer met the criteria for insomnia after four weeks. However, readers are not told how the researchers defined insomnia. Was it a complete inability to sleep? How frequently did the participants have trouble sleeping? How much more did they sleep after treatment? Without these and other details, it is difficult to get a feel for what effect the treatment had.\nWhile this story reported how many people needed to be treated in order to make a difference for at least one\u2026 a statistic we encourage journalists to use more\u2026 the story reported twice as many people benefited as the researchers actually said they saw. The researchers wrote that one person either had remission (no more insomnia) or response (significantly less insomnia) for every 2.4 people treated. But the story says that for every 2.4 participants treated one responded and one overcame insomnia.", "answer": 0}, {"article": "We've had a lot of migrants from European nations, so they're fair-skinned ... and we do have a very intense sun here,\" Ziman said.\nFor potential sufferers in remote areas, away from skin specialists, diagnosis can be especially tricky, he said, making a simple blood test an easy alternative to identify those at risk.\nPatients who returned a positive result would still need a biopsy to confirm the blood test and determine how far the cancer had developed, Ziman said.\nZiman said current methods of melanoma detection are expensive and invasive, involving a trip to a clinician, who must biopsy the lesion to discover whether it is cancerous.\nThe test could speed up the diagnosis process, saving thousands of lives.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides both sensitivity and specificity for the test and notes that both need to be in excess of 90% for it to be useful.\nOf course, there is an assumption that the test\u2013if proven to be validated\u2013would reduce deaths from melanoma due to early detection. That will take a lot more research to determine. \u201cEarly detection saves lives\u201d is not always true.", "answer": 1}, {"article": "According to the American Cancer Society, melanoma accounted for more than 68,000 cases of skin cancer in 2009, and 8,650 deaths.\nThe study is the first to test ipilimumab in patients whose skin cancer had spread to the brain, and the findings, released in an abstract or brief summary, support its potential use in these patients, the researchers said.\n\u201cThese findings may have implications for the use of ipilimumab therapy in the long-term management of advanced melanoma,\u201d the researchers reported in the abstract.\nResults of a late-stage study of the drug in melanoma patients will be detailed in a \u201clate-breaker\u201d session at ASCO\u2019s annual meeting in June.\nIn the phase 2 trial, researchers said four out of 51 patients with at least one brain lesion had a partial response to the drug, and in 5 out of 51 patients, both brain and other tumors in the body stabilized after 12 weeks of treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThese trials did not compare the experimental drug ipilimumab to standard therapy. Although the story accurately transcribes what the researchers wrote about the potential use of the drug, it should have pointed out to readers that this sort of experiment is usually not designed to be able to answer questions about the relative benefits of the experimental intervention.", "answer": 0}, {"article": "His doctor prescribed a C.P.A.P.\nIn those people, Provent typically doesn\u2019t work.\nBut not everyone finds that Provent alleviates their apnea.\nIt is also more expensive, and it doesn\u2019t work for every patient.\nDr. Lee A. Surkin, a cardiologist and sleep medicine specialist in Greenville, N.C., said patients typically start with a 10-day trial pack that costs $27.50.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story references \u201ca large study of 250 apnea sufferers published in the medical journal Sleep and subsidized by Ventus,\u201d the maker of the Provent patch. But it fails to quantify the benefits found in this study. Instead it says \u201cthose who used Provent devices over a three-month period saw their apnea episodes fall sharply, compared with people who were given a sham, or placebo, device. A follow-up study tracked people over the course of a year and had similar results.\u201d\nLet\u2019s put this in perspective:\u00a0 One of the patients profiled in the story awakened 42 times a hour prior to using the Provent device.\u00a0 Subjects who used the Provent device in the published study reduced awakenings by about 50%.\u00a0 So someone like Mr. Bleck would be expected to reduce awakenings to ONLY 21 per hour.", "answer": 0}, {"article": "\u201cIt\u2019s like eating a whole bottle of Tums every day,\u201d Dr. Evans said.\nDr. Ronald M. Evans, a leading expert on the hormonal control of metabolism at the Salk Institute, said that the report by Dr. Auwerx\u2019s team had \u201cshown very convincingly that resveratrol improves mitochondrial function\u201d and fends off metabolic disease.\nThat is the process that he says is reversed by resveratrol and, he hopes, by the more powerful sirtuin-activator drugs that his company is developing, though many years of clinical trials will still be needed to demonstrate whether they work and are safe to use.\nBut even Longevinex\u2019s capsules, which at present contain 40 milligrams of resveratrol each, would have to be gulped in almost impossible quantities for a human to obtain doses equivalent to those used in mice.\nWhether much lower doses would benefit athletic performance is not clear, Dr. Evans said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The opening statement of the story, discussing 100% improvement in performance takes results observed in a single study of mice and extrapolates to humans.\u00a0 Later in the story, there is mention of a 30% increase in lifespan in mice, though these results are again\u00a0from a study of a single strain of mice. (Strains of mice are genetically identical individuals and therefore results observed in a single strain need confirmation in several strains before it can be concluded that the results are generalizable to the entire species.)\nMention of a genetic analysis of different forms (alleles) of a human gene and energy expenditure was based on a very small study and in itself should not be seen to imply that the mechanism in mice and humans was the same as stated in the story.", "answer": 0}, {"article": "\"She had a persistent boil on her buttocks,\" he explained.\nThe most promising research, he and many other scientists say, focuses instead on bioactive honey's potency as a topical application.\nHence the hope that a naturally occurring substance such as honey might help fill the void.\n(And there's wide agreement among medical professionals that people should not test the treatment themselves by slathering their cuts and burns with honey from the pantry shelf.)\nFor biochemist Peter Molan, honey's ancient power to heal is not a matter of faith.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story talks about \u2018success rates\u2019 for the honey compared to \u2018conventional interventions\u2019, it is not clear\u00a0how this was defined, how it was measured, etc.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Taking multivitamins may help women without cardiovascular disease to ward off a heart attack, new research shows.\nAmong the women with heart disease, 13 percent of the non-supplement-users had heart attacks, compared to 14 percent of women who took multivitamins only, which wasn\u2019t a statistically significant difference (meaning it could have been due to chance).\nFor the women without heart disease at the study\u2019s outset, taking a multivitamin for less than five years reduced heart attack risk by 18 percent compared with non-users of supplements.\nBut vitamin pills seemed to have less of an effect in women with heart disease, Dr. Susanne Rautiainen of the Karolinska Institutet in Stockholm, Sweden, and her colleagues found.\nTo investigate the relationship between vitamin use and heart disease in women, Rautiainen and her team followed 31,671 women with no history of heart disease and 2,262 women who did have cardiovascular disease for about 10 years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided the numbers so that readers could calculate the absolute reduction in heart attacks in the group of women taking multivitamins who did not have heart disease (with multivit = 2.6%; without multivit = 3.4%). \u00a0However, it is unfortunate that instead of choosing to report that there was \u00a0a1% reduction in heart attacks, a decision was made to report it as a 27% reduction in heart attacks. \u00a0While a 27% difference sounds pretty exciting, it is a bit misleading.", "answer": 1}, {"article": "Zinc lozenges appear to influence the common cold through the release of free zinc ions into the oro-pharyngeal region.\nThus, zinc doses of over 100 mg per day do not seem to provide any more benefit.\nAlthough the binding difference between zinc acetate and zinc gluconate is a fact, it is not evident whether that causes significant differences at the clinical level for treating the common cold.\nThere is no significant difference between zinc acetate lozenges and zinc gluconate lozenges regarding their efficacy in shortening the duration of common colds according to a meta-analysis published in Journal of the Royal Society of Medicine Open.\nHowever, in future studies the optimal composition of zinc lozenges should be investigated.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release release gives details from the original study regarding benefits of both types of zinc lozenges, as well as dosages.\nBut the benefits are only given in relative terms, and not actual numbers. The release would have been improved if it had\u00a0included the number of days a cold lasts with or without zinc supplements. We\u2019re not sure a 30 percent shorter duration is a meaningful measure, especially without mentioning how long the average cold lasted, with ot without zinc supplementation. Another important consideration is when the zinc was taken. Does it need to be taken continuously as a preventative or does it need to be started immediately at the first sign of symptoms? If you don\u2019t start right away does that affect how well it works?", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nEfficacy of Intrarosa, a once-daily vaginal insert, was established in two 12-week placebo-controlled clinical trials of 406 healthy postmenopausal women, 40 to 80 years of age, who identified moderate to severe pain during sexual intercourse as their most bothersome symptom of VVA.\nIntrarosa, when compared to placebo, was shown to reduce the severity of pain experienced during sexual intercourse.\nThe U.S. Food and Drug Administration approved Intrarosa (prasterone) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.\n\"Intrarosa provides an additional treatment option for women seeking relief of dyspareunia caused by VVA.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states simply, \u201cIntrarosa, when compared to placebo, was shown to reduce the severity of pain experienced during sexual intercourse.\u201d No data are provided to back up this claim.\nWithout any numbers, it\u2019s impossible to evaluate how beneficial the treatment actually is. How many women from the treatment group experienced this benefit? And although it\u2019s difficult to quantitatively assess pain, it could still be addressed by scores (e.g. On a scale from one to ten, how bad was the pain before treatment and then after treatment?). Without any idea of how much pain was actually reduced, readers have no idea whether the advantages of this therapy outweighs its costs and risks.\nThis is a point that we recently addressed in one of our blog posts, since news releases put out by the FDA often miss the mark on this criterion. More details, especially in the form of quantitative data, are badly needed.\nAs a result, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "Urothelial carcinoma is the most common type of bladder cancer and occurs in the urinary tract system, involving the bladder and related organs.\nTherefore, today the FDA also approved the Ventana PD-L1 (SP142) assay to detect PD-L1 protein expression levels on patients' tumor-infiltrating immune cells and help physicians determine which patients may benefit most from treatment with Tecentriq.\nThe Ventana PD-L1 (SP142) assay companion diagnostic for Tecentriq is marketed by Ventana Medical Systems, based in Tucson, Arizona.\nThis trial measured the percentage of patients who experienced complete or partial shrinkage of their tumors (objective response rate).\nTecentriq is the first FDA-approved PD-L1 inhibitor and the latest in the broader class of PD-1/PD-L1 targeted biologics approved by the FDA in the last two years.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This release gives the preliminary results from a single study of 310 patients. Because the drug is experimental, long-term results haven\u2019t been studied. Of the 310 patients enrolled in the lone trial upon which the approval is based, 14.8 percent showed some shrinkage of tumors during the assessment period lasting from 2.1 to about 13.8 months. For a subset of patients who were classified as having a positive response to PD-L1 expression, the response was 26 percent.\nAs noted above, tumor shrinkage doesn\u2019t always lead to improvements in survival or quality of life. It is a surrogate endpoint \u2014 a substitute \u2014 for the main outcome which is survival. Although this drug looks promising, to be fully transparent about its benefits as currently known, the release should have explained this. As noted in the \u201cSummary,\u201d another larger study is underway to assess the drug\u2019s impact on extending life and improving quality of life.", "answer": 0}, {"article": "Aug. 4, 2010 -- The plant extract resveratrol, found in the skin of red grapes, appears to suppress inflammation and may fight aging in humans, according to a new study.\nBlood samples from those on placebo showed no significant change in pro-inflammatory markers.\nResults showed that resveratrol suppressed the generation of \u201cfree radicals\u201d -- unstable molecules known to cause oxidative stress and release pro-inflammatory substances into the blood, resulting in damage to the blood vessel lining.\nNow, Ghanim and colleagues say they have found that resveratrol reduces inflammation in humans that could lead to heart disease, stroke, and type 2 diabetes.\nThe researchers signed up 20 people and put them at random into two groups, one receiving a placebo and the other a supplement containing 40 milligrams of resveratrol.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "How many of the 10 people taking resveratrol had changes in \"pro-inflammatory markers\"?\u00a0 All of them?\u00a0 Half of them?\u00a0 How big were the changes?\u00a0 How meaningful were the changes?\u00a0 We weren\u2019t told any of this.\u00a0 ", "answer": 0}, {"article": ".\nThe researchers investigated patients enrolled in the randomized, double-blind, comparative, multicenter international phase 3 ACTIVE trial to evaluate the efficacy and safety of 80 micrograms of abaloparatide-SC in preventing fractures in otherwise healthy, ambulatory, postmenopausal women with osteoporosis.\nOverall, 2,463 patients between 49 and 86 years of age were randomized to one of three treatment arms for 18 months: double-blind 80 micrograms of abaloparatide-SC, blind-matched placebo, or open-label 20 micrograms of subcutaneous teriparatide (an FDA-approved prescription drug known to increase bone density and strength).\nThe authors found that the risk of new vertebral or nonvertebral fractures dropped consistently among the participants taking abaloparatide-SC, irrespective of their baseline risk factors; and they found an increase in bone mineral density by abaloparatide in each of the baseline risk subgroups.\nThe data suggest that abaloparatide appears to be an effective treatment for a broad group of postmenopausal women with osteoporosis.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release would have been much more helpful to the reader if it had included some absolute numbers along with the relative risk reductions. The release notes that of 2,463 osteoporosis patients, ages 49 to 86, the drug increased bone mineral density in the lumbar spine by 9.2%, in the hip 3.4% and in the femoral neck by 2.9% compared to placebo. The release also describes the reduction in vertebral fractures by 86%, and other risk reductions, also in terms of percentages. But what were the actual rates of fractures in each group? That would give readers the best sense of the size of the benefit.", "answer": 0}, {"article": "So does cardiologist Roger Blumenthal, who heads the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins.\nAnywhere from 50 to 200 healthy people need to take a statin daily to prevent a single heart attack for five years, so even small harms may outweigh the potential benefits, the Swiss scientists say.\nPuhan says, based on his assessment, perhaps 15 to 20 percent of older adults should be taking statins \u2013 far less than the 30 or 40 percent suggested by current medical guidelines.\nBut that test, which Grundy says is available for about $100, is controversial among some physicians.\nThe study, in the Annals of Internal Medicine, argues that current medical guidelines haven't adequately considered the risks from these widely used drugs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We learn that \u201canywhere from 50 to 200 healthy people need to take a statin daily to prevent a single heart attack for five years.\u201d That\u2019s helpful information. It also notes that the observed benefit is less for older patients.\nThe story could have added that even those numbers might disputed by some experts who perceive no meaningful benefit. For example, one review found being on a statin does not help people with low risk for heart disease live longer.", "answer": 1}, {"article": "November 16, 2015.\nIn the article the authors offer suggestions to how both individual consumers and the food industry can use seaweed to make our everyday meals healthier.\nAdding seaweed to processed foods such as frozen pizzas, hot dogs and dried pasta will reduce cardiovascular diseases, concludes a new scientific article.\nHe and the co-authors suggest that seaweed should be added fast food, thus making this type of food healthier.\nBy adding seaweed to processed foods we can make food healthier.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are no actual quantifications of benefits in this release. It says that, \u201cBy eating bread containing 4% of dried seaweed the overweight men ingested more dietary fiber (4.5 g more fiber per. 100 g) than when they ate the control whole-meal bread. Another effect was that they consumed 16.4% less energy in the 24 hour period after eating the seaweed enriched bread.\u201d Honestly, we have no idea what this means. Is 4.5 grams more fiber meaningful? Does it have any measurable health impact? Does consuming less energy during a 24-hour period lead to positive health benefits or negative? There\u2019s no help in interpreting this information.", "answer": 0}, {"article": "To learn more, visit stjude.org or follow St. Jude at @stjuderesearch\nThey found that the mice showed drastically reduced AIM2 function, confirming the finding in humans with the cancer.\nThey found that AIM2 deficiency causes uncontrolled proliferation of intestinal cells.\nThey also found that mice genetically altered to have reduced AIM2 function, when treated with the chemicals, showed significantly more tumors than normal mice.\nSurprisingly, they also discovered that AIM2 influences the microbiota -- the population of gut bacteria -- apparently fostering the proliferation of 'good' bacteria that can protect against colon cancer.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is overrun with general statements and specificity is mostly missing.The release says that AIM2 suppresses \u201cabnormal expansion of intestinal stem cell populations,\u201d but it doesn\u2019t quantify what that means. How much more proliferation of these stem cell populations was there in mice that had a \u201cmalfunction of AIM2\u201d? And how does stem cell proliferation translate to cancer growth? Similarly, the release noted that when \u201cnormal\u201d mice and AIM2-deficient mice had the opportunity to exchange gut bacteria, \u201cscientists found a striking reduction in colon tumors in the AIM2-deficient mice and an increase in tumors in the normal mice.\u201d But it doesn\u2019t give readers any numbers that tell us how different those tumor numbers were or what that meant in terms of survival rate.\nAlso, importantly, the release does not make clear how much can be inferred about the behavior of AIM2 in humans from the behavior of AIM2 in mice. What level of uncertainty is there? What are \u201cgood bacteria\u201d and how are they transferred to experimental mice?\u00a0 How would that happen in humans?\u00a0 The release speaks of AIM2 findings and suggests possible meanings but fails to provide conclusive evidence to support the researchers\u2019 conjecture.", "answer": 0}, {"article": "Paul Delios of Saugus, Mass.\nHutcher says it's now about one in 1,000, which makes it less deadly than most major surgeries.\nYet most people who have this operation do not get skinny.\nA big reason the operation works is because it seems to suppress appetite.\nBut here's something the medical world is just realizing: that the gastric bypass operation has other even more dramatic effects.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The segment uses figures repeatedly to back up assertions made by the sources. But with the exception of the American Cancer Society data on cancer, the information comes from sources that are either self-interested (surgeons who perform the surgery) or not specified.\u00a0 ", "answer": 0}, {"article": "The dorsal root ganglions are nerve cells, on both sides of each of the spine's vertebra, and are the gateway to pain between nerves in different parts of the body, spinal cord and brain.\nFor most patients, the device reduced pain by 33 percent, which was significant, the researchers reported.\nThe therapy, which targets the root ganglion nerves, is more effective than other spine stimulation procedures because it places tiny leads precisely at the area where pain originates, unlike other devices that provide more generalized stimulation, the researchers said.\nIt shows long-term data that patients experienced significant pain relief and functional improvements, she said.\nOne pain specialist not involved with the study saw the benefits of this procedure.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes this claim high up:\nThe [DRG] therapy, which targets the root ganglion nerves, is more effective than other spine stimulation procedures because it places tiny leads precisely at the area where pain originates, unlike other devices that provide more generalized stimulation, the researchers said.\nWhile there are theoretical reasons why DRG stimulation may be better than spinal cord stimulation, only studies directly comparing these treatments can determine this, and there is no mention of such studies in this piece.\nBased on the study findings that are discussed, it may have helped some patients, but the story needed to make it clear that we can\u2019t know from this one study if it\u2019s better than alternatives. It\u2019s also unfounded to speculate that it may reduce the use of opioid drugs.", "answer": 1}, {"article": "\"This refutes that.\"\nThe findings may reverse the mastectomy trend, said Dr. Laura Kruper, co-director of the breast oncology program at the City of Hope Comprehensive Cancer Center in Duarte, Calif., who was not involved in the study.\nThis may indicate that the women who underwent lumpectomy were generally healthier, Hwang said.\nHwang and others suspect that women told they could safely opt for lumpectomy were still afraid to try it.\nThe new research, which was funded by the U.S. National Cancer Institute, suggests that if a lumpectomy is possible, it may actually increase survival, Hwang said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only attempted to quantify a benefit for one subset of women, when it reported:\n\u201cThe group that benefited the most \u2014 who had the biggest difference in breast cancer survival \u2014 were those women over 50 with estrogen-receptor positive disease,\u201d Hwang said. This means their cancer depends on estrogen to grow.\nAmong those women, the lumpectomy group had a 13 percent lower risk of death from breast cancer and a 19 percent lower risk of death from any cause than those who had a mastectomy.\u201d\nBut that was only a subset of women.\u00a0 And even in that subset, what was the risk of death? Was the difference of 13% and 19% really that much of a difference?", "answer": 0}, {"article": "There are two common surgical approaches for a total hip replacement: anterior, which involves entering surgically through the front of the hip, and posterior, or entering surgically through the side or buttocks.\nAnd to be quite honest, if the pain is controlled and the patient is healthy and medically completely stable there is no reason for them to be in the hospital.\nDavidovitch makes it clear that this kind of surgery is not one-size-fits-all.\nThose who have risk factors must plan on staying overnight in the hospital, not going right home.\nHowever, not every surgeon is embracing the same-day trend.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The basic premise of the story is that \u201csame-day\u201d hip replacement offers important advantages to patients, but the only benefit specifically noted in the story is that people who opt for this procedure are less likely to spend a night in the hospital. Even then, there are only vague references and quotes from the surgeon on how many patients really go home the same day. Indeed, the one patient named in the story did not go home the same day.\nThe story does note that studies following hip replacement patients for at least six months find no important differences in how they fare depending on which sort of procedure they had. Still, the overall thrust of the story is that \u201csame-day\u201d is superior, without critically evaluating the differences between going home that day or the next.", "answer": 0}, {"article": "J Natl Cancer Inst.\nThese key benefits of 3D MAMMOGRAPHY\u2122 could lower the costs associated with needless follow-up exams, and improve patient experience for women seeking a more accurate screening mammogram.\n\"This new analysis confirms that Genius\u2122 3D MAMMOGRAPHY\u2122 exams reduce unnecessary follow-up exams in dense-breasted women.\nMARLBOROUGH, Mass., April 26, 2016 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced that study results published today in a research letter in JAMA conclude that breast tomosynthesis (Hologic's Genius\u2122 3D MAMMOGRAPHY\u2122) exams reduce recall rates, and increase invasive cancer detection in women with both dense and nondense breasts.\nGenius\u2122 3D MAMMOGRAPHY\u2122 exams have been available in the U.S. since 2011, and are only available on the Hologic Selenia\u00ae Dimensions\u00ae mammography system.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release mentions a 50% increase in invasive cancer detection which on the surface sounds impressive, but they don\u2019t provide enough detail to understand what the 50% increase really means. According to the original study, the digital mammography plus tomosynthesis increased detection of invasive cancers from 3 per 1000 screens to 4.5 per 1000 screens and this high percentage increase was seen in only one of the four groups of breast tissue density. The other two groups had lower increases. (\u201cMammograms are categorized into four density groups: almost entirely fat, scattered fibroglandular densities, heterogeneously dense, and extremely dense,\u201d according to the release.)\nThe news release failed to mention that in women with extremely dense breasts, the 3D mammography was not significantly better at detecting invasive cancer than digital mammography alone. The published study called for caution \u201cin drawing conclusions regarding the performance of tomosynthesis [3D mammography] for the small proportion of women with extremely dense breasts.\u201d\nWe also question the release\u2019s portrayal of 3D mammography providing a \u201chigh percentage increase\u201d in detection over conventional mammography. Our calculations show a 0.15% increase in detection rates (0.3% detection rate for conventional vs. 0.45% for 3D).\nFinally, we need to address outcomes. There is no evidence from the study that finding these additional cancers leads to better outcomes. Finding more cancers with a more sensitive test could be\u00a0leading to over-diagnosis. Furthermore, the value of finding these cancers earlier is of uncertain value in the absence of outcomes data\u2013which ideally should come from a randomized trial to avoid bias in lead-time.\nThe many broad claims in the release are not fully supported by the evidence.", "answer": 0}, {"article": "POPGis one of several lipids found in the fluid that lines the air sacs of the lungs.\nNew research suggests the substance, a lipid known as POPG, may prevent RSV infection as well as limit the spread of the virus once infection has occurred.\nTherefore, together with the results of this study, researchers say the compound merits further research as a treatment for RSV infection in humans.\nApplying POPG to the cells after RSV infection also inhibited the spread of the virus to neighboring healthy cells.\nIn addition, the study showed treating infected mice with POPG dramatically reduced infection and prevented the spread of the inflammatory cells into the lungs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story simply stated, \"the study showed treating infected mice with POPG dramatically reduced infection and prevented the spread of the inflammatory cells into the lungs.\"\u00a0 What does dramatically mean?\u00a0 Totally?\u00a0 Partially?\u00a0 Was this in all mice?\u00a0 Half the mice?\u00a0 You can easily start to see how the story doesn\u2019t ask or answer tough questions about the evidence. ", "answer": 0}, {"article": "In skin testing, a practitioner makes rows of pricks on a patient\u2019s back or forearm so allergen-containing extracts can seep into the skin.\nWhile most allergy patients are seen by these generalists, he says, many allergies are not adequately diagnosed.\nBecause the test comes with a small risk of a serious reaction, it should not be performed in very young children and pregnant women, among others.\nDr. Roberts says that if primary-care physicians used the blood test, many more patients would be treated appropriately.\nThe blood test is also part of a larger debate about who should be treating allergy sufferers.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of the blood test compared to the skin test. It is not clear from the story if the blood test results in better outcomes for the patient other than convenience and fewer side effects. The question of whether using the blood test in combination with treatment results in better outcomes for the patient is unanswered.", "answer": 0}, {"article": "\"When people have serious injuries, whether from accidents or violence, and when they have severe hemorrhage they can bleed to death.\nIn fact, a trial to see whether TXA can reduce postpartum bleeding has started, the team noted.\nCurrently, TXA is not generally used in emergency rooms to treat trauma patients, but Roberts believes that this study could change that.\nDr. Jerrold H. Levy, deputy chair for research at Emory University School of Medicine in Atlanta and author of an accompanying journal editorial, said that, \"these data are really neat, because any therapy to reduce mortality in trauma is, I think, a major finding.\"\n\"I think people should consider it [TXA] following trauma on the basis of this study,\" he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Unlike some competing coverage, this story describes the benefits of TXA in both\u00a0relative and absolute\u00a0terms, providing readers with an accurate view of the magnitude of the\u00a0effect observed in the study. Unfortunately, the story\u00a0loses this balance when it\u00a0unquestioningly passes along the claim that TXA could save 100,000 lives in a\u00a0year if it were used around the globe. While\u00a0a back-of-the-envelope calculation may suggest that this is possible, many hurdles stand in the way of\u00a0this drug being\u00a0universally dispensed for trauma cases worldwide.\u00a0It\u2019s also far from clear that the findings of this study can be replicated under everyday conditions in emergency departments around the globe. The story should have tapped an expert to help put this\u00a0pie-in-the-sky figure in a more appropriate context for readers.\u00a0\n\u00a0\u00a0\u00a0\u00a0", "answer": 0}, {"article": "In a study published in the Jan. 19 issue of Neurology, Carlesimo and colleagues found that DTI scanning predicted declines in memory performance with more accuracy than traditional MRI.\n\"This type of brain scan appears to be a better way to measure how healthy the brain is in people who are experiencing memory loss,\" Carlesimo says in a news release.\nBut it is increasingly clear that DTI can also be used to identify very small structural changes in the gray matter of the brain, which is critical for learning and memory, researcher Giovanni A. Carlesimo, MD, PhD, of Italy's Tor Vergata University tells WebMD.\n\"This might help doctors when trying to differentiate between normal aging and diseases like Alzheimer's.\"\nThe technique, known as diffusion tensor imaging (DTI) or diffusion MRI, is used to assess changes in the white matter regions of the brain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story always qualified any potential benefit as possibility by qualifying every claim with the term \u2018may\u2019. \u00a0It would have improved this piece to include an explicit statement that there is currently no way to quantify what the benefit of early detection might be. \u00a0", "answer": 0}, {"article": "New vertebral fractures occurred less frequently in the active treatment groups vs placebo: in 0.58 percent (n = 4) of participants in the abaloparatide group; in 0.84 percent (n = 6) of participants in the teriparatide group; and in 4.22 percent (n = 30) of those in the placebo group.\n\u201cFurther research is needed to understand the clinical importance of risk difference, the risks and benefits of abaloparatide treatment, and the efficacy of abaloparatide vs other osteoporosis treatments,\u201d the authors write.\nOverall, there were no differences in serious adverse events between the treatment groups.\nIt has been estimated that the lifetime risk of osteoporotic fracture for a 60-year-old woman is 44 percent.\n: This study was funded by Radius Health.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "High in the release, the benefits of the drugs being studied and the placebo being compared are quantified clearly in both relative and absolute terms. Readers can see clearly that we are talking about quite a small group of people who saw benefits from either drug compared to the rather large group of women who were studied.\nMost of the data presented was absolute risk which was excellent. This shows the benefit as well as the fact that most patients didn\u2019t have a fracture regardless of which treatment was given.", "answer": 1}, {"article": "Lobular breast cancer forms in the milk glands.\nOther supplements were not linked to breast cancer risk in the new study, including black cohosh, dong quai, soy, and St. John's wort, which are often taken to relieve some of the symptoms of menopause.\nExactly how fish oil may affect breast cancer risk is not fully understood, but it may be related to its strong anti-inflammatory properties.\nThe use of fish oil was linked to lower risk of invasive ductal breast cancer.\nResearchers did not have information on the doses of fish oil that were taken by women in the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Only relative risk reduction figures were used \u2013 \"32% reduced risk.\"\u00a0 But readers should be told \"32% of what?\"\u00a0 What were the actual absolute numbers in the group that took the supplements versus the numbers in the group that didn\u2019t take the supplements.\u00a0 Why is that so difficult to include?\u00a0 It would be far more meaningful than 32%. ", "answer": 0}, {"article": "To place an electronic embedded link to these articles in your story These links will be live at the embargo time: http://jama.\nThe researchers add that close contact casting may be an appropriate treatment for older adults with unstable ankle fracture.\nAt 6 months, casting resulted in measures of ankle function equivalent to that with surgery.\nFurther studies are needed to help identify which patients will not benefit from casting.\nCasting required less operating room time compared with surgery.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release includes a list of benefits of the modified casting method, with some quantification, mostly in terms of reduced complications. It says, \u201cAt 6 months, casting resulted in measures of ankle function equivalent to that with surgery. Infection and wound breakdown were more common with surgery (10 percent vs 1 percent), as were additional operating room procedures (6 percent vs 1 percent).\u201d", "answer": 1}, {"article": "According to the FDA, \"Testosterone products are FDA-approved only for use in men who lack or have low testosterone levels in conjunction with an associated medical condition.\nWhile the new study results do seem to advocate for testosterone replacement therapy, Barua stresses the need for \"appropriate screening, selection, dosing, and follow-up of patients to maximize the benefit of testosterone therapy.\"\nDr. Rajat Barua, the paper's corresponding author, says the study is also noteworthy because of its finding that administering the right dose is critical: Treating \"low T\" but not restoring levels to normal doesn't appear to impart much benefit, at least in terms of cardiovascular risk.\nThe findings may sway the ongoing debate over testosterone therapy's benefits and risks, especially for the heart.\nThe sharpest contrast emerged between Group 1 (those who were treated and attained normal levels) and Group 3 (those whose low testosterone went untreated).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the press release does provide likelihood estimates of illness or death as a result of testosterone treatment, indicating that individuals whose treatment returned their testosterone to normal levels were less likely to suffer a heart attack, a stroke or to die during follow up, it provides no baseline numbers that would permit us to evaluate those ratios. We learn that the differences are statistically significant, but we have no means of determining if they are important. The absolute reductions are not quantified.", "answer": 0}, {"article": "The researchers, Drs.\nBut the findings are not likely to be practice-changing, said Dr. Richard E. Greenberg, chief of urologic oncology at Fox Chase Cancer Center in Philadelphia, who was not involved with the study.\nAlso, he said, erectile dysfunction can also be a factor of aging and can be treated in most cases.\n\"The management of early stage prostate cancer continues to require further randomized controlled studies, which are underway, to determine the true benefit of treatment versus expectant management,\" said Dr. Marc Danziger, an attending urologist at Lenox Hill Hospital in New York City, who was not involved with the study.\nThe earlier study also found that undergoing a radical prostatectomy lowered the risk of the cancer spreading, as well as the death rate from prostate cancer or any other cause.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While describing some of the differences observed in general terms without quantification, the story provided absolute percentage of men dying from prostate cancer in the two study groups.\nThe story then went on to explain that the difference was in the men who were less 65 years of age at the time of diagnosis. \u00a0The story would have been better if it had more clearly explained this important caveat about the benefit seen.", "answer": 1}, {"article": "Eat as you dare.\nLook at it this way: if 100 people ate the highest proportion of Mediterranean foods and 100 ate the least, there would be three fewer heart attacks, strokes, or deaths among those who ate more foods from the Mediterranean diet.\nA new study of over 15,000 people in 39 countries explored the benefits of this diet for one special group: those already diagnosed with heart disease.\nIn fact, every one-point increase in a participant\u2019s Mediterranean diet score was linked with a 7 percent reduction in risk of heart attack, stroke, or death.\nNow here\u2019s the interesting part: eating more foods thought to be less healthy \u2014 those typical of Western diets \u2014did not link to an increase in heart attacks, strokes, or deaths.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story helped clarify the somewhat confusing data points in the study by quantifying the benefits\u00a0this way (italics added by us):\n\u201cOver nearly four years, 1,588 (about 10 percent) of the study participants suffered either a heart attack or stroke, or died. Those who ate more foods in the Mediterranean diet category were 3.5 times less likely to experience one of these three events than people whose diets more closely resembled the Western standard.\nIn fact, every one-point increase in a participant\u2019s Mediterranean diet score was linked with a 7 percent reduction in risk of heart attack, stroke, or death. Look at it this way: if 100 people ate the highest proportion of Mediterranean foods and 100 ate the least, there would be three fewer heart attacks, strokes, or deaths among those who ate more foods from the Mediterranean diet. These findings held for every geographical region.\u201d\nWe applaud the writer for including\u00a0the 100 people example to help readers understand the risk reduction.", "answer": 1}, {"article": "\"Nobody has the answer at this time,\" Perle said.\nThe analyses indicated that SMT -- which involves manual manipulation of the spine and surrounding muscles -- has only a short-term impact on pain relief, although it eases pain faster than other treatments.\nBut which treatment is right for any patient depends not only on their specific pain, but their doctor's recommendations and their own comfort level with various options, said Stephen Perle, a spokesman for the American Chiropractic Association.\nReviewing 26 studies comparing spinal manipulative therapy (SMT) to other treatments such as medication, exercise or physical therapy, researchers from the Netherlands found that SMT appears to be no better or worse than other options at relieving back pain long-term.\nIn all evaluations, patients were randomly assigned to SMT or another comparison treatment, including active treatments such as exercise or inactive placebo treatments.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\nThe article offered only broad characterizations about the treatment effects of spinal manipulation for chronic low back pain. It did not attempt to quantify the treatment effects in terms of pain relief or functional improvement.\nHowever, the systematic review that served as the focus of the article is complex and somewhat difficult to decipher, with outcomes including pain and function at different time points.\nAnd the story did provide the reader with a reasonable summary. Manipulation appears as good or bad as other treatment options\u2014and it may lead to more rapid pain relief.\n \n \n \n", "answer": 1}, {"article": "The liquid is called silver diamine fluoride, or S.D.F.\nIt\u2019s been used for decades in Japan, but it\u2019s been available in the United States, under the brand name Advantage Arrest, for just about a year.\nNow there\u2019s an alternative: an antimicrobial liquid that can be brushed on cavities to stop tooth decay \u2014 painlessly.\nBut studies show it can halt the progression of cavities and prevent them, and dentists are increasingly using it off-label for those purposes.\nThe Food and Drug Administration cleared silver diamine fluoride for use as a tooth desensitizer for adults 21 and older.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In many ways, the story does a very nice job of explaining the benefits of SDF. It addresses cost, the ability to avoid anesthesia, and the ease with which it can be applied. It even discusses the limits of those benefits, noting that patients with mouth sores or a silver allergy can\u2019t use SDF \u2014 and that patients with \u201csevere\u201d cavities still need fillings. The story also includes links to supporting materials, which we like to see.\nHowever, this criterion is very specifically focused on whether a story quantifies benefits, and this story does not do that\u2013we\u2019re given little information on the status of the medical evidence for this procedure overall.\nA 2009 paper, linked to from this story, looked at two clinical trials of SDF and found that it \u201carrested\u201d at least 96.1 percent of cavities (i.e., prevented them from getting worse). If the story had noted that, it would have gotten an enthusiastic thumbs up here.", "answer": 0}, {"article": "A little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\nYou must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided some insight into possible regain of function (i.e. eating and hair brushing).\u00a0 From this, the reader could infer that while the treatment might provide some benefit, it did not hold out promise of complete recovery.\u00a0 However \u2013 the reader is not provided with any guidance about what percentage respond to this treatment.\u00a0 It is not possible for the reader to derive a sense about the probability of success or failure.", "answer": 0}, {"article": "Stroke is the single largest cause of adult disability and the third-largest cause of death in the developed world.\nRoger Bonomo, director of stroke care at Lenox Hill Hospital in New York, said another way to look at the implications of this trial would be as justification for treatment of post-stroke depression before it progresses.\nExperts commenting on the findings said they had \u201cenormous potential to change clinical practice\u201d and raised the question of whether most stroke patients with motor skill problems should be treated with this relatively cheap type of antidepressant.\nCommenting on the study, Robert Robinson and Harold Adams from the University of Iowa in the United States, said it could change the way doctors treat stroke victims in future, but more research is needed to see if the effects continue over time.\nA few previous small trials had already suggested that giving drugs like Prozac, which belongs to a drug class known as selective serotonin re-uptake inhibitors (SSRIs), might improve motor skill recovery after stroke.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites the absolute improvements on motor skill test scores.\nBut these numbers are unanchored from context. All we know is that it was the score on a test of motor skills. We don\u2019t know the measurement, the scale, or baseline values. So the numbers have no meaning for readers. It\u2019s as if I told you \u201cmy running speed has increased by 10.\u201d The lack of a baseline score is particularly relevant in this story because, as it turns out, the group receiving fluoxetine started with slightly more severe problems than the control group. Although the difference was not reported to be statistically significant, any difference in baselines scores for the primary outcome may reflect a flaw in how the study randomized people.\nSecond, none of the \u201cpositive effects\u201d of the drug mentioned are challenged. In light of the preliminary nature of the study, these apparent benefits are not conclusions, they\u2019re open questions. That perspective is missing, misaligning the tone of the piece.\n Please see some related comments under Quality of Evidence.", "answer": 0}, {"article": "Ralph Sacco and Tatjana Rundek of the University of Miami in an accompanying editorial.\nThe study was also noteworthy because, over the long haul, patients did a particularly good job of taking the medications they were given.\n\u201cAlthough this was not a randomized trial and there was no comparison group to assess whether specialized units performed better than nonspecialized (stroke) units, these (newly-reported) risks are substantially lower than expected.\nOutcomes in this study were at least 50 percent lower than those reported in previous studies,\u201d Sacco and Rundek write.\nThe ongoing study, which used previous stroke estimates for comparison, was based on data from 4,789 patients from TIAregistry.org, an international registry designed to follow cases for as long as five years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story satisfactorily quantified the benefits, by including relative and absolute reductions in stroke risks when patients are treated at a TIA unit. It also makes it clear that the measured benefits seen weren\u2019t\u00a0obtained via a comparative trial, but by looking at older data on stroke risks from TIA and comparing it to this newer set of data. (See quality of evidence criteria for why these benefits are shaky, though.)", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\nThere is no attempt to quantify the benefit of total knee replacement, either for older patients or younger ones, except in the testimony of one knee surgeon. Although the scientific literature reports that most patients are satisfied after surgery, the results are neither as spectacular nor as risk-free as the article suggests.\n", "answer": 0}, {"article": "Restless leg syndrome (RLS) is a neurologic disorder causing unpleasant sensations and an urge to move the legs when at rest.\nPatients using the RLS device also reported an 82 percent decrease in sleep loss.\nThe eight-week clinical trial involved 30 otherwise healthy adults with moderate to severe restless leg syndrome.\nPilot study published in the Journal of the American Osteopathic Association finds targeted pressure device significantly increased sleep for those with moderate to severe symptoms\n\nAuthors from Lake Erie Research Institute in Pennsylvania report an adjustable foot wrap caused to treat restless legs syndrome (RLS) is 1.4 times more effective than the standard pharmaceutical treatment.\nAdverse effects were reported by seven patients in the study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release reports summaries of two types of measures of restless leg syndrome. However, the release would have been better if, in addition to the numerical results for the two scales, it had offered some definition of what the numbers mean in more common terms, such as how many nights per week people lost a lot of sleep because of leg movements. Or, since this treatment is focused on improving sleep, one could have focused on the number of nights with uninterrupted sleep.\nAnd as noted below, the release offers a comparison only to one type of drug, without any reference to numerous alternatives.", "answer": 1}, {"article": "2016.\n\u201cThe recovery some patients showed was not just minimal, it was significant,\u201d said Steinberg, who has researched stem cell therapies for more than 15 years.\nThey hypothesized that injecting stem cells into the brains of chronic stroke patients would increase their survival rates.\nRecently, researchers from the Stanford University School of Medicine have made it their mission to improve these outcomes.\nFurthermore, there were no life-threatening effects linked to the procedure used to administer them.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The\u00a0story\u00a0is clearly upbeat about the promise of the therapy and uses a great deal of positive\u00a0language from the news release. But the story\u00a0did not really quantify the results in a way that would give readers a sensible picture of just how many of the 18 could \u201cwalk again\u201d and what exactly the metrics used to assess results consist of.", "answer": 0}, {"article": "Meningitis is a condition \u2014 inflammation of the membranes that surround the brain and the spinal cord \u2014 that can be triggered by some viruses and several types of bacteria.\nThat may explain why the B vaccine appears to offer some protection against Neisseria gonorrhea.\n\u201cMathematical modeling has shown that even a vaccine of moderate efficacy and duration could have a substantial effect on the transmission and prevalence of gonorrhea, if coverage in the population is high and protection lasts during the highest risk period,\u201d Kate Seib, of Australia\u2019s Institute for Glycomics, wrote in a commentary that accompanied the study.\nClinical trials will need to be conducted to see if the effect researchers have observed is actually due to the meningococcal B vaccine.\nBut the same component is one of several in the Bexsero vaccine, which was used in Quebec when the government decided to vaccinate against meningococcal B disease in a part of the province with a high relative rate of cases a few years ago.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story just passes the bar, giving actual numbers far down in the story. It states researchers \u201cfound people who were vaccinated were 31 percent less likely to be infected with gonorrhea than those who hadn\u2019t received the meningococcal B vaccine.\u201d\nWe would have liked to see that data higher in the story. Instead, the story states in the third paragraph that the gonorrhea rate was \u201csignificantly lower\u201d among those who were vaccinated. The story doesn\u2019t give the overall risk of getting gonorrhea, so it\u2019s hard to tell whether a 31 percent drop amounts to a significant benefit for individuals.\nThe study itself states that the findings provide preliminary evidence of \u201cmoderate\u201d cross-protection, and we think that should have been given more discussion so people get a better sense of how little is known about the efficacy compared to other vaccines.", "answer": 1}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article doesn\u2019t report much in the way of quantitative data and results.\u00a0 The article could have included additional detail about the specific results.\u00a0 The findings that are presented are somewhat overstated and not entirely accurate.\u00a0 The article states that the \"results showed a modest improvement in vision\" when the improvement in vision was based on self-report for the three patients in the U.S. study and but was only found by objective measure in one patient in the British study.\u00a0 While the results of\u00a0both studies suggest efficacy in\u00a0improving the pupil\u2019s ability to respond to light, improved visual function\u00a0and mobility was only found for one patient in the British study.\u00a0Further, the patient in the\u00a0British study\u00a0who experienced\u00a0the best results had the least advanced retinal disease compared to the other patients.\u00a0 Other improvements including a reduction in nystagus or roaming eye movements in all patients in the U.S. study (not measured in the British study).\nNitpicking details?\u00a0 We don\u2019t think so in a story headlined \"hope for a cure.\" \u00a0", "answer": 0}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story used absolute reduction numbers, instead of relative risk figures. The WebMD story and the press release led with how hypnosis could help cut hot flashes by as much as 74%. But the LA Times writes, \u201cThe frequency of hot flashes in the hypnotherapy group dropped by 48% at six weeks and 56% at 12 weeks, compared to drops of 7% and 13% at six and 12 weeks, respectively. among those in the trial\u2019s control condition.\u201d That does a better job putting the benefits of the therapy into perspective.\nSome aspects of the data presentation were still confusing, especially since there is no explanation at the end of the article regarding all the numbers. For example, what is the exact difference between \u201cdrop in frequency of hot flashes\u201d versus \u201cimprovement in severity and frequency of hot flashes?\u201d And how was improvement measured?\nNonetheless, because the story gave readers detailed views of what the study found, we think it earns a satisfactory grade.", "answer": 1}, {"article": "\n\u2022 Read this story at www.uab.edu/news\n\u2022 The UAB News Studio is available for live or taped interviews with UAB experts.\nResults from inferior corneal staining tests \u2014 used by physicians to detect abrasions on the cornea \u2014 showed improvement in three of the four studies.\nThere are more than 30-plus new dry eye basic, translational and clinical studies being funded by the NEI/National Institutes of Health to further explore these lipids and proteins, with more than 50 papers being published monthly.\nSpecialty testing for dry eye is performed at the Dry Eye Relief Clinic at UAB Eye Care, in the School of Optometry.\n\u201cFunding from NIH is helping the optometry world make significant strides in understanding the cause and treatment of dry eye,\u201d Nichols said.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits were summarized this way: \u201cIn all four studies, eye dryness was significantly reduced, with two of the studies showing improvements at week two. Results from inferior corneal staining tests \u2014 used by physicians to detect abrasions on the cornea \u2014 showed improvement in three of the four studies.\u201d\nHow was eye dryness measured? How reduced was \u201csignificantly reduced?\u201d How was \u201cimprovement\u201d of abrasions measured? How improved was the improvement?\nThe news release does not say.", "answer": 0}, {"article": "In an editorial accompanying the study, Emily Jungheim and Graham Colditz of Washington University School of Medicine in St. Louis wrote that the findings indicate that while there \u201cmay still be a role for short-term use of unopposed estrogen for treating some women with menopausal symptoms ... this role may be vanishing as existing and emerging data continue to be better understood.\u201d\n\nRowan Chlebowski, one of the researchers who worked on the analysis, stressed that the study only looked at women who were taking estrogen alone.\nIn fact, the women who took the hormone ended up being at somewhat higher risk for fractures.\nBut the Women\u2019s Health Initiative stunned doctors and women when researchers reported that the risks of the hormones outweighed any benefits.\nThere\u2019s some good news and some bad news for women who took estrogen to help them get through menopause until the health risks of taking the hormone were discovered.\nBut the increased risk for strokes and blood clots disappeared and the protective effect for breast cancer persisted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story didn\u2019t quantify the benefits.\u00a0 The competing NY\u00a0Times did a somewhat better job, although it got an unsatisfactory score as well.\n", "answer": 0}, {"article": "PHILADELPHIA - According to a new study, women experiencing difficulty with time management, attention, organization, memory, and problem solving - often referred to as executive functions - related to menopause may find improvement with a drug already being used to treat attention deficit hyperactivity disorder (ADHD).\n\"It is also important for clinicians to confirm that a woman's complaints of worsening memory are in the executive function domains, are temporally related to the transition to menopause, and are not indicative of some other pathological cognitive impairment before prescribing a trial of LDX.\"\n\"Although we observed that short-term use of LDX was well tolerated and effective in several subjective and objective areas, long-term studies of menopausal women receiving LDX are needed, similar to those conducted for ADHD patients,\" said Epperson.\n\"Reports of cognitive decline, particularly in executive functions, are widespread among menopausal women,\" said lead author, C. Neill Epperson, MD, professor of Psychiatry and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, and director of the Penn Center for Women's Behavioral Wellness.\nThe Penn-led team administered a once-daily dose of LDX for four weeks to 32 healthy, non-ADHD-diagnosed women between the ages of 45 and 60 experiencing difficulties with executive functions as a result of mid-life onset menopause, and as measured using the Brown Attention Deficit Disorder Scale (BADDS).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release describes benefits like this: \u201cThe researchers found a 41 percent overall improvement in executive functions for women receiving LDX, compared to a 17 percent improvement when taking placebo medication.\u201d\u00a0 And it points out that in four of the five areas of cognitive loss, those taking the drug experienced \u201csignificant improvements,\u201d although it fails to provide specific details on those areas.\nWe\u2019d add that on the objective measures of cognitive function (the neuropsychological tests where performance is externally graded), only 2 of 12 tests showed a statistically significant improvement, and these would not have been significant if the study authors had made the appropriate statistical adjustments for multiple comparisons. This is perhaps more of a problem with the study itself and the journal that published it rather than the release per se, but it\u2019s a problem that deserves comment. And while the subjects\u2019 self-rated improvements in function were greater, as would be expected, than the objective measures, it\u2019s hard to know whether these statistically significant changes are clinically meaningful. In other words, are they large enough and durable enough to make a real difference in people\u2019s lives? The release doesn\u2019t say or give us any context for judging the importance of the benefit.", "answer": 0}, {"article": "For example, Kramer says, what if a man got a PSA test when his prostate cancer was in the very earliest stages of metastatic disease?\nMessing says this misses the point of his study, which appears in the online July 30 issue of the journal Cancer.\nBut it's not that simple, says Barnett Kramer, MD, MPH, associate director for disease prevention at the National Institutes of Health.\nThe new study seems to make a powerful argument in favor of PSA testing.\nJuly 30, 2012 -- If it weren't for routine PSA prostate cancer screening, an extra 17,000 Americans each year would learn that they had the worst form of the disease, a new study suggests.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantified the benefits claimed in the University of Rochester study, saying, \u201cIf it weren\u2019t for routine PSA prostate cancer screening, an extra 17,000 Americans each year would learn that they had the worst form of the disease, a new study suggests.\u201d\nMore important, it made an effort to question this type of statistical modeling \u201clook-back\u201d study.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nBecause Noctiva is approved only for adults with nocturia caused by nocturnal polyuria, health care providers should confirm overproduction of urine at night with a 24-hour urine collection, if one has not been obtained previously.\nUse of Noctiva should be discontinued temporarily in patients with certain nasal conditions such as colds or allergies until those conditions have resolved.\nThe U.S. Food and Drug Administration today approved Noctiva (desmopressin acetate) nasal spray for adults who awaken at least two times per night to urinate due to a condition known as nocturnal polyuria (overproduction of urine during the night).\nNoctiva is being approved with a boxed warning and a Medication Guide because it can cause low sodium levels in the blood (hyponatremia).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release is vague on benefits, stating that although trials \u201cshowed a small reduction in the average number of night-time urinations with Noctiva compared to placebo, more patients treated with Noctiva were able to at least halve their number of night-time urinations, and patients treated with Noctiva had more nights with one or fewer night-time urinations.\u201d\nThe benefit of being able to \u201chalve the number of night-time urinations\u201d is uninterpretable.\nIn fact, data submitted to the FDA shows patients using the drug went from an average of more than three urinations per night to about two, but the placebo was almost as effective. By our calculation, those using a placebo got up an average of one extra time every three nights compared with those who took the real drug. In other words, not a huge difference. The percentage of patients who experienced one or fewer nighttime urinations was 40 to 45 percent for those using Noctiva versus 30 to 34 percent for those taking a placebo. Again, a modest benefit.", "answer": 0}, {"article": "While some teenagers want to switch from insulin injections to pump therapy to gain more flexibility in their lives, doctors said device problems such as a blocked tube can lead quickly to dangerous episodes of high blood sugar.\nParents should be vigilant in watching their children\u2019s use of the pumps, researchers from the Food and Drug Administration wrote.\nBut they called for more study to address safety concerns in teens and even younger children who use the popular pumps.\nIn the FDA study, appearing in the May issue of the journal Pediatrics, the reports of adverse events and deaths in adolescents using the pumps occurred from 1996 to 2005.\nAnd they\u2019re a growing segment of diabetes care, with $1.3 billion in annual sales worldwide, said Kelly Close, a San Francisco-based editor of a patient newsletter.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This article fairly communicates the risks and benefits of insulin pump use among adolescents.\u00a0 It does not overstate the main benefit of allowing young people to live more normal lives by eliminating the need for multiple daily insulin injections.", "answer": 1}, {"article": "\"Those stem cells are given back to the patient where they can go back to the bone marrow and make the blood cells for the rest of the patient's life,\" Kohn said.\nDr. Kohn said of an experimental treatment for SCID, \"It's gone from a 'one day, maybe' to a real clinical reality.\"\nIt's a genetic disorder that leaves the body with a weakened immune system, making infants extremely vulnerable to illness.\nDr. Kohn is currently working with the FDA to make his treatment available nationwide.\nClinical trials for that treatment are now underway.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story relies heavily on one child\u2019s journey and notes that \u201d \u2026the treatment has restored immune systems in all 23 patients in the most recent clinical trials.\u201d \u00a0But we aren\u2019t told how long these children were followed after the procedure or what a \u201crestored immune system\u201d is or how it was measured. There is simply too little information provided to assess this treatment\u2019s potential.", "answer": 0}, {"article": "In coherent breathing, the goal is to breathe at a rate of five breaths per minute, which generally translates into inhaling and exhaling to the count of six.\nThe subjects\u2019 saliva was tested at various intervals during the exercise.\nThe research was presented in May at the International Congress on Integrative Medicine and Health in Las Vegas.\nWhile the study was small and lacked a control group, Dr. Streeter and her colleagues are planning a randomized controlled trial to further test the intervention.\nThe findings were published in the journal BMC Complementary and Alternative Medicine in August.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story asserts that controlled breathing \u201chas been shown to reduce stress, increase alertness and boost your immune system.\u201d It also states that studies have found breathing practices \u201ccan help reduce symptoms associated with anxiety, insomnia, post-traumatic stress disorder, depression and attention deficit disorder.\u201d\nBut none of these purported benefits\u00a0are quantified in any measurable way\u2013i.e., by how much does it reduce symptoms? And for how long? \u00a0And the story\u2019s opening line that you will have \u201ccalmed your nervous system\u201d by taking just five deep breaths isn\u2019t backed up by evidence.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not adequately quantify the harms of oophorectomy. Specifically, the story provides quantification in relative terms only by stating that \"surgical removal of the ovaries before menopause raises by half a woman\u2019s risk of neurological problems.\" What that statement does not show is how rare those neurological problems are. By stating the increased risk in purely relative terms, the story appears to inflate the actual risk. See our primer on absolute versus relative risks. ", "answer": 0}, {"article": "Asians are at high risk of developing diabetes even at a healthy weight.\nBy following this recommendation, 53 percent of patients who had prediabetes or type 2 diabetes would not be screened.\nThe study showed that screening patients using an expanded set of risk factors, which the USPSTF suggests but does not formally recommend, would identify most cases of prediabetes and type 2 diabetes.\nThis is the first study to report how these expanded screening criteria would perform in practice among a nationally representative sample of U.S. adults.\nOnly 23 percent of patients with prediabetes or diabetes would be missed if expanded screening criteria were used to make screening decisions, the study found.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that \u201cOnly 23% of patients with prediabetes or diabetes would be missed if expanded criteria were used to make screening decisions, the study found.\u201d\nWhile the study itself dived into the sensitivity of the tests used in screening, none of that data are shared in the release.\nThe larger problem is that it\u2019s not clear whether finding more cases of prediabetes or diabetes would actually lead to improvements in outcomes people care about like fewer heart attacks and less nerve damage.\u00a0 The release should have clarified this.", "answer": 0}, {"article": "Compared with the 16% of people who didn't drink coffee at all, those who downed two or more cups each day were about 18% less likely to have died during the study period. In addition, those who drank just one to six cups of coffee per week were 12% less likely to die. Both of these figures were calculated after taking into account known risk factors for early death, such as smoking (which is often paired with coffee drinking), diet and body mass index.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job of describing groups for comparison: coffee-abstainers, light drinkers (1-6 cups per week), and heavier drinkers (>2 cups per day). However death rates were presented as relative risk. How many of the 18,000-plus subject died during the average 16 years they were followed? What does \u201c18% less likely to have died\u201d look like in absolute numbers?", "answer": 0}, {"article": "\"The results and especially the rapidity of the effects observed in the gantenerumab trial went beyond our expectations,\" Luca Santarelli, MD, study co-author and Roche senior vice president of neuroscience, writes in an email.\nIn the study, patients who received monthly gantenerumab injections showed reductions in such brain plaques.\nThe experimental compound, known as gantenerumab, is being developed by Roche, the Swiss pharmaceutical company.\nWhat is not entirely known at this point, though, is if these plaques cause Alzheimer's or are by-products of the disease.\nOct. 10, 2011 -- A small study shows that a new drug being tested for the treatment of Alzheimer's disease reduces the buildup of plaques in the brain associated with the fatal disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate explanation of results observed in study participants at different dosing levels.\nMore importantly, the story simply explained: \u201cSince it\u2019s not completely clear what reductions in brain plaques mean for Alzheimer\u2019s patients, the researchers are unable to say whether treatment with gantenerumab will bring improvement to patients with Alzheimer\u2019s. They are currently involved in a new study that they hope will answer that question.\u201d", "answer": 1}, {"article": "Flu season has already begun, and last year\u2019s was one of the most lethal in decades; about 80,000 Americans died of flu or its consequences, the Centers for Disease Control and Prevention said earlier this month .\nThe pill will cost $150, according to a spokeswoman for Genentech, which will sell Xofluza in this country.\nstill strongly recommends that every American over the age of six months get a flu shot as soon as possible.\nGenentech will offer coupons that lower the price to $30 for patients with health insurance and to about $90 for the uninsured.\nsaid, and should be taken only in the first two days after symptoms like fever, aches and sniffles appear.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a really close one. The story does a lot of things well here. It notes that, in one trial, there was no difference in the benefits between Xofluza and existing flu treatment drug oseltamivir (better known as Tamiflu). However, it does not actually quantify the benefits associated with Xofluza. Instead, the story states that it \u201cmay alleviate some symptoms and shorten the time patients feel sick.\u201d\nWe approve of the cautious language used throughout the story, but we like to see quantified benefits in instances where the information is available. In this case, an article published in the New England Journal of Medicine in September reported that Xofluza reduced the \u201ctime to alleviation of symptoms\u201d by a mean of 25-38 hours, compared to placebo (the difference depended on the age group of the patient). Ergo, a not satisfactory rating here.", "answer": 0}, {"article": "Still, he adds, \u201cit\u2019s an important step forward.\u201d\n\nThe technology is likely prohibitively expensive and time-consuming at this point, he says.\n\u201cThis test looks very promising, but it is also very expensive,\u201d\n\nWhile there are risks attached to amniocentesis and CVS screens, these are minimized when the test is performed by a skilled obstetrician, she says.\nJoyce Fox, MD, the chief of medical genetics at Cohen Children's Medical Center in New Hyde Park, N.Y., definitely sees a role for a test such as the one described in the new study.\nThe new test looks \u201cvery promising,\u201d says Cathy Sullivan, a genetic counselor at the University of Texas Health Sciences Center in Houston.\nIt is not a diagnostic test for Down syndrome, she says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As with the harms, the story does quantify the benefits in one way. It says, \u201cIt could help avoid up to 98% of these screening procedures, according to the study, which appears in BMJ.\u201d It also says, \u201cThe new study included 753 pregnant women who were at high risk for having a child with Down syndrome. Of these, 86 women were determined to be pregnant with a child with Down syndrome.\u201d", "answer": 1}, {"article": "In more than 22% of cases, implantable defibrillators are given to heart patients who don\u2019t meet the guidelines for receiving the pricey devices, according to a study just published in JAMA.\n\nThe research, based on 111,707 cases submitted to a national registry over a three-and-a-half-year period, also finds that those patients who didn\u2019t meet the guidelines had a higher risk of dying in the hospital and of complications from the implantation.\n\nICDs, which can cost north of $30,000, monitor the rhythm of the \u2026", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As with the harms, the benefits are not quantified.", "answer": 0}, {"article": "A complex and expensive pacemaker-defibrillator can significantly improve the chance for survival among the tens of thousands of heart-failure patients with only mild symptoms, according to a major, multiyear clinical study.\n\nThe research, regarded as likely to change medical practice, showed that the device to \"resynchronize\" the hearts of such patients lowered the death rate by 29% in such patients over 40 months, compared to those who had a standard defibrillator implanted.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As explained above, the story analyzes the benefits in both relative and absolute terms.", "answer": 1}, {"article": "Human monoclonal antibodies are naturally occurring human antibodies that are genetically altered in a laboratory, cloned in large numbers and introduced into the patient to target disease sites.\n\"The most interesting aspect of this study is use of a novel approach using monoclonal antibodies -- a subtype of antibodies -- in the management of elevated LDL cholesterol,\" said Dr. Kenneth Ong, acting chief of cardiology at the Brooklyn Hospital Center.\n\"For those patients with elevated LDL who are intolerant to statins, this provides a viable option,\" said Dr. Suzanne Steinbaum, a preventive cardiologist at Lenox Hill Hospital in New York City.\nThe patients who received AMG145 had 41 percent to 63 percent reductions in \"bad\" (LDL) cholesterol and did not experience significant muscle-related side effects, said study leader Dr. David Sullivan, of the Royal Prince Alfred Hospital in Australia, and colleagues.\nThe study was published online Nov. 5 in the Journal of the American Medical Association, to coincide with a planned presentation at the American Heart Association's annual meeting in Los Angeles.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story tosses around the word \u201cbenefit\u201d in a way that would make most readers believe that anything that lowers LDL \u201cbad\u201d cholesterol always reduces the risk of future heart-related problems. However, tests of some unrelated drugs (e.g., clofibrate) showed that despite lowering LDL, the risk of heart problems was not reduced. It may turn out that this drug reduces future health risks for certain patients, but that is not what this trial tested. This story perpetuates common confusion between a mere lab test number and meaningful health outcomes.", "answer": 0}, {"article": "Many Americans take aspirin to lower their risk of heart disease, but a new study suggests a remarkable added benefit, reporting that patients who took aspirin regularly for a period of several years were 21 percent less likely decades later to die of solid tumor cancers, including cancers of the stomach, esophagus and lung.\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\nParticipants who had been assigned to the aspirin arms of the studies were 20 percent less likely after 20 years to have died of solid tumor cancers than those who had been in the comparison group taking dummy pills during the clinical trials, and their risk of gastrointestinal cancer death was 35 percent lower.\n\u201cThis is important as a proof of principle that a single simple compound like aspirin can reduce the risk of cancer substantially,\u201d said the study\u2019s lead author, Dr. Peter M. Rothwell, professor of neurology at the University of Oxford.\nAs part of the new study, published online Monday in the journal Lancet, researchers examined the cancer death rates of 25,570 patients who had participated in eight different randomized controlled trials of aspirin that ended up to 20 years earlier.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not adequately quantify the potential benefits. For one, the story relies to heavily on the relative differences between the aspirin group and the placebo group. As the study itself notes, for some of the cancers studied, the number of deaths in both groups was quite small \u2013 16 versus 14, 10 versus 19, 15 versus 19. This story and the other stories reviewed should have made this clear. What\u2019s more while the story highlights the total number of participants included in the data analysis (25,570) it doesn\u2019t tell readers that only 674 of them died of cancer. And then for the longer-term follow-up there was a total of 1634 cancer deaths among 12,659 participants.  Overall, the study that 3 percent of the patients in the control (placebo) group died of cancer during the original trials, compared to 2.3 percent of the patients who were assigned to recieve aspirin. Yes, that is a 23 percent reduction overall, but a 0.7 percent absolute reduction. Put another way, if indeed aspirin is preventive, you would need to treat 150 people to prevent one death from cancer during that time period. The way this story is written creates an inflated impression of the potential cancer prevention benefits of aspirin seen in this study.", "answer": 0}, {"article": "George E. Jordan may be reached at gjordan@starledger.com or (973) 392-1801.\nThe study said there were still many unanswered questions about Pfizer's pill, torcetrapib, the first in a new class of heart medicines known as a CETP inhibitors, which raise HDL, or good cholesterol, and lower LDL, or bad cholesterol.\nIt was unclear what the mixed bag of data presented at the American Heart Association's Scientific Session in Orlando would mean for CETP drugs under development by Merck and Roche, and another candidate in early-stage development by Pfizer.\nCardiologists had hoped it would reduce the buildup of plaque in blood vessels that can cause heart attacks.\nHowever, the study found the tablet triggered an increase in the hormone Aldosterone, which helps regulate both blood pressure and bodily fluids.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job of presenting the harms of the failed drug in terms of natural frequencies (actual numbers) instead of relative rates.", "answer": 1}, {"article": "For example, children with Down syndrome often have flat nasal bridges \u2014 as do typically developing African or African-American children.\nTo continue to fix this problem, both the NIH and Face2Gene need help from more researchers who can upload more patients\u2019 faces \u2014 but that\u2019s easier said than done.\nMeanwhile, Muenke and his colleagues at the NIH last month published an important advance: the ability to diagnose disease in a non-Caucasian face.\nThe ultimate goal would be a simple tool that any doctor could use anywhere to get fast results and better diagnose their patients.\n\u201cSince Face2Gene is a search and reference informational tool, the terms sensitivity and specificity are difficult to apply to our output,\u201d Gelbman cautioned.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies benefits for a related bit of science but not for the core product being described in the piece. For that, it says, \u201cFace2Gene declined to provide similar numbers for their technology. \u2018Since Face2Gene is a search and reference informational tool, the terms sensitivity and specificity are difficult to apply to our output,\u2019 Gelbman cautioned.\u201d\nIf we don\u2019t know anything about sensitivity and specificity, we\u2019re not sure how this can play any role in helping with diagnosis, even in narrowing the list of possible/probable disorders. The story needed to explore this problem more.", "answer": 0}, {"article": "To test this theory, the Italian researchers compared 25 healthy infants who were randomly assigned to receive drops of Lactobacillus reuteri to 21 healthy infants randomly assigned to receive placebo drops.\nColic affects up to 28% of infants and has no known cause or cure.\nResearchers from the University of Turin, Italy, found that a few daily drops of Lactobacillus reuteri, a bacterium that can help improve digestion, significantly reduced crying among infants with colic.\nSome researchers question whether symptoms could be alleviated using probiotic therapy, or \"healthy\" bacteria to restore bacterial balance in the gut.\nThe infants' mothers were also advised to avoid cow's milk in their own diets during the study period.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports the number of minutes per day that children cried in the probiotic and placebo group \u2014 a\u00a0reasonable characterization of the main findings. Although we\u2019ll award a borderline satisfactory, we wish the story\u00a0had avoided some of the following\u00a0vague\u00a0language:\u00a0", "answer": 1}, {"article": "Men who only father daughters appear to be at greater risk of developing prostate cancer, according to a study published last week in the Journal of the National Cancer Institute.\nThe study found that hypochondriacs who got cognitive behavior therapy, which encourages people to challenge the validity of their disabling beliefs, also improved -- as much as those given the drug.\nIn the first controlled study that compared a group of hypochondriacs given the drug with a group that got psychological talk therapy and another group that received sugar pills, the medication significantly reduced people's fears about imaginary illnesses.\nResearchers suggested that a combination of this talk therapy and medication might be especially effective.\nThe study was published this month in the American Journal of Psychiatry by researchers at Leiden University in the Netherlands and other Dutch centers.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story contained an anecdote on the improvement one person observed after taking Paxil.\u00a0 However, there was no quantification of the average benefit, the range of benefit observed, or even an explanation of what benefit was observed.", "answer": 0}, {"article": "For decades, researchers have searched unsuccessfully for ways to automatically coordinate insulin delivery with real-time changes in blood sugar to essentially create an artificial pancreas that maintains target blood sugar levels with minimal effort.\nAaron J. Kowalski, PhD, of the Juvenile Diabetes Research Foundation, which was involved in funding the research, says the study represents an important step forward in the search for a clinically feasible artificial pancreas to improve outcomes and quality of life among insulin-dependent diabetes patients.\nThe system proved better than a conventional insulin pump for maintaining optimal blood sugar levels during the night in a study from the U.K.'s University of Cambridge.\nNow new technology is making this possible, and new research shows that an experimental system can improve nighttime blood sugar control.\nFeb. 4, 2010 - It has been called the Holy Grail of treatment for insulin-dependent diabetes, and it may be close to reality.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Compounding the effects of the sensational headline and use of the term \"artificial pancreas\" (which, as we explain in our review of the competing New York Times piece, is an overly promotional and misleading term), this story wasn\u2019t\u00a0careful enough in its description of the benefits reported in the study. It had most of the same problems as the Reuters story (see that review for detailed analysis), including\u00a0reporting relative and not absolute benefits, and not mentioning the fact that the primary outcomes of the study were negative. \nOn the positive side, the story did mention that experimental group in this study had no instances of severe hypoglycemia compared with 9 episodes in the control group. This is a potentially important finding that was not mentioned by Reuters.", "answer": 0}, {"article": "The American Heart Association has more on heart failure.\nResults were even more heartening at higher doses, where participants had an 88 percent decrease in risk for death, cardiac transplant, hospitalizations and other outcomes, the study authors said.\nAt both six months and a year later, the patients who had received the new gene saw their risk for death, cardiac transplantation, worsening heart failure and hospitalization decline by half.\nThe study authors hope that, if replicated in larger trials, the gene-therapy treatment could actually delay or obviate the need for heart transplants in patients with heart failure.\nFor this phase 2 study, 39 patients with advanced heart failure were randomly chosen to receive either the gene therapy (through cardiac catheterization) or a placebo.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\nThis story doesn\u2019t seem to distinguish between \u201cgetting better\u201d and \u201cnot declining as fast.\u201d As one line states, \u201cAt both six months and a year later, the patients who had received the new gene saw their risk for death, cardiac transplantation, worsening heart failure and hospitalization decline by half.\u201d That sentence seems to say that the patients had lower risks than before they enrolled in trial, when what researchers actually reported was that the patients given the gene therapy were only half as likely as the patients who got a placebo to have one of those bad events.\nThe story reports only relative benefits without telling readers the absolute numbers. One result reported in a company news release was particularly striking, that during the year following treatment, the average number of days spent in the hospital was 0.4 per patient for the 9 patients who got the highest dose and 4.5 days per patient for the 14 who received a placebo. The story could have at least included the actual numbers of deaths reported in each group. ", "answer": 0}, {"article": "For more information on stroke, visit the U.S. National Library of Medicine.\nThose who would benefit from the ultrasound test are people with known carotid stenosis who are fit for surgery, Topakian said.\nMarquardt noted that the risks associated with the surgery are a lot higher than leaving the stenosis as it is and starting aggressive medical treatment.\nThe problem is identifying the patients at the highest risk for stroke, he said.\nThe patients who are at high risk are candidates for surgery, he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story got the \u201cgist\u201d correct that surgery\u2019s benefit increases with increasing risk. One of the saving graces of the piece was this independent perspective:\n\u201cIt is also unclear how optimal medical management [lifestyle changes in addition to anti-platelet medication and statins] would affect overall stroke and cardiovascular risk, and stroke-free survival,\u201d he said.", "answer": 1}, {"article": "\"They are a gateway out of smoking,\" says Etter.\nBut some critics argue these electronic nicotine delivery systems (ENDS) are fueling a new addiction to nicotine -- particularly among young people experimenting with them.\nThat's backed up by Etter's research as well as a recent study by researchers at Penn State College of Medicine, in which e-cigarettes were found to be less addictive than tobacco cigarettes.\nBauld's research hasn't identified a dependence on nicotine with e-cigarettes in the same way as the addiction resulting from regular cigarettes.\nWhilst Etter says that use among young people should be monitored, he believes the role of e-cigarettes in reducing global tobacco consumption is more important.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story suggests that e-cigarettes could be a better alternative to combustible tobacco. It\u00a0walks us through many different points of view on the topic, but its quantification of potential benefits isn\u2019t satisfactory. The story notes, for example, that a third of smokers trying to quit turn to e-cigarettes, and that ENDS are \u201cabout 60% more effective than going cold turkey or buying nicotine replacement therapy over the counter.\u201d But since the success rates for the other approaches are never stated, it\u2019s impossible to tell just how big that 60% improvement is. Providing the actual success rates of those who quit with ENDS compared with other approaches would\u2019ve given readers the best perspective on the size of this potential benefit.", "answer": 0}, {"article": "Consultant hematologist John Snowden said: \u201cThe immune system is being reset or rebooted back to a time point before it caused MS ...\nA treatment traditionally used on patients with certain cancers is being tried on a small number of people with multiple sclerosis with \u201cremarkable results\u201d, according to a professor involved in the research.\n\u201cIt is important to stress, however, that this treatment is only suitable for patients with relapsing remitting multiple sclerosis disease who have had two or more significant relapses in the past 12 months, failed to respond to standard drug treatment and who have had the illness for at least 10 years.\u201d\n\nOne patient who has undergone the treatment, known as autologous haematopoietic stem cell transplant (HSCT), told the BBC\u2019s Panorama programme that he had made incredible progress.\n\u201cThe MS Society has recently funded a study looking into the impact of HSCT on the immune system and we\u2019d like to see larger trials in this area.\nThe hospital is part of an international trial also involving patients in the US, Sweden and Brazil to see whether the treatment can benefit those with relapsing remitting multiple sclerosis, a form that involves flare-ups of symptoms such as loss of vision, fatigue, muscle problems and difficulties with balance that can last from a few days to a few months.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Quantification of benefits may not be possible at this point, as the \u201cabout 20 patients\u201d in this UK branch of an international trial are still presumably embedded in the trial protocol.\u00a0 The story, instead, relies on personal testimonials from two patients who had received the treatment, who describe major improvements in their conditions. \u00a0Note: There seems to have been at least some empirical data available. \u00a0At least one earlier study, published in January 2015 in JAMA, showed that the treatment was linked to reduction in level of disability in 64% of the 123 patients treated.\nIt isn\u2019t clear why this story is coming out now. If this is part of a larger trial, why are these results being shared? Presumably this isn\u2019t a blinded trial, but it isn\u2019t even clear if there is a control group that received standard treatment without the bone marrow transplant.", "answer": 0}, {"article": "Unlike the more common obstructive sleep apnea, in which the airway partially collapses and causes pauses in breathing, central sleep apnea (CSA) occurs when the brain fails to control breathing during sleep.\nAbout a third of patients in the treatment group reported therapy-related discomfort that was resolved with some reprogramming of the device.\nBetween six and 12 months of follow-up, all patients received the neurostimulation treatment.\nAt the six month evaluation, the device reduced CSA events per hour by half or more for 35 of the 68 members (51 percent) of the treatment group.\nIn the randomized study, 151 patients were implanted with the device.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We were glad to see absolute numbers and not just percentages used to quantify the benefits of the study.\n\u201cAt the six month evaluation, the device reduced CSA events per hour by half or more for 35 of the 68 members (51 percent) of the treatment group. Only eight (11 percent) of those in the control group achieved the same reduction.\u201d\nA bit more discussion on how the device might impact future quality of life or how long the benefit might be sustained \u2014 provided the data was available \u2014 would have been useful context.", "answer": 1}, {"article": "Fat tissue has been linked to higher levels of damaging metabolic stress compounds, so losing weight and becoming more fit may create more hospitable conditions for sperm and improve its quality and volume.\nIn the current study, the men in the moderate intensity, continuous activity program showed the most improvements compared to men in the other two more intense groups.\nNow, researchers publishing in the journal have found that another lifestyle change\u2014exercise\u2014may also help improve sperm quality.\nThey wanted to see what effect different types of exercise, and different intensity activity, had on sperm quality and count.\n\u201cBut this is a much better done study than almost anything that\u2019s been done before on the subject.\u201d He notes that most previous studies did not randomly assign people to exercise groups and compare the outcome on sperm quality, but rather recorded sperm measures among men who reported their exercise habits after the fact.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There was no quantification of benefits provided in this story, only a statement that \u201call of the men who followed a physical activity program showed improvements in a variety of measures of their sperm,\u201d compared to those men who were in the non-exercise group. The story states that, \u201cthe men in the moderate intensity, continuous activity program showed the most improvements compared to men in the other two more intense groups,\u201d but it doesn\u2019t characterize those improvements except in the vaguest of ways. Readers are left to wonder the degree of differences between the three exercise groups.", "answer": 0}, {"article": "Also low are haddock, pollock, flounder and sole, Atlantic croaker, crawfish, catfish, trout, Atlantic mackerel, crab and mullet.\nBut a federal panel has reignited the debate about the benefits and risks of eating tuna and other seafood during pregnancy.\nIn the report, the panel argues that albacore tuna is a \u201cspecial case.\u201d They noted that even when women ate double the recommended weekly amount of tuna, the benefits far outweighed the risks.\nFor people who want to safely eat more seafood, the magazine recommended shrimp, scallops, sardines, salmon, oysters, squid and tilapia as the lowest-mercury seafood.\nThe report also acknowledges the risk of mercury exposure from certain kinds of seafoods, and notes that women who are pregnant, nursing or may become pregnant should avoid certain kinds \u2014 tilefish, shark, swordfish and king mackerel \u2014 because of their high mercury content.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains that fish are rich in nutrients that \u201care particularly important for brain development in fetuses and nursing infants,\u201d and discusses a 2005 study that found a link between fish consumption in general by pregnant women and how well their children later scored on visual recognition memory tests. While that\u2019s useful context, the story is specifically about tuna and the supposed fact that tuna is a \u201cspecial case\u201d \u2014 i.e. a high-mercury fish that doesn\u2019t require strict consumption limits.\u00a0Quoting the Dietary Guidelines Committee, the story says that \u201call evidence [for tuna] was in favor of net benefits for infant development and (cardiovascular disease) risk reduction.\u201d But what specifically were those tuna-related benefits? Why should we make an exception for tuna? The story\u00a0would have been stronger if it had quantified these tuna-specific benefits, and discussed the nutrient profile that makes tuna different from other fish.", "answer": 0}, {"article": "HONG KONG (Reuters) - Boosting the effect of acupuncture needles with small electric currents may be effective in treating depression, a study in Hong Kong has found.\n\u201cThe drop (in depression scores) among the group receiving active treatment was more significant than the placebo group,\u201d said Roger Ng, another researcher in the group, which published their findings in the journal PLoS (Public Library of Science) ONE.\nHalf the patients received electroacupuncture nine times over three weeks, while the other half - the placebo group - only had needles inserted superficially into their heads.\nThey were later assessed by experts for their depression levels and the group that received genuine electroacupuncture was found to be a lot happier.\nLed by Zhang Zhang-jin at the School of Chinese Medicine, University of Hong Kong, the researchers used electroacupuncture to stimulate seven spots on the heads of 73 participants, who had suffered several bouts of depression in the last 7 years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No description of the size of the potential benefit \u2013 only this vague quote:\n\u201cThe drop (in depression scores) among the group receiving active treatment was more significant than the placebo group,\u201d said Roger Ng, another researcher in the group, which published their findings in the journal PLoS (Public Library of Science) ONE.\nThe researchers measured response using 3 scales (2 interviewer-administered and 1 self-administered). \u00a0There was only a clear response on one scale (and it looks clinically significant). \u00a0One scale showed no response and one was equivocal.", "answer": 0}, {"article": "We keep them at that temperature for the first 24 hours, at which time we re-warm them,\" Likosky explains.\nThe idea is that cooling a comatose patient after a heart attack prevents brain damage.\nIt's called induced hypothermia.\nWhen 57-year-old Dean Cowles suddenly suffered a heart attack, he was lucky that he worked at a company that made defibrillators,reports.\nSays Likosky: \"If you cool the brain down, it may be that it uses less energy and (is) less likely to damage itself over that first 24 hours.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit of this treatment was described as an improved survival rate by 14%.\u00a0 However, without the starting point, i.e. the number of individuals who have had a heart attack and are brought to an emergency treatment facility within a specified amount of time, it is not possible to understand the magnitude of the benefit that may be gained. Viewers are left wondering \"14% of what?\"", "answer": 0}, {"article": "SCOTTSDALE, Arizona - A migraine is much more than just a bad headache.\n\"The migraine brain is hyperexcitable, and basic science studies have demonstrated modulation of neuronal excitability with this treatment modality,\" says Amaal Starling, M.D., a Mayo Clinic neurologist, who is first author of the study.\nThe U.S. Food and Drug Administration already had approved the sTMS device for the acute treatment of migraine with aura.\nBased on the current study and prior studies in acute migraine attack treatment, sTMS not only helps to stop a migraine attack, but it also helps prevent them.\"\n\"Our study demonstrated that the four pulses emitted from this device twice daily reduce the frequency of headache days by about three days per month, and 46 percent of patients had at least 50 percent or less migraine attacks per month on the treatment protocol.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that twice daily, self-administered TMS reduced the frequency of headache days by nearly three days per month. Also, just under half the patients had at least 50% or less migraine attacks per month with treatment.\nThe release reports that patients had nine migraine days per month at baseline and this was reduced by 2.75 days with TMS treatment. This earns a satisfactory for describing the benefit in numerical terms. However, quantifying the improvement at followup would have been more helpful for readers wanting to assess TMS as a treatment option.\nThe release would have been improved had it included what the baseline severity and frequency of the 95 volunteers headaches were, and that claims of benefits were self reported. Furthermore, there was incomplete information regarding the concomitant use of pain medications during the 3-month study period.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nIn the trial, patients who received Rydapt in combination with chemotherapy lived longer than patients who received chemotherapy alone, although a specific median survival rate could not be reliably estimated.\nIn addition, patients who received Rydapt in combination with chemotherapy in the trial went longer (median 8.2 months) without certain complications (failure to achieve complete remission within 60 days of starting treatment, progression of leukemia or death) than patients who received chemotherapy alone (median three months).\nThe FDA granted this application Priority Review, Fast Track (for the mastocytosis indication) and Breakthrough Therapy (for the AML indication) designations.\nThe drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the release does provide some numerical context, it\u2019s insufficient to give credit here. The release could have provided much more useful information about the quantitative benefits. For example, a summary of the trial upon which the approval was based stated,\n\u201cAt a median follow-up of 57 months, midostaurin reduced mortality risk by 23% compared with placebo plus chemotherapy. The median OS was 74.7 months for the group receiving midostaurin versus 26 months for the placebo group (P = .007), representing a 23% reduction in the risk for death favoring midostaurin.\u201d The release should have provided both absolute as well as relative benefits, both of which were available from the trials.\nWhat the release does say is that patients who received a combination\u00a0of standard chemotherapy and Rydapt for treating AML \u201clived longer than patients who received chemotherapy alone, although a specific median survival rate could not be reliably estimated,\u201d compared to patients receiving chemotherapy plus a placebo.\u00a0 That\u2019s pretty vague. In addition, it said that \u201cpatients who received Rydapt in combination with chemotherapy in the trial went longer (median 8.2 months) without certain complications (failure to achieve complete remission within 60 days of starting treatment, progression of leukemia or death) than patients who received chemotherapy alone (median three months).\u201d ", "answer": 0}, {"article": "First, help with work or school such as assistance in deciding which classes or opportunities are most appropriate, given a person\u2019s symptoms.\nIn the new study, doctors used the medications as part of a package of treatments and worked to keep the doses as low as possible minimizing their bad effects.\nThe gains for those in typical treatment were apparent to doctors, but much less obvious.\nThe group that started on the combined treatment scored, on average, more poorly on both measures at the beginning of the trial.\nAbout half got the combined approach and half received treatment as usual.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says drug doses were 20-50% lower, which is a very big deal considering the side effects of these drugs. But overall it leaves us hungry for numbers. It says patients in the therapy group, who received more one-on-one talk therapy and family counseling \u201cmade greater strides in recovery over the first two years of treatment than patients who got the usual drug-focused care.\u201d But nowhere in the story does it tell us how \u201cstrides\u201d were measured or give us a percentage by which they exceeded those for the control group.\nIt would have taken some additional legwork to find these numbers, which were not reported in plain English in the study itself. But the paper did report some numbers that were very easy to understand and were not mentioned in the story:\n\u201cOver the 2 years, 34% of the NAVIGATE group and 37% of the community care group (adjusted for length of exposure) had been hospitalized for psychiatric indications (not significant).\u201d\nWe wished the story had pressed the study authors more about this.", "answer": 0}, {"article": "This is in line with some of our recent studies which indicate that the GI tract microbiome in Alzheimer's is significantly altered in composition when compared to age-matched controls, and that both the GI tract and blood-brain barriersbecome significantly more leaky with aging, thus allowing GI tract microbial exudates (e.g.\nEven though this increase is moderate, and all patients remained severely cognitively impaired, these results are important because they are the first to show that probiotics can improve human cognition.\nIn a new clinical trial, scientists show that a daily dose of probiotic Lactobacillus and Bifidobacterium bacteria taken over a period of just 12 weeks is enough to yield a moderate but significant improvement in the score of elderly Alzheimer's patients on the Mini-Mental State Examination (MMSE) scale, a standard measure of cognitive impairment.\nFuture research, on more patients and over longer time-scales, is necessary to test if the beneficial effects of probiotics become stronger after longer treatment.\nIn mice, probiotics have indeed been shown to improve learning and memory, and reduce anxiety and depression- and OCD-like symptoms.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that over the 12-week intervention period, \u201cthe average score on the MMSE questionnaire significantly increased (from 8.7 to 10.6, out of a maximum of 30) in the group receiving probiotics, but not in the control group (from 8.5 to 8.0).\u201d\u00a0 While the exact numeric values are correct, and the release is to be applauded for attempting to quantify the results (even going so far as to include the range of the scale being used \u2014 very helpful), the word \u201csignificantly\u201d is incorrectly applied in this statement. The MMSE scores at the end of the study are being compared between groups \u2014 not within the same group. A correct comparison might read, \u201cWhen comparing the change in MMSE scores over the 12-week study, there was a statistically significant difference between the two groups- \u2013 the intervention resulted in an improvement in MMSE score in the probiotic group compared to the control group.\u201d The researchers phrased it right in the original publication, but the news release misinterpreted the finding.\nIdeally, the release (as well as the published study) would have discussed what the improvement in MMSE scores means to an individual with Alzheimer\u2019s. Authors stated that \u201call patients remained significantly cognitively impaired\u201d \u2014 so what effect would a two-point increase in MMSE have on a person\u2019s daily life? It would be beneficial for readers to understand the clinical and personal significance of these improvements.", "answer": 0}, {"article": "He reviewed the findings for WebMD.\nAlthough approved by the FDA, the femtosecond laser procedure is not widely used in the U.S., according to the American Academy of Ophthalmology.\n\"If you have a technique to soften the cataract, there appears to be less chance of damage [to the eye ],\" Salz says.\nThe surgery is performed to remove the natural lens of the eye after it has become clouded over time.\nThe new studies looked at using the so-called femtosecond laser to deliver near-infrared light to fragment the cataract into tiny segments prior to removal.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We felt that the caveats presented in this article came too late, and were took weak, to provide readers with a balanced perspective on the findings. The headline and first three paragraphs include talk of the laser procedure being \u201csafer\u201d and offering a \u201cbenefit\u201d in terms of \u201cless damage to the eye.\u201d There is also the suggestion later down that the procedure might lead to \u201cfewer complications, less inflammation and swelling of the eye, and faster recovery of vision.\u201d Only far down in the piece does it begin to become clear that these studies looked only at surrogate outcomes such as the amount of ultrasound energy applied during the procedure and the number of movements the surgeon performed. As the story belatedly points out, it is uncertain if improvements in these outcomes reflect benefits that actually matter to patients.", "answer": 0}, {"article": "Xarelto already is approved for use by those with atrial fibrillation (irregular heartbeat) and by people who are having hip- or knee-replacement surgery.\n\"While it is true that these bleeding events typically do not lead to death or irreversible harm, these events may represent the biggest problem for both patients and health care providers if rivaroxaban is approved.\"\nIn the FDA briefing documents, an agency reviewer recommended approving the drug for treatment of acute coronary syndrome, mostly because trial data showed there was a reduction in cardiovascular death, even though there was also an increased risk of potentially fatal bleeding.\n\"However, what is not reflected in the sponsor's analysis are minor bleeding events,\" FDA reviewer Dr. Karen Hicks wrote in the briefing documents.\nOf those patients, 136 had bleeding in the brain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Exactly how should one interpret, \u201c\u2026mostly because trial data showed there was a reduction in cardiovascular death, even though there was also an increased risk of potentially fatal bleeding.\u201d\u00a0 Without any level of quantification, how is this information at all helpful to the reader.\u00a0 There is a suggestion that the bottom line is fewer deaths but that is merely implied.\u00a0 How much did it lower cardiovascular events, What were the bleeding events and how did the two balance out?\u00a0 Isn\u2019t that the real question that needed to be answered?", "answer": 0}, {"article": "\u201cWe had hoped to identify some of the characteristics of the women who benefitted from acupuncture, but like so many treatments, we could not really tell ahead of time who would benefit,\u201d Avis said.\nOf the 170 women who received acupuncture, a small group of women (11.9 percent) had an 85 percent reduction in hot flashes by the eighth week of the study, Avis said.\nForty-seven percent of the study group reported a 47 percent reduction over this same time frame.\nWomen who had a reduction in their hot flashes saw a benefit beginning after about three to four weeks of weekly treatments.\u201d\n\nThe National Institutes of Health-funded study was designed to examine different patterns of responses to acupuncture.\nParticipants included 209 perimenopausal and postmenopausal women ages 45 to 60 who had on average at least four hot flashes or night sweats per day.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a nice job here, breaking down the results in a detailed, quantified way: \u201cOf the 170 women who received acupuncture, a small group of women (11.9 percent) had an 85 percent reduction in hot flashes by the eighth week of the study, Avis said. Forty-seven percent of the study group reported a 47 percent reduction over this same time frame. However, 37 percent showed only a minimal reduction of 9.6 percent in frequency of hot flashes, while 4 percent reported a 100 percent increase in hot flashes.\u201d\nWhat would have made the release stronger would have been to note that 79.5 percent of the control group \u2014 who received no acupuncture \u2014 saw a 10 percent decline in hot flash frequency. That casts the 37 percent of the acupuncture group who had a reduction of 9.6 percent in a different light. i.e., it indicates that any reduction they saw may not have been tied to the acupuncture at all.", "answer": 1}, {"article": "\"Shireen had the idea, 'Why can't I just test my food and figure out what's in it?'\nNima is not FDA-approved and it's not intended for medical use, but the company intends it as a \"consumer\" tool to use when dining out, Sundvor said.\nMarilyn Grunzweig Geller, chief executive officer of the Celiac Disease Foundation, said she is not familiar with the new gluten-sensing device and was unable to comment on it directly.\nThe company, 6SensorLabs, has started taking pre-orders for the device it calls Nima, which can test food for gluten and get rapid results, said co-founder and chief technology officer Scott Sundvor.\nThe company plans to deliver the product by the middle of next year after they've tested it more thoroughly, Sundvor.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story references a company official who says that\u00a0Nima can tell if the food sample has 20 parts per million or more of gluten. But the story never provides any data tor numbers to back this up.\u00a0The inventors claim that they are doing \u201ca huge amount of testing,\u201d to \u201cbe sure\u201d of \u201c99.9%\u201d accuracy, but there are no test data given in the story.\nOne could argue that since the company owns up to the fact that it has carefully elected not to seek FDA approval, it has no requirement to offer hard data about the product\u2019s accuracy or benefits for peer review or to the public. But we hold news stories to a higher standard. Clearly the company has done some testing \u2014 what have those tests found? The story had an obligation to push for and analyze those numbers, or make it more clear to readers that we have no idea how accurate this test might be.", "answer": 0}, {"article": "Tobacco kills one-third to one-half of those who smoke.\n\u201cThis important laboratory study, together with prior laboratory and epidemiology research, suggests that metformin may be useful in cancer prevention and treatment,\u201d said Dr. Michael Pollak of McGill University in Montreal, who wrote a review on metformin research in the same journal.\nThey said metformin prevented lung tumor growth in mice exposed to a cancer-causing agent found in tobacco smoke, and because it is already widely used in people, it may be worth further study.\nThe findings were so strong the team now wants to test it in smokers to see if it can keep then from developing tumors.\n\u201cAlthough smoking cessation is the most important step for current smokers, over half of lung cancer cases are diagnosed in former smokers, raising the importance of identifying those at highest risk and identifying effective preventive treatments,\u201d Dennis, whose findings were published in the journal Cancer Prevention Research, said in a statement.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Unsatisfactory because all risk reduction figures were in relative terms, not absolute.\u00a0 Read our primer on this.\u00a0 Why not tell us 40-50% fewer tumors THAN\u00a0WHAT?\u00a0 72% fewer tumors \u2013 compared TO\u00a0WHAT? ", "answer": 0}, {"article": "Bipolar disorder effects around 1 percent of the population worldwide and sufferers can experience moods that swing from one extreme to another, and have periods of depression and mania lasting several weeks or longer.\n\u201cNow we urgently need to see if it works like lithium in people.\u201d\n\nSome 60 years after it was first discovered, lithium - a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide - remains the most effective long-term treatment.\nScientists say the drug, ebselen, may be a swift answer to long-sought after better medications for patients with the manic depressive disorder, since it is already known to be safe.\nBut it is very toxic - at only twice the right dose it could kill a patient, Churchill said - and its adverse side-effects mean many people stop taking the drug and relapse into episodes of mania and depression.\nIf the drug could be \u201crepurposed\u201d and licensed for the treatment of bipolar disorder, it could reduce the unpleasant side effects of weight gain, thirst and potential kidney damage that patients risk when taking lithium.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story misses the mark in two main areas. No benefits are quantified, and no risks are quantified. Readers are only told \u201cmice\u2026were able to be calmed again with ebselen\u2026.In mice ebselen works like lithium.\u201d\u00a0 Even if the technical explanation for how the mice improved in the study is difficult to explain to a general audience, we think readers deserve some hard data here. All mice were calmed?\u00a0 Half the mice?\u00a0 How many mice were made manic?\u00a0 How big was the experiment?\u00a0 Over what period of time.\nAt a very high level, it is troubling to see a study in mice headlined as \u201cExperimental drug may help people.\u201d\u00a0 It may just as readily be found NOT to help people.", "answer": 0}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although lots of suggested benefits are mentioned and not quantified, we will still give this story a passing mark, because the \u201cVerdict\u201d is that there isn\u2019t enough evidence to prove red palm oil provides any specific health benefits. To put it another way, readers are given a clear message that while there are many claims and hints bouncing around, the documented health benefit of red palm oil is zero\u2026 and that is a hard number.", "answer": 1}, {"article": "\"Whether the vaccine is going to look anything like this one I don't know.\nIt is unlikely -- but not impossible -- that any country would consider it effective enough to be used as a public health measure against HIV.\nThe study cost $105 million, most of it provided by the National Institutes of Health.\nThe vaccine, a complicated mixture of six \"prime\" and \"booster\" shots, reduced a person's risk of becoming infected by about one-third compared with people getting placebo injections.\nOther researchers were less sanguine about the study but did not want to be quoted by name as being skeptical when only a few details of the results have been released.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It provided the outcomes in absolute terms \u2013 which we appreciate:\u00a0 \"Of 8,197 people who got vaccine, 51 became infected in the three years after their shots. Of the 8,198 who got placebo injections, 74 became infected. While that difference \u2014 23 infections out of more than 16,000 people studied \u2014 is significant, it could have occurred by chance.\"", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070805/13knee.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article explains that there is so far no independent data quantifying the benefits of the new Gender Knee implant for women. ", "answer": 1}, {"article": "\"With my technique, there is a much more limited scar and it limits the scarring in the fold of the breast, which is usually the most uncomfortable. By the third day, most women are up and around and doing most of their activities.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes the benefits of breast reduction surgery but does not use any data to quantify the frequency or magnitude of the benefit. ", "answer": 0}, {"article": "In nonsurgical spinal decompression, a patient is placed on a special type of table with harnesses on the pelvis and rib cage.\nI would say a quarter of my patients fall asleep.\u201d\n\nThe decompression therapy is used to treat herniated discs, ruptured discs, sciatica, bulging discs, degenerative discs, posterior facet syndrome and spinal stenosis/arthritis.\nIt is designed for patients who have not had surgery.\nThe treatment, which includes several 20-minute procedures and rehabilitation, costs between $3,500 and $4,000.\nIt is less than half the cost of surgery but is rarely covered by insurance.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies the benefits of treatment in relative terms only. The story says, \u201cResearch has shown an 86 percent to 94 percent success rate.\u201d Readers need to know: 86 to 94 percent of what? And how is \u201csuccess\u201d measured? Also, the story does not compare the effectiveness of spinal decompression with that of other alternatives.", "answer": 0}, {"article": "Lauren Dunn is a medical producer for NBC News; Linda Carroll is a contributor for NBCNews.com\nIt\u2019s functioning in your day-to-day life.\u201d\n\nEkstadt has the privilege of being the first person in the nation to get the Raindrop outside of a clinical trial.\n\"You need to be monitored by your surgeon during that period of time.\u201d\n\nOne downside: the implants aren\u2019t covered by insurance or Medicare, says Hamilton, adding \u201cthe cost is around $4,000 to $5,000.\u201d\n\nThere are other risks with the procedure, but they are rare, according to clinical trials.\nAlso, Hamilton notes, the implants aren\u2019t a \u201cbe all end all.\nWithout the glasses, she can\u2019t read anything.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story gives us an anecdote about a single patient, who is apparently the first person to have the implant outside of clinical trials.\u00a0This is not helpful for the readers who want to know the research evidence about the surgical implant(s)\u2013what were the measured benefits in clinical trials?", "answer": 0}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately describes the main outcome, energy expenditure, and puts it into context, noting that the low-carb group burned about 300 calories more per day than those on the low-fat diet\u2014\u201dabout the same as an hour of moderate exercise\u201d \u2014 and that the low-glycemic group burned about 150 calories less than the low-fat group.", "answer": 1}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives the absolute number of participants (697) who were enrolled in the trial and then reports the percentages of participants who stopped smoking. While it reported reduced cigarette consumption in relative numbers, it did specify that participants smoked at least 15 cigarettes a day, giving somewhat more meaning to these percentages (e.g. \u201cdecrease their smoking by an average of 29%\u201d). It told us quit rates at four weeks and six months, too\u2013so we get some sense of change over time on results. It also placed these results in the greater context of what we know about quit rates among smokers.", "answer": 1}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not explain why it is that these two medications might be so commonly prescribed for the same patient. \u00a0It should have explained that Plavix, which is strongly recommended for use by patients who have had a revascularization procedure (such as coronary bypass or stent implantation), can often result in stomach upset \u00a0and bleeding. \u00a0 The use of a PPI was thought to confer benefit as a preventative by lessening this gastric distress side effect.", "answer": 0}, {"article": "U.S.\nThe paper outlines the case study of a 56-year-old male with a chronic meniscus injury.\nThe arthroscopic images showing resolution were also consistent with quality of life improvements for the patient, including a reduction in pain and resumption of normal activities.\nThe patient experienced very little downtime and was able to resume normal activities in less than 1 week.\nDuring the 12-month follow-up period, the patient reported a reduction in pain and an improvement in knee function.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t give any data on how large/small are the potential benefits. It only offers general statements\u00a0such as,\u00a0\u201cthe patient reported a reduction in pain and an improvement in knee function.\u201d The release notes that two images were taken, the latter which shows the absence of a tear while the former shows the tear present. The release also offers, \u201cThe arthroscopic images showing resolution were also consistent with quality of life improvements for the patient, including a reduction in pain and resumption of normal activities. The patient experienced very little downtime and was able to resume normal activities in less than 1 week.\u201d\u00a0 As noted above, this report is of\u00a0a single patient case \u2014 there was no clinical trial involved.", "answer": 0}, {"article": "B vitamins, including B12 and folate, have been shown to help lower homocysteine levels, so high levels of the amino acid suggest low levels of B12.\nThe relationship between vitamin B12 and Alzheimer's risk is \"complex,\" says Dr. Sudha Seshadri, M.D., an associate professor of neurology at the Boston University School of Medicine and the author of an editorial accompanying the study.\n\"Lowering these in general is important for cardiovascular health, and this study strengthens our knowledge about its role in risk for Alzheimer's disease.\"\nDr. Sam Gandy, M.D., the associate director of the Alzheimer's Disease Research Center at the Mount Sinai School of Medicine, in New York City, says that it may make sense for people to get blood tests to measure their levels of B12 and folate.\nHealth.com: 9 foods that may help save your memory\n\nOver the next seven years, 17 study participants were diagnosed with Alzheimer's disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "Hernias occur when part of an internal organ, such as the intestines, bulges out through muscle.\nThe researchers followed up with 75 percent of the patients after an average period of five years.\nIn the study, researchers randomly assigned 660 hernia patients to one of the two surgical procedures.\nRecurrences decreased to 0.5 percent and 4 percent, respectively, if the procedures were performed by experienced surgeons.\nThe traditional approach may be appropriate when it's too risky to place patients under general anesthesia, Brunt said, such as in elderly patients and those with multiple health problems.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantified how often the hernias recurred in each group and how many patients had chronic pain at follow-up. It noted that \u201cthe vast majority of patients do well, regardless of the approach.\u201d This is enough for a satisfactory, though the story could have provided data about how quickly patients were able to return to work with each procedure, and how satisfied they were overall with their results.", "answer": 1}, {"article": "Children slept in the MRI machine while researchers read them bedtime stories.\nBefore bringing it to clinics, researchers need to make sure this test isn't detecting other developmental delays such as dyslexia, he noted.\nAbout 50 percent of kids with autism never develop language,\" she noted.\nAnd when it is ready for prime time, it probably won't be applicable to all children with autism.\n\"We now feel pretty confident that, in many children with autism, there are alterations either in structure growth or connectivity of the brain, but we really don't understand the implications of that for core features of autism, one of which is problems with communication,\" Amaral said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It talks about the potential benefits, but it doesn\u2019t quantify them. There were 30 children in the study with autism and 14 without. It does not make it clear whether all 30 children showed differences in their brain activity patterns or some fraction of them. Instead of a he said/she said between experts, the research may show that all children, no matter where they are on the autism spectrum, show a clear difference in brain activity compared to chilldren without autism. This is what the story indicates, but it doesn\u2019t make it clear. It also does not even attempt to estimate how many people might benefit from this.", "answer": 0}, {"article": "Calorie levels, as well as protein, carbohydrate, and total fat, were kept the same.\nIn this placebo-controlled crossover study of 26 men and women (average age 59 years), all meals were provided to carefully control their food intake.\nWhile a growing body of evidence has linked tree nuts such as pecans to reduced risk of CVD, this is the first study to look at the effects of pecan consumption on factors other than blood lipid levels and specifically those related to T2D.\nA new study published in Nutrients shows that eating just 1.5 ounces of pecans - one small handful - every day may protect adults at risk for developing cardiovascular disease (CVD) and type 2 diabetes (T2D).\nConducted by researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, this study found that incorporating pecans into a typical American diet significantly improved insulin sensitivity and had a significant effect on markers of cardiometabolic disease in otherwise healthy overweight and obese adults with excess belly fat.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does not give us numerical measures of the benefits it reports from the study. Instead, the release uses the phrase \u201csignificantly improves\u201d in relation to \u201cinsulin sensitivity\u201d and further states that pecans had a \u201csignificant effect on markers of cardiometabolic disease in otherwise healthy overweight and obese adults with excess belly fat.\u201d\nNone of that helps readers gauge the impact of pecan supplementation.\nThe lead researcher is quoted saying, \u201cWhat\u2019s really interesting is that just one small change \u2014 eating a handful of pecans daily \u2014 may have a large impact on the health of these at-risk adults.\u201d But no where in the releases are readers provided any evidence of a large impact.", "answer": 0}, {"article": "Watch Sanjay Gupta MD Saturday at 4:30pm and Sunday at 7:30am ET.\nAgatston says relatively new imaging tests give real-time pictures showing whether plaque is building up in key blood vessels, alerting doctor and patient to an increased risk of a potentially deadly heart attack.\nAgatston thinks the coronary calcium scan should be routinely scheduled at age 50, like a colonoscopy, or earlier for people with family histories of heart disease.\n(Agatston does not make any money from the coronary calcium scan.)\nThe other imaging test Agatston recommends is an ultrasound of the carotid artery, looking at plaque in the main blood vessel leading to the brain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only quantifiable statement about benefits included in this story is that \u201cdoctors who are practicing aggressive prevention are really seeing heart attacks and strokes disappear from their practices.\u201d A claim that any combination of tests and treatments can completely prevent heart attacks and strokes is unbelieveable. The incremental benefits that some recent studies have reported in certain patient groups are not clearly spelled out in this story. Those the kinds of numbers that readers should have been provided.", "answer": 0}, {"article": "\"This is the first study looking at women who have failed so many other treatments,\" Krop tells WebMD.\nAll the women, who had breast tumors for an average of three years, had cancer that had metastasized, or spread to other parts of the body.\nThe findings were presented at the San Antonio Breast Cancer Symposium.\nDec. 15, 2009 (San Antonio) -- A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin, failed.\nThe women remained cancer-free for an average of seven months -- results unheard of in patients this sick, he says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the article does present numbers for the outcomes, it does not mention the number of subjects in the study, a key piece of information needed to put the outcomes in perspective. There are further concerns\u00a0about the language used to describe the results. Most importantly,\u00a0the article claims that \"Women remained cancer-free for an average of seven months.\" This sentence appears to be a significant misinterpretation of the data because the\u00a0Dana Farber press release\u00a0states that the median time to\u00a0progression\u00a0was 7.3 months. That doesn\u2019t mean the cancer vanished in these subjects for 7 months: it was there but it just didn\u2019t progress.\u00a0The study abstract from the conference does not provide the relevant data, and thus we cannot confirm the numbers and metrics presented by the author.\u00a0If, however, this was a misinterpretation, it\u2019s significant because a reduction in tumor size (only\u00a0observed in one third of women) is not the same as being cancer free.\nThere are several other points of critique regarding how potential benefits are described. The key result that \"Tumors shrank in one-third of women with metastatic breast cancer given T-DM1\" fails to mention that this population was\u00a0a minority subset of metastatic breast cancer: those with HER2-positive disease. Perhaps readers would infer this caveat from the discussion of HER2 prevalence in the article\u2019s second section, but it should have been stated much earlier, at the very least when the study population was described. Otherwise it overstates the potential applicability of the benefits.\nThe title of the article \"drug shrinks tumors\" is an exaggeration: tumors only shrunk in one third of subjects. Growth was stable in another 12% of subjects, which means that the other half of subjects progressed during the study.\nThe editorial definition of the term \"refractory\" as \"sick\" is\u00a0overly simplistic and perhaps misleading.", "answer": 0}, {"article": "Patients taking briakinumab had more serious infections and more cancers than those taking methotrexate.\nBut as successful as the drug appears to be for some patients, it may come with a significant risk.\nGordon was not involved in the current study, but he has been involved in research of the drug and has been a paid consultant and investigator for Abbott.\nThe study is published in the New England Journal of Medicine.\n\"Many of us were disappointed it was withdrawn because there would be a subset of patients who wouldn't respond to anything else and it would have been nice to have for them.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate explanation of the potential benefits seen in the study.", "answer": 1}, {"article": "In a month, I bodysurfed at the beach,\u201d says Ellsberg, who is 81 .\nUnger says that most surgeons have used the posterior approach for years, have fine results, and see no need to switch.\nSo when students leave and begin their practices, it\u2019s no longer foreign to them.\u201d\n\nHamilton, who has performed 1,100 anterior procedures and strongly supports the method, says that despite growing interest, \u201cit will take a generation of new surgeons\u201d before use of the anterior approach is widespread.\nFor this reason, new techniques are adapted slowly with extreme care, and in some cases, not at all.\u201d\n\nUnger adds that surgeons are naturally cautious and typically wait to see results from many studies before they switch methods.\nAccording to those who use this anterior technique, the benefits are substantial.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of the anterior approach to hip replacement, and so we give it a failing grade here. But it should be noted that the story, unlike many in this vein, actually points to the lack of evidence that the approach is superior. The story says: \u201c\u2018He says that while he\u2019s heard about the benefits of the anterior approach, he\u2019s \u2018not aware of a randomized, controlled trial comparing the posterior and anterior approach that shows a definite superiority of one over the other.\u2019 What\u2019s key is that \u2018surgeons need to do the approach they\u2019re most comfortable with to get the best outcomes.'\u201d\nThe clear implication in this story is that most doctors aren\u2019t doing this technique because of convenience around retraining. It should have been pointed out that if there were stuies showing a clear benefit, providers would be morally pushed to make the effort and appropriately pushed by well-informed patients.", "answer": 0}, {"article": "Once a woman hits puberty the number drops to 300,000 and by age 30 the amount decreases by 90 percent.\nThe test doesn\u2019t measure the quality of the eggs and it\u2019s not a guarantee of fertility.\nFor Alyssa Gold, the AMH test was a wakeup call.\nFor years, it\u2019s been a staple in fertility clinics; it\u2019s officially called the Anti-M\u00fcllerian hormone (AMH) test.\nTurns out there\u2019s a simple blood test that could tell her.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t provide any quantified information, such as research outcomes involving this test, and instead relied heavily on patient and physician anecdotes. If research is lacking, that should be noted.\u00a0Presumably this test has been studied among women actively struggling to get pregnant, but the quantified benefits of this test for that patient group aren\u2019t\u00a0discussed, either.", "answer": 0}, {"article": "When researchers compared patients who had gastric bypass surgery to those who lost the same amount of weight by dieting, they found that the surgery patients had lower levels of amino acids that have been linked to insulin resistance.\nBut researchers say the preliminary findings could one day lead to diabetes treatments.\nThe study was small, including just 10 patients who had the surgery and 11 patients who followed severely calorie-restricted diets.\nNow a new study from Duke University Medical Center and Columbia University may help explain why.\n\u201cCertainly weight loss by any means improves type 2 diabetes, but there is something else going on with gastric bypass surgery,\u201d study researcher Blandine Laferrere, MD, of Columbia University\u2019s St. Luke\u2019s and Roosevelt Hospital Center, tells WebMD.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported on the impact of gastric bypass surgery on diabetes in a very small group of patients (10) in which all of them experienced improvement in their diabetes. \u00a0However \u2013 there are numerous larger studies which have been conducted that have examined the impact of this surgery on diabetes. \u00a0While the impact on diabetes is good, rather than all patients demonstrating benefit, broader experience indicates that about 80% of those with type Ii diabetes will see improvement.\nThe story also implies that there could be some benefit to readers of knowing that branch chain amino acids are reduced by surgery. There is no quantifiable benefit to this piece of the puzzle.", "answer": 0}, {"article": "The associated pain can last months or even years.\nAnother new study, published in the American Journal of Preventive Medicine, finds that by 2008, less than 7% of U.S. adults aged 60 and older had gotten the vaccine, which has been available just since 2006.\nHowever, he tells WebMD, the 55% risk reduction ''is pretty high compared to other adult vaccines.\"\nGetting the vaccine makes it less likely that adults will get the painful rash that can occur when the varicella zoster virus, which causes childhood chickenpox, reactivates to cause shingles.\n\"Compared to childhood vaccines, people would [probably] think 55% is not too impressive, because many childhood vaccines are in the range of 80% to 90% [effective],\" says researcher Hung Fu Tseng, PhD, MPH, a research scientist at Kaiser Permanente Southern California.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nAlthough this story leads with only the relative risk reduction of 55 percent that researchers found in this study, it quickly places that effect in context with that of other vaccines (which generally provide greater protection). The story also reports the absolute risk figures of 6.4 cases per 1,000 people per year among those vaccinated and 13 cases per 1,000 people per year among those who were not vaccinated. These numbers help readers put the effects into the overall context of the risk of shingles. We think readers would have benefitted from also being told that based on the results of this study, one case of shingles is prevented for every 71 people vaccinated. This figure makes clear that while some people who are vaccinated are spared from a shingles attack, not everyone should expect to personally benefit from vaccination.\nThe story should have pointed out  that the study looked at a limited time span and that the researchers can\u2019t say whether the effects of the vaccine persist through later years. That\u2019s an important caveat, since a 60-year-old who had chicken pox as a child is at risk for a shingles attack for the remaining decades of life. If the vaccine cuts the risk of attacks in half, but only for the first few years after vaccination, then the lifetime reduction in risk would be much smaller.", "answer": 1}, {"article": "Consumers can wake up with Red Bull and then wind down with Slow Cow.\nNow, the field includes a slew of new drinks promising a better night's sleep using such ingredients as melatonin, valerian root and - think turkey - tryptophan.\nThe back of the Snooz'n bottle says the beverage will \"combat stress, energy drinks and sleeplessness\" and takes about 30 minutes to take effect.\nOral doses of melatonin haven't worked much better at inducing sleep than a placebo in most studies, Scharf says, and a single, concentrated shot of the stuff doesn't exactly mimic the body's time-release system.\nThe relaxation drink market is tiny compared with the energy drink market, says Garima Goel Lal, a senior analyst at the consumer research firm Mintel.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not report in detail on any one study,\u00a0but comments from a sleep expert\u00a0 tell readers what they need to know here. He remarks that melatonin\u00a0(a constituent of many of the drinks) doesn\u2019t seem to work much better than a placebo, and that we have\u00a0no idea how\u00a0well valerian\u00a0root\u00a0\u00a0(another supplement found in some drinks) works compared with prescription sleep medicines because they haven\u2019t been compared.", "answer": 1}, {"article": ".\nThe findings, which are published in BJU International, could change the way men are treated for low testosterone.\n\"This study confirmed that Enclomiphene can maintain spermatogenesis while restoring testosterone levels to normal.\"\nOver five months, patients had 10 clinic visits with one overnight stay.\nAs this study has shown in a randomized, double-blind, double-dummy, placebo-controlled manner, exogenous testosterone therapy with Androgel can clearly decrease sperm production and potentially impact fertility,\" said Dr. Kim.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release simply states that \u201cenclomiphene citrate restored blood testosterone levels to normal after 16 weeks.\u201d\nBut in a news release for which the headline states testosterone \u201chelps safeguard a man\u2019s fertility,\u201d we look for something more. And even the limitations discussion of the journal article in question discusses what isn\u2019t revealed in the news release. \u00a0Excerpts:\n\u201cImprovement in patient-reported outcomes (PROs) was not addressed in the present study\u201d\n\u201cThe true impact of a medication on male fertility is difficult to assess without actual pregnancy or live birth data,\u201d admitting that semen analysis is \u201cfar from being a true proxy for fertility.\u201d\n\u201cFinally, the duration of the study is relatively short-term compared with the length of therapy seen in clinical practice.\u201d\nThe release doesn\u2019t tell us about the fertility rates in subjects receiving the new drug, nor to what degree the \u201cmarked reductions\u201d in\u00a0sperm counts in the testosterone group affected fertility.", "answer": 0}, {"article": "\"It appears that women who reported taking prenatal vitamins starting three months prior to conception and through the first month after conception seem to have a reduced chance their child will develop autism ,\" says study researcher Irva Hertz-Picciotto, PhD, professor of epidemiology and environmental health at the MIND Institute and Department of Public Health, University of California, Davis.\nChildren who had the high-risk COMT gene form were seven times as likely to have autism as children without it whose mothers did take the vitamins.\nStill, she says, the finding points to a gene-environment interaction that may possibly help explain some cases of autism.\nThe risk rose if the mothers or the children had a high-risk gene form.\nExactly why the prenatal vitamins may protect against autism is not clear, she says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story communicates the results using relative\u00a0terms, noting that women who didn\u2019t take vitamins had \u201cabout a 60% higher risk of having a child with autism.\u201d In women with a high-risk genetic profile who didn\u2019t take vitamins, the risks were 4.5 to 7 times higher compared with women who didn\u2019t have the high risk genes and took prenatal supplements, according to the story. While\u00a0these relative numbers probably give readers an overinflated sense of the benefits of taking supplements (or the harm of not taking them),\u00a0using absolute numbers, which we normally\u00a0prefer,\u00a0would be inappropriate and probably\u00a0even more misleading in coverage of a case-control study such as this one \u2014 for the reasons discussed here. The use of relative numbers is acceptable in a case-control study\u00a0if there is some indication of the underlying population-wide risk, which this story\u00a0provides when it says that autism\u00a0affects \u201cup to one in 110 children\u201d\u00a0\u2014 or\u00a0about 1%.\u00a0\u00a0While admittedly complicated and imperfect, this mix of numbers\u00a0should help readers\u00a0draw appropriate conclusions about the significance of the findings.", "answer": 1}, {"article": ".\nWhile on the whole grain diet, participants saw a three-fold improvement in diastolic blood pressure (the lowest pressure when your heart relaxes between beats) compared to the refined grain diet.\nThe findings, published in the Journal of Nutrition today, suggest that whole grains can be a key regulator of blood pressure, and could provide an effective nutritional strategy to reduce cardiovascular-related deaths and disorders.\nAt the beginning and end of each diet period, participants spent three days undergoing metabolic testing in a clinical research setting.\nWednesday, Oct. 19, 2016, Cleveland: A team of Cleveland Clinic researchers, in collaboration with Nestl\u00e9 Research Center, conducted one of the largest controlled studies of its kind on whole grains and concluded that a diet rich in whole grains may significantly lower the risk of cardiovascular disease in overweight and obese adults under the age of 50.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that, \u201cWhile on the whole grain diet, participants saw a three-fold improvement in diastolic blood pressure (the lowest pressure when your heart relaxes between beats) compared to the refined grain diet. This improvement equates to reducing the risk of death from heart disease by almost one-third, and the risk of death from a stroke by two-fifths.\u201d However that is a relative risk reduction, not an absolute risk reduction which would have provided readers with a better understanding of the observed change.\nThe release also said, \u201cOverall, there were substantial reductions in body weight, fat loss, systolic blood pressure, total cholesterol, and LDL cholesterol during both diet periods,\u201d but provided no numerical data explaining those reductions.", "answer": 0}, {"article": "\"It's clearly muddying the waters,\" he said.\nBut since the advent of routine mammograms in the 1990s, the rate of death from breast cancer has dropped 30 percent, he observed.\nBut Kopans noted that mammography is still the only test that has been proven to reduce the death rate from breast cancer and that this study should not divert attention away from that fact.\nThe analysis, published in the Sept. 23 issue of the New England Journal of Medicine, raises new questions about the benefits versus risks of screening mammography and is already reigniting tensions over its frequency of use in the United States.\nThe other two-thirds of the reduction is probably due to such factors as increased cancer awareness, improved therapy and use of more sensitive diagnostic tools, the study authors suggest.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Right off the bat, the story says, \"Routine mammograms account for only about one-third of the decline in breast cancer death rates, according to a large new analysis of data from Norway\u2019s expansive breast cancer screening program.\" It takes too long, we think, for the story to follow this up with more data. Instead, we are given this dubious statistic from an oft-quoted member of the American College of Radiology. He says that \"since the advent of routine mammograms in the 1990s, the rate of death from breast cancer has dropped 30 percent.\" Ask an oncologist about what has happened to cancer care since the 1990s, and you may get a different answer as to why that death rate has dropped. ", "answer": 0}, {"article": "\u201cIt all depends on how you approach risk,\u201d Dr. Zelen said.\nBut, cancer experts said, no one would do such a study today when mammograms are generally agreed to prevent breast cancer deaths.\nMarvin Zelen, a statistician at the Harvard School of Public Health and the Dana-Farber Cancer Institute, who was a member of the research team said even though the mammography benefit is small, if he were a woman he would get screened.\n\u201cThis is the first time researchers used real populations to compare the effects of treatment and mammography in the modern era of treatment,\u201d Dr. Kramer said.\nThe study, published Thursday in The , looked at what happened in before and after 1996, when the country began rolling out mammograms for women ages 50 to 69 along with special breast cancer teams to treat all women with breast cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nThis story uses several different statistics and expert perspectives to explain what the researchers found in their examination of the effects of mammography screening. It not only include the relative risk reduction (10 percent) and an absolute risk reduction statistic (among women in their 50s, a decade of screening would boost the likelihood of avoiding a fatal breast cancer from 995.6 out of 1,000 to 996 out of 1,000), but it also offered comments from different experts about how they would personally value effects of that size. ", "answer": 1}, {"article": "That accounts for a small percentage of people.\nThe prescription-free test is the first to report on three specific BRCA1 and BRCA2 breast cancer gene mutations, according to the FDA.\nStill, the company, which already tests DNA for other health risks as well as ancestry, said this cancer test is \"a step in the right direction.\"\n\u201cThe test should not be used as a substitute for seeing your doctor for cancer screenings or counseling on genetic and lifestyle factors that can increase or decrease cancer risk,\u201d he said.\nThe test detects only three out of more than 1,000 known BRCA mutations.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits in this context would, presumably, be an increased awareness of one\u2019s risk for breast cancer; information that can be used to make informed decisions about monitoring and prevention. However, the story does not use numbers in a way that would help women choose the best course of action. For example, it does not explain how accurate the test is, nor does it tell readers how much their cancer risk is increased with a positive result. It also does not explain what women might do to mitigate that increased risk, and how much their risk would decrease as a result.\nWhile it might be too much to ask the story to include all of this information, providing at least some of these numbers would be necessary to meet our expectations for this criterion.", "answer": 0}, {"article": "\u201cIt\u2019s just not a good operation,\u201d he asserted.\nBut the risks of nutrient deficiencies are greater with duodenal switch, and include some not seen with gastric bypass, Livingston pointed out.\nTwo years after surgery, duodenal switch patients had lost more weight: about 50 pounds more, on average.\nThe average weight loss seen with either gastric bypass or duodenal switch will improve or reverse obesity-related ills like diabetes, sleep apnea and knee arthritis, according to Livingston, who wrote an editorial published with the study.\nIn this study, one-quarter of gastric bypass patients still had a BMI that high two years after surgery \u2014 versus none of the duodenal switch patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes clear that the duodenal switch surgery, in comparison with the bariatric surgery, may give patients greater weight loss in pounds but the value of that reduction is not clear. The additional information from the paper published by Livingston demonstrating no advantage to surgery over medical management was very useful.", "answer": 1}, {"article": "Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma in adults.\nArmin Ghobadi, an oncologist at Siteman who was an investigator in the Kite trial, said the new treatment is \u201cjust the first step\u201d and that researchers are working to make it safer and more effective.\n\u201cThese are patients who knew they were out of options,\u201d he said, noting that lymphoma patients who relapse or don't respond to treatment have just a 50 percent chance of surviving for six months.\nLocke said about 13 percent of patients in the trial had a severe side effect known as cytokine release syndrome, which produces high fevers, low blood pressure and other flulike symptoms.\nAn independent review committee found that 72 percent of patients treated with a single infusion responded to therapy, including 51 percent who then showed no evidence of remaining cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes the scope of the benefits for the patients this way:\n\u201cAn independent review committee found that 72 percent of patients treated with a single infusion responded to therapy, including 51 percent who then showed no evidence of remaining cancer. Kite has said that at six months, 44 percent of patients were still responding, with 39 percent having no sign of cancer.\u201d\nWhile the story is murky on the details, this is in reference to 101 patients who received the therapy. This survival outcome was compared to historical data related to how long most people survive if they have no response to first-line treatments. This comparison is not the same as having an actual control group, and the story should have been clearer about that and what it means.", "answer": 0}, {"article": "Briakinumab works by dampening the immune system response that causes psoriasis, said Bruce Bebo, director of research and medical programs for the National Psoriasis Foundation, based in Portland, Ore.\n\nMore serious infections were seen in people taking briakinumab (2.6 percent) vs. those taking methotrexate (1.8 percent).\nThe current study included 317 people with moderate to severe psoriasis.\nAn ongoing three-year trial involves 248 people from the current study.\nThe study was funded by the drug's manufacturer, Abbott Laboratories.\n\"Very high levels of response\" were observed and maintained throughout the study period, said lead researcher Dr. Kristian Reich, a professor of dermatology at the University of Gottingen and a managing partner at Dermatologikum Hamburg, both in Germany.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate explanation of what the study showed for potential benefits.", "answer": 1}, {"article": "Espiritu started work at Henry Ford just as the program was starting, and she remembers the initial staff meetings: \"There was a lot of, 'How can you do this?\nWhen patients came in talking about suicide, health providers took notice.\nThe behavioral health provider in Nashville implemented the Henry Ford approach for nearly 200 patients who'd already made a suicide attempt.\nThe story of the health system's success is a story of persistence, confidence, hope and a strict adherence to a very specific approach.\nFifteen years ago, suicide prevention care at Henry Ford, like in many places, was mostly reactive.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that the Henry Ford Health System currently has a suicide rate of 20 per 100,000 among patients with mental health and/or substance abuse problems, which is 80 percent lower than than it had been when the \u201cperfect depression care\u201d was launched in 2001. It also notes that the overall suicide rate for system patients is five per 100,000 \u2014 which is significantly lower than the national average of 12.6 per 100,000. It would have been good if the story had simply given the starting suicide rate among patients with mental health and/or substance abuse problems in 2001 (according to Henry Ford it was apparently 89 per 100,000), rather than asking readers to do the math.", "answer": 1}, {"article": "Stryker says that none of the problems underlying the recall or the warning letter from the F.D.A.\nNow that the squeaking has raised caution flags, researchers are weighing the noted durability of ceramic-on-ceramic hip joints like Stryker\u2019s Trident model against products with other combinations of materials.\nBut Dr. Fabio Orozco, a surgeon at the Rothman Institute, a major orthopedics group in Philadelphia, said that a recently completed review of about 1,500 Rothman patients with ceramic hips had found that the squeaking condition occurred in 49 of them, or about 3 percent.\nWhatever the actual frequency, some investigators who have looked at the problem say the squeaking seems to be associated with extreme flexing of the ceramic implants, but exactly how is unclear.\nAlready, dozens of patients have elected to endure subsequent surgeries to replace the noisy hips.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news story notes in a sentence that hip replacement has a success rate of more than 90%, and defines \u201csuccess\u201d as \u201crelatively pain-free mobility.\u201d The article also clearly states why this new device was developed \u2014 to provide longer lifetime use prior to device failure. It quantifies this benefit vaguely, saying the device is \"much more durable\" and lasts \"much longer.\"", "answer": 1}, {"article": "(Adenoids, glands at the roof of the mouth, are often removed along with tonsils.)\nThere aren't strong guidelines regarding the use of tonsillectomy to treat sleep disorders, so the doctors reviewed the evidence to see whether the surgery outperformed so-called watchful waiting -- monitoring the situation.\nTo qualify for the surgery, a child must have many recurring throat infections within a short span of time or severe sleep disturbances, said Dr. Sivakumar Chinnadurai, a co-author of the reviews.\nHowever, this strong benefit only applies to the first couple of years following surgery, Chinnadurai said.\nStill, Chinnadurai and Hackett warned against automatically choosing the surgery for every sore throat.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is little quantification of the benefits claimed in this story. It summarizes the findings: \u201cChildren experienced nearly half as many sore throats when they underwent a tonsillectomy, even if they didn\u2019t meet the guidelines.\u201d\u00a0 But half of three infections occurring during a 1 to 3 year time period is 1 infection in a year. This is hardly life-changing.\nIt does say that in terms of throat infections, that kids receiving tonsillectomies showed fewer infections in the year following the procedure than did kids not undergoing the surgery, but that advantage disappeared after the first year or so.\nThe story rightfully points out that kids experiencing obstructive sleep-disordered breathing (OSDB) appeared to benefit from the surgery compared to those in the watchful waiting group. But regardless, nowhere in the story is there any quantification to get readers a clear picture of the extent of improvement following surgery.", "answer": 0}, {"article": "Only 30-50 people with type 1 diabetes in the UK currently receive an islet transplant each year, owing to a lack of donors and the difficulty of extracting islets from pancreatic tissue.\nThe pre-clinical results have encouraged CGT and Aberdeen University to create a spin-out company, called Islexa.\nGrowing islets will \u201csignificantly increase the number of patients who can receive the treatment,\u201d Keith Thompson, CGT\u2019s chief executive, told the World Stem Cells and Regenerative Medicine congress in London on Wednesday.\nInsulin shots could become a thing of the past for type 1 diabetes patients thanks to a technology being developed by Cell and Gene Therapy Catapult, a London-based not-for-profit organisation, and Aberdeen University.\nIslexa will use CGT\u2019s labs at Guy\u2019s and facilities at Aberdeen University.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article refers to preclinical \u201cresults,\u201d but gives no data or explanation of what those results involve, much less any quantified benefits. From what we could find, this was based on\u00a0research using mice\u2014a level of evidence hardly worthy of the headline \u201cType 1 diabetes treatment could end need for insulin shots.\u201d", "answer": 0}, {"article": "They found that rats with strokes who received DBS had more proteins in the brain that are associated with brain plasticity\u2014and twice as many synapses or connections between nerve cells compared to rats with strokes who did not undergo DBS.\nThat\u2019s why doctors at the Cleveland Clinic will test deep brain stimulation (DBS)\u2014a procedure in which electrodes are implanted in the brain to provide small electric pulses as a way to help people recover control of their movements.\nDBS has been used to treat tremors associated with Parkinson\u2019s disease, but Machado said the new approach, if successful, will achieve something novel.\nThe stimulation will hopefully jump-start the brain\u2019s recovery process and help them gain more control while undergoing standard therapy.\nIf ultimately successful, DBS could become a treatment used in tandem with physical rehabilitation.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Human trials have not yet begun. \u00a0The story discusses rat research:\n\u201cBut for 10 years, Machado and his team have been studying the effects of DBS on rats. They found that rats with strokes who received DBS had more proteins in the brain that are associated with brain plasticity\u2014and twice as many synapses or connections between nerve cells compared to rats with strokes who did not undergo DBS.\u201d\nBut no data were provided to explain what \u201cmore proteins\u201d means \u2013 how much more? In how many of the rats? \u00a0What is the significance of twice as many synapses? \u00a0So the discussion\u00a0of the animal research is almost meaningless.\nNonetheless, we\u2019ll grade this Not Applicable since it\u2019s clear there are no human data to report. However, this does raise the question of why this pre-trial announcement is newsworthy in a national news outlet.", "answer": 2}, {"article": "Highlighting the significance of the findings, the study\u2019s senior author, George A. Macones, MD, the Mitchell and Elaine Yanow Professor and head of the Department of Obstetrics and Gynecology, said, \u201cThis study is a tremendous addition to the literature on preventing surgical-site infections after cesarean.\nOf 575 patients who randomly received the iodine-alcohol combination, 42 developed a surgical-site infection.\nBut according to Tuuli, the unique circumstances of a C-section \u2014 that bacteria come from both skin and vagina and that a woman\u2019s immune system is altered during pregnancy \u2014 mean the results of these studies may not apply.\nAlthough the new study was conducted at only one hospital, the researchers said the patient population was racially diverse and that more than 60 percent received public insurance.\nThe investigators pointed out that all other standard procedures for reducing the risk of infection after surgery, including giving preventive antibiotics beforehand, were the same in both groups.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies the benefits well, explaining that a randomized-controlled trial showed \u201cpatients in the chlorhexidine-alcohol group developed significantly fewer infections than patients in the iodine-alcohol group. Those who received the chlorhexidine-alcohol combination had a 4 percent infection rate, which is nearly half that of the patients who received the iodine-alcohol combination \u2014 7.3 percent.\u201d\nThe news release includes both relative and absolute numbers \u2014 a big plus. The absolute numbers included the number of women who developed infections after being treated with either chlorhexidine-alcohol (23) or iodine-alcohol (42) and the size of their co-hort (572 vs. 575).", "answer": 1}, {"article": "About half of breast cancers develop in the upper-outer quadrant of the breast, which is largely inaccessible to mammography scanners.\nShe stopped routinely teaching self-exams to patients after the large trials in China and Russia showed no benefit.\nBut finding a lump also is no reason to panic, given the limited accuracy of the self-test.\nThe preferred method, known as the vertical strip, three-pressure test, has proved the most sensitive and least likely to produce false alarms, Steiner said.\nIt defies common sense, she says, for scientists to conclude that breast self-exams do women more harm than good.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story discusses two international studies upon which the Cochrane report is based and discusses the findings that there is no demonstrated benefit from regular BSE. ", "answer": 1}, {"article": "Clostridium novyi flourishes in low-oxygen environments.\nA potentially dangerous bacteria appears to target malignant cells and could provide a new means of fighting cancer, a small, preliminary study reports.\nPatients in this clinical trial were left with the bacterial infection for one week, and then everyone was given antibiotics to kill off the Clostridium novyi-NT, Janku said.\nPatients also could be susceptible to immune response side effects, such as low blood pressure or fever, he added.\nThe strain used in this clinical trial, Clostridium novyi-NT, had been weakened to prevent it from producing its toxin, which can be lethal in humans, Janku said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did provide some specific numbers on the scope of the benefit, but we found the wording confusing and unclear:\nThe bacteria germinated in the cancers of 11 out of the 24 patients, with tumor cells dying off as a result.\nTumor shrinkage of greater than 10 percent was observed in 23 percent of patients. However, Janku said this could be an underestimate since the infection causes surrounding tissue to become inflamed, making the lesion appear larger than it actually is.\nFollowing bacterial therapy, cancer stabilized in 21 patients. When both injected and uninjected lesions were included, the stable disease rate was 86 percent, the researchers reported.\nDid the tumor shrinkage occur in 23% of the 24 patients in trial, or the 11 patients in which the bacteria \u201cgerminated?\u201d It appears to be the latter, meaning it\u2019s an even tinier subset of patients who had tumor shrinkage greater than 10 percent\u2013just about 3 patients. (The story also could have explained why researchers picked 10 percent as a measuring point for tumor shrinkage. It did explain that the therapy could have caused inflammation that made the tumors harder to measure.)\nBased on the next sentence\u2013that 21 out of 24 patients had unchanged cancer\u2013the story would have been more clear had it simply explained that\u00a0most tumors neither significantly grew nor significantly shrunk after the therapy. Also, it\u2019s not clear when these measurements were taken\u2013if this was after a year, it seems notable that the majority had stable tumors. But if they measured tumors after just one week, it\u2019s not very surprising.\nContext is also lacking\u2013we don\u2019t know the cancer stage, what is considered a \u201cclinically important\u201d tumor shrinkage, and how the observed shrinkage compares with current treatments. Lastly,\u00a0all of this needs to be taken into consideration with the fact that there was no control group to compare these results against.", "answer": 0}, {"article": "CHICAGO -- Many patients treated with Byetta, a diabetes drug by Amylin Pharmaceuticals Inc. and Eli Lilly & Co., were able to maintain good blood-sugar control and also lose weight after three years on the drug, according to a study.\n\nThe study, described at the American Diabetes Association's annual meeting here, examines clinical data from the longest trial involving Byetta presented to date.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides absolute numbers (a percentage) of people in the study who achieved a blood sugar level (A1C) less than 7%, which is the national recommendation, although this goal\u00a0is not appropriate for all.\u00a0 The story also provides the proportion of people who reached an A1C of less than 6.5%.\u00a0 However, there appears to be no comparison group or reference to compare these numbers with.\u00a0 Readers don\u2019t know how much better these results might be compared to other treatment alternatives.\u00a0 So, although it appears absolute numbers are provided, readers don\u2019t have any sense for the absolute benefit these represent.\u00a0\u00a0 ", "answer": 0}, {"article": "The first figure is systolic pressure, generated when the heart is pumping, and the second figure is diastolic pressure, created when the heart is relaxing and filling with blood.\nThis is the first study that shows evidence of dietary nitrate supplementation's long-lasting benefit in a group of patients with high blood pressure.\nThe authors note that the reduction achieved in the active supplement group is close to that achieved by medication.\nThe patients in the active supplement group also experienced a 20 percent or so improvement in blood vessel dilation capacity, and their artery stiffness reduced by around 10 percent.\nTo put the importance of these findings in context: The authors note that large-scale observational studies show that for every 2 mmHg increase in blood pressure, the risk of death from heart disease goes up 7 percent and the risk of stroke by 10 percent.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains that people in the experimental group who consumed the nitrate-containing beetroot juice showed a reduction of 8/4 mmHg in their blood pressure\u00a0after drinking the juice.\u00a0 In addition, the experimental group showed as much as a 20 percent increase in blood vessel dilation, which may be helpful in reducing the risk of heart disease.\u00a0 No such changes appeared in those people taking the placebo. Finally, the story notes how the changes in blood pressure might be expected to influence overall cardiovascular risk: \u201cThe authors note that large-scale observational studies show that for every 2 mmHg increase in blood pressure, the risk of death from heart disease goes up 7% and from\u00a0stroke\u00a0by 10%.\u201d", "answer": 1}, {"article": "- People born without the CCR5 gene are generally healthy, but will deleting it have unforeseen consequences?\nThis is the first time researchers have permanently deleted a human gene and infused the altered cells back into patients.\nThe sixth man also had modified cells, but fewer than expected.\nThree months later, five men had three times the number of modified cells expected.\nDr. Jacob Lalezari, director of Quest Clinical Research of San Francisco, led the first test of this with the company and colleagues at the University of California in San Francisco and Los Angeles.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gave very specific details on what happened to trial subjects\u2019 cell counts \u2013 and over what span of time. Of course it\u2019s too soon to know if those lab results will translate into differences in the peoples\u2019 lives.\nBut a MedPage Today story carried a more significant statement from a member of the conference program committee:\u00a0 \u201cWe do not know yet from the experiments whether there is any antiviral activity.\u201d", "answer": 1}, {"article": "\u201cThe decreased risk of breast cancer in this group is something we totally didn\u2019t expect when we started the W.H.I.\nBut the data are reassuring for millions of middle-aged women without a uterus who take estrogen to relieve hot flashes and other menopause symptoms.\nThe research, part of the landmark Women\u2019s Health Initiative study, is likely to surprise women and their doctors, who for years have heard frightening news about the risks of hormone therapy.\nNobody is suggesting that women start using estrogen to prevent breast cancer, but the finding opens a potentially new avenue of research in the prevention of the disease.\nAlthough all the women in the estrogen study stopped using the treatment in 2004, the investigators have continued to monitor their health, as is typical in large clinical trials.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Mixed bag here. The story does some of this, giving readers a \u201cquantifier\u201d example about how many of 10,000 women might forgo heart attacks due to taking estrogen, based on the study\u2019s findings. But sadly, they don\u2019t give a similar quantifier for the perhaps exaggerated headline: \u201cEstrogen lowers breast cancer risk.\u201d\u00a0 The same type of absolute risk calculation shows that the margin of benefit, if it exists, would be small: 8 fewer cases per 10,000 women per year. There may be a statistically significant difference, but it is small.\u00a0 Because of this omission, we judge this one unsatisfactory.", "answer": 0}, {"article": "Elevated sweat chloride confirms that an infant actually has CF.\nThe findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers.\nThe biomarkers also point to other underlying mechanisms that contribute to the progression of CF and could lead to better therapeutic interventions earlier in life.\nBut there are some obstacles that complicate clinical decision-making, explains Britz-McKibbin, because sweat chloride can result in ambiguous diagnoses in some borderline cases and does not reveal how the disease might progress for individual patients.\nTesting for these biomarkers could be done in cases in which the chloride sweat test result is unclear, say researchers.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit here would appear to be that diagnostic testing for CF would be better able to identify infants who have CF, and possibly understand more about the expected course for individual patients \u2014 particularly patients with borderline results on the sweat chloride test currently used to diagnose CF in newborns. However, it\u2019s not clear how common these cases are. Are there a lot of patients who have borderline sweat chloride tests?\nIn addition, the release doesn\u2019t tell us how much better the new biomarkers are at diagnosing CF. It suggests that the new tests add accuracy to the diagnosis \u2014 but by how much? ", "answer": 0}, {"article": "\u201cUsing these multiple, possible endpoints was something unique to this study,\u201d Jaffe said.\nJaffe said the study\u2019s results are significant not only because they indicate adalimumab delays treatment failure, but also because the investigation considered several signs as causes for treatment failure.\n\u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\n\nThe study authors note, however, that patients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\nJaffe said the study focused on time to treatment failure because delaying or preventing inflammation is the key to successful treatment.\nPatients in the adalimumab group were also significantly less likely to experience treatment failure during the duration of the study (80 weeks) and they were at lower risk of treatment failure due to each of the four signs.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are well-represented in the release, and so is their context. By working adalimumab into the standard treatment, most of the key measurements of uveitis are held in check for nearly twice as long in a typical patient \u2014 24 weeks instead of 13 weeks.\nThis represents improvement \u2014 but not a cure \u2014 for a chronic disease.", "answer": 1}, {"article": "New York Eye and Ear Infirmary of Mount Sinai is ranked No.\nThis is the first study to demonstrate that among advanced cancer patients admitted to an inpatient oncology service, standardized use of triggers for palliative care consultation is associated with substantial improvement on multiple quality measures.\nPublished today in the Journal of Oncology Practice, the study also determined that a systemized process of referrals resulted in significant improvements in 30-day readmission rates, hospice referral, and receipt of chemotherapy after discharge in patients with advanced cancers.\n\u201cPalliative care involvement helps patients understand their prognosis, establish goals of care, and formulate discharge plans in line with those goals, and this study is the first to confirm the impact of using standardized criteria and automatic palliative care consultation on quality of cancer care.\u201d\n\nCo-authors of the study include Kerin Adelson, MD, Division of Hematology/Oncology at Yale University School of Medicine.\nPalliative Care Consults for Patients with Advanced Cancers Reduces Hospitalization and Improves Quality of Care\n\nIntegration of Palliative Care Improves Many Measures of Quality\n\nNewswise \u2014 (NEW YORK \u2014 March 15, 2017/Embargoed until March 17, 4:00 pm ET) Cancer patients admitted to the hospital with advanced stages of disease who were referred early to palliative care had decreased health care utilization and increased use of support services following discharge, according to a new study led by researchers at the Icahn School of Medicine at Mount Sinai.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers learn from this announcement that early referral to palliative care \u201cdecreased health care utilization and increased use of support services following discharge\u201d for cancer patients at advanced stages of the disease. But how much? Did health care utilization decrease by 1%? 5%? 40%? The specific results of the study are not reported. To be able to interpret the importance of these results, readers need numbers. Without that, the assertion by one of the researchers that hospitals across the country should adopt this practice appears tenuous.\nThe study in the Journal of Oncology Practice provided both relative and absolute risk numbers for the claimed benefits of palliative care (PC) referrals. It would have made the release much stronger had the absolute numbers been included.\nAmong patients that were part of the study in either the control group or the intervention group, 30-day hospital readmission rates decreased from 35% (17 of 48) of patients in the control group compared to 18% (13 of 65) of those receiving the intervention. Referrals to hospice increased from 14% (7 out of 48 patients) among controls to 26% (17 of 65 patients) of the intervention group, and receipt of chemotherapy after discharge decreased from 44% (21 of 48) of controls to 18% (12 of 65) of those in the intervention group.", "answer": 0}, {"article": "With Cognivue, patients sit before a video screen that shows a series of images, such as a group of dots, that move around and fluctuate in clarity.\nDuffy said his tool holds promise as a relatively inexpensive and easy way to test people\u2019s memory and ability to think.\nThe test, which has been around since 1975, offers only a broad indication of cognitive abilities and fails to pick up borderline problems, she said.\nBut the alternative involves referring patients for a battery of neuropsychiatric tests that can take hours to complete and cost $1,000 or more.\nThe device would be available only for use by medical professionals as part of a more comprehensive assessment of cognitive function.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The headline suggests that the FDA approved the test for \u201cdiagnosing dementia in the doctor\u2019s office.\u201d But the actual FDA approval notice says: \u201cThe Computerized Cognitive Assessment Aid is not intended as a\u00a0stand-alone or adjunctive diagnostic device.\u201d The story\u00a0does later qualify that the device \u201cis not intended to be a stand-alone diagnostic tool,\u201d but the FDA says the device isn\u2019t a diagnostic device at all, which is a confusing disparity. We acknowledge that reporters often don\u2019t have any control over their headlines but nonetheless the issue needs to be raised. We thought this needed more explanation.\nThe story suggests that this non invasive, simple and quick (10 minutes sitting at a computer terminal) is either more accurate or just about as accurate as a commonly used test called the Mini Mental State Exam and is easier to use.\u00a0 The suggestion is supported by comments from the inventor of the test and two primary care physicians.\u00a0\u00a0We are also told that the device/test was applied in a sample of 401 older adults who were classified as cognitively normal, slightly impaired or impaired and compared to the results of another test with the acronym SLUM.\u00a0 But, we are never provided with any information about the\u00a0test characteristics that have to do with accuracy (e.g. sensitivity, specificity) or how the two tests compared in the actual study. What were the rates of false positive and false negative results seen with Cognivue as compared to SLUM?\nTo the article\u2019s credit, it does bring up an important point about how the tool can be incorporated into physician workflow in a way that may make adoption easier (patient does the test right before or after seeing the doctor, for example). That\u2019s useful context, but not enough for Satisfactory rating here.", "answer": 0}, {"article": "Like rheumatoid arthritis, osteoarthritis is a chronic, degenerative joint disease.\nStudy researcher Gabriel Chodick, MD, called the risk reduction \"important and meaningful,\" but he says more research is needed to confirm the association.\nBetween 1998 and 2007, 2,578 new cases of rheumatoid arthritis were identified in this group.\nThe regular use of statins was associated with a 42% reduction in rheumatoid arthritis (RA) risk in a newly reported study of patients enrolled in one of Israel's largest health plans .\nBut it is not driven by inflammation, so statin use is not as likely to affect its development or progression.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story does not clearly explain what a 40 percent reduction in the risk of developing rheumatoid arthritis really means. How many fewer cases developed than were expected? The story doesn\u2019t say. It reports that the researchers reviewed medical records of almost 2 million health plan members in Israel and that about 2,500 new cases of rheumatoid arthritis were diagnosed during the study period. But readers can\u2019t tell from this information what the typical risk of rheumatoid arthritis might be, so they are left to ask: 40 percent of what?", "answer": 0}, {"article": "UCH-L1 is released by brain nerves when they\u2019re stressed, and its levels rise more rapidly immediately after injury and peak at eight hours.\nAnd because levels of GFAP tend to remain higher for many days, Papa says it might be useful in cases where patients don\u2019t come in immediately after a head injury, thinking they\u2019re okay, but see the doctor several days later because they\u2019re concerned.\n\u201cI don\u2019t think a blood will be the be-all and end-all but it would be a beautiful tool for us to have in the clinic to support a lot of our decision making.\u201d\n\nTesting for levels of UCH-L1, for example, might be helpful for emergency medical teams in an ambulance trying to assess whether a patient has any serious head injuries, since its levels peak in the hours immediately after a trauma.\nBut there aren\u2019t good ways to distinguish between mild blows that don\u2019t require additional care and mild to moderate traumatic brain injury (TBI), which could have more serious consequences.\nMORE: A New Blood Test to Diagnose Concussions On The Field\n\nIn the emergency room, a blood test for UCH-L1 could also help doctors decide which patients should get a CT scan \u2014 the higher their levels of the protein are, the more likely they are to have TBI and would benefit from a scan, while those with lower levels probably don\u2019t need one.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers should be informed of how many people with a concussion were accurately identified, and how many people without concussions were accurately ruled out. The story doesn\u2019t tell us, nor any other quantified benefits.", "answer": 0}, {"article": "If necessary, he suggests finding an indoor place to move, whether it's the gym, a staircase or a shopping mall.\nFortunately, new research shows there is a simple antidote: 30 minutes of exercise a day, year-round.\n\"Just 30 minutes a day of walking, riding a bike, doing yoga -- anything active, really -- can result in significant reduction of asthma symptoms.\"\nCould a prescription for exercise be the result of this study Bacon is hopeful.\nIt's something to keep in mind during winter months, when fitness levels tend to drop along with the temperature, and cold air provides another trigger for asthma symptoms.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release reported the benefits of physical activity in relative numbers, stating \u201cthose who engaged in optimal levels of physical activity on a regular basis were nearly two-and-a-half times more likely to have good control of their symptoms, compared with those who did no exercise.\u201d To which we respond:\u00a0Two-and-a-half times more than what? While the statistic is technically accurate, there is no translation of this into an absolute number that a reader could use to interpret the result \u2013 such as x% of those who exercise reported adequate control versus y% of those who did not. The news release also prefaced this statement with \u201cResults were overwhelmingly clear.\u201d But many questions were left unanswered. What does it mean to have \u201cgood control of their symptoms?\u201d And who exactly experienced these benefits? Does \u201coptimal levels of physical activity\u201d mean 30 minutes every day? More clarification would have been welcome here.", "answer": 0}, {"article": "If the child said a word, the parent repeated it and added something.\nMy impression is that this is an intervention that reduces the severity of autistic symptoms, rather than curing autism.\n\u201cThese results at follow-up are pretty consistent in showing the benefit of this early intervention for autism across a range of measures.\nNevertheless, for parents of children with autism, even a modest reduction would be worthwhile.\u201d\n\nDr Max Davie, of the Royal College of Paediatrics and Child Health, said it offered \u201ca hugely cheering message for families\u201d, while Uta Frith, emeritus professor of cognitive development at University College London, called it \u201ca remarkably positive story, because the intervention itself was neither intensive nor invasive\u201d.\nThe success of the preschool autism communication trial (Pact) has surprised even the researchers who designed it.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story attempts to quantify the benefits with this statement:\nAt the start of the trial, 50% of those in the control group who did not get the therapy and 55% of those who did were assessed as severely autistic. The children in the intervention group, though, got better. The proportion assessed as severe in the control group was 63% by the end of six years, compared with 46% in the intervention group.\nBut as we point out in the summary, there were some important limitations to this finding.", "answer": 0}, {"article": "\u201cThis is a first step,\u201d he said, \u201cand all these applications will require further work.\u201d But, he added, if the testing is successful, \u201cI think it will be very popular.\u201d\n\nThe idea for second skin originated more than a decade ago when Dr. R. Rox Anderson, a professor of dermatology at Harvard Medical School, was approached by Living Proof, which had been working on a polymer to be used as a hair product.\n\u201cWe were looking for safety, spreadability, adherence, and the right kind of mechanical and optical properties.\u201d\n\nThe \u201cskin\u201d can last for more than a day.\nThe skin still has to be able to breathe through this stuff.\n\u201cWhen we move skin, it doesn\u2019t snap back to what it used to be.\u201d\n\nWhat if there was a way to restore the elastic nature of skin?\nDr. Anderson listed what would be needed: \u201cIt has to be nearly invisible.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Though we\u2019re told there\u2019s a new published paper about several pilot studies, the story does not include any hard numbers from the research on what the measured benefits were. The photos included with the story\u2013do they represent a best-case scenario? They have the potential to skew reader perception.", "answer": 0}, {"article": "Needle-phobia, or trypanophobia, is a recognized medical condition that causes sufferers to avoid medical care.\nThe microneedle technology may also be used for other vaccinations, such as polio and measles, said Prausnitz.\nThe muscle into which needles deliver vaccine is not nearly as active immunologically.\nThe patch, which is lined with microscopic needles that dissolve into the skin, could provide a painless alternative to hypodermic needles and make visits to the doctor's office or clinic for a traditional flu shot a thing of the past.\nIn a mouse study reported Sunday in the online edition of Nature Medicine, Prausnitz's team found the patch improved the immune system's antibody memory and was more efficient at clearing the lungs of the flu virus, compared to a placebo and hypodermic needle-delivered vaccine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It is simply not accurate to state, as this story did in the first sentence, that this patch \"vaccinates against the flu\"\u00a0because it hasn\u2019t been tested in humans yet. We\u00a0also can\u2019t believe the story quoted a researcher saying the patch\u00a0\"appears to vaccinate against influenza at least as well and probably better than a traditional hypodermic needle.\" Again, these are mice, not people, we\u2019re talking about here, and so these statements\u00a0go far beyond what the evidence reasonably supports.", "answer": 0}, {"article": "\"Started looking in the cupboard and I saw pie pans and I said, 'These are perfect.\nThe last thing John Kanzius thought he'd ever do was try to cure cancer.\nHere's the important part: if clinical trials pan out - and there's still a long way to go - the Kanzius machine will zap cancer cells all through your body without the need for drugs or surgery and without side effects.\nKanzius put his hand in the field to demonstrate that radio waves are harmless to humans.\nIt was the worst kind of luck that gave Kanzius the idea to use radio waves to kill cancer cells: six years ago, he was diagnosed with terminal leukemia and since then has undergone 36 rounds of toxic chemotherapy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only evidence of benefits given is a brief description of the effects the technique appears to have had on the cells of rat tumors. Even within the realm of animal testing, there is no quantification of benefit.\u00a0 Were all cancer cells killed in all rabbits and rats tested?\u00a0 Some in all?\u00a0 Some in some?\u00a0 None in some?\u00a0 Sweeping statements such as \"They\u2019ve already shown that the Kanzius machine can heat nanoparticles and cook cancer to death in animals\" does nothing to educate viewers. \u00a0 ", "answer": 0}, {"article": "Scientists still haven\u2019t discovered a cure for the common cold, but researchers now say zinc may be the next best thing.\nAlthough a majority of trials have shown some benefit from zinc, many of them have been criticized for failing to \u201cmask\u201d the treatment, meaning the participants most likely knew they were using zinc, which may have skewed the results.\nThe review found that not only did zinc reduce the duration and severity of common cold symptoms, but regular zinc use also worked to prevent colds, leading to fewer school absences and less antibiotic use in children.\nSince that study, 18 more trials of zinc for colds have been conducted: 11 of them showed it to be a useful treatment, while seven of them showed no benefit, according to the review.\nThe authors declined to make recommendations about the optimal dose, formulation or duration of zinc use, saying that more work was needed before they could make recommendations.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story indicates that when zinc is taken within the first 24 hours of developing cold symptoms, it cuts the duration of a cold by an average of 1 day. No data from the review were provided regarding other outcomes, such as severity of symptoms, reduced absences from school, and reduced antibiotic use. Also, the story should have noted that a preventive effect was found after 5 months of zinc use and people who experienced a therapeutic benefit took zinc for at least 5 days during their cold.\u00a0", "answer": 0}, {"article": "Viagra, known generically as sildenafil, is sold by Pfizer Inc for erectile dysfunction and under the brand name Revatio to treat a heart condition called pulmonary hypertension.\nIt is not clear just how the drug is helping the mice, they reported in the Proceedings of the National Academy of Sciences, but they said it may be worth trying it as a treatment for muscular dystrophy.\nTests in mice genetically engineered to have a condition similar to Duchenne muscular dystrophy showed the drug could improve how the heart works, Joseph Beavoa of the University of Washington and colleagues at the University of North Carolina found.\n\u201cAlthough PDE5 inhibitors will certainly not cure DMD, the current studies suggest that they could be used in combination with current or future therapies,\u201d the researchers wrote.\nMany patients die of heart failure and most patients with the condition die before age 40.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n \nThe story has just a vague reference to treating heart symptoms. It does not offer any specific data, not even about the mice in this trial. \n ", "answer": 0}, {"article": "\u2022 Measure baseline omega-3 intake or status of study participants to determine the extent to which it confounds results.\n\"The 6 percent reduced risk among RCTs, coupled with an 18 percent risk reduction in prospective cohort studies -- which tend to include more real-life dietary scenarios over longer periods -- tell a compelling story about the importance of EPA and DHA omega-3s for cardiovascular health.\"\n\"It's also important that the observed risk reductions were even stronger in patient populations with elevated triglycerides and LDL cholesterol levels, two risk factors that affect more than one quarter of the American population.\"\n\"There are important public health implications related to reducing the risk of coronary heart disease, and therefore we are encouraged by the results of this comprehensive analysis,\" said Dr. Harry Rice, Vice President of Regulatory and Scientific Affairs for the Global Organization for EPA and DHA Omega-3s (GOED), which funded the study.\n\u2022 The study compared the results of RCTs, which explore interventions under strict clinical conditions, to those of prospective cohort studies that are observational, and followed larger populations for longer periods of time.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release tells readers that, among the RCTs, \u201cthere was a statistically significant reduction in [coronary heart disease] risk in higher risk populations, including\u202616 percent in those with high triglycerides and 14 percent in those with high LDL [low-density lipoprotein] cholesterol.\u201d So the release is claiming that seafood, supplements and pharmaceuticals offer a 16 percent reduction in risk of coronary heart disease for people with high triglycerides. That sounds good, right? But over what time span? A year? A lifetime? And how high does a person\u2019s trigylceride count need to be in order for that person to have \u201chigh triglycerides?\u201d The release doesn\u2019t tell us. And then things get really confusing. Consider this statement: \u201cA non-statistically significant 6 percent risk reduction among all populations in RCTs, a finding supported by a statistically significant 18 percent reduced risk of [coronary heart disease] among prospective cohort studies.\u201d Does the statistically significant finding somehow make the non-statistically significant finding more, well, significant? No. Does bundling those two things together into one sentence muddy the waters for readers? You bet. Does the release still fail to explain the time-frame it is using when discussing risk reduction? Yes.\nProviding readers with figures describing the absolute risk reduction would have been very helpful here. ", "answer": 0}, {"article": "Studies of adults find that social jet lag is associated with higher BMI, insulin resistance, depression, and a higher likelihood to engage in dangerous behaviors like smoking.\nBut even if later school start times only improve sleep time, that\u2019s a positive step for public health.\nThe study also found some preliminary evidence that later school start times were associated with better mental health outcomes.\nIt finds that when school starts up to an hour later, students typically do get around 19 minutes more sleep, on average.\nAnd many of the studies were short in duration, comparing sleep duration in snapshots before and after a school made a switch.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is specific about the average sleep advantages of a later start time among teenage participants in the 18 studies evaluated. For this reason, it rates satisfactory.\nHowever, its discussion of other benefits\u2014including fewer accidents involving teens behind the wheels of cars, mental health indices and actual school performance\u2014is general and, with respect to school performance, more optimistic than the meta-analysis\u00a0that is the centerpiece of the story.", "answer": 1}, {"article": "SAMe may influence the expression of genes involved in depression or alter the function of different receptors and structures that transport neurotransmitters in the brain.\nDr. Nelson, who was not involved in the Harvard study, said the results need to be replicated in a larger study, and that more information is needed on dosing, side effects and long-term treatment with SAMe, among other things.\nThat\u2019s probably the best hypothesis.\u201d\n\nOther studies have suggested that SAMe can relieve symptoms of depression.\nThe research offers hope to patients who haven\u2019t been helped by traditional antidepressant treatment.\n\u201cIn the last 60 years of depression research, all the treatments have focused on similar mechanisms of action.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re given the proportions of the active and control groups who showed improvement and experienced complete remission. The piece could\u2019ve been more specific about what improvement meant.\n It was too vague when summarizing the 2002 AHRQ analysis that found \u201cclinically meaningful benefits\u201d and that SAMe worked \u201cas well as tricyclic antidepressants.\u201d (See our comments on Novelty.)", "answer": 1}, {"article": "\"My impression is, even with the newer band, the results are not significantly better,\" he says.\nEven so, a majority of the patients in their small study said they were satisfied with the procedure.\nThe critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\nBut a spokesman for the company that manufactures Lap-Band says the study is flawed.\nBut some, including the manufacturer of the Lap-Band -- used in a technique called laparoscopic adjustable gastric banding -- take exception to the study, criticizing the small sample size and the number of patients lost to follow-up.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only benefit reported on in this story was the average loss of excess weight experienced by those who had had the procedure and in those who still had their Lap-Bands at the end of the study period.", "answer": 1}, {"article": ".\nThe rate of fractures in the treated women who had osteoporosis declined by 50 percent during the 10-year-long study.\nThe study, \"Effect of Growth Hormone Treatment on Fractures and Quality of Life in Osteoporosis - A 10-year Follow-up,\" was published online at http://press.\n\"Our study is the largest and longest controlled study of growth hormone treatment for osteoporosis in postmenopausal women to date,\" said one of the study's authors, Emily Krantz, MD, of S\u00f6dra \u00c4lvsborgs Hospital in Bor\u00e5s, Sweden.\nMore than half of the participants had fractured bones prior to the start of the study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release notes that the rate of bone fractures among study participants declined by 50 percent over the 10-year course of the study and provides an absolute measure of that benefit: 56 percent of participants had experienced a bone fracture before the study, and 28 percent had a bone fracture over the course of the study. We\u2019ll give credit for the quantification, however it must be noted that this before and after comparison is seriously limited in what it can tell us about the benefits of growth hormone treatment \u2014 something addressed below under the \u201cEvidence\u201d criterion.", "answer": 1}, {"article": "\"This is a very expensive drug,\" he said.\nDr. Michael A. Becker, a professor emeritus of medicine at the University of Chicago, described the findings as \"very promising.\"\n\"(And) this trial provides well-controlled evidence that this IL-1 blocker is effective in preventing acute gout flares in this setting,\" he added.\nHowever, he cautioned that the high cost of rilonacept will most likely curtail its use.\nTHURSDAY, Jan. 5, 2012 (HealthDay News) -- Preliminary findings suggest a drug used to treat another disease might also reduce painful flare-ups in gout patients starting new medication regimens.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that \u201cRilonacept patients were less likely to have flare-ups, with 15 percent experiencing flare-ups three-months into the study compared with 45 percent among the non-rilonacept group.\u201d\nBut not all flare-ups are equal.\nHow was a flare-up measured?\u00a0 The story doesn\u2019t explain.\nWas it a measurement of uric acid levels?\u00a0 Or was it patient self-reporting?\nIn other words, what difference did this make in subjects\u2019 lives?\u00a0 We can\u2019t judge from the story the way it was reported.", "answer": 0}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes an astonishing mess of the key data:\nAfter more than six years of tracking, the study found that 44% of the patients had tumors that had a 12% risk of recurrence within three years, which the researchers considered low risk. An additional 26% had a three-year recurrence risk of 22%, which researchers put in the high-risk group. The rest were in the middle.\nEven a reader lucky enough to have within easy reach a calculator and a high school student taking advanced statistics is unlikely to figure out what this means in practical terms.\nBut this is what you get when you report on abstracts far in advance of any possible publication.\u00a0 ", "answer": 0}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story starts with the premise that screening for bone density is recommended by many health care organizations and that doing so will lead to fewer bone fractures and, in the case of hip fractures, perhaps reduce deaths in men whose health declines after a fracture. The story says that the study \u201cfound women were about three times as likely as men (53% versus 18%) to be tested using a bone-density scan.\u201d But that doesn\u2019t tell us the benefits of doing the scan. The assumption is that scanning everyone who comes in with a fracture for bone density will lead to health improvement. Some proof to back that up would have been nice. The closest the story comes to this is an anecdotal reference to Kaiser Permanente in Southern California, which apparently started a screening program in 1997 and, since then, \u201cthe rate of hip fractures at Kaiser is down 40%.\u201d\nTo be clear, our understanding is that evidence supporting a fracture prevention benefit for screening in men doesn\u2019t exist, so the best the story could have done would be to extrapolate from studies involving women. The story doesn\u2019t go that far or acknowledge an evidence gap in this area. But that\u2019s an omission we\u2019ll penalize the story for below in the Evidence section, while ruling the Benefits description satisfactory.", "answer": 1}, {"article": "Steroids can cause severe weight gain, acne and the weakening of bones, among other side effects.\nMore patients on the drug had the required improvement in symptom severity.\nIt also changed the measurement of success and lengthened the trial to give the drug more time to work.\nThe company said high levels of the protein might spur the immune system to attach the body\u2019s own tissues.\nIn 2000, the company\u2019s share price soared to over $100 on anticipation that understanding the human DNA blueprint \u2014 the human genome \u2014 would lead to a cornucopia of drugs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided quantitative information about meaningful improvement of symptoms, comparing two doses of the drug with placebo. \u00a0However \u2013 the story gave no insight about what symptoms it was measuring and whether the difference between the two doses significantly differed from one another. \u00a0It should have provided more detail about the nature of the improvements observed.", "answer": 0}, {"article": "Immunotherapy moves to the front lines in fight against lung cancer\n\nThe cancer death rate has dropped again.\nExperts said it was especially significant that the study showed that patients benefited from the Keytruda-chemo combination regardless of the levels of a protein, called PD-L1, found on their cancer cells.\nAnd he said the trial showed that \u201ctumor mutational burden\u201d is a reliable way to predict who will benefit from the medications.\nDrew Pardoll, director of Hopkins\u2019 Bloomberg-Kimmel Institute for Cancer Immunotherapy, said that it is too early to know whether the findings will translate into longer survival.\nThe patients experienced a significantly longer period during which their disease did not worsen, compared with people who received only chemotherapy, said Memorial Sloan Kettering Cancer Center oncologist Matthew Hellmann, who led the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "When it comes to the overall survival benefit, the story reports that after a median follow-up time of 10.5 months patients who received both Keytruda and chemotherapy were 51 percent less likely to die, compared with patients who received only chemo.\nBut actual percentages aren\u2019t given. According to the study, the estimated proportion of patients who were alive at 12 months was 69% in the combination group and 49% in the chemo-only group.\nThe story also describes \u2014 but doesn\u2019t give numerical data \u2014 on a different Keytruda trial that it says \u201cshowed that the medication prolonged survival even when used alone, compared with chemo.\u201d\nThe story mentions two other immunotherapy lung cancer studies, one using two medications called Opdivo and Yervoy to treat newly diagnosed patients with advanced non-small cell lung cancer with a high number of mutations in their tumors, and another treating patients with early-stage lung cancer with Opdivo before and after surgery. Only some data were reported for those studies.", "answer": 0}, {"article": "Evofem\u2019s Amphora gel works by regulating vaginal pH within the normal range of 3.5 to 4.5, creating a hostile environment for sperm and certain viral and bacterial pathogens that can cause sexually transmitted diseases.\nAmphora was found to have an 86 percent efficacy rate in avoiding pregnancies and no serious side-effects were observed in the study, which evaluated about 1,400 healthy women belonging to the age group 18-35 years, Evofem said.\nThe rate stands at about 91 percent for oral pills and intrauterine devices, according to brokerage Roth Capital Partners.\nEvofem is also testing Amphora as a preventive treatment for chlamydia and gonorrhea - two of the world\u2019s most common sexually transmitted infections.\nThe company plans to resubmit the marketing application for Amphora in the second quarter next year and if approved, plans to launch the product in January 2020.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story briefly describes a study in 1,400 young women, from which researchers calculated that the gel had an 86% efficacy rate \u2014 a common measure of birth control efficacy. However, it could have explained that better: In the contraceptive research world, this generally means that the failure rate is 14 pregnancies per 100 women in a year. But researchers only studied the gel for seven menstrual cycles.\nThe story compares this pregnancy rate to a couple of of other forms of birth control, which is good, but it\u2019s worth pointing out that those failure rates have far more evidence behind them. The efficacy rate for this new product is based on just one industry study.\nAlso, the story makes a vague reference that the gel may kill \u201ccertain viral and bacterial pathogens that can cause sexually transmitted diseases.\u201d Only at the end of the story do we find out that researchers have no data yet for this claim.", "answer": 1}, {"article": "\"We don't want to treat any man unnecessarily with that type of treatment.\nThese findings are good news for some men, since the effects of short term of hormone therapy are reversible, D'Amico said.\nOverall, hormone therapy reduced the risk of dying from prostate cancer over 10 years from 8 percent to 4 percent, Jones said.\nHe noted that the radiation treatments in use today differ from those given in 1994 when the trial began.\nBut when the researchers looked closely at those findings, they found that patients with low-risk prostate cancer did not need hormone therapy because the chance they would survive with radiation alone was already almost 99 percent, Jones said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided a clear description of the potential benefit seen in the group of men with intermediate risk prostate cancer who were treatment with male hormone therapy in addition to radiation therapy alone.", "answer": 1}, {"article": "One therapy at M.D.\nNow, because drugs are mostly tested on patients whose cancer has resisted previous treatment, it's usually used on tumors advanced to often fatal stages.\nThat's why immunotherapy's greatest successes will come when it can be used early in treatment, they say.\nThe treatment \u2014 shots that grab the immune system and jolt it to fight against rebel tumor cells \u2014 has been a dream for more than a century.\nResearchers acknowledge immunotherapy's promise is furthest from realization for bulky solid tumors, perhaps too advanced for the immune system to beat.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of immunotherapy.", "answer": 0}, {"article": "No one knows why some women have this capability and others do not, but for those who lack it the Inovio vaccine is \"giving our immune system a little boost,\" Kim said.\nThe vaccine consists of three injections in the arm over three months, Kim said.\nThe vaccine trains T-cells in the body to go after cervical cells with potentially cancerous genes embedded in them.\nThe phase 1 results are very early in the experimentation of this vaccine.\nGiven those drawbacks, it\u2019s not appropriate to draw too many conclusions from this study, says Dr. Diane Harper, a prominent HPV researcher at the University of Missouri \u2013 Kansas City\u2019s School of Medicine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t quantify the benefits of the vaccine in the first clinical trial.", "answer": 0}, {"article": ".\nShah and Mazhari say that their patients, many of whom have undergone both kinds of catheterizations, much prefer the wrist approach.\n\"I think there is a reluctance among physicians who are used to doing procedures a certain way\" to change, said Mazhari, who learned to do the procedure last year and uses it about 80 percent of the time.\nShe and others say they know of no other physician in the Washington area who favors the radial approach.\nRaybuck, who learned to perform the procedure in Quebec 12 years ago, estimates he uses it fewer than two dozen times annually, and only when circumstances require it.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit of the treatment was presented in terms of patient comfort and time, and presented quantitative information indicating the radial approach results in a reduction in bleeding complications as compared with the femoral artery. But it did not provide any data about the outcomes of the procedure, namely, \"How did it do in opening arteries?\"\u00a0 It is interesting to note that the meta-analysis cited in the story concluded that additional studies are needed to better define the role of this approach, which was not mentioned in the story.\u00a0 ", "answer": 0}, {"article": "For more information, click here.\nThe hope is that patients can train their body to eat in a much healthier fashion without feeling overly hungry.\nIn addition to eliminating the scarring and risks involved with more invasive options, Chattoo said that the recovery time is also much faster.\nChattoo said that even if the balloon were to pop, the saline would be absorbed and pose no harm to the patient.\nDr. Prem Chattoo, a New York based gastroenterologist, told FoxNews.com that the balloon is placed it into the stomach through the mouth.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not address benefits in any kind of meaningful way, much less offer any quantification of the benefits. Instead, the story tells readers what the \u201cobjective\u201d of Orbera is. It also offers an anecdote from one patient who used Orbera and credited it with helping her lose weight.\u00a0Is this one patient\u2019s experience normal for other users of Orbera? The story doesn\u2019t tell us. Other than this one patient\u2019s testimony, the story offers no evidence that Orbera works at all, much less how well it might work. Is the weight loss short-term or long-term? Obesity is a chronic disease, but this device is temporary. How does that impact the patient\u2019s weight in the long range?\nThe story also doesn\u2019t tell readers how weight loss might be related to an individual\u2019s actual health. Instead, it notes that Orbera should not be used by people who are \u201cmorbidly obese.\u201d The story says Orbera is for people with a body mass index of 30 to 40 and \u201cis meant for people looking for an extra jumpstart on a diet, whether the purpose is cosmetic or for health reasons.\u201d Why that BMI range? Another question the story doesn\u2019t answer.", "answer": 0}, {"article": "Breast cancer strikes more than 180,000 women each year in the United States and kills more than 40,000, making it the most common form of cancer after skin cancer and second leading cancer killer among women.\nWhile welcomed by some patient advocates and doctors, the $1,625 test raises concerns among others.\n\"There is at least a significant chance this test will could falsely reassure some women and alarm others,\" said Eric Winer, a breast cancer expert at Harvard Medical School and a spokesman for the American Society of Clinical Oncology.\nAn FDA spokeswoman said the agency had just become aware of the new test and could not say whether it would take any action, though she noted that in August the agency sent a letter expressing concern to another company marketing a questionable genetic test for ovarian cancer.\nPreviously, the only tests for breast cancer risk were for relatively rare genes, leaving most women with no way to assess their individual genetic predisposition.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It is not clear how this test improves on these current practice as there was no evidence presented about it. The story appropriately expresses caution when presenting the value of this new test to predict a woman\u2019s lifetime risk of developing cancer.\u00a0 There is a wide range of experts interviewed, all of whom express concern about the current available evidence for the predictive value of this test.\u00a0 Most experts advise against women taking this test, and the American Cancer Society does not promote the test.", "answer": 1}, {"article": "A 6-month supply of vitamin D supplements can be bought for less than $10, and many multivitamins contain the recommended daily dose of vitamin D.\n\nAs for calcium, the NIH advises 1,000 mg per day for men ages19-70, and then 1,200 mg per day for men older than 70.\nDespite the findings, people still need to get enough calcium and vitamin D to reduce the risk of osteoporosis, or bone thinning, said Dr. Mone Zaidi, an osteoporosis researcher at the Mount Sinai School of Medicine in New York, who was not involved in the study.\nHowever, there isn\u2019t enough data to say if vitamin D can help treat or prevent these diseases, Zaidi said.\nAdding the supplements to the exercise program provided no extra benefit, hinting that the men already had enough vitamin D and calcium in their diets to be able to boost their bone strength through exercise alone.\nHowever, exercise did boost bone mineral density, a proxy for bone strength, their report shows.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "From a purist\u2019s perspective, we wish the story had quantified the benefit seen from exercise.\u00a0 We\u2019re told that adding supplements to the exercise program didn\u2019t provide any extra benefit.\u00a0 But just what was the degree of benefit from exercise?\u00a0 We\u2019re never told.", "answer": 0}, {"article": "An enzyme is a protein that performs a chemical reaction.\n\"It will probably be helpful to someone who gets a low-level exposure [to glutens] by accident,\" he said.\nThe re-engineered enzyme, named KumaMax, appears to be highly effective, at least in a test tube.\nMurray said that dismantling 95 percent of the protein component that is thought to trigger celiac disease may still not be enough to provide celiac patients protection.\n\"People need alternatives, and this is an example of the scientific community taking novel approaches to helping people with celiac disease,\" Murray said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is far more\u00a0generous in discussing potential benefits than these results warrant. Quoting a study author,\u00a0the story\u00a0suggests that patients with mild cases of celiac disease\u00a0could \u201cpop one [pill] before each meal and eat anything they want.\u201d\u00a0Really? Based on a single test tube experiment?\u00a0Even if the enzyme was capable of dismantling\u00a095%\u00a0of the harmful protein, as the story suggests,\u00a0we\u2019re never told how quickly\u00a0the protein\u00a0was neutralized, or how much enzyme was\u00a0needed to break down how much\u00a0gluten, or what amount of actual food the gluten in the test corresponded to.\u00a0In other words, we\u2019re given no reason to believe that these data have any real-world application to celiac patients at this time, and so such\u00a0speculation would only be acceptable if accompanied by strongly worded caveats. Unfortunately, the only caveats\u00a0come at the very end of the story, long after it has been\u00a0suggested that the pill might allow celiac patients to \u201ceat freely.\u201d", "answer": 0}, {"article": "\"Most people, especially athletes, when they had hip symptoms, usually they just got diagnosed as a chronic groin pull,\" said J.W.\nAnd they've found that it can be fixed using arthroscopic surgery, which uses narrow instruments inserted through smaller incisions than traditional surgery.\nBut those experiencing hip pain or stiffness have had more-limited options.\nWith the hip, however, doctors using arthroscopes discovered a host of conditions, including labrum tears and FAI, that had not been recognized.\nIn the past 10 to 15 years, doctors have discovered one specific cause of hip pain: a tear in the acetabular labrum, a condition in which the cartilage that lines the hip socket is damaged.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n \nThe story provides no quantification of benefit. The anecdotal evidence of long-term benefit provided by one surgeon\u2013that \u201chip arthroscopy may be a way of delaying or even possibly preventing hip arthritis\u201d\u2013is controversial, and viewed with skepticism by many experts. (Clin Orthop Rel Res 2009;467:605-7) ", "answer": 0}, {"article": "\"Usually we expect the results of a phase 1 clinical trial to give us data that we can use to guide the results of future treatments.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\nWorking with Borges's Young Women's Breast Cancer Translational Program at CU Cancer Center, young investigator Elena Shagisultanova, MD, PhD, recently earned a $1.4m competitive ASPIRE grant from Pfizer, Inc., to conduct a clinical trial exploring the use of tucatinib against so-called \"triple positive\" breast cancer - those cancers driven by both estrogen and progesterone receptors and the HER2/neu oncogene.\n'There are women who are alive today because of this drug,' says University of Colorado Cancer center researcher\n\nPhase 1 clinical trial data published this week in the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer.\nTwenty-seven percent of these heavily pretreated patients saw clinical benefit from the drug, with at least \"stable disease\" at 24 or more weeks after the start of treatment.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The discussion of benefits is somewhat confusing. The news release says that 27% of the women treated with tucatinib \u201csaw clinical benefit\u201d from the drug. However, the article itself states that evaluation of the drug\u2019s impact was possible for only 35 women, and of these women, 20 showed no progression of their disease, while there was a \u201cpartial response\u201d for three women, meaning that their tumors shrank by at least 50%. The most important benefit identified by the original study actually was that tucatinib caused less frequent and less severe side effects (including diarrhea and rash) than the alternatives currently used in treating these types of breast cancers. The news release barely mentioned this finding, stating simply that the drug \u201chas a very favorable side effect profile\u201d without explaining what that means.", "answer": 0}, {"article": "The U.S. Centers for Disease Control and Prevention has more on hepatitis C.\nThe greater possibility of a cure and fewer side effects, in turn, will lead more people who think they have hepatitis C to \"come out of the woodwork,\" said Schiff, who's familiar with the study findings.\nCombination treatments using these drugs will become the standard treatment for many people, he said, and boost cure rates into the range of 70 to 80 percent.\nHowever, Meanwell said, it could become part of a combination treatment of several drugs.\nStill, the drug -- or others like it in development -- could add to the power of new drugs in the pipeline that are poised to cure many more people with hepatitis C, said Dr. Eugene R. Schiff, director of the University of Miami's Center for Liver Diseases.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "According to the story, patients who received BMS-790052 had lower levels of the hepatitis-C virus in their bodies for several days.\u00a0While this is an appropriately\u00a0sober description of an early phase clinical test, the discussion of the other two experimental drugs mentioned in the article was, as discussed above,\u00a0not nearly as judicious.\u00a0Saying these unapproved drugs will\u00a0\"boost\u00a0cure rates,\" without delving into any of the\u00a0evidence which supports the claim, strikes\u00a0us as hype rather than help.\u00a0\u00a0", "answer": 0}, {"article": "Rates are rising, in part because tanning became fashionable.\nNew data about to be released to a meeting of cancer specialists shows that 40 percent of the patients who have been taking the drug are still alive three years later.\nThat compares to about 5 percent of patients given the standard therapy, interleukin, the American Society for Clinical Oncology (ASCO) says.\nAbout 15 percent of these patients have what\u2019s called a complete remission, meaning there is no trace of their tumors.\n\u201cThis is huge in the melanoma community,\u201d said Tim Turnham, executive director of the Melanoma Research Foundation.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re given the total study population of 655 people with advanced melanoma, and how the average patient lived 2 years. The story also notes a 3-year survival of 40%, which the headline teases, and notes a 15% \u201ccomplete remission\u201d result. We\u2019re also glad the story was frank about the fact that 60% of patients didn\u2019t live three years.\nThe story does a nice job putting those numbers into perspective by quoting Tim Turnham, executive director of the Melanoma Research Foundation, who notes people with a similar diagnosis typically only live 11 months.\nAlthough no study can account for all variables, a doubling of lifespan with limited side effects is worth writing home about.", "answer": 1}, {"article": "Multiple neurological disorders, including Parkinson\u2019s disease and dementia with Lewy bodies, involve the abnormal clumping of a protein called alpha-synuclein into brain deposits called Lewy bodies.\nImportantly, test results were available within two days, compared to related assays that require up to 13 days.\nThis research was supported in part by NIH funding awards ZIA AI001086-08, AGO5131, and PHS P30-AG010133.\nThe test correctly excluded all the 31 controls and diagnosed both Parkinson\u2019s disease and dementia with Lewy bodies with 93 percent accuracy.\nThe research findings were published in Acta Neuropathologica Communications.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release says the test \u201ccorrectly excluded all the 31 controls and diagnosed both Parkinson\u2019s disease and dementia with Lewy bodies with 93 percent accuracy.\u201d The author also noted the number of people tested.", "answer": 1}, {"article": "\"Coronary artery disease involves not only the blockage of major arteries, but the death of small vessels, or capillaries, of the heart muscle,\" he says.\nThe patients received 10 such injections during a single catheterization procedure.\nPatients were given a drug for several days to increase the number of CD34+ stem cells in the blood.\nResults from a pivotal study of the treatment were reported today in the American Heart Association (AHA) journal Circulation Research.\nThe approach also showed promise in a 2007 pilot study involving fewer than 30 patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Again, the bulleted breakdown of impact on number of angina attacks, exercise tolerance test scores, and nitroglycerin use was appreciated.", "answer": 1}, {"article": "Nov. 24, 2016.\n\u201cIt\u2019s exciting to think we may have a therapy that has the potential to improve response rates in this group of high-risk patients.\u201d\n\nThe research is supported by an AML-SPORE grant and the Genomics of AML Program Project grant, both from the National Cancer Institute at the National Institutes of Health (NIH), grant numbers P50 CA171963 and P01 CA101937.\n\u201cWhat\u2019s really unique here is that all the patients in the study with TP53 mutations had a response to decitabine and achieved an initial remission,\u201d said the study\u2019s senior author, Timothy J. Ley, MD, the Lewis T. and Rosalind B. Apple Professor of Medicine, noting that in AML, TP53 mutations have been correlated with an extremely poor prognosis.\nBut, remarkably, all 21 patients whose leukemia cells carried TP53 mutations went into remission.\n\u201cWith standard aggressive chemotherapy, we only see about 20 to 30 percent of these patients achieving remission, which is the critical first step to have a chance to cure patients with additional therapies.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release describes the benefit of the preliminary trial in sufficient depth and with appropriate cautions. It relates that each of the 21 patients with TP53 mutations had a remission, compared to 46 percent of the entire trial group of 116 that achieved some remission following treatment. According to the release, standard treatment typically induces remission in about 20 to 30 percent of patients with TP53 mutations.\u00a0 While the numbers look good from this trial, the researchers note that larger studies need to be done.", "answer": 1}, {"article": "\"I could ride a bike!\nThere were other things the 12-year-old boy said he would do if he had two hands.\nHe was wrapped in the joy of leading and advising students on how to help children like himself,\" she wrote in her iReport.\nThey gave it to Alex for free.\nIn truth, she had been more concerned about getting him therapy for his autism-related delays -- the limb difference was secondary.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that this sort of 3D printed arm can be made to look really cool. Other than that, it doesn\u2019t say anything about how well the arm actually works. The cheery impression conveyed by the story oversells the performance of this sort of device. The website of the E-Nable group mentioned in this story cautions that their 3D printed hands \u201cshould be seen as TOOLS and not a fully functional prosthetic device.\u201d", "answer": 0}, {"article": "The oldest cyclists had less muscular power and mass than those in their 50s and early 60s and considerably lower overall aerobic capacities.\nBut even the oldest cyclists in this study averaged barely 5 seconds for the walk, which is \u201cwell within the norm reported for healthy young adults,\u201d the study authors write.\nBut even so, both of those measures were higher among the oldest cyclists than would be considered average among people aged 70 or above.\nOn almost all measures, their physical functioning remained fairly stable across the decades and was much closer to that of young adults than of people their age.\nMany older people require at least 7 seconds to complete the task, with those requiring 9 or 10 seconds considered to be on the cusp of frailty, Dr. Harridge said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story made a reasonable attempt to quantify the study results in a way that would make sense to readers. It explained what the \u201cTimed Up and Go\u201d test is, and compared the results from the study participants with those of typical older adults and normal young adults.", "answer": 1}, {"article": "It is the inception of an entirely new way of treating ED that has never been seen before,\u201d he said.\nInitial findings showed two-thirds of men who underwent the 1- to 2-hour procedure improved by at least 4 points on the 30-point Internal Index of Erectile Dysfunction scale, he said.\nHe also noted that men who take certain drugs for heart disease cannot use the popular pills.\n\u201cED is largely a vascular disease and that\u2019s why Medtronic was interested in this,\u201d said Dr. Jason Rogers of UC Davis Medical Center, one of the researchers of the company-sponsored trial.\nThe medical device maker said it completed an initial feasibility study of 30 men, average age of 60, who suffered from erectile dysfunction (ED).\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As stated above in the \u201cevidence\u201d criterion, the potential benefit wasn\u2019t made clear.\u00a0 There was no critical evaluation or explanation of what it means to improve by 4 points on the 30-point index of erectile dysfunction scale.\nWhat difference does such an improvement mean in men\u2019s lives?\nBasically, to interpret the results, we would also need to know baseline function and then post-procedure function. More interpretable data would be responses to specific standard questions about erectile function, e.g., whether erections were firm enough for intercourse, how often did the man have an erection when he wanted one.", "answer": 0}, {"article": "Each person's genome, or complete set of DNA, is like a word that's the length of 3 billion characters; but spelled with only the letters A, T, C or G. Traditional DNA sequencing techniques decode sections of DNA 700 characters at a time, while NGS takes advantage of parallel computing capabilities, enabling scientists to decode millions of DNA fragments.\nIf successful, the researchers say the type of blood test in development also may be useful for other disorders, such as infant leukemia.\nIn the study, the research team profiled blood samples collected in a blinded study from children and adolescents 9-19 years to explore whether patients with spastic CP showed differences at the cellular level that routine orthopedic patients (needing ACL repairs, spinal fusions or other surgeries) did not.\nIn fact, there is no national surveillance here, but the CDC estimates that 1 in 323 American children have the condition.\nThe earlier the diagnosis, the earlier we can direct therapies at the child.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t provide much numerical context to tell us how this test would benefit patients. It does state that the test predicted with 73% accuracy whether a blood sample came from a child with CP. This phrasing could be misleading to readers since 73% accuracy means that just over one-in-four of the samples was wrong.", "answer": 0}, {"article": "Moderate-fat diet with one avocado a day lowered 'bad' cholesterol by 13.5 mg/dL\n\nThe researchers found that participants' levels of low-density lipoprotein (LDL) - referred to as the \"bad\" cholesterol - were an average of 8.3 milligrams per deciliter (mg/dL) lower after following the lower-fat diet without an avocado and 7.4 mg/dL lower after following the moderate-fat diet without an avocado, compared with their baseline average.\nAlthough these findings demonstrate that an avocado a day alongside a moderate-fat diet has the potential to reduce bad cholesterol, the team notes that their research was a controlled feeding study.\nWhat is more, the team found that a number of additional blood measurements - such as total cholesterol, small dense LDL, triglycerides and non-HDL (high-density lipoprotein) - were better after participants followed the moderate-fat diet with one avocado a day, compared with the other two diets.\nStill, the team believes their findings indicate that people should consider replacing saturated fatty acids in their diet with healthier fats from avocados and other sources.\nIt should be noted that this research was supported by the Hass Avocado Board, but the researchers say the organization played no other role in the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The reduction in LDL or \u201cbad\u201d cholesterol levels are clearly stated for each study group referenced in the article. However, we\u2019re never told what the participants\u2019 baseline LDL cholesterol values were, so it\u2019s difficult to know how meaningful these changes are. The competing NBC story, by comparison, told us that an LDL level below 100 is considered healthy, so the reader has some context from which to judge the 13-point drop seen in the study.\nThe story also fails to communicate any bottom line assessment of what the findings mean for outcomes that matter to readers \u2014 for example, their risk of suffering a heart attack or stroke. It doesn\u2019t explain that LDL is one of many factors that may affect the likelihood of suffering heart disease. To provide the appropriate context, the story might have communicated how the changes seen in the study would affect an individual\u2019s 10-year risk of suffering a heart attack or stroke.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The absolute difference in heart disease risk between women who took hormones and those who did not, and the differences among age groups, are not provided. ", "answer": 0}, {"article": "\"Some people are doing three on and three off.\"\n\"So although we believe there is an increased risk of these unusual fractures, it doesn't outweigh the benefit\" of taking osteoporosis drugs.\nStill, the accumulating evidence that there is a risk of these serious, unusual fractures associated with bisphosphonates is getting a lot of attention in the medical community.\nBut the \"absolute risk\" of these unusual fractures is still pretty low \u2014 13 fractures per year for every 10,000 people taking bisphosphonates for five years or longer.\nThe idea is that perhaps they'd get the osteoporosis benefit without the risks of osteonecrosis and unusual fractures.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did a good job explaining the tradeoffs of benefits and harms and quotes a doctor who worries that fear of rare events may be preventing women from taking drugs that could save them from the typical hip fractures.\nIf only the article took the extra step by talking about treatment benefits in absolute terms, rather than relative. The competing Reuters article tries to put the absolute benefit in perspective by noting that about half of people with osteoporosis will have a fracture in their lifetime.", "answer": 1}, {"article": "Hyperbaric wound treatment, often for diabetics, is booming.\nHyperbaric therapy, he said, can return them to full function, even years after the injury.\nOften, Efrati and others say, injured brain cells don't die, but may persist for years or decades, alive but hobbled.\nThe organ requires large amounts of energy under normal circumstances, and even more to heal when injured.\nThe nature of the human brain makes it particularly susceptible to chronic injury.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It\u2019s made clear that for at least some of the research, no benefit was found\u2013that it didn\u2019t work. For the studies that are mentioned that did see a positive benefit to hyperbaric therapy, the results are not quantified.\nAlso, there were some details that had the potential to confuse readers about the potential benefits. First, the story uses two anecdotes of dramatic improvement with the therapy, and this runs the risk of misleading readers. It\u2019s not until the very end that we find out that \u201csuch anecdotes are not the same as rigorous scientific research.\u201d\nOne of these anecdotes involved a woman recovering from brain tumor removal. The mechanisms of injury are very different from a mild traumatic brain injury and post-concussion syndrome.\nLastly, this quote was problematic:\nEfrati said the brain is no different from any other part of the body. Pressurized oxygen has the power to repair many kinds of tissue damage. \u201cA non-healing wound in the leg and a non-healing wound in the brain,\u201d he said, \u201cthey are the same basic thing.\u201d\nThe statement that a wounded brain and a wounded leg are basically the same thing isn\u2019t quite accurate: One is typified by damage to brain cells, which are notoriously slower growing than soft tissue cells in the legs.", "answer": 0}, {"article": "Sigmund Freud often included one of his dogs in psychoanalysis sessions.\nMore generally, Serpell said, the popular idea that pets make you happier \u201cis not a harmless distortion.\nAnd that\u2019s just as important.\u201d\n\nFocusing too much on scientific support sometimes feels like a form of \u201cphysics envy,\u201d Beck added, \u201cwhere you try to quantify everything without appreciating it.\u201d\n\nBut there are good reasons for rigorous research on animals and mental health.\nIn other words, people are recognizing that anecdote isn\u2019t enough.\u201d\n\nUsing animals in mental health settings is nothing new.\nCherry-picked positive results also are a problem, as he says happens in promotional materials from the Human-Animal Bond Research Initiative (HABRI).\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a tricky one, given that the focus of the story is on the dearth of quantifiable benefits associated with therapy animals. So, what do we look for? Well, in this case, we looked for some meaningful, big-picture discussion of benefits. For example, the story notes that the body of evidence regarding therapy animals \u201csometimes has shown positive short-term effects, often found no effect and occasionally identified higher rates of distress.\u201d Is that quantifiable? No. Does it offer meaningful insight into the nature of benefits found in a wide variety of studies on the subject? Yes. Given the thrust of the story, and the in-depth discussion of benefits (or lack thereof), we think this qualifies for a Satisfactory rating.", "answer": 1}, {"article": "Doppler ultrasound, done in the third trimester, is an established way to monitor high-risk pregnancies \u2014 those complicated by problems like poor fetal growth or health conditions in the mother, such as high blood pressure and heart and kidney diseases.\nOne thing that is clear, the researcher stressed, is that Doppler ultrasound is not necessary for women with average, healthy pregnancies.\nAnother question, Alfirevic said, is whether ultrasounds of blood vessels other than the umbilical artery might improve pregnancy outcomes.\nHowever, with Doppler an established technique for monitoring high-risk pregnancies, Alfirevic said it is very unlikely that any future studies will test Doppler against no Doppler \u2014 as most studies in this review did.\nBut in the new review, researchers found that across 16 studies of more than 10,000 high-risk pregnancies, Doppler ultrasound testing was linked to a 29 percent reduction in fetal and newborn deaths.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story clearly states the reduction in fetal death rates the review authors calculated by combining the results of the studies ithey looked at. It reports the absolute risk calculation of fetal or newborn deaths (1.7 percent among women who did not receive ultrasound monitoring vs. 1.2 percent among those who did). This reporting of absolute (as opposed to relative) risk reduction is a strong point of the story since it conveys to readers that while the intervention did improve outcomes, the underlying risk is small. We only wish, however, that the story had cited the Number Needed to Test that was included in the study \u2013 203 would need to be tested in order to find one case of fetal distress that would otherwise not have been seen using other routine exams.\u00a0\u00a0", "answer": 1}, {"article": "\u201cThere is a lot more to be done to fill in the research on the biological mechanism,\u2019\u2019 Dr. Horne said.\n\u201cWe were able to replicate the findings and show that people who fast routinely have a lower prevalence of coronary disease.\u2019\u2019\n\nThe downside of the study is that it didn\u2019t ask for specific details on the type and duration of fasting among the patients.\nThat\u2019s the finding of a new study from doctors in Utah who looked at the relationship between periodic fasting and cardiovascular disease.\nBecause about 90 percent of the patients were Mormons, a faith that encourages its members to fast for one day a month, the doctors expected to find a relatively high rate of regular fasting among the study participants.\n\u201cBut what it does suggest is that fasting is not a marker for other healthy lifestyle behaviors.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that \u201cpeople who fasted regularly had a 58 percent lower risk of coronary disease compared with those who said they didn\u2019t fast.\u201d\u00a0 But 58% of what?\u00a0 The story could have noted baseline risk in the general population or in people diagnosed with coronary heart disease.\u00a0 But even in the latter category, that\u2019s a very wide spectrum of disease.\u00a0 All of which shows how the 58% figure lacks any context for readers.", "answer": 0}, {"article": "That 1.7 percent difference is not considered statistically significant.\nAbbott Laboratories' newly approved Absorb stent comes with one important caveat: it hasn't yet been shown to be safer than older metal implants.\nThe new stent is designed to gradually dissolve over three years.\nDoctors who studied Absorb said it may take several years before its advantages become clear.\nIn the company study submitted to the FDA, patients who got Absorb fared about as well as those receiving Abbott's older metal stent after one year.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A major message of this story, to its credit, is that the benefit\u00a0of these dissolving stents has not yet been established\u2013there is no data yet. This is important, because the whole point of designing a dissolvable stent is to minimize longer-ranging complications resulting from metal stents.\nThe story does briefly describe a company-conducted study. It says \u201cpatients who got Absorb fared about as well as those receiving Abbott\u2019s older metal stent after one year.\u201d However, we\u2019re not told really what that means in terms of survival and reduced cardiac events.", "answer": 1}, {"article": "Colorectal cancer is the third most common cancer diagnosed in both men and women (excluding skin cancers) and a leading cause of cancer death, the American Cancer Society reports.\nA government panel of experts released updated guidelines today spelling out who should be taking a daily low-dose aspirin for heart health, which also offers the added benefit of protection against colorectal cancer.\nThose who would benefit from the regimen, according to the U.S. Preventive Services Task Force, must meet a strict list of criteria -- including a high risk of heart disease and a low risk of bleeding side effects.\nAt this time, the task force reports that more research is needed to assess whether taking aspirin is beneficial for people who are younger than 50 or those who are 70 and older.\nSpecifically, the group recommends that adults 50 to 59 years old who have a 10 percent or greater 10-year cardiovascular disease risk, are not at an increased risk for bleeding, and have a life expectancy of at least 10 years take a daily low-dose aspirin to prevent heart attack, stroke, and colorectal cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While we are told of the benefits to cardiovascular prevention, those effects are never quantified. This strikes as a missed opportunity to \u201cshow the numbers,\u201d which are easily obtainable from the USPSTF recommendations and tables that\u00a0discuss the quantified benefits.", "answer": 0}, {"article": "GHRH, a hormone produced by the hypothalamus in the brain, is linked to the insulin system, but also has a host of other effects.\n\u201cWe recommend commonly that people start exercising when they are having mild cognitive impairment,\u201d Baker said.\nBaker said researchers have failed so far to come up with effective drugs to treat mild cognitive impairment, just as there is no known treatment to stave off the normal memory decline that comes with age.\nBut Baker said people who got the hormone were more likely to report improvements in their ability to focus during the day.\n\u201cOn self-report, many of the folks in the active group reported they felt better,\u201d Baker, who led the study, told Reuters Health.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We wish the story had quantified the test results a bit more explicitly.\u00a0 However, the story got the gist right \u2013 and, more importantly, added that \u201cit\u2019s unclear how the test differences will translate into real life.\u201d", "answer": 1}, {"article": "However, antibiotics do come with significant side effects including diarrhea, rashes, yeast infections and vomiting.\nThe foundation for the \"watchful waiting\" treatment recommendation instead of taking drugs is based on this and previous studies that did not have very many children under age 2 in the clinical trials.\nAccording to one of the studies, ear infection, or acute otitis media, is the most frequently diagnosed illness in children in the United States, and most children with these ear infections are routinely given antibiotics.\nOne of the strengths of both studies, Rosenfeld said, is that the researchers took the time to make a solid diagnosis.\nIn treatment outcomes for pain, there was no difference, he notes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although a bit more detail would have been useful on the findings from both studies, the story does provide an account of the absolute rate of symptom relief after 7 days for antibiotic (80%) and placebo-treated (74%) patients, which is the expectation for this criterion. It also provides valuable expert commentary on how parents can put these benefits into context vs. the risk of harm and the likelihood of spontaneous recovery in children who don\u2019t receive antibiotics.", "answer": 1}, {"article": "Nov. 5, 2012 (Los Angeles) -- An IV infusion of \"good\" HDL cholesterol seems to rapidly remove cholesterol out of plaque-clogged arteries following a heart attack, a small, early study suggests.\nHDL removes cholesterol from artery walls, but current HDL-boosting drugs, such as niacin and fibrates, take years to work, according to Gille.\nStandard heart attack medications, such as aspirin and anti-clotting drugs, prevent clotting but don\u2019t eliminate an underlying factor: cholesterol that has built up on artery walls, he says.\nThe goal of the new treatment is to reduce the high risk of a second heart attack in people who have had a heart attack.\nAnd half of them happen in the first month, says researcher Andreas Gille, MD, PhD.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In the second sentence, the story states that \u201cThe goal of the new treatment is to reduce the high risk of a second heart attack in people who have had a heart attack.\u201d\u00a0 But it never addressed whether that goal was addressed by the findings reported.\nWhat does it mean for cholesterol removal from the cells of health volunteers to rise 164%?\u00a0 That sounds whopping.\u00a0 But what does it mean?\nWhat does it mean for levels of ApoA-1 to double?\u00a0 Again, sounds impressive.\u00a0 But does this translate to any clinical benefit?\nCome on!\u00a0 This was a study in 57 healthy volunteers who received a single infusion of CSL 112 and were followed for a short period of time.\u00a0 Suggesting any benefit is pure speculation", "answer": 0}, {"article": "In a study published last month in Nature, 80 percent of infants diagnosed with autism as toddlers had an increased rate of growth in the surface area of their brains in their first year, compared to toddlers who were not diagnosed with autism.\nExcess brain fluid may be more than an early marker for autism, Di Martino said.\nCompletely different mechanisms may be at work for kids without an older sibling with autism, said Shen and Dimartino.\nSuch a marker would allow doctors to identify infants at high risk of developing autism before symptoms are present.\nIt may also be a mechanism in the development of autism, and it opens up new possibilities for research, she said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits in terms of detection are described, including limitations of the current state of knowledge. The article is careful to draw parameters around the immediate significance of the findings and to express the need for further research. Numbers are even provided for how accurate researchers would like the MRI to be in predicting autism in infants before the procedure could be\u00a0recommended\u00a0for siblings of autistic children.", "answer": 1}, {"article": "This is a way of getting closer to an answer,\" said Weiner.\nIt's an early test for those who already have cognitive concerns and who wonder whether Alzheimer's disease may be the cause.\nWith growing understanding that the changes of Alzheimer's disease may be decades in the making, the value of early detection is gaining adherents, said Weiner.\nLast week, the FDA approved an agent called Florbetapir F 18 injection (to be marketed as Amyvid), which will allow physicians using a positron emissions tomography (PET) scan to detect the presence and extent of amyloid plaques in patients concerned about declining mental function.\nAmong patients diagnosed with mild cognitive impairment, about 60% have amyloid plaques and will go on to develop dementia that is likely Alzheimer's disease, said Dr. Michael W. Weiner of the Department of Veterans Affairs' Center for Imaging of Neurodegenerative Diseases.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is not careful enough in its description of what information the test provides and how it should be interpreted. The story states that the test \u201cis an early test for those who already have cognitive concerns and who wonder whether Alzheimer\u2019s disease may be the cause.\u201d The implication is that the test can distinguish Alzheimer\u2019s disease from other forms of dementia in people with cognitive impairment, which is not true.\nAs manufacturer Eli Lilly makes clear in its statement about the FDA approval, a negative scan indicates the absence of amyloid plaques and suggests that the cognitive impairment is probably not due to Alzheimer\u2019s. However, amyloid plaques are found in patients with many other neurologic conditions and in patients with normal cognition. Thus, a positive scan cannot tell us if the patient has Alzheimer\u2019s disease or some other cognitive problem or even if they are destined to develop dementia.", "answer": 0}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nThis is the first study that evaluates whether walnut consumption can cause changes to micro-ribonucleic acids (miRNA), the nucleotides that are involved in altering gene expression.\nAs this study was conducted on animals, results cannot yet be implied for humans.\nTumor growth rate was also significantly slower in the walnut group compared to the control group.\n\"While future studies are needed, we're optimistic of the role of miRNAs as biomarkers of disease and prognosis, and may demonstrate a potential therapeutic target for colorectal cancer treatment.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The research on a small group of mice showed slowing of the growth of colon cancer tumors. The research proved that tumors in mice fed walnuts had \u201c10 times the amount of total omega-3 fatty acids, including plant-based alpha-linolenic acid (ALA), in the tissue compared to the mice fed the control diet.\u201d Although the quantification here is limited, we\u2019ll give the story credit for accurately reporting the outcomes in broad strokes. The detailed results of what happened in a mouse study have limited use for the average human reader anyway.\nBut while the release does not state that the mouse study could lead to prevention for humans, we\u2019re worried that a normal reader may see the suggested effects of an enhanced walnut diet \u2014 increased anti-inflammatory activity, reduced angiogenesis, increased protective lipid content \u2014 and assume that these affect actual cancer outcomes. Set aside the major caveat that it is an animal study for a moment \u2014 the release says that walnuts \u201cmay\u201d slow the growth of colon cancer.\u00a0 It also equally may not.", "answer": 1}, {"article": "\"It's just like physical exercise -- when we are approaching the new year we will buy a pass for the gym and go fervently in January and then slack off,\" Willis said.\nThe researchers also showed that the benefits of the brain exercises extended well beyond the specific skills the volunteers learned.\nRather, as is the case with physical exercise, strengthening the mind appeared to slow decline.\nThe study did not indicate that mental training can hold off all cognitive decline permanently.\nIf anything, the study suggests, there is a bigger payoff to mental exercise, because the brief training sessions seemed to confer enormous benefits as many as five years later.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits that a senior citizen might reasonably expect to obtain through cognitive training were not presented clearly.\u00a0\u00a0 The reader has no idea from the information presented the size of the changes observed.", "answer": 0}, {"article": "Lung cancer is the most common cause of cancer death in the U.S. for men and women.\nThe researchers say the framework of the new compound is different from that of other cancer drugs and acts against a protein that carries a structural defect, according to a news release.\nThe new compound seems promising in mouse models, the researchers say, adding they hope it proves effective in clinical trials and is better tolerated than drugs now used.\nThe researchers say their new compound shows how fast lung cancer research and development are moving forward.\nMuch work lies ahead in determining whether the compound and related ones will prove to be effective therapies, but the researchers say their discovery demonstrates the power of screening specially designed compounds against cancers \"with certain genetic quirks.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are considerable benefits to be had, presumably. Because the number of patients is so huge, even a small improvement over present diagnositic techniques could have a big impact. As the study itself points out, \"Presently, the only specific, approved therapy for acute ischemic stroke is IV tissue plasminogen activator (tPA) given within 4.5 hours.\u00a0 tPA use has been limited due to the short treatment window, concerns about the limitations of CT-based diagnosis, and fear of hemorrhagic risks.\" Does the story get into this, though?\u00a0No. There is no attempt to quantify the benefits.", "answer": 0}, {"article": "\"However, there are gaps in knowledge about what is the best way to alleviate pain during vaccination.\"\n\"We found that, when used consistently during vaccine injections in the first year of life, only liposomal lidocaine combined with parental video instruction and orally administered sucrose showed a benefit on acute pain when compared with placebo, video alone, and video and sucrose together,\" wrote the authors.\nThe study was conducted by researchers at SickKids, the University of Toronto, York University and several Toronto-based pediatricians.\n\"The effects of consistent pain management on the development of preprocedural anxiety (fear), hypersensitivity to pain and compliance with future vaccination warrant future investigation,\" they recommend.\nFor babies under age 1 year, lidocaine cream, combined with a small amount of sugar given by mouth and infant soothing, can help relieve pain from routine vaccinations, according to a study in CMAJ (Canadian Medical Association Journal).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There were no absolute numbers included here, and that\u2019s a big omission. The CMAJ study notes how, per a score of 1-10 on the Modified Behavioral Pain Scale (MBPS) \u2014 with 10 being the highest level of pain \u2014 an improvement of 0.6 is generally necessary for doctors to change their practice on a procedure. Yet the study showed that the absolute effect of lidocaine cream (plus an educational video and sugar water) on vaccination pain was less, at 0.5.\nThere\u2019s also this: As\u00a0noted in the comments at a NEJM Journal Watch post,\u00a0it can take more than an hour for lidocaine creams to make pain relief effective for tissues deeper than the skin (and vaccines are often injected into muscles). For the CMAJ study\u00a0only about 20 minutes elapsed, since the cream was applied right before parents watched a 20-minute video and taken off immediately afterward.", "answer": 0}, {"article": "Editor\u2019s Note: Please see article for additional information, including other authors, author contributions and affiliations, etc.\nIn addition, more high-quality studies are needed to clarify the biological mechanisms underlying this association between breastfeeding and lower childhood leukemia morbidity,\u201d the study concludes.\nThe authors suggest several biological mechanisms of breast milk may explain their results, including that breast milk contains many immunologically active components and anti-inflammatory defense mechanisms that influence the development of an infant\u2019s immune system.\n\u201cBecause the primary goal of public health is prevention of morbidity, health care professionals should be taught the potential health benefits of breastfeeding and given tools to assist mothers with breastfeeding, whether themselves or with referrals to others who can help.\nA separate analysis of 15 studies found that ever being breastfed compared with never being breastfed was associated with an 11 percent lower risk of childhood leukemia.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "According to the release, this analysis of 18 studies found that \u201cbreastfeeding for six months or longer was associated with a 19 percent lower risk compared with no breastfeeding or breastfeeding for a shorter period of time.\u201d A sub-analysis of 15 studies further showed that \u201cever being breastfeed\u201d for a shorter period of time was associated with an 11 percent lower risk in developing leukemia compared to those who were never breastfed.\u00a0But how big really is a \u201c19% lower risk\u201d? That depends upon whether leukemia is generally common or rare. A 19% reduction in a rare condition like childhood leukemia won\u2019t amount to a very large absolute benefit. The release could have put a number on it.", "answer": 0}, {"article": "African-American women are more likely than white women to report hot flashes.\nThe study is the first to examine whether there are any racial differences in how well an antidepressant works in alleviating hot flashes.\nIn the new study, Ellen Freeman of the University of Pennsylvania School of Medicine in Philadelphia and colleagues gave 205 women who were either starting to go through menopause who had already gone through menopause either Lexapro or a placebo for eight weeks.\nAlthough the benefit was modest, it appeared to be significant enough that women might consider trying it, the researchers said.\nA study involving 205 women found those taking the antidepressant Lexapro experienced a 47 percent reduction in number of hot flashes they were experiencing and the hot flashes they did have tended to be less severe, researchers reported in the Journal of the American Medical Association.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies the benefits of treatment in appropriate\u00a0terms using measures that are meaningful to readers. It explains that women taking Lexapro had a 47 percent decrease,\u00a0or about 4.6 fewer hot flashes per day, whereas women taking a placebo had a 33 percent decrease or 3.2 fewer hot flashes per day.\u00a0The\u00a0story could have made the effects even clearer with a statement along the lines of \u2026 \u201cOn average, women with moderate to severe menopausal hot flashes had 5.4 hot flashes daily when taking lexapro and 6.4 hot flashes daily when taking placebo, a difference of 1 fewer hot flash daily.\u201d\u00a0As usual, the emphasis on percent reduction tends to obscure the absolute benefit.\nThe story\u00a0did\u00a0attempt to put the size of this\u00a0effect into some kind of context \u2014 calling it \u201cmodest\u201d \u2014\u00a0which is something the WebMD coverage failed to do.", "answer": 1}, {"article": "It develops in four stages.\nWe currently have to rely on liver biopsy to measure fibrosis at its early stages - by examining a piece of the liver under the microscope.\nIt is the first time an epigenetic signature in blood has been discovered which is diagnostic of the severity of fibrosis for people with Non-alcoholic Fatty Liver Disease (NAFLD).\nPublishing in the academic journal GUT, the Newcastle team describe the proof of principle research in which they measure specific epigenetic markers to stratify NAFLD patients into mild or severe liver scarring, known as fibrosis.\nThe test detects chemical changes on tiny amounts of \"cell-free\" DNA that are released into the blood when liver cells are injured.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits here are not clear, much less quantified. At one point, the release quotes a researcher as saying: \u201cWe know that the presence of even mild fibrosis of the liver predicts a worse long-term outcome for patients with NAFLD and so it\u2019s important to be able to detect liver scarring at an early stage.\u201d But why is that important? Are there therapeutic treatments or interventions available to change the course of the disease or otherwise affect the patient\u2019s health and well-being? Lower down, a second researcher is quoted as saying \u201cIf we are able to accurately tell the extent of a person\u2019s liver damage with a blood test, and even track the scarring as it gets better or worse, it could provide reassurance for patients, save NHS [National Health Service] resources and avoid patients having to undergo a liver biopsy.\u201d So, the benefit is that patients could avoid having a biopsy? Is that the benefit?\nWithout knowing the prognostic value of the test results, it\u2019s hard to see how it could provide reassurance for patients. \u00a0As noted above, the value of knowing this diagnosis in terms of directing targeted therapy is uncertain and the authors actually note that their data do not suggest superiority to existing fibrosis biomarkers.", "answer": 0}, {"article": "Their waistlines shrank by 1 to 2 inches.\nIn effect, the diet reduced the study participants' risks for cancer, diabetes, heart disease and other age-related diseases, according to the findings published Feb. 15 in Science Translational Medicine.\nThe research team found that the beneficial effects -- from weight loss, smaller waistlines and lower glucose, blood pressure and IGF-1 levels -- were sustained.\nThe researchers also noted that participants considered \"at risk\" because they had risk factors such as high IGF-1, cholesterol, blood pressure or blood sugar levels, made significant progress toward better health.\nPeople in the second group were placed on a three-month test of the fasting-mimicking diet.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This release reports only surrogate or intermediate endpoints of disease risk, not a change in disease risk itself. For example, changes were reported\u00a0in blood pressure, waist circumference, and body weight in participants after three fasting diet periods, which the release equates with a reduction in disease risk. However, measuring surrogate endpoints or disease biomarkers without looking at actual disease incidence is not a measure of individual health outcomes. To do this, researchers would need to measure endpoints like the number of cardiovascular events that occurred during or after the study or the number of people diagnosed with diabetes \u2014 which requires much longer than a few months of follow-up.\nSome of the claims made in the release were inappropriate. For example, \u201cIn effect, the diet reduced the study participants\u2019 risks for cancer, diabetes, heart disease and other age-related diseases, according to the findings published Feb. 15 in Science Translational Medicine.\u201d", "answer": 0}, {"article": "\u201cWe need more information on how this works precisely in people before we can advise them to take anything,\u201d he said.\nIf Elysium Health were developing Basis as a drug, it would have to conduct clinical trials with humans to prove that it works, and the Food and Drug Administration would have to sign off on its scientific evidence before it could be sold as medicine.\n\u201cWe are filling a space by combining natural compounds with scientific validation.\u201d\n\nThe active ingredients in Basis are nicotinamide riboside, a substance that makes NAD and is found in traces in many foods such as milk, and pterostilbene, an antioxidant found in blueberries.\nIndeed, one scientist not involved with Elysium questions the company\u2019s marketing pitch, saying there is too little information to know what Basis can do.\nBut as a supplement, Basis and similar products only have to be shown to be safe for humans to take, with labels that are not misleading.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article quotes the company as saying that higher levels of the \u201cnatural compound\u201d (found already in the human body) that is targeted by active ingredients in Basis has been associated with improved health in older mice, and that the pill has not been studied in humans. However, the article doesn\u2019t tell us anything about the mouse studies directly: What sort of \u201cimproved health\u201d did researchers find in the mice? Have researchers studied the active ingredients in Basis, or just the compound that these ingredients target?\nTo be clear, the story also quotes skeptical researchers who are asking very similar questions. For example:\u00a0\u201cWhat does it mean, to improve metabolic health? And what exactly is being repaired in the body? And is the outcome the same for everyone?\u201d But did the story pose these tough questions to the company and fail to get a response? If so, a brief acknowledgment of that effort would have earned the story a satisfactory rating here.\nAnother route to a satisfactory score would have been to summarize some previous studies involving the active ingredients in Basis, such as pterostilbene.", "answer": 0}, {"article": "Current ACS prostate screening cancer guidelines recommend that men make an informed decision with their doctor about whether to be tested for prostate cancer.\nThe men in the study were all from the placebo arm, meaning they had not received the drug.\nHigh levels of PSA can be a marker for prostate cancer, although it's far from a perfect screening tool, experts say.\nThe National Cancer Institute has more on the PSA test.\n\"The velocity didn't add anything more to detecting aggressive prostate cancers.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t quantify the potential reduction in biopsies.", "answer": 0}, {"article": "First published on June 22, 2006 at 12:00 am\nDr. Julia Zehr, a Michigan State University researcher who led the study, said the findings suggest that biological factors may influence those behaviors, not just the psychological effect of changes in body composition during puberty.\nBut Dr. George Merriam, a professor of medicine at the University of Washington, cautioned that much more study is needed to determine whether the medication should become widely available to help counteract the effects of aging.\nAnother researcher who presented a different study at the conference also emphasized the importance of staying active and maintaining a proper diet.\nOther researchers involved in the study were affiliated with Duke University, Stanford University, the University of Arkansas, Johns Hopkins University, the Veterans Affairs health care system, and Pfizer, which supported the project.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story mentions there was an increase in physical functioning in the growth hormone group, but we are not told how much they improved in physical functioning or increased muscle mass. How big was the benefit? Was it statistically significant? And, more important, was it clinically significant for these people?", "answer": 0}, {"article": "\u201cThe take-home message now is that for the right patient, hormone therapy is safe and effective.\u201d\nFor women who started hormones in their 60s or 70s, however, there wasn\u2019t a meaningful difference in death rates according to whether they got the treatment or a placebo during the initial years of the study.\nThe current study, however, looked at longer-term data from the WHI study and found no increased risk of death from all causes, or from cancer or cardiovascular issues in particular, associated with hormone use.\nAfter 18 years, including both the treatment period and a decade or more of follow-up, women\u2019s age when they joined the study no longer appeared to significantly influence death rates.\nOne limitation of the study is that the WHI didn\u2019t look at different dosages of hormone pills, and the findings may be different for other dosages or different types of therapy such as gels or creams or skin patches.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This study does not aim to quantify the benefits of treatment, rather to show whether there is any difference in risk of death associated with taking hormone therapy for 5 to 7 years.\u00a0 The original Women\u2019s Health Initiative trial was designed to examine whether there was any benefit of hormone therapy for prevention or heart disease, which had been suggested by earlier studies.", "answer": 2}, {"article": "Almost everyone suffering from back pain says something like, \"I want to feel better, I want to play golf again, or I want to be able to play baseball with my grandkids,\" anesthesiologist and lead author Steve P. Cohen tells Shots.\nPatients don't care much about the finer points of diagnostic accuracy.\nThe study's suggestion on how to manage back pain also runs counter to current guidelines from major medical groups.\nDoing away with a painkilling injections, or nerve blocks, as a test to determine the root cause of the back pain didn't hurt patients who went on to have their pain treated by zapping nerves with electrodes.\nDoctors may not change their approach anytime soon, however.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No quantification of potential benefits.\u00a0 Only a vague, borrowed (from Reuters) reference to \"the value of the diagnostic tests\" and an anecdote from the researcher supposedly supporting the case that they can be skipped.\u00a0 ", "answer": 0}, {"article": "Most thyroid cancers can be treated successfully, but advanced cases can be difficult to treat, especially if they do not respond to radioactive iodine (RAI) therapy.\nQ: What did you find?A: At the time we reported our results, six of the 22 patients remained on treatment.\nIt\u2019s an exciting time in early phase drug development when we are observing these results in so many different types of cancer.\nIn blocking this activity, these new immunotherapy drugs help T cells get back to work in protecting the body.\nThe work is being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting which begins tomorrow in Chicago.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release used careful language when describing the limited benefits seen in this Phase 1, safety oriented clinical trial. We appreciate the fact that this is not a journal article, but an abstract presentation for a conference. But we think that readers deserved a bit more information\n\u201cAt the time we reported our results, six of the 22 patients remained on treatment. Of those who completed therapy, two patients had a partial response for an overall response rate of 9.1 percent, and there was a stable disease rate of 54.5 percent. The six-month overall survival rate was 100 percent and the six month progression free survival rate was 58.7 percent.\u201d\nThat being said we are not provided with any information about the expected stable disease rate or progression-free survival rate in untreated patients. While the stable disease and progression free survival rates were provided, the reader has nothing to compare them to.", "answer": 1}, {"article": "Professor Marianne Thoresen said: \"Even if we account for a lesser severity of perinatal asphyxia, our research has shown that therapeutic hypothermia reduces the number of children who develop epilepsy later in childhood.\nThe study showed that more children had epilepsy when they reached the age of four to eight years with seven per cent on regular medication.\nEven if a lesser severity of perinatal asphyxia is accounted for, cooling therapy has increased the number of healthy survivors and there are very few children with epilepsy needing drug treatment.\nUntil recently, 20 to 30 per cent of these patients would develop epilepsy and many need regular antiepileptic treatment.\nThe research found that babies, born after 2007, who received the cooling treatment, had much less epilepsy than before cooling treatment was introduced.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The headline claims a reduction in epilepsy but the release does not provide any numbers backing up that claim. The closest the release comes to describing a benefit is stating that the children \u201chad much less epilepsy than before cooling treatment was introduced.\u201d How much less?\nThe release would have been somewhat stronger if it had offered some firm numbers for this group of patients given the lack of a control group.", "answer": 0}, {"article": "Previous research has also suggested that fructans stimulate the growth of beneficial bacteria in the large intestine in a way that increases the body's absorption of minerals, including calcium and magnesium, which are needed for bone growth.\nTUESDAY, March 23, 2010 (HealthDay News) -- An ingredient in agave -- the plant used to make tequila -- may help fight bone-weakening osteoporosis and other diseases, Mexican researchers say.\n\"These results suggest that the supplementation of the standard diet with agave fructans prevented bone loss and improved bone formation, indicating the important role of agave fructans on the maintenance of healthy bone,\" Lopez said.\nBut drinking tequila won't help, the study authors noted.\n\"They can be used in many products for children and infants to help prevent various diseases, and can even be used in ice cream as a sugar substitute.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "First, this was in mice \u2013 a fact that was minimized in the story.\u00a0 But we don\u2019t know how many mice were tested. Was it two?\u00a0 Was it 200? And we\u2019re only given a relative benefit statistic \u2013 \"50 percent increase in levels of a protein associated with the build-up of new bone tissue.\"\u00a0 50% of what?\u00a0 \nYet this mouse story allowed the researcher \u2013 based on a quote from a news release \u2013 to say:\u00a0\nShameful. ", "answer": 0}, {"article": "Ultraviolet light can alter chromophores so they no longer absorb color, but UV light can damage the retina.\nThe laser treatment reduces the light absorption and also helps restore the lens proteins to their proper structure.\nTo make cataract treatment available to more people around the world, a less-invasive, less-expensive technique is needed.\nIn their approach, described in the open-access journal PLoS ONE, they \u201cbleach\u201d the lens with a laser.\nMuch more research and development work remains, Dr. Kessel said, but the goal is a relatively simple procedure that would last half an hour at most and use largely automated equipment in mobile clinics.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019ve already told you what the story didn\u2019t:\u00a0 that this was an experiment on 9 human organ donor lenses.\u00a0 But the story also didn\u2019t say if the approach had the intended effect on all 9, half of them, or how many.\u00a0 The story also didn\u2019t capture what the researchers reported:\u00a0\nSo the leap to knowing how this might work in the bodies of living people is large, despite a headline that stated, \"Laser Treatment May Work For Cataracts.\" ", "answer": 0}, {"article": "Chemotherapy deals heavy damage to tumors \u2014 but often, the cancer cells are able to regroup and repair themselves.\nIts results built upon exciting data it released in June \u2014 showing that its drug can increase the window of time in which a woman\u2019s cancer doesn\u2019t get worse.\nIt showed that patients with recurrent ovarian cancer treated with the drug got an extra 15 months without their disease getting worse, compared to a control group.\nOther groups of patients treated with the drug also had significantly better outcomes than control groups.\nIn a pilot study of 13 breast cancer patients on the drug at MD Anderson Cancer Center in Houston, tumors shrank on average 78 percent.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u2019s description of benefits is uneven. The story touts one drug \u2014 niraparib \u2014 as being \u201cthe clear front-runner\u201d because among BRCA ovarian cancer patients taking it they \u201cgot an extra 15 months without their disease getting worse,\u201d compared to a control group. The story also said that Pfizer\u2019s drug \u2014 talazoparib \u2014 \u201crecently showed similarly compelling results\u201d and that \u201ctumors shrunk on average 78 percent\u201d in a pilot study of breast cancer patients. But an \u201caverage\u201d result can mask great variation in response among patients \u2014 was this representative of what most patients experienced? The third drug \u2014 Clovis Oncology\u2019s rucaparib \u2014 \u201cdidn\u2019t measure up to the other two trials,\u201d the story said, but the only data provided about it was that its stock price dropped 18 percent after data was released, but the story offered none of that data.", "answer": 0}, {"article": "\"Using this approach, which was totally independent of diagnosis, we were able to identify patients with Alzheimer's disease,\" Vanderstichele says.\nIn one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\nThe signature was found in the cerebrospinal fluid (CSF) of 90% of people with a diagnosis of Alzheimer's disease and 72% of people with mild cognitive impairment (MCI) -- a disorder that often progresses to Alzheimer's.\nAug. 9, 2010 -- Researchers have identified a protein \"signature\" in the spinal fluid of patients with Alzheimer's disease, which could represent an important advance in its diagnosis.\nLow levels of the amyloid protein amyloid-beta 1-42, along with high levels of total tau and elevated phospho tau 181 (P-tau 181), identified Alzheimer's disease in three independent study groups, Hugo Vanderstichele, PhD, of the Belgian biotech company Innogenetics, tells WebMD.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThis story appropriately characterizes this spinal fluid test as something that could help improve the confidence of Alzheimer\u2019s diagnoses. It would have been helpful to point out that the test is most likely to be used first by researchers testing potential treatments. The story points out that this sort of test could be useful for screening once effective treatments are available. However, the story should have been more clear that the test as presented in this study, if used in isolation, could lead to many people being incorrectly labeled as having Alzheimer\u2019s Disease.", "answer": 1}, {"article": "It takes an hour or less,\" he said.\nAll the patients had devices that were recalled by manufacturers, Canada's national health system or the FDA.\nA new Canadian study provides the first estimate of the risk of major complications from replacement surgery, important information for patients facing the choice.\nKrahn said the rate of complications from surgical removal will surprise doctors, because replacing a defibrillator is considered a minor procedure.\n\"That risk is much higher than we initially thought,\" said study co-author Dr. Andrew Krahn of the London Health Sciences Center in Ontario.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article includes the numbers of patients who had serious complications after replacement surgery, as well as how many had minor problems. Data are also included that would help readers assess how the risks of replacing a device compare with the device manufacturers\u2019 estimates of how often something could go wrong if it was left in place. ", "answer": 1}, {"article": ".\nHow the Study Was Conducted and Results: Patnaik, Shapiro, and colleagues enrolled 225 patients with a variety of types of advanced cancer in the phase I clinical trial designed to evaluate the safety and preliminary efficacy of abemaciclib.\nBottom Line: The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.\n\"The results of the trial supported the FDA decision to grant breakthrough therapy designation to abemaciclib (previously known as LY2835219) for patients with refractory hormone receptor-positive advanced or metastatic breast cancer,\" added Patnaik.\nLimitations: Patnaik explained that because this study included 225 patients with different types of cancer, confirmatory clinical trials in specific patient populations are necessary to precisely define the role of abemaciclib in cancer care.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is appropriately restrained in its description of the potential benefits of a drug just starting the long process of trials in patients. It specifically reports the number of trial participants whose tumors appeared to respond or at least not advance during the test, without making premature claims of effectiveness. However, we would like to see news releases about early trials of cancer drugs go further, to state explicitly that signs of partial responses or stable disease do not imply potential cures or even extended survival. More emphatic cautionary statements seem particularly appropriate to releases like this one that point out an experimental drug has been given \u201cbreakthrough therapy designation\u201d by the FDA, which is a technical definition that the FDA notes is frequently misinterpreted by the public and even health care professionals. Since it referenced \u201cdurable response,\u201d it would have been nice to see the release include a definition. In brief, the term refers to the length of time that a partial or complete response is observed as a result of treatment.", "answer": 1}, {"article": "In the study entitled \"Long-term physiological T3 supplementation in hypertensive heart disease in rats,\" aging female rats with hypertension progressing to heart failure were treated for one year (half their lifetime) with a low oral dose of the active form of thyroid hormone, T3.\n\"Thus, T3 treatment inhibited the major cause of stiffening of the heart in hypertension.\nI predict the same will eventually be true for thyroid hormones in a large subpopulation of cardiac patients.\nGerdes has long argued that medical opinion on thyroid treatment for patients with heart disease is largely shaped by outdated studies that used toxic doses of thyroid hormones.\n\"This low dose of thyroid hormone safely restored depressed cardiac tissue T3 levels to normal while largely preventing the accumulation of collagen, or scar tissue, resulting from sustained high blood pressure,\" said Gerdes.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release refers to \u201cencouraging cardiac improvements\u201d and says \u201ccardiac health improved,\u201d but those benefits are not quantified. The release also tells readers that \u201cT3 treatment inhibited the major cause of stiffening of the heart in hypertension\u201d and \u201coverall improvement in\u2026heart function.\u201d But it doesn\u2019t tell readers what this means. How much improvement was there? And what, exactly, was improving?\nWe recognize that this issue would have been difficult to address, since the paper itself does not provide specifics on these benefits. But we maintain a high standard, and the researchers could have been prodded to provide answers. It would have been nice at the least to have some sense of how the changes compared with those observed other studies.", "answer": 0}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites several studies to support the story\u2019s statement that \u201ca handful of new studies have shown it helps relieve back, neck, carpal tunnel and knee pain.\u201d\u00a0 However, none of the alleged benefits are ever quantified, and that\u2019s our expectation with this criterion.\u00a0 The article uses phrases, such as \u201cmore effective on average in relieving pain\u201d and \u201csignificantly reduced chronic neck pain.\u201d But what do these mean? And how were these benefits measured? A discussion on some numbers from the trials (how many patients experienced relief, how much pain relief), as well as the research methods to measure benefits, would have been welcome.", "answer": 0}, {"article": "\"This shows that the strategy does work,\" he said.\nThe HPV test works a step further back in the process, looking to see if women are infected with HPV.\nThe HPV test should become the screening tool of choice for women 35 and older, the researchers said.\nIt could be done less frequently than the Pap test, which could be used only in women who have tested positive for HPV, they said.\nScreening for HPV DNA appeared more effective in older women, but the testing in younger women led to over-diagnosis of a particular type of cervical lesion, the study found.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t really quantify the benefits of HPV DNA testing in terms that are particularly useful to consumers. The story describes the \"callback rate\", or the number of women who will need additional testing after the initial screening, which makes HPV DNA testing appear as though it catches many\u00a0 more cancers than pap smears. However, according to the study, the number of cancers found in the first round of screening was similar in both groups (7 in the HPV DNA group, 9 in the pap smear group). It was in the second round of screening two years later that HPV DNA testing appeared to prevent cases of cervical cancer relative to pap smears (7 cancers in the HPV DNA group versus 18 in the pap smear group). ", "answer": 0}, {"article": "When that occurs, the next step is to examine the suspicious area, with the physician ordering a biopsy or inserting a scope into the lungs to evaluate further.\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\nHe is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n\nAbout 219,000 new cases of lung cancer were expected to be diagnosed in the U.S. in 2009, according to the American Cancer Society, and about 159,000 deaths were expected.\n''Currently, 20% to 25% of surgeries done for suspected lung cancer turn out to be benign diagnoses,\" says Steven Dubinett, MD, professor of medicine and pathology and director of the Lung Cancer Research Program at the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine, University of California, Los Angeles.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article provides n values and quantifies the results from the first stage of the study. The potential benefits of the test have to do with its ability to rule out malignancy based on X-ray results; thus, the specificity and sensitivity data are particularly relevant.\u00a0\nWe wish the paragraph on subjects with stage I disease would have quantified the results. It provides no sensitivity or specificity rates to justify the conclusion of the technique\u2019s potential application in early stage disease.", "answer": 1}, {"article": "These latest findings do not alter that advice.\nOf the 34,433 HRT users, 193 were diagnosed with colon cancer during the study period; that compared with 151 cases among the 13,778 women who had never used hormone replacement.\nAmong these women, HRT use was linked to a 55 percent lower risk of the disease versus non-use.\nHRT \u2014 with either estrogen alone or a combination of estrogen and progestin \u2014 was linked to a lower colon cancer risk even when the researchers accounted for the women\u2019s age, weight, exercise levels and race.\nHenderson\u2019s team also found that the beneficial effect of HRT was stronger among women who had had a first-degree relative diagnosed with colon cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\nOf the 34,433 HRT users, 193 were diagnosed with colon cancer during the study period; that compared with 151 cases among the 13,778 women who had never used hormone replacement.\nHRT \u2014 with either estrogen alone or a combination of estrogen and progestin \u2014 was linked to a lower colon cancer risk even when the researchers accounted for the women\u2019s age, weight, exercise levels and race.\n", "answer": 1}, {"article": "Doctors diagnose Alzheimer\u2019s by excluding other causes of memory loss, such as stroke, tumors and heavy drinking.\nWhen they looked to see how accurate these signatures were at spotting the disease, they found 90 percent of those with Alzheimer\u2019s had the disease pattern in their spinal fluid.\nThe study is the latest to show that measuring disease-related proteins in spinal fluid is useful in diagnosing Alzheimer\u2019s disease.\nIn the study, De Meyer and colleagues analyzed spinal fluid from 114 adults with normal brain function, 200 who had mild cognitive impairment \u2014 a precursor to dementia \u2014 and 102 who had Alzheimer\u2019s.\nThey were also able to detect 100 percent of people with memory impairments who would progress to Alzheimer\u2019s disease within five years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nAlthough this story does a generally careful job of highlighting the potential use of spinal fluid testing to help diagnose Alzheimer\u2019s Disease in people who are already experiencing severe memory problems, it states that the results \u201cpredict\u201d which patients with memory problems will develop the disease. What the researchers actually reported was that all of the patients who progressed from mild cognitive impairment to Alzheimer\u2019s Disease during the study period had the disease-associated biomarker pattern. They did not state that having the \u201cdisease\u201d pattern predicted progression. Indeed, while 142 participants with impairment had the \u201cdisease\u201d pattern, only 57 (less than half) progressed from impairment to Alzheimer\u2019s during the study.", "answer": 0}, {"article": "Connect with GUMC on Facebook (Facebook.com/GUMCUpdate), Twitter (@gumedcenter) and Instagram (@gumedcenter).\nWhether the reduction in symptoms accounts for longtime use of soy and cruciferous vegetables needs further investigation, says the study's senior author, Judy Huei-yu Wang, PhD, of Georgetown Lombardi's Cancer Prevention and Control Program.\nThe lead author on the study, Sarah Oppeneer Nomura, PhD, of Georgetown Lombardi, said that while further research is needed in larger study populations and with more detailed dietary data, this project addresses an important gap in research on the possible role of lifestyle factors, such as dietary habits, in relation to side effects of treatments.\nWASHINGTON -- Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, say a team of scientists led by Georgetown Lombardi Comprehensive Cancer Center.\nIndeed, in this study, Chinese breast cancer survivors ate more than twice as much soy and cruciferous vegetables.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Beyond vague descriptions of benefits such as \u201cfewer reports of menopausal symptoms,\u201d the news release does not offer any meaningful measure of what the patient\u2019s symptoms were at the beginning of the study and how much symptoms were reduced among those who ate \u201cmore\u201d of the soy and cruciferous vegetable diets. It also isn\u2019t clear on which menopausal symptoms were decreased.", "answer": 0}, {"article": "Irritable bowel syndrome can be highly debilitating, if not virtually paralyzing, and affect work, sleep and personal and family relationships.\nBecause of the many unknowns about the chemical causes and triggers of IBS, the list of \u201cbad\u201d foods is exhaustive and elusive, and help from a dietician is highly recommended.\nThat\u2019s the result of research by the University of Michigan Health System, presented at Digestive DiseaseWeek, that studied for the first time in the United States the result of following a carefully controlled diet to improve the symptoms and quality of life for those with irritable bowel syndrome.\n\u201cThis is the only methodically rigorous clinical trial to show that diet-based therapy can not only improve symptoms, but also quality of life in patients with IBS,\u201d says U-M assistant clinical professor and gastroenterologist Shanti Eswaran, M.D., who researches the role of diet and food in functional bowel diseases such as IBS.\nNewswise \u2014 A change in diet can improve the lives of those diagnosed with a common, but hard-to-treat gut disorder.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release reports some numbers. It says more than half of the patients on the low FODMAP diet experienced \u201cmajor improvement\u201d of their abdominal pain compared with 20 percent of the control group, and 61 percent of low FODMAP patients had a \u201cmeaningful improvement\u201d in quality of life versus 27 percent for the control group. However, it should have described for readers what these improvements mean from a clinical standpoint. Is the researchers\u2019 definition of \u201cmajor improvement\u201d the same as what patients expect when they hear that term? Offering some specifics would have helped clarify.", "answer": 0}, {"article": "\"We didn't expect that at all,\" Dackis says.\nAddiction specialists gave it a look because even though modafinil isn't a classic stimulant, it triggered something in the brain to also improve patients' mood, energy levels and ability to concentrate _ effects that might counter cocaine withdrawal.\nThe prospect of that double-whammy has the National Institutes of Health spending $10.8 million researching modafinil as a potential cocaine treatment.\nHundreds of cocaine users are testing whether that legal pill, called modafinil, could help them kick the addiction, and there's early evidence that it may.\nIn a small safety study to ensure that modafinil didn't make cocaine worse, some users found the once-a-day pill blocked that high.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t give any quantitative evidence of the benefits of this drug over placebo to reduce withdrawal symptoms and cravings for cocaine, though this evidence is provided in the journal article for the small pilot study. Abstinence from cocaine was measured as clean urine tests and of the 24 test required, 43% of the modafinil group vs. 24% of the placebo group were without evidence of recent cocaine use. Futher evidence from larger randomized trials is needed. The discussion of modafinil allowing former cocaine user to \u201cthink strategically\u201d might be an overstatement as there is no evidence in the pilot study of improved decision making with modafinil. ", "answer": 0}, {"article": "\u2022 Try to stay indoors, and avoid mowing lawns or raking leaves.\nOver-the-counter treatments should not take the place of professional care \u2014 especially if you have never been formally diagnosed with allergies, if you have additional medical problems or if your symptoms persist or worsen, Eghrari-Sabet and Sublett say.\nIt's a myth, he adds, that older, sedating antihistamines, such as Benadryl, are extra effective against nasal allergies.\nThey should be used daily during your vulnerable season or seasons, ideally starting before symptoms do, Eghrari-Sabet says.\nThe non-prescription steroid nasal sprays are selling for about $17 to $23 for a one-month supply (at the typical two-squirts per nostril adult starting dose).\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story claims steroid nasal sprays are the \u201csingle most effective drug class for treating nasal allergies\u201d \u2014 a quote that is attributed to the American College of Allergy, Asthma & Immunology\u2019s website. But this statement is not backed up with any quantitative data. How effective are these treatments? And how do they compare to other alternatives out there, like antihistamines and decongestants? How many patients put on this treatment would report experiencing a benefit? The story acknowledges that these sprays won\u2019t\u00a0work for everyone, but it wouldve been better to provide an estimate. There are several Cochrane reviews (meta-analyses based on multiple studies) on this topic, such as this one\u00a0and this one, that could\u2019ve been used to help quantify the story\u2019s claims.", "answer": 0}, {"article": "... Then a lot of guys eventually were like, 'I'll go.\n\"To a certain extent, I was surprised by the magnitude of the effect of the intervention,\" said Ciantel Blyler, a clinical pharmacist at Cedars-Sinai Medical Center in Los Angeles who was a co-author of the study.\nBy the end of the study, the researchers found that the barbers' role in encouraging the men to monitor and improve their health resulted in a significant reduction in blood pressure, when coupled with medication from the pharmacists.\nAdditionally, more research is needed to determine whether similar study results would occur on a national level, since the study was conducted only in the Los Angeles area.\nAlso, pharmacists aimed to lower blood pressure in the program participants to less than 130/80, whereas the primary care providers of those in the control group probably targeted a blood pressure of less than 140/90.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story clearly states that men in the intervention group experienced a much greater reduction in their blood pressure readings as compared to the control group. It included this quantified statement, \u201cIt turned out that, when the guidance was coupled with medication, a blood pressure level of less than 130/80 was achieved among 63.6% of men who participated in the study\u2019s program, versus 11.7% of those who didn\u2019t.\u201d", "answer": 1}, {"article": "Side effects of dopamine agonists can include euphoria, hallucinations, weight loss, nausea, insomnia, tiredness or weakness, dizziness and drowsiness.\nNonetheless, for people with moderate to severe restless legs syndrome symptoms, these medications provided important benefits, at least in the short term, Wilt said.\nThe harms of medications may outweigh benefits for these individuals, Wilt said.\n\"Up to 25 to 50 percent with even moderate to severe and longstanding symptoms stop taking these medications after more than a year due to either side effects or lack of benefit,\" he noted.\nPatients should tell their doctors if they have bothersome sensations in their legs that include distressing, irresistible urge to move them that is relieved by rest, Wilt said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides the absolute percentage of patients who experienced at least 50% reduction in symptoms in the treatment groups and control groups. Although it\u00a0specified that these benefits were \u201cshort-term,\u201d we wish\u00a0the story\u00a0had quantified the length of these studies more precisely.\nSee our comments above in the \u201cWhy This Matters\u201d section about the framing of the benefit. Short-term 60% vs. 40% reduction in symptoms of at least 50% with 25-50% stopping the medicine over a year. This should have been the first point. Then the results don\u2019t seem quite as remarkable.", "answer": 0}, {"article": "Using the gentler technique, called laparoscopy, a surgeon makes small cuts in the abdomen before inserting a tiny camera inside, then performing the operation by watching a television monitor.\nYet again, the patients who had laparoscopy fared much better than those who had conventional surgery.\nOn average, it cost $17,594, compared to $12,125 for the laparoscopic surgery.\n\u201cIn healthy individuals, the death rate is very (small) for all groups of patients.\nWith his colleagues, he looked back at some 40,000 such surgeries done at dozens of academic medical centers in the U.S. \u2014 roughly 14,000 open procedures and 26,000 laparoscopic ones.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As already noted, the story did a good job comparing death rate, readmission rate and hospital stays between the two procedures.", "answer": 1}, {"article": "\"Try a serving in a snack bag.\nThe research shows the well-known cholesterol-lowering effect of eating walnuts works equally well in the elderly, even in the long term, the authors reported at the Experimental Biology conference in San Diego.\nOther walnut studies presented at the conference, funded in part by the California Walnut Commission, suggested the omega-3 fatty acid-rich nut may also benefit gut bacteria and help reduce inflammation.\n\"Given walnuts are a high-energy food, a prevailing concern has been that their long-term consumption might be associated with weight gain,\" said study author Dr. Emilio Ros, director of the Lipid Clinic, Endocrinology & Nutrition Service at the Hospital Clinic of Barcelona, in a press statement.\nIt's still important to remember portion control, especially for people on weight loss programs, warned Politi.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no quantification in this story. The story says that the walnut eaters had reductions in bad cholesterol, but not how much. Is it even clinically significant? The story also says that neither group showed weight gain or changes in other cardiovascular markers, but nothing concrete is presented.\u00a0 A mention of good gut effects of walnuts is totally without any supporting information.\u00a0 About the only information actually given is that walnuts can be a fattening food and that portion control is necessary.", "answer": 0}, {"article": "Platelets, the blood cells that promote clotting, contain hundreds of proteins, called growth factors, that are important in repairing injuries.\nFerrell told me not to use nonsteroidal anti-inflammatories, such as ibuprofen, for a week after the injection because the goal is to encourage, not stifle, inflammation.\nThe outcome was excellent, but the recovery was long and horrible.\nThose who seek this treatment must look for a clinician with considerable PRP experience \u2014 someone who does the procedure several times a day, not once or twice a month \u2014 and who has a good success rate, Ferrell says.\nStill, \u201cit has significant cost savings\u201d compared with surgery, Ferrell says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives no information on quantified benefits measured in PRP research, and instead focuses only on the author\u2019s experience.", "answer": 0}, {"article": "\u201cI don\u2019t want to throw cold water on an interesting thing, but that\u2019s what it is \u2014 an interesting thing,\u201d Gallo said.\n\u201cOur results strongly suggest that cure of HIV has been achieved in this patient,\u201d they wrote in the journal Blood.\nSchneider\u2019s team has been following the patient, taking samples from his colon, liver, spinal fluid and brain as he developed various conditions that justified the tests.\nSchneider\u2019s team found no evidence of HIV anywhere.\n\u201cFrom these results, it is reasonable to conclude that cure of HIV infection has been achieved in this patient,\u201d they wrote.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re giving this one a pass here. The story makes quite clear that it is a report on the experience of only one patient and that while the researchers say there are now no signs of HIV infection in this individual, the tests don\u2019t completely rule out the possibility that the virus is lurking somewhere. In particular, the comments of Dr. Gallo to place the apparent benefit in this single patient into context.", "answer": 1}, {"article": "According to the Skin Cancer Foundation, metastatic melanoma accounts for only about 1 percent of skin cancer cases but causes the majority of skin cancer deaths.\n\"Based on this study, it appears that patients with advanced melanoma who have their disease completely removed by surgery should go on to receive additional therapy with Opdivo,\" said Dr. Gary Deutsch.\nThe international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma.\nAll underwent surgery for their cancer before they began treatment with either Opdivo (nivolumab) or Yervoy (ipilimumab), the drug that's the current standard of care.\n\"Our results demonstrate that [Opdivo] is more effective in treating patients with stage III and IV melanoma, cutting the risk of relapse by a third,\" lead researcher Dr. Jeffrey Weber, professor of medicine at NYU School of Medicine, said in a university news release.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story clearly defines the benefit (survival without recurrence of the cancer) and offers clear numbers: \u201cAfter a year of treatment, 71 percent of patients in the Opdivo group were alive without any recurrence of the disease, compared with 61 percent of those treated with Yervoy. And at 18 months, the rate was 66 percent for Opdivo and 53 percent for Yervoy, the findings showed.\u201d\nOne detail we think would have been good to add\u2013\u201crecurrence-free survival\u201d doesn\u2019t tell you how many patients are actually living longer specifically because of the treatment. It\u2019s just telling you how much time elapses before recurrence.", "answer": 1}, {"article": "They\u2019re not producing the antimicrobials they need,\u201d he explained.\nIn one early test, those customized creams guarded five patients with a kind of itchy eczema against risky bacteria that were gathering on their cracked skin, researchers reported Wednesday.\n\u201cIt\u2019s boosting the body\u2019s overall immune defenses,\u201d said Dr. Richard Gallo, dermatology chairman at the University of California, San Diego, who is leading the work.\nHis team tested five volunteers with atopic dermatitis who had Staph aureus growing on their skin\u2019s surface \u2014 what\u2019s called colonization \u2014 but didn\u2019t have an infection.\nThe study couldn\u2019t address the bigger question of whether exposure to the right mix of protective bacteria might improve atopic dermatitis itself, cautioned Mount Sinai\u2019s Guttman-Yassky.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We learn that \u201ccustomized creams guarded five patients with a kind of itchy eczema against risky bacteria that were gathering on their cracked skin\u201d and later, \u201cmuch of the staph on the treated arms was killed \u2013 and in two cases, it was wiped out \u2013 compared to the untreated arms,\u201d according to Gallo, the lead researcher.\nIs two out of five a proper measure of effectiveness? A bit of skeptical context would have helped explain these benefits.\nMoreover, this study, even if taken at face value, does not in any way assure that infections will be prevented, simply that the bad bacteria will be lowered. Sure, the researchers have a theoretical hypothesis that this would translate to fewer infections, but at this point, zero proof.", "answer": 0}, {"article": "Menstrual cramps, known by the medical name dysmenorrhea, typically begin just before or at the start of a woman's menstrual period and can last several days.\nExperts wondered if women with higher blood levels would experience such dramatic cramp relief as observed in the study.\nThe 300,000 IU dose of vitamin D3 given in the study also far exceeds the daily intake of 600 IUs recommended for American women of reproductive age, both Graham and Rabin said.\nGraham and Rabin agreed that much larger trials should be done before they would recommend vitamin D3 use to any of their patients for cramp relief.\nAnd since the study period lasted only two months, there was no way to tell whether such a high dose produced any toxic long-term effects.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article states that pain was reduced in the experimental group by 41% (where the control group experienced no pain reductions), but 41% of what?\u00a0 And in reality, was this reduction significant enough that women were able to resume their normal level of activity?\n\u00a0", "answer": 0}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides some quantitative comparisons between folks in a treatment group relative to those in a control group: \u201cIn late-stage studies, roughly half of patients taking crisaborole had their diseases cleared or nearly cleared, a statistically significant improvement compared with 30% to 41% of patients using moisturizing placebos. The most common side effect was pain where the ointment was applied, experienced by about 4.4% of crisaborole patients and 1.2% of control-group patients.\u201d\nThis is sufficient for a Satisfactory rating. However, it doesn\u2019t say how long the follow-up period was or if the disease clearing lasted, which are very important pieces of information.", "answer": 1}, {"article": "For more on losing weight, visit the U.S. National Library of Medicine.\nA potential player in fighting the obesity epidemic, lorcaserin is a new type of weight-loss drug that works by acting on serotonin, a chemical associated with feelings of well-being and feeling full, and does not appear to increase blood pressure or cause any other heart problems, according to the researchers, whose work was sponsored by the drug manufacturer.\nFor the lorcaserin study, Smith's team randomly assigned 3,182 obese or overweight people to lorcaserin or placebo.\nAfter one year, 47.5 percent of those taking lorcaserin had lost 5 percent or more of their body weight.\n\"If weight-loss drugs are tailor-made to hit only the right receptor, based on physiological knowledge, it seems to be possible to develop weight-loss medications that do not possess any serious adverse effects,\" Astrup added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did give weight loss amounts for people in the study.\u00a0 We wish they had calculated the number needed to treat \u2013 how many people would have to take the drug for how long in order to have one benefit.\u00a0 The one truly independent voice in this story, Dr. David L. Katz, says \"What\u2019s most impressive about this two-year clinical trial is how unimpressive it is.\"\u00a0Instead of going on to attribute all of the analysis of what that is to Katz, the story could have gone the extra step of seeing if others shared that view and really bearing down on the numbers to see how strong the results really are. By our rough count, by the second year, they were dealing with a trial consisting of fewer than 500 people.\nNonetheless, because the story met the minimum standard for this criterion, we\u2019ll judge it to be satisfactory.", "answer": 1}, {"article": "Moffitt is the No.\nThey also show that the vaccine was able to stimulate an immune response in the majority of the patients.\nThe researchers report that the dendritic cell vaccines were well-tolerated and patients only experienced low-grade toxicities.\nApproximately 80% of evaluable patients had a detectable immune response in their peripheral blood and/or in their sentinel lymph node wherein their cancer is most likely to spread to first.\nInterestingly, patients who achieved a pCR had a higher immune response within their local sentinel lymph nodes.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that \u201capproximately 80% of evaluable patients had a detectable immune response in their peripheral blood and/or in their sentinel lymph node wherein their cancer is most likely to spread to first.\u201d It also states that 13 patients achieved an absence of disease after treatment, though it doesn\u2019t give a percentage, and that patients who had early non-invasive disease called ductal carcinoma in situ (DCIS) achieved a higher rate of disease absence than patients who had early-stage invasive disease.\nFurther, it says those patients who saw absence of disease had a higher immune response in their lymph nodes, which, says a researcher, \u201cmay serve as a more meaningful immunological endpoint.\u201d\nThe news release states that immune responses were similar regardless of whether the vaccine was administered into a lymph node, a breast tumor, or both, though it doesn\u2019t explain why this is an important finding.", "answer": 1}, {"article": "Whole plasma must be matched to blood type.\nThere was no measurable effect on memory or thinking, the team told the Clinical Trials on Alzheimer\u2019s Disease conference in Boston.\nAnd, McCracken says, the company is working to figure out just what it is in the plasma that might affect aging and disease.\nStanford was doing what\u2019s called a proof of concept trial, just to check the safety of the treatment, in 18 volunteers with moderate Alzheimer\u2019s disease.\n\u201cThere is a theory that there is an inflammatory process that is driving the disease and the plasma is helping that,\u201d she said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no quantifiable data reported in this story. In fact, there\u2019s little if anything that can be considered to be actual data. The \u201csuccess\u201d of this approach, the story says, is based on the reported observations of Alzheimer\u2019s patients\u2019 caregivers to the researchers.\u00a0This is all just subjective opinion, not actual fact. Moreover, it refers only to half of those in the so-called trial, and they were no longer blinded to whether they received plasma or a sham transfusion.\nAdditionally, the report states that researchers told a conference that, \u201cThere was no measurable effect on memory or thinking,\u201d which are arguably the most important effects that Alzheimer\u2019s has on its victims. Given that and the paucity of other real information in the story, its questionable why it was even written at all.", "answer": 0}, {"article": "RA Nash et al.\nFive years after HDIT/HCT, most trial participants remained in remission, and their MS had stabilized.\nFive years after receiving the treatment, called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT), 69 percent of trial participants had survived without experiencing progression of disability, relapse of MS symptoms or new brain lesions.\nIn HALT-MS, researchers tested the safety, efficacy and durability of HDIT/HCT in 24 volunteers aged 26 to 52 years with relapsing-remitting MS who, despite taking clinically available medications, experienced active inflammation, evidenced by frequent severe relapses, and worsened neurological disability.\nThree participants died during the study; none of the deaths were related to the study treatment.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states:\n\u201cFive years after receiving the treatment, called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT), 69 percent of trial participants had survived without experiencing progression of disability, relapse of MS symptoms or new brain lesions\u2026.\nFive years after HDIT/HCT, most trial participants remained in remission, and their MS had stabilized. In addition, some participants showed improvements, such as recovery of mobility or other physical capabilities.\u201d\nIt also points out that none of the participants resumed MS drugs after their treatment.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story mentions that the drug may lower blood pressure, glucose and cholesterol, as well as making dieting less painful, there was no estimates for the amount of weight a person might expect to lose or the extent to which these other parameters\u00a0 (blood pressure, glucose and cholesterol) might be improved.", "answer": 0}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n \nThis story reports the absolute survival numbers of 15 months for advanced prostate cancer patients who received the new drug and a steroid vs. 11 months for those given a placebo and a steroid. However, it reports only the average survival figures. With many new cancer drugs, it appears that certain patients get most of the benefit, while most patients get little or no benefit, perhaps because of genetic or metabolic differences. The story should have addressed this issue.\nAlso, while the story notes that the drug has been tested only in patients with advanced disease who have run out of treatment options, it goes on to dangle the hope that the drug \u201cwill lead to much longer survival when studied in patients with early-stage disease.\u201d Will it? The statement is premature. No one knows if other types of patients will benefit from this treatment because it has not been tested in them.", "answer": 1}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only states that, \u201cfremanezumab, an immunotherapy drug, has been found to reduce the number of days that chronic migraine sufferers experienced headaches.\u201d\u00a0 This is not enough numerical information to help readers understand the scope of the benefits. By how much did it reduce the number of days? By 1? 5? 10?", "answer": 0}, {"article": "No more than a few days later, the samples were transported to labs at the university, where they remained frozen until they were processed by researchers. This ensured that none of the bacteria had a chance to grow or change from the time the sample was collected. Also, it guaranteed that all samples were treated the same way.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is nothing in the news story\u00a0that quantifies the\u00a0benefits of the claim made\u2013that drinking wine or coffee is \u201cgreat for your microbiome.\u201d This is a major problem with the story, as it\u2019s making a claim not found anywhere in the findings.", "answer": 0}, {"article": "[3] Yokell et al.\nRICHMOND, Va., March 29, 2016 /PRNewswire/ -- kal\u00e9o, a privately-held pharmaceutical company, today announced that EVZIO\u00ae (naloxone HCl injection) Auto-injectors have been reported to help save more than 1000 lives.\nEVZIO was the first naloxone product specifically designed, FDA approved and labeled for the emergency treatment of opioid overdose by individuals without medical training.\nOur mission is to provide innovative solutions that empower patients to confidently take control of their medical conditions.\n\"Having EVZIO available in Baltimore is helping us do everything possible to help prevent opioid overdose deaths in our community and across the country.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release asserts that Evzio is reported to be saving lives. It then offers testimonials, but no data. For example, the president and CEO of the company says that, since October 2014, \u201cwe have received reports that EVZIO Auto-injectors have helped save an average of 14 lives per week.\u201d\nThat\u2019s it. No mention of where the reports came from, how they were compiled, what happened in October 2014 to start those reports being filed. It turns out the drug/delivery combo was approved by the Food and Drug Administration in April 2014.\nThen, Laurie Fugitt, RN, BSN, co-founder of Georgia Overdose Prevention, says this: \u201cIt has already helped save many, many lives in Georgia.\u201d How does she know? How many are \u201cmany, many?\u201d When she says \u201chelped save,\u201d does she mean that something else was needed to complete the save? If so, what was it?\nThen, we get another anecdote, this one from Dr. Michael Kilkenny of the Cabell-Huntington Health Department in West Virginia: \u201cFollowing initial deployment of EVZIO on February 3, we had a confirmed life saved on February 12th.\u201d \nWho made the confirmation? How? What happened?", "answer": 0}, {"article": "May 23, 2011 -- Researchers in Europe say a fermented dairy product containing a specific bacterium known as a probiotic did not relieve constipation in children more than a dairy product without a probiotic.\nBut in a new study the kids who consumed the fermented dairy product did no better, based on number of stools produced, than youngsters in a comparison group.\nThe study examined 159 children with constipation for at least two months with a defecation rate of less than three times per week.\nThe finding is significant, the researchers say, because probiotics have helped some adults with constipation.\nIt seemed logical that probiotics, live microorganisms that are often called \u201cfriendly\u201d or \u201cgood\u201d bacteria, might work for children.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explained that the product \u201cincreased stool frequency, but not significantly.\u201d\u00a0 Given the apparent existing controversy over the use of these products \u2013 at least as framed in the story \u2013 we think the story should have provided actual numbers.\nIt became very confusing when the story jumped", "answer": 0}, {"article": "Adult brains contain oligodendrocyte progenitor cells (OPCs), which are stem cells that generate myelin-producing cells.\nIn the current study, Dr. Tesar wanted to see if drugs already approved for other uses were able to stimulate OPCs to increase myelination.\nThe compounds screened in this study were obtained from a drug library maintained by NIH\u2019s National Center for Advancing Translational Sciences (NCATS).\nNext, they examined whether the drugs, when injected into a mouse model of multiple sclerosis, could improve re-myelination.\nDr. Tesar\u2019s team found that two compounds in particular, miconazole (an antifungal) and clobetasol (a steroid), stimulated mouse and human OPCs into generating myelin-producing cells.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides insufficient detail regarding what occurred in this study and the outcomes that were reported. The release states that \u201cboth drugs were effective in activating OPCs to enhance myelination and reverse paralysis. As a result, almost all of the animals regained the use of their hind limbs.\u201d But how many animals were studied, and how many of them regained use of their limbs? Was there total resolution of symptoms or only partial resolution, and how was this measured? The release never quantifies these results.", "answer": 0}, {"article": "Opiate overdoses are now the leading cause of death for adults under age 50 -- an especially compelling reason to find approaches to chronic pain that don't involve narcotics.\n\"Yoga was as effective as physical therapy for reducing pain intensity,\" Saper said.\nDr. Robert Saper at Boston Medical Center is one of the authors.\nOne person who might agree is 74-year-old Judith Zaborowski, who took up yoga more than 10 years ago to help with her aching back.\n\"I feel, the more that one can do for one's self and not depend on medication, the healthier it is for your body,\" Zaborowski said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify how much \u201cbetter\u201d patients felt who received yoga classes compared to patients who received only education, or who received only physical therapy.\nHere is the statement by the researcher. Italics by editor.\n\u201cYoga was as effective as physical therapy for reducing pain intensity,\u201d Saper said. \u201cPerhaps most importantly reducing pain medication use.\u201d\nThere should have been numbers for \u201cas effective as\u201d showing us the comparison of some measurement.\nWhat this news story and many others missed: The study\u2019s primary outcomes were pain and functional status. It found that neither yoga nor physical therapy were statistically better than education (the control group). And due to the lack of numbers in this story, it\u2019s not clear how effective any of them are.", "answer": 0}, {"article": "Infection with H. pylori is associated with increased risks of stomach and throat cancers.\nThe findings, reported in the Canadian Medical Association Journal, give some extra weight to fecal occult blood testing (FOBT) as a valid option for early detection of colon cancer.\nImmunochemical FOBT is now largely replacing the older test.\nBut there\u2019s been surprisingly little evidence that it really is highly \u201cspecific\u201d to colon cancer, according to Dr. Yi-Chia Lee of National Taiwan University Hospital, one of the researchers on the new study.\nBut as far as cutting the risk of death from colon cancer, stool testing is similarly effective, according to the U.S. Preventive Services Task Force.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Sensitivity and specifity of the test were explained very well.", "answer": 1}, {"article": "ASDs mainly affect a person\u2019s social interaction and communication, with symptoms that can include speech disturbances, repetitive and/or compulsive behaviour, hyperactivity, anxiety, and difficulty adapting to new environments.\nAt this stage, the results presented are not strong enough to suggest that this method could be used for the diagnosis of autism.\nThey found the most reliable of the tests they developed was examining protein in blood plasma, which found children with ASD had higher levels of the oxidation marker dityrosine (DT) and certain sugar-modified compounds called advanced glycation end-products (AGEs).\nScientists said their research found a link between ASD and damage to proteins in blood plasma.\nThey said the next steps were to repeat the study with further groups of children to confirm the good diagnostic performance and to assess if the test could identify ASD at very early stages, indicate how the ASD is likely to develop further to more severe disease, and assess if treatments were working.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says the study found \u201ca link between ASD and damage to proteins in blood plasma \u2026 the most reliable of the tests they developed was examining protein in blood plasma, which found children with ASD had higher levels of the oxidation marker \u2018dityrosine\u2019 (DT) and certain sugar-modified components called \u2018advanced glycation end-products (AGEs).\u201d\nHowever, the story doesn\u2019t include actual data, so the reader has no way of knowing how reliable these tests might be.\nAccording to the study, a computer was used to analyze several combinations of various biomarkers, and the best diagnostic association was found in children with ASD who had higher levels of DT and AGEs.\nThe sensitivity of this model (ie. how many children with ASD were correctly identified) was 92 percent. The specificity of the model (ie. how many people without ASD were correctly identified) was 84 percent.\nIt means that 8 percent of the children with ASD were missed by the model, and 16 percent of the children that were diagnosed with ASD didn\u2019t actually have the condition.", "answer": 0}, {"article": "\"Our idea was to find a way to do a quick examination that would allow, during a boxing or American football match for example, to determine whether the athlete can return to the field or if his condition requires hospitalization.\nHis team has developed a rapid diagnostic test (POCT) called TBIcheck, inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 nanograms per millilitre of blood.\nToday, the injured patients have to go to the emergency rooms of hospitals equipped with a CT Scan, an expensive examination that sends X-rays to the brain to detect the presence or absence of brain trauma.\nYet 90% of these patients will be able to return home safely, as no trauma has been detected.\nResearchers from the University of Geneva (UNIGE), in collaboration with the Hospitals of Barcelona, Madrid and Seville, have developed a small device - Point-of-Care Test (POCT) - that analyses the level of proteins in the blood and allows, using a single drop of blood, to diagnose the possibility of a mild traumatic brain injury.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that the device \u201cwill not only relieve emergency departments, free patients from often long waits, but also save on costly medical examinations.\u201d A physician was quoted stating that the test was designed \u201cto determine whether the athlete can return to the field or if his condition requires hospitalization.\u201d\nBut it did not give sufficient data to demonstrate all of those claims.\u00a0The accuracy of the test is not described by the release nor is it clear if the test improves care in any way. Also, important long term outcomes (disability, difficulty concentrating, etc.) were not part of the study so any claims made on these outcomes would be inappropriate.\nThe news release did state that measuring the level of one protein, H-FABP, \u201cmakes it possible to confirm that there is no risk of trauma in one third of patients,\u201d based on a study of patients who had already been admitted to a hospital after undergoing a shock to the head. It stated: \u201cThe rest of the patients will have to undergo a CT scan to confirm the diagnosis.\u201d\nThe release also stated \u2014 prematurely \u2014 that the company is \u201ccurrently preparing an even more effective TBIcheck, which will allow 50% of patients to be sent home,\u201d based on the levels of two proteins.", "answer": 0}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides statistics on the percentage of people who lost weight after one year of wearing the device \u2014 \u201c38.3% of subjects who received the active Maestro device lost at least a quarter of their excess weight, and 52.5% of subjects lost at least 20% of their excess weight.\u201d \u00a0But how much \u201cexcess weight\u201d did these participants have when they started the study? Since we don\u2019t know that number, we can\u2019t calculate what \u201cat least a quarter\u201d of that weight amounts to. To make sense of this study for the average reader, the story could have said what a typical/average patient weighed at the start of the study and much weight they lost over the course of the study.", "answer": 0}, {"article": "Related links:Department of PsychologyCentre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain\u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9alMAB-Mackay Rehabilitation Centre\n\u201cWhen we took previous experience into account, we found that participants who had used iPads before read on average 30 words per minute faster than those who were using the iPad for the first time.\n\u201cTablet computers offer many of the same benefits while being socially acceptable,\u201d says Aaron Johnson, the study\u2019s senior author, and an associate professor in the psychology department, and a member of the Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal (CRIR).\n\u201cUnsurprisingly, we found that most participants found it hard to read small and medium text, while nearly a quarter of them reported that reading large text was much easier,\u201d says Elliott Morrice, an MA student in Concordia\u2019s Department of Psychology and the study\u2019s first author.\nA study recently described in Good Times Magazine provides the first experimental evidence that the Apple iPad is as good as technology traditionally used in reading rehabilitation for individuals with visual impairment.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The short release does not quantify benefits in a way that is easy for us to understand. It promises a comparison of the seniors reading \u201cquality\u201d on an iPad with the same patients reading on a different device. Here is an excerpt: \u201cThe researchers used questionnaires and tests to gauge participants\u2019 visual ability, and then compared the Apple iPad versus two traditionally used magnification devices, to see if reading rates varied across devices.\u201d But we are never given a true apples to apples number for how many of the readers showed better or equal visual ability on the iPads compared to their ability on other devices. We are told it is \u201cunsurprising\u201d that about one-quarter (25) of the 100 volunteers could read magnified text better whether using an iPad or two other magnification devices. What were the other devices? How large was the magnification?\nThe release did quantify one benefit, namely it said that study volunteers who had previous experience reading on an iPad or closed circuit television system (CCTV) device could read 30 words faster than those trying the iPad for the first time. This seems like a side observation, not entirely relevant to the central issue of comparing iPads and more expensive alternative devices.\nThe release also cited social acceptance of the iPad as a benefit. People are seen carrying their portable devices everywhere and so an older person seen using their tablet as a reading aid won\u2019t draw attention to their age-related vision impairment. It would have been nice to see some quantification of this benefit, even if it was drawn from a survey of the volunteers.", "answer": 0}, {"article": "recommend.\u201d\n\nDr. Nestle finds the situation so confusing \u201cno rational person can possibly figure out how to make sense of it,\u201d she said.\nDr. Malden C. Nesheim, chairman of the institute\u2019s committee and a provost emeritus at Cornell, said, \u201cWe are quite cautious because the studies we looked at are not controlled for all the variables, and we can\u2019t distinguish between the effects from omega-3\u2019s or replacement of other foods in the diet.\u201d\n\nThe National Oceanic & Atmospheric Administration had requested the institute\u2019s report because it said consumers were confused about how much and what kind of fish they should eat.\nreports to address the risks of mercury in tuna,\u201d said the consumer organization, \u201cwe are also concerned that both reports dismiss concerns about PCB\u2019s in most fish.\u201d\n\n\u201cThese reports are urging Americans to eat more seafood as if it were a crisis,\u201d Dr. Goldberg said.\nDr. Mozaffarian agreed that, because the evidence is based on observational studies and clinical trial data, it is not definitive, but he added, \u201cIt\u2019s the best evidence we have.\u201d As for the study\u2019s finding that total mortality could be cut by 17 percent, he said, \u201cWhile one can argue over the precise size of benefits, even if the benefit is only one-half or one-quarter as large, it still greatly outweighs the risk.\u201d\n\nThe report from the Institute of Medicine tells the government that much more research is needed.\n\u201cThe high degree of certainty in one report and the extreme caution in the other,\u201d said Rebecca Goldberg, a senior scientist with Environmental Defense, an advocacy group, \u201cwill make people more confused than ever.\u201d\n\nTo the surprise of Institute of Medicine officials, NOAA sponsored the hastily called press conference at which the Harvard report was released, even though that study conflicted with the one prepared by the institute.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article expresses the most significant reported benefits of fish consumption\u2014decreases in coronary death and total mortality\u2014as reductions in relative risk. The article does not explain how this translates into reductions in absolute risk. (Read more about absolute vs. relative risk.) The story also doesn't explain what the risk of death is for those who do not consume fish\u2014but neither does the JAMA study that makes the health claim. The story does quote one source who quips, \u201c[The study] would indeed make eating fish the single most important decision you can make for your health.\u201d", "answer": 0}, {"article": "\"Current FDA-approved treatments for depression fail for millions of people because they don't work or don't work fast enough,\" said senior author Ruben Abagyan, PhD, professor of pharmacy.\nThat control group eliminated the possibility that people who take ketamine have less depression because they have less pain.\nAccording to Abagyan, it is possible that another factor common to patients taking ketamine was driving the antidepressant effect, such as the fact that ketamine also relieves pain.\nBut ketamine has not been tested in a large clinical trial, and all evidence of its antidepressant effects has come from anecdotes and small studies of fewer than 100 patients.\nThey found that depression was reported half as often among the more than 41,000 patients who took ketamine, as compared to patients who took any other drug or drug combination for pain.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release strongly suggests ketamine is beneficial for depression, but gives almost no evidence. It states that compared to other patients in the database, ketamine users showed a 50 percent reduction in depression, but no absolute numbers of people aided by the drug were provided. The absence of depression as a side effect is a novel but invalid way of defining effectiveness.", "answer": 0}, {"article": "To compare the effects of linagliptin to glimepiride (the most commonly used sulphonylurea), the researchers conducted a double-blind study over the course of two years.\nThe researchers pointed out that most patients are prescribed a class of drugs called sulphonylureas to supplement metformin.\nResearchers in Germany noted that the new drug, linagliptin (Tradjenta), is intended for use in patients that do not fare well with metformin, the most common first-line drug used to treat the disease.\nOne expert said patients and doctors may still have to balance the superiority of linagliptin against its higher cost in comparison to older drugs.\nThe study authors pointed out linagliptin was licensed in 2011 and this is the first long-term study examining its safety and effectiveness.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits were not fully described to back up the lead.\u00a0 The information on the decreased number of heart attacks and strokes with linagliptin treatment is mentioned in the Lancet abstract and could have easily been added to this article.\u00a0 Instead, all we got were vague comments of \u201cworked as well\u201d or \u201ceffectiveness of the drugs were (sic) similar. \u201c", "answer": 0}, {"article": "Bladder cancer is the fourth most common cancer in men, but it is less common in women.\nSixty-seven percent of robotic surgery patients experienced adverse effects such as urinary tract infections and intestinal obstructions, compared with 69 percent in the open surgery group.\nThe RAZOR trial found that two years after surgery, 72.3 percent of patients in the robotic surgery group were alive, with no disease progression and essentially cured, compared with 71.6 percent in the open surgery group.\nThe study is called RAZOR (randomized open versus robotic cystectomy trial) and was funded by the National Cancer Institute.\nLoyola is among 15 centers that participated in the nationwide trial of 350 patients, who were randomly assigned to undergo robotic surgery or open surgery to remove cancerous bladders.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does report the percentage of patients in the robot-assisted and open surgery groups that were still alive with no signs of disease progression two years after their procedures: 72.3 percent of patients in the robotic surgery group compared with 71.6 percent in the open surgery group\u2026 and it notes the difference was not statistically significant. It also reports that the robot-assisted surgery patients checked out of the hospital after six days on average, compared to 7 days for those in the open surgery group. The release reports only half as much blood loss in the robot surgery group, but does not report the amounts, which averaged 300 mL in the robot-assisted group vs. 700 mL in the open surgery group\u2026 that\u2019s a difference of less than one pint.", "answer": 1}, {"article": "Followers of the popular regime eat during an eight-hour window, in this case between 10 a.m. and 6 p.m. And for the 16 hours in between, they consume only calorie-free drinks, such as water.\nThe authors noted that the results mirror those from previous studies of other forms of intermittent fasting, including alternate day fasting, where an individual eats normally every other day.\nThe study's authors acknowledged that their preliminary data offers \"promise for the use of time-restricted feeding as a weight loss technique in obese adults, but longer-term, large-scale randomized controlled trials [are needed].\"\nCommenting broadly on fast-style diets, James Catterson of the Institute of Healthy Ageing at University College London, who was not involved in the study, previously told Newsweek the jury is still out on fasting diets.\nKrista Varady, one of the study's authors and associate professor of kinesiology and nutrition at the University of Illinois at Chicago's School of Applied Health Sciences, said in a statement that the take-home message from the study is that cutting out certain foods or counting calories aren\u2019t the only effective methods for losing weight.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story said people on the diet \u201cconsumed\u00a0around 350 fewer calories, resulting in a loss of 3 percent body weight, and their blood pressure dropped by around 7mm Hg. However, their fat mass, insulin resistance\u00a0and cholesterol levels were similar to the control group\u2019s.\u201d\nThat\u2019s a start. The story would have been more informative if it gave actual weights and blood pressure readings along with information on how big the changes need to be to lower a person\u2019s metabolic disease risk, which is the real goal.\nFor example, according to the study, evidence suggests at least 5% weight loss is required to improve cholesterol and glucose regulation.\nThe story incorrectly reported that the results \u201cmirror those\u201d of other intermittent fasting diets. In fact, the researchers said compared with other forms of intermittent fasting, time-restricted feeding \u201cappears to produce less weight loss.\u201d", "answer": 0}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article does a good job in cautioning the reader that the study\u2019s\u00a0sample size was too small and that the study time too short to draw firm conclusions of \u201cno increase in breast cancer, stroke, heart attack or blood clots.\u201d However, the article states : \u201cWomen on both forms of estrogen reported fewer hot flashes, night sweats and mood swings, as well as an improvement in bone density,\u201d but this statement is not supported with any data in the story. Similarly, the story points out that estrogen in pill form, but not the patch, improved symptoms of depression, anxiety and tension \u2013 but again, these benefits were not quantified. In addition, how were these benefits measured by researchers?\nThe statement about the NIH-funded branch study on mood symptoms and cognition was particularly awkward. From the little we know of the published description of the KRONOS trial, it was not designed to look at effects of hormone therapy vs placebo specifically in women with mood and/or cognitive symptoms related to menopause. Showing a global benefit on such symptoms is not surprising, but we don\u2019t know enough to understand whether the methods used were appropriate to the task. This study should not be interpreted as a justification for menopausal women to run to the doctor for estrogen prescriptions if they are feeling depressed or noticing some trouble remembering names\u2013and the article doesn\u2019t make that clear.", "answer": 0}, {"article": "Seizures can be obvious, causing unconsciousness or convulsions, but often they trigger subtler changes in a person's perceptions or behavior -- like a short staring spell, confusion or an altered sense of taste or smell.\nStill, Mehta agreed that the technology could prove helpful to some people with epilepsy.\nThe findings, reported online May 2 in the journal Lancet Neurology, are based on only 15 patients, and the device worked far better in some than others.\nTwo patients ultimately had the implants removed.\nOver those four months, the implants worked fairly well for eight patients -- correctly giving the high-risk warning anywhere from 56 percent to 100 percent of the time.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was appropriately cautious in describing the potential benefits based on what was observed in only 15 patients.\u00a0 The limitations were clearly presented.", "answer": 1}, {"article": "Source: Australian Bureau of Statistics, 2016, National Health Survey: First results, 2014-15, ABS cat.\n\u201cThis study shows that the new MedDairy works better than a generic low-fat diet, ensuring better health outcomes for people at risk of cardiovascular disease.\u201d\n\nImportantly, the MedDairy diet also meets additional calcium requirements recommended by Australia\u2019s national health bodies.\nSimilarly, the Mediterranean diet (MedDiet) has been shown to deliver significant health benefits.\nNewswise \u2014 Thousands of people can take heart as new research from the University of South Australia shows a dairy-enhanced Mediterranean diet will significantly increase health outcomes for those at risk of cardiovascular disease \u2013 and it\u2019s even more effective than a low-fat diet.\n\u201cThe new MedDairy diet allows for three to four servings with dairy, which means Australians can more sustainably meet their recommended daily nutrient intakes while also maintaining the significant health benefits offered through the MedDiet.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A statistically significant reduction in blood pressure doesn\u2019t always translate to a clinically significant reduction. This release doesn\u2019t make that distinction for readers. It mentions that a dairy-supplemented Mediterranean diet significantly improved blood pressure, heart rate, cholesterol, mood and cognitive function, but it doesn\u2019t describe how much each outcome improved.", "answer": 0}, {"article": "\u201cBut now, we\u2019re seeing this whole new spectrum of treatments.\nIt\u2019s a risky proposition to give patients the foods they\u2019re deathly allergic to \u2014 inducing anaphylactic reactions simply to test drugs in clinical trials.\n\u201cThat hypothetically decreases the risk for adverse events.\u201d\n\nFor all the research on allergies, none of the drugs in the pipeline is a sure thing.\n\u201cThere\u2019s really no doubt that there have been cold feet in the industry about this issue.\u201d\n\nBut investigators around the world have shown they can carry out these \u201cfood challenge\u201d trials safely \u2014 which could help hasten the development of new drugs.\nLooking at IgE from a different angle, Harvard statistical geneticist Liming Liang has been hunting for new drug targets that might modulate how, exactly, the antibody is expressed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the article finally does get to the point that biologics, immunologics, and quicker ways to achieve desensitization may not \u2014 for many patients \u2014 work better than golden oldies like antihistamines, the story could have, but didn\u2019t, make any attempt to pin down what kinds of patients and how many of them might need or want the newer drugs, which are at best mostly years from being available.", "answer": 0}, {"article": "\"We compare the colored glasses to being like a brace or cast but for the brain,\" he says.\nPhotophobia is so common that many neurosurgical intensive care units consider it standard operating procedure to keep lights dimmed in rooms containing TBI patients says Clark.\nWe believe the use of the colored glasses that provide photophobia mitigation has added benefits superior to dark sunglasses, especially for indoor lighting.\"\n\"We believe that an athletic trainer, in consultation with team physicians, may find it useful to apply this photophobia assessment and recommend colored glasses to his or her athlete,\" Clark says.\n\"What is needed is a light mitigation strategy that can be readily employed indoors, which can optimize relief in those who suffer from photophobia, or light sensitivity.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The study provides no actual numbers to back up the claim that 85 percent of the patients had improvements in their symptoms. The only hard number it mentions is \u201c51 patients.\u201d But the study itself says, \u201cOf the 39 patients studied who had vision symptoms, 76% complained of photophobia\u2026symptoms were relieved in 85% of patients reporting photophobia.\u201d So first that drops the number to 30 (depending on how they rounded). Then, 85 percent of that would be 26 (generously rounding up), which is a pretty small number. Not to mention that we have no idea what relief of symptoms means. And for how long did these symptoms go away?", "answer": 0}, {"article": "After all, our immune system evolved over millions of years to respond to infections of injured skin, not vaccines delivered by hypodermic syringe into muscle,\" he noted.\nThey also found that a melanoma vaccine delivered by scarification was much more effective than injected vaccines in protecting animals against melanoma tumor growth.\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\nIn a series of tests, the Brigham and Women's Hospital researchers also found that the memory of T-cells -- the cells that mount an immune response against invading viruses -- may be more important than the antibodies generated by injected vaccines.\nSUNDAY, Jan. 17, 2010 (HealthDay News) -- Giving a vaccine through a scratch on the skin (scarification) triggers a stronger immune response than injected vaccines, say U.S. researchers, who also found that scarification requires 100 times less vaccine to prompt an immune response.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gave no data on scarification vaccination effectiveness in the animals studied.\u00a0 The story described \"much greater effectiveness\" but didn\u2019t explain nor quantify.\u00a0 \nIt did say that \"scarification requires 100 times less vaccine to prompt an immune response\" but did not project whether that result in mice might translate to humans.\u00a0", "answer": 0}, {"article": "New medtech apps put specialist knowledge in patients' pockets\n\nDeep-learning networks have already been applied to produce algorithms capable of diagnosing diseases like melanoma and blindness caused by diabetes.\nFurther tests are required before this latest method can be used within a clinical setting.\nThe method\u2014detailed in a paper published on Monday in the Nature journal Biomedical Engineering\u2014involves analyzing blood vessels in an area of the eye called the retinal fundus.\nThe researchers concluded: \u201cThe opportunity to one day readily understand the health of a patient\u2019s blood vessels, key to cardiovascular health, with a simple retinal image could lower the barrier to engage in critical conversations on preventive measures to protect against a cardiovascular event.\u201d\nTraining deep-learning models on data from more than a quarter of a million patients, the scientists were able to predict the cardiovascular risk factors that were not previously thought to be present in retinal fundus images.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only numerical data offered by this story is that they used \u201cdata from more than a quarter of a million patients.\u201d\u00a0 There is no comparison of the success rate of this new approach with other mechanisms for determining cardiovascular risk, so readers have no way of assessing its potential value.", "answer": 0}, {"article": "\"It's not.\"\nThe investigators further noted that even eight months after treatment launch, no serious adverse effects were directly attributable to the new drug.\nBut initial indications suggest that the new antibody drug, called ocrelizumab, successfully targets these renegade cells with hopeful results: a significant reduction in disease-related inflammatory brain lesions.\nTUESDAY, Nov. 1, 2011 (HealthDay News) -- Multiple sclerosis patients may eventually benefit from a novel treatment that takes aim at the abnormal behavior of a specific type of immune cell, preliminary research suggests.\nTo test the drug, Kappos and his team recruited patients aged 18 to 55 seeking MS treatment in 79 centers in 20 countries.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Same criticisms as in the \u201cevidence\u201d criterion:\nWhat does an 89 percent drop in lesion count mean?\u00a0 What is the relationship between lesion count and symptoms or eventual outcome? How does a patient relate lesion count to something meaningful in his/her life?\nRelapse rates may have been a more helpful indicator, but we\u2019re only told they were \u201cmuch lower.\u201d\u00a0 How much lower?\u00a0 What does that mean to patients?\nAnd if the Mayo expert says that a competing drug has been in early trials for years \u2013 why not provide the evidence from those trials?\nThe headline says \u201cpromising\u201d but the independent expert says \u201cI see no major advantage of this drug versus that older drug. It\u2019s not better or worse. It\u2019s the same\u201d\u00a0and that it\u2019s not a breakthrough.", "answer": 0}, {"article": "Some doctors are raising concerns about a new cancer-treatment device that uses electrical jolts to zap tumors but that hasn't been through a large clinical trial to prove it's safe and effective in people.\n\nThe device, called NanoKnife, is currently being used in about 13 U.S. hospitals including Baptist Health Medical Center in Little Rock, Ark., University of Louisville, and Shands Hospital/University of Florida in Gainesville, Fla. Each machine costs as much as $300,000. Some of the hospitals are aggressively promoting...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As with the harms, it is difficult to quantify the benefits because of the lack of evidence. Here we think the story relies a little too much on anecdotal evidence. On balance, the story presents a complete picture, though.", "answer": 1}, {"article": "For more on chemotherapy, visit the American Cancer Society.\nSpecifically, nearly 70 percent of those in the fish oil group either kept their pre-chemo muscle mass or gained muscle.\nWhat's more, blood analyses revealed that those in the fish oil group who had the biggest bump in bloodstream EPA concentrations also had the greatest muscle mass gains.\nThe finding is based on a small study involving just 40 lung cancer patients.\n\"But I would caution that the amount of pure concentrated fish oil supplement the people in this study were given is a lot,\" she added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The weight loss figures for the two groups were given.\u00a0 But the muscle mass figures were given in percentages, which is clumsy.\u00a0 Rather than 70% in the fish oil group kept their pre-chemo muscle mass, why not say 11 out of 16.\u00a0 And rather than less than 30% in the standard care group, why not just say 7 of 24? (Or whatever the actual numbers were.)\nBut let\u2019s drop back to the big picture.\u00a0 Rather than merely reporting numbers, why didn\u2019t the story report on what difference these results may have had in peoples\u2019 lives, if any?\u00a0 Or is that impossible to gauge after just a 10-week study?\u00a0 If so, perhaps that, too, should have been discussed because it again reflects on the limitations of such a small, short-term study.", "answer": 0}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nSlightly more than half (53 percent) of eyes in the laser group received Lucentis injections to treat DME.\nFunded by the National Eye Institute (NEI) and conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net), the trial compared Lucentis injections with a type of laser therapy called panretinal photocoagulation, which has remained the gold standard for PDR since the mid-1970s.\nAbout 6 percent of eyes in the Lucentis group received laser therapy, mostly for issues other than DME.\n\u201cLucentis should be considered a viable treatment option for people with PDR, especially for individuals needing anti-VEGF for DME,\u201d said Jeffrey G. Gross, M.D., of the Carolina Retina Center in Columbia, South Carolina, who chaired the clinical study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are, for the most part, reasonably well explained. But those explanations lack numbers to back them up and are overstated in at least one place.\n\u201cOne benefit discussed in the release is that study participants who received laser treatment were more likely to suffer peripheral vision loss than participants who were treated solely with Lucentis \u2014 although this isn\u2019t quantified. A second benefit was that participants who received laser treatment were more likely to require subsequent surgery to remove blood from the eye \u2014 and this was quantified. But the release pushes things a bit when it comes to vision, or visual acuity. The release states: \u201cAt two years, vision in the Lucentis group improved by an average of about half a line on an eye chart, compared with virtually no change in the laser group.\u201d But here\u2019s how the journal article puts it: \u201cThere was no statistically significant visual acuity difference between the ranibizumab and PRP [laser] groups at 2 years.\nThe language in the journal article itself stresses that what was being evaluated was whether Lucentis was at least as good as laser treatment \u2014 and they found that, after two years, the visual acuity of patients who took Lucentis (and had no laser treatment) was as good as patients who had the laser treatment. The release could have simply stated this and avoided confusion.\nIn short, this was a close one \u2014 but the lack of numbers on peripheral vision and the overstatement of the visual acuity results make this a \u201cNot Satisfactory.\u201d", "answer": 0}, {"article": "The General Director of the Danish section of MSF Jesper H. Brix notes:\n\n\"Acute malnutrition is still a major global health problem.\nThe results of the study can be used directly both in the treatment and prevention of acute malnutrition.\nThe main Treatfood results are presented in the paper: Effectiveness of food supplements in increasing fat-free tissue accretion in children with moderate acute malnutrition: A randomised 2 \u00d7 2 \u00d7 3 factorial trial in Burkina Faso, published in the open access medical journal PLOS Medicine.\nDuring the trial, 1609 small children with moderate acute malnutrition were given either LNS or corn-soy porridge for 12 weeks.\nThe study found that children who received LNS experienced greater weight gain, and the large majority of the weight gain was healthy lean tissue.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The primary outcome in this study was weight gain that was not primarily fat; it is important to note that this study did not address survival or neurodevelopment, which are the presumed benefits of greater fat-free weight gain. The news release tells us that children who received LNS gained more weight than children on the corn-soy porridge, and that weight was primarily lean mass. It doesn\u2019t tell us how much more weight they gained, nor does it describe the difference in progression to severe acute malnutrition. Studies with large samples like this one can give results that are statistically significant even when differences are small. Specific information about the size and clinical importance of the difference should have been included.", "answer": 0}, {"article": "\"Oh, absolutely!\"\nTo put the difference in perspective, the avocado diet decreased LDL cholesterol about 14 milligrams per deciliter of blood.\nIt's also possible that the fiber in avocados plays a role in the cholesterol-lowering effect, she says.\nShe says she'd like to do follow-up research to look at the bioactive compounds in avocados, which may explain the added reduction in LDL cholesterol in the study participants.\n\"I was surprised to see the added benefit [of the avocado],\" Penny Kris-Etherton, a nutrition scientist at Penn State and the lead author of the study, tells us.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does compare the reduction of LDL cholesterol in study participants who ate avocado to reductions in LDL among study participants who did not. However, it is not clear if the differences are significant relative to the overall amount of LDL cholesterol found in blood \u2014 and the story never explains how LDL cholesterol is linked to human health. It would have been nice if the story had explained why people should care about their LDL cholesterol or why it is termed the \u201cbad\u201d cholesterol. Comparing the reductions seen with a common dose of Lipitor (atorvastatin), or explaining how the changes would affect one\u2019s overall cardiovascular risk, would be helpful for readers.", "answer": 0}, {"article": "\"It was surprising, and exciting,\" Dr Belmer said.\n\"While it could possibly have that effect, it might be able to help reboot the brain and reverse the deficits the alcohol abuse causes - both the inhibition to the brain's ability to regenerate, and the behavioural consequences that come from what alcohol is doing to the brain, like increases in anxiety and depression.\"\n\"This opens the way to look at if neurogenesis is associated with other substance-abuse deficits, such as in memory and learning, and whether this compound can reverse these.\"\nAlcohol is specifically very damaging for neurons.\n\"Other studies in mice have shown that tandospirone improves brain neurogenesis, but this is the first time it has been shown that it can totally reverse the neurogenic deficits induced by alcohol.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release assumes that binge-drinking in selectively-bred rodents and the brain and behavior changes they evidence have some relevance to humans. Quantification of benefits are irrelevant since rodent drinkers are not the same as human drinkers. Some evidence on human benefit is needed.\nAs to the benefits of using tandospirone in mice, the release provides the following:\u00a0 \u201c\u2026.two weeks of daily treatment with the drug tandospirone reversed the effects of 15 weeks of binge-like alcohol consumption on neurogenesis \u2013 the ability of the brain to grow and replace neurons (brain cells).\u201d Simply saying it \u201creversed the effects\u201d or \u201cthe drug was effective\u201d isn\u2019t adequate for conveying any potential benefits from the drug\u2019s use.", "answer": 0}, {"article": "Lactoferrin supplementation also enhances the expression of salivary immune proteins, which may help reduce oxidative stress and resulting side effects.\nAlthough TSA is widespread and a frequent complaint of cancer patients, until now, there have been no established therapies that reliably prevent or treat this problem.\nTheir most recent study builds on the previous body of work through the application of lactoferrin supplements in treating taste and smell abnormalities.\nThe team's findings will make it possible for cancer patients to taste foods properly and to enjoy a healthier appetite, enabling more optimal nutrition during a critical period of recovery.\nThis research could help us develop TSA-targeted biomarkers and strategies for improving quality of life during chemotherapy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A study author is quoted as speculating that lactoferrin \u2026\n\u201celicits changes in the salivary protein profiles in cancer patients \u2014 changes that may be influential in helping protect taste buds and odor perception\u201d \u2014 which in turn \u2014 might \u201creduce TSA (\u201ctaste and smell abnormalities\u201d), restoring their ability to enjoy food during a time in which nutrition can play a key role in recovery.\u201d\nAlthough the logic here appears sound there is no data included to support this chain of eventualities.", "answer": 0}, {"article": "Vitamin D is found in certain foods and beverages such as fortified milk and cereals, and fatty fish such as salmon.\nIt revealed that women born to mothers who had the highest intake of vitamin D had a much lower risk of developing MS as an adult.\nThe study involved more than 35,000 female nurses whose mothers answered questions about their diet habits during pregnancy.\nGrowing evidence has suggested that vitamin D, found in fortified milk, may lower one\u2019s risk of MS. Now, researchers with the Harvard School of Public Health in Boston have shown that it\u2019s possible this protective benefit could begin while a baby is developing in the womb.\n\"The risk of MS among daughters whose mothers consumed four glasses of milk per day was 56% lower than daughters whose mothers consumed less than three glasses of milk per month,\" Harvard researcher Fariba Mirzaei, MD, says in a news release.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only presented the results in terms of relative risk, rather than absolute risk (56% lower than what?).\u00a0 Additionally, the story suggests that daughters of mothers who drank 4 glasses of milk per day had a lower risk of MS compared to those whose mothers who drank 3 glasses of milk per day.\u00a0 However, we\u2019re not told whether this difference is statistically significant. ", "answer": 0}, {"article": "According to traditional medicine, specific acupuncture points on the skin are connected to internal pathways that conduct energy, or qi (\u201cchee\u201d), and stimulating these points with a fine needle promotes the healthy flow of qi.\nThe study, which followed 150 pregnant women with major depression, tested \u201cdepression-specific\u201d acupuncture against massage and acupuncture sessions that, according to traditional Chinese medicine, does not specifically target depression.\nOverall, Manber\u2019s team notes, the response to acupuncture in this study was comparable to what has been seen in studies of psychotherapy for depression during pregnancy.\n\u201cHowever,\u201d she added, \u201cunlike a pill, which always has the same ingredients, acupuncture, like psychotherapy, varies from one provider to the other.\u201d\n\nSo while the specific regimen used in this study appeared effective, Manber said, \u201cI do not think we can say that our study proves that acupuncture is effective for depression during pregnancy.\u201d\n\nIt\u2019s estimated that 3 to 5 percent of pregnant women are diagnosed with depression, Manber and her colleagues note in their report.\nResearchers found that after eight weeks, women who received depression-specific acupuncture were more likely to have a treatment response \u2014 meaning the severity of their symptoms fell by at least half and they no longer met all of the criteria for diagnosing major depression.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only reported benefits in percentages in each group that \"responded to therapy,\" but later the story provided the actual numbers of women assigned to the three study groups \u2013 so it\u2019s possible for readers to do the math.\u00a0 Nonetheless, why make them do the math?\u00a0 Why not just give the absolute numbers of how many in each group responded?\n", "answer": 0}, {"article": "The United States recommends that men and women over age 31 eat 420 and 320 milligrams of magnesium daily, respectively.\nMost of the studies allowed the researchers to rule out other factors, such as family history.\nMore in-depth studies are needed before researchers can say that the magnesium was what actually reduced the stroke risk, she added.\n\u201cDietary magnesium intake is inversely associated with risk of stroke, specifically ischemic stroke,\u201d wrote lead author Susanna Larsson, a professor at the Karolinska Institute in Stockholm, Sweden.\nBut Larsson told Reuters Health in an email that she could not say whether other aspects of what the people ate partially or entirely explained the finding.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided the absolute number of strokes observed in the analysis, and the relative risk reduction observed. With a meta-analysis it is not statistically appropriate to pool absolute risk reductions, so the way the story treated the evidence is as good as can be done (showing the relative risk reduction and an \u201canchor\u201d in terms of absolute risk.)", "answer": 1}, {"article": "For more information, see www.scripps.edu.\nThe antibiotic has been prescribed by doctors for 60 years, and bacteria are only now developing resistance to it.\nThe original form of vancomycin is an ideal starting place for developing better antibiotics.\nBoger called vancomycin \u201cmagical\u201d for its proven strength against infections, and previous studies by Boger and his colleagues at TSRI had shown that it is possible to add two modifications to vancomycin to make it even more potent.\n\u201cDoctors could use this modified form of vancomycin without fear of resistance emerging,\u201d said Boger, whose team announced the finding today in the journal Proceedings of the National Academy of Sciences.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release tells readers that \u201cCombined with the previous modifications, this [new] alteration gives vancomycin a 1,000-fold increase in activity, meaning doctors would need to use less of the antibiotic to fight infection.\u201d It\u2019s not entirely clear what this means. Does it kill relevant bacteria more quickly? More efficiently? Clinical trials in humans haven\u2019t been conducted, so it\u2019s not clear what the benefits would look like in patients \u2014 and the release doesn\u2019t tell readers that.\nAs the final sentence in the abstract of the scientific article states: \u201cSuch antibiotics are expected to display durable antimicrobial activity not prone to rapidly acquired clinical resistance.\u201d No where could we find quantifiable benefits of the drug in fighting antibiotic-resistant infection.", "answer": 0}, {"article": "Diseases like Alzheimer\u2019s start years, even decades, before the first symptoms of memory loss shows up.\n\u201cBut what\u2019s nice about it is that it\u2019s a nice non-cognitive, motor factor so it\u2019s looking at another aspect of brain function.\u201d\n\nMORE: This Alzheimer\u2019s Breakthrough Could Be a Game Changer\n\nPetersen suggests that every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\nFor now, even if doctors identify patients around age 65 who might be at higher risk of developing cognitive impairment, there isn\u2019t much they can do to interrupt the process.\nMORE: New Test May Predict Alzheimer\u2019s 10 Years Before Diagnosis\n\nWhile his test is a possible solution to that problem, he acknowledges that the results need be repeated before it\u2019s recommended on a wide scale to physicians across the country.\nPetersen believes that the test they came up with could become a useful tool for any physician, even those without special training in the brain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We give the story credit for pointing out that there are few if any meaningful interventions available for MCI, and the testing may be useful in the future to identify patients who might benefit. But we have some concerns.\nOur first issue with the story is the emphasis on the early diagnosis of Alzheimer\u2019s disease. \u00a0The study was actually directed at early identification of mild cognitive impairment and not Alzheimer\u2019s per se. \u00a0The distinction is important. Although many people with mild cognitive impairment go on to full blown Alzhemier\u2019s, not all do.\nOur second problem with the story is the lack of any meaningful quantification of the results. The story notes, \u201c\u2026those who scored higher on the test of risk factors had a seven-fold higher chance of developing mild cognitive impairment than those with lower scores.\u201d That doesn\u2019t really tell us anything useful about the test results. As a reader, I want to know how good is the test at predicting whether I\u2019m going to be impaired? As it turns out, the \u201c7-fold increase\u201d is not as definitive as suggested by the story. For example, a 70-year-old man with the highest score in the tests has a 1 in 4 chance of developing mild cognitive impairment in the next 5 years. \u00a0That same individual would have about the same risk of a major cardiac event based on the American Heart Association risk calculator. So individuals who score highly on the test are hardly condemned to develop Alzheimer\u2019s, or even mild cognitive impairment. The story would have done well to communicate that fact to readers.", "answer": 0}, {"article": "Anderson.\nTo further stir the pot, a Norwegian study released last week found that routine mammograms accounted for only about one-third of the decline in breast cancer death rates seen recently.\nThe benefits were greater in women aged 45 to 49, vs. those aged 40 to 44, the researchers said.\nThe study, done in Sweden, found that women who were screened cut their risk by 29 percent.\nWhile the optimal schedule of regular mammograms continues to be discussed by experts in the field, the critical message here is that all women starting at age 40 should talk to their doctor to understand the benefits and risks of screening and to understand what is best.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does note the benefit of screening at age 40-44, 44-49 and for women 50 and older; however, only the relative benefit was given. The story should have reported the number of women in the cohort, who was screened, how long they were followed, and the absolute reduction in breast cancer mortality observed. That has been our standard all along on this site and this is no time to change. \n", "answer": 0}, {"article": "Nathan Mumford, who is African-American, tried to find a bone marrow donor after his leukemia was diagnosed not long after he graduated from college.\nAlso, patients can get the treatment in about three weeks -- as opposed to six to eight for bone marrow from an adult donor, said Laughlin, founder and medical director of the Cleveland Cord Blood Center.\nAt that point, Mumford said, his choices were to continue chemotherapy and live for, maybe, another year and a half.\nBut Tirpak's physician, Dr. Mary Laughlin, turned to something deemed medical waste until recently: umbilical cord blood.\nAnd patients still must endure months of recovery.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "See the larger discussion of the evidence evaluation.\nNone of the potential benefits were quantified \u2014 survival, quality of life, etc. Advantages over bone marrow transplant are enumerated, but the only patient outcome discussed is 100% cure for these two patients and, in a vague afterword, the potential for rejection. The lack of more detail about outcomes fans the flames of this \"medical breakthrough that\u2019s saving lives.\" The truth is that this procedure doesn\u2019t cure everyone who gets it. One 2004 study found that adults with leukemia who received cord blood transplants didn\u2019t live any longer than those who received bone marrow.\u00a0", "answer": 0}, {"article": "If all it requires is to take a closer look at the images, how can we ignore it?,\" he said.\nFuture prospective trials are needed to see what the prognostic significance of breast arterial calcification might be.\nIn an accompanying editorial in JACC: Cardiovascular Imaging, Khurram Nasir, M.D., M.P.H., and John McEvoy, from the Center for Healthcare Advancement and Outcomes at Baptist Health South Florida, said that the report provides impetus to document breast arterial calcification in mammography reports, to improve education of primary care and radiology providers on the link with heart disease, and other actions to establish best practices for incorporating this research into care.\nWhen researchers added 33 asymptomatic women with established CAD, breast arterial calcification was more powerful than both risk assessment formulas, which suggests the presence of subclinical atherosclerosis may be a more important indicator of heart disease than other risk factors.\n\"Whether the best use of breast arterial calcification is to trigger additional testing or to directly inform preventive treatment decisions, either by flagging high-risk women to their providers or by reclassifying traditional (heart disease) risk estimates, is worth further discussion.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does attempt to quantify the accuracy of the test when it states that 70 percent of the women that were shown to have breast arterial calcification (BAC) were also found through CT scans to have coronary artery calcification (CAC). While that may sound impressive, the release doesn\u2019t acknowledge that this equates to a 30 percent false-positive rate. So 30 percent of women may be unnecessarily worried or inconvenienced and sent for additional testing based on these results. Also, we\u2019re not told what percentage of women who tested negative for breast calcification in fact would have have had CAC according to a CT scan of their chest. That\u2019s an important piece of information that speaks to the test\u2019s usefulness. And if it wasn\u2019t addressed in the study, we think the release should have said so. We always encourage news release writers to address both the sensitivity and specificity of screening tests.\nThe release also suggests that measuring breast arterial calcification is a better, more accurate risk factor assessment tool than standard risk scores (Framingham Risk Score and the 2013 Cholesterol Guidelines Pooled Cohort Equations). But it doesn\u2019t provide us with any quantification. Instead it says calcification is a \u201cmore powerful\u201d measure for assessing risk than the standard risk assessment. What exactly does that mean?", "answer": 0}, {"article": "According to Dr. Anthony L. Komaroff, a Harvard internist and epidemiologist who has written a commentary to accompany the study, \"For many years medical scientists have speculated that the symptoms of ME/CFS might be caused by cytokines, molecules that the immune system use to wage war against foreign invaders of the body.\nWhat's more, the findings also point to possible treatment with immune-modifying or anti-inflammatory therapy.\nThe link to gradation in severity, rather than simply seeking a positive versus negative result, represents a new approach to the search for biological markers for the illness.\nThis is significant because symptoms in these patients and findings from other studies also suggest that chronic inflammation plays a major role in the illness.\nTwo classic laboratory measures of inflammation are sedimentation rate \u2014 the ability of red blood cells to clump together, which isn't a factor in ME/CFS \u2014 and C-reactive protein, which reflects levels of a single cytokine that wasn't one of those linked to severity in this study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The most relevant text here is: \u201cOut of 51 cytokines investigated via sophisticated\u00a0fluorescence-based testing, only two of the cytokines differed, in their total concentrations, between the ME/CFS and control groups. But, levels of 17 of the cytokines varied dramatically between the patients with mild versus severe ME/CFS symptoms. Of those 17 cytokines, 13 were types that promote inflammation.\u201d\nThe issue is, though, what does this actually mean in terms of diagnosing a patient as having ME-CFS and treating them with a potentially risky drug such as rituximab that is mentioned in this piece. While the story could have done a better job on that point, we think the discussion here is sufficient for a satisfactory grade. We\u2019ll address the broader implications and the story\u2019s shortcomings below under the evidence quality criterion.", "answer": 1}, {"article": "[It's 3 a.m. and you're depressed.\nThe researchers said enough clinical evidence now supports mental health professionals recommending light therapy as a treatment for depression.\nBut now a study has found that light therapy also works in treating non-seasonal depression.\nAlthough the light therapy helped many patients, it provided the most benefit to those who were also taking the antidepressant.\nLight therapy is cheap, easy to use and comes with few side effects compared to medication such as antidepressants, said lead author Raymond Lam, a professor of psychiatry at the University of British Columbia.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only attempt to describe benefits is vague.\nHere it is, with italics by editors:\n\u201cAlthough the light therapy helped many patients, it provided the most benefit to those who were also taking the antidepressant. About 60 percent of those using light therapy with the antidepressant reported feeling almost back to normal, Lam said.\u201d\nQuantifying means we\u2019d like to know some metric or measure that researchers used to compare the different groups of patients. In the original journal article, the authors said they used MADRS (Montgomery-Asberg Depression Rating Scale) changes from baseline to 8 weeks into the different therapies. It would be useful to know where they started on that scale and where they ended up \u2014 and whether that difference was meaningful.", "answer": 0}, {"article": "Asked if he's suggesting that it's some kind of a rejuvenation drug that would turn a 70-year-old into a 35-year-old, Westphal tells Safer, \"That might be pretty hard to do.\nEveryone from plastic surgeons to your friendly snake oil salesman have been promising a ticket to eternal youth for some time, so the prospect of a prescription pill based on red wine that could trigger a longevity gene sounds too good to be true.\nAnd yet scientists have actually known for years of one surefire of doing that: stay hungry.\nIf they're right, we all may soon be taking a pill that could give us an extra decade or two of healthy old age.\nIt's normally inactive, but when it is active, Sinclair believes it triggers a survival mechanism that extends life.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a lot of speculating about the number of years of life extension possible, without any basis to back up these claims. The story also has the audacity to imply that somehow this pill will help us have a better death \u2013 that with this pill people will die \"quietly in their sleep\". As if anything could have that kind of control over how we die! ", "answer": 0}, {"article": "\u201cIt\u2019s a combination,\u201d Hagan said.\nSpecifically, the researchers found that the most optimistic women had:\n\nThe researchers controlled for a number of factors that could have had an impact on lifespan, including marital status, education level, and other socioeconomic factors.\nOptimistic people are likely to have better diets, they\u2019re exercising more, and they\u2019re getting better sleep.\u201d\n\nHowever, even after the researchers accounted for these factors, the results still suggest that optimism itself is linked to a longer life.\nHowever, they note, \u201cthere is no clear basis for believing that the effects of optimism on health differ by sex or race.\u201d\n\nFinally, the researchers emphasize that while some people may think they\u2019re just not optimistic, it is something that is modifiable.\n\u201cSo in our study we wanted to expand that and look at all-cause mortality and be able to see whether optimism improves other health behaviors that then affects mortality, or whether there\u2019s an independent effect of optimism on mortality.\u201d\n\nFor the study, the researchers analyzed data on from 2004 to 2012 on 70,000 women who participated in the Nurses\u2019 Health Study, a long-running research project tracking women\u2019s health via surveys every two years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers are told that the most\u00a0optimistic\u00a0nurses (top 25%) had nearly a one-third lower chance of dying, at least compared to the the most\u00a0pessimistic\u00a0group (lowest 25% of the survey group for\u00a0optimism). We\u2019re also clued into some of the data behind the longevity numbers: the drop in risk of diseases and conditions that kill the most Americans. For example, according to the study\u2019s analysis, the most optimistic nurses had a 39% lower risk of\u00a0having\u00a0(and dying from) a stroke.\nThe problem? All these numbers are presented in relative risks, instead of absolute\u00a0risks. To know how meaningful these findings were, we need to see the absolute risk of death among the most optimistic of nurses compared to the least optimistic.", "answer": 0}, {"article": "Smith also embarked on a new diet, cutting out dairy and red meat.\nBut the report doesn\u2019t note that just 1 percent of women have that condition in the first place, making the odds still overwhelmingly in her favor.\nAnd even the company\u2019s founder and CEO acknowledges the test can\u2019t provide clear and definitive answers on which treatments women should try next if they\u2019re struggling with infertility.\nBut the company is also beginning to market directly to women \u2014 including younger women who aren\u2019t trying to get pregnant yet.\nBut others caution that Fertilome is just the latest genetic test promising more than it can deliver \u2014 and, in this case, playing to the fears of women who are anxious about becoming a mother.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A primary goal of the story is to drive home the point that benefits are highly uncertain. The text is clear about the intended benefit, to provide genetic information that could inform a woman\u2019s reproductive decisions.\u00a0 But it also tells the reader, in no uncertain terms, that there is as yet \u201cno evidence\u201d that the test actually accomplishes that. It even busts the company for using fictitious patient anecdotes to sell women on the benefits of the test.\nA strong point for the story is its characterization of one woman\u2019s increased risk of a condition known as primary ovarian insufficiency, which the test notes is 4-fold higher than in women without a specific genetic variant.\nThat sounds alarming, and might prompt a younger woman who\u2019s planning to delay pregnancy to freeze her eggs to be sure she has them available down the road. But the report does not explain that the condition is fairly rare \u2014\u00a0affecting just 1 in 1,000 women by age 30 and 1 in 250 women by age 35 \u2014 so the absolute risk is still very small.\nWe have a primer on the difference between relative and absolute risk that readers can turn to for more information.", "answer": 1}, {"article": "Each year, almost 800,000 Americans suffer a stroke, and more than 140,000 die.\nDr. Walter J. Koroshetz, deputy director of the institute that sponsored the North American trial, said the Crest trial was the first in which the results of stenting and surgery had been found to be equivalent \u2014 suggesting that the stent procedure had improved with time.\nAmong the possible explanations offered for the disparities are that the European study included only symptomatic patients, who may have had more advanced disease, and that the North American trial carefully screened the doctors doing the stenting procedure, including only highly skilled physicians with a lot of experience.\nLong-term follow-up of patients, which was two and a half years on average but is continuing, found both groups at equal risk of suffering a stroke that should have been prevented by the procedure: 2 percent of those in the stent group compared with 2.4 percent of the surgical patients.\nThe most important message is that the overall death rate was extremely low, 0.6 percent, said one of the study\u2019s principal investigators, Dr. Gary S. Roubin, the chairman of cardiovascular medicine at Lenox Hill Hospital in New York.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a satisfactory job of presenting the major findings using the appropriate statistics.\u00a0Like the LA Times,\u00a0however, this\u00a0story suggests that the disparate findings of the two studies might be explained by the better training and experience of the\u00a0American CREST surgeons compared with their European counterparts in the ICSS trial. We wish it had spent some time exploring whether the typical patient in the U.S. can expect to receive the kind of expert care offered by the top CREST surgeons.\u00a0In many cases, the\u00a0\"real-world\" outcomes\u00a0of patients will be less favorable than what the CREST team reported.\u00a0\u00a0", "answer": 1}, {"article": "\u201cThis is great science,\u201d says J. Stephen Jones, MD, chairman of the department of regional urology at the Cleveland Clinic in Ohio.\nThe company that developed the test, Gen-Probe, helped to pay for the study, and several authors said they had a personal financial interest in the technology.\nThe two tests together appeared to generate both sensitive and specific results.\nTo increase the accuracy of the test, researchers also looked for another gene, called prostate cancer antigen 3, or PCA3, which is also found in urine.\nResearchers then narrowed their analysis to see how the urine test scores matched the men\u2019s Gleason score, which helps doctors gauge how aggressive a cancer may be.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not quantify the benefit of using these markers to avoid unnecessary biopsies. Typically, biopsy thresholds for the markers will be set to detect a large majority of the cancers (>= 90%) which will then reduce the number of unnecessary biopsies\u2013which can be quantified.", "answer": 0}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits of these tests are touted, but not quantified. An officer of the National Ovarian Cancer Research Fund Alliance, an advocacy group, testifies that the outcomes of women who have surgery from a gynecologic oncologist\u00a0\u201care much better.\u201d But we don\u2019t know\u00a0what that means. Is it longer survival?\nLater the story explains\u00a0that combining the two blood tests with assessment by a clinician \u201cbetter determined the patients who should be referred to a [gynecological oncologist], identifying well over 90 percent of the women who actually had cancer.\u201d \u00a0(Note that this statistic reflects only referral to a gyn-onc, not patient survival.) But how does that compare to the\u00a0standard assessment tools?\nA 2016 study described\u00a0as publication \u201cof the first clinical utility data\u201d demonstrating that use of OVA1 resulted in referral of ovarian patients to gynecologic oncologists offers similar outcomes but is not mentioned in the story.", "answer": 0}, {"article": "It may also improve vision in those with mild myopia (nearsightedness).\nAfter training, the older adults\u2019 ability to see low-contrast images improved to the level that the college-age ones had before training.\nScientists don\u2019t know exactly how perceptual learning relieves presbyopia, but they have some clues based on how our brain processes visual information.\nOne study also examined functions of the eye itself and found none of these improvements were because of changes in the eye.\nThen the brain must coordinate activity across sets of neurons to assemble these features into recognizable objects like chairs, faces, letters or words.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article cites a couple of studies that offer qualified support for\u00a0benefit of the vision training, but specifics were lacking. For example, it says that through use of this training, \u201cpresbyopia lessens.\u201d But how much does it lessen?\nThe piece does describe one small study as finding that older adults who used the training were able to see \u201clow-contrast images\u201d as well as college-aged participants. Does this mean they could read without glasses? And how long do these improvements last? Is continual training required?", "answer": 0}, {"article": "In Japan, \u201cfood and health care companies have found cosmetic applications for their ingredients, so they are creating skin care brands.\u201d\n\nFor example, Frutarom, a flavor-ingredient house based in Israel, makes Alguard, a purified polysaccharide shield from a red microalgae that it says protects skin from daily assaults and reduces roughness as well as the look of fine lines.\nDr. Dana Sachs, an associate professor of dermatology at the University of Michigan, Ann Arbor, wrote in an e-mail after looking at Algenist\u2019s dossier that \u201cthe claims on cell regeneration and elastin synthesis are based on in vitro models, which is hard to extrapolate to in vivo, and again no statistical significance is presented, so this is a weak claim.\u201d\n\nDr. Day, who has a doctorate in biochemistry, said that statistical significance was found but not included in press materials.\nThe patent-pending alguronic acid in Algenist is a \u201csingle, purified, highly bioactive compound,\u201d said Tony Day, the vice president for research and development at Solazyme, and therefore delivers \u201cmuch higher activity to the skin\u201d than products using only a microalgae extract.\nAnd, according to the company, a study of 30 women showed that after 10 days of using the Algenist serum, they had a 25 percent decrease in wrinkles as shown by silicone replicas of their faces.\nThere are more than 100 algae-derived ingredients used in cosmetics worldwide, Mrs. Lewis said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The reporter apparently had access to an \u201c84-page patent application\u201d for the product being sold, but\u00a0the story\u00a0does not present\u00a0quantify any of the evidence that\u00a0may have bene found there.\u00a0Instead, it allows a company vice president to say that \u201ca study of 30 women showed that after 10 days of using the Algenist serum, they had a 25 percent decrease in wrinkles as shown by silicone replicas of their faces.\u201d", "answer": 0}, {"article": "Symptoms include serious memory loss, confusion, and mood changes that develop gradually and worsen with time.\nCoffee was the main, or only source, of caffeine among people in the study.\nThis is equivalent to drinking several cups of coffee a few hours before giving blood.\nThe findings will appear in the Journal of Alzheimer's Disease.\nThere may even be a reason to start for people in their late 30s and up, he says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story just had too many unsupported statements about the benefits of coffee to earn a satisfactory here. Examples:", "answer": 0}, {"article": "Then at 9 to 10 weeks the mother's blood takes over to feed the embryo,\" said Kliman.\n\"This study has shown that the EFT can also be an important tool for patients with recurrent pregnancy loss,\" he said.\n\"The positive results show us that next we need to study progesterone as a treatment for recurrent pregnancy loss with a prospective randomized trial to validate the findings.\"\n\"We are very pleased to find that these results reinforce the evidence that progesterone could be a very beneficial, inexpensive, and safe treatment for many women with a history of recurrent pregnancy loss,\" said Stephenson.\nKliman and the team focused on the nCyclinE molecular marker as a way to assess patients with recurrent pregnancy loss.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release claims that progesterone prevents miscarriages. How many miscarriages did it help prevent and how was this assessed? There aren\u2019t any numbers.", "answer": 0}, {"article": "In an outpatient procedure under local anesthesia, doctors funneled a catheter into the patient's heart and removed peppercorn-sized bits of tissue from the part of the patient's heart that was unaffected by the heart attack.\nNot only did this show that the procedure was safe, it also showed that the cells can help reduce scarring and even cause new heart muscle to grow.\nMarb\u00e1n says when the first patient data came in, he and his colleagues were relieved to see the procedure was safe.\nMarb\u00e1n says the amount of new heart tissue that grew was not subtle.\nTo qualify for this clinical trial, patients had to have suffered a recent heart attack and \"had to have a significant amount of damage to begin with and weren't squeezing [blood into the body] as well as they should have,\" says Dr. Peter Johnston, one of the study authors who injected the new heart cells into patients treated at Johns Hopkins Hospital.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not provide a lot of hard data on benefits, and we would have liked to have seen more. For example, it says that \u201cabout half of their scar tissue dissolved and the reduction in scar size appears to get bigger after the first six months.\u201d But we appreciated some of the specific details it does provide, including: \u201cMarb\u00e1n says the amount of new heart tissue that grew was not subtle. [On average] \u201c22 grams (about .78 ounces) of new heart tissue grew,\u201d which he says is quite remarkable considering this had never been done before and the average weight of the part of the heart that is responsible for pumping the blood through the body is about 150 grams (about 5.3 ounces).\u201d\nHaving said that however, the story misses an important point.\u00a0 The patients treated with the stem cells did not have an improvement in their overall heart function.\u00a0 So while there appeared to be a considerable amount of regenerated heart muscle, it did not make any difference in the performance of the heart so that patients did not likely see any benefit to the procedure.", "answer": 0}, {"article": "Arthritis pain is caused by bones rubbing together after protective cartilage is damaged or worn away.\nAfter years of cortisone treatments and therapy, wrist replacement became a last resort.\nShe still can't lift more than 11 pounds, but the pain has greatly subsided.\nMore than a dozen bones lie beneath the skin and muscles of the hand and wrist, compared with two or three for those larger joints.\nAfter replacement surgery and months of physical therapy, patients can lift no more than 15 or 20 pounds, he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no quantification of benefits. The story reports ony the anecdotal experience on one patient with one surgeon.", "answer": 0}, {"article": ".\nBut self-experimenters such as Burke often don\u2019t restrict themselves to medication alone.\nPlease don\u2019t take it, people!\u201d\n\nFor Burke and other brain hackers, the evidence for nootropics is strong enough.\nIt\u2019s a weird but handy trick for someone who swallows 25 pills a day, most of them purchases off the Internet.\nBut while some studies have found short-term benefits, Doraiswamy says there is no evidence that what are commonly known as smart drugs \u2014 of any type \u2014 improve thinking or productivity over the long run.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t quantify any known benefits of these brain enhancers, for example if memory increased by a certain percent.", "answer": 0}, {"article": "But the F.D.A.\nSo injecting it is an off-label use.\n\u201cOtherwise they\u2019ll just come back.\u201d\n\nToday, sluggish underlying veins are best addressed with radio-frequency or laser treatment, said Dr. Min, who developed such a laser.\nBy contrast, he said by e-mail, Asclera \u201cis very safe for skin.\u201d\n\nAn injector\u2019s experience matters, because if the injection misses the vein, (or open sores) can occur.\nShe said veins as large as a Sharpie marker can be tackled with foam sclerotherapy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits discussed in this story\u00a0were ALL anecdotal. \u00a0In addition, the story reports on a newly approved pharmaceutical intervention without citing any success rates, absolute or relative.\u00a0Not\u00a0satisfactory. \u00a0", "answer": 0}, {"article": "WINSTON-SALEM, N.C. - Aug. 17, 2015 - Every year falls affect approximately one in three older adults living at home, with approximately one in 10 falls resulting in serious injury.\nThe study showed that the monthly vitamin D supplement was effective in increasing the concentrations of vitamin D in the blood from insufficient to sufficient levels in all but one of the 34 people who received it, and to optimal levels in all but five people.\nAt the beginning of this pilot study, the research team found that more than half of the participants had insufficient concentrations of vitamin D in the blood (less than 20 ng/ml), while less than a quarter had concentrations in the optimal range (30 ng/ml or more).\nSixty-eight study participants received either a monthly vitamin D supplement of 100,000 international units or placebo delivered with their MOW meal.\nThe study included the participants' history of falls and their fear of falling, blood tests at the beginning and at end of the trial to measure 25-hydroxyvitamin D (biomarker for vitamin D in blood), and a monthly diary recording falls during the trial period.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "On the positive side, the release notes that participants in the vitamin D group had higher blood levels of the vitamin and tells us how many achieved \u201csufficient\u201d and \u201coptimal\u201d levels. It provides the cutoffs that were used to determine those outcomes.\nHowever, with respect to the key clinical outcome \u2014 falls \u2014 the story says, \u201cpeople in the vitamin D group reported approximately half the falls of those in the control group.\u201d It\u2019s not clear from this description how many falls were actually prevented. The study itself clarifies this in absolute terms: \u201cThe mean number of reported\u00a0falls over the 5-month follow-up period was 0.5 (range 0\u2013 4) in participants randomized to vitamin D3 and 1.1\u00a0(range 0\u20138) in participants randomized to active placebo.\u201d", "answer": 0}, {"article": "It's a success story you might dream of when you start, but it actually seeing to happen is a great feeling.\"\nLead author Claudia Buntrock, a PhD candidate in clinical psychology at Leuphana, says that because the study only tracked participants' mental health over the course of 12 months, the long-term effectiveness of the intervention is unknown.\nSimilar programs have been used to treat depression, but this may be the first one tested to prevent it, the researchers say.\nThe study, which was conducted by researchers from Leuphana University in Lueneburg, Germany, recruited 406 people with subthreshold depression, which is defined as having some symptoms of depression but not enough to be diagnosed with major depressive disorder.\nOf the 406 participants that began the study, 335 completed the telephone follow-up at the end of 12 months.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story made clear that patients who participated in one of two online self-help interventions had a 27 percent rate of experiencing major depression disorder (MDD)\u00a0in the 12 months following the study, compared to a 41 percent rate for those who did not participate in the online interventions. That\u2019s enough to earn a satisfactory rating.\nIt would have been even better if the story had addressed whether there was any difference in performance for patients who received the \u201ccognitive behavioral therapy\u201d intervention versus the \u201cproblem-solving therapy\u201d intervention. And if the study didn\u2019t differentiate between results for the two interventions, the story could have said that. This is significant because it\u2019s not clear to readers whether one approach might have been significantly more effective at preventing the onsite of MDD, or if they had comparable results.", "answer": 1}, {"article": "People with poorly controlled diabetes, for example, may have breath that smells fruity due to an overproduction of chemicals called ketones; people with kidney or liver failure can have fishy breath.\nCleveland Clinic pulmonologist Peter Mazzone, MD, who is conducting lung cancer studies, says a breath test for cancer may be a reality in as little as five years if all goes well.\nIn a new study from Italy, researchers were able to identify patients with colorectal cancer with an accuracy of over 75% by analyzing samples of their breath.\nDec. 5, 2012 -- A breath test similar to the one used to determine when a driver has had too much to drink shows promise as a screening tool for cancer .\nSimilar research is under way to develop breathalyzer-like devices to detect lung, breast, prostate, and other cancers.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story never\u00a0clearly explained why breath testing would be an advantage over current screening methods, and it didn\u2019t tell what stage of cancer the patients being tested had or whether the test would be useful for detecting precancerous polyps. In addition, as we noted with the competing HealthDay piece, good diagnostic tests not only have to be able to identify people who have a\u00a0disease correctly, but they also have to be able to rule out people who don\u2019t have the disease correctly. Given that context, it\u2019s unclear\u00a0what the accuracy statistic provided by the story means.\u00a0The story says that the test was\u00a0able to distinguish between the cancer and non-cancer patients 76% of the time. We would have preferred to see the absolute numbers of people in each group (the cancer patients and controls) who were accurately diagnosed, and a comparison of how this\u00a0stacks up against\u00a0existing screening methods.\n\u00a0", "answer": 0}, {"article": "Folic acid is naturally present in green, leafy vegetables and legumes.\nO\u2019Connor, of the University of Toronto and the Hospital for Sick Children in Ontario, Canada, called the findings \u201cpretty significant.\u201d\n\nStill, she said, you can\u2019t be sure if the kids who performed better had a better diet in general or if some other hidden factor could explain the results.\nThe researchers looked at 386 15-year-olds who were finishing up ninth grade.\nDuring the study, Sweden did not fortify foods, nor did kids use a lot of supplements.\nWhen all their grades from ten core classes were added up, there was a clear difference between teens who got the most and the least folic acid in their diets.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided the data on the summation of grades showing the difference in folic acid levels in the children in the highest and lowest groups. \u00a0While it is nice to have absolute grade difference provided, it would have been useful to indicate whether these differences were statistically significant or whether the differences in folic acid intake were clinically significant.", "answer": 1}, {"article": "This signal is passed to a computer that decodes it, and the resulting instruction is then sent to a sleeve he wears on his forearm that stimulates the muscles that move his wrist and fingers.\nFor starters, the device that records the brain signals will need to be much smaller so it's fully implanted under the paralysed person's skin.\nThat's why the device requires training every time Burkhart uses it.\nOur understanding of how brain signals change will also be crucial to making this technology usable on a large scale.\nDr Jonas Zimmerman, a neuroscientist at Brown University in the US, who was also not involved with the study, echoed Jackson's point.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This article included important caveats about the limited actions that the patient was able to perform, and made it clear that this device was highly experimental. But most of these details are mentioned only near\u00a0the end of the story. We might have given the story a Satisfactory rating if the headline and opening paragraphs had matched the tone of these later sections. However, the overly broad claims at the top of the story overwhelm the cautionary details.\nAlso, the story should\u00a0have more clearly pointed out that (as a Nature news article specifically noted) this approach may not work for people who, unlike this patient, don\u2019t still have at least some ability to move their shoulders and elbows. As a result, the story implies that this experiment is relevant to a far broader group of people than the researchers claim.", "answer": 0}, {"article": "N-acetylcysteine reduced PTSD symptoms, cravings, and depression in veterans with PTSD and substance use disorder in a randomized controlled pilot trial conducted at the Medical University of South Carolina and the Ralph H. Johnson VA Medical Center\n\nN-acetylcysteine, when combined with group cognitive behavioral therapy (CBT), reduced symptoms of posttraumatic stress disorder (PTSD), cravings, and depression significantly more than CBT alone in veterans with co-occurring PTSD and substance use disorder, a particularly difficult-to-treat population, according to the findings of a randomized controlled pilot trial conducted by researchers at the Medical University of South Carolina (MUSC) and the Ralph H. Johnson VA Medical Center.\nOf the veterans enrolled in the trial, 83% completed it, a very high rate for this difficult-to-treat population.\nBecause evidence suggests that SUDs and PTSD share overlapping neurobiological pathways, Sudie E. Back, Ph.D., lead author on the article, hypothesized that NAC treatment with CBT would be a novel approach to treat co-occurring PTSD and SUD.\nVeterans in the study had low rates of substance use during the trial, and the study found little effect of medication on use, perhaps due to the fact that all participants were receiving SUD treatment and exhibiting low levels of use.\nThis trial is the first to use NAC as a pharmacotherapy for PTSD and a broad range of SUDs.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The intent of the pilot study was to determine the effect of N-acetylcysteine on PTSD symptoms, cravings and substance use. All three endpoints are described in the news release albeit in relative terms.\nWe are told that the 8-week trial randomized 35 veterans with PTSD and substance use disorder. Some received N-acetylcysteine and others a placebo, but all of the participants received cognitive behavioral therapy (CBT).\nThe release reported that \u201cVeterans in the NAC-treated group showed a 46% reduction in PTSD symptoms, compared with a 25% reduction in the placebo group on the Clinical-Administered PTSD Scale (CAPS), which assesses trauma history and symptom severity. The threshold CAPS score for diagnosis of PTSD is 50.\u201d\nThe release quotes the lead author: \u201cAs a group, the NAC-treated veterans were below diagnostic level for PTSD at the end of treatment.\u201d This establishes that the benefit was clinically meaningful. But we prefer to see absolute rather than relative numbers as used here. For example, the actual before and after scores on the PTSD scale would have better illustrated how large the benefit was.", "answer": 1}, {"article": "\"At the end of the day, our findings might modestly over - or under-estimate the health burdens,\" he told us.\nBut, here's the flip side: The researchers also found there's a significant risk in eating too little of certain healthy foods.\nScientists at Tufts University identified the foods that seem to contribute the most to the risk.\nNow, the task of estimating death or disease linked to diet is tricky.\nAnd eating more \u2014 or less \u2014 of just 10 types of food can help raise or lower the risk of death from these causes, the researchers found.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The study includes some numbers, for instance that \u201cConsuming too much salt was associated with 9.5 percent of the deaths\u201d and that \u201cdiets low in seafood, whole grains and fruits and vegetables were found to contribute to about 6-8 percent of the deaths.\u201d \u00a0It also paints the larger picture: \u201cIn 2012, about 700,000 Americans died from these diseases. Diet was linked to nearly 319,000 of these deaths.\u201d\nThis is a satisfactory summary of the numbers as far they go, though the story could have provided more examples of how much more or less of these foods people would have to eat in order to achieve the claimed benefits. (How much salt is too much?) \u00a0The bigger issue is the claim that certain dietary factors \u201ccontributed\u201d to deaths, which overstates what the evidence can tell us. We\u2019ll address that issue below under the \u201cEvidence\u201d criterion.", "answer": 1}, {"article": "\u201cA 5 percent loss of weight is associated with a 50 percent lower risk of diabetes and a 10 percent loss is associated with an 80 percent lower risk.\u201d\n\nPatients in Bohula\u2019s study did see improvements in hypertension and blood sugar levels with weight loss.\nPeople need to realize that in obesity treatment, just as in hypertension therapy, one drug won\u2019t fit all, Aronne said.\n\u201cThat\u2019s why treatment of hypertension is so effective.\nThat\u2019s how we need to start looking at drugs for obesity.\u201d\n\nWhat many don\u2019t understand is that weight gain leads to changes in the brain that may not be reversible, Aronne said.\nThey won\u2019t make a morbidly obese patient model-thin, but they\u2019ll shave off enough excess fat to improve heart disease risk factors such as hypertension, high blood sugar and high cholesterol, experts say.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Th story claimed the latest generation of diet pills can help \u201cshave off enough excess fat to improve heart disease risk factors such as hypertension, high blood sugar and high cholesterol.\u201d\nSpecifically,\u00a0that the drug lorcaserin (Belviq) helped \u201cnearly\u201d 40% of patients have sustained weight loss of more than 5% of body weight, which it said \u201cis associated with a 50 percent lower risk of diabetes and a 10 percent loss is associated with an 80 percent lower risk.\u201d\nIt also said patients in a lorcaserin study \u201cdid see improvements in hypertension and blood sugar levels with weight loss.\u201d\nWhen we looked up the results in a large\u00a0study published in the New England Journal of Medicine, the numbers aren\u2019t as impressive sounding:", "answer": 0}, {"article": "\"It's only been relatively recently that energy surplus has become a problem,\" Wu said.\nResearchers in the lab of Jun Wu, research assistant professor at the LSI, wanted to better understand cinnamaldehyde's action and determine whether it might be protective in humans, too.\nNow, before anyone goes dumping tons of extra cinnamon in their egg nog in hopes of keeping holiday-season pounds at bay, Wu cautioned that further study is needed to determine how best to harness cinnamaldehyde's metabolic benefits without causing adverse side effects.\nAnd because it is already used widely in the food industry, it might be easier to convince patients to stick to a cinnamon-based treatment than to a traditional drug regimen.\n\"Scientists were finding that this compound affected metabolism,\" said Wu, who also is an assistant professor of molecular and integrative physiology at the U-M Medical School.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This news release does not offer any numbers providing context beyond making the claim that triggering fat burning in cells could reduce obesity. There are no numbers on how much or how quickly cinnamaldehyde induces fat burning, While we recognize that the objective of the study was to determine the mechanism through which cinnamaldehyde acted and to determine its metabolic pathways, we\u2019d still like to see some description of the type of measurements used by researchers.", "answer": 0}, {"article": "Sometimes, individuals with CDE have trouble opening their eyes, but Tomei said she went to the doctor and reported mild but incessant itchiness and dryness, and was diagnosed with CDE.\nOn Restasis.com, you can take the brand\u2019s \u201cdry eye quiz\u201d\u2014 for every quiz taken, Allergan has agreed to donate $1 to the organization.\nTo raise awareness about CDE and help other people find relief, the \u201cMy Cousin Vinny\u201d and \u201cThe Wrestler\u201d star has teamed up with pharmaceutical company Allergan and Guide Dogs for the Blind, an organization that trains dogs and pairs them with visually impaired individuals.\nAfter toting around eye drops, Tomei said she has found a solution with Allergan\u2019s prescription drug RESTASIS\u00ae, which works by increasing the eyes\u2019 natural ability to produce tears.\nIf you think you may be suffering from CDE, Tomei advised visiting your doctor to receive a diagnosis.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We learn that \u201cAllergan\u2019s prescription drug RESTASIS\u00ae, works by increasing the eyes\u2019 natural ability to produce tears,\u201d but nothing about\u00a0how it was tested or how well it actually works.", "answer": 0}, {"article": "The Society works closely with many other sports medicine specialists, including athletic trainers, physical therapists, family physicians, and others to improve the identification, prevention, treatment, and rehabilitation of sports injuries.\nOf this group, 68 patients had experienced their first dislocation, while 53 had recurrent dislocations after being initially treated non-operatively.\nSurveys given to patients during follow-ups asked for information such as test for shoulder functionality, whether patients returned to sport, postoperative instability events, and if further surgery was required on the shoulder.\nAfter treatment with an arthroscopic bankart repair, the postoperative dislocation rate in the first-time injury group was 29%, compared to 62% in those who did not have surgery after their initial injury.\n\u201cHowever, this study shows a substantial benefit for athletes undergoing surgery to prevent recurrent instability down the road.\u201d\n\nThe research data was collected between 2003 and 2013 from eight fellowship trained surgical practices, with patient ages ranging from 16 to 30 years old.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release encapsulates the differences observed: \u201cThe study examined 121 patients at an average of 51 months post-surgery,\u201d it says. \u201cOf this group, 68 patients had experienced their first dislocation, while 53 had recurrent dislocations after being initially treated non-operatively. After treatment with an arthroscopic bankart repair, the postoperative dislocation rate in the first-time injury group was 29%, compared to 62% in those who did not have surgery after their initial injury.\u201d\nAnd 7% of those with surgery after the initial dislocation vs 32% after a recurrent dislocation had to have another surgery, according to the release.", "answer": 1}, {"article": "During such a surge, healthy vessels dilate, or relax, but unhealthy ones stiffen and narrow, impairing blood flow and indicating possible incipient heart disease.\nThe volunteers, all of whom exercised, generally became more physically fit during the study, Dr. Stewart said.\nRetested with the blood pressure cuff, the group eating the American Heart Association-style diet continued to display normal, healthy blood flow.\nThe study did not include a control group of men and women who performed no exercise, making it impossible to tease out the exact physiological role that exercise played, Dr. Stewart said.\nSuch fatty, low-carbohydrate Atkins-type diets are well established as a means of successful weight reduction, Dr. Stewart said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story described the rate of weight loss as being faster on the low-carbohydrate diet than the low-fat diet (45 days versus 70 days) though there was no information about how the two groups compared in terms of sustaining the weight that was lost or whether weight loss continued beyond the initial 10 pounds. The story also did not mention whether the difference reported was significant or if the range of time it took the two groups was overlapping.", "answer": 0}, {"article": "Nancy U. Lin and Harold J. Burstein, of the Dana-Farber Cancer Institute and Harvard Medical School in Boston, said: \"EMBRACE provides much needed, high-level evidence for chemotherapy use in patients with heavily pretreated breast cancer.\n\"This global phase 3 study establishes a potential new standard treatment for women with heavily pretreated metastatic breast cancer, for whom there was previously no chemotherapy treatment with proven survival benefit,\" the authors wrote.\nThe study included 508 women who were given eribulin and 254 women who received treatment of the physician's choice, which was defined as: any single-agent chemotherapy, hormonal or biological treatment approved for cancer treatment; radiotherapy; or symptomatic treatment alone.\nThe researchers found that among patients whose cancer had spread, those who took the drug lived a median of 2.5 months longer than those who received a physician-chosen treatment -- 13.1 months versus 10.6 months.\nThe study, known as the EMBRACE trial, was funded by Eisai Inc., which markets eribulin.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit of eribulin over various treatments chosen by the physicians was clearly stated in the article.\u00a0 \u201cThe researchers found that among patients whose cancer had spread, those who took the drug (eribulin) lived a median of 2.5 months longer than those who received a physician-chosen treatment \u2014 13.1 months versus 10.6 months.\u201d", "answer": 1}, {"article": "Our technology keeps the cells in the body under immune surveillance, so immune suppression is not necessary,\" said Sen, who also is executive director of Ohio State's Comprehensive Wound Center.\nWith this technology, we can convert skin cells into elements of any organ with just one touch.\nIn my lab, we have ongoing research trying to understand the mechanism and do even better.\n\"This is difficult to imagine, but it is achievable, successfully working about 98 percent of the time.\nThe cargo is delivered by zapping the device with a small electrical charge that's barely felt by the patient.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We are told that \u201c..it is achievable, successfully working about 98 percent of the time,\u201d yet there\u2019s no accompanying description of what \u2018works\u2019 really means, how the technology benefit is measured, or how it would compare to a similar technology.", "answer": 0}, {"article": "The 12 poses, by their English names, were tree, triangle, warrior II, side-angle, twisted triangle, locust, bridge, supine hand-to-foot I, supine hand-to-foot II, straight-legged twist, bent-knee twist and corpse pose.\nBut all told, the team concluded, the results may lend support to Dr. Fishman\u2019s long-held belief that yoga can help reverse bone loss.\nAt the time the study was submitted for publication, \u201cwith more than 90,000 hours of yoga practiced largely by people with osteoporosis or osteopenia, there have been no reported or X-ray detected fractures or serious injuries of any kind related to the practice of yoga in any of the 741 participants,\u201d Dr. Fishman and his colleagues wrote.\nFurthermore, a special study of bone quality done on 18 of the participants showed that they had \u201cbetter internal support of their bones, which is not measured by a bone density scan but is important to resisting fractures,\u201d Dr. Fishman said.\nThe findings, as reported last month in Topics of Geriatric Rehabilitation, showed improved bone density in the spine and femur of the 227 participants who were moderately or fully compliant with the assigned yoga exercises.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes, \u201cThe findings, as\u00a0reported last month in Topics of Geriatric Rehabilitation, showed improved bone density in the spine and femur of the 227 participants who were moderately or fully compliant with the assigned yoga exercises.\u201d\u00a0[emphasis ours] What exactly does that mean? How much did bone density improve? Did all 227 subjects see improvement or was the improvement seen in aggregate? \u00a0There is a big difference between the two and the common take away would be that all saw improvements, which is far from the reality. We also would like\u00a0to know why only 227 out of 741 original enrollees are reported on. How many of the remaining 500+ participants dropped out? Research study dropout is an important factor as it gives us some idea of the tolerability or acceptability of the \u2018treatment.\u2019", "answer": 0}, {"article": "About Milken Institute School of Public Health at the George Washington University: Established in July 1997 as the School of Public Health and Health Services, Milken Institute School of Public Health is the only school of public health in the nation's capital.\nVery little help is provided to pregnant smokers who want to quit so the study's findings are important, especially if the strategy can be adjusted to be more effective, Abroms says.\nThe researchers recruited pregnant women who were already enrolled in an established text messaging program called Text4baby.\nThe more intensive intervention did seem to help two subgroups quit smoking at least in the short run, Abroms says.\nAbroms and her team wanted to find out if a more intensive mobile phone program called Quit4baby would be more effective.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release appropriately describes the outcomes in absolute terms. For example, \u201c16 percent of the women who were enrolled in both Text4baby and Quit4baby had quit compared with just 11 percent of women getting just Text4baby.\u201d\nBut while the body of the release clarifies that this difference between groups was not statistically significant, the headline and lead sentence gloss over this fact. We\u2019ll address that issue below under the Evidence criterion.", "answer": 1}, {"article": "Smokers who count on nicotine patches or gum to help them quit may want to reconsider: A new study finds that these and other nicotine replacement products aren't effective at preventing former smokers from relapsing in real-world conditions.\nThose who had used nicotine patches, gum, inhalers or nasal sprays were just as likely to relapse as those who had quit without them, researchers from Harvard University and the University of Massachusetts found.\nIn those trials, volunteers using such products were up to three times more likely to kick the smoking habit.\nIn some cases, studies have found that people who use products like nicotine patches and gums are more likely to relapse than their counterparts who go cold turkey.\nBut the latest results are in line with other studies that have found little \u2014 if any \u2014 benefit from the products when used by smokers in real life.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story and the New York Times story both failed to mention the actual number of people in the study who used nicotine products. Instead, it talked about the overall number of study participants and then provided percentages for the people who relapsed, perhaps leaving readers confused about whether and to what extent nicotine products made a difference in smoking cessation. It says, \u201cThe new study examined former smokers three times over a five-year period. At the midpoint of the study, 30.6% of recent quitters had gone back to smoking. By the end, 31.3% had relapsed.\u201d It isn\u2019t clear whether we are talking about the same 30% in each period or a total of roughly 60%.", "answer": 1}, {"article": "An estimated 5.4 million Americans have Alzheimer's disease, the most common form of dementia, according to the Alzheimer's Association.\nHis test is one of numerous such tests under study, says Heather Snyder, PhD, a spokesperson for the Alzheimer's Association, who reviewed the research results.\nThe research results on the new test are published online in PLoS ONE.\nThe only definitive way to diagnose the disease is by direct examination of brain tissue after the patient dies.\nNone are highly accurate, and some are costly and not practical to use on a widespread basis, experts say.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nIt would be difficult for readers to get a true sense of the value of this test from this story. Readers should have been told more clearly that in this study, the test failed to correctly identify 4 percent of the Alzheimer\u2019s patients and it mislabeled more than 7 percent of the healthy participants. Also, the phrase that \u201cknowing early has many advantages\u201d is likely to create a misperception about the potential benefits of testing \u2013 at least until some treatments are developed. The story mentioned only two potential benefits, financial planning and the ability to participate in clinical trials of experimental treatments.\n\n\n\n\n", "answer": 0}, {"article": "The U.S. National Institutes of Health has more on insomnia.\nThese new medications -- known as dual orexin receptor antagonists (DORA) -- target a more specific region of the brain than popular sleep drugs such as Ambien and Lunesta, promoting sleep without affecting learning and memory (also called \"cognition\"), according to the new research.\nThat means, theoretically, fewer side effects and perhaps less of a tendency to be habit forming, Thorpy explained.\n\"We've shown that these compounds improve sleep at doses that don't impact cognition,\" said Jason Uslaner, lead author of a study published in the April 3 issue of Science Translational Medicine.\nIn each case, the minimum dose to achieve sleep was compared with the minimum dose that altered memory and thinking.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The lead sentence is simply wrong. It says this type of drug \u201cappears to help people fall asleep without causing grogginess the next day.\u201d But besides the fact that this experiment didn\u2019t actually include any people (just animals), the researchers specifically pointed out that the \u201ccurrent study design is limited in that it does not address the issue of next-day \u201changover\u201d or carryover effects.\u201d In other words, grogginess the next day was not tested.\nFurther, allowing the lead author, an employee of the drug company studying the drug to say, \u201cWe\u2019ve shown that these compounds improve sleep at doses that don\u2019t impact cognition,\u201d allows the reader to assume that the benefits of DORA-22 have already been shown.", "answer": 0}, {"article": "Vaginal and vulvar cancers are usually caused by the human papillomavirus, which also causes cervical cancer.\nBut raloxifene's edge in blood-clot and uterine-cancer avoidance was not statistically significant, and tamoxifen proved better at reducing the rate of noninvasive breast cancer.\nWhile both drugs reduced cases of breast cancer by about half from what would have been expected for the women in the study, raloxifene caused fewer cases of blood clots, cataracts and uterine cancers, making it initially appear the winner.\nThe editorial in the journal said the new data \"still may not be enough to convince primary care physicians to be more aggressive than they have been to date in breast cancer chemoprevention.\"\nAs for the data on vaginal and vulvar cancer prevention, they came from combining data from three trials used to test the ability of the vaccine, Gardasil, made by Merck & Company, to prevent cervical cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article states that both tamoxifen and raloxifene cut the risk of breast cancer in half, but does not indicate how many fewer cases that reduction represents. For balance, it would have been useful to have stated more explicitly how many women would have to take the drug to prevent one case of cancer, and how many women will experience a serious side effect.", "answer": 0}, {"article": "For an early version of the study abstract, click on \u201cContents,\u201d then \u201cVolume 44, No.\nAlso, among those in the 40-milligram group, people carrying what is sometimes called the Alzheimer\u2019s gene (APOE-e4) showed more improvement than non-carriers.\nCAVEATS The study involved a relatively small number of participants and lasted a short time; a larger and longer study would be needed to adequately test effectiveness and safety.\nNonetheless, conclusive evidence about a treatment's effectiveness is rarely found in a single study.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Neither this story nor a competing story by Fox News actually quantified the benefits adequately. At least the Fox News story talked about the people who took the nasal spray experiencing a \u201c25 percent\u201d improvement in mental function. In both cases, it would have been good to explain how many people in the study saw how much improvement in both groups.", "answer": 0}, {"article": "The results were striking.\n\u201cThere is a body of literature that argues that the whole approach to studying acupuncture doesn\u2019t lend itself to the Western reductionist scientific method.\u201d\n\nBut the study\u2019s lead author, Dr. Maria E. Suarez-Almazor, notes that the sham treatment was developed with the help of trained acupuncturists.\nRather than proving that acupuncture does not work, in other words, the study may suggest that it works even when administered poorly.\nThe results came out with no difference between the groups.\u201d\n\nThe MD Anderson research and other recent acupuncture studies have fueled speculation that the prick of a needle, whether from real acupuncture or a sham version, can influence the way the body processes and transmits pain signals.\nThis year, researchers at Henry Ford Hospital in Detroit solved the problem of creating a sham acupuncture treatment: they didn\u2019t have one.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "      \n\n\n \n\n \nMixed bag.\u00a0 \nOn the knee arthritis study, the story didn\u2019t explain what \"an average reduction of one point on a scale of 1 to 7\"\u00a0for pain relief really meant to people. It says \"critics contend that the study was poorly designed\" but didn\u2019t explain how it was poorly designed. That could be letting critics get away with potshots without explaining whether their criticism was well-founded. \nOn the NIH knee arthritis study, it said \"acupuncture significantly reduced pain and improved function\" but that doesn\u2019t meet our standard for quantifying the benefit. What does \"significantly\" mean in their lives? Again, in this case, the story said \"that result has been called into question\" but this time the story explained why.\u00a0 \nOn the Henry Ford Hospital study of hot flashes in breast cancer patients, the story said the results were \"striking\" but again didn\u2019t quantify what that meant. \nSo we can\u2019t give this a satisfactory score but it didn\u2019t meet the true spirit of our criterion.\n ", "answer": 0}, {"article": "Lack of F.D.A.\nThere was a great need, the authors concluded, to \u201cimprove awareness of this important advice.\u201d\n\nThe fact that fish oil is also sold as a nutritional supplement has made it harder for some doctors to regard it as a powerful drug, experts said.\nThis summer, a critical review of existing research in BMJ, The British Medical Journal, \u201ccast doubt over the size of the effect of these medications\u201d for the general population, said Dr. Roger Harrison, an author of the paper, \u201cbut still suggested that they might benefit some people as a treatment.\u201d\n\nDr. Harrison said he believed that people should generally increase their intake of omega-3 acids, best done by eating more fish.\nThe fact that heart patients receive such different treatments in sophisticated hospitals around the world highlights the central role that drug companies play in disseminating medical information, experts said.\nBut the landmark Gissi-Prevenzione trial of fish oil had methodological weaknesses: the patients treated with prescription fish oil pills were compared with untreated patients, rather than with patients given a dummy pill.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The overall focus of this story is that because fish oil is more often prescribed in Europe than in the United States, that the disease is better treated there than here. The study cited to support the contention that fish oil reduces the number of deaths three years after a heart attack involved patients that consumed a Mediterranean diet which differs than typical American fare, and also did not compare the patients taking fish oil to a placebo control. The article contains more enthusiasm for the use of fish oil than examination of the data supports. The story also framed trial results only in relative terms (20% reduction in the number of deaths and 40% reduction in the number of sudden deaths), not in absolute terms. ", "answer": 0}, {"article": "A female testosterone patch showed promise at boosting older women's enjoyment of sex, but concerns about the cancer risk of hormone therapies mean U.S. women won't be getting an equivalent of Viagra anytime soon.\n\nProcter & Gamble Co., the Cincinnati consumer-products giant, has worked since 1999 to secure U.S. approval for its Intrinsa patch, intended to increase sex drive and satisfaction in women after menopause.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The report adequately describes the methodology and outcomes of the study in question. It does a good job raising the question of potential harms, while indicating that data supporting those harms aren\u2019t statistically significant.", "answer": 1}, {"article": "\"This is a decision that should belong to the woman with appropriate info on hand.\"\nShe found that fewer clinicians were recommending annual mammograms after the task force's guidelines were issued.\nAlthough the task force concluded that the net benefit of mammography in the 40s is small, Hardesty said: \"If you're the one person we find your cancer, it's the world to you.\"\nThat decrease, Hardesty said, \"is a statistically significant difference,\" but it also showed more doctors were discussing mammograms with patients.\nThese cancers were more treatable because they were caught in earlier stages, Plecha said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states:\n\u201cThe data that we have suggests that 1 in a thousand will benefit from mammograms in the 40-49 age,\u201d (the USPSTF chair) said. \u201cThere are whole lots of assumptions that are not supported by the data they presented.\u201d", "answer": 1}, {"article": "Trans fats raise bad cholesterol, lower good cholesterol and ultimately increase the risk of heart attacks and strokes.\n\u201cHere we find on a population level when we restrict them, it benefits society by reducing heart attacks and strokes.\u201d\n\nThe findings suggest the FDA\u2019s action will lead to health benefits across the country, he added.\nAfter three years or more, the combined rate of hospitalizations for heart attacks or strokes was about 6 percent lower in the counties with trans fat regulations.\nStill, the study can\u2019t say the trans fat restrictions caused fewer admissions in those counties.\n(Reuters Health) - - People were less likely to go to the hospital with heart attacks or strokes after several counties in New York State restricted the use of trans fats, according to a new study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The reader is offered both percentage and\u00a0absolute numbers to describe the decreases in hospitalization for heart problems. The story also makes clear what differences are or are not statistically significant. Lastly and importantly, the story makes clear that the study established an association, not a causal link.", "answer": 1}, {"article": "Fibromayalgia is a condition marked by fatigue, disturbed sleep, and pain.\nCyclobenzaprine, marketed in higher doses by others as Amrix, Fexmid, and Flexeril, is already widely used ''off-label'' for patients with fibromyalgia, Lederman says.\nHowever, a rheumatologist not connected to the study does not expect the new drug to be a ''game-changer.\"\n\"Bedtime treatment of fibromyalgia patients with low-dose cyclobenzaprine was safe and appears to be effective,\" says Seth Lederman, MD, president of TONIX Pharmaceuticals, which funded the study.\nTONIX is developing a lower-dose version and improving the formula, Lederman says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nWhile the story is accurate in reporting that researchers saw signs of improved sleep and reduced pain in the small number of fibromyalgia patients in this trial, the relative attention given to the self-promoting claims of the drug company president as compared to the dismissive comments of the independent source leave readers with an unbalanced view. If the independent expert says he is \u201cnot impressed with the findings\u201d and that the new drug dose \u201cis not going to change things substantially,\u201d it\u2019s hard to see how a headline, sub-head, and lead paragraphs all devoted to grand claims about the benefits of the drug can give readers a fair view of the potential benefits.", "answer": 0}, {"article": "But, that's an entirely different problem, compared with atrial fibrillation,\" he said.\nWith apixaban, patients can use a standard dose that doesn't need monitoring and adjusting, Ansell said.\nIn that trial, published in July in the New England Journal of Medicine, apixaban's use was associated with raised odds for bleeding -- without providing patients with any reduction in heart attack risk.\nCommenting on the latest study, Dr. Gregg C. Fonarow, a professor of cardiology at the University of California, Los Angeles agreed that \"atrial fibrillation substantially increases the risk of stroke and death.\"\nAlso, unlike warfarin, apixaban has few interactions with other drugs or foods, he added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided the absolute decrease in the number of strokes or clots, major bleeding events and hemorrhagic stroke as compared to the people in the study taking warafarin.", "answer": 1}, {"article": "Airways became less likely to close off after exposure to an allergen.\nThe drug also improved overall airway function, an effect researchers hadn't expected, Israel said.\nPhysical examinations showed that people taking Gleevec actually experienced a slight overall widening of their airways, Israel added.\nBut, this powerful cancer drug can't be recommended for them on the basis of this small study, Israel and other specialists noted.\nTwo generic versions of the drug were launched last year, which could make it less pricey than new-wave asthma drugs headed for the market, Israel added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quotes a researcher saying the drug \u201creduced the \u2018twitchiness\u2019 of airways\u201d by a third, which \u201cwas significant compared with the placebo group,\u201d making airways less likely to reflexively constrict when exposed to an allergen or asthma trigger.\nThat\u2019s a good start, but we wanted to know, by a third of what? Also, it\u2019s not clear if this measurement\u2013or any of the other benefits mentioned\u2013resulted in fewer symptoms for patients, or just improved their lab values.", "answer": 0}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not claim that smartphone apps are beneficial, just that the potential benefits are being studied.", "answer": 2}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\n\"The simple message from this study is that eating an overall healthy diet, including certain foods, such as walnuts and other whole foods, may help women with the ability to do key everyday tasks as they age, like carrying groceries or dressing themselves.\"\n(1)\n\nThis paper emphasized that overall diet quality, rather than individual foods, may have a greater impact on reducing risk of physical function impairments.\nthat other lifestyle habits which are more common in adults who eat walnuts could contribute to the study findings); and, thus, the results should be interpreted with caution.\nThe sample only included women, so these results may not be generalizable to men.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does not quantify the purported benefits of including walnuts in one\u2019s diet. It says the study \u201csuggests that consuming 1-2 servings of walnuts per week (1/4 cup per serving) was associated with reduced risk of developing impairments in physical function, which helps enable older women to maintain independence throughout the aging process.\u201d What was the reduced risk? How did women who followed a healthy diet compare in their physical function to those who did not?\nThe release later tempered the message that walnuts \u2014 specifically \u2014 reduce the risk of physical impairment. It notes that the researchers \u201cemphasized that overall diet quality, rather than individual foods, may have a greater impact on reducing risk of physical function impairments. Specifically, diet quality traits most associated with reduced rates of incident physical impairment were higher intake of fruits and vegetables; lower intake of sugar-sweetened beverages, trans fat, and sodium; and moderate alcohol intake.\u201d It adds that among specific foods studies, \u201cthe strongest relations were found for increased intakes of oranges, orange juice, apples, pears, romaine or leaf lettuce, and walnuts.\u201d\nIt also provides this insight from a researcher: \u201cThe simple message from this study is that eating an overall healthy diet, including certain foods, such as walnuts and other whole foods, may help women with the ability to do key everyday tasks as they age, like carrying groceries or dressing themselves.\u201d\nNor does it state that walnuts were the only nuts examined in the study, so we don\u2019t know if similar benefits might be found for women who consumed large quantities of almonds or pine nuts, for example.", "answer": 0}, {"article": "And tobacco kills one in 10 people worldwide, according to the World Health Organization.\nSmokers who took the pill, sold as Chantix in the U.S. and Champix elsewhere, were much more likely to quit after cutting back on cigarettes than smokers who didn\u2019t use the drug, the study found.\n\u201cThis allows us to reach a much broader population of smokers who aren\u2019t willing to quit abruptly or set a quit date, and it shows that people can quit without going cold turkey,\u201d said lead study author Dr. Jon Ebbert, a professor in primary care and internal medicine at the Mayo Clinic in Rochester, Minnesota.\nOther treatments, such as nicotine patches and gum, can also help some smokers cut back gradually, she said.\nWhile the study shows that Chantix, which is known generically as varenicline, can be effective for some smokers, the group taking the pill also experienced more side effects such as nausea, abnormal dreams, insomnia, constipation, vomiting, and weight gain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are two ways to think about benefits in a story like this one: the benefit of quitting smoking and the benefit of using the smoking cessation drug. The story thoroughly addresses both. First, the story tells readers exactly how much more likely people were to quit smoking when using the drug (compared to those using a placebo) \u2014 and that they were able to stay smoke-free for up to a year. Second, the story offers some specifics on how quitting smoking reduces health risks. For example, the story states: \u201cTen years after quitting [smoking], the risk of lung cancer drops by half, according to the CDC.\u201d\nAnother area where the story excelled is in characterizing the motivation level of the study participants. It noted that they wanted to quit and were willing to start reducing their cigarette consumption \u2014 they just couldn\u2019t \u201cgo cold turkey.\u201d The competing Times piece wasn\u2019t as clear on that point.", "answer": 1}, {"article": "Plaque psoriasis is an autoimmune condition that causes cells to build up on the surface of the skin, forming thick red patches and flaky silver-white scales.\nHe adds that the data on Siliq suggests that it is not only effective in treating psoriasis, but that many patients experience improvement in anxiety and depression, as well.\nIn the three clinical trials considered for drug approval, more than 50% of patients who used Siliq achieved total skin clearance\u2014the ultimate goal of psoriasis treatments\u2014within a year.\nIn order to prescribe it, doctors must be certified with the program and must counsel patients about this risk.\nBecause of these events, the labeling for Siliq will include a Boxed Warning, and the drug will only be available through a restricted REMS (Risk Evaluation and Mitigation Strategy) program.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This also is\u00a0a barely passing satisfactory. The story states that, \u201cIn the three clinical trials considered for drug approval, more than 50 percent\u00a0of patients who used Siliq achieved total skin clearance\u2014the ultimate goal of psoriasis treatments\u2014within a year.\u201d\u00a0 It would have been more helpful to provide more data, but this statement at least gives us a sense of the scale of the benefit.", "answer": 1}, {"article": "Severe obesity is associated with serious physical and psychological conditions affecting quality of life.\n\u201cThe median BMI reduction of 10 kg/m2 with the lap band is a good result when compared to BMI reduction using the few medications available or lifestyle measures, which is around 1-3 kg/m2,\u201d says Dr Pe\u00f1a.\n\u201cAlthough gastric banding has been controversial and is currently less used in adults with severe obesity, lap band surgery is one of the most studied surgeries for obesity management, has a high safety record and can be a temporary option to manage severe obesity during adolescence,\u201d says Mr Khurana, who is also a Senior Lecturer in the University of Adelaide\u2019s Discipline of Paediatrics.\nThe study found that weight and BMI improved significantly at all follow-up times following surgery from three months through to 45 months and, in some cases, as long as five years.\nHowever there is no data available in Australian adolescents beyond 24 months post-surgery.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We give this a tepid \u201csatisfactory.\u201d The release specifies the range of BMI loss for individuals in the study but never gets around to explaining what BMI is or how a reader should interpret the numbers. As discussed in more detail in the Evidence section below, the release doesn\u2019t share that a third of patient volunteers had the laparoscopic bands removed due to no change in weight loss or regained weight.", "answer": 1}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported: \u201cA September 2011 Cochrane Review of 14 studies found \u201cweak\u201d evidence that probiotics could help prevent the common cold and other upper respiratory infections in infants, children and younger adults. And an April 2011 study in the European Journal of Clinical Nutrition found a Lactobacillus probiotic seemed to improve the immune system\u2019s response following a flu vaccination.\u201d\nWe would have preferred to read some of the actual data about \u201chow weak\u201d (in the Cochrane Review) and how much improvement in the other study. But we liked that the story quantified, via an independent expert, how many people might expect to avoid a cold by taking probiotics, if these \u201cweak\u201d studies are correct: \u201cperhaps as few as 1 in 30.\u201d\n\u00a0", "answer": 1}, {"article": "The U.S. National Cancer Institute has more on prostate cancer.\nOf the blood thinners used in the study, aspirin was the one which seemed to account for most of the benefit, the researchers said\n\nThere has already been some evidence that cancer and the body's coagulation system might be linked in some way.\n\"This benefit was seen whether these patients were treated with surgery or radiotherapy,\" Choe added.\nOf the almost 2,000 patients on anticoagulants in the study, 1,649 were taking aspirin, 428 warfarin, 287 clopidogrel (Plavix), 26 enoxaparin, and 408 a combination of blood thinners.\nAn initial review at six years suggested that those taking the combination therapy had a 43 percent reduced risk of dying from prostate cancer, while side effects were not \"major,\" Mason said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n \nWhen reporting the results of observational studies, it is important to avoid saying the results show cause-and-effect, when such studies can only identify associations. This story flunks that test by saying the study suggested that aspirin and other anticoagulants \u201cmay cut the risk of dying.\u201d Indeed, the story quotes the researcher saying it would be premature to recommend treating prostate cancer patients. The story should have put that caveat near the top of the story, rather than burying it.\nThe story further errs by stating that those who were taking anticoagulants had lower death rates. What the researchers actually reported was only the death rates from prostate cancer, not how many of the men overall were still alive after several years.\nOn the plus side, this story tells readers how many men were included in this research analysis. It also reports the actual differences in death rates, not just the relative differences (though as noted above, the researchers actually reported differences in death rates from specifically prostate cancer only.) Still, the story emphasized relative risk reduction twice in the story \u2013 \"risk of dying from cancer was reduced by more than half\" and \"this translates to a risk reduction of about 50 percent.\"\u00a0 That seems pointless when you\u2019ve already provided the absolute numbers. ", "answer": 0}, {"article": ",org *2014 Journal Citations Report published by Thomson Reuters \u00a92015\n\nElsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress.\nA total of 601 patients with a superficial BCC participated in this study: 202 patients were treated with methylaminolevulinate photodynamic therapy (MAL-PDT), 198 with imiquimod cream, and 201 with fluorouracil cream.\nA three-year randomized controlled clinical trial has found that two topical creams are effective in most primary, low-risk superficial BCC, comparing favorably with photodynamic therapy (PDT), as reported by investigators in the Journal of Investigative Dermatology.\n\"The main advantages of noninvasive treatments are good cosmetic outcome, preservation of surrounding tissue, and potential for home application of either creams,\" explained lead investigator Marieke Roozeboom of the Department of Dermatology, Maastricht University Medical Center in the Netherlands.\nThere are over two million cases a year in the U.S. and the lifetime risk of developing a BCC before the age of 85 years is one in five people.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release gives us lots of data \u2014 a total of 601 patients with a superficial BCC participated in this study: 202 patients were treated with methylaminolevulinate photodynamic therapy (MAL-PDT), 198 with imiquimod cream, and 201 with fluorouracil cream.\nAnd then it gives us the results: \u201cAround 80% of patients with superficial BCC were tumor free after imiquimod treatment after three years. The clearance rate was 68% for patients treated with fluorouracil and 58% for individuals receiving PDT.\u201d", "answer": 1}, {"article": "Regions of the brain that typically contain accumulated tau protein include the temporal lobe, parietal lobe and occipital lobe, among others; grey matter in the cerebellum is thought to contain low or no tau in patients with Alzheimer's.\nThey verified that detailed quantification of the tested and retested tracer in those five patients with Alzheimer's and five older controls generated good and reproducible results.\nIn the second part of the study, researchers tested the optimal tracer, called F-18 RO948, with additional brain imaging in five patients with Alzheimer's and five older controls, with follow-up of previously seen patients to evaluate the potential progression of tau protein tangling after an average span of approximately 16 months.\nThese three most promising tracers were previously tested in nonhuman primates, and the results looked promising enough to test in people.\nTwo studies will be published back-to-back in the December issue of Journal of Nuclear Medicine--one as featured article of the month--describing testing of three candidate molecules in patients with Alzheimer's disease, as well as the use of one molecule to measure the accumulation of tau proteins.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit here would be the accurate diagnosis of tau protein tangles in patients with Alzheimer\u2019s disease. There is no quantification of findings in this regard. Instead, the release uses general language, such as the statement that one of the studies \u201cgenerated good and reproducible results.\u201d\nAlso, the news release could have been clearer that no diagnostic tool has been developed, as the few people tested with heavy tau tangle loads already were known to have Alzheimer\u2019s.", "answer": 0}, {"article": "Testing cholesterol in toddlers and babies?\nThe study also revealed parents who had the condition but didn\u2019t know it, and had passed it on to their children.\nNinety percent of them started taking preventive medicines after finding out.\n\u201cIt\u2019s reasonable to screen for something that\u2019s common, dangerous and has a treatment that\u2019s effective and safe.\u201d\n\nDr. William Cooper, a pediatrics and preventive medicine professor at Vanderbilt University, called it \u201can innovative approach\u201d that finds not just kids at risk but also parents while they\u2019re still young enough to benefit from preventive treatment, such as cholesterol-lowering statin drugs.\nStatins aren\u2019t recommended until around age 10, but certain dietary supplements such as plant sterols and stanols could help younger kids, Urbina said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantified the findings this way: \u201cFor every 1,000 people screened in the study, four children and four parents were identified as being at risk for early heart disease. That\u2019s nearly twice as many as most studies in the past have suggested.\u201d That lets us know how many more people might get identified if screening was widened, but readers should also be informed that it isn\u2019t clear if this ultimately reduces cardiac deaths.", "answer": 1}, {"article": "Dr. John Richmond disagrees.\nThe authors of the study discourage patients from getting this treatment.\nThe researchers in Switzerland reviewed the existing studies and concluded that viscosupplementation was associated with an increase in these and other adverse events.\nHowever, Richmond says patients considering viscosupplementation should discuss this as a treatment option with their doctor.\nNow, a new report questions the efficacy of this treatment for osteoarthritis in the knee.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only discussed the Swiss meta-analysis conclusion of \u201cminimal benefits and potential for harm.\u201d Yet it allowed a US orthopedist to claim that \u201cThis is most effective in relatively younger patients, 40 to 50 to 60 year olds, and\u2026in people with mild to moderate forms of the disease.\u201d\u00a0 Neither statement is backed up by any numbers.", "answer": 0}, {"article": "Antioxidants are found in different levels in fruits and vegetables, such as blueberries or broccoli.\nAccording to the findings, among 50 patients drinking pomegranate juice for a year, about two would have to go to the hospital at least twice.\nBy comparison, that number would be nearly 11 in patients not drinking the juice.\nThey found that such patients who gulped a few cups of the tart liquid every week lowered their chances of infections, the second-leading killer of the more than 350,000 Americans on dialysis.\nBrosius was skeptical of the benefits, although he said the juice was unlikely to cause harm.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Good use of absolute risk reduction:\n\u201cAccording to the findings, among 50 patients drinking pomegranate juice for a year, about two would have to go to the hospital at least twice. By comparison, that number would be nearly 11 in patients not drinking the juice.\u201d\n\u00a0", "answer": 1}, {"article": "Find her on Twitter at @aliceparkny.\nBut given the growing body of data linking aspirin use to lower cancer risk, the researchers say it may be worth factoring in the drugs\u2019 anticancer effects when patients and doctors discuss options for pain relievers.\nIn the current trial, researchers looked at all cancer cases in the Danish Cancer Registry from 1991 to 2009 and compared this data against that of a prescription-drug database that recorded patients\u2019 histories of using aspirin, NSAIDs or COX-2 inhibitors, drugs that all work in similar ways to reduce inflammation and dull pain.\nHowever, the researchers didn\u2019t have information on other key skin cancer risk factors like exposure to UV radiation.\nIt\u2019s not the first study to show a potential anticancer effect of aspirin and other similar painkillers \u2014 a class of medications known and nonsteroidal anti-inflammatory drugs, or NSAIDs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although absolute risks generally cannot be estimated from case-control studies such as this one, we think the story could have done a better job putting these statistics into context. For example, the story notes that researchers found a 17% lower risk of basal cell carcinomas (\u201cthe most common form of skin cancer in the U.S..\u201d) in those taking long-term, high dose NSAIDs, but doesn\u2019t mention that this cancer almost never spreads beyond the skin. Squamous cell carcinoma is also a slow-growing type of cancer that is usually treated before it can cause complications. Meanwhile, melanoma \u2014 a very dangerous type of cancer \u2014 is thankfully quite rare, and so the modest 13% relative reduction reported in this study is likely to represent a very small number of cancer cases when put in absolute terms. In the grand scheme of things, the reductions seen were small and many of the cancers possibly prevented would not be clinically important.", "answer": 0}, {"article": "Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, said it's clear that \"some women with metastatic breast cancer have benefited from Avastin, but others not only have not benefited, they've been harmed.\nThe results of those studies were a bitter pill for patients thriving on Avastin and researchers excited by the promise of the early data.\n\"Survival was consistently better at one year in all of the studies, indicating that this is a safe and effective option.\nThe announcement does not affect Avastin's status as an approved therapy for lung cancer, kidney cancer, colorectal cancer and brain cancer.\nBased on the new data, an FDA advisory panel voted 12-1 to reverse the accelerated approval in July.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article meets the standard here by presenting data for progression-free survival and explaining that none of the trials showed a survival benefit for Avastin compared to standard chemo. (The quantity 0 seems implied.)\u00a0While it\u2019s notoriously difficult to explain the ins and outs of cancer studies in such a short space,\u00a0we nonethless criticize the article on this criterion because, although most of the messages were generally accurate, readers could\u2019ve benefited from more clarity on one of them and a little help overall in squaring up some potentially contradictory messages. We\u2019ll explain in 3 acts.\nAct I: Story Highlights. One of these summary bullets states that \u201cSubsequent studies showed no greater survival benefit.\u201d In isolation this statement may be misleading. It seems they mean it to refer to progression-free survival. But that doesn\u2019t jibe with the practical meaning of the term \u201csurvival benefit\u201d as actually used in the body of this article: overall survival. And in fact, as we learn, all 4 studies showed\u00a0no\u00a0survival benefit compared to standard chemo.\nAct II:\u00a0Dr. Sparano\u2019s zinger. In his opposition to the FDA decision, the source notes that one-year survival for Avastin was consistently better in all studies. How is a reader to reconcile that message with the message that survival was not better for Avastin in ANY\u00a0study? What was needed was not just quantification but qualification. Perhaps it would\u2019ve been as simple as giving us the timeframe for Dr. Woodcock\u2019s conclusion that there was no survival benefit in all studies, or more context about Dr. Sparano\u2019s point. Without some explanation somewhere, we think Dr. Sparano\u2019s\u00a0line should not have been quoted, since it\u2019s essentially out of context and it somewhat throws the messages up in the air for a reader, perhaps with consequences on the balance of the story.\nAct III:\u00a0Mixed messages?\u00a0The story gives us 2 messages that, taken together, may also seem contradictory for lay readers:\n1. Later trials showed that Avastin offers a small increase in progression-free survival compared to standard chemo \u2014 but still an increase. 2. The 4 studies together shown no survival benefit.\nHow is a non-clinician to make sense of these messages? How can it slow tumor growth \u2014 and lengthen the time people lived without progression \u2014 but not lengthen the time people lived? These head-butting messages\u00a0might\u2019ve been reconciled by clarifying, as the FDA press release\u00a0starts to, how these data show that Avastin\u2019s effects on tumor growth were temporary enough that people taking Avastin didn\u2019t live any longer,\u00a0on average.", "answer": 0}, {"article": "Neurosurgeons performing EDAS reroute arteries from the scalp and the membranes that cover the brain and place these arteries under the skull near areas of the brain at risk of stroke.\nTwo of the EDAS patients had small wound openings that required additional surgical interventions, but there were no intracranial hemorrhages or other serious adverse events, the researchers reported.\nThe trial, led by Nestor R. Gonzalez, MD, professor of Neurosurgery and director of the Neurovascular Laboratory at Cedars-Sinai, enrolled 52 patients with severe brain atherosclerosis, also known as intracranial atherosclerotic disease, or ICAD, who showed symptoms of either a recent stroke or a mini-stroke, called a transient ischemic attack.\nWhile this Phase IIa trial selected patients from previous studies as the control group, the Phase III study would enroll new ICAD patients for both the control and experimental groups, he explained.\nGonzalez said his team is working with the stroke prevention working group of the National Institutes of Health to develop a proposal for a Phase III randomized clinical trial across multiple institutions to further test the effectiveness of EDAS as compared with intensive medical management.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides readers with a numerical comparison of the study\u2019s results, in this case, the prevention of subsequent strokes or death among these patients.\u00a0 According to the release, in those receiving the EDAS procedure, after one year, 9.6% of patients had a later stroke or died, compared to more than twice that number (21.2%) from a matched control group who didn\u2019t receive this surgery.\n(We discuss the limitations of these results under the Evidence criteria, below.)", "answer": 1}, {"article": "All compared people taking at least 200 milligrams of Vitamin C each day with people taking placebos.\nThe message from the researchers, Senay observed, is that, if your activity profile doesn't match that of people like these, vitamin C won't keep colds away.\nIt makes us look toward other methods, aside from vitamin C, Senay concluded.\nShe explained that a review of numerous studies concluded that vitamin C isn't what it's cracked up to be, failing to help prevent the common cold in any meaningful way, except in some people exposed to extremely high stress.\nBut, she emphasized, this doesn't mean vitamin C is useless, not by a long shot.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The physician-journalist accurately describes the findings in a way people can easily understand on television\u2013essentially that there is no benefit of taking C in preventing colds, with\u00a0the exception\u00a0of one key subgoup of little relevance to most Americans.\u00a0Given the nature of the findings, more precise quantification is not needed. ", "answer": 1}, {"article": "\u201cI was exhausted all the time, from the time I woke to the time I went to bed,\u201d says Turner.\nFor Kothare, the out-of-pocket expense for the device, the risks of surgery, plus the potential for the mechanism \u2014which moves the tongue forward \u2014 to break, doesn\u2019t make it a viable option for everyone.\nWhat's more, a recent study in the New England Journal of Medicine found that the bulky CPAP machines \u2014 standard treatment for many patients with sleep apnea \u2014 doesn't help prevent heart attacks or stroke, although it does help patients sleep better and improve mood.\nThe main side effect from the device is that people can wake up with a sore tongue.\nInspire is an invasive procedure, so it is not recommended as a first-line treatment and not everyone is a candidate.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We learn that a \u201cclinical trial of Inspire therapy found a 78 percent reduction in the number of sleep apnea events per hour for patients.\u201d \u00a078% reduction\u2013compared to what? And how does that compare to the CPAP machine?\nThe story also creates a false sense of equivalence between the large body of evidence behind CPAP machines and the small uncontrolled pilot studies on the new device.", "answer": 0}, {"article": "As a result, sticky mucus builds up in a patient's lungs, causing infections and making it hard to breathe.\nBut for people who do have that mutation, the drug works remarkably well.\nAt the time, scientists predicted that a genetic test for CF was just around the corner.\nOne of those chemicals ultimately became a successful drug, but it had to be modified so patients could take it by mouth, and so it would last the right length of time in a patient's body.\nIt took awhile to find a drug that would help restore the function of the protein the CF gene makes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We kept reading this piece and listening to the audio for any sort of data to back up some of the claims made. We understand that numbers don\u2019t always translate well on the radio, but even a supplementary graphic illustrating how effective this drug is would have provided some much needed context. The story does say, \u201cIt only works on a small subset of people with CF. They have to have a particular mutation in the CF gene, or the drug is of little use.\u201d Then it says, though, \u201cBut for people who do have that mutation, the drug works remarkably well.\u201d How small is that subset? And how well does it work?", "answer": 0}, {"article": "\u201cI really cannot overstate the size of this effect.\u201d\n\nThe key finding is that there is often more time than doctors realized in which brain cells can still be rescued by a procedure to remove the clot.\nHowever, the findings do not apply to every stroke victim.\nThe researchers used a special type of brain imaging to identify the patients who still had live brain tissue that could be saved if the blood supply was restored.\nMany more stroke victims than previously thought can be saved from disability or death if doctors remove blood clots that are choking off circulation to the brain, a new study has shown.\nOnly about half the patients who were screened qualified for treatment, known as thrombectomy, which uses a mechanical device to pull clots out of a blood vessel.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article describes the impact of blood clot removal on \u201cfunctional independence\u201d and death rates for stroke patients. Readers learn that 45 percent of patients who had blood clots removed became functionally independent compared to 17 percent who did not have their blood clots removed. Additionally, the death rate was 12 percentage points lower in the group who had their blood clots removed compared to patients who didn\u2019t have them removed.\nHowever, since the story\u2019s headline says that extending the time window for blood clot surgery will \u201csave lives,\u201d it would have been more informative if the article reported on the additional lives saved by expanding the treatment window to 16 hours, by including the sizes of the treatment and control group. All we know is that there were 182 patients involved in the study.", "answer": 1}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We understand that the focus of this story was the FDA approval.\u00a0 Nonetheless, we wish that even a brief description of the data that led to approval had been provided.\n\u00a0\n\u00a0\n\u00a0", "answer": 0}, {"article": "The lower the amount of free PSA, the more likely cancer is the cause and the more likely the disease is aggressive, requiring treatment, according to Dr. Patrick C. Walsh, a Johns Hopkins urologist and the author of \u201cDr.\nFor them, if other factors like prostate infection are not the cause of the high level, a biopsy is in order.\nThe revised guidelines are expected to reduce the cost of screening, the cost per life saved and overall deaths from prostate cancer.\nThis rate, known as PSA velocity, will be part of the new guidelines, which will suggest that in men with low readings, doctors consider the changes in levels over the course of three measurements.\nThey will also suggest that testing start at 40 to obtain a baseline measurement, with the test repeated at 45 and 50, after which it should be given annually until 70.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article doesn't provide any evidence of the potential benefits of PSA screening.\u00a0 ", "answer": 0}, {"article": "A tiny balloon is inflated to flatten the clog and a mesh scaffold stent is usually placed.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\nIn the study, only one-third of the people treated with drugs ultimately needed angioplasty or a bypass.\nAbout 40 percent of patients in the study had a prior heart attack more than three months previously.\nAlso, the clogs treated with angioplasty are not the really dangerous kind.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does give the rate of heart attack or death as 19% within 7 years for both the stent and the medication group.", "answer": 1}, {"article": "DURHAM, N.C. - Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.\nThe researchers determined that eliminating the first annual screening after the initial negative test might have resulted in, at most, an additional 28 lung cancer deaths in the LDCT group (186 vs. 212 deaths per 100,000 per years) over the course of the study.\nOf the initial 19,066 participants with a negative initial LDCT scan, 444 (2 percent) were diagnosed with lung cancer at the time of the last available follow-up.\nAn additional 75 patients (0.4 percent of the initial negative group) were diagnosed with lung cancer between the first and second annual screening.\nIn the first year after a negative screen and before the scheduled first annual screen, 17 patients (0.09 percent of all initial negative LDCT participants) were diagnosed with lung cancer.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A thorough discussion of the absolute numbers affected gives a good sense of the magnitude of the benefits. The release noted, \u201cIn the first year after a negative screen and before the scheduled first annual screen, 17 patients (0.9 percent of all initial negative LDCT participants) were diagnosed with lung cancer.\u201d\nAnother benefit described is the potential to dramatically reduce the number of false positive tests. According to the release, almost 40 percent of the entire group of patient volunteers (26,231 people) in the 7-year National Lung Screening Trial were given a false positive study result.", "answer": 1}, {"article": "\"So many people say `how can cancer screening be harmful?'\nThe last study is a warning to people who get screening tests that aren't recommended, or who question whether screening can ever hurt.\nThe new study gives \"very, very solid support\" for screening less often, Lichter said.\nThe results are \"provocative,\" but this type of study can't prove that screening prevents deaths, said Dr. Matthew R. Smith of the Massachusetts General Hospital Cancer Center.\nThe new study was the first big one to examine a newer screening tool, HPV tests, with or without Pap smears in routine practice.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies the benefits, or lack of benefits, in terms that everyone can understand. For example, it says, \u201cOnly about three out of 100,000 women each year developed cervical cancer after negative HPV and Pap tests. HPV tests were twice as good as Paps for predicting risk. Adding a Pap after a negative HPV test did little to improve risk prediction.\u201d", "answer": 1}, {"article": "National Jewish Health is the leading respiratory hospital in the nation.\nExperts say there is more research to be done, but that the goal of the trial is to discover the best combination of bacteria to clear eczema from the skin and then make it available to patients as a prescription cream.\nWhile it may seem counterintuitive to treat bacteria with more bacteria, experts say this approach seeks to restore the natural microbial balance of healthy skin.\nResearchers hope that using the bacteria-infused cream will offer a long-term solution where other treatments fall short.\nPowerful antibiotics are commonly prescribed for eczema, but they kill good bacteria on patients' skin along with the bad.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told the lotion contains \u201cbeneficial bacteria to fight harmful bacteria,\u201d and the lead investigator is quoted as saying that this will \u201chelp the skin gain back it\u2019s natural balance and create that barrier needed to keep it healthy.\u201d\nBut we\u2019re given no data from the trials to support this. We\u2019re also not given any context regarding what good bacteria, natural balance, or \u201cthat barrier\u201d are.\nThe only example of a \u201cbad\u201d bacteria mentioned is Staphylococcus aureus. The news release informs us that Staph. aureus makes eczema worse. Previous studies have shown that high levels of Staph. aureus do correlate with increasing severity of eczema.\nThe lead investigator suggests that applying the lotion twice a day will \u201celiminate all staph aureus.\u201d But there\u2019s no evidence included to show that this lotion actually improves the eczema.\nIt should have been acknowledged that staph aureas colonization might be associated with eczema severity and not a cause of it. For example, if people with more severe eczema scratch more, they are more likely to colonize themselves with bacteria they pick up in the environment around them.\u00a0 This does not indicate that reducing the staph will result in improvement of the underlying disorder.", "answer": 0}, {"article": "They found that Chinese women who ate the most soy were also less likely to die of lung cancer, the No.\nThe findings, published in the Journal of Clinical Oncology, lends support to the idea that adding soy foods to the diet can help people in multiple ways, says Dr. Jyoti Patel, a lung cancer specialist at Northwestern University in Chicago, who was not involved in the study.\n\u201cThis finding, along with our previous observation of an approximately 40 percent reduction in risk of incident lung cancer associated with high intake of soy food, provides further support for the role of soy food intake in lung cancer development and prognosis,\u201d the researchers wrote.\nOf the 444 patients with lung cancer, 318 died during the three years of follow-up, the researchers wrote.\n\u201cThe high soy level patients were eating what the FDA has said is heart-healthy, or 25 grams of soy a day,\u2019 she said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is careful to describe the amount of soy food you\u2019d need to eat on a daily basis to match the intake of the high soy consumers group \u2014 important info to include. But we were disappointed that the\u00a0story used relative risk figures to describe the benefits of increased soy intake on cancer survival. \u00a0It says that low soy consumers were \u201c1.8 times as likely to die\u201d\u00a0compared with the average and that \u201cThose who ate the most were about 11 percent less likely to die.\u201d It would have been more informative\u00a0and accurate to tell readers\u00a0the absolute percentage of subjects who had died at follow-up in the low,\u00a0average, and high soy consumption groups.", "answer": 0}, {"article": "Dr Davide Pellacani, who began these studies in York, before moving to the University of British Columbia, said: \"Using this computer analysis, not only could we see which tissue samples had cancer and which didn't, but also which cancers were dangerous and which ones less so.\nIt is now understood that to find the different levels of cancer, scientists have to identify genes that have been altered in different cancer types.\nA team at the University of York and the University of British Columbia, Canada, however, have designed a test that can pick out life-threatening prostate cancers, with up to 92% accuracy.\nIt is believed that success rates could be hindered as a result of treating all prostate cancers in the same way.\nThey were able to do this using a computer algorithm, which left the team with 17 possible genetic markers for prostate cancer.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release tries to quantify benefits in two ways. First, it says that \u201cA recent study showed that more than 25 men were being unnecessarily treated with surgery or radiotherapy, for every single life saved.\u201d But how recent was this study? And who published it? Next, the release says that the news test \u201ccan pick out life-threatening prostate cancers, with up to 92% accuracy,\u201d although this is not technically correct. In the published study, the authors say that the algorithm resulted in \u201can AUC of 0.92.\u201d AUC stands for Area Under the Curve, which is not the same measurement as accuracy.\nThe AUC is considered the best measure of whether a test can distinguish between diseased and non-diseased people.\u00a0 In this case, the investigators used their test to differentiate between cancers that were confined to the prostate and those that had spread beyond the prostate among men who had undergone prostatectomy. \u00a0While these advanced cancers can be life-threatening, that\u2019s a bit of hyperbolic description. Metastatic cancers are clearly the most likely to be life threatening. \u00a0Additionally, estimates of AUC have 95% confidence intervals. \u00a0If the AUC, as it appears, was based on results from 4 patients, then 92% is a very imprecise estimate.", "answer": 0}, {"article": "Oct. 17, 2010 -- Women aged 65 and older are advised to undergo bone mineral density (BMD) screening every two years, but those with normal results at age 67 may be able to wait 10 years before their next screening test, a new study suggests.\nTheir findings are based on the women's T-score, which is a measure of bone density.\n\"Our study found it would take about 16 years for 10 percent of women in the highest bone density ranges to develop osteoporosis.\nThe new findings are slated to be presented at the annual meeting of the American Society for Bone Mineral Research in Toronto.\nResearchers analyzed bone mineral density data from 5,035 women aged 67 or older who had their BMD tested at least twice during the 15-year study period.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are no numbers in this story attached to the benefits of less frequent bone density testing.", "answer": 0}, {"article": "This level is equivalent to two to three 8-oz cups of coffee per day, five to six 8-oz cups of black tea, or seven to eight 12-ounce cans of cola.\nIn 10 years or less of follow-up with annual assessments of cognitive function, 388 of these women received a diagnosis of probable dementia or some form of global cognitive impairment.\nDriscoll and her research colleagues used data from 6,467 community-dwelling, postmenopausal women aged 65 and older who reported some level of caffeine consumption.\nAmong a group of older women, self-reported caffeine consumption of more than 261 mg per day was associated with a 36 percent reduction in the risk of incident dementia over 10 years of follow-up.\nThe findings come from participants in the Women's Health Initiative Memory Study, which is funded by the National Heart, Lung, and Blood Institute.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that among older women in a large study, \u201cself-reported caffeine consumption of more than 261 mg per day was associated with a 36 percent reduction in the risk of incident dementia over 10 years of follow-up.\u201d\nThe release would have been better with some explanations of what the 36 percent reduction in risk of incident dementia actually meant.\nThe published study doesn\u2019t include any numbers in the primary tables to allow for a calculation of absolute risk reduction. The only statistics provided, even in the body of the paper, are the Hazard Ratios, including the 0.76, which gives rise to the 36 percent reduction for the higher caffeine consumers.\u00a0 In this instance, the release writer may have done their best with the available information from the paper, but the writer could have consulted with the study authors to provide this important additional detail. At the very least, providing some estimate of the baseline risk in the study would have helped put the 36 percent reduction in perspective. If that baseline risk was low to begin with, then a 36 percent reduction might not be very meaningful.", "answer": 0}, {"article": "The goal is to find what's right for you.\"\nBut participants robustly used the IntelliCare interactive apps as many as four times daily -- or an average of 195 times -- for eight weeks of the study.\nBut Northwestern researchers hope participants will provide confidential feedback, via four weekly questions, that will be used to further develop the system.\nThe IntelliCare algorithm recommends new apps each week to keep the experience fresh, provide new opportunities for learning skills and avoid user boredom.\nThe data will help the system make even better recommendations and provide more personalized treatment.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release makes several claims but doesn\u2019t back them up with data. For example:\n\u201c13 novel mini-apps reduced depression and anxiety by nearly 50 percent in a preliminary research study\u201d\nWhat kind of depression and anxiety are we talking about here? Feeling a little blue or so severely depressed you can\u2019t get out of bed? Which tools were used to measure or rate participants\u2019 level of depression or anxiety?\n\u201cparticipants reporting significantly less depression and anxiety by\u00a0using\u00a0 the apps on their smartphones up to four times a day\u201d\nAgain, what does \u201csignificantly\u201d refer to?\n\u201cThe short-term study-related reductions are comparable to results expected in clinical practice using psychotherapy or with that seen using antidepressant medication.\u201d\nClaiming that using the apps for 8 weeks is comparable to a similar period of psychotherapy or antidepressant use is unfounded without a randomized clinical trial. The study itself notes that 64% of participants were taking antidepressant medication, and 22% were receiving psychotherapy, when they enrolled in the study.", "answer": 0}, {"article": "Some insurance plans cover EMDR.\n\u201cEMDR processing is untangling the knot.\u201d\n\nOnce the memories are processed, therapists say, they are less vivid \u2014 less like the film reel Henn would see in her mind.\nEMDR, Henn said, allowed her to have a do-over \u2014 to be able to grieve properly and then to move beyond grief.\n\u201cIt helped me realize feelings were normal,\u201d she explained, and that she was not weak for reeling from the tragedy.\nThis distraction had a positive effect on her, she said, allowing her to dive deeply into the therapy without freezing in the face of fear.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story provides vivid details of a patient\u2019s reactions to the intervention, the text makes little effort to describe the nature of the benefits that EMDR therapy might confer, much less quantify them.\nThe only reference is to the movement of traumatic memories from short-term to long-term memory.\u00a0 The individual who is the subject of the narrative never speaks to that; instead, she notes that the therapy made her trauma memories \u201cless powerful\u201d and that she is \u201cnot hurt by it anymore.\u201d\nIt\u2019s our opinion that much more should have been described about the benefits\u2013what percentage of people respond, and to what degree?", "answer": 0}, {"article": "This was unheard of.\nThe non-responders who were immediately referred for surgery had better outcomes too.\nOver 10 years, 153 stage 3 and 4 laryngeal cancer patients were treated at Michigan Medicine, with about half receiving the induction chemotherapy.\nAfter a decade of using this approach, researchers are reporting \"exceptional\" survival rates nearing 80 percent, even for the most advanced patients.\nIn a clinical trial, they saw disease-specific survival rates of 80 percent in patients with advanced disease.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release explains the benefits for patients with stage 3 and stage 4 laryngeal cancer: \u201cAverage disease specific survival at five years for the induction chemotherapy patients was 79 percent \u2013 equivalent to the results in patients with early stage disease, and significantly better than the 66 percent survival for patients who had chemo-radiation without the induction strategy.\u201d However, there were some shortcomings here.\nAccording to the study, surgery achieved the best survival results. It may not be possible to conclude anything about the \u201cchemo trial\u201d group because the study was observational \u2013 taking a retrospective look at 10 years of patient charts \u2013 which does not prove cause and effect.\nIn each of the 153 cases, patients and doctors chose which treatment type they preferred; 71 were given a test dose of chemotherapy and then had further treatment decided based on the response. The release doesn\u2019t tell us how many were then treated with surgery due to lack of response and how many completed chemotherapy/radiation treatment.", "answer": 0}, {"article": "\"I know scientists are supposed to be objective and dispassionate,\" Hendricks says.\nOnly two population studies to date, this one included, specifically address the relationship between mental illness and psychedelics.\nThe scientists recognize, too, that it's still unknown if classic psychedelics concretely led to a drop in psychological distress and suicidality; perhaps those who participated in the study and had reported using psychedelics in the past had personalities that made them less susceptible to distress and suicidality in the first place.\nHe believes the data support the idea of demoting psychedelics to schedule 3 or 4, and that they can be used in controlled therapy situations.\nA lack of resources and funding is a hindrance to continuing studies, however, as psychedelics are still classified as schedule 1 narcotics in the U.S. and criminal offenses accompany their possession.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites \u201cabout 27,235 people\u201d who said they had used \u201cclassic\u201d psychedelics, which it identifies as magic mushrooms, DMT, mescaline and LSD. And it lists the reduction in the odds that these people had exhibited psychological distress in the prior month (-19%) or suicidal thoughts (-14%) or suicidal attempts (-36%) during the prior year. But it does not give total numbers of individuals for any of those categories.\nAs a side note, we\u2019d point out that the study technically reported on the \u201codds\u201d and not the \u201cprobability\u201d of exhibiting suicidal thoughts or attempts (the latter being language used in the story). A small point, to be sure, but we think these details matter.", "answer": 1}, {"article": "\"The first time those three letters were uttered in a group setting, everyone's like, 'Oooo, that's scary, do we want to do that?'\nThere are several scientists who say this field is so new that it's lacking in good evidence that brain changes actually occur.\nThey see the potential of these games to not only make money \u2014 but to save money, too.\n\"The qualities of a good video game, things that hook you, what makes the brain \u2014 snap \u2014 engage and go, could be a perfect vessel for actually delivering medicine,\" he says.\nSo some scientists believe that by playing this game \u2014 Project Evo \u2014 you can improve a range of cognitive skills and, by extension, relieve a range of symptoms associated with cognitive disorders.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story includes claims that these games could be effective for a range of symptoms of cognitive disorders; that they could be as effective as drug treatment; and that they could cut the size and length of certain clinical trials in half. But there are no hard numbers that pin down what these claims mean.", "answer": 0}, {"article": "\"One day I turn to my wife and I'm like, 'I feel calm today.\nThe fear was \"overwhelming,\" he says.\nBefore ketamine, James was unable to work or focus his thoughts.\nAnd he couldn't stop thinking about gruesome scenarios, like a murderer coming for his family.\nAnd that could explain why patients like James usually stop overheating once they are taking ketamine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story relies largely on a single anecdote of a person who says ketamine \u201chelped me get my life back\u201d. The expert sources use only vague descriptions of ketamine as \u201ctransformational\u201d and that patients in one trial \u201cgot dramatically better.\u201d There are references to clinical trials, but none cites any specific results in quantified terms.", "answer": 0}, {"article": "One found improvement in infants given fennel extract compared to infants given a placebo; another found that infants given a tea containing chamomile, vervain, licorice, fennel and balm-mint seemed to work; while a third found infants given a tea containing fennel, lemon balm and chamomile cried less than infants given a placebo.\nAll of the trials reviewed had \"major limitations,\" such as having too few patients, relying on parental reports of symptoms, or the study design (such as not being double-blinded).\nBecause pediatricians can't offer parents much help with it -- for the most part, babies grow out of colic in time -- desperate parents often turn to alternative or complementary treatments, according to the study.\nBut those studies were small and flawed, so no conclusions can be made about the technique, according to the new review.\nBut because fennel extract, certain herbal teas and sugar water are generally safe, and because the research does suggest babies may benefit, pediatricians said they would feel comfortable recommending them to parents.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is about a review of several studies, and we don\u2019t expect the benefits to be quantified for each study reviewed.\u00a0Instead, the story used\u00a0vague phrases such as \u201cfound improvement.\u201d In on area, the story provides numbers, saying, \u201cA study of probiotics, which are reputed to help digestion, found that 95 percent of infants given L. reuteria probiotics seemed to reduce their average crying time compared to 7 percent of babies given simethicone, which is marketed to relieve gas under the brand names Mylicon and PediaCare Infants\u2019 Gas Relief.\u201d But even here, we would have liked to have seen some absolute numbers. We appreciate that it is difficult to tease these numbers out of the review, but, at a minimum, the small study size (90 children) would have been good context for readers.", "answer": 0}, {"article": "\"Anything we can do to get those rates up has the potential to save lives.\nDetection rates for the first doctor were about 67 percent while listening to music and 30 percent with no music.\nThis was up from a baseline detection rate of 21 percent before the study began.\nBetter detection of these so-called adenomatous polyps could save lives, the study authors noted, as survival rates for colorectal cancer are better than 90 percent if the disease is detected early.\nThe study authors suggested that the findings could help reduce the number of people affected by invasive colorectal cancer -- the third most common cancer diagnosed in men and women in the United States, according to background information in the news release.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The absolute dfference in adenomas was not reported, only percentages.\u00a0 We\u2019re told it was a small study.\u00a0 How small?", "answer": 0}, {"article": "Lower disk herniation results when the insulating disks that sit between spinal vertebrae tear open, allowing jelly-like material to protrude and exert pressure on surrounding nerve roots.\nHe noted that because \"the majority of people with back pain improve with time and exercise alone,\" it remains an open question as to whether the pRF procedure really cured the condition.\n\"Steroid injections are effective only in portion of the patients, and generally require more sessions,\" he noted.\nThe therapy is not new, having first received U.S. Food and Drug Administration approval in the 1980s.\nAnd the new research suggests the treatment could prove a boon to back pain patients for whom standard therapies have failed to do the trick.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story calls this treatment a potential \u201cboon to back pain patients for whom standard therapies have failed,\u201d and includes a glowing personal endorsement by the study\u2019s lead author.\nOnly near the end do we get a small amount of data:\n\u201cBy the one-year mark following either treatment, a full \u2018perceived\u2019 recovery was reported by 95% of the pRF patients, compared with just 61% of the steroid injection patients.\u201d\nThe story doesn\u2019t tell readers what \u201cperceived\u201d recovery means and how it was measured.", "answer": 0}, {"article": "\u201cThe Holy Grail is to have a relatively non-toxic therapy that could potentially use the body\u2019s own immune system to prevent recurrence,\u201d he says.\n\u201cTo give you some idea of how significant that is, with chemotherapy we normally see the same degree of response around 20% of the time.\u201d\n\nForde says that the strong response seen in people at the beginning of the disease could suggest that immunotherapies might be useful in re-training the immune system to fight cancer for long periods of time \u2014 possibly even a lifetime.\nDoctors can also determine if a person\u2019s lung cancer is genetically vulnerable to the checkpoint inhibitor drugs tested in the current study.\nIn addition, \u201ca year after treatment, three times more people on immunotherapy were doing well compared to those who just got chemotherapy.\u201d\n\nThe results could play a role in changing standard treatments for people diagnosed with advanced NSCLC, by making a strong case for starting people immediately on the immunotherapy combination rather than giving them chemotherapy first, as many doctors currently do.\n\u201cAnd while our study is only with 21 patients, the early indications from this study are very positive.\u201d\n\nTaken together, the results could fundamentally change the way lung cancer is treated, significantly improving people\u2019s ability to both hold off lung cancer for longer periods of time, as well as live longer with the disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t give absolute data for two of the three studies it mentions.\nIt says the two-drug combination of Opdivo and Yervoy found that after nearly a year, the lung cancer in people taking the immotherapy was \u201c42% less likely to have progressed than among people getting chemotherapy,\u201d and patients taking Keytruda with chemotherapy were \u201c51% less likely to die after 10.5 months\u201d than people getting just chemotherapy.\nAbsolute numbers would have given a clearer picture of what portions of patients saw a benefit. For example, in the Keytruda study, 69% of patients originally assigned to Keytruda were alive at the end of the study period versus 49% of those who received chemotherapy alone.\nFor the third study, the story says taking Opdivo before surgery \u201cshrunk those tumors drastically and lowered the chances for relapse\u201d and \u201cin about half of the people treated \u2026 the growths showed significant destruction by immune cells in the blood and certain targets on the tumor cells.\u201d\nHere the coverage could have been improved with a quantitative description of what\u2019s meant by terms such as \u201csignificant destruction.\u201d Also, this third study was very small and experimental, which we\u2019ll discuss under evidence quality below.", "answer": 0}, {"article": "(Reuters Health) - Waning eyesight may hasten the pace of cognitive decline in older people, suggests a U.S. study.\nThe good news, Whitson added, is that poor vision is one of the few risk factors for cognitive decline that is potentially modifiable.\n\u201cThis study provides additional evidence that would suggest that people who can keep their vision healthy as they age might also be protecting their cognitive health,\u201d said Dr. Heather E. Whitson of Duke University School of Medicine and Durham VA Medical Center, who wasn\u2019t involved in the research.\nTo investigate, Zheng\u2019s team followed 2,520 adults for eight years, testing their vision and cognitive status every other year.\nOver the course of the study, average visual decline was roughly equivalent to losing the ability to read one line of an eye chart.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes a relationship between vision and cognition, but we never get a feel for how strong that link might be.", "answer": 0}, {"article": "Surgery is considered by some to be the most definitive treatment, and there is evidence from other studies that it has better long-term cancer outcomes than radiation for higher-risk cancers, but it has more sexual and urinary side effects than radiation.\n\u201cUrinary incontinence was reported as a moderate or big problem in 14 percent of men three years after surgery compared to 5 percent of men who had radiation,\u201d Barocas said.\n\u201cMen who had radiation reported more problems with bowel function and hormone side effects compared to men who had surgery, but these differences were only seen within the first year following treatment,\u201d he said.\n\u201cThis study shows that, despite technological advances in the treatment of prostate cancer, both surgery and radiation still have a negative effect on quality of life,\u201d said co-author David Penson, M.D., MPH, Paul V. Hamilton, M.D., and Virginia E. Howd Professor of Urologic Oncology and professor and chair of the Department of Urologic Surgery.\nThree-year survival from prostate cancer was excellent in the study at over 99 percent for patients regardless of whether they chose surgery, radiation or active surveillance.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release did not provide many numbers. For example, it reported erectile dysfunction and urinary incontinence as \u201cmore common\u201d in men treated with surgery than radiation, but did not give a quantity for the \u201cmore.\u201d\nThe release did include a numeral in this sentence, but it wasn\u2019t very enlightening: \u201cUrinary incontinence was reported as a moderate or big problem in 14 percent of men three years after surgery compared to 5 percent of men who had radiation,\u201d Barocas said.\u201d", "answer": 0}, {"article": "Our new test is therefore a potential game changer,\" says Professor James Paton, Director of the University of Adelaide's Research Centre for Infectious Diseases.\nThe team has now engineered a harmless portion of the toxin to enhance its specificity for the cancer glycan and used this to detect it in blood samples from women with ovarian cancer.\nA paper published this month in Biochemical and Biophysical Research Communications has shown that the new test detected significant levels of the cancer glycan in blood samples from over 90% of women with stage 1 ovarian cancer and in 100% of samples from later stages of the disease, but not in any of the samples from healthy controls.\nThe new blood test has the potential to dramatically improve early detection of the disease, although it will require further testing before it is available for clinicians.\nThe team is currently seeking scientific and commercial partners to further test the technology with larger numbers of patient samples and to adapt it for mass screening.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only benefit mentioned is this:\n\u201cthe new test detected significant levels of the cancer glycan in blood samples from over 90% of women with stage 1 ovarian cancer, and in 100% of samples from later stages of the disease, but not in any of the samples from healthy controls.\u201d\nWe\u2019re glad to see it made clear that the blood test was increasingly positive for cancer in those women already known to have increasingly advanced cancer.\nHowever, it should have been made even more clear the overall study group is quite small (69 women), with only 23 women having known stage I/II disease; therefore, this study can not show if the blood test would be effective as a screening tool in healthy women.\nIt\u2019s very important to show how the test looks in populations with and without cancer \u2014 which will likely be done in the future. The public needs to know and be clear about that when a person has cancer, the test is positive and if we know there is no cancer the test is negative.", "answer": 0}, {"article": "tears.\nHe points out that in The New England Journal of Medicine study, only 8 percent of the patients in the first surgical group subsequently tore a meniscus, a fragile pillow of cartilage that can rip if a knee gives way.\nThe treatments were almost identical, too, in terms of whether the athletes could return to sports and whether they reported subsequent knee problems.\ntreatment is \u201ccontroversial,\u201d The New England Journal study\u2019s authors, Richard Frobell, Ph.D., and Stefan Lohmander, M.D., Ph.D., of Lund University, wrote in their e-mail.\nIn the current study, most of the group members who had reconstructive surgery reported that their injured knees felt healthy after two years and that they had returned to activity \u2014 not, in most cases, at the same level as before their injuries, but they were active.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "(As noted, some of the measures in\u00a0these studies\u00a0can be considered either benefits or harms, depending on how you look at it.)\u00a0\nThis piece provides the absolute changes for each treatment group, and then tells us the key outcome: the results weren\u2019t statistically different and demonstrated non-superiority. The piece reports the relative proportions of each group who tore their meniscuses. Qualitatively, it tells us about stability outcomes. The controversy surrounding the importance of these measurements is explored and sometimes implied; it would\u2019ve been clearest for the author to explain (or wonder aloud) the meaning of increased mensical tears and instability in light of equivalent scores on the primary outcome. This story mentions that in the 2009 retrospective study, all subjects eventually developed similar and high levels of early-onset arthritis.\u00a0\nThe piece also provides some analysis of other outcomes, such as two \"almost identical\" results in the 2009 study. While quantified results are scant overall in this piece, that seems justified given that the comparisons between results often showed no statistical differences, which is clearly the important message. Of importance was the story\u2019s exploration of the controversy surrounding the meaning of outcomes in stability and meniscus tears.\nAs mentioned in our introduction, this study raises the question of treating all ACL injuries as if patients are pro athletes. On that note,\u00a0in an environment where we see pros jump at surgical therapy,\u00a0one facet of the decision that would\u2019ve been nice to raise is the recovery time. What are the outcomes, expectations, and/or trade-offs for getting back on the court sooner?\u00a0The piece reports study outcomes 2 years after surgery.\u00a0", "answer": 1}, {"article": "Too much LDL cholesterol circulating in the blood can lead to the thickening of artery walls, making them less flexible and therefore impairing their function and increasing the risk of heart disease.\nIn this phase one clinical trial, which is designed to determine if a drug is safe, researchers found that using a monoclonal antibody (lab-produced protein) called REGN727, was not only safe, but effectively blocked PCSK9 and therefore signficantly reduced bad cholesterol in healthy patients as well as those also taking the popular cholesterol-lowering drug Lipitor.\nEarlier studies had shown this effect in primates, but this new study, published Wednesday in the New England Journal of Medicine, provides the first clinical trial data for testing the drug on humans.\nTwo arms used 72 healthy volunteers who were either injected with a single dose of the drug in increasing amounts to test for side effects, which is the purpose of a phase one clinical trial.\nAll of those subjects were also receiving treatment with the statin Lipitor.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated that \u201cthe subjects who received REGN727 had a striking reduction of 60 to 65% \u00a0in LDL cholesterol,\u00a0according to (the lead researcher who characterized the results of the trial as \u2018pretty dramatic.\u2019 \u201d\nThe story also quoted an American Heart Association spokesman as calling this \u201cgame changing science\u201d \u2013 putting that phrase in the headline as well \u2013 and \u201ca very important breakthrough.\u201d\nTo describe results of potential efficacy from a small Phase I study this way without emphasizing to the general public that Phase I studies aren\u2019t designed to focus on efficacy is troublesome.\nNeither the Cardiobrief blog, nor MedPage Today, in reporting on the same studies, used any such hyperbole.\nIn fact, MedPage Today ended its story with the reminder: \u201cGiven the small number of subjects and the short duration of exposure, our ability to evaluate the safety profile of REGN727 in these trials was limited,\u201d the researchers cautioned.\nIf a Phase I trial, which is designed to measure safety and not efficacy, is too small and short to fully evaluate safety, then making bold claims about efficacy is even more of a reach at this point. A consumer-targeted story needs to make such points with emphasis.\u00a0 This story did not.\n\u00a0", "answer": 0}, {"article": "The study was supported by the Andrew Sabin Family Fellowship Program; the American Association for Cancer Research \u2013 Stand Up to Cancer; the National Institutes of Health (CA219896-01A1, HL124112); the Cancer Prevention & Research Institute of Texas; and the Melanoma Moon Shot\u2122, part of MD Anderson\u2019s Moon Shots Program\u2122, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients\u2019 lives\n\nIn addition to Wang, other MD Anderson authors include: Diana Wiesnoski, Christopher Sanchez, and Chia-Chi Chang, Ph.D., all of Genomic Medicine; Beth Helmink, M.D., Ph.D., and Vancheswaran Gopalakrishnan, Ph.D., both of Surgical Oncology; Hamzah Abu-Sbeih, M.D., Gottumukkala Raju, M.D., and John Stroehlein, M.D., all of Gastroenterology, Hepatology & Nutrition; Edwin Parra, M.D., Ph.D., and Alejandro Francisco-Cruz, Ph.D., both of Translational Molecular Pathology; Matthew Campbell, M.D., Jianjun Gao, M.D., Ph.D., and Sumit Subudhi, M.D., Ph.D., all of Genitourinary Medical Oncology; Dipen Maru, M.D., of Pathology; Jorge Blando, DVM, and James Allison, Ph.D., both of Immunology; Padmanee Sharma, M.D., Ph.D., of Genitourinary Medical Oncology and Immunology; Michael Tetzlaff, M.D., Ph.D., of Translational Molecular Pathology and Pathology; Jennifer Wargo, M.D., of Genomic Medicine and Surgical Oncology; and Robert Jenq, M.D., of Genomic Medicine and Stem Cell Transplantation.\nBoth patients in the study had a complete resolution of their colitis following treatment with FMT.\nWith endoscopic evaluation before and after treatment, both patients displayed significant improvements in inflammation and ulcerations, including a reduction of inflammatory immune cells.\nAdditionally, distinct new populations of bacterial species were evident in these patients following FMT compared to pre-treatment samples, including several species known to be protective or reduce inflammation.\nThe two patients included in the study were treated at MD Anderson between June 2017 and January 2018.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release clearly states the outcomes of fecal transplants in the two patients that constitute the study.", "answer": 1}, {"article": "Stephen Buckley, head of information at the mental health charity Mind, said: \u201cWe welcome research which adds to our understanding of treatments and medications that may work for people experiencing mental health problems.\n\u201cThis study provides a clinically suitable approach for personalising antidepressants therapy.\nIf the test proves effective it is hoped that by measuring patients\u2019 level of blood inflammation it would identify which of them would benefit from receiving antidepressants soon after their diagnosis to stop their condition worsening.\nThe Royal College of Psychiatrists said that, if it worked, the test could prove to be a key moment in the quest for the holy grail of biological psychiatry.\n\u201cSuch a finding and a test to back it up would be critical to advancing our understanding of the biological causes of depression.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story talks about \u201cbreakthroughs\u201d and \u201choly grails,\u201d but doesn\u2019t provide any numbers to that effect.\u00a0The accuracy figures are included in the study\u2019s abstract and the story should have discussed them along with an explanation of what they mean.", "answer": 0}, {"article": "The 20-year project examined data from 2,560 men taking part in a randomised clinical trial to test the effects of statins versus a placebo.\nResearchers from Imperial College London and the University of Glasgow found impressive results among those on statins, who were given the widely-prescribed type pravastatin.\n\u201cThis legitimises current guidelines which recommend treating this population with statins.\u201d\n\nRay said people with lower levels of cholesterol, around 4mmol/L, who otherwise appear healthy, should also be treated with statins.\n\u201cOur study lends support to LDL\u2019s status as a major driver of heart disease risk, and suggests that even modest LDL reductions might offer significant mortality benefits in the long-term.\nAll the men had very high levels of LDL, or \u201cbad\u201d cholesterol, (higher than 4.9mmol/L) but had no evidence of heart disease at the start of the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only told readers the relative risk improvements for taking a statin. It did not present the terms in absolute numbers. By the relative measure, taking statins seems very effective: 28% fewer men died from heart disease when taking statins compared to a placebo.\nBut the absolute risk is more sober and should always be presented along with relative numbers. Of the group taking statins, 6.69% of people with very high LDL died from cardiovascular heart disease within 20 years. Of the group taking a placebo (and it\u2019s not immediately clear to us what their LDL status was), 9.03% died from heart disease.", "answer": 0}, {"article": "During the luteal phase, estrogen and progesterone levels are at their highest, which may help a woman keep addictive cravings at bay and reduce feelings of cigarette withdrawal.\nThe brain scans showed that during the follicular stage, cigarette imagery activated five areas of the brain which the researchers say are linked to higher-level cravings.\nA new study finds hormone fluctuations that occur over the course of a woman's menstrual cycle may impact her ability to kick the cigarette habit.\nThe researchers tested 13 of the female participants twice to assess how their response changed at a different point in their menstrual cycle.\nThey called for more studies to help understand all the factors that contribute to sex and gender differences in smoking.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In the original study that\u2019s being reported on, the authors state that they \u201conly observed subtle differences in brain activations between the follicular and luteal phases.\u201d But the article does not make clear that the findings were \u201csubtle.\u201d In fact, there was no discussion about the strengths of the relationships observed. In addition, the story states that other areas of the brain showed activity during certain phases of menstrual cycle. Do these areas of the brain also show activity for other responses? Are there other parts of the brain that are also associated with cravings that were not activated? The story could have done a lot more to describe what the researchers actually found in the study and why it might be relevant to readers.", "answer": 0}, {"article": "The BRCA1 and BRCA2 gene mutations put women at high risk for breast, ovarian and other cancers, but mutations of other genes are believed to confer extra risk as well.\nEven among all appropriate candidates who are sent for genetic testing, only nine percent will test positive for the BRCA mutations, so an additional four percent who have non-BRCA mutations is a significant number, Ellisen said.\nAnd for many, family testing would be recommended for first-degree relatives, according to the report in JAMA Oncology.\nThough these results indicate that additional genetic screening is clinically useful, some genetic test results will be uncertain, and it can be psychologically difficult for patients to deal with this uncertainty, Ellisen said.\nEarlier this year, 17 genetic experts argued against testing for a wider panel of breast cancer-related gene mutations until they are proven to be valid and useful in clinical practice (see Reuters story of May 27, 2015 here: reut.rs/1TvOoDf).\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story relays the benefits described in the study for the study population. It notes that 63 (about 4%) out of more than 1,000 women who test negative for BRCA mutations tested positive for non-BRCA mutations. \u201cOf those, the researchers decided that 33 would have been considered for additional screening or prevention measures based on their results.\u201d That description earns to the story a Satisfactory rating. Additional details on what screening and prevention measures might be recommended for which women \u2014 and some statement about whether those results are likely to apply to people outside of the study \u2014 would have been welcome.", "answer": 1}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "5-year estimated outcomes were given after only 2 years of data. No quantitative data on safety presented. Absolute numbers \nprovided. Limited long term data and small absolute benefit are key issues here. ", "answer": 1}, {"article": "Chinese herbal medicine increased IELT by about two minutes, Ayurvedic herbal medicine increased IELT by nearly a minute and topical cream increased IELT by more than eight minutes.\nThe improvements were small, and the studies were of varying quality, but preliminary evidence suggests that acupuncture, Chinese herbal medicine, Ayurvedic herbal medicine and a Korean topical cream may all have desirable effects, researchers conclude in the journal Sexual Medicine.\nBias was unclear in most of the studies, and only five used stopwatches to measure IELT, which is the \u201cgold standard\u201d for premature ejaculation studies, Patrick said.\nWhen they were reported, the adverse effects were generally mild, the study team writes.\n\u201cThis is a common condition that has serious psychological effects on relationships,\u201d said Patrick, who wasn\u2019t involved in the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While we don\u2019t really know what particular ingredients might be in the tested Chinese herbal treatments, the Ayurvedic herbal medicine or the Korean topical cream, we do learn that \u201cChinese herbal medicine increased IELT by about two minutes, Ayurvedic herbal medicine increased IELT by nearly a minute and topical cream increased IELT by more than eight minutes.\u201d \u00a0We would have benefited from knowing what the baseline times were, ie: if the two acupuncture studies were found to increase\u00a0intravaginal ejaculatory latency time (IELT) by about half a minute compared to placebo, how much additional time did the placebo provide?", "answer": 1}, {"article": "MRI uses a powerful magnetic field and pulses of radiowave energy to create images.\nIndeed, CT appears to be better for assessment of coronary artery disease, matched against not only MRI but other methods, such as echocardiography, he said.\nCT is the preferred noninvasive technology for assessing the condition of heart arteries, whether there is narrowing that might end with the total blockage that causes a heart attack, Schoepf said.\nThat difference helps explain why there are so few studies doing head-to-head comparison of CT versus MRI, he said.\nIndeed, CT and MRI are not contenders in clinical practice but are used for different reasons to make different assessments, Schoepf said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does provide some important details on the meta-analysis, including the number of studies and patients, as well as sensitivity results. However, we have two critiques:\n1) It notes that the sensitivity results, 97% and 87%, were for the studies of people with suspected coronary artery disease. We believe that\u2019s incorrect. According to the\u00a0published study, these figures are for the overall population in the meta-analysis, which includes those with suspected OR known disease, including those with heart attacks. For the analysis just of patients with suspected coronary artery disease, the results were different: 98% and 89%. But that\u2019s a minor problem.\u00a0 A bigger issue,\u00a0 to us, is the following. \u00a02) We would have liked to have seen the specificity results, too. We\u2019re unsure why they choose to report just sensitivity and not specificity. False positives are important, too, besides just false negatives.\n3) The study had clear limitations that were ignored in the story. \u00a0The authors of the study concluded, \"Randomized studies are\u00a0clearly needed to address the potential of coronary CT angiography for use in triage as a means of positively altering\u00a0management and outcomes in patients with suspected\u00a0CAD (coronary artery disease).\"\u00a0 The take home message for readers of this story may be that CT scans are \"Best for Checking Heart Arteries\"\u00a0 \u2013 as the headline states \u2013 a conclusion that has yet to be clearly demonstrated.", "answer": 0}, {"article": "It will enable us to have more potent countermeasures to jet lag than continuous light, which is the current prescribed light therapy treatment,\" Zeitzer said.\nThis study builds on previous research published in 2014, which found that light therapy works best at night because the body's circadian rhythms are more sensitive to light at night, even through closed eyelids.\nIn this latest study, Zeitzer and Raymond Najjar, a former postdoctoral scholar at Stanford now at Singapore Eye Research Institute, found that short flashes of light at night are more effective than continuous light exposure and could speed up the process of adjusting to a different time zone before a trip.\nZeitzer's latest study, published Monday in the Journal of Clinical Investigation , could make treatment easier by providing light exposure during sleep, before the trip, without changing or interrupting your routine.\nParticipants were able to sleep through the flashes of light without waking.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Details on the benefits are minimal but we do get a sense that two different groups of volunteers were tested with different light exposures (continuous vs. intermittent flashing) and those with the intermittent flashing light had \u201ctwo hours of change in circadian timing, compared with 36 minutes for those exposed to continuous light.\u201d Changes in \u201ccircadian timing\u201d is not explained.", "answer": 1}, {"article": "...\nEven the study's lead author says the research should not be used to recommend chelation therapy, and he acknowledges that its findings could have been due to chance.\nUnder the best of circumstances, that's not a strong result, says anesthesiologist Kimball Atwood of Newton-Wellesley Hospital in Massachusetts, who has followed the study from its beginning.\nMore than half the trial sites were led by doctors who practice chelation, says Paul Armstrong, a professor of cardiology at the University of Alberta, chosen to discuss the study on a panel at the heart meeting.\nThis study's findings are even more questionable, however, Kopecky says, because patients who got chelation had lower bad cholesterol levels than the placebo group at the start of the trial.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says the\u00a0benefits were \u201cvery small, with 26.5% of those randomly assigned to chelation experiencing a cardiovascular problem, compared with 30% of those randomly assigned to a placebo infusion.\u201d That\u2019s\u00a0a satisfactory handling of the statistics.\nThe story could have\u00a0also pointed out that the primary outcome\u00a0was a so-called \u201ccomposite endpoint\u201d encompassing a lot of different results, including death, heart attack, stroke, referral for cardiovascular procedures, and others.\u00a0Most of the\u00a0benefit attributed to chelation was due to fewer cardiovascular procedures\u00a0being performed in that group, which is\u00a0an important detail.\u00a0Because this outcome involves some subjective determination about who should\u00a0and who should not be referred for\u00a0these procedures, it is considered a \u201csofter\u201d or less reliable\u00a0outcome than rates of death or heart attack, which are outside of the investigators\u2019 control. If chelation provided a substantial\u00a0benefit, we presumably would have seen\u00a0a larger difference on these other \u201charder\u201d endpoints.\nWe\u2019re also a little uneasy with\u00a0the\u00a0story\u2019s discussion\u00a0of\u00a0statistical significance, which it says is \u201cthe\u00a0standard for judging whether a result is real or a fluke.\u201d\u00a0It says it was \u201cconcerning\u201d that the results\u00a0of this study passed\u00a0the significance bar \u201cby only 0.001,\u201d implying that the results\u00a0would have been considered a \u201cfluke\u201d\u00a0if the results were a\u00a0few hundredths different. In fact, the results, taken at face\u00a0value, suggest that there was about a\u00a097%\u00a0probability that this result could not have\u00a0occurred by chance, and a change of .001\u00a0would not have altered that fact appreciably \u2014 even if it did mean that\u00a0the findings would no longer be considered \u201cstatistically significant.\u201d We think it\u2019s a stretch to question\u00a0this result \u2014 something which is almost never done\u00a0in coverage of\u00a0other studies that also \u201cbarely clear the bar\u201d for significance \u2014\u00a0\u00a0without a more complete discussion of what this means.", "answer": 1}, {"article": "Worldwide, meningitis and encephalitis affect more than four million adults and children each year.\n\u201cBeing able to rapidly identify a central nervous system disorder as infectious can be crucial in rapid response.\u201d\n\n\u201cIn addition, the test could distinguish viral from non-viral infections, a distinction that could spare a child with a viral infection from an unnecessary course of antibiotics, and tailor the care toward antiviral and supportive measures as needed,\u201d said Dr. Curtis.\nRather than testing for the presence of bacteria or virus, the researchers looked at the first tell-tale signs of infection: the cytokines produced by the patient\u2019s immune system in response to pathogens and other injury processes.\nNow, researchers at Jefferson (Philadelphia University + Thomas Jefferson University) have developed a test that could rapidly parse out infections of the brain from other diseases.\nChanges in cytokine levels of cerebrospinal fluid offer a very early measurable sign of infection.\u201d\n\nDr. Curtis and colleagues decided to see if they could detect patterns within the cytokines that might differentiate infections from other brain diseases or disorders.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits described are put in some numerical context. The results might show the presence of an infection, or something else (like tumors or autoimmune disease). It\u2019s seemingly innocuous, but for young children and babies, who can\u2019t describe their symptoms, such a tissue test could be beneficial, as the release explains.\nHowever, it would have strengthened this release to explain why some cytokine signals (and which ones) might be better indicators than others, and to what extent based on the small sample size.\nAnother thing that would have been helpful to explain is the fact that cytokines can also be inappropriately released (without infection, etc). This is a rare occurrence but we\u2019d still want to know that this distinction could be made as well.", "answer": 1}, {"article": "About CVS Health \n\nCVS Health (NYSE: CVS) is a pharmacy innovation company helping people on their path to better health.\n\"In fact, our patients report high satisfaction with our Coram home infusion services, citing convenience and comfort as key elements that improved their overall experience.\"\nResearchers compared measures of quality, safety, clinical outcomes, quality of life and costs of home infusion services to those provided in medical settings.\n\"Our research shows that home infusion care is a promising model that is both cost- and clinically-effective and is overwhelmingly preferred by patients when intravenous therapy is required.\"\nThe research showed that patients receiving intravenous therapy at home had as good or better clinical outcomes as those patients who received the same therapy in a traditional health care setting.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We found the news release skimmed over giving crucial numbers and metrics for benefits. Separate from the cost benefit to home infusion versus hospital or clinic infusion, the release should have given us some numbers for safety.\nHere is what the release stated (emphasis ours):\n\u201cThe research showed that patients receiving intravenous therapy at home had as good or better clinical outcomes as those patients who received the same therapy in a traditional health care setting. In addition, patients overwhelmingly preferred receiving their infusion therapies at home, reporting fewer disruptions in personal schedules and responsibilities.\nWe need numbers to demonstrate how \u201cas good\u201d the clinical outcomes were. We need numbers to represent \u201coverwhelmingly preferred.\u201d By what percentage did what number of patients demonstrate preference?\nThis is where the release could have taken some quantitative data from the study.", "answer": 0}, {"article": "Their overall risk of death was 30% lower than the sedentary adults, with the risk of cardiovascular and cancer deaths lower by 40% and 18% respectively.\nA study of more than 60,000 adults in England and Scotland found that \u201cweekend warriors\u201d lowered their risk of death by a similar margin to those who spread the same amount of exercise over the whole week.\nThe findings will reassure people who find it hard to make time for a daily exercise routine and opt instead to break a sweat once or twice a week in the hope of keeping fit.\nUlf Ekelund at the Norwegian School of Sport Sciences in Oslo said the study emphasised what researchers have found time and again: that even a small amount of regular exercise wards off death.\nPeople who cram all their exercise into one or two sessions at the weekend benefit nearly as much as those who work out more frequently, researchers say.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Like the story in Newsweek, which we also reviewed, this story does not provide an adequate sense of the size of the potential benefits, stating:\nIn the study, those who met the physical activity target by exercising through the week had a 35% lower risk of death than the inactive adults, with cardiovascular deaths down 41% and a 21% lower risk of cancer death.\nUsing only relative risk rates such as these\u00a0doesn\u2019t tell the full story. \u00a0Read more on why absolute risk rates should also be included in news stories.\nIt also makes the study sound like it was experimental in fashion, conflating association with causation.\n\u201cPeople who cram all their exercise into one or two sessions at the weekend benefit nearly as much as those who work out more frequently, researchers say. \u00a0A study of more than 60,000 adults in England and Scotland found that \u201cweekend warriors\u201d lowered their risk of death by a similar margin to those who spread the same amount of exercise over the whole week.\u201d\nSee more on the importance of not overstating observational findings.", "answer": 0}, {"article": "Breast cancer has a high rate of metastasis to bone, lung, liver, lymph nodes, and the brain.\n\u201cWe showed with this technique that we can detect very tiny tumors of just a few hundred cells,\u201d Lu said, adding that the study pushed imaging boundaries, revealing smaller cancers than can be detected with current clinical imaging modalities.\nTheir approach detects micrometastases, breakaway tumor cells with the potential to develop into dangerous secondary breast cancer tumors elsewhere in the body.\nUsing a microscopic imaging approach, called cryo-imaging, and MRI, the researchers verified that the MRI technique could detect micrometastases, even observing bone micrometastases that were less than 0.5mm \u2014 the diameter of a very fine pencil lead.\nAnalysis of images showed that the contrast used by the research team bound almost exclusively to the fibrin-fibronectin complexes, producing a strong and prolonged image enhancement of micrometastases and tumors compared with normal tissue.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release didn\u2019t include information about how much better the enhanced MRI technology was shown to be (compared to MRI alone and cryo-imaging combinations)\u00a0in detecting metastases. The release does note that the investigators\u00a0\u201cverified\u201d that the new MRI method could detect micro metastases less than 0.5 mm, but offered no comparative measures of what other detection methods have to offer.", "answer": 0}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story lacks precision in describing\u00a0the benefits of some products that have actually been studied in human tests (e.g. lactase and Bean-o), but then gives too much detail about products that have only been tested in lab studies. Does anybody care that a pill results in \u201c60% [of] large gluten molecules broken down in a half-hour and 75% at 90 minutes\u201d in a test tube? No. We care what happens inside people\u2019s bodies\u00a0and whether the products produce actual symptom relief.\u00a0It\u2019s particularly upsetting that the story concludes\u00a0with a plug for these test tube benefits, when a few paragraphs earlier we are told\u00a0that the products have never been tested in human trials.", "answer": 0}, {"article": "UCLA's Bhat noted another limitation in the study: \"These are all genetic cataracts.\nShe said, even without answers to the question of whether it will work in aging eyes, it creates hope for children with congenital issues.\nHe's said it's unclear if the results will be mirrored in older cataract patients, the same concern expressed by others in the field.\nIf it takes months to get to an outcome, it's not superior to the lens technologies we have now.\nShe also had questions about how the procedure was done with such a tiny incision.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states the new procedure \u201crestored vision in babies for the first time\u201d but doesn\u2019t describe any quantified benefits of this newer method. At the end of the story, we are told the researchers claimed a \u201c100 percent\u201d success rate three months after surgery. However, that\u2019s not specific enough: Readers should be informed of how the researchers measured success\u2013what were the outcomes they measured?\u2013especially in such a young patient group where vision testing is tricky.", "answer": 0}, {"article": "Please see paper for the complete list.\nThe study, which comes jointly from the Buck Institute for Research on Aging and the UCLA Easton Laboratories for Neurodegenerative Disease Research is the first to objectively show that memory loss in patients can be reversed, and improvement sustained, using a complex, 36-point therapeutic personalized program that involves comprehensive changes in diet, brain stimulation, exercise, optimization of sleep, specific pharmaceuticals and vitamins, and multiple additional steps that affect brain chemistry.\nResults from an approach dubbed metabolic enhancement for neurodegeneration are now available online in the journal Aging.\n\u201cFollow up testing showed some of the patients going from abnormal to normal.\u201d\n\nOne of the more striking cases involved a 66-year old professional man whose neuropsychological testing was compatible with a diagnoses of MCI and whose PET scan showed reduced glucose utilization indicative of AD.\n\u201cThe magnitude of improvement in these ten patients is unprecedented, providing additional objective evidence that this programmatic approach to cognitive decline is highly effective,\u201d Bredesen said.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The research consists of 10 case studies in which all subjects showed some degree of improvement. But the news release gives information about only three patients \u2014 out of 10 in the study \u2014 who had the most dramatic improvements.It relates those patients\u2019 self-reported advances in functionality and gives measurements in memory improvement for two patients. It does not warn that self-reported improvements are likely to be biased by the patient\u2019s expectation of benefit from the program. It does not describe the specific interventions used for each patient. The news release doesn\u2019t tell us the total number of patients that were enrolled in this protocol. Were only the 10 that showed improvement included in the case study? What about the rest?\nThe release appears to cherry pick some data regarding risks and uses relative risks only, no absolute numbers. For example, you cannot tell from this release what your chances are of getting Alzheimer\u2019s if you have one or two APOE genes.\nClaims found in the release such as \u201cFollow up testing showed some of the patients going from abnormal to normal\u201d are both grandiose and unsubstantiated, but they could raise patient and caregivers\u2019 hopes that they or a loved one could reverse their Alzheimer\u2019s symptoms.", "answer": 0}, {"article": "Age-related macular degeneration, or AMD, is the leading cause of vision loss among seniors, gradually eroding crucial central vision.\nWhile the study is too small to prove if lampalizumab really helps maintain vision, that\u2019s a bigger difference than the overall results suggested.\n\u201cFrom the basic science perspective, it makes a lot of sense.\u201d Macular degeneration tends to occur after age 60, but it sometimes strikes earlier.\nIt turns out that nearly 6 in 10 of the study\u2019s participants carry a gene variation that makes part of the immune system go awry \u2014 a genetic flaw already known to increase the risk of getting macular degeneration in the first place.\nThe experimental drug, lampalizumab, aims to slow the destruction of light-sensing cells in the retina, creeping lesions that characterize the stage of dry AMD called \u201cgeographic atrophy.\u201d When those cells die, they can\u2019t grow back \u2014 the vision loss is irreversible.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us that patients who had the genetic variation and were treated with the drug had \u201c44 percent less eye damage than the untreated patients.\u201d However, since there is no information on what the baseline measurements were, we\u2019re not sure what that means. Is this a little or a lot in absolute terms? Did the treated group have noticeably improved vision?\nAs the study shows, all patients got worse after 18 months. But the lesions in the gene-carrier placebo group grew by about 4.2 millimeters, whereas the treated gene-carrier group\u2019s lesions grew 2.3 millimeters. It\u2019s not clear at all if that provides any actual vision benefit\u2013or is worth the risk of side effects, since presumably the patients will need to be treated indefinitely. We wish the story had explored this important aspect.", "answer": 0}, {"article": "A recent study has found evidence suggesting text messages could reduce one\u2019s odds of a second heart attack.\n\nA six-month clinical trial in Australia found that patients recovering from a heart attack were more likely to maintain lower blood pressure, less body fat and lower cholesterol levels than a control group when the patients received text messages asking and giving suggestions about their health routines. Patients receiving the texts also were more likely to be active and to quit smoking than the patients in the control...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A clear and readable chart in the story quantifies\u00a0the apparent benefits of these text messages. But what\u2019s missing here is some nuance:\u00a0The control group saw a rise in blood pressure, whereas the experimental group remained relatively the same\u2013their blood pressure didn\u2019t actually get lower. So, does that even translate to an actual reduced heart disease risk?\u00a0And does any of this actually prevent heart attacks? These unanswered questions could have been better emphasized.", "answer": 1}, {"article": "Drugs such as aspirin and ibuprofen treat inflammation, the body's immune response to infections or pathogens.\nKhandaker said that five of the 20 studies focused on one specific cytokine.\nThese trials form the basis of the Cambridge research that was published Tuesday in the journal Molecular Psychiatry\n\nBased on previous findings about depression, the team looked at the side effects experienced by patients given anti-cytokine drugs in 20 separate studies.\n(CNN) In the future, a new class of anti-inflammatory drugs could be used to treat depression, say University of Cambridge researchers.\n\"We need more studies,\" he said, particularly research involving patients with depression who are inflamed but healthy to investigate the effect of these drugs on depression.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes\u2013and attributes\u2013statements saying studies showed the use of the anti-cytokines \u201cimproved symptoms of depression\u201d and \u201clessened symptoms of depression\u201d even in the absence of efficacy for reducing inflammation. But there are no statistics given to explain what \u201clessened\u201d or \u201cimproved\u201d means and very\u00a0little about the 20 studies\u00a0on which the researchers\u2019 conclusions about the potential anti-depressant benefits of the new drugs\u00a0are based.", "answer": 0}, {"article": "Dec. 14, 2009 -- Every cup of coffee a person drinks per day may lower the risk of diabetes by 7%.\nWhen the information from the individual studies was combined, researchers found each additional cup of coffee drunk per day was associated with a 7% lower risk of diabetes.\nThey say several studies have suggested that drinking coffee may lower the risk of developing type 2 diabetes and others have shown that decaffeinated coffee and tea may offer similar benefits, but there has not been a recent review of the research on the issue.\nThe study also showed that people who drank more than three to four cups of decaffeinated coffee per day had about a one-third lower risk of developing type 2 diabetes than those who didn\u2019t drink any.\nThe results showed that people who drink more coffee, whether it\u2019s regular or decaffeinated, or tea appear to have a lower risk of developing type 2 diabetes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story provided several data points about potential benefits, but never discussed the limitations of drawing conclusions from observational studies.\u00a0 ", "answer": 0}, {"article": "\u201cIt\u2019s not a decision made on a single visit,\u201d she said.\n\u201cThis is the first study to prove women survive longer with these preventive surgeries and shows the importance of genetic testing when there is a family history of early breast or ovarian cancer,\u201d Dr. Virginia Kaklamani of Northwestern University in Chicago wrote in a commentary about the study published in the Journal of the American Medical Association.\nShe said primary care physicians, gynecologists and women \u201cneed to be more aware that these tests exist.\u201d\n\nDr. Sandhya Pruthi, a breast cancer expert at the Mayo Clinic in Rochester, Minnesota, who counsels women with BRCA mutations, said the study adds more evidence that the surgery can help save lives, but the choice is never easy.\nThe study shows the benefits of genetic tests that give women with a family history of cancer the chance to take steps to increase their chances of survival, they said.\n\u201cOur results confirm that risk-reducing mastectomy is associated with a significant reduction in breast cancer risk,\u201d Domchek and colleagues wrote.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nMost of the references to benefits are vague, such as, \u201cyou can save the majority of women who would have died of breast cancer.\u201d The story also does not make clear that the reduction in the risk of death was due entirely to removal of ovaries and that the researchers did not report that preventive mastectomy reduced the risk of death among these women. In addition, the factual errors in the description of cancer risks facing these women (described above) makes it impossible for readers to get an accurate understanding of the potential benefits of preventive surgery.", "answer": 0}, {"article": "\u201cWe can\u2019t tell from the existing study if that is going to hold up or not,\u201d he said.\n\u201cI don\u2019t think this paper is inconsistent with previous work.\u201d\n\nNichols, who was not involved in the study, said aspirin is clearly beneficial for people who\u2019ve already had heart disease, and that it also seems to help those at high risk.\n\u201cIt refines our knowledge of how beneficial aspirin is,\u201d Dr. Graham Nichol, an expert in emergency care at the University of Washington in Seattle, said about the study.\nThe task force advises that men age 45 to 79 take aspirin to stave off heart attacks, as long as the benefit outweighs the risk of bleeding.\nLeFevre added that while the new study did add extra evidence compared with earlier work, it failed to analyze the effects on men and women separately.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Appropriate context.\u00a0 With a meta-analysis it is not statistically appropriate to pool absolute risk reductions, so the way the story treated the evidence is as good as can be done (showing the relative risk reduction and an \u201canchor\u201d in terms of absolute risk. Excerpt:\n\u201cThe researchers found a 19-percent reduction in non-fatal heart attacks among participants who took aspirin compared to those who did not.\nThey don\u2019t mention how many people actually suffered such a heart attack, but an earlier analysis of six of the trials showed that out of every 1,000 people, 18 individuals taking aspirin had heart attacks every year, compared to 23 individuals taking placebo pills.\nOn the other hand, that analysis also found aspirin increased the rate of bleeding from 0.7 to 1 per 1,000 people per year, making the authors conclude the drug was of \u201cuncertain net value.\u201d", "answer": 1}, {"article": "A new study has an intriguing finding: Advanced cancer patients who received early palliative care in conjunction with standard care for their disease not only reported better quality of life, but lived a few months longer than patients who received only standard care.\n\nThe research, published in the New England Journal of Medicine, included 151 patients diagnosed with metastatic non-small-cell lung cancer who were randomly assigned to one of those treatment plans. At 12 weeks, 86% of those who were still alive filled out assessments \u2026", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story adequately quantifies the survival benefit and at least mentions the improvements in quality of life and depression scores. It also provides some reasonable explanations as to why palliative care may be beneficial when administered early. Although we wish it had been more precise in its characterization of the depression and quality of life benefits (how big was the improvement? on which specific symptoms?), we feel there\u2019s enough\u00a0here for a satisfactory.\u00a0\u00a0", "answer": 1}, {"article": "Colorectal cancer is the third most common cancer in men and women, and strikes 1.2 million people each year.\nThis is not the first study to suggest Celebrex and similar drugs \u2014 known as COX-2 inhibitors - may reduce the risk of developing colon cancer, he said, but people need to balance that potential benefit with the higher risk of cardiovascular complications.\nOnly half of the people who originally agreed to participate in the study remained after 5 years, and it\u2019s unclear how this might affect the results, noted Chan, whose own research suggests aspirin could prevent deaths from colorectal cancer.\nThe study, published in the American Journal of Gastroenterology, received financial support from Pfizer, which sells Celebrex.\nBut to people who have no underlying cardiovascular problems and a particularly high risk of colon cancer - they were diagnosed with it before perhaps, or have a strong family history - regular screening may not be enough, Chan noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports the benefits in appropriate statistical terms, noting that \u201cnew polyps were found in 58 percent of people on placebo, and only 51 percent on Celebrex.\u201d The story could also have given us the number of advanced polyps that were prevented in each group. And, as noted above under the \u201cEvidence\u201d criterion, the story should have explained that these differences in polyp incidence\u00a0might not translate directly to the number of actual cancers prevented. Since we\u2019ve already docked the points for this omission, however, we\u2019ll award a satisfactory here to recognize the appropriate use of absolute risk numbers.", "answer": 1}, {"article": "Zeitzer was on the committee that removed jet lag as a \u201cdisease\u201d from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the guide that psychiatrists use to diagnose mental illnesses.\nIn a previous study, the short flashes of light at night did not interrupt sleep or reduce its quality, he added.\n\u201cFor moving your system to an earlier time, such as would be necessary when traveling West-to-East, light during the last few hours of the night is ideal.\u201d\n\nThe night flashes require special technology and equipment, beyond just a smartphone, which are still in development, Zeitzer said.\n\u201cThis is one of the real advantages of this system - you can change circadian timing while you sleep, without interfering with sleep,\u201d he said.\n\u201cHowever, the treatments that are developed for jet lag can be used for less prevalent, though far more significant societal problems including delayed sleep in teens (in whom we have an ongoing clinical trial using the flash technique) and shift workers who try to flip between a night time schedule for work and a day time schedule for leisure,\u201d he told Reuters Health by email.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits of those who experience the flashing light therapy over those who have the continuous light therapy were\u00a0described this way: \u201cA series of flashes similar to a camera flash delivered every 10 seconds over a 60-minute period delayed sleepiness by two hours, compared to a 36-minute delay for those exposed to continuous light for an hour.\u201d\nThese quotes were also helpful in quantifying and understanding the benefits:\n\u201cIn essence, using the night before you traveled from California to N.Y. would move your circadian system two-thirds of the way there before you even left,\u201d Zeitzer said.\nArriving in New York, you would be synced to the local time after one day, he said.", "answer": 1}, {"article": "on Sept. 2.\nIn a note to clients in October, Joshua Schimmer, an analyst at Leerink Swann, estimated that a typical treatment would last 3.5 months and cost $126,000, or about $36,000 a month.\n\u201cA peripheral T-cell lymphoma patient,\u201d he said, \u201cat first blush will see this therapy as a very good thing.\u201d\n\nAllos, which is still unprofitable, has lost $350 million since its founding in 1992 and failed to win approval of a previous drug.\nMr. Schimmer\u2019s note was entitled \u201cFolotyn Prices High, Reiterate Outperform.\u201d He estimated annual sales of the drug in the United States reaching about $300 million by 2014.\nAbout $60,000 of the cost would be incurred in the first eight weeks, when the drug is given more frequently.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately quantitifes the benefits of Folotyn, which are not that impressive. The story provides the percentage of patients with reductions in tumor size and the median time that the benefits lasted.", "answer": 1}, {"article": "For more on omega-3 fatty acids, visit the National Institutes of Health.\nNone of the low-dose supplements seemed to stave off such events in most of the patients.\nThe amount of supplementation added to the various margarines was deemed to be \"low-dose.\"\nIn the study, researchers focused on a group of more than 4,800 Dutch heart attack patients between the ages of 60 and 80, slightly more than three-quarters of whom were men.\nAll had experienced a heart attack at some point in the decade leading up to the study, and all were taking blood pressure medications, anti-clotting drugs and statins.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate. The story mentioned that there did appear to be a subcategory of benefit in women who consumed the ALA fortified margarine. \u00a0It didn\u2019t to mention the benefits seen in individuals with diabetes from the use of fortified margarine.", "answer": 1}, {"article": "Actinic keratoses are typically red, scaly skin lesions that can over time develop into a type of skin cancer.\nThe new study was funded by Picato manufacturer LEO Pharma.\n\u201cThe shorter application period is what makes ingenol mebutate a breakthrough in the treatment of actinic keratosis,\u201d researcher Mark Lebwohl, MD, says in a news release.\nBecause the new gel is only used for a few days, any irritation is usually short-lived.\nOther available topical treatments must be used for several weeks, and often irritate the skin.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story delivers information on how the gel compared with placebo.", "answer": 1}, {"article": "Feb. 1, 2012 -- A new drug appears to be effective for shrinking uterine fibroids and controlling the heavy menstrual bleeding they often cause, according to new research from Europe.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\nBoth studies appear in the Feb. 2 issue of The New England Journal of Medicine.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate discussion of benefits as seen in the two published studies.", "answer": 1}, {"article": "It is also not available for pregnant women, people with heart conditions or very high blood pressure, patients with kidney disease or clotting disorders, patients on blood thinners, patients with a history of strokes or brain tumors and people with substance abuse issues.\nThe essential tremor research has been supported by InSightec, the Focused Ultrasound Foundation and the BIRD (US-Israel Binational Industry Research and Development) Foundation.\nNot only did the researchers determine that the procedure was safe and effective, they found that it offered a lasting benefit, reducing shaking for trial participants throughout the 12-month study period.\nThe paper outlines the results of an international clinical trial, led by Jeff Elias, MD, of the University of Virginia Health System, that evaluated the scalpel-free approach called focused ultrasound for the treatment of essential tremor (ET), a condition that afflicts an estimated 10 million Americans.\nParticipants who received the sham procedure, on the other hand, showed no significant improvements.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019ll give this release credit for including numerical data on patient improvement during the study: \u201cthey found that mean tremor scores improved by 47 percent at three months and 40 percent at 12 months. Participants reported major improvements in their quality of life. People who couldn\u2019t feed themselves soup or cereal could again do so.\u201d\u00a0 Unfortunately, it omits a host of other numerical data contained in the NEJM paper that places the patient improvement in a less-glowing perspective, issues like the reduction in improvement over time experienced by some patients and the extent of adverse effects (see below). It\u2019s quantification data was based on relative rather than absolute improvements and it was not clear what those improvements meant functionally. The release could have described the range of the scale and given the actual tremor scores. This would have been more informative than describing a 47% reduction which could represent a very large or relatively small changedepending on what the baseline scores were.\nHad the release included some of the caveats pointed to in an editorial about the same study carried in the journal, readers would have a clearer picture of just how important this new procedure was.", "answer": 0}, {"article": "For more information on healthful eating for kids, visit the U.S. Department of Agriculture.\nThis is particularly true during the first three years of life when the brain is developing rapidly, the study authors explained.\nHowever, to truly understand the effect of diet on children's intelligence, further studies are needed, they said.\nThe key seemed to be the diet at age 3, since diet at 4 and 7 seemed to have no effect on IQ, the research team noted.\nConversely, every one point increase in healthy eating translated into a 1.2 point increase in IQ, the researchers found.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although some data are presented, the results are not clearly explained. For example, the story says that \u201cfor every one point increase in processed foods consumption,\u201d the children\u00a0\u201clost 1.67 points in IQ.\u201d We are never given any explanation as to what a\u00a0\u201cone point increase in processed foods\u201d might mean. An extra hot dog each week? An additional serving of mac and cheese? There should have been some attempt to characterize these measurements in terms corresponding to actual food. Similarly, there\u2019s\u00a0also no discussion of what these IQ differences translate to in terms ability to read, write, and function in a classroom or in other aspects of life.\u00a0In\u00a0their study, the authors characterized the associations between\u00a0diet and IQ as \u201cweak.\u201d", "answer": 0}, {"article": "Why?\nThe current study, she added, shows that \u201chigh quality (stroke) care is available in hospitals on the weekends and weekdays.\u201d In fact, care might even be more aggressive on weekends.\nOverall, Kazley added, this study offers \u201cgood news that indicates that the quality of care is similar regardless of when patients present at the hospital for treatment.\nIn fact, that authors note that patients who received tPA were more likely to die in the hospital.\n\u201cEven in a country with universal health insurance coverage (such as Canada), disparities in resources, expertise, or the number of healthcare providers working during weekends\u201d may affect the stroke mortality rate, the researchers concluded.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes the vague claim that tPA\u00a0\"can improve patient outcomes following stroke.\" Some detail on what outcomes are improved, and by how much,\u00a0would have been useful for readers. The story also did not quantify the results of this study very well.\u00a0 It says there was a\u00a0\"20% difference\"\u00a0in the use of tPA between the groups, but fails to show that it is 1.1% vs 0.9% \u2014 a 2 in\u00a01000 difference in absolute terms. Given the relatively finely balanced benefit to harm ratio, this finding is not clinically important even though it is statistically significant due to the huge sample size.", "answer": 0}, {"article": "\"This may simply indicate that some of the causes for preterm birth may not pre-exist before the pregnancy,\" Graves said.\nPhysicians will \"be able to use a simple blood test and then know that this woman is at increased risk or reduced risk of a preterm birth,\" said Graves, whose laboratory performed the research in the study.\nThe test wasn't as effective at 24 weeks of gestation.\nEven if the test is found to indicate that a birth will be premature, physicians would have limited options.\nStill, the test \"should be an important tool for an obstetrician who currently has no clue\" if premature birth is a possibility until it happens, said Brigham Young University (BYU) chemistry professor Steven W. Graves.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Mixed bag here.\u00a0 We\u2019ll give it a somewhat satisfactory grade. Here\u2019s why.\nThe story stated that the test \u201cpredicted 80 percent to 90 percent of the premature births at 28 weeks of gestation. The false positive rate \u2014 referring to tests that wrongly indicated premature birth \u2014 was 20 percent. The test wasn\u2019t as effective at 24 weeks of gestation.\u201d\u00a0 It didn\u2019t give any numbers to back up the experience at 24 weeks.\nBut we would have appreciated somewhere a note that it is the very early preterm births that are the most crucial to predict. The story fixates on 28 week testing. What\u2019s really needed are means to identify and study the 23 to 28 weekers. The story also doesn\u2019t acknowledge that we have no effective interventions to stop preterm birth and somewhat incorrectly explains how betamethasone for lung maturity works.\nIt also had an independent expert\u2019s quote: \u201cIf you are going to be alarming a patient by saying that she may have premature delivery, you want to make sure that\u2019s truly the case.\u201d\u00a0 That\u2019s a very important contribution to the story.", "answer": 1}, {"article": "Randomized trials allow for the strongest inferences to be made about the true effect of an intervention such as a medication or a procedure.\nAuthors: Andrew K. Chang, M.D., M.S., of Albany Medical College, Albany, New York, and coauthors\n\nResults: After 2 hours pain was less in all participants, without any important difference in effect between the four groups.\nStudy Limitations: The results apply only to pain after two hours.\nWho: 416 patients (ages 21 to 64 years) with moderate to severe acute extremity pain in two urban emergency departments were randomly assigned to receive\n\nWhat (Study Measures): The between-group difference in decline in pain two hours after taking the study drugs.\nAbout 1 in 5 patients required additional medication to control their pain.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a tough one, since the release does not quantify the extent of the pain reduction. The release notes only that \u201cAfter 2 hours pain was less in all participants, without any important difference in effect between the four groups.\u201d There were differences between the groups, but those differences were not statistically significant. However, given that we often call out news releases that make a big deal out of statistically insignificant differences, we approve of the way that issue is handled here \u2014 thus the satisfactory rating.", "answer": 1}, {"article": "The researchers thank the Biotechnology and Biological Sciences Research Council (Grant 324594, Systems Biology studentship for J.M.H.\n\u201cIt is clear that a new generation of drugs is necessary to save more lives and our research points to a highly effective way of defeating cancerous cells\u201d.\nThe research could also lead to substantial improvements in cancer survival rates, suggests co-researcher Dr Isolda Romero-Canelon:\n\n\u201cCurrent statistics indicate that one in every two people will develop some kind of cancer during their life time, with approximately one woman dying of ovarian cancer every two hours in the UK according to Cancer Research UK and two deaths every hour from bowel cancer.\nThe researchers argue that the drug could be cheaper to produce, less harmful to healthy cells than existing treatments and has been shown to be active against cancer cells which have become resistant to platinum-based drugs.\nOur new compounds work by attacking the energy balance in cancer cells\u201d.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release claims that FY26 is \u201c49 times more potent than Cisplatin\u201d \u2014 a statement that strikes us as hyperbolic. There\u2019s no explanation at all of how the researchers measured the \u201cpotency\u201d of the drug, and we\u2019re left wondering how they concluded that it was exactly \u201c49 times\u201d more potent. Rather than focus on this promotional-sounding claim, we\u2019d have preferred some description of what the researchers actually did in the experiment and what their results showed.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit of treatment, immune responsiveness to bird flu, was accurately reported as occurring in 54% of those receiving the highest dose of the vaccine administered.", "answer": 1}, {"article": "Dr. Farah, who serves as the Chief Medical Officer for the Phoenix Health Center in Hagerstown, prior NE Regional Medical Director for United Healthcare Clinical Services and Director ASAM explains, \"Based on ASAM's definition of addiction, about half of substance abuse is due to genetic factors.\nStudy author, Gregory A. Smith, M.D, former Director of Pain Management at Harbor UCLA, explains, \"Having used this technology for 6 years, this data provides further evidence that clinicians can use Proove Opioid Risk\u00ae for ruling out patients unlikely to exhibit aberrant behaviors, and identifying high-risk patients for alternative therapies.\"\nPeer-reviewed clinical studies show that the Proove Opioid Risk\u00ae profile accurately identifies patient risk for opioid abuse.\nProove\u00ae's medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers, such as the University of North Carolina at Chapel Hill, the University of Utah, and other institutions.\nDistinguished Fellow American Society of Addiction Medicine (ASAM), Diplomate American Board of Addiction Medicine and Fellow American College of Preventive Medicine, J. Ramsay Farah, MD, MPH, MRO, CPE, led a research team that showed Proove Opioid Risk\u00ae identifies patients at risk for Opioid Use Disorder (OUD) with nearly 97% accuracy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that the algorithm correctly identified patients with a history of opioid misuse nearly 97 percent of the time, rarely mis-classifying the healthy controls as being at high or even moderate risk of opioid misuse. One question that remains unanswered in the release is whether the POR test would successfully distinguish people with opioid use disorder from individuals who have used opioids without becoming addicted.", "answer": 1}, {"article": "Toshiaki Higashihara, President & COO of Hitachi, Ltd. stated that, \u201cWe are greatly honored that Johns Hopkins selected Hitachi as their proton partner.\nPBT improves the quality of life for cancer patients since the patient experiences no pain during treatment and the procedure has very few side effects compared with that of traditional radiotherapy.\nThree primary benefits are: (1) more accurate irradiation which reduces the side effects to healthy tissues surrounding the tumor compared with irradiation from conventional double scattering irradiation; (2) patient-specific collimators and boluses become obsolete, shortening set up times for patients; and (3) high proton beam usage factor reducing unnecessary secondary radiation.\nThe next-generation system \u201cPROBEAT\u201d, which comes with IMPT (Intensity Modulated Proton Therapy) and cone-beam CT, will have improved spot scanning capability in all 3 gantry-type treatment rooms, along with a fixed irradiation room dedicated to cancer research.\nThe same spot scanning system has already been installed at Nagoya Proton Therapy Center and Hokkaido University in Japan.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "PBT\u2019s advantage over other types of radiation treatment is its ability to focus narrow beams of radiation onto tumors with reduced radiation spillover into other organs. That\u2019s why it\u2019s most beneficial for tumors of the CNS and in pediatric patients where oncologists strive to limit damage to surrounding tissues. Unfortunately, the news release didn\u2019t specify which types of cancers are good targets for PBT. There\u2019s the implication that PBT should be used in a wider number of cancers. However, there\u2019s ongoing disagreement over the evidence that PBT has a significant advantage over other types of radiation treatments in prostate cancer, for which it is coming into wider use.\nThere are two reasons PBT is becoming a common treatment for prostate cancer. With protons, only two fields (or radiation passes) are needed to cover the prostate compared with 7 to 9 fields using photon intensity-modulated radiation therapy (IMRT) in order to achieve an effective dose. The other reason is that clinics that have an expensive proton facility need to justify having it, and prostate cancer is very common. There is no shortage of available patients.", "answer": 0}, {"article": "\"We can get that whole process of what a meal does without actually having the meal,\" he said.\nThat makes it much safer than, say, systemic stimulants that also rev up the heart and other parts of the body and cause strong side effects, according to the research.\nExperts rightfully caution against relying on miracle diet drugs, but a new study offers a novel approach that bears watching.\nOther researchers are working on similar approaches, he said, but this drug, so far, passes harmlessly out of the intestine after doing its work.\nResearchers at the Salk Institute for Biological Studies in La Jolla, Calif., reported Monday that they have developed a compound that tricks the metabolism into responding as if a meal has been eaten, causing it to burn fat to make room for new calories.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says the compound causes the body to burn fat to make room for new calories, relieves cellular inflammation, and reduces insulin resistance. Even though these benefits were only seen in mice, we\u2019d still expect to see some quantification of what was observed.", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThese findings indicate that the test can reliably predict the absence of intracranial lesions and that health care professionals can incorporate this tool into the standard of care for patients to rule out the need for a CT scan in at least one-third of patients who are suspected of having mTBI.\nThe FDA evaluated data from a multi-center, prospective clinical study of 1,947 individual blood samples from adults with suspected mTBI/concussion and reviewed the product\u2019s performance by comparing mTBI/concussion blood tests results with CT scan results.\nAvailability of a blood test for concussion will help health care professionals determine the need for a CT scan in patients suspected of having mTBI and help prevent unnecessary neuroimaging and associated radiation exposure to patients.\nThe Brain Trauma Indicator was reviewed under the FDA\u2019s De Novo premarket review pathway, a regulatory pathway for some low- to moderate-risk devices that are novel and for which there is no prior legally marketed device.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release refers to a multi-center prospective study of 1,947 blood samples, but does not tell us the citation for publication of that study. The blood sample tests were able to \u201cpredict the presence of intracranial lesions on a CT scan 97.5 percent of the time and those who did not have intracranial lesions on a CT scan 99.6 percent of the time. These findings indicate that the test can reliably predict the absence of intracranial lesions.\u201d\nThe release claims that the blood testing will rule out the need for a CT scan in \u201cat least one-third of patients who are suspected of having mTBI.\u201d This is the main purported benefit, along with reducing costs.\nThe Brain Trauma Indicator was able to predict the presence of intracranial lesions on a CT scan 97.5% of the time and those who did not have intracranial lesions on a CT scan 99.6% of the time. These findings suggest that the test can reliably predict the absence of intracranial lesions and that health care professionals can incorporate this tool into the standard of care for patients to rule out the need for a CT scan in at least one-third of patients who are suspected of having mTBI.", "answer": 1}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Because this story reports on the risks of clots from hormone therapy, this criteria will be\u00a0judged against how well the story quantified the risks, not\u00a0the benefits, of\u00a0the treatment.\u00a0The story should have quantified the risk in absolute terms, not relative terms. The story states that \"women who took hormone pills were 4 times as likely to suffer a serious blood clot.\" 4 times higher than what? The story could have provided more context for the reader on these numbers by giving the actual risk of clotting from the pills compared to the patch.", "answer": 0}, {"article": "Dr Douglas Morrison, author of the paper from the Scottish Universities Environmental Research Centre at the University of Glasgow, commented: \"We developed inulin-propionate ester to investigate the role of propionate produced by the gut microbiota in human health.\nThe team found that when volunteers drank the milkshake containing inulin-propionate ester, they had less activity in areas of their brain linked to reward -- but only when looking at the high calorie foods.\nIn a second part of the study, which is published in July edition of the American Journal of Clinical Nutrition, the volunteers were given a bowl of pasta with tomato sauce, and asked to eat as much as they like.\nThis study illustrates very nicely that signals produced by the gut microbiota are important for appetite regulation and food choice.\nThis study is filling in a missing bit of the jigsaw -- and shows that this supplement can decrease activity in brain areas associated with food reward at the same time as reducing the amount of food they eat.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told by the release that participants who drank a milkshake with inulin-proprionate ester had \u201cless\u201d activity in areas of their brain linked to reward when shown pictures of high calorie foods. But no information is given about how much less, whether all of the participants experienced the same effect (or how many actually did and did not), or how many of the participants who drank the supplement ate 10 percent less than the control group that drank a shake with an apparently less concentrated\u00a0form of inulin (the fiber) alone. Similarly, the reader is told that \u201coverweight volunteers\u201d who got the ester supplement daily \u201cgained less weight\u201d over six months, but not how much less or how overweight they were. It\u2019s impossible to tell from the release (but it would have been very useful to know) the age and gender of the volunteers. If they were college students, for example, or mostly female, metabolic and hormonal factors might have played an outsized role in the results. Finally, references to \u201cprevious studies\u201d were nonspecific, and did not even mention if they were animal or human studies.", "answer": 0}, {"article": "Radiologists and urologists have been frustrated for decades by the inability of conventional imaging tests, such as CT and MRI, to distinguish benign from malignant kidney tumors.\nThe addition of sestamibi SPECT/CT increased the reviewers\u2019 diagnostic certainty in 14 of the 48 patients, or in nearly 30 percent of all cases.\nThe research team reports that the potential improvement in diagnostic accuracy will spare thousands of patients each year in the United States alone from having to undergo unnecessary surgery.\nEven for patients whose tumors were not reclassified, the addition of sestamibi SPECT/CT increased physicians\u2019 ability to more confidently classify malignant tumors, which reduces the risk of misdiagnosis and unnecessary surgery for all patients, the researchers say.\nOverall, the investigators said, adding sestamibi SPECT/CT helped identify 7 of 9 benign tumors, and conventional imaging with added sestamibi SPECT/CT outperformed conventional imaging alone, as measured by a statistical analysis that measures tradeoffs between sensitivity and specificity.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that \u201cThe addition of sestamibi SPECT/CT increased the reviewers\u2019 diagnostic certainty in 14 of the 48 patients, or in nearly 30 percent of all cases,\u201d and that \u201cConventional imaging combined with sestamibi SPECT/CT had a value of 0.85, while conventional imaging alone had a value of 0.60.\u201d The release offers that \u201ca value of 0.50 indicates that a diagnostic test is no better than chance,\u201d to give readers a benchmark for comparison.", "answer": 1}, {"article": "Enrollment ran from 1993 to 1998.\nWomen with the least-inflammatory diets had lower bone mineral density overall at the start of the study, but lost less bone than their high-inflammation peers, the researchers found.\nFurthermore, diets with low inflammatory potential appeared to correspond to lower risk of hip fracture among one subgroup of the study -- post-menopausal white women younger than 63.\nBecause the study was observational, it's not possible to definitively link dietary patterns and bone health and fracture outcomes.\n\"This suggests that a high-quality, less-inflammatory diet may be especially important in reducing hip fracture risk in younger women,\" the researchers wrote.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We were disappointed to see little actual quantification of the benefits found in the study. Most of the\u00a0numbers in the release were numbers quantifying the number of women being studied in different ways and the number of dietary components that were studied. One sentence said this:\n\u201cHigher scores were associated with an almost 50 percent larger risk of hip fracture in Caucasian women younger than 63, compared with the risk for women in the group with the lowest inflammatory scores.\u201d\nIt\u2019s very hard to know what to make of that sentence without knowing the actual number of women who saw a benefit or did not see a benefit. This is an issue of reporting relative risk (which this study did) versus absolute risk, which would give us actual numbers of women that were affected. (See our primer on writing about absolute vs relative risk.)", "answer": 0}, {"article": "When nicotine enters the body, it binds to the same receptors in the brain that acetylcholine binds to, resulting in smoking's rewarding and reinforcement effects.\nFinally, the researchers asked the study subjects to do their best to not smoke for seven straight days, a time during which the participants still took either galantamine or a placebo.\nBefore the trial began, researchers assessed the smokers' cognitive function to get a baseline.\nThe findings sparked the CIRNA clinical trial, which has to date studied 33 smokers ages 18 to 60.\nFor both drugs, \"we were able to show a reduction in total nicotine self-administered,\" Schmidt said; however, there was a caveat.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release may overstate things in the headline which claims, \u201cAn FDA-approved Alzheimer\u2019s drug could help smokers quit.\u201d The study didn\u2019t look at quit rates and lasted only 23 days, so the effect on quitting is entirely unknown. We\u2019ll give the benefit of the doubt here though since the release notes that\u00a0people involved in the trials (there was also an animal trial component) reduced their cigarette use by 2.3 cigarettes a day \u2014 a 12% decrease \u2014 after being on the drug for two weeks. The volunteers also related that they felt \u201cless satisfied\u201d with smoking after being on the drug, although this benefit was not quantified.", "answer": 1}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story meets our standard by explaining that 1,000 milligrams daily of bergamot extract lowered cholesterol from an average of 278 milligrams per deciliter of blood to 191 in the study. But while\u00a0many readers with high cholesterol likely understand the significance of these numbers, readers without them (but who are nonetheless interested in the story) would benefit from a clear example or description of the risks posed by high cholesterol. The story would also have been stronger had it told us how this reduction in cholesterol would affect one\u2019s overall risk of a heart attack or stroke.", "answer": 1}, {"article": "Anderson Cancer Center in Houston.\nThe goal of the vaccine, Hale said, is to educate the body to respond to that HER2-based peptide, so it will recognize the cancer when it recurs and attack it.\nBut until the vaccine is linked to an actual survival benefit or improvement in tumor status, Diamond said, no one can say if it helps the patients in a meaningful way.\nThe study involved 217 breast cancer survivors who had gone through their treatment and were free of disease at the start of the trial.\nThe study is a phase 2 study, meant to evaluate the vaccine's effectiveness and any side effects.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article was vague in describing the results and did not elaborate on what the response was that those in the vaccinated group exhibited:\n\u201cThe investigators found that in the vaccinated group, 86 percent of patients showed a significant response, compared with 27 percent of those in the \u201ccontrol\u201d group who did not get the injection.\u201d\nTo its credit, the story included important caveats: the subhead of the story said \u201ctrue significance unknown\u201d and later in the story was this independent expert\u2019s quote, \u201cWhether it actually has an increase in survival remains to be seen.\u201d\nBut the vagueness on the main finding of the study leads us to give this an unsatisfactory score. What does \u201csignificant response\u201d mean?", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\nThe story does not cite the absolute benefit of vitamin supplements on weight control. The trial showed that women who took calcium and vitamin D were on average less than a third of a pound lighter (0.13 kg or 0.29 lbs) seven years later than women who did not. Despite the headline \u201cAdd bone, drop pounds,\u201d the story also fails to mention whether the dietary supplements influenced bone health or the incidence of fragility fractures. A closer reading of the trial could easily lead a postmenopausal woman to question both the accuracy of the article\u2019s headline and the clinical relevance of the study it reported.\n", "answer": 0}, {"article": "The P-Cure team is committed to enabling all oncology centers and hospitals globally to establish cost-effective proton therapy services for the best possible care and cure,\u201d said Dr. Marash.\nIn addition to the clinical benefits of P-Cure\u2019s solution, there are also significant economic advantages to treating patients in a seated position.\nThe P-Cure system is based on a diagnostic-quality computed tomography (CT) enabling treatment planning, positioning and treatment delivery for cancer patients in a seated position.\nP-Cure is the innovative provider of image-guided solutions for better clinical effectiveness of proton therapy at a fraction of the current capital and operating costs.\nThe P-Cure Patient-Centric solution is a paradigm shifting change from the current method of treatment with the patient in the horizontal position.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are many claims of benefits in this release, none of them quantified:\nFor the patient, the real question is whether this device makes the treatment any better. If not, then does it make it any easier, more comfortable or shorter? There is no data provided. ", "answer": 0}, {"article": "Heart researchers have long known that plaques in coronary arteries start out as pimplelike bumps but get waxy and hard and filled with calcium as time passes.\nIt turned out that the actual incidence of heart attacks or disabling chest pain in those with zero calcium was half or less than what the risk calculator predicted.\nAccording to today\u2019s guidelines, half had risk scores high enough that a statin would be recommended or should be considered.\nCurrent guidelines have vastly increased the number of people who are eligible to take statins.\nFor example, a person who, according to the current risk calculator, has a 12 percent risk of a heart attack in the next decade should take a statin, the guidelines say.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that among study participants, those with a zero calcium score on a heart CT scan had only half the expected number of heart attacks or disabling chest pain over a 10-year period. That\u2019s a relative comparison, which as we frequently note does not provide the full picture regarding benefit. But the story goes on to give readers a better sense of what these numbers mean in absolute terms. It\u00a0explains the example of a person with a 12 percent risk of a heart attack over a decade based on the risk calculator recommended by the American college of Cardiology and others. That person actually turned out to have only a 4 percent 10-year risk, below the widely-used 7.5 percent risk threshold for recommending a statin.\nThe story makes clear that the scan does not provide a direct health benefit, but it provides information to people who are trying to decide about whether to start taking cholesterol-reducing statins. To help with that decision, it would have been nice for the story to include some discussion of the benefits associated with statin use, especially the\u00a0numbers needed to treat (NNT) with a statin in order to save a life.\nThe story includes only one patient anecdote, a woman who was feeling depressed and had trouble getting out of bed when she took statins, and then decided to stop taking the drugs after having a CT scan that showed zero calcium. We often find fault with stories that introduce readers to only one patient, who claims to have greatly benefited; however, the placement of the anecdote low in the story and the preceding context that included limitations and expert cautions mean this single patient story doesn\u2019t overwhelm the other information.\nLink to online Atherosclerotic Cardiovascular Disease (ASCVD) Risk Estimator: http://tools.acc.org/ASCVD-Risk-Estimator/", "answer": 1}, {"article": "Powers said, \"I think what's going to happen is that we will develop systems of rapid triage and rapid transport.\nAll of these studies showed that the device can safely and effectively stop a stroke by removing blood clots, he added.\nThe major risk of using the device is that it could tear an artery and cause bleeding in the brain, particularly since it will be used on people who have already received very potent blood thinners, Kandzari said.\nThat last point is especially important, because the stent retrieval device will not fit into the smaller blood vessels that branch out further into the brain, Powers said.\nThe tool, called an endovascular stent retrieval device, is made up of wire mesh that resembles a tiny ring of chicken wire, Powers said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story is not about a single research study, so it is perhaps understandable that it remains general in its comments about benefits. But we found only statement from an expert that addresses the issue:\u00a0\u201cAll of these studies showed that the device can safely and effectively stop a stroke by removing blood clots.\u201d\nWhile stopping a stroke is clearly a benefit, that sentence does not tell us by what percentage of people randomly chosen to receive the new procedure have a better long-term outcome in terms of quality of life, or die less often of later complications, or any other measurable difference.\nThe outcome assessed in the studies, \u201cfunctional independence after stroke,\u201d is easy to understand. And the benefits were significant: 53-71% of treated patients were functionally independent following the stroke, compared to 29-40% of untreated patients.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the story provides some quantification of benefits from screening, it\u00a0also exaggerates these benefits in qualitative terms. The story claims that the study is a \"shining light\"\u00a0and that screening\u00a0could \"cure or substantially lengthen the lives\" of lung cancer patients.\u00a0Unfortunately, the current study does not\u00a0prove that screening actually lengthens lives.\u00a0", "answer": 0}, {"article": "Tactics being tested include renal nerve ablation, a procedure that emits low-power radiofrequency along the nerves next to the kidneys, interrupting signals that trigger high blood pressure.\nIn the case study, a 55-year-old man was implanted with a deep brain stimulator to treat severe pain stemming from a stroke.\nThe finding introduces the possibility that deep brain stimulation -- a surgical implant that delivers electrical pulses to the brain -- might one day become a treatment for drug-resistant hypertension or lead to clues about the brain's role in regulating blood pressure.\nAbout 10 percent of high blood pressure cases either can't be controlled with medication or patients cannot tolerate them, study author Dr. Nikunj K. Patel, a neurosurgeon at Frenchay Hospital in Bristol, England, said in a journal news release.\nThe study adds to other recent research focused on neuromodulation, which harnesses the power of electrical impulses in the body for therapeutic benefit.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story never actually describes how high this patient\u2019s blood pressure was prior to DBS, or how much it was reduced after treatment. Providing this data \u2014 limited though it may be \u2014 would have given readers a better idea of DBS\u2019s effects on blood pressure, at least for this\u00a0particular patient.", "answer": 0}, {"article": "We need to assess these options before jumping to possible universal screening.\"\nFurther, Neal says, the findings apply not only to heart-disease risk but also to the risk of diabetes, since high cholesterol at a young age is a strong predictor of prediabetes and diabetes.\nExperts believe using family history is a good way to identify children who may be at greatest risk of high cholesterol \u0097 and therefore of future heart disease.\nSacco notes that both the AHA and the American Academy of Pediatrics now recommend cholesterol screening in children with risk factors for heart disease other than family history, such as obesity, high blood pressure and diabetes.\nA new study finds that current guidelines for cholesterol screening in children may miss nearly 10% of those who have high levels of LDL, or bad cholesterol.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nThis story not only fails to question the assumption that treating children with elevated cholesterol can prevent heart disease, it allows a researcher to claim that screening children for cholesterol would help reduce the risk of diabetes. There is no reference to any evidence that cholesterol screening is a better predictor of diabetes risk than either other screening tests, obesity or other factors linked to diabetes. The statement also implies that identifying diabetes risk before symptoms appear is better than either recommending lifestyle changes to reduce diabetes risk for all children (regardless of cholesterol test results) or treating diabetes once symptoms appear.\n", "answer": 0}, {"article": "This, too, is suggested by sense and common experience, as it is affirmed by the science reported here,\" Katz said.\nLower stress by itself predicted more weight loss during the first phase of the trial, they added.\nThis study shows that people are more likely to lose weight when not impeded by sleep deprivation, stress or depression, he said.\n\"We found that people who got more than six but less than eight hours of sleep, and who reported the lowest levels of stress, had the most success in a weight-loss program,\" said study author Dr. Charles Elder.\n\"If sustained, the dietary choices made by people undergoing short sleep could predispose them to obesity and increased risk of cardiovascular disease,\" the researchers wrote in an American Heart Association news release.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story presented the outcome of 472 obese individuals and examined in more detail those who were able, on average, to loss 14 pounds over a period of 26 weeks. \u00a0The story did not provide any insight as to whether this amount of weight loss resulted in any health improvement in the obese individuals who were studied.\u00a0 So the true benefit \u2013 the true significance of the potential benefit \u2013 was not explained.\nFurther \u2013 while the study found that those who got an adequate amount of sleep were among the cohort of individuals who were found to lose the most weight, the story did not explicitly point out that the study does not inform us about whether enforced hours of sleep would impact weight loss and weight loss management. So, again, the headline, the story\u2019s first sentence, and the call to action by the researcher were not balanced.", "answer": 0}, {"article": "\u201cThe baby will grow and the biodegradable material will disappear,\u201d he said.\nThe findings, which follow similarly promising 6-month and 9-month data on the plastic device, were described at the annual scientific sessions of the American College of Cardiology in New Orleans.\nHe said bioresorbable materials have great potential for other uses, particularly for stents to repair the pulmonary arteries and aortas of babies.\n\u201cThe trial\u2019s results would be equivalent to an excellent metallic stent - that type of performance,\u201d said Dr. Patrick Serruys, a cardiologist from Erasmus University Hospital in Rotterdam, who led the study.\nSerruys said current stents are essentially \u201ccages\u201d that hamper the flexibility of arteries and make them more prone to reclogging as they develop scar tissue and plaque builds up.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story simply stated, \u201cno blood clots were reported among patients who were far enough along in testing to be evaluated.\u201d\nYet the first sentence says the device \u201chas proven safe and effective.\u201d\nThe story begs a much broader much discussion of what benefits one would hope for from device implantation \u2013 and how this study (as the Wall Street Journal reported) raises perhaps more questions than it answers.", "answer": 0}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only provides quantification of the harms of hormone therapy in relative terms. Because the incidence of stroke and breast cancer was very low in this population (particularly in the younger women), only presenting the risks in terms of\u00a0relative\u00a0risk tends to exaggerate the true risk to the patient. In this situation, presenting the harms in terms of absolute risk would be much more helpful to a patient trying to make a decision about whether to take hormone therapy. For example, the lifetime risk of breast cancer for a 50 year old woman is 13%. An increase of 19% in risk as cited in the article translates to a lifetime risk of about 15%. In this situation, a woman can decide if the tradeoff of increasing her risk of breast cancer from 13% to 15% is worth\u00a0the relief from\u00a0her menopausal symptoms.", "answer": 0}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story focuses on how these new techniques and technologies can address perceived shortcomings in conventional surgery. And it uses compelling language to describe these potential benefits: \u201cThe resulting real-time 3D visuals\u2014known as \u2018intraoperative imaging\u2019\u2014help surgeons excise tumors and tissue with greater accuracy, reducing risks, such as nicked nerves from an errant knife, and the potential need for repeat surgery. The images also help surgeons spot bleeding, blood clots or other unexpected complications outside their field of vision.\u201d\nHowever, the story doesn\u2019t offer any numbers to demonstrate whether that potential is being fulfilled. For example, the story notes that the Advanced Multimodality Image-Guided Operating Suite program at Brigham and Women\u2019s Hospital, which focuses on these real-time imaging techniques, has conducted 700 surgeries since 2011. Did those surgeries have better outcomes than comparable surgeries that didn\u2019t use these imaging technique? The story doesn\u2019t say.", "answer": 0}, {"article": "Obstructive sleep apnea (OSA) is marked by interruptions in breathing while asleep; it is common among children with enlarged tonsils or adenoids.\nHowever, half of the 417 children in this latest study who had sleep apnea and were bedwetters stopped wetting the bed after they had their tonsils or adenoids removed.\nThose who did not stop wetting the bed after the surgery were more likely to be born prematurely, be male, be obese or have a family history of bedwetting, the investigators noted.\nChildren with sleep apnea can be difficult to rouse, which may cause the bedwetting, said Dr. Dennis Kitsko, an otolaryngologist at the Children's Hospital of Pittsburgh.\n\"If they haven't seen an ear, nose and throat specialist, see one to see if the child who wets the bed has OSA that can be cured by tonsil or adenoid removal,\" said study author Dr. Yegappan Lakshmanan, chief of pediatric urology at Children's Hospital of Michigan, in Detroit.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Right in the lead, the story quantifies the benefits, saying, \u201cHalf of children with sleep apnea who also wet the bed might stop their bedwetting if their tonsils or adenoids are removed, new research suggests.\u201d The story satisfies our criteria of absolute risk reduction. However, we would have liked to\u00a0have seen\u00a0more details, such as the average length of time it took for half of the 417 children to stop wetting. And, do the researchers\u00a0mean COMPLETELY stopped wetting, or went from wetting most nights to wetting rarely, for example. ", "answer": 1}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately reported the benefits from the study of 861 patients that was released by the manufacturer and scheduled for presentation at a scientific meeting.Rather than falling victim to presenting the drug\u2019s benefits in relative terms (27% increase in median survival, more than doubling of the two year survival) the story provides the readers with absolute numbers.", "answer": 1}, {"article": "Among those 40 to 49 who had regular screening, for every 1,000 women tested, 121.2 had a false positive.\nFor every 10,000 women screened repeatedly over 10 years, four lives are saved in women 40 to 49; eight in women 50 to 59; 21 in women 60 to 69; and 13 in women 70 to 74, the task force found.\nThe guidelines relied in part on a study of records from 405,191 women who had digital mammograms from 2003 to 2011, which found that false positives were common, especially in younger women.\nDr. Constance Lehman, a professor of radiology at Harvard Medical School and director of breast imaging at Massachusetts General Hospital, who is not on the task force, said she was pleased to see that although its advice had not changed, the group had placed more of an emphasis than before on the importance of women\u2019s having the freedom to decide how often to be screened and when to start.\nThe task force said it concluded \u201cwith moderate certainty\u201d that the benefit was moderate in women 50 to 74 and small in women 40 to 49.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job of articulating the benefits of mammography screening for different age groups. For example, it notes that \u201cFor every 10,000 women screened repeatedly over 10 years, four lives are saved in women 40 to 49; eight in women 50 to 59; 21 in women 60 to 69; and 13 in women 70 to 74, the task force found.\u201d However, the story does not explain what it means to be \u201cscreened repeatedly\u201d \u2014 does that mean every year, or could it mean every other year? Still, we\u2019re very happy to see the story include numbers rather than referring solely to a general increase or decrease in benefits. The story also notes that the recommendations apply only to women with average risk of breast cancer. The story would have been significantly stronger if it had explained what \u201caverage risk\u201d means \u2014 most readers probably don\u2019t know.\nThe quote from the Susan G. Komen For the Cure Foundation demonstrates the importance of reinforcing that these guidelines apply to average risk patients \u2013 they express concern that \u201ca lack of coverage would hit \u2018high risk and underserved\u2019 women hardest\u201d \u2013 high risk women are not affected by these recommendations.\nA discussion on risk assessment is absent from most stories covering screening mammography, and has led to much confusion. One issue is that there are a variety of risk assessment models, and their use in particular patient populations is not always well understood by physicians. However, a brief discussion about how risk is assessed would be helpful for patients and others reading these stories.", "answer": 1}, {"article": "\"It's basically a piece of plumbing to bypass blockages,\" he said.\nThe vessels failed in three of the patients, which experts said was not surprising in patients so seriously ill. One other patient withdrew from the study and another died of unrelated causes.\nDr. Bryan Becker, president of the National Kidney Foundation in the U.S., said about half of kidney patients could benefit from these vessels if further tests confirm they work.\nIn the five remaining patients, the vessels worked for at least 6 to 20 months after they were implanted.\nIn 2007, the scientists published preliminary findings for another 4 patients in the New England Journal of Medicine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated that the experimental grafts made it \"easier and safer\" for patients to use kidney dialysis machines. However, the study did not actually compare the tissue-engineered grafts to standard artifical grafts. The story also stated that when the experimental grafts worked, those patients fared better than regular dialysis patients. But, again, the study did not include any such direct comparisons.", "answer": 0}, {"article": "It appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.\nThe treatment gave patients with metastatic, castration-resistant prostate cancer only an extra four months of life.\nThe study was funded by Johnson & Johnson, which is developing the drug.\nAnd while the average patient survived only four months longer than those on standard chemotherapy -- 14.8 months vs. 10.9 months -- some patients did much better.\nThis study was presented at a medical conference.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "WebMD reports the data incorrectly\u2013it\u2019s median survival, not average survival. This implies that 50% of the patients had more than a 4-month survival, but the story (assuming that investigators provided data, which they might not have) should then provide the upper range of survival times (e.g., 11 months) to quantify \"better.\"\u00a0 They could also report that X% survived for 6 months, Y% for 12 months, etc. (though the latter may be 0).\u00a0\n This story seemed determined to put this study in the best possible light, reporting that \"The treatment gave patients with metastatic, castration-resistant prostate cancer only an extra four months of life. But there\u2019s more hope than that from the study\u2026\"\u00a0 What does that mean?\u00a0", "answer": 0}, {"article": "It also includes UCSF Health, which comprises top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children's Hospitals in San Francisco and Oakland -- and other partner and affiliated hospitals and healthcare providers throughout the Bay Area.\nThe fMRI method and analysis developed for the study highlighted abnormal patterns of brain activity that pointed to a higher risk for long-term, post-concussive symptoms, even among the 44 study participants who had no evidence of bleeding or bruising in the brain in the immediate aftermath of brain trauma on computed tomography (CT) or ordinary MRI scans.\n\"This is an exploratory, proof-of-concept study showing that we can identify patients soon after mild brain trauma who may have more persistent symptoms, despite no other evidence of injury within the brain,\" said Pratik Mukherjee, MD, PhD, professor of radiology and biomedical imaging at UCSF and the senior author of the study.\nIn the new study, the researchers focused on well-known networks of activity that are observed when the brain is in a resting state.\nIn their new study, published online January 13, 2017 in the Journal of Neurotrauma, the researchers used a technique called functional MRI (fMRI), coupled with sophisticated statistical analysis, to track activity in the brain networks of 75 patients, aged 18 to 55, within the first two weeks of their having experienced concussions.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release talks about the benefits of getting a fMRI early on \u2014 in this case, within the first two weeks of the mTBI. It states fMRI highlights abnormal patterns of brain activity, which helps physicians predict which patients are at a higher risk for post-concussive symptoms after six months.\nBut there\u2019s no mention of any quantitative data to help readers understand the scope of the benefit. How accurate was the fMRI in distinguishing patients who might later experience symptoms? Did all mTBI patients exhibit reduced connectivity in the \u201cdefault mode network?\u201d And how much worse did mTBI patients perform on cognitive and behavioral tests?\nSince only comparative words are used without any quantitative data, we give the news release a Not Satisfactory rating here.\nThe original journal article also doesn\u2019t give numbers so it falls on the shoulders of the writer to seek clarity from the researchers when benefits are being claimed. ", "answer": 0}, {"article": "They look impressive,\" said Dr. Gordon Weir of Joslin Diabetes Center in Boston.\nFor now, the new treatment does not apply to the nearly 20 million Americans with Type 2 diabetes, reports CBS News medical correspondent Dr. Jon LaPook.\nIn addition, Ross said that the study should have had a comparison group to make sure the treatment was indeed better than standard diabetes care.\nBurt and other diabetes experts called the results an important step forward.\nBurt, who wrote the study protocol, said the research was done in Brazil because U.S. doctors were not interested in the approach.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify benefits, e.g. 13 out of 15 patients were able to stop taking insulin.\u00a0 And even though these results look promising at first glance, the story provides cautionary statements that these are just preliminary results.\u00a0 ", "answer": 1}, {"article": "Dr. Roger Fielding (Tufts University) is partially supported by the U.S. Department of Agriculture, under agreement No.\nWe wanted the physical activity sessions to include exercise that participants could do outside of the study, and we hope that learning of these results might motivate others to try to make safe, incremental changes to their activity levels.\nThe researchers acknowledge limitations of this study, including examining the different quantities of exercise participation achieved in the LIFE study participants and not specifically prescribing different amounts of exercise to different study groups.\nWhile the researchers saw improvements in all participants who added some physical activity to their routine, those who got more exercise saw greater changes.\nIn our first LIFE study, we confirmed that regular exercise can help improve physical function and prevent mobility loss.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provided only bare-bones results. We\u2019d have liked to see some indication of the changes in mobility \u2014 from what to what \u2014 following the exercise program.\nThe release says \u201cChanges in activity were significantly greater in the physical activity intervention group than the health education group from baseline through 24 months.\u201d What does that mean exactly? How much improved were those who took part in physical activity compared to those who didn\u2019t?\nIn addition, the headline and text refer often to reduced risks, but we\u2019re never told exactly what those risk factors are.", "answer": 0}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Look at the headline of this story: \u201cIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug.\u201d Now look at the first sentence: \u201cA little-known drug company announced modestly\u00a0encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\u201d We had to do a triple take because this level of reflection and circumspection is so rare and so welcome.\nThe story then goes on to spell out why the reporter used terms like \u201chints of modest benefit\u201d and \u201cmodestly encouraging\u201d and, if you read the links, the story also backs up the history of failure in this field.\nWhen it comes to quantifying the benefits, we\u2019re told, specifically, that \u201cthe patients who received all six low doses\u00a0did the best; their average improvement after the 12 weeks was 1.5 points on the 100-point cognitive test.\u201d It then says, \u201cPatients receiving a placebo (most were also on standard Alzheimer\u2019s drugs) lost 1.1 points.\u201d We\u2019re told the difference was not statistically significant.", "answer": 1}, {"article": "As technologies and processes continue improve this is likely to be reduced,\" she continues.\nHe added, however, that the studies confirm the potential of cancer vaccines.\nThese vaccines are not necessarily the future of personalized cancer treatment.\n\u201cIt is still unknown whether these vaccines will extend the survival of cancer patients, or whether they are more effective than other recently developed immunotherapies.\nCornelius Melief, from the Leiden University Medical Center, Netherlands, said in an accompanying News & Views article that controlled, randomized Phase II clinical trials will be needed to work out if the vaccines are effective.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that four of the six patients had no cancer recurrence after 25 months in the first study, and in the second study, eight of the 13 patients remained tumor free after 23 months.\nBut the studies cited are both phase I clinical trials designed to address safety, not efficacy. Any claims regarding the latter, especially given the limited number of subjects, would be highly speculative. Therefore, the headline is misleading. As noted in the final sentence of the article:\n\u201c\u2026\u00a0The next step will be to test these personalized vaccines in larger clinical trials to see if they are better than existing treatments, if they improve survival, and what their long-term side effects could be.\u201d", "answer": 1}, {"article": "Keytruda \u2014 known generically as pembrolizumab \u2014 targets the activity of genes called PD-1 (anti-programmed-death-receptor-1) and PD-L1.\nIt helped patients live longer overall and helped them live longer without their tumors growing or spreading, Merck said.\nUsually, cancer drugs are only tested at first in patients who have tried everything else available and their cancer has come back, anyway.\nThe researchers wanted to see how it worked against the standard chemotherapy cocktails.\nSo it\u2019s an important break for a company if its drug is the first one a patient gets and it works better than the so-called standard of care.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits. We recognize this would be difficult given that the details around the study have not been released, but we also think that, because the details have not been released, more caution should have been used. It\u2019s unfortunate to see a statement like this, for example: \u201cIt helped patients live longer overall and helped them live longer without their tumors growing or spreading, Merck said.\u201d This is an unchallenged statement with no numbers to back it up, and it\u2019s not even attributed to a human. It\u2019s attributed to a company.", "answer": 0}, {"article": "Kids with August birthdays are more likely to get an ADHD diagnosis.\nThe participants in the small study ranged in age from 20 to 70 and had suffered from back pain for an average of 7.3 years.\nThe study looks at adults with chronic low back pain, one of the leading cause of disabilities in the United States and one reason why more and more people are addicted to painkillers.\nLed by Daniel C. Cherkin of Group Health Research Institute in Seattle, the experiment involved randomly assigning 342 adults with the condition to meditate, talk with a psychologist or continue with their normal techniques for addressing the pain, such as medication.\nThe results for both techniques were very positive.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells readers what percentage of study participants who got MBSR treatment reported improvement in pain, as well as what percentage of MBSR participants \u201creported improvement in the activities they could do.\u201d\nIt also offered the same numbers for participants who received CBT and for the control group, which received typical medical care for this condition. These details\u00a0deserve\u00a0a Satisfactory rating. But:", "answer": 1}, {"article": "UW-Madison establishes state\u2019s first and only addiction hotline for providers\n\nIn what is believed to be a national first, the University of Wisconsin-Madison, in conjunction with UW Health, has established a new resource for Wisconsin primary-care physicians and other providers to help them successfully manage patients with...\nThe new awards provide up to $600,000 each over three years to support the work of collab...\n\nUW to test using MDMA to treat PTSD\n\nThe Department of Family Medicine and Community Health of the UW School of Medicine and Public Health will take part in a multisite Food and Drug Administration-approved Phase III trial investigating MDMA as an adjunct to psychotherapy for the tre...\nThe Wisconsin Partnership Program at the University of Wisconsin School of Medicine and Public Health has awarded four grants through its New Investigator Program.\nUW team shows progress in search for new antibiotics\n\nCollecting bugs across the globe is paying off for a multidisciplinary research team at the University of Wisconsin-Madison.\nRyan Coller wins federal challenge for app to help children with complex care needs\n\nA team of researchers at the University of Wisconsin School of Medicine and Public Health and the College of Engineering have won a share of a $100,000 award to develop technology for families caring at home for children with complex medical needs...\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although we appreciate the release\u2019s attempt to quantify benefits in terms of ADAS-cog scores, these numbers lack any significance for those who are not familiar this particular scale. Is this a 10-point scale or a 100-point scale? The importance of the 3 and 4-point drops described in the release will be judged differently depending on this crucial context.\nIn addition, while the benefits were corroborated by mention of another study that showed \u00a0a reduction in the risk of developing Alzheimer\u2019s disease among men who receive Lupron, there is an important clinical difference between reducing risk of developing Alzheimer\u2019s disease and slowing progression of the cognitive deficits of Alzheimer\u2019s disease. The release didn\u2019t make this clear.", "answer": 0}, {"article": "This didn't stop MS.\"\n\n\"But, this is extremely hopeful research,\" he added.\nAnd it's also important to note that this is not a cure.\nIf the experimental medication is eventually approved for use, it would be only the second oral MS drug available to patients, alongside a number of long-standing injectable options.\n\"And MS is probably not a single disease.\n\"However, we still need to have a head-to-head comparison with other drugs,\" cautioned Birnbaum, who was not part of the study team.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A general comment \u2013 not necessarily directed at this story nor at those responsible for it:\u00a0 We\u2019ve recently heard from some journalists that they can\u2019t or won\u2019t report on absolute risks or NNT (harms or conflicts of interests, either, for that matter) if the researcher doesn\u2019t provide that information.\u00a0 We have no patience for that stance or argument.\u00a0 That\u2019s akin to admitting that we\u2019ll only report what we\u2019re spoonfed.", "answer": 0}, {"article": "The average daily dose of insulin dropped almost 39 percent after 12 weeks for the group with some beta cell function and 25 percent in those with no beta cell function, suggesting that the group with no beta cell function now produced insulin.\nAlthough the treatment didn't wean anyone off insulin completely, average blood sugar levels dropped significantly, which would reduce the risk of long-term complications.\nThis was an initial clinical trial designed to test for safety.\nIf we can control the autoimmunity, we may reverse the diabetes.\nBoth experts said the treatment appears safe, with no risk of rejection.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story does a good job reporting the results of this trial and it notes that patients in this trial reduced their use of insulin, but were not able to discontinue taking insulin shots. It includes cautionary statements from an independent expert who says that the trial didn\u2019t last long enough \u201cto declare victory over diabetes yet.\u201d\nBut we can\u2019t give it a passing score here because it misleads readers about the important long-term health outcomes that people with diabetes really care about. The story claims that the reductions in blood sugar levels seen in these patients \u201cwould\u201d reduce the risk of long-term complications. These researchers did not look at rates of complications. Indeed, the trial was far too short to produce meaningful results about rates of heart disease, blood flow problems, skin ulcers or other complications of diabetes, so any claims about reductions in complication rates are mere speculation.\nThis should have been framed as a preliminary safety study of a new approach that now needs to be tested in a randomized design with adequate numbers of subjects and duration to be able to truly say something about benefit or harm.\u00a0 Novel, promising, passed the first safety test.\u00a0 Period.", "answer": 0}, {"article": "Other immunotherapy approaches are in the pipeline, along with fancier versions of drugs to block the hormones that feed prostate cancer.\nBut, after all, Provenge is just the first cancer immunotherapy on the market.\nThat's better than the only other approved treatment for such advanced cancers.\nThe primary mystery is how Provenge extends life, since it doesn't shrink prostate tumors, as far as anyone can tell.\nThe way the study was done, he says, \"does not allow one to conclude\" that Provenge is working because it mobilizes the immune system specifically against prostate cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In a broad overview comment, it\u2019s sufficient for the story to have stated \"men with prostate cancer that no longer responds to hormone therapy (basically, chemical castration) lived about four months longer if they took Provenge than if they got placebo treatment.\"", "answer": 1}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was a tricky one. The story certainly reflects the strong belief of two patients who were treated with eBx that their skin cancers were banished. \u00a0And it gives ample space to representatives of two companies that manufacture the radiation device, one of whom describes the treatment as a \u201cpainless alternative\u201d (a claim not supported by evidence in the story). The text also discusses findings from studies of older radiation techniques, but it rightly notes that these are not necessarily valid for judging the success rate of eBx. The story makes clear that skin cancer recurrences can take four or more years to appear, while the median follow-up time in studies of eBx to date can be measured in months.\nThe tiebreaker here for us is the headline and accompanying photos. Added to the anecdote-heavy text, these elements that radiate \u201cbenefits\u201d throw the story out of balance. We acknowledge that the reporter on this story may not have had any control over those elements.", "answer": 0}, {"article": "The F.D.A.\ninstead said it wanted more proof that the drug worked and would await results from a trial that was then under way.\nDr. Gold said there were about 100,000 men who get such a diagnosis each year.\nJudy Leon, a spokeswoman for the F.D.A., said the agency sympathized with patients but that it was necessary for drugs to meet agency standards for safety and efficacy.\nMr. Girgus, 65, who also owns Dendreon stock, said patients like himself were \"looking into the abyss.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The drug maker\u2019s chief executive is quoted saying the results were \"an unambiguous hit on the primary endpoint of overall survival.\" It paraphrases his saying the outcome met the goals the FDA had previously set for the drug. \nThe story additionally paraphrases the chief executive verifying that the drug \"would have had to reduce the risk of death by 22 percent compared to a placebo\" to meet FDA requirements.\nThe chief executive is parsing his language very carefully, skillfully avoiding making an explicit claim about the drug\u2019s proven benefits.\u00a0\u00a0 \nRather than stating that the chief executive would not plainly describe the results, the reporter enables his evasion by connecting the dots between what the FDA said must be shown with the chief executive\u2019s assurances that it had been.\u00a0 \nFor context, see \"Relies on Press Release,\" below. ", "answer": 0}, {"article": "Anticipating wide interest in the psilocybin research from scientists, clinicians and the public, the journal solicited 11 commentaries to be co-published with the study results written by luminaries in psychiatry, palliative care and drug regulation, including two past presidents of the American Psychiatric Association, a past president of the European College of Neuropsychopharmacology, the former deputy director of the U.S. Office of National Drug Control Policy, and the former head of the U.K.\nSix months after the final session of treatment, about 80 percent of participants continued to show clinically significant decreases in depressed mood and anxiety, with about 60 percent showing symptom remission into the normal range.\nOther questionnaires assessed quality of life, death acceptance, meaningful existence, optimism and spirituality -- generally defined as a search for the meaning of life and a connection to something bigger than one's self.\nFor the study, the investigators recruited 51 participants diagnosed with life-threatening cancers, most of which were recurrent or metastatic.\nMost participants had breast, upper digestive, GI, genitourinary or blood cancer, and each had been given a formal psychiatric diagnosis, including an anxiety or depressive disorder.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a tricky one. The release does tell us what percentage of patients benefited from psilocybin treatment, but does not explicitly quantify the extent of those benefits \u2014 which is what this category is designed to address.\nHowever, the release does address benefits in a meaningful way. Here\u2019s how: First, the release makes clear that all of the study participants had received a formal psychiatric diagnosis. That tells us that they were suffering from symptoms of clinical anxiety or depression. Second, the release states that six months after the treatment \u201cabout 80 percent of participants continued to show clinically significant decreases in depressed mood and anxiety, with about 60 percent showing symptom remission into the normal range.\u201d That language telling us that about 60 percent were in the normal range is important, because it means they were no longer exhibiting clinical anxiety or depression \u2014 and that is sufficiently meaningful to earn the release a satisfactory rating here.\nThe release would have been better if it had been more clear that this was a cross-over study so all participants received both the low-dose (placebo) and the full therapeutic dose in either the first or second treatment session. In addition, no comparison is given between the low-dose and high-dose therapeutic effects. Instead, the release describes benefits five weeks and six months after the second session, after all participants had received the strong dose.", "answer": 1}, {"article": "Aside from hair transplants, which can cost about $10,000 each and do not always look natural, the only current hope for complete replacement is hair cloning, the act of producing entirely new hair from the DNA of an existing one, which researchers have been attempting, unsuccessfully, for years.\n\u201cIt was a noticeable difference.\u201d\n\nBut Latisse does not appear to be a silver bullet for hair loss.\nBut the fact is that many men \u2014 and women \u2014 simply do not accept baldness easily.\n\u201cWe keep on moving back that time, but I think there\u2019s absolutely no doubt that it\u2019s going to be done.\u201d\n\nHe believes hair cloning will be commercially available within 10 years.\nThe result is an enhanced, refortified hairline rather than a brand new head of hair.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not quantify any of the benefits of Latisse or the other hair loss products.", "answer": 0}, {"article": "\"This is the holy grail,\" says Suresh S. Ramalingam, MD, associate professor and director of the lung program at Emory University's Winship Cancer Institute in Atlanta.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\n\"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers,\" says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors.\nAug. 17, 2011 -- German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.\nHe was not involved in the research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The study was not designed to compare CT with dog-sniffing, yet the researcher is allowed to say that the dog-sniffing \u201ceven surpasses the combination of chest computed tomography (CT) scan and bronchoscopy.\u201d", "answer": 0}, {"article": "When dentists administer lidocaine or another local anesthetic, they usually combine it with another drug called epinephrine, which acts to constrict the blood vessels.\nIn the clinical trials there were no serious side effects, Novalar said.\nThose patients would be expected to have lingering pain, and should not get Oraverse, Dr. Moore said.\nNovalar and some dentists who advise the company said it might be useful for children, who can injure themselves by biting their lip or tongue without knowing it.\n\u201cIt is reversing the epinephrine.\u201d\n\nThe label for the hypertension drug phentolamine contains warnings about heart attacks and occlusion of blood flow to the brain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article does a good job describing the clinical trials and the results.\u00a0 Kudos for including both relative and absolute differences. ", "answer": 1}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Like a story in Reuters on the same study, this story uses the same dramatic relative reduction figure, but, unlike the Reuters story, it also provides the hard numbers. It says, \u201cDuring the entire 12 weeks, three of the patients taking dupilumab experienced a worsening of asthma compared with 23 on the placebo, a relative reduction of 87 percent.\u201d It also disclosed that there were 104 patients in the study.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story mentioned that the study \"provided strong evidence that taking just one multivitamin a day did not cause harm.\", which could be considered a benefit of treatment.", "answer": 1}, {"article": "Dr. Andrew Adesman is chief of developmental and behavioral pediatrics at Cohen Children's Medical Center of New York, in New Hyde Park, N.Y.\nThe goal of the therapy -- delivered over five months while the infants were ages 7 to 10 months -- was to improve the infant's attention, communication, early language development, and social engagement.\nThe research involved 54 families of babies who were at increased risk for autism because they had an older sibling with the condition.\nSome of the families were assigned to a therapy program in which a therapist used video feedback to help parents understand and respond to their infant's individual communication style.\nTwo experts agreed that early intervention is key.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story offered just one sentence describing the benefits of the study, but it included no quantification: \u201cAfter five months, infants in the families in the video therapy group showed improvements in attention, social engagement and social behavior, according to the study published Jan. 22 in The Lancet Psychiatry.\u201d\u00a0 How big were these improvements?\u00a0 How significant were they?", "answer": 0}, {"article": "Inflammation can make urination difficult.\nResearchers found 21 of the 27 participants had no or mild inflammation, but 15 had biopsy-confirmed malignancies.\nSymptom scores on the IPSS test also showed improvement.\nThose with the highest levels of inflammation benefited the most from the periodontal treatment.\nDuring the periodontal care, the men received no treatment for their prostate conditions.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The journal article that\u2019s the basis for the release provided quantitative data about the percentage of reduction of gum disease and PSA levels, as well as reports of reduced symptoms. The release, however, sticks to generalities, noting \u201creduced symptoms,\u201d quoting the principal investigator about \u201cimproved\u201d symptoms of prostatitis in those treated for gum diseases, and noting \u201csignificant improvement\u201d for those with the \u201chighest level\u201d of inflammation. The release includes no quantification.\nIn addition, the release mentions that PSA levels dropped in 21 of the 27 men who received periodontal treatment, but this is a misleading claim. A closer look at the study data shows that the reductions in PSA levels were not statistically significant. And\u00a0in the participants who had low levels of inflammation at baseline, the mean PSA level actually went up.", "answer": 0}, {"article": "They might be more health conscious or conscientious, or have other traits associated with longevity.\nIf the new analysis is correct, one of the influential PSA studies, called PLCO, reduced deaths from prostate cancer by 27 percent to 32 percent, not the zero percent that PLCO researchers themselves found.\nThis is a screening test that saves lives.\u201d\n\nThose gains come at some cost to health, though: For every life saved, she estimated, five men will be told they have cancer when in fact their abnormal cells would never grow, spread, or harm them.\nThe analysis, published Monday in Annals of Internal Medicine, drew wildly different reactions, as is often the case with research on PSA screenings.\nThe finding that assigned-to-screening men were no more likely to avoid death from prostate cancer might therefore have been because their screening behavior wasn\u2019t different enough from the \u201cunscreened\u201d (but in fact partly screened) men\u2019s, not because PSA screening doesn\u2019t save lives.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is good depth here discussing the benefits. Early in the story it indicates that \u201cfor a man in the U.S., the risk of dying of prostate cancer is about 2.5 percent. A mortality reduction of 30 percent would lower the death rate to 1.75 percent.\u201d \u00a0Later this is described in relative terms, saying that more frequent PSA screening \u201cmoved some prostate cancers from too-advanced-to-treat to treatable, reducing prostate cancer mortality by 27 percent to 32 percent over 11 years.\u201d", "answer": 1}, {"article": "The world\u2019s biggest maker of cancer drugs is counting on growing sales of Tecentriq, which notched 487 million Swiss francs in 2017, to help offset falling revenue from its older cancer medicines Avastin, Rituxan and Herceptin whose patent expirations are exposing them to rivals\u2019 cheaper copies.\nAnalysts from Baader Helvea said its announcement completes an \u201calready robust\u201d set of data for regulators who now must sign off on Tecentriq\u2019s use as an initial treatment of lung cancer.\nWhile Roche did not provide specific overall survival data, the headline result helps its bid to catch up to better-established immunotherapies from Merck and Bristol-Myers Squibb and its shares rose about 1 percent in early trading.\nThis could help Roche make the case that its cocktail is suitable for broad patients groups, not just those with specific biomarkers.\n\u201cWe continue to see Roche efficacy more than sufficiently competitive to grant a 43 percent market share in the indication, translating in 4.9 billion francs Tecentriq peak sales and 1.2 billion francs in 2018,\u201d Baader\u2019s Bruno Bulic said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is essentially a data-free story, as noted above. How long does this drug cocktail help patients live compared to the other treatment groups? This critical question goes unanswered.", "answer": 0}, {"article": "\"We were worried that there'd be too much scar tissue in the retina itself to be able to deliver the material to the correct spot,\" he said.\nBut the most dramatic result brought Manuela one step closer to her dream of reading.\nAfter her surgery the difference was dramatic.\nThe medical procedure was developed by a husband-and-wife team \u2014 eye surgeon Dr. Al Maguire and gene therapy expert Dr. Jean Bennett.\nThe surgery could be a glimpse into a new medical frontier.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This piece tugged at one\u2019s heart strings by presenting a young blind woman who could talk about her perceived visual improvement. Notwithstanding her experience, the story failed to communicate that not every patient in this small study showed even the small improvement of the woman featured in the story. \u00a0The study this story was built on reported that there was no clinically significant change in visual acuity \u2013 something this story didn\u2019t make clear at all.\u00a0 ", "answer": 0}, {"article": "Tiny channels collect perspiration and route it to different compartments where it interacts with chemicals that change color to reflect sweat loss, the perspiration\u2019s acidity level, and concentrations of chloride, glucose and lactate.\nWhile Wednesday\u2019s studies used an early version that analyzed sweat just once during the exercise, he\u2019s now testing a design capable of multiple measurements over time.\nBy simply looking at a color change, \u201csuch a patch allows people to now have an opportunity to understand their health and how it changes depending on activities.\u201d\n\nIt\u2019s a growing field: Other research groups around the country, including some of Bao\u2019s colleagues, are pursuing wearable biosensors.\n\u201cSweat has biochemical components within it that tell us a lot about physiological health,\u201d said John A. Rogers, who directs Northwestern University\u2019s Center for Bio-Integrated Electronics and led the new research.\nThe experimental gadget goes well beyond activity monitors like the Fitbit.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t give quantified benefits because there aren\u2019t any\u2013and it should have made that point much stronger versus expanding on speculative uses for the device. We\u2019re told a study \u201cfound it worked on sweaty bicyclists, sticking even during a long-distance race in Arizona.\u201d\u00a0 So what does that mean in clinical terms? Nothing yet. The purpose of the study was to show that the patch would stick and collect good data, not to show that it generates a health benefit.\nThe story also allowed speculation of benefits beyond electrolyte monitoring, too:\n(Researcher John A.) Rogers envisions more sophisticated use of such devices, such as real-time monitoring of how the body adjusts during military training, or even to screen people for diseases such as diabetes or cystic fibrosis.", "answer": 0}, {"article": "Current methods for determining if a prostate has become cancerous include a physical examination of the prostate (known as a digital rectal examination or DRE), MRI scans, a biopsy or tests to determine levels of the chemical prostate-specific antigen (PSA) in the blood.\nThe Dundee University-based team say they have used an ultrasound process called shear wave elastography (SWE) to detect prostate tumours.\n\u201cThe technique now needs to be tested in a much larger number of men to confirm just how well it can detect the aggressive cancers, while also ruling out those who do not have prostate cancer,\u201d said Simon Grieveson, head of research funding at Prostate Cancer UK, which funded the Dundee project (with support from the Movember Foundation).\nThe new method aims to get round the problems by targeting the prostate with ultrasound.\nSWE technology is already used in diagnosing breast cancer and liver diseases.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story lists the supposed benefits of this new approach, compared to existing methods used for detection and delineating prostate cancer.\u00a0 A source is quoted as saying, \u201cOur new method is far more accurate and also allows us to identify the difference between cancerous and benign tissue in the prostate without the need for invasive surgery.\u201d\nBut the story offers no data or information that would quantify the supposed improvements over existing screening mechanisms.", "answer": 0}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The description of benefits could have been stronger. The article states that researchers have found a way to identify the presence of a protein that indicates pancreatic cancer \u201cwith perfect accuracy and no false positives.\u201d That\u2019s technically true in this study, but it\u2019s only part of the story. As the story notes, the main benefit of the test would be its ability to detect cancer at an early, treatable stage. But the study included only 5 patients with such early stage cancers \u2014 something the story didn\u2019t explicitly tell us. While experts quoted in the article urge caution in reading too much into a small study, the claim of \u201cperfect accuracy,\u201d based on such a tiny sample, deserved a more aggressive and immediate challenge. It isn\u2019t until the very end of the story that any caveats are introduced. In addition, while patients who are able to undergo early treatment might be cured of the disease, the NCI cancer summary points out that the 5-year survival rate for patients who underwent complete resection for small tumors that were confined to the pancreas (the target for screening) was still only 18 to 24%. So, patients may still face long odds even when their tumors are caught early \u2014 context the story could have provided.", "answer": 0}, {"article": "But high blood pressure also appears to increase a person's risk of developing Alzheimer's disease, which is associated with the accumulation of plaques and tangles in the brain.\nAnd he says other people with high blood pressure should follow his lead.\nAt least two large studies have revealed an alarming trend among stroke patients, Koroshetz says.\nKoroshetz is using all of these approaches.\nHe is responsible for the institute's public health campaign called Mind Your Risks.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes several references to \u201cgreatly magnified\u201d and an \u201cincrease\u201d in risk of AD or vascular dementia among those with high blood pressure that goes untreated, but there are no solid data offered to support the claim, nor how treating blood pressure reduces that risk (and to what extent).", "answer": 0}, {"article": "The page you are looking for has moved. Please go to the main EurekAlert! homepage to locate the section you are interested in and reset your bookmarks.\n\nFor further assistance, please contact webmaster@eurekalert.org.", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a major weakness of the news release. Both the headline and the accompanying text strongly suggest that ibuprofen can \u201cprevent\u201d or \u201cward off\u201d Alzheimer\u2019s disease. However, no data are included to support this.\nThe news release suggests that the way to diagnose AD early is by looking for elevated levels of Abeta42 in the saliva, thereby allowing early treatment with ibuprofen. However, no data on the accuracy of this screening method is included.", "answer": 0}, {"article": "New research is helping Pfizer Inc. build a case for getting an important drug in its portfolio approved to treat a mysterious pain condition that could offer a big additional source of sales.\n\nThe New York drug maker said Tuesday that Lyrica, already on the market to treat certain types of pain, reduced painful symptoms among sufferers of fibromyalgia, a chronic and controversial condition that may affect as many as six million Americans. And today, it will unveil results from another study that it says shows Lyrica has a lasting...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided information from a single study showing a dose response to the medications.\u00a0 This was a large study (750 patients).\u00a0 While providing information about the drug's effect on pain, the reader is not left with sufficient information about whether this amount of pain reduction was sufficient to change the quality of life for the patients studied. In addition, the story did not provide information about the length of time patients took the medication in order to obtain the benefit that was described.", "answer": 0}, {"article": "Women who took hormones had an average of 24 fewer hot flashes per month, while those who took soy had 12 per month fewer.\nThat means that if women do take hormones, Bachmann told Reuters Health, it should be the lowest dose and for the shortest possible period of time.\nWomen typically suffer between 30 and 150 hot flashes a month, said Dr. Rafael Bolanos-Diaz, professor of health economics at San Marcos University in Lima, Peru, who co-authored the study.\nAnd not every woman needs treatment, notes Bachmann, who was not involved in the study.\nThe study did not look at whether eating soy in food has the same effect on hot flashes as supplements, Bolanos-Diaz said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explained that \u201cwomen who took hormones had an average of 24 fewer hot flashes per month, while those who took soy had 12 per month.\u201d", "answer": 1}, {"article": "He uses an electric mobility scooter for long distances, but he can still walk.\nMany of the clinical trials failed to satisfy the statistical requirement to prove a drug works\u2014at least not for the main outcome the company was looking at.\nIf they do say no, the Vertins could lose access to the drug that has stabilized their condition.\nTo Betty, the benefits are clear, even if they aren\u2019t easily quantified.\nBut the family\u2019s struggles with DMD were just beginning.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Most of the \u201cbenefit\u201d information in this story is provided by the mother of the three boys with Duchenne muscular dystrophy, who reflects in detail on a level of activity among her sons that she feels demonstrates the drug\u2019s effectiveness. The reporter reflects briefly on clinical trial results that offered \u201csome slight positive results,\u201d but we never learn what those are.", "answer": 0}, {"article": "But most of the success so far has been with blood cancers like lymphomas and leukemias.\nIf the patient had not received the CAR T therapy, he likely would only have survived a few weeks after his cancer recurred, says Badie.\nBased on this man\u2019s case, his team is hoping to now inject not just the tumor site but also the ventricular space in the brain, since that may help control spread of the cancer.\nBadie says it\u2019s not obvious why, but his analysis showed that these tumors did not contain much of the protein targeted by the CAR T cells that were injected.\nThis is the first time that immune cells have been injected into these brain regions, because introducing anything into the ventricles can cause dangerous and possibly deadly inflammation.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story fairly describes the patient\u2019s course before and after the experimental treatment, and cites some data about the short life expectancy of patients with his type of brain cancer (glioblastoma). It could have done a much better job, however, of quantifying what actually occurred or is happening now in\u00a0the other eight people undergoing the same therapy at City of Hope, and of defining specifically what it means to say the patient in the story had his tumor \u201cunder control\u201d for \u201calmost\u201d eight months.", "answer": 0}, {"article": "\"Unfortunately, that is not the case.\nIn this case, the cap proved to have 66 percent lower error rates than the headband.\nThey have designed a \"granular jamming cap\" filled with coffee grounds that does a better job of tracking patient head movements than current methods.\nTheir tests showed that these models could reduce the targeting error by about 50 percent.\nThe researchers decided to see if this technique could be applied to the problem.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release says that researchers \u201cdesigned three tests to determine how well this \u2018granular jamming cap\u2019 performed relative to the current headband in reducing targeting error:\nBut the release doesn\u2019t say how often these errors occur using the current headband method, so it\u2019s impossible to know whether this is an improvement that would amount to a significant advance.\nAlso, the news release does not explain how these tests translate to something meaningful for patients, such as fewer surgical errors, shorter procedure times, greater safety, or lower costs.\nIt does state that in about one operation out of seven, the target error is so large that the surgeon is forced to \u201credo the registration process,\u201d which orients the markers. But what that means is unclear. Does that prolong surgery to a significant extent? Does it result in greater risk or higher costs? The news release doesn\u2019t say.\nThe gold standard for fiducial (or placement) markers is the use of anchors for attachment to rigid structures such as the skull. This approach is routinely used in proton beam therapy, for example, where precise location and targeting is necessary. The coffee ground cap was not tested against the anchored\u00a0placement method but with what is recognized as a painless but flawed method.", "answer": 0}, {"article": "Surgeons may also perform what\u2019s known as angioplasty, which uses a catheter to insert a tiny balloon and inflate it to open the valve; sometimes surgeons will also insert a stent, or tiny wire mesh cage, to keep the artery propped open.\nResults of the current study reaffirm that a minimally-invasive procedure can be a viable option, even for elderly people who are high-risk surgical patients, said Dr. Samir Kapadia, a cardiovascular medicine researcher at the Cleveland Clinic in Ohio.\nAfterward, patients could walk significantly further in six-minute walking tests used to assess their functional capacity.\nPatients in the study had minimally-invasive surgery that fixes the problem by inserting a replacement valve to send blood around the damaged valve while leaving it in place.\nThe analysis focused on people with what\u2019s known as aortic stenosis, which occurs when the large blood vessels leading away from the heart narrow, forcing it to work much harder to pump blood.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While it can be difficult to report on a complex synthesis of data, more numbers were needed to give readers a sense of the scale of improvements patients experienced.\nThe story says after patients \u201ccould walk significantly further in six-minute walking tests used to assess their functional capacity. On average, they added almost 42 meters (138 feet) to their performance before\u201d the procedure. But, according to the study appendix, this 6-minute walk statistic was based on only 4 studies and, more importantly, was not considered a clinically important difference.\nThe story also also says patients \u201creported clinically meaningful improvements in their quality of life and their ability to complete daily tasks after surgery.\u201d But there is no data to explain how that was measured.", "answer": 0}, {"article": "Your office thermostat is set for men's comfort.\nBased on other studies in the past that seemed to allude to marijuana use and later development of psychotic symptoms such as delusions or hallucinations, the researchers had thought they might find some associations to disease or other health conditions.\nThe participants fell into four groups: those with no use or low use of marijuana, early chronic users, those who only smoked during their teens and those who began using it later and continued using the drug.\nUpdate: The study's findings generated significant controversy along with requests for supplemental analysis, according to the editors of the Psychology of Addictive Behaviors.\nThe researchers found no links to physical or mental health issues -- including depression, psychotic symptoms or asthma -- in any group, even those with very high use.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story is about research examining harms we think that a brief line or two\u00a0about the reasons for marijuana use would have been informative. \u00a0Especially when the author is allowed to say that he wanted to \u201chelp inform the debate about legalization of marijuana.\u201d \u00a0Debates involve tradeoffs of benefits and harms and we heard only one side of it in this story (and incompletely at that).", "answer": 0}, {"article": "In their study, published in the Feb. 23 issue of the Journal of the American Medical Association, Miglioretti and her colleagues found that false positives and interval cancers were both higher in women with a history of breast cancer than in those without such history.\nDr. William Audeh, medical director of the Samuel Oschin Cancer Center and the Wasserman Breast Cancer Risk Reduction Program at Cedars-Sinai Medical Center in Los Angeles, described the findings as \"not at all surprising.\"\nIt points to the need, she said, for women to remain vigilant about screening after their breast cancer treatment -- and to report any symptoms to their doctor immediately.\n\"Despite poorer performance compared with women without a prior history of breast cancer, overall screening mammography was effective at detecting the majority of breast cancer in women with a [history] at an early favorable stage, with the majority of tumors being diagnosed as ductal carcinoma in situ or stage 1,\" Smith said.\n\"Screening mammography does work well in women with a history of breast cancer, so they should continue to get their annual screening mammogram,\" said Diana Miglioretti, senior investigator at Group Health Research Institute in Seattle and a co-author of the new research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "By quantifying the benefits of screening mammography for women with a personal history of breast cancer in absolute numbers, the story presents this information accurately and in a useful, understandable way for women with breast cancer.", "answer": 1}, {"article": "Oxidative stress refers to a situation where levels of reactive oxygen species or \u201cfree radicals\u201d \u2014 damaging byproducts of energy use in cells \u2014 rise beyond the body\u2019s capacity to neutralize them.\n\u201cBut,\u201d she added, \u201cit should be noted that yoga controlled the blood sugar levels which otherwise rose in the control group.\u201d\n\nIn addition to that, the study found, signs of so-called oxidative stress declined in the yoga group.\nThey found that, on average, the yoga group\u2019s levels of the chemicals dipped by 20 percent.\nThe yoga used in this study was a gentle form, Hegde said, and parts of the practice were adapted for people who had additional health problems; certain poses were avoided in people who had heart disease, for example.\nMeanwhile, their average blood sugar levels held steady \u2014 in contrast to the non-yoga-practicing \u201ccontrol\u201d group, whose blood sugar levels rose.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided much discussion about the impact of the yoga on levels of \u2018oxidative stress\u2019. \u00a0Besides the fact that the link between oxidative stress and disease is tenuous at best, the story reported that those in the yoga group had a 20% reduction in oxidative stress when the study results showed that they had a 20% reduction in one marker of oxidative stress but at the same time showed reductions in two pathways form managing oxidative stress \u2013 which could be interpreted as increasing their risk from oxidative stress. Even the weight loss was not really quantified (the writer mentioned \u201ca handful of pounds\u201d lost).", "answer": 0}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of treatment.", "answer": 0}, {"article": "Symptoms range from mild stomach or skin reactions to a constriction of the airways.\nA medically supervised daily dose of peanuts may help children with peanut allergies greatly increase their tolerance to the food, according to two new studies that raise the possibility of a cure for this potentially life-threatening condition.\nNearly half of the 150 deaths attributed to food allergies each year in the United States are caused by peanut allergies, according to Duke University.\nWhile drugs can be used to treat an allergic reaction, there are no approved treatments for food allergies.\nAn estimated 12 million Americans suffer from food allergies, including about 2.2 million children.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The report includes sufficient detail about the studies\u2019 methodology and outcomes to help readers [eventually] understand the small numbers of children involved and the basic findings. \nThe story states that \"most\" of the 33 patients in the first test appeared to have improved resistance to peanut allergens, that 5 could tolerate peanuts without reaction, and that 4 had to withdraw because they could not tolerate the treatment.\u00a0\nThe story reports that the second test split the 18 subjects into treatment and placebo groups, and described approximate outcomes for each group.\u00a0 ", "answer": 1}, {"article": "\"It's like 'Star Trek.'\nAnd while some patients like Campbell do well with the implant, there are some who struggle.\nAnd just recently, during a vision test, Campbell was able to correctly identify a sequence of letters for the first time in decades.\nThen earlier this year, she went from coping with blindness to hoping she might see again.\nToday, the artificial retina is primarily for sufferers of retinitis pigmentosa, but it could expand to other diseases, like dry age-related macular degeneration, Mech said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "When a news organization decides to report on early Phase I research in 14 patients so far, it runs the risk of implying that benefts exist when, indeed, they have not yet been proven. \nThere are numerous studies of various artificial retina devices dating back at least 15 years, including those published by this device maker. A diligent story would have at least discussed those results to provide context.\u00a0 ", "answer": 2}, {"article": "TUHS neither provides nor controls the provision of health care.\nThe study, published online in the journal Molecular Neurobiology, raises new hope for human patients affected by dementia.\nOther researchers contributing to the study include Phillip F. Giannopoulos and Jian Chiu at the Alzheimer's Center at Temple, LKSOM.\nTheir superior performance suggested a successful reversal of memory deficiency.\nMicroscopic examination revealed vast differences in synaptic integrity between the groups of mice.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is light on data describing how much better at maze navigation the treated mice were compared to non-treated mice. \u00a0\u201c\u2026\u00a0significantly better on the tests\u2026\u201d and \u201c\u2026superior performance do not provide an adequate quantification of the test results. There is also a tacit and unfounded assumption that the reductions in leukotrienes and in tau are sustainable during prolonged treatment.", "answer": 0}, {"article": "Unlike insulin shots, which help Type 1 diabetics break down sugar and starches in the blood, metformin lowers blood-sugar levels primarily by squelching the liver\u2019s tendency to release stored-up sugar into the bloodstream.\nThe question is whether the rate-of-living theory is operational in mammals.\u201d\n\nPollak says that none of the most exciting possible benefits for the drug have yet been proved in randomized clinical trials of non-diabetics.\nMoreover, the drug was being studied in clinical trials as a way to lower the risk of cancer, heart disease and dementia \u2014 not just for diabetics, but for everyone.\n\u201cIf we can even slightly lower their average blood sugar with metformin,\u201d Wilkin said, \u201cI believe we can have a big benefit on their risk of developing Type 1.\u201d\n\nDespite all these potential benefits of metformin \u2014 and despite a recommendation from the American Diabetes Association that it be tried before any other drug for newly diagnosed Type 2 diabetics \u2014 a recent study found that only about half of all such people get metformin as their first prescribed medication.\nThe author of the study, Niteesh Choudhry, an associate professor of medicine at Harvard Medical School, also found that newly diagnosed Type 2 diabetics who start on metformin are the least likely to need an additional diabetes drug later.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The Not Satisfactory rating here stems in part from the prominent personal narrative that begins the story. In it, an individual begins taking metformin to help control her type 1 diabetes and reports a variety of positive outcomes, including becoming pregnant! This anecdote is far more vivid than the summaries of\u00a0studies that follow, and it is likely to color the reader\u2019s perception of the drug\u2019s benefits. The story also suggests high up that there are a litany of potential health benefits observed in studies \u2014 for example, \u201cthose who take metformin tend to have lower rates of cancer, heart disease and dementia, and to live longer overall than those who take other drugs for diabetes.\u201d Only\u00a0later does it proceed to highlight that overall, the evidence so far does not support any of the claims made in the article\u2019s title or the first few paragraphs. This framing, which front loads discussion of benefits and saves caveats and cautions for later, is unbalanced.", "answer": 0}, {"article": "Swaminath noted that one study published in 2012 found that \"colonoscopy reduced the risk of death from colon cancer by 53 percent, by removing polyps.\nOne expert said more efforts are needed to get people to undergo colonoscopy, which is currently recommended once every 10 years beginning at age 50.\nImperiale's team noted that not all people deemed to be at \"average risk\" for colon cancer face the same risk of the disease, and so some might benefit more from invasive colonoscopy than others.\nSwaminath pointed out that even the new study found that \"low- to intermediate-risk patients still have a risk between of between 1.9 percent to 9.9 percent of harboring a polyp that can develop into cancer.\"\nAnd while some areas of the United States have rates of compliance with colonoscopy guidelines of 75 percent or more, \"many areas have poor colon cancer screening rates,\" he added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites a study that credits colonoscopy with reducing the risk of death from colon cancer by about 50 percent, by removing polyps. It would have been helpful for the story to explain what that relative reduction in risk means in absolute terms (e.g. did the rate of cancer death go from 50% to 25% or from 2% to around 1%?)\nThe story also notes that the study found that patients with a low to intermediate risk score \u201cstill have a risk between of between 1.9 percent to 9.9 percent of harboring a polyp that can develop into cancer.\u201d\nWe\u2019ll give credit here for the story\u2019s provision of these key statistics, which do give a sense as how well the test accurately identifies truly low-risk individuals. However, we\u2019d note that the benefit here should ideally refer to the\u00a0ability of the algorithm to classify people at all risk levels (including high-risk), and therefore target the highest-risk patients for colonoscopy. The story doesn\u2019t really get into discussion of the predictive power of the test, referred to as a likelihood ratio, which is in the study manuscript. However, this is a difficult concept for most health care providers and patients, and we think it\u2019s understandable that the story did not include a full discussion of this topic.", "answer": 1}, {"article": "By far, the lowest incidence of colorectal cancers was seen in pesco-vegetarians, people who eat fish at least once a month but eschew all other types of meat. Compared to omnivores, pesco-vegetarians were 43% less likely to be diagnosed with these cancers during the course of the study.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story uses only relative risk reductions to describe the impact of vegetarian diets, which provides readers with an exaggerated sense of the overall size of the benefit.\nLet\u2019s look at what is said in the story: \u201c\u2026researchers from Loma Linda University found that vegetarians were 22% less likely than meat-eaters to be diagnosed with colon cancer or rectal cancer.\u201d But here are the absolute numbers from the published article: During the 7.3 year follow up period, a total of 252 cases of colorectal cancer were identified in the 40,367 vegetarians studied (62.4 cases per 10,000) and 238 cases in the 37,292 non-vegetarians studied (63.8 cases per 10,000). That is a difference of 1.4 cases per 10,000 subjects. The relative reduction in risk does not play out to be very large in absolute numbers.\nAnd again the story says: \u201cLacto-ovo vegetarians (who eat eggs and dairy foods but not fish or other meats) came in second, with an 18% reduced incidence of colorectal cancer. They were followed closely by vegans (who don\u2019t eat eggs, dairy products or any kind of meat), who were 16% less likely to get a colorectal cancer diagnosis.\u201d But when we look at the actual study, we find that the confidence interval in both of these cases crosses 1, which means that the findings are not statistically significant (and would certainly be very small in absolute terms).\nWhen rolled up together, there does appear to be a slightly smaller risk of colorectal cancer associated with a vegetarian diet compared with a non-vegetarian one.\u00a0 Having said that, when you drill down into the different sub-diets, only the pesco-vegetarian diet was statistically significant on its own.\u00a0 None of the other diets are associated with a reduce risk of either colon or rectal cancer. Compared with the relative risks touted in the story, the absolute numbers derived from the study provide a somewhat different and less enthusiastic picture of the benefits.", "answer": 0}, {"article": "Get the facts.\nThis, sadly, is expected; more than 178 million doses of Gardasil have been given worldwide, and given that huge number it\u2019s a statistical certainty that some young people will die not long after getting them.\nIt\u2019s very frustrating; mounds of data show these vaccinations are incredibly low-risk, but it only takes a little bit of doubt and fear to make vaccine rates drop.\nAnd, just like essentially every claim made by the anti-vaccination movement, these arguments are wrong.\nAll the evidence shows Gardasil to be safe and to be effective against a virus that causes horrific illnesses.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story focuses on safety to the exclusion of efficacy. It does not say which strains of HPV Gardasil protects against or how effective it is.at preventing the cancers those strains cause. It does not tell the reader that the more recently formulated vaccine, Gardasil 9, has expanded the protection conferred by the earlier version.", "answer": 0}, {"article": "Visit the American Heart Association for more on statins.\nOne expert doesn't think sufficient evidence exists yet to take statins to prevent or treat cancer.\nAt this time, people without high cholesterol should not be taking statins in the hope of warding off cancer or living longer with cancer, he said.\n\"There is little evidence that statins affect cancer risk or survival, but clear evidence that they can help some people lower risk of heart attacks and strokes,\" he said.\n\"We cannot, however, recommend statins for cancer prevention without a positive clinical trial.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story clearly states several times that there is no clinical benefit known, but only a correlation between people taking the medications and lowered incidence of certain cancers. Of course, based on the actual release, this is wrongly stated. The correlation is between high cholesterol levels and a lowered incidence of certain cancers.\nAlso, importantly, we\u2019re only given relative risk numbers here, not absolute risks, and that should have been explained. Also, we\u2019re told the \u201cstatin\u201d group lived longer overall, but that doesn\u2019t mean much without numbers.", "answer": 0}, {"article": "Psoriasis is a skin condition that causes patches of skin redness and flaking.\nSiliq is also approved with a Medication Guide to inform patients of the risk of suicidal ideation and behavior, and that because Siliq is a medication that affects the immune system, patients may have a greater risk of getting an infection, or an allergic or autoimmune condition.\nBecause of the observed risk of suicidal ideation and behavior, the labeling for Siliq includes a Boxed Warning and the drug is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Siliq REMS Program.\nA causal association between treatment with Siliq and increased risk of suicidal ideation and behavior has not been established.\nSiliq\u2019s safety and efficacy were established in three randomized, placebo-controlled clinical trials with a total of 4,373 adult participants with moderate-to-severe plaque psoriasis who were candidates for systemic therapy or phototherapy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does not give any numbers to describe the magnitude of benefit shown in the three clinical trials. All we know is that \u201cmore patients treated with Siliq compared to placebo had skin that was clear or almost clear.\u201d But how many more patients and by how much? And how was this exactly assessed? The news release vaguely mentions a scoring system that looked at the \u201cextent, nature and severity of psoriatic changes of the skin\u201d without elaborating any further.\nIn a 2016 FDA briefing document online, there is some data related to the drug\u2019s effectiveness, but the number of analyzed subjects falls short of the total 4,373 trial participants cited in the news release.\nWithout any numbers describing the benefit, we have no idea how effective Siliq really is, which is why we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": ".\n\"Many would have predicted that tendon healing is inflammation-linked,\" said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal, \"but that the anti-inflammatory roles of TSCs could be so potent, and so amplifiable, is a striking finding.\"\nIn vivo, the researchers evaluated inflammatory responses by TSCs, including infiltration of macrophages (white blood cells that consume damaged or dead cells) and expression of anti-/proinflammatory cytokines, at different time points.\n\"Our findings represent an important foundation for the development of a new treatment that would regulate overwhelmed inflammation for tendon ruptures and tears, tendonitis, tendinopathy, and other tendon injuries and diseases.\"\n\"Inflammation plays a critical role in acute and chronic tendon injuries and healing,\" said Chang H. Lee, Ph.D., a researcher involved in the work and an assistant professor at the Regenerative Engineering Laboratory (Columbia University Irving Medical Center, New York).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release\u00a0briefly notes two findings: that human stem cells in petri dishes, prodded by proteins that promote inflammation, expressed genes involved in regulating inflammation, and that inflamed rat tendons exposed to stem cells demonstrated improvement.\u00a0 But without further study details, we have little idea of what to make of these results.", "answer": 0}, {"article": "Traditionally, dentists were taught that the only way to deal with decay was to drill it out.\nThat's still important in some cases, Featherstone says, but without fixing the underlying problem of bad bacteria, patients just keep coming back for more fillings.\nBut if you catch decay early, Featherstone says, it can be reversed using fluoride treatments like varnish and concentrated toothpaste and gels.\nAnd he expects that at some point all dentists will follow a preventive protocol.\nWhen Featherstone put his patients on personal treatment plans, he found the strategy worked.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the story includes links to some studies that report specific results, the only number reported in the story is a reduction in adult tooth fillings of 30 to 50 percent. But without any absolute numbers, this number isn\u2019t useful. Is it a cavity a year? A cavity a decade? The story refers to people at \u201chigh risk\u201d for cavities, but does not define what that term means. Without some anchoring in absolute numbers, all readers are left with is a vague sense that preventive treatment is \u201cbetter\u201d for some people, without pinning down how much better or for whom.", "answer": 0}, {"article": "Try to eat a pound of vegetables each day, half of which are cooked and the other half eaten raw, as well as half a pound of raw fruit.\nBut while certain common foods \u2014 like raw onions, garlic, citrus juices, coffee and chocolate \u2014 are likely to cause reflux in most people with the condition, Dr. Aviv and other experts emphasize that everyone is different, and trial and error is the most effective way to determine an individual\u2019s trigger foods and drinks.\nLosing weight is one of the best ways to find relief without having to rely on medication.\nHe said they should be taken 30 to 60 minutes before eating breakfast or dinner (or both), but not used as an \u201cantidote\u201d to consuming acidic foods.\nIf adopting the above measures fails to fully control acid reflux, taking a proton pump inhibitor may also be needed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story talks about a suite of lifestyle changes, from losing weight to quitting smoking to altering one\u2019s diet. However, the story does not make clear to what extent any of those things reduce the symptoms of acid reflux or GERD, as measured by clinical studies.\u00a0 And there\u2019s a lot of research out there on this subject. For example, this 2006 paper in JAMA Internal Medicine looks at 100 earlier studies related to lifestyle changes and GERD. The story also pays particular attention to the approach laid out in a book titled The Acid Watcher Diet, but offers no information about how effective the book\u2019s guidance may be in ameliorating symptoms or addressing underlying causes.", "answer": 0}, {"article": "Dextromethorphan is a cough suppressant commonly found in over-the-counter cough medicines, and quinidine is a drug used to control heart rhythm disorders.\nThere are no currently approved treatments for agitation, and we\u2019re very enthusiastic about this finding.\u201d\n\nCorrection: October 8, 2015 \n\nA report in the In Brief column on Sept. 29 about a combination drug that could ease the agitation of Alzheimer\u2019s disease described incorrectly a disorder treated with the combination drug, dextromethorphan and quinidine.\nNow researchers report that a combination drug already in use for treating certain neurological problems may be a better remedy.\nResearchers then rated them using a well-validated scale that measures aggression and agitation.\nThen the researchers re-randomized those who did not respond to placebo to receive either drugs or placebo, and found similar encouraging results for the drug combination.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes an attempt to quantify the findings: \u201cAggression scores declined to 3.8 from 7.1 in the dextromethorphan-quinidine group and to 5.3 from 7.0 in those who took a placebo,\u201d so we\u2019ll give the benefit of the doubt on the rating. But we think the story could have provided a lot more context. Is this a 10-point scale? What does this change represent in terms that would mean something to patients and caregivers? \u00a0The accompanying editorial provides some of the needed explanation when it notes that \u201ca minimum clinically important difference (MCID) has not been established\u201d for this scale and that \u201cThe apparently modest numerical benefit, as evidenced by the approximately 1.5-point between-group difference for the primary outcome measure, is therefore difficult to interpret.\u201d \u00a0The editorial also notes that there was no improvement in the quality of life measurement during the 10-week trial.\nAnother concern is the story\u2019s description of benefits from the study\u2019s lead author. He says\u00a0\u201cFifty-five percent of the people who were on drugs had a 50 percent reduction in their agitation.\u201d \u00a0Although this is accurate and the drug\u2019s benefits were significantly different from placebo, the placebo group also improved significantly. The story could have noted that there\u2019s a strong placebo effect happening here that accounts for some of the benefits.", "answer": 1}, {"article": "\"We were pleased by the results of this first clinical study,\" he says.\nThe research was presented at the American Association for Cancer Research's special conference, Colorectal Cancer: Biology to Therapy.\nAt the meeting, Ahlquist presented the results of the first clinical evaluation study, which enrolled 1,100 patients.\n''One in every 17 of us will have colon cancer in our lifetime,\" says David Ahlquist, MD, professor of medicine and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn., who presented his findings on the new colon cancer screening test.\nThe new test, a next-generation stool test known as a DNA methylation test, detects tumor-specific alterations or methylations in the DNA in the cells shed into the stool from cancerous or precancerous lesions.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gave the same basic benefits data that the other stories gave, but it, too, didn\u2019t compare this data with any of the existing colon cancer screening methods, leaving readers with no good sense of the potential scope of the benefits suggested. There was only one vague reference to the new approach being able to find tumors on both sides of the colon, \u201ca feat that is not always accomplished by colonoscopy.\u201d", "answer": 0}, {"article": "\u201cMore often than not, it\u2019s not clear-cut which way to go,\u201d explained Barry Rosenstein, professor of radiation oncology at Mt.\nThat hope is evident to other researchers, such as Dr. Ithaar Derweesh, a urologic oncologist and associate professor of surgery at the University of California San Diego Moores Cancer Center.\nDoctors usually can\u2019t predict whether a man will suffer all or none of those side effects.\nThe next step, he said, is for group members to validate the predictive power of the markers his team found.\nIf you see a radiation oncologist he\u2019ll say oncology.\u201d\n\nDetermining what type of treatment a man should receive is only part of the dilemma of prostate cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Despite the headline that states that \u201cDNA markers may predict impotence after prostate cancer,\u201d the story correctly indicates that any benefit from the work is speculative; even if these markers are confirmed to be valid, there are currently no available treatments to target the genetic abnormalities. \u00a0However, another underlying issue, which was not addressed, is whether radiation treatment benefited men in terms of cancer control.", "answer": 0}, {"article": "In one study, the number of daily hot flashes experienced by postmenopausal women taking 1,800 milligrams of the drug per day declined from around 10 to around 2.\nAbout 60% of women who took the experimental drug in one study reported side effects, compared to about 50% of women taking placebo pills.\nBut side effects, including dizziness and daytime sleepiness, were commonly reported by users.\n\u201cThis drug was about 60% to 65% effective, which is about the same efficacy that has been reported with antidepressants [for treatment of hot flashes].\u201d\nNAMS founder and former executive director Wulf Utian, MD, says Serada does not appear to be as effective as hormonal therapy, but it may be a useful alternative treatment for women who can\u2019t take hormones or don\u2019t want to.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "Stress tests measure the heart's response to exertion, letting doctors see or hear any disease.\nEven more surprising, the rate of bad outcomes among the heart patients studied were extremely low.\nThe first showdown pitting 3-D, heart-imaging exams against older stress tests atop treadmills or stationary bikes found that among 10,003 heart patients, their rates of eventually having serious heart events were the same \u2014 no matter which method doctors used to check their tickers, researchers said.\nWhich prompts a big question: Could the use of stress tests or expensive scans become less frequent for heart patients, replaced by more watchful waiting?\nUntil this study, doctors have been \"guessing\" which form of those two diagnostic tests is best, Douglas said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is an example of a story thrown off course by a single misleading anecdote.\nDiscussion of benefits is quite reasonable for 90% of the story, and we noted that the report offers specific information on the incidence of heart attacks or complications\u20143%\u2014in the course of making the point that the incidence does not differ between patients undergoing stress tests versus CTA. The story also notes that\u00a0CTAs \u201cresult in fewer instances of patients with suspected heart issues undergoing unneeded catheterization procedures.\u201d\u00a0That\u2019s all very well and good.\nBut at the very end, we learn of one patient who underwent CTA even though his stress test was normal, and whose life was apparently saved as a result. The man convinces his two brothers to get CTAs, which apparently reveal blockages that they were unaware of. \u00a0\u201cJust because I had a CTA, that had a domino effect to my brothers getting it, and it very well saved all three of our lives,\u201d the man says.\nUnless this man can predict the future, how could he possibly know that getting a CTA saved his life or those of his brothers? These men may have had blockages, but it\u2019s not at all clear that these blockages would have resulted in fatal heart attacks. In fact, a major concern with CTA is that it may reveal blockages that would never cause a serious problem, leading to unnecessary procedures. The point of the study is that there was no difference at all in the incidence of serious cardiac complications between those who undergo stress tests and those who get CTA.\nUnfortunately, that careful science-based message is badly undercut by the story\u2019s failure to push back against this anecdotal crystal ball-gazing. It\u2019s likely that any readers who make it to the end of this story will conclude that it\u2019s best to get a CTA, just in case.", "answer": 0}, {"article": "\u201cThis wakes up the immune system and says, \u2018Hey!\nJohn O\u2019Donnell, a retired math teacher in Piscataway, N.J., was one of those who tried the combination therapy, but ultimately responded only to Imlygic.\nApproved by the Food and Drug Administration on Tuesday for treating advanced-stage melanoma, the virus \u2014 called Imlygic, which was developed in part in a Massachusetts lab \u2014 is a modified version of the herpes virus that both attacks the cancer and sparks the immune system into action against tumors.\n\u201cIt\u2019s a low-toxicity treatment, and for the right patients you see quite stunning results,\u201d said Robert Coffin, a virologist who created Imlygic at BioVex, the Woburn-based company he founded.\n\u201cThe field is exploding, and this would be another arrow in the quiver that oncologists use.\u201d\n\nImlygic is part of a new group of immune-stimulating viral therapies that could change how cancer is treated and managed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story indicates that the treatment caused some tumors to shrink for at least 6 months, particularly in those\u00a0whose cancer had not yet spread to internal organs. But the overall discussion of benefits is lacking some important details. What does \u201cshrink\u201d mean? And when it says that 16% \u201cresponded,\u201d what exactly does that mean? (Of course, 84% did not respond \u2014 a statistic that was also worthy of comment in our view.) Finally, important outcomes, such as length of survival, are not presented or compared with alternatives. One study reported that median survival was 23.3 months with the new drug vs.\u00a018.9 months with the comparison treatment \u2014 a finding that would have been easy to include. The FDA cautioned in a news release that \u201cImlygic has not been shown to improve overall survival.\u201d", "answer": 0}, {"article": "But in this case, if anything, we're taking money out of our own pockets.\"\nThe American Cancer Society, which has led the opposition to the mammography guidelines issued by the U.S. Preventive Services Task Force, was involved in the discussions leading up to the Pap test guidelines and will consider them in reevaluating its own recommendations, an official said.\nThe change comes amid sharp controversy over new recommendations from a federal task force that women wait until age 50 before they begin having routine mammograms and that women age 50 to 74 scale back to getting the exams routinely every two years.\nThe National Cervical Cancer Coalition, a patient advocacy group, endorsed the recommendations.\n\"We are persuaded that the guidelines are really consistent with the evidence,\" said Robert Smith, the society's director of cancer screening.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story fails to quantify the benefits or risks of screening. ", "answer": 0}, {"article": "\u201cBut even without that firm answer at this point I don\u2019t see the harm in supplementing.\u201d\nMore studies need to replicate and confirm the role that omega 3 fatty acids might play in fertility, but for now, Skaznik-Wikiel says that there isn\u2019t much harm in consuming more omega 3 fats.\nThe study, presented at the American Society of Reproductive Medicine annual meeting, was in mice, so more research needs to be completed before omega 3 foods or supplements become part of treatment for infertility.\n\u201cOur study shows that there may be some relationship between dietary factors and things like egg quality so one idea may be recommending supplementation with omega 3s to improve fertility.\u201d\n\nExactly how the healthy omega 3 fatty acids are helping the ovary to produce better quality eggs isn\u2019t clear yet.\n\u201cBased on this study, it looks very encouraging that omega 3s can potentially improve fertility,\u201d says Skaznik-Wikiel.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Given that the research under consideration here involved 10 mice \u2014 and genetically bred mice at that \u2014 there\u2019s no way to determine whether increasing omega 3s in a woman\u2019s diet would have any benefit at all, let alone to quantify the likely benefits.\nThe story does explain that the mice bred to have higher ratios of omega 3 fatty acids seemed to produce more \u201cprecursors to egg cells\u201d and also produced higher quality eggs, meaning they would be more likely to have eggs that would be fertilized and develop into baby mice.\nThe bottom line, however, is that a woman reading this story and hoping to improve her fertility would find no information that would help her assess how much of an increase in omega 3s she might need, nor how much of an improvement in fertility this dietary change might produce.", "answer": 0}, {"article": "To place an electronic embedded link to this study in your story This link will be live at the embargo time: http://jamanetwork.\nNicholas S. Reed, Au.D., of the Johns Hopkins School of Medicine, Baltimore, and colleagues compared five of these devices (costs, approximately $350 to $30) with a conventional hearing aid (cost, $1,910) among 42 adults (average age, 72 years) with mild to moderate hearing loss.\nAccording to nationally representative estimates, less than 20 percent of adults with hearing loss report hearing aid use.\nA comparison between less-expensive, over-the-counter hearing assistance devices and a conventional hearing aid found that some of these devices were associated with improvements in hearing similar to the hearing aid, according to a study published by JAMA.\nThe researchers found that the change in accuracy in speech understanding from unaided to aided varied by device.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This release didn\u2019t dive into the PSAP versus hearing aid benefit numbers and this was a missed opportunity. According to the full study, hearing aids alone improved speech recognition by 12 percent. Meanwhile, the three most expensive PSAPs (all more than $300) improved speech recognition by at least 10 percent. It would also have been helpful to point out that the least expensive PSAP ($30) actually worsened speech recognition by 11 percent.", "answer": 0}, {"article": "\u201cI\u2019m amazed,\u201d she said.\nIt\u2019s no miracle cure \u2014 only about 20 percent of patients with gliomas were helped \u2014 but some are alive six years later, the team reported in the New England Journal of Medicine.\nBut the 21 percent or so of patients helped by the vaccine all survived at least three years.\nAll but one of those previous patients died after an average of 11 months.\nJust 14 percent were still alive two years after diagnosis and 4 percent were alive three years later.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did give numbers, reporting that \u201c21% or so of patients helped by the vaccine all survived at least three years,\u201d while 4% of patients in the the historic control group were alive after three years. But in a small study, why not give readers the absolute numbers: how many out of how many? \u00a0Why make them do the math in their heads?\nSome of data were incomplete. For example, the story said of the 61 treated, \u201ceight patients had no evidence of the tumors growing any more and two had no evidence of a brain tumor at all,\u201d without indicating how much time had passed since those patients were diagnosed and treated.", "answer": 1}, {"article": ".\nAfter five weeks of treatment, subjects receiving dTMS lost more than 3 percent of their body weight and more than 4 percent of their fat--significantly more than controls did, Luzi reported.\nResults of the fecal analysis demonstrated that, after five weeks, dTMS-treated subjects had greatly increased quantities of several beneficial bacterial species with anti-inflammatory properties, such as are found in healthy people.\nThis study expands on the researchers' previous finding that dTMS reduced food cravings and induced weight loss in obese individuals.\nLuzi said scientists now know that an impaired gut microbiota can alter the brain's signals for appetite and satiety, or fullness.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "One of the least straightforward ways to present research results is by stating changes in percentages rather than absolute differences between groups \u2014 and this release does exactly that. The release states, \u201cAfter five weeks of treatment, subjects receiving dTMS lost more than 3 percent of their body weight and more than 4 percent of their fat \u2014 significantly more than controls did.\u201d And yet, the release doesn\u2019t report actual body weight or body fat data, leaving readers out in the cold as to what a 3 or 4% change in weight or fat loss really means. This is unintentionally misleading for people trying to assess the value of the treatment.\nCurrent guidelines for treating obesity recommend a 5 to 10 percent weight loss within one year for benefits to be clinically meaningful, and it\u2019s uncertain if participants would achieve this goal, given the short time frame of the study. Neither the release or the abstract it\u2019s based on addressed whether volunteers in the sham group (those who didn\u2019t receive dTMS therapy) also lose weight or fat mass. Without this comparison, it\u2019s difficult to understand the impact of dTMS itself or if the placebo effect played a role in these results.", "answer": 0}, {"article": "A surgically implanted electrical device that stimulates the sacral nerve can calm an overactive bladder, according to a company that sells it. Physicians say sacral neural stimulation works well for many patients, but a test period with an external device is recommended first.\n\nMillions of Americans suffer from \"urge incontinence,\" accidents caused by a strong, sudden need to get to the bathroom, or overly frequent urination, defined as eight or more times a day. Quality of life is affected, as sufferers must...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides some quantification of benefits of the device but leaves many questions unanswered. The story states that 80% of the patients experienced at least a 50% improvement in symptoms with the device. Compared to how many with conventional treatment? What does an \"improvement\" mean? In what symptoms? How was improvement measured?", "answer": 0}, {"article": "The closed loop insulin delivery system, for example, computes insulin doses and administers them according to glucose levels detected by a sensor.\nWithout replacement insulin, people with type 1 diabetes couldn't survive.\nThe current study included 24 people with type 1 diabetes and challenged an artificial pancreas prototype in two different real-life scenarios.\nFor the eating out scenario, the average time good blood sugar control was increased was 28 percent on average.\nThe hope is that an artificial pancreas will closely mimic the way the human pancreas normally releases insulin in response to food or stress.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "All benefits are presented in relative terms, which is misleading to readers. For example, the third sentence says, \u201cResearchers found that people who took statin medications had about a 16% reduced risk of renal failure and a 21% lower risk of dying after their surgeries, compared to people who weren\u2019t taking the drugs.\u201d What are the absolute numbers? Well, out of 67,941 people, 1,208 people suffered an acute kidney injury while not taking statins, and 1,039 suffered one while taking statins. That means 169 fewer people suffered an acute kidney injury, and this is making the big assumption that statins had anything to do with it.", "answer": 0}, {"article": "\"There's lifestyle and diet, there is getting to the right doses of medications, there are adherence issues.\nThe procedure is safe as well as effective, the study authors said.\n\"High blood pressure is a major contributor to heart attack, stroke, heart failure, and [kidney] failure,\" said Fonarow, who was not involved in the study.\nIf it is applicable, it could mean patients need not take blood-pressure drugs, Esler suggested.\nSingh also noted that although this procedure is used in other countries it is not yet approved in the United States.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately reports what the researchers reported about decline in systolic blood pressure.", "answer": 1}, {"article": "People with insomnia may have one or more sleep problems, including difficulty falling asleep, trouble staying asleep and difficulty getting back to sleep after waking in the night.\nOn average, it took patients 21.6 fewer minutes to fall asleep with the 40 mg dose of MK-4305 than a placebo on night one, Merck said.\nThe drug, MK-4305, helped patients sleep for a larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment, Merck said.\nThe drug also demonstrated superiority to placebo in the time it took to fall asleep and time spent awake after initially falling asleep, Merck said.\nIn the one-night measure, patients who took the highest dose of the Merck drug slept 12.2 percent more of the eight hours than those who got a placebo.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are 28 numbers in this 495-word story, not including the name of the drug. These numbers add up to very little. For one, there are a lot of comparisons of performance levels at different doses of drug. This seems to be aimed at scientists who may be working on similar drugs and are trying to come up with the perfect dose. Why would anyone else need this information? The absolute numbers are missing, as they often are, leaving us to wonder whether a 12.2% higher than placebo means much. Let\u2019s say you\u2019re an insomniac and you only sleep four hours a night. If you take this drug, you will have slept an extra\u00a029 minutes. At least that appears to be what this means. It\u2019s hard to say because of that odd caveat: \"larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment.\" When the second sentence in a story reads like that, you know you are in trouble.", "answer": 0}, {"article": "At week 40, for example, 81 percent of patients taking a 200-mg dose of guselkumab had a score of 0 or 1, compared to 49 percent of patients taking adalimumab.\nIn the study, published in the New England Journal of Medicine, investigators compared guselkumab to adalimumab, the most common medication currently used to treat psoriasis.\nThis study was supported by Janssen Research and Development, the manufacturer of guselkumab.\nIn the multi-center trial, 293 adult patients with moderate-to-severe psoriasis (defined as covering 10 percent or more of the body) were randomly assigned to receive varying doses of one of the two drugs or a placebo over 52 weeks.\nAn ongoing phase III trial is continuing to test the safety and efficacy of guselkumab as a psoriasis treatment.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is fairly clear in this regard, reporting that 81 percent of patients taking a 200-milligram dose of guselkumab reported \u201cminimal\u201d or no psoriasis symptoms after 40 weeks of treatment, compared to 49 percent of patients taking adalimumab. The release doesn\u2019t note that patients taking 200-mg doses of\u00a0guselkumab did only slightly better than patients taking a 100-mg dose, and that the 100-mg dose fared slightly better at various points during the first 40 weeks of treatment. But that\u2019s a level of detail that perhaps we can\u2019t expect.\nThe release would have been better if it specifically noted that further study will be needed in order to find out if the observed benefits last longer than a year. The release also could have noted that the patients in this study were overwhelmingly white (91%) and male (71%), so it remains to be seen if a more diverse patient population would get similar benefits.", "answer": 1}, {"article": "Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors.\nDr. Austen and colleagues conclude, \"Chronic pain questionnaires such as the PSEQ add to our understanding of functional outcome after surgery and put pain in migraine surgery patients in perspective to better-known pain conditions.\"\n\"The results also show that migraine surgery can lead to dramatic improvements in functioning and coping ability, even in patients who are very disabled before surgery.\"\nOne year after migraine surgery, the patients had a very large percent improvement in average PSEQ score: on average, 112 percent higher than baseline.\nThat's in contrast to patients with musculoskeletal problems such as low back pain, in whom low PSEQ scores predict poor treatment outcomes.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The description of benefits of this research is a bit cloudy, since it seemed to have two endpoints: first, the study attempted to quantify the extent of disability in migraine patients by using the\u00a0Pain Self-Efficacy Questionnaire (PSEQ). Second, it looked to see if PSEQ numbers improved following migraine surgery. The release says that the study found that after the migraine surgery, patients improved an average of 112% over their baseline PSEQ score. However, as we have pointed out on numerous occasions, these types of statistics often don\u2019t tell us much. We don\u2019t know if this means that migraine patients\u2019 self-efficacy went from \u201cbad\u201d to \u201cgreat,\u201d or just from \u201cterrible\u201d to \u201cless terrible.\u201d Did this improvement mean that patients were able to go back to work, or that they were able to get out of bed? Without concrete numbers, it is hard to tell.", "answer": 0}, {"article": "Several companies, including one owned by Koniver, make herbal combinations.\nGiven these two rejections, it could be a while before another pharmaceutical company decides to sink money into developing a new drug for women with sexual problems.\n(CNN) -- Losing interest in sex would be unfortunate for most people, but for Linda Poelzl it was a professional hazard.\nShocked and not quite sure what to do, she turned to medical doctors, and found there wasn't much they could offer, as there's no prescription medicine like Viagra to help a woman when her sex life gets stuck.\nOne of Blakeway's patients wrote an article for the magazine, Cookie, about her experience with acupuncture for her flagging sex life.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We can understand why this story was a bit short on data showing the benefits of these\u00a0treatments, since there really aren\u2019t\u00a0any. But that\u2019s no excuse to fill the void with\u00a0rosy anecdotes from patients and alternative medicine providers.\u00a0The story could have earned a satisfactory by seeking out a\u00a0skeptical perspective\u00a0and spending a bit more time on the\u00a0potential downsides of these approaches. Unfortunately, it didn\u2019t. \u00a0\u00a0", "answer": 0}, {"article": "Whitcomb, whose research on the determinants of fertility and pregnancy outcomes usually involves studying biomarkers at the molecular level, adds, \"Lifestyle is definitely relevant to these outcomes because it can have an effect at the molecular level.\nWhitcomb says, \"We don't know what to make of the finding that high intensity physical activity may have different biological effects than walking, but our study doesn't offer enough detail to get at why vigorous activity would work differently than other levels.\"\nAmong a number of cautions the researchers point to in this work is that physical activity is related to other behaviors and lifestyle factors, and women who are more physically active may be different from women who are less active in many ways.\nThe researchers also note that the overall generalizability of this work is limited because the study population may not be representative of the general population with regard to fecundability, and exercise habits may differ in women with prior miscarriage compared to those without.\nModerate activity, sitting and other activity categories were not associated with fecundability overall or in BMI-stratified analyses, they add.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release mentions two benefits of physical activity with regards to \u201cfecundability\u201d (the ability to become pregnant):\nSo the study put into context the amount of physical activity associated with an increase in fertility rates but it didn\u2019t tell us how much more likely vigorous walkers were to conceive compared to those who didn\u2019t walk, or those who walked only a little.", "answer": 0}, {"article": "An experimental Alzheimer\u2019s drug showed positive results and raised hopes anew that pharmaceutical companies were moving closer to a medicine that could finally disrupt the disease\u2019s memory-robbing course, though a string of failures shadow the efforts.\n\nAlzheimer\u2019s has proved an especially tough drug target. Approved therapies only relieve symptoms temporarily, and one experimental treatment after another promising to stymie the neurodegeneration has ultimately failed to work. Some pharmaceutical companies, after costly failures,...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There was no mention of the size of the benefit observed.\nA STAT news story on this same trial noted that the study failed to meet its primary endpoint, which means the trial failed. As in many past Alzheimer\u2019s drug trials, the company found positive results only in a sub-group of patients. As we\u2019ve written previously, in larger subsequent studies, the drugs have all failed.", "answer": 0}, {"article": "of fat lost over 30 days.\n\"Capsimax is supported by multiple studies with findings showing safety, increased lipolysis and satiety and improved healthy body composition.\nNow, with the publication of the MR Study, there is yet another demonstrated benefit of Capsimax as a natural, stimulant-free approach to weight management, sports nutrition and a healthy lifestyle as we age.\"\n\"Since Capsimax is made using a proprietary beadleting technology, OmniBead, which coats the capsicum extract, releasing it only when it reaches the intestines where it is absorbed without discomfort, we were able to deliver beneficial levels of capsaicinoids to our subjects, which made the MR Study possible.\"\nThe MR Study was a placebo-controlled, crossover open label study with 40 healthy adults examining the effects of either 2 mg capsaicinoids from 100 mg of Capsimax or placebo on resting energy expenditure, heart rate and blood pressure.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release claims that the supplement would increase a person\u2019s metabolic rate which would be equivalent to burning an additional 116 calories a day. The release further suggests that this could translate into 1 pound of fat loss monthly.\u00a0But it\u2019s important to note that as weight is lost, the metabolic rate decreases. What starts as 1 pound per month, regardless of the method used to lose weight, the metabolic rate would decrease with time and not remain linear. That should have been noted in the release.\nMore importantly, perhaps, the study lasted just two weeks. Participants received the active ingredient for one week and then crossed over to placebo. That\u2019s a very brief period of time from which to draw conclusions about benefit.", "answer": 0}, {"article": "\"Daniel's obstruction was both at the level of the soft palate and at the back of the tongue,\" Thaler says.\nAnd even then, success rates aren't high; they're effective only 20 to 30 percent of the time.\nSheiner is one of only about a half-dozen patients to have this robotic surgery for apnea.\nA sleep study confirmed Sheiner had one of the worst cases of apnea his doctors had ever seen.\nThaler was starting to perform it on sleep apnea patients, to remove tonsils and excess tissue.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Mixed bag but we\u2019ll give the story the benefit of the doubt.\nIt said the CPAP \u201cworks for about half who try it\u201d \u2013 but we wish it had provided a source for that info.\nIt said surgery (apparently referring to non-robotic surgery) is effective only 20-30%\u00a0of the time.\nAnd it said that maxillomandibular advancement is effective more than 90 percent of the time.\nWe don\u2019t really know anything about the harms or benefits of the robotic surgery. The story could be more explicit about that.", "answer": 1}, {"article": "\u201cAnd it might be of some help.\u201d\nThat study\u2019s lead author, Dr. Ingrid Helland of Oslo University Hospital, said that perhaps the benefit shown at age 4 existed at 7 but was difficult to identify amid other developmental factors.\nBut the new study, which mainly assessed full-term babies, found no cognitive difference at 18 months whether mothers received DHA supplements or placebos.\nAnd the new study showed small reductions in postpartum depression in women with histories or high risk of depression.\nThe lead researcher, Dr. Maria Makrides of the University of Adelaide in Australia, said this suggested that full-term babies already get enough DHA in the womb, and that \u201cthere\u2019s no extra boost\u201d from getting more.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "On the \"smarter babies\"\u00a0issue, the story reported \"no cognitive difference at 18 months whether mothers received DHA supplements or placebos.\"\u00a0Perhaps that\u2019s sufficient on the one issue.\u00a0\nBut then it also reported \"the new study showed small reductions in postpartum depression in women with histories or high risk of depression.\"\u00a0 What does \"small reductions\" mean?\u00a0 Did it make much of a difference in women\u2019s lives? \u00a0\nAnd which issue mattered more to women \u2013\u00a0\"smarter babies\" or postpartum depression?\u00a0", "answer": 0}, {"article": "\"Nobody wants to sedate a healthy infant,\" says Dawson.\nWiznitzer \u2013 a pediatric neurologist at Rainbow Babies & Children's Hospital in Cleveland, Ohio \u2013 notes that what the study can't tell us is what the differences in brain activity between the two groups of babies actually mean.\nDoctors and scientists not connected to the study are intrigued by the results but caution that this is very early research and not something concerned parents can be looking for as a screening tool for their babies any time soon.\nHe said that, judging by the differences in brain activity, he and his colleagues could detect which babies were in the high-risk group.\nThe EEG technique is much easier to use because the baby can be awake and moving and wiggling around, says Dr. Geraldine Dawson, chief science officer for the advocacy group Autism Speaks, which partially funded this research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Nowhere does the story address the significance of this:\u00a0 that the main benefit of this test appears to be that it detected with 80% accuracy during a very small timeframe that a child had an older sibling with autism. This means that the study correctly identified most of the time a risk factor that was already known to the parents of the chlid and to the researchers. So, in effect, the study had no actual benefit for the kids or the parents. At least the HealthDay story paraphrased one independent expert who noted that\u00a0 \u201cthe study predicted who was at high risk of autism, but it\u2019s unknown if those babies actually went on to develop autism\u201d. This seems like a giant hole that should have been explored.", "answer": 0}, {"article": "It's the first study to specifically examine...\nNow, it may be good for the brain as well.\nNow, it may be good for the brain as well.\nWe've long known that the Mediterranean diet is good for the heart.\nWe've long known that the Mediterranean diet is good for the heart.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "When you find this story online on WSJ.com, it carries the banner:\u00a0 \u201cThe Diet That Saves The Brain.\u201d\nThere isn\u2019t any discussion in the body of the story to back up that bold claim.\nWe don\u2019t blame the reporter for this but someone at WSJ has to take responsibility for this hype.\nWe\u2019ll also add this to our wish list: an explanation that higher \u201cwhite-matter volume burden\u201d is a surrogate measure of health \u2014 i.e. it does not necessarily translate to more brain damage. These white spots are often found in normal people and might not mean anything. The differences the researchers found were statistically significant, but there\u2019s no attempt to sort out whether the changes observed are clinically meaningful.\n\u00a0", "answer": 0}, {"article": "Even today, in much of the developing world, people exercise through activities such as farming and fetching water that are necessary for survival.\nWhat is a bit surprising about this chart is that running faster or farther doesn\u2019t seem to reduce death rates any more than running slowly and, in fact, in both cases is slightly worse.\nNothing in the data suggests that running more \u2014 farther, or faster \u2014 will do more to lower your risk of death.\nWe may tend to attribute the health of this group to their running habits.\nEven if we dismiss the possibility that running harder is worse, it is probably useful to note that running harder or farther doesn\u2019t seem to be better.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The sole benefit discussed in the story is percent reduction in risk of death in a given year. The story explains this clearly, so it gets a satisfactory. It would have been more interesting \u2014 but significantly more complicated \u2014 if it had discussed the ways in which cardiovascular exercise reduces the risk of death. Which health risks are addressed here? Heart disease? Hypertension? Also, the story doesn\u2019t look at some of the other benefits of running or jogging, such as possible quality of life benefits. Most runners, for example, actually enjoy running. Still, that wasn\u2019t the focal point of the story.", "answer": 1}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only presents the relative risk reduction of making the switch from tamoxifen to anastrozole. No absolute benefit provided.", "answer": 0}, {"article": "(H\u00f6gqvist Tabor says it's tricky because it depends on the individual, and can range from a few beats per minute to 10 beats per minute.)\nIf you\u2019re curious exactly what kind of increase in resting heart rate you should look out for, Clue hasn\u2019t revealed that information yet, but says it will publish that and other data in a paper later.\nBut as Clue\u2019s and Ava\u2019s fertility research indicates, increasingly sophisticated sensors and algorithms could significantly open up wearables\u2019 capabilities \u2014 and make them that much more able to tackle bigger, complicated health issues.\nRather, it was exploring whether the device could reliably track an already-known occurrence: how a woman\u2019s resting heart rate changes when she\u2019s experiencing rising hormonal levels linked to ovulation.\nThat\u2019s because resting heart rate data can be captured at its purest when a person is asleep and not moving.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit here would presumably be that women wishing to become pregnant would be more likely to become pregnant more quickly if they were using a Fitbit to track their ovulation cycles. To our knowledge, no study has been done to determine whether that\u2019s the case \u2014 and the story doesn\u2019t address this.\nWhat\u2019s more, it\u2019s not clear whether the 5 women studied are part of the 90% of childbearing-age women who would be able to become pregnant without resorting to this device.", "answer": 0}, {"article": "Alcohol is known to activate some of the same receptors in the brain that opioids do, and studies find that by tempering the pleasure from alcohol, naltrexone can help people drink less.\nNaltrexone is certainly not a cure-all, researchers say.\nBut there's good evidence that the combination of counseling and drugs such as naltrexone can help people cut back on drinking, or move toward abstinence.\n\"I use these medications as an adjunct to therapy, and group [sessions] and 12-step meetings\" says Dr. Jeffrey Hsu, a psychiatrist at Johns Hopkins University who is certified in addiction medicine.\nMany physicians are \"unaware that there are medications to treat alcohol use disorders,\" says Koob.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story talks about a meta-analysis that looked at a large grouping of studies on the effectiveness of naltrexone and another drug, and it mentions general take-aways from the analysis. But, we\u2019re not given much\u00a0on what the evidence showed, such as how many people are helped by this drug, and to what extent they\u2019re helped.\nLooking at the meta-analysis cited in the story, one might be disappointed to learn that 9 people would need to be treated with naltrexone to prevent one additional person from returning to heavy drinking. The effects are modest, but real.", "answer": 0}, {"article": "Bushra Imtiaz, Heidi Taipale, Antti Tanskanen, Miia Tiihonen, Miia Kivipelto, Anna-Mari Heikkinen, Jari Tiihonen, Hilkka Soininen, Sirpa Hartikainen, Anna-Maija Tolppanen.\nThe study also showed that the postmenopausal removal of ovaries, uterus or both was not significantly linked to the risk of Alzheimer's disease, irrespective of the indication of surgery or hormone therapy use.\nPostmenopausal estrogen-based hormone therapy lasting longer than ten years was associated with a decreased risk of Alzheimer's disease in a large study carried out at the University of Eastern Finland.\nHowever, studies on humans have yielded inconsistent results on the association between postmenopausal estrogen-based hormone replacement therapy and dementia risk.\nHormonal therapy may protect cognition if started at the onset of menopause\n\nIn the present study, long-term use of hormonal replacement therapy was associated with a better performance in certain cognitive domains - global cognition and episodic memory - and a lower risk of Alzheimer's disease.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides no numbers to back up the claims about the benefits of hormone replacement therapy.\u00a0 It references two studies, a case control study (one that starts with an outcome and then then traces back to investigate what the patient was exposed to) of 230,000 women and a prospective cohort study (one that follows people over time to determine how specific factors affect rates of a specific outcome) of about 8,195\u00a0women, both of which find very small decreases in Alzheimer\u2019s disease only in those women who had been taking estrogens for more\u00a0than 10 years. The decrease is barely significant in both case and could be due to unrelated variables\u00a0that are not discussed in the release.\nThe large case control study published in\u00a0Maturitas  concludes: \u201cOur findings do not suggest HT is an important determinant of AD risk.\u201d\nThe prospective cohort study published in Neurology concludes: \u201cOur results do not provide strong evidence for a protective association between postmenopausal HT use and AD or dementia, although we observed a reduced AD risk among those with long-term self-reported HT use.\u201d", "answer": 0}, {"article": "2.\nBut there is a menu of options beyond colonoscopies \u2014 and they\u2019re not necessarily any better or worse, according to the USPSTF\u2019s recently finalized updated recommendations for screening among average-risk adults.\nBut that lack of trial data is why the Canadian Task Force on Preventive Health Care earlier this year recommended against using colonoscopy as a first-line screening method.\nOf the two, Richard Wender, a physician and chief cancer control officer of the American Cancer Society, said the FIT is preferable, both because it\u2019s more accurate and because it requires only one poop sample and no changes in diet.\nIncluded on the list are two cheap, at-home poop tests intended to be done annually: the guaiac-based fecal occult blood test (gFOBT) and a more sensitive test called the fecal immunochemical test, or FIT.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story focuses on the\u00a0available methods of colorectal screening, comparing them based on available data, and points out that the two at-home screening kits are comparably effective to the two invasive procedures: sigmoidoscopy and colonoscopy.\u00a0 One of the at-home tests \u2014 the FIT, or fecal immunochemical test \u2014 when used, is estimated to prevent 20-23 deaths per thousand people screened, while estimates among those using colonoscopy suggest 22-24 deaths are prevented per thousand people screened.\u00a0 The story is clear in saying that there has been no head-to-head comparative study pitting the techniques against each other.", "answer": 1}, {"article": "Tissue that dies in the brain from stroke is absorbed, leaving a cavity, devoid of blood vessels, neurons or axons, the thin nerve fibers that project from neurons.\nThe mice with new neurons showed improved motor behavior, though the exact mechanism wasn't clear.\n\"This study indicated that new brain tissue can be regenerated in what was previously just an inactive brain scar after stroke.\"\nThis research was designed to explore recovery in acute stroke, or the period immediately following stroke - in mice, that is five days; in humans, that is two months.\nAfter 16 weeks, stroke cavities in mice contained regenerated brain tissue, including new neural networks - a result that had not been seen before.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release mentions:\n\u201cAfter 16 weeks, stroke cavities in mice contained regenerated brain tissue, including new neural networks \u2014 a result that had not been seen before. The mice with new neurons showed improved motor behavior, though the exact mechanism wasn\u2019t clear.\u201d\nAlthough we appreciate the inclusion of the caveat that the gel\u2019s mechanism of action is unclear, we\u2019re not given any sense of just how much of an improvement in the motor skills of the mice was observed. And can it actually be attributed to the new growth?", "answer": 0}, {"article": "\u201cPatients readmitted after surgery almost always have a postoperative complication, either medical or surgical,\u201d Drs.\nDoctors who did not perform the surgery won\u2019t have that context, which may explain part of the survival benefit of returning to the original hospital, he said.\nIt might be harder for patients to get appropriate care at the other hospitals, where they don\u2019t have a pre-existing relationship with a surgeon, and so treatment might be delayed, Dimick and Miller wrote.\n\u201cA lot of readmissions are patients who have time to be transferred or triaged, if they are not bleeding to death or having a heart attack,\u201d he said.\nPatients should try to stay in the immediate vicinity of their surgical hospital for at least a week, Brooke said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes the authors\u2019 finding of a 26 percent drop in 90-day mortality.\nBut it fails to mention that the authors\u2019 instrumental variable analysis \u2014 intended to reduce confounding \u2014 yielded just an 8 percent drop in mortality risk for those patients who were readmitted to the original hospital. Though less dramatic, it is still a potentially important finding.", "answer": 0}, {"article": "To learn more about ASTRO, visit www.astro.org.\nToxicity rates were extremely low, with essentially no major complications encountered in this initial group of 58 patients.\u201d\n\nWhile findings highlight the potential tolerability of a single fraction of HDR brachytherapy for localized prostate cancer, the article also emphasizes the need for additional follow-up to compare long-term cancer control rates with conventional treatment approaches, which generally administer larger cumulative doses than the 19 Gy dose used in this trial.\nIn this study, researchers found that patients who received a single fraction of 19 Gy HDR brachytherapy experienced similar clinical outcomes as with LDR brachytherapy, but with the convenience of a single visit.\n\u201cGiving the entire dose in a single treatment theoretically could have had a greater negative impact on the normal tissues in close proximity to the prostate\u2014meaning the bladder, urethra and rectum\u2014but this was not found to be the case.\nAt an average of nearly three years following treatment, cancer control rates were favorable and the toxicity profile was highly favorable.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The main benefit focused on a vaguely described \u201cbiochemical progression,\u201d which means that there was some evidence that prostate-specific antigen (PSA) levels increased.\u00a0 PSA is a protein produced by both cancerous and noncancerous tissue in the prostate. Determining PSA progression is more complicated following radiation because it takes time for the PSA level to stabilize (unlike following surgery to remove the prostate) before you can determine whether the PSA is rising. \u00a0Biochemical progression is also a surrogate measure and does not imply that the cancer is\u2013or will\u2013clinically progress.\nThe researchers did acknowledge that the actual benefits are unknown, saying that \u201cas the follow-up interval lengthens, 19 Gy dosing in a single fraction may or may not be sufficient to result in cure rates comparable to historical standards.\u201d", "answer": 1}, {"article": "The requested document is forbidden. Please try your operation again .", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story clearly mentioned the reduction in hospitalization time, need for blood transfusions, and internal scarring were benefits of the procedure though it did not provide quantitative details. \u00a0In addition,\u00a0the story did provide quantitative data on the 30-day risk of\u00a0\u00a0sexual and urinary function complications.", "answer": 1}, {"article": "For more information on bisphosphonates, visit U.S. Food and Drug Administration.\n\"There is no overall difference in recurrence rates or survival rates [between patients who got the bone drug and those who did not], except in older patients, defined as more than five years after menopause.\"\nWhen Coleman's team looked at subgroups, however, they found the benefit among older women, a finding they say warrants more study.\nAnderson Cancer Center, was not involved in the study but put it in perspective.\nSaid Coleman: \"Zoledronic acid cannot be routinely recommended for prevention of cancer returning, but it remains a very good drug for patients where the cancer has already spread to the bone.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article accurately framed the only potential benefit documented by the AZURE study: that it might provide a recurrence and survival advantage among a subgroup of post-menopausal women\u2026 and that this results is something to be studied further. ", "answer": 1}, {"article": "Collaborating with Dr. Pisco were Marisa Duarte, M.D., Tiago Bilhim, M.D., Ph.D., Jorge Branco, M.D., Ph.D., Fernando Cirurgi\u00e3o, M.D., Marcela Forjaz, M.D., L\u00facia Fernandes, M.D., Jos\u00e9 Pereira, M.D., Nuno Costa, M.D., Joana B. M. Pisco, M.D., and Ant\u00f3nio G. Oliveira, M.D., Ph.D.\n\nRadiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc. (http://pubs. )\nFor the new study, Dr. Pisco and colleagues assessed pregnancy rates in 359 women with uterine fibroids who were unable to conceive and who underwent either conventional or partial UFE.\nDr. Pisco suggested that UFE may become the first-line treatment for women with fibroids who wish to conceive, particularly for those with numerous or very large fibroids.\nThe procedures had a clinical success rate of approximately 79 percent for fibroid-related symptoms.\nHowever, myomectomy is not always possible or effective and can result in major complications including hysterectomy, according to study co-author Jo\u00e3o Martins Pisco, M.D., Ph.D., from the Department of Interventional Radiology at Saint Louis Hospital in Lisbon, Portugal.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does a good job providing absolute numbers in describing the trial results:\nAfter an average follow-up of almost six years, 149 of the 359 women, or 41.5 percent, had become pregnant one or more times, and 131 gave birth to a total of 150 babies. It was the first pregnancy for more than 85 percent of the women who gave birth.\nThe procedures had a clinical success rate of approximately 79 percent for fibroid-related symptoms.\nHowever, to understand the actual benefits, we\u2019d need to know more about the women who were treated with UAE.\u00a0 This study enrolled women who had fibroids and/or\u00a0adenomyosis (a different condition)\u00a0that apparently caused symptoms, and had not become pregnant after a year of unprotected sex; it offered them the option of UAE, even though its fertility effects were not well understood at the time of the study. There is no information on whether these women had fibroids as the cause of their failure to conceive after a year.\u00a0\u00a0Thus, the pregnancy rates achieved after UAE are difficult to interpret.\nThe release would also have been more informative had it broken down pregnancy rates by full or partial UAE.", "answer": 1}, {"article": "Also, mice that received the drug had slower blood clot formation than untreated mice, but the treated mice did not bleed longer than untreated mice.\nThe serpent-medicine connection isn't new, one cardiologist noted, since venom typically kills by disrupting the blood's clotting mechanisms.\nThe snake's venom contains a protein called trowaglerix, the researchers explained.\nStill, experiments in animals often don't translate to success in humans, so further research is needed.\nWhen mixed with blood, the new compound prevented blood cells called platelets from clotting.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes benefits in qualitative terms, \u201cthat mice who received the compound had slower blood clot formation than untreated mice.\u201d However, it provides no specifics on how this was measured or how this might or might not translate to humans. While there was one cautionary statement near the end of the story about the limitations of mouse studies, the story\u2019s headline and first paragraph emphasized claims that the compound might work for \u201chuman heart patients.\u201d That\u2019s unbalanced.", "answer": 0}, {"article": "\u201cIt\u2019s easier to pop a pill,\u201d Dr. Altman said.\nBut a number of new controlled trials and meta-analyses like Dr. Moore\u2019s suggest that topical Nsaids are as effective as their oral counterparts for treating osteoarthritis in the knee and hand as well as musculoskeletal injuries like soreness and tendinitis.\n\u201cSuddenly there were tons of folks who thought topical Nsaids were a good idea.\u201d\n\nDr. Roy D. Altman, a rheumatology professor at the David Geffen School of Medicine at the University of California, Los Angeles, said the drugs might be especially helpful for \u201cthe elderly or those taking multiple medications, who were not getting treated but who can now use topical Nsaids and get some benefit.\u201d\n\nAnother leading pain researcher, Dr. Roger Chou, an associate professor of medicine at Oregon Health and Science University, noted that the skin creams delivered \u201cvery high joint concentrations of the topical Nsaid, higher than with standard oral doses, with very low blood levels\u201d \u2014 less than 5 percent of those found with oral Nsaids.\nStill, in one of the only head-to-head trials between topical and oral Nsaids, subjects taking the pills had a much higher rate of indigestion, diarrhea, abdominal pain, abnormal liver tests and anemia than those using the creams.\nIn clinical trials, the skin creams are linked to a higher rate of redness, irritation and rash.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nAlthough the story explains the available evidence comparing topical NSAIDs to oral pain relievers, highlights the limited number of direct comparisons, and carefully states the general consensus of experts, all of this solid reporting is undermined by a focus on personal anecdotal evidence over quantifiable benefits. Indeed, the reporter claims one medication provided immediate relief, a statement at odds with clinical trials that conclude that it usually takes hours for patients to feel the pain-relief effects of topical NSAIDs. ", "answer": 0}, {"article": "All rights reserved.\nApproval as an initial treatment likely would boost that sharply.\nIf approved, Tykerb \u2013 known as Tyverb in Europe \u2013 will be used along with another drug that prevents hormones from making cancer cells multiply.\nIt targets cancer cells more than healthy ones, Roychowdhury said.\nThe British pharmaceutical company's Tykerb was approved here two years ago as part of a treatment for most women with advanced breast cancer that wasn't stopped after chemotherapy and other drugs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There was no quantification of benefit in the story \u2013 strange when the entire story is about the drugmaker seeking new approval for the drug.\u00a0 Upon what evidence is that request based? ", "answer": 0}, {"article": "CNN Films Presents:\" Glen Campbell ...\nMuch more research is needed\n\nThe study was not big enough to answer some important questions, such as whether patients taking resveratrol actually had lower levels of amyloid-beta plaques in their brain, and most importantly, whether they experienced less decline in their mental faculties.\nIf resveratrol does pan out in further research, it may add to the medications that are currently available, such as Aricept and Exelon, which slow, but do not halt, progression of the disease, Hendrix said.\nAnd anecdotally, patients who took resveratrol told the researchers that they felt like they were maintaining their mental ability.\nThe main goal of the current study, which included 119 patients, was to find out whether high doses of resveratrol could be safe.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The key finding of the study is that high doses of resveratrol can have an effect on the production of amyloid-beta40, a biomarker that declines in spinal fluid as Alzheimer\u2019s disease advances. The story describes these effects, but doesn\u2019t provide specifics. Similarly, the story mentions that some patients \u201chad slight improvements in their ability to carry out a daily task,\u201d but \u2014 again \u2014 doesn\u2019t give readers any way to quantify what \u201cslight improvements\u201d means (more on this under \u201cQuality of Evidence\u201d).\nAnother problem is the statement that resveratrol \u201cmay actually have benefit in slowing progression of this disease,\u201d which is not consistent with the findings of the journal article. In fact, the journal article specifically states that\u00a0\u201cThe altered biomarker trajectories must be interpreted\u00a0with caution. Although they suggest CNS effects, they do not indicate benefit.\u201d\nWhile we have to rate the story Not Satisfactory for those concerns, the story does a good job of noting that the real goal of the study was to determine whether high doses of resveratrol are safe, so that more research can be done. That\u2019s an important point, and one worth making. Similarly, the story makes clear that: \u201cThe study was not big enough to answer some important questions, such as whether patients taking resveratrol actually had lower levels of amyloid-beta plaques in their brain, and most importantly, whether they experienced less decline in their mental faculties.\u201d That\u2019s crucial, and the story is clear on the point.", "answer": 0}, {"article": "Most recently, the F.D.A.\nIf the vaccine helps smokers quit, Dr. Reus said, a central question will be whether booster shots could help prevent relapse.\nBecause the compound is too big to cross the blood-brain barrier, the vaccine is expected to diminish or eliminate the pleasure associated with puffing a cigarette.\nThomas E. Rathjen, a spokesman for Nabi Biopharmaceuticals, said the results of the study should be available sometime next year.\nAn effective vaccine could play a major role in reducing smoking around the world, said Dr. Vocci, who estimated that current rates of smoking would lead to one billion deaths in the 21st century.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story claims that this vaccine will help smokers quit by producing antibodies that attach to nicotine molecules and prevent them from reaching the brain, thus reducing the pleasure associated with smoking. The story notes that \u201cresearchers report high rates of quitting in early studies\u201d, but there is no data provided to support this statement. It is not enough to say that there is excitement about the vaccine\u2019s approach. Some data are needed to judge whether excitement is warranted. The drug company website provides some preliminary short term results from former trials, and there was a 33% 30-day abstinence rate for active vaccine versus 9% for placebo, but the duration and size of this trial were not mentioned. Would the article\u2019s optimism be dampened by inclusion of this rate?", "answer": 0}, {"article": "There are three types of omega-3 fatty acids: a-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).\nProf. David Ma has discovered that marine-based omega-3s are eight times more effective at inhibiting tumour development and growth.\nPublished in the Journal of Nutritional Biochemistry, the study involved feeding the different types of omega-3s to mice with a highly aggressive form of human breast cancer called HER-2.\nBased on the doses given in the study, Ma said humans should consume two to three servings of fish a week to have the same effect.\nOmega-3s from fish pack a stronger punch than flaxseed and other oils when it comes to cancer prevention, according to a first-ever University of Guelph study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There aren\u2019t benefits to quantify, only results, but the news release reports even those in confusing fashion. It states in the second paragraph that \u201cmarine-based omega-3s are eight times more effective at inhibiting tumor development and growth\u201d without giving any sort of baseline for what\u2019s being measured. Further down it states that \u201cexposure to marine-based omega-3s reduced the size of the tumors by 60 to 70 percent and the number of tumors by 30 percent\u201d without saying how much omega-3s the mice consumed or giving the sizes or frequency of tumors. Also, there\u2019s no data on how many mice died.\nThe Cochrane Collaboration (a non-profit that researches and reports on evidence-based medicine) looked at many different human studies and says that so far there is no proof fish oil can treat or prevent cancer-related weight loss, depression, dementia and many other conditions.", "answer": 0}, {"article": "\"It's an important step along the way,\" Dr. Hadley said.\nPart of the reason for the study, Dr. Ravussin said, was to find out whether people could stand calorie restriction.\nAmong the main findings of Dr. Ravussin's study was that calorie restriction led to decreases in insulin levels and body temperature.\nBut Dr. Ravussin and Dr. Hadley cautioned that the study was preliminary, and that it did not prove that calorie restriction could make people healthier or add years to their lives.\nHe called the results \"striking,\" even though the experiment was only a pilot study for a two-year trial of calorie restriction due to begin in the fall.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t quantify the suggested benefits (decreased insulin level, decreased body temperature, drop in thyroid hormones, and decline in DNA damage) gained by the study participants. And the study didn\u2019t mention the parameters that failed to demonstrate change during the study (protein carbonyl, glucose, and dehydroepiandroestrone sulfate (DHEAS).", "answer": 0}, {"article": "Doctors usually try to start people off with lifestyle treatment, such as weight loss, drinking less caffeine and alcohol, and avoiding lifting heavy objects.\nIt\u2019s good news for women with severe urge incontinence, who can choose between treatments based on preference, said Dr. Cindy Amundsen of Duke University, who led the study.\nThe Botox injections freed 20 percent of the women in the study of incontinence, compared to 4 percent who had a nerve stimulator implant, Amundesen and colleagues reported in the Journal of the American Medical Association.\nThe women in the study had to suffer at least six episodes of incontinence over three days.\n\u201cForty-six percent in the onabotulinumtoxinA (Botox) group and 26 percent in the sacral neuromodulation group had at least a 75 percent reduction in the number of episodes of urgency incontinence,\u201d they added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are stated as such:\nThe Botox injections freed 20 percent of the women in the study of incontinence, compared to 4 percent who had a nerve stimulator implant, Amundesen and colleagues reported in the Journal of the American Medical Association.\n\u201cForty-six percent in the onabotulinumtoxinA (Botox) group and 26 percent in the sacral neuromodulation group had at least a 75 percent reduction in the number of episodes of urgency incontinence,\u201d they added.\nand\nOn average, both treatments cut the number of \u201caccidents\u201d \u2013 Botox by almost four times a day and the nerve stimulator by about three times a day.\nThis is sufficient for a Satisfactory rating on this criterion. We would have liked to have seen more discussion about actual improvements (perceived and otherwise) to patient quality of life. The closing line of the study brings this into question, i.e. how the work is of \u201cuncertain clinical importance,\u201d and good interview questions with both a study author and independent expert source could have greatly clarified the issue.", "answer": 1}, {"article": "Drs.\nBupropion should be considered the first-line drug of choice for people who are overweight or obese, Dr. Simon said.\nSo those who took bupropion ended up weighing 7 pounds less than did those on fluoxetine.\nPrior research on antidepressants and weight change was limited to one year or shorter.\nSo for up to two years the new study followed more than 5,000 Group Health patients who started taking an antidepressant.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that \u201cAfter two years, nonsmokers lost an average of 2.4 pounds on bupropion\u2013compared with gaining an average of 4.6 pounds on fluoxetine (Prozac). So those who took bupropion ended up weighing 7 pounds less than did those on fluoxetine.\u201d", "answer": 1}, {"article": "While heart disease is the leading cause of death in the United States, according to the Centers for Disease Control and Prevention, blacks have higher rates of cardiovascular disease and death than whites and the disease tends to occur earlier in life.\nParticipants taking 4,000 international units - more than six times the daily 600 IUs the Institute of Medicine currently recommends for most adults and children - received the most benefit, says Dr. Anas Raed, research resident in the MCG Department of Medicine and the study's first author.\nSo researchers looked at baseline and again 16 weeks later in 70 African-Americans ages 13-45 - all of whom had some degree of arterial stiffness - taking varying doses of the vitamin best known for its role in bone health.\nIn what appears to be the first randomized trial of its kind, they found that arterial stiffness was improved by vitamin D supplementation in a dose-response manner in this population, they write in the journal PLOS ONE.\nThe test essentially measures the speed at which the blood is moving, and in this case, fast is not good, Raed says.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release quantifies the benefits in each group with this statement: \u201cTwo thousand IUs decreased stiffness by 2 percent in that timeframe. At 600 IUs, arterial stiffness actually increased slightly \u2013 .1 percent \u2013 and the placebo group experienced a 2.3 percent increase in arterial stiffness over the timeframe.\u201d\nBut we\u2019re concerned that the release did not describe any of the statistical testing results. The 2% decrease seen by the group that got 2,000 units per day was not statistically significant. Nor was there a statistical significance in any group that received smaller doses. A difference was only seen in the group that got the highest dose of 4,000 units per day. That distinction was not made clear.\nFurther, what does a 2% decrease in arterial stiffness mean in terms that would matter to a patient? The 2% decrease in reduced stiffness is a proxy or surrogate marker for a health outcome, but not one that tells us the actual impact on patient health.\nOn the plus side, the release explains that the study consisted of 70 participants, and that those taking the most vitamin D showed the greatest reduction in arterial stiffness \u2014 10.4 percent in 4 months \u2014 but it does not say how many participants that was. The study does make it clear, however. The high-dose group included 18 people.", "answer": 0}, {"article": "According to World Cancer Research Fund International, 84 percent of cervical cancers occur in less developed countries, with the highest rates in Africa, Latin American and the Caribbean.\nThe next step, the researchers report, was to verify that the four-gene test worked using freely circulating DNA from blood and urine, rather than DNA taken directly from cervical tissue.\nUsing methylation as a value to diagnose malignancy, the three genes together showed a 90 percent sensitivity, meaning that their presence was able to predict a true positive cancer sample this percentage of the time.\nTo further improve the accuracy of the test, the investigators added a new gene marker to the test.\nUsing all four genes, the test now had a sensitivity of 90.9 percent and a specificity of 60.9 percent.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We rate this a borderline satisfactory.\u00a0 On the one hand, the release offers numerical summaries of the test\u2019s abilities to both correctly detect cancer (sensitivity) and correctly identify someone who does not have the disease (specificity).\u00a0 But the text does a relatively dense job of explaining how the investigators reached the urine-test stage, creating a narrative that will require a determined reader and could thwart\u00a0someone giving the text a more cursory view.", "answer": 1}, {"article": "When Downing expressed concerns about the drug, she said the doctor blew her off: \"He said, 'What are you worried about?\nCandace's treatment, Downing said, involved a one-size-fits-all approach to mental health that sees medications as a magic pill.\nBy contrast, she said, the multiple screenings that Caroline received carefully evaluated the child as an individual and homed in on the kind of therapy that was best for her.\nThe idea of a psychiatric evaluation sent chills down the spine of Caroline's mother, Mathy Milling Downing, who believed that her younger daughter, Candace, had committed suicide because of an adverse reaction linked to a psychiatric drug -- the antidepressant Zoloft.\nThe screening, unsurprisingly, found that Caroline's emotional problems were linked to her sister's death.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not provide any information about the success rates associated with any of the treatments discussed.\u00a0 A number needed to screen should be available.\u00a0\u00a0 Is it 100 that need to be screened to achieve one additional depression remission?\u00a0 Or what is it? ", "answer": 0}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A couple of problems here. First, the story describes the overall cancer prevention benefit for Avodart\u00a0in relative terms (\u201ca 23% reduction\u201d) but never gives us the absolute numbers. It would have been much more meaningful if the story had told us, as the original study did,\u00a0that\u00a0 \u201c659 of the 3305 men in the dutasteride [Avodart] group (19.9%) and 858 of the 3424 men in the placebo group (25.1%) received a diagnosis of prostate cancer, representing an absolute risk reduction with dutasteride of 5.1 percentage points.\u201d\u00a0(As noted above, even these absolute risk data are somewhat misleading.)\nSecond,\u00a0a Glaxo representative\u00a0makes the reasonable point that although the cancers prevented by Avodart may be slow-growing, many men with\u00a0these kinds of cancers undergo\u00a0invasive surgery that reduces\u00a0their quality of life. To understand the scope of this benefit,\u00a0however, it is important to know just\u00a0how many men with these lower-risk cancers go on to receive surgical treatment, and what kinds of consequences\u00a0they might\u00a0avoid by\u00a0taking the drug.\u00a0Otherwise there\u2019s\u00a0no way to measure this benefit against the\u00a0potential harms of treatment, such as increased risk of aggressive cancer and\u00a0sexual dysfunction. ", "answer": 0}, {"article": "JACC is ranked No.\nThe study and editorial are part of a comprehensive Population Health Promotion issue of the Journal of the American College of Cardiology focusing on issues that broadly impact public health and the prevention of cardiovascular disease and related conditions.\nThe largest positive changes in body fat were seen in the 3-year-old group that received three years of interventions.\nIn an accompanying editorial, Deepak L. Bhatt, M.D., M.P.H., executive director of interventional cardiovascular programs at Brigham and Women's Hospital Heart and Vascular Center and professor of medicine at Harvard Medical School in Boston, said the program is groundbreaking, and follow-up studies to further pinpoint the exact mechanisms by which the program achieved positive effects on young children's health will be vital for implementing the program in other areas and informing the design of future global programs.\nProgram, researchers in Madrid implemented a three-year healthy lifestyle intervention for 3 to 5 year olds that used their school, teachers and families to promote cardiovascular health through healthy diet, increased physical activity, understanding of the human body and managing emotions.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does quantify benefits \u2013 but it leaves readers a bit underwhelmed. The numerical differences shown are rather small for the conclusion that the release trumpets. We would have liked some context to justify the excitement about this study.\nChildren who received intervention scored 5.5 percent higher in \u201cknowledge, attitude and habits\u201d than the controls, after the first year. However, that difference lowered to just 4.9 percent after the third year of intervention. We suspect that quantifying the \u201cknowledge\u201d of a 4-year-old is tricky and perhaps a bit more subjective than a blood test or other study data.\nChildren who received the intervention had obesity rates of 1.1 percent in the group compared to 1.3 percent in the control group. The release should have explained why the authors believe the difference of only 2/10 of a percent qualified as \u201cgroundbreaking.\u201d\nIn addition, we\u2019d note that the release touts reductions in body fat, measured through skinfold measurements, as a positive outcome. But skinfold measurements are a questionable marker of body fat given not only risk of inter-, but intra-operator error in terms of landmarking the exact same skinfold location for repeated measurements.", "answer": 1}, {"article": "\"That's the main natural compound in unroasted coffee, and roasted coffee has much, much less of it than unprocessed coffee,\" Vinson said.\n\"Those studies demonstrated that patients experienced somewhat mild weight loss.\nIn one section, study participants, who were all between the ages of 22 and 26, consumed a capsule filled with 700 milligrams of green coffee extract.\n\"This was indeed a small study,\" acknowledged corresponding study author Joe Vinson, a professor of chemistry at the University of Scranton, in Pennsylvania, but he noted that prior research has been conducted in both France and Japan.\nThe apparent result: Daily consumption of a small amount of green coffee extract translated into a nearly 11 percent drop in body weight, on average.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that the patients lost an average of 17 pounds or 10.5 percent of their bodyweight after 6 months. Ok, but the story also says that the study involved three distinct phases where subjects were taking different doses of the coffee extract or a placebo. Was the weight loss seen only while the subjects were taking the active extract, or did it also occur when patients were taking the placebo pills (indicating that the weight loss was due to some other factor, such as their overall diet or exercise levels)? The story doesn\u2019t tell us. To score a satisfactory here, we\u2019d need to see a more thorough reporting of how much weight was lost during the three trial periods.", "answer": 0}, {"article": "\u201cI\u2019ve been doing clinical trials for 30 years in C.F.\nThe drug also reduced the frequency of disease exacerbations that required treatment with antibiotics.\nDr. Ramsey, a professor of pediatrics at the University of Washington, was briefed on the results by Vertex.\nThe company is awaiting results of a second trial of the drug, this one in younger children.\nShe said other results of the trial were encouraging.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": ".\nThe early results highlighted above, along with other data obtained using MRIdian will be tested in a multi-center, prospective, single-arm clinical trial for inoperable, locally advanced or borderline resectable pancreatic cancer.\nFurther studies, including the planned prospective multi-institutional study referenced in this press release, as well as patient data covering longer periods of time post-treatment, could lead to different or contrary results from those expressed during ASTRO or in the poster presentation.\nThis data highlighted compelling early results using the company's MRIdian system for the treatment of inoperable, locally advanced pancreatic cancer.\nForward looking statements with respect to predicted improved survival described in the poster presentation and video, are based on current expectations from the presented retroactive study and involve inherent risks and uncertainties about the potential health and medical benefits of MR-guided Radiation Therapy for the treatment of patients with locally advanced pancreatic cancer.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides exact information about increased survival rates in the cohorts of individuals treated with the adaptive versus the convention radiotherapy techniques.\n\u201cThe cohort receiving a higher dose demonstrated a near doubling of median overall survival (Kaplan-Meier estimated median overall survival of 27.8 months compared to 14.8 months).\u201d", "answer": 1}, {"article": "?\nTo prove it is effective in reducing hot flashes, the Mayo team needed to demonstrate that it was superior to sham, or placebo, treatment.\nVincent's group recruited 103 women between the ages of 45 and 59 who reported that they had at least five hot flashes per day and were not using any other treatments for them.\nExperts in women's health say they are one of the most common ailments for which women use alternative medicine and that interest in non-hormonal treatments has increased as a result of the WHI findings.\nResearchers knew who was receiving sham treatment, but the women, who completed questionnaires detailing the extent of their hot flashes, did not.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes how many women in the acupuncture and sham treatment groups were still having hot flashes at the end of the active treatment part of the trial. ", "answer": 1}, {"article": "A systematic review of C.B.T.\nIt demonstrated progress \u2014 the nights in which I got only four or five hours of sleep became less common, and, on average, my nights of sleep lengthened by 30 minutes.\nImprovements like mine and those reported in the study bring sleep statistics for those with insomnia quite close to those without it.\nThis further emphasizes the point that many insomniacs aren\u2019t that different from normal sleepers.\nMy experience is consistent with these averages.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story carefully lists several benefits from the Annals study: patients treated with CBT fell asleep almost 20 minutes faster and were awake in the night almost half an hour less and their total time \u201csleeping in bed\u201d was increased by 10 percent.\nWe have only two minor quibbles. One is that the writer compares himself to the study participants, and he may not meet the same criteria as they did.\u00a0\u201cFor me, and many patients, C.B.T. works. And as studies show, it works better than drugs,\u201d he wrote. But the Annals study had \u201cnarrow inclusion criteria\u201d that perhaps deserved some comment.\nThe second is that total sleep time gain is described in relative terms with a figure of 10%. The absolute increase in sleep time was 7 minutes, according to the study.", "answer": 1}, {"article": "PHILADELPHIA - Patients with atrial fibrillation (AF), a rapid irregular heartbeat caused by pooling blood in the heart which can lead to heart failure and stroke, are often treated with an ablation, a minimally invasive procedure used to remove the tissue which causes the pooled blood.\n\"These are patients who were actively seeking, preparing for and are committed to the alternate treatment method, and who are informed about how to diligently and effectively monitor their pulse throughout the day.\"\n\"It is extremely common for patients with AF to seek treatment that does not involve the use of chronic oral anticoagulants therapy, as there are other risks associated with their long term use,\" said co-author Francis E. Marchlinski, MD, FHRS, director of Electrophysiology for the University of Pennsylvania Health System and Richard T. and Angela Clark President's Distinguished Professor in the Perelman School of Medicine at the University of Pennsylvania.\n\"The goal of this study was to find a safe and effected treatment option, and our initial results support 'as-needed' blood thinners and pulse monitoring as the alternative.\"\n\"This kind of approach to anticoagulation therapy requires an open line of communication between the patient and the care team, and calls for a specific type of patient.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We are told that 100 participants were followed for 23 months and of those hundred, 28 \u201cstarted taking the blood thinner at least once for a suspected or detected AF episode, and only 10 patients transitioned back to chronic oral anticoagulation therapy for recurrent AF.\u201d \u00a0What is missing from this is any detail on what kind of stroke or ischemic attack that could have been present in a control group. In other words, we have no idea if this\u00a0is a meaningful result or not. \u00a0Interesting, yes. Meaningful? \u00a0Not so much.\nThe headline claim, \u201cBlood thinners on \u2018as needed\u2019 basis is safe and effective for lowering stroke risk as compared to long-term use,\u201d isn\u2019t borne out by the reported research results.\nTo get credit here, one would need information on what one would have expected if they had not received this treatment. The goal of anticoagulation is to prevent stroke. Would we have expected strokes in this population if it hadn\u2019t been treated this way? While the results are reassuring, the risk of stroke in AF is small and accrues over time.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated that after 28 weeks of treatment, 25 percent had a \"sustained virologic response\" (SVR) and after 48 weeks 55 percent did.\u00a0 \nBut why not use absolute numbers \u2013 how many out of how many?\u00a0 It tends to gloss over the fact that was mentioned but not emphasized \u2013 that this was only in 50 patients.\u00a0\nThere was also no attempt made to explain what a change in virologic response actually meant in peoples\u2019 lives.\nFinally, the story doesn\u2019t challenge the researcher\u2019s use of the term \"cure.\"\u00a0 What does that mean to him? And what does it mean to readers?\u00a0 \n\u00a0", "answer": 0}, {"article": "Recipients were at most seven years older or younger than the donors.\nA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\nGenerally, guidelines classify donors older than 50 as \u201cextended criteria donors,\u201d but shortages have led to using these donors more frequently.\nIn an average follow-up of five years, they found that the rate of unusable donor kidneys and the long-term outcomes of recipients varied little among the first three age groups \u2014 around 18 percent of the organs had to be discarded, and the five-year survival was about 88 percent\nOld age is not necessarily a barrier to kidney donation.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies benefits here:\nIn an average follow-up of five years, they found that the rate of unusable donor kidneys and the long-term outcomes of recipients varied little among the first three age groups \u2014 around 18 percent of the organs had to be discarded, and the five-year survival was about 88 percent. With donors over 80, survival outcomes were similar, but the discard rate increased sharply to 48 percent.\nHowever, the\u00a0story appears to make a jump in correlation about the benefits that isn\u2019t supported by its own facts.\nAt the beginning the story makes this claim: \u201cA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\u201d But the researchers never compared a 79-year-old kidney to a 49-year-old kidney in similar recipients \u2014 which is what many readers may assume the story is talking about. The story later says the researchers only transplanted kidneys at most seven years older than the recipient.", "answer": 1}, {"article": "LONDON (Reuters) - British scientists have discovered a \u201crogue gene\u201d which helps cancer spread around the body and say blocking it with the right kind of drugs could stop many types of the disease in their tracks.\nChantry said in a telephone interview the findings mean drugs could be developed in the next 10 years that could be used to halt the aggressive spread of many forms of cancer, including breast cancer, brain, colon and skin cancer.\nIn tests in the laboratory, the UEA team found that by blocking WWP2, levels of the natural inhibitor protein were boosted and the cancer cells remained dormant.\nIf a drug was developed that deactivated WWP2, he said, conventional therapies such as chemotherapy and radiotherapy could be used on primary tumors with no risk of the disease taking hold elsewhere.\nResearchers from the University of East Anglia said their findings could lead within a decade to the development of new medicines to halt a critical late stage of the disease known as metastasis, when cancer cells spread to other parts of the body.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not attempt to quantify the benefits. It says that \u201clevels of the natural inhibitor protein were boosted and the cancer cells remained dormant.\u201d Did this happen every time the scientists blocked the gene? How many times did they repeat this exercise? Did their actions ever make the cancer worse?", "answer": 0}, {"article": "In 2012, a federally funded panel of experts on preventive care concluded there are more risks than benefits to screening American men for prostate cancer with the PSA test. And in April 2017, the U.S. Preventive Services Task Force dumped the decision squarely into the laps of patients and their doctors. Some men between 55 and 69 years of age might well decide to get their PSA checked, the task force said. After hearing the ledger of pros and cons, however, others in that age bracket might just as reasonably skip the screening test, the panel concluded.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports only the study\u2019s estimate of a relative risk reduction of 25 to 32 percent. This figure is meaningless without reporting the underlying absolute risk of dying from prostate cancer. The American Cancer Society states that \u201cAbout 1 man in 39 will die of prostate cancer.\u201d To put it another way, of every 100 men in the US, fewer than 3 will die of prostate cancer and more than 97 will die of something else. The study\u2019s estimate of relative risk reduction might translate into fewer than 2 men dying of prostate cancer and more than 98 dying of something else. However, since many men are already screened with PSA tests, the actual reduction in deaths is likely to be smaller than that. For a more accurate way to capture the measured benefits, see STAT\u2019s story.", "answer": 0}, {"article": "\"With milk that\u2019s not too hard,\" Wood says, because one could \"eat pizza a couple of times a week.\"\nSome participants have shown they can safely eat milk products up to a year after stopping the therapies, Wood said.\nThis is the first time the sublingual therapy has been studied in terms of its benefit as a precursor to the oral immunotherapy, Wood said.\nIt's not known yet whether children respond better to this kind of treatment than adults, since there have been so few participants in this research.\nBut tree nuts may be harder to treat, Wood said, because tree-nut allergic individuals often have multiple kinds of nuts they can't eat.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported benefits in this way:\nThe results suggested that children who went through a year of sublingual therapy followed by one to two years of oral immunotherapy were less likely to have significant allergic reactions when undergoing the oral immunotherapy. Still, it did not eliminate all symptoms.\nWhy not quantify/specify what terms like these really mean:", "answer": 0}, {"article": "Schizophrenia is a long-term mental health condition that causes a range of psychological symptoms, ranging from changes in behavior through to hallucinations and delusions.\nThe researchers said this was important, since lack of motivation is a common feature of schizophrenia.\nScientists at Cambridge University said tests on a small number of patients who played the game over four weeks found they had improvements in memory and learning.\n\u201cThis proof-of-concept study...demonstrates that the memory game can help where drugs have so far failed.\nThey also improved their scores on the Global Assessment of Functioning (GAF) scale, which doctors use to rate the social, occupational and psychological functioning of adults.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits aren\u2019t quantified at all. The story simply tells us that patients who played the game \u201cmade significantly fewer errors and needed significantly fewer attempts to remember the location of different patterns specific tests.\u201d This is somewhat understandable, since the paper itself offers no specific numbers, and includes a graph that makes it difficult to assign numbers to patient performance. However, one way to address this would have been to ask one of the researchers.\nIt\u2019s\u00a0questionable whether a 7.9 change on the Functioning scale (100 points total) translates into improved functioning in the real world. On the cognitive tasks, pretty much anyone who does cognitive tests (even some with\u00a0dementia) get better over time, whether they are aware they are going testing or not. It\u2019s a practice effect.", "answer": 0}, {"article": "\"There were times when I would yell at myself: 'I can't do this.\nBecause of this, Weiner said, three-dimensional letters and numbers, perhaps made out of plastic or clay, help a dyslexic child grasp the shapes better.\nIt is hard to know who will be able to improve reading skills over time, and how much extra help is necessary.\nThe most important intervention is a direct, explicit teaching of phonics, or how symbols correspond with sounds, Branstetter said.\nOf course, the results of the study are only preliminary.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nWe will give this story a satisfactory rating because it portrays this research as providing information for researchers seeking to understand dyslexia, rather than offering important direct benefits to individuals. However, most of the story is about what it is like to live with dyslexia. These anecdotes have little or nothing to do with the research. The list of celebrities who may have or had dyslexia also seems irrelevant and distracting. Then the story tosses in discussion of a study that looked at correlations between dyslexia and spatial skills; again, unrelated to the topic of the primary study reported here. The jumble of extraneous personal tales and other research muddles the point of the story.", "answer": 1}, {"article": "\u201cI would be with Ava during the day, and then when Jay got home, he would stay with Ava, and I would spend time with Audrey,\u201d she said.\nThat\u2019s a major achievement in a group whose cancer is emboldened by every treatment failure.\nIt seemed an equally promising target that could broaden the therapy\u2019s impact, researchers thought.\nAs it happened, Fry, head of the blood-cancer section in NCI\u2019s pediatric oncology branch, had already launched the world\u2019s first trial using CAR T-cell therapy to focus on CD22.\nBy the time 8-year-old Ava Christianson got to the National Institutes of Health this summer, she had lost several grueling rounds to leukemia and was bracing for the next one.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides a broad overview of multiple trials, rather than spending a lot of time on any specific study. That can be dicey, given variability between trial results. However, the story still manages to offer some real numbers \u2014 and grounds the benefits with qualifiers. For example, in referring to multiple trials in both adults and children, the story says that some trials have reported \u201cremission rates of up to 90 percent.\u201d The story then notes that \u201crates in other trials are considerably lower, and many patients relapse.\u201d\nElsewhere, the story quotes one researcher as saying \u201cThe treatment is great about getting people into remission but not at keeping everyone in remission.\u201d The story then offers some information on one study by the same researcher, stating \u201c39 of 42 patients went into complete remission. By a year, about half had relapsed.\u201d That combination of real numbers, with a sobering qualifier, is important.\nWhat we would have liked to have seen: Along with remission discussion, some\u00a0extra\u00a0assessment of what the research shows on overall survival rates, and how long people on the drug can be expected to live.", "answer": 1}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story just squeaks by on this, but we want to especially compliment the story for pointing out that the benefits are short-lived. While the story does not use a lot of numeric quantification, it does provide important context for how to view the study results.\nHere\u2019s what it says about benefits: \u201cTheir work confirmed that sleep deprivation \u2014 anything from three to four hours of sleep followed by 20 to 21 hours awake to no sleep for 36 straight hours \u2014 is indeed a powerful antidote to depression.\u00a0In the 66 studies they analyzed,\u00a045 percent to 50 percent reported feeling less depressed.\u201d\nBut this is the part that puts a context around that for readers:\n\u201cThat sounds great, but there\u2019s a huge problem: For more than 80 percent of patients, the antidepressant effects are lost as soon as they get a good night\u2019s rest. Repeated exposure to sleep deprivation has had mixed results.\u201d", "answer": 1}, {"article": "For Patients and the General Public:", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t include any statistics on the benefits of the treatments but does make strong pitches on their effectiveness:\n\u201cCompared to standard therapies alone, the drugs tested in the trial substantially reduced the presence of residual disease in the breast tissue and lymph nodes (known as achieving pathological complete response, or \u201cpCR\u201d) when administered before surgery,\u201d according to a co-investigator.\n\u201c\u2026 when added to standard, neoadjuvant chemotherapy, the combination of the molecularly targeted experimental drug veliparib plus carboplatin showed sufficient improvement to meet the pre-specified threshold for \u201cgraduation\u201d from the trial, signifying a high likelihood for success in a modest, confirmatory phase 3 neoadjuvant trial in the triple negative subset. Likewise, the experimental drug neratinib was found to have sufficient improvement in the pCR rate for patients in the HER2-positive/HR-negative subset, that it too was \u201cgraduated\u201d from the I-SPY 2 trial.\u201d\nThis is a close call. These are small, phase 2 trials, and therefore not designed to provide clear data on drug efficacy. And had the release made that point explicitly, perhaps we\u2019d be more inclined to rule this Satisfactory. However, we think that readers deserve to know what \u201csubstantially reduced\u201d and \u201csufficient improvement\u201d refer to, particularly when the researchers are making strong claims about potential efficacy. How many patients benefited? What is meant by \u201chigh likelihood of success\u201d in a future trial? We wished for some numbers to make this clearer.", "answer": 0}, {"article": "They had 68 percent fewer spine fractures and 40 percent fewer hip fractures than the study participants who got dummy shots.\nDenosumab, an injection just under the skin, would have to compete against eight major types of pills and injected medicines, including estrogen and generic and brand-name Fosamax pills, long the market leader.\nA first-of-its-kind osteoporosis drug lowers the risk of bone fractures better than some existing treatments, two studies suggest, and could soon add a more expensive but easier to manage treatment option to the booming market.\nDr. Jacob Warman, an osteoporosis expert at Brooklyn Hospital Center, said denosumab might have potential as an add-on to existing drugs to boost results.\nThe effectiveness of denosumab and existing drugs appears to plateau after two or three years, she added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The relative risk reduction for each of the trials is provided, but the story fails to provide the absolute risk reduction (62% of what?).\u00a0 The writer also mentions that spine bone density loss in the men receiving denosumab was \u201cfar smaller\u201d compared to the placebo group; however, the reader is not given any quantitative data to determine the clinical significance of this.\nIn addition to\u00a0comparing the absolute risk reduction observed in the denosumab group to the placebo group, it would have been helpful to the reader to know what the risk reduction was for approved and potentially more affordable medications.\u00a0 ", "answer": 0}, {"article": "\"Women should recognize that CAD comes with some potential risks,\" Fenton said.\nWhile he calls finding more DCIS with computer-aided detection also ''likely a good thing,\" he acknowledged the debate about the possibility that a very early cancer in an elderly woman may not cause a problem in her lifetime.\nDr. Daniel Kopans, a professor of radiology at Harvard Medical School and senior radiologist in the breast imaging division at Massachusetts General Hospital, said the study provides additional information to doctors and women, but has some limitations.\nThe additional tests that turn out to be unnecessary, because no cancer is found, are not desirable, he said.\nSome of the very early cancers diagnosed in older women, he noted, may not have caused them a problem during their lifetime.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story pointed out that CAD use did increase the likelihood that a woman\u2019s cancer would be diagnosed at an earlier stage. \u00a0Readers should also have been told that the study found the increased association between using CAD & an earlier stage of cancer diagnosis may be stronger among women older than 75.\nThe endorsement of the use of CAD & minimization of its problems by Dr. Daniel Kopans, should have been balanced by comments from another expert not connected with the study.", "answer": 1}, {"article": "The Lancet.\nThe study suggests that one hip fracture could be prevented for every 111 women screened and early analysis suggests the approach is likely to be cost-effective.\nThe randomised controlled trial 'SCreening for Osteoporosis in Older women for the Prevention of fracture' (SCOOP) was funded by the Medical Research Council and Arthritis Research UK.\nThis recommendation was acted upon by the women and their GPs so that over three quarters of the women at high risk were on osteoporosis medications within six months of screening.\nAmong those screened, treatment was subsequently recommended for one in seven women deemed at high risk of hip fracture.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are quantified. We learn how many women in the treatment arm of the study were placed on osteoporosis medication following screening and how many hip fractures were potentially avoided among the women who received the screening procedure. The release reports both the relative and absolute risk reductions associated with screening. It also projects how many hip fractures might be prevented in Britain on an annual basis if the screening procedure were adopted nationwide.", "answer": 1}, {"article": ".\nThe bottom line is that patients who used statins were more likely to survive during and after an elective endovascular procedure.\"\n\"However, further research is needed to assess the benefits of using statins before surgical repair of other types of aneurysms.\"\n\"Although this condition usually occurs in men older than 50 with a family history of the disease, anyone can have an abdominal aortic aneurysm,\" said Todd Vogel, associate professor and chief of the Division of Vascular Surgery at the MU School of Medicine, and lead author of the study.\nPatients who took statins and had traditional open procedures also did better, but the difference was not nearly as significant as with endovascular repair.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We are giving this a failing grade because there are no absolute numbers in the release. It describes a 26% reduction in mortality, but we have no idea how many patients that actually represents. If there were 20,000 records reviewed, how many died? We don\u2019t know. How many who did not die were taking statins? We don\u2019t know. There are ample data in the paper, none of which is in the story. When you read the study, you see that \u2014 depending on the group being compared \u2014 the mortality rates were quite close. For example, in the group of patients studied who underwent an endovascular surgical repair for their aortic aneurysm, 1% of those who took statins died. And 1.45% of those who did not died.\u00a0Both of these are very low rates.", "answer": 0}, {"article": "In fact, Papa envisions the development of mobile devices that could diagnose concussions on the spot, much like the devices diabetics use to test their blood with a simple finger prick and a drop of blood.\nMoreover, the study showed that the blood test detected symptoms of concussions, even when brain injuries were not visible on the CT scan.\nAs expected, the high definition imagery from the CT scans was able to identify which patients had suffered visible traumatic brain injuries.\nCT scans can provide a more definitive profile of the injury, \"however, they are expensive and are associated with radiation exposure,\" said Papa.\nResearchers plan to do more studies with the blood test, but they hope it will be commercially available within the next 5 years.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release tells readers that the study correctly identified the presence of traumatic brain injuries 94 percent of the time, and that the levels of GFAP in the blood corresponded to the severity of the injuries. However, the release emphasizes only one side of the biomarker story, focusing entirely on the positive predictive value. While important, we think that the other side of the coin should have been addressed as well. Another presumed benefit of an easy-to-use biomarker blood test to detect concussion would be eliminating the necessity of a CT scan if, in fact, the biomarker had a high negative predictive value. \u00a0The study notes a 98% negative predictive value. That means if the test comes back negative, there is a very low likelihood that the person has suffered a concussion. This could eliminate the need for a CT scan and any additional treatments. In reality, it is unlikely that a positive test would obviate the need for a CT scan. In fact, one could argue that the presence of a positive result would require a CT scan. \u00a0The 94% accuracy notation in the press release is incorrect. \u00a0It should have noted a 94% sensitivity (true positive) and a 47% specificity (true negative). The low specificity means that many positive results will be wrong (see more below under \u201cHarms\u201d).", "answer": 0}, {"article": "Learn more at: www.DecipherTest.com and follow Decipher on Twitter @DecipherTest and on Facebook.\nThe study was designed to evaluate how the Decipher Prostate Cancer Classifier, which predicts the risk of metastasis after prostatectomy, would impact adjuvant treatment recommendations made by urologists and radiation oncologists.\n\"The Decipher test's tendency to make the two specialties more concordant in their treatment recommendations provides significant value toward standardizing care for patients.\"\n\"As genomic tests like Decipher become used more routinely in urologic cancer patient care, they will have a greater impact on treatment recommendations in clinical practice and allow for better personalization of therapy.\"\nThe Decipher test results altered 45% and 35% of treatment recommendations made by urologists and radiation oncologists, respectively.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that, according to the latest study, Decipher has the ability to change the minds of both urologists (45%) and radiation oncologists (35%), and get more of them to agree what or what not to do with a patient after removal of his cancerous prostate gland.\nWe\u2019ll give the release credit here for quantifying the main findings of the study. But we\u2019d note that there was potential to go deeper. We\u2019re never told how many patients have issues with recurrent cancer or metastasis. (The Centers for Medicare and Medicaid Services suggests about 40,000 men each year face a high risk.) We also\u00a0aren\u2019t told\u00a0how effective radiation or other therapies are after a prostatectomy, nor\u00a0how effective Decipher might be in saving lives.\u00a0Most of the clinical trials cited in the article mention only reductions in biochemical progression\u2013a surrogate endpoint.\nMost of what\u2019s found in the release are rather general statements from doctors who have financial relationships with GenomeDx Biosciences, e.g. \u201cit helped ensure that the ones selected for adjuvant therapy are the ones most likely to benefit from it.\u201d", "answer": 1}, {"article": "For more about corneal transplants, try the U.S. National Library of Medicine.\n\"We were pleasantly surprised that in six patients, vision improved from about 20/400 to 20/100, meaning that these patients could see objects four times farther away than before the operation,\" said Griffith, director of the Integrative Regenerative Medicine Center at Linkoping University in Sweden.\n\"The patients' own cells and nerves grew back, and there was an overall improvement in vision,\" said study co-author May Griffith.\nArtificial corneas are another option, but they're difficult to implant into the eye and can cause side effects, the researchers said.\nThe next step in research, Griffith said, is to create a \"new generation\" of cornea implants and test them on a wider variety of patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are quantified about as well as in the other two stories, and the story avoids putting the benefits in relative terms. The one big advantage of this story is that it puts a number to the vision improvement. \"We were pleasantly surprised that in six patients, vision improved from about 20/400 to 20/100, meaning that these patients could see objects four times farther away than before the operation,\" said Griffith, director of the Integrative Regenerative Medicine Center at Linkoping University in Sweden.", "answer": 1}, {"article": "Vegetable and canola oils, soybeans, flaxseed, walnuts and vegetables including spinach, kale and salad greens are also a source of omega-3 fatty acids.\nTan\u2019s team studied 1,575 people with an average age of 67 who were free of dementia.\nTan said the next step in the research is to follow these people to see if the risk factors they observed translates into a higher rate of cognitive deterioration.\nThey found people in the bottom 25% scored lower on such mental tests as problem solving, multi-tasking and abstract thinking.\nThe only people who should avoid DHA are patients on a blood thinner like Cumadin, he added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story includes many sketchy statements about DHA, citing benefits for \u201cimproving mood\u201d and \u201creducing symptoms of depression.\u201d The story made these as flat statements of fact, but this is far from established science.\nIt also failed to provide quantified benefits from the study in question. Where are the absolute risk reduction figures?\n\u201cThey found people in the bottom 25% scored lower on such mental tests as problem solving, multi-tasking and abstract thinking\u2026..The MRIs showed higher white matter hyperintensity volume, tiny lesions in the brain, raising the risk for death, stroke and dementia for the low omega-3 fatty acids group.\u201d", "answer": 0}, {"article": ".\nThe drug also proved to be highly selective, meaning it hit the intended targets inside the body and did not cause troubling side effects.\nThe drug was pulled from the market in 1997, costing Wyeth millions of dollars.\nIf approved, lorcaserin would be Arena's first marketable product.\nThe trial looked at the effects of three dose levels of the drug.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story detailed that individuals taking lorcaserin lost more weight in 12 weeks than did the individuals who were taking the placebo. \u00a0However the story did not provide any information about the magnitude of the difference between the groups, nor did it actually provide absolute quantitative information about the actual amount of weight lost.\u00a0 The phrase \"significantly more weight loss, at least 5 percent of their weight\" doesn\u2019t tell readers how much.\u00a0 ", "answer": 0}, {"article": "The Ache: Nearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\n\nThe Claim: Two new easy-to-use devices work like plungers to suck out obstructions in the airway, providing another option if standard treatment\u2014such as abdominal thrusts developed in 1974 by Henry Heimlich\u2014fail to clear the airway, say the companies who sell them.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article carefully reminds readers that both devices need further testing. Under \u201cVerdict,\u201d the article reads\nSo far there haven\u2019t been any scientific publications detailing lives saved with the LifeVac or another device, from Dechoker LLC, of Salisbury, N.C.\nIn particular, we understand from the article that\nOn the market less than two years, neither LifeVac nor Dechoker has published evidence of successful uses in humans.\nThe successes of LifeVac have been studied only in cadavers where success was observed \u201c49 out of 50 times.\u201d", "answer": 1}, {"article": "\"Our thinking is similar to how you might approach a battle against two enemies,\" said Dr. Soran.\nDr. Soran began the trial in 2007, ultimately recruiting a total of 274 women newly diagnosed with stage IV breast cancer from 25 institutions.\nThe study received scientific advisement from UPMC and assistance with statistical analysis from epidemiologists at the University of Pittsburgh Graduate School of Public Health.\nThe study was selected for the society's \"Best of ASCO,\" an effort to condense the research \"most relevant and significant to oncology\" into a two-day program to increase global access to cutting-edge science.\nAt about 40 months after diagnosis, the women who received the surgery plus standard therapy lived an average of nine months longer than their counterparts who received standard therapy alone.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does quantify the benefits, but we have concerns with how the release states: \u201cAt about 40 months after diagnosis, the women who received the surgery plus standard therapy lived an average of nine months longer than their counterparts\u2026\u201d This is a difficult sentence to follow since 40 months was the median\u00a0survival (with a range of 20-51 months). The sentence might be interpreted by some readers that most women lived to at least 40 months, which was not the case.", "answer": 1}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nAt the start of the trial, 660 adults with DME were enrolled: their average age was 61 years and 90 percent had type 2 diabetes.\nAll three drugs improved vision substantially, with aflibercept showing more visual gains in patients with worse vision at the start of the trial.\nOne year after starting treatment, all participants had improved vision.\nHowever, one drug, aflibercept, provided greater improvement for people with more severe vision loss when treatment was initiated.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "These drugs are already used for treatment of macular edema and the purpose of the study was to compare the three. In general, all three show good results, with aflibercept producing slightly better results for those initially exhibiting poorer vision. The release quantifies this clearly in terms of improved ability to read an eye chart.", "answer": 1}, {"article": "\"There was a trend toward less severe psoriasis severity in people taking statins,\" says researcher Adam Perry, a fourth-year medical student at Emory University in Atlanta.\nAnd no one should start taking statins in an attempt to ward off psoriasis symptoms, doctors stress.\nThe study is preliminary and doesn't prove cause and effect.\nMarch 8, 2010 (Miami Beach, Fla.) -- Once again, cholesterol-lowering statin drugs have been shown to be good for more than the heart.\nBut the findings, presented at the American Academy of Dermatology annual meeting, raise an interesting possibility worthy of further study, experts agree.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The study reported on failed to find a statistically significant improvement in psoriasis. \u00a0Despite this, the story headline, first sentence and overall tenor report about benefit even though this is inappropriate given the study results. \u00a0\u00a0", "answer": 0}, {"article": "God watches out for fools and little children.\nThose who got the therapy also had significantly more improvement in other measures of symptoms, according to the study that will appear today in the Journal of the American Medical Association.\nNausieda said much of the benefit found in the study could be due to a placebo effect.\n\"That's huge,\" said lead author Fran Weaver, a researcher with the Hines VA Hospital in Hines, Ill.\n\nShe said the best drugs provide only one to two hours of added improvement, or \"on time.\"\nBeyond that, doctors need to do a better job of optimizing drug therapy, he said, noting that there are thousands of potential combinations of drugs that can be used to control symptoms.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does an adequate job of quantifying the benefits, using hard data to indicate the duration of the study, the number of patients involved and the most signficant outcome. \nThe reporter also does a good job of quantifying the side effects, which it does with even more specificity.\u00a0\n\u00a0", "answer": 1}, {"article": "Stay in touch on Linkedin, on Twitter @EpicSciences or on Facebook.com/EpicSciences.\nThis is the second blinded, multi-center clinical utility validation study utilizing the nuclear-localized AR-V7 test.\nThis independent, multicenter, blinded study is one of the first studies to validate that a liquid biopsy test can predict therapeutic response and demonstrate a survival benefit.\nIt is estimated that 50,000 patients a year may be eligible for and benefit from the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test.\nThrough a blood draw, the test detects AR-V7 protein in the nucleus of circulating tumor cells utilizing Epic Sciences' No Cell Left Behind\u00ae platform to accurately identify patients who are resistant to androgen receptor (AR)-targeted therapies and who should instead switch to chemotherapy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release stated that \u201cThe results were that patients positive for AR-V7 who were treated with taxane-based chemotherapy had superior overall survival (OS) relative to those treated with ARSI therapy (median OS, 14.3 vs. 7.3 months). Importantly, patients negative for AR-V7 who were treated with ARSi therapy had superior OS relative to those treated with taxanes (media OS, 19.8 vs. 12.8 months).\u201d\nBut in the published paper, the results state: \u201cThe median survival of patients negative for AR-V7 was 19.8 months for those treated with an ARS inhibitor and 12.8 months for those treated with a taxane (hazard ratio, 1.67; 95% CI, 1.00-2.81;\u00a0P\u2009=\u2009.05) (Figure 2A). In contrast, for patients with AR-V7\u2013positive CTCs, those receiving taxanes had longer observed median survival times relative to those treated with ARS inhibitors (14.3 vs 7.3 months; hazard ratio, 0.62; 95% CI, 0.28-1.39;\u00a0P\u2009=\u2009.25)\u201d\nSo, for those with a negative test, the androgent (hormone) therapy had improved survival. However, for those with a positive test, there was a trend but the sample size was very small and the p-value was >0.05 (indicating weak evidence), so the results could have been due to chance. As such, we rate this unsatisfactory since the piece provides misleading information for part of the results.", "answer": 0}, {"article": "Barley reduced both low-density lipoprotein, or LDL, and non-high-density lipoprotein, or non-HDL, by seven per cent.\nDespite its benefits Dr. Vuksan said barley is not as well-established as some other health-recommended foods -- such as oats.\nThe research review, published today in The European Journal of Clinical Nutrition, included 14 studies on clinical trials conducted in seven countries, including Canada.\nIt is the first study to look at the effects of barley and barley products on both LDL and non-HDL cholesterol in addition to apolipoprotein B, or apoB, a lipoprotein that carries bad cholesterol through the blood.\n\"Barley has a lowering effect on the total bad cholesterol in these high-risk individuals, but can also benefit people without high cholesterol.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There was no quantification of benefits. You have to go back to the original study to learn this: \u00a0\u201cA median dose of 6.5 and 6.9 g/day of barley \u03b2-glucan for a median duration of 4 weeks significantly reduced LDL-C (MD = \u2212 0.25 mmol/l (95% CI: \u2212 0.30, \u2212 0.20)) and non-HDL-C (MD = \u2212 0.31 mmol/l (95% CI: \u2212 0.39, \u2212 0.23)), respectively, with no significant changes to apoB levels, compared with control diets.\u201d \u00a0It would have been nice to have had these reductions contextualized in a form that makes sense to the readers.", "answer": 0}, {"article": "Moffitt is the No.\nThe researchers found that delaying surgery due to neoadjuvant radiation therapy was not a detriment to survival.\nThe study was supported by funds received from the American Cancer Society and the DeBartolo Family Personalized Medicine Institute Pilot Research Awards in Personalized Medicine.\nThey included female patients in the analysis who were diagnosed between 1973 and 2011 with early-stage breast cancer.\nThe researchers discovered that among the breast cancer patients who tested positive for the estrogen receptor (ER) biomarker, patients who had neoadjuvant radiation therapy had a significantly lower risk of developing a second primary tumor than patients who had adjuvant radiation therapy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t provide any numbers to support the benefit claims. It states, \u201cResearchers discovered that among the breast cancer patients who tested positive for the estrogen receptor (ER) biomarker, patients who had neoadjuvant radiation therapy had a significantly lower risk of developing a second primary tumor than patients who had adjuvant radiation therapy.\u201d\nHow much lower was the risk? Some absolute risk numbers should have been included here. They were available in the published study.", "answer": 0}, {"article": "This is relatively new thinking.\nEarly introduction didn\u2019t seem to make a difference for autoimmune diseases, at least according to the available evidence; eating gluten young wasn\u2019t associated with the risk of developing celiac disease.\nThat advice has been amended, and newer evidence has shown that introducing foods earlier is actually better for preventing food allergies.\nThey found evidence of \u201cmoderate certainty\u201d that introducing peanuts early, between ages 4 and 11 months, is linked to a reduction in the risk of developing a peanut allergy.\nMore research is necessary to figure out the ideal amounts of these allergens, the optimum times of introduction and the reasons behind the link.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Even in this short story, we need some metric for measuring the benefit. The story says there was evidence that introducing peanuts earlier to infant diets provided a \u201crisk reduction\u201d of later allergy. How much of a risk reduction? Was the reduction similar between eggs and peanuts?\nThe journal article itself gives some absolute risk numbers. For egg allergy, the study shows a reduction of 24 cases per 1,000 children. For peanut allergy, the risk is reduced by 18 cases per 1,000 children. But the authors warn that the \u201ccertainty of the evidence\u201d was downgraded due to some gray areas in how the studies were done.", "answer": 0}, {"article": "\"It was the end of our world and we didn't know why, because this child was a perfectly normal healthy child, Never had a problem,\" Miller says.\nFDA said it asked the company to dig deeper into its data on Singulair for evidence of possible links to suicide.\nFDA said it is reviewing a handful of reports involving mood changes, suicidal behavior and suicide in patients who have taken the popular allergy and asthma drug.\nThe agency said it has not established a \"causal relationship\" between Merck's drug and suicidal behavior.\nThe company said none of the 11,000 patients enrolled in 40 Singulair trials has committed suicide.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The segment specifies that four suicides, and a higher number of other mental health effects, have been reported to the FDA. \u00a0\nIt also specifies that 11,000 patients participated in the pre-approval clinical trials and with no reports of similar incidents.\u00a0 \nBut it fails to make clear to viewers the important differences between data from clinical trials and from post-surveillance voluntary reports. \u00a0\nThe story didn\u2019t quantify potential benefits.\u00a0 ", "answer": 0}, {"article": "This website is archived for historical purposes and is no longer being maintained or updated.\nHHS\u2019 Health Resources Services Administration recently released a grant opportunity aimed at reducing opioid overdose deaths in rural communities through funding for communities to purchase naloxone and train health care professionals and emergency medical staff on its use.\nDepartment of Health and Human Services Secretary Sylvia M. Burwell has made addressing opioid abuse, dependence, and overdose a priority and work is underway at multiple HHS agencies on this important issue.\nThe use of naloxone by rural EMS staff, however, was only 22.5 percent higher when compared with urban EMS naloxone use.\n\u201cMany of these deaths can be prevented by improving prescribing practices to prevent opioid addiction, expanding the use of medication-assisted treatment, and increasing use of naloxone for suspected overdoses.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does not quantify the benefits of allowing staff with less experience to administer this drug. It says only that, \u201cadvanced EMS staff were more likely than basic EMS staff to administer naloxone.\u201d\nIt kind of quantifies some other things in relative terms. It says, for example, that \u201cthe rate of opioid overdose death was 45 percent higher in rural areas compared with urban areas.\u201d OK. That\u2019s a measure of the problem, although it would be nice to know how many deaths in absolute terms happened in rural areas in the year studied. It also says that \u201cThe use of naloxone by rural EMS staff, however, was only 22.5 percent higher when compared with urban EMS naloxone use.\u201d But\u00a0it is not known whether the rate of death was higher or lower in those patients who received or did not receive naloxone. Not knowing the absolute numbers here and not knowing whether naloxone actually made a difference in health outcomes when comparing rural areas to urban areas makes this number difficult to interpret.", "answer": 0}, {"article": "\"In some cancers, a part of the TRK gene has become attached to another gene, which is called a fusion.\nThe larotrectinib research was supported by Loxo Oncology Inc., the National Institutes of Health, the Cancer Prevention and Research Institute of Texas, the National Center for Advancing Translational Sciences, and Alex's Lemonade Stand Foundation.\nThe results of the larotrectinib trial in adult patients - a 75 percent response rate - were published last month in the New England Journal of Medicine.\nLarotrectinib is the first cancer drug to receive FDA breakthrough therapy designation for patients with a specific fusion of two genes in the cancer cell, no matter what cancer type.\nEqually important, the response was long-lasting for most patients.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The primary endpoint of the phase 1 study was safety and tolerability of the drug among a small number (17) of pediatric patients with and without specific genetic mutations. These results are essential to demonstrate before larger trials to demonstrate clinical effectiveness can commence.\nThe release presented the anecdotal story of one patient\u2019s tumor response and claimed a \u201c93 percent tumor response rate\u201d in the headline. With so few patients, this is just a rough estimate and very misleading.\nIn addition, the release reports that the \u201cresponse was long-lasting for most patients\u201d without clarifying that the median follow-up period for the trial was just 8.2 months.", "answer": 0}, {"article": "The main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center.\nPrevious survey research completed by Dr. Kingsberg and others has shown that while 32 million women may be experiencing symptomatic VVA and suffering from related impacts on sexual function, interpersonal relationships, self-esteem and overall quality of life, only 7 percent are currently using a prescription therapy to alleviate symptoms.\nThe survey, which included 731 respondents with a 96 percent response rate, sought to quantify participants' satisfaction with the application method and overall treatment delivery system.\nThe majority of women taking either TX004HR or placebo (85.4 - 92.1 percent) found the product easy to use.\nThe new results were part of a multi-center randomized, placebo-controlled phase 3 clinical trial for TX004HR, an investigational bio-identical 17\u03b2-estradiol applicator free vaginal softgel capsule.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release includes next to nothing in the way of numbers to back up its claim. It includes only one measured benefit: the majority of around 700 women or \u201c(85.4 \u2013 92.1 percent) found the product easy to use.\u201d This was based on a post-trial survey, according to the release.\nAn interesting finding of the survey not mentioned in the news release was that 57% of women were satisfied with the placebo, compared with 69% to 76% of those treated with the active drug. While it is not surprising that the study, which was supported by the pharmaceutical manufacturer, chose not to focus on this result, it would have provided useful context for understanding the product\u2019s impact on symptoms.", "answer": 0}, {"article": "\"There are many gaps in the evidence,\" Reiss said.\n\"It is uncertain whether the strength and consistency of the relationship between these metabolites [in saliva] and Alzheimer's risk will be maintained in a large multicenter study.\"\n\"This is a very preliminary study with a small number of subjects and the results are far from conclusive,\" said Dr. Allison Reiss, head of the Inflammation Section at Winthrop-University Hospital in Mineola, N.Y.\n\nShe believes the current study lacks information on possible confounding factors -- things such as \"coexisting illnesses, medications, hydration state, tobacco use and multiple other variables\" that could influence what's found in the saliva samples.\n\"Saliva is easily obtained, safe and affordable, and has promising potential for predicting and tracking cognitive decline, but we're in the very early stages of this work and much more research is needed,\" study author Shraddha Sapkota, a neuroscience graduate student at the University of Alberta in Canada, said in a news release from the Alzheimer's Association.\nStill, Dr. Paul Wright, chair of neurology at North Shore University Hospital in Manhasset, N.Y., said the research \"is still in its infancy but very promising.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The main investigator states, \u201cSaliva is easily obtained, safe and affordable, and has promising potential for predicting and tracking cognitive decline,\u201d which gives readers a sense of the potential benefits. But that\u2019s only a partial account of what readers need to know.\u00a0We think any story about diagnostic testing or screening should discuss the sensitivity and specificity of the test \u2014 numbers which tell us about how well the test finds people who actually have the disease and rules out people who don\u2019t have it.\u00a0But the closest the story comes to this is the following: \u201cThey found that the saliva of people with Alzheimer\u2019s had different levels of certain substances compared to the saliva of healthy people or those with mild cognitive impairment.\u201d\nWe\u2019d note that another story about this study from the Wall Street Journal (which we didn\u2019t review) had most of the details we were looking for here. It said, \u201cSome 80% of the sample predicted by the biomarker combination to go on to develop abnormal memory problems truly went on to develop them, while 20% would have been classified as a false negative. The algorithm, 75% of the time, correctly predicted who wouldn\u2019t go on to develop memory problems.\u201d", "answer": 0}, {"article": "Each stage was 15 minutes.\n\u201cThese results suggest that non-exercise active thermogenesis, which we call NEAT, can increase movement and calorie burning, and may have the potential to impact health,\u201d said Horswill, the senior author on the study.\n\u201cWe expected to see the metabolic rate increase with each progressive stage, but instead found that metabolic rates from movement while seated were either equal to or higher than rates while standing.\u201d\n\nHorswill says the study needs to be further validated, but that the findings should be especially applicable to individuals poised to benefit from NEAT but unable to access popular standing desks because of injury, disability or discomfort.\nOn a second visit, researchers collected metabolic rate and heart rate data during three progressive stages: seated, seated with the device and standing.\nCraig Horswill, clinical associate professor of kinesiology and nutrition at the University of Illinois at Chicago, says the study adds to the growing body of evidence that suggests strategies for increasing non-exercise active thermogenesis \u2014 defined as spontaneous activity unrelated to a fitness routine \u2014 are needed to help overcome the detrimental effects of prolonged sitting.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release did briefly mention the benefits found in the study: \u201cmodest movement while seated elevated the metabolic rate more than sitting and more than standing, by 17 and 7 percent respectively.\u201d But it gives us no context for these numbers \u2014 in terms of metabolic rate variability, is 7% a lot? A layperson reading this news release has no frame of reference to determine if these numbers are significant. Would 7% increase over the course of a lifetime reduce sitting-attributed mortality?", "answer": 0}, {"article": "\u201cNumerically this is hardly a major risk, just something we need to keep an eye on,\u201d Holman said.\nThe detailed results also showed no increase in hospitalization for heart failure, which had been a particular concern with DPP-4 inhibitors, the class to which Januvia belongs.\nThere were 228 such hospitalizations for Januvia and 229 in the placebo group, according to data also published in the New England Journal of Medicine.\n\u201cWe can be reassured we can use this drug for glucose lowering without affecting the already high cardiovascular risk in people with type 2 diabetes,\u201d said Professor Rury Holman, the study\u2019s lead investigator, who presented the data at the American Diabetes Association meeting in Boston.\nDeath from any cause occurred in 7.5 percent of Januvia patients versus 7.3 percent for placebo.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The focus of the story is on the drug\u2019s risk profile, but we think the story should have provided at least some information about whether this drug has been shown to be more efficacious than other therapies. The story missed what was in our view one of the most important points of the study: the practically nonexistent benefit in reducing blood sugar compared with existing therapy. And, while the drug did not increase rates of cardiovascular disease, it also did not reduce them. Also, the study followup was relatively short; median follow up of 3 years. That could have been mentioned somewhere.", "answer": 0}, {"article": "\u2022 Khin NA, et.al.\nHowever, the study narrowly missed statistical significance for its primary efficacy endpoint.\nWhat makes this even more significant is that the response was rapid and this milestone was achieved in patients deemed to be treatment-resistant.\nThese findings represent two of the five Phase 3 studies that comprise Janssen's treatment-resistant depression program with esketamine nasal spray.\nThe primary efficacy endpoint \u2013 change from baseline to day 28 in MADRS total score \u2013 was assessed among patients who received \u22651 dose of (nasal spray and oral) study medication by mixed-effects model using repeated measures using a one-sided significance level of 0.025.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does include numbers for the one trial that produced statistically significant benefits, but it\u2019s a very technical explanation and probably too difficult for most lay readers to interpret. It states:\n\u201cThe primary efficacy endpoint, change from baseline in the Montgomery-\u00c5sberg Depression Rating Scale (MADRS) total score, demonstrated the statistically significant clinical improvement in patients\u2019 depressive symptoms for esketamine nasal spray plus an oral antidepressant at day 28 (Least Squares Mean Difference Standard Error from placebo nasal spray plus a newly initiated oral antidepressant: -4.0 [1.69], 95% Confidence Interval [CI]: -7.31, -0.64; one-sided p=0.010).\u201d\nThat gets it a satisfactory rating here. However, it\u2019s worth noting that a news release (or a news story) should be expected to provide some context and to help non-experts grasp technical concepts in real terms. How big a difference would these numbers make? An expert may be able to tell readers that, but that expertise is missing from the release. It would have been much stronger if it had provided even a concise explanation of what these numbers mean.", "answer": 1}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify any benefits. What\u2019s more, the story doesn\u2019t give any idea what the benefits might be or what improvemements might be expected. See comments in \u201cEvidence\u201d section. ", "answer": 0}, {"article": "At the end of the day I don't know that this will be the best technology out there, but it is a step forward to allow continued innovation in this area,\" Foreman said.\nThe company's study was not intended to show that screening with the device saves lives, only that it can help improve a doctor's ability to spot melanoma.\n\"The diagnosis of melanoma is the most serious one a dermatologist makes, and we have sleepless nights worrying about it,\" said Pariser, who consulted for the device's maker, Mela Sciences Inc. of Irvington, N.Y., on its presentation to FDA.\nRegulators said this week that they ultimately approved the device after Mela Sciences agreed to limit its use to board-certified dermatologists who undergo a specialized training course.\nAt a meeting last fall, FDA scientists said Mela Sciences had not shown how its device would influence day-to-day decisions by doctors.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story shows that the device is fairly effective at finding cancerous lesions. \u201cIn a company-sponsored study published last year involving around 1,300 patients, some with multiple growths, doctors reported that MelaFind correctly suggested biopsies on 125 of 127 melanomas that doctors had removed.\u201d", "answer": 1}, {"article": "Others mixed them with applesauce and cinnamon in a blender or chopped them up and added them to meatloaf, hamburger, and spaghetti sauce.\nEating 2.5 ounces of walnuts a day -- a little more than half a cup -- for 12 weeks improved sperm quality in healthy young men, researchers report.\nThe researcher looked at sperm concentration, vitality, ability to move, shape and size, and chromosome abnormalities, all thought to be related to fertility.\nTheir study is part of a growing body of evidence that men\u2019s dietary and lifestyle choices might affect their fertility.\nThe new study, funded in part by the California Walnut Commission, enrolled 117 men aged 21 to 35 who ate a typical Western diet.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t make over-the-top claims about the benefits of walnuts, but it also doesn\u2019t provide enough info to allow readers to judge the signficance of the research. The story says that eating walnuts \u201cimproved sperm quality,\u201d but it doesn\u2019t\u00a0say by\u00a0how much. A look at the original paper shows that sperm vitality and motility increased by about 5%, while the percentage of sperm with normal size and shape\u00a0increased by 1%.\u00a0We\u2019re not expert enough to know if these are clinically meaningful changes, but the point is that news consumers shouldn\u2019t have to be. The story should have clued them in\u00a0to what these changes mean, perhaps by including some more pointed feedback from an independent source.", "answer": 0}, {"article": "The National Institutes of Health, as well as the Michael J.\nIn a proof-of-concept study, published in the journal Neurobiology of Disease, the drug nortriptyline, which has been used to treat depression and nerve pain, stopped the growth of abnormal proteins that can build up in the brain and lead to the development of the disease.\nCollier is already looking for funding for the next phase of his research and hopes to lead a human clinical trial using the drug in the future.\n\"What we've essentially shown is that an already FDA-approved drug that's been studied over 50 years and is relatively well tolerated could be a much simpler approach to treating the disease itself, not just the symptoms,\" Collier said.\nCollier and collaborator Katrina Paumier, an assistant professor of molecular medicine, began looking at previous patient data to see if individuals who were on antidepressants experienced any delay in their need to go on a standard Parkinson's therapy called levodopa.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No numbers are offered in the release. We don\u2019t know how many patient records were examined. We don\u2019t know the number of rats in the animal studies. We don\u2019t know the number of test tubes in the cell-only stage of this early proof-of-concept study.\nThe release includes this statement on benefits:\n\u201cIn a proof-of-concept study, published in the journal Neurobiology of Disease, the drug nortriptyline, which has been used to treat depression and nerve pain, stopped the growth of abnormal proteins that can build up in the brain and lead to the development of the disease.\u201d\nWhat does \u201cstopped the growth\u201d mean if we don\u2019t have a measurement of growth in the absence of nortriptyline? For how long was the growth stopped? Was the impact temporary or permanent?The release doesn\u2019t say.\nThe research was not done in humans but only in rats and in cells. The release should have included this information early in the text and in the headline.", "answer": 0}, {"article": "Testosterone (T) is the primary male sex hormone.\n\"The low CV events observed in the T-group compared to the untreated (control) group strongly suggest that TTh is protective.\nAccording to the researchers, long-term TTh in men with hypogonadism appears to be an effective approach to achieve sustained improvements in cardiometabolic function and reduces the risk of CV events.\nTo date, there are limited studies comparing the effects of long-term TTh in hypogonadal men who were treated or remained untreated with T.\n\nResearchers at Boston University Schools of Medicine (BUSM) and Public Health (BUSPH), along with researchers in Germany, established a registry to assess long-term effectiveness and safety of T in men.\nFor this study, they sought to compare its effects on a host of parameters (obesity, cholesterol levels, diabetes, liver function) considered to contribute to cardiovascular disease.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The text does a good job of describing the differences in cardiovascular outcomes between men receiving testosterone treatment and those who chose not to. But the release never tells us how many people were in each group or what the event rate was, which makes it difficult to make a comparison. And, as the release alludes, the observational design of the study means the cardiovascular outcomes\u00a0are not conclusive.", "answer": 1}, {"article": ".\nAs part of the PARTNER-I trial, Vinod H. Thourani, MD, from Emory University in Atlanta, and colleagues from 12 other institutions in the United States found that transcatheter aortic valve replacement (TAVR) is a safe and effective way to treat aortic stenosis in nonagenarians who qualify for the surgical technique.\nOur study shows that age alone should not preclude referral for TAVR in patients age 90 years and older.\"\nHowever, with the advent of TAVR technology, we can now offer these extreme elderly patients a treatment option that otherwise would have been high-risk or prohibitive.\"\nWhile the current study did not evaluate other alternative options for TAVR, these techniques may include transaortic, transcaval, transcarotid, or trans-subclavian.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release tells readers that within six months of having a TAVR procedure, patients had quality-of-life measurements that were \u201cconsiderably better\u201d than they had been before the surgery. Unfortunately, the release doesn\u2019t offer any specific information about how much the quality-of-life measurements improved or which quality-of-life metrics were being used. The release would have been stronger if it had backed up qualitative terms like \u201cconsiderably better\u201d with quantitative information. Given the risks associated with the procedure, one would be interested in demonstrating that this procedure improved quality of life in individuals who, given their age, have limited life expectancy.", "answer": 0}, {"article": "Can a high-tech scan reveal whether Alzheimer's disease is the cause of your forgetfulness? Advocates of Positron Emission Tomography scans for the diagnosis of Alzheimer's say the scans significantly aid in the early and accurate diagnosis of the memory-robbing disease. Neurologists say PET is useful in distinguishing between Alzheimer's and a similar-acting dementia. However, opinions differ on whether the scans are useful in predicting the likelihood of Alzheimer's in people with only mild memory problems.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not attempt to quantify the benefits of PET scanning. The story states, \u201cseveral studies suggest it can effectively provide an early warning\u201d, but does not give any quantification for the magnitude of effects observed in these studies. Most importantly, the story does not mention that even if Alzheimer\u2019s is detected early, there is not much that can be done for it. Aricept has only minor affects on the progression of the disease.", "answer": 0}, {"article": "Among parents of children with autism, Mr. Frank said, \"some will say, 'Come on, who are you kidding?'\nThe Children's Institute plan would be taking what is arguably a fringe movement into the mainstream: It would be the first autism treatment of this kind staged in an American hospital setting.\nWith roots in autism treatment theories that until now have lived mostly on the Internet, the pediatric clean room plan would be the first of its kind in a mainstream American hospital environment.\nWith so many doubts -- and so few answers -- about effective autism treatments among the growing community of families affected by the condition, the institute said openness is vital to the experimental method's success.\nBasically, it would be pushing a \"reset\" button on the child's body, with the hope of wiping autistic symptoms away.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This article did not present the details of any specific benefits, only speculation regarding potential benefits on the part of the project\u2019s lead pediatrician. What evidence of benefit is there to warrant the million-dollar-plus investment?\u00a0 ", "answer": 0}, {"article": "\"But at the same time it's something we'll continue to look at, and hopefully confirm absence of risk.\"\nThe vaccine won approval from the Food and Drug Administration on Feb. 3, and some doctors have received supplies of it.\nThe federal Centers for Disease Control and Prevention and the manufacturer, Merck & Co. Inc. of Whitehouse Station, N.J., have promised elaborate studies to catch any safety problems.\nMerck has tested the vaccine in about 70,000 babies in 11 countries, one of the biggest vaccine trials ever conducted.\nThat means many doctors are likely to charge more than $300 retail, putting the Merck product in league with Prevnar, an expensive Wyeth vaccine that has been widely used in the United States for five years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No quantitative estimates of benefit are provided. How well does the vaccine work?", "answer": 0}, {"article": "Too much insulin can cause low blood sugar (hypoglycemia), which can be life-threatening, while too little causes the serious damage of diabetes such as kidney, vision and circulation problems.\nHowever, teenagers did not see a benefit, probably because they were less likely to wear the device, Tamborlane said.\nThese results were similar to findings in children where the system extended the amount of time spent at target blood sugar levels, he added.\nRitholz's team found that people who were better at coping with the frustration of using the device were more successful at keeping their blood sugar under control.\nAll patients felt self-conscious wearing the device, Ritholz noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We do receive one set of data on benefits, the 70% vs. 47% for time spent in target blood glucose. We\u2019re unable to verify these numbers, as the\u00a0abstract\u00a0available online and MedPageToday coverage both cite \"Time in Target\" as 72% and 50%. Perhaps 70% and 47% come from a different source, such as the press teleconference or presentation. We cannot verify it.\nRegardless, as we said for the harms, the comparative benefits are not meaningful if we don\u2019t know who the comparator group was. Furthermore, we feel than an independent voice should\u2019ve been provided to tell us the meaning of the benefits. According to the abstract, the key benefits were a) reduced variability and\u00a0b) reduced time duration and severity of hyperglycemia. What does that mean for patients, or even doctors? Why does glucose deviation matter if, as the abstract says, the average glucose levels\u00a0were the same in both groups? Just giving us \"70%\" next to a lower number, without an explanation or an identity for the comparator group, says zilch about the value of this research.", "answer": 0}, {"article": "In a study recently published in the European Journal of Applied Physiology, Seeley and a group of BYU colleagues, as well as Dr. Eric Robinson from Intermountain Healthcare, measured inflammation markers in the knee joint fluid of several healthy men and women aged 18-35, both before and after running.\nHyldahl said the study results indicate running is chondroprotective, which means exercise may help delay the onset of joint degenerative diseases such as osteoarthritis.\nSpecifically, they're looking to do similar tests on people who have suffered ACL injuries.\nWhen the same fluids were extracted before and after a non-running condition, the inflammation markers stayed at similar levels.\n\"What we now know is that for young, healthy individuals, exercise creates an anti-inflammatory environment that may be beneficial in terms of long-term joint health,\" said study lead author Robert Hyldahl, BYU assistant professor of exercise science.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits of this approach are in no way quantified. The news release states that the amounts of inflammation markers decreased, but does not say by how much although the published study includes this information. It should be kept in mind that the inflammation markers are a proxy for what we really care about \u2014 actual rates of osteoarthritis. It is doubtful that measuring two biomarkers after a 30-minute run can tell us much about the impact of running over a lifetime.\nIn addition, the release does not mention that this is a pilot study and that only 11 subjects were used and only 6 actually completed the tests because synovial fluid is difficult to obtain from a healthy joint. The paper does include statistics, but the p values (the probability of obtaining a result equal to or exceeding what was actually observed) may not be of any use when applied to only 6 subjects. This does not seem to be a statistically valid study. The release was probably premature.", "answer": 0}, {"article": "The brain\u2019s synapses control how much of these chemicals are released, and drugs like Zoloft effectively prevent the little serotonin being produced from reabsorbing back into the nerve cells from which they were released, resulting in a higher concentration of serotonin.\nMore studies will be needed to determine whether this method can be used as a widespread treatment for other brain-related disorders, but if today\u2019s research is any indication, TMS could be a key to improving the lives of Americans suffering from a multitude of disorders.\nThe biggest drawback to TMS, according to advocates, is the limitations on just who can undergo the treatment.\nEven those who are approved to undergo the treatment face another barrier as TMS is not widely covered by health insurance.\nAt this point, specific symptoms can be targeted depending on the patient\u2019s needs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only notes that studies employing TMS sessions to treat Parkinson\u2019s and autism \u201chave seen some success,\u201d but the reader will find no specific information about what that means. Also missing: What percentage of patients with depression respond to treatment, and if the effects are short-term or long-term.", "answer": 0}, {"article": "Caused by defective genes, cystic fibrosis affects multiple organs.\nAlthough HGH not a cure for the disease, which afflicts 30,000 people in the U.S., the researchers found that it reduced the number of hospitalizations among those who have the disease.\nBut with antibiotics and other medical advances, the median age for people with the disease increased to 37 by 2008.\n\"Hopefully, this is going to encourage cystic fibrosis care providers to use it more frequently in patients at the lower end of weight and of short stature,\" Lapin said of the findings.\nHuman growth hormone is a promising tool in treating cystic fibrosis, a new University of Connecticut study suggests.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Immunotherapy usually starts with clinicians harvesting immune system cells called T cells that have attached themselves to a tumor in an effort to attack.\nIn one of those patients, the treatment resulted in complete remission of his metastatic melanoma and evidence that his immune system stands ready to fight any return of the cancer after three years.\nThe last step was to infuse the resulting army of cancer-fighting clones back into the patient.\nThe researchers hoped that by choosing T cells more selectively and cloning only those judged most likely to vanquish their foe, the treatment would be more effective.\nSeveral independent researchers said the study results were promising.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019ll give the story the benefit of the doubt for reporting:\n\u201cIn six of the 11 patients in the trial, the melanoma stopped progressing for 12 to 19 weeks. Another patient was declared in remission because his cancer ceased to spread and, after several months, disappeared altogether. Three years later, researchers continue to detect the presence of the cloned cells they infused into the patient\u201d", "answer": 1}, {"article": "Lung cancer is the No.\n\u201cThis new information adds to the growing body of evidence that metformin may help prevent and inhibit the progression of lung cancer,\u201d Gutterman said.\n\u201cOur study, as well as other research, suggests an association between metformin and/or TZD use and the risk of developing lung cancer,\u201d said Dr. Peter Mazzone of the Cleveland Clinic in Ohio, who led the study.\nBut Dr. David Gutterman, president of the American College of Chest Physicians, said more research would be needed before this could be proposed.\nMetformin is one of the most widely used drugs for type 2 diabetes, with 41 million prescriptions written in the United States in 2008, the American College of Chest Physicians said in a statement.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article presents the rates of metastatic disease for each group in the study. That said, we suggest some areas where we believe it could\u2019ve been stronger.\nWe would\u2019ve liked to have seen absolute quantities here. We would have liked to see the number of subjects in each treatment group (the \u201clittle n\u2019s\u201d) in addition to the study\u2019s total headcount (the \u201cbig N\u201d). What if 150 people were in one group and 7 in the other? It\u2019s necessary to evaluate the quality of the study and add meaning to the 20% and 42% statistics.\nSeveral more benefits were summarized in prose without quantities, including claims about the comparative superiority of metformin to TZDs. While space would not permit all the numbers, surely there was space for more than one. \nNow, we know that the abstract itself didn\u2019t quantify these other benefits, present the little n\u2019s, include absolute quantities, or explain the evidence behind the trend of metformin superiority over TZDs. (By the way, the term \u201cinitial trend\u201d suggests the result may not have been statistically significant.) While true, these facts aren\u2019t in the abstract or ACCP statement, but we think that\u2019s not a suitable reason for not acknowledging at least the importance of missing context\u2013 it\u2019s instead a known peril of reporting on unpublished research. Before research goes through peer review and full publication, it has more inherent unknowns, both in the science,\u00a0the vetting of quality and conflicts of interest, and\u00a0the final level of information that the public gets to see. Thus, we think,\u00a0when the decision is made to report on preliminary research,\u00a0those unknowns need to be acknowledged to distinguish it from more mature research.\n Dr. Gutterman says that more research is needed before the preventative use of metformin in smokers \u201ccould be proposed.\u201d It balances Dr. Mazzone\u2019s proposal of the same potential benefit; but is the cat already out of the bag since Dr. Mazzone (and Reuters) have, at this point in the article, already proposed this potential benefit? As the proposal is one with a broad audience, and broad appeal, more caveats about the status of this hypothesis would\u2019ve been ideal.", "answer": 0}, {"article": "\n\u2022 Detailed Results of Phase 2 Trial Presented at the American College of Gastroenterology 2016 Annual Scientific Meeting\n\u2022 93.3% of Patients Treated Using the Lead Formulation of Novel Prep Achieved a Colonoscopy Rating of Excellent or Good, Compared to 85.7% of Those Using Standard Prep Products in Colonoscopist-blinded Trial\n\u2022 More 'Patient-friendly,' Palatable Prep Could Help Increase Patient Acceptance of Colonoscopies for Colorectal Cancer Screening\n\nNewton, MA (October 17, 2016) - Detailed results from a Phase 2 study of a novel colonoscopy prep (ECP) under development by ColonaryConcepts, LLC show the investigational treatment to be at least as effective and safe as two currently available colonoscopy prep formulations, while offering a much higher level of patient satisfaction and preference than standard preps.\n\"Results from this study show that this innovative investigational product performed as well as or better at colon cleansing than two currently available colonoscopy prep formulations.\nMoreover, the higher levels of patient satisfaction reported by those who used the lead ECP formulation in the trial suggest this new approach to colonoscopy prep may have a positive impact on patient willingness to undergo this potentially life-saving colorectal cancer screening procedure.\"\n\"We are very pleased with the efficacy and safety results of this study, which clearly support advancing this product to a Phase 3 trial,\" said Corey A. Siegel, M.D., M.S., a co-founder of ColonaryConcepts, and Director of the Inflammatory Bowel Disease Center at the Dartmouth-Hitchcock Medical Center and Associate Professor of Medicine at The Geisel School of Medicine at Dartmouth.\nResults from the randomized, single-blind study will be presented today at the American College of Gastroenterology 2016 Annual Scientific Meeting, being held in Las Vegas, NV, by principal investigator, Douglas K. Rex, M.D., Distinguished Professor of Medicine, Indiana University School of Medicine.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides a modest amount of information on the results of the study providing both percentages and actual numbers on the success and acceptability of the comparisons. We would have liked to have seen an acknowledgement that the sample size is rather small and while the percentages seem impressive, they may not be clinically or statistically significant.", "answer": 1}, {"article": "\"We always assume there's luxury,\" Wright said.\nWhen validating a new biomarker for disease, \"one should always analyze at least two different (groups of patients and controls) to make sure that the results are reproducible,\" said Hansson, who added that participants should also include both early- and late-stage patients established at different clinics.\nAccording to Dr. Paul Wright, chairman of neurology at North Shore University Hospital in Manhasset, New York, and Long Island Jewish Medical Center in New Hyde Park, New York, the importance of this study is that it brings to light that there are new biomarker tests that can delineate between these neurological diseases.\n(CNN) A new blood test may be as accurate as a test requiring a painful spinal tap for differentiating Parkinson's disease from similar disorders, according to a study published Wednesday in Neurology, the medical journal of the American Academy of Neurology.\nThe correct diagnosis is also key to treatment since \"most patients with atypical parkinsonism disorders do not respond well to dopamine-targeting medications\" that are usually prescribed for Parkinson's patients, Hansson said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Atypical for many news stories like this, this one provided the actual specificity and sensitivity numbers for the blood test, and how that compares (in general) to the typical spinal fluid test.\nThat said, the story could have been a little more thorough in its discussion of what sensitivity and specificity mean. It says sensitivity is \u201cthe percentage of positives that are correctly identified, and specificity, the percentage of negatives that are correctly identified.\u201d That\u2019s accurate, but the story could have gone further to explain, for example, that a low specificity test means it will have a high false-positive rate (more people who don\u2019t have the disease are erroneously told that they have it). A low-sensitivity test, by contrast, will have a high false-negative rate (more people who actually have the disease are falsely reassured by a negative test result).", "answer": 1}, {"article": "For example, blood pressure (BP), not only tends to increase but as well become more irregular.\nNone of these effects was found in 34 placebo treated seniors, thus ruling out the possibility that rhythms could be improved just because of regular schedule and presence of medical personal who took measurements.\nMoreover, the higher the mean systolic BP was during the first week, the more it dropped on the second week of melatonin administration.\nThe present study was aimed to investigate whether such changes can be reversed by daily melatonin ingestion.\nThe hypotensive effect was dependent on time.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We rate this a\u00a0Satisfactory because the release provides the absolute decrease in BP that was achieved in 63 participants. However, the way the benefit was quantified may not be useful to readers. The statement: \u201cNighttime and morning BP decreased more profoundly on average -8/3.5 mm Hg for SDP/DBP, respectively\u201d may be too technical for most readers.", "answer": 1}, {"article": "\u201cThere is a larger program we are putting into place.\u201d\nBYL719 plus fulvestrant cut risk of death or progression in those patients by an estimated 35 percent, Novartis said.\nOther drugmakers including Roche have seen similar investigational medicines stumble, making Novartis\u2019s progress here hopeful news, doctors involved in the trial said.\nNovartis plans to file with regulators for approval of the drug this year, Hirawat said, adding he also has strategies to broaden the indication, including tough-to-treat triple-negative breast cancer.\nThe Swiss drugmaker\u2019s BYL719, a so-called PI3K inhibitor also known as alpelisib, combined with hormone therapy fulvestrant boosted median progression-free survival (PFS) to 11 months, up from 5.7 months for patients who got only hormone therapy, the company said on Saturday.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The first paragraph says the drug BYL719/alpelisib can \u201ccut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.\u201d\nIn the second paragraph we learn this effect was seen when BYL719/alpelisib was combined with Faslodex, a drug currently used to treat advanced breast cancer. In patients who received both drugs, the median progression-free survival was 11 months. It was 5.7 months for patients on Faslodex alone.\nIn the next paragraph, we are told the drug combination cut the risk of death or progression by 35 percent, but there are no statistics about the absolute number of people who died included in the story.\nTo learn more, we looked at the news release and study abstract put out by the organizers of the European Society for Medical Oncology (ESMO) 2018 conference in Munich, where the study was presented. This allowed us to discover that the study randomized 572 postmenopausal women or men with hormone-sensitive, HER2-negative advanced breast cancer. Of these, 341 were found to have the PIK3CA mutation when their tumor was tested. The findings reported from the study were specific to that group of patients who had the mutation. The news release explains that 36% of 262 patients with this mutation responded to the combination.\nWe also learn, in a quote from the study\u2019s lead author, that \u201cthe follow-up is short so we cannot say whether there is a long-term survival benefit.\u201d They hope that the progression-free survival will translate into an overall survival benefit\u2013but they don\u2019t know.\nIn short: There is no data to support the headline\u2019s claim that BYL719/alpelisib reduces the risk of death from breast cancer by 35 percent.", "answer": 0}, {"article": "Lung cancer kills more Americans than any other type of cancer, nearly 160,000 last year.\nJanne, also a professor at Harvard Medical School, said more research is needed before lung cancer patients should be routinely treated with Opdivo, Keytruda or similar drugs.\nThe new trial looked at a type of lung cancer called squamous cell non-small cell lung cancer, which accounts for about 20%-30% of lung cancers.\nThe study, in 234 patients, was the largest trial of the drug in lung cancer.\nMerck is also studying Keytruda in people with advanced lung cancer to better understand how they are responding to treatment, what determines how well a patient will respond, and how to get good results for more patients, Perlmutter said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says only that Opdivo \u201cis working so well that pharmaceutical giant Bristol-Myers Squibb announced Monday it is stopping a trial in lung cancer two years ahead of schedule.\u201d But \u201cworking well\u201d doesn\u2019t give readers any idea of the scope of potential benefits. The story also calls Opdivo a \u201cbreakthrough\u201d \u2014 how we can we know that if we don\u2019t know anything about what happened in this study? Even the relevant news release offered more information, stating that \u201cthe study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm\u201d (i.e., those patients receiving docetaxel). Even if Bristol-Myers Squibb chose not to release any numbers, it may still have been possible to find and discuss survival rates for squamous non-small cell lung cancer patients outside of the study who are treated with docetaxel. Failing that, the story could have noted the lack of quantifiable benefit information provided by Bristol-Myers Squibb.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not include information for the reader that the observed association between bone mineral density and cola consumption exhibited a dose response. In addition, since there is no known biologic basis for finding this association in women but not men, the relationship needs to be examined further to be sure that the association is real and robust, and that other confounding factors aren\u2019t at play. ", "answer": 0}, {"article": "For more information on asthma, visit the U.S. National Library of Medicine.\nThese drugs carry a note on their labels warning of the possibility of severe adverse events, including death, he noted.\nIn addition, the combination of an inhaled steroid and Spiriva was not less effective than using an inhaled steroid plus Serevent, they said.\nHowever, the study authors and an outside expert stressed that these are early findings and much longer, larger clinical trials are needed.\nThe results need to be confirmed in a much larger pool of patients, Peters said, and he noted that the patients were not followed long enough to see if Spiriva was able to reduce the severity of asthma attacks and hospitalizations.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits observed in the study were not quantified. As with harms, the story didn\u2019t tell readers how often events occurred. ", "answer": 0}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided comparative quantified specifics on the benefits of sulforaphane in the three groups of rabbits, in the form of percentage decrease in lipid levels.\u00a0We\u2019ll call that good enough for a Satisfactory rating, although ideally we\u2019d like to see some discussion of what the results might mean for cardiovascular risk in a human. We\u2019ll address that deficiency below under the Evidence criterion.", "answer": 1}, {"article": "The average age of people in both groups was 73.\nThe researchers found that people who went on to experience cognitive decline had significantly more signs of damage to their white matter.\nWhen the researchers focused on specific parts of the brain most likely to show damage, the accuracy rose to 95 percent.\nThe findings, presented Sunday, Nov. 25 at the Radiological Society of North America meeting in Chicago, suggest that doctors may one day be able to use widely available tests to tell people their risk of developing dementia before symptoms arise.\nOne day, MRI brain scans may help predict whether older people will develop dementia, new research suggests.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release said MRIs \u201cpredicted with 89 percent accuracy who would go on to develop dementia within three years\u201d when looking at the whole brain, and accuracy rose to 95% when researchers focused on \u201cspecific parts of the brain most likely to show damage.\u201d\nThose percentages might sound impressive. However, the news release didn\u2019t say how many people might benefit from a scan to detect Alzheimer\u2019s early, and how many might be subjected to testing that doesn\u2019t help them but could cause harm (see \u201cExplain Harms,\u201d below).\nFor example, the lifetime risk of developing Alzheimer\u2019s has been estimated at around 10-20%. According to our back-of-the-napkin calculations, if 100 older people were regularly screened using MRIs, as many as 19 might benefit from an early warning. The other 81 or so would not benefit or might be harmed.\n\u00a0", "answer": 0}, {"article": "(image: transmission electron micrograph of Zika virus, NIAID)\n\n\"If we could find a way to specifically target those GSCs that are the source of recurrence, then that might provide an option to prevent recurrence or even a cure,\" says Qin.\nIn a study published this week in mBio\u00ae, an open-access journal of the American Society for Microbiology, the team shows that a live, attenuated version of the Zika virus could form the basis of a new treatment option for this fatal brain cancer.\nIn addition, the Zika virus was much less efficient at attacking the differentiated, healthy brain cells.\nComparing those profiles, the team found that in the treated cells, the virus triggered a strong antiviral response in the cells, which induced inflammation and eventually cell death.\nNext, the team wanted to show whether the ZIKA-LAV could work to infect and kill human patient-derived GSCs in a mouse model.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We learn from the release that mice with the attenuated zika virus lived 50 days, in comparison to mice in the control group that lived 30 days.\nWe\u2019ll award a marginal satisfactory grade for this description, but we emphasize that it\u2019s a huge leap from mice to humans. We\u2019ll address that issue in more detail below under the evidence criterion.", "answer": 1}, {"article": "For more information about Hebrew SeniorLife, visit http://www.\n\"We found that that the presence of calcifications increased the likelihood of having cardiovascular disease such as heart attacks, and even the likelihood of cardiovascular deaths and mortality in general.\"\n\"Our study highlights the fact that having a bone density test not only tells women about their risk of fracture, but also their long term risk for cardiovascular disease.\nBOSTON -- Researchers from Hebrew SeniorLife's Institute for Aging Research, University of Western Australia, University of Sydney, and Edith Cowan University have discovered that bone density scans, typically used to determine fracture risk, could also be an aid in identifying cardiovascular disease.\nResearchers analyzed the bone density scans of over 1000 older women from Australia for the presence of calcium deposits in the large artery in the abdomen called the aorta.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The proposed benefit is to find people at increased risk of heart disease with a bone density scan and treat them.\nOne of the authors is quoted:\n\u201cWe found that that the presence of calcifications increased the likelihood of having cardiovascular disease such as heart attacks, and even the likelihood of cardiovascular deaths and mortality in general.\u201d\nHowever, the release doesn\u2019t provide numbers that put the presumed benefit in context.", "answer": 0}, {"article": "For more information, please see www.arthrokinex.com\nThis therapy has recently been highlighted by several professional football players traveling to Europe for treatment.\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\nThis treatment was developed by a German physician, Dr. Peter Wehling, in the 1980s.\nTypically, the treatment process is painless and just takes a few minutes and consists of one injection per week for three weeks, followed by quarterly injections, as needed.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release gives no numbers to help readers assess the new therapy\u2019s benefit. In fact, it says very little about the therapy benefit at all besides the fact that \u201csuccess has been achieved\u201d by using the treatment, and that the new treatment is \u201csignificantly better\u201d than a rival European treatment.\u00a0\nThere was no study mentioned in this news release. On the website of Arthokinex, the joint pain clinic that has released the new treatment, there is a link to a 2015 study published in the journal Cytokine by one of the clinic\u2019s doctors. The study looked retrospectively at the charts of 53 of the clinic\u2019s patients who had undergone this treatment, and concluded that the treatment was effective in treating mild to moderate osteoarthritis.\u00a0\nAs noted in this news release, the use of a patient\u2019s own blood as a treatment option has been available for some time. However, evidence demonstrating its benefit compared to placebo or other injections is very limited. Instead, the release implies benefit by referring to the use of this type of treatment by professional athletes.", "answer": 0}, {"article": "Critically ill children in intensive care are unable to eat independently.\nPrevious research by Professor Van den Berghe and her team (2011 and 2014) had already shown that early artificial feeding should be avoided to treat adults in intensive care.\nThese findings provide strong evidence against current practice and can thus be expected to change paediatric intensive care worldwide.\nThe current standard of care for such children is based mostly on the assumption that they need to eat to regain their strength.\nAn international team of researchers from University Hospitals Leuven (Belgium), Sophia Children's Hospital Rotterdam (The Netherlands), and Stollery Children's Hospital Edmonton (Canada) has now challenged the validity of this common practice.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release quotes the lead coordinating investigator saying \u201cthe current practice of feeding children in an early stage does not contribute to their recovery,\u201d but it offers not a single data point. There is no information provided other than the number of total participants, and no mention of the makeup of the randomized groups, the specific findings, or the comparative rates of new infections and lengths of ICU stay (the two endpoints of the study overall). The release does note more correctly at one point that the study was designed to \u201cchallenge the validity\u201d of early parenteral feeding, but it never explains the details or context of those feedings. The absolute difference in the outcomes between groups is left unanswered.", "answer": 0}, {"article": "Professor Francesca Cordeiro at UCL Institute of Ophthalmology, who led the research, said: \"Detecting glaucoma early is vital as symptoms are not always obvious.\nFurther studies will now be carried out to into DARC and how it can be used not only to diagnose and treat glaucoma patients but also for other neurodegenerative conditions.\nWhile we cannot cure the disease, our test means treatment can start before symptoms begin.\nNow, for the first time, we have been able to show individual cell death and detect the earliest signs of glaucoma.\nIn clinical trials, the pioneering diagnostic -- developed by researchers at University College London (UCL) and the Western Eye Hospital -- allowed doctors to see individual nerve cell death in the back of the eye.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release claims that \u201cour developments mean we could diagnose patients 10 years earlier than was previously possible\u201d but what does that mean in terms of disease prevention or reversal?\nThe release could have put the benefits in context by telling us more about what was involved with the test and how many people were diagnosed with early signs of glaucoma. What were these signs?", "answer": 0}, {"article": "\"Surprising thing was it didn't really matter what type of probiotic was used or in which setting,\" Allen says.\nAllen says that since the original review, there's been increasing interest in probiotics and, therefore, more research.\nEven so, Allen says more research is needed to determine the specific strains of bacteria that are most effective.\nStephen Allen, a pediatrician at Swansea University in the United Kingdom who lead the review, tells Shots that probiotics were effective in almost all the studies, which had more than 8,000 participants total, his team evaluated.\nAuthors of the review note that probiotics can work in several ways, including robbing the offending bacteria, viruses or parasites of nutrients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was clear that outcome studied was the duration for a bout with acute diarrhea. \u00a0However by opening the story with mention of possible ability to \u2018soothe fickle bowel\u2019, this piece plays into the marketing of benefit from probiotics beyond treating the condition studied. In addition, the story gives only relative risk reduction for the risk of prolonged diarrhea \u2013 reduced by 59%.\u00a0 But 59% of what?", "answer": 0}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The reader is left to ponder statements such as \u201cmice that\u00a0got night milk were significantly less active\u2026\u201d But how much less active?\nThe story does make a good faith effort to report some number-based outcomes from the study. It says, for example, \u201cBalance and coordination were measured by the number of falls from a rotating bar during a 20-minute period: Mice fed night milk on average fell four to five times, about twice as often as mice given day milk. Diazepam-treated controls fell about nine times, while the water-fed controls fell twice.\u201d But then again, it\u2019s not exactly made clear\u00a0how this result relates to the outcomes that readers are interested in such as sleep or anxiety. We\u2019ll reluctantly rate this Not Satisfactory.", "answer": 0}, {"article": "If an AAA is found, doctors sometimes use a stent to repair the aorta, but it doesn't always work since the aneurysms are often in places where a stent can\u2019t fit.\nWe can anticipate challenges by practicing the procedure beforehand.\u201d\n\nSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients.\nWhen they would open me up [the aorta] could just blow.\u201d\n\nThe bulge in the large artery that carries blood away from the heart can be immediately life-threatening if it grows large enough to rupture.\n\u201cAn aneurysm in no way means that you're going to die.\nThe cardiology community now prefers the endovascular approach.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Actual data is nowhere to be found to back up the assertion that this technique saves lives and results in quicker recoveries than other treatments, and it\u2019s not clear what the procedure is being compared to. Instead, there\u2019s one patient anecdote with an unsubstantiated statement that her condition \u201cnearly killed her.\u201d\nIdeally, the story should have made clear what data, if any, compares these customized stents to standard stents.", "answer": 0}, {"article": "In particular, it measures rhythmic patterns known as theta and beta waves.\nOn the other hand, Rabiner says, neurofeedback may offer something other treatments can't.\nBut it will take better research to figure out whether neurofeedback can live up to that promise, Rabiner says.\nUntil a large study comes along using this sort of approach, parents and consumers will have to decide for themselves whether neurofeedback is worth the time and effort.\nIn the meantime, he says, the study has shown that it is possible to do neurofeedback research that involves a placebo.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was the biggest hole in\u00a0an otherwise reasonably solid story. The article claims that there is \u201cgrowing evidence\u201d that neurofeedback can help treat people\u00a0with ADHD. However, the story never describes any of the results of this purported increase in research that supposedly documents these benefits.\u00a0The closest we come is the description of a study which hasn\u2019t even been published yet.\nThe story also suggests that neurofeedback\u2019s benefits might last longer than those of medication. Again, however, we are never given any sound basis to believe that neurofeedback works at all \u2014 let alone better than other treatments.\nAt the same time, the story leans heavily on testimony from a journalist who has written a book about ADHD and claims neurofeedback worked for her and her son.\u00a0\u00a0We are told that the primary improvement she saw with\u00a0her son\u00a0was that he was \u201ceasier to live with.\u201d\u00a0Although this kind of anecdotal report\u00a0can be useful\u00a0to add context to scientific findings,\u00a0it is\u00a0certainly no substitute for reporting on the actual clinical outcomes\u00a0of research.", "answer": 0}, {"article": "Nerve cells that communicate and control the voluntary muscles of the body (such as those in the arms, legs and face) degenerate or die.\n\"People who do these studies should be considered medical heroes,\" Goldstein said, adding, \"The selflessness of these people when they're told they're gonna die.\"\nIn Pharr's opinion, this and other stem cell studies are certainly fair from a participant's perspective, since beforehand, \"patients are presented with all the risk factors involved so they can make an informed decision.\"\nWhat he discovered during that experiment was that none of the patients suffered long-term effects (from either the surgical procedure or the implantation of stem cells), and no unusual acceleration of disease occurred.\n\"He did not want to go on the ventilator,\" she said, adding that many people prefer a \"natural death.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Since this was primarily a safety study, there are no measurable benefits to quantify, and the story lets us know with this statement:\u00a0\u201cUnfortunately, the procedure provided no benefit to patients.\u201d\nWe\u2019ll count this as sufficient for a Satisfactory rating.\nHowever, we encourage journalists to think twice about giving air time to early-phase trials, especially for stem cells. In many cases, there isn\u2019t a lot to report yet, since benefits haven\u2019t been established in any meaningful way. Better to wait until bigger trials are conducted, which was even implied with this ending quote in the story:\n\u201cWe are just now getting started with testing our hypotheses about using stem cells as therapeutics,\u201d Glass said. \u201cWe do not know if these treatments will work, and it will take time to test these therapies in a systematic and safe way.\u201d", "answer": 1}, {"article": "About the American Academy of OphthalmologyThe American Academy of Ophthalmology is the world\u2019s largest membership association of eye physicians and surgeons.\nDuring the baseline measurement, diets rich in vitamin C were associated with a 20 percent risk reduction for cataract.\nThe research is also the first to show that diet and lifestyle may play a greater role than genetics in cataract development and severity.\nThese results make the study the first to suggest that genetic factors may be less important in progression of cataract than previously thought.\nResearchers noted that the findings only pertain to consuming the nutrient through food and not vitamin supplements.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news releases notes that, \u201cDuring the baseline measurement, diets rich in vitamin C were associated with a 20 percent risk reduction for cataract. After 10 years, researchers found that women who reported consuming more vitamin C-rich foods had a 33 percent risk reduction of cataract progression.\u201d\nThe release would have been stronger if it had used absolute numbers (the actual total rate of cataracts in women with vitamin C-rich diets vs. those with diets low in vitamin C) in addition to the relative risk figures.", "answer": 0}, {"article": "Editor's note: Tune in as Dr. Sanjay Gupta explores the signs, tests and lifestyle changes that could make cardiac problems a thing of the past on \"The Last Heart Attack,\" Saturday, August 27, 8 and 11 p.m.\nLead author Dr. David Jenkins, Canada research chair in nutrition and metabolism at the University of Toronto and St. Michael's Hospital, had previously shown the effectiveness of a cholesterol-lowering diet when all the meals were provided to participants.\nJenkins said participants achieved these results even though compliance to the whole grain, vegetarian diet was only about 40%.\nThe 351 participants in the study suffered from high cholesterol but were not on a cholesterol-lowering statin medication.\nTo put the diet to the real-world test, participants received a one-hour counseling session with a dietitian and an illustrated study booklet at the outset and, later, received a 30-40 minute follow up session.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us how much the diet reduced cholesterol, providing the actual\u00a0values from the lab report.\u00a0It could have also\u00a0estimated the expected reduction in 10-year cardiovascular risk that this would\u00a0correspond to.", "answer": 1}, {"article": "\"Are [aromatase inhibitors] better than tamoxifen?\nAromatase inhibitors are not effective in this age group, the experts note.\nAll three aromatase inhibitors on the market - Arimidex (anastrozole), Femara (letrozole) and Aromasin (exemestane) - were essentially equal in their benefit.\nYes, in two areas: preventing recurrent disease in other parts of the body and in preventing a second, separate breast cancer.\n\"In general, for postmenopausal women, we are offering them aromatase inhibitors based on the single studies that have been referenced [in these guidelines] and what has already been reported in national meetings.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "Nothing worked.\nBy middle age, Ms. Gallagher, 51, the owner of a pet-sitting business in Torrance, Calif., was avoiding mirrors and considering liposuction, but she worried about the effects of anesthesia and the recovery time.\nThen she discovered another option: a series of fat-reducing injections intended to slim down a double chin.\nShe stood ramrod-straight, head held high, to make the bulge less apparent.\nEven as a pigtailed child, Ashley Gallagher was self-conscious about a certain fullness in her face.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides a good deal more information on the benefits seen in the clinical trials than does the corresponding Washington Post coverage. We are told, \u201cThe pooled results from both trials found that 68.2 percent of patients who got the drug saw at least a one-grade reduction in fat, compared with 20.5 percent of patients who got sham injections. Grading was determined by clinical examination and answers on a standardized form. Sixteen percent of patients who received the real injections saw a reduction of two grades in under-chin fat. Only 1.5 percent of the placebo group saw that level of improvement.\u201d\u00a0We would have liked to have seen some detail about what a two-grade change in under-chin would look like, however.\nAnd while the story does focus extensively on one patient\u2019s anecdotal success story, it also notes that not every patient is a good candidate for treatment. Example: \u201cIf a patient has excess fat and loose skin, Dr. Rohrich said, \u2018you\u2019ll have a crepey neck and need a neck lift\u2019 after fat is reduced with the shot. Neck lifts can cost $5,000 or more.\u201d", "answer": 1}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t quantify benefits, instead focusing on one patient\u2019s experience with the technique and noting that it \u201chas been getting positive reviews so far\u201d in a U.S. clinical trial. The story also notes that Sonata was approved in Europe. A 2015 paper in the journal Gynecological Surgery offers information on\u00a0outcomes for 50 patients in a \u201cFAST-EU\u201d trial for Viz-Ablate (which appears to be another name for Sonata). For example, 12 months after the procedure, 38 of 48 patients had reduced menstrual bleeding by at least 22 percent (which study authors described as the threshold mark for being \u201cmeaningful\u201d to most women).\u00a0 The Sonata trial is designed to measure effectiveness (defined as more than 50% reduction in blood loss) and safety in a U.S. population.", "answer": 0}, {"article": "More: The hidden side of dementia: Families fight over care, end-of-life decisions, finances, estates\n\nDementia is a term used to broadly describe symptoms of cognitive decline; Alzheimer's disease is the most common cause of dementia.\nDoris Lambracht-Washington, a professor of neurology and neurotherapeutics at the University of Texas Southwestern Medical Center, said researchers believe the vaccine could extend lives by preventing the disease from developing.\nIf the vaccine proves safe and effective in humans, it could slice the number of dementia diagnoses in half, the study's senior author told USA TODAY.\nTesting in mice showed that the vaccine safely prevents the buildup of substances in the brain associated with the fatal disease, the team reported this week in the journal Alzheimer's Research & Therapy.\nAn experimental vaccine that could hold off Alzheimer's disease showed promising results in animal testing, according to researchers at the University of Texas Southwestern Medical Center.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives no data to describe the differences in the buildup of amyloid in the brains of mice given the vaccine versus those not given it.\nA news release stated: \u201cThe latest study \u2013 consisting of four cohorts of between 15 and 24 mice each \u2013 shows the vaccine prompted a 40 percent reduction in beta-amyloid and up to a 50 percent reduction in tau, with no adverse immune response.\u201d\nAlso, the story doesn\u2019t explain whether there\u2019s any data behind these speculative comments about potential human benefits from a researcher:\n\u201cIf the onset of the disease could be delayed by even five years, that would be enormous for the patients and their families. \u2026 The number of dementia cases could drop by half.\u201d", "answer": 0}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Mentioned lack of \nbenefit from statins for this purpose; also provided some details of side effects of statins", "answer": 1}, {"article": "The Kennedy Institute's Professor Kim Midwood said: 'What is particularly exciting is that when we looked at samples taken from people before their arthritis began, we could see these antibodies to cTNC up to 16 years before the disease occurred - on average the antibodies could be found seven years before the disease appeared.\nA team from the Kennedy Institute of Rheumatology at Oxford University found that a blood test that looks for antibodies that recognize the protein tenascin-C could reliably show those who will contract the condition.\nWhile tests for individual proteins usually have a relatively low diagnostic sensitivity, a more general test called CCP, that detects synthetic citrullinated peptides, identifies a lot more RA cases.\nFor that reason, tests that spot antibodies to citrullinated proteins are already used to diagnose the disease.\nThis latest research provides the basis of tests that could improve diagnosis and, importantly, detect disease at a very early stage, with the promise even that people at risk of developing rheumatoid arthritis can be followed before the disease begins.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release asserts that the key benefit of the test for tenascin-C protein is early detection of RA that can be used to initiate early treatment. After looking at results from 2,000 patient volunteers, the lead researcher was quoted saying the test \u201ccould diagnose RA in about 50% of cases\u201d and that the test was 98% accurate in ruling out RA. It isn\u2019t clear from the release if all 2,000 patients started out healthy and half went on to develop RA, or if the test accurately detected the RA precursor protein in only half the patients that went on to develop RA.\nOverall, the release provides insufficient information to quantify the benefits. Accuracy is a reflection of both sensitivity (diagnosing the condition when it really exists) and specificity (not diagnosing the condition when it doesn\u2019t exist). The very high accuracy implies the test is both sensitive and specific. However, this may be misleading depending on the nature of the population studied. If the population includes patients with established rheumatoid arthritis it may make the test look better than studying a population of individuals who don\u2019t have the condition or may have a different condition.", "answer": 0}, {"article": "\"In these types of studies you think of things like this,\" Haber said, \"but how real it is, is something we're going to have to see.\nSo it's difficult to generalize this study's results to other diseases that affect memory, she said, and the research didn't show if effects of temporary deep brain stimulation last beyond the study period.\nStimulation of the entorhinal cortex -- a region considered crucial to transforming daily experience into lasting memories -- produced the improvement, the researchers said.\nAlthough the results are still preliminary, the method may potentially hold promise for boosting memory in patients with early Alzheimer's disease, the researchers said.\n\"Critically, it was the stimulation at the gateway into the hippocampus, and not the hippocampus itself, that proved effective,\" senior study author Dr. Itzhak Fried, a professor of neurosurgery at the David Geffen School of Medicine at UCLA, said in a university news release.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that the test looked only at a simulation of learning how to navigate a virtual city. It points out that this test does not prove that electrical brain stimulation can overcome memory problems caused by Alzheimer\u2019s disease or other types of dementia. An independent source quoted in the story points out the experiment did not show if the effects last.", "answer": 1}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\nPodiatrists have begun using a laser treatment that combats the infection \u2014 or wastes their patients\u2019 money because it doesn\u2019t work, depending on whom you ask.\nThere\u2019s no one route of infection, but sources include pedicures and locker room showers.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are not well quantified. The FDA approved the Pinpointe FootLaser noting it is, \u201csubstantially equivalent to the predicate devices and is safe and effective for use for the temporary increase of clear nail at 6 and 12 months following treatment in patients with onychomycosis.\u201d We are unable to locate any studies comparing it or any laser to prescription drugs in the treatment of toenail fungus. We think that the story was a bit over the top in its enthusiasm.", "answer": 0}, {"article": "The quality of what you get can differ from one practitioner to another,\" said Manber.\nA response rate was defined as a 50 percent reduction in depression symptoms, Manber said.\nMONDAY, Feb. 22, 2010 (HealthDay News) -- Women who experience depression during pregnancy may have another treatment option, new research suggests.\nThe depression-specific protocol was designed just for this study, and the control acupuncture was specifically designed to avoid using acupuncture needles in any areas known to affect depression.\nDr. Shari Lusskin, director of reproductive psychiatry at the New York University Langone Medical Center, echoed that sentiment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only reported benefits in relative terms, but those percentages were juxtaposed to the actual numbers of women assigned to the three study groups \u2013 so it\u2019s possible for readers to do the math.\u00a0 Nonetheless, why make them do the math?\u00a0 Why not just give the absolute numbers of how many in each group responded? \nOne thing we did like is that the story explained that the study defined a \"positive response\" from treatment as an improvement of more than 50% in depressive symptoms. It would be interesting to know if the women in the study would self report this amount of improvement as a significant improvement in how they were feeling.", "answer": 1}, {"article": "Feb. 10, 2011 (Los Angeles) -- Giving clot-busting drugs to people with mild strokes could prevent more than 2,000 of them from becoming disabled each year, researchers say.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nBut people with mild strokes are typically denied tPA because the studies that established its effectiveness excluded mild cases, says Pooja Khatri, MD, of the University of Cincinnati.\nThose parts of the brain soon start to die.\nIt's been assumed that people with mild strokes \"generally [do] well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit,\" she says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No, as in \u201cevidence\u201d above, the benefits in the 4 patients are really never explained.", "answer": 0}, {"article": "Newswise \u2014 RESEARCH TRIANGLE PARK, NC\u2014 Major depressive disorder affects more than 32 million Americans, and their first stop for treatment is often their primary care provider.\nHowever, the evidence shows that cognitive behavioral therapy can be just as effective, providing important information for patients and their physicians to consider when choosing among available treatment options.\"\nA recent evidence review of several alternatives to medication found that using cognitive behavioral therapy as the first treatment for depression can be equally effective as using a second generation antidepressant.\nThe authors focused specifically on comparing second generation antidepressants, such as Wellbutrin, Lexapro and Prozac with cognitive behavioral therapy, which includes several in-person or phone sessions with a therapist to examine how actions and thoughts can impact depression.\n\"Major depressive disorder is a disabling and prevalent form of depression, experienced by more than 16 percent of U.S. adults during their lifetime,\" said Arlene Bierman, M.D., Director, Center for Evidence and Practice Improvement, at the Agency for Healthcare Research and Quality, which funded the study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There was no quantification of benefits. That\u2019s a big omission considering people with major depressive disorder are being told that talk therapy and medications yield the same outcome.\nSome of the important quantifiers missing include:\nHow long was the treatment? What percent improved after treatment? How much did they improve? What was the rate of relapse? How long did they improve?", "answer": 0}, {"article": "\"That's where the money is,\" Malmgren said.\nMalmgren, a breast cancer survivor, says more focus should be placed on the benefit of early diagnosis, because it often means less treatment is needed.\nHowever, she said, the study does not provide support for all women aged 40 to 49 to have routine mammograms.\n\"The data from randomized trials and modeling show there is a very modest improvement in mortality with mammograms from 40 to 49,\" she said.\nWhen considering its recommendation, the task force took all available evidence into account, including published studies, Moyer noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019ll give the story the benefit of the doubt for presenting lots of numbers \u2013 in contrast with the WebMD story that included NONE.\nHowever, more critical analysis would have been appreciated.", "answer": 1}, {"article": "\"This is a small study, but also very intensive with direct, accurate pressure measurements,\" Moon said.\n\"Some cases of SIPE appear to have been the result of cardiac problems,\" said Moon, who was lead author of the study published online February 16 in Circulation: Journal of the American Heart Association.\nNone of the participants in either group had heart abnormalities, but the SIPE-susceptible athletes had higher pulmonary arterial pressure and pulmonary artery wedge pressure during the underwater exercise, confirming that SIPE is a form of pulmonary edema caused by high pressure in the blood vessels within the lungs.\nHe also said research is ongoing to further illuminate the causes of SIPE and potential ways of diagnosing it early.\nMoon and colleagues studied these responses in 10 athletes who had experienced the condition while exercising or competing in triathlons.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the press release indicates that measures of pulmonary arterial pressure \u201cwere no longer as elevated\u201d in individuals who received sildenafil, the document got no more specific than that. The author described the benefit very vaguely in this statement:\n\u201cIt appears that the drug, which dilates the blood vessels, could be creating more capacity in the blood vessels in the arms and legs, reducing the tendency for blood to redistribute to the thorax, and therefore reducing the high pressure in the pulmonary vessels.\u201d\nWe\u2019re also concerned with the glowing anecdote that the release uses to illustrate the drug\u2019s benefits. The study itself looked at pulmonary arterial pressure and had nothing to say about sildenafil\u2019s ability to prevent bouts of SIPE during competition. Nevertheless, this study participant gushes,\n\u201cI have successfully raced in 20 triathlons since I started taking sildenafil, including five ultra events that require 10-kilometer swims,\u201d Calder-Becker said. \u201cI have not had an incident since then. I didn\u2019t want to give up racing \u2014 this is something my husband and I do together, and we travel together to competitions \u2014 so it has meant everything to me to continue.\u201d\nThe anecdote goes well beyond the limited parameters of the study and overwhelms any cautions regarding the limitations of current evidence.", "answer": 0}, {"article": "The Mount Sinai Hospital is in the \"Honor Roll\" of best hospitals in America, ranked No.\nThe research also determined that the best surgical approach for cochlear implant procedures did not involve drilling into the bone around the ear.\nThe results, published in the June 23, 2017, online edition of The Laryngoscope, may transform how doctors approach cochlear implant procedures to give patients the best possible outcomes.\nMore specifically, the non-wire electrodes were less traumatic, causing less injury and minimizing fractures inside the inner ear.\n\"This study is a breakthrough for patients with hearing loss, and improvements in practice and techniques will allow them to enjoy many hearing benefits such as music enjoyment, listening in complex environments, and sound localization.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Two types of benefits are discussed in the news release.\nThe study looked at 230 patients (it was actually 196 patients but 225 implants) \u00a0with \u201cevery type of cochlear implant, including three FDA-approved implants that use different types of electrodes to stimulate the auditory nerve.\u201d \u00a0The benefits were not quantified but we are told that the researchers \u201cfound that electrodes designed with no wire (called lateral wall electrodes) performed the best in maintaining residual hearing in the inner ear, compared to electrodes made with wire.\u201d \u00a0How much better? We don\u2019t know.\nThe other benefit compares \u201ccochleostomy\u201d (which requires drilling into the bone to get inside the inner ear) versus the \u201cround window\u201d approach and \u201cthe round window approach had a much better chance of keeping their residual hearing in the long term.\u201d\nHow much better? \u00a0We aren\u2019t told.", "answer": 0}, {"article": "\u2022 The percentage of days with full asthma control were virtually the same for acetaminophen and ibuprofen: 85.8 and 86.8 percent, respectively.\nWhile the study was modest in size, it was powered to detect any clinically significant differences, more so than past retrospective studies, Phipatanakul notes.\nThe study enrolled 300 children 1 to 5 years old with mild persistent asthma.\n(The asthma therapies were given in varying order as part of a concurrent randomized trial, making this, in effect, a \"trial within a trial.\")\nThe 18-site study should settle a debate that originated when several retrospective studies seemed to indicate that children had exacerbations of their asthma when receiving Tylenol for pain and/or fever.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "One of the questions the study attempted to answer was whether ibuprofen is a safer drug than acetaminophen in children with mild persistent asthma. This release does a laudable\u00a0job laying out the figures for the number of asthma exacerbations for each group. It\u00a0also includes quantitative data for the percentage of days with full asthma control, use of \u201crescue medication\u201d and unscheduled healthcare visits. It also used the term \u201csignificant\u201d correctly, stating that there \u201cwere no statistically significant differences between groups\u201d (a common mistake we\u2019ve seen in other releases).\nDue to all these factors, we give the news release a Satisfactory rating here.", "answer": 1}, {"article": "\"We adjusted for as many of those differences as we could,\" Wong said.\nOther experts expressed skepticism, saying the study's design may have missed another explanation for the lower death rate among men who were treated: They were probably healthier in ways that doctors can tell only by examining them, not by looking at their medical records, which is what the study's authors did.\nThe research, published in today's Journal of the American Medical Association, is the first to directly examine what has become conventional wisdom: that many older men need not treat early prostate cancer because it tends to grow so slowly that they will probably die of something else first.\n\"For many years, the thinking has been that observation or 'watchful waiting' was the safest option for elderly patients with early prostate cancer,\" said Yu-Ning Wong of the Fox Chase Cancer Center in Philadelphia, who led the study.\nThe findings prompted debate among specialists, who said the results could have potentially far-reaching implications because they address one of the central quandaries about prostate cancer and because the disease is so common.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article only provides relative risk reductions when absolute risk reductions are best (and are provided in the study findings).\u00a0 The article also claims that the study findings \"indicate that treatment offered a clear advantage,\" which is premature since this is not a randomized trial. The quote from an \"expert\" (the story gives no information about his expertise)\u00a0 is misleading:\u00a0 \"This debunks the idea that older men do not benefit from treatment.\"\u00a0 Clearly, the study is completely insufficient to 'debunk' watchful waiting as a treatment option for prostate cancer, especially in older men. ", "answer": 0}, {"article": "Tim Barham, the vice president of HBB, the maker of Lazy Cakes, said, \u201cWe look at the brownie as a supplement.\u201d\n\nNews reports have classified Lazy Cakes as dietary supplements, but last month, Douglas Karas, an F.D.A.\nBut she added, \u201cI don\u2019t want to go on the record saying this drug \u2018can\u2019 cause respiratory issues, that should be a \u2018may.\u2019 \u201d\n\nLazy Cakes appear harmless, even amusing, with swirly purple packaging; Kush Cakes have a tie-dye-printed wrapper.\nOf melatonin, Dr. Seres warned, \u201cIf you take it while you\u2019re driving a car, you will find yourself in a ditch.\u201d\n\nMaybe.\nFor me, it\u2019s to get a good night\u2019s sleep.\u201d\n\nYet the products, intended for adults only, are being marketed as a novel way to relax in a stressed-out, wired world.\nThat said, he would not advise eating Lazy Cakes, partly because he was not sure that their other purportedly sleep-inducing ingredients like valerian root work and partly because food delays rather than hastens the absorption of melatonin.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is clear that \u2013 despite the claims made by some who stand to profit \u2013 there is no quantifiable information about benefits documented about these products.\u00a0 And there\u2019s this closing skepticism from Dr. Lewy: \u201che was not sure that their other purportedly sleep-inducing ingredients like valerian root work and partly because food delays rather than hastens the absorption of melatonin.\u201d", "answer": 1}, {"article": "J Nucleic Acids pli:725071. doi:10.4061/2010/725071.\nIt is a serious intervention to improve health.\nFormulation development was guided by over 15 small clinical trials to ensure that beneficial properties of the bar were retained.\nThese trials were conducted over a 4-year period using very similar bar formulations.\nThe CHORI-team thinks the broad scale improvements observed with the CHORI-bar may be the result of \"oiling\" multiple joints by the complex nutrient mixture.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The peer-reviewed article on which the news release is based quantifies the results of the study, which don\u2019t seem to square with a claim of \u201cbroad scale health improvement.\u201d According to the study abstract, a group of \u201cless-inflamed\u201d participants lost 2.4 pounds of body weight over the course of 2 months while eating the bars. But the news release refers generally only to such things as \u201cimproved metabolism\u201d and \u201creduction in weight and waist circumference,\u201d offering no specifics.", "answer": 0}, {"article": "Heart disease is still the leading killer of Americans \u2014 790,000 people have heart attacks each year \u2014 and stenting is a mainstay treatment in virtually every hospital.\nThe devices are lifesaving when used to open arteries in patients in the throes of a heart attack.\nSometimes patients get stents when they have no pain at all, just blockages.\nTheir study focused on the insertion of stents, tiny wire cages, to open blocked arteries.\nMore than 500,000 heart patients worldwide have stents inserted each year to relieve chest pain, according to the researchers.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes clear there was no significant difference between a sham procedure or stent insertion, but it only describes the benefit as \u201cless pain.\u201d We would like to see how the pain was measured, some numbers on how much pain was reduced, and how many patients benefitted in each group.", "answer": 0}, {"article": "\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says.\nShe calls the findings \u201cintriguing\u201d but says they \u201cdo not equate a randomized clinical trial and should be used with appropriate caution in making broad recommendations.\u201d\n\nSuzanne Steinbaum, MD, director of women and heart disease at Lenox Hill Hospital in New York, says moderate use of olive oil in cooking and on bread may help protect against stroke in people older than 65.\nShe agrees with the study authors and editorialist that it is too early to make any recommendations about olive oil intake and stroke risk.\nThis is one of very few studies that looks at olive oil intake and risk for neurologic diseases, including stroke, Nikolaos Scarmeas, MD, of Columbia University in New York City, says in an email.\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only cited a 41% lower risk of stroke but didn\u2019t give the actual numbers of how many versus how many in the different groups. That may give an inflated sense of benefit or risk reduction.", "answer": 0}, {"article": "Transcendental meditation involves shutting out the outside world and focusing thoughts inward, or resting while remaining alert.\nBut while the magnitude of those results is remarkable, the study involved a relatively small number of participants, and did not reveal how meditation may be lowering heart disease risk.\nMORE: Medical Meditation: Say Om Before Surgery\n\nAfter roughly five years of follow-up, the researchers found a 48% reduction in the overall risk of heart attack, stroke, and death from any cause among members of the meditation group compared to those from the health education group.\nPrevious studies have linked better health outcomes among heart patients who practiced meditation compared to those who did not, but none of those trials could definitively credit the brain-focusing program with the better health results.\nStudies Say Meditation May Help\n\n\u201cThe main finding [of our research] is that, added on top of usual medical care, intervention with a mind-body technique \u2014 transcendental meditation \u2014 can have a major effect on cardiovascular events,\u201d says Robert Schneider, lead author on the study published in Circulation: Cardiovascular Quality and Outcomes and a professor at the Maharishi University of Management, an institution in Iowa that was founded by the creator of transcendental meditation.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us there was a \u201c48%\u00a0reduction in the overall risk of heart attack, stroke, and death from any cause among members of the meditation group compared to those from the health education group.\u201d However,\u00a0the absolute difference in outcomes between groups was not quite as striking as this figure would suggest. There were 20 events in the meditation group and 32 in the control group \u2014 data the story easily could (and\u00a0should) have provided.\nThe story did not provide any information on cardiovascular endpoints which were secondary outcome measures.\u00a0 There were 4 deaths from cardiovascular disease in the meditation group and 5 in the health education subjects.", "answer": 0}, {"article": "Two new devices\u2014one that deflates fat cells, one that destroys them\u2014have just been cleared for \"body contouring\" in doctors' offices by the Food and Drug Administration.\n\nZeltiq grabs onto love handles and belly pouches and freezes the fat cells inside, causing them to self-destruct over several months. Zerona...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story provided no insight about the amount of circumference that could be reduced with the use of these devices or whether the reduction was predictably long term or not.", "answer": 0}, {"article": "For more about blood pressure drugs, visit the American Heart Association.\nAccording to the new analysis, published online Jan. 4 in the Mayo Clinic Proceedings, the only difference between the medications is that ARBs are more easily tolerated.\nAlthough ACE inhibitors were developed 10 years earlier, both types of drugs showed similar effects in the analysis, challenging previous findings that suggest ACE inhibitors have greater benefits.\nHowever, when trials were conducted at similar times, one drug was not more effective than the other, the findings showed.\nScientists at the NYU Langone Medical Center in New York City said their findings settle a longstanding debate about which of two types blood-pressure lowering medications studied are better.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story never says what outcomes exactly we\u2019re talking about \u2014 deaths, heart attacks, blood pressure? Nor does it say how effective these medications were at improving these outcomes \u2014 merely that they are equivalent. We think both of these issues should have been addressed in order to earn a Satisfactory rating here.", "answer": 0}, {"article": ".\nIn this context, the phase III \"Helix\" study is being carried out in more than 30 hospitals in Spain, Germany, Estonia, Portugal, Slovakia and Italy, in 300 patients to evaluate the efficacy of this compound in the treatment of the sign and symptoms of dry eye syndrome.\nThe novel mechanism of action of tivanisiran, based on genetic silencing through RNA interference (RNAi), is targeted at the treatment of the signs and symptoms of this pathology, making it a firm candidate for the treatment of dry eye disease.\nWe currently have a robust therapeutic program in ophthalmology with two candidates under development in Phase II and III studies for glaucoma (bamosiran) and ocular pain (SYL1001) , respectively.\nTivanisiran is a product under development for the treatment of signs and symptoms related to dry eye syndrome and has the potential to be developed for other pathologies that cause ocular pain (corneal lesions, refractive surgery, etc.)\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no effort made in this release to provide any numbers that would put the benefits of using tivanisiran in context. It does quote a scientist working on the treatment endorsing the drug:\nAccording to Ana Isabel Jim\u00e9nez, Director of R&D at Sylentis, \u201cwe trust in our technology, innovative in this field, and we hope that tivanisiran will soon become a real alternative for the treatment of millions of people that suffer dry eye disease around the world.\u201d", "answer": 0}, {"article": "\"What we found is that kids get home from school around 4 p.m.\nParticipants in the study were part of a larger longitudinal study on a school-based obesity intervention program.\nThe researchers conclude that afterschool programs and schools can replace energy dense, unhealthy snacks with peanuts to provide a healthier alternative for children (researchers in the study ensured students did not suffer from nut allergies).\nFollowing the 12-week intervention, students spent 12 more weeks maintaining the healthy snacking habit.\nThe study acknowledged that snacking is more common during the adolescent years and that the unhealthy eating habit can lead to an unhealthy weight.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release confuses or misses some key points about the study and the data it obtained and set out to measure. The intervention was not a \u201c12-week\u201d study, but lasted six months overall. Moreover, the goal of the study was not to measure the impact of eating peanuts on weight loss. It was to compare the weight loss or BMI-reduction outcomes in Mexican-American children who were either high adherents or low adherents to a suggested (and freely offered) snack of peanuts or peanut butter on a daily basis at the end of the school day. And the study also included educational and physical activity components. The release is unclear about the actual number of students in the comparison groups who lost weight. It is silent on how much the teens weighed on average or across a range at the start and end of the study in the comparison groups, and it tells us nothing about the number of calories in the snacks or how much physical activity was involved. The published abstract did not either, but presumably the full study was available in the preparation of the release. The release does note that students who got the snack more regularly decreased their overall BMI by .7kg/m2 compared to those who did not get the snack regularly, but most readers will not do the math or understand what the figure means. It needs to be pointed out that the 0.7kg/m2 drop was not deemed statistically significant, even by way of the often-denigrated p value where it was found to be 0.21 (a value less than .05 is traditionally deemed \u201csignificant\u201d). It\u2019s also worth noting that the absolute difference in weight between the two groups was the high adherence kids GAINING\u00a01.54 pounds less than the low adherence kids \u2014 a difference deemed not to be statistically significant either (P 0.63).", "answer": 0}, {"article": "Trials were conducted on nine healthy individuals in a blinded comparative study on absorbable versus fermentable carbohydrates.\nThe findings show the revolutionary gas-sensing capsule developed by researchers at RMIT University in Melbourne, Australia, could surpass breath testing as the benchmark for diagnosing gut disorders, paving the way to solving previously undiagnosed conditions.\nNew trials of a breakthrough swallowable sensor have revealed the device is 3,000 times more accurate than current technology used to diagnose many gut disorders.\nThe vitamin pill-sized capsule, currently being commercialised by Atmo Biosciences, provides real time detection and measurement of hydrogen, carbon dioxides and oxygen in the gut.\n\"Importantly this test is non-invasive and allows the patient to continue with their daily life as normal.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The main benefits touted are:\nUnfortunately, we\u2019re not given any supporting data, or context to place these results in perspective.\nAre readers expected to know what high sensitivity and signal-to-noise ratio are?\nWe\u2019re told the capsule measures gases, but how do those relate to disease?\nFurthermore, where\u00a0exactly\u00a0did the\u00a0\u201c3000 times more accurate\u201d figure come from and what does it mean? Based on our analysis of the study itself, it seems that the\u00a0capsule detected about 12 times as much hydrogen as the breath test in the point of the intestine with the greatest difference.\nAnd \u201csensitivity\u201d (the ability to correctly identify patients with disease) cannot be measured since there are no patients with confirmed disease in this study. (We provide an overview of sensitivity and other issues related to medical testing in our primer: Understanding medical tests: sensitivity, specificity, and positive predictive value.)", "answer": 0}, {"article": "Medical-device makers, venture capitalists and surgeons are racing to turn a once-controversial weight-loss procedure into the next big thing in elective surgery.\n\nOnce dismissed by some surgeons as a gimmick, gastric banding -- in which a silicone band is wrapped around the upper stomach to restrict food intake -- is now the focus of a fierce competition pitting consumer-products giant Johnson & Johnson against Botox maker Allergan Inc. Venture-capital-backed outpatient centers are popping up to implant the bands. Growing...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the story mentioned weight loss, health improvement, and longer life, it failed to provide quantitative estimates for these. \u00a0\nThe story provided quantitative information on the disease reduction obtained with the use of this device in individuals with type II diabetes. \u00a0 Although the story did mention that weight loss is slower with gastric banding than with gastric bypass, it\u00a0failed to provide quantitative information about the amount or rate of weight loss attained with banding. \u00a0The story should also have mentioned that long-term followup finds for those whose diabetes resolves following gastric banding, about half re-develop diabetes at 10 years. \u00a0\n\u00a0", "answer": 0}, {"article": "1Wiseman JT, Guzman AM, Fernandes-Taylor S, et al.\nDr. Gunter said they were very successful in giving patients knowledge and access to technology so they could participate in the study.\nThe study results appear as an \"article in press\" on the website of the Journal of the American College of Surgeons ahead of print.\nThe WiSOR research team addressed this issue by having participants undergo tailored training to learn to use the WoundCheck app.\nThis protocol also has a cost-savings component, in addition to the patient safety and satisfaction aspects.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release reports \u201can overall data submission rate of 90.2 percent among participants, and submissions were reviewed within an average of 9.7 hours. During the study, seven wound complications were detected and one false negative was found.\u201d\nBut with no control group and no long term outcomes studied, it\u2019s likely the benefits of the app are much more modest than these numbers suggest.  ", "answer": 1}, {"article": "Men and women with mildly high blood pressure who ate three kiwi fruits a day for eight weeks had systolic blood pressure levels that were 3.6 millimeters of mercury lower than those of volunteers who ate an apple a day.\nIn addition, the study looked at the whole fruit, not individual nutrients.\nBecause this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nDon't start popping lutein in supplement form based on these results, he noted.\n\"Three kiwis a day or 21 kiwis a week does not seem like moderation, and I would caution against eating that much,\" he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantified the benefits but didn\u2019t put them in any meaningful perspective. What difference does it make to lower systolic blood pressure by 3.6 points?\nIs this truly newsworthy?\nEnough to raise the question in the story, \u201cSo is kiwi the new \u2018wonder\u2019 fruit?\u201d", "answer": 0}, {"article": "\u201cWe want to alleviate the suffering and get them back to their life,\u201d he said.\nRight now, medications available for treating either major depression or bipolar illness can take weeks, or even months, to work, notes Dr. Carlos A. Zarate Jr. of the National Institutes of Health in Bethesda, Maryland, one of the researchers on the study.\nIt\u2019s also a drug of abuse, at much higher doses than those used in Zarate\u2019s research; while patients in the current study received about 50 milligrams during a 40-minute period, a dose too low to induce anesthesia, recreational users of ketamine, known as \u201cSpecial K,\u201d may take hundreds of milligrams per week.\nBut, according to Zarate, more research is needed on how to use the drug in the safest and most effective way.\nBy developing more specifically targeted drugs, Zarate noted, it may be possible to treat patients effectively while avoiding these symptoms.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tosses in a few numbers, but it uses them in such a way that they make the benefits seem more impressive than they really are. An honest approach would have been to start with the 18 patients and then give the absolute number of all patients who benefited, did not, or suffered side effects. Instead, the story says, for example, that \" Six percent responded to placebo.\" That\u2019s roughly\u00a0one person. One person versus the 12 who responded to the drug. Whether this ratio would shrink or expand in a larger, controlled study is never discussed with any other scientists.", "answer": 0}, {"article": "But it is also relevant to anyone who takes their weight management seriously and wants to stay lean and healthy.\"\nHowever, we also showed that a vegetarian diet is much more effective at reducing muscle fat, thus improving metabolism.\nLosing muscle fat improves glucose and lipid metabolism so this finding is particularly important for people with metabolic syndrome and type 2 diabetes, says lead author, Dr. Hana Kahleov\u00e1, Director of Clinical Research at the Physicians Committee for Responsible Medicine in Washington DC.\nHowever, subfascial fat was only reduced in response to the vegetarian diet, and intramuscular fat was more greatly reduced by the vegetarian diet.\nThe vegetarian diet was found to be almost twice as effective in reducing body weight, resulting in an average loss of 6.2kg compared to 3.2kg for the conventional diet.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This release describes the weight loss benefits of a vegetarian diet in terms of average weight lost. It states that participants in the vegetarian diet group lost an average of 6.2 kilograms in comparison to participants in the conventional diet group who lost an average of 3.2 kilograms. It also claims those on the vegetarian diet lost more subfascial and intramuscular fat than those on a conventional diet.\nThe release never tells us how long the study lasted, you have to go to the published report for that. When we did, it wasn\u2019t clear whether the weight loss was maintained at 6 months and beyond. It is very common for weight-loss studies to show that initial weight loss is greater than later weight loss, especially when there is no blinding involved.\u00a0", "answer": 1}, {"article": "Silicone breast implants were pulled off the market in 1992 amid concerns that leaks from the implants could lead to cancer or autoimmune disease.\nMoreover, that data are limited to just the last two or three years \u2014 not enough, Wolf says, to make any real claims about the long-term safety of the implants.\nBut ultimately she decided she didn't want to go through more surgery.\nDoctors reassured her it wasn't her implants.\nSo you have to at least expect that sometime in your life, you are going to need a reoperation.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 This was about safety.\u00a0 No good way to quantify benefits.", "answer": 2}, {"article": "High blood pressure increases the risk for heart attack, stroke and kidney problems.\nThe rate of side effects was no greater among those who took the three-in-one pill than among the usual care group.\n\"Based on our findings, we conclude that this new method of using blood pressure-lowering drugs was more effective and just as safe as current approaches,\" lead author Ruth Webster said in a news release from the American College of Cardiology.\nThe findings, she said, \"should prompt reconsideration of recommendations around the use of combination therapy.\"\nAmong those who took the so-called \"triple pill\" for six months, 70 percent had achieved their blood pressure targets, compared with 55 percent of those who received their usual care.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Among those who took the so-called \u201ctriple pill\u201d for six months, 70 percent had achieved their blood pressure targets, compared with 55 percent of those who received their usual care. The story doesn\u2019t state this, but we found via the news release that \u201cusual care\u201d meant taking whatever blood pressure medicine their doctor prescribed.\nAlso, there was no information in the news story about what the blood pressure targets were. According to the release, the blood pressure target was 140/90 mm Hg or less, with a lower target of 130/80 mm Hg or less for those with diabetes or chronic kidney disease.\nLastly, the story should have cautioned that lowering blood pressure might not reflect benefits on patient-centric outcomes like heart attacks and strokes. It is a surrogate marker.", "answer": 0}, {"article": "\"Hopefully, there will be less anxiety about getting a recall.\"\nThe task force says the decision to start regular, biennial mammograms before age 50 should be an individual choice based on each patient's situation.\nWomen can halve their risk of a call-back for a false-positive if the interpreting radiologist has previous mammograms for comparison, the researchers found.\nThose false-positives may cause inconvenience and anxiety, and biopsies can cause pain and scarring, the researchers note.\nAfter 10 years of annual screening, more than half of women will be called back at least once for another mammogram.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This article leads with valuable information for all women over age 40 by stating \u201cGetting screening mammograms every two years instead of annually reduces the chance of a false alarm, a new study shows.\u201d\u00a0 Unfortunately the writer doesn\u2019t quantify or elaborate adequately on that reduction.\u00a0 Instead, the writer later focuses on how women undergoing screening mammography shouldn\u2019t be anxious if they experience a recall because over half of women who have screening mammograms for 10 years will be recalled.\nReaders would have been better served if the writer had emphasized the significant reduction in both recall mammograms & false-positive biopsies in women who are screened every two years rather than annually.\u00a0\u00a0Part of the continuing controversy\u00a0over screening mammography\u00a0focuses on\u00a0annual versus biennial screening.\u00a0 Because this\u00a0study showed a significant reduction in the percentage of those recalled & needing biopsies among women who are screened\u00a0every other year, with no\u00a0statistically significant increase in late-stage diagnosis of breast cancer, the article should\u00a0have emphasized those important findings.", "answer": 0}, {"article": "\"We should offer all women the possibility of a cure.\"\nThe possibility of a 50 per cent cure rate would be a significant improvement over the current 20 per cent survival rate resulting from more conventional treatment options offered to patients, which consist of a combination of different methods including: chemotherapy before surgery; post-operative chemotherapy delivered intravenously to the whole body (as opposed to localized into the abdomen); and surgery that leaves minimal residual disease in the abdomen, rather than removing all visible cancer cells.\n\"Women need support to endure surgery and the rigours of intraperitoneal chemotherapy, but should be encouraged to do so whenever possible, considering the potential survival benefits,\" said Narod.\nThe goal is to have no cancer visible to the naked eye of the surgeon after the surgery.\n\u2022 The surgery should be aggressive in an attempt to remove all visible signs of the tumour, and to avoid leaving any residual disease.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The key benefit here is the survival rate and, on this point, the release is fairly clear. It notes that the current survival rate for advanced stage ovarian cancer is 20%, and that adopting a new standard of treatment could increase that survival rate up to 50%. The release would have added clarity by including an explanation of what is meant by \u201cup to 50 percent\u201d survival. It\u2019s a bold claim about a devastating disease so precision is desirable. The reviewer uses 12-year survival as a proxy for cure in the original article but the release equates this to being \u201ccured\u201d of ovarian cancer. Some might debate that long-term survival equates to a cure \u2014 we\u2019ll give the benefit of the doubt here and dock points below under the \u201cUnjustifiable Language\u201d criterion.", "answer": 1}, {"article": ".\nThe data review did not look at any health outcomes associated with pasta consumption except for the ones specified below.\nThe research, \"Pasta Consumption in American Children and Adolescents is Associated with Greater Daily Intake of Shortfall Nutrients as Defined by the 2015 Dietary Guidelines, Improved Diet Quality and Lower Added Sugar Intake,\" was conducted by Nutritional Strategies, Inc. on behalf of the National Pasta Association.\nNPA is the leading trade association for the U.S. pasta industry.\nThe study examined associations between pasta consumption, shortfall nutrient intakes as defined by the 2015 Dietary Guidelines (2015 DG) and diet quality in comparison to non-pasta consumption in U.S. children and adolescents (ages 2-18).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does not give us any numbers that allow us to see the proof of the association described. Here is one statement from the release.\nThe study \u201cdemonstrated that young pasta-eaters have greater intakes of important vitamins and minerals and lower intakes of saturated fat and total fat in the diet compared to their peers who do not consume pasta.\u201d\nReaders need to see definitions of greater, lower and important in that paragraph. Without numbers and definitions, there is no context for the reader.\nFor more discussion on pasta association research, see this blog post, \u201cEat Pasta, Lose Weight,\u201d published here in 2016.", "answer": 0}, {"article": "It will also help remove the uncertainty surrounding which sub type of the disease an individual has and therefore be a catalyst for better outcomes for all people with MS.\"\n\nMultiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS).\nThe team also validated eight out of nine micro-RNA molecules in an independent group of progressive MS cases, confirming the reproducibility of the findings.\nThe research team assessed the utility of microRNAs (miRNA) in serum (blood) exosomes as biomarkers of MS disease.\nUsing next generation sequencing and integrative bioinformatics they found that serum exosome micro-RNA profiles not only distinguish MS from healthy controls, but also distinguish relapsing-remitting MS (RRMS) from progressive MS with high accuracy.\nPublished today in Scientific Reports, the discovery identifies tiny 'dysregulated' micro-RNA molecules that correctly diagnose MS and discriminate between patients at different disease stages - all in a simple blood test.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A source describes possible benefits stemming from earlier and more accurate MS diagnosis \u2014 but these benefits from earlier and more accurate diagnosis are hypothetical. There was no discussion or numerical context relating to the differences in the RNA levels between MS patients and controls. Benefits of the test were not quantified. ", "answer": 0}, {"article": "In those procedures, doctors either extract a small amount of the fluid that surrounds the fetus (amniocentesis) or they take a sample of the placenta (chorionic villus sampling).\n\u201cIf parents are using it to determine gender and then terminate the pregnancy based on that, that could be a problem,\u201d she told Reuters Health.\nThat leaves some room for error, which could be important if parents are making medical decisions based on the results \u2014 such as whether or not to get an invasive procedure to look for genetic disorders.\nSome European hospitals already rely on the method, called cell-free fetal DNA, although it\u2019s not available from doctors in the U.S.\n\n\u201cWhat they are finding in England is that many women are not going on to have the invasive tests,\u201d Bianchi told Reuters Health.\nHowever, the current non-invasive alternative \u2014 an ultrasound done at the end of the first trimester \u2014 isn\u2019t always good at spotting a baby\u2019s sex, Bianchi\u2019s team reported in the Journal of the American Medical Association.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Reuters examines how parents may benefit from earlier results in pregnancy if their unborn child is at risk of a serious genetic defect that is sex-linked. However, the story also points out that there is some chance of mistakes with the early testing.\nWe\u2019re just surprised that neither Reuters nor the NY Times pointed out in absolute terms that 5 out of every 100 tests of girls and 1 of every 100 boys will be wrong \u2013 6 out of a hundred multiplied by millions of pregnancies a year is a lot of errors even if uptake is small.\nIt\u2019s also worth noting that most research achieves better performance results than when the tests are used in the real world.", "answer": 1}, {"article": "More than one million athletes experience a concussion each year in the United States.\nEach of the concussed athletes had their brain blood flow measured with the advanced ultrasound headset within an average of six days after the injury.\n\"This research suggests that this advanced form of ultrasound may provide a more accurate diagnosis of concussion,\" said Hamilton.\n\"This important work provides insight into a tool that may yet prove useful in the recognition and management of concussion,\" said Jeffrey Kutcher, MD, FAAN, with the The Sports Neurology Clinic in Brighton, Michigan.\nTesting of the TCD technique at the sideline at the time of injury will be an important next step to determine its ultimate utility,\" said Randolph S. Marshall, MD, MS, with Columbia Presbyterian Medical Center in New York and a member of the American Academy of Neurology's Science Committee.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that the TCD ultrasound device \u201cwas able to differentiate between healthy and concussed athletes 83 percent of the time\u201d compared to lower success rates for other procedures. But that is not the only important statistic.\nWhile the concordance between the clinical criteria and the ultrasound was 83 percent, the test has a sensitivity of only 70 percent, suggesting that 30 percent of concussions are missed. In addition, there is a 17 percent false positive rate, It was not made clear by the news release when the test was performed. It appears that the test was well after the traumatic event, so we do not know what the test performance is at the time of injury.\nThe release also makes clear that physicians do not yet know\u00a0what to \u201cmake\u201d of this ability when it comes to clinical care.", "answer": 0}, {"article": "But don't rush out to adopt a furry friend just yet.\n\"The abundance of these two bacteria were increased twofold when there was a pet in the house,\" said Kozyrskyj, adding that the pet exposure was shown to affect the gut microbiome indirectly--from dog to mother to unborn baby--during pregnancy as well as during the first three months of the baby's life.\nWhat's more, Kozyrskyj's study suggested that the presence of pets in the house reduced the likelihood of the transmission of vaginal GBS (group B Strep) during birth, which causes pneumonia in newborns and is prevented by giving mothers antibiotics during delivery.\nHer team of 12, including study co-author and U of A post-doctoral fellow Hein Min Tun, take the science one step closer to understanding the connection by identifying that exposure to pets in the womb or up to three months after birth increases the abundance of two bacteria, Ruminococcus and Oscillospira, which have been linked with reduced childhood allergies and obesity, respectively.\nIt's far too early to predict how this finding will play out in the future, but Kozyrskyj doesn't rule out the concept of a \"dog in a pill\" as a preventive tool for allergies and obesity.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We learn from the release: \u201cThe abundance of these two bacteria were increased twofold when there was a pet in the house,\u201d and those effects take place \u201cduring pregnancy as well as during the first three months of the baby\u2019s life.\u201d\nBut we\u2019re left wondering, twofold of what? \u00a0And what kind of effects are related to a twofold increase in these two bacteria? The release doesn\u2019t tell us.", "answer": 0}, {"article": "Furthermore, erectile dysfunction is reported in 21 to 85 percent of all prostate cancer patients, while urinary incontinence is reported in 24 percent of men with this disease.\nThe possible explanation for the benefits of yoga seen in the study stems from physiologic data demonstrating its ability to help reduce cancer- as well as treatment- related fatigue and to strengthen pelvic floor muscles and increase blood flow.\nThe new, first-of-its-kind study, led by Neha Vapiwala, MD, an associate professor in the department of Radiation Oncology at PSOM and Penn's Abramson Cancer Center, found that general quality of life and measurements of side effects often experienced by prostate cancer patients--including fatigue, sexual health, and urinary incontinence--were stable throughout a course of outpatient radiation therapy among the men participating in an intensive yoga program.\n\"Despite these figures, we found that a structured yoga intervention in the form of twice-weekly classes is feasible for patients during a six- to nine-week course of outpatient radiotherapy for prostate cancer,\" said Vapiwala.\nThe effect of yoga was measured by participants' responses to a series of questions that assess overall quality-of-life, cancer-related fatigue, and prevalence of sexual and erectile dysfunction and urinary incontinence.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Numbers might have helped the reader decide whether, in fact, the news release was really about how yoga may lessen the side effects associated with prostate cancer treatment, or whether it was about the feasibility of such a study.\nBut numbers were lacking. \u201cMost yoga participants reported a sense of well-being at the end of each class, and upon finishing the yoga program and concluding their study involvement, many patients requested and received an at-home practice routine to fit their needs,\u201d one researcher says.\nMost? 51%? 99%?\nMeasuring how someone feels is often subjective and can be difficult. In this case, yoga\u2019s effect was measured by participants\u2019 responses to questions about quality of life, cancer-related fatigue and the prevalence of impotence and urinary incontinence.\nThe comment that scores were variable but then improved suggests that they did not achieve statistical significance. \u00a0Even if they did, the question would be whether the differences were considered clinically important \u2014 and how they would compare versus other interventions. There was a\u00a0substantial loss to follow-up (40%), but the investigator seemed most pleased that 27 men completed the study (and that 45 out of 68 eligible men agreed to participate). We would like to have known what the criteria were for eligibility. This is where it would be be wonderful to have a study to look at. Unfortunately, we\u2019re told only that the study will be published sometime in 2016.", "answer": 0}, {"article": "Natural Cycles uses a woman's body temperature and menstrual cycle data to tell her when she is fertile.\nAnd if the app gives you a \"red day\" \u2013 meaning you could be fertile \u2013 you have to abstain from sex, or use another method of protection such as condoms.\nEven so, the FPA advises that natural family planning is most effective if you\u2019re taught how to do it by a specialist teacher, and you monitor all three fertility indicators \u2013 temperature, menstrual cycle length, and cervical secretions.\nFor starters, it can only protect against pregnancy, not STIs.\nYou don't actually need an app to practise natural family planning \u2013 although it does cut down on paperwork.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites a study that the app, when used precisely as directed\u2013or so-called perfect use\u2013has a failure rate such that 0.5 in 100 women will get pregnant over a year of use. People aren\u2019t perfect, so with so-called typical\u00a0use, 7 people will get pregnant out of 100 users over a year. The pill by comparison, results in 0.3 out of\u00a0100 people with perfect use, and 9 out of 100 with typical use.\nIn addition, the writer makes clear that the method requires abstaining from sex or using other protection for as many as 10 day per cycle, although that interval may decrease with longer use.", "answer": 1}, {"article": "Actually, nitrous is making a comeback in U.S. maternity circles. It has remained a staple of childbirth in Canada, Australia, and Britain \u2014 Catherine, Duchess of Cambridge (the former Kate Middleton), who welcomed her third royal baby, Louis Arthur Charles, last month, reportedly has used it. But it basically disappeared in the United States in the 1970s. American women preferred to be numbed below the waist with epidural anesthesia, or at least that became the gold standard for pain relief.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story lists these benefits:\nBut these benefits are presented anecdotally. This is unsatisfactory because \u2014 as the story rightly points out \u2014 there is extensive experience with the obstetric use of nitrous oxide in Great Britain, Finland, Canada, and Australia. Providing supportive evidence from this international experience is highly relevant.", "answer": 0}, {"article": "Floaters become more common with age, and although some people simply get used to them, others are bothered by them or their vision is impaired.\nFor her part, Goldberg said that although \"there was significant improvement in patients' symptoms following treatment, and no significant complication was seen,\" these findings are early and \"it is difficult to predict the long-term safety of this laser procedure.\"\nHowever, Shah and Heier said there are few published studies on the laser treatment's effectiveness in treating floaters.\nNineteen patients (53 percent) in the YAG group reported significantly or completely improved symptoms, compared with none of the patients in the placebo group, the researchers added.\nThere were no differences between the two groups in harmful side effects, according to the study, which was published July 20 in JAMA Ophthalmology.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify the benefits of the procedure in question, saying, \u201cSix months after treatment, 54 percent of patients in the YAG group reported significantly greater improvement in floater-related visual disturbances, compared with only 9 percent of those in the placebo group.\u201d\u00a0 It goes on saying, \u201cNineteen patients (53 percent) in the YAG group reported significantly or completely improved symptoms, compared with none of the patients in the placebo group.\u201d", "answer": 1}, {"article": "To me as a doctor that\u2019s a big worry because my main aim is to help people to be well and if you aren\u2019t doing that with the best available evidence then you are failing patients,\u201d said Hayes.\nThe new research, published in the medical journal PLOS Medicine, found that the side-effects of the mood-stabilising alternatives used by most patients are either the same as or worse than lithium, Hayes said.\nThe lead author behind the research told the Guardian that widespread \u201clithium stigma\u201d among patients is leading to them receiving the wrong treatment and ending up admitted to hospital unnecessarily because their condition is not as well controlled as it could be.\nSeparate research has shown that patients on the other three medications are 40% more likely to harm themselves than those on lithium.\nMeanwhile, lithium patients were less likely to put on weight than patients on the other drugs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The research examined the side effect profiles of\u00a0\u00a0lithium, valproate, olanzapine, and quetiapine and provided hazard ratios for the most commonly recognized side effects.\nThe Guardian story reflects those findings in a qualitative way with some quantitative details, such as: \u201cMeanwhile, lithium patients were less likely to put on weight than patients on the other drugs. While 15%-20% of those on the three other drugs were more likely to gain more than 15% of their body weight, just 10% of those on lithium put on the same amount of extra pounds.\u201d", "answer": 1}, {"article": "\"We know that art therapy can work, music therapy can work.\nThe researchers found that tablet use was safe for every patient, regardless of the severity of their dementia, and that with proper supervision and training, the engagement rate with the devices was nearly 100 percent.\n\"Tablet use as a nonpharmacologic intervention for agitation in older adults, including those with severe dementia, appears to be feasible, safe, and of potential utility,\" said Vahia.\nThis research builds upon previous studies demonstrating that art, music, and other similar therapies can effectively reduce symptoms of dementia without medication.\nThe study also found that the tablets demonstrated significant effectiveness in reducing symptoms of agitation, particularly--but not exclusively--among patients with milder forms of dementia.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We applaud the release writers for noting this was a \u201cpilot\u201d study only, and just intended to get the research started. But we have to quibble with this statement about benefits because it has no quantifiable metric.\n\u201cThe study also found that the tablets demonstrated significant effectiveness in reducing symptoms of agitation, particularly\u2013but not exclusively\u2013among patients with milder forms of dementia.\u201d\nWe aren\u2019t given any metric for \u201csignificant\u201d \u2014 did it cut symptoms of agitation by half? And when they call out \u201cmilder\u201d dementia, why aren\u2019t we given a definition for that? In the published study the authors clearly state: \u201cWe did not perform standardized diagnostic assessments or use objective measures of agitation before and after each episode of tablet use.\u201d", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although one source quoted in the story quantifies the potential harm of improper use of sunscreen\u2014 inadequate skin coverage causes \u201c25% less value\u201d\u2014there is no attempt to quantify the reported benefit of slathering up with new, specially formulated sunscreens. ", "answer": 0}, {"article": "\"It is not inconceivable that in the near future you will see the I-Portal goggle used on every sideline in America,\" Hoffer said.\nAnother benefit for this research was that \"this next generation test has the considerable advantage of not requiring baseline testing,\" said study co-author Carey Balaban, Ph.D., of the University of Pittsburgh.\nThe results of the trial met the expectations of Hoffer and his team of researchers.\nHowever, to best manage mTBI, researchers have felt it critical to develop objective tests to substantiate the diagnosis.\nThe goal was to identify OVRT performance metrics that differentiated between mTBI and control groups and to create a model that could accurately evaluate mTBI neurologic status in patients.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Besides stating the sensitivity and specificity figures, the news release does not provide any additional information on the meaning behind these numbers. These are technical terms that can easily be confused with accuracy.\nSensitivity, also called the true positive rate, refers to the rate at which the test correctly identifies those who do have the condition.\nSpecificity, also called the true negative rate, identifies the correct proportion of negatives in a test (i.e. its ability to rule out those who do not have the condition).\nAlthough 89% sensitivity and 95% specificity sound as if the test is quite accurate,\u00a0it misses the main point, which is that the test performs less well than looking at symptoms. The study compared the new \u201cobjective test\u201d to standard criteria for diagnosing TBI. What the study showed was that compared to standard methods, this new one missed 11% of those with TBI and over-diagnosed it in 5% of the non-TBI controls.\nAlthough the sensitivity and specificity figures were given in the news release, none of these terms were explained for reporters and general readership. This is why we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "\"I refuse to believe that there's going to be any other outcome than 'it's all going to be okay' because the alternative is unfortunately not something I want to think about.\"\nThe study, funded by Illumina, a maker of one non-invasive prenatal test, looked at eight women with abnormal test results.\nBut doctors told Mejia they needed to investigate what caused the irregular finding.\nMore testing showed she had anal cancer.\nFurther testing showed the baby was healthy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The CBS story says that the study \u201clooked\u201d at eight women. But this is an incomplete description. The study involved\u00a0125,426 samples from which abnormal results (typically indicating a chromosomal disorder in the fetus) were detected in\u00a03757 (3%). Ten cancers were subsequently identified in women whose babies were found to be normal despite an abnormal test result, with further analysis done on the eight women mentioned in the story. Without this\u00a0quantitative data, readers have no sense of the rarity of the eight cases described or of the scope of the benefit that might be realized if such testing were offered more widely.", "answer": 0}, {"article": "Patients with Type-1 diabetes typically compensate by monitoring their blood sugar levels every few hours and injecting themselves with insulin as many as five times a day.\nThe experimental therapy eliminated the need for insulin injections for months or even years in 14 of 15 patients who were recently diagnosed with the disease.\nBut other doctors said that even if the benefits of the therapy are temporary, the research provides valuable insight into the mechanism behind the disease.\nThe study suggests a new avenue for treating the intractable disease, in which the immune system destroys insulin-producing beta cells in the pancreas.\nEven if patients continue to require insulin shots, the treatment should be considered a success if it halts the destruction of beta cells, said Dr. Jay Skyler, with the Diabetes Research Institute at the University of Miami Miller School of Medicine, who wrote an editorial accompanying the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that the new therapy eliminated the need for injections for months or years in 14 of 15 patients, thereby describing absolute benefits. ", "answer": 1}, {"article": "The average age of children in the study was 7.\nThe findings suggest that non-verbal tests related to smell might serve as useful early indicators of ASD, the researchers say.\nThe findings suggest that a sniff test could be quite useful in the clinic, although the researchers emphasize that their test is in no way ready for that yet.\n\"This raises the hope that these findings could form the base for development of a diagnostic tool that can be applied very early on, such as in toddlers only a few months old.\nThe researchers now plan to test whether the sniff-response pattern they've observed is specific to autism or whether it might show up also in people with other neurodevelopmental conditions.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release mentions a diagnostic accuracy rate of 81%, but where exactly does this number come from and what does the term \u201caccuracy\u201d mean here? We\u2019d prefer a more detailed discussion that includes an explanation of the sensitivity and specificity of the test. Or at least a mention of false positive and false negatives. The study that\u2019s the basis for the test told us there was 1 false positive and 6 false negatives out of the 18 people in each group. But later on in the release, we learn that the researchers aren\u2019t sure yet if the test can distinguish between autism and other similar neurodevelopmental conditions, so the low number of false-positives reported may not hold up with additional research. In addition, the release says that while typical children adjusted their sniffing almost instantly when smelling an odor, \u201cchildren on the autism spectrum showed no such response.\u201d If that\u2019s the case, why wasn\u2019t the test 100% accurate?\nThe release did a reasonable job here and emphasized that the study isn\u2019t ready for clinical use. But we don\u2019t think it quite met our standard for reporting on the complex issue of diagnostic accuracy.", "answer": 0}, {"article": "\"This is a test that doesn't just diagnose prostate cancer.\nWASHINGTON \u2014 Prostate cancer is more likely to be life-threatening if the man's PSA level rose rapidly during the years before he was diagnosed, says a new study that may help change how PSA tests are used.\nAnd men diagnosed with prostate cancer whose PSA is rising slowly may be ideal candidates for monitoring instead of surgery or other treatment, he added.\nA study with just 20 deaths is far too small to prove the value of PSA velocity, cautioned Dr. Durado Brooks, a prostate specialist with the American Cancer Society.\nThe work is \"another step on the road to more sophisticated\" prostate cancer screening and treatment, Dr. Timothy Church of the University of Minnesota wrote in an editorial accompanying the work.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides survival rates for men with high PSA velocities\u00a0and low PSA velocities (although the time period for the estimates is not so clear).\u00a0 Because this is an observational study, absolute risk reductions are not possible.\u00a0 While this is adequate, the story overstates what the findings mean.\u00a0 A quote from the lead author stating,\u00a0\"It doesn't just diagnose prostate cancer, it diagnoses prostate cancer that's going to actually cause harm,\"\u00a0is unfounded and not supported by the\u00a0evidence.\u00a0\u00a0Additionally, the story's inclusion of a recommendation from the lead author that men have \"baseline\" PSA tests at 40 to use as a comparison for future changes is another example of enthusiasm despite evidence. \u00a0 ", "answer": 0}, {"article": "Red and purple fruits owe their colors to...\nAlthough it's a challenge to eat the raw fruit without getting a mouthful of seeds and astringent pith, pomegranates are everywhere now in the form of juice, concentrates and extracts, all heavily promoted for better health.\nThe juice is a beautiful wine-red color and tastes delicious.\nMuch of the popularity is the work of a California-based company, Pom Wonderful.\nIt pays researchers to study the benefits of pomegranate juice, gives doctors information on positive studies and, of course, sells pomegranate products.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article states that pomegranates produce cardiovascular benefits through decreased blood pressure (unquantified), decreased oxidation of LDL cholesterol (unquantified), improved coronary blood flow (unquantified), and reduced PSA (unquantified).", "answer": 0}, {"article": "LDL was 8.3 points lower on the moderate-fat diet without the avocado and 7.4 points less on the lower-fat diet.\n\u201c\n\nAmericans may not be used to eating avocado but Kris-Etherton says it\u2019s easy to add.\nJust an avocado a day can significantly lower your cholesterol and reduce the risk of heart disease, a new study shows.\n\u201cWe need to focus on getting people to eat a heart-healthy diet that includes avocados and other nutrient-rich food sources of better fats,\u201d Kris-Etherton said.\nAnd it\u2019s one more piece of evidence in favor of adding good fats to the diet.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story accurately compares the reduction of LDL cholesterol in study participants who ate avocado to reductions in LDL among study participants who did not \u2014 the avocado group\u2019s LDL levels dropped by just over 13 milligrams per deciliter of blood (13.5 according to the news release), compared to reductions of 8.3 and 7.4 for two other groups. The story also provides readers with a frame of reference for those numbers, noting that overall LDL levels should be below 100 (which makes a difference of 5 or 6 mg/dl fairly significant). The story also explicitly makes the connection between LDL cholesterol and human health, noting that it is a significant risk factor for heart disease.\nWe wish the story had explained how the changes observed in the study would affect someone\u2019s risk of a heart attack or stroke. In addition, there\u2019s a reference to the \u201cplaque-busting\u201d properties of monounsaturated fatty acids that is a bit of unnecessary hype. There is no medication or nutrient that \u201cbusts\u201d plaque, but rather a healthy lifestyle, diet, and medications for some will help prevent its accumulation. Given the other strengths discussed above, we don\u2019t think these problems are sufficient enough to warrant an unsatisfactory rating.", "answer": 1}, {"article": "Weight gain is a common side effect of Zyprexa.\nIn the first year of a two-year trial, 5 of the 31 of those on medication developed full-blown psychosis, compared with 11 of 29 of those who were taking dummy pills.\nFrom 20 to 45 percent of people who score high on the scale go on to develop full-blown psychosis, in which these symptoms become extreme, researchers have found.\nThe scale rates severity of more than a dozen symptoms, including suspiciousness, grandiosity and bizarre thoughts.\nThe new study was intended in part to clarify the trade-off between the risks and the potential benefits of preemptive treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Provides some quantification of the benefit of taking Zyprexa to delay psychosis after one year of treatment, but this difference was marginally statistically significant, which is also mentioned. What the story does not report: After the medication was stopped, these patients showed more severe psychotic symptoms than when they were first recruited for the study, suggesting that while symptoms were blunted, the disorder progressed despite the use of anti-psychotic medication. ", "answer": 1}, {"article": "The scientists, meanwhile, collected blood samples from the men several weeks before the race, as well as immediately before to the start, at the finish line and on select days afterward.\nBut, said Dr. Scherr, it almost certainly involves the beverage\u2019s rich bouquet of polyphenols, chemical substances found in many plants that, among other things, \u201csuppress viral replication\u201d and \u201cinfluence the innate immune system positively,\u201d all beneficial for fighting off a cold.\nIt began with human marathoners completing a punishing, unsimulated race, and showed demonstrable benefits, in terms of minimizing postrace damage.\nThe men drinking the nonalcoholic beer reported far fewer illnesses than the runners swallowing the placebo beverage.\n\u201cIt can be speculated that the training frequency could be higher (with shorter breaks after vigorous training sessions)\u201d in those drinking beer, he wrote in an e-mail response.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did quantify the benefits of one parameter by quoting the abstract \u201cincidence of upper respiratory tract infections was 3.25-fold lower\u201d \u2013 but it was not mentioned that these were self-reported upper respiratory tract infections.\nThe story mentions that there was \u2018significantly less evidence of inflammation\u2026.and lower counts of white blood cells than the placebo group\u201d but does not provide numbers. The story also states that the \u2018beer experiment\u2019 showed benefits of minimizing post-race damage. But the study didn\u2019t measure damage, it measured blood markers of immune function.", "answer": 0}, {"article": "\u201cOur clinical trial participants were overwhelmingly receptive to this new technology,\u201d Pillsbury said.\nUNC participated in the EAS System clinical trials and implanted the device in more patients than any other hearing center that participated.\nMED-EL expects that the SYNCHRONY EAS Hearing Implant System will be available in the coming months.\nThe EAS System FDA approval is for candidates who are 18 years old and older who have normal to moderate sensorineural hearing loss in the low frequencies, sloping to a severe-to-profound hearing loss in the high frequencies.\n\u201cOn average, patients performed more than twice as well on tests of speech understanding with EAS than they did with their hearing aids preoperatively, which speaks to the benefits of this technology,\u201d Pillsbury said.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release claims that 97 percent of participants in the clinical trial at UNC \u201creported a benefit\u201d from the device within the first year and 90 percent reported overall satisfaction. It says \u201con average, patients performed more than twice as well on tests of speech understanding\u201d compared to those without the implant.\nIt is not clear if the benefit experienced by 97 percent of participants translated into clinical (real-life) significance for patients. What exactly does \u201csatisfaction\u201d represent in this context? The release doesn\u2019t specify. And how big a benefit is performing \u201ctwice as well\u201d as patients who didn\u2019t get the device? The answer depends on what the baseline hearing losses were for each group of participants \u2014 something not discussed in the release. There are no data at all on failures, removals, infections, etc. They are not mentioned.", "answer": 0}, {"article": "The study was published online Oct. 1 in The Lancet.\n\"This analysis provides further support for the benefit of apixaban, but given the very low risk of bleeding with apixaban, it also suggests that the current stroke and bleeding risk scores may not be sensitive enough to tease out those patients with the very lowest risk of stroke who might benefit from apixaban therapy,\" said Ansell, who is chairman of the department of medicine at Lenox Hill Hospital in New York City and a consultant to Bristol-Myers Squibb and Pfizer, the companies that are marketing the drug as Eliquis.\nThe findings suggest that the current risk scoring systems for tailoring anti-clotting (anticoagulant) treatment to individual patients may be less relevant when using apixaban for patients with atrial fibrillation who have at least one risk factor for stroke, according to the Duke University Medical Center researchers.\nMONDAY, Oct. 1, 2012 (HealthDay News) -- A new anti-clotting drug called apixaban was better than warfarin at preventing stroke in patients with the heart rhythm disorder atrial fibrillation, a new study found.\nAspirin is less effective than warfarin, but carries a lower risk of bleeding for patients with atrial fibrillation and one risk factor for stroke.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify the benefits, albeit only in relative terms. The story says, \u201cApixaban showed a 21 percent relative reduction in the incidence of strokes or systemic embolisms (clots) when compared to warfarin, a 31 percent relative reduction in major bleeding and an 11 percent relative reduction in overall mortality, the researchers found.\u201d We would have liked to have seen these comparisons in absolute terms. When you read in the story, for example, that 18,000 patients were studied, you might assume that a huge number of them died, meaning that 11% percent difference represents hundreds of people. In reality, the differences were quite small.\u00a0 For example, the 21% relative reduction in stroke or embolism is an absolute difference of 1.27% with apixaban as compared to 1.6% with warfarin. The 31% relative risk reduction in major bleeding is an absolute difference of 2.13% with apixaban and 3.09% with warfarin.\u00a0 This is a great example of why absolute numbers are so important in this type of story.", "answer": 0}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The quantification here was presented in such a way to make it clear to readers that there was no significant benefit found to surgical intervention, which is a fair conclusion to draw from the study. The story says, \u201cIn the Stich study, 41% of patients assigned to treatment with drugs alone died during the follow-up period, which averaged five years. That compared with a mortality rate of 36% among patients who received bypass surgery plus medication. Although the relative reduction in risk of death was 14%, the result didn\u2019t meet tests for statistical significance, meaning it could have resulted from chance alone.\u201d\u00a0That\u2019s a great way to describe the lack of statistical significance. It would have been even more powerful to show readers the actual number of patients who died in each group.", "answer": 1}, {"article": "While smoking is a public health scourge, the nicotine in cigarettes may have some promise in treating another growing problem, mild cognitive impairment (MCI), which can be a precursor to Alzheimer\u2019s disease or other forms of dementia.\nHowever, when clinical experts rated overall general change in the patients, they did not see a significant difference between the two groups.\nThe authors conclude, \u201cThis initial study provides evidence for nicotine-induced cognitive improvement in subjects with MCI; however, whether these effects are clinically important will require larger studies.\u201d\n\nThe study found no problematic side effects associated with the nicotine patch and none of the patients had withdrawal symptoms when it was stopped.\nThe study was led by Dr. Paul Newhouse of Vanderbilt University and published in Neurology.\nIntriguingly, it appeared to be more effective among people with two copies of the APOE4 gene, a genetic combination that increases risk for Alzheimer\u2019s by a factor of 20 or higher.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Quantifying changes in cognitive function for readers is a challenge.\u00a0 Exactly what does a long term memory performance of 46% of normal mean?\u00a0 Are these changes important for daily living or are they statistically significant but clinically irrelevant?\u00a0 The story included that important caveat from the researchers:\u00a0 \u201cwhether these effects are clinically important will require larger studies.\u201d", "answer": 1}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story really does not provide a crisp rationale for a bioabsorbable stent.\u00a0An important limitation of existing stents is that they are associated with increased risk of clots. The absorbable stents are designed to\u00a0help with this problem, but the story doesn\u2019t communicate this. It only\u00a0refers to the\u00a0possibility that the\u00a0new stents may also cause clots in some people.\u00a0The comments of the Abbott spokesperson aside, the reader is not provided with any idea of how often the existing stents create difficulties and why the Abbott stent will alleviate the problem.", "answer": 0}, {"article": "If a woman's doctor tells her she does not need radiation after a mastectomy, the woman should be told why and she should ask if the radiation oncologist weighed in on the decision.\nThe guidelines don't offer a single formula for which patients need radiation therapy, Edge noted.\nEdge was a panel representative from the American Society of Clinical Oncology, which created the guidelines along with the American Society for Radiation Oncology and the Society of Surgical Oncology.\nAndrews said that one take-home message for patients is to expect the surgeon to have consulted with the radiation oncologist and others on her team.\nDoctors need to weigh the risks and benefits, Edge added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits aren\u2019t quantified in the story. In fact, benefits are barely discussed in the story. The story simply notes \u201cthe guidelines say there\u2019s enough evidence to show radiation treatment after a mastectomy decreases the risk of breast cancer recurrence.\u201d But how much does it decrease the risk of breast cancer recurrence? \u00a0If the benefits aren\u2019t clearly defined, it\u2019s virtually impossible to determine if the costs and risks outweigh them. Granted, the decreased risk of recurrence likely varies widely based on the patient and type of cancer (a point the story makes). But the story would have been much stronger if it had tried to offer more detail on benefits for readers.", "answer": 0}, {"article": "Autistic children are prone to seizures.\nThe drug is not approved for children \u2013 except a rare few with premature puberty \u2013 because it can impair bone development crucial to growth, said Dr. Gary Berkovitz, chief of pediatric endocrinology at the University of Miami medical school.\nOther doctors said Geier's studies were small, were not scientifically sound and were published in journals that do not follow the standard practice of having experts review the methods.\nLupron critics said autism parents may not understand the dangers.\nGeier's promotional materials said he has treated hundreds of children with Lupron and has launched nine ASD Centers in eight states.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story, as noted, cites the Maryland researcher\u2019s claims from small published studies, but also states: \"      \nnumerous physicians, researchers and therapists insist there\u2019s no proof mercury causes autism, that Lupron removes mercury or that autistic kids have excessive testosterone.\"", "answer": 1}, {"article": "Amgen reported just $40 million in third-quarter sales.\n\u201cThese results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimized statin therapy,\u201d Amgen research chief Sean Harper said in a statement.\nThe company said Repatha would be well on its way to becoming a $1 billion seller if all prescriptions written had been filled.\nNo new safety problems cropped up in the 27,500 patient study called Fourier, Amgen said.\nDetails on the magnitude of benefit will be revealed in mid-March at the American College of Cardiology meeting in Washington, D.C. Industry analysts have been looking for a 15 percent to 20 percent reduction of major adverse heart events.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that the drug \u201csignificantly reduced the risk of heart attacks, strokes and death in patients with heart disease\u201d and quotes an Amgen officer as saying, \u201cThese results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction.\u201d\u00a0 Unfortunately, the story fails to provide any actual data that would support those claims. It does at least explain that this is because Amgen hasn\u2019t released any details yet on the magnitude of benefit. We\u2019d argue that it\u2019s better journalism to wait until that data is in hand, and can be assessed by independent experts.", "answer": 0}, {"article": "Reiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain. Several studies suggest a benefit to patients, but scientists say more large, rigorous studies are needed.\n\nCancer patients\u2014due to the disease and to side effects of chemotherapy\u2014often suffer from severe mental and physical fatigue, doctors say. Anxiety, nausea and pain are also common. In recent years, many cancer centers have been offering Reiki, a form of...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Another mixed bag.\nBut if we gave a barely satisfactory grade on \u201cevidence,\u201d we must balance the scale here and render this unsatisfactory.\u00a0 Why?", "answer": 0}, {"article": "Systolic blood pressure (the upper number in blood pressure readings) indicates how much pressure your blood is exerting against your artery walls when the heart beats.\nAdditionally, some of the participants showed favorable changes in the production of breath methane, an indication of the potential influence on gut fermentation.\nThe researchers conclude that mangos may be a heart-healthy fruit that may help play a role in reducing the risk of cardiovascular disease.\nFollowing the 14 days of mango consumption, the study participants resumed their normal daily diet but eliminated mango intake for 13 days.\nYet once mango was consumed, systolic blood pressure was significantly lower two hours after mango intake compared to baseline values.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t quantify the benefits, instead noting that \u201conce mango was consumed, systolic blood pressure was significantly lower two hours after mango intake compared to baseline values.\u201d The release described benefits \u2014 all surrogate markers for health \u2014 in a similar way for reduced pulse pressure and reduced methane levels in the breath of three of the six patients who produced methane. What does \u201csignificantly lower\u201d mean? And since all of the patients were described as healthy, do the reductions actually matter?", "answer": 0}, {"article": "\u201cDefinitely it doesn\u2019t look like antidepressants are placebos,\u201d he concluded.\nIrving Kirsch, who studies antidepressants and placebos at Harvard Medical School in Boston, said the new report didn\u2019t make him more optimistic about the drugs.\nThe researchers said they couldn\u2019t be sure there would be similar improvements with other types of antidepressants \u2014 especially given the more limited data in kids and the elderly \u2014 or that the longer-term benefits would be as clear.\nStill, not everyone in the studies improved \u2014 on average, about five people had to be treated with one of the drugs for one person to feel better, and the benefits seemed to be diminished among some of the oldest patients.\nWhat\u2019s more, one researcher not involved in the study said its findings still don\u2019t mean the drugs are any better than non-drug methods of treating depression, such as talk therapy and being more physically active.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gave detailed breakdowns of percent improvement in scores on depression tests and provided an estimate of the number needed to treat in order for one to benefit.\u00a0 The difference in benefits between older and younger patients was highlighted.", "answer": 1}, {"article": "1.\nResearchers sought to determine the clinical effectiveness of acupuncture or Alexander Technique lessons compared with usual care for persons with chronic, nonspecific neck pain.\nOver time, both interventions resulted in a greater increase in self-efficacy than did usual care, and these improvements were associated with better NPQ outcomes.\nThe researchers found that acupuncture and the Alexander Technique lessons both led to a significant reduction in neck pain at 12 months compared with usual care alone.\nBoth interventions had a high rate of acceptability, and greater adherence was associated with better pain outcomes.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that both acupuncture and the Alexander Technique led to a significant reduction in neck pain at 12 months, as determined by the Northwick Park Questionnaire (NPQ). Statistical significance does not, however, necessarily indicate strong treatment effects. For instance, with enough data in hand, we can discover that minute differences between treatment and control can\u00a0have very significant p-values (calculated probability), although we are not claiming this is the case here. From the original study, we learn the\u00a0treatment effects of 3.92% reduction in NPQ versus usual care for acupuncture, and 3.79% for the Alexander Technique.\nEven with these numbers, the information is still lacking in interpretability. What does a 3-4% reduction in NPQ score really mean? Is the benefit worth the number of sessions of each therapy?", "answer": 0}, {"article": "In the United States, about 10 percent of people say they have chronic insomnia, according to the U.S. Centers for Disease Control and Prevention.\nStandard sleep medications work more widely throughout the brain, Bazil explained, which is why they can have a host of side effects.\nThe effect was essentially comparable to what has been seen with other sleep medications, said Bazil, who was not involved in the research.\nA drug, ideally used for a short time, may help encourage sleep and get people on the right track, Bazil said.\nBut, he said, suvorexant is seen as a potentially important development in the world of sleep medicine, because the drug blocks specific brain chemicals called orexins, which help keep people awake.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The following paragraph is a confusing, convoluted presentation of numbers:\n\u201cAt the outset, when patients spent eight hours in bed, they were typically asleep for 66 percent of that time. One day on suvorexant boosted that by anywhere from 5 percent to 13 percent, relative to the placebo. Between 21 and 37 fewer minutes were spent awake during those sleep periods.\u201d\nFirst, percentages of time asleep were used, then minutes of wakefulness.\u00a0 So the descriptors are switched, leaving readers like us losing sleep.\nSuggestions:\nWe were also troubled by a couple of comments:\n\u201cThere are sleep aids on the market, but they do not work for everyone and they can have side effects that include sleepwalking, daytime drowsiness and confusion.\u201d\u00a0 There is an implied suggestion that Suvorexant will not have these side effects but no data is provided\n\u201cSuvorexant works differently from those drugs, zeroing in on specific brain chemicals involved in the ability to sleep, explained study author Dr. William Herring, executive director of clinical research at Merck.\u201d\u00a0 Yes, indeed Suvorexant does work differently than the currently available drugs but suggesting that \u201czeroing in\u201d on sleep is a bit of an overstatement.\u00a0 The orexin 1 and 2 receptors have been shown in previous studies to effect energy, fluid homestasis, emotion regulation and stress responsiveness to name a few non-sleep effects (Vitamins & Hormones. 89:19-33, 2012)", "answer": 0}, {"article": "\"It's my job to see that she gets what she needs to protect herself,'\" he says.\nBut some worry that may sends a mixed signal by protecting girls against a sexually transmitted disease while at the same time telling them they shouldn't have sex.\nMillions of Americans have seen the ad blitz for Merck's new drug Gardasil.\nBut is it something that we are in position to sort of ramrod down people's throats?\nHe's not only a dad, he's an expert on pediatric infectious diseases at the University of Chicago.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story does state that the vaccine could reduce HPV-related cervical cancer by 70%, this is not adequate quantification of the benefits. 70% of what? The reader should be informed\u00a0whether HPV-related cancer accounts for a small or large amount of cancer cases.", "answer": 0}, {"article": "Professor Norman Ratcliffe said, \"There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.\nOur aim is to create a test that avoids this procedure at initial diagnosis by detecting cancer in a non-invasive way by smelling the disease in men's urine.\nEven with detailed template biopsies there is a risk that we may fail to detect prostate cancer in some cases.\nThe test involves inserting urine samples into the Odoreader that are then measured using algorithms developed by the research team at the University of Liverpool and UWE Bristol.\nThis is then translated into an algorithm enabling detection of cancer by reading the patterns presented.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no quantification of the benefits. An allusion is made to the necessity of early diagnosis and the eventual ease of testing, but there is no quantification of how this test compares to other tests. It is unknown how accurate the test might be when used in the general population (no discussion of sensitivity or specificity) or if a biopsy will be needed if the test is positive or if the test will detect cancer at a stage that can be cured nor if it will lead to a decline in mortality. Thus, benefits cannot be quantified and they release should have made that clear.", "answer": 0}, {"article": "\"So before we activated the device, we have all sorts of problems\u2026 This is basically your brain saying, 'I'm not breathing.'\nFor Siravo, she said her memory is back to 100 percent.\n\"And then that didn't work.\nIt's only for moderate to severe cases, and like any surgery, there is risk of infection.\nExhausted, the 59-year-old could barely do her job as a nurse \u2013 and she knew something wasn't right.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are not quantified. Beyond one patient\u2019s anecdotal experience, the story refers to a study that found \u201c68 percent of patients experienced less sleep apnea after getting the implant.\u201d How bad was the apnea before? How did the compare against a control group (if there was one)?\nBut there is virtually no information about the study, the extent of the improvement, how long it lasted, etc. More detailed information is needed here. However, the biggest concern here is that the story doesn\u2019t make sufficiently clear that Inspire is designed to address just one particular type of sleep apnea. It does say that Inspire is for \u201cmoderate to severe cases,\u201d but that\u2019s pretty vague \u2014 and doesn\u2019t address the core problems here. First off, there are two large classes of sleep apnea: obstructive (in which the airway becomes blocked) and central (in which the brain doesn\u2019t send the appropriate signals for normal breathing). Inspire can only address obstructive sleep apnea. What\u2019s more, it can only address some types of obstructive sleep apnea. For example, Inspire\u2019s website notes that \u201cInspire therapy is not intended for patients with a complete concentric collapse at the level of the soft palate.\u201d What exactly does that mean? How common is that condition? I wish the story had told us. What\u2019s more, Inspire\u2019s website also notes that \u201cInspire therapy has not been clinically tested in patients with a body mass index greater than 32.\u201d In other words, no one knows whether Inspire would work on one of the groups of people at greater risk of sleep apnea.\nThere\u2019s also this hyperbolic quote:\u00a0\u201cThis has been revolutionary. It\u2019s been a game changer,\u201d Dr. Maurits Boon said. Considering the device doesn\u2019t work for everyone, is expensive, invasive, and may cause side effects, it doesn\u2019t seem revolutionary.", "answer": 0}, {"article": "Rheumatoid arthritis, which is felt throughout the whole body, is caused when a person's immune system attacks his or her own tissues.\nThe studies included arthritis patients aged 18 or older who had hip or knee replacements.\nThe findings are published in the Nov. 28 online edition of Arthritis & Rheumatism.\nThe study team found no differences between the two groups of arthritis patients in rates of follow-up surgery, or 90-day blood clot or death risk.\n\"Joint arthroplasty is successful in relieving the pain and disability caused by hip or knee arthritis,\" study author Dr. Bheeshma Ravi, from the University of Toronto and Women's College Research Institute, said in a journal news release.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story includes a quote pulled from a news release that says, \u201cJoint arthroplasty is successful in relieving the pain and disability caused by hip or knee arthritis,\u201d without any details about how successful or any of the specific characteristics of the patients.", "answer": 0}, {"article": "\"It's been a miracle to me,\" Wolfe said.\nThe study, published in today's Journal of the American Medical Association, was funded by the maker of the drug, Johnson & Johnson Inc.'s Ortho-McNeil Neurologics.\nAddiction specialists not involved in the study said the findings are promising, although side effects such as trouble concentrating, tingling and itching caused about one in five people to drop out of the study.\nBy the end of the study, 27 of the 183 people, or 15 percent, who took Topamax had quit drinking entirely for seven weeks or more.\nIt's unclear whether the findings will make a dent in an addiction that affects millions of Americans.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided some idea of the magnitude of benefit from the use of this drug \u2013\u00a0significantly more people using this medication\u00a0were able to abstain from drinking entirely for at least 28 days out of the 98 days of the study.\u00a0 Similarly, there was also a reduction of the average 11\u00a0 drinks per day to 6 1/2\u00a0drinks per day for those using this medication as compared with 7 1/2 for those in the placebo group.\nThe inclusion of the anecdotal report of someone who remained sober years after taking the drug implies a duration of effect well beyond the duration of this study: 3 1/2 months.\u00a0 While there is no formal exaggeration of the effect, a cheery anecdote may falsely raise expectations in the reader.", "answer": 1}, {"article": "\"They say, 'Oh my God, this has changed my life.\nStreicher, an associate professor of clinical obstetrics and gynecology at the Northwestern University Feinberg School of Medicine, said the study drew \"erroneous conclusions.\"\nIn their editorial, Woloshine and Schwartz said Sprout and others put pressure on FDA to approve the drug.\n(CNN) A new review of the \"little pink pill\" for women with low sexual desire says the drug doesn't work very well -- but some doctors and patients who've been using the treatment disagree.\nShe said she and her colleagues included the results of the unpublished studies because sometimes negative studies of a drug don't get published.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This rating is borderline as the article noted: \u201cThey said for women using the drug, the number of additional \u2018satisfying sexual events\u2019 averaged out to about 0.5 per month.\u201d \u00a0What would give this increased meaning is what the baseline was. If the baseline is zero or 0.5, maybe increasing that by half a satisfying sexual encounter might be meaningful. If the baseline is 10, does half an additional encounter make any difference? \u00a0Later in the article we learn that \u201c10%\u00a0more patients\u201d had meaningful sexual encounters, but what exactly does that mean? \u00a0\u201c10%\u201d of what? The article tips decisively into Not Satisfactory territory with its unbalanced focus on unrepresentative anecdotes depicting women who had \u201clife-changing\u201d improvements.", "answer": 0}, {"article": "Before treatment recommendations are made, doctors put most prostate tumors through other tests, too, like the Gleason score, and they look at the percentage of biopsies that are positive for cancer cells.\nThey say what's really needed is a set of tests that classify prostate tumors by what genes are turned on or off in the cells.\nThe new study discrediting the test, coupled with persistent questions about how useful prostate screening is for most men anyway, add up to a whole lot of discussion points patients should take to their doctors.\nOnce this is sorted out, doctors treating prostate cancer will be less like the blind men who try to guess what kind of creature they're dealing with when they grasp the elephant's trunk or tail.\nEven so, Andriole says, the findings may not make too much difference in the real world.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story covered a study that raised questions about clinical staging being \u201cworthless.\u201d\u00a0 The story made clear that there were serious new questions about the absence of benefit.", "answer": 1}, {"article": "\"We have found the same thing with all of our trials.\"\nAll the participants reported eating about 2,000 calories a day when the study began.\nBut as researchers noted, if participants ate as little as they said, all the groups would have lost much more weight.\nWomen who followed the Atkins plan had a significant drop in triglycerides, one of the unhealthful blood fats linked to a higher risk of heart disease.\nThe study found that while LDL rose slightly for those in the Atkins group, their blood levels did not differ statistically from the other groups.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The primary outcome of the study was weight loss; after a year, individuals on the Atkins diet were reported to have lost about 10 pounds\u00a0as compared to about a six pound loss on the other four diets.\nThe quantitative\u00a0information on the other clincial parameters measures\u00a0were not reported.", "answer": 1}, {"article": "Staying sexually active\u2014and considering sexuality an important part of life\u2014may be linked to higher cognitive functioning as people age, according to a study in the March issue of the American Journal of Geriatric Psychiatry.\n\nOlder men and women who were satisfied with their sexual relationships and considered sexuality an essential component of aging performed better on tests of cognitive function than those who felt sexuality and intimacy were unimportant, the research showed.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story posits a cognitive benefit for older adults with more fulfilling sex lives. However, it never quantifies that benefit. It says the sexually less-fulfilled had \u201clower average cognitive scores compared with those who felt sexuality was important and were satisfied with their current sexual activity. The association between lower cognitive functioning and the belief that sexuality was unimportant was significant in both sexes, but seemed stronger in women.\u201d\nHow significant was the difference here, and would it matter to people in their daily lives? Or is it just a statistically significant difference that has no real-word meaning? How much stronger was the association in women? The story doesn\u2019t tell us.\nWe\u2019d also note that this is a cross sectional study that took a snapshot of participants\u2019 cognitive ability at one point in time. The study tells us nothing about potential for sex to prevent cognitive decline, just its association with cognitive abilities at one particular moment.", "answer": 0}, {"article": "Computed tomography coronary angiography (CTCA), is a high-resolution X-ray of the heart that can be used to diagnose the reason for angina, or chest pain, symptoms and clarify what other treatments might be needed.\nWhen the CTCA results revealed something less than a blockage, so-called nonobstructive disease, as the cause for the patient\u2019s chest pain, patients\u2019 quality of life got worse in the following weeks and months.\n\u201cAlthough CTCA removes diagnostic uncertainty and halves the rate of subsequent heart attacks, quality of life can be negatively impacted in those who are worried about their health and are found to have nonobstructive coronary artery disease,\u201d Newby said.\nAlthough getting CTCA is associated with a lower likelihood of having a heart attack later on, its effects on symptoms and quality of life may vary, the researchers note in the journal Heart.\n\u201cIn my opinion, CTCA does have added value in the diagnostic process (improved decision making), it is less invasive than coronary angiography (CAG), and can provide more clarity in the cardiac symptoms experienced by patients,\u201d Mommersteeg concluded.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story is about how patients felt and the symptoms they reported, not purely medical outcomes. It notes that the benefits vary from person to person and makes no claim of dramatic benefits. But we\u2019d like to see the claim that was made backed by some numbers. It says \u201c\u2026 patients\u2019 quality of life got worse in the following weeks and months.\u201d How much worse?", "answer": 0}, {"article": "1.\nA new study, 'Fresh Pear Consumption is Associated with Better Nutrient Intake, Diet Quality, and Weight Parameters in Adults: National Health and Nutrition Examination Survey 2001-2010,' published in Nutrition and Food Science, revealed new information regarding the health benefits of pear consumption.1 Of particular interest given the high rates of obesity in the United States, the study found that adult pear consumers had a lower body weight than non-pear consumers and they were 35 percent less likely to be obese.\nThe epidemiologic study, led by Carol O'Neil of the Louisiana State University Agricultural Center, used a nationally representative analytic sample to examine the association of fresh pear consumption with nutrient intake, nutrient adequacy, diet quality, and cardiovascular risk factors in adults.\nThe USA Pear Bureau continues to collaborate with researchers to commission additional studies that show the relationship between pears and positive health outcomes.\nIn addition to discovering a correlation between fresh pear consumers and lower body weight, the study found that pear consumption was associated with higher diet quality (as defined by the Healthy Eating Index).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release, as noted above, says pear consumers had a lower body weight and were \u201c35 percent less likely\u201d to be obese compared to non-pear consumers, but there is no hint of context. Was this over time? Did the correlation vary according to age groups? (The age ranged from 19 years old to senior status.) What were the absolute numbers? The release does state that the study found no differences in calories (energy) intake and physical activity between the pear eating and non-pear eating group. And while it mentioned that the analysis looked at cardiovascular risk factors, it was silent about\u00a0any differences (or lack thereof) in cardiovascular disease (CVD) or CVD risk in pear eating and non-pear eating subjects.\nAside from the poorly quantified main point about the association between pear consumption and body weight, the release did mention some of the dietary benefits of pears: \u201cPears are an excellent source of fiber and a good source of vitamin C. One medium pear provides about 24 percent of daily fiber needs for only 100 calories. They are sodium-free, cholesterol-free, fat-free and contain 190 mg of potassium.\u201d", "answer": 0}, {"article": "NASHVILLE -- Sick with depression, Harriet Bruce spent her days lying in bed for months at a time.\nThe devices cost around $100,000, Cochran said, who has treated 45 patients with the therapy.\nIt's an alternative to electroconvulsive therapy \u2014 shock treatments \u2014 for patients who have not responded to drugs or psychotherapy.\nA clinical trial funded by the National Institutes of Health revealed a \"significant effect of treatment\" when patients received TMS treatment.\nThe NeuroStar system resembles a dentist's chair.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes a single patient anecdote and does provide us with some information about the NIMH sponsored clinical trial: \u201cBoth Cochran and West cite high patient response rates. A clinical trial funded by the National Institutes of Health revealed a \u201csignificant effect of treatment\u201d when patients received TMS treatment. It compared outcomes of patients who actually received the magnetic pulses against patients in a \u201csham\u201d group, who sat down in the treatment chair for fake sessions.\u201d \u00a0\nHere is what the lead author of the NIMH funded study said about the results (http://www.nimh.nih.gov/science-news/2010/magnetic-stimulation-scores-modest-success-as-antidepressant.shtml) performed in 190 patients with depression who failed standard drug therapy::\nHardly the results suggested by the story", "answer": 0}, {"article": "Enter EllaOne, a member of a new class of drugs called selective progesterone receptor modulators.\nAlthough EllaOne is not available in the U.S., an FDA advisory panel recently voted that it should be.\nFibroids may cause severe abdominal pain, heavy bleeding, and interfere with fertility in some women.\nAs many as 80% of all women have uterine fibroids (noncancerous growths in the uterus), according to the nonprofit National Uterine Fibroids Foundation.\nAs of now, EllaOne is used in Europe as a morning-after pill because it blocks the effects of key hormones -- namely progesterone -- involved in ovulation.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that 80 to 95% of women have no bleeding after taking the drug. However, that leaves a lot of open questions about the effectiveness of the drug. For example, how long does this benefit last? What about other symptoms of fibroids like abdominal pain and pressure? The story repeatedly mentions that the drug shrinks fibroids. By how much? Is that difference clinically meaningful? In other words, can women perceive an improvement in bulk symptoms\u00a0(pain, pressure) as a result of the decreased fibroid size? Do the fibroids grow back?", "answer": 0}, {"article": "About the University of Maryland School of Medicine\n\nThe University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine.\nWhile most cancer patients are well served with today's state-of-the-art radiation therapy technology, up to 30 percent are expected to have a greater benefit from the new form of targeted proton beam therapy.\nThe results have particular relevance for the University of Maryland School of Medicine; this fall the school will open the Maryland Proton Treatment Center (MPTC).\nThis technique can precisely direct radiation to the most difficult-to-reach tumors.\nProton therapy did not make a difference in all of these side effects, but had significant effects on several.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states in the opening paragraph that \u201cpatients treated with proton therapy experienced significantly less toxic side effects than patients treated with older radiation therapies.\u201d But it never offers detailed information on what that means. For example, the release later states that proton therapy resulted \u201ca significantly lower number of side effects, including nausea, blood abnormalities, and loss of appetitite.\u201d How much less likely were patients that received proton therapy to experience these side effects? Did they not experience any of these side effects, or did the benefits vary from patient to patient? What type of blood abnormalities are they talking about? Frustratingly, the release goes on to list a wide range of possible side effects from radiation therapy, but then says that \u201cproton therapy did not make a difference in all of these side effects, but had significant effects on several.\u201d Which ones?", "answer": 0}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job of discussing the manufacturers\u2019 claims of their products\u2019 effectiveness through tests in the lab, including the removal of micro-particles and \u201cclearing\u201d smoke close to the wearer.\u00a0 But more importantly, the story is specific in pointing to the difference between supposed \u201cair-quality\u201d measurements in the lab and any thwarting of the transmission of actual pathogens which would lead to real infections.\u00a0 The story also points out that much of the transmission of cold and flu viruses occurs when hands touch contaminated surfaces, something these devices have no effect upon.", "answer": 1}, {"article": "Soy has been touted as an alternative treatment to hormone replacement therapy after HRT was linked to an increased risk of breast cancer.\nNow, researchers who took another look at 19 published studies find that soy supplements may help, at least over time.\nAlthough all the studies looked at soy supplements, Melby says that getting soy from food is a better bet.\n\"I personally think foods [containing soy] are better.\"\nTwo co-authors, not including Melby, have ties to the soy industry.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story dances all around \u2013 but never delivers specific data on the absolute benefit seen in the meta-analysis.\nThe closest it comes is this:\u00a0 \u201csoy supplements with higher amounts of the isoflavone called genistein were more than twice as good at reducing hot flash frequency than those with low amounts.\u201d\nAnd this non-evidence statement from one of the author-researchers: \u201cWhat this study shows is that ingesting soy isoflavones will help you. I personally think foods [containing soy] are better.\u201d", "answer": 0}, {"article": "Other scientists and companies have long sought ways to measure risk from multiple, additive gene effects \u2014 the \"poly\" in polygenic \u2014 and Myriad Genetics has begun selling a type of polygenic test for breast cancer risk.\nBut specialists in heart disease and genetics who weren't involved with the research called the new findings exciting because of their scope.\n\"This is the first time polygenic scores have really been shown to reach the level of precision where they can have an impact\" on patient health.\nInstead, Kathiresan can calculate risk scores for those five diseases \u2014 eventually maybe more \u2014 simply by reanalyzing the kind of raw data people receive after sending a cheek swab to companies like 23andMe.\nResearchers say a new way of analyzing genetic test data may one day help identify people at high risk of having a heart attack at a young age in time to help.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story has the researchers estimating that as many as 25 million Americans may have three times the average risk for coronary artery disease, even though their research used \u201ca DNA database from Britain.\u201d\u00a0 The story also says that the \u201cscoring system also can predict an increased risk of Type 2 diabetes, inflammatory bowel disease, breast cancer and an irregular heartbeat called atrial fibrillation,\u201d but doesn\u2019t offer what those increases might be.\nThe big question goes unaddressed and unanswered: Is there proof this test will help anyone?", "answer": 0}, {"article": "Measuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting\n\nMeasuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting.\nThe findings suggest that irisin could be a marker for PCOS allowing the condition to be diagnosed more easily.\n\"If high irisin levels in teenagers with PCOS is established, this could lead to the development of treatments for PCOS.\nLifestyle changes and different exercise-related signals that regulate the secretion of irisin could provide a potential option for the management of PCOS.\nIn this study, Greek researchers from Aghia Sophia Children's Hospital in Athens compared the hormones of 23 teenagers with PCOS with 17 healthy teenagers of the same age and BMI.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit here would be identifying levels of irisin found in patients with PCOS that are distinct from irisin levels in the control group of study participants who do not have PCOS. So, what we were looking for here is quantification \u2014 what were the irisin levels in the PCOS patients? And what were the irisin levels in the control group? The release doesn\u2019t tell us. Instead, it says only that \u201cteenagers with PCOS had significantly higher irisin levels compared to the control group.\u201d\nEstablishing the superiority of a diagnostic test requires comparisons in much larger populations than were enrolled in this study.", "answer": 0}, {"article": "Breast MRI currently is used to screen women at high risk of breast cancer and as a diagnostic adjunct to mammography.\nThe new approach is not intended to replace current contrast-enhanced breast MRI protocols in general, Dr. Bickelhaupt emphasized, but to expand the spectrum of options available for answering specific clinical questions.\nShould the results hold in larger trials, the model has potential advantages in the clinic beyond its ability to reduce unnecessary biopsies in women with BI-RADS 4 lesions.\n\"Diffusion kurtosis imaging has been introduced in DWI to provide important information on tissue structures at a microscopic level,\" said study lead author Sebastian Bickelhaupt, M.D., from the German Cancer Research Center in Heidelberg, Germany.\nIn an independent test set of 127 women, the radiomics analysis reduced false-positive findings by 70 percent, while detecting 60 of 61 malignant lesions, or 98 percent.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers learn that after the technique was developed, the radiomics analysis reduced false-positive findings by 70%, while detecting 60 of 61 malignant lesions in a test set of 127 women, or 98%. In order to give full meaning to these statistics, we need to know what the number of false positives was in the comparison group, rather than being given only the percentage of change.\nSimilarly, a brief statement is made about the advantage of the consistency provided by a software algorithm in comparison to readings of images by human technicians. That statement, too, is not quantified. How much error does result from the variability introduced by human reading of images? To what extent is that a problem?\nAlso, the publication stated that the rate of malignant lesions was higher than expected in this group so they would need to replicate this technique to make sure they didn\u2019t have bias within their sample.", "answer": 0}, {"article": "medical personnel.\nIt is still too early to say, however, whether the King-Devick test can replace other, more conventional concussion evaluations for young athletes, including the standardized assessment, despite its shortcomings in this study, Dr. Galetta cautioned.\nOverall, the King-Devick test had by far the greatest accuracy and lowest risk of false positives.\nThe Standardized Assessment of Concussion had performed rather miserably, correctly identifying only two of the concussed athletes, missing 10, and finding that three of the uninjured control athletes had supposedly sustained a concussion, since their scores had declined compared with their baseline (almost certainly, the study\u2019s authors believe, because these young athletes were physically tired).\nresearchers compared how well the various sidelines tests had done at pinpointing the brain injury.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides a good discussion of how the vision test compared in reliability with the standard testing protocol including a cognitive test and a balance test. The tests were applied to 243 young (age 5-18) and 89 college athletes playing a season of hockey or lacrosse.\nAmong the 12 students that sustained head injuries, the researchers found the King-Devick test correctly assessed concussion in 75 percent of the injured players and misidentified one. In comparison, the standard testing protocol accurately assessed only two of the concussed athletes and missed 10. The standard tests also misidentified three athletes as having sustained a concussion, according to the study. The study authors concluded that the vision test was the more sensitive, accurate test.", "answer": 1}, {"article": "\"Now I feel relieved.\"\n\"I think it's a very good vaccine, and it's a safe vaccine, but obviously there needs to be continuing surveillance of usage of the vaccine to make sure there are no adverse effects that are seen in one in a 100 million cases versus one in five or 10,000 people,\" said Sumaya, also a member of CDC's Advisory Committee on Immunization Practices.\n\"It does bolster our confidence that it's effective in the real world,\" said Dr. Bruce Hirsch, an attending physician in infectious diseases at North Shore University Hospital in Manhasset, N.Y., who was not involved with the study.\nTseng's team wanted to test the vaccine's real-world performance, so they compared 75,761 vaccinated members of the Kaiser Permanente health plan to 227,283 members who elected not to have the shot.\n\"People 60 and over can consider talking to their physician about the possibility of receiving the vaccine to reduce their risk, and the doctor can evaluate if they are eligible,\" said Tseng.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nInterestingly, while other stories about this study touted the finding that vaccination cut the risk of shingles by more than half, this story points out that compared to many other vaccines, a 55 percent reduction in relatively risk is a weak performance. The comment from one individual that the vaccine is \u201cbetter than nothing\u201d also helps readers put the benefits into perspective. The story does include endorsement of vaccination and descriptions of the terrible pain shingles attacks can inflict. It also points out that this study provides information about a reduction in the risk of serious eye problems caused by shingles that was collected by the clinical trial that led to the vaccine\u2019s approval.\nThe story reports the absolute annual shingles attack risk figures of 6.4 per 1,000 among the vaccinated participants versus 13 per 1,000 among those not vaccinated. We would have like to also see the story mention that the results indicate that about 71 people need to be vaccinated to prevent one from suffering a shingles attack. And since the story reported relative risk reduction statistics for ophthalmic herpes zoster cases, it should have also told readers the absolute numbers.\nThe story should have pointed out that the study looked at a limited time span and that the researchers can\u2019t say whether the effects of the vaccine persist through later years. That\u2019s an important caveat, since a 60-year-old who had chicken pox as a child is at risk for a shingles attack for the remaining decades of life. If the vaccine cuts the risk of attacks in half, but only for the first few years after vaccination, then the lifetime reduction in risk would be much smaller.\n\nAlso, the final quote from an expert saying \u201cthe benefit, I think, is overwhelming\u201d may overpower all the statistics, leaving readers with an unbalanced summary of the benefits of this vaccine.\nSo, while overall the story had a mixed performance on this criterion, we\u2019ll give it a satisfactory score.", "answer": 1}, {"article": "Vasopressin, an anti-diuretic, reduces urine production.\nIn the United States there's no approved drug to treat the problem, the study authors said.\nThis suggests that the anti-inflammatory impact of routine exercise may minimize nocturia, he said.\nDesmopressin spray prompted \"a significant decrease\" in the frequency of nightly bathroom trips compared with the untreated group, Kaminetsky said.\nThe study team said two of the higher-dose patients developed significantly low blood sodium levels (hyponatremia) as did one person taking the placebo.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re giving the benefit of the doubt on the rating, though we wish the story were more precise. The story says the results showed\u00a0\u201ca significant decrease,\u201d and the average was \u201ctwo fewer episodes\u201d per night,\u00a0but a reduction from how many episodes total is unclear. \u00a0 The same lack of\u00a0details complicate the discussion of the measured increase in uninterrupted sleep and quality of life. The numbers in the story, though a little vague, at least give some sense of the magnitude of the benefit in terms that are meaningful to people with this condition.", "answer": 1}, {"article": "Prof Johann de Bono, Regius professor of cancer research at the ICR, and consultant medical oncologist at the Royal Marsden NHS foundation trust, said: \u201cOur study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.\nThirdly, they used the test to monitor a patient\u2019s blood throughout treatment to quickly pick up signs that the cancer was evolving genetically and might be becoming resistant to the drugs.\nThe liquid biopsy, less invasive than a tissue biopsy, also detects early signs of resistance to olaparib and monitors the cancer\u2019s evolution over time, according to the paper, published in Cancer Discovery on Monday.\nThey also used the test to analyse DNA in the blood after treatment had started, so people who were not responding could be identified and switched to alternative therapy in as little as four to eight weeks.\n\u201cFrom these findings, we were able to develop a powerful, three-in-one test that could in future be used to help doctors select treatment, check whether it is working and monitor the cancer in the longer term.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not quantify the benefits of using the three-in-one liquid biopsy. Readers learned that results of the biopsy were used to initiate (or not) and continue (or not) treatment with a cancer therapeutic drug that targets certain types of prostate cancers in men. Readers did not learn anything about the trial design or how effectiveness of the biopsy was measured. At the very least, it would have\u00a0been helpful to know what proportion of patients \u201cbenefited\u201d (changing drug vs. initiating drug).", "answer": 0}, {"article": "The armpits, palms, and soles are often affected.\nAll had hyperhidrosis, a condition where a person sweats much more than the body needs to cool itself.\nHe presented the findings here at the annual meeting of the American Academy of Dermatology.\nThe study was small and the findings are preliminary.\nIt works, he says, by heating and destroying the sweat glands under the arm.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We are given relative estimates of sweat reduction after treatment \u2013 but no context to judge the scope.\nWhat does an 80% reduction of sweat in a person with excessive sweating amount to?\u00a0 Does that bring them back to near \u201cnormal\u201d?\u00a0 \u2013 Which, of course, raises questions about \u201cWhat is normal?\u201d\n\u00a0", "answer": 0}, {"article": "FDA approves breakthrough cholesterol drug, but only for certain high-risk patients\n\nOvereating may be caused by a hormone deficiency, scientists say\n\nCDC report: Lyme disease is spreading to new territories\n\nResearchers retract study claiming marriages fail more often when wife falls ill\nThe study reported that \"taking aromatase inhibitors for 5 years reduced the risk of postmenopausal women with breast cancer dying of their disease by 40 percent within 10 years of starting treatment, compared with no hormonal treatment.\"\nThe researchers wrote in the study that a substantial number of the trial participants switched from tamoxifen to aromatase inhibitors after they heard that it could reduce recurrence, which affected their results.\nIn a study published in The Lancet on Thursday, researchers found that a class of inexpensive, existing generic called aromatase inhibitors, which suppress hormones, reduce recurrence rates by 30 percent as compared with tamoxifen.\nA separate analysis by the same group, also published in The Lancet, looked at bisphosphonates, which are typically used for osteoporosis.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article reports risk reduction of dying from breast cancer in relative numbers, but we think benefits of an intervention should always be stated in absolute figures when possible. We believe relative risk numbers tend to inflate the impression of how much impact the drug really has. For example, the story states that bisphosphonates could reduce the risk of death by 18% over 10 years. It would be more informative to note that the 10-year risk of death was 14.7% for women who took bisphosphonates vs 18.0% for women who did not receive bisphosphonates \u2014 a 3.3% absolute reduction.\nAnother issue here is that\u00a0aromatase inhibitors are only used in postmenopausal women \u2014 either natural menopause or induced. The story doesn\u2019t explain this.", "answer": 0}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Provides relative risk reduction of chemoprevention with hormone therapy for high-risk women, however, no absolute risk reduction provided. No quantitative risks mentioned for taking hormone therapy for chemoprevention. Incomplete discussion of reduced rate of side effects in raloxifene group. ", "answer": 0}, {"article": "Because this important step is out of the way in advance, it completely changes the patient\u2019s day of surgery experience.\u201d\n\nRadar can target abnormality within 1 mm, sparing more healthy tissue\n\nUnlike mastectomy, which treats breast cancer by removing an entire breast, lumpectomy surgery \u2014 also known as breast-conserving surgery \u2014 is used to remove only the tumor and a small amount of tissue surrounding the tumor.\n\u201cUntil now, a patient would go to the imaging center to have the thin wire precisely placed in the breast.\n\u201cWhen the marker was inserted near the lump, it was similar to a biopsy.\nThe SAVI SCOUT Radar Localization System helps to decrease the time a woman is in the operating room, increase the success rates of lesion removal and reduce the amount of healthy breast tissue that is removed during the procedure.\nIn addition to enhancing the patient\u2019s surgical experience, the more precise localization of the surgical site enable surgeons to plan the procedure better.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although there are theoretical advantages to the Savi Scout device, the news release takes that speculation one step further suggesting not just convenience for the patient but also implying superiority: \u201c\u2026surgeons can target the affected tissue within 1 millimeter of the reflector,\u201d and \u201c\u2026the more precise localization of the surgical site enable surgeons to plan the procedure better.\u00a0That advantage may lead to less tissue needing to be removed and a better appearance of the breast after surgery.\u201d\nSince the Savi Scout has not been compared to the standard approach these are unvalidated statements.", "answer": 0}, {"article": "...\nSimilarly, BE episodes decreased in the 50- and 70-mg/d treatment groups.\nThe U.S. Food and Drug Administration has not approved pharmacologic treatments for BED, according to background information in the study.\nResults also indicate the percentage of patients who achieved four-week BE cessation was lower with the placebo group (21.3 percent) compared with the 50-mg/d (42.2 percent) and 70-mg/d (50 percent) treatment groups.\nThe one-week BE episode response status was improved in the 50- and 70-mg/d treatment groups, and a greater proportion of participants achieved four-week cessation of BE episodes and global improvement of symptom severity with all lisdexamfetamine dosages.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While some quantification is given for a secondary study outcome (the proportion who stopped binge-eating for four weeks), no specific numbers are given for the primary study outcome (binge-eating days per week). Since this was the main measure of the success of the study, we think this result should have been described more thoroughly.", "answer": 0}, {"article": "\u201cIt\u2019s a tough disease because we don\u2019t have a way to bring vision back once it\u2019s lost,\u201d he said.\n\u201cThis makes sense, but we\u2019ll see if it holds up in future studies.\u201d\n\nFuture studies should look at the habits, activities and nutrition that affect lifestyle and glaucoma risks, said Idan Hecht of Tel-Aviv University in Israel, who wasn\u2019t involved in the research.\n\u201cExercising, eating healthy and trying novel ways to improve your health is something you should definitely explore and bring up with your physician.\u201d\n\nEnvironmental factors could play a role in glaucoma risk as well, said Dr. Ahmad Aref at the University of Illinois at Chicago.\nIn this group, Coleman\u2019s team found that just over 5 percent, 82 people, had glaucoma.\n\u201cGlaucoma can lead to blindness, and it would be great if it could be prevented because there is no cure,\u201d said lead author Dr. Anne Coleman of the University of California, Los Angeles.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story mentions that study participants who drank one cup or more of hot caffeinated tea daily \u201chad 74 percent lower odds of having glaucoma\u201d compared to those who don\u2019t drink hot tea.\nOur standard response to a statement like this is to ask, \u201c74% lower than what\u201d? A 74% reduction from an already-small number might not be very meaningful.\u00a0Absolute numbers would have helped\u2013here\u2019s more about how to provide them and why this is important.", "answer": 0}, {"article": "Through its divisions in 54 subfields of psychology and affiliations with 60 state, territorial and Canadian provincial associations, APA works to advance the creation, communication and application of psychological knowledge to benefit society and improve people's lives.\nThis study is the first to examine similar positive effects from college courses taken by older adults, said Lenehan, of the University of Tasmania.\n\"The study findings are exciting because they demonstrate that it's never too late to take action to maximize the cognitive capacity of your brain,\" said lead researcher Megan Lenehan, PhD.\nThe participants who took college classes volunteered for the study so they probably had a greater interest in continuing education that the general senior population, the journal article noted.\nThe participants' age, gender, feelings of well-being or level of social connectedness didn't affect the findings.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The authors report the proportions in each group for whom cognitive capacity, or actually \u201ccognitive reserve\u201d improved. It\u2019s difficult, though, to evaluate the magnitude of the change from either the news release or the article. It would have been helpful if the author of the news release pressed one of the scientists to translate this into English. We also don\u2019t know whether the increase the scientists measured has any clinical significance. Contrary to what the title of the press release implies, the findings are a long way from saying dementia risk may be reduced by the university studies intervention. The scientific article authors make this clear by saying in their last paragraph that this question is one for further study.", "answer": 0}, {"article": "Neither option is considered ideal.\nIn the study, researchers evaluated the safety and effectiveness of SBRT in treating 55 people with early-stage but medically inoperable lung cancer.\nA new study shows stereotactic body radiation therapy (SBRT) effectively controlled more than 87% of early-stage inoperable non-small-cell lung cancer tumors for up to three years.\nThis type of radiation therapy has not yet been approved by the FDA as a lung cancer treatment, but this study brings it one step closer.\nThree years after the treatment, the study showed that 28 participants had a complete response to the therapy and 21 had a partial response.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately quantifies the benefits of treatment by providing the number and percentage of participants who had complete or partial response to the therapy. However, the story should have defined what \"complete\" or \"partial\" response means. More importantly, the story was not explicit about the fact that the observed results can only be compared to historical data, not concurrent\u00a0\"best\" standard care. We know what happened to the study patients, but what would have happened if they got standard therapy can only be speculated on.", "answer": 0}, {"article": "\u201cOur lab is on an island in the South.\n\u201cThat can make sun-exposed skin feel better,\u201d she said, \u201cBut there\u2019s nothing you can do to reverse sun exposure.\u201d And while Henry Lim, president of the American Academy of Dermatology, believes that the Yale study was important, he cautions that you only have a three-hour window after sun exposure to take advantage of any potential product benefits\u2014and that antioxidants \u201care notoriously not very stable and must be formulated carefully in order to be effective.\u201d\n\nBut believers like True Nature Botanicals\u2019 Ms. Peterson are undeterred.\nA new school of thought in the beauty world is pushing the idea that what you put on your skin after a day at the beach could play a part in reducing sun damage.\nThis information is in the early stages of transforming the category of after-sun care\u2014a category traditionally limited to aloe vera-laden moisturizers and gels that lowered the temperature of sun-parched skin but not much else.\nNot everyone is convinced of the effectiveness of after-sun care.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that \u201cProduct formulators are now seeing after-sun care as another line of defense to stop cell mutations and aging in its tracks.\u201d But the story does not cite evidence to show whether their products do that.\nIn the accompanying video, the reporter is more blunt about the uncertainty:\n\u201cWe don\u2019t really know how long it takes for antioxidants to act on the skin,\u201d says the reporter, who then cites several products. \u201cThey feel great and they smell great and they feel good on your skin after it\u2019s been sun-parched. As to whether it\u2019s helped my skin defend itself from the sun, it\u2019s too soon to say. I\u2019ve only been using them for a couple of weeks, but I think it\u2019s worth a try.\u201d", "answer": 0}, {"article": "But in the U.S., most prostate cancers are identified by PSA screening, and less than half have palpable tumors.\nSo \"low risk\" in the Swedish study means higher-risk than the current \"low risk\" men diagnosed in the United States.\nSo there's reason to think men followed with active surveillance and treated when necessary would fare better than the \"watchful waiting\" group in the newly published study.\nBy the way, 9 out of 10 prostate cancers in the U.S. these days is considered low risk.\nFirst, only about 1 in 20 men in the Swedish study had a prostate cancer diagnosis based on a high PSA level.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported only the relative difference in the number of men in each treatment group who died during the follow-up period. \u00a0For readers to understand what the real difference in risk is, information about the absolute difference in risk needs to be reported. See the AP story for comparison. ", "answer": 0}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\n\nNew shingles vaccine is highly effective \u2014 and in short supply\n\nResearchers use immune-cell 'army' to battle another tough cancer\nFDA Commissioner Scott Gottlieb said the approval was \u201ca reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies.\u201d The medication, tested in three randomized, placebo-controlled trials with more than 500 patients, was effective in reducing seizures, the FDA said.\nShlomo Shinnar, president of the American Epilepsy Society and a neurologist at Montefiore Medical Center in New York, has said the drug will be \u201ca very valuable addition\u201d to the limited options for treating severe childhood-onset epilepsy.\nHowever, it isn\u2019t clear whether such a reclassification would involve CBD products in general, the CBD formulation used specifically in Epidiolex or something else.\nThe drugmaker is testing other CBD treatments for glioblastoma and schizophrenia.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Some would argue that FDA approval automatically means that benefits and risks of a new drug have been quantified to experts\u2019 satisfaction. But that is not necessarily the case and readers with an interest in this drug would be better informed if some of the clinical trial evidence had been included in the story. As it stands, the article offers no information at all about reduction in seizures of those who take the drug, or a basis for which to compare its value to other treatments for severe epilepsy.", "answer": 0}, {"article": "Exercise, and in particular strength-training routines that develop muscles of the trunk and core, can help reduce pain and improve function, though many people avoid them for fear of doing further harm.\nThose in the third group served as \u201cself-care\u201d controls and received a book containing advice on back exercises and ways to reduce pain.\nDr. Sherman recommended taking an intensive stretching class, then establishing a routine at home.\n\u201cThe smaller studies which hinted that yoga might be helpful all had problems one way or another.\nThose in the stretching group saw just as much benefit as the people taking yoga.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The journalist adequately framed and quantified the benefits in terms of both primary and secondary outcome measures.\n\n\n\n ", "answer": 1}, {"article": "About the University of Louisville Physicians Group and The James Graham Brown Cancer Center:\n\nThe James Graham Brown Cancer Center is a key component of the University of Louisville Health Sciences Center.\nThe data was presented at the American Surgical Association annual meeting in San Diego.\n\"The STAR data adds to the growing body of evidence that IRE ablation may represent a new treatment paradigm for patients with locally advanced pancreatic cancer,\" said Robert Martin, M.D., Ph.D., F.A.C.S., director of the Division of Surgical Oncology, and Professor, Department of Surgery, University of Louisville, James Graham Brown Cancer Center.\nThe NanoKnife\u00ae IRE system is approved by the U.S. Food and Drug Administration for the surgical ablation of soft tissue.\nIRE was successfully administered to all patients.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release clearly states that nearly three-quarters of pancreatic cancer patients die within a year of diagnosis and 94 percent die within\u00a05 years. It then goes on to\u00a0say the NanoKnife IRE treatment doubles overall survival to 24 months. But the release never provides the absolute numbers from either the treatment or control group to substantiate this. The percentage of patients alive at 24 months may be higher in one group or the other, but the data are not there to tell. In addition, the release states that existing treatment \u201cwill only stabilize the disease and not destroy the tumor,\u201d whereas the new treatment \u201covercomes rapid growth of the tumor by killing all malignant cells at once so they cannot continue to grow and spread.\u201d But it\u2019s not clear that the new treatment does, in fact, do more than \u201cstabilize the disease\u201d or that the cancer won\u2019t \u201cgrow and spread\u201d with the new treatment, since a chart in the abstract suggests that the disease unfortunately remains uniformly fatal even with the new treatment.", "answer": 0}, {"article": "Bathing-suit season is here and with it, anxiety over cellulite. A new laser device that burrows under the skin is getting praise from some doctors who say it gives more dramatic and longer-lasting results than previous treatments, but others caution that more research is needed.\n\nCellulite is a dimpled, uneven appearance of skin caused by fat underneath. It affects some 85% of women and about 5% of men. Until recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Deep in the story, a company-funded study of 10 (!) women was discussed \u2013 resulting in \u201cskin that was 25% thicker after a year.\u201d\u00a0 What does that mean? What is the true benefit of that?\u00a0\u00a0 The story says doctors graded cellulite reduction as \u201cgood to excellent.\u201d\u00a0 In all 10 women?\u00a0 Was this a subjective judgment?\nThen the story cites unpublished data from a company-financed trial trial.\u00a0 Might as well have been a news release.\u00a0 Hardly a good source of evidence to cite at this point.\nBy the end, there really was no good quantification of benefit.\nInterestingly, the story provides no information about what the subjects thought about the results.", "answer": 0}, {"article": "Botox is now being used by men, some of whom did not even run for President. The number of men in the U.S. who paid to get a series of tiny injections in their face nearly tripled from 2001 to 2007--to 300,000, or about 7% of the total Botoxed population. And despite the recession, those numbers aren't going down yet; one of the many things the laid-off cannot afford is to look their age.\n\nMen usually get Botox to remove those two vertical lines between their eyebrows that make them look angry and confused and thus, one could argue, masculine. They...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article assumes Botox reduces the appearances of wrinkles. But it provides no data to verify this. ", "answer": 0}, {"article": "For further information or interview requests contact Sandy Fleming at the University of Kent Press Office.\nNot only does the tailored anti-gravity treadmill programme provide a great environment for healing, it also helps the person restore their belief that they can make a successful return to the sport they love.\nThe team individually tailors rehabilitation programmes to support people in returning to sport and exercise activities after injury or surgery.\nAn eight week return to running programme using the anti-gravity treadmill was individually designed by Dr Hambly.\nUsing space age technology in the Sports Ready clinic at Medway Park, Gillingham, Dr Karen Hambly, an international expert on knee rehabilitation, works with clients who have been given the all clear to start to return to sporting activities but may have concerns about moving from being a patient with an injury to being an athlete again.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does not offer any units of measurement to describe the benefits. The descriptions of benefits also lean pretty heavily on abstractions that are tricky to measure.\nIn the following example, the benefits are \u201ca great environment for healing\u201d and \u201cbelief\u201d that a patient can make a successful return.\n\u201cNot only does the tailored anti-gravity treadmill programme provide a great environment for healing, it also helps the person restore their belief that they can make a successful return to the sport they love.\u201d\nIn another example, the researcher is paraphrased as saying the machine could be helping to \u201creduce fears about re-injury and increase self-belief.\u201d Basically they are saying that the runner re-gained some confidence in running. This cannot be extended to generalizations about health outcomes.", "answer": 0}, {"article": "When skin is exposed to sun, it makes vitamin D.\n\nStill, the doctor wanted to run a blood test to see if Rebecca Rosen had adequate vitamin D.\n\n\"So my wife said, 'Well, why do I need to have a vitamin D [test]?'\nThe evidence is strongest for colorectal cancer, she says.\nThe fact that the government is funding the study is an indicator that the idea has traction.\nNeither study subjects nor investigators will know until the end which regimen they are on.\n\"We don't yet have the large-scale, randomized clinical trials showing benefits in terms of prevention of cardiovascular disease, cancer, diabetes, hypertension, cognitive decline, depression, autoimmune disease,\" Manson says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story did not contain any quantification of the potential benefits from vitamin D.\u00a0 On the one hand, the story mentioned about 12 conditions that might be helped.\u00a0 On the other hand, JoAnn Manson basically said we don\u2019t really know where the true benefits will be until after the clinical trial is done. That was an appropriate balance or the story. ", "answer": 1}, {"article": "\u201cIt\u2019s a survival thing,\u201d she said.\nFor other women, a double mastectomy might eliminate another breast cancer, but it won\u2019t stop cancer from resurfacing in vital organs, Tuttle said.\nIt\u2019s an emotional decision that women often make quickly, considering that surgeries often take place within days of their cancer diagnosis.\nThe survey results came a decade ago, however, when the safety of breast implants was a major issue, said Mayo\u2019s Dr. Lynn Hartmann.\nThe rising use of magnetic resonance imaging, MRI, is likely contributing to the increase in double mastectomies, said Dr. Joseph Leach, a medical oncologist with Park Nicollet Health Services.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Generally the article does a good job of using data to show how the number of double mastectomies has increased over six recent years.\u00a0 \nBut there is one serious flaw: The report states that, \"Women removing a single cancerous breast have a 1 percent chance per year of suffering cancer in the other breast.\" That sounds fearsome, and like a reasonable motivation to undergo double mastectomy. But we have no idea how that 1 percent compares to a woman of a similar age who has not been diagnosed, to a woman with high risk who has not been diagnosed, etc.\nIn addition, the reporter is rounding up from a recurrence rate of between .5 percent to .75 percent, as stated in the research article. The average reader may estimate a 40 year old woman with 40 more years life expectancy has risk of recurrence in other breast of 40 percent; but data suggest it is closer to 20 to 30 percent. \nThe article is also unclear about the evidence regarding mortality: Have no studies looked into the question of whether a double mastectomy increases lifespan, or are there studies that show no difference?\u00a0 ", "answer": 0}, {"article": "All rights reserved.\nAmong the thirteen IBS options that Dr. Enck and the authors reviewed, only peppermint oil had the lowest NNT (number needed to treat) of 2-3 patients needed for one patient to benefit from the therapy.\nIn a meta-analysis by Dr. Enck, entitled \"Therapy Options in Irritable Bowel Syndrome,\"3 published in The European Journal of Gastroenterology & Hepatology, Dr. Enck and the authors concluded that the highest efficacy in the management of IBS is currently found in peppermint oil.\n\"IBS considerably affects quality of life and places an enormous burden on patients, physicians and the health-care system,\" said Brooks D. Cash, M.D., A.G.A.F., F.A.C.G., F.A.C.P., F.A.S.G.E., Professor of Medicine in the Gastroenterology Division at the University of South Alabama in Mobile, Ala. \"The results of these studies add to the growing body of medical evidence supporting the utility of IBgard\u00ae, a novel formulation of peppermint oil, in improving the symptoms, patient satisfaction and quality of life of patients with IBS.\nAdditionally, the support from the medical community builds on a previously important review article about the use of peppermint oil in IBS.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does not quantify the benefits of IBgard or generic peppermint oil. It makes vague statements about benefits or effectiveness without specifying what they are:\n\u201cThe published data showed that IBgard\u00ae demonstrated a statistically significant reduction in the Total IBS Symptom Score (TISS) in as early as 24 hours and at four weeks. The TISS represents a composite score of eight individual IBS symptoms.\u201d\nWhich symptoms were reduced? By how much were they reduced? How many patient volunteers were involved in the study? The release doesn\u2019t say.\nA strength of the release is the inclusion of information on number-needed-to-treat (NNT). But lack of comparability in the outcomes measured in different studies makes comparison of NNT across treatments difficult. The release tries to make such comparisons nonetheless.", "answer": 0}, {"article": "\"Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department\" is published August 20, 2018.\nThe score, published in CMAJ (Canadian Medical Association Journal), can also identify patients at risk of subsequent heart issues after discharge.\nIn this international study, researchers from Canada, Australia, New Zealand and Germany combined common laboratory blood tests available at many hospitals around the world to create a single laboratory score, or clinical chemistry score, to diagnose heart attack.\nA negative (or low-risk) clinical chemistry score at emergency department presentation missed only one of these events compared with up to 25 missed heart attacks/death when using a high-sensitivity cardiac troponin test alone.\nAccording to Professor Andrew Worster, also from McMaster University, \"This lab score may reduce both the number of blood tests and time spent in the emergency department for chest pain patients.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The text gets specific about more accurate predictions stemming from the scoring system.\u00a0 But other benefits are not well explained.\u00a0 For example, although the lead of the news release describes the proposed laboratory score as \u201csafer,\u201d it clarifies that statement in a rather murky way lower in the release by noting that the use of an existing diagnostic test, high-sensitivity cardiac troponin, has not been demonstrated to be safe. Why that is the case is never explained.\nAlso, the study design was not reported in the release. In fact, the study was retrospective, so investigators don\u2019t actually know whether outcomes were better among those who underwent the new test vs. the standard troponin.", "answer": 0}, {"article": "Source: Brightling C, et al.\nBy measuring the sputum eosinophil \u2014 the inflammation marker that shows how white blood cells increase during asthma attacks \u2014 the researchers were able to track the effects of the drug.\nWe already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.\u201d\n\nUltimately, the researchers hope that the drug \u201ccould likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms \u2013 making it a \u2018game changer\u2019 for future treatment,\u201d said Brightling.\n\u201cMost treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all the types of tests.\n\u201cA unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works,\u201d said Brightling in the press release.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains that the study involved 61 participants, about half of whom were given fevipiprant and half were given a placebo. It accurately reports that over the course of 12 weeks, researchers found that those taking the drug saw a decrease in their level of sputum eosinophil, a marker of white blood cells associated with asthma symptoms, from an average of 5.4 percent to 1.1 percent, which is close to that of a person without symptoms.\nHowever, importantly, the news story stated that the drug\u00a0\u201cwas shown to reduce asthma symptoms as well as inflammation.\u201d But the researchers specifically stated that future studies would have to be done to see if the decline in eosinophil counts resulted in improved symptoms. Right now, no one knows if it will help symptoms. For this reason, we\u2019re rating this Unsatisfactory.", "answer": 0}, {"article": "\"This is certainly a provocative study,\" said Dr. Gerald Weissmann, a physician and biochemist at New York University.\nOf the 16 volunteers, six wound up with a body mass index in the healthful range.\nThe pilot study drew strong cautions from several scientists who weren't involved in the research.\nJoe Vinson, the University of Scranton chemist who conducted the pilot study, said the findings should pave the way for more rigorous research on coffee bean extract's effects.\nThough the study was small, the results were striking: Subjects lost an average of 17.5 pounds in 22 weeks and reduced their overall body weight by 10.5%.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As with the competing Health Day story, this story didn\u2019t provide some key details of the \u201ccross-over\u201d study.\nWas the weight loss seen only while the subjects were taking the active extract, or did it also occur when patients were taking the placebo pills (indicating that the weight loss was due to some other factor, such as their overall diet or exercise levels)? The story says that weight loss \u201cappeared to be greater while subjects were taking the pills than when they were on the placebo\u201d but offers no specifics. To score a satisfactory here, we\u2019d need to see a more thorough reporting of how much weight was lost during the three trial periods.", "answer": 0}, {"article": "He explained: \"When teixobactin was discovered it was ground breaking in itself as a new antibiotic which kills bacteria without detectable resistance including superbugs such as MRSA.\nThe Lincoln team has successfully synthesized new simplified versions of teixobactin which harness the same powerful antibiotic effects in a way that could be produced on a commercial scale.\nWe have been investigating a way to simplify the design while retaining the high potency against resistant bacteria such as MRSA.\nScientists working to develop a 'game-changing' new antibiotic have made a significant advance towards creating commercially viable drug treatments by producing two simplified synthetic versions of the substance which are just as potent at killing superbugs like MRSA as its natural form.\nTeixobactin is a recently discovered natural antibiotic which many in the international scientific community believe could lead to creation of the first commercially viable new antibiotic drug in 30 years.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release says the simplified versions of teixobactin \u201chave identical potency\u201d to the natural form. A quote also claims teixobactin \u201ckills bacteria without detectable resistance including superbugs such as MRSA.\u201d But nowhere are readers told that teixobactin has yet to be tested in people. All the claims of benefits are based on laboratory tests. Readers should be told that the benefits for patients have not yet been tested.\nAs one commentary about new antibiotics published last spring noted, \u201cResistance development may not have been observed in initial experiments yet, but similar beliefs for e.g. vancomycin, have been proven wrong. As of yet, teixobactin has not yet reached testing in clinical trials.\u201d", "answer": 0}, {"article": "Hair changes about as fast as grass grows, which is to say it\u2019s extraordinarily slow and not visible to anyone checking impatiently in the mirror every day.\nFor now, Maryanne Senna, a dermatologist and the director of the Hair Academic Innovative Research Unit at Massachusetts General Hospital in Boston, said the best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\nClients must also use the company\u2019s shampoo, conditioner and styling products, forsaking all others \u2014 a psychological as well as a financial buy-in, Dr. Senna said.\nOne is how much emphasis the company places on compliance, the major stumbling block in the efficacy of any treatment, said Dr. Senna, an author of studies on the subject.\nIn the 1990s, clients mixed it with Rogaine, Mr. Skjoth said, \u201cand then we took the Rogaine part away and started focusing on the actual liquid.\u201d\n\nSmall studies have shown the efficacy of various plant-derived ingredients, mostly in mice.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The company doesn\u2019t give detailed data on how much hair growth their customers experience and what types of people benefit, and there\u2019s no independent analysis of its product. That\u2019s a problem, and the story should have pointed out this lack of reliable data. Instead, the story says its \u201cresults are certainly compelling.\u201d\nThe story does attempt to give readers an idea of the scope of the claimed benefits, modest as they may be. It states:\nAfter four months of daily application \u2014 that is, working the tea-colored tonic into the hair section by section, then letting it sit on the scalp for six hours \u2014 most users regain at least 30 percent of lost density, and some as much as 60 percent, according to company figures.\nBut the story relies heavily on two anecdotes: a 42-year-old woman who replied that after three months of use, \u201cYou can\u2019t see holes in my hair anymore.\u201d Another user, a 35-year-old man, said he \u201cstarted seeing peach fuzz after four months.\u201d There\u2019s no interview with someone who didn\u2019t achieve a benefit.", "answer": 0}, {"article": "Coleman RE, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero JC, Rojo F, Gregory W, and Gomis RR.\nThe new study, which is published in the journal Lancet Oncology, was part of an international phase 3 clinical trial involving 3,360 women with stage II or III breast cancer.\nWomen who do not carry the gene - approximately 80 per cent of women with breast cancer - were found to benefit from the bone strengthening treatment.\nThe results need to be confirmed in a second trial, currently underway in the United States, before the test is likely to receive approval for wider use in patients.\nLarge scale clinical trials indicate a group of bone strengthening drugs known as bisphosphonates can help prevent the disease from spreading to bone in breast cancer patients if given early enough.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release did not provide numerical context for the specific benefits of having the MAF amplification genetic testing nor of taking a bisphosphonate drug. \u00a0All readers, but especially those diagnosed with breast cancer, deserve to know specific benefits of testing and treatment. General statements such as \u201c\u2026could benefit thousands of breast cancer patients\u2026\u201d and \u201c\u2026can help prevent the disease from spreading to the bone\u201d do not inform decisions.\nThe published study used invasive disease-free survival as the outcome. \u201cDisease-free survival\u201d is a surrogate or proxy for overall survival \u2014 which is the outcome that patients care about most. To learn more see our toolkit page on the use of surrogate markers in clinical trials.\nFinally, readers should have been provided some context as to what extent the researchers found positive outcomes.", "answer": 0}, {"article": ".\nAnd because of the risks associated with parasites, going around infecting people isn't a viable treatment option.\nThe doctor wanted to know whether there might be a connection between the dramatic success of deworming programs around the world and the rise of immune system problems like asthma and celiac disease.\nOnly so many people are willing to have a parasite put inside them for science.\nThis study would also suggest that humans lost something when we rid ourselves of the microbes and parasites that had evolved alongside us for tens of thousands of years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The heading of the article is eye catching: blood-sucking parasitic worms! The health of millions improved! It\u2019s not until about two-thirds of the way\u00a0through the article that it becomes clear these claims are based on the findings of a laboratory study of asthmatic\u00a0mice, and so there are no actual benefits to report on. The treatment hasn\u2019t yet been tested in humans. The article does make an attempt to explain how similarities in mouse and human anatomy suggest that humans might benefit from the same treatment. It also notes that \u201ctheir [the researchers\u2019] next step is a phase one clinical trial, which would test the effectiveness of an AIP-2 pill.\u201d Actually, phase I trials assess safety and appropriate dosage for new medications. Final effectiveness of new treatments is not assessed until much later, in phase III trials. Any\u00a0possible benefits of this treatment to the public, therefore, are considerably farther down the road than the article implies. Furthermore, findings from other studies in the line of research are mixed. All in all, the statement\u00a0that AIP-2 \u201cmay make millions of people healthier\u201d is premature.\nAs we\u2019ve stated many times, mouse research is usually not newsworthy because of these challenges.", "answer": 0}, {"article": "The study appeared online May 13 in The Annals of Rheumatic Diseases.\nAfter controlling for factors including smoking and education level, they found that women who breast-fed for 1 to 12 months reduced their risk of arthritis by 25 percent, and that those who breast-fed for more than a year cut their risk in half.\n\u201cBut even if you breast-feed for a month or two, it makes a difference.\u201d\n\nAlthough the mechanism is not clear, the scientists write that the protective effect may come from long-term changes in the mother\u2019s immune system induced by breast-feeding.\nThe community-based approach and the fact that data on breast-feeding was collected before the onset of disease give the study strength.\nBut they found that the number of children born to a mother did not affect the results.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\nThe news brief says women who breast-feed reduce their risk of rheumatoid arthritis by 25% to 50%. But ideally, readers would also learn the absolute numbers on which these estimates of relative benefits are based. However, the published study also failed to report the reduction in absolute numbers. What\u2019s a reporter to do? Run the numbers on a calculator? Ask the researchers for more information? If the estimated prevalence of RA is 72/100,000, a 25% reduction might be somewhere in the neighborhood of 18/1000,000 or about two-hundredths of one percent (0.02%), and a 50% reduction might be an absolute reduction of 0.04%\u2013a small number any way you look at it. At the least, readers should be made aware that the true meaning of these numbers is uncertain. \n", "answer": 0}, {"article": "The median age was 75 years (range 41to 94).\n\"In addition to providing important support for using SBRT to treat early-stage lung cancer in elderly patients, these findings highlight the value of multi-institutional collaborations and large data sets that can provide statistically meaningful answers to critical questions about treatment outcome and guide clinical decision making.\"\n\"This study is the largest series of its type to evaluate SBRT outcomes in patients aged 80 years and older,\" says Joel Goldwein, MD, Senior Vice President, Medical Affairs for Elekta.\nThe study evaluated safety and efficacy outcomes of 1,083 patient reports collected in a multi-institutional database.\nThe results of our study clearly support the use of SBRT for elderly patients, especially those who may not be able to tolerate longer courses of radiotherapy or more invasive treatment options,\" says Meredith Giuliani, MBBS, FRCPC, MEd, a radiation oncologist in the Cancer Clinical Research Unit at Princess Margaret Cancer Centre, University Health Network in Toronto and lead study author.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No where in the release does it back up the claims made in the headline and the lead that SBRT that the research supports use of SBRT on those 80 and older. Where are the data to support this? The release says:\nStudy results show no significant differences among the three age groups with respect to 2-year local recurrence, regional recurrence, distant metastases or the incidence of grade 3 or higher toxicity. Cause-specific survival was similar among all three age groups (90.3 to 90.6 percent). Two-year overall survival was lower in older patients, which is likely related to other medical issues.\nSo we are apparently to take this to mean that because cancer recurrence in older patients was no different than in younger patients that the treatment was successful? We need numbers to back up these claims.\nWe\u2019d also like the release to be transparent about the fact that the treatment was not compared with any others.", "answer": 0}, {"article": "And general practice physicians missed cancers 60 percent more often than gastroenterologists.\n\u201cThis is very different from a population undergoing screening.\u201d\n\nColonoscopy would probably miss a smaller percentage of cancers in such a large population, Lieberman said, because the rate would be lower.\nCanadian researchers note that their finding should be a heads-up to clinicians performing the exam, as well as to patients preparing for it.\nGiven the wide variation in colonoscopy training, the researchers call for standardizing it, including credentialing and re-credentialing.\nDr. Charles Kahi of the Indiana University School of Medicine, in Indianapolis, noted that the rate found in the new study was a bit higher than previously reported.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story includes a lot of numbers and, for this reason, we\u2019ll give it the benefit of the doubt on this criterion although we would have liked to have seen more numbers in absolute terms. Saying that women had a 30 percent higher chance of having their cancers missed, for example, sounds like cause for a significant health policy overhaul. But what does that mean in hard numbers?\u00a0How many women were included in this study, for one. And what was the ratio of missed cancers for them? We\u2019re told 1 in 13 overall, but what was the breakdown for men and for women? It also would have been helpful to see the absolute numbers by gastroenterologist versus primary care physician, as the skill set of the person operating the colonscopy also appears to be a factor.", "answer": 1}, {"article": "METs, or metabolic equivalents, are a measure of physiological measure expressing the energy cost of physical activities.\nThe findings from this PROOF study were confirmed in a meta-analysis preformed by the same group and reported at this same EuroPRevent congress.3 This analysis, drawing on data involving almost 120,000 subjects, found that \"low-dose\" moderate-to-vigorous physical activity - of, say, 75 minutes per week or 15 minutes per day - significantly reduced mortality in the elderly.\nDr Hupin emphasised that the widespread acceptance of this message would encourage more elderly people to include even \"low doses\" of physical activity in their usual daily activities, without experiencing high levels of fatigue or of pain.\nBased on the results, Dr Hupin said that a revision of the recommendations for physical activity in the elderly may thus be warranted and beneficial - low dose physical activity can significantly reduce mortality.\nIn commenting on the results, Dr Hupin said several conclusions might be drawn but notably that the level of physical activity in the elderly was negatively associated with mortality rate in a \"dose-dependent\" way and that even a low level of exercise below current recommendations had some protective effect.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release started off strong by giving the absolute death rate, but thereafter cited relative risk reductions.\nFor example, the release states: \u201c\u2026starting or restarting physical activity during retirement reduced the risk of death by two-thirds, but in contrast any reduction, even in low levels of activity, exposed the elderly to a higher risk of death.\u201d\nBut two-thirds of what? And exactly what figure corresponded to a higher risk of death?\nBenefits reported as relative risk reductions may inflate the impression of how effective the intervention really is. This is why we give the release a Not Satisfactory rating here, since we prefer news releases to report benefits data in absolute numbers.", "answer": 0}, {"article": "S. Raman; M. Pless; A. Cubillo; A. Calvo; R. Hecht; C. Liu; E. Chan; J. Chesney; A. Prat; David Geffen School of Medicine, University of California, Los Angeles, CA;, Department of Oncology, Kantonsspital Winterthur, Winterthur, Switzerland; HM Universitario Sanchinarro, CIOCC, Madrid, Spain; Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain; Amgen Inc., Thousand Oaks, CA; James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Hospital Cl\u00ednic, University of Barcelona, Barcelona, Spain.\nAs part of the study, researchers will follow patients for up to two years, and new trials to investigate the effectiveness of the drug in treating advanced cancer in the liver are being planned.\n\"This minimally invasive treatment offers patients a novel way to directly and indirectly attack the cancer cells.\"\nAmgen, the pharmaceutical company that makes T-VEC, was a sponsor of the trial.\nPatients were given escalating doses of T-VEC, up to the maximum FDA-approved dose for melanoma.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The trial was not designed to test the effectiveness of this therapy, so we don\u2019t expect the news release to describe any benefits.", "answer": 2}, {"article": "\u201cThere\u2019s some danger of kids getting a rash, and it would be inadvisable to give it to women in the early stages of pregnancy,\u201d he said.\nSome might not have a large enough sample to find a small but statistically significant effect.\nThere are more than 200 species of virus that cause colds, Dr. Coleman said, and a study could test one species against which echinacea proves ineffective, while leaving open the question of whether it works for others.\n\u201cIf you\u2019re testing the same intervention on the same population using the same outcome measures, then meta-analysis is a very good technique,\u201d Dr. Barrett said.\nDr. Barrett said there was probably little harm in using echinacea, and he was cautiously optimistic that the herb does have a very small positive effect.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The reporter says the study showed a 58 percent reduction in cold risk, and some unspecified ability to shorten duration.\u00a0It would be useful to know how likely an average adult or child is to get a cold each year, and how long it lasts.\u00a0This would also help\u00a0people understand the possible payoff of taking echinacea\u2013and compare it to the costs. \u00a0", "answer": 1}, {"article": "Separate strands of material become stronger when they link up.\nThe cream\u2019s effects are detailed in a scientific report in the journal Nature Materials, but as part of the school\u2019s close association with the companies, it\u2019s being patented and produced at almost the same time.\n\u201cCreating a material that behaves like skin is very difficult,\u201d added Dr. Barbara Gilchrest, a dermatologist at the Massachusetts General Hospital who worked on the study.\nLanger said it might also be used to help burn patients.\nThe stuff can just be peeled off, or taken off with makeup remover, the researchers said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story outlines the improvements arising from the use of this material, but no numerical\u00a0data was offered.", "answer": 0}, {"article": "NEW YORK -- Scientists acknowledged that an HIV vaccine recently tested in Thailand may be less effective than they originally suggested, but said it still provided valuable leads for further research.\n\nWhen first publicly disclosing the outcome of the vaccine trial in September, researchers said the vaccine had lowered the risk of infection by about 31%. That result was modest but statistically significant. Coming after two decades of failed HIV-vaccine trials, the announcement was welcomed by researchers around the world.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The piece does a nice job of presenting the results of the initial report in terms of absolute and relative risk reduction; however, absolute data is not provided for the secondary analyses. \u00a0To its credit, the story clearly and effectively explained statistical significance as it relates to this research. \u00a0As stated in previous coverage, the story reiterates that the benefits of the vaccine are modest and additional research is needed. ", "answer": 1}, {"article": "\"Take some individual responsibility to stay healthy during the flu season,\" said Health and Human Services Secretary Kathleen Sebelius, who scheduled her own seasonal shot for Friday.\nThe report from the Centers for Disease Control and Prevention Friday also came with good news: Testing of vaccines for swine flu show that they work with a single dose and take effect rapidly.\nAustralian and U.S. researchers said Thursday that one dose of the new swine flu vaccine looks strong enough to protect adults \u2013 and can begin protection within 10 days of the shot.\nBut scientists had feared that people of all ages would need two shots about a month apart because the new H1N1 strain is so genetically different from normally circulating flu strains that most of the population has little if any immunity.\nBut different manufacturers make different formulations of the vaccine, so more evidence was needed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nNear the top, the story notes that the new trials indicate the H1N1 flu shots appear to be as effective as seasonal flu shots. However, there is no explanation of the phrase that \u201c75 percent and 96 percent of vaccinated people should be protected with one dose.\u201d Does it mean that that percentage of people won\u2019t get sick? This story uses the term \u201ceffective\u201d without defining just what it means for individuals or society.", "answer": 0}, {"article": "\"One caveat is that other agents that have shown clear efficacy in this model of PD have subsequently failed to show benefit in clinical studies in PD (e.g.\n\"The treatment also protected the area of the brain that is normally damaged by Parkinson's.\"\nThis study, published online in Brain Research, involved Parkinsonian mice that were given Carbidopa/Levodopa (sold as Sinemet\u00ae), a drug used to boost levels of the neurotransmitter dopamine, which is lost in PD.\nThe third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition.\n\"For patients these side effects are just as devastating as the freezing that is associated with PD.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We aren\u2019t really provided with much in the way of information here \u2014 the number of animals involved or how they measured the actual improvement in abnormal movements or what the results were. One of the researchers talks about \u201csignificant behavioral improvement,\u201d but is that \u201csignificant\u201d only in a statistical sense or something that would be noticeable to an average person? We are also told, \u201clithium boosted the expression of tyrosine hydroxylase which increases dopamine synthesis via the inhibition of calpain-1, an enzyme that normally reduces dopamine synthesis\u201d but without really informing the reader with why this is important. We are also told about findings from two earlier studies,\u00a0\u00a0\u201cWe clearly saw a prevention of the motor difficulties we would expect to see in the animals,\u201d said Andersen. \u201cThe treatment also protected the area of the brain that is normally damaged by Parkinson\u2019s.\u201d It would have been helpful to have some numbers here, or a more thorough description of what the study actually showed.", "answer": 0}, {"article": "\"It's odd and it's tough and people say, 'I'm sorry.'\nMason believes the stem cells accelerated his recovery.\nResearchers have followed Mason and five other patients -- all with the most severe spinal cord injuries.\nToday, the company sponsoring the trial reported four of the six patients experienced improvement in both motor strength and function.\nCBS News met up with Mason again three months after the surgery.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story relies on comments from the patient, James Mason, and his doctor, Arthur Jenkins, M.D., a neurosurgeon at Mount Sinai Hospital in New York City. Mason is shown in video footage moving his arms and legs in physical therapy. Three months after surgery, he reports that his wrists have become stronger. Six months post-surgery, he says his improvement has \u201cdoubled,\u201d sensation has returned to his feet and legs, and there\u2019s slight movement in his hips. The physician, Jenkins, says: \u201cMy two cents is it worked that this actually changed his neurological recovery and function, that his actual functional improvement is from the stem cells that were injected.\u201d\nNo data is presented to back up these statements. The narrator, CBS chief medical correspondent Jonathan LaPook, M.D., says the company sponsoring a trial of this therapy, which isn\u2019t named, reported that four out of six patients it was following experienced improvement in motor strength and function. However, there are no measurements provided for any of these observed improvements.\nIf these patients are being followed as part of a trial, readers ought to know what outcomes the researchers are looking for (even if the trial isn\u2019t complete as yet) and how they would objectively measure their improvement.", "answer": 0}, {"article": "AURORA, Colo. (Nov. 16, 2016) - Researchers at the University of Colorado Anschutz Medical Campus have found that high doses of vitamin D reduce the incidence of acute respiratory illness (ARI) in older, long-term care residents.\nBut Ginde said the primary finding that vitamin D can reduce ARI is a major step forward in treating these dangerous infections.\nThey also had over double the incidence of falls, the study said.\nHe cautioned that the study is not definitive proof that vitamin D can prevent ARI but it suggests that it can and at little risk to the patient.\nThe findings of the clinical trial, published today in the Journal of the American Geriatrics Society, could help reduce one of the leading causes of serious illness, debilitation and death among patients in nursing homes and other long-term care facilities.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release did\u00a0not provide adequate\u00a0quantification of benefits. It said that of the 55 elderly people who received high doses of vitamin D, \u201cthose with higher doses saw ARIs cut nearly in half.\u201d That\u2019s quite vague. What was the rate before? Would all 55 have developed ARIs or only two?", "answer": 0}, {"article": "\"It's phenomenal.\"\nMuch more follow-up research is needed to better assess and hopefully improve the treatment's effectiveness, the researchers say.\nAnd starting at two years after treatment, the two groups' survival rate began to diverge, the researchers reported.\nThe treatment can cause a dangerous swelling in the brain that can lead to seizures and other complications, the researchers found.\nDr. David Reardon, clinical director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute in Boston, says the Duke group's results may represent \"a good, solid, important step forward\" for patients with no alternatives.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did a good job of reporting the scope of the observed benefit, stating that 21% of patients \u201cexperienced a prolonged survival\u201d and then breaking down that number with more specifics. For example, it reported that after three years, 21% the treated patients survived versus 4% of a historical control group.\u00a0But in a small study, why not cite the actual numbers \u2013 how many out of how many? \u2013 rather than make readers do the math in their heads.", "answer": 1}, {"article": "An inexpensive drug therapy far surpassed a conventional laser procedure in fixing a leading cause of blindness in babies born prematurely, according to a new study.\n\nThe results of the study, to be published this week in the New England Journal of Medicine, were so significant that the 15 hospitals participating in the research have stopped using lasers in favor of the drug, Avastin, which is injected into the eyes of the affected newborns. Avastin, made by Roche Holding AG's Genentech unit, is designed to be used for treating...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Consider this rating a partial credit. We were happy to see some results in absolute terms and the important subgroup result for babies with type 1 disease. But the article gets enough dings to withhold a satisfactory grade.\nFirst are the qualitative summaries. \u201cAn injection of Avastin stopped blood-vessel growth.\u201d That\u2019s a bit vague for such a zinger. For one thing, one of Avastin\u2019s apparent advantages was that it doesn\u2019t stop vessel growth in the peripheral retina. For another, does this sentence mean Avastin cured all babies? (Retinopathy came back in 4 of 70.) Or does it mean Avastin universally stopped vessel growth at the outset? (The main endpoint of the study was recurrence of disease. Maybe the laser also stops vessel growth at first.)\nAnd we think the story could set a neater table before comparing the benefits of Avastin and the laser therapy. It names 3 downsides of laser therapy, but efficacy (50% recurrence in zone I disease) wasn\u2019t one. Since the study was designed to compare recurrence rates, we assume this downside of the laser is prominent. Another downside of the laser was given: some babies need several treatments. But, in comparison, we\u2019re told that \u201cin many cases\u201d Avastin only needed one treatment. \u201cSome do\u201d means the same thing as \u201cmany don\u2019t,\u201d so a\u00a0cleaner comparison would\u2019ve been nicer.\nHere\u2019s a final aside, not of the same magnitude as the prior comments. In an ideal world,\u00a0the article could\u2019ve addressed the different types of retinopathy of prematurity. Indeed Avastin was superior in the overall cohort, especially in Zone I disease, and the article accurately quotes the editorial as suggesting Avastin should become the treatment of choice in Zone I. But absent is the fact that this study showed no significant benefit in Zone II disease, the larger group of enrolled babies. There was a trend towards benefit, but it wasn\u2019t statistically significant. The message from the editorial is that Avastin is possibly superior in Zone II, but we\u2019ll need more studies. This thread would\u2019ve added some nice balance to the story\u2019s conclusion that Avastin \u201cfar surpassed\u201d laser therapy in treating this disease, and would allow them to be more specific about the 15 hospitals that stopped using the laser (for whom? all zones?).", "answer": 0}, {"article": "Women who carry a defective gene on one X chromosome can compensate with the good copy on their other X chromosome, but they bequeath the defective copy to half their children.\nDr. High is listed as a co-author of the report because her laboratory helped monitor the patients and provided proof for regulators that the virus would not insert its human gene into the patients\u2019 sperm and make the change hereditary.\nTwenty more patients will be treated to assess the best dose of the virus, the goal being the highest dose that does not set off an immune system attack, Dr. Tuddenham said.\nHigh of Children\u2019s Hospital of Philadelphia, said the new therapy had worked because the delivery virus had been made more efficient and because the research team had treated the patients with steroids to suppress immune system attacks on the virus.\nDr. Nathwani and his team reported that they treated the patients by infusing the delivery virus into their veins.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that six patients were \u201csuccessfully treated\u201d and explained that treated patients \u201ccontinued to produce their own Factor IX for up to 22 months,\u201d and notes that one patient had an initial good response but his Factor IX levels declined.\u00a0 It also points out that because his immune system recognized the viral vector, it is now sensitized to respond in the future and he now can\u2019t be treated again.\u00a0 That would mean that five of six \u2013 not six of six \u2013 were successfully treated.\nThere was also no comment about what difference these blood test changes made in patients\u2019 lives \u2013 how they felt.\nNonetheless, we\u2019ll give the story the benefit of the doubt.", "answer": 1}, {"article": "Men with low-risk prostate cancer are currently put under active surveillance, where the disease is monitored and only treated when it becomes more severe.\nResults of a trial in 413 patients showed that the drug, which is activated with a laser to destroy tumor tissue in the prostate, was so effective that half the patients went into remission, compared with 13.5 percent in a control group.\n\u201cThese results are excellent news for men with early localized prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,\u201d said Mark Emberton, a University College London consultant urologist who led the trial.\nThe trial involved 47 treatment sites in 10 European countries, most of which were performing VTP for the first time.\nIn the trial, only 6 percent of patients treated with VTP needed radical therapy compared with 30 percent of patients in the control arm who were under active surveillance.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states:\nResults of a trial in 413 patients showed that the drug, which is activated with a laser to destroy tumor tissue in the prostate, was so effective that half the patients went into remission, compared with 13.5 percent in a control group.\nIn the trial only 6% of patients treated with VTP needed radical therapy compared with 30% of patients in the control arm who were under active surveillance.\nWhile it\u2019s good to see some numbers, we have concerns about the \u201cradical therapy\u201d statistic and what it means, which we\u2019ll address below in the \u201cEvidence Quality\u201d criterion.\nWe also call foul on a quote by the researcher who says the treatment represents \u201ca huge leap forward,\u201d which is an exaggeration. It\u2019s too soon to say if this is a real advance or merely a costly and ineffective treatment that exposes patients to potential harm for no reason.\nHere\u2019s one reason why readers would do well to temper their enthusiasm: The study follow-up was\u00a0too short to show a survival benefit\u2013which is the ultimate goal of treating prostate cancer. We wish the story had called attention to that limitation.", "answer": 0}, {"article": "EULAR aims to promote, stimulate and support the research, prevention, and treatment of rheumatic diseases and the rehabilitation of those it affects.\nOf the 47 patients who reduced, then stopped their TNFi after six months, 45% (21/47) succeeded without flaring, and their final mean DAS28 score after stopping treatment was 2.2, demonstrating low disease activity.\nThere were no significant differences in self-reported measures of disability (Health Assessment Questionnaire score) with either dose reduction strategy at six months.\nIn some cases however, patients maintained a clinical response after stopping the TNFi altogether.\nA two-thirds dose reduction increased the odds of a flare occurring by four times compared with a one-third dose reduction, with flares occurring in 37% of patients.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release notes that there was no significant difference in outcome between those who got the standard dose and those who got the dose that was reduced by a third. It gives the absolute percentage of patients experiencing flares in both groups.", "answer": 1}, {"article": "\"What they do is give you a really small dose, like a crumb, basically,\" explains Jula.\nIn Jula's case, her allergists at National Jewish Health in Denver, Colo., repeated the standard allergy blood tests last summer.\nShe says the results aren't that surprising, since allergists had classified these patients as low-risk for reacting to the foods they were being tested for.\nLanser says it can be tricky to diagnose food allergies.\n\"If the symptoms were treated with just Benadryl or another antihistamine, they were considered mild or moderate.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides the percent of patients who were categorized as having no response, mild allergic response, and anaphylaxis. Because this wasn\u2019t a randomized controlled trial, those numbers summarize the important findings of the study.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - In a small study, people who had chronic pain as a result of damage to the nervous system reported feeling less pain, as well as less depression and anxiety, when they smoked marijuana compared to when they smoked a drug-free placebo.\nThere was also no difference in the quality of life or mood scores that participants reported when they were on any of the four treatments.\nThe study\u2019s five-day treatment sessions also leave questions about patients with chronic conditions who might need treatment for months or years.\nDuring each treatment, participants were asked about their pain, sleep patterns, mood, and overall quality of life.\nFor that reason, the finding that marijuana may actually help improve patients\u2019 sleep, she said, is \u201cparticularly noteworthy.\u201d\n\nThe cannabinoid family, which includes marijuana, is \u201cemerging as an interesting new class of drugs for pain management,\u201d Ware said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Both stories did a decent job of quantifying the benefits.This story provided more details, though, including the differences in patient experiences between the three different concentrations of marijuana. It also repeated this important bit of information:\u00a0\"There was also no difference in the quality of life or mood scores that participants reported when they were on any of the four treatments.\" The story also does a great job of pointing out that the treatment duration of five days in each dosage phase is too short to judge utility for chronic pain, which is\u00a0a long-term affliction.", "answer": 1}, {"article": "The results appear in Nutrition Journal.\nThe study shows that within hours of drinking it, beet juice lowered systolic blood pressure (the top number in a blood pressure reading) by an average of 4-5 points among a small group of healthy men .\nIn this case, Coles says it may be partially explained by the fact that the women in the study tended to be older, and many were on prescription medications, such as oral contraceptives.\nAmong both men and women, the results showed a trend to lower systolic blood pressure six hours after drinking the beet juice.\nBut researchers say this is the first study to look at the effects of adding beet juice to a heathy person\u2019s diet without making any other diet or lifestyle changes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story selectively reported the outcomes for a subgroup of men, and did not report that there was no significant effect in the study as a whole.\nIn addition, it\u2019s important to note that these results are based on findings for one day after a single dose of beet juice.\u00a0One of the study authors speculates that the effect\u00a0\u201cmight be even greater over the long term if they are drinking it day upon day,\u201d but it\u2019s perhaps just as likely that the effect will dissipate over time. It\u2019s also possible that the \u201cbenefits\u201d are due to chance, a poorly conducted study, or data mining. The truth is we don\u2019t know, but this story reported\u00a0only on the optimistic interpretations of this research.", "answer": 0}, {"article": "According to Henning, the molecules in green tea are smaller and can more readily be absorbed into the body and reach the liver directly, while black tea molecules are larger and stay in the intestine rather than being absorbed.\nThe new findings show that black tea polyphenols, which are too large to be absorbed in the small intestine, stimulate the growth of gut bacterium and the formation of short-chain fatty acids, a type of bacterial metabolites that has been shown to alter the energy metabolism in the liver.\n\"Our new findings suggest that black tea, through a specific mechanism through the gut microbiome, may also contribute to good health and weight loss in humans.\"\nThe new study also concluded that both green tea and black tea have different effects on liver metabolism.\nThe findings build on a 2015 UCLA study that demonstrated that both green tea and black tea helped prevent obesity in mice that consumed a high-fat, high-sugar diet.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It\u2019s disappointing that we are left without any idea of the magnitude of the findings. We are told merely that \u201cthe weights of the mice that were given green or black tea extracts dropped to the same levels as those of the mice that received the low-fat diet throughout the study.\u201d", "answer": 0}, {"article": "Even the issues of how much vitamin D adults should take and whether calcium supplements help keep bones strong have been matters of debate.\nAlso missing, Nelson said, are randomized studies that would indicate how often patients should be screened.\nStill, this group stressed the risk was very small, resulting in 2 cases of throat cancer in 1,000 people ages 60 to 79, compared with the normal rate of 1 per 1,000.\nHer task force recommended that an international registry be created for tracking such cases to help researchers better pinpoint which patients might be at risk.\nThe report identified possible benefits of screening, but noted that there is no solid evidence \u2014 in the form of randomized trials, medicine\u2019s gold standard \u2014 comparing fracture rates of patients who have been screened with those who have not been screened.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article provided adequate discussion of the relative benefits of the treatments and screening methods under discussion. \n\u00a0\n ", "answer": 1}, {"article": "Toxins produced by bacteria, such as salmonella, can severely harm the digestive system by damaging nerves critical to healthy gut function.\nThe tests, created by Mark Pimentel, MD, director of the GI Motility Program and Laboratory, confirm when a patient has developed IBS because of food poisoning, a major cause of the disorder.\nFor more information on IBS and the new blood test for the disorder, watch this video:\n\nFirst Ever Blood Test for IBS\n\nCedars-Sinai has entered into an exclusive license agreement with Commonwealth Laboratories for several patent applications covering the blood tests, developed by Pimentel to detect both anti-CdtB and anti-vinculin antibodies in the diagnosis of irritable bowel syndrome and inflammatory bowel disease.\nThe new blood tests identify the presence and amount of specific antibodies reacting to the toxins.\nIBS is the most common gastroenterological disorder in the United States, affecting nearly 40 million people.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits of these tests would be a clear and early diagnosis, allowing patients to receive relevant treatment earlier. But the release\u2019s statement that the blood tests identify these antibodies with 90% certainty is at best misleading. The story never points out that only 33% to 44% of patients with diarrhea-predominant IBS tested positive \u2014 suggesting that most people with IBS will test negative (even though they do, in fact, have IBS). Any release about a new test should explain both the sensitivity and specificity of the test.\nMoreover, the release doesn\u2019t tell readers that there is no cure for IBS. Instead, as the NIDDKD notes on its site, doctors \u201ccan manage the [IBS] symptoms with a combination of diet, medicines, probiotics, and therapies for mental health problems. You may have to try a few treatments to see what works best for you.\u201d Or, as the Mayo Clinic summarizes, \u201ctreatment focuses on the relief of symptoms so that you can live as normally as possible.\u201d Even without a confirmed diagnosis of IBS, patients would be able to share symptoms with their doctors. As a result, the physical health benefit here may be negligible.", "answer": 0}, {"article": "According to the World Health Organization's 2008 figures, at least one in three of the world's adult population is overweight, and almost one in 10 people is obese.\nThe study notes physical activity is also an important part in preventing the risk factors for the metabolic syndrome.\nThe Mediterranean diet isn't just a little extra olive oil, noted Dr. Robert Eckel, an endocrinologist and past president of the American Heart Association.\nAside from helping to prevent the metabolic syndrome\u2013 a cluster of risk factors for heart disease and diabetes- a new study in the Journal of the American College of Cardiology says, the diet can have positive global effects on the individual risk factors: low HDL (\"good\") cholesterol, high triglycerides, high blood pressure and a high blood sugar rate, as seen by your doctor through a blood test.\nThe researchers say what's responsible are the antioxidant and anti-inflammatory effects.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story described the health benefits associated with consumption of a\u00a0\u2018Mediterranean diet\u2019\u00a0\u00a0in the broadest of terms. \u00a0It was not clear from this story the extent to which improvements in the parameters mentioned would impact health or even the obesity epidemic described in the second half of the piece.\nWhat were the data results of the meta-analysis?\u00a0 That\u2019s what supposed to be news here.", "answer": 0}, {"article": "However, prostate cancer is one of the few cancers that\u2019s not strongly linked to smoking (and falling cigarette consumption over the past 40 years is a major reason for falling cancer rates).\nIt\u2019s saying that, for most men, the (albeit small) risk of sexual dysfunction and urinary leakage from eventual treatment is not worth it, given the even smaller chance that PSA testing could save your life.\nAs for the new paper this week, which suggests that three times as many men would be diagnosed each year with metastatic prostate cancer if it weren\u2019t for PSA testing, that study is published in the journal Cancer \u2014 and its numbers deserve a little explanation.\nAnd, as the debate over PSA testing shows us, early diagnosis is only useful if early treatment can help patients live longer and healthier lives, preventing progression to advanced-stage cancer down the line, but without increasing the risks of other health problems too much in the process.\nMany health experts think that\u2019s too much risky treatment to justify the results.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify the purported benefits of PSA screening as described in this recent study. And it at least made a stab at questioning the basis of these projected benefits \u2013 and the statistical modeling study that was just published.", "answer": 1}, {"article": "But another found that the stroke rate was 22 percent lower in people who ate chocolate once a week, and a third reported that death from stroke was 46 percent lower in those who ate 50 grams of chocolate once a week.\nBut Keith-Thomas Ayoob, an associate professor at Albert Einstein College of Medicine in New York City who studies nutrition, said chocolate does have its benefits.\nFor now, said registered dietitian Katie Clark, \"caution should be taken not to promote chocolate as a health food,\" even though it's fine in moderation.\nBut the findings, based on a review of existing research, aren't conclusive, and they don't prove that chocolate is good for your heart.\nThe health benefit may come from antioxidants called flavonoids that are present in chocolate, Saposnik said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Used only relative risk reduction, not absolute. We have a primer on this as well. So when it talked about 22% lower stroke rate or a 46% lower stroke death rate, we\u2019re not told 22% of what?\u00a0 Or 46%\u00a0of what?\u00a0 \nLater there\u2019s mention of chocolate helping to reduce blood pressure or increase blood flow but no data are provided. ", "answer": 0}, {"article": "Some years ago, Italy instituted a countrywide rule requiring competitive athletes to undergo an electrocardiogram, a test that records the electrical activity of the heart.\nCurrently, an EKG and echocardiogram would cost parents a minimum of $2,500, Anderson says.\nBut the Children's Hospital study is showing more than twice that rate and a higher rate for more minor abnormalities as well, perhaps because of better technology, Grenier says.\nSince the study began about a year ago, 500 local teens have been screened and 26 diagnosed with heart abnormalities.\nIf an ongoing program of testing happens, the hospital would try to tap into third-party funding, donations and grants, Towbin says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story reports that false positive results in an existing screening program in Italy unnecessarily restricted sports participation and quotes a researcher as saying that \u201cThere\u2019s got to be a better way,\u201d the story presents the methods being used in this screening research study as clearly beneficial, even though the study has not even finished collecting data. Readers are not given any information about the numbers of deaths that proponents say screening might prevent; indeed the story does not even provide an estimate of the number of teens who collapse and die on sports field, so readers are unable to judge the size of the health threat.\nSome of the statistics presented seem inconsistent. In one place, the article says \u201cheart conditions that put one in 10,000 people at risk when doing top-level physical activities.\u201d Then later, the story says one person in 100 is \u201cborn with potentially life-threatening heart defects.\u201d The researchers say they recommended that 4 out of 500 students tested stop playing sports, close to the one in 100 figure, but then they also said another 22 teens (or more than 4 out of every 100) had some sort of abnormality requiring lifelong monitoring. The discrepancies are not clearly addressed.", "answer": 0}, {"article": "Chronic diseases of aging, like diabetes, hypertension, heart problems, cancer, joint disorders and Alzheimer\u2019s, are all believed to have inflammation in common.\nTo the age-old question \u201cIs coffee bad for you?\u201d, researchers are in more agreement than ever that the answer is a resounding \u201cno.\u201d A new study published in the journal found that older people with low levels of inflammation \u2014 which drives many, if not most, major diseases \u2014 had something surprising in common: they were all caffeine drinkers.\n\u201cClearly in aging something is breaking down, and we become less effective at managing this inflammation,\u201d says Mark Davis, director of the Stanford institute.\nWe are able to point, with a much higher resolution picture, at aging and the things that should be markers for inflammation.\u201d\n\nThe key will be to figure out when the inflammatory response starts to spiral out of control.\nCaffeine inhibits this circuit and turns the inflammatory pathway off, the researchers say.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides no numbers that would help readers grasp the size of the benefit offered by coffee. Instead, the story uses sweeping language that offers readers little real insight. For example: \u201colder people with low levels of inflammation \u2014 which drives many, if not most, major diseases \u2014 had something surprising in common: they were all caffeine drinkers.\u201d Or: \u201cPeople who drank more than five cups of coffee a day showed extremely low levels of activity in the inflammatory gene pathway.\u201d That second line is particularly unusual, since it\u2019s not clear where it came from \u2014 the journal article doesn\u2019t mention how many cups of coffee study participants drank per day. In fact, the closest the journal article comes is to note that \u201cmoderate coffee consumption may suppress systemic inflammation that is caused by inflammasome activation, which may account for its correlation with decreased mortality.\u201d ", "answer": 0}, {"article": "Dr. Gaetan Michel, Chief Executive Officer of Volition's wholly-owned subsidiary, Belgian Volition SPRL, commented, \"We would like to thank the Walloon Region for their continued support of the company.\nBased on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with low-grade tumors or no tumor.\nThese forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and/or other disease applications.\nISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (\"Volition\") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q\u2122 assays to diagnose men with high-grade prostate cancer.\nAt 88% specificity, the Volition panel of five assays (including PSA) identified 94% of high-grade prostate cancers that require treatment (as defined by Gleason Score1).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It\u2019s impossible to judge the potential benefits because basic information is missing. For example, the release does not define what it means by \u201chigh-grade\u201d prostate cancer. It says it used the Gleason Score, but not what cutoff the company used in this analysis. Did they consider a Gleason score of 7 to be high-grade? Without such specifics, it is impossible to interpret the meaning of \u201c94% accuracy.\u201d\nThe release states:\n\u201cAt 88% specificity, the Volition panel of five assays (including PSA) identified 94% of high-grade prostate cancers that require treatment (as defined by Gleason Score1). This compares with just 33% identified by Prostate-Specific Antigen (PSA) alone.\u201d\nThere are problems with this data on several levels. First, they refer to the 94% as accuracy. But the description implies something else. The 94% refers to what sounds like the sensitivity of the test, not its accuracy. Sensitivity is the number of true cancers (a gold standard defined based upon the biopsy result showing a \u201chigh-grade\u201d cancer) picked up by the test. So the 94% implies sensitivity or that 6% of patients with true cancers were missed by this new test. What is confusing is that this is compared to a 33% accuracy of the PSA test.\u00a0And here also the new test is stated to have a specificity of 88%. So we\u2019re left wondering if the 33% refers to the PSA\u2019s specificity, and not the accuracy. If it\u2019s not clear to us, it may not be clear to lay readers either.\nFor more explanation on sensitivity\u00a0and specificity see our toolkit article on the topic.", "answer": 0}, {"article": "Their conclusion?\n\"There is clear evidence that supports the health benefits of circumcision,\" said Susan Blank, who led the 14-member task force that formulated the new policy being published in the journal Pediatrics.\nAt that time, the group, which represents about 60,000 pediatricians nationwide, concluded that there was no clear evidence for or against circumcising newborns.\nSome think the academy's position is long overdue, and that the group should have gone even further and more forcefully recommended circumcision.\n\"It drops the risk of heterosexual HIV acquisition by about 60 percent.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Only relative risk reduction figures were given for UTI and HIV risk reduction.\nThe AAP website notes: \u201cA slightly lower risk of urinary tract infections (UTIs). A circumcised infant boy has about a 1 in 1,000 chance of developing a UTI in the first year of life; an uncircumcised infant boy has about a 1 in 100 chance of developing a UTI in the first year of life.\u201d\u00a0 This would have given readers a bit more of an idea of what the numbers are.\nNonetheless, the NPR story did a better job on this by giving some numbers than did the competing AP story, so we\u2019ll give it a pass.", "answer": 1}, {"article": "Neurostimulation works by sending low-intensity electrical impulses to targeted portions of the spinal cord.\nIf the experiment proves successful, it would provide an entirely different approach to heart failure, a chronic, progressive disease that affects nearly 6 million Americans.\nTorre said though patients may feel some euphoria in the early days, it likely will take about a month before doctors have a good idea whether the therapy is working.\nThere is considerable data showing connections between the brain, nervous system and heart, said Torre, but until now, no one has attempted to take advantage of the relationship therapeutically.\nThe study calls for Torre to implant the system, done through small puncture holes in the lower back, in 20 patients with advanced heart failure, then conducting tests on them after one, two and three months to measure heart function.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story frames the research through the experience of Mr. Hollis Bardwell, the first patient in the study to have a neurostimulation device implanted. The\u00a0story tells us\u00a0Mr. Bardwell\u00a0is \"looking forward to rocking and rolling again\" \u2014 an optimistic outlook that will no\u00a0doubt serve him\u00a0well as a patient. But as\u00a0readers, we want to and\u00a0deserve to\u00a0know whether Mr. Bardwell\u2019s\u00a0enthusiasm is justified, and unfortunately this story doesn\u2019t provide a balanced perspective. As discussed above, the objectives of this phase 1 study are modest and include mostly safety-related assessments. And even if the study does report dramatic benefits for the device on heart function, we won\u2019t know until larger studies are performed\u00a0whether the results are broadly applicable to\u00a0other patients with heart failure. By focusing on the experience of one patient\u00a0and failing to mention the many hurdles that that lie ahead in the development of this\u00a0device, the story paints an\u00a0unacceptably rosy portrait of\u00a0the technology.", "answer": 0}, {"article": "\"We do not want to give anyone false hopes that this is ready for the clinic yet.\nThe images of the brains helped researchers correctly identify those with autism with 94 percent accuracy, says Nicholas Lange, an associate professor of psychiatry at Harvard Medical School and one of the study authors.\nCarissa Cascio, an assistant professor of psychiatry from Vanderbilt University School of Medicine, who specializes in autism and neuro-imaging, believes these study results are important.\nThe scans revealed that the wiring of the brains of those with autism was disorganized compared with the brains of a typical person without autism.\nThis is how they could determine which brains scans belonged those study participants with autism.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story and the Reuters story use the 94 percent accuracy figure with no context. \u00a0\u201cBy scanning the brain for 10 minutes using magnetic resonance imaging, researchers were able to measure six physical differences of microscopic fibers in the brains of 30 males with confirmed high-functioning autism and 30 males without autism.\u00a0The images of the brains helped researchers correctly identify those with autism with 94 percent accuracy, says Nicholas Lange, an associate professor of psychiatry at Harvard Medical School and one of the study authors.\u201d What exactly does this mean? Was autism found in all of the 30 who had autism and none of the 30 who did not? Were there any false diagnoses?\u00a0", "answer": 0}, {"article": "\"We now have a unique approach with some positive findings, but it's still early.\nThis is the latest of several stem cell studies to show promising results for the treatment of type 1 diabetes, Ratner notes.\nEight teens who took part in the study have remained insulin-free for two years, on average.\nIn the new study, 15 of 28 teens with type 1 diabetes who got an experimental treatment using their own stem cells went into remission and did not need insulin injections for an average of about 1.5 years.\nAs a result of the immune-system suppressing drugs, most of the patients in Gu's study experienced side effects including low white blood cell counts, fever, nausea, vomiting, hair loss, and suppression of bone marrow.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that \u201cEight teens who took part in the study have remained insulin-free for two years, on average. One patient has gone without insulin injections for 3.5 years.\u201d\nA significant limitation of this report is that it fails to note that this procedure (at least in the previous literature) is only effective immediately after the diagnosis of Type 1 diabetes, generally in the first six weeks or so.\u00a0 The procedure works by dampening the immune response that is destroying pancreatic insulin-producing cells, and after about six weeks the great majority of these cells are already destroyed, so treating the immune system will have little effect. Were the patients in the current study identified very early after diagnosis, as has been described in the previous literature (e.g., Couri et al. JAMA 2009)?\nThe problem is that the article implies that this approach could potentially be beneficial for the millions of existing patients with Type 1 diabetes, rather than merely future patients identified very early after disease onset.", "answer": 0}, {"article": "Sacroiliac joint dysfunction is a common cause of disabling pain in the lower back, buttocks, or groin.\nBased on reduction in pain and absence of complications at 6 months, treatment was rated successful in 81 percent of subjects assigned to the SIJ implant procedure, compared to 26 percent with nonsurgical treatment.\nThe results show \"clinically and statistically important\" improvements in clinical outcomes for patients undergoing the SIJ implant procedure, according to Dr. Cher and colleagues, with \"profound differences\" between the surgical and nonsurgical groups.\nThe study is the first randomized controlled trial to directly compare the results of surgical and nonsurgical treatment for SIJ dysfunction.\nThe minimally invasive SIJ implant approach evaluated in this trial has been cleared by the US Food and Drug Administration.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release cited the primary outcome of the implant procedure in terms of an absolute percentage.\nUsing reduction in pain and absence of complications at 6 months as the primary outcome, \u201ctreatment was rated successful in 81 percent of subjects assigned to the SIJ implant procedure, compared to 26 percent with nonsurgical treatment,\u201d according to the release. In addition, the average pain score decreased to 30 in the surgical group versus 72 in the nonsurgical group. \u201cSeventy-three percent of subjects undergoing the implant procedure had \u201cclinically significant\u201d reduction in disability scores, compared to just 14 percent in the nonsurgical group.\u201d\nWe thought that the release\u2019s implication that it is easy to figure out who has chronic pain due to\u00a0SI joint inflammation was inadequate. In practice, it is very difficult to diagnose patients with sacroiliitis and it\u2019s often mistaken for other types of back pain, as the study itself indicates.", "answer": 1}, {"article": "Cortisol is known as the \u201cstress hormone\u201d because it is released in response to acute stress to help the body react and cope.\nThe greater number of traumatic events a child had experienced, such as divorce, injury, moving house, severe illness or the death of a family member, the higher the hair cortisol concentrations were, the researchers found.\nSimmons said the results did not mean all children with elevated cortisol levels would go on to develop behavioural problems or mental illness, with many other social, environmental and genetic factors also involved.\n\u201cWhat\u2019s less commonly understood is that beyond poor mental health, it can also be associated with the development of other illnesses such as diabetes, obesity and cholesterol issues, because cortisol is also central to glucose availability, blood pressure and immune function, so identifying these children is important.\u201d\n\nWhile blood or saliva tests could be used to detect cortisol levels, these methods were sometimes problematic, especially in children, Simmons said.\nIt suggests hair cortisol levels may provide a marker of trauma exposure in children and identify those at risk of developing psychosocial and behavioural problems, and who may need medical and psychological support, leader of the study and a fellow in child and adolescent mental health at the University of Melbourne, Dr Julian Simmons, said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The magnitude of the correlation or association between cortisol and traumatic events was not mentioned, and it is very small. As per the scientific article, the history of traumatic events accounts for only 5 to 13% of the variance in the cortisol levels; the biggest effect on those levels was male or female sex, with boys having about two times higher levels than girls. So many, many other factors are influencing cortisol levels besides these reports of traumatic events.", "answer": 0}, {"article": "Weight training or cardio?\nCo-authors on this paper included W. Jack Rejeski and Anthony Marsh, co-principal investigators of the CLIP-II study, and Jessica Sheedy, Beverly Nesbit and Jill Gaukstern, all of the Wake Forest University Department of Health and Exercise Science; and Walter Ambrosius, Michael Walkup, Jonathan Burdette and Barbara Nicklas of the Wake Forest School of Medicine.\nLosing weight is generally recommended for those with obesity, but preserving muscle - while losing fat - is particularly important for older adults in order to maximize functional benefit, Beavers said.\nThis is the latest study from the Cooperative Lifestyle Intervention Program (CLIP-II), a single-blind, randomized controlled trial.\nLoss of lean mass could have important consequences given the high risk of physical disability among the growing population of older adults.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release did a nice job at citing statistics from the study, especially at the end of the release. It rephrased some of the statistics to make them easier for a general audience to understand such as with the percentage of weight loss coming from muscle mass.", "answer": 1}, {"article": "Ginger, an herb, is found in supplements and in many foods such as ginger snaps and Asian dishes.\nPrevious research in animals has suggested that ginger can reduce inflammation but isn't potentially toxic to the stomach like aspirin, Zick noted.\nTUESDAY, Oct. 11, 2011 (HealthDay News) -- A small, preliminary study finds that ginger root supplements seem to reduce inflammation in the intestines -- a potential sign that the pills might reduce the risk of colon cancer.\nIf more funding becomes available, the researchers hope to launch a larger study, Zick said.\nBut for now, she said, \"if you want to embrace ginger because you like the taste, go ahead,\" but there's no solid evidence that it prevents colon cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "What does a decrease in inflammation level of 28% mean?\nNo context is given for the scope of this effect.", "answer": 0}, {"article": "\"The pace is unbelievable.\"\nPatients with a limited time to live may not be so positive, Turnham says.\nDoctors now dare to hope that giving these new drugs in sequence, or in combination, will help people with melanoma live for years while feeling relatively good.\nMany of the new drugs aim to remove melanoma's \"cloaking device,\" allowing it to be recognized and killed by the immune system, says Roy Herbst, chief of medical oncology at the Yale Cancer Center.\nUnlike traditional chemo, which indiscriminately kills growing cells, the new generation of melanoma drugs work in a precise way, based on a better understanding of the specific genes and proteins that drive cancer growth, says Timothy Turnham, executive director of the Melanoma Research Foundation.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "With so many different drugs discussed in one overview story, it\u2019s difficult to give complete data on all. And, while we had some reservations, we give the story the benefit of the doubt on this criterion.\nIn general terms the story states, \u201cNo one can claim to have cured melanoma.\u201d Also in general terms, it stated, \u201cWhen the new immune therapies work, they often keep cancer at bay for a long time.\u201d\nIt gave specific details on two studies released in advance of the upcoming ASCO meeting \u2013 what percentage of patients had what percentage of tumor shrinkage. But we would have liked to have seen additional comments on why this level of tumor shrinkage is important to the patient. Tumor shrinkage may be a surrogate outcome that doesn\u2019t translate into a meaningful improvement in a person\u2019s life. Was there an improvement in survival or quality of life? \u00a0How long were the subjects followed in the studies?\nIt also included this quote from the executive director of the Melanoma Research Foundation: \u201cDrugs such as ipilumumab can seem like breakthroughs to doctors because they help 15% of patients. Patients with a limited time to live may not be so positive.\u201d", "answer": 1}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story said that the risk of strokes was reduced by 55% in men with the highest lycopene levels, a relative comparison. But it also gives readers a look at what the absolute risks looked like: \u201cThere were 25 strokes among 258 men who were considered to have the lowest levels of lycopene while there were 11 strokes among men with the highest lycopene levels.\u201d It was the only one of the three stories we reviewed that included the absolute risk figures.", "answer": 1}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The \"paint\" was touted as having use for identifying \"the micrometastases that can make breast cancer so dangerous\" although it is not clear that it would be sufficiently sensitive for this purpose.\u00a0 More importantly, the implication is that detecting these would automatically mean a difference in terms of outcome (decreased morbidity or increased mortality) \u2013 however there is no evidence to suggest that this is the case.", "answer": 0}, {"article": "Body temperature, heart and breathing rate normalize more quickly.\nAnd if mothers or babies are very sick and have to be isolated, Gray suggests mothers take any opportunity to hold their infant skin to skin.\nAt Ronald Reagan UCLA Medical Center where Ali was born, the technique is routinely practiced for healthy mothers and newborns.\n\"The baby gets landed in a trusting environment,\" he says, reassuring them that life outside the womb can also be \"soft, comfortable and warm.\"\nOne of the first places to show how this technique can help preemies was Colombia in the 1990s.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the story consistently suggests that this practice is beneficial, there is no quantification of benefits.\nBut data isn\u2019t hard to find. For example, the news release from the 20-year follow-up study contains a wealth of statistics, including details like:\n\u201cLooking at mortality, the research found that Kangaroo Mother Care offered significant protection against early death. The mortality rate in the control group (7.7 percent) was more than double that of the KMC group (3.5 percent).\u201d\nThe study also included this information using absolute terms: 8 deaths (3.5%) of 229 children in the kangaroo group and 16 (7.7%) of 204 in the control group.", "answer": 0}, {"article": "For example, robots that provide sensory feedback could eventually help a disabled person cook a meal or clean up things at home.\nThat makes it very challenging to perform simple tasks like grasping a foam coffee cup without crushing it, McLoughlin says.\nOf course, mind-controlled robots are still years away from consumer applications, McLoughlin says.\nAnd there's no good way to control them without implanting electrodes in the brain.\nThen they waited for the brain to heal, as it adjusted to the presence of the electrodes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t overstate the benefits to this one patient. It explains\u00a0that the benefits seen here\u2013the sense of \u201ctouch\u201d provided to this paralyzed individual through a brain-computer interface\u2013does not replicate what most of us might think of as a complete sense of touch. For example, one quote says\u00a0\u201cwe\u2019re really not at the point where we could, say, get him to feel the difference between silk and burlap.\u201d We did feel\u00a0the headline strays over the line a bit, by claiming \u201cimplant restores sense of touch.\u201d\nWhat is needed here is more qualification that this is just one patient, and given the variability in spinal cord injuries, it\u2019s really unknown how this will play out for other people. We also\u00a0took issue with the ending quote of the story that states we\u2019re \u201con the verge of something here that\u2019s going to transform lives.\u201d This needs to be hedged with the reality of the slow pace of the scientific and medical research process.", "answer": 1}, {"article": "HPV is the most common sexually transmitted disease.\nGardisil is likely to be approved in early June, After that, the vaccine will move into the hands of the Centers for Disease Control, which will have to decide if it should be a mandatory vaccine or just a recommended vaccine, CBS News correspondent Elizabeth Kaledin reports.\nMerck said the vaccine could be used in females age 9 to 26, but would work best when given to girls before they begin having sex.\nAdvocates are recommending the vaccine be given to 11- and 12-year-old girls before they become sexually active, but argue that it is not a license to behave promiscuously, Kaledin reports.\nThe anticipated cost of the vaccine, administered in three shots over six months, is $300 to $500, a possible impediment to widespread vaccination campaigns.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does explain that the vaccine is effective against 70% of HPV infections, potentially saving 3,500 deaths from cervical cancer per year. The story should have provided more context. In order to realize the purported benefits, every eligibile individual would need to be vaccinated and the vaccine would have to be 100% effective. These are both unrealistic because women in lower socioeconomic groups have a higher incidence of HPV and lack access to healthcare.", "answer": 1}, {"article": "There are some caveats to the study.\nKeith Humphreys, a drug policy expert at Stanford University and one of the authors of the study, said this reveals an underappreciated policy lever for reducing drug overdoses: making sure patients prescribed to opioids aren\u2019t also prescribed to benzodiazepines, and vice versa.\nFinally, since the study looked at correlation (not causation), it\u2019s possible that it missed some other factor driving up overdose deaths among concurrent benzodiazepine and opioid users \u2014 perhaps, for whatever reason, these users may be more likely to misuse their drugs.\nBut there\u2019s a catch: Such overdoses seem to be very closely tied to the opioid epidemic, with the majority of benzodiazepine overdose deaths involving both benzodiazepines and opioids.\nStill, it\u2019s well established that benzodiazepine and opioids compound each other\u2019s overdose risk.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job conveying the risk increase of combining drugs versus using opioids alone, and we especially like its use of a bar graph to give a visual representation of the added danger. The story states that eliminating concurrent benzodiazepine and opioid use could reduce the risk for an opioid overdose\u2013related emergency room or inpatient visit by 15 percent. Further, it says the study found that among all opioid users, concurrent use of benzodiazepines more than doubled the risk of an ER or inpatient visit for a drug overdose.\nOne quibble: It wanders into sketchy territory by extrapolating deaths: \u201cIf that reduced risk applies to overdose deaths as well, eliminating concurrent opioid and benzodiazepine use could have prevented up to 2,630 opioid painkiller\u2013related overdose deaths in 2015.\u201d This is an interesting perspective, but we\u2019re wondering if it\u2019s valid to assume that deaths would decline proportionally to hospital visits. An independent expert source would have been helpful here.", "answer": 1}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The column allows promoters of products to make their claims, but then quotes an independent professor of pharmacy saying that, to his knowledge, there are no well-designed studies showing that caffeine works better than placebo for weight loss.", "answer": 1}, {"article": "\"They got it completely wrong,\" he said.\nLike other mass screening tests including mammography, the overarching question is whether the benefits of virtual colonoscopy outweigh the risks.\nIts supporters, many of them radiologists who read CT scans, tout virtual colonoscopy as a more palatable alternative that has the potential to boost low rates of screening.\nAt issue is whether virtual colonoscopy will enhance quality or whether it is, in the words of one physician blogger, \"a proxy for high-tech excesses.\"\nInitially regarded as a high-tech novelty, the new procedure has in recent months received key endorsements as a first-line screening test from influential medical groups, notably the American Cancer Society, after several large studies found it to be effective at finding large polyps.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not adequately quantify the benefits of virtual colonoscopy. While it does provide the frequency of incidental findings, it does not indicate what percentage of polyps are found relative to standard colonoscopy.", "answer": 0}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story clearly explains that the eight cases of maternal tumor DNA findings came from a collection of more than 125,000 blood samples submitted to one of the companies over a two-year period, and that about 3 percent were positive for one or more chromosomal abnormalities. It also points out that follow-up tests showed the fetus was normal in a \u201cvery small number of instances\u201d and that among those just 10 cases of maternal cancer were suspected. Further, of the eight women featured in the published report, just three had their cancers diagnosed because of the findings.\nThe story earns a Satisfactory grade here. Some additional questions that could have been addressed by the coverage include:", "answer": 1}, {"article": "\u201cI wouldn\u2019t use the word excited too much,\u201d said Anthony Fauci, director of the NIH\u2019s National Institute of Allergy and Infectious Diseases.\nBut so far, the HIV community is carefully watching the Ad26 vaccine research because the approach seems quite promising.\nThe mosaic approach seems promising in very early clinical research\n\nIn the 35 years of the HIV epidemic, only four HIV vaccine concepts have been tested in humans.\nSo it\u2019s difficult to think about how a single shot might work against all the different HIV subtypes circulating around the world.\n\u201cThe mosaic strategy is one way to attempt to deal with the global virus diversity.\u201d\n\nA word of caution, though: We\u2019re only in the early phase of human testing, and the vaccine could ultimately fail to prevent the virus from spreading among people.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The APPROACH trial randomly assigned 393 volunteers from five countries to receive one of seven experimental vaccines or a placebo. \u00a0While the report notes that \u201cthe mosaic vaccine was the best tolerated and also capable of generating anti-HIV immune responses in all the people who received the shots,\u201d one is tempted to ask: Compared to what? How is it possible to determine the benefits of the vaccine when we don\u2019t have any quantitative sense of how the vaccine/ comparators performed?\nThat being said, the story makes it clear that these immune response results, interesting though they may be, are not the outcome that matters \u2014 and this is a very important qualifier. It also uses results from previous animal studies to suggest how the vaccine might ultimately perform in people. It does this in a way that isn\u2019t inappropriately optimistic.\nWe\u2019re on the fence with this rating but will give the benefit of the doubt.", "answer": 1}, {"article": "The results have not previously been published or presented.\nThese phase III trial results demonstrate that C-Tb is safe, has comparable diagnostic performance to QFT-GIT and addresses the problem of false positive TST results in BCG vaccinated persons.\nIn the second double-blinded trial, researchers were primarily concerned with testing how accurate C-Tb was in HIV-positive patients and in young children--populations in which the accuracy of the TST and the IGRA is known to be compromised.\nDr. Ruhwald said another advantage of C-Tb is that the measurement of infection, a 5mm or larger induration, is universal across patients with different risk factors, including HIV infection.\nThe test, known as C-Tb, combines the \"field friendliness of the PPD-based tuberculin skin test with the high specificity of interferon gamma release assays, or IGRAs,\" said lead researcher Morten Ruhwald, MD, PhD, head of human immunology at Statens Serum Institut in Denmark, which developed the test.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides information that the new test \u2014 the C-Tb \u2014 is almost as effective as the IGRA, or interferon gamma release assays, which are more expensive, require blood samples and complicated lab work. It also explains that C-Tb is less prone to produce false positives than the TST in BCG-vaccinated individuals. News releases on diagnostic tests should also address the balance between sensitivity \u2014 which is how good the test is at positively identifying people who actually have the problem \u2013 and specificity \u2013 how good the test is at ruling out people who don\u2019t have the problem. This release addresses the specificity issue, stating \u201cThe specificity of C-Tb, unlike the TST, was not impacted by the BCG vaccine, the partially effective vaccine that many residents in the developing world receive. TST specificity in this group was only 62 percent. The sensitivity of C-Tb was comparable to the IGRA in confirmed TB cases (77 percent vs. 81 percent), indicating similar abilities to detect infection.\u201d", "answer": 1}, {"article": "In a transvaginal ultrasound (TVU), sound waves emitted from a probe placed in vagina help a physician check if Essure has been placed properly.\nAll physicians who offer Essure are expected to be trained to perform the TVU confirmation test by mid-2016, the company said.\nBut since its approval in 2002, women using the device have sent the FDA more than 5,000 complaints, ranging from pain and menstrual problems to pregnancies and even deaths.\nThis test is an alternative to the generally-prescribed modified hysterosalpingogram (HSG) test in which an x-ray of the uterus and fallopian tubes is used to check for proper device placement.\nA woman using Essure must do a test to confirm that the device is properly placed within three months of the procedure and until she receives a confirmation from her doctor, she must use alternate birth control methods, Bayer said in a statement on Wednesday.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article raises questions on how the TVU improves outcomes for women undergoing Essure device placement. How is the test an improvement over HSG, the current test? \u00a0Though invasive, as suggested by its name (transvaginal), the procedure is less involved, invasive and painful than a HSG (which requires the injection of dye directly into the cervix/uterus \u2014 \u00a0and which frequently causes pain and cramping). However, this fact is not mentioned in the report at all. Also not mentioned is the benefit of using ultrasound to minimize exposure to radiation vs. the x-rays needed for an HSG (which do emit radiation). \u00a0Readers are not given any description of the potential benefits of TVU over HSG, or how they compare vis-a-vis the visualization of Essure placement. Was there a study that looked at the accuracy of TVU in determining the correct placement? \u00a0And if the device is found through TVU to be improperly placed, or it\u2019s determined through the exam that the device has broken or migrated, what are the next steps?", "answer": 0}, {"article": "Some see Qnexa as a test of the FDA trying to recalibrate how it weighs risks and benefits for weight-loss drugs.\nThe setbacks put a spotlight on how the FDA handles these drugs.\nAs the FDA works through this, many are watching how the agency handles Qnexa.\nBut some say the agency's aversion to accepting any risks is outdated.\nPart of what's going on is that the FDA has gotten a lot more cautious about approving new drugs in general after some serious drug-safety problems, such as heart problems linked to the painkiller Vioxx.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Here\u2019s the good part. \u00a0 The story focuses on the regulatory hurdle.\u00a0 We appreciate the sidebar that includes a link to FDA\u2019s 200-page review documents.\u00a0 From those documents, the story notes that \u201cmany people lose 5% of their body weight\u201d after using the drug. And there was reference to some data on lowering blood pressure.\nBut here\u2019s where we yearned for more/better info: Instead of riding the patient anecdote, the story could have provided some real data.\u00a0 The past proceedings of the Advisory Committee are readily available.\u00a0 The biggest issue with \u201cdiet pills\u201d is that if you have not altered your lifestyle, you will gain the weight back again. As noted in our summary above, the story could have directly included \u2013 even at a high level \u2013 some of the data from the clinical trials so that readers could have an appreciation for the magnitude of the weight loss seen. The one line \u2013 \u201cQnexa does appear to help many people lose at 5 percent of their body weight\u201d \u2013 just doesn\u2019t tell the story.", "answer": 0}, {"article": "For more on obesity, visit the U.S. National Institutes of Health.\nThe authors said such side effects were typically \"mild.\"\nThey concluded that the higher-dose zonisamide showed promise as a weight-loss aid, but advised clinicians to carefully weigh the pros and cons on a patient-by-patient basis.\nCaution is vital when using any drug that has been approved for one condition for another, Sandon said.\nBut they also suffered more side effects than patients not taking the medication.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We weren\u2019t very happy with the headline and lead of this story, because they make the benefits sound more spectacular than they really were. The story goes on to explain, though, that a larger percentage of the study participants who took the highest does of the drug managed to lose 5 percent of their weight. The story says, \u201cAlthough nearly 55 percent of those on the higher-dose medication shed 5 percent or more of their pre-study weight, that figure was 34 percent among the lower-dose group and 31 percent among the non-medication participants.\u201d", "answer": 1}, {"article": "The American Academy of Family Physicians outlines medicines used to treat patients with acute coronary syndrome.\nA study author agreed that for most patients, using the drug with a lower dose of aspirin is usually warranted.\n\"A higher aspirin dose (325 mg versus 81 mg) increases the risk of bleeding without increasing the efficacy of the drug.\"\nThe panel's recommendation was based in part on prior findings from this study, called the Platelet Inhibition and Patient Outcomes (PLATO) trial.\nMONDAY, June 27, 2011 (HealthDay News) -- Brilinta, an experimental anti-clotting medication currently awaiting U.S. Food and Drug Administration approval, performed better than the industry standard, Plavix, when used in tandem with low-dose aspirin, a new study finds.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We have a few suggestions here. Most importantly, we think the take-home message of the study was too oversimplified. The headline claims that Brilinta \u201cBeats Plavix When Paired With Low-Dose Aspirin.\u201d In fact, this study was a geographic analysis to explain why Brilinta wasn\u2019t better than Plavix in the US, unlike in other countries, and the lead conclusion was: \u201cThe regional interaction could arise from chance alone.\u201d Next, it says that the aspirin dose was \u201ca possible explanation.\u201d In fact, since last year the dose of\u00a0aspirin has been suggested\u00a0as a possible explanation for the regional differences in Brilinta\u2019s effects, and that hypothesis has generated controversy. This new study is important to raise our antennae and spur new research, but it wasn\u2019t designed to prove the effect of aspirin.\nOf course, the article\u2019s take-home message is the same one that many in the field (including the FDA) may derive from this study. The aspirin finding is most relevant to current practice, both for the use of ticagrelor globally now and perhaps soon in the US. It\u2019s also valuable for thinking about aspirin in this setting in general. However, we think the \u00a0context should not be boiled off from the message. \nIt\u2019s important to keep in mind the limitations of this reported benefit, as we discussed under Evaluate the Quality of Evidence. The details are statistical, such as the weakening of a study\u2019s power by repeatedly slicing and dicing the same data, which is beyond the scope of this article. But we think more of the big picture would have been appropriate.\u00a0For journalists, the big picture is a question of tone, of conveying the caution urged by the researchers, For doctors, the big picture is that only future randomized trials can investigate whether the pattern observed in this study with aspirin dose is a true effect, a red herring resulting from chance, or a surrogate marker of another factor that\u2019s more important to target.\nAdditionally, the benefit is quantified as a relative risk reduction. If you\u2019re a regular here, you know\u00a0how we feel about relative risks vs absolute ones. In absolute terms, the difference between the two drugs was about 2% for heart attack, stroke, and death.\u00a0", "answer": 0}, {"article": "Additional UT Southwestern researchers include lead authors Dr. Wenfang Chen, Haley Hill, Alana Christie, and Min Soo Kim, as well as Eboni Holloman, Andrea Pavia-Jimenez, Farrah Homayoun, Dr. Yuanqing Ma, Dr. Nirav Patel, Dr. Guiyang Hao, Qurratulain Yousuf, Allison Joyce, Dr.\nThe findings show that HIF-2 is a promising target to combat kidney cancer, said Dr. Brugarolas, senior author and a Virginia Murchison Linthicum Scholar in Medical Research at UT Southwestern.\nHIF-2 inhibitors also are the target of UTSW's recent $11 million SPORE (Specialized Program of Research Excellence) award.\nPart of the SPORE grant, one of just two directly related to kidney cancer in the nation, is focused on further researching HIF-2 inhibitors.\nHIF-2 inhibitors, which grew out of research begun more than 20 years ago at UT Southwestern Medical Center, work by interfering with processes that fuel the growth of cells.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We are told that \u201cmice transplanted with kidney cancer from over 20 patients\u201d found that \u201cthe HIF-2 inhibitor PT2399 controlled cancer in half of the tumors.\u201d\u00a0 This is unsatisfactory on a number of levels. How many mice? \u00a0How well did the comparator mice do? \u00a0What does \u201ccontrolled cancer\u201d mean? \u00a0Were the differences statistically or clinically meaningful? \u00a0These are, admittedly awkward questions, but the kind of questions that need to be explained in a press release that claims \u201cNew HIF-2 kidney cancer therapy more effective than current treatment, study shows.\u201d", "answer": 0}, {"article": ".\nThe solution was a special device made by Kurve Technology that delivers a spray of insulin deep into the nose.\nAnd patients would need a special device to get it deep into the nose.\nThe problem was to find a way to get more insulin to the brain but not to the body.\nThat led to the current study, lasting four months.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that insulin-treated patients \u201ceither improved slightly or remained the same in tests of memory and assessments of their ability to handle day-to-day activities.\u201d The statement is not misleading, but\u00a0it is\u00a0not\u00a0detailed enough to satisfy\u00a0this criterion. Unfortunately the story did not place the study results into context. How relevant to the patient were the changes seen and would they or their family members notice the improvement? The story could have described the scales that researchers used to\u00a0measure function, and provided the actual values for the treatment and placebo groups. This would\u00a0have given readers a more objective accounting of how \u201cslight\u201d the improvement was.\u00a0Notably, the researchers acknowledge in their paper that \u201calthough we achieved statistical significance for our primary outcome measure, the observed effects were small in absolute terms, and thus their clinical significance is unclear.\u201d", "answer": 0}, {"article": "\"Some will benefit in a very large way.\nWhy would a woman at normal risk of breast cancer want to get routine mammograms?\nSo should U.S. women continue to get routine mammograms?\nThe obvious answer is that these tests save lives.\nIt is not wrong to want a routine mammogram, and it is not wrong not to want one.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "The machine, which is made by the Bedford company Hologic and developed partly at MGH under Rafferty\u2019s supervision, produces images that are so vivid and clear they seem to speak out loud: \u201cHey, right here!\nThere\u2019s an intuitive argument for why 3-D mammography might be more accurate.\nOnly a prospective, randomized trial with mortality as its \u201cendpoint\u201d can say for sure, and that\u2019s how long it takes to conduct one.\nSo perhaps it\u2019s not surprising that the company\u2019s PowerPoint presentation to the FDA included the unsubtle phrase \u201chuge breakthrough,\u201d or that the first American patient to undergo 3-D mammography \u2013 Laura Lang, a polished 55-year-old Boston marketing executive and breast cancer survivor \u2013 did so in front of a CBS camera crew last February.\nTrials like this are the gold standard of medical evidence.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The author fails to quantify the potential benefits of 3-D mammography.\u00a0 Dr. Rafferty, a consultant on the development of 3-D imaging, and Andy Smith, vice-president of Hologic, sole provider of FDA approved 3-D imaging equipment, provide very positive, glowing quotes about the benefits of 3-D imaging but the story provides no independent, evidence-based information to support these claims of benefit.\nThe author refers to 3-D mammography trials that Dr. Rafferty has been running since 2007 but there is no specific information about the type of trials, how many women are in the trials, the specific focus of the trials (2-D imaging vs 3-D imaging?), the source of funding for the trials, and the designated endpoint for the trials.", "answer": 0}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article notes that the patient was in remission for seven months, but like the TIME article, says nothing specifically about what the patients tumor status was during those seven months. If the tumors shrunk, it would be at least useful to know the baseline measurements and degree of shrinkage and disappearance, as well as any improvements or (setbacks) in quality of life.", "answer": 0}, {"article": "Brain scans and spinal taps are helpful but they're not certain.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nToday only an autopsy can establish for sure that a patient had Alzheimer's.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nIn a study of 259 blood samples, the test identified early markers for Alzheimer's with 90 percent accuracy, reports CBS News correspondent John Blackstone.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not provide any means for assessing benefit of advanced knowledge about whether one were to develop Alzheimer\u2019s disease. The enthusiasm for the test should be limited to its role as a research tool.\u00a0 The tone of the broadcast implied that knowing about the disease early would allow for treatment to benefit the patient when this is not the case.\u00a0\u00a0\u00a0 ", "answer": 0}, {"article": "I'll keep going as long as I can enjoy what's to be enjoyed.\u201d\nThe study shed new light on a question of prime interest to cardiologists: whether the injected stem cells actually transformed themselves into heart muscle, or improved heart function in some other way.\nThe trial was primarily about the safety of the procedure, and all eight patients came through without significant side effects, he said.\nIt worked in patients such as Eaton, whose heart attack was 11 years ago, Hare said.\nBy implication, it almost certainly improves the patient's health, although that was not directly measured in the small, early study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We appreciate that this is the rare story to point out that clinical significance was not considered, but we think the story leads readers down the wrong path by comparing a 25% reduction to a 5% reduction and not providing the absolute numbers.\u00a0In addition, the story should have pointed out that the reduction was measured by comparing the patients\u2019 baseline volume to their volume at the end of the study, as opposed to comparing their results to a similar group who did not receive the therapy. \u00a0", "answer": 0}, {"article": "A health claim, in the language of the FDA, characterizes the relationship between a substance and a reduction in the risk of contracting a particular disease.\n\"There is no credible evidence to support qualified health claims for green tea or green tea extract and a reduction of a number of risk factors associated with (cardiovascular disease),\" the FDA said on its Web site last week.\nThe Food and Drug Administration said it reviewed 105 articles and other publications submitted as part of the petition but could find no evidence to support claims of the beverage's health benefits.\nIto En Ltd., a Japanese company that bills itself as the world's largest green tea company, and its U.S. subsidiary, Ito En (North America) Inc., petitioned the FDA in June, seeking to make the claim that drinking at least five ounces of green tea a day may reduce the risk of heart disease.\nNonetheless, the belief that drinking green tea confers health benefits has driven its popularity over the past decade, the Tea Association of the United States has said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article reported that the FDA found no evidence of heart disease benefit associated with consumption of green tea.", "answer": 1}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0There was no real discussion about the potential benefits to be derived from early and accurate diagnosis of Alzheimer\u2019s disease. Ideally, a diagnostic test should reliably distinguish between those with and those without the disease. \u00a0In addition the test should have a low incidence of side effects. \u00a0The potential benefits of the use of florbetavir are noted as a strong association. \u00a0The strength of the association is not provided leaving the average reader (amplified in the headline) with the impression that the test works and can distinguish between those with and without Alzheimers.\nThe story did explain that \"Another study presented at the conference looked at people with mild cognitive impairment, which can precede Alzheimer\u2019s. It found that 22% of patients with plaques identified using florbetapir (vs. 3% of those without plaques) progressed to full-blown Alzheimer\u2019s within a year.\u2019\u00a0 But it didn\u2019t comment on the quality of that evidence.\u00a0", "answer": 0}, {"article": "Type 2 diabetes is the most common form of the disease and is linked to obesity.\nIn calculating the combined number of cardiac deaths, non-fatal heart attacks and non-fatal strokes, 14 percent fewer events were seen in patients taking Jardiance in combination with standard treatments, compared with patients who took standard treatments alone, meeting the study\u2019s main goal.\nZinman, in an interview, predicted the new study would prompt medical societies to recommend that Jardiance be used by type 2 diabetics who have a history of heart disease or who are at risk of cardiovascular events.\nIn the study, patients taking Jardiance had a 38 percent reduction in cardiovascular death, including from heart attacks and strokes.\nThe vast majority of those patients could be candidates for Jardiance, which costs over $4,000 per year, Morningstar analyst Damien Conover said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story relies entirely on relative risks to convey the benefits found in the study \u2014 most notably in the headline. We think that estimates based on relative risk can be misleading in isolation, and so we always prefer for stories to include a measure of absolute risk reduction as well. \u00a0For example, the abstract of the study explains that the \u201cslashing\u201d of deaths mentioned in the headline means that the death rate was 5.7% in the Jardiance group compared with\u00a08.3% in the placebo group.", "answer": 0}, {"article": "They have gained nearly 8 percent since December 18.\nThe study, named Reset, was a 20-patient trial designed to test the maintenance effect of a 20 mg dose of the drug, tasimelteon.\nThe second trial showed that patients treated by the drug maintained their clinical benefits while placebo-treated patients showed significant deterioration in measures of night-time sleep, daytime naps and timing of sleep.\nVanda on December 18 said the drug performed better than a placebo in the first of the four planned late-stage trials on the drug.\nThe drug is being tested for \u2018non-24-hour disorder\u2019 that has no approved treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The description of benefits was vague, with no quantification.\nFor example, the story reported: \u201cThe second trial showed that patients treated by the drug maintained their clinical benefits while placebo-treated patients showed significant deterioration in measures of night-time sleep, daytime naps and timing of sleep.\u201d\nMaintained what clinical benefits? What was the actual comparison with the placebo group?", "answer": 0}, {"article": "''It's been known anecdotally,\" says researcher Mark Ware, MD, assistant professor of anesthesia and family medicine at McGill University in Montreal.\nThe new study ''adds to the trickle of evidence that cannabis may help some of the patients who are struggling [with pain] at present,\" Henry McQuay, DM, an emeritus fellow at Balliol College, Oxford University, England, writes in a commentary accompanying the study.\nBut Ware's study is more scientific -- a clinical trial in which his team compared placebo with three different doses of cannabis.\n\"About 10% to 15% of patients attending a chronic pain clinic use cannabis as part of their pain [control] strategy,\" he tells WebMD.\nThe research is published in CMAJ, the Canadian Medical Association Journal.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "March 29, 2011 -- A minimally invasive procedure that cuts off the blood supply to an enlarged prostate may help when medications fail, and it appears to provide good symptom control without sexual dysfunction, a new study shows.\nDespite the promising results of this small trial, experts said it was far too early to recommend PAE to patients.\nThe authors report that the dead tissue required surgical removal.\n\u201cThe results are excellent.\u201d\n\nIn a small pilot study, most men were able to leave the hospital four to eight hours after the procedure, which is called prostatic artery embolization (PAE), researchers report.\nThe study was presented at the Society of Interventional Radiology annual meeting in Chicago.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported on the technical success of the procedure but more importantly reported on the percentage of men who reported experiencing \u2018excellent\u2019, \u2018slight\u2019 or \u2018no\u2019 improvement. \u00a0Although the starting score of the patients was reported, it would have been valuable to translate this into information that readers could grasp. \u00a0The story should have mentioned whether the difference in symptom severity was something that the patient could detect or simply a change in a clinical score. \u00a0And to be comprehensive, the story should have provided information about the benefit that might be expected from other treatment options (e.g. TURP) for comparison.\nWithout a clear context about what was \u2018improved\u2019 and whether it was sufficiently better than what is was noticed by the patients themselves \u2013 it is not possible for readers to know how much value to put on what the new technique has to offer.\n \n \n", "answer": 0}, {"article": "Learn more about Mayo Clinic.\nDr. McBane noted that cancer and cancer treatment can be associated with kidney injury, which can limit the drug's use further.\n\"As a class, these drugs have a number of advantages, including oral delivery, lack of interactions with foods or other medications, and the lack of a need for monitoring drug levels.\"\nHowever, it was unclear whether these drugs could be used safely in cancer patients until now.\nTheir findings were presented at the annual meeting of the American Society of Hematology by Robert McBane II M.D., a Mayo Clinic cardiologist.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release was vague and did not include any absolute numbers. The lead author said that quality of life surveys showed that patients preferred apixaban over heparin, but there was no information about whether the medication was equally effective at preventing blood clots. The abstract of the conference presentation actually does show that apixaban may have been more effective than heparin; none of the patients that received apixaban had major bleeding, and fewer had deep vein blood clots than those that received heparin. These concrete numbers should have been included in the news release.", "answer": 0}, {"article": "Both drugs could win approval from the Food and Drug Administration by this summer.\nStill, the findings could help smooth the way for regulatory approval, wider use of the drugs by doctors and possibly reimbursement by insurers.\n(However, the PCSK9 drugs are taken by injection every two weeks or four weeks, which could deter some users.)\nExecutives at CVS Health, a leading pharmacy benefits manager, recently said that PCSK9 inhibitors might cost $7,000 to $12,000 a year and would strain health care budgets because so many people might use them.\nAnalysts say the drugs will have billions of dollars in annual sales and will be taken by millions of people who cannot lower their cholesterol enough using statins alone or cannot tolerate statins.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did a good job of clarifying the risk of cardiovascular events in each study. For evolocumab, the article said, \u201cAfter one year, 0.95 percent of those in the group that received the drug had suffered a heart attack, stroke or other cardiovascular problem, compared with 2.18 percent in the group that did not take the drug.\u201d The article went into the same nitty gritty for alirocumab: \u201cAfter one and a half years, the rate of cardiovascular events was 1.7 percent in those who received the drug, versus 3.3 percent in those who received a placebo.\u201d\nWe applaud that the piece reported the raw percentages, since it puts the benefits into perspective. But high up in the story, it cites the figures in terms of relative risk reduction, making the benefits sound more impressive: \u201cBoth drugs reduced the rate of such cardiovascular problems by about half.\u201d\nWe encourage stories to report benefits in absolute terms so that readers have a clearer idea of what \u201crisk reduction\u201d really means. And since many readers will not read a long story in its entirety, we encourage journalists to put that information somewhere that readers are likely to see it. If an eye-popping relative risk figure is mentioned high up in the story, it should be accompanied by immediate discussion of what that means in absolute terms.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits of adding MRI for diagnosis of clots was reported this way \u2013 that the \"MRI detected more clots and heart damage that could lead to them.\"\u00a0 How much more?\u00a0 In another place it said nearly twice as many, but twice as many as what baseline? \u00a0 \n\u00a0The success of the Angiojet was reported as 83%; however there was no estimate of 'success' in patients who were not treated with the Angiojet.\u00a0 The measure of success was defined in the story as getting patients \"back in the flow\".\u00a0 This\u00a0is not a quantitative measure.\u00a0 Further \u2013 it is not even clear what it means.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story does state the \"accuracy rate\" for the new twofold screening protocol with and without the addition of the quadruple screen, there is no comparison to existing screenings such as amniocentesis. Furthermore, the more important information to give consumers would be the positive predictive value of the screening, or the probability of Down syndrome given a positive test result. This is especially important when the prevalence of Down is so low, causing most\u00a0positive test results to be false positives.", "answer": 0}, {"article": "\u201cThat\u2019s something that we almost never see in someone who\u2019s manifested the degree of disease one needed to have in order to get into the study,\u201d Smith said.\nHowever, while only 10 percent of patients who received the drug had double vision before the study, that rose to 50 percent by 24 weeks.\nHigh blood sugar was also a key side effect in participants who already had diabetes, the study team notes, but adjusting diabetes medications solved that problem.\nMore people who received the drug had sizeable reductions in disease activity and reductions of 3 mm or more in eye bulge compared to the placebo group, the researchers note.\nThe duration of response to the autoimmune inflammatory disease, along with the quick response to initial therapy, suggests fewer infusions may be just as effective, \u201cbut future studies will sort that out,\u201d Smith said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story clearly states that 43 percent of the patients who were given teprotumumab\u00a0in this trial experienced a reduction of \u201cat least 2 millimeters in eye protrusion by the sixth week compared to 4 percent in the placebo group.\u201d\u00a0 One of the researchers is quoted as saying, \u201cThat\u2019s something that we almost never see in someone who\u2019s manifested the degree of disease one needed to have in order to get into the study.\u201d\u00a0 The story also points out that this level of reduction \u201cis similar to that reported after decompression surgery.\u201d", "answer": 1}, {"article": "SpermCheck Fertility is designed to help couples determine more quickly whether male infertility might be a problem for them, said Ray Lopez, CEO of SpermCheck, based in Charlottesville, Va.\nAt-home sperm tests are a fairly new idea, Imler said, but SpermCheck Fertility is not the first one.\nBut there is not a strict cutoff point between normal or abnormal, Brannigan said.\nThis test, which is noninvasive, could be wake-up call for some.\nThere are several characteristics of sperm alone \u2014 at least three that aren't addressed by SpermCheck \u2014 that affect male fertility.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was the story\u2019s one big failing. There is no attempt in the story to actually quantify how well the test works. What\u2019s the sensitivity?\u00a0 What\u2019s the specificity?", "answer": 0}, {"article": "6 Kowdley KV, et al.\n\"These data establish the use of the oral direct-acting antivirals as an important treatment option in HCV-infected children aged six to 11 years old.\"\n\"This study is a breakthrough for the management of children aged six to 11 years old with Hepatitis C, demonstrating that the new DAA regimen is highly efficacious and, more importantly, safe in this group of HCV-infected children\", said Prof Frank Tacke, University Hospital Aachen, Germany, and EASL Governing Board Member.\nThe study, presented at The International Liver Congress\u2122 2017 in Amsterdam, The Netherlands, also showed that the fixed-dose combination of LDV/SOF was well-tolerated, and no patients experienced a serious adverse event considered related to the study drug.\nThis ongoing, open-label study enrolled 90 children aged between six and 11 years with chronic HCV, mostly genotype 1 (n=86).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that 99 percent, or 89 out of 90, children treated with the ledipasvir/sofosbuvir combination had undetectable levels of hepatitis C virus 12 weeks after treatment.\nWe do caution that sustained virological response (SVR) and the reduction in viral load, which is what this study measured, may or may not reflect outcomes that people care about. As discussed in another review on a different hepatitis C drug announcement, \u201cPatients care most about conditions that affect them and not how many virus particles are in their blood.\u201d", "answer": 1}, {"article": "AstraZeneca PLC's cholesterol drug Crestor sharply lowered risk of heart attacks among apparently healthy patients in a major study that challenges longstanding heart-disease prevention strategies. The findings could substantially broaden the market for statins, the world's best-selling class of medicines.\n\nHeart experts said the findings, presented Sunday at the annual scientific meeting of the American Heart Association in New Orleans, could reshape cholesterol-treatment guidelines used for more than a decade to fight cardiovascular...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story mentioned the number of people in the two study groups who had heart-related death, heart attacks and other serious cardiac problems during the course of the study, it could have a done a better job at clarifying that this represented a small percentage of affected individuals.\u00a0 A more direct statement an juxtaposition of absolute versus relative risk reduction would have been helpful. ", "answer": 1}, {"article": "A growing number of doctors who treat the estimated 6.4 million American children diagnosed with A.D.H.D.\nDr. F. Xavier Castellanos, director of research at the New York University Child Study Center, called assertions that stimulants are neuroprotective \u201cexaggerated,\u201d adding: \u201cThe best inference is that there is no evidence of harm from medications \u2013 normalization is a possibility, but far from demonstrated.\u201d\n\nA.D.H.D.\nThe question is whether these effects can last once the drugs have left the bloodstream.\nYet Dr. Bertin has recently changed the way he talks about medication, offering parents a powerful argument.\nOne possible reason, as the report noted, was that many children refuse to continue taking medication after a year or so, something most parentsof such children well know.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story seems to assume that readers are familiar with ADHD and the common range of treatment effects in children. It would have been nice to see more background, including specific numbers, rather than vague references to how children may feel \u201cmore focused and in control\u201d or \u201cimpressive short-term relative benefits of medication.\u201d Different people may have different definitions of \u201cimpressive.\u201d Numbers would help.", "answer": 0}, {"article": "In 2008, Medicare paid for 480,000 injections of Avastin to treat macular degeneration and 337,000 injections of Lucentis, according to a study led by Dr. Philip Rosenfeld of the University of Miami.\nIf this finding is considered valid, it could render the results of the National Eye Institute trial somewhat moot by raising safety questions about Avastin.\nA far less expensive alternative proved roughly as effective as Genentech\u2019s costly drug Lucentis in preserving or improving vision in elderly people with a common eye disease, according to two people familiar with the results of a closely watched clinical trial.\nHowever, experts say that with only 1,200 patients, the trial will be able to detect only major differences in safety.\nSales of the drug for each company were about $1.5 billion last year.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It did as much as it could given the lack of data, detailing the noninferioirty criteria and describing how the results are expected to fall. We think the blog is clear that peer-reviewed benefits data will be available upon publication. While in many cases we\u2019d ding this approach, since this study was of the noninferiority variety, the \u2018quantity\u2019 of primary interest is a binary, yes or no, and it is explored. The study also hints at another endpoint of interest, retinal thickness. Although some seems speculative or hearsay, there\u2019s much more here than about the harms.\nOn a sidenote, we would\u2019ve liked some exploration of the clinical significance of either drug\u2019s benefits. We understand business concerns about how the drugs stack up to each other financially, but it\u2019s of interest to patients how well they fight this disease at all. And a blog piece like this reaches all readers, not just the business community.  \n", "answer": 2}, {"article": "\u201cWhat makes our study stronger than those others is that we used a device that was able to measure all of the movements we do in our daily lives,\u201d she says.\nActivities like these account for more than 55% of older adults\u2019 daily activity, says LaCroix, so the fact that they were protective in this study is very good news.\nLaCroix says her new study refutes that research and shows that older adults can still benefit at levels below the moderate-to-vigorous guidelines.\nQuestionnaires used in self-reported studies don\u2019t do a good job of encompassing all the ways people get physical activity throughout the day, she says, which may have skewed previous study results.\n\u201cBut what we have here is solid evidence that light physical activity reduces a woman\u2019s risk of dying over the next three to four years\u2014and we see the benefits are substantial and independent of moderate-to-vigorous physical activity.\u201d\n\nThe study could not show a cause-and-effect relationship between activity level and risk of death, only an association.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that engaging in light activity for 30 minutes per day reduced relative risk of mortality during the study period by 12 percent. It also noted that engaging in moderate activity for 30 minutes per day reduced that risk by 39 percent. But what about the absolute risk reduction?\u00a0", "answer": 0}, {"article": "\"The disc is made up of mostly water, and it get tears in it.\nHe says his intent was not to put some orthopedic surgeons out of business.\nBut no matter where you live, surgery is not necessarily the best or only option.\nWhether you have surgery often depends on where you live and what doctor you see.\n\"However what was really interesting is that patients who decided not to have surgery who could wait also did very well.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of treatment and presents qualitative results only.", "answer": 0}, {"article": "[Watch how the body\u2019s \u2018serial killers\u2019 stalk and attack cancer cells]\n\n\"This is a first in class agent, a brand new therapy,\" Harrington said.\nWhen the latest trial was started, Harrington explained, there was no standard of treatment for melanoma -- so it's compared to a treatment that no one expected to outpace T-VEC.\nBut this is the first time a modified virus has been successful in carrying out that treatment.\nNow that other therapies -- ones that target specific mutations in patients' cancer cells -- are showing more success than what was available when the trial was formed, researchers will have to see how T-VEC compares.\nBut cancer cells aren't as savvy, and T-VEC has its run of them.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Melanoma is a cancer on the rise and a treatment for inoperable melanoma that increases survival rate is beneficial. But we\u2019d prefer a bit more precision in the way the statistics were handled and communicated. The 16.3 vs. 2.1% comparison is accurate, but the story could have done a better job explaining what \u201cshowing results\u201d means and how the outcome was measured.\nMore problematic is the story\u2019s description of survival benefit, which suggests an average survival of 41 vs. 22 months in the treatment vs. control groups. The more appropriate outcome to report is median overall survival. The difference for that outcome was 23 vs. 19 months. This is a statistically and clinically meaningful difference, but isn\u2019t quite as stellar as what is reported by the story. Average survival could be misleading because it can be affected by outlier patients who do very well on the drug but are not representative of typical outcomes. Median survival\u00a0is the time at which an equal number of patients do better and an equal number of patients do worse. It\u2019s the standard outcome for such studies and what was reported in the abstract of the paper being covered.", "answer": 0}, {"article": "General.\nWhile the results, from only nine patients, must be replicated in a larger study, said Dr. Joseph Bellanti of Georgetown University Medical Center, \u201cif what they found is true, they really have something here.\u201d Bellanti, who was not involved in the research, said the study\u2019s eight-year follow-up and use of a placebo control arm made him \u201ccautiously optimistic\u201d that two doses of the BCG vaccine \u201ccan decrease levels of A1c,\u201d a measure of blood glucose that predicts the likelihood of serious complications such as stroke and kidney failure.\nAfter the vaccine showed signs of effectiveness, an additional six patients were vaccinated five years ago, and 111 more recently.\nThe experimental treatment, a decades-old generic vaccine for tuberculosis called bacillus Calmette-Gu\u00e9rin (BCG), seems to alter both cellular metabolism and the immune system, said Dr. Denise Faustman of Massachusetts General Hospital, senior author of the study published Thursday in npj Vaccines.\nThe new paper describes how the BCG vaccine, which has been used for nearly 100 years against tuberculosis and is considered extremely safe, might affect diabetes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Wisely, the story quantifies reduction in absolute terms: \u201cIn the vaccinated patients, A1c levels fell from an average of 7.36 before the first dose to 6.18 after five years, holding almost steady at 6.65 in the eighth year. In patients receiving a sham injection, levels showed almost no change from their initial levels of 7.10: 7.07 in the fifth year and 7.22 in the eighth.\u201d\nThe story also explains exactly how much the drop in hemoglobin A1c was (9-16%) and how that compared to the levels in patients receiving the placebo injections and to normal A1c levels. The story also noted that a 10% drop in A1c levels reduces the likelihood of complications such as stroke and heart attack by a third. In addition, the story explained that the patients treated with the BCG vaccine now need one-third less insulin than they did before the treatment, \u201creducing their risk of hypoglycemia, in which insulin lowers blood sugar to dangerously low levels.\u201d One relatively minor shortcoming is that the story did not explain that the reduction in hemoglobin A1c levels didn\u2019t occur until the third year after the vaccinations had been given.", "answer": 1}, {"article": "As we cut calories and lose weight, our resting metabolic rate eventually slows and our bodies become less efficient at shedding mass in a process known as adaptive thermogenesis.\nAnd while it\u2019s common to regain a few pounds after returning to previous eating habits, the two-week dieters kept the pounds off, maintaining a nearly 18-pound loss six months after the study.\nThe experimental group stuck to the eating plan for two weeks, before ditching the diet for two weeks.\nFor the small study just published in the International Journal of Obesity, the team enlisted 51 obese men from the ages of 25 to 54 years old.\nAll participants had maintained their current weight for six months leading up to the study and did not exercise regularly.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that the men following the intermittent diet plan lost 47percent more weight than the control group, but not what the study group participants actually weighed before and after. It also notes that the intermittent dieters maintained an 18-pound loss six months after the study, but not whether they stayed on the diet or what other factors may have accounted for that outcome. Readers also won\u2019t learn how many calories were consumed in each cycle of the study or what foods were involved.", "answer": 0}, {"article": "A serious mood disorder that affects as many as 1 in 7 women after childbirth, postpartum depression can lead to panic attacks, inconsolable sadness, and deep feelings of inadequacy.\nOne of the drug\u2019s most promising features: It appears to work quickly \u2014 some women in the study started experiencing relief after 24 hours.\nThe company has not submitted study data to federal regulators and isn\u2019t at this point seeking approval of the drug, known as SAGE-547, for postpartum depression.\nThe early results are \u201cpromising and exciting,\u201d said Dr. Allison Baker, a psychiatrist at Massachusetts General Hospital\u2019s Center for Women\u2019s Mental Health, but \u201cwe need to see replication of this data over a much wider range in terms of numbers.\u201d\n\nThe study is small and has not been peer-reviewed; Sage disclosed the results in a press release.\nSage Therapeutics, based in Cambridge, Mass., reported on Tuesday that 7 of the 10 women who took the drug in the trial experienced significant improvement in their depression within 60 hours of the injection.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We will give the story a satisfactory rating because it specifies that 7 of 10 patients given SAGE-547 reported significant improvement in their depression within 60 hours, which persisted for up to 30 days.\nHowever, the story did not tell readers that the depression questionnaire used in this study, Hamilton Depression Rating Scale (HAM-D), has been criticized as placing greater emphasis on sleep than on suicidal thoughts, so that the scores of some patients may improve even if their thoughts of suicide increase.\nReaders should have been told that the form of the drug used in this trial is given as an IV solution and that it will not be known if a pill can produce similar results until separate trials are completed.", "answer": 1}, {"article": "According to the U.S. Department of Agriculture\u2019s 2010 Dietary Guidelines, most Americans don\u2019t get enough fiber.\n\u201cIncreasing dietary fiber intake in the general public is of great public health significance,\u201d the Chinese team concludes.\nSo to get more clarity, the researchers combined 10 earlier studies that looked at women\u2019s diets and followed them over seven to 18 years to see who developed cancer.\nThat was after accounting for differences in risk factors like alcohol drinking, weight, hormone replacement therapy and family members with the disease.\nTheir findings don\u2019t prove fiber itself lowers cancer risk, however, because women who consume a lot of it might be healthier overall than those who don\u2019t.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019ll give the story the benefit of the doubt, although suggest a minor change in the future.\nThe story only used relative risk reduction figures. It could have included just a line to explain why it may not be statistically appropriate to pool absolute risk reductions in such a meta-analysis.", "answer": 1}, {"article": "No serious adverse events were reported.\nLarger and longer studies are now needed to prove that the twice-daily pill can also reduce severe asthma attacks, known as exacerbations.\nNovartis believes the medicine could be filed for regulatory approval in around 2019.\nPills for asthma used to be standard treatment 40 or 50 years ago, but those older products were often associated with worrying side effects.\nThe Novartis pill works in a very precise way to block the action of inflammatory cells called eosinophils.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported that fevipiprant \u201creduced a biological marker of asthma nearly five-fold in the 12-week trial involving 61 patients.\u201d It states: \u201cThe Novartis pill works in a very precise way to block the action of inflammatory cells called eosinophils.\u201d", "answer": 1}, {"article": "ET.\nAlthough the results provide evidence that PDE5 inhibitors may benefit heart health, the retrospective study design makes it impossible to ascertain direct cause and effect, Andersson noted.\n\"This type of erectile dysfunction treatment is beneficial in terms of prognosis, and having an active sex life seems to be a marker for a decreased risk of death.\"\nA limitation of the study is that the researchers did not assess the effects of untreated erectile dysfunction, or conversely, the effect of having an active sex life without taking erectile dysfunction drugs.\n\"From the perspective of a doctor, if a patient asks about erectile dysfunction drugs after a heart attack and has no contraindications for PDE5 inhibitors, based on these results you can feel safe about prescribing it.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release notes, \u201cMen who filled prescriptions for erectile dysfunction drugs in the years following a heart attack had a substantially lower risk of dying or being hospitalized for heart failure than men who did not use these drugs.\u201d And it states there was a 33% reduction in death and a 40% reduction in hospitalization for heart failure among patients prescribed ED drugs. But these are relative risk numbers and we think absolute risk numbers are more useful for readers.\nA quote from Dr.\u00a0Andersson;\u00a0\u201cThis type of erectile dysfunction treatment is beneficial in terms of prognosis, and having an active sex life seems to be a marker for a decreased risk of death\u201d is a bit of a stretch given the study was observational and does not prove cause and effect.", "answer": 0}, {"article": "CRISPR stands for \"clustered regularly interspaced short palindromic repeats.\"\nDr. Kmiec said the lung cancer work reflects an approach adopted by the Gene Editing Institute to move cautiously in developing medical applications of gene editing.\nDr. Kmiec said there are chemotherapies that have helped patients achieve remission or at least live longer and enjoy a better quality of life by significantly slowing the progress of the disease.\nThat was the conclusion of a new study published today in the journal Molecular Therapy Oncolytics by scientists from The Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute at Christiana Care Health System.\nDr. Kmiec noted that while his team is working to move into human trials, the CRISPR application being developed for lung cancer does not involve directly editing a patient's genome --only the genes in the tumor.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is unable to claim a benefit in humans since the study was done in cell cultures and mice models and findings in the lab don\u2019t always translate to similar outcomes in humans.\nBut even in describing the benefits in animal models and cell culture, the release fell short. It says, \u201ctumor growth stopped and there was a dramatic decrease in the volume of existing tumors when chemotherapy was combined with CRIPSP-Cas9, which was used to disable a tumor gene known as NRF2.\u201d\nBut there\u2019s no data to give readers a sense of the scope of this potential benefit, such as how much the volume decreased, for what period of time, and in what percentage of the tested samples.", "answer": 0}, {"article": "\"Just telling people to do things doesn't work,\" says Sean Duffy, CEO of Omada Health.\nAnd he says the convenience of having the program delivered on a smartphone was key, too.\nNot every Omada Health participant makes the progress they're aiming for.\nAnd he says he's pleased with the results of the pilot study of Omada's program.\nThere is some evidence that these kinds of programs are working.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantified the benefits of the treatment program in one study, informing readers that in a study of 200 people at risk for developing diabetes, \u201c75 percent of the participants completed the Omada program and lost at least 5 percent of their body weight. And about 1 in 4 participants lost 7 percent of their body weight or more.\u00a0\u201d\nWell give this a barely passing satisfactory, though we also wanted to know: What was the average weight loss? How long did it take to lose the weight? How successful are people at keeping the weight off? It\u2019s also useful to point out that there was no control group to measure this program against.", "answer": 1}, {"article": "They then matched each statin user \u2014 who was aged over 40 when first prescribed a statin between 1995 and 2006 \u2014 with up to five non-statin users for comparison.\nDouglas noted that since this study looked at patients who were already taking statins when they developed pneumonia, a full randomized clinical trial was needed to find out whether starting a statin at the time of diagnosis has a similar effect.\n\u201cGiven the potential low number needed to treat to prevent a death suggested by this study, we believe that a strong case exists for randomized trials of statins in people with serious infection to determine if a simple and practical intervention at the point of diagnosis of pneumonia has a beneficial effect.\u201d\n\nDouglas\u2019s team, whose research was published in the British Medical Journal, used data from computerized medical records of doctors\u2019 practices in Britain to identify statin users.\nPrevious studies have suggested statins, which are also available as cheaper generics, may be linked to better outcomes after bacterial infection.\n\u201cStatins are safe, cheap, and an easy intervention in terms of delivery,\u201d said Ian Douglas, a lecturer in epidemiology at the LSHTM who led the research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "To its credit, the story presents the benefits in appropriate statistical terms when it says, \u201c13 percent (109 out of 847) of statin users died compared with 20 percent (578 out of 2,927) of non-statin users.\u201d This is better than saying statin users had a 35% lower risk of dying from pneumonia, which is how many stories would have put it. Nevertheless, many readers will probably come away from this story with an exaggerated sense of the benefits, as the story never provided the absolute death rate due to pneumonia among all statin users compared with non-statin users. Since pneumonia is not very common,\u00a0any benefit according to this measure would have been much smaller than the 7%\u00a0reduction mentioned in the story. Even if this statistic was not available, the story could have provided some data about the likelihood of developing pneumonia, which would have put the findings in\u00a0perspective. It\u2019s important for people to understand that statins won\u2019t reduce their chances of dying by 7% compared to people who don\u2019t take statins. \u00a0", "answer": 0}, {"article": "\"I feel like I can accomplish what I want to accomplish.\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\nIt's unclear how many patients have had to stop or chosen to stop treatment for depression due to side effects.\n\u201cOnce the genetic testing became available it provided Sarah with more than just physical relief,\" says Dr. Matthew B. Stanley of the Avera Medical Group in Sioux Falls, South Dakota.\nAccording to a study conducted by the Mayo Clinic that looked at one genetic test similar to many used in hospitals \u2014 GeneSight Psychotropic \u2014 symptoms of depression were reduced by 70 percent compared to treatments prescribed without genetic testing.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article is nominally about the\u00a0Genefolio test that\u2019s offered by the Avera Institute for Human Genetics. But the only specific numbers provided in the story pertain to a different test called GeneSight. That\u2019s misleading, since it suggests that the two tests are interchangeable. These are two different products looking at different genetic profiles to make recommendations. It\u2019s like using data from the AT&T cell network to show how great T-Mobile\u2019s coverage is.\nThe story also doesn\u2019t do enough to explain what the numbers provided mean. Does the 70% reduction mean that patient symptoms went from a 10 out of 10 to a 3 out of 10? Or from 2 out of 10 to 0.6 out of 10? Both are possible and the story should have clarified the difference between relative and absolute numbers.", "answer": 0}, {"article": "Media campaigns, increased tobacco and tightening of smoking laws have all had an effect as well.\n\u201cPatient compliance is a very big issue,\u201d said Dr. Richard Hurt, director of the Nicotine Dependence Center at the , who was not involved in the study.\nDoctors who treat smokers said that the study findings were not unexpected, given the haphazard way many smokers used the products.\nAt each stage, about one-third of the people trying to quit had relapsed, the study found.\nDr. Hurt said products like nicotine gum and patches \u201care absolutely essential, but we use them in combinations and doses that match treatment to what the individual patient needs,\u201d unlike smokers who are self-treating.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was less successful than the other two in quantifying the benefits. It did not put any hard numbers to the findings, saying instead, \u201cAt each stage, about one-third of the people trying to quit had relapsed, the study found. The use of replacement products made no difference, whether they were taken for the recommended two-month period (they usually were not), or with the guidance of a cessation counselor. One subgroup, heavy smokers (defined as those who had their first cigarette within a half-hour of waking up) who used replacement products without counseling, was twice as likely to relapse as heavy smokers who did not use them.\u201d While using vague terms like \u201ctwice as likely\u201d may make the story a little less daunting for some readers, we think that a story on a scientific study, especially a study as controversial as this one, should provide the actual numbers from the study as much as possible. Also, all three stories failed to make it clear whether the same 30% or so of people continued to relapse throughout the study or whether a total of two-thirds of the participants fell back to smoking.", "answer": 0}, {"article": "As rates of sugar-related disorders such as diabetes, obesity and heart disease climb, many experts believe that when Americans rid themselves of fat, they simply replaced it with sugar in all its forms.\n\u201cThis is causation.\u201d\n\nThe diet he provided the children isn\u2019t considered ideal from a health perspective \u2014 starches are still a considerable source of calories and can contribute to weight gain.\nBut that the rise of the chronic diseases was actually linked to higher sugar consumption is a challenge.\nNow, in a paper published Tuesday, he and his colleagues believe they have come up with the definitive evidence that sugar, as Lustig says, \u201cis toxic.\u201d\n\nIn most lab studies, the doses of sugar that scientists test are quite high; they want to see what the effect is quickly and, depending on the research, they may not have time to wait to study the more gradual effects that might emerge.\nThey\u2019re worried that the findings may shift attention away from what they consider to be the more fundamental issue \u2014 that overall, we\u2019re eating too much.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The quantification of the results does not quite clear our bar here. The story says this:\nOverall, their fasting blood sugar levels dropped by 53%, along with the amount of insulin their bodies produced since insulin is normally needed to break down carbohydrates and sugars. Their triglyceride and LDL levels also declined and, most importantly, they showed less fat in their liver.\nWe would have preferred more numbers documenting the changes for each outcome, in absolute terms (the \u201c53%\u201d figure is a relative reduction), along with a comment or some description of how meaningful the changes were clinically.", "answer": 0}, {"article": "The W.H.I.\nfindings have been seriously misunderstood and misinterpreted,\u201d and millions of women for whom the benefits clearly outweigh the risks are needlessly being denied treatment.\nIn a Danish randomized controlled trial of 1,006 women entering menopause, among those given hormones for 10 years, \u201cthere was a reduction in cardiovascular disease and breast cancer \u2014 a clear benefit with nominal risk,\u201d Dr. Hodis said.\nfindings, many new analyses and studies have prompted experts to rethink the wisdom of avoiding hormone replacement, especially for women within a few years of menopause whose personal and family history do not place them at high risk of breast cancer.\n\u201cThe cardiovascular protection found in observational studies involved women who were younger and within a few years of menopause when they started taking H.R.T.,\u201d he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story is about risks and benefits, and about the misunderstandings that can result. But we did not find the absolute risk and benefit numbers that would have helped to clarify.\nHere is a benefit statement, which we found incomplete. We would have preferred some absolute numbers.\n\u201cIn a Danish randomized controlled trial of 1,006 women entering menopause, among those given hormones for 10 years, \u201cthere was a reduction in cardiovascular disease and breast cancer \u2014 a clear benefit with nominal risk,\u201d Dr. Hodis said. These benefits persisted after 16 years of follow-up, according to the study, which was published in 2012.\u201d\nHow big was the \u201cclear benefit?\u201d What does Dr. Hodis consider a \u201cnominal risk?\u201d Readers may look at these issues differently than Dr. Hodis does, so it\u2019s important to clarify.", "answer": 0}, {"article": "Acupuncture, a popular form of alternative medicine, involves inserting ultra-thin needles into the skin.\nThe question is whether the acupuncture reduced the hot flashes or a placebo effect played a role, said Freedland, who's familiar with the study findings.\nIt's also possible, he said, that the symptoms went away on their own, which commonly happens to men on hormone therapy.\n\"We are now designing a randomized clinical trial to further evaluate acupuncture after prostate cancer treatment,\" Ashamalla added.\nMONDAY, April 25, 2011 (HealthDay News) -- Acupuncture might help reduce the hot flashes that frequently affect prostate cancer patients while they're on hormone therapy, a small study suggests.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Probably the weak point of the story.\nThe story only says \u201cTheir reported levels of hot flashes dropped markedly.\u201d\u00a0 What does that mean?\u00a0 From what to what?\u00a0 Measured how? And in how many of the men?\u00a0 With no indication of what their baseline symptom severity was, there\u2019s no way to interpret the sketchy results reported in the story.\nThe story also throws in a tag line that the same study \u201calso found that acupuncture relieved the heart palpitations and anxiety often associated with hormone therapy for prostate cancer.\u201d\u00a0 But no data were given to back up these claims.", "answer": 0}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies results appropriately. It notes that in one test, \u201c67% of the patients were judged \u2018very good\u2019 or having \u2018marked improvement\u2019 after they took the expensive placebo, compared with 58% of patients after they took the purportedly cheap placebo.\u201d Readers can tell from the story\u2019s numbers that we\u2019re talking about a relatively modest amount of improvement.", "answer": 1}, {"article": "Ten years ago, scientists started looking at the hormones made in the pituitary gland to see how they act on certain targets.\nBut it could also be a unique drug because it lowers body fat and makes bones stronger.\nThey found some of these hormones had an effect on bone mass.\nTheir next step is to \u201chumanize\u201d the antibody, so it can be tested without triggering an immune response.\nThat would then lead\u2014if all goes well\u2014to the first human trials in three to four years.\u201d\n\nAt present, the researchers are focusing on the adiposity, rather than bone loss, for drug development: \u201cI think obesity is a more prevalent disease\u2014but osteoporosis at the tail end can be tagged on.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Given that the research was on mice, there\u2019s no way to determine whether the intervention\u00a0would have any benefit at all to people, let alone to determine the scope of\u00a0the likely benefit. The story should have made this point before it starts discussing benefits like \u201cthe antibody caused significant weight loss and gains in bone mass.\u201d The story tells readers that \u201cMice [sic] a fairly close genetic match to [h]umans, and\u2026[the corresponding author] is hopeful there will be similar effects in humans.\u201d That doesn\u2019t give readers much insight. In short, readers don\u2019t get a very good idea of what the antibody did to the mice, nor how relevant that is to human biology.", "answer": 0}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story does not quantify the benefits at all except for saying that the safety and efficacy was tested on over 400 patients.\u00a0 What benefits they received from the treatment are totally omitted from the story. This is unacceptable, especially as the FDA provided some quantification in their news release.", "answer": 0}, {"article": "Fish like salmon, herring and sardine are a common source of EPA-DHA, while ALA is found in vegetables including soybeans, flax seeds and walnuts.\nDaan Kromhout of Wageningen University, who led the study, told the European Society of Cardiology the lack of efficacy might reflect the good background drug treatment patients were receiving, with 85 percent on cholesterol-lowering statins, as well as blood pressure and blood-thinning tablets.\nUnilever, whose margarine brands that contain omega-3 include Flora and I Can\u2019t Believe It\u2019s Not Butter, said the lack of benefit seen with EPA and DHA was surprising, considering the weight of evidence published to date.\n\u201cThe results indicate that more investigation is required into the efficacy of vegetable omega 3, but do not question the current authoritative dietary recommendations and advices for omega 3 intakes on which our products are based,\u201d the company said in a statement.\nThe results of the study, which was supported by the Netherlands Heart Foundation, the National Institutes of Health, and Unilever, were also published in the New England Journal of Medicine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re going to be a bit tougher on this one. The story failed to mention the benefits reported in the results section of the paper demonstrating that\u00a0for those who had diabetes in addition to having had a heart attack, there did appear to be some benefit in terms of reduced incidence of coronary artery disease, death from coronary heart disease and incidence of arrhythmia.", "answer": 0}, {"article": "Schafer Cardiovascular Research Fund, the Johns Hopkins Magic That Matters Research Fund for Cardiovascular Research, grants from the National Center for Advancing Translational Sciences (UL1-TR-000040 and UL1-TR-001079), and contracts from the National Heart, Lung, and Blood Institute (HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169).\nThus, even though their calculated heart disease risk is relatively low and their blood pressure is below traditional cutoffs for treatment, the researchers say people in this category with calcium over 100 are high risk and may benefit from more aggressive blood pressure treatment.\nIn the study, published on Jan. 10 in Circulation, the researchers say these calcium scores allow physicians to go beyond the traditionally calculated risk factors to determine which blood pressure treatment strategy may be most appropriate for a particular patient.\nPreviously, the appropriate blood pressure treatment for these patients used risk calculations and some guesswork, potentially leaving many vulnerable to heart disease or taking drugs they don't need.\nIn contrast, participants with systolic blood pressure under 140 millimeters of mercury -- below the current cutoff for treatment -- and rated with a low predicted risk of heart disease who had a calcium score over 100 had a high actual event rate of 19.7 events per 1,000 person-years.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does a good job of explaining the findings with numbers. It says the study shows \u201cheart CT scans can help personalize treatment in patients whose blood pressure falls in the gray zone of just above normal or mild high blood pressure.\u201d It says the study suggests \u201cpeople with the highest calcium levels would benefit most from aggressive blood pressure treatment, whereas those with little or no calcium may not need to be treated as intensively, depending on their other heart disease risk factors.\u201d\nIt gives some detailed numbers to show the risk differential between people with no calcium buildup and those with a lot of calcium. To paraphrase the release, among participants with borderline blood pressure readings, those with calcium scores of zero and high predicted risk of heart disease had a low actual event rate, of 12.7 events per 1,000 person-years. Those with calcium scores over 100 but a low predicted risk of heart disease ended up with a higher rate of actual cardiac events, 19.7.\n\u201cThus,\u201d the release says, \u201ceven though their calculated heart disease risk is relatively low and their blood pressure is below traditional cutoffs for treatment, the researchers say people in this category with calcium over 100 are high risk and may benefit from more aggressive blood pressure treatment.\nGiven that the difference in cardiac event rates between people with low calcium scores and those with high calcium scores isn\u2019t extreme, this might amount to a marginal benefit; we would have liked some discussion of how many patients might fall into this \u201cgray zone\u201d and thus benefit from this approach.\nBasically, the benefits, including the number needed to treat (NNT), cost-effectiveness, as well as harms and costs of obtaining these calcium scores are unknown. All we know is the magnitude of the increased potential risk associated with higher calcium scores, not whether this risk can be reduced.", "answer": 1}, {"article": "\"You don't get back the time you lost at work or the time you lost with your children.\"\nBut about 80% will get relief, he says \u2014 defined as a headache reduction of at least 50% \u2014 after trying three or four drugs, alternative remedies and lifestyle changes.\nBut nearly 40% have headaches that are so frequent (at least once a week), severe or hard-to-treat that they qualify, Silberstein says.\nFinding the right medication for the right patient can take a lot of trial and error and careful dosing, Silberstein says.\nStudies find that just 3% to 13% use the treatments.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quotes one of the guideline authors who says that \u201cabout 80% will get relief \u2026\u2014 defined as a headache reduction of at least 50% \u2014 after trying three or four drugs, alternative remedies and lifestyle changes.\u201d\nThis may well be true, but we think the 80% figure puts the benefits in the best possible light and misplaces the emphasis. If it takes 3 or 4 drugs, alternative remedies and lifestyle changes to achieve a benefit for 80% of people, clearly a much smaller number of people are likely to experience a clinically significant benefit from any individual treatment.\nA close call here, but the story does mention that treatment can \u201ctake a lot of trial and error and careful dosing\u201d \u2014 enough context to merit a satisfactory rating.", "answer": 1}, {"article": "High blood pressure, or hypertension, is a major risk factor for cardiovascular diseases \u2014 the leading causes of death worldwide.\nThe Cochrane review attracted sharp criticism from nutrition experts.\nWhile previous trials have found there is a blood pressure benefit from cutting salt, research has yet to show if that translates into better overall heart health in the wider population.\nSimon Capewell, a professor of Clinical Epidemiology at Liverpool University, said the review was \u201cdisappointing and inconclusive\u201d and did not change public health consensus that dietary salt raises blood pressure.\nIn a systematic review published by The Cochrane Library, British scientists found that while cutting salt consumption did appear to lead to slight reductions in blood pressure, that was not translated into lower death or heart disease risk.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news of this piece is that, not withstanding the recommendations of many guidelines and experts, \u00a0the recently published Cochrane review failed to demonstrate that a small reduction in dietary salt intake decreased the chance of developing heart disease or dying prematurely.", "answer": 1}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not mention the number of adult smokers under age 65 who would need to be vaccinated to prevent one case of pneumonia.\u00a0 There was little data on this point in the source material, which the story should have noted.\u00a0 ", "answer": 0}, {"article": "Oncologist Dr. Marisa Weiss is the founder and chief medical officer of Breastcancer.org.\nIn January, the FDA approved the first PARP inhibitor, Lynparza, to treat BRCA-mutated breast cancer.\nSimilar drugs have already been used to treat advanced, BRCA-mutated ovarian cancer, according to the agency.\nThis targeted form of treatment takes advantage of a weakness in the BRCA gene to further cripple the cancer cell's ability to repair itself, grow and spread, said Weiss, who was not involved with the study.\nIn addition, several ongoing studies are looking at combinations with PARP inhibitors \"to try to expand who may benefit or lengthen how long they may work,\" Litton said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes the drug\u2019s benefit in terms of \u201cprogression-free survival.\u201d Women who took\u00a0talazoparib went three months longer without their cancer progressing, on average, as compared to women on standard chemotherapy. However, it did not give us precise numbers on this: What was the total, in months, before cancer progressed, in both groups?\nAccording to OncLive, \u201cat a median follow-up of 11.2 months, the median progression-free survival (PFS) was 8.6 months with talazoparib compared with 5.6 months\u201d for the control group.\nThe HealthDay story also said women on talazoparib had a \u201chigher response rate\u201d than women on standard chemotherapy, but never explained what that means.\nMost importantly, the story didn\u2019t address the most important statistic: overall survival. Does the drug help women live longer? As we\u2019ve explained, PFS is what\u2019s known as a \u201csurrogate marker\u201d and is no guarantee of a longer life.\nDrugs are frequently approved on the basis of uncertain markers such as \u201cprogression free survival,\u201d which is the amount of time between treatment and worsening of symptoms. The drug Avastin won accelerated FDA approval to treat metastatic breast cancer based on its ability to delay tumor growth, but that approval was revoked when multiple randomized trials showed the drug didn\u2019t improve survival and had significant side effects.", "answer": 0}, {"article": "However, Owens said, \u201cit\u2019s hard to do all of that in your head.\nThe problem with the old-fashioned way, he told Reuters Health in an email, is that there are many pieces of information about a patient to consider.\nBut the new study looked at a more sophisticated way of estimating individual patients\u2019 needs.\nA researcher not involved in the work said it was a \u201cnice study\u201d that is a first step toward showing that tailored guidelines could have benefits.\nThis gives them a tool.\u201d\n\nNow the looming questions are how to implement risk calculators in doctors\u2019 practices \u2014 and, Owens said, whether that benefits patients\u2019 health in the real world.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Mixed bag here, but we\u2019ll give the story the benefit of the doubt.\nThe benefits from the use of models to better fit treatment recommendations were described as relative improvements rather than absolute benefits.\u00a0 That\u2019s how the data were described in the abstract of the paper reported on; the predicted numbers were contained within the body of the article. Given the size of the population in question, we can look the other way on the use of relative risk reduction figures.\nAnd, as already noted, the story injected some caution about real world benefits by quoting an independent expert:", "answer": 1}, {"article": "Article reference: Thomas L. Jang, Neal Patel, Izak Faiena, Kushan Radadia, Dirk F. Moore, Sammy E. Elsamra, Eric A.\nThey found that 10 years after treatment, 89 percent of the prostate removal plus radiation group was still alive.\nAnother interesting finding from the research was that slightly more than half of men diagnosed with the disease did not receive combination therapies for their prostate cancer.\n\"For high-risk prostate patients we started the use of aggressive radiation therapy after surgery 20 years ago,\" said Adam Dicker, Senior Vice President and Chair of the Department of Enterprise Radiation Oncology at Jefferson Health, who was not involved in the study.\n\"Our study suggests that removing the prostate followed by adjuvant radiotherapy is associated with greater overall survival in men with prostate cancer.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release stated the survival difference in clear, absolute terms: \u201cThey found that 10 years after treatment, 89 percent of the prostate removal plus radiation group was still alive. That compared with the 74 percent survival at ten years in the group that received only radiation plus hormone therapy, amounting to a 15 percent survival advantage in the group that was treated with prostate removal.\u201d", "answer": 1}, {"article": "Instead, they pass through to the large intestine, where they draw water into the gut and start to ferment.\nIf your gut can handle FODMAPs, foods that contain a lot of them can be very good choices \u2014 partly because the fermentation helps your gut biome and partly because the way FODMAPs are digested means you\u2019re absorbing fewer calories than indicated on a FODMAP-rich product\u2019s label.\nGibson estimates that, overall, about 10 percent of the population may be FODMAP-sensitive.\nEven some people who don\u2019t have celiac disease feel better when they don\u2019t eat wheat.\n\u201cFollowing strictly the low-FODMAP diet is associated with changes in the microbiota that many would not equate with good health,\u201d says Gibson, who stresses that a low-FODMAP diet should be used to reduce specific symptoms, not as a way to improve health.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article only provides us with a glimmer of understanding concerning the perceived benefits of a low-FODMAP diet in people with non-celiac gluten intolerance. There is no quantification of the benefit. \u00a0The story says, \u201cA low-FODMAP diet eased their symptoms, as it does for about 70\u00a0percent of people who suffer from irritable bowel syndrome, a condition that causes abdominal pain and bowel changes.\u201d \u00a0How much were their symptoms reduced? Was the reduction clinically important or statistically significant but unimportant? \u00a0Did everyone fare equally as well with the diet change?", "answer": 0}, {"article": "Alexander who had troubles with chronic laryngitis whenever he performed.\nAfter a year, those who had massage were no better off.\nThose who had six Alexander lessons showed some improvement.\nBut finding a remedy for back pain can be a lot like a guessing game.\nHe led a study of some 460 patients who were given Alexander lessons, massage, or the usual care of pain killers and exercise.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article provided skeletal information on only one of two primary outcome measures in the study, the one that cast the Alexander Technique in the most positive light. The article noted that subjects who had 24 lessons in the Alexander Technique went from 21 days of pain to 3 days of pain without ever mentioning what this means in real life terms. This statistic referred to the number of days in the last month during which the study subjects experienced any back pain. Without information on back pain intensity, or disability attributed to back pain, this statistic is difficult to interpret. So this article did not adequately frame this benefit.\nThe results of this study are not easy for journalists to characterize or present\u2014given the way the study was conducted and reported. The journalist did a better job of attempting to quantify the benefit of the Alexander Technique than she did in evaluating the quality of the evidence. \n\u00a0\n", "answer": 0}, {"article": ".\nThe study, reported online Nov. 2 and in the December issue of the journal Radiology, reinforces results from similar research, Oppenheim said.\nDr. Wally Ghurabi, emergency department director at Santa Monica-UCLA Medical Center, said a group of ongoing studies there include a similar focus on MRIs and stroke.\n\"These results will be useful for centers that offer 24-hour access to acute stroke patients.\nOppenheim said the next step would be clinical trials to validate whether MRIs serve as a \"surrogate clock\" for stroke onset.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported that the test was 90% accurate, but it could have provided more insight to readers about what this \u00a090% means.\nThis study is really just about predicting whether the stroke was in the past 3 hours or not. It would have been helpful to show the net effect size for strokes within 3 hours vs. those > 3 hours \u2013 it is not a very big absolute difference, but that is the cut-point that has been used.\nIt also could have included some information about how the rates of complication change when tPA is given to patients beyond this 3 (or 4.5 even) hour window.\nNonetheless, we\u2019ll give it the benefit of the doubt on this criterion.", "answer": 1}, {"article": "\"We try to time the pattern to stimulation so that it's integrated with their ability.\nTraining with the system improved McGlynn's speed when it was turned off to 23 yards per minute, indicating therapeutic benefit.\nBoth men gained strength and endurance through repeated use of the systems and fine-tuning by the researchers.\n\"I went in there and I could barely take two steps,\" said Bush, 42, who researchers believe is the world's first MS patient to \"test-drive\" an implanted FES system.\nDue to his improvements, the research team is developing a system that McGlynn can use at home and outside.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release describes both men\u2019s improvement in terms of distance walked with the aid of electronic nerve stimulation. For example, the stroke patient\u2019s ability to move \u201cwithout the system was about 19 yards per minute; with the system, 47 yards per minute,\u201d the news release states, while training improved his speed with the system turned off to \u201c23 yards per minute, indicating therapeutic benefit.\u201d His distance improved from 83 yards to 1,550 yards, almost a mile.\nIt states that the multiple sclerosis patient \u201cwent from the two steps to consistently walking more than 30 yards during the (90-day) trial. In that time, he used a walker to help maintain his balance.\u201d\nThe news release also provides quotes from the men and links to videos that show the men\u2019s abilities to walk with and without electronic stimulation.", "answer": 1}, {"article": "Glover acknowledges that \"it's not a perfect solution.\nHe added that although the study proved the treatment's effectiveness and safety only in children, adults would probably benefit in the same way.\nThree-quarters of the study participants were given the treatment in increasing amounts every two weeks until reaching maintenance, when they received the equivalent of one peanut daily.\nOverall, participants experienced fewer side effects during the study than the researchers had anticipated.\nTo test the experimental therapy, 66 research centers in 10 countries recruited 551 participants who ranged in age from 4 to 55 and who all had a peanut allergy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that two-thirds of people who underwent months of treatment were able at the end of the study to tolerate the equivalent of two peanuts.\u00a0\u00a0\nUnlike the Fox News story, CNN reports on how the control group fared, saying that 53% of those subjects required rescue epinephrine with the final peanut challenge test compared to 11% of subjects in the treatment group. ", "answer": 1}, {"article": "Metastatic SCCA, a cancer often associated with human papillomavirus (HPV) infection, is normally treated with chemotherapy, although no trials have established a standard of care.\n\"This study demonstrated responses in five of 18 patients treated at MD Anderson, and many of the patients had significant reductions in their tumor size.\"\nThe study revealed encouraging correlations between immunologic biomarkers and responses to treatment.\nStudy results showed a decrease in frequency of CD8 T-cells in post-treatment tumor samples among responder-patients.\nThe phase II study, for which findings are being presented at this week's American Association for Cancer Research's annual meeting in New Orleans, was designed and led by researchers at The University of Texas MD Anderson Cancer Center's Human Papillomavirus-Related (HPV) Cancers Moon Shot Program.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The patients\u2019 response was modest and the news release reflects that. The release quotes a researcher saying, \u201cThis study demonstrated responses in five of 18 patients treated at MD Anderson, and many of the patients had significant reductions in their tumor size.\u201d It also gives details of some of those treatment responses.", "answer": 1}, {"article": "The company, which says gammaCore is already available in the European Union, expects to start selling it later this year in the U.S.\n\nVagus nerve stimulation is used to treat a range if disorders, including epilepsy, depression and overeating.\nRelated: New Migraine Drugs Would Treat Pain Before it Starts\n\nSilberstein helped test the device, which users press against the neck.\nBoth approaches are limited \u2014 it\u2019s not safe to use the injection more than twice a day \u2014 and inconvenient.\nThis went up to about a third of patients with so-called episodic cluster headaches.\nThe device is a vagus nerve stimulator and it\u2019s not entirely clear how it works.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article uses percentages to vaguely describe the benefits (\u201cappeared to help\u201d) in the treatment vs sham treatment groups, but it does not\u00a0mention the absolute number of patients in the two arms of the study, or what \u201chelp\u201d meant. It relies mostly on complimentary statements by one of the investigators who conducted a study of the device, and by the company.\u00a0But the major lapse in full disclosure comes with the absence of information about the failure of the clinical trial to reach its statistical goal. The apparent benefit of the device over the sham device was only seen after a pre-specified subgroup analysis. As noted in the accompanying editorial: \u201cThe primary endpoint was not achieved in this study \u2013 ie, differences in reduction in pain severity between active and sham groups were not significant\u2026..conclusions drawn in this way are notorious for failing to replicate.\u201d", "answer": 0}, {"article": "Suits against tobacco companies have sought to force cigarette makers to pay for annual CT screens of former smokers.\nDr. Claudia Henschke, a clinical professor of radiology at Mount Sinai Medical Center and a longtime advocate for use of CT to screen for lung cancer, said the study was likely to have underestimated the benefits of CT scans because participants were screened only three times.\n\u201cWhat we also have found is that low-dose CT scan gives information on cardiovascular disease, emphysema\u201d and other pulmonary diseases, Dr. Henschke said.\nBut Dr. Peter B. Bach, a pulmonologist at Memorial Sloan-Kettering Cancer Center in New York, said no one should rush out and get a CT scan yet because further analysis will better define whom the screening helped.\nBut health officials involved in the study refused to endorse widespread screening of current or former smokers, saying more analysis of the study\u2019s results is needed to further identify who benefited most.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThis story might have met this criterion if not for a misleading lead sentence. Researchers did announce that the heavy smokers in this trial who were offered CT scans had a 20 percent lower rate of death from lung cancer than those offered chest x-rays. The story does report the total number of deaths in the body of the story (354 vs. 442), but it does not point how that because so many smokers were in this trial, the lung cancer death rate in each group was less than 2 percent. That context is important, because while the relative difference in death rates is indeed 20 percent, the absolute difference is less than one-third of one percent (1.32% vs. 1.65%). A letter sent by the National Cancer Institute to trial participants points out that based on these results, 300 heavy smokers would have to be screened in order to extend a single life. Those statistics would have helped readers put the results in perspective.\nThe story does include valuable comments from one of the researchers about how much more analysis and study is needed in order to understand whether and for whom this sort of screening might be beneficial.\nAnother problem with the lead sentence is that it is not quite accurate to say that \u201cannual CT scans\u201d produced this result, since the trial didn\u2019t offer ongoing annual screening, but rather three scans done at one-year intervals and then no more.\u00a0 ", "answer": 0}, {"article": "Rosie Dow, Head of Sing with Us at Tenovus Cancer Care and co-author of the research, added: \"This research is so exciting, as it echoes everything all our choir members tell us about how singing has helped them.\nWe have been building a body of evidence over the past six years to show that singing in a choir can have a range of social, emotional and psychological benefits, and now we can see it has biological effects too.\nThe research raises the possibility that singing in choir rehearsals could help to put people in the best possible position to receive treatment, maintain remission and support cancer patients.\nThis research is exciting as it suggests that an activity as simple as singing could reduce some of this stress-induced suppression, helping to improve wellbeing and quality of life amongst patients and put them in the best position to receive treatment.\"\nFollowing on from this research, Tenovus Cancer Care is launching a two year study looking in more depth at the longitudinal effect of choir singing over several months.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The actual benefits in the results section of the manuscript were very modest, albeit statistically significant. This needed attention in the news release. The release does not use any numbers to give us a firm grasp on benefits for the study group. The release claims study participants had \u201csignificant reductions in stress hormones,\u201d but does tell us the significance. Here is an excerpt that tantalizes but disappoints:\n\u201cThe study tested 193 members of five different choirs. Results showed that singing for an hour was associated with significant reductions in stress hormones, such as cortisol, and increases in quantities of cytokines \u2014 proteins of the immune system \u2014 which can boost the body\u2019s ability to fight serious illness.\u201d\nWe wish this paragraph \u2014 explaining how samples were taken \u2014 had included some numbers for at least one of what it calls the \u201cchanges:\u201d\n\u201cChoir members gave samples of their saliva before an hour of singing, and then again just after. The samples were analysed to see what changes occurred in a number of hormones, immune proteins, neuropeptides and receptors.\u201d\nWe\u2019d also like to see the findings put into context. Since these biomarkers have been studied for many years by others, it would be appropriate to explain how the research community agrees on the significance of a change. What level of cortisol change, for example, is considered \u201csignificant?\u201d", "answer": 0}, {"article": "Drs.\nBy pooling the data of several studies, Thomas Jefferson University researchers showed that a higher rate of IV fluids not only decreased c-section rates, but also shortened the overall length of labor by one hour, as well as shortened the pushing phase.\nThis study suggests that IV fluids could help women maintain hydration at appropriate levels, reduce the likelihood of c-section, and decrease length of labor,\" says Dr. Berghella.\nThis study and others are providing evidence for changes in obstetric practice that could help safely reduce c-section rates.\nWomen getting the faster fluid rate (250 milliliters per hour) were less likely to get a cesarean section.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the release offers a clear, succinct statement of the benefits provided by increased IV fluids, it provides no numbers describing the magnitude of those benefits. The research report on which the release is based found that the differences in number of cesarean procedures and in the duration of labor were real but relatively modest.\u00a0 For example, a c-section\u00a0was deemed necessary for 12.5% of women who got higher levels of hydration and for 18.1% of those who received lower levels of fluids during labor. Length of labor declined by about an hour, a statistically significant but still modest clinically significant outcome.", "answer": 0}, {"article": "This is sent to the USB stick, which shows the result on a computer or electronic device.\nIt could be particularly useful in remote settings to help HIV patients manage their treatment more effectively, since current tests to detect virus levels take at least three days and involve sending a blood sample to a laboratory.\nThe device, created by scientists at Imperial College London and the privately-held U.S. firm DNA Electronics, uses a drop of blood to detect HIV, then creates an electrical signal that can be read by a computer, laptop or handheld device.\nBut in some cases the drugs stop working - sometimes because virus has developed resistance to them - and the first sign of that would be a rise in a patient\u2019s so-called \u201cviral load\u201d.\nAny HIV in the sample triggers an acidity change, which the chip transforms into an electrical signal.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t correctly report the sensitivity of the lab-on-a-chip method, and an Imperial College London (ICL) news release (which the Reuters story seemed to rely on heavily) gets this wrong, too. The key thing each piece missed: There were two tests. The study used a scaled-up and better-understood test tube assay (which indicates a positive through a\u00a0fluorescence reaction)\u00a0to\u00a0validate and compare to the lab-on-a-chip test (which uses acidity/pH). The researchers ran biological samples through each test to cross-reference them.\nHere\u2019s how the numbers break down: The tube assay was 95% sensitive (meaning it missed 5% of HIV-positive samples) when more than 1,000 copies of HIV-specific RNA were present per milliliter \u2014 a limit WHO says is an acceptable sensitivity. Between 50-1,000 copies, the tube assay dropped to 88.75% sensitivity. (We\u2019ll note here that some lab-grade tests can detect 100 times fewer copies with close to 100% sensitivity.)\u00a0The pH-based lab-on-a-chip test, meanwhile, was 88.8% sensitive at more than 1,000 copies and 76.1% with 50-1,000 copies. That\u2019s a far cry from 95% accurate.", "answer": 0}, {"article": "Modern water dispensers may be more effective than old-fashioned water fountains since water quality and cleanliness may deter kids from using older fountains, and they're not as efficient at serving large numbers of children, experts noted in an accompanying editorial.\nThe editorial, entitled \"Power of a Simple Intervention to Improve Student Health: Just Add Water,\" said the study's findings are significant.\nThe study, published in JAMA Pediatrics, analyzed data collected from 1,227 elementary and middle schools across New York City - some with and some without \"water jets.\"\nIn this study, the findings demonstrate that water access in schools can promote healthy weight outcomes among students,\" Turner and Hager said.\n\"We associated these water dispensers with almost a one percentage point reduction in the likelihood of being overweight for boys and a little over a half a percentage point reduction for girls,\" said lead researcher Brian Elbel, an associate professor of population health and health policy at NYU School of Medicine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The CBS story does a good job quantifying the benefits in absolute terms, when the lead researcher points out that water dispensers were associated with \u201ca one percentage point reduction in the likelihood of being overweight for boys and a little over half a percentage point reduction for girls.\u201d The article translated this for readers as \u201ca modest weight drop among students.\u201d\nThe piece also notes that water jets were linked with \u201ca decrease\u201d in the amount of half-pints of milk students bought, but it does not give any specific numbers. Specifically, researchers found a 12.3 decrease in the number of all types of milk purchased per student per year.\nWe think the quantification of benefits in absolute terms is enough to merit a Satisfactory rating here.", "answer": 1}, {"article": "Traditionally, highly sensitized patients in need of a kidney have languished on waiting lists because it's so hard to find a compatible donor.\nBut the findings mark another step forward for patients like these, according to Jordan, who is medical director of the kidney transplant program at Cedars-Sinai, in Los Angeles.\nResearchers found that the treatment -- dubbed IdeS -- quickly wiped out the dangerous antibodies, allowing all but one of 25 patients to have a successful transplant.\nThose patients were all successfully treated with standard anti-rejection drugs, according to the researchers.\nLead researcher Dr. Stanley Jordan agreed that more work is necessary.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does an adequate job of noting the actual numbers of patients in the study group, the absolute number that were able to have a successful transplant and the absolute number who later had a rejection episode that required standard anti-rejection therapy.", "answer": 1}, {"article": "\u201cI couldn\u2019t wear a brassiere for three months,\u201d she recalled.\nIn fact, if screening finds cancer, some seniors won\u2019t withstand the surgery, usually a lobectomy, that may cure it.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\nNationally, deaths from this operation run two to four times higher, and they increase with the patient\u2019s age.\nThe post-surgical death rate in the national trial was just 1 percent, but that involved major medical centers with specialized radiologists and surgeons \u2014 the ideal setting.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does an admirable job of explaining the modest benefit of these scans. The story\u2019s effort to explain the statistics in several ways, including the use of absolute numbers, could serve as a model for other journalists. Example: \u201cIn the national trial, those screened with chest X-rays had about a 1.7 percent chance of dying from lung cancer during the study period; in the CT scan group, it was about 1.4 percent.\u00a0For every thousand people screened with a low-dose CT, three fewer died of lung cancer.\u201d\nAnother way to express this benefit would be the number need to treat (NNT) \u2014 the number of patients screened to prevent one lung cancer death. In this case, the NNT appears to be around 1 in 400. This is considerably better than other screening programs such as breast or prostate cancer.", "answer": 1}, {"article": "Anthony Cunningham, Executive Director of the Westmead Institute for Medical Research in Australia and Principal Investigator of the ZOE-70 study said: \"These data show that this investigational vaccine maintains high efficacy against herpes zoster in people over 70 and 80 years of age, the age groups who are most affected by the disease.\nThe primary objective of this study is the overall vaccine efficacy against shingles in people aged 50 years or older, compared to placebo.\nThe co-primary objectives of the pooled analysis over both studies are the assessment of overall vaccine efficacy in reducing the risk of developing shingles and PHN in people aged 70 years and over, using pooled data from both ZOE-70 and ZOE-50 studies.\nThe study, from which headline results were reported in October 2015, showed that the two-dose candidate shingles vaccine had 90% efficacy (95% confidence interval: 84-94%) compared to placebo in people over 70 years old.\nThe candidate vaccine was shown to be 89% (95% confidence interval: 68-97%) efficacious in preventing PHN in people aged 70 years and older and 91% efficacious (95% confidence interval: 75-98%) in people aged 50 years and over1.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release, like the original\u00a0article on which it reports, states that the vaccine effectively prevented shingles in 90% of participants, including preventing the pain often associated with shingles.\nAbsolute numbers in addition to or rather than relative reductions would have been a more meaningful quantification for readers.", "answer": 1}, {"article": "In May, British researchers reported that patients taking them have a higher risks of liver dysfunction, kidney failure, muscle weakness and cataracts.\nThe longer people took the highly popular cholesterol-lowering pills, the lower their risk of later developing colon cancer, the researchers told a meeting of the American College of Gastroenterology.\nAnd U.S. health officials have been watching data that suggests some statins such as Merck & Co\u2019s blockbuster drug Vytorin may actually raise the risk of cancer, although they have saidf this is unlikely.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted,\u201d Samadder added in a statement.\nSamadder\u2019s team did what is known as a meta-analysis, combining the findings of 22 scientific studies with more than 2.5 million volunteers.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only presented relative risk of being diagnosed with colon cancer (i.e. \u2018patients \u00a0who took statins had a 12 percent lower risk of being diagnosed with colon cancer than people who did not take the drugs\u2019) rather than the absolute risk of being diagnosed with colon cancer in the two groups. Readers should ask, \"12% of what?\"\u00a0 See our primer on this topic. ", "answer": 0}, {"article": "Close to 800,000 people in the U.S. suffer a stroke each year, mostly older adults.\nHe said that larger studies at multiple treatment sites are needed to determine how helpful magnetic stimulation can be in stroke recovery.\nThe researchers said that it\u2019s not clear what the amount of improvement they observed would mean for patients in their daily lives.\n\u201cThey\u2019re less likely to become completely independent.\u201d\n\nMost of those patients can improve with therapy and exercises, she said, but the process is often slow, and keeping people in the hospital during it is costly.\nThe ideal option might end up being a combination treatment that involves stimulation in certain patients and other therapies that address a range of skills important for regaining function, Barrett added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story provides a more nuanced look at potential benefits of TMS than the competing WebMD coverage. In addition to providing statistics on the amount of improvement seen in the stimulation group, the story notes that\u00a0\u201cit\u2019s not clear what the amount of improvement they observed would mean for patients in their daily lives.\u201d \u00a0It also explains that the benefits were more pronounced among those with more serious symptoms. This is important context for patients or caregivers who\u00a0want to know how the research findings might apply to them.", "answer": 1}, {"article": "In the 1970s, the FDA required warnings on drugs containing progesterone, as 17-HP does, because of an increased risk of birth defects.\nFleischman, the March of Dimes official, says there's no such risk from 17-HP, partly because it's not used before the 16th week of pregnancy, when fetal organs have already formed.\nThe FDA is apparently satisfied that 17-HP is safe, but it's requiring its sponsors KV Pharmaceuticals and TherRx to conduct further studies of women who have taken it and children exposed during pregnancy.\nAccording to the best research, the drug reduces the risk of premature birth by one-third among women who are at high risk because they had a previous preterm birth.\nAnd even for the 30,000 or so women who are eligible, 17-HP, which will be marketed as Makena, isn't a magic bullet.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As already noted, the story explained that the drug \u201cisn\u2019t a magic bullet. The study showed that 37 percent of women who got weekly injections of it delivered prematurely, compared to 55 percent of women who got injections of a placebo.\u201d", "answer": 1}, {"article": "When his heart disease was first diagnosed four and a half years ago, Mr. Del Sontro, now 50, told his cardiologist he wanted to run one more Bay to Breakers race, a century-old 12-kilometer race in San Francisco.\nThat strategy alone, Dr. Biesecker said, has eliminated the vast majority of candidate genes.\nThe researchers are now searching for culprits among genes that remain \u2014 a search that could take years.\nHe and his colleagues know the gene mutation in the Del Sontro family must be rare.\nSo the researchers are hoping the Del Sontro family\u2019s heart disease is caused by a mutated gene.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story suggests that the purpose of this research is to\u00a0\u201csee if genetics can explain why heart disease strikes apparently healthy people.\u201d\u00a0But how many people are we talking about who might benefit from this information? The story doesn\u2019t say.\u00a0And even if we can identify these \u201capparently healthy\u201d people, will treating them with existing medications (which mainly target the traditional risk factors) improve their outcomes? Or will new medicines be developed that can treat them? Again, the story does not address the issue.The story should have explained that\u00a0for most of us, traditional risk factors are very effective\u00a0at predicting who is at increased risk of heart disease and should receive preventative\u00a0treatment. It\u2019s only toward the end of this long story that we learn that this family must have a \u201crare\u201d mutation that causes their\u00a0disease through some other pathway.\u00a0This information should have come much sooner, and with more detail.", "answer": 0}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the article provides data about the total number of people randomized to the two arms of the study, it does not go beyond what the news release offers about the percentage/relative increases in remission of symptoms and response to drugs. No absolute numbers are given, so it\u2019s impossible to know how many of the patients in each arm actually benefited and to what extent. All it provides is the relative improvement in \u201cresponse\u201d to medication: \u201cresearchers found a 30% greater response to the medicine when the test was applied.\u201d No data is provided for remission.\nBut when you look at the raw numbers regarding remission rates, and compare the results of both groups, they don\u2019t look as impressive: Of those who didn\u2019t receive genetic testing, 10% reached remission. With the tests, it was 15%. This gives the reader perspective that the absolute difference was 5%.\nAlso, the news release hints that at least some of the results might not have been statistically significant, and we\u2019re curious about that and think it should have been explained in the story:\n\u201cThe GeneSight-treated cohort also demonstrated higher symptom improvement which approached statistical significance (Chart 1).\u201d", "answer": 0}, {"article": "Charli Scouller \n\nPR Manager (School of Medicine and Dentistry) \n\nQueen Mary University of London \n\nc.scouller@qmul.ac.uk \n\nTel: 020 7882 7943\n\nQueen Mary University of London (QMUL) is one of the UK's leading universities, and one of the largest institutions in the University of London, with 20,260 students from more than 150 countries.\nThe new vaccine, Gardasil 9, is not only safe but will offer greatly improved protection against cervical and other cancers.\nA pivotal international clinical trial compared the safety and efficacy of the new vaccine, Gardasil 9, with the current vaccine, Gardasil, in more than 14,200 women aged between 16 and 26 years old.\nThe new vaccine offers significantly greater protection than the current vaccine, which protects against only two cancer causing types of HPV.\nUntil late last year, there were two available vaccines to protect against HPV related disease (Cervarix and Gardasil).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release headline says the new version of the vaccine is \u201cbetter\u201d than the existing version, and the study backs this up. As the release notes, \u201c\u0085Gardasil 9 was 97 per cent effective at preventing high-grade cervical, vulvar and vaginal disease caused by HPV 31, 33, 45, 52 and 58, and was equally effective as the current Gardasil vaccine in preventing diseases caused by HPV 6, 11, 16 and 18.\u201d\nBut while \u201c97 percent effective\u201d sounds very impressive, what exactly does that mean? \u201c97 percent effective\u201d compared with what? The study published in the NEJM has the statistics that can put this into perspective. The paper notes the exact rate of disease that was observed in both the old and new vaccine groups: \u201cThe rate of high-grade cervical, vulvar, or vaginal disease related to [various HPV subtypes] \u2026 was 0.1 per 1000 person-years in the 9vHPV [new vaccine] group and 1.6 per 1000 person-years in the qHPV [existing vaccine] group.\u201d \u00a0For a more reader-friendly description, the release could have said the rates were 0.1 vs. 1.6 cases per thousand people in the study annually.\nIn addition, the accompanying editorial in the NEJM rightly points to the less than spectacular successes to date in actually immunizing young and adolescent girls with three doses over 6 months. \u201cAt 57%, coverage for the first dose of HPV vaccination among girls 13 to 17 years of age lags behind coverage for other vaccines recommended for children 11 to 12 years of age by approximately 20 to 25 percentage points.\u201d Greater emphasis on the need to follow through with all three doses would have been welcome.", "answer": 0}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided no information about how effective the radiation from this device is in the treatment of prostate cancer. \u00a0How do the lifespans of men treated with the RapidArc compare to men receiving radiation treatment from other devices? \u00a0How about those having surgery?\nThe major cited benefit is that treatment time is reduced from 5 to 10 minutes to less than 2. \u00a0It does not reduce the number of treatments.\u00a0", "answer": 0}, {"article": ".\nBut now, according to a study published Sunday in the New England Journal of Medicine, there appears to be a new, much less invasive way of determining whether a growth is malignant.\nIf the test is negative, its accuracy will allow doctors to wait and watch a lesion.\nIf it shows a malignancy, a biopsy still would be needed to confirm the cancer.\nThe next logical question is whether those changes might be detected early enough to predict and prevent lung cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Overall, the benefits of the new test appear to be potentially substantial, but the article should\u00a0have quantified them with a bit more precision. For example, the \u201c97 percent\u201d accuracy rate used to describe the study results refers to the combined use of bronchoscopy and the new test \u2014 not the test by itself. Bronchoscopy alone is still accurate 75 percent of the time, and the test alone had an \u201carea under the curve\u201d of 0.74 \u2013 0.78 \u2014 meaning that 74-78% of the time it could correctly classify whether or not a patient had cancer. It\u00a0also would have made more sense, and brought more important context to readers, if the article had noted that the new test was able to reclassify a particular group of people at risk\u00a091 percent of the time. This group is composed of those considered at intermediate risk. The ability to place them in a \u201cwatch and wait\u201d or \u201clow-risk\u201d category is important because for some that will bring reassurance, but for others more anxiety and more tests.", "answer": 0}, {"article": "Serotonin imbalances have also been linked to depression.\nGuss says, \u201cThe randomization, placebo control, and double-blind procedures maximized the validity of the study results.\u201d\n\nOne of the key findings was that improvements in clinical evaluation scores for anxiety and depression lasted for the remainder of the study\u2019s extended monitoring period \u2014 specifically, eight months for those who took psilocybin first.\nPublished in the Journal of Psychopharmacology online Dec.1, the study showed that one-time treatment with the hallucinogenic drug psilocybin \u2014 whose use required federal waivers because it is a banned substance \u2014 quickly brought relief from distress that then lasted for more than six months in 80 percent of the 29 study subjects monitored, based on clinical evaluation scores for anxiety and depression.\nAll patients in the study \u2014 mostly women age 22 to 75 who are or were patients at the Perlmutter Cancer Center of NYU Langone \u2014 had either advanced breast, gastrointestinal, or blood cancers and had been diagnosed as suffering from serious psychological distress related to their disease.\nStudy participants, he says, experienced no serious negative effects, such as hospitalization or more serious mental health conditions.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does tell readers what percentage of patients benefited from psilocybin treatment, but does not explicitly quantify the extent of those benefits \u2014 which is what this category is designed to address. Instead, readers are given qualitative assessments of the treatment \u2014 that it \u201csignificantly lessens mental anguish\u201d and brought \u201crelief from distress.\u201d But those terms are vague. What does \u201csignificantly lessens\u201d mean? For example, did patients return to clinically normal levels of anxiety?", "answer": 0}, {"article": "PD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells.\nKeytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.\nEsophageal cancer is the seventh most commonly diagnosed cancer in the world, the company said.\nMerck said trial results would be presented at an upcoming medical meeting.\n\u201cThis marks the sixth tumor type where Keytruda has demonstrated a survival benefit, and represents the first time an anti-PD-1 therapy has achieved overall survival for this patient population,\u201d said Roy Baynes, chief medical officer of Merck Research Laboratories.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Passing along the drug company\u2019s announcement that a drug \u201cmet the main goal of a late-stage trial\u201d doesn\u2019t come anywhere close to explaining what was found in that trial.\nThe story said \u201cKeytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer.\u201d\nBut what percentage of patients lived longer? And by how much? How did the drug affect their quality of life? Those questions weren\u2019t addressed.", "answer": 0}, {"article": "Radiation oncologist Dr. Richard Stock, of Mt.\n\"With four treatments left, I have 98 percent of my vision left,\" Rianta said.\nIt's the most expensive device in medicine today.\n\"There is no good evidence, medical evidence that it is better than the current state of the art intensity modular radiation therapy,\" Stock said.\nThe technology is two decades old, but Mass.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of treatment.", "answer": 0}, {"article": "Women with breast tumors have low levels of Syk.\nNobody is exactly sure of the role Syk plays in rheumatoid arthritis.\nNow Harvard researcher Michael E. Weinblatt, MD, reports results from a phase II clinical trial in which 457 patients with active rheumatoid arthritis despite methotrexate treatment received R788 or placebo for six months.\nAmong patients getting the twice-daily 100 milligram dose:\n\u2022 19% had diarrhea, compared to 3% getting a placebo.\nFor now, R788 looks very promising, the researchers report.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As with the harms, the story provides a long list of comparisons in relative terms to tout the benefits of the drug. This is more helfpul than most stories, but the story could have done a better job by providing some numbers in absolute terms. The first comparison, for example, says, \"67% had at least 20% fewer arthritis symptoms, compared to 35% of patients getting a placebo.\" It\u2019s hard to know how big of a benefit this really is.\u00a0We tried to do the math\u00a0using the number of people in the study and quickly realized\u00a0that without the number of symptoms,\u00a0there\u00a0is no way to calculate the true size of the benefit here.\u00a0", "answer": 0}, {"article": "The print edition is scheduled to be published in August.\nWhile preliminary studies have suggested a link between meditation, a sense of spirituality or faith and the risk of Alzheimer's disease, the article's author, Dharma Singh Khalsa, M.D., states that a cultivation of higher levels of psycho-social well-being, such as independence, resilience and life purpose represents \"an important new frontier that deserves further research as it is freely available to anyone, anytime, anywhere.\"\nTUCSON, Ariz., July 15, 2015 /PRNewswire/ -- Meditation and spiritual fitness are key components in reducing the risk of Alzheimer's disease according to a new article, \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\", published in an early online version of the Journal of Alzheimer's Disease 48(1).\n\"We've been studying the impact of meditation on memory for more than 20 years, and are as encouraged as we've ever been on its powerful role in maximizing brain health,\" said Khalsa, president and medical director of the Alzheimer's Research and Prevention Foundation and a clinical associate professor of integrative medicine at the University of New Mexico School of Medicine.\nThe article reviews decades of research into the impact that various meditation techniques have had on the prevention of Alzheimer's disease, focusing on one evidence-based practice that Khalsa says can be a powerful part of any Alzheimer's prevention and spiritual fitness program, Kirtan Kriya (KK), a meditation technique which has been successfully used to improve memory in studies of people with subjective cognitive decline and mild cognitive impairment.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release claims that the 12-minute meditation has been successfully used to \u201cimprove memory\u201d in people with subjective cognitive decline and mild cognitive impairment. There\u2019s no quantification offered.\u00a0 What was the health status before and after performing the meditation exercises?\nThe headline is particularly concerning, suggesting that a research journal article finds meditation and spiritual fitness beneficial in preventing Alzheimer\u2019s. But the news release mainly focuses on vague claims and a description of the technique without explaining \u201chow\u201d the technique benefits the brain other than activation of a certain area.\nWhen we looked at the review article that the release is based on, we found that the few actual studies cited on meditation were very small. There was no mention of randomization, and again no design where development of dementia was compared between those practicing meditation and not. The studies themselves mentioned they were \u201cpilot\u201d or \u201cpreliminary.\u201d", "answer": 0}, {"article": "Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin.\nFurther analysis showed those who lost the most excess weight a year after surgery showed the biggest improvements in their disease activity.\nAccording to the study's authors, the findings suggest that losing excess weight may improve symptoms in people who have these lifelong conditions.\nThe researchers found 55 percent of patients with psoriasis and 62 percent of patients with psoriatic arthritis reported improvements in their disease.\nPatients who underwent surgery saw significant reductions in their disease severity scores at post-surgical follow-up -- according to a 0 to 10 rating scale -- with disease severity scores in patients with psoriasis dropping from 5.6 to 4.4, and scores falling from 6.4 to 4.5 for those with psoriatic arthritis.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although it is hard for a reader to picture what a severity score of 5.6 for psoriasis would actually look like, the news release at least gives us the range of possible scores (0-10) and the absolute reduction in scores for disease severity. It would have been helpful to know if such a reduction would allow a psoriasis patient to stop using one of their medications or need fewer interventions. We assume that these are the averages of the scores of the 86 patients who underwent surgery (the \u201csignificant reductions in their \u201cdisease severity scores dropping from 5.6 to 4.4, and scores falling from 6.4 to 4.5 for those with psoriatic arthritis.\u201d)\nThe study monitored patients on average for\u00a0more than six years, \u201cwith an average excess weight loss of 46.2 percent body weight.\u201d \u00a0It would have been helpful to also include the average pre-surgery starting weight of the volunteers.", "answer": 1}, {"article": "\u201cIt\u2019s time for her to be a kid again and get her childhood back,\u201d Mr. Whitehead said.\nBut such drugs tend to be extremely expensive.\nBut Mr. Hoppenot said Novartis was taking a different path with cancer drugs, looking for treatments that would have a big, unmistakable impact on a small number of patients.\nDr. June knew that a drug could lower IL-6 \u2014 his daughter takes it for .\nSome patients have had the cells for years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We think the story leaves readers with an improbably rosy portrait of the experimental treatment\u2019s benefits. Here\u2019s why:", "answer": 0}, {"article": "In traditional Chinese medicine, acupuncture involves inserting long, very thin needles just beneath the skin's surface at specific points on the body to control pain or stress.\nTheir study isn't proof, but it adds to evidence that acupuncture may benefit a range of conditions.\nThe analysis was more rigorous than most research based on pooling previous studies' results, because the authors obtained original data from each study.\nThe results \"provide the most robust evidence to date that acupuncture is a reasonable referral option,\" wrote the authors, who include researchers with Memorial Sloan-Kettering Cancer Center in New York and several universities in England and Germany.\nThat kind of analysis is not the strongest type of research, but the authors took extra steps including examining raw data from the original studies.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are clearly explained by the story: \u201cThe patients\u2019 average baseline pain measured 60; it dropped to 30 on average in those who got acupuncture, 35 in those who got fake acupuncture, and 43 in the usual treatment group.\u201d It would have been helpful to include some comparison here.\u00a0 For example, how well do NSAID\u2019s work for these conditions?", "answer": 1}, {"article": "The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top \"Honor Roll\" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751.\nIn addition to the benefits for antibiotic stewardship, Barbieri pointed to several studies showing long-term oral antibiotic use may be associated with antibiotic resistance, lupus, inflammatory bowel disease, and even colon and breast cancer.\nWithin a year, 14.4 percent of spironolactone patients and 13.4 percent of antibiotic patients had switched to alternative treatments, suggesting each treatment was working at almost the same rate, despite the fact that tetracycline-class antibiotics are prescribed five times as frequently.\nThe prescription change is a proxy for ineffectiveness, since switching is often the result of treatment failure due to lack of efficacy, side effects, cost, or other factors.\nThe study, published this month in the Journal of Drugs and Dermatology, found patients who were originally prescribed spironolactone changed to a different drug within one year at almost the same rate as those who were prescribed antibiotics.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This criterion rates a Not Satisfactory because the study did not set out to quantify benefits of a specific drug or drugs and yet the release makes numerous claims about one drug\u2019s benefits while calling for a change in practice. The study that was undertaken can not tell us how well the drug worked or which factors contributed to discontinuance of any of the drugs.\u00a0The release provided the absolute numbers of women who stopped taking a drug and switched to an alternative drug but the measurement of switching drug therapies was only a proxy for effectiveness.", "answer": 0}, {"article": "Dr Webster added: \"Patients are brought back at frequent intervals to see if they are meeting their targets with multiple visits required to tailor their treatments and dosage.\nA trial led by The George Institute for Global Health revealed that most patients - 70 per cent - reached blood pressure targets with the 'Triple Pill', compared to just over half receiving normal care.\nDr Ruth Webster, of The George Institute for Global Health, said this was a major advance by showing that the Triple Pill was not only more effective than standard care, it was also safe.\nWith high blood pressure the leading cause of disease burden worldwide, it's expected the findings published in JAMA will change guidelines globally.\nThe trial, which was conducted in Sri Lanka, enrolled 700 patients with an average age of 56 and blood pressure of 154/90 mm Hg.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The target blood pressure (BP) for this study was below 140/90 (or below 130/80 in patients with diabetes or chronic kidney disease).\nThe news release states that: \u201c70% (of subjects) reached blood pressure targets with the \u2018Triple Pill\u2019, compared to just over half receiving normal care.\u201d (Normal or usual care is defined in the release as \u201ctheir doctor\u2019s choice of blood pressure lowering medication.\u201d)\nIt should have been made more clear this was measured after 6 months in the study.\u00a0And as a result, the effect on cardiovascular (CV) risk reduction of the combination is unknown.", "answer": 1}, {"article": "\u201cWhen people engage in risky behaviors like driving or smoking, they\u2019re encouraged to take measures that minimize their risk, like wearing a seatbelt or choosing cigarettes with filters.\n\u201cAlthough no substitute for systematic lifestyle improvements, including healthy diet, regular exercise, weight loss, and smoking cessation, complimentary statin packets would add, at little cost, one positive choice to a panoply of negative ones,\u201d the scientists write in their paper.\nWhile statins might combat some of the toll that fatty foods take on cholesterol, there\u2019s a lot they can\u2019t negate: \u201csodium content is high, fibres are absent, and caloric load gargantuan,\u201d Messerli said of the fast food the authors looked at.\n\u201cIt makes sense to make risk-reducing supplements available just as easily as the unhealthy condiments (such as salt or ketchup) that are provided free of charge,\u201d Francis said in his report of the research.\n\u201cStatins are a vital medicine for people with \u2014 or at high risk of developing \u2014 heart disease,\u201d he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "        \nA balance was struck between the claims of the study author and those of several unaffiliated experts.\u00a0 While the study centered on the cholesterol lowering effects of a statin condiment, the negative effects of a high fat, high sodium, high calorie diet were highlighted providing a balance to the story.\u00a0 \nThe story mentions\u00a0that\u00a0\"A study in June in the Archives of Internal Medicine suggested, in fact, that statins do not save lives in patients without heart disease, although they may prevent some non-fatal heart attacks.\" But this wasn\u2019t the only study to come to that conclusion, and, in fact, the drug company\u2019s own research backs this claim up, as has been well documented in previous news stories.\nWe wish the story had clarified whether the research team was suggesting popping a single statin pill in response to a single cheeseburger, or whether they were suggesting a regular regimen of statin use.\u00a0 This is a key point, and is relevant to any discussion about the quality (or lack) of evidence, and about potential harms and benefits.\u00a0 ", "answer": 1}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article did a pretty good job of presenting the complicated data modeling and reasons for the recommendations regarding breast density risk calculations and screening intervals. But it needed some actual numbers to quantify the benefits. In this case, it\u2019s the number breast cancer deaths averted.\nAs the study abstract stated,\u00a0\u201cbreast cancer deaths averted were similar for triennial versus biennial screening for both age groups (50 to 74 years, median of 3.4 to 5.1 vs. 4.1 to 6.5 deaths averted; 65 to 74 years, median of 1.5 to 2.1 vs. 1.8 to 2.6 deaths averted).\u201d", "answer": 0}, {"article": "If a robot is to be enlisted, he recommends asking how the procedure would be performed if the robot is not available or if it doesn\u2019t work.\n\u201cHowever, if the surgeon is skilled enough to do the hysterectomy without the robot by laparoscopy then the outcomes will be similar.\u201d\n\nNezhat further noted that while robotic assistance can be a good \u201cenabler\u201d for a minimally invasive approach, surgeons should have at least the basic knowledge of regular laparoscopy too, as there may be times when the robotic equipment doesn\u2019t work.\nThe researchers found that the two advanced minimally invasive techniques led to similar results, and both appeared to be generally superior to the traditional open procedure.\nBased on their review, the researchers found that minimally invasive surgeries done with a human hand and instruments or with robotic assistance equipment took around the same time and resulted in similarly long stays in the hospital.\nThe robotic equipment provides better three-dimensional vision, increased range of motion and intuitive, downscaled movements, while adding a few thousand more dollars to the procedure\u2019s price tag, the authors note.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story summarized the findings succinctly: the robotic and laparascopic surgeries: \u201ctook around the same time and resulted in similarly long stays in the hospital. However, about half as much blood was lost when robots were enlisted than with standard laparoscopy. Both minimally invasive techniques resulted in longer-duration operations than open surgery. But both also led to shorter hospital stays and, in the case of robotic surgery, less blood-loss. Further, the average number of lymph nodes removed was about the same in the robotic and open procedures, suggesting that both approaches result in about equal surgeon accuracy in staging endometrial cancer.\u201d\nHowever, we would have liked to have seen a bit more discussion on the issue of blood loss. Although the amount of blood loss seen in the patients who underwent a robot-assisted procedure was statistically lower, there was no difference in the patients\u2019 need for a transfusion. The 8 studies also had dramatically different blood loss in all three groups. The range of blood loss in patients undergoing a robot-assisted procedure was almost 3 fold (66.6ml in the Veljovich study as compared to 166 in the Bell study).", "answer": 1}, {"article": "BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health.\nThe potential of this assay to detect pathogen materials was demonstrated in both animal studies and a prospective human clinical study, whose results also suggest that it also could serve as a companion diagnostic to monitor the success of antibiotic and dialysis-like sepsis therapies.\nTogether, the findings suggest that the FcMBL-based pathogen detection technology with its rapid handling time, high sensitivity and broad specificity towards infection-causing pathogens could provide a real-world advance to diagnose life-threatening infections in both clinical microbiology laboratories and point-of-care settings.\nAs a prerequisite to their clinical study, the Wyss Institute's team had successfully tested the assay in rat and pig models of infection with pathogenic E. coli bacteria.\nPrevious efforts in Ingber's team at the Wyss Institute have established FcMBL as a key component of an advanced dialysis-like, pathogen-extracting therapeutic device, and of a method for the fast retrieval of infectious pathogens from complex clinical samples to enable their identification and antibody susceptibilities.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The published study has substantial quantification of its findings, and the range of pathogens detected. The release notes that the assay \u201cpicked up infection within an hour in 85 percent of patients who exhibited clinical symptoms of sepsis,\u201d but offers no actual number of patients. The release states that the Wyss team \u201csuccessful tested the assaying rat and pig models\u201d of E.coli infection, but left out any data about the strength or accuracy of the experiments in pigs.\nThe sensitivity and specificity of the test in the emergency department patients studied is key. The release quantifies the sensitivity, but only mentions specificity in a qualitative way. The published study, by contrast, notes:\n\u201cIn patients with suspected sepsis, the FcMBL ELLecSA detected infection in (55 of 67 patients) with high sensitivity (>81%), specificity (>89%), and diagnostic accuracy (0\u00b787). It also distinguished infection from trauma-related inflammation in the same patient cohorts with a higher specificity than the clinical sepsis biomarker, C-reactive Protein.\u201d", "answer": 0}, {"article": "Kilmer McCully of the V.A.\nAlthough the new studies did show that the vitamins cut homocysteine levels, that did not translate into a reduction in the risk for heart attacks or strokes.\nThe new findings undermine a theory that taking B vitamins to reduce levels of an amino acid in the blood called homocysteine could protect against heart attacks and strokes.\nThe findings follow a number of disappointing studies testing vitamins and other dietary supplements for health reasons.\nIn the second study, Kaare Harald Bonaa of the University of Tromso in Norway and colleagues researchers gave 3,749 patients who had had a heart attack within the previous week the vitamins or a placebo for more than three years on average.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We give this story a satisfactory score, but the story could have helped readers understand why measuring surrogate markers such as homocysteine levels can be different than tracking true outcomes such as heart attack or stroke. Here, the surrogate endpoint (homocysteine levels) \u201cimproved,\u201d but the real endpoint \u2013 heart attack and stroke \u2013 did not. ", "answer": 1}, {"article": "The effectiveness of oral levodopa reduces as Parkinson\u2019s disease progresses in the patient and can lead to involuntary movements, or dyskinesia.\n\u201cWhat we are hoping for with this device is to find a treatment for movement disorders where Levodopa, Parkinson\u2019s disease where Levodopa is not enough.\nThe research was led by Associate Professor Filip Bergquist, who said the simple device was similar to the TENS (Transcutaneous Electrical Nerve Stimulation) therapy which is used for pain relief, for example in child birth.\nAccording to the research institute, the experiments showed that the active noise stimulation improved both the patients\u2019 balance and the combined symptoms.\nThe plan is now for the device to be tested in a longer-term study, where patients will be using it at home.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019d like to point out this story\u2019s reporting on a patient who didn\u2019t receive any benefit from the device. These kinds of anecdotes are rare and valuable in health stories, which too often focus on patients who achieve spectacular, unrepresentative results. The reality for many patients is often more prosaic, as this quote nicely conveys: \u00a0\u201cI have become hardened in the sense that I do not have too great expectations. But I still believe that something will be found at some point which could be useful. There is extensive research in this field and I hope that it eventually will come up with a result.\u201d\nThat being said, we have to rate this story Not Satisfactory because it never quantifies the apparent benefit, summarizing it instead in general terms: \u201cAccording to the research institute, the experiments showed that the active noise stimulation improved both the patients\u2019 balance and the combined symptoms.\u201d Patients need to know something about degree of benefit to determine if this is something that may be worth exploring.", "answer": 0}, {"article": "And in an accompanying journal editorial, medical professors Dr. Bo Abrahamsen and Dr. Opinder Sahota wrote that due to study limitations, \"it is not possible to provide reassurance that calcium supplements given with vitamin D do not cause adverse cardiovascular events or to link them with certainty to increased cardiovascular risk.\nThe case against calcium became stronger when researchers added in data from 13 other, unpublished trials involving almost 30,000 women.\nBut even when added to previous studies with similar findings, the new conclusions don't necessarily mark a death knell for calcium supplements, say the authors of a study released online April 19 in the BMJ.\n\"Our own recommendation is to critically review the use of calcium supplements, since the data in this paper suggests that they do more harm than good,\" added Reid, who is professor of medicine and endocrinology at the University of Auckland in New Zealand.\nIn addition, the mammoth, U.S.-government funded Women's Health Initiative (WHI) earlier found no negative link between calcium and heart health.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Because this study was focused on avoiding the risk of heart attack and stroke, we think that the benefits category is not applicable here.\n", "answer": 2}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nA reliable lab test would help ensure that children who have a head injury don't go back to school, or to the soccer field, before their brain has healed, Bhomia says.\nA reliable test would help overcome a major obstacle in assessing and treating concussions, which affect more than one million children and adolescents in the U.S. each year.\nBut saliva may not be the best place to measure microRNAs, Bhomia says.\nHicks and a team of researchers have been looking for an objective test that might help.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story attempts to quantify benefits with this statement:\nA test that measures fragments of genetic material in saliva was nearly 90 percent accurate in identifying children and adolescents whose symptoms persisted for at least a month, a Penn State team told the Pediatric Academic Societies Meeting in San Francisco, Calif.\nThe story overstates both the accuracy of the test and the meaning of the study results. First, regarding the accuracy, while it is technically correct that the researchers reported their spit test \u201cwas nearly 90 percent accurate in identifying children and adolescents whose symptoms persisted for at least a month,\u201d that statement is likely to give most people an inflated sense of what test results would mean in the real world.\nThe researchers reported in their conference abstract\u00a0(see session ID 255639) that the test had a sensitivity (ability to detect true cases) of 90 percent and specificity (ability to rule out non-cases) of 87 percent. But the lead researcher estimates that only 25 percent of children have prolonged symptoms after a concussion. Putting those numbers into a statistical calculator indicates that in a typical group of patients, a positive result would mean the likelihood of prolonged symptoms would be actually less than 70 percent. Still, a negative result would be correct more than 96 percent of the time.\nAlso,\u00a0where is the evidence that predicting symptom duration improves outcomes? Would the test result change treatment? Would it alter decisions about when it is safe for a child to return to sports? Of course, parents want to know \u201c\u2019When is my child going to be back to normal again?,\u2019\u201d but most readers would infer that the test must have some value beyond making predictions that don\u2019t change how the child is actually treated.\nWhat\u2019s more, the story includes a claim that doesn\u2019t make sense based on the evidence the researchers presented. It paraphrases an expert who says \u201cA saliva test could greatly improve care for young people who don\u2019t have obvious symptoms of a concussion.\u201d But that\u2019s not what the researchers looked at\u00a0\u00a0They reported that the saliva test was able to predict the duration of symptoms, which doesn\u2019t reveal anything about its ability to detect brain damage that does not produce symptoms. That is an important question that still has to be tested.", "answer": 0}, {"article": "Diabetes, high cholesterol, high blood pressure, stroke and being overweight jeopardize vascular health.\nBy detecting Alzheimer's disease long before symptoms emerge, Dr. Nagele hopes those with disease-related autoantibody biomarkers will be encouraged to make beneficial lifestyle changes that may help to slow development of the disease.\nWhile the cause of Alzheimer's remains elusive, it is clear that maintaining a healthy blood-brain barrier is a critical preventative measure.\nPotentially, this early intervention could help those with preclinical Alzheimer's avoid or delay the most devastating symptoms.\n\"I can't think of a single patient who wouldn't take steps to prevent the progression of Alzheimer's if they could directly affect their prognosis.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No details are given about how the test has performed. \u00a0Nothing about sensitivity or specificity. \u00a0If the test is \u201cnearing development,\u201d the researcher should be able to provide positive and negative predictive values \u2013 the best measures to judge the performance of such a test. \u00a0How many people who test positive really have the disease, and how many who test negative don\u2019t?\nThen, in this data-free zone in which this news release resides, it goes even further\u00a0beyond Alzheimer\u2019s to say that \u201cthe blood test has also shown promise in detecting other diseases, including Parkinson\u2019s, multiple sclerosis and breast cancer.\u201d \u00a0Again, without a shred of evidence provided.", "answer": 0}, {"article": "The resource you are looking for might have been removed, had its name changed, or is temporarily unavailable.", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release merely says \u201cit works.\u201d The release notes that the author lost 70 pounds 12 years ago, although it appears that his personal weight loss was the result of applying techniques discussed in an earlier book, not the specific methods pitched in this release.\nAnd, while Lou Piniella is trotted out of the bullpen to impress with his name, no data about his results are provided in the news release.\nIt is important to note that while the release claims that \u201cThe Baseball Diet\u201d will produce results within nine weeks, in order to improve health a diet plan must help people maintain lower weight indefinitely.", "answer": 0}, {"article": "Filing for approval in the EU has been completed.\nThe primary endpoint of the so-called Tropic trial was overall survival.\nThe clinical trial results will be presented at the 2010 American Society of Clinical Oncology (ASCO) on June 6.\nThe French drugmaker said on Thursday that the combination of the treatments led to an improved median overall survival of 15.1 months against 12.7 months in patients who took a chemotherapy of mitoxantrone with prednisone/prednisolone.\nThe FDA\u2019s review should happen in the third quarter, Sanofi said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story included the mean overall improvement in survival. But it didn\u2019t comment at all on the tradeoff of 2.4 months in improved median survival versus a 3% higher risk of death from side effects.\u00a0 A barely satisfactory grade on this. \n", "answer": 1}, {"article": "Learn more about Parkinson's disease and its symptoms at the Parkinson's Disease Foundation.\nThe researchers can't say exactly how -- or even if -- statins reduce the risk of Parkinson's.\nThe data are compelling evidence that statins are not detrimental for people with or at risk of Parkinson's disease, he said.\nHowever, the risk reduction was modest and may have been due to chance, the authors said, noting that more research is warranted, especially because statins can cause adverse side effects.\nIt's thought these drugs may have potent anti-inflammatory effects, which could protect the brain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story nicely summarizes what researchers did in the study, but it does not provide any numbers for the benefits found in the study. This is unfortunate because it would have given readers a better sense of what \u201cslightly lower risk\u201d meant in the lead.", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe safety and efficacy of Dupixent have not been established in the treatment of asthma.\nThe safety and efficacy of Dupixent were established in three placebo-controlled clinical trials with a total of 2,119 adult participants with moderate-to-severe atopic dermatitis not adequately controlled by topical medication(s).\nOverall, participants who received Dupixent achieved greater response, defined as clear or almost clear skin, and experienced a reduction in itch after 16 weeks of treatment.\nDupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In terms of benefits, the release offers the following: \u201cOverall, participants who received Dupixent achieved greater response, defined as clear or almost clear skin, and experienced a reduction in itch after 16 weeks of treatment.\u201d But readers are left to interpret on their own what \u201cgreater response\u201d and \u201ca reduction in itch\u201d mean.\nThe release would have been better if it had told readers how the improvement was measured and how many patients experienced improvement rather than using the term \u201coverall.\u201d", "answer": 0}, {"article": "Cardiac arrest involves the abrupt loss of heart function, breathing and consciousness.\nWhen ambulances took up to 10 minutes to arrive, bystander CPR was associated with tripled survival odds, the study also found.\nWhen the ambulance arrived within five minutes, 14.5 percent of patients in the bystander CPR group survived at least 30 days, compared with 6.3 percent in the group that didn\u2019t get this help.\nAfter 13 minutes, patients who got CPR at the scene continued to have better survival odds but the difference was no longer statistically meaningful.\nThe study is observational and doesn\u2019t prove bystander CPR increases survival odds, the authors note in Circulation.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job of giving exact numbers of survivors who did and didn\u2019t receive CPR in the study. It provides exact survival times for ambulance arrivals\u00a0at 5, 10, and 13 minutes. These statistics are provided both in terms of percentages\u00a0and ratios.", "answer": 1}, {"article": "Anderson Cancer Center.\nIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer.\nThat is due in part to the lack of any easy way to detect the cancer in its earliest stages.\nThe new finding could lead to a blood test that would allow doctors to screen for pancreatic cancer much more effectively.\nThe researchers found that the presence of the protein could distinguish with 100 percent accuracy whether patients had early stage pancreatic cancer or chronic pancreatitis, a major risk factor for the cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits of the tests are presented only in vague terms. The expert quoted claims that earlier diagnosis of pancreatic cancer would reduce death rates, but in the next sentence he states that a new screening tool also offers an \u201cunprecedented opportunity\u201d to design \u201cpotential curative surgical options.\u201d That doesn\u2019t give us a lot of confidence that curative surgical options currently exist. As we discussed in the competing NBC and LA Times reviews, patients whose cancers are caught early may still face long odds for survival. And the 100% accuracy figure touted in the story is based on a very small number of subjects. The story didn\u2019t hint at any of this context.", "answer": 0}, {"article": "They can also keep heart vessels more elastic and flexible, which helps combat the growth of plaques that can build up and rupture, causing heart attacks.\nThe benefits for the heart of eating strawberries and blueberries can build up over a lifetime, according to the latest research.\n\u201cAlthough we know about the effects of antioxidants and flavonoids, and their effects in wine and chocolate, it is interesting to look at their effects in such a large group of women over a long period of time,\u201d says Dr. Suzanne Steinbaum, director of women and heart disease at Lenox Hill Hospital in New York City, who was not involved in the study.\nThe results are particularly encouraging because they showed that a change in diet could affect heart-disease risk for relatively young women.\nThat means that regular consumption of berries might be a relatively easy way to lower a woman\u2019s risk of having a heart attack later in life, possibly even insulating her from heart problems.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The piece mentions that \u201cwomen who ate three or more servings of blueberries and strawberries per week reduced their risk of heart attack by up to one third.\u201d Again, this is the figure associated with anthocyanin, after adjustment of multiple variables. The limited understanding of anthocyanin and its levels in the body introduces an important limitation in the study. The protective effect may have been due to other factors, which is something the researchers acknowledge in their journal article.\nFinally, the story did not make a clear statement about this study\u2019s ability only to point to a statistical association \u2013 not to establish cause-and-effect \u2013 something we describe more in the \u201cEvidence\u201d criterion below.", "answer": 0}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story offers good narrative explanations and opinions about the added value of the nuclear imaging tests, but no hard data to support the conclusions. The FDA approval processes certainly require data\u2013both preclinical and clinical\u2013and at least some of it should be cited.\nThe story\u00a0makes claims about earlier detection of recurrence, but provides no data on how much more likely this is compared to following PSA or other currently available tests, and whether this earlier detection leads to better clinical outcomes. We already have good tests to evaluate spread to bone (advanced cancers)\u00a0and\u00a0lymph nodes. We would need data to show whether the new technology is more accurate\u2013and cheaper than current tests.", "answer": 0}, {"article": "For more information, visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.\nTom Judd, who lives near Portland, Oregon, knows what it is like to be diagnosed with a deadly cancer for which there is no approved drug.\nHis team foundational work on the role of immune cells in MCC paved the way for immunotherapy trials in the disease, including one he leads of another immunotherapy drug with a similar mechanism of action (Merck\u2019s Keytruda), whose results were published last year and changed the field overnight.\nBecause of the data from this clinical trial, avelumab (brand name Bavencio) has become the first systemic therapy approved by the FDA for MCC, and the first treatment of any kind approved for metastatic MCC.\nWithin six weeks of that first infusion, more than one-third of the cancer throughout his body was gone, and today, more than 90 percent of his tumor mass has disappeared.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release alludes to a study in the Lancet Oncology but it does not provide any of the measurable benefits found in that study, namely that out of 88 patients who received at least one dose of the drug avelumab, 28 achieved an \u201cobjective response\u201d within an average of about 10 months. That means that less than a third of the patients who took the drug saw something positive happen as a result. The release might make you think that, in fact, the majority of patients who take the drug see their tumors shrink. But even when a 90% reduction in tumor mass occurred (as was the case of the patient profiled), it would not automatically translate into longer survival for all patients.\nThe release states that almost a third of patients in the trial \u201cwith no hope at all of surviving\u201d benefited from the drug. What does no hope at all mean? Were all of the patients in the trial at stage 4 of the disease? The release doesn\u2019t tell us.", "answer": 0}, {"article": "Unlike the 2012 campaign, which aired for 12 consecutive weeks, the 2014 campaign aired in two phases, from February 3 to April 6 and from July 7 to September 7.\nThe latest outcomes measuring the impact of CDC\u2019s national tobacco education campaign are as strong as those achieved in its first year, and suggest that three years into the campaign, the ads were still having a significant impact.\nAbout 80 percent of U.S. adult cigarette smokers who were surveyed reported seeing at least one television ad from Phase 2 of the 2014 campaign.\nMore than 1.8 million smokers attempted to quit smoking because of the nine-week-long 2014 Tips From Former Smokers ( Tips ) campaign.\nTips ads encourage smokers to call 1-800-QUIT-NOW or to visit www.cdc.gov/tips to view the personal stories from the campaign.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is focused on a study that used survey data to estimate the impact of the Tips campaign. And the release does a good job of articulating those estimated benefits. The most concrete benefit was the estimate that 104,000 people \u201cquit smoking for good\u201d as a result of the Tips campaign. That\u2019s enough to earn a \u201csatisfactory\u201d rating. But the release doesn\u2019t tell readers what quitting smoking \u201cfor good\u201d means. It appears to mean, based on the study itself, that smokers had quit for six months \u2014 that\u2019s good to know. It also doesn\u2019t place those 104,000 quitters in context. Based on the information in the release itself, there are 40 million adult smokers in the U.S., and approximately 80 percent of those smokers saw at least one of the Tips ads. That comes to 32 million smokers. If 104,000 of those smokers quit, that means that the 2014 Tips campaign helped approximately 0.3 percent of smokers who saw the campaign to quit. Is that good? Bad? It\u2019s hard to tell without comparing the 2014 Tips campaign outcome to the outcomes of other campaigns \u2014 which the release doesn\u2019t do.\u00a0 It\u2019s also important to note that the 104,000 is an extrapolation based on surveying only 4,428 subjects. Given that\u00a0about 3,500 of these subjects saw the ads, the 0.3 percent quit rate equals 10 study subjects.", "answer": 1}, {"article": "\u201cIt cannot be simplified to a neat, effortless passage of the infant through the birth canal,\u201d he said.\nBut in terms of their bacterial colonies, the infants swabbed with the microbes closely resembled vaginally delivered babies, she found, especially in the first week of life.\nAnal samples from the swabbed group, oddly, contained the highest abundance of bacteria usually found in the mouth.\nNow, in the first study of its kind, researchers on Monday confirmed that a mother\u2019s beneficial microbes can be transferred, at least partially, from her vagina to her baby after a C-section.\nAnd all infants delivered by C-section were exposed to antibiotics, which also may have reduced the number and variety of bacteria colonizing them.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article does a nice job of detailing the potential benefits of the microbial transfer and the results seen in the study, while giving the caveat that longer follow up studies are needed to understand the implications of various microbiome make-ups.\u00a0But to be fair, the results are from a total of 4 newborns, hardly a number on which to base any strong conclusions.", "answer": 1}, {"article": "\"This is one more reason to consume fruits and vegetables - at least 5 a day - and it's good to include tomatoes in that mix,\" Willett said.\nTomatoes could contribute to reducing stroke in other ways, Willett says, because they are a good source of potassium, which is known to reduce blood pressure.\nIn other words, perhaps better health habits - not necessarily just the lycopene - lead to fewer strokes.\n\"It's a compelling study and it fits with other data that we have about risk of stroke and vegetable and fruit consumption,\" explains Dr. Daniel Labovitz, director of the Stern Stroke Center at Montefiore Medical Center in New York.\nThough the researchers tried to take these lifestyle factors into account when calculating their findings, it may be that these things influenced the outcomes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story frames the benefit in relative terms, stating: \u201c\u2026those with the highest levels of lycopene were 55% less likely to have a stroke than those with the lowest amounts in their blood.\u201d\nBut since we don\u2019t know how many strokes occurred in these high- and low-lycopene groups, there\u2019s really no way to tell how meaningful this 55% reduction is. The story would have done better to put the statistics in more useful absolute terms, as\u00a0a press release that accompanied the study did: \u201cAmong the men with the lowest levels of lycopene, 25 of 258 men had a stroke. Among those with the highest levels of lycopene, 11 of 259 men had a stroke.\u201d", "answer": 0}, {"article": "score of 0.9 or higher at the age of 50.\ntesting is not helpful for men with 10 years or less of life expectancy.\n\u201cThere\u2019s a strong case that they should be exempted from screening.\u201d\n\nThe advice is less clear for men with scores between 1.0 and 2.0 at the age of 60.\nA man with a higher score may want to do more frequent testing.\nBut the score does put them in a higher-risk group of men who have more to gain from regular screening, he concluded.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The way the study results were reported in this study, 75% of men have a PSA level at age 60 that is less than 2 meaning that their risk of having a problematic prostate cancer in their lifetime is less than 6%. \u00a0\nIt might have been useful to provide some context for evaluating what a 6% risk means. \u00a0How does it compare, for example, of a man\u2019s chance of dying of heart disease? \u00a0Or other types of cancer?", "answer": 1}, {"article": "A viral vector is a virus that has been modified to deliver foreign genetic material into a cell.\nIn fact, the experiment was largely successful, with cells now able to produce WAS protein, resulting in increased platelet counts and improvement of some immune-system cells.\nHowever, one of the 10 kids in the study developed acute T-cell leukemia, apparently as a result of the viral vector that was used to insert the healthy gene.\nPreviously there had been some concern that drugs needed to get the stem cells out of the bone marrow and into the bloodstream where they could be accessed might pose a risk of leukemia.\nIn this study, the researchers inserted a healthy gene capable of producing WAS protein into hematopoietic stem cells (the \"granddaddy\" cells that give rise to different blood cells), then transferred these stem cells back into the patient using a viral vector.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that the therapy resulted in\u00a0\u201cincreased platelet counts\u201d and \u201cimprovement of some immune-system cells.\u201d The story should have provided quantitative data and tried to explain what these changes might mean for patients.\u00a0Another problem is that the story didn\u2019t tell us how long\u00a0the patients were followed and how long the benefits lasted. The effects of some gene therapies fade with time because the cells injected with\u00a0DNA by viruses ultimately die and stop producing the therapeutic protein.", "answer": 0}, {"article": "\"People say, 'What's the harm in screening?'\nIt did find enough new data to recommend for the first time against screening for older men.\nBut they drew strong criticism from others who are convinced that routine screening is necessary.\nThe new review of the scientific literature found no evidence to alter that assessment for younger men.\nMen younger than 75 should be carefully counseled about the potential risks associated with the test and the lack of evidence about any benefit before getting it, the panel said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story outlined for readers that the benefits of routine screening for prostate cancer are uncertain.", "answer": 1}, {"article": "But not a whole lot.\nThe bottom line: After seven days of treatment, those taking the supplements had less than half the chance of still being sick.\nExactly how well zinc works is a matter of future research, and the one day estimate may well change, the researchers note.\nAnother two trials found that zinc helped stave off colds, but the quality of that research was low.\nStill, with an infection that currently has no good treatment and leads to an estimated 275 million lost work days a year in the U.S., well, what a difference a day makes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided fewer numbers than the WebMD story, and we wish it had presented some of the evidence in absolute terms.\u00a0The story seems to want it both ways. While the story opening does provide the reader with some understanding of the uncertainty of the review results, the quotes from one of the study authors appear to provide an endorsement that is well beyond that in the study conclusions. For example, the story notes, \u201cThe bottom line: After seven days of treatment, those taking the supplements had less than half the chance of still being sick.\u201d What is left unsaid is that the authors of the paper rated the evidence for that conclusion as low and \u201cFurther research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.\u201d Far from the declarative statement in the story.", "answer": 0}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the ideal would be a story that reported numerical data about what was actually found\u2013what the scope of potential benefits/harms were in the trial\u2013we\u2019ll nonetheless give this a satisfactory score. There\u2019s little doubt about the take-home message from this paragraph in the story: \u201cA year of testosterone treatment was no better than a placebo for memory and thinking, and it increased fatty plaque in coronary arteries, a risk factor for heart disease. The hormone helped anemia and low bone density in the minority of men with those conditions, which can be treated with other, proven therapies.\u201d", "answer": 1}, {"article": "\u201cThe studies are small and the longest of them lasted only three years.\nAlthough low hormone levels are widely thought to increase a man\u2019s risk of depression, the researchers found that \u201cpsychological symptoms had little or no association with the testosterone level.\u201d\n\nThere are four main approaches to testosterone therapy available in this country: intramuscular injections every one to three weeks; skin applications through a patch or gel; and pellets implanted under the skin that last for months.\nBefore the most recent study, at doses considered normal, the testosterone gel showed little or no effect on cardiovascular risk, the two doctors reported.\nThe researchers, who published their findings in The New England Journal of Medicine, noted that the deck might have been stacked in favor of a hazardous outcome because study participants, especially the group that received testosterone, had high rates of high blood pressure, diabetes, obesity and elevated blood lipids.\nThen again, this may be a realistic population to study, given that many candidates for hormone therapy are likely to have such health issues.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story notes that testosterone has\u00a0inconsistent effects\u00a0on sexual function, the primary reason men seek out this type of treatment. Other potential benefits of testosterone therapy\u00a0are listed as improved muscle mass, increased\u00a0bone density, decreased body fat\u00a0and total cholesterol, and improved blood sugar\u00a0metabolism.\u00a0\u00a0\nAs with the harms,\u00a0this story never provides statistical data on how often these benefits\u00a0occur and how big a benefit can be expected.\u00a0However, we\u2019re not sure these numbers with would have been helpful, since the benefits are reflected in some\u00a0fairly arcane scales (e.g. the \"libido scale,\" \"subjective vitality scale,\" etc.) that would be difficult to describe in a relatively brief piece like this. Does a 20% increase in the libido scale number mean anything to anyone other than researchers? We think the piece satisfies the spirit of the criterion\u00a0and offers enough detail for a satisfactory grade. \u00a0\u00a0", "answer": 1}, {"article": "\u201cIt was a little humiliating, to be honest,\u201d she said of the testing.\nEach participant carried out the word-memorization tests repeatedly, with different words every time; some lists were memorized with brain stimulation, and other lists with no stimulation, which served as a control.\nAll the while, the scientists monitored a handful of \u201chot spots\u201d in the brain which, previous work had shown, were strongly related to memory encoding.\nBefore the stimulation tests, the team determined the precise settings for each patient\u2019s high- and low-functioning states.\nThe team then statistically analyzed the results and found that people scored slightly higher than usual on words when stimulation arrived during a low or foggy state \u2014 and worse, when the pulse arrived in a high state.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers get two sets of numbers on the effect size: Patients who were gently zapped when their brains were learning words during a foggy, \u201clow-functioning state\u201d\u00a0could remember words 12%-13% better. Stimulation during a clear-minded, \u201chigh-functioning state,\u201d however, resulted in 15%-20% worse performance.\nWhat\u2019s missing, however, is a definition and context for these numbers. We had a lot of questions: Do they reflect the number of words recalled? How correct (or incorrect) their order during recall was? Or that people remembered them more or for less time compared to no stimulation? Or some other measure? Were these statistically significant results? Also, how did the researchers determine if a person was experiencing a \u201chigh-functioning\u201d or \u201clow-functioning\u201d state?", "answer": 0}, {"article": ".\n\"PPF could be easily translated to the clinic as an adjuvant therapy in combination with standard of care treatment for GBM patients.\"\nHowever, this security system is so effective at protecting the brain that it prevents many life-saving drugs -- all but some small molecules -- from being able to treat cancer and other diseases of the brain.\nThis study was funded, in part, by The Ben & Catherine Ivy Foundation.\nSince then, the Foundation has contributed more than $50 million to research in gliomas within the United States and Canada, with the goal of better diagnostics and treatments that offer long-term survival and a high quality of life for patients with brain tumors.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is riddled with suggestions \u2014 but no specifics \u2014 of potential benefits. Some examples:\nThe release is explicitly silent on the fact that the research was confined to the laboratory and did not involve patients.", "answer": 0}, {"article": "Journal of Child and Adolescent Psychopharmacology.\nBoth findings reaffirm the potential that mindfulness therapy could bring to the table.\n\"These integrative approaches expand traditional treatments and offer new strategies for coping with psychological distress,\u201d said the study\u2019s co-author Sian Cotton, director of the UC's Center for Integrative Health and Wellness, in a statement.\nAfter the 12-week experiment, Cotton and his colleagues found mindfulness therapy increased neural activity in a part of the brain that plays in a role in processing cognitive and emotion information known as the cingulate.\n\"Mindfulness-based therapeutic interventions promote the use of meditative practices to increase present-moment awareness of conscious thoughts, feelings, and body sensations in an effort to manage negative experiences more effectively.\u201d\n\nChildren who are at a high risk for bipolar disorder or other anxiety disorders, such as the participants, often have poor coping skills when confronted by stress, and only a lucky few get help.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job of not \u201cover-selling\u201d the benefits seen in the cognitive therapy study on children with anxiety disorders. It refers to \u201cintegrative approaches\u201d and expanding treatment options. When discussing study results, the story talks about \u201cthe potential that\u00a0mindfulness therapy could\u00a0bring to the table,\u201d and notes that \u201cIf nothing else, it might\u00a0allow people who would\u00a0be reluctant to take medication\u00a0more\u00a0treatments to\u00a0choose from.\u201d That sort of cautious language is all to the good. However, when it comes to describing the study\u2019s findings, the language is extremely vague: \u201cCotton noted the anxiety of [study] patients was significantly reduced following treatment, and the more mindfulness they practiced, the less anxious they felt.\u201d What does \u201csignificantly reduced\u201d mean? Even a tiny improvement can be statistically \u201csignificant\u201d \u2014 is that what we\u2019re talking about here? It\u2019s not clear. This is why the criterion asks for quantified benefits, and that\u2019s lacking here.", "answer": 0}, {"article": "(His group was one of the sponsors of the Lancet study.)\nThe study not only indicated that the algorithm system prevented very low glucose overnight, Dr. Hovorka said, but it also indicated that the experimental system was better able to keep blood glucose in an acceptable range.\nResearchers call such a hypothetical integrated system an \u201cartificial pancreas\u201d because it would mimic the way a healthy pancreas works, sensing glucose and dispensing insulin in the right dose at the right time.\nAlthough the Lancet study was small \u2014 only 17 children completed the entire protocol \u2014 it is significant because it demonstrated that a computer algorithm could safely interpret glucose data and calculate appropriate insulin doses for a pump, he said.\nEven so, Dr. Kowalski said, using separate devices that are not designed to work in concert poses limits to treatment, particularly overnight.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We applaud the Times for avoiding the term \"artificial pancreas\" in the headline and using it sparingly in the body of the story.\u00a0The competing stories couldn\u2019t resist it. We can understand why\u00a0marketers and media relations people would favor this term because of its promotional value, but we don\u2019t think it\u2019s a\u00a0good way to describe this technology in an objective piece of journalism. \"Artificial pancreas\" is misleading because we\u2019re not really anywhere close to\u00a0being able to replicate what the normal human pancreas\u00a0does through artificial technology.\u00a0Forgetting for a moment\u00a0that the pancreas does much more\u00a0than simply dispense insulin (it also\u00a0produces a number of other hormones and\u00a0digestive enzymes that aren\u2019t impacted by diabetes),\u00a0what\u2019s more important is how the pancreas works\u00a0in concert with\u00a0the brain and other systems to regulate\u00a0glucose in a very tight range.\u00a0The normal human pancreas starts releasing\u00a0insulin before\u00a0we eat in response to complex environmental cues, whereas any artificial system would need to\u00a0be told that\u00a0meal is coming or react to the\u00a0rise in glucose after the\u00a0fact. Plus,\u00a0insulin\u00a0produced by the body\u00a0starts acting right\u00a0away, whereas insulin analogues take about 20 minutes to take\u00a0effect. Put this all together and we see that the \"artificial pancreas\" will, for the foreseeable future, require human intervention to predict\u00a0post-meal\u00a0insulin needs and dosing or else patients will be at risk of post-meal blood sugar spikes. And it\u2019s not at all clear that such a system\u00a0will improve overall blood\u00a0sugar management compared with existing methods. The term\u00a0\"artificial pancreas\" conjures up a vision of totally automated glucose management and essentially a \"cure\" for type 1 diabetes. This is\u00a0overselling what the technology can do.\u00a0 ", "answer": 1}, {"article": "Nearly 800,000 Americans suffer a stroke every year, with about a sixth of them dying of it and many more left disabled.\n\u201cGiven the observational design of the study, findings from this study cannot prove that it\u2019s chocolate that lowers the risk of stroke,\u201d Susanna Larsson from Karolinska Institutet in Stockholm told Reuters Health in an email.\nAmong those with the highest weekly chocolate intake \u2014 more than 45 grams \u2014 there were 2.5 strokes per 1,000 women per year.\nOver the next decade, there were 1,549 strokes, and the more chocolate women ate, the lower their risk.\nThe results add to a growing body of evidence linking cocoa consumption to heart health, but they aren\u2019t a free pass to gorge on chocolate.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story went the extra mile here, providing the\u00a0absolute rates of stroke seen in the groups consuming the lowest and highest quantities of chocolate.\u00a0 \u201cAmong those with the highest weekly chocolate intake \u2014 more than 45 grams \u2014 there were 2.5 strokes per 1,000 women per year. That figure was 7.8 per 1,000 among women who ate the least (less than 8.9 grams per week).\u201d These statistics weren\u2019t provided in the study text, suggesting that the writer made the calculations based on data contained in one of the study tables. We applaud the\u00a0extra effort made to provide meaningful statistics to readers!", "answer": 1}, {"article": "U.S. experts familiar with the study call it interesting but say the treatment needs more study and wonder if it would catch on in the U.S.\nAt 15 weeks, visual acuity with eyeglasses improved by about 1.8 lines on the vision chart in the patched eyes and 2.3 lines in those who had acupuncture.\nAmbylopia was evaluated as resolved in nearly 17% of patched eyes but nearly 42% of the acupuncture group.\nAn improvement of two lines or more occurred in nearly 67% of those in the patching group but nearly 76% of those in the acupuncture group.\nDec. 13, 2010 -- Acupuncture treatments to treat one type of lazy eye proved as good as the traditional patching of the eye used to help the eyes work together, according to a new study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did a better job than the competing coverage of quantifying the extent of the benefit observed with acupuncture. It explained that children in the acupuncture group had their vision improve by about 2.3 lines on the vision chart, compared with\u00a0about 1.8 lines\u00a0in the patch group. (HeathDay, by contrast, merely said that vision \u201cimproved markedly\u201d in the acupuncture group.) It also explained that the amblyopia was considered \u201cresolved\u201d in 42% of acupuncture and 17% of patch patients. (The HealthDay we also reviewed described these patients less precisely as \u201csuccessfully treated.\u201d) Lastly, this story noted that the benefits of acupuncture were much less pronounced after 25 weeks than they were at 15 weeks, whereas HealthDay only mentioned the 15-week outcomes.", "answer": 1}, {"article": "Stay out of the sun, or utilize a proper sunscreen.\nA few potential caveats to note include the reliance on self-reporting when it comes to a man's history of STIs, as well as his sexual partners.\nBut a new study published Monday in Cancer suggests that at least one decision our parents make FOR us may have an impact on our predisposition to certain types of cancer.\nParticipants in the study were asked about their family\u2019s medical history, which may increase a man\u2019s risk of developing prostate cancer, and their PSA screening history, which can lead to overdiagnosis of the condition.\nThe bottom line from the American Cancer Society: While this is an interesting finding, it's not likely to spur any change in recommendations or medical practice.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The headline for this article \u2014 \u201c\u2018Cutting\u2019 your risk of prostate cancer\u201d \u2014 fails on two levels. Not only is the pun quite bad, but the use of the active verb suggests that there is a causal relationship between circumcision and prostate cancer, which is something this observational study can\u2019t prove. Although the text of the story communicated this fact appropriately, it should be reflected in the headline as well.\nWhile absolute risks generally cannot be estimated from case-control studies,\u00a0 extrapolating the 15% relative risk reduction to the 16% lifetime risk for being diagnosed with prostate cancer would suggest that circumcision would be associated with at most a 1% or 2% absolute risk reduction\u2013likely less for clinically important cancers.\u00a0 Of\u00a0course, the study provides no information on whether circumcision is related to prostate cancer mortality\u2013an important issue given that most prostate cancers are indolent.", "answer": 0}, {"article": "Hialeah bucket list: All the things you need to do in Hialeah before you die\n\nYou can spend your whole life working on this list.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits in this case are estimates of 10-year survival in those found to have lung cancer through screening, which is provided.\u00a0 Since there is no control group, there would be no way to provide an absolute risk reduction.\u00a0 But, the story does provide a 5-year chance of death estimate for those diagnosed conventionally, e.g. as a result of symptoms.\u00a0 This provides some relative comparison of what screening MIGHT offer, although it's not known for sure and readers are cautioned that direct comparisons are not possible.\u00a0 ", "answer": 1}, {"article": "The study, conducted at the University of Texas M.D.\nThe findings, published in today's Journal of the American Medical Association, are a setback to the hope that better diets can prevent breast cancer recurrence.\nPrevious research into diet and breast cancer has shown mixed results, but the authors of this study said the earlier ones were not rigorous.\nThe study focused on more than 3,000 women \u2014 average age 53 \u2014 who had been treated successfully for early-stage breast cancer.\nAn earlier analysis of the study concluded that women who ate five servings of fruit and vegetables and exercised 30 minutes a day had significantly improved cancer-free survival.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story not only provided the information that the two groups did not differ in terms of rates for breast cancer recurrence or death, but included the estimates of this from the study summary.", "answer": 1}, {"article": "She said: \"My first thought on diagnosis was that I wanted to survive, I gave little thought to long term or late effects of treatment.\nThe results will be crucial to future large scale trials looking at optimum care for anal cancer patients.\nIt is crucial that we tackle what is becoming an increasingly common form of cancer through research studies like this.\nBy identifying a unique phenomenon, these results will be taken into account by future work and ultimately could lead to better diagnosis of tumour stage and thus better treatment.\nThe study worked with data on more than 10,000 patients, examining whether current methods of checking if anal cancer has spread to lymph nodes are giving experts an accurate picture of survival rates.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that the study \u201cuncovered a phenomenon suggesting rates of lymph node spread are being overestimated, potentially leading to overtreatment of patients with chemo radiotherapy.\u201d There are no data offered in support of that statement.\nIt also makes the claim that \u201cThese findings will help us to better understand how anal cancer patients should be treated, ultimately improving survival rates and quality of life.\u201d Again, there are no numbers provided showing how survival rates and quality of life can be improved with a change in treatment.\nThe release should have attempted to put the main findings in meaningful context for lay readers.", "answer": 0}, {"article": "A healthy cholesterol level is less than 200 mg/dL, according to the American Heart Association, while 200 to 239 mg/dL is considered \u201cborderline high.\u201d\n\nIn the groups taking 100 and 200 micrograms of selenium daily, total cholesterol dropped an average of 8.5 mg/dL and 9.7 mg/dL, respectively, compared to the group taking a placebo pill.\nResearchers measured participants\u2019 cholesterol levels at the beginning of the study and after six months on the selenium supplements or placebo.\nThey recruited about 500 older adults in the UK to take one of three different doses of selenium daily \u2014 100, 200, or 300 micrograms \u2014 or a placebo pill with no selenium.\nStill, the finding is \u201creassuring\u201d because previous research had linked high selenium with higher cholesterol levels, said study author Dr. Eliseo Guallar, from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nThe authors reported no serious side effects associated with selenium during the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "1 Sperling RA, Aisen PS, Beckett LA, et al.\nThe concept that cognitive decline can be identified early and prevented by applying quantitative brain imaging techniques is the focus of \"Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline,\" a review published online in American Journal of Neuroradiology (AJNR).\nThese imaging findings can help spur beneficial lifestyle changes in patients to reduce risk for Alzheimer's disease.\nThese markers, including structural, functional, and molecular imaging are being used in the AD diagnositc criteria [AA/NIA], (1)\" says Howard Aizenstein, M.D., Ph.D., a psychiatrist at University of Pittsburgh.\n\"We are working closely with neuroradiologists to redefine how we can reduce risk for Alzheimer's with quantitative neuroimaging that helps us pinpoint symptom-relevant volume loss in the brain and subsequent targets for tracking our lifestyle-based interventions,\" says Dr. David Merrill, a geriatric psychiatrist at UCLA Medical Center.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The main contention of the news release is that \u201cimaging findings can help spur beneficial lifestyle changes in patients to reduce risk for Alzheimer\u2019s disease.\u201d But there\u2019s no evidence presented to show that these images have any effect \u2014 good or bad \u2014 on patients\u2019 adoption of beneficial lifestyle changes. Does performing an MRI increase the likelihood that someone will lose weight, exercise, and stop smoking?\nThe release also states, \u201cinstitutions\u2026 meld these approaches into novel ways to improve patient care,\u201d but the report doesn\u2019t detail what those \u201cnovel\u201d therapies are. Experts in the report talk about pinpointing \u201cvolume loss in the brain\u201d and characterizing imaging markers, but these are all surrogate endpoints. In other words, how do these translate to tangible health outcomes for patients?\nBottom line: The idea that a brain MRI is going to help motivate people to adopt meaningful lifestyle changes \u2014 and that those changes will, in turn, lead to an actual reduction in the number of Alzheimer\u2019s disease cases \u2014 requires several leaps of logic that have very limited support from evidence. The release owed it to readers either to point out the preliminary nature of the hypothesis or provide some evidence to back it up. The release did neither.", "answer": 0}, {"article": "\"This could be an important tool worldwide, and even here in the United States.\"\nThe test, known as the \"Xpert MTB/RIF\" test for Mycobacterium tuberculosis and resistance to rifampin (RIF), appears to be more than 97 percent accurate and is even able to diagnose drug-resistant TB, researchers said.\nFor the study, a research team led by Dr. Catharina C. Boehme, of the Foundation for Innovative New Diagnostics in Geneva, Switzerland, used the Xpert MTB/RIF test on 1,730 patients suspected of having drug-sensitive or multidrug-resistant pulmonary tuberculosis.\nThe test diagnosed tuberculosis in 99.2 percent of the patients, the researchers found.\n\"The test that we developed finally makes it possible to detect TB in a single clinic visit,\" Dr. David Alland, chief of infectious diseases at the UMDNJ-New Jersey Medical School, said in a university news release.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story\u00a0 reported on and emphasized the speed and accuracy of the new test, noting its\u00a0advantage in\u00a0this regard over conventional TB testing.\u00a0It also mentioned the test\u2019s\u00a0ability to detect\u00a0TB that is resistant to rifampin \u2014 a drug commonly used to treat the condition.\u00a0 Nevertheless, the story never attempted to quantify\u00a0the real-world implications of the research from a data-oriented perspective. Some questions we feel the story should have attempted to answer, in quantitative terms,\u00a0include:\nWe also think the\u00a0story\u00a0should had paid a bit more attention to the issue of simultaneous\u00a0infection with tuberculosis and HIV\u2013something the new test could potentially help with.\u00a0Tuberculosis in patients with HIV is harder to detect using current\u00a0techniques, which usually involve\u00a0evaluation of lung sputum under\u00a0a microscope (called a \"smear test\"). The resulting misdiagnoses and treatment delays can be especially harmful for HIV patients given their compromised immune status. TB progresses more rapidly and is more deadly in HIV-infected individuals compared with non-infected individuals. The\u00a0new test\u00a0appears to\u00a0be effective\u00a0at diagnosing\u00a0TB even in patients who had a negative \"smear test\" \u2014 a group that would\u00a0include many HIV-positive individuals.\u00a0A comment about this potential benefit would have been appropriate.\u00a0\u00a0\u00a0\n\u00a0", "answer": 0}, {"article": "Asthma patients suffer fewer attacks and need fewer hospital visits.\nThe one-time cost of $20,000, they say, is dwarfed by the tens of thousands of dollars in hospital bills and medication costs that a severe asthmatic can easily accumulate in a single year.\n\u201cIt\u2019s not going to get rid of asthma, but it is going to reduce symptoms and hospitalizations and make patients more functional in their daily life.\u201d For now, the procedure is only for severe asthmatics, who \u2014 unlike a vast majority of asthma patients \u2014 cannot keep flare-ups at bay with standard medications, said Dr. Kyle Hogarth, an assistant professor of medicine at the University of Chicago who was involved in clinical studies of the treatment.\nBut several five-year studies showed no long-term safety issues.\nAfter the procedure, the airways no longer are so prone to constricting, studies show.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The anecdotes and statistical reporting in this piece are skewed. Two anecdotes describe patients whose symptoms are almost totally resolved following treatment, but this is not representative of the experience of most patients who receive bronchial thermoplasty. In the most rigorously conducted trial\u00a0to date, the average improvement in asthma-related quality of life after a year was about 1.4 points on a 7-point scale in the active treatment group compared with 1.2 points in patients who received a sham treatment (a 0.2-point difference favoring the procedure). In addition, the percentage of patients who experienced a clinically meaningful improvement in that study was only slightly lower among those received a sham treatment (64%)\u00a0compared with those receiving the real treatment (79%).\u00a0\u00a0When reporting on this study,\u00a0the story does not convey\u00a0these findings (which were the study\u2019s primary outcome measures), and instead\u00a0reports only on secondary outcomes\u00a0for asthma attacks,\u00a0emergency room visits, and the number of days\u00a0lost from work and school. The story uses relative improvements to describe these benefits and does not provide absolute percentages. These choices lead to an overemphasis on the benefits of the procedure.", "answer": 0}, {"article": "The Web site naturalaugmentation.com lists several doctors, mostly ob-gyns and family medicine physicians, not plastic surgeons, who offer coupons for \u201cnatural augmentation\u201d and even something called \u201cstem-cell breast augmentation.\u201d\n\nA company called makes a machine used in that concentrates the cells within fat tissue that aren\u2019t strictly fat cells, including .\n\u201cI didn\u2019t have to put anything foreign in my body.\u201d\n\nAt the October meeting of the American Society of Plastic Surgeons, Dr. Khouri presented a long-term study that suggested liposuctioned fat was now a \u201cviable alternative to breast implants.\u201d It tracked 50 women, ages 17 to 63, for an average follow-up of 3.5 years.\nNor has \u201cconcentrating\u201d cells in fat been proved to make a difference in controlled studies, said Dr. Karol A. Gutowski, chairman of the plastic-surgery society\u2019s task force.\nThe pleased mother of three in the news clip said her breasts grew \u201covernight,\u201d which is misleading.\n\u201cAnyone can take fat and inject it into the breast, and the patient will look good immediately afterwards,\u201d Dr. Khouri said, but a few months later, the fat injected by a doctor with sub-par skills may result in \u201coil cysts, masses, and scarring.\u201d\n\nTo some, this kind of fat recycling seems simple.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nWhile this story cautions against misleading promises made by some surgeons, the story then features only women who said they had positive results and strongly recommended the fat graft procedure, thus leaving readers with a one-sided perspective on likely outcomes.", "answer": 0}, {"article": "\"It took quite a bit of time to get approval,\" Mithoefer says.\n(All of the participants received additional therapy sessions that did not involve the drug.)\nTwo months later, 10 of the 12 people who took MDMA had improved to the point where they no longer met the diagnostic criteria for PTSD, and three participants whose condition had prevented them from holding down a job were able to return to work.\nThe resulting sense of euphoria and emotional warmth seems to help patients connect with their therapists, says Michael Mithoefer, M.D., the lead author of the study and a Mount Pleasant, South Carolina-based psychiatrist who specializes in PTSD.\nThe study, which appears in the Journal of Psychopharmacology, included 20 people with PTSD stemming from traumas such as sexual assault and combat stress.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quickly shows the actual numbers behind the hype in the lead. The second graph says, \"The study, which appears in the Journal of Psychopharmacology, included 20 people with PTSD stemming from traumas such as sexual assault and combat stress. On two separate occasions, 12 of the people took a dose of MDMA and then spoke for several hours with a pair of trained therapists. The others took a placebo but received the same therapy. (All of the participants received additional therapy sessions that did not involve the drug.)\" One dozen people took a drug twice and talked to a therapist. Of those, \"Two months later, 10 of the 12 people who took MDMA had improved to the point where they no longer met the diagnostic criteria for PTSD, and three participants whose condition had prevented them from holding down a job were able to return to work.\" What the story fails to do, though, is explain whether, even with this small number of people, a significant benefit could be attributed to the drug. The press release actually does a better job by explaining that \"Prior to enrolling in the MDMA study, subjects were required to have received, and failed to obtain relief, from both psychotherapy and psychopharmacology.\"", "answer": 0}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes the benefits of these drugs in broad, qualitative terms. E.g., a drug appeared to slow down cognitive decline. That makes it difficult or impossible to tell how well either of these drugs performed in the relevant trials. Were these marginal benefits? In other coverage of these studies, an Eli Lilly consultant noted that the results \u201cdo not have a direct relationship to clinically apparent benefit.\u201d So it seems premature for anyone other than investors to be getting too excited about these findings just yet.", "answer": 0}, {"article": "Uterine serous carcinoma makes up less than 10 percent of all cancers of the endometrium, or lining of the womb, diagnosed in the United States each year, but it accounts for more than a third of the 10,000 endometrial cancer deaths annually.\nBut the results of the trial, they add, were strong enough to warrant submission to the National Comprehensive Cancer Network, which guides the design of standard treatment plans around the country.\nFader cautions that a larger study of the drug combination, or other combinations, is needed to confirm the findings and potentially extend survival even more.\nThe researchers say this may lead to new national guidelines for treating this cancer subtype, known as uterine serous carcinoma.\nThe results of the trial, published online ahead of print on March 27 in the Journal of Clinical Oncology, show that the drug extended the length of time to tumor progression by four to eight months in the seven-year trial.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a good job articulating what the benefits were (as expressed in months of survival during which the cancer did not spread) and how those benefits differed depending on whether patients had an advanced stage of USC or a recurrent case.\nBut the release didn\u2019t explain the limitations of progression-free survival as a surrogate for overall survival and that\u2019s a big omission.  ", "answer": 0}, {"article": "In the current review, researchers found several trials that compared different doses of radiation and different types of radiation therapy, including external beam radiation therapy, in which a radiation is delivered through a beam through the skin, or brachytherapy, in which radioactive isotopes are delivered via injection into the prostate.\nFor those methods, too, there was too little research to say with confidence which method was superior in preventing deaths from prostate cancer, the researchers said.\nFinally, patients and their doctors should weight the potential debilitating side effects of the treatments, such as incontinence and erectile dysfunction, against how comfortable the man is with holding off on treatment, experts say.\nIn part, that's because researchers found no randomized controlled trials -- considered the gold standard of research -- that compared radiation therapy with watching waiting, Ip said.\nProton beam therapy in particular is expensive, but according to this report, there isn't enough evidence to show it's any better than other option.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The lack of evidence of benefit was clear in the story.", "answer": 1}, {"article": "LONDON (Reuters) - An \u201celectronic nose\u201d could be used as a simple breath test to detect lung, breast, bowel and prostate cancers, Israeli scientists said Wednesday.\nTheir findings, published in the British Journal of Cancer, build on earlier research published by scientists at the same institute last year showing that a sensor made with gold nanoparticles could detect lung cancer in breath.\n\u201cIf we can confirm these initial results in large-scale studies, this new technology could become a simple tool for early diagnosis of cancer along with imaging,\u201d said Abraham Kuten of Technion Israel Institute of Technology.\nKuten and his colleagues studied the breath of 177 people \u2014 some healthy and some with various types of cancer \u2014 to detect the different chemicals emitted from the surface of cancer cells as they grow.\nUsing the sensor to pinpoint chemical variations, the team found they could not only distinguish between healthy and malignant breath but also identify the four different common tumor types.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": " ", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nPatients should not get live vaccines if receiving Ilaris.\nPatients should not receive Ilaris if they are allergic to canakinumab or any of the ingredients in Ilaris.\nHealth care professionals should review the prescribing information in the labeling for detailed information about the approved uses.\nThe most common adverse reactions for these indications are injection site reactions and being more susceptible to catching colds.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "All we learn about the benefits for patients is that the treatment \u201cmay help improve their quality of life.\u201d \u00a0It would be hard to give less information about the benefits of the treatment. The statement that \u201capprovals for the new indications were based on clinical studies, including safety, efficacy and pharmacokinetic data\u201d is inadequate.", "answer": 0}, {"article": "If you're loading up on vitamin C and zinc to stave off the sniffles, you should try an earlier bedtime instead.\nIn fact, sleep was more important than any other factor, including age, stress or income level, in predicting who would get sick after being exposure to the cold virus, the researchers say.\nPeople who regularly sleep six hours or less each night are four times more likely to get a cold than people who sleep just an hour longer, a new study finds.\nThe study provides more evidence of the link between healthy sleeping habits \u2014 which experts say means at least seven hours of sleep each night \u2014 and overall good health.\nThe study is unique because it used objective measures to show that poor sleep habits make people more vulnerable to a cold virus, says Badr, who was not involved in the research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites as benefits the reduced risk of getting a cold among those who got at least six hours\u2019 sleep. But this benefit is described in relative terms (e.g. \u201cthose who slept for five hours or less each night were 4.5 times more likely to catch the cold). We think absolute terms are more informative. From figure 1 in the study, we can see that about 17% of those w/ >7hrs of sleep got the cold vs. ~45% of those with <5 hrs.", "answer": 0}, {"article": "All rights reserved.\nThe results translate to 43 fewer heart attacks and strokes per 100,000 people, said lead author Dr. Eric Brandt, a Yale University cardiology fellow.\nDr. Mark Creager, former American Heart Association president, said the results echo previous studies \u201cand are consistent with the thinking of most scientists\u201d on potential benefits of these bans.\nThe study hints at the potential for widespread health benefits from an upcoming nationwide ban, the authors and other experts say.\nHospital admissions for heart attacks and strokes in those areas declined 6 percent starting three years after the bans, compared with counties without bans.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story employs both absolute\u00a0numbers and percentages, so that we know how great a magnitude the change was (e.g., 43 fewer heart attacks and strokes per 100,000 people).", "answer": 1}, {"article": "Both the American Heart Association and the World Health Organization recommend getting at least 150 minutes of moderate- to high-intensity physical activity a week for cardiovascular and overall health.\nIf their hypothesis is right, they say, 12% of depression cases could be prevented if everyone got just one hour of exercise a week.\nThe study could not prove a cause-and-effect relationship between exercise and the risk of depression, but the authors say it strongly suggests one\u2014especially because they controlled for other potential factors, including age, gender, social support, smoking, drinking and body mass index.\n\u201cGiven that the intensity of exercise does not appear to be important,\u201d the authors wrote in their paper, \u201cit may be that the most effective public health measures are those that encourage and facilitate increased levels of everyday activities, such as walking or cycling.\u201d\n\nOf course, there are other benefits to more frequent and more intense bouts of exercise.\n\u201cThere is good evidence that physical activity can help people recover from depression, though we recommend it be used in addition to the usual treatments we would prescribe for established depression, like medication and counseling,\u201d says Harvey.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story barely passes this criterion with, \u201cPeople who said they didn\u2019t exercise at the study\u2019s start were 44% more likely to become depressed, compared to those who exercised at least 1 to 2 hours a week.\u201d Also, \u201cthey say, 12% of depression cases could be prevented if everyone got just one hour of exercise a week.\u201d\nBut to be fully informative it\u2019s important to put the 44% percent in absolute terms. How many people in the exercise group developed depression, and how many people in the non-exercise group developed depression?", "answer": 1}, {"article": "Unfortunately, condoms and vasectomy have remained the only commercially available contraception options for men.\nA new formulation currently being developed that contains half the amount of testosterone might decrease or eliminate that problem, Wang speculated.\nAnother question is how reversible this would be in terms of restoring sperm counts, Alukal said.\nBecause the new study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nThat's apart from mild-to-moderate acne or an increase in acne, which was seen in about 21 percent of participants.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Like many early stage drug studies, the study looked for surrogate markers (sperm count and motility) rather than ability to fertilize.\u00a0 The distinction is not subtle.\u00a0 The true test of the combination gel will be in the rates of unintended pregnancies.\u00a0 The story explains what percentage of men in each group had undetectable levels of sperm or levels that were below a cutoff level defined by the investigators. However, to be of value to readers, the story would need to give some sense as to how this result would affect pregnancy rates. Although the story says that the\u00a0treatment would have the effect of \u201clowering, but not eliminating, unwanted pregnancies,\u201d this isn\u2019t really specific enough. People want to know that a contraceptive will be close to 100% effective, or else it\u2019s not worth taking. The story should have asked someone \u2014 either a study researcher or the independent source \u2014 whether the effects seen in the study are likely to be consistent with that standard.\nThe story also missed an opportunity to explain what is new and potentially better about the hormone gel tested in this study compared with similar treatments delivered by injection or implant. The benefit is that the gel could potentially be applied by men at home as opposed to needing a health professional to administer it in the office.\n\u00a0", "answer": 0}, {"article": ".\nWhile surprised to note how strong the correlation was between daily doses of zinc and its effect on colds' duration, he said he and his colleagues still don't know why it seems to work.\n\"Much of the variation in the published study findings can be explained by the daily dose of zinc administered in the zinc lozenges,\" said Hemila, who funded the research himself.\n\"When focusing on those studies which have used large daily doses of zinc, there is strong evidence that zinc lozenges shorten the duration of colds.\"\nResearcher Dr. Harri Hemila, of the University of Helsinki in Finland, reviewed 13 placebo-controlled trials examining the effect of zinc lozenges on cold infections.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives us many figures, but it may not reveal enough for a consumer to gain much insight on benefits. It says that some clinical trials comparing zinc acetate lozenges to placebo reduced the duration of colds by an average of 42 percent. But other trials, considered by the author of the research article, used zinc salts (not acetate) at a different dosage, and got results more like 20 percent. The story gives information on the duration of a cold in aggregate and in relative but not not absolute terms. Consumers are left without critical details. It could have explained 42% of what?\u00a0 A week?", "answer": 0}, {"article": "(Reuters Health) - When a migraine strikes, patients might one day be able to make the experience less painful by using a smartphone-controlled device to deliver mild electric shocks to their arm, a company-funded experiment suggests.\n\u201cAll stimulation treatments given so far have been in the head,\u201d said lead study author Dr. David Yarnitsky, an advisory board member for Theranica, the company developing the device.\nResearchers asked participants to put the device on their upper arm as soon as possible after the start of a migraine and use it for 20 minutes.\nOne shortcoming of the current study is that researchers didn\u2019t examine how long the pain relief lasts beyond two hours, Schoenen said by email.\nIt\u2019s designed to stimulate nerves under the skin in the arm and block pain signals from reaching the brain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a nice job laying out the results. Readers are not only told how effective the treatment was measured to be at certain shock frequencies, but also how the placebo arms of the study fared, too.", "answer": 1}, {"article": "In deep brain stimulation, surgeons insert wires into the brain that allows a specific region to be continuously hit with an electronic pulse.\nDr. Samuel James Collier, an assistant professor of psychiatry at the University of Texas Southwestern Medical Center at Austin, predicted that even if deep brain stimulation turns out to be an effective treatment for depression, it'll be far from the first line of defense.\nDeep brain stimulation has been around for more than 20 years, Mayberg said, and is commonly used to treat Parkinson's disease.\nIf patients are interested in deep brain stimulation treatment, they should try to get into the study that's ongoing, Mayberg said.\nAnd for now, the research is preliminary, so it's too early to know for sure if the treatment is appropriate to be used for any kind of depression.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story attempts to quantify the benefits in both relative and absolute terms, but it leaves readers confused because of the shifting nature of the study cohort. It looks as if the study started with 17 patients but then later it says that the study looked at 14 patients. It says, \u201cThe researchers found that 18 percent of patients went into remission after 24 weeks, 36 percent (of 14 patients) after one year. After two years, of the 12 patients still in the study, seven patients (58 percent) were in remission.\u201d The change in the number appears to be because the researchers stopped doing the deep brain stimulation on three patients, a fact that is not fully explored in the story. This all would have been more easily explained and less confusing if the story had just stuck with the absolute numbers. If you try to do the math on 18 percent of 14 patients, for example, you get 2.52 patients. Was it two patients? Was it three?\nWhy not just tell readers x number out of x number?", "answer": 0}, {"article": "In macular edema, fluid from those damaged vessels leaks into the macula, the part of the retina that is responsible for the straight-ahead vision important for driving, recognizing faces and reading.\nHe said treatment with Lucentis in the clinical trial virtually eliminated those incidents.\nThe trial involved 691 patients, some of whom had both eyes treated, resulting in 854 total eyes.\nDr. Neil M. Bressler of Johns Hopkins University, the chairman of the group that conducted the trial, said a two-line improvement in vision would allow some people to read normal-size print or to drive again.\nAbout 1 percent of those getting Lucentis injections suffered an inflammation of the eye from an infection.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story provided quantitative information about the possible impact on vision. But we wish there information about any measurement of\u00a0 the patients\u2019 perspective on whether they are functioning better after receiving this treatment versus standard treatment", "answer": 1}, {"article": "Oral and injectable medications are also prescribed.\nHowever, previous research led by Dr. Zhovtis-Ryerson's group found extending the dose up to 8 weeks did not negatively affect the medication's efficacy in a retrospective sample of 2,000 people.\nThe new study, however, reports safety data through up to 72 months, or 6 years, when the extended dosing regimens were applied, with risk reduction for PML as high as 94 percent.\nResearchers reviewed data on all patients who have been exposed to JCV who are enrolled in TOUCH, the U.S. Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy (REMS) program for natalizumab that requires manufacturers to document all uses of a medication to ensure that the benefits of a drug outweigh its risks.\nThe new research showed that extending dosing of natalizumab from every 4 weeks to every 5 to 12 weeks significantly reduced the risk of developing progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal brain infection.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release mentions the main benefit of less frequent dosing of natalizumab (infusions every five to 12 weeks, instead of the standard every 4 weeks) as a \u201crisk reduction for PML as high as 94 percent\u201d up to 6 years. The news release mentions \u201cthe optimal extended dose schedule is not known.\u201d\nWhat we like news releases and news articles to provide readers are absolute risk reductions, rather than the relative risk reductions provided here.\nThe news release does make it clear that these results only apply to patients who test positive for antibodies to the JC Virus (JCV; the virus that causes PML) and this study did not look at drug efficacy comparing the extended to standard monthly dosing.", "answer": 0}, {"article": "March 30, 2011 -- Two highly anticipated hepatitis C drugs are poised to usher in a new era in the treatment of the viral disease as early as this summer, experts say.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\n\u201cTriple-drug therapy represents a major advance in the treatment of hepatitis C for patients,\u201d he says.\nResults from two phase III boceprevir trials are published in the New England Journal of Medicine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The piece presents the results in percentages; however, it would have been more meaningful to the reader if the story had also provided the actual numbers, particularly since it did not mention how many people were in each of the treatment arms. \u00a0In addition, one of the trials evaluated the efficacy of boceprevir in a black cohort\u2014a population group that usually does not respond as well to treatment\u2014but these results were not discussed in the story. Furthermore, the story does not provide any data for telaprevir, but only states that \u201coutcomes were similar\u201d to boceprevir.\n \n", "answer": 0}, {"article": "Early menopause is often a side effect for women treated with chemotherapy for breast cancer, but a new study reveals some guarded promise for preventing early menopause breast cancer patients.\nAn accompanying editorial by Dr. Hope S. Rugo and Dr. Mitchell P. Rosen of the University of California-San Francisco says that trptorelin therapy should not be recommended as a standard treatment and should be approached with caution in women with hormone-sensitive disease.\nItalian researchers conducted a phase three study that included 281 women with breast cancer, aged 18 to 45 years and who had not experienced menopause.\nFor younger women still hoping for children, these treatments can cause devastating short-term or long-term loss of menstrual periods, and loss of fertility.\nAmong the women who had received triptorelin, the rate of early menoapuse was 8.9%, which is 17% lower.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The primary benefit from the described approach to loss of fertility in women of child-bearing age with early-stage breast cancer was described as a lowered rate of early menopause.\u00a0 The article did an excellent job of putting this in perspective by including the editorial statement cautioning the reader to not equate resumption of menstrual cycles with preserved fertility.\n", "answer": 1}, {"article": "He whips up a homemade concoction using frozen elderberries, blueberries and honey.\nThe University of Maryland Medical Center says European elder, also called black elder, is the variety most often used for medicinal purposes.\nThat would be similar to prescription antiviral medications like Tamiflu or Relenza, which have been proven effective in much larger studies and approved by the FDA to shorten the duration of the flu.\nOne small study found an elderberry extract called Sambucol could shorten the duration of flu symptoms after a person gets sick by about 3 days.\nBut Kevin Brennan says, for his family, the natural alternative seems to be working.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While this story reports a specific claim of shortened flu symptoms, it also tosses in several vague claims about less severe and less frequent unspecified illness. The family that\u2019s the focus of the story seems to take elderberry to prevent illness, but the story doesn\u2019t tell us if elderberry has ever been shown to do that. Overall, the presentation is more likely to confuse than inform readers.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/01/17/national/a130050S19.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not provide enough information on\nthe effect of pain or the limits a hernia might place on daily activities. There is some information on this in the study in\nJAMA, but little is mentioned in story. 30% of the watchful waiting group decided to have surgery during the 4 years,\nthough reports of pain at 2 years were similar in both groups. More information on why they decided to have surgery and the\neffect of hernia pain on quality of life would be useful in order to better inform patients who are trying to make a choice.\nHowever, overall, this criterion was met. The reporter used absolute numbers, not just relative \u2014 always a good idea.", "answer": 1}, {"article": "For more about multiple sclerosis, visit the National Multiple Sclerosis Society.\n\"Although alemtuzumab [Lemtrada] treatment is associated with safety risks, those risks are manageable in most patients,\" Miskin said.\nStill, one MS specialist who reviewed the new study said patients need to be cautious about taking the drug.\n\"Although the safety profile is generally manageable for the right patient, risks probably outweigh benefits in patients with mild or early stage disease,\" Miskin said.\nThe decision to start Lemtrada should be made in the context of the risks, including infusion-associated reactions, infections, and autoimmune adverse events, she said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes\u00a0how the\u00a0researchers assessed disability levels at the start of the study and every three months for two years. By the study\u2019s end, nearly 28 percent of those given Lemtrada had improved by at least one point on a 10-point disability test, versus about 15 percent of those receiving interferon, the researchers found.\nBut the story said\u00a0the patients randomized to\u00a0Lemtrada were \u201c2.5 times more likely to have their thinking skills improve compared to those given interferon. And they were more than twice as likely to see improvement in their ability to move without tremor or clumsiness, the findings showed.\u201d\nWe need\u00a0absolute numbers to compare what the baseline levels (thinking skills, move without tremors) were, and more details on what \u201cimprovement\u201d means here, since this description alone doesn\u2019t tell us if patients improved a little bit, or a lot.\nAdditionally, this statement had us scratching our heads: \u00a0\u201cGiovannoni believes the drug could offer real relief from MS symptoms. Not only does alemtuzumab improve disability, but most patients go into long-term remission of at least five to eight years, he said.\u201d\nWhere did that determination come from? The study was only for two years and nothing presented within it showed remission.", "answer": 0}, {"article": "About the Society of Breast Imaging\n\nThe Society of Breast Imaging (SBI), established in 1985, is a professional medical organization dedicated to improving the practice of breast imaging and the quality of medical education in breast imaging.\nWASHINGTON, Sept. 29, 2015 /PRNewswire/ -- The American College of Radiology (ACR), Society of Breast Imaging (SBI) and major medical organizations experienced in breast cancer care continue to recommend that women start getting annual mammograms at age 40.\nFor information on mammography visit Mammography Saves Lives or the Society of Breast Imaging website.\nThe SBI also provides a medium for the exchange of ideas among those involved in breast imaging.\nThis approach saves many more lives than screening started at a later age or with less frequent exams.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There aren\u2019t any numbers on this, and it\u2019s a crucial part of the sales pitch. The release says that screening regularly starting at age 40 \u201csaves many more lives\u201d than screening later or done less frequently. But how many more lives are we talking about? A quick look at at hyperlink in the release \u2014 which takes you to the ACR-produced advocacy website mammographysaveslives.org \u2014 and clicking \u201cAre you confused?\u201d takes you to a page that suggests mammography has reduced the U.S. breast cancer death rate by 30 percent. But that\u2019s a relative risk reduction, and since the rate of breast cancer for women in their 40s is low, this figure may tend to inflate the size of the benefit for these women. \u00a0We would have preferred to see a number describing the absolute reduction in breast cancer deaths. For example, according to a recent US Preventive Services Task Force evidence review, screening mammography prevents 4 deaths for every 10,000 women who are screened for at least 10 years compared with no screening.\u00a0", "answer": 0}, {"article": ".\nOnly four pregnancies occurred among the men's partners during the efficacy phase of the study.\nDuring this period known as the efficacy phase of the study, the men continued to receive injections every eight weeks for up to 56 weeks.\nDespite the adverse effects, more than 75 percent of participants reported being willing to use this method of contraception at the conclusion of the trial.\nThe prospective Phase II single arm, multi-center study tested the safety and effectiveness of injectable contraceptives in 320 healthy men ages 18 to 45.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that hormone shots were effective at reducing sperm count to less than 1 million/mil within 24 weeks in 274 participants and was effective in nearly 96 percent of continuing users, with four pregnancies occurring among the men\u2019s partners during the efficacy phase of the study. It also stated that more than 75 percent of participants reporting being willing to use this method of contraception at the conclusion of the trial.\nThat\u2019s the plus side. One omission from the release was the absence of a control group. Without a control group it\u2019s not possible to accurately calculate the effectiveness. The study reported four pregnancies among the men taking the injection. How many pregnancies would be expected for a similar group not getting the shots? The news release doesn\u2019t say.", "answer": 1}, {"article": "Attention, memory, and language improved.\nBy sticking to the Mediterranean diet the study showed that people had slowed rates of cognitive decline, reduced conversion to Alzheimer's, and improved cognitive function.\nThe researchers stress that research in this area is important due to the expected extensive population aging over the next 20-30 years.\nTwo of the included studies focused on younger adults and they both found improvements in cognition using computerized assessments.\nMoreover, the benefits to cognition afforded by the MedDiet were not exclusive to older individuals.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release mentions three outcomes\u2014\u201cslowed rates of cognitive decline, reduced conversion to Alzheimer\u2019s, and improved cognitive function\u201d\u2014and explains those outcomes a bit more specifically lower in the text.\u00a0 But missing from the text is information supporting the benefit claims. Slower than what? Reduced relative to what? \u00a0Improved relative to what?\u00a0 Our criteria call for releases to report the risk reduction in absolute terms if at all possible, but this release gives no numbers at all.\u00a0 ", "answer": 0}, {"article": "SAN FRANCISCO \u2014 Tech company developer conferences always feature a wacky demo or three.\nThe goal of further research is to determine whether Emma Watch could help other people with similar Parkinson\u2019s symptoms.\"\nBut at Build 2017 in Seattle Wednesday, Microsoft went for the waterworks at the conclusion of CEO Satya Nadella's keynote address: it showcased a prototype watch that temporarily eliminated the arm shaking that often plagues those suffering from the neurological disease Parkinson's.\nAfter a speech that both heralded and warned about coming leaps in technological power, Nadella screened a video that told the story of two British Microsoft Research employees, Haiyan Zhang and Nicolas Villa, who developed the tremor-interrupting device for a BBC documentary, The Big Life Fix.\n\"Rather, its technology has the potential to help Parkinson\u2019s patients manage symptoms that impede regular functions.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It appears the \u201cEmma\u201d watch helped a patient regain some of her hand control, enough to draw her name (which was presumably impossible \u201cfor ages,\u201d according to the patient) and a cleanly drawn square (when her pre-watch attempt was squiggly). But how much are the watch and its vibrations actually helping and for how long \u2014 we don\u2019t know, because there\u2019s no control group. It\u2019s a sample size of one, and what\u2019s shown in the video may very well be a placebo effect without either the patient, designer, or anyone else knowing.\nOnly a well-designed research study could responsibly attempt to determine the benefits of this device or its durability, but there doesn\u2019t appear to be one. The story should have made this point very strongly.", "answer": 0}, {"article": "Wisdom teeth, also called the third molars, are four teeth that grow at the very back of each corner of the mouth.\nA simple surgical extraction for a wisdom tooth that's showing through the gums should run about $230, according to Healthcare Bluebook.\nThe question comes down to which side of the fence medical professionals fall on\n\nIt's worth noting that oral surgeons make a good chunk of their paychecks by removing wisdom teeth, so there is a financial incentive involved.\nAmericans spend an estimated $3 billion a year having their wisdom teeth removed\n\nSome doctors, though, still see preventative oral surgery as being two steps ahead of the problem.\nBut there's a serious debate between dentists and oral surgeons: should they preemptively remove someone's wisdom teeth if the patient doesn't have any symptoms?\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While thorough in its discussion of the potential benefits and risks of either preventative surgery or a \u201cwait and see\u201d approach, this story is rather thin on numbers. This is a deficiency we\u2019ll address here rather than under the \u201cHarms\u201d or \u201cEvidence\u201d criteria \u2014 both of which we rated as satisfactory.\nFor example, the story gives plenty of space to discussion of the benefits that may be realized with preventative wisdom tooth removal \u2014 including the convenience of being able to plan your surgery and recovery dates and a reduced risk of facing a more complicated extraction in the future. But it does not attach any numbers to these benefits. An expert story source points out that older people have a higher risk of complications, experience more pain due to more deeply rooted wisdom teeth, and face a longer period of recovery from surgery. But how much less often do these complications occur in younger people and how much shorter is the recovery time for earlier surgery?\nSimilarly, when discussing the benefits of a \u201cwait and see approach,\u201d the debate is framed in general terms and there is little quantification. The story notes that the risk of surgical complications may outweigh any benefit from preventative removal. But it would\u2019ve been nice to have some estimate of how frequently wisdom teeth will end up overcrowding if they are left in, or how often patients experience surgical complications if they opt for the preventative surgery.", "answer": 0}, {"article": "Then President Richard Nixon declared drugs \u201cpublic enemy No.\nIn the past 20 years or so, a small amount of research has once again begun to focus on these chemicals, showing that they have promise for treating a range of conditions, from addiction to depression and anxiety, says Evan Wood, a psychiatric researcher at the University of British Columbia.\nThat said, when studied under controlled and supervised conditions, these chemicals have not been found to cause lasting negative health consequences, the Canadian Medical Association Journal review noted.\nHe points out that psychedelics should never be used carelessly, and that the \u201cset and setting\u201d (meaning the dose, mood, environment, company and surroundings) where a person takes them are of paramount importance.\nAll of which adds up to a compelling argument that psychedelics \u201cshould be the focus of intensive study for treating mental illness,\u201d Wood says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Unfortunately the details on the various studies cited are few and far between, though the links to the actual studies are helpful for those wishing to dig deeper. \u00a0Because of the lack of quantification of benefits permeates the piece, it can only rate as Not Satisfactory.", "answer": 0}, {"article": "\"Previous patients got sick, but it wasn't clear at the time whether it was due to the T cells or an infection,\" said pediatric oncologist Stephan Grupp, who oversaw Emily's care at Children's Hospital of Philadelphia. \"Now we know the main reason they were sick was the cells. But now we can intervene. She taught us.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story focuses primarily on\u00a0one girl\u2019s miraculous recovery from leukemia. But unlike the competing New York Times piece, it\u00a0did provide the balancing perspective of other patients receiving this experimental treatment, at least one of whom has not\u00a0recovered completely. That gives a more realistic take on what the story calls the \u201croller-coaster learning curve\u201d associated with the treatment. The story\u00a0also largely refrained from using the hyperbolic language that was sprinkled throughout the Times\u2019 account.\nThe reader comes away with the idea that this is highly experimental and that only a handful of sustained remissions have occurred from a handful of attempts.", "answer": 1}, {"article": "Co-authors are: Leslie Donato, Ph.D.; Sandra Bryant; Grant Spears; Peter Berger, M.D.\nThe study found that individuals with the highest levels of blood ceramides were found to have a 3- to 4-times greater risk of having a cardiovascular event compared with those with the lowest ceramide score, regardless of their LDL cholesterol level or the presence of a blockage in the heart\u2019s arteries.\nIn patients without coronary artery disease following angiography, the rate of cardiovascular events was only 3.1 percent, lower than the average overall.\nIn the study, 499 Mayo Clinic patients who were referred for coronary angiography to check for possible artery blockages were included and followed prospectively for approximately eighteen years.\nBut when researchers examined cardiovascular disease in this population by ceramide scores, people with the highest levels of ceramides were four times more likely to have an event compared with those with the lowest (7.8 vs. 2.2 percent, respectively).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The primary benefit of the test is that it might enable doctors to identify people who are at higher-than-normal risk for heart attacks and strokes even though they have normal levels of cholesterol and show no evidence of heart blockages. The news release does a good job of explaining the likelihood of having a cardiac event for those with low versus high levels of blood ceramides. In particular, it reports both absolute and relative risk, noting that, among individuals with low LDL (bad cholesterol) levels, cardiovascular disease occurred in 3.7% of those with low ceramide levels but in 16.4% of those with high ceramide levels.", "answer": 1}, {"article": "It\u2019s actually a double breakthrough,\u201d said Professor Graham.\nThis discovery is akin to the revolutionary breakthrough made last century that confirmed folic acid supplementation can prevent spina bifida and other neural tube defects in babies.\nThis breakthrough, led by Professor Sally Dunwoodie from the Victor Chang Institute, has identified a cause of recurrent miscarriages as well as heart, spinal, kidney and cleft palate problems in newborn babies.\nThe landmark study found that a deficiency in a vital molecule, known as NAD, can prevent a baby\u2019s organs from developing correctly in the womb.\nWorld first research at the Victor Chang Institute has found that this deficiency can be particularly harmful during a pregnancy as it can cripple an embryo when it is forming.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release made no mention of any numbers or figures from the study that put the benefits in context. The release was also misleading since it implied that vitamin B3 supplements could prevent miscarriages and birth defects in humans when this has never been directly studied. \nThe release seems to combine two sets of research findings: The first is from a 12-year study of 13 human families that found the genetic causes of a rare birth defect called VACTERL association (the cause was found to be a deficiency of the molecule NAD).\nThe second study was done in mice, who were genetically mutated to have an NAD deficiency, and then were given niacin. The researchers reported that these mice had offspring with fewer birth defects. \nCrucially, however, the theory that niacin can prevent birth defects or miscarriages has never been tested in humans. The release was worded in a way that is very misleading considering the amount of human research that still needs to be done.", "answer": 0}, {"article": "The results were published in Wednesday\u2019s edition of the Journal of the American Medical Assn.\nIn an editorial that accompanies the JAMA study, they write that the discrepancy \u201cmay be attributable to changes in diagnosis and surveillance but also may reflect a concurrent real increase in the risk of ASDs attributable to as-yet undescribed risk factors and exposures.\u201d They also note that data from the National Health Examination and Nutrition Survey published in 2009 show that the typical American consumes only 150 mcg of folic acid per day even with mandatory fortification.\nIt\u2019s unclear how these findings apply to mothers and children in the United States.\nThe researchers also found that the popularity of folic acid supplements rose as time went on.\nThese children were more likely to be born to women who did not take folic acid.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story reports both the raw data differences in autism risk between the folic acid and non-folic acid groups (a 2-to-1 difference) and the much smaller 39 percent difference the researchers reported after adjusting for education and other maternal characteristics. However, by stating the overall absolute risk of a child with autism as 0.13% instead of about 1 in a thousand, readers of this story may not get as good an understanding of the absolute risks as readers of the Reuters Health story we also reviewed.", "answer": 1}, {"article": "Psilocybin acts on the serotonin system, suggesting it could be developed for treating depression.\nA small-scale pilot study of psilocybin\u2019s use in cases of treatment-resistant depression showed it was safe and effective, the British researchers said.\nRobin Carhart-Harris, who led the study at Imperial College London\u2019s department of medicine, said the results, published in the Lancet Psychiatry journal, were striking.\nThe trial involved six men and six women, aged between 30 and 64, all diagnosed with treatment-resistant depression.\nThe patients were given psilocybin capsules during two dosing sessions, seven days apart.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does offer some specific information about the outcomes of treatment for the 12 individuals in the study. Ideally it would have explained how those outcomes were actually measured\u2013how did researchers measure what \u201csome decrease\u201d in symptoms meant? The same with \u201cpositive response.\u201d", "answer": 1}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is tricky. We had a couple of issues with the way in which the benefits are described. The use of relative changes (\u2018\u2026reduced relapses among MS patients by 54%. Disability progression was reduced by 30%, using a standard measurement of this process.\u201d) and comparisons to other drugs studied in other clinical trials without a bit more clarification was troubling. Patients with the most common form of MS suffer between 0.4 and 0.6 relapses a year (according to Up to Date). Although the story does note that, \u201c..it is difficult to directly compare two different clinical trials,\u201d it does this anyway. Providing apparently comparative data from different studies does not educate the reader on the relative value of different treatment options. A few extra words would have clarified: \u201cNone of the available drugs to treat MS have been compared directly in a large enough clinical trial to identify true differences.\u201d", "answer": 0}, {"article": "Grocers shelves add new coconut-water products regularly.\nEven so, Little, a coconut enthusiast, doesn\u2019t recommend loading up on coconut fats.\nIt\u2019s simple all the way around.\u201d\n\nOne tablespoon of coconut oil contains 120 calories and 14 grams of fat, 12.5 grams of which is saturated.\n\u201cIt\u2019s a holistic approach.\u201d\n\nThe fruit\u2019s appeal rests, in part, on this versatility.\nThat translates into a broad slate of products.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "For all the claims being made in this story, not a single benefit is quantified.", "answer": 0}, {"article": "People who were given the 60 mg doses saw a nearly 16 percent reduction in the amount of amyloid, and those given the 200 mg doses saw a 36 percent reduction.\nThere are approximately one dozen therapies, including vaccines, for Alzheimer's disease that are currently in the pipeline, Lyden noted.\n\"This is problematic in that use of these treatments may carry a very high risk for neurologic complications, thus necessitating heightened monitoring, and diminishing its applicability as a treatment for a larger patient population such as the Alzheimer's disease population,\" she said.\nThe new study, which appears online Oct. 10 in the Archives of Neurology, is among the first to show the effects of an anti-amyloid drug in humans with Alzheimer's disease, but experts caution that while promising, more research is needed before this drug can be deemed safe or effective.\nThe hope is that gantenerumab or other drugs like it will not only prevent amyloid from accumulating in the brain, but also slow down the cognitive impairment that occurs in people with Alzheimer's disease, she added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately described the responses of study participants at different dose levels. And it clearly established that \u201cit\u2019s by no means certain that reducing levels of amyloid plaque would stave off memory loss and other mental declines.\u201d\nOther important caveats included:", "answer": 1}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\n\u201cAfter following patients for more than five years, we found that serious side effects from a brief course of SBRT were uncommon and that cancer control rates were very favorable compared to historical data.\nIn low-risk patients, the cancer control rates was superior to historical controls.\nActuarial five-year nadir+2 RFS was 97.1 percent for all patients, representing 97.3 percent of low-risk and 97.1 of intermediate-risk patients.\nBiochemical failure was assessed using the ASTRO-consensus and the nadir+2 definitions.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release gives a lot of data. It states that 97 percent of patients were free from prostate cancer progression after five years, exceeding a historical control of 93 percent. It also says that fewer than 2 percent of patients experienced severe toxicities in their gastrointestinal, reproductive, and urinary systems, and no patients reported life-threatening or fatal toxicity. However, the news release does not attempt to say how these rates compare with other treatment options, which would help readers put the data in perspective. There are important caveats left out in the description of findings that are discussed under the evidence criterion.", "answer": 1}, {"article": "The skin, she says, \"has been irreparably damaged by the stretch [and it] doesn't shrink down like the rest of the body does.\nSeven weeks after surgery, Baez concluded the pain and effort had been worth the result: an end to the recurrent skin infections in her thighs and abdominal folds.\nIntense discomfort that interferes with activity is a common problem after bariatric surgery, says plastic surgeon Sarah Holland, an instructor at Columbia University Medical Center in New York -- and it can be almost constant.\nWhile the surgical techniques used in contouring operations have been around for decades, bariatric patients present \"a unique challenge\" to plastic surgeons, says D'Amico.\nThat should be the norm, says Holland.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article did not provide any data indicating the percentage of individuals who had had plastic surgery to remove excess skin after weight loss surgery who were satisfied with the outcomes. The perspective of a single patient was presented, concluding that for her \u201cthe pain and effort was worth the result. \u201d But the reader has no idea if this is typical or not.", "answer": 0}, {"article": "\"You start doing research on that type of tumor, and you're saying, 'Oh my God, you're history.'\nThe chemo failure was the latest in a string of personal setbacks.\nThere are side effects, of course.\nMore doctors are taking advantage of the information to treat patients with a targeted approach.\nBut in the meantime, patients like Anselmo are grateful to have time they wouldn't have had otherwise.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are described as extending a person\u2019s survival while increasing her quality of life, and a number\u20131 year, so far\u2013is attached to the treatment. The story also includes this quote from a researcher, which clarifies that the treatment is not expected to work indefinitely:\u00a0\u201cWe all have patients that have been on these drugs for years. But I don\u2019t know, I mean, I think if I was being honest eventually our expectation would be that it would stop working.\u201d\nWe\u2019ll call this good enough for a Satisfactory rating, but it would help to have more context here. For example, the article could have stated the median survival for the typical adult diagnosed today with glioblastoma, which is\u00a0about 15 months. It would also be useful to know if there are studies of patients similar to the one profiled here, and what their experience has been. That\u2019s a deficiency we\u2019ll address below in the Evidence section.", "answer": 1}, {"article": "The decrease we saw was larger than is seen with the currently used medications,\" Lanctot said.\nHowever, many study patients suffered from sedation due to the drug, noted Keith Fargo, director of scientific programs and outreach at the Alzheimer's Association.\n\"We hoped it wouldn't have the side effects associated with cannabis, but would have the calming effects.\"\n\"There's virtually no data on whole-plant marijuana, whether or not it's effective or safe in people with Alzheimer's disease.\"\n\"It's a milder form of TCH\" compared to whole-leaf marijuana, Lanctot said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says 36 patients were treated for 6 weeks with nabilone, followed by 6 weeks with placebo. While taking nabilone, the patients experienced a \u201csignificant decrease in agitation \u2026 the decrease was larger than is seen in currently used medications.\u201d\nHow this was measured, the dosage used, and what the quantitative changes were, are not provided.", "answer": 0}, {"article": "A sticky mucus clogs organs, particularly the lungs and liver.\nIn an editorial accompanying the study, Dr. Pamela Davis, of Case Western University paraphrased Winston Churchill, \u201cThis study is also a great victory in the war against genetic diseases and marks the end of the beginning for the treatment of the cystic fibrosis defect.\u201d\n\nIvacaftor has been submitted to the FDA for approval, and could be available next year, according to Konstan.\nThat trial is ongoing and the treatment is at least four or five years away from approval, but if it works, Beall says, it could help 90% of the people with cystic fibrosis.\nHe points to other research under way with ivacaftor combined with another drug that could help people with the most common mutation of cystic fibrosis.\n\u201cThis is the first time that we have a therapy that is directed at the cause of cystic fibrosis,\u201d says Dr. Michael Konstan, the chair of the Department of Pediatrics at Rainbow Babies and Children\u2019s Hospital in Cleveland and one of the authors of the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nAlthough this story accurately reports the specific results of this drug trial, including lung function, disease symptoms, weight and sweat chloride (a measure of disease); it misses important aspects of the big picture. As the journal editorial accompanying this research report noted, the trial does not prove that this drug halts the progression of disease or that patients who take the drug will live longer.\nThe story could also have been clearer about the distinction between the small percentage of patients who have the specific gene mutation that is the target of this drug and the 90 percent of cystic fibrosis patients who have a different mutation that may not respond to this treatment. The editorial notes that the complexities of CF \u201csuggest that no single drug will be entirely suitable as a therapeutic agent.\u201d Readers should have been given this important context. \nWhen the story reported that patients doubled their ability to walk, it should have noted that this apparent benefit was not something that was measured as part of the formal trial.", "answer": 0}, {"article": "However, relatively little research has been conducted into ketamine's antidepressant effects in adolescents.\nJames Stone, a clinical senior lecturer from the Institute of Psychiatry, Psychology and Neuroscience at King's College London, who was not involved in the study, told Newsweek that there is \"a lot of potential for the use of ketamine as a second or third line antidepressant where other treatments have failed.\"\nThe study serves to point out the need for further, rigorous, study designed to answer the many questions that remain about ketamine for TRD, such as optimal dosing and route of administration, dosing interval and treatment length, and long-term effects\u2014just to name a few.\"\nHowever, they note that the study was limited by its small sample size, so future research will be needed to confirm these results.\nFive of the participants met the criteria for clinical response and remission.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did the bare minimum, pointing to \u201can average decrease of 42 percent\u201d in criteria contained in a depression assessment tool. It also stated that five of the 13 participants \u201cmet the criteria for response and remission\u201d and three of those were still in remission after six weeks, with the remaining two relapsed within two weeks.\nThe story would have served readers better by emphasizing those figures higher up and spelling out what \u201cresponse and remission\u201d mean in terms of a patient\u2019s symptoms.", "answer": 1}, {"article": "But this study doesn't tell us about long-term outcomes or what transpired over a long period of time,\" he said.\nAnd the women who were screened earlier had smaller tumors.\nOne group had a mammogram within the 24 months before their breast cancer diagnosis.\nAnd Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, noted that this was an observational study that only looked at the experience of one institution.\nPort noted that screening guidelines tend to be based on the ability of mammograms to save lives and how often they give a false positive result.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story detailed the relative harms of earlier mammograms, but did not translate those percentages into absolute numbers. For instance, women who were diagnosed with breast cancer 25 months or more after their last mammogram were \u201c50 percent more likely\u201d to need chemotherapy,\u00a0\u201c32 percent more likely\u201d to need mastectomy, and \u201c66 percent more likely\u201d to need lymph nodes removed. However, relative risk can be misleading, sometimes inflating numbers to sound scarier than when absolute numbers are used.\nAlso, we don\u2019t know what kind of risk these women had at baseline, so it\u2019s hard to know if they were higher risk.", "answer": 0}, {"article": "But are they receiving it?\nThis fear, however, is not based on actual evidence and cannot be used to suppress or otherwise keep the public uninformed of what is clearly known about the lower risks of these products,\u201d adds Kozlowski, PhD, one of the world\u2019s leading researchers on smoking behavior.\nA briefing posted on the site specifically states: \u201cCompared to tobacco products, electronic cigarettes are significantly safer.\u201d\n\nIn their paper, the researchers note that information on comparative risks is common for other products and activities, like over-the-counter medicines and even safety ratings of vehicles.\n\u201cYet, such facts are being kept from adult consumers of legal tobacco/nicotine products, either by not informing or actively misinforming consumers.\n\u201cThe public is dramatically misinformed about the relative risks of substitutable tobacco and nicotine products.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release gives the example that 3 in 5 regular users of cigarettes die prematurely, while smokeless tobacco products cause \u201cmassively fewer deaths.\u201d\nA\u00a0news release that is going to focus on risk reduction needs either better quantification of that risk reduction, or a sentence explaining why a more detailed description of the risk reduction is not possible.", "answer": 0}, {"article": "\"I just didn't want to do that for my children.\nIt confirms what smaller studies have suggested in the past: Women who have a family history of breast cancer can greatly reduce their chances of getting the disease by having a double mastectomy.\nWomen like Toby who chose both ovary and breast removal had dramatically lower risks of getting both cancers after the surgery.\nThe study findings are extremely reassuring to Rebbeck -- no breast cancer diagnoses among women who had double mastectomies after three years of follow-up.\n\"We found mastectomy provided huge risk reduction of subsequent breast cancer diagnosis and death.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThe findings of this study do provide new evidence of benefits of preventive surgery for women with BRCA1/2 gene mutations. However, the story does not provide a balanced or complete picture. It reports only relative risk reductions without also including the absolute numbers of women who did or did not develop cancer. Also, the story includes a quote from a researcher claiming mastectomy reduced the risk of death, but the study did not report that outcome. While none of the women who had a preventive mastectomy was diagnosed with breast cancer during the study \u2013 and the women who had their ovaries removed were less likely to die \u2013 the researchers did not report that mastectomy reduced the risk of death for these women.\nAlso, the only woman included in this story was someone who had preventive surgery and did not develop disease. The story obscures the fact that the overwhelming majority (93%) of women chose not to have surgery also did not develop cancer during the course of the study.\n", "answer": 0}, {"article": "March 7, 2011 -- Traditional Chinese acupuncture may be useful in reducing the severity of hot flashes and other symptoms of menopause, a new study suggests.\nA five-point scale was used to measure the severity of hot flashes, vaginal dryness, urinary symptoms, mood swings, and other symptoms in the postmenopausal women.\nTwenty-seven women received traditional Chinese acupuncture twice a week for 10 sessions from an experienced and licensed acupuncturist.\nThose in the comparison group were treated with shams needles at the same acupuncture points.\nThe rest were treated with \u201csham\u201d acupuncture needles that were blunted and did not penetrate the skin.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story told us that a five-point scale was used to measure the severity of symptoms.\u00a0 That\u2019s better than the HealthDay story did.\u00a0 But only slightly better because the story never went on to tell us how much the scores dropped on that scale.\u00a0 So the story didn\u2019t give any sense of the scope of the benefit, using just vague, nonspecific language \u2013 \u201csignificantly lower scores.\u201d\nBy saying \u201csignificantly lower\u201d and never providing real numbers, the story leads readers to believe the evidence is definitive. Some readers may never even reach the bottom of the story. They will see the headline and the lead and assume that acupuncture may be right for them.", "answer": 0}, {"article": "But when it recurs and becomes metastatic, it's very difficult to treat,\" she explained.\nMore than one-half of the women responded to the combination treatment (meaning the tumor volume decreased) versus only about one-third of those receiving chemo alone.\nBut caveats notwithstanding, she concluded, the results may herald improved therapy \"for an underserved subgroup of patients with breast cancer.\"\nO'Shaughnessy, who is co-director of breast cancer research at Baylor-Sammons Cancer Center, US Oncology, and Texas Oncology in Dallas, said the results of a larger (about 500 patients) phase 3 trial should be available within one to three months.\nA similar drug, in fact, has shown benefit in patients with BRCA 1 or BRCA 2 mutations predisposing them to breast and ovarian cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are quantified.\u00a0 Women who received Iniparib plus chemotherapy lived an average of 12.3 months while those receiving chemotherapy alone lived an average of 7.7 months.\u00a0 Tumor volume decreased\u00a0in 50% of the women receiving Iniparib & 33% of women receiving only chemotherapy.", "answer": 1}, {"article": "Dr Golam Khandaker, who led the study, says: \"It's becoming increasingly clear to us that inflammation plays a role in depression, at least for some individuals, and now our review suggests that it may be possible to treat these individuals using some anti-inflammatory drugs.\n\"It's too early to say whether these anti-cytokine drugs can be used in clinical practice for depression, however,\" adds Professor Peter Jones, co-author of the study.\nAnti-inflammatory drugs similar to those used to treat conditions such as rheumatoid arthritis and psoriasis could in future be used to treat some cases of depression, concludes a review led by the University of Cambridge, which further implicates our immune system in mental health disorders.\nMeta-analyses of the other types of clinical trials showed similar results.\nThe team of researchers carried out a meta-analysis of these clinical trials and found that the drugs led to an improvement in the severity of depressive symptoms independently of improvements in physical illness.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no indication of how much these anti-inflammatory drugs help relieve depression because the anti-depressive effect was a secondary effect of these clinical trials. It would be nice to know how they rated the effects on depression, but that information is not included.", "answer": 0}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explicitly notes more than once that there are no clinical trials or peer reviewed publications to support the claims\u2013and therefore no quantifiable data.\nIn the absence of medical evidence, the story uses a doctor\u2019s claims and a patient\u2019s experience to discuss what the benefits might be. The doctor\u2019s enthusiastic claims are balanced well by an independent expert who discusses the potential drawbacks.\nTo help better balance the piece, we do wish the story also had presented a range of patient opinions, instead of only a favorable one.", "answer": 1}, {"article": "May 14, 2012 -- Acupuncture may allow people with the lung disease COPD (chronic obstructive pulmonary disease) to breathe a bit easier.\nIn a new study of 68 people with COPD, some got acupuncture, along with their daily medication, for three months.\nThe study showed that acupuncture may improve stomach function, making it easier for people with COPD to eat a healthy diet and maintain a normal weight.\nMany people with COPD have problems getting optimal nutrition because of their condition.\nThose who received acupuncture along with their daily medication for three months were able to walk longer without becoming breathless, compared to those who got the sham acupuncture treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article did not quantify any results from the study. It didn\u2019t quantify the size of the benefit?\u00a0 Was this a real \u201cgame changer\u201d or statistically significant while offering little real improvement in daily activities? How many acupuncture treatments did participants experience before seeing improvements in their quality of life? How much longer were these participants able to walk without becoming breathless? And how were improvements in quality of life measured by the researchers? The story also mentions that acupuncture \u201cmay improve stomach function,\u201d but how was this measured? None of these data were discussed further.", "answer": 0}, {"article": "However, there is a caveat.\nAnd while many medical groups recommend daily aspirin to lower heart disease risk, not all federal agencies agree.\nThe Food and Drug Administration actually issued a warning against routinely taking aspirin to prevent heart disease in people without significantly high risk.\nAdults between the ages of 50 and 59 who have a 10 percent or greater risk of having a heart attack or stroke in the next 10 years benefit the most from taking about 81 milligrams of aspirin every day, the panel says.\nConcerns have been raised about whether aspirin is really effective enough, when so many other medicines are available to help control heart disease risk.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is clear about age ranges and health conditions that may make taking aspirin useful but does not offer any quantitative translation of the extent of benefits for these groups.\u00a0 It similarly doesn\u2019t make the quantitative case for the dearth of benefits for individuals who fall outside of these conditions.\u00a0The recommendations issued by the U.S. Preventive Services Task Force (USPSTF) suggest that the absolute benefit is in fact quite modest, unless you are already at high risk for cardiovascular diseases.", "answer": 0}, {"article": "For example, insulin resistance, where the body does not use insulin effectively, occurs long before blood sugars reach the level seen in type 2 diabetes.\n\"These findings could provide insight into metabolic pathways that are altered very early in the process leading to diabetes,\" says researcher Thomas Wang, MD, of Massachusetts General Hospital's Cardiovascular Research Center, in a news release.\nResearchers found that blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes in otherwise healthy adults as well as in those with traditional risk factors such as obesity.\nResearchers say metabolic abnormalities that eventually lead to type 2 diabetes can be present years before diabetes is diagnosed.\n\"They also raise the possibility that, in selected individuals, these measurements could identify those at highest risk of developing diabetes so that early preventive measures could be instituted.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The claim high in the story that \u2018blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes\u2019 sounds a little too\u00a0premature. This wasn\u2019t a screening test that reaped any results from patients. It was lab research that is\u00a0several steps behind any actual screening test. This may be why neither the study nor news release use the words screen or screening. \nThe researcher\u2019s press release quote promotes the idea that in the future we could have a screening test that could identify people at high risk for diabetes, which would lead to early intervention. That would be a nice benefit. Unfortunately this research does not say it\u2019s possible. What if, by the time you have elevated amino acids, it\u2019s too late? What if these amino acids\u00a0reflect genetic or largely nonmodifiable risk factors for diabetes?\u00a0The story has\u00a0arrived early to a party that\u2019s not on the calendar yet.\n", "answer": 0}, {"article": "The development has been complicated by the fact that the organism that causes leprosy cannot be grown in culture in the laboratory,\" Reed explained.\nBased on data generated in preclinical studies, the vaccine candidate, called LepVax, has progressed to Phase I clinical testing in the United States, the first stage of safety testing in human volunteers.\nThe vaccine candidate will serve as part of an overall strategy to end leprosy, which will require detection, prevention and treatment.\nThe clinical trial is focused on safety, as well as evaluating the immune response to the vaccine.\nThe vaccine was developed through significant efforts in screening and identifying M. leprae proteins that trigger an effective immune response.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does note that the study will be focused on safety and immune system response which earns a minimal Satisfactory rating for clearly establishing the purpose of a phase 1 study. \nThere is currently no information on how effective this vaccine is in human subjects. There is also no mention of how this vaccine weakens the mycobacterial load in those already exposed.", "answer": 1}, {"article": "Animals such as scorpions have venoms that block potassium and other ion channels.\nWhen the researchers treated rat models of the disease with iberiotoxin, they stopped the progression of the disease.\nCurrent treatments target the immune cells involved in the disease and none are specific for FLS.\n\"In previous work, we identified a potassium channel on FLS of patients with rheumatoid arthritis and found that the channel was very important for the development of the disease,\" Beeton said.\n\"We think that this venom component, iberiotoxin, can become the basis for developing a new treatment for rheumatoid arthritis in the future.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release says treatment with iberiotoxin \u201cstopped the progression of the disease. In some cases they reversed the signs of established disease, meaning that the animals had better joint mobility and less inflammation in their joints.\u201d\nThere\u2019s no data to quantify the amount of improvement that was observed. The abstract of the study also lacked any information about the degree of the improvement in rheumatoid arthritis symptoms.\nThe main point readers should keep in mind is that\u00a0 this is an early animal study and it would be inappropriate to make projections about its usefulness in humans.", "answer": 0}, {"article": "For further information, please contact:\nThe previously unrecognized PMS/PMDD benefit of PS Plus came about when 2,000 volunteers received and consumed Lipogen's PS Plus for brain health and stress management.\nThese symptoms qualify as PMS in 20% to 30% of pre-menopausal women.\n\"We also have begun an ongoing, double-blind, randomized, placebo-controlled clinical trial with daacro GmbH, Trier, Germany, to learn more how Lipogen's formulation can help alleviate PMS and PMDD symptoms.\nUp to 80% of women report having some symptoms prior to menstruation.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The description of the benefits is very poor, vague and unscientific. No information is given on study participants such as ages, inclusion criteria, type of symptoms, duration, and severity of symptoms at baseline and post-intervention. The release does report that 23 out of a subset of 220 women among\u00a02,000 volunteers who took PS Plus for brain health and stress management over a two-month period, \u201cnoticed relief of premenstrual syndromes.\u201d The company claims these are \u201cstrong\u201d results.", "answer": 0}, {"article": "It\u2019s of phenomenal significance in that regard,\u201d he told Reuters.\nExperts described the study results as phenomenal and said the device, developed by German researchers, could eventually change the lives of up to 200,000 people worldwide who suffer from blindness due to a degenerative eye disease called retinitis pigmentosa.\nThe implant device, which sits completely within the eye, is a tiny plate, measuring just 3 mm squared and a 10th of a millimeter thick, which has around 1,500 tiny light sensors connected to amplifiers and electrodes.\nZrenner said further trials of the implant should be completed in two to three years and if those proved successful the device could be on the market and available for thousands of patients in about five years\u2019 time.\nEberhart Zrenner, chairman of the University of Tuebingen Eye Hospital in Germany and director of a small company called Retinal Implant AG which is developing the device, said the trial results were a \u201cproof of concept\u201d and would now be taken into further trials in around 25 to 50 patients in Europe.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Beyond saying in the lead that three people were able to \u201csee shapes and objects,\u201d there is not much else in the story to help readers understand the levels of vision improvements that were seen and how those should be compared to the preexisting conditions or other treatments. Then, confusingly, the story narrows its focus to just one patient saying, \u201cone blind patient who had the device implanted was able to identify and find objects placed on a table in front of him, and was able to walk around a room independently.\u00a0He could even read a clock face and differentiate between seven shades of grey, the researchers said. Tests were conducted starting from seven to nine days after the device was implanted.\u201d It\u2019s tough when writing a story about a study this small to put hard numbers to the benefits, but even some acknowledgment of this limitation would have been better than some of the overly optimistic sentiments expressed. The study itself and the press released provided more ways for the story to quantify the benefits.", "answer": 0}, {"article": "In an interview, Sakoda said, \"Metformin use was not associated with lung cancer risk when we looked at all patients with diabetes.\nOur results suggesting that the risk associated with metformin might differ by smoking history were unexpected.\nAssiamira Ferrara, Charles Quesenberry Jr., and Laurel Habel, coauthors on this study, have received research funding from Takeda to Kaiser Foundation Research Institute for a study of pioglitazone and cancer and from Sanofi through a subcontract from University of North Carolina to Kaiser Foundation Research Institute for a study of insulin glargine and cancer.\nThe researchers conducted this study to further clarify the association between metformin use and lung cancer risk.\nDuring 15 years of follow-up, 747 patients were diagnosed with lung cancer.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We appreciate that the release attempts to quantify the reduction in risk associated with metformin use. However, there\u2019s a problem with the release\u2019s description of these results. The\u00a0research paper\u00a0points to\u00a0a statistically significant reduction in lung cancer risk only among diabetic patients who have never smoked. But the release generalizes this finding to all \u201cnonsmokers.\u201d The release doesn\u2019t delineate between people who have never smoked and those who did smoke but quit. The benefits appear to apply only to the group of never smokers. This is an important distinction.", "answer": 0}, {"article": "Most American women begin to experience menopause around age 50, with some changes in their menstrual cycles earlier.\nThe doctors emphasized not just the medical benefits, but that the treatment can enable and boost a woman\u2019s overall day-to-day existence, too.\n\u201cThis requires a thorough exam and a thorough history, and individualized care, but women need to know: It\u2019s not a death sentence or a dependence.\nThe sheer number of choices today and the need for a thorough initial health assessment make the decision on hormone therapy highly dependent on close communication between a woman and her doctor, experts say.\nDr. Noushin A. Firouzbakht, an obstetrician-gynecologist at Texas Health Harris Methodist Hospital Fort Worth, says that despite the alarm provoked by the Women\u2019s Health Initiative study, much was learned, especially about the ideal candidate for hormone replacement.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Vague references to potential benefits of HRT with statements such as:\n\u201c(Drs) Johnson, Firouzbakht and other experts will tell you that hormone therapy protects against heart disease, a much more common killer of women than breast cancer, as well as against dementia, colon cancer, osteoporosis and other health issues.\u201d\nFirst, who are these \u201cother experts\u201d and where are the appropriate references for these claims?\nSecond, re-analysis of the data from the Women\u2019s Health Initiative study shows:", "answer": 0}, {"article": "\"What we wanted to find out was: 'Would cooling the surface of the brain of insomnia patients result in lower metabolism and improved sleep?\nThe cooling cap was, however, associated with an increased amount of slow-wave sleep -- or the deepest, restorative portion of sleep, the researchers reported.\nPrevious research has shown that the brains of people with insomnia are \"hyperaroused\" and have a higher brain metabolism in the frontal lobes, which helps explain why they have trouble drifting off to sleep and staying asleep, said study co-author Dr. Daniel Buysse, a professor of psychiatry and clinical and translational science at University of Pittsburgh School of Medicine.\nIn this preliminary study, about three-quarters of those with insomnia said the cap helped them sleep better when the water temperature was about 57 degrees Fahrenheit.\nAt higher temperatures -- 72 and 86 degrees -- patients reported no benefit, according to the study presented Monday at SLEEP 2011, the Associated Professional Sleep Societies meeting in Minneapolis.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t adequately place the findings into context.\nIt stated:\u00a0 \u201cWhile wearing the cooling cap, it took insomnia patients an average of 13 minutes to fall asleep and they spent 89 percent of their time in bed actually sleeping, about the same as controls who didn\u2019t have insomnia (the latter group averaged 16 minutes to fall asleep and 89 percent of the time in bed sleeping).\u201d\nBut it didn\u2019t ever define the baseline degree of insomnia these trial patients experienced.\u00a0 In other words, how long did it usually take them to fall asleep and what percent of thier time in bed did they usually sleep?", "answer": 0}, {"article": "Sumathi Reddy has details on Lunch Break.\nBut some researchers are investigating the beneficial bugs for conditions that have nothing to do with the digestive tract.\nThey are live microorganisms\u2014or \"good\" bacteria\u2014that when consumed in capsules or yogurt are said to confer a health benefit.\nProbiotics, believed to help with digestion, are increasingly being studied to treat wide-ranging conditions, from colic to cholesterol and the common cold.\nProbiotics are widely used to aid digestion and help restore gut bacterial balance after antibiotics.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the story doesn\u2019t make any\u00a0extravagant claims regarding the benefits of probiotics, it doesn\u2019t attempt to quantify the benefits that it does mention. That might be helpful, for example, when the study mentions that probiotics may \u201creduce the symptoms and recovery time for the common cold.\u201d In one trial that is\u00a0frequently cited to support\u00a0claims that probiotic yogurts prevent the common cold, researchers found that children would have to\u00a0consume probiotics every day for 100 days to prevent two days with cold symptoms. That kind of context would help readers determine whether the benefits are worth the expense and hassle.\nThis is the major shortcoming of the piece.\u00a0 Many alternative therapies are found to have \u201cbenefit\u201d in short and poorly conducted trials.", "answer": 0}, {"article": "People with abdominal obesity are at higher risk of heart disease and early death than people with slimmer waistlines.\nIn effect, those guidelines say there's no particular benefit from working out harder, other than saving time.\nThat intensity was equivalent to brisk walking for the previously sedentary participants, Ross told Shots.\nThe result makes sense, since there's some previous evidence suggesting that higher-intensity exercise is tied to improving how the body processes sugar, said Neal Pire, an exercise physiologist who puts together medically based training programs at HNH Fitness in Oradell, N.J., a program of Holy Name Medical Center.\nThe rest of us want to know how much we have to exercise to see health benefits.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story (complete with table) did a fair job of balancing a digestible message with the caveats of research. It tells us that all the exercise groups lost about 2 inches off their waistline and about 5% to 6% of their bodyweight. Since average people don\u2019t really think about weight loss in terms of \u201cpercentage bodyweight,\u201d however, it would have been better for the story to tell us how much participants weighed at the start of the study and how much weight each group lost in pounds.\nAnd while the story suggests that brisker walking gives more benefit by improving glucose tolerance, it expressly cautions that this change may not be meaningful to patients: \u201cIt\u2019s unclear whether the 9 percent improvement seen will be enough to cut their risk of heart disease, though.\u201d That\u2019s a useful distinction.", "answer": 1}, {"article": "The Food and Drug Administration does not endorse DHA or fish oil capsules, but recognizes doses of up to 3 grams a day of fish oil as generally safe.\nBut, she adds, epidemiological studies consistently show positive health effects from fish consumption on mortality, cardiovascular risk factors and, now, dementia.\nEating fish is not a guarantee of having high levels of DHA.\nDr. Ernst J. Schaefer, the lead author of the study, was cautious in interpreting the results.\nThe average level of DHA among all the participants was 3.6 percent of all fatty acids, and the top 25 percent of the population had values above 4.2 percent.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Early in the story, it mentioned that the\u00a0research involved 899 people and that 99 people developed dementia during the course of the study.\u00a0 This works out to a total incidence of dementia of 11%, something that was not explicitly stated in the story.\u00a0 The piece then went on to discuss that\u00a0 that two\u00a0or more servings of fish a week reduced the risk of dementia by 39%.\u00a0 This is a relative risk reduction.\u00a0 Before readers can put that in context, they would really need to have the absolute risk of developing dementia. \u00a0 (Read more about absolute vs. relative risk.) \nWhile it is true that the original source piece for this story did not contain this information, the story could have raised the question.", "answer": 0}, {"article": "\u201cThat\u2019s a simple enough statement, and people are not put off by that,\u201d she said.\n\u201cWe are now trying to see if people can learn, perform and have continuing confidence without the physician reinforcement,\u201d said Robinson.\n\u201cTheir confidence level goes up and plateaus at eight to 12 months, and it doesn\u2019t go down,\u201d said Robinson.\nThe new results show people can ask friends or relatives to help examine their bodies for suspicious moles, said Robinson.\n\u201cThere was concern that they might be embarrassed by examining areas of the body that aren\u2019t normally seen close up,\u201d said lead author Dr. June Robinson, of Northwestern University Feinberg School of Medicine in Chicago.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The research letter in JAMA\u00a0Dermatology\u00a0used survey questions to assess the confidence and embarrassment that partners\u00a0felt when helping to search for cancerous moles. The story from Reuters\u00a0reported the survey results, though it didn\u2019t quantify them:\nAmong people who received the skin exam training, the researchers found a steep increase in their confidence at performing skin exams between the start of the study and four months later.\n\u201cTheir confidence level goes up and plateaus at eight to 12 months, and it doesn\u2019t go down,\u201d said Robinson.\nThe exams didn\u2019t become more embarrassing or less comfortable, either.\nBut, we\u2019re left to wonder: How much did their confidence levels go up? When the study or news release doesn\u2019t spell that out clearly (nor use\u00a0laymen\u2019s terms), it\u2019s up to the reporter to find out and let readers know. We recognize this isn\u2019t easy to do on deadline, but it would have made an average\u00a0story stand above the competition.", "answer": 0}, {"article": "I wouldn\u2019t wish it on my worst enemy, but I have to go through with it.\u201d\n\nDr. Lowy explored the entire cavity from the diaphragm to the pelvis.\n\u201cIt\u2019s maximally invasive,\u201d said Dr. Sugarbaker, who often removes the \u201cspare parts\u201d \u2014 organs a patient can live without, like the spleen, the gall bladder, the ovaries and the uterus.\nOne randomized trial done more than a decade ago involving 105 patients in the did show a striking benefit.\nAnd critics say that since that trial was conducted, new drugs have come to market that allow patients with metastatic colorectal cancer to live two years with intravenous chemotherapy alone.\nMr. S. left the hospital eight days later, happy to have undergone the treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explained:\n\u201cOne randomized trial done more than a decade ago involving 105 patients in the Netherlands did show a striking benefit. The median survival of those getting surgery and Hipec, plus intravenous chemotherapy, was 22.3 months, almost double the 12.6 months for those getting only the intravenous chemotherapy\u201d\nThat being said, the story also included the proviso that newer drugs are now available that have been shown to increase survival.", "answer": 1}, {"article": "The full article, \"OFF!\nClip-On caused high mosquito mortality and knockdown rates up to 0.3 meters from the device, enough to protect a single person wearing the device.\nA product called the OFF!\u00ae Clip-On\u2122 repellent device could be an effective tool for preventing bites from the Aedes aegypti mosquito -- the primary vector of Zika, chikungunya, dengue, and yellow fever -- according to an article in the Journal of Medical Entomology.\nThe effectiveness of the device came as a pleasant surprise to the researchers.\nIn order to test the effectiveness of the device, Christopher Bibbs and Rui-De Xue of the Anastasia Mosquito Control District in Florida studied how the device performed against hungry Aedes aegypti mosquitoes.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release makes a very modest result sound more beneficial than it might actually be. According to the release, \u201cThey found that the OFF! Clip-On caused high mosquito mortality and knockdown rates up to 0.3 meters from the device, enough to protect a single person wearing the device.\u201d\nWhat they don\u2019t say is that the devices were suspended from stationary cages and were effective at repelling mosquitoes only within a foot or a foot and half away when the weather was calm.\u00a0 In other words, if you are using the device outside, don\u2019t move. Also, it\u2019s probably best not to count on the device if it\u2019s windy out. As the product website warns, \u201cif you move, allow a few minutes for the unit to rebuild its protection.\u201d\nIn addition, as shared in the study, but not the release, the time to cause high mortality in mosquitos was in the 30 to 60 minute range, implying (or scientifically stating) that a person wearing the device would have to be 0.3 meters from the mosquito for a prolonged period of time without either of them moving.\nWe also aren\u2019t given any quantification \u2014 percentage or absolute number \u2014 for the claim that the device caused \u201chigh mosquito mortality and knockdown.\u201d", "answer": 0}, {"article": "It also triggers the release of the stress hormone norepinephrine, as well as the mood regulator serotonin.\n\"Acupuncture together with enhanced self-care for three months is effective in reducing hot flashes in women with breast cancer,\" said study author Giorgia Razzini, a clinical trial project manager in the oncology unit of Ospedale di Carpi (Carpi Hospital), in Bologna, Italy.\nThose in the acupuncture group also seemed to have a generally higher overall quality of life in terms of both physical and mental health, with no serious side effects, the study authors said.\nOne group of 105 patients was offered a three-month regimen of self-care advice on diet, exercise and psychological support.\nThe second group, of 85, was offered the same advice in the same time frame along with 10 half-hour weekly sessions of \"traditional\" acupuncture.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u2019s only quantified assessment is \u201cby the end of the treatment period, those in the acupuncture group were found to have hot flash scores that were 50 percent lower than those in the non-acupuncture group.\u201d That\u2019s not enough to merit a Satisfactory rating, for several reasons, including:", "answer": 0}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only said that more than two-thirds of those taking the drug had at least a 75% reduction in psoriasis.\u00a0 That\u2019s not clear. Does that mean 75% a reduction in the number of psoriatic plaques?\u00a0 Or does it mean a 75% reduction in the severity of existing plaques?\u00a0 And 75% of what baseline?\u00a0 Were these people wth extensive psoriasis?\u00a0 What precisely were the measurements? ", "answer": 0}, {"article": "Happiness won\u2019t help you live longer (but unhappiness won\u2019t kill you either)\n\nGuinea is finally declared Ebola-free, but that does not mean the crisis is over\n\nMost popular Washington Post health stories of 2015: A mother tells her story of how she lost her darling daughter a few weeks short of her 29th birthday when she stepped in front of a train in Baltimore.\nThe other piece of good news regarding the medications is that ACE inhibitors, as well as many ARBs, are now generic -- meaning that the cost difference is minimal.\nBut some doctors and researchers were puzzled by the fact that in head-to-head comparisons between the two classes of drugs they appeared to equally safe and effective.\nNow a large new analysis involving 250,000 patients shows that these medications may be as effective and safe as their older cousins, the angiotensin converting enzyme, or ACE inhibitors.\nThat led many doctors and standards groups to conclude that ACE inhibitors were more effective than ARBs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story points out that the two classes of drugs prescribed for cardiovascular disease are mostly equally effective.\u00a0 It also points out that the main difference lies with the fact that patients report that ARBs are linked to fewer unpleasant side effects, compared to ACE inhibitors.\u00a0 And since patients are\u00a0usually kept on the drugs for long periods of time, if not indefinitely, that information is important to readers. But the story never says what outcomes exactly we\u2019re talking about here \u2014 deaths, heart attacks, blood pressure? Nor does it say how effective these medications were at improving these outcomes \u2014 merely that they are equivalent. We think both of these issues should have been addressed in order to earn a Satisfactory rating here.", "answer": 0}, {"article": "The main reason for the surgery is osteoarthritis.\nMany more people facing surgery for knee problems would be better off with a partial rather than total knee replacement, which should allow them to recover faster, say experts.\n\u201cThis has allowed us to provide strong proof that partial knee replacements are both better for patients and cheaper for the NHS.\u201d\n\nWhether people had a partial or total replacement varied by surgeon, as did the success of the operation, the researchers discovered.\nThose surgeons who carried out more partial replacements had better outcomes from them than surgeons who did fewer.\nResearchers from the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) publishing in the BMJ Open journal found that the less invasive procedure was being used less than it could be.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells readers that \u201cMany more people facing surgery for knee problems would be better off with a partial rather than total knee replacement, which should allow them to recover faster.\u201d But it doesn\u2019t tell readers how much faster. It also doesn\u2019t make clear what the benefits of the surgery are compared to, well, not having any surgery at all.\nIn addition to not quantifying the benefits, the story also doesn\u2019t tell readers exactly what the researchers were measuring, which were \u201cquality adjusted life years\u201d (QALYs). QALYs are a way of accounting for both the quantity and quality of a patient\u2019s life, and are used primarily in an economic context. i.e., QALYs are used to assess the cost-effectiveness, or value, of a medical procedure.\nIn this case, the study found that patients had QALY gains for partial replacements, compared to total knee replacements, and that the gains varied depending on both the patient\u2019s sex and age. The QALY outcomes were also influenced by whether the person conducting the partial surgery did such operations frequently.", "answer": 0}, {"article": "Please visit http://www.\nIn the study, published today, Nov. 17, 2015, in the Journal of the National Cancer Institute, the researchers analyzed data from two U.S. studies: the Health Professionals Follow-Up Study that tracked more than 42,000 males ages 40 to 75, from 1986 to 2010; and a second, the Physicians' Health Study that followed more than 20,000 males ages 40 to 84, from 1982 to 2010.\nWhile there were fewer cases and less detailed data collected in the physicians' study, the score was similar in both populations, indicating the potential benefit of healthy lifestyle habits in warding off lethal prostate cancer, said the authors.\nTo gage the effects of lifestyle habits, the researchers developed a score based on the results of the health professionals survey, then applied it to the physicians' study.\nThe researchers also calculated that lethal prostate cancer among American men over 60 would be cut by 15 percent if they consumed at least seven servings of tomatoes per week and that 17 percent would be spared this diagnosis if they consumed at least one serving of fatty fish per week.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is where things get a little tricky. The research described in this journal article looked at data from two different studies: the Health Professionals Follow-Up Study (HPFS) and the Physicians\u2019 Health Study (PHS). The HPFS tracked 42,701 men from 1986-2010. The PHS tracked 20,324 men from 1982-2010. The release (and journal article) explain that the researchers used the HPFS data to develop a \u201chealthy lifestyle score,\u201d and then applied that score to the men in the PHS to see if it predicted whether someone would contract a lethal form of prostate cancer. The researchers identified the number of lethal cases of prostate cancer in each group to calculate benefits. The release states: \u201cParticipants with 5 to 6 points [the highest scores] in the HPFS had a 68 percent decreased risk of lethal prostate cancer[,] and a 38 percent decreased risk was observed in the [PHS] for the same comparison.\u201d Several points to make here. First, the \u2018healthy\u2019 group appeared to have been compared to the \u2018least healthy\u2019 group (score 0-1) and not all the other groups combined. This was noted in the published results but not mentioned in the release. That\u2019s important. Second, the release does not note (but the journal article does) that the 38 percent decreased risk seen in the PHS was not found to be statistically significant. That\u2019s also an important distinction. Third, this is the relative reduced risk, and doesn\u2019t tell readers what the actual, absolute reduction of risk is.", "answer": 0}, {"article": "Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School.\nSignificant hearing loss was seen in 12 percent of patients three years after treatment and in 16 percent at five years, which compares with around 25 percent reported in studies using photon radiotherapy.\nHowever, no cardiac, pulmonary, gastrointestinal, seizure or secondary tumor effects - all of which have been reported in photon therapy studies - were seen in the current study's participants.\nSurvival rates and the incidence and type of tumor recurrence all were similar to what has been reported for photon radiotherapy.\nThe cognitive effects of proton therapy - primarily affecting verbal comprehension and processing speed - were also less serious than what has been reported with photon radiotherapy, and those effects were primarily seen in children who were under the age of 8 when treated.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release quantifies some outcomes, as in this statement: \u201cOf 59 patients who enrolled, 12 died from their tumor during the study period and one from a traumatic brain injury. Significant hearing loss was seen in 12 percent of patients three years after treatment and in 16 percent at five years, which compares with around 25 percent reported in studies using photon radiotherapy.\u201d The release later indicates that key outcomes are comparable to photon therapy: \u201cSurvival rates and the incidence and type of tumor recurrence all were similar to what has been reported for photon radiotherapy.\u201d We\u2019ll call this good enough for a Satisfactory rating, although the release certainly could have provided more detail on what previous studies have found with respect to photon therapy.", "answer": 1}, {"article": "CHICAGO (Reuters) - Two new drugs using very different scientific approaches can extend survival among patients with the deadliest form of skin cancer, offering the first new hope for real progress in many years.\nBristol-Myers\u2019 Yervoy was approved in March for patients with inoperable or metastatic melanoma, based on a previous study which showed the drug given alone extended survival by four months in patients who had failed other treatments.\nShe and others expect vemurafenib to be approved this year.\nThe five-year survival rate for the aggressive cancer is just 15 percent.\nDr. Paul Chapman of Memorial Sloan-Kettering Cancer Center in New York and the study\u2019s lead investigator called the results an \u201cunprecedented level of difference\u201d for patients with advanced melanoma, who typically survive just eight months on current treatments.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate job reporting the benefits seen in the two trials.", "answer": 1}, {"article": "She said the findings are important because, \"they help us understand why individuals with autism have difficulty with complex behaviors, such as social interaction and language.\nThe study, conducted by researchers at Harvard University Medical School, looked at the synchronization of brain activity across different brain regions, as measured by EEG.\n\"This reduced functional connectivity in the brain helps us understand impairments associated with autism,\" she added.\nThis was especially true in the left hemisphere regions of the brain responsible for language.\n\"Consistent with many previous studies using EEG and functional MRI with both children and adults with autism, these investigators found that, overall, children with autism show reduced coordination (coherence) across brain regions.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was about a test.\u00a0 Stories about tests should quantify how well the test worked, how sensitive, how specific, how often, how many times out of how many times tried, etc.\u00a0 This story provided none of those measurements.", "answer": 0}, {"article": "\"That's about what you see with standard drug therapy,\" says researcher J. David Prologo, MD, assistant professor of interventional radiology at Case Western Reserve University\u2019s School of Medicine in Cleveland.\nResearchers tested the technique on 24 men who hadn't been helped by standard treatments.\nAlso unknown: whether men would opt for the treatment.\nBut other experts tell WebMD that questions about the long-term consequences remain.\nIts supporters say the technique, or a similar one involving heat therapy, could someday become a standard treatment for the condition.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us that men in the study lasted three times longer after the procedure, an increase from 36 seconds to 110 seconds. While this is important information to communicate, it is arguably just as important to tell us how\u00a0this increase in stamina affected the men\u2019s satisfaction with their performance. While definitions vary,\u00a0ejaculation is typically considered \u201cpremature\u201d only if it causes distress or dissatisfaction. So\u00a0treatments need to be judged on the basis of whether they improve\u00a0the individual\u2019s subjective perception of their performance. Is an additional 80 seconds of intercourse enough to make a difference in how these men felt about their sexual experiences? (Or how their partners felt?) The story does tell us that all men \u201cimproved on at least one sexual-related\u00a0symptom,\u201d but\u00a0it doesn\u2019t tell us which symptoms were affected or how much improvement was seen.", "answer": 0}, {"article": "Sharon Samuels was a teenager when she was first diagnosed with essential tremor.\nHe added that since these patients were only followed for a year, there isn\u2019t enough data available yet to determine the long-term efficacy of the treatment.\nFor now, the treatment has had an immense impact on patients\u2019 lives.\nThe doctors at Brigham will follow up with Samuels \u2014 and others who undergo the treatment \u2014 for up to five years and run more MRI scans and neurological exams to find out for how long the lesion lasts and keeps the tremor suppressed.\nBut the procedure brings lasting side effects in some patients, and its long-term usefulness is still being studied.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is long on description but short on numbers.\nSaying the treatment \u201chas had an immense impact on patients\u2019 lives,\u201d the story devotes quite a bit of print along with video footage to show rapid functional and quality-of-life improvements experienced by patients, focusing on one women who said her tremor \u201chas almost disappeared\u201d since she had the procedure in June. Video showing this patient before and after treatment\u2013including her attempts to write her name, trace a spiral and pour water from one cup to another\u2013do a great job of conveying the improvements. This is terrific news for this woman, but\u00a0we\u2019re not told how representative her experience\u00a0is of overall outcomes. Is she a best-case scenario? Middle of the road?\nThere are also inspiring quotes from a researcher, including a description of the \u201cremarkable moment\u201d patients experience when they realized the tremor has subsided. \u201cThey can write their names again, they can feed themselves, they are not embarrassed about being in public. So it really is extraordinarily helpful for people,\u201d he says.\nIn terms of study data, the story says researchers \u201cfound that the severity of essential tremor reduced significantly\u201d in patients who underwent the treatment as well as reported improvements in quality of life. But there are no figures. In fact, according to the study, patients experienced a 47 percent improvement in tremor scores, dropping from 18.1 points on a 32-point scale at baseline to 9.6 points three months after the procedure. That data should have been included. Also, the story should have spelled out that 56 patients received the treatment, versus 20 who experienced a fake procedure. \u00a0Also worth pointing out: We don\u2019t know the meaning or clinical significance of a reduction of this magnitude in the total score.\u00a0", "answer": 0}, {"article": "Hot flashes, which mostly affect women transitioning to menopause and already in that phase of life, involve a sudden sensation of heat, sometimes accompanied by sweating or visible reddening of the skin.\nSo far, Freedman noted, the only hot-flash treatment that has consistently worked in studies is hormone replacement therapy (HRT).\nFreedman said that the overall research on antidepressants and hot flashes is still inconsistent.\nIn fact, Freedman said, there\u2019s some evidence that lowering serotonin levels does not worsen hot flashes \u2014 which would be expected if the \u201cserotonin theory\u201d is correct.\nThose findings appear in a separate report in the journal Menopause.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate quantitative description of the extent and timing of hot flash reduction for the treatment group.\u00a0 Describing the response in placebo group as \u201coccurring more slowly and to a lesser degree\u201d provides an adequate sense of the difference.\u00a0 And story provided quantitative comparison for the outcome of insomnia between placebo and treatment groups.\n\u00a0", "answer": 1}, {"article": "Studies in mice, dogs, pigs, and monkeys have shown that so-called focused ultrasound waves can be used to heat tiny bubbles that then mechanically push open gaps in blood vessels, allowing drugs to leak out into the brain.\nHall felt nothing from the seconds-long bursts from 1,024 ultrasound beams aimed at different points around her skull, and an MRI scan confirmed that the brain barrier was successfully traversed.\nBecause the trial was designed solely to determine the safety of focused ultrasound to the brain, the patient was not given a therapeutic dose of doxorubicin and the procedure is not expected to help in her recovery, Mainprize said.\nNew, safe doses of drugs will need to be determined, once medication is not being diverted by the blood-brain barrier, noted Dr. Gordon Li, a neurosurgeon at Stanford.\n\u201cIt really opens up a lot to the imagination.\u201d\n\nMost drugs are blocked from entering the brain by the \u201cblood-brain barrier,\u201d which protects against infection, but also makes it tricky to treat brain tumors, diseases like Alzheimer\u2019s, and mental illness.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Since this is a single patient there is no quantification involved, so N/A.", "answer": 2}, {"article": "Watson shares were up 50 cents, or 1.2 percent, to $43.20 in morning trade.\nIf it is approved, it should be clearly labeled as an abortifacient, which would limit its distribution, the American Association of Pro Life Obstetricians & Gynecologists said in a letter to the FDA earlier this month.\nThe drugmaker has said its pill, also known by its chemical name ulipristal, works primarily by preventing ovulation of a woman\u2019s egg.\nWomen\u2019s health advocates have welcomed the potential for another contraceptive option, but some critics contend the drug is more akin to the abortion pill, sold by Danco Laboratories as Mifeprex and also known as RU-486 or mifepristone.\nData shows the one-pill treatment, called ella and made by French drugmaker HRA Pharma, is effective when taken as many as five days after unprotected sex, Food and Drug Administration staff reviewers said in documents released ahead of a public meeting on the drug scheduled for Thursday.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides no quanitification of benefits from the drug. Ideally, the story would have described the likelihood of pregnancy after uNPRotected sex with or without the drug. According to British sources \"It is estimated that for every 100 women who take Ellaone up to five days after uNPRotected sex, approximately two women will become pregnant. The tablet is more effective at preventing pregnancy the earlier it is taken, so it is important to take it as soon as possible after uNPRotected sex, rather than delay it to the fifth day.\"", "answer": 0}, {"article": "The F.D.A.\nNovartis said that about 2.2 million Americans would be eligible for the drug, which was approved for patients with so-called Class II to Class IV chronic heart failure with so-called reduced ejection fraction.\nNovartis is sponsoring another study to see if the drug is effective for those with preserved ejection fraction, which accounts for half of heart failure cases.\nPatients in both groups of the study could also take other drugs, such as beta blockers, as their doctors saw fit.\nNovartis is considering trying so-called risk-sharing with some health plans, meaning it might charge more if the drug really does keep people out of the hospital and less if it doesn\u2019t.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gets a hesitant satisfactory score here. Now, we know that reporters rarely, if ever, write the headlines. But somebody at the Times must take responsibility for the confusion caused by this headline, which states that the drug is \u201cSaid to Cut Death Risk by 20%.\u201d This starts the story off on an uncertain note, since it\u2019s not clear who said this or where this information is coming from. In the second paragraph, the story cites results from a clinical trial showing \u201ca 20 percent reduction in the risk of death from cardiovascular causes or hospitalization for worsening heart failure.\u201d So, it seems that the drug is not cutting the risk of death by 20 percent, but the risk of death or hospitalization for worsening heart failure. Then again, if you go to the study itself, you learn that there was indeed a 20% reduction in the outcome of \u201cdeath from cardiovascular causes,\u201d although this doesn\u2019t seem to be the figure that the headline is referring to, since it\u2019s not mentioned in the text. In terms of overall death from any cause \u2014 the outcome that most closely resembles the \u201cdeath risk\u201d mentioned in the headline \u2014 the study shows that there was a 16% reduction.\nBut that\u2019s not the whole story. Much lower down in the article, we learn that this was actually a relative risk reduction \u2014 patients in the clinical trial who took Entresto were 20 percent less likely to die or be hospitalized than patients who took a competing drug called enalapril. This sort of risk reduction is not the same as absolute risk reduction, which provides a more meaningful view of the benefit. The story does get credit for eventually providing the absolute risk of hospitalization/mortality in both groups (21.8 percent of those taking Entresto vs. 26.5 percent for those taking enalapril, or \u00a0a 4.7% difference), but putting this information far down in the story, after a confusing headline, is less than ideal.", "answer": 1}, {"article": "Kidney stones are small, hard mineral deposits that form inside the kidneys, affecting up to 12 percent of men and seven percent of women.\nThe head-to-head studies of CA and HCA determined that while both compounds inhibit the growth of calcium oxalate crystals, HCA was more potent and displayed unique qualities that are advantageous for the development of new therapies.\nThis finding could lead to the first advance in the treatment of calcium oxalate stones in 30 years.\nThe work offers the first evidence that the compound hydroxycitrate (HCA) is an effective inhibitor of calcium oxalate crystal growth that, under certain conditions, is actually able to dissolve these crystals.\n\"HCA shows promise as a potential therapy to prevent kidney stones,\" the researchers wrote.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release merely states that, in lab tests, hydroxycitrate appears to be capable of dissolving a common component of kidney stones and could be more effective than citrate, which is often recommended in addition to diet and lifestyle changes as a way to help prevent kidney stones. There is also a cautionary note at the end of the release (which could have been placed near the top) stating that long-term safety, dosage and additional human trials are needed.", "answer": 1}, {"article": "University of Eastern Finland, Institute of Public Health and Clinical Nutrition, tel.\nHowever, the researchers found that a very high consumption on non-fermented dairy products was associated with an increased risk of incident coronary heart disease.\nWhen the study participants were divided into four groups on the basis of their consumption of fermented dairy products with less than 3.5% fat, the risk of incident coronary heart disease was 26% lower in the highest consumption group compared to the lowest consumption group.\nA very high consumption of non-fermented dairy products, on the other hand, was associated with an increased risk of incident coronary heart disease.\nThe new study provides further evidence on the health benefits that fermented dairy products may have over non-fermented ones.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Main findings mentioned include:\nReaders are given no sense of just how much the risk is increased or decreased in these groups.\nThe only data provided from the study is this:\nThe risk of CHD was 26% lower in those men who consumed the highest amount of low fat (<3.5%) fermented dairy (compared to the lowest consumption group).\nIt would be difficult for many readers to put that number into context without knowing how much low-fat/fermented dairy was consumed.\nSome data contained in the study might have helped put the numbers in context. According to the tables in the published manuscript, there is a modest reduction from 14 CHD events per 1,000 person years in the low intake group (of fermented dairy) to 10 CHD events per 1,000 person years in the high intake group (of fermented dairy).", "answer": 0}, {"article": "\u201cShe would wake up in the middle of the night with night terrors at a very young age, she stopped napping around 15 months \u2026 any type of change in our schedule could set off an epic tantrum.\u201d\n\nOakes didn\u2019t know it then, but her daughter Mallory was one of more than 10 percent of American children living with attention deficit hyperactivity disorder (ADHD)\n\n\u201cShe was diagnosed in first grade after there were some difficulties in the classroom,\u201d Amy said.\n\u201cWe tried some medication therapies that ended up being really a nightmare for us, and making matters worse.\u201d\n\nMedication is often the first line of defense in conventional medicine for kids with ADD and ADHD, with doctors prescribing everything from stimulants to antipsychotics and even antidepressants to help control the symptoms.\n\u201cI thought we weren't going to get accepted to the program, and they told us they could help us and we never looked back.\u201d\n\nThe specialized learning centers, of which there are now 80 throughout the country, were developed by Dr. Robert Melillo, a neurology researcher and author of the book \u201cDisconnected Kids,\u201d to help balance the brains of kids with learning disorders, like Mallory.\n\u201cIf you get a child who has really strong left brain and delayed right brain, those are kids that may be labeled with attentional problems or behavioral problems or social issues,\u201d Melillo said.\nFor Mallory, the disorder led to a pattern of epic meltdowns which left Amy reeling\u2014 and willing to try anything to control them.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "An anecdote about one person\u2019s experience does not amount to quantifying potential benefits for readers. The story provides no studies/evidence to quantify benefits of the approach described.", "answer": 0}, {"article": "Please use our search feature and update your bookmarks. Thank you!", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a pretty good job of noting the apparent benefits in its narrative, but hard data are notably missing or under-reported. Readers would benefit from knowing, for example:\nHow many of the women who took estriol along with their conventional medications showed reduced relapse rates, and to what degree, compared to women who took the placebo with conventional drugs? (Telling us that these women had \u201ca third to a half as many relapses\u201d is a relative comparison \u2014 we wanted to see absolute numbers.)\nIf there were extended breaks between relapses, how long were they?\nWhat was the rate of inflammatory lesions in the brain and when did they occur? These numbers should be included for the current study, not the 2002 findings.\nFinally, the release could have noted an important reduction-in-the-reduction of relapse rates over time. For example, a\u00a0Medscape news report on the 2014 presentation noted a 47% reduction in confirmed relapses compared to placebo group in the first year and a 32% relapse rate reduction in the second year.", "answer": 0}, {"article": "For more information about the study contact ket.study@unsw.edu.au or call 02 9382 9509.\n\"Not only was ketamine well-tolerated by participants, with none experiencing severe or problematic side effects, but giving the treatment by a simple subcutaneous injection (a small injection under the skin) was also shown to be an acceptable method for administering the drug in a safe and effective way.\"\nFollowing the RCT, participants also received 12 ketamine treatments in an open-label phase to investigate the effectiveness of multiple doses of ketamine.\nAs part of the double-blind, placebo-controlled trial, an active control treatment which causes sedation similar to ketamine, was used to substitute for one of the treatment sessions.\n\"Our results indicate a dose-titration method may be particularly useful for older patients, as the best dose was selected for each individual person to maximise ketamine's benefits while minimising its adverse side effects.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release\u2019s presentation of study outcomes is baffling. The published paper describes a 5-week randomized controlled trial followed by a longer 6-month follow-up phase that was open label (meaning patients and doctors knew who was getting ketamine). The RCT period provides the strongest evidence, but the news release seems to offer only the 6-month open label results when it says,\n\u201cBy the six-month follow up, 43 percent of participants (7 of 14) who completed the RCT had remitted, with five remitting at amounts below the commonly-used dose of 0.5 mg/kg. Repeated treatments also resulted in a higher likelihood of remission or a longer time to relapse, with an overall response and remission rate of 68.8 percent for the patients receiving ketamine treatment.\u201d\nFirst of all, according to the published paper, the outcomes described in the news release \u2014 \u201c7 out of 14\u201d remitters and \u201c68.8% overall response and remission rate\u201d \u2014 are from the initial 5-week RCT. The news release, however, describes them as being from the 6-month open label follow-up. That\u2019s simply incorrect. Second, 7 out of 14 is exactly 50 percent but is described as being \u201c43 percent\u201d in the news release. This 43 percent figure does not not seem to appear anywhere in the published study and we\u2019re not sure what it represents.\nLastly, the release lacks specifics that would help readers understand the magnitude of benefit.\u00a0What is an \u201coverall response and remission rate\u201d? How much better does one have to be to be considered a \u201cresponder\u201d or \u201cin remission.\u201d", "answer": 0}, {"article": "Like all laparoscopic procedures, a camera is inserted through a tiny incision to see into the abdomen; two other small incisions are made so that tools can be inserted to perform the surgery.\n\"You would want them to have the least invasive procedure possible.\"\nThe surgery she's upset about may be archaic - but it's very common.\nIt's all over in about an hour, and patients are usually home within a day and back to normal within a week or two.\nLiterally, no pain.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify the main benefit of laparoscopic surgery \u2013 reduced recovery time \u2013 relative to abdominal hysterectomy.", "answer": 1}, {"article": "Dr Weaver said: \"We have shown that all our patients in the study had their insulin doses reduced after taking metformin and have not suffered any serious adverse effect.\n\"The results, which indicate that metformin, a drug commonly used in the treatment of Type 2 diabetes, could also have a powerful effect in people with Type 1 diabetes is unexpected.\n\"For the first time, this study has shown metformin has additional benefit beyond improving diabetes control when given to patients with relatively well controlled Type 1 diabetes.\nFindings of the clinical trial are published today in the journal, Cardiovascular Diabetology.\nShe believes this new research is a major development in understanding the best ways to further improve treatment in Type 1 diabetes.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release makes clear that cardiovascular disease is a major risk for patients with diabetes and the study was intended to show whether the additional drug, metformin, could lower that risk. The release states that the study showed a decrease in markers indicating damaged blood vessels and an increase in markers showing blood vessel repair, among other findings. But the release falls short by not providing\u00a0any numerical data suggesting the degree of improvement in these markers, and therefore denies readers the ability to make their own determination as to the importance of this research.", "answer": 0}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\nIt\u2019s not known if the diet leads to any nutritional deficiencies or keeps working in the long run \u2014 especially for patients who get little support from doctors or dietitians.\nIn 2014, IBS treatment guidelines from the American College of Gastroenterology said the diet showed promise, but that the quality of evidence was \u201cvery low.\"\nBut few dietitians are trained in the diet, and insurers typically do not cover the visits, Lacy notes.\n\u201cPhysicians are largely administering the diet by giving patients sheets of paper with foods to exclude,\u201d Chey says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story looks at the big picture here, and it does do a pretty good job quantifying the benefits, when relevant. For example, one recent study in the United States gets detailed attention in the story. In it, patients on the low-FODMAP diet perceived better relief from pain and bloating than did patients on a less restrictive diet. We\u2019re told both the percentage of subjects who reported \u201cadequate relief,\u201d hovered around 40-50% for both diets. The story quickly follows that by explaining there was no\u00a0statistically significant difference.\nThe story also highlights another study in which the low-FODMAP diet fared no better than another, less restrictive diet. \u201cThe data are not overwhelming,\u201d notes one scientist. And the story, while mentioning that the 2014 American College of Gastroenterology guidelines stated that the diet showed promise, also quotes the organization as indicating that the quality of the evidence is \u201cvery low.\u201d", "answer": 1}, {"article": "Oxytocin is produced naturally in the bodies of humans and animals.\nResearchers who were not involved in the study praised the work, saying the findings were promising and could lead to the first effective treatment for the central problems affecting people with autism.\n\"Many families are using it with success and reporting improvement,\" said Wendy Fournier, president of the National Autism Association.\nAlthough more research is needed to confirm and explore the findings, the results are the latest in a growing body of evidence indicating that the hormone could lead to ways to help people with the often devastating brain disorder function better.\n\"All the data seem to suggest that manipulating the oxytocin system has a powerful effect on the core symptoms of autism,\" said Eric Hollander, director of the compulsive, impulsive and autism spectrum disorders program at the Montefiore Medical Center in New York.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There were, however, wide variations in individual responses, the team noted.\n\"It\u2019s not clear whether this would be effective at all in children or in young adults who had intellectual problems.\" warned (one independent expert.)\nAlso, scientists would need to come up with a different method of delivery, (one independent expert) said.\n\"The nasal [inhaled] drugs only work for a few minutes. Potentially it would be very difficult to be using this drug once an hour or something. It doesn\u2019t make a whole lot of sense,\" he pointed out. \"But it does point the way to the possibility of raising oxytocin levels with other kinds of compounds to increase oxytocin levels more generally over a longer period of time. I don\u2019t know whether this is a realistic therapy as we have it now but, potentially, in the future it could really help these people whose primary autistic symptoms are having to do with reduction in social activity.\"", "answer": 0}, {"article": "MS can cause many symptoms, including blurred vision, loss of balance, poor coordination, slurred speech, tremors, numbness, extreme fatigue, problems with memory and concentration, paralysis and blindness.\nThose deaths are a major concern, one neurologist said, because MS is not in itself life-threatening.\nA trial that compares stem cell transplants with other therapies to see whether stem cell transplants can become a treatment for patients who have progressive MS is about to start, added Racke, who co-authored an editorial that accompanied the study.\nBut the treatment can be risky because the patient's immune system has to be wiped out before the stem cells are transplanted, the researchers said.\nThe researchers think these deaths were most likely due to the transplant technology used before 2006, which has since improved.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "One\u00a0benefit here is progression-free survival. This is basically a yes/no question: did the patient\u2019s MS progress? For 46% of the 239 patients who could be analyzed, the answer was yes. The story tells readers that. It also tells readers that a certain subset of patients was more likely to experience these benefits than others: \u201cyounger patients with a relapsing form of MS who were not severely disabled and who hadn\u2019t found relief with other treatments fared better than others over five years.\u201d\nHowever, the story didn\u2019t convey important context for this progression-free survival figure. The reason that the 46% figure is interesting is because of this: Conventional wisdom says patients with aggressive disease would still continue to accumulate disability even if their inflammation is stopped, yet among the group\u00a0studied among which 75% had progressive disease, 46% had not progressed at the 5-year mark. This means that\u00a0some patients with progressive disease benefited from stem cell treatment\u2013against conventional wisdom.\nAs we explain below in our evidence quality criterion, the story should have made it clearer that these findings were not obtained via a randomized controlled trial.", "answer": 1}, {"article": "For more information on breast cancer, visit the American Cancer Society.\nEating bitter melon could also have a beneficial effect, Ray said.\nThe next step is to see if the team can repeat these findings in animals, Ray said.\nThe extract slowed the growth of these breast cancer cells and even killed them, the researchers found.\nBut their work was done in a laboratory, not in humans, she noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Potential benefits were exaggerated far beyond what this laboratory-only research showed.\u00a0 Again, the story stated: \nAlso?\u00a0 No human benefit was proven in this story! ", "answer": 0}, {"article": "Fibromyalgia is a syndrome marked by widespread pain \u2014 including discomfort at specific \u201ctender points\u201d in the body \u2014 along with symptoms such as fatigue, irritable bowel and sleep problems.\nThe study, of 45 women with fibromyalgia, found that those who learned a technique called \u201caffective self-awareness\u201d were more likely to show a significant reduction in their pain over six months.\nPart of that, according to the researchers on the new study, may be because standard treatments do not specifically address the role psychological stress and emotions can play in triggering people\u2019s pain.\nSchubiner also acknowledged that this general \u201cmodel\u201d for understanding and addressing fibromyalgia pain is controversial.\nA key difference, Schubiner said, is that affective self-awareness asks people to \u201cdirectly engage\u201d the emotions that may be helping to drive their symptoms.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that 46% of patients receiving affective self-awareness therapy had a 30% or greater reduction in pain severity, which was the study\u2019s primary outcome, compared to zero patients in the control group. \u00a0This succinct summary, presented in absolute terms and unembellished with patient anecdotes, is enough to merit a satisfactory. But we wish the story had explained whether\u00a0a 30% reduction in this pain rating scale\u00a0is\u00a0a clinically important finding.\u00a0In addition,\u00a0it is\u00a0not clear why the article failed to\u00a0mention that patients receiving\u00a0affective self-awareness therapy\u00a0had improved self-reported functional status.\u00a0This is an important measure of how patients are able to get along in their daily lives.\u00a0", "answer": 1}, {"article": "Dr. Jeffrey Tice, an internist at the University of California, San Francisco, who wrote an editorial accompanying the study, said: \"With hormones, we really were thinking we were preventing a lot of diseases and it was good for the long term.\nAmong the antidepressants, Paxil seemed to have the strongest evidence of benefit.\nAll the nonhormonal drugs have side effects.\nOf 10 studies on antidepressants, for instance, the researchers judged only two of the studies to be good, and the rest fair or poor.\nShe took a cautious view because she and her colleagues found that there was relatively little reliable data on using the drugs for hot flashes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Absolute reduction in number of hot flashes per day is presented for non-hormonal treatments and these are compared to the number of hot flashes with hormone treatment.", "answer": 1}, {"article": "Andrew Keaveney, now 73, shattered his ankle in a fall from a truck while hanging flags as an American Legion volunteer.\nEach year about two million Americans visit the doctor for ankle pain from arthritis or fracture.\nAnkle replacement has been around for three decades, but it has been slow to catch on.\nThe procedure is among the most difficult that foot and ankle surgeons perform, and one of the biggest challenges is getting proper alignment of the replacement joint.\nNow another aging joint is fast becoming a candidate for replacement.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Potential benefits including, decreased pain, improved physical function and quality of life, are mentioned \u2013 but no data is provided.\u00a0 How often do these occur?\u00a0 That\u2019s a pretty important piece of information for readers. ", "answer": 0}, {"article": "Anorexia has one of the highest mortality rates of any psychiatric disorder and is among the most common psychiatric disorders in girls aged between 15 and 19 years.\nCommenting on the results of this small trial, Janet Treasure and Ulrike Schmidt of King\u2019s College London\u2019s Institute of Psychiatry said the technique looked promising and would give hope to patients with especially pernicious forms of anorexia.\nThis success, in a small study designed as a pilot to test the safety of the technique, suggests larger trials will confirm the effectiveness of the deep brain stimulation (DBS) device, the researchers wrote in the medical journal The Lancet.\nAndres Lozano, who led the study, said the results were encouraging because they pointed to a genuine therapeutic effect, rather than a placebo or hunger-increasing effect.\nDoctors implanted a device similar to a pacemaker in the brains of six severe anorexics and found at least half put on weight and showed improvements in mood.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story \u2013 awkwardly \u2013 in the second sentence, states that this was a trial in 6 people that \u201cfound at least half put on weight and showed improvements in mood.\u201d\nAt least half of 6?\u00a0 Does that mean 3?\u00a0 4?\nLater, much deeper in the story, it explains that \u201cafter nine months, three patients weighted more than before treatment\u201d \u2013 so we guess the answer to \u201cat least half\u201d was, indeed, three. But then it says \u201cAround half also had better moods and less obsessive-compulsive behaviour.\u201d\u00a0 Again, around half of 6?\nWhy not give the precise number of people?\nAnd why did the story never give the precise amount of weight gain (in pounds or percentage of ideal body weight ) that was actually observed.\nWithout that, again, readers are lead to believe the weight gain was substantial.", "answer": 0}, {"article": "Jerry St. Peter, Vice President and Head of Sun Ophthalmics, added: \"A key strategic imperative for our ophthalmic business is to participate in the rapidly growing, underserved, and dynamic Dry Eye market, which is expected to reach $5 billion by 2020.\nLifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.\nAfter 12 weeks of treatment, as compared to vehicle, Seciera\u2122 showed statistically significant improvement in the primary end point, Schirmer's score (a measurement of tear production) (p<0.0001).\n\"As a clinician who specializes in diagnosing and treating dry eye, this novel formulation of cyclosporine A would be a unique and welcome addition to our armamentarium to treat these patients\".\n[1] Additionally, several key secondary endpoints showed statistically significant improvements compared to vehicle with some showing an even earlier onset of action.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t provide any quantification of the results of this trial, instead it offers vague terms such as \u201cshowed statistically significant improvement in the primary end point,\u201d and \u201cshowed statistically significant improvements compared to vehicle.\u201d\u00a0 It also offers, \u201cBased on published data, the efficacy and safety endpoints in these trials compared favorably to other formulations of cyclosporine A with the advantage of early onset,\u201d a statement which also provides no numerical information for readers.", "answer": 0}, {"article": "Anthony's asthma diminished over time, and he says he can still play soccer, run fast and breathe \"just fine.\"\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\nThere's no official policy from the American College of Cardiology, but officials say most members support screening student athletes.\nThese surprise attacks are due to inherited problems that children are born with.\nAccording to Zipes, \"The adrenalin that is released when you're participating [in sports] can stimulate this abnormally thick heart muscle and cause a fatal heart rhythm problem, that is a very rapid heartbeat with no effective contraction, no blood being ejected to the brain and other organs.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\n\u00a0 \n\n \n  The story amplifies the potential benefit of routine screening of high school athletes by focusing unduly on a couple of positive anecdotes. In particular, the reporter describes the experience of one child diagnosed with a serious heart problem for whom the EKG was said to be \u201clife-saving.\u201d This characterization is problematic because we don\u2019t of course know whether this patient ultimately has been \"saved\" (the patient is said to be on a heart transplant list and the outcome of any intervention is as yet undetermined). Similarly, it is impossible to say whether this problem would have been detected by other means even if the child never received an EKG. The author leans heavily on this anecdote but provides no real data to support the contention that global screening of all athletes would identify more students at risk than the current approach. \n  \n", "answer": 0}, {"article": "Fluctuating levels of levodopa result in erratic periods of muscular control and involuntary movements throughout the day, disrupting activity at least half a dozen times a day.\nAn estimated 90 percent of levodopa-treated patients, about 200,000 people in the United States, suffer from LID, the company said.\nWith Gocovri, which targets both dyskinesia and off time, patients will be able to reclaim about 3.6 hours of their day, CEO Gregory Went said in an interview ahead of the decision.\nThese patients have little recourse, other than opting for deep brain stimulation, a surgical procedure that involves blocking electrical signals from targeted areas in the brain.\nThe long-acting therapy is taken once-daily at bedtime.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only benefit information we receive is this: \u201cWith Gocovri, which targets both dyskinesia and off time, patients will be able to reclaim about 3.6 hours of their day, CEO Gregory Went said in an interview ahead of the decision.\u201d\nOne wonders how the drug was tested, and how the comparator group fared. Without this information, the story is robbed of its relevance. There is little to no information to help patients understand the potential benefits. For example, how many hours had the patients in this study \u201clost\u201d prior to going on this medicine? What is the impact on quality of life of this extra time? For how long do patients benefit from the drug?", "answer": 0}, {"article": "\"That time frame is not anything to write home about,\" Gulley says.\nOne woman who got the investigational vaccine now has no X-ray evidence of cancer, says study researcher James Gulley, MD, PhD.\nOverall, however, the limited success in some patients and the complete success in one is good news, he says.\nAs exciting as that is, he says, \"a lot of work needs to be done to prove whether this can be effective [for more patients].\"\nThe study, funded by the National Cancer Institute, is published in Clinical Cancer Research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does explain that only one patient remains cancer free following the study. It then details how for most of the patients cancer continued to progress after 2 months. It says that the median overall survival in both the breast cancer and ovarian cancer patients was less than 16 months. But the story is framed in such a way to highlight the one potentially positive outcome of the study and to downplay the negative. We read more sooner about the one patient who may have responded well to the vaccine than we do about the 25 other patients who did not.", "answer": 1}, {"article": "One of the top research universities in the world, MSU focuses its vast resources on creating solutions to some of the world\u2019s most pressing challenges, while providing life-changing opportunities to a diverse and inclusive academic community through more than 200 programs of study in 17 degree-granting colleges.\n\u201cWhat we learn from this could also have implications to other brain-related diseases like Alzheimer\u2019s and Parkinson\u2019s since the same inflammatory cells have been found to be involved.\u201d\n\nKnowing more about this interaction could ultimately lead to new therapeutic agents that could help HIV patients specifically maintain their mental function.\n\u201cThis happens because the immune system is constantly being stimulated to fight off disease.\u201d\n\nKaminski and his co-author, Mike Rizzo, a graduate student in toxicology, discovered that the compounds in marijuana were able to act as anti-inflammatory agents, reducing the number of inflammatory white blood cells, called monocytes, and decreasing the proteins they release in the body.\n\u201cIn fact, those who used marijuana had levels pretty close to a healthy person not infected with HIV.\u201d\n\nKaminski, director of MSU\u2019s Institute for Integrative Toxicology, has studied the effects of marijuana on the immune system since 1990.\n\u201cIt\u2019s believed that cognitive function decreases in many of those with HIV partly due to chronic inflammation that occurs in the brain,\u201d said Norbert Kaminski, lead author of the study, now published in the journal AIDS.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The first sentence makes a bold claim about benefits: \u201cA chemical found in marijuana, known as tetrahydrocannabinol, or THC, has been found to potentially slow the process in which mental decline can occur in up to 50 percent of HIV patients, says a new Michigan State University study.\u201d\nBased on the research, this statement about benefits is problematic. There is nothing in the study that showed the people who used marijuana had higher cognitive function than non-users. No cognitive function was measured. Instead, researchers were looking at biomarkers for inflammation that may\u2013may\u2013be linked with cognitive decline, but no one is sure yet. So even if marijuana users have less of these particular inflammatory biomarkers, they may still suffer mental decline for other reasons. \nIt\u2019s also not clear what \u201cup to\u201d 50 percent of patients means. Does this mean that 50 out of 100 HIV patients saw their mental faculties preserved by marijuana? Or does it mean that 20 out of the 40 people mentioned in the study saw a benefit? It is unclear and misleading. That phrase \u201cup to\u201d always gives us pause. Be clear with your audience. Show them the math.", "answer": 0}, {"article": "Lead researcher Professor David Newby, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"This relatively simple heart scan ensures that patients get the right treatment.\nThis is the first study to look at the impact of the scans on long-term survival rates.\nThe study had previously found that around a quarter of patients had their diagnoses reclassified after receiving the scan, prompting new treatments in many cases.\nResearchers say current guidelines should be updated to incorporate the scans into routine care.\nThis is the first time that CT guided management has been shown to improve patient outcomes with a major reduction in the future risk of heart attacks.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told the diagnostic procedure:\nSupporting data from the study are not provided. It appears the release misinterpreted the results. As noted above, it would have been preferable to include absolute and not just relative numbers.", "answer": 0}, {"article": "But at this stage, the company itself has been careful not to promote its device directly to consumers since its F.D.A.\nHourlong treatments are best spaced out by two months, said Dr. Dover, who charges $700 per spot.\nAfter reviewing Erchonia Medical\u2019s clinical study, Dr. Brian M. Kinney, a plastic surgeon in Los Angeles, said, \u201cI can\u2019t prove that it works.\u201d His concerns are that the tape measure method of gauging circumferential changes \u201cisn\u2019t consistently reliable.\u201d What\u2019s more, study participants and the placebo group were assessed only two weeks after their last treatment, not long enough to measure adequately whether results last.\nDr. Bass was not a clinical investigator for Zeltiq, but he said, \u201cI\u2019m convinced both on the science and clinical experience, it\u2019s able to eliminate fat noninvasively.\u201d\n\nNadine Tosk, a publicist for Zeltiq, explained that the rollout of the device was \u201cvery limited right now.\u201d Dr. Jeffrey Dover, a dermatologist in Chestnut Hill, Mass., who advises Zeltiq and participated in its clinical trial, said a few board-certified plastic surgeons and dermatologists were \u201chandpicked\u201d because \u201cwe know they do good work.\u201d Restraint is key, he said, because a doctor could apply Zeltiq to \u201cthe same spot\u201d in the same day, which isn\u2019t how it\u2019s meant to be used.\nThat said, a doctor with a Zeltiq device isn\u2019t hard for patients to find.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story duly reports that unpublished research showed Zeltiq resulted in 22 percent body fat loss in targeted areas. It reports that published, funded research showed patients lost an average of 3.5 inches after six sessions of Zerona laser work. \nGiven the thin body of research, this is adequate reporting of benefits. ", "answer": 1}, {"article": "The potential use of psilocybin in patients diagnosed with life-threatening diseases comes at a moment when medical care at the end of life is a subject of growing concern among patients and physicians. Research finds it's still common for dying patients to get painful and futile procedures. Palliative and hospice care, both aimed at easing the discomfort of the seriously ill, are growing specialties in American hospitals. An increasing number of patients, meanwhile, are demanding the right to die with a physician's help.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a tough one. While the story tells us what percentage of patients benefited from treatment, it does not, in fact, quantify the extent of those benefits\u2013which is precisely what this category is designed to assess. However, the story does do a good\u2013and thorough\u2013job of describing the benefits in qualitative terms.\nThat said, if the story had only chosen one or two examples of changes in the standardized measures of depression or anxiety, this would have received an enthusiastic \u201cSatisfactory\u201d rating. One strong word of caution though: The story cites one source as saying that psilocybin may one day be used to treat a wide range of mental health issues ranging from drug addiction to obsessive-compulsive disorder. The story offers no evidence to support these claims, which were made by a source associated with an organization that exists specifically to promote research on hallucinogens. Substantial claims require substantial evidence. The story would have been much stronger if it had eliminated the unsubstantiated remarks from the source \u2014 particularly since they had no bearing on the subject of the story.", "answer": 0}, {"article": "He is an associate professor in the department of infection and obesity at the Pennington Biomedical Research Center in Baton Rouge, La.\nThe research was funded by the American Egg Board, and will be presented at the19th European Congress on Obesity in Lyon, France.\n\"This study shows that diets with higher protein quality may enhance satiety, leading to better compliance and success of a weight loss diet,\" researcher Nikhil Dhurandhar, PhD, says in a news release.\nMay 11, 2012 -- Starting your day off with an egg may help curb your appetite better than cereal, new research suggests.\nScientists suspect that egg protein may be better at making people feel full longer compared to the protein found in wheat.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There was no quantification of results, like hunger levels or changes in hormone levels. The story also didn\u2019t tell us how much less participants ate at the buffet following the egg breakfast vs. cereal breakfast.\u00a0 We really need such details in order to figure out if the findings are a big deal or not.", "answer": 0}, {"article": "But they can have large effects on muscles and joints, often making muscles work as much as 50 percent harder for the same movement and increasing stress on joints by a similar amount.\nThe findings were somewhat puzzling: While the group that used inserts had about half as many injuries \u2014 defined as pain that kept them from exercising for at least half a day \u2014 there was no obvious relation between the insert a soldier chose and his biomechanics without it.\n\u201cI guess the main thing to note is that, as biomechanists, we really do not know how orthotics work.\u201d\n\nOrthotists say Dr. Nigg\u2019s sweeping statement does not take into account the benefits their patients perceive.\nBut when it comes to science and rigorous studies, he added, \u201ccomparatively, there isn\u2019t a whole lot of evidence out there.\u201d\n\nIn his studies, he found there was no way to predict the effect of a given orthotic.\nThe only indication seems to be that a comfortable orthotic might be better than none at all, at least for the activities of people in the military.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article offered a brief characterization of the magnitude of benefits related to orthotics among soldiers in one study. But in general the article did not adequately frame the potential benefits of shoe inserts. \u00a0For instance, in the review that reported a benefit for orthotics in the prevention and treatment of plantar fasciitis and tibial stress fractures, how impressive was that benefit?\n\n \n", "answer": 0}, {"article": "Visit http://www.\nThe study, New Multiple CT Assessment of Acute Stroke Patients: Are We Ready for Prime Time?, shows that recent advances in imaging software in the angiosuite give neurointerventionalists the essential details required to diagnose a patient with large vessel occlusion (LVO) for an endovascular thrombectomy (EVT).\nThis study suggests that in the future, stroke patients can bypass the CT scan or emergency department and go directly to the angiosuite for imaging and proper care.\nPreliminary results show that the cone beam imaging software compares favorably with baseline and follow-up CT scans.\nThe lead PI on this study, Professor Vitor Mendes Pereira, concluded by saying, \"By reducing intra-facility transfer times, patients can receive EVT treatment sooner, which can significantly impact patient outcomes\".\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are not quantified. The release says only that the new software \u201ccould decrease delays in care\u2026giving patients a better chance at making a full recovery.\u201d In addition, it\u2019s not clear here if improved response times are purely hypothetical, or if they are based on some sort of study.\nThe release provides no direct information on how the new test results compared to the standard version. Moreover, the study was not intended to see whether outcomes were improved as a result of this new test because it was added to the standard assessment. As a result, it may have actually delayed care for patients included in the study.", "answer": 0}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not adequately quantify the benefits of the sports drink. The story does say that the protein-containing drink provides 15% more hydration than the conventional sports drink and provides the caveat that this is not a crucial difference for most people, but this is not enough information on the benefits. The story fails to explain the magnitude of the effects observed in the source studies. ", "answer": 0}, {"article": "Brain waste includes amyloid \u03b2 (amyloid) and tau proteins, chemicals that negatively affect brain processes if they build up.\nDr. Benveniste cautioned that while the research team speculates that the human glymphatic pathway will clear brain waste most efficiency when sleeping in the lateral position as compared to other positions, testing with MRI or other imaging methods in humans are a necessary first step.\n\u201cThe study therefore adds further support to the concept that sleep subserves a distinct biological function of sleep and that is to \u2018clean up\u2019 the mess that accumulates while we are awake.\nThe method enables researchers to identify and define the glymphatic pathway, where cerebrospinal fluid (CSF) filters through the brain and exchanges with interstitial fluid (ISF) to clear waste, similar to the way the body\u2019s lymphatic system clears waste from organs.\nIn the paper, \u201cThe Effect of Body Posture on Brain Glymphatic Transport,\u201d Dr. Benveniste and colleagues used a dynamic contrast MRI method along with kinetic modeling to quantify the CSF-ISF exchange rates in anesthetized rodents\u2019 brains in three positions \u2013 lateral (side), prone (down), and supine (up).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We identified two important problems with the way benefits are described:", "answer": 0}, {"article": "First published on July 1, 2008 at 12:00 am\nThe study's lead author, Dr. Paul M. Palevsky, said the results may lead to a large savings in U.S. health care costs, estimated at $100 million to $250 million a year for this type of patient.\n\"When a patient transitions from one therapy to another, the dialysis dose is unlikely to be equivalent,\" he said, adding that results could be affected by different methods in the high-intensity and low-intensity groups.\nDr. Bonventre wrote that the study had \"a predominance of male patients,\" so there is a question of whether its results can be applied to female patients.\nAnd, he said, the results cannot be simply applied to patients with chronic kidney disease, who then have acute kidney injury, since the study excluded any patients with advanced chronic kidney disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did mention that the two approaches to treating acute kidney injury did not have different outcomes and specifically mentioned death rates, recovery of kidney function and rates of other organ failure.\u00a0 The story also mentioned a death rate in one health care system of 50-80% from acute kidney injury. ", "answer": 1}, {"article": "Involuntary muscle spasms (spasticity) are common symptoms of MS.\nSide effects varied greatly and depended on the amount needed to limit spasticity, the researchers write.\nBut subjective assessment of relief of spasticity suggested significant improvement after treatment, they write.\nThe researchers say that many existing therapies for this condition are difficult to obtain, ineffective, or associated with intolerable side effects.\n\"Considering the distress and limitations spasticity brings to individuals with MS, it is important to carefully weigh the potential for side effects with the potential for symptom relief, they say in the news release.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Absolutely no numbers were provided to give a sense of the scope of the suggested benefit.\u00a0\u00a0 How many people who took the extracts benefited?\u00a0 You\u2019d never know from the story.", "answer": 0}, {"article": "\u201cIt felt as though my head was a cement block,\u201d Kaufman told NBC News.\nAnother advantage: it could lead to a decrease in the amount of medications used by patients to handle headaches acutely.\nRelated: Placebos Help Kids with Migraine as Well as Drugs Do\n\nKudrow says that there is a reduction in the frequency and intensity of the headaches for a large number of his patients taking the new class of drugs, but not all.\nFor 63-year-old Lynn Kaufman, the battle against migraines consumed her life.\nThe aim of the medication is to stop a migraine before it even starts.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told only that \u201cpreliminary studies sponsored by one drug maker shows patients had three to four fewer migraine days each month.\u201d Three to four fewer migraine days each month\u2013what was the starting point?\nAnother concern we had was this claim: \u201cIf we can block CGRP [a molecule], then we can abort a migraine attack,\u201d says Kudrow.\u00a0Do scientists really know that blocking this molecule is all it takes to stop migraines in all people who get them? Or does this molecule-blocking action only work for some people, and if so, for whom?\nAlso, it sounds like results from several clinical trials are due out later this year\u2013why not wait to write the story then, when there\u2019s more evidence to assess?", "answer": 0}, {"article": "It\u2019s this type of innovation that sets MPTC apart from other proton treatment centers.\u201d\n\nAbout the University of Maryland School of Medicine\n\nCommemorating its 210th Anniversary, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States.\nRadiation oncologists at UMGCCC already use external thermal therapy to treat a range of cancers, but do not currently use it for cancers that are deeper in the body.\nMPTC offers a robust clinical trial program to all its patients to further evidence-based medicine.\nStudies have found that adding thermal therapy to standard treatments can significantly shrink tumors and can improve survival for some patients.\nAt MPTC, each treatment room is equipped with the most advanced form of \u201cpencil beam\u201d proton therapy, which essentially paints the radiation onto the tumor while stopping precisely at the site of the tumor.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are no numbers providing context on the claimed benefits, only an assertion that the combined treatments offer \u201ca potential way to boost survival chances for certain cancer patients.\u201d But how much is survival \u201cboosted?\u201d By weeks? Years? And which cancer patients are eligible? The news release broadly states that the hyperthermia equipment will be used to treat cancer in the bladder, rectum, cervix, ovaries, pancreas, and connective tissue, but does not get more specific. \nThere is no information provided about any specific study or data demonstrating the benefits of either proton beam therapy or hyperthermic therapy for patients with these cancers.", "answer": 0}, {"article": "Labor may be induced by breaking the amniotic sac or by using hormones called prostaglandins or medication such as oxytocin, which can set off contractions.\n\u201cIt\u2019s obvious that a blanket policy of 39-week inductions would not affect all of the stillbirths that happen before 39 weeks,\u201d Dekker said, adding that the CDC report concludes, \u201cDespite intensive investigations, for a substantial number of fetal deaths a specific cause of death cannot be determined.\u201d\n\nAnd, Dekker said, the public has the misconception that inductions are simple, noninvasive procedures.\n\u201cThere are anywhere between 25,000 to 30,000 stillbirths a year in the United States.\u201d\n\nLockwood and Norwitz\u2019s support for induction at 39 weeks not only surprised many of the doctors at the session, it also upset those who believe less intervention is the safest route for mother and baby.\nDekker said there were flaws in the research showing that women who received elective induction had lower rates of Caesarean delivery.\nStill, he was surprised by an audience poll at the end of the discussion: 70 percent now supported the idea that women deliver at 39 weeks, 21 percent remained unsure and only 9 percent were against the idea.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quotes advocates of inducing labor at 39 weeks as saying it might lead to fewer Caesarean deliveries and might reduce complications, but no numbers are provided. The story also quotes an advocate as saying the risk of stillbirth and neurological injuries rises after 39 weeks.\nNot only are no numbers cited, there is also no mention of any evidence that inducing labor would change the long-term outcomes for those babies; that is, what if inducing labor earlier prevented a stillbirth, but that baby had underlying problems that lead to death soon after birth? These important questions about how to weigh any potential benefit of inducing labor earlier are not addressed in the story.", "answer": 0}, {"article": "\"They take them because they have a disease that impacts their daily life,\" Economy says.\nThe FDA advisory pointed to a single study showing a six-fold increased risk of a condition called persistent pulmonary hypertension in newborns whose mothers were taking antidepressants.\n\"The risk increase of taking antidepressants late in pregnancy, if present, is much more modest than previous studies have found,\" says Krista Huybrechts, Ph.D., an epidemiologist at Brigham and Women's Hospital.\nDr. Economy warns patients about the potential risks like withdrawal in the newborn and a small risk of heart defects, but says for many women, the worst time to stop their medications is at the end of pregnancy when postpartum depression becomes a concern.\nBut now a new, large-scale study finds that the risk is negligible -- much lower than previously believed, reports CBS Boston's Dr. Mallika Marshall.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are described in broad strokes but never really quantified. We\u2019re told the FDA, back in 2006, said taking SSRI antidepressants late in pregnancy might increase the rate of PPHN six-fold \u2013 but we\u2019re never told what the absolute rates are. Mentioning a few numbers from the study would have made this story\u2019s look at the benefits more informative.\nFor example, of the 3.8 million women looked at in the study, about 102,000 took SSRI antidepressants. The rate of PPHN for that group was about 31 cases per 10,000 births, compared to 20.8 cases per 10,000 births in women who didn\u2019t take SSRIs.\u00a0The HealthDay story again did this nicely \u2014 it helps to have the overall rate of PPHN, the rate in depressed women not taking anti-depressants, and the rate on non-SSRI anti-depressants for comparison. These figures reinforce the finding that PPHN is uncommon overall, and that the risk in women who take SSRIs is not much higher than in those who don\u2019t.", "answer": 0}, {"article": "If a pill could prevent teenagers from taking dangerous risks, would you consider it for your children?\n\nI\u2019d be tempted. My skateboard- and bicycle-riding son was hit by a car\u2014twice\u2014when he was a teenager. I would have welcomed anything that could have averted those dreadful phone calls from the emergency room.\n\nWhile some bumps and scares...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides some percentages\u00a0but no absolute numbers. It says:\nThe researchers found fewer and less severe injuries and health problems among the treated children: a 3.6% reduction in sexually transmitted infections; 5.8% fewer children who sought screening for sexually transmitted infections (suggesting they had had an unprotected sexual tryst); and 2% fewer teen pregnancies.\u00a0That adds up to a lot fewer teenagers in trouble.\nThe Princeton news release about the study provides actual numbers related to outcomes, including injuries, which is missing from the Wall Street Journal story even though the story makes a claim about injuries being less likely.\nIn absolute numbers in a sample of about 14,000 teens diagnosed with ADHD, it translates into 512 fewer teens contracting an STD and 998 fewer having a substance abuse disorder. There also would be 6,122 fewer yearly injury cases for children and teens under 19 years old.\nWe would have liked to have seen both types of statistics included in the story.", "answer": 0}, {"article": "Such screening is increasingly used in research.\nThe findings also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify people for clinical trials of drugs to prevent Alzheimer\u2019s.\nExperts say previous trials of anti-amyloid drugs on people with dementia failed because their brains were already too damaged or because some patients, not screened for amyloid, may not have had Alzheimer\u2019s.\nThe largest analysis to date of amyloid plaques in people\u2019s brains confirms that the presence of the substance can help predict who will develop Alzheimer\u2019s and determine who has the disease.\nTwo linked studies, published Tuesday in JAMA, also support the central early role in Alzheimer\u2019s of beta amyloid, the protein that creates plaques.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies only two specific findings from the studies: 30 percent of the patients with mild cognitive impairment (often a precursor to Alzheimer\u2019s) that were screened in one study had no amyloid, and 88 percent of volunteers with any type of Alzheimer\u2019s or other dementia (frontotemporal, vascular or dementia with Lewy bodies) had amyloid in their brains. That\u2019s not much in the way of numbers. And the headline may set unrealistic expectations with its description of amyloid \u201cpredicting\u201d Alzheimer\u2019s. If we\u2019re going to talk about\u00a0\u201cpredicting\u201d Alzheimer\u2019s, then it\u2019s not unreasonable to expect a specific accounting of how often the test is right and how often it\u2019s wrong \u2014 which is something the story doesn\u2019t really get into.\nAs the story later explains (to its credit), the benefits at this point are more in the context of research \u2014 in identifying people who are candidates for clinical trials (which really isn\u2019t a new contribution for this study). These methods are not meant to identify people at risk of Alzheimer\u2019s in the general public.\u00a0The authors of the journal article in dementia patients conclude it has \u201cpotential clinical utility.\u201d", "answer": 0}, {"article": "WASHINGTON (Reuters) - An experimental drug being developed to fight influenza may fight a common but little-known virus called parainfluenza virus, researchers and the company said on Friday.\nMoscona said tests were needed that would show the drug actually helped reduce disease symptoms in animals.\nThe researchers said that means patients with flu-like symptoms could get the drug without the need for a test to show whether their infection was caused by influenza or parainfluenza.\nDr. Anne Moscona of Weill Cornell Medical Center in New York and colleagues tested varying doses of the drug, also known as DAS181, in lab dishes and on cotton rats, a species accepted by scientists for testing parainfluenza.\nBecause Fludase affects the human cells that viruses infect, not the virus itself, it is less likely to cause the virus to develop resistance, the company believes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "       \n \nThe story did not provide any data and did not tell us anything about the cells used or the number of rats included in the study. \nThe story suggests that the test drug, \u201c\u2026could stop the virus from  replicating\u2026.\u201d\u00a0In actuality, the study drug reduced the viral load as  compared to animals treated with a placebo.\u00a0The story fails to note the  small sample (20 rats total) and the limited time of treatment (3 days)  before the animals were euthanized.\u00a0The story fails to place the study  results in context potentially giving the reader a false interpretation  of the study.\n ", "answer": 0}, {"article": "Visit the U.S. National Cancer Institute for more on aspirin and cancer risk.\nMoreover, the benefit of aspirin in reducing overall cancer risk appeared to depend on how much one took.\nSpecifically, no link was found between aspirin use and a lower risk of breast cancer, advanced prostate cancer or lung cancer, the researchers said.\nThere was a 20 percent lower risk of cancers of the gastrointestinal tract, especially in the colon and rectum, among people taking aspirin, said lead researcher Yin Cao, a postdoctoral research fellow at the Harvard School of Public Health in Boston.\nAnd the study only showed an association between aspirin use and gastrointestinal cancer risk, not a cause-and-effect relationship.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The second sentence of the story notes that \u201cthere\u00a0was a 20 percent lower risk of cancers of the gastrointestinal tract, especially in the colon and rectum, among people taking aspirin.\u201d We think that statistic is likely to give readers an inflated sense of the benefits. Instead, we wish the story had presented the absolute reduction in risk for people taking aspirin vs. not. In other words, what was the rate of cancer in the aspirin group and what was the rate of cancer in the no-aspirin group? That would help readers understand if this is a very meaningful reduction, or if the 20% reduction is merely making an already-low risk even lower.", "answer": 0}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The nature of the study was to determine if the app was feasible for wider research\u2013and not to see if it was more beneficial than another app (or no app at all) at tracking activity concussion symptoms. For this reason, we\u2019ll give the story a N/A rating on this one.\nHowever, we did want to stress that the story focuses on a secondary finding of the study that makes it sound like it was an intervention trial comparing cognitive activity\u00a0to physical\u00a0activity and their impact on concussion symptoms and recovery. We\u2019re told that\u00a0patients who spent more time reading, playing online games, watching television or working on a computer (so called cognitive activities) reported \u201cmore severe symptoms\u201d on the day they engaged in the activity and two days after. And it stated that more physical activity tended to correspond with fewer symptoms over the following two days. Ordinarily, we\u2019d expect to see that put in quantified terms\u2013i.e., how many symptoms is \u201cfewer?\u201d 1 or 10 or 100?", "answer": 2}, {"article": "Lisinopril is a member of a drug family called ACE (angiotensin-converting enzyme) inhibitors.\nCalled angiotensin receptor blockers, these drugs have a greater protective effect against dementia than ACE inhibitors, the study found.\nThe risk was nearly halved for those taking both angiotensin-targeting drugs.\nWolozin said that it's not clear why the drugs would have a beneficial effect on the brain, but improved blood flow probably plays a role.\nThe angiotensin hypothesis makes sense, Lipton said, because improved blood flow to the brain helps nerve cells and reduces formation of Alzheimer's-related amyloid protein.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are given only in relative, not absolute terms.\u00a0 See our primer on this topic.\u00a0 So when the story says \"24 percent lower incidence of dementia\" or \"The risk was 19 percent lower\" or \"The risk was nearly halved\" \u2013 readers need to know 24%\u00a0of what?\u00a0 19% of what?\u00a0 Half of what? ", "answer": 0}, {"article": "We have to really ask the question: 'How low do you go?'\nAlthough the reason for the increased risk remains a mystery, Nabel and other experts stressed that the benefits of blood sugar control have been well established for diabetics and said patients should not make any changes in their care without consulting their doctors.\nBut the findings cast doubt on a major hope about diabetes treatment -- that pushing levels below current targets would be beneficial -- and would force experts to rethink how to treat one of the nation's leading health problems.\nThe researchers stressed that the findings would not alter current guidelines or treatment for most diabetics, many of whom can control their blood sugar without drugs.\nBecause some of the patients were taking the drug Avandia, which has been the focus of concern that it might increase the risk of heart attacks, the researchers specifically examined whether that was a factor.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story differentiated the two groups as having been treated to have blood sugar levels like \u2018the average person with diabetes\u2019 and \u2018closer to those of someone without diabetes.\u2019\u00a0 We would wish for more specific information about what those blood sugar levels were.\nThe point of the story was not that blood sugar levels ought not be treated, but rather what the goal ought to be in order to maximize the benefit of treatment.\n\u00a0\n\u00a0\n", "answer": 0}, {"article": "NEW YORK (Reuters Health) - In a new study of middle-aged New Jersey men, taking cholesterol-lowering drugs was linked to a lower chance of dying from prostate cancer.\nThe researchers also couldn\u2019t tell whether men started using statins before or after they were diagnosed with aggressive cancer.\nResearchers agreed that until there\u2019s clearer evidence for benefit, men with healthy hearts shouldn\u2019t seek out statin prescriptions for the purpose of lowering their prostate cancer risks.\nThat type of study, especially involving healthy, disease-free men, would be very expensive and time consuming, said Dr. Nelly Tan, from the University of California, Los Angeles, who has studied statins and prostate cancer risk.\nBut Freedland said that other strategies for lowering cholesterol \u2014 such as eating better and exercising regularly \u2014 are ways almost everyone can lower their disease risks in the meantime.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Story explains that those with fatal cancers were 63% less likely to have ever taken a statin, but then goes on to explain that \u201cit\u2019s also possible that statins don\u2019t prevent certain cancers at all.\u201d", "answer": 1}, {"article": "A study of more than 20,000 patients with traumatic injuries and at risk of bleeding to death found those who were treated with tranexamic acid were significantly less likely to die than those who got a placebo.\nAlso, there was no difference in deaths from clots blocking blood vessels in either group, a potential safety concern for the medicine.\nThat improvement may not seem so dramatic, but drug is pretty easy to give -- an initial 10-minute infusion within 8 hours of injury, followed by a second infusion over 8 hours.\nThat means 66 people would have to get tranexamic acid to prevent one death.\nSome 14.5 percent of patients who got the drug were dead within a month of being injured compared with 16 percent of those who got the dummy medicine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story focuses on mortality difference between the TXA and placebo groups and presents the results in absolute terms. It helpfully notes that TXA would need to be adminstered to 66 patients to prevent one death.\nAlthough it passes along the claim that TXA might save \"tens of thousands of people\" without questioning it,\u00a0the story\u00a0doesn\u2019t hype the assertion quite as vigorously\u00a0as the competing coverage.\u00a0\u00a0", "answer": 1}, {"article": "But how?\nAs an alternative, there's a relatively new product called Fernblock, which claims to protect the skin internally by systemically inhibiting the absorption of ultraviolet rays.\nIf you're squeamish about vitamin A, there are a number of alternatives.\nOur two cents' worth:There's no reason not to take a flyer on Fernblock \u2014 actress Reese Witherspoon gives it a hearty endorsement - but keep slathering up, too.\nA cautionary note:The damning evidence against vitamin A, which has long been used as a skin-cancer treatment, came from experiments done on mice, which have a far higher susceptibility to skin cancers than humans.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no attempt to present any quantification of the benefits of Fernblock for preventing burns or, by extension, cancers and photo-aging.", "answer": 0}, {"article": ".\n\"For the first time, this study demonstrates the use of OCT for imaging tumor margins within the tumor cavity, in the patient, during surgery,\" Boppart said.\nThe interdisciplinary research team led by Stephen Boppart, a University of Illinois professor of electrical and computer engineering and of bioengineering, performed the study on 35 patients with breast cancers at the Carle Foundation Hospital in Urbana, Illinois.\nThe researchers will continue clinical studies with the OCT device, looking at other types of solid-state tumors.\nDiagnostic Photonics, a start-up company Boppart co-founded that also collaborated on the study, is commercializing the OCT probe technology for broader use.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release describes the accuracy of the device as follows:\nThe study found that the OCT device analysis identified the differences between normal and cancerous tissue with 92 percent sensitivity and 92 percent specificity. They also found that the way that OCT spotted cancer in the removed tissue was closely correlated with the results from the postoperative pathology reports, which often came days later.\nIt also quotes the study author who says:\n\u201cFor the first time, this study demonstrates the use of OCT for imaging tumor margins within the tumor cavity, in the patient, during surgery,\u201d Boppart said. \u201cIt is likely better to check to see if any residual tumor cells might be left behind, rather than checking the tissue mass that was taken out. Then, the surgeon can intervene immediately.\u201d\nWe\u2019re inclined to give the benefit of the doubt given the story\u2019s good-faith attempt to use some numbers to describe the device\u2019s accuracy. However, we think the study itself had many details, not communicated in the release, that would have added to the release\u2019s credibility, understandability, and potential impact. It would have been very useful to know more about how many of the 35 women participating in the study had mastectomies, for example, how many had invasive cancers, in situ cancers, or ductal cancers; and how large a range the tumors covered.\nFor the sake of background, we\u2019d add that breast cancer surgeons used to go after wider margins (i.e. more healthy tissue at the edge of the removed tumor) than they do today. There is a large body of evidence that demonstrates that wider margins do not translate to better outcomes, and the SSO-ASTRO margin guideline statement is now fairly well accepted, noting that \u201cno ink on tumor\u201d is sufficient in many cases of invasive cancer; of course this may not apply to all cases. As more physicians adopt the 2014 guidelines, the utility of these devices may be called into question.", "answer": 1}, {"article": "Autism is a group of complex brain developmental disorders characterized by impairments in social interaction, communication, and stereotypical and repetitive behaviours.\nThis is the first time a medical treatment has shown this type of benefit for children with autism and findings reinforce outcomes from a longer sustained program of research by this team.\nStudy co-author and co-director of the Brain and Mind Centre, Professor Ian Hickie noted the new results were a critical first advance in the development of medical treatments for the social deficits that characterize autism.\nA five week treatment with the synthetic hormone oxytocin significantly improved social, emotional and behavioral issues among young children with autism, according to University of Sydney research published today in Molecular Psychiatry.\nMost recently the team has linked observed changes from treatment to brain changes associated with social circuitry.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release headline says that oxytocin \u201chas social, emotional and behavioral benefits in young kids with autism.\u201d But our reviewers found that claim questionable. Of numerous ratings done, one caregiver-measure of social responsiveness came out as statistically positive, and a clinician-rated measure of Clinical Global Improvement came out positive. Our reviewers did not think it was accurate to report that emotional and behavioral symptoms were affected since none of the measures that specifically evaluated these symptoms came out as positive.\nThe release also says that symptoms in children with autism were \u201csignificantly improved,\u201d but it never quantifies the improvement. We are told only that children were said by their parents to be more socially responsive at home and that independent clinical ratings showed improvements in social responsiveness.\nWhat were the exact measurable benefits? According to the published study, 72% of the patients were rated by the clinical staff\u00a0 to have improved in terms of social interaction and responsiveness compared to 41% who showed such improvement when treated with a placebo. The patents were assessed at baseline and at the end of 5 weeks of treatment.", "answer": 0}, {"article": "Animal studies have suggested that omega-3 fatty acids may have anti-cancer effects, but the results from human epidemiological studies have been inconclusive.\nThe researchers found no effect in men, and no effect of omega-3 consumption on hyperplastic polyps, which are more likely to be benign.\nThe analysis appears online in The American Journal of Clinical Nutrition.\n\u201cThis is more evidence to suggest that omega-3s are beneficial and may have anti-inflammatory action helpful in reducing cancer risk,\u201d said the lead author, Dr. Harvey J. Murff, an associate professor of medicine at Vanderbilt.\nAfter controlling for age, race, body mass index, smoking and other factors, the researchers found that women in the highest fifth for omega-3 consumption \u2014 those who consumed three or more servings of fish a week \u2014 were 33 percent less likely than women in the lowest fifth to have adenomatous polyps, a type likely to become cancerous.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The language matters.\nThe story states:\u00a0 \u201cThe researchers found no effect in men, and no effect of omega-3 consumption on hyperplastic polyps.\u201d\u00a0 (emphasis added)\nObservational studies can\u2019t prove cause and effect, so language like this just confuses the communication of the findings.", "answer": 0}, {"article": "In 2005, she was told she was having a boy, and she chose a name, bought boy clothes and told everyone.\n\u201cIt\u2019s very important to educate health care providers that pregnant women are buying these tests.\u201d\n\nAnother type of test not studied by the researchers has become popular because it is cheaper and can be done at home.\nMost tests that were highly accurate were conducted on a mother\u2019s blood, not urine.\nOne potential worry is that women might abort fetuses of an undesired sex.\nThese tests analyze hormones in women\u2019s urine, a method that several experts said has not been studied as rigorously as DNA.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Parents who fear their child may inherit gender-linked disorders, such as hemophilia, could use this test earlier in pregnancy and possibly avoid more invasive procedures, such as amniocentesis. Amniocentesis carries a risk of miscarriage. We would have liked some numbers about how many women in the US are facing this dilemma; the situations that carry benefit are few. The average gestational \u201cage\u201d at enrollment in prenatal care in the US is after the window in which most of these tests are marketed. So that means if a couple did not know that they needed to think about X-linked mental retardation \u201cfragile X\u201d (which affect males) or hemophilia, the use of the test would not really be integrated into their care. Could have been more skeptical of why they are really being marketed \u2013 closer to entertainment ultrasounds than medical care.", "answer": 0}, {"article": ".\nCherian noted that the study does not prove that the DASH diet leads to a reduced risk of depression; it only shows an association.\nThe odds of becoming depressed over time was 11 percent lower among the top group of DASH adherers versus the lowest group.\n\"Future studies are now needed to confirm these results and to determine the best nutritional components of the DASH diet to prevent depression later in life and to best help people keep their brains healthy,\" said Cherian.\nFor the study, 964 participants with an average age of 81 were evaluated yearly for an average of six-and-a-half years.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that \u201cThe odds of becoming depressed over time was 11 percent lower among the top group of DASH adherers versus the lowest group.\u201d\u00a0 Here the release is relying on relative risk reduction figures which are far less meaningful to patients than numbers that explain the absolute risk reduction.\nWe also are left wondering how closely the \u201ctop group of DASH adherers\u201d followed the DASH diet? To what extent did that differ from the \u201clowest group\u201d?", "answer": 0}, {"article": "Anton P. Porsteinsson, MD, Professor of Psychiatry at the University of Rochester School of Medicine and Dentistry and Director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester in Rochester, NY, and an investigator in the North American Phase 3 clinical trial, commented: \"The genetically-defined population of APOE4 carriers has an 8-12 fold increased risk of developing AD and has more rapidly progressive disease, usually becoming symptomatic a decade earlier than non-carriers of the APOE4 genotype.\nThe results published in JPAD are the first evidence from a large clinical trial to associate efficacy of an amyloid-targeted agent with APOE4 status in AD patients.\nThe efficacy and safety analyses with tramiprosate published in JPAD reveal a therapeutic effect in patients who are carriers of APOE4 after segmenting them from the larger, non-genetically-defined study population in the Phase 3 clinical program, involving more than 2,000 AD patients in North America and Europe.\nThese analyses with tramiprosate in the APOE4 subgroups are compelling, and suggest a meaningful clinical benefit, on top of the existing symptomatic AD treatments, in Alzheimer's patients who are in great need of new treatments.\nEfficacy Results in APOE4/4 Homozygous Patients from the JPAD Phase 3 Analyses\n\nThe published results showed the largest clinical benefit in the Alzheimer's APOE4/4 homozygous AD patients, who represent approximately 15 percent of patients in the study.3 APOE4/4 homozygous patients who received the high dose of tramiprosate showed efficacy benefit compared to placebo on both cognitive and functional measures in the Phase 3 analyses.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that there is a \u201cmeaningful clinical benefit\u201d to the study medication, known as tramiprosate.\nBut we couldn\u2019t find a meaningful description of the benefit in clear language. What we did find was a densely technical section where effects were described as follows:\n\u201cThe effects on the ADAS-cog cognitive outcome were significant at Week 65 (LS means difference from placebo: 3.47, nominal p = 0.007) and Week 78 (2.60, nominal p = 0.043), and corresponded to 66 percent and 40 percent benefit from tramiprosate compared to placebo. These effects were supported by functional benefits on the CDR-SB that showed a positive trend at Week 65 (LS means difference from placebo: 0.79, nominal p = 0.063) and were numerically in favor of tramiprosate at Week 78 (0.54, nominal p = 0.21).\u201d\nBut even if the p values here were significant, this analysis would not mean the drug showed benefits.\nThe study itself \u2014 not the release \u2014 contains some helpful context on the sub-group analysis that might have improved the release.\n\u201cDrug effects in AD trials are considered clinically meaningful if they provide at least 25% benefit over placebo. The cognitive effect of the 150 mg BID dose in APOE4/4 AD patients corresponds to 40% benefit over placebo at week 78, and is thus clinically meaningful. This cognitive effect is also supported by positive trends on global function, which corresponds to 25% benefit on CDR-SB at the week 78 endpoint, as well as a numerically consistent effect on disability with 25% benefit on DAD. \u201c\nA news release is intended to communicate with a non-technical audience of news professionals but this release fell short of translating the science well. We would have liked some discussion of how the \u201ccognitive effect\u201d is measured in these patients. What exactly is a positive trend in global function? Some examples could have helped. ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that patients with sciatica got better faster if they had disc surgery. But it does not say how much better or how much faster\u2014very important information. For example, patients actually had worse disability scores at 4 weeks if they had disc surgery. The greatest advantage for surgery was between weeks 8 to 12, and surgery continued to speed recovery only through week 36. The story also does not quantify the benefits of treatment for patients enrolled in the second study on degenerative spondylolisthesis and stenosis. If it had, readers might come away with a more nuanced message about the efficacy of both surgery and nonoperative therapies. (See also \u201cEvidence\u201d above.) For example, the majority of patients receiving nonsurgical care showed \u201cmoderate\u201d improvement, a fact the news story never mentioned but the study reported in both absolute and relative estimates. And when the researchers analyzed patients in the randomized cohort according to the treatment they were assigned (\u201cintention-to-treat analysis\u201d), they found no differences in the outcomes of the surgical and nonsurgical care. When they analyzed patients according to the treatment they actually received (\u201cas-treated analysis\u201d), they saw big differences. As the accompanying editorial in the New England Journal of Medicine by Richard A. Deyo points out, the truth probably lies somewhere in between. ", "answer": 0}, {"article": "Dennis Halmi, a member of the Bluepoint Surgical Group in Woodbridge, says that in 2002 \"we did a handful\" of second operations on obesity patients, \"maybe five, six.\nOf course, a second obesity surgery comes with increased risk.\nThat's an often frightening attack of sweating, nausea, faintness, diarrhea, cramps and rapid pulse that bypass patients sometimes suffer after eating just a bite of a sugary food -- a deterrent to consuming certain calorie-dense items.\nAlong with the risk comes the uncertainty of how well people will be able to lose -- and keep off -- weight the second time around.\nThe second time around, many, like Thayer, are opting for the adjustable band, which works differently from the bypass.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story indicated that gastric banding may re-impose limitations on caloric intake that had initially been established with gastric bypass. \u00a0While it indicated that good long-term data about the utility of banding after bypass was not available, this was overshadowed by the examples of the weight loss seen in a few individuals it detailed. \u00a0", "answer": 0}, {"article": "\u2022 Retrograde menstrual flow: During a period, when a woman is shedding her uterine lining, some of that tissue can flow through her fallopian tubes and into her pelvis, which researchers think may cause endometriosis.\nWe have no idea about the long-term effects of taking the drug because there are no trials lasting for longer than a year, or how it stacks up against other painkillers (since the trials only compared it to placebo).\nSo it\u2019s no surprise it takes between three and 11 years after the onset of symptoms to diagnose endometriosis.\nIn the trials, women who took the drug had greater bone loss than did those who received placebo, and this wasn\u2019t entirely surprising.\nSoon, it seems, women like Dunham with endometriosis pain will have a new option for relief.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story needed to include more information about the study results\u2013in particular, how both the drug and the placebo performed in the trials.\nAs we learn from the NEJM study, the drug reduced pain for about half of the women who took it\u2013but the placebo also reduced pain for about 35% of the women who took it. That\u2019s a good detail to include as it provides a better sense of the drug\u2019s effectiveness.", "answer": 0}, {"article": "\"We don't yet have a full understanding--nobody does--of how the bile acid actually does what it does in heart cells,\" explains Michalak.\n\"Prevention of fibrosis will extend the ability of the heart to function, even if at a reduced capacity.\nThis research was supported by the Canadian Institutes of Health Research.\nThe study discovered the specific triggers activating the development of fibrosis which accelerates heart failure.\nThe team is now pushing forward with additional studies to see if the same therapeutic effect can be achieved in humans.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Beginning with the headline (\u201cCanadian discovery may soon lead to the prevention of cardiac fibrosis\u201d) and first sentence (\u201cGroundbreaking research from the University of Alberta and McGill University\u2026\u201d) the release over reaches in its description of benefits \u2014 at least to humans, transgenic mice however should be thrilled.\nJumping directly from a mouse model to humans is simply wrong in our view. \u00a0As we pointed out above, suggesting that a drug in a pre-clinical study \u00a0\u201c\u2026offers hope to those who are living with heart failure,\u201d \u00a0given the long and arduous process of regulatory approval does a disservice to people living with the disease.", "answer": 0}, {"article": "\u2022 Prostatectomy, the surgical removal of the prostate gland, which can be done with minimally invasive techniques and robotic assistance;\n\u2022 Brachytherapy, in which doctors implant numerous small radioactive seeds about the size of a grain of rice into the prostate gland using multiple large needles inserted through the skin in the operating room.\nThe SBRT study for prostate cancer was supported by a grant from the U.S. Department of Defense.\nThe study - the first trial to publish five-year results from SBRT treatment for prostate cancer - found a 98.6 percent cure rate with SBRT, a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target.\nDr. Timmerman, Director of Image-Guided Stereotactic Radiation Therapy, Medical Director of Radiation Oncology, and holder of the Effie Marie Cain Distinguished Chair in Cancer Therapy Research, has served as the lead investigator in several national trials designed to evaluate the efficacy and safety of SBRT to treat other types of cancer, including cancer in the lung, liver, and spine.\nOther clinical trials at the UTSW Department of Radiation Oncology are seeking to expand the application of SBRT to high-risk (Stage III) prostate cancer patients.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is an odd news release. The study, described as a Phasel/ll, was conducted to assess the safety of escalating doses of radiation with the goal of determining whether varying doses of SBRT had an acceptably low rate of\u00a0toxicities. The study was not intended to\u00a0provide any definitive assessment of survival benefit, and yet that\u2019s what the release is about.\u00a0 It states:\n\u201cThe study \u2014 the first trial to publish five-year results from SBRT treatment for prostate cancer \u2014 found a 98.6 percent cure rate with SBRT, a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target.\u201d\nThe \u201ccure\u201d rate referred just to men who had no evidence of rising PSA \u2014 and the study acknowledges that most men were not actually followed for 5 years so\u00a0\u201ccure rate\u201d was statistically estimated. \u00a0However, over a third of the men had low-risk cancer where the 5-year cancer-specific survival is estimated to be 100 percent. It\u2019s not certain that these men actually required treatment.\nBeyond that, the release did not quantify benefits precisely. There was only one sentence directly addressing the study results. There was no description precise study group demographics. The release does not define \u201ccure\u201d as it is used in the sentence below and the headline.", "answer": 0}, {"article": "Though randomized controlled clinical trials of bright light are difficult to do properly \u2014 one expert is fond of saying that it is difficult to \u201cblind\u201d studies of bright light \u2014 the American Psychiatric Association considers bright-light therapy an effective low-risk treatment for both S.A.D.\n\u201cIf you can fix the drift, you can fix the depression.\u201d\n\nLight therapy may even help with major nonseasonal depression, experts say, and with sleep disorders.\n\u201cStudies have also shown that light influences serotonin and epinephrine pathways in the brain, the same neurotransmitter systems known to be affected in people with general depression.\u201d\n\nBut while part of the appeal of light therapy is that it can be self-prescribed, using a light box is not as simple as it may appear.\nAnd because it has few side effects, researchers are studying whether light therapy can help with depression during pregnancy and be used to treat elderly people with dementia.\nSome say their patients don\u2019t have the patience to sit in front of a light for 30 to 45 minutes every morning.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story did not provide any quantified detail about the results of using light therapy for seasonal affective disorder. It quoted two patients, anecdotally, about how much they believed they had been helped. It quoted the American Psychiatric Association as saying the therapy is \u201can effective low-risk treatment\u201d for both seasonal and major depressive disorder. But it did not give any metric for how well the treatment works, or how quickly or for how long.\u00a0 How many patients getting light therapy get a little bit better?\u00a0 Much better?\u00a0 No better?", "answer": 0}, {"article": "Medtronic Inc. and Eli Lilly & Co. agreed to collaborate on an early stage research project for a potential Parkinson's-disease treatment that involves delivering medication directly to the brain\u2014a goal that has long eluded drug makers.\n\nThe pact, announced Tuesday, adds to Medtronic's roster of projects aimed at using implantable drug pumps and catheters to circumvent the blood-brain barrier. The tightly packed network of cells in brain capillaries only lets certain substances through, such as key nutrients, making brain-based...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "What we especially appreciated was the tone and the framing of the story.\nIt didn\u2019t call this idea a treatment.\u00a0 It called it a \u201cpotential treatment.\u201d\u00a0 It\u2019s not a treatment until it\u2019s been shown to actually treat someone for something.\nIt used the word \u201cpotential\u201d three times in the story.", "answer": 1}, {"article": "Her mother, aunt and grandmother died of cancer.\n\u201cProphylactic removal of ovaries and fallopian tubes is strongly recommended in women before age 40 in BRCA1 and BRCA2 mutation carriers,\u201d said Dr. Susan Domchek, executive director of the University of Pennsylvania\u2019s Basser Research Center, which specializes in BRCA mutations.\nIt is unclear how common the mutations are in other racial and ethnic groups.\nCancer experts said Tuesday that the actress and filmmaker Angelina Jolie Pitt was wise to have had her ovaries and fallopian tubes removed last week because she carries a genetic mutation, BRCA1, that significantly increases the risk of ovarian cancer, a disease so difficult to detect that it is often found only at an advanced, untreatable stage.\n\u201cThere is no effective screening for ovarian cancer and too many women with advanced stage ovarian cancer die of their disease.\u201d\n\nWriting for The New York Times\u2019s Op-Ed page, Ms. Jolie Pitt, 39, said she had expected to have her ovaries and fallopian tubes removed, a procedure called a laparoscopic bilateral salpingo-oophorectomy, but that a cancer scare made her decide to undergo the procedure sooner.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story never really provides any data on the risk reduction seen in women with BRCA1 or BRCA 2 mutations due to removal of their ovaries and breasts. Readers are advised that removal of ovaries reduces risk of breast cancer, but no mention is made of the reduction in risk of ovarian cancer. Risk is not totally eliminated.", "answer": 0}, {"article": "Traditional heart catheterization through a vein in the neck can take 20 minutes or longer.\nBut because it's self-contained, the catheter theoretically should provide little margin for contamination that can lead to infection.\nHe recently procured a bank loan agreement and is hoping the award recognition and hospitals' willingness to try the catheter will attract a venture capitalist.\nReavill won a prestigious contest in London late last year called the OmniCompete Health Pitch Battlefield, whose independent judges said his invention is a simple way to catheterize the heart.\nHe plans to bear the cost of any prostheses the veterans need to work on the catheters.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that the catheter:\nBut there isn\u2019t one piece of data \u2013 of evidence \u2013 presented in the entire 718-word story.\u00a0 That\u2019s not a short story these days \u2013 so there was plenty of space afforded.", "answer": 0}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe study was a small one and deserves many cautions in its interpretation. The authors of the study for example, noted, \u201c\u2026these findings suggest that brain imaging may play a valuable role in neuroprognosis\u2026.\u201d Compare that caution conclusion with, \u201cScientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\u201d Although the study did not speak to any interventions, the story suggests otherwise in a subheading, \u201cStudy Suggests Interventions to Help Dyslexics Learn to Read.\u201d\u00a0 ", "answer": 0}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not present quantitative evidence, but rather presents qualitative viewpoints of experts.", "answer": 0}, {"article": "Paul is on Procter & Gamble's advisory board but holds no stock in the company and will not profit financially.\nThere were no side effects in the two other groups.\nThe next day parents were questioned about their child's symptoms overnight.\nThe current study shows that Vaporub is more effective than placebo.\"\nThat night, 30 minutes before bedtime, Vicks or petroleum jelly was rubbed onto the child's chest and neck.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story does not tell readers how much of a difference there was between the treatment groups. The parents did report improvements, but readers can\u2019t tell from this story just how much. The story would have been better if it pointed out that the parents were asked to rate symptoms on a seven-point scale. For instance, the effect on sleep ranged from 1 or \u201cnot at all much\u201d to 7 or \u201cvery much\u201d and the VapoRub on average nudged the symptoms just one point more than the petroleum jelly. What does it mean to feel one point better on this scale? The vague description of the relative improvement might lead readers to believe the differences were dramatic.", "answer": 0}, {"article": "Another difference is that Zostavax contains a live, weakened virus, making it unsuitable for people with poor immunity, whereas Shingrix contains a nonliving virus particle and may eventually be approved for those with compromised immunity, who are especially susceptible to a severe case of shingles.\nAlthough most people get shingles only once, it can happen again, especially if you have a weakened immune system, which most everyone does with advancing age.\nBut for about 15 percent of people, shingles does not end there.\nHere\u2019s how it compares to its predecessor Zostavax, which over all reduces the risk of shingles by 51 percent and of PHN by 67 percent.\nMore than half the cases of PHN affect people over 60.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides relative numbers, noting that the previous shingles vaccine, Zostavax, \u201creduces the risk of shingles by 51 percent and of PHN by 67 percent\u201d, but this new vaccine, Shingrix \u201ccan protect 97 percent of people in their 50s and 60s and 91 percent of those in their 70s and 80s. It also reduces the risk of PHN by 86 percent.\u201d\u00a0\nBut what does this mean in terms meaningful to readers, such as absolute numbers? According to a clinical trial published in the New England Journal of Medicine, of the\u00a06,541 people who got the vaccine, 23 developed shingles (about 0.35%). Of the 6,622 who got the placebo, 223 people got shingles (about 3.4%). This difference, of 3.36%, means that for every 29 people over age 70 who get the two-shot dose of Shingrix, one case of the shingles will be prevented. Another way to say this is 28 out of 29 people will see no benefit from the vaccine over three and a half years. The numbers needed to vaccinate to prevent one case of postherpatic neuralgia is more than 200.", "answer": 0}, {"article": "Imaging equipment makers such as GE Healthcare, Siemens, Philips and Toshiba Medical Systems are working to develop low-dose CT scanners.\nThe researchers said efforts need to be taken to minimize CT radiation exposure, including reducing the number of unnecessary tests, cutting the dose per study, and standardizing the doses across facilities.\nThe findings, published in the Archives of Internal Medicine, add to mounting evidence that Americans are overexposed to radiation from diagnostic tests, especially from a specialized kind of X-ray called a computed tomography, or CT, scan.\nThey estimated the scans done in 2007 will cause 29,000 cancers.\nRedberg, who wrote a commentary on the studies, said U.S. doctors\u2019 enthusiasm for the tests has led to an explosion in their use that is putting patients at risk.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Because the story focused on the cancer risk associated with radiation exposure from CT scanning, it would not be necessary for the story to also quantify the benefits of CT scanning. How the story could go about quantifying the benefits of something so generic as CT scanning is also not clear.", "answer": 2}, {"article": "\"For example, we know that certain changes in the retina, like thinning tissue [due to cell loss] or weakening electrical activity, occur alongside loss of brain tissue and reduced brain activity in patients with neurological disorders like multiple sclerosis and Parkinson's disease.\nThe results show the device accurately indicated reduced electrical activity in the retina in multiple cell layers in the participants who had schizophrenia, including in cell types that had not been studied before in this disorder.\nIn the just-published study, the researchers evaluated 50 participants: 25 with schizophrenia and 25 with no diagnosed psychiatric disorder.\n\"However, since every prior study has found that people with schizophrenia exhibit reduced retinal wave forms and slowed retinal responses, our research shows that we closing in on an accurate test that is faster, less invasive, inexpensive and more accessible to patients.\"\nAlthough we know quite a bit about it, it's still not that well understood,\" said Steven Silverstein, professor of psychiatry at Rutgers Robert Wood Johnson Medical School and director of research at Rutgers University Behavioral Health Care (UBHC), who designed the study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release stated the results \u201cshow the device accurately indicated reduced electrical activity in the retina in multiple cell layers in the participants who had schizophrenia, including in cell types that had not been studied before in this disorder.\u201d\nPresumably this meant that all of the patients with schizophrenia were identified, but there are no numbers. Also, the news release didn\u2019t explain whether the device accurately ruled out schizophrenia in those who didn\u2019t have it.\nThe news release and scientific article both referred to group (averaged) data, which is distinct from individual diagnosis.", "answer": 0}, {"article": "In addition, people can obtain folic acid from breads, cereals and other grain products enriched with folic acid, as well as folic acid supplements.\nHowever, there is no scientific evidence that taking folate supplements will be beneficial, Armstrong noted.\nIn previous studies, folic acid levels have been linked to mental ability; however, until now this had not been linked with improved school performance, the study authors said.\nNone of the other factors they examined accounted for their finding, Nilsson's team noted.\nNot only should health providers monitor folic acid levels in teens, but the findings should influence school meals, school teaching and information given to parents, according to the researchers.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not quantify the improvement in scores as was done in the Reuters story.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "For balance, an estimate of the benefit of statin use should have been presented.\u00a0 While the story did mention that statin medications provide benefit from heart disease, it did not provide any estimate for the magnitude of this benefit.", "answer": 0}, {"article": "Newswise \u2014 Human papillomavirus-positive oropharynx cancers (cancers of the tonsils and back of the throat) are on rise.\n\u201cAnd while traditional chemoradiation has demonstrated good tumor control and survival rates for patients, too often they encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration and feeding tube dependence,\u201d said Dr. Burtness.\nPatients with good clinical response then received reduced radiation.\n\u201cRadiation dose reduction resulted in significantly improved swallowing and nutritional status,\u201d she said.\n\u201cYounger patients may have to deal with these side effects for decades after cancer treatment.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release did include some quantification of benefits, but we would have liked a bit more. Here is what was provided:\n\u201cThe study\u2026showed that patients treated with reduced radiation had less difficulty swallowing solids (40 percent versus 89 percent of patients treated with standard doses of radiation) or impaired nutrition (10 percent versus 44 percent of patients treated with regular doses of radiation.\u201d\nThe release would have been improved with a discussion of how \u201cless difficulty\u201d\u00a0and\u00a0\u201cimpaired nutrition\u201d were measured.\nThe published\u00a0paper makes it clear that the swallowing difficulties and nutritional impairment were self-reported using a questionaire of some kind. This also would have been useful information to include in the release.", "answer": 1}, {"article": "Collaborating with Dr. De Giglio were Francesca Tona, M.D., Francesca De Luca, Psy.D., Nikolaos Petsas, M.D., Ph.D., Luca Prosperini, M.D., Ph.D., Valentina Bianchi, Psy.D., Carlo Pozzilli, M.D., Ph.D., and Patrizia Pantano, M.D.\nThe results suggest that video-game-based brain training is an effective option to improve cognitive abilities of patients with MS.\nAt follow-up, the 12 patients in the video-game group had significant increases in thalamic functional connectivity in brain areas corresponding to the posterior component of the default mode network, which is one of the most important brain networks involved in cognition.\nThe modifications in functional connectivity shown in the video game group after training corresponded to significant improvements in test scores assessing sustained attention and executive function, the higher-level cognitive skills that help organize our lives and regulate our behavior.\nIn the future, the researchers hope to study whether the plasticity induced by video games in MS patients is also related to improvements in other aspects of their daily lives.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release says that the research showed \u201csignificant increases in thalamic functional connectivity\u201d but fails to quantify the extent of those increases. Nor does it show that increased connectivity improves the patients\u2019 quality of life, although it certainly suggests that outcome. More important for patients, the release states, \u201cThe modifications in functional connectivity shown in the video game group after training corresponded to significant improvements in test scores assessing sustained attention and executive function\u2026\u201d This improvement is not quantified, nor is it put into a perspective where the patient can know what this may or may not mean in terms of life functioning (see quality of evidence section).", "answer": 0}, {"article": "Their metabolism slows down, they expend fewer calories when they exercise because their muscles become much more efficient, and their thyroid hormone and adrenaline levels drop.\nAnd the leptin study suggests that the weight loss solution may eventually be a pill that tricks the brain into thinking that no weight has been lost.\nWhen they took leptin, their calorie burning increased to pre-diet levels.\nLeptin, they reasoned, tells the brain how much fat is on the body.\nThe answer, published in the current issue of The Journal of Clinical Investigation, was that the leptin trick worked.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story presented as a benefit that leptin increased number of calories used during low level \nactivity. But it fails to mention that at higher levels of energy expenditure, this effect was not observed. ", "answer": 0}, {"article": "FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer\u2019s Inlyta drug in a late-stage study.\n\nThe drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.\n\nThe trial will continue to show whether Bavencio plus Inlyta also prolongs patients\u2019 lives.\n\nWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes clear to readers that it has no idea about the extent of the benefits: \u201cWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival.\u201d We\u2019re glad that the story makes its ignorance clear, but it raises the very serious question of why they would cover a story about which so little information is available.", "answer": 0}, {"article": "Learn more about intrauterine devices from the Association of Reproductive Healthcare Professionals.\nThe researchers randomly assigned nearly 600 women with heavy menstrual bleeding to receive either the IUD or standard medical care.\nBritish researchers found that the treated IUD was more effective at reducing the effects of heavy menstrual bleeding (also called menorrhagia) on quality of life compared to other treatments.\nFor women who may be hesitant to use an IUD because of pelvic infections linked to an early version called the Dalkon Shield, Gupta said that as long as women are screened for sexually transmitted diseases before getting an intrauterine system, the risk of infection is low.\nAnother expert said the findings show promise for women bothered by heavy bleeding.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated that women using Mirena improved 32.7 points compared with 21.4 points on a symptom scale. \u00a0Unfortunately, it\u2019s not clear what symptoms were being measured.\nThe symptom scale reports a combined score that represents the effect of heavy menstrual bleeding on physical and mental health, daily life, and other areas. Researchers like scales because they are easier to work with statistically, but they don\u2019t measure something we can understand intuitively. This rating is a tough\u00a0call because the researchers themselves used a quantitative, validated measure that is virtually meaningless to readers (and confusing to doctors).The best we can say is that the story accurately reported the findings, but the outcome measure was difficult to interpret. And health care stories often need to do more than regurgitate what researchers report, but to offer some interpretation.", "answer": 0}, {"article": "Prostate cancer killed an estimated 258,000 men around the world in 2008 and is the second most common cause of cancer death in men in the United States.\n\u201cThe protein is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk of developing the disease,\u201d said Hayley Whitaker of the Cambridge institute, who led the study.\nWhitaker said that while it could be around five years before the results of this study are translated into a test for doctors to use in clinics, she hoped it would then also help them to determine which patients have aggressive tumors.\nBut PSA testing is problematic because it has low specificity, which generates high false positive rates and leads to unnecessary surgical and radiotherapy treatment.\n\u201cAt the moment, PSA testing is the best method we have to detect prostate cancer but it has significant limitations, so there is an urgent need to find new biomarkers such as MSMB that could be used in screening and diagnosis,\u201d said Rosalind Eeles of the ICR and The Royal Marsden Hospital, who also worked on the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers could extrapolate that if the MSMB test results are demonstrated to be reliable and reproducible, then it could be expected to reduce the number of men treated for prostate cancer who likely would never suffer ill effects from the disease.\u00a0 However it is appropriate to withhold some enthusiasm until the test\u2019s performance is demonstrated to live up to its potential. And, true to what we expect in this criterion, the story never explained the sensitivity or specificity of the test in absolute numbers; it only used unhelpful general terms such as \"found at significantly lower levels.\"\u00a0 How often?\u00a0How reliably? All the time? ", "answer": 0}, {"article": "Seventeen percent were having moderate to severe vasomotor symptoms, and 18 percent reported moderate to severe sexual symptoms.\nThere is also, she said, a complete lack of understanding that for most women, these symptoms are not fleeting.\n\u201cWomen and doctors simply are not aware that symptoms can last this long.\u201d\n\nFinally, many women don\u2019t realize that non hormonal options can be safe and effective, she added.\n\u201cExtrapolating our findings to 3.7 million Australian women aged 40 to 64 years, we found that 455,000 women are likely to have moderate to severe vasomotor symptoms, with most women (385,000) remaining untreated,\u201d they write.\nVaginal estrogen preparations are very safe and effective for this problem but were prescribed to less than 5 percent of the women, the authors say.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is ostensibly about the findings of a survey which found that women with moderate to severe menopausal symptoms aren\u2019t being treated for those symptoms. While those results are adequately quantified, the story never quantifies the claim, made three times in the text of the article, that alternatives to HRT are \u201ceffective\u201d for reducing these symptoms. What evidence supports that claim and what do the numbers say? Which treatments is the story talking about? It refers to \u201cnon-hormonal options,\u201d which might include a variety of supplements that are advertised for menopausal symptoms. Such\u00a0complementary therapies are almost uniformly poorly studied in small, uncontrolled trials. Being more specific here would have been very helpful for readers.", "answer": 0}, {"article": "Guidelines from the American Cancer Society and other organizations recommend that women age 30 and older are screened using Pap smears and tests for the human papillomavirus, or HPV.\nIn that case, women would need more invasive tests to rule out disease, Roland said, and risk \u201cundue harm\u201d from those procedures.\nWomen should talk to their doctors about screening, especially if they think they are being screened too often, researchers added.\n\u201cOften a provider just does the HPV test\u201d without telling the patient.\nIn addition, Roland added, some doctors might be afraid of missing very early cervical cancer and getting sued if they screen less frequently.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The story wasn\u2019t about benefits, but rather, the suggested lack of benefit from screening too often.", "answer": 2}, {"article": "The research team, led by Cleveland Clinic's Eric Klein, M.D., conducted a multicenter prospective study of 261 men scheduled for prostate biopsy at five academic and community centers in the U.S. enrolled between August 2015 and December 2016.\n\"Despite criticism, PSA has transformed the landscape of early detection, screening, and management of prostate cancer in the last few decades,\" said Dr. Klein, chair of Cleveland Clinic's Glickman Urological & Kidney Institute.\nThe IsoPSA test was developed by Cleveland Diagnostics, a company co-founded by Cleveland Clinic, in which it has financial interest.\nThe study directly compared the clinical performance of a new test based on PSA, called IsoPSA, to PSA itself with patients already scheduled for prostate biopsy.\n\"The methodology used in the IsoPSA assay represents a significant departure from conventional ways to define biomarkers in blood, and may be applicable to improving other cancer biomarkers,\" said Dr. Klein.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release uses vague, comparative language to describe the benefits of the new blood test, such as IsoPSA may \u201csubstantially reduce\u201d the need for biopsy and IsoPSA proved \u201csignificantly superior\u201d to PSA. Here, the word \u201csignificant\u201d is ambiguous because it means \u201cstatistically significant,\u201d instead of the colloquial meaning of the term.\nIn addition, IsoPSA could \u201csignificantly reduce the rate of unnecessary biopsies by almost 50 percent.\u201d Instead of relative terms, we prefer benefit data to be written in absolute reduction risk to provide a more accurate impression of how effective the new test really is. Even if the journal article reports its results relatively, we still expect the writer to follow up with the researchers and provide some quantitative data for readers.\nBasically, the study used\u00a0the gold standard of the biopsy result to compare PSA (the current test) to IsoPSA (the new test). The study itself provides numbers for the sensitivity and specificity of these two tests to detect any cancer as well as to detect higher risk cancer. These numbers could have been provided and explained.\nWithout any raw numbers, it\u2019s hard for us to judge whether IsoPSA is indeed more accurate than PSA. We give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "Dr. Gerald Bernstein coordinates the Friedman Diabetes Program at Lenox Hill Hospital in New York City.\nAccording to Bernstein, if only one diagnostic test were needed, \"this would mean that a follow-up visit would be a look at the treatment benefits -- rather than a confirmation of an abnormal glucose.\"\nBut taking the test twice takes up time and money and could still result in missed diagnoses, said a team from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\n\"I'm hoping that these results will lead to a change in the clinical guidelines when they are revised in early 2019, which could make identifying diabetes a lot more efficient in many cases,\" Selvin said.\n\"Given these numbers, any abnormality of glucose should be regarded as sufficient reason to start preventative treatment with an education program, lifestyle change and first-line medication such as metformin.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story referred to the potential for a single test to result in quicker diagnosis and treatment of diabetes, thus \u201csaving patients time and health care costs\u201d and leading to better outcomes.\nBut it offered no data on how much more rapidly diagnosis and treatment might occur with single-sample testing, or more importantly how much difference it would make in heading off the many complications of diabetes.\nAccording to the news release, 90% of those who tests positive in both tests went on to be diagnosed with diabetes within 15 years.", "answer": 0}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "According to the story, kratom users and advocates say the herb \u201chelps to relieve pain, gives a mild boost like coffee (the tree is part of the coffee family) \u2014 and can even help ease the pain of opioid withdrawal.\u201d\nThese benefits aren\u2019t quantified, but that\u2019s because there is no good-quality research that demonstrates those benefits. The story calls attention to the lack of evidence on kratom, which is why we\u2019ll rate this satisfactory.", "answer": 1}, {"article": "Makers include General Electric Co\u2019s GE Healthcare Siemens AG, Toshiba Corp, Hitachi and Philips.\nThe researchers waited until an independent panel could document a 20 percent reduction in cancer deaths, or could determine that there was no significant benefit.\nAs of last month, 354 people who got CTs had died of lung cancer, compared to 442 who got ordinary X-rays.\nDr. Bruce Johnson of the Dana Farber Cancer Institute in Boston, who is on the board of the American Society of Clinical Oncology, said he doubted most people would see the findings as a green light to smoke.\nIt is also possible the scans will turn up tumors that would never have killed the patients, and that some people will undergo unnecessary surgery if they are screened.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story presented some of the raw, absolute numbers, although we wished it had gone further. It says, \u201cAs of last month, 354 people who got CTs had died of lung cancer, compared to 442 who got ordinary X-rays. This worked out to a 20.3 percent lower risk of dying for the spiral CT group and the researchers stopped the study.\u201d What it should have added was\u00a0that, assuming 50 percent of all participants were put in each group, that would mean 1.32% died in the CT scan group and 1.65% died in the X-ray group. That\u2019s an absolute difference of 0.33%, not quite as exciting as a 20% reduction in deaths. Also, the number of people needed to treat to save one life (or NNT) is 304. That may be a justifiable number for added investment in spiral CT scans, but it should be part of the discussion. Nonethless, we\u2019ll give it the benefit of the doubt on this criterion.\n", "answer": 1}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story made health claims without reference to data supporting the claims. \u00a0In fact, the medical literature does not support the claims made in this story.", "answer": 0}, {"article": ".\nAlthough electro-acupuncture produced significant sleep improvements, researchers noted that sleep quality for the participants was still not as good as it should be, implying that more research is necessary to explore possible combinations of pharmacologic and nonpharmacologic treatments.\nThe study showed electro-acupuncture to be comparable to, if not better than, gabapentin in helping to reduce hot flash severity and frequency and improving overall sleep quality (including falling asleep faster and fewer sleep disruptions).\n\"This study shows that, for women who need or choose to avoid medications, electro-acupuncture may be an option because it has minimal risks, but blinded controlled trials are needed,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nA new study shows that electro-acupuncture may be effective in providing some relief.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release stated that the use of electro-acupuncture was \u201ccomparable to, if not better than\u201d the drug (gabapentin) that was used in this comparative study in reducing \u201chot flash severity and frequency and improving overall sleep quality.\u201d\u00a0 This kind of vague statement doesn\u2019t help readers looking for some quantification, or degree of change, provided by this alternative therapy.\nThe release also states that \u201calthough electro-acupuncture produced significant sleep improvements, researchers noted that sleep quality for the participants was still not as good as it should be.\u201d\u00a0 But again, there is no scale of benchmark provided which would\u00a0help a reader gauge the effectiveness, and therefore the worth, of trying electro-acupuncture.", "answer": 0}, {"article": "However, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\nAt the start of the study, the men's PSA levels were doubling every 12 months.\nThe study is the latest to demonstrate pomegranate's promising antitumor effects, says study head Michael Carducci, MD, professor of oncology and urology at Johns Hopkins Medical Institutes.\nThe new study involved 92 men with cancer that had not spread beyond the prostate and rising PSA levels.\nAfter six months of taking the capsules, it took 19 months for their PSA levels to double.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is the crux of our criticism.\nThe story states:\u00a0 \u201cAt the start of the study, the men\u2019s PSA levels were doubling every 12 months. After six months of taking the capsules, it took 19 months for their PSA levels to double.\u201d\nSo what?\nAs one independent expert points out, \u201cit\u2019s never been proven that slowing down the PSA doubling time improves a patient\u2019s prognosis.\u201d\nSo why the headline suggesting that the pills fight prostate cancer?\nThe story also should have reported whether the differences between the groups were statistically significant and/or clinically meaningful.", "answer": 0}, {"article": "Harder\u2019s PSA was 9.\nThat\u2019s one of our strengths.\u201d\n\nYu has seen how MRI technology has changed prostate patients\u2019 care.\nMuch like someone would have an MRI to investigate the cause of back pain, the technology gives doctors eyes on what is happening in prostate tissue.\nIn 2012, he started on a treatment plan: hormone therapy for six months to shrink the tumor and prostate, and then external beam radiation to finish the job.\nHis doctor recommended the traditional next step: a transrectal ultrasound (TRUS) biopsy, which involves taking random tissue samples from 12 cross sections of the prostate.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release offers some solid data along with confusing statements. It says MRIs and targeted biopsies have \u201cprovided relief\u201d for patients who have not been able to get an accurate diagnosis, citing data from the 2015 NCI study that showed targeted MRI biopsies detected 17 percent fewer low-risk tumors than standard biopsies. It says MRI \u201cis 30 percent more accurate\u201d in diagnosing high-risk, aggressive cancers than a standard biopsy, a misstatement. The study actually says MRI-guided biopsies \u201cdiagnosed 30 percent more high-risk cancers.\u201d\nThe news release tells readers that VCU performs about 1,200 MP-MRI-guided biopsies annually, which is useful information. But it also claims a \u201cmore than 90 percent success rate\u201d without ever explaining what that means or where the number comes from. It even quotes a patient who says he compared \u201csuccess rates\u201d at various medical facilities. Where did the patient get his figures, and what do they mean? We aren\u2019t told.\nIdeally one would like to read the sensitivity and specificity of the test \u2014 the parameters that make up a test\u2019s accuracy. Sensitivity is the test\u2019s ability to identify those who have the disease, and specificity refers to the test\u2019s ability to exclude those who do not have the disease.\nAnother statement implies that VCU\u2019s procedures are superior to \u201cmost\u201d hospitals because they have a single professional reading results and performing biopsies. There\u2019s no data to back this up.\nThe news release includes two glowing anecdotes involving patients whose cancers were promptly detected at VCU and safely treated. Were there other patients who traveled to VCU only to come away with an inconclusive finding, a negative finding, or a fatal tumor?", "answer": 0}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports the benefit in terms of an intermediate outcome, A1C. The study tells how many participants achieved an A1C < 7% by taking the new drug plus metformin vs. metformin alone. However, the story could have pointed out that the study was short-term (6 months), so it's not clear what long-term outcomes might be. While the absolute benefits are provided, the story lacks context. ", "answer": 0}, {"article": "But this is important enough and impressive enough to tell people about,\" said Robert Temple of the Food and Drug Administration, who spoke to reporters about the findings.\nExposure to ACE inhibitors early in pregnancy nearly tripled the risk of birth defects, the study showed.\nAll new drugs are tested on pregnant animals to see whether they cause malformations, but those tests can be misleading.\nThe number of women taking them early in pregnancy is unknown but probably is small, the study suggests.\nA popular class of blood-pressure medications thought to be safe in the first trimester of pregnancy appear to have caused serious birth defects in about 7 percent of babies whose mothers took them, a new study has found.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There was no quanitification of possible benefits to the mother for using this drug during the first trimester of pregnancy. In some women the risks of taking the drug may be less than the risk of undertreatment. ", "answer": 0}, {"article": "\"As soon as you stop the chemo, you feel stripped, and you think, 'Wow, what do I do now?'\n\"\n\nServan-Schreiber did what he knew best -- he hit the books, and was surprised to find studies on how nutrition and exercise might help the body fight cancer -- information doctors never told him.\nIn addition, LaPook spoke with several other cancer patients who told him they're left in the dark, too, about how exercise and eating the right foods might help them in their battles against the disease:\nHe says vegetables and fruits such as brussel sprouts, asparagus and raspberries can target specific cancers, at least in test tubes.\n\"There's tremendous evidence that physical exercise helps prevent cancer, and also helps people who already have cancer prevent a recurrence,\" he says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not attempt to quantify the benefits of a healthy diet in terms of cancers prevented or improved survivorship.", "answer": 0}, {"article": "U.S. alone, seventy-five percent of teens and adults are vitamin D deficient.\nTyler Kalajian and his research team, led by Dr. Michael F. Holick, Ph.D., M.D., and supported by Boston University School of Medicine and a Boston University Ignition Award, found that skin samples exposed to RayVio's UV LED for just 0.52 minutes produced more than twice as much vitamin D3 as samples exposed to 32.5 minutes of sunlight.\nThe research shows that RayVio's UV LEDs could be used for treating patients that are vitamin D deficient.\nResearch published today in Scientific Reports shows that light from RayVio's 293nm ultraviolet (UV) LED is more efficient than sunlight at producing vitamin D3 in skin samples.\n\"This study will lead to a new generation of technology that can be labeled as photopharmacology in which the use of LEDs with targeted wavelengths can cause specific biologic effects in human skin to help treat and prevent chronic illnesses.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states skin samples exposed to RayVio\u2019s UV LED produced \u201cmore than twice as much vitamin D3\u201d after 0.52 minutes compared to samples exposed to 32.5 minutes of sunlight.\nWe applaud the news release for giving readers absolute values for the time instead of providing relative figures. However, we\u2019re not sure from the news release exactly how much vitamin D3 was produced in these samples. And how was this measured? Was there any variation in the amount of vitamin D3 produced depending on the wavelength and skin type?\nIn the original journal article, researchers looked at the percent conversion from an intermediate chemical compound to previtamin D as a way to measure vitamin D production.\nSince benefits data were only half released, we rate this one Not Satisfactory.", "answer": 0}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Dr. Batzofin discusses his own \"numbr needed to treat\" in order to consider IVM a success (20 to one pregnancy), however, this seems arbitrary. The story should include the typical success rate of IVM compared with IVF and with other fertility treatment methods.\u00a0 There is no sense of valid expected outcomes from data. Doing this story when even the outcomes of the first three transfers is unknown is showmanship not reporting. ", "answer": 0}, {"article": "Both show that antibiotics are more effective than placebos in relieving ear-infection symptoms such as fever, poor appetite, decreased activity and irritability and suggested that their benefits warrant their being administered early on, regardless of the seeming severity of a child's symptoms.\nInterestingly, antibiotics were no more effective at reducing pain, as reported by parents or children, than placebos.\nNow two new studies (bolstered by an accompanying editorial) in the New England Journal of Medicine demonstrate what we parents have suspected for years: When it comes to ear infections, antibiotics are in order.\nStill, some of the placebo-group kids required \"rescue treatment\" when their symptoms grew markedly worse.\nStudies show that for kids' ear infections, antibiotics work better than waiting\n\nBeing a parent these days sometimes entails this hypocrisy: Yes, I know overuse of antibiotics is creating superbugs that may soon conquer the universe.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Insufficient data here. The blog says antibiotics are \u201cmore effective than placebos in relieving ear-infection symptoms.\u201d But the question is how much more effective are they and\u00a0does this\u00a0difference outweigh the downsides of treatment? The story could have helped readers answer this question by providing\u00a0some data on the absolute rates\u00a0of improvement reported in the\u00a0these studies.\u00a0Had it done so, readers might have observed that in one of the studies, rates of symptom resolution were 80% in the antibiotic\u00a0group after 7 days compared with 74% in the placebo group. This\u00a0might have opened\u00a0the door to a discussion of whether this 6% difference\u00a0is worth the potential risks of antibiotic therapy. Or, the story could have pointed out in the second\u00a0study,\u00a0only 18.6% of antibiotic children failed to get better by day 8,\u00a0compared to 44.9% of the placebo group \u2014 a much bigger benefit for antibiotics.\u00a0This may have prompted an exploration of the differences between the studies (for one thing, the second study was conducted in Finland, whereas the first was done in Pittsburgh) and consideration of which study\u00a0may be more representative of the benfits\u00a0readers can expect for their children. \nThe author\u2019s reliance on an unrepresentative personal anecdote about her 17-year-old daughter also deserves comment. The story suggests that the study data from infants and toddlers somehow vindicate the author\u2019s decision to procure antibiotics for her daughter. This is an extremely tenuous connection, made worse by the closing suggestion that parents are always justified in asking for antibiotics without thought to creating \u201csuperbugs.\u201d Careful consideration of benefits and harms is the cornerstone of good health care decision-making. \u00a0 ", "answer": 0}, {"article": "\u201cThis is great news,\u201d says Kay Dickersin, PhD, an epidemiologist with the Johns Hopkins School of Public Health and director of the U.S. Cochrane Center.\n\u201cThe evidence from the recent trials does support the use of zinc lozenges in treatment of common cold,\u201d says study researcher Meenu Singh, MD, a pediatric pulmonologist at the Post Graduate Institute of Medical Research in Chandigarh, India.\nIt updates a 1999 Cochrane review that found no strong evidence to recommend zinc as a help for colds.\n\u201cWe really don\u2019t have interventions for colds that work.\u201d\n\nThe review of 15 studies with 1,360 participants was published by the Cochrane group, an international collaboration of researchers that reviews evidence behind therapeutic interventions.\nFeb. 15, 2011 -- Taking zinc, either as a syrup or lozenge, through the first few days of a cold may shorten the misery of an upper respiratory infection, a new research review shows.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story did quantify the potential benefits, but it did so in a way that was all over the map. At first it says, \u201cWhen taken within the first 24 hours of symptoms, results from six trials showed that using zinc lozenges or syrup appeared to shorten the duration of a cold by about a day.\u201d But later it says, \u201c\u2018Usually it takes about eight days for a cold to disappear,\u2019 Prasad says, \u2018but with zinc, it cuts down by about 50%.\u2019\u201d\u00a0And then there is the absolute difference versus relative difference problem. The story never presents the data in absolute terms. \u201cAn analysis of two combined studies, representing more than 1,500 people, found about 40% fewer colds in those who were taking zinc supplements to prevent colds compared to those taking a placebo.\u201d Does that mean 10 people had colds in the placebo group, and 6 had them in the zinc group? It would be good information for readers to have because with a number like 1,500, people might leap to the assumption that hundreds of people avoided colds by taking zinc.", "answer": 0}, {"article": "But study author Dong Wang, a graduate student with the departments of nutrition and epidemiology at Harvard T.H.\nDr. Sonia Anand, a professor of medicine and epidemiology at McMaster University in Hamilton, Canada, praised the study, saying it's \"reasonable\" to link changes in diet to death rates in this way.\nChan School of Public Health in Boston, cautioned that it's not time to declare victory in the battle against unhealthy eating.\nBut other research has pinpointed a decline in death rates in this century, Wang said.\nMONDAY, Nov. 2, 2015 (HealthDay News) -- Despite the stereotype that Americans are eating more unhealthful foods that leave them vulnerable to assorted diseases, a new study suggests the opposite may be true.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The major claim in the story is that better diets prevented more than one million premature deaths. But as noted above, this is an estimate based on a model derived from observational studies. Although better diets may be associated with lower death rates, there\u2019s no way to tell based on these studies whether dietary changes caused the benefits that the story claims. The coverage should have been clearer about this.", "answer": 0}, {"article": "Autism is a complex brain disorder characterized by difficulties in social interaction and communication, ranging from mild to profound impairment.\nThe accuracy of the scan in predicting autism was so high that the results were strongly significant, despite the small number of patients involved.\nIt could be a boon for patients and their doctors by reducing reliance on time-consuming and emotionally trying assessments based on interviews and behavioral observation.\n\u201cAlthough this method is not ready for normal diagnostic situations, any step to easier diagnosis is welcome,\u201d said Terry Brugha, professor of psychiatry at the University of Leicester.\nThe new scanning method \u2014 which picks up on structural changes in the brain\u2019s grey matter \u2014 could be ready for general use in a couple of years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Many of the deficiencies discussed above in the \"Evidence\" criterion could also be applied to this criterion.\u00a0Importantly, the story\u00a0didn\u2019t do enough to call attention to the small and highly selected sample of patients, which likely\u00a0biases the results towards greater accuracy than what would be observed in a larger and more diverse sample.\u00a0There was\u00a0also inadequate acknowledgment of the fact that this was a study of adults whereas the real need is\u00a0for diagnostic tool for use in\u00a0children. Yes, it was acknowledged that the childrens\u2019 studies hadn\u2019t been done but the outcome of these not-yet-done studies was almost treated as a fait accompli. Lastly, we\u00a0would like to have seen some discussion of a somewhat subtle but important issue that wasn\u2019t addressed.\u00a0That is, whenever we diagnose a condition with new technology, the group of individuals identified as having the condition, in this case autism, will change.\u00a0Some previously undiagnosed children will be labeled with autism and some previously labeled with autism will be told that this is not the diagnosis. In addition, the severity of the disease may change (a more sensitive test will likely identify milder cases). Anytime the spectrum of disease changes, we have to ask ourselves, Will the treatments produce the same benefits and harms? Since benefits are often smaller for individuals with milder disease but the adverse effects are the same, the risk benefit ratio often\u00a0increases with the more sensitive test.\u00a0\u00a0\u00a0\u00a0", "answer": 0}, {"article": "\"Are you angry?\"\nThe results showed that machine learning algorithms can tell the differences between the groups with up to 93 percent accuracy.\nThey then used machine learning algorithms to classify the patients into one of the three groups.\nThe researchers extracted and analyzed verbal and non-verbal language from the data.\nThose enrolled included patients who were suicidal, were diagnosed as mentally ill and not suicidal, or neither - serving as a control group.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told the algorithm can identify someone who is actually suicidal with \u201cgreat accuracy.\u201d\u00a0And it also throws out a few numbers, including that it\u2019s \u201cup to 93 percent accurate\u201d\u00a0(from a read of the study, this is in a combined group of kids and adults when assessed on speech) and \u201c85 percent accurate in identifying a person who is suicidal, has a mental illness but is not suicidal, or neither.\u201d\u00a0But, these numbers in and of themselves don\u2019t provide enough information to make sense of the findings: What are they being compared against? How has it been decided that these measurements are correct?", "answer": 0}, {"article": "(Reporting by Susan Kelly, editing by Dave Zimmerman)\nIn the study, patients on pump therapy saw a reduction in average A1C levels of 0.8 percent, compared with a 0.2 percent average reduction for those who received multiple injections.\nBergenstal said patients who are not achieving their goals with multiple daily injections should consider using a pump and sensor.\nAdult and pediatric patients using the pump and continuous glucose monitoring device saw reductions in levels of A1C, a commonly used measure of blood sugar, that were four times greater than those who received regular insulin injections in the study of 485 patients ranging from age 7 to 70.\nPatients in the study, which was presented at a meeting of the American Diabetes Association in Orlando, Florida, and sponsored by Medtronic, achieved better glucose control over a one-year period without an increase in hypoglycemia, or dangerously low blood sugar.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nAs mentioned above, the story implies that the degree of improvement in the control of blood sugar levels reported by the researchers will reduce the risk of eye, kidney and heart disease, even though these health outcomes were not measured. Although control of blood sugar levels is a widely accepted target of diabetes treatment, the trial did not measure whether or not there were any noticeable improvements in real health outcomes.", "answer": 0}, {"article": "The Biggest Loser diet and the DASH diet came in second and third, respectively, in the diabetes category.\nThe Raw Food diet was also considered the most difficult diet to follow, though it was one of the top ranked weight-loss diets, the panel found.\nThe panel of experts -- including nutritionists and doctors specializing in diabetes, heart health and weight loss -- scored each diet for short-term and long-term weight loss.\nThe DASH (Dietary Approaches to Stop Hypertension) diet was designed to lower blood pressure and cholesterol levels by limiting fats, red meat and sugar in favor of healthy grains, poultry, low-fat dairy and nuts, the U.S. National Heart, Lung, and Blood Institute says.\nThe DASH diet scored highest when it comes to healthy eating, followed by the TLC diet.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives a nod to some of the diet\u2019s benefits (it\u2019s called \u201cheart healthy,\u201d for example) but offers no hard numbers on what that means in terms of outcomes.\nThe story gives only relative rankings of the various diets. It is unknown if the second best diet is only microscopically worse than the first, or dramatically substandard. There is no indication of range.\u00a0 Also, by not indicating how the diet ranked in all categories, it is hard to differentiate what might be important to some \u2014 cost for example \u2014 as compared to ease of implementation.\nThe National Institute of Health\u2019s decision some years ago to promote the DASH diet was based on three large trials that involved thousands of patients. Perhaps some data could have been drawn from one of the studies to engage readers and show how a diet can make a difference in health outcomes.", "answer": 0}, {"article": "Scientists have slowed down the ageing process by implanting stem cells into the brains of animals, raising hopes for new strategies to combat age-related diseases and extend the human lifespan.\nThe work, described as a tour de force and a breakthrough by one leading expert, suggests that ageing across the body is controlled by stem cells that are found in the hypothalamus region of the brain in youth, but which steadily die off until they are almost completely absent in middle age.\nThe animals died months earlier than healthy control animals.\nImplants of stem cells that make fresh neurons in the brain were found to put the brakes on ageing in older mice, keeping them more physically and mentally fit for months, and extending their lives by 10-15% compared to untreated animals.\nHaving proved that it was neural stem cells that were important for ageing, the scientists ran further tests to work out what the cells were doing.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says the stem cell intervention extended the rodents\u2019 lives \u201cby 10-15% compared to untreated animals.\u201d\u00a0 At another point, it said, \u201cthe mice lived longer than controls, typically several months more, an increase of about 15%.\u201d", "answer": 1}, {"article": "The findings are published in TheJournal of the American Medical Association.\nIn the study, Freeman found the antidepressant reduced both the number and severity of hot flashes compared to placebo.\nPrevious studies of other antidepressants have yielded mixed results, according to Freeman.\nThe new study findings suggest Lexapro can provide an option for women reluctant to take hormone therapy.\n''We believe escitalopram provides an option for treating moderate to severe hot flashes that are disrupting people's lives and quality of life,\" says study researcher Ellen Freeman, PhD, a research professor in the department of obstetrics-gynecology and psychiatry at the University of Pennsylvania School of Medicine, Philadelphia.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies the benefits of treatment in appropriate absolute terms. It explains that women taking the\u00a0antidepressant went from about 10 hot flashes per day to\u00a05.26 hot flashes a day, a decline of 47% or about\u00a04.5\u00a0fewer hot flashes a day.\u00a0By comparison,\u00a0women taking the placebo reported 6.43 hot flashes a day after treatment, a decline of 33% or about\u00a03 fewer a day. The story also quantifies the severity of the hot flashes in terms that are useful to the reader.\nThe story perhaps could have provided some context\u00a0regarding the size of the benefit compared with placebo, which was relatively small. It also could have noted noted that\u00a0symptom reductions were much more modest than\u00a0those seen with hormone treatment.", "answer": 1}, {"article": "April 18, 2011 -- The FDA has approved a new noninvasive portable device for the treatment of a deadly type of brain tumor. The device uses electrical fields to slow and possibly reverse tumor growth.\n\nThe device, manufactured by Novocure, is called the NovoTTF-100A System and is meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment.\n\nGlioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No quantification of benefits \u2013 only this:\u00a0 \u201cThe FDA says the study showed comparable overall survival rates in patients in both groups.\u201d\nDoes that mean a week?\u00a0 A month?\u00a0 A year?\u00a0 Longer?\nAnswer \u2013 not in the story:\u00a0 Both treatment groups had a median survival of about 6 months.", "answer": 0}, {"article": "\"However, if your child is overweight or obese I recommend that you consult your primary care physician for advice, and consider having their vitamin D levels tested.\"\n\"Although these initial findings indicate that vitamin D could be used in the treatment of obesity, there remains a lack of evidence on the safety and long-term effects of supplementation, particularly if there is no vitamin D deficiency,\u201d said Charmandari.\nChildren who took vitamin D had a significantly lower BMI, the researchers found.\nIn their next investigation, the team will study whether vitamin D supplements can improve the health of obese children and adolescents who have been diagnosed with disorders linked to obesity, such as high cholesterol, high blood sugar levels, and high blood pressure.\nTaking vitamin D could help overweight and obese children lose weight, scientists believe.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told kids who took vitamin D \u201chad a significantly lower BMI\u201d and \u201clower body fat, as well as healthier cholesterol levels.\u201d But this is not adequate. How much did BMI appear to improve for the kids who took vitamin D? How much fat did they appear to lose relative to kids who didn\u2019t take vitamin D? And just how much better were their cholesterol levels? We don\u2019t know, because those numbers are not included.\nThe story hints that researchers didn\u2019t provide this information, via this quote:\u00a0\u201cAlthough the effect sizes are not given, these outcomes are certainly positive.\u201d Lay readers may not understand what \u201ceffect sizes\u201d mean and why they matter.", "answer": 0}, {"article": "Dr Francoise Soussaline, PhD, DSc, IMSTAR's president said: \"To bring a universal 'liquid biopsy' blood test for cancer to market, it must achieve a number of criteria, including high sensitivity and specificity and be fully automated with high throughput for a medical routine use.\nThe research team believes that the test could be the first screening tool to 'rule in, or rule out' cancer in patients under suspicion of the disease, alongside other traditional diagnostics methods.\nUK researchers behind a potential 'universal' liquid biopsy blood test for cancer detection have licensed the technology to an industrial partner to take it to market.\nCo-first author Dr Mojgan Najafzadeh from the University of Bradford said: \"We feel that we've taken it as far as we can in proving that the test works with high predictability for cancer outcome, and IMSTAR are the right partners to improve it still further.\"\nThese findings are published in FASEB BioAdvances journal.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that a modified version of the original test can identify individuals with cancer more than 93% of the time.\nIt\u2019s unclear what the 93% success rate means in this context. Is that the sensitivity? What is the false positive rate? Why these terms matter.", "answer": 0}, {"article": "Uridine, which is produced by the liver and kidneys, is also found in some foods as a part of RNA, which helps make protein in the body.\nTo be effective, all three compounds must be given together, the researchers said.\nTo show the drink's effect on the brain, patients underwent electroencephalography (EEG) throughout the trial.\nPrevious experiments in animals showed that giving them the three compounds included in the drink increased the production of synapses improving brain function, he said.\nWhether Souvenaid will slow the progression of Alzheimer's isn't known.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The results were only discussed in broad, general terms \u2013 no quantified details were provided.", "answer": 0}, {"article": "Patients who had lumpectomy plus radiation had more local recurrences than the mastectomy patients but had fewer deaths.\nRelated Material: The invited commentary, \"Systemic Effects of Radiotherapy in Ductal Carcinoma In Situ,\" by Mira Goldberg, M.D., and Timothy J. Whelan, B.M., B.Ch., of McMaster University, Ontario, Canada, also is available on the For The Media website.\nAuthors: Steven A. Narod, M.D., of Women's College Research Institute, in Ontario, Canada, and co-authors\n\nResults: A small improvement in breast cancer survival was associated with radiation plus lumpectomy for DCIS.\nTo Learn More: The full study is available on the For The Media website.\nPlease see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The summary gives an\u00a0absolute risk reduction percentage of 0.27% for patients who received radiation compared to those who did not.\u00a0It also includes the number needed to treat (370) to save one patient. This is good detail, but we would also have liked more context on the controversies of DCIS treatment. A HealthNewsReview.org podcast provides a deeper look here.", "answer": 1}, {"article": "Sept. 26, 2017.\nUnlike prior studies, GIFT took into account genetic variants in three genes for 11 days of warfarin therapy.\nThe research, published Sept. 26 in the Journal of the American Medical Association, reports results from the clinical trial known as GIFT (Genetics Informatics Trial of Warfarin to Prevent Deep Venous Thrombosis).\nCompared with patients receiving traditional warfarin dosing, patients dosed with the genetic approach had a 27 percent reduction in adverse events, which was statistically different.\nOne group received warfarin dosing based on standard factors such as age, height and weight; the second group was dosed based on these clinical factors plus genetic variants.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release gives results in both actual numbers of patients and the percentage of reduction of adverse events in those given the genetic test and a comparison group.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of treatment.", "answer": 0}, {"article": "Research has shown that our unhealthy eating habits and sedentary lifestyles are playing a major role in the development of lifestyle-related metabolic diseases such as diabetes, heart disease and obesity.\nThe fasting regime helped lower fat build-up in the white fat by increasing the brown-like fat (involved in burning energy and producing body heat) of mice on the high fat diet.\nThe research team in this study wanted to better understand the reactions that interventions such as fasting trigger on a molecular level in the body.\nThe lower body weight of the mice in the fasting group was not the only effect.\nThrough an analysis into the underlying biology involved, the researchers found that such intermittent fasting tempers an immune reaction in fat cells.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are given very sketchy treatment. For example, the release says, \u201cFour months later the mice in the fasting group weighed less than those in the control group who continued to eat the same volume of food.\u201d\nThe release never tells us how many mice were in the study nor how much less they weighed than the control group at the end of the trial.\nThe release also provides what it calls molecular detail about benefits to the experimental fasting mice vs. the control mice. But again, the quantities and context are not there.\n\u201cThrough an analysis into the underlying biology involved, the researchers found that such intermittent fasting tempers an immune reaction in fat cells. There are changes in certain gene pathways involved in the immune system and the body\u2019s reaction to inflammation. A type of white blood cell known to play a role in fighting inflammation is triggered. Known as anti-inflammatory macrophages, these cells stimulate the fat cells to burn stored fats or lipids by generating heat. This happens during periods of intermittent fasting because there is an increase in vascular growth factor (VEGF) that help form blood vessels and activate anti-inflammatory macrophage.\u201d\nWhat are the changes? How were they measured? We don\u2019t see any numbers in this description to help the reader evaluate the credibility of the data.", "answer": 0}, {"article": "\"If someone really feels they need to take this and they need to try it, well go ahead and do it.\nDr. Lon S. Schneider, director of the state of California's Alzheimer's Disease Research and Clinical Center at the University of Southern California, Los Angeles, said that these findings were \"straightforward and expected.\"\n\"Further, the subjects in the study were not monitored for certain cognitive parameters until several years after the trial began, creating difficulty in determining accurately whether they experienced a decline in cognition or not.\nEarlier results from the same study found that ginkgo did not prevent or slow the development of Alzheimer's or other dementias, DeKosky said.\nThese results remained the same regardless of sex, age, race or education, the researchers noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated that the researchers found no evidence that ginkgo delayed or prevented cognitive declines. ", "answer": 1}, {"article": "But on Oct. 23, the F.D.A.\nAlthough there are still questions about peramivir\u2019s true effectiveness, some critics say the government moved too slowly to make the drug available, and that even now, access is too restricted.\nAnecdotes like Ms. Gurno\u2019s aside, the efficacy of peramivir is still in question, according to the government.\nSome of the push to make the drug more widely available is coming from investors in BioCryst, including Kleiner Perkins Caufield & Byers, the prominent Silicon Valley venture capital firm.\nRight now, Dr. Lurie said, peramivir is the only drug that can be used intravenously so the government had to pay a high price.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n \nThe story points out that the benefits of peramivir have yet to be proven and that it is being offered only because some patients are not helped by approved drugs or are they are so sick they need a drug that can be given intravenously. The approved antiviral drugs are currently available only in pill or inhaled form.", "answer": 1}, {"article": "\"Oral morphine versus ibuprofen administered at home for postoperative orthopedic pain in children: a randomized controlled trial\" is published October 10, 2017.\nIn the first 24 hours, more than 80% of the children in the study needed pain relief at home.\nThey note that as neither treatment completely relieved pain, more research is needed into effective pain relief, especially for more severe pain.\n\"Morphine did not provide superior analgesia, but was associated with significantly more adverse effects, making ibuprofen a better analgesic option,\" write the authors.\nThe study included 154 children aged 5 to 17 years who underwent minor orthopedic surgery, such as keyhole surgery on joints, ligament and tendon repair, suture or hardware removal at London Health Sciences Centre in London, Ontario.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This news release is missing a few details about the benefits that would make it better. We learn that 80 percent of children required pain relief at home and that there was no difference in the effectiveness of the two medications.\nThe advantage appears to be in the reduced amount of side effects from ibuprofen compared to oral morphine. The release states:\n\u201cPain scores for children in both the oral morphine and ibuprofen groups were similar, but the children receiving oral morphine reported more adverse effects, such as nausea, vomiting, drowsiness, dizziness and constipation.\n\u201cMorphine did not provide superior analgesia, but was associated with significantly more adverse effects, making ibuprofen a better analgesic option,\u201d write the authors.\nWe\u2019d like the release to define what \u201csignificantly more adverse affects\u201d really means.\nHarms, or adverse effects, are a central part of this study, so a numerical comparison would be useful. As it turns out, 69 percent of children given oral morphine complained of negative side effects compared to 39 percent of those taking ibuprofen, according to the study. That\u2019s a pretty big difference. We also don\u2019t learn exactly which negative effects were most common, which turn out to be drowsiness (48 percent of study participants) and nausea (46 percent of participants).", "answer": 0}, {"article": "Men whose prostate cancer comes back after surgery are more likely to survive if, along with the usual radiation, they also take drugs to block male hormones.\n\nThe finding, published Wednesday in The New England Journal of Medicine, comes from a long-running study that experts say will help clarify treatment for many patients.\n\nAfter surgery to remove the prostate, more than 30 percent of men have a recurrence, and until now there has not been clear evidence about the best way to stop the disease from killing them. Most are given radiation, but prescribing drugs to counter the effects of male hormones has been inconsistent.\n\nThe study, paid for by the National Cancer Institute, showed that among men who received radiation and hormonal treatment, 76.3 percent were still alive after 12 years, compared to 71.3 percent who had radiation alone.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re given the data in absolute terms, which is very useful: 76.3% of men who got the combo radiation-hormone blocker treatment lived after 12 years, whereas 71.3% of those who received radiation alone survived 12 years after a recurrence of prostate cancer. This lets the reader clearly see how small but significant the benefit (a 5.2% difference) is. Going a step further, readers are also given the data on what actually killed men who received either treatment.", "answer": 1}, {"article": "Gluck et al.\nObesity 4 Nov.\n\nNIDDK Research Clinical Psychologist Marci Gluck, Ph.D., is available to comment on this study.\nMore study is needed to confirm the safety and effectiveness of tDCS for weight loss.\nOn each visit, the participants ate a weight-maintaining diet for five days.\nThen for three days, they unknowingly received either active or sham (fake) transcranial direct current stimulation, or tDCS.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify the very slight benefits of a very small study (fewer than 10 patients). Unlike the control group, five people who received active stimulation of their brain \u201cconsumed an average of 700 fewer calories and lost an average of 0.8 pounds on the second visit.\u201d But the story misses an important point here \u2014 the reduction in calories consumed was not statistically significant. That important detail deserved comment.", "answer": 0}, {"article": "Another sensor, just approved by the F.D.A.\nOver the next six weeks of testing, I came down to earth as I realized that while the sensor enabled me to drastically cut my usual number of lows, it did not eliminate them.\nEven with the help of an expert trainer from MiniMed, I found that injecting the catheter took much more dexterity than injecting one for a pump.\nThe main problem was that the sensor was simply not as accurate as a blood-glucose tester.\nI kept following the recommendations of the embedded calculator, taking only very small amounts of insulin to bring my sugar level down.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no discussion about clinical outcomes, such as by how much it might improve A1C levels, or on average, how many severe low blood sugar episodes were avoided by using this device compared to traditional devices. ", "answer": 0}, {"article": "For more information, visit https://www.nichd.nih.gov.\nThe authors noted that further studies are needed to confirm whether measuring HbA1c levels in early pregnancy could determine a woman\u2019s later risk for gestational diabetes.\nAccording to the authors, comparatively few studies have examined whether the HbA1c test could help identify the risk for gestational diabetes, and these studies have been limited to women already at high risk for the condition.\nIn the current study, researchers evaluated whether the HbA1c test (also called the A1C test), commonly used to diagnose type 2 diabetes, could identify signs of gestational diabetes in the first trimester of pregnancy.\nSimilarly, research is needed to determine whether lowering HbA1c with lifestyle changes, either in early pregnancy or before pregnancy, could reduce the risk for the condition.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release quantifies the results and potential benefits by noting that each 0.1 percent increase in HbA1c levels above 5.1 percent \u00a0in early pregnancy was associated with a 22 percent higher risk for gestational diabetes.", "answer": 1}, {"article": "Ishdori A, Capps O, Murano PS.\nAn overarching conclusion from the various papers included in the supplement, \"Science and Policy: Adopting a Fruitful Vegetable Encounter for Our Children,\" is that potatoes are a vegetable that tend to be well-liked by young children and are a good source of potassium and provide 8 percent of the recommended daily value of fiber.\nThe forum was supported by the Alliance for Potato Research and Education, a not-for-profit organization dedicated to expanding and translating scientific research into evidence-based policy and education initiatives that recognize the role of all forms of the potato--a nutritious vegetable--in promoting health for all age groups.\nThe journal supplement features seven papers authored by leading nutrition scientists that explore the state of the science pertaining to vegetable consumption in children.\nThe supplement is the outcome of a November 2014 USDA/ARS Children's Nutrition Research Center at Baylor College of Medicine roundtable on vegetable consumption in children.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release says that potatoes are the \u201cbest hope\u201d for delivering more fiber and potassium to kids. Based on what evidence? The study certainly doesn\u2019t show this. Here\u2019s what the study concludes:\n\u201cThe results suggest that patterns of potassium, [dietary fiber], and vitamin D intake for young children should be studied further in order to develop strategies for increasing intakes of these crucial nutrients. The consumption of a variety of all vegetables, including [white potatoes], is important to increase potassium and [dietary fiber]\u00a0intakes and should be encouraged.\u201d", "answer": 0}, {"article": "Dr. William Nelson, co-vice chair of the SU2C Scientific Advisory Committee and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland, said:\n\n\"Understanding the link between prostate cancer and DNA repair mutations is incredibly important for patients and their families.\nThe next trial includes only men with these mutations in their tumours, with the aim of proving that olaparib is highly effective for them.\"\nThe trial is a milestone in cancer treatment as the first to show the benefits of 'precision medicine' in prostate cancer - with treatment matched to the particular genetic characteristics of a man's tumour.\nIts efforts have helped produce a 20-fold increase in government funding for prostate cancer.\nThe trial, called TOPARP-A, received support from a wide range of funders including Cancer Research UK, the Prostate Cancer Foundation, Stand Up To Cancer, Prostate Cancer UK and the Movember Foundation.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release lacks information on key outcomes such as months of disease-free survival or death rates.\nThis is the closest we get to any quantification of benefits: \u201cWe showed that a subset of men whose tumours had mutations in their DNA repair machinery responded particularly well to treatment with olaparib.\u201d", "answer": 0}]